FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Park, JH
   Ihn, YK
   Hong, JT
AF Park, Jong-Hyeok
   Ihn, Yon Kwon
   Hong, Jae Taek
TI Significance of Provocative Perfusion Computed Tomography for Evaluation
   of Bow Hunter Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bow hunter syndrome; Diagnosis; Perfusion computed tomography;
   Provocative test; Vertebrobasilar insufficiency
AB Bow hunter syndrome (BHS) is a rare vascular phenomenon of vertebrobasilar insufficiency caused by dynamic stenosis of the vertebral artery (VA) by osteophytes, fibrous bands, or disk herniation with neck rotation. We present a rare case of a patient with bilaterally patent VAs on neutral imaging and bilateral dynamic compression of VA with left head rotation. Provocation tests are critical toward understanding dynamic pathophysiology of BHS because normal neutral vascular imaging does not preclude diagnosis of BHS. Although dynamic angiography is the gold standard for diagnosis of BHS, cerebral angiography could be invasive and risky. Provocative test using perfusion computed tomography scan is a simple and noninvasive method to assess BHS on an outpatient basis.
C1 [Park, Jong-Hyeok; Hong, Jae Taek] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
   [Ihn, Yon Kwon] Catholic Univ Korea, St Vincents Hosp, Dept Radiol, Suwon, South Korea.
   [Hong, Jae Taek] Catholic Univ Korea, Eun Pyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
RP Hong, JT (reprint author), Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.; Hong, JT (reprint author), Catholic Univ Korea, Eun Pyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM jatagi15@gmail.com
CR Bulsara KR, 2006, SURG NEUROL, V65, P625, DOI 10.1016/j.surneu.2005.08.016
   Horowitz Michael, 2002, Spine (Phila Pa 1976), V27, pE495, DOI 10.1097/00007632-200212010-00015
   Jost GF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14791
   SORENSEN BF, 1978, NEUROSURGERY, V2, P259, DOI 10.1227/00006123-197805000-00013
   Yoshimura K, 2011, EUR SPINE J, V20, pS266, DOI 10.1007/s00586-010-1669-2
NR 5
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 1
EP 3
DI 10.1016/j.wneu.2018.09.107
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000120
PM 30261398
DA 2020-05-12
ER

PT J
AU Bartschi, P
   Luna, E
   Gonzalez-Lopez, P
   Abarca, J
   Herrero, J
   Costa, E
   Paya, A
   Sales, J
   Moreno, P
AF Bartschi, Patrick
   Luna, Enrique
   Gonzalez-Lopez, Pablo
   Abarca, Javier
   Herrero, Joaquin
   Costa, Estela
   Paya, Artemio
   Sales, Juan
   Moreno, Pedro
TI A Very Rare Case of Right Insular Lobe Langerhans Cell Histiocytosis
   (CD1a(+)) Mimicking Glioblastoma Multiforme in a Young Adult
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-ALA; Birbeck granules; Histiocytosis; Insula; Langerhans cell
ID THERAPY
AB BACKGROUND: Langerhans cell histiocytosis (LCH) is a multisystemic dendritic cell proliferation that is relatively uncommon in adults. Central nervous system LCH outside the pituitary gland is even more uncommon.
   CASE DESCRIPTION: We report the case of a 42-year-old man who had complained of right-side hemicranial pain and left arm minor paresis. The symptoms were due to a right insular lobe heterogeneous-enhancing lesion associated with extensive vasogenic edema. The first diagnostic impression suggested glioblastoma multiforme or localized metastasis. The thoracic, abdominal, pelvic computed tomography scan only detected small upper lung inactive nodules suggesting silent focal LCH. A very hard lesion was almost completely removed through a pterional craniotomy approach, with no fluorescence after aminolevulinic acid infusion. The intraoperative biopsy findings ruled out glioma but could not confirm lymphoma. The definitive cerebral biopsy findings showed lymphocytes and histiocytes (CD1a(+), S-1001(+)), with a diagnosis of intracerebral parenchymal LCH. Fractioned radiotherapy resulted in clinical and radiological remission.
   CONCLUSIONS: The present case is so rare it should not be used as a guide. We probably will never see a single intraparenchymal supratentorial central nervous system LCH lesion. However, we hope our report will help colleagues in the future with the thought process.
C1 [Bartschi, Patrick; Luna, Enrique; Gonzalez-Lopez, Pablo; Abarca, Javier; Sales, Juan; Moreno, Pedro] Univ Gen Hosp Alicante, Fdn Promot Hlth & Biomed Res Valencian Reg, Dept Neurosurg, Alicante, Spain.
   [Herrero, Joaquin] Univ Gen Hosp Alicante, Fdn Promot Hlth & Biomed Res Valencian Reg, Dept Oncol, Alicante, Spain.
   [Costa, Estela; Paya, Artemio] Univ Gen Hosp Alicante, Fdn Promot Hlth & Biomed Res Valencian Reg, Dept Pathol, Alicante, Spain.
RP Gonzalez-Lopez, P (reprint author), Univ Gen Hosp Alicante, Fdn Promot Hlth & Biomed Res Valencian Reg, Dept Neurosurg, Alicante, Spain.
EM gonzalez_pab@gva.es
OI Gonzalez-Lopez, Pablo/0000-0001-8614-0992
CR Abla O, 2015, HEMATOL-AM SOC HEMAT, P565, DOI 10.1182/asheducation-2015.1.565
   Allen CE, 2015, BLOOD, V126, P26, DOI 10.1182/blood-2014-12-569301
   Dhall G, 2008, PEDIATR BLOOD CANCER, V50, P72, DOI 10.1002/pbc.21225
   EGELER RM, 1992, J PEDIATR ORTHOPED, V12, P811, DOI 10.1097/01241398-199211000-00021
   Favara BE, 1997, PEDIATR PATHOL LAB M, V17, P769, DOI 10.1080/107710497174471
   Grois N, 2006, PEDIATR BLOOD CANCER, V46, P228, DOI 10.1002/pbc.20425
   Grois N, 2005, BRAIN, V128, P829, DOI 10.1093/brain/awh403
   Haupt R, 2013, PEDIATR BLOOD CANCER, V60, P175, DOI 10.1002/pbc.24367
   Hoover KB, 2007, SKELETAL RADIOL, V36, P95, DOI 10.1007/s00256-006-0193-2
   Hund E, 1999, J NEUROL SCI, V171, P145, DOI 10.1016/S0022-510X(99)00258-0
   Idbaih A, 2004, PEDIATR BLOOD CANCER, V43, P55, DOI 10.1002/pbc.20040
   Kotecha R, 2014, AM J CLIN ONCOL-CANC, V37, P592, DOI 10.1097/COC.0b013e318281d6ce
   Kriz J, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-233
   Lampert F, 1998, HEMATOL ONCOL CLIN N, V12, P213, DOI 10.1016/S0889-8588(05)70506-2
   Li CW, 2016, J THORAC DIS, V8, DOI 10.21037/jtd.2016.04.64
   Malpas JS, 1996, MED PEDIATR ONCOL, V27, P540
   Nicholson HS, 1998, HEMATOL ONCOL CLIN N, V12, P379, DOI 10.1016/S0889-8588(05)70517-7
   Pardanani A, 2003, MAYO CLIN PROC, V78, P301, DOI 10.4065/78.3.301
   Perren F, 2011, J NEUROL SCI, V301, P96, DOI 10.1016/j.jns.2010.11.006
   Safaei A, 2015, IRAN J MED SCI, V40, P282
   Simko SJ, 2014, PEDIATR BLOOD CANCER, V61, P479, DOI 10.1002/pbc.24772
   Tazi A, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0249-2
   Woo KI, 2003, OPHTHAL PLAST RECONS, V19, P429, DOI 10.1097/01.IOP.0000092800.86282.27
   Yagci B, 2008, PEDIATR HEMAT ONCOL, V25, P399, DOI 10.1080/08880010802107356
NR 24
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 4
EP 11
DI 10.1016/j.wneu.2018.09.093
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000121
PM 30261373
DA 2020-05-12
ER

PT J
AU Qiu, YQ
   Du, MX
   Yu, BF
   Jiang, S
   Feng, JT
   Shen, YD
   Xu, WD
AF Qiu, Yan-Qun
   Du, Mao-Xin
   Yu, Bao-Fu
   Jiang, Su
   Feng, Jun-Tao
   Shen, Yun-Dong
   Xu, Wen-Dong
TI Contralateral Lumbar to Sacral Nerve Rerouting for Hemiplegic Patients
   After Stroke: A Clinical Pilot Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemiplegia; Nerve rerouting; Nerve transfer; Spasticity; Stroke
ID SELECTIVE DORSAL RHIZOTOMY; INTRATHECAL BACLOFEN THERAPY; SPASTIC
   CEREBRAL-PALSY; SPINAL-CORD-INJURY; PERIPHERAL NEUROTIZATION; XIAO
   PROCEDURE; GLOBAL BURDEN; CHILDREN; EFFICACY; LIPOMYELOMENINGOCELE
AB BACKGROUND: Spasticity and muscle weakness are common severe neurologic sequelae after stroke. Contralateral peripheral neurotization has been applied successfully to promote motor function of the hemiplegic upper extremity in patients with central neurological injury. To our knowledge, we present the first report of contralateral lumbar to sacral nerve transfer for the lower extremities in hemiplegic patients after stroke.
   CASE DESCRIPTION: Two patients were enrolled in the study. The first patient is a 57-year-old man who experienced permanent muscle weakness in his left leg after a right cerebral infarction. The second patient is a 42-year-old man who had spasticity and hemiplegia in both upper and lower limbs on the right side 32 months after a left cerebral hemorrhage. Both patients underwent contralateral lumbaretoesacral nerve rerouting to improve lower-limb motor function. Twenty months after surgery, both patients experienced significant improvement in ambulatory status.
   CONCLUSIONS: Although long-term follow-up and a randomized controlled trial are required, this study demonstrates the safety and possible benefits of contralateral lumbaretoesacral nerve transfer for hemiplegic patients after stroke. This novel surgical approach could provide a new means for lower-limb motor functional recovery.
C1 [Qiu, Yan-Qun; Yu, Bao-Fu; Jiang, Su; Feng, Jun-Tao; Shen, Yun-Dong; Xu, Wen-Dong] Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai, Peoples R China.
   [Qiu, Yan-Qun; Xu, Wen-Dong] Jingan Dist Cent Hosp, Dept Hand & Upper Extrem Surg, Shanghai, Peoples R China.
   [Qiu, Yan-Qun; Du, Mao-Xin; Xu, Wen-Dong] Jingan Dist Cent Hosp, Limb Funct Reconstruct Ctr, Shanghai, Peoples R China.
   [Qiu, Yan-Qun; Jiang, Su; Feng, Jun-Tao; Shen, Yun-Dong; Xu, Wen-Dong] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
   [Du, Mao-Xin] Jingan Dist Cent Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Xu, Wen-Dong] Minist Hlth, Key Lab Hand Reconstruct, Shanghai, Peoples R China.
   [Xu, Wen-Dong] Shanghai Key Lab Peripheral Nerve & Microsurg, Shanghai, Peoples R China.
   [Xu, Wen-Dong] Fudan Univ, State Key Lab Med Neurobiol, Shanghai, Peoples R China.
RP Xu, WD (reprint author), Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai, Peoples R China.; Xu, WD (reprint author), Jingan Dist Cent Hosp, Dept Hand & Upper Extrem Surg, Shanghai, Peoples R China.; Xu, WD (reprint author), Jingan Dist Cent Hosp, Limb Funct Reconstruct Ctr, Shanghai, Peoples R China.; Xu, WD (reprint author), Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, Shanghai, Peoples R China.; Xu, WD (reprint author), Minist Hlth, Key Lab Hand Reconstruct, Shanghai, Peoples R China.; Xu, WD (reprint author), Shanghai Key Lab Peripheral Nerve & Microsurg, Shanghai, Peoples R China.; Xu, WD (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai, Peoples R China.
EM wendongxu@fudan.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81601977]; National Key R&D Program of China
   [2017YFC0840100, 2017YFC0840106]; Shanghai Talent Development Fund
   [2017064]
FX This work was supported by grants from National Natural Science
   Foundation of China (81601977), National Key R&D Program of China
   (2017YFC0840100 and 2017YFC0840106), and Shanghai Talent Development
   Fund (2017064).
CR Albright AL, 2007, J NEUROSURG, V107, P324, DOI 10.3171/PED-07/10/324
   Bowden JL, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00239
   Bunata R, 2014, J HAND SURG-AM, V39, P1425, DOI 10.1016/j.jhsa.2013.12.017
   Caplan LR, 2016, CAPLANS STROKE CLIN, P621
   Carda S, 2010, J BONE JOINT SURG BR, V92B, P1262, DOI 10.1302/0301-620X.92B9.23580
   Carlstedt T., 2007, CENTRAL NERVE PLEXUS
   Creamer M, 2018, J NEUROL NEUROSUR PS, V89, P642, DOI 10.1136/jnnp-2017-317021
   Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511
   Dvorak EM, 2011, TOP STROKE REHABIL, V18, P195, DOI 10.1310/tsr1803-195
   Eppinger MA, 2015, SURG NEUROL INT, V6, pIII
   Espay AJ, 2018, JAMA NEUROL, V75, P1132, DOI 10.1001/jamaneurol.2018.1264
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   Francisco GE, 2006, TOP STROKE REHABIL, V13, P74, DOI 10.1310/tsr1304-74
   Fukuhara T, 2004, NEUROSURGERY, V54, P1268, DOI 10.1227/01.NEU.0000119605.32216.2E
   Ghany WAA, 2016, NEUROSURGERY, V79, P336, DOI 10.1227/NEU.0000000000001271
   Gracies JM, 2017, NEUROLOGY, V89, P2245, DOI 10.1212/WNL.0000000000004687
   Grunt S, 2014, DEV MED CHILD NEUROL, V56, P302, DOI 10.1111/dmcn.12277
   GU YD, 1992, J HAND SURG-BRIT EUR, V17B, P518, DOI 10.1016/S0266-7681(05)80235-9
   Gump WC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13294
   Hasnat MJ, 2015, COCHRANE DB SYST REV, pD4552
   Hoffmann G, 2016, TOP STROKE REHABIL, V23, P384, DOI 10.1179/1945511915Y.0000000023
   Hoving MA, 2009, EUR J PAEDIATR NEURO, V13, P240, DOI 10.1016/j.ejpn.2008.04.013
   Hua XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep18784
   Hua XY, 2015, NEUROSURGERY, V76, P187, DOI 10.1227/NEU.0000000000000590
   Knorr S, 2011, Exp Brain Res, V214, P303, DOI 10.1007/s00221-011-2826-5
   McManus L, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00569
   MUNRO D, 1952, NEW ENGL J MED, V246, P161, DOI 10.1056/NEJM195201312460501
   Myung W, 2016, J AFFECT DISORDERS, V191, P36, DOI 10.1016/j.jad.2015.11.028
   Parot C, 2016, SURG RADIOL ANAT, V38, P597, DOI 10.1007/s00276-015-1593-6
   Passingham RE, 2010, TRENDS COGN SCI, V14, P16, DOI 10.1016/j.tics.2009.11.001
   Patrizi F, 2006, THESCIENTIFICWORLDJO, V6, P472, DOI 10.1100/tsw.2006.98
   PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302
   Romero JR, 2006, BEHAV NEUROL, V17, P17, DOI 10.1155/2006/137532
   Scannell B, 2015, PHYS MED REH CLIN N, V26, P79, DOI 10.1016/j.pmr.2014.09.003
   SHARRARD W J, 1964, Ann R Coll Surg Engl, V35, P106
   Sievert KD, 2016, EUR UROL, V69, P771, DOI 10.1016/j.eururo.2015.11.016
   SINDOU M, 1974, J COMP NEUROL, V153, P15, DOI 10.1002/cne.901530103
   Sitthinamsuwan B, 2017, ACTA NEUROCHIR, V159, P2421, DOI 10.1007/s00701-017-3322-x
   Tedroff K, 2015, DEV MED CHILD NEUROL, V57, P484, DOI 10.1111/dmcn.12665
   Thibaut A, 2013, BRAIN INJURY, V27, P1093, DOI 10.3109/02699052.2013.804202
   Tuite GF, 2016, J UROLOGY, V196, P1735, DOI 10.1016/j.juro.2016.05.111
   Tuite GF, 2016, J NEUROSURG-PEDIATR, V18, P150, DOI 10.3171/2015.10.PEDS15271
   Wenderoth N, 2005, EUR J NEUROSCI, V22, P235, DOI 10.1111/j.1460-9568.2005.04176.x
   Xiao CG, 2003, J UROLOGY, V170, P1237, DOI 10.1097/01.ju.0000080710.32964.d0
   Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1
   Zheng MX, 2018, NEW ENGL J MED, V378, P22, DOI 10.1056/NEJMoa1615208
   Zheng MX, 2018, J NEUROSURG, V128, P304, DOI 10.3171/2016.4.JNS152046
NR 47
TC 2
Z9 3
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 12
EP 18
DI 10.1016/j.wneu.2018.09.118
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000122
PM 30266703
DA 2020-05-12
ER

PT J
AU Xu, HW
   Guan, S
   Liu, C
   Wang, L
   Yan, BJ
   Han, HJ
   Quan, T
AF Xu, Haowen
   Guan, Sheng
   Liu, Chao
   Wang, Li
   Yan, Baojun
   Han, Hongjie
   Quan, Tao
TI Rescue Glue Embolization of Vessel Perforation During Mechanical
   Thrombectomy for Acute Ischemic Stroke: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glue; Ischemic stroke; Mechanical thrombectomy; Vessel perforation
ID ENDOVASCULAR TREATMENT; SOLITAIRE STENT; RECANALIZATION; OCCLUSIONS;
   TRIAL
AB BACKGROUND: Vessel perforation is a serious technical complication during mechanical thrombectomy (MT) for the treatment of acute ischemic stroke with large vessel occlusion. Routine rescue strategy includes balloon occlusion for tamponade, procedure suspension, and lowering or normalizing blood pressure. However, this complication is still associated with poor outcome and high mortality.
   METHODS: In this paper, the authors report their experience by using glue to embolize the ruptured vessel secondary to microcatheter/microwire perforation, preventing further deterioration in clinical outcome. Rescue glue embolization was attempted in 2 patients who developed intraprocedural vessel perforation while trying to gain access through the blocked artery with a microcatheter/microwire.
   RESULTS: The ruptured vessels were effectively occluded. Stent retriever thrombectomies were then continued, and TICI 2b and 3 recanalizations were achieved. Both patients' neurologic status improved.
   CONCLUSIONS: The key benefit of this method exists in embolizing the ruptured vessel without affecting the following MT. We propose the rescue glue embolization is simple yet effective in managing vessel perforation complication during MT.
C1 [Xu, Haowen; Guan, Sheng; Liu, Chao; Yan, Baojun; Quan, Tao] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurointervent Radiol, Zhengzhou, Henan, Peoples R China.
   [Wang, Li] Childrens Hosp, Dept Neurol, Zhengzhou, Henan, Peoples R China.
   [Han, Hongjie] Second Peoples Hosp, Dept Neurosurg, Pingdingshan City, Peoples R China.
RP Quan, T (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurointervent Radiol, Zhengzhou, Henan, Peoples R China.
EM touxingaoshou@qq.com
CR Akins PT, 2014, AM J NEURORADIOL, V35, P524, DOI 10.3174/ajnr.A3707
   Baek JM, 2014, AM J NEURORADIOL, V35, P989, DOI 10.3174/ajnr.A3813
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Derdeyn CP, 2013, NEUROSURGERY, V72, P777, DOI 10.1227/NEU.0b013e318286fdc8
   Ding D, 2015, J STROKE, V17, P123, DOI 10.5853/jos.2015.17.2.123
   Dorn F, 2016, AM J NEURORADIOL, V37, P305, DOI 10.3174/ajnr.A4520
   Dorn F, 2012, CEREBROVASC DIS, V34, P70, DOI 10.1159/000338903
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Mokin M, 2017, J NEUROINTERV SURG, V9, P922, DOI 10.1136/neurintsurg-2016-012707
   Nguyen TN, 2008, AM J NEURORADIOL, V29, P974, DOI 10.3174/ajnr.A0958
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Shi ZS, 2010, STROKE, V41, P2775, DOI 10.1161/STROKEAHA.110.587063
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 19
EP 23
DI 10.1016/j.wneu.2018.09.131
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000123
PM 30266702
DA 2020-05-12
ER

PT J
AU Rao, AJ
   Teton, Z
   Rodriguez, V
   Tieu, BH
   Raslan, AM
AF Rao, Abigail J.
   Teton, Zoe
   Rodriguez, Victor
   Tieu, Brandon H.
   Raslan, Ahmed M.
TI Distal Ventriculoatrial Shunt Revision in Adult Myelomeningocele Patient
   Performed via Endovascular Transvenous Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid diversion; Endovascular; Hydrocephalus;
   Myelomeningocele; Revision; Ventriculoatrial shunt
ID PLACEMENT; RETRIEVAL
AB BACKGROUND: Myelomeningocele patients with shunt-dependent hydrocephalus often require multiple shunt revisions, eventually exhausting first-line distal diversion sites. Ventriculoatrial (VA) shunts are used less commonly than ventriculoperitoneal shunts, but knowledge of their use and complications is important to the neurosurgeon's armamentarium. VA shunts differ from ventriculoperitoneal and ventriculopleural shunts in that the ideal distal catheter target is an anatomically small area in comparison with the peritoneal and pleural cavities.
   CASE DESCRIPTION: Here we present a case of an adult myelomeningocele patient who experienced migration of a distal VA shunt catheter. A minimally invasive revision technique that does not require recannulation of the vessels or open manipulation of the shunt is presented.
   CONCLUSIONS: This is the fourth reported instance of successful distal revision of a migrated VA shunt catheter via transfemoral endovascular snaring. Knowledge of the opportunities afforded by this technique and collaboration with thoracic surgery colleagues is of benefit to all neurosurgeons.
C1 [Rao, Abigail J.; Teton, Zoe; Raslan, Ahmed M.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Rao, Abigail J.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
   [Rodriguez, Victor; Tieu, Brandon H.] Oregon Hlth & Sci Univ, Dept Surg, Div Cardiothorac Surg, Portland, OR 97201 USA.
   [Rodriguez, Victor] Univ Calif Davis, Dept Surg, Div Cardiothorac Surg, Sacramento, CA 95817 USA.
RP Raslan, AM (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
EM raslana@ohsu.edu
CR Chuang Huo-Li, 2002, Chang Gung Med J, V25, P62
   Gonzalez LF, 2007, J NEUROSURG, V106, P319, DOI 10.3171/ped.2007.106.4.319
   Hanak BW, 2017, PEDIATR NEUROSURG, V52, P381, DOI 10.1159/000452840
   James CA, 1997, PEDIATR RADIOL, V27, P330, DOI 10.1007/s002470050142
   Konar SK, 2015, WORLD NEUROSURG, V84, P1437, DOI 10.1016/j.wneu.2015.05.080
   Machinis TG, 2006, J NEUROSURG, V105, P153, DOI 10.3171/jns.2006.105.1.153
   McGovern RA, 2014, J NEUROSURG, V120, P1458, DOI 10.3171/2014.1.JNS131808
   MCSWEENEY WJ, 1972, J NEUROSURG, V36, P512, DOI 10.3171/jns.1972.36.4.0512
   Mori Takahisa, 1993, Neurologia Medico-Chirurgica, V33, P713, DOI 10.2176/nmc.33.713
   REDO SF, 1992, J PEDIATR SURG, V27, P642, DOI 10.1016/0022-3468(92)90467-L
   Surov A, 2009, CLIN NEUROL NEUROSUR, V111, P310, DOI 10.1016/j.clineuro.2008.10.011
   TATSUMI T, 1970, J NEUROSURG, V32, P593, DOI 10.3171/jns.1970.32.5.0593
   Xu Botao, 2012, Neurointervention, V7, P109, DOI 10.5469/neuroint.2012.7.2.109
   Yavuz Celal, 2013, Surg Neurol Int, V4, P10, DOI 10.4103/2152-7806.106284
NR 14
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 24
EP 27
DI 10.1016/j.wneu.2018.09.129
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000124
PM 30266696
DA 2020-05-12
ER

PT J
AU Zhang, DH
   Wang, HL
   Liu, TY
   Feng, YL
   Qi, Y
   Xu, N
AF Zhang, Donghuan
   Wang, Honglei
   Liu, Tianyi
   Feng, Yingli
   Qi, Yuan
   Xu, Ning
TI Re-Recurrence of Intracranial Aneurysm with Proximal Vascular Stenosis
   After Primary Clipping and Secondary Endovascular Embolization: A Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Clipping; Endovascular embolization; Intracranial aneurysm; Recurrence
ID CEREBRAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; COILING; RUPTURE; TRIAL
AB BACKGROUND: It was known that a small number of patients could have intracranial aneurysm recurrences after either surgical clipping or endovascular embolization treatment. However, early recurrence within 1 month after the treatment and re-recurrence has rarely been reported before.
   CASE DESCRIPTION: We report a 46-year-old man with a medical history of smoking and hypertension who was noncompliant with the treatments. He presented to the hospital with right extremity paralysis and aphasia and was found to have a ruptured middle cerebral artery aneurysm. Aneurysm was successfully treated by surgical clipping. Within 1 month after the treatment, the patient had a recurrent aneurysm at the same location and intracranial hemorrhage. The recurrent aneurysm was treated by endovascular embolization. However, during the follow-up visit 8 months after the treatment, angiography showed aneurysm recurrence with proximal vascular stenosis.
   CONCLUSIONS: Re-recurrence of intracranial aneurysm could happen after initial successful treatment with surgical clipping and endovascular embolization. In addition to the patient's medical history and characteristics of the aneurysm, local vascular stenosis might also contribute to its recurrence. Close postoperative follow-up is required for these patients.
C1 [Zhang, Donghuan; Wang, Honglei; Liu, Tianyi; Feng, Yingli; Qi, Yuan; Xu, Ning] Jilin Univ, Hosp 1, Dept Neurosurg, Jilin, Jilin, Peoples R China.
RP Xu, N (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Jilin, Jilin, Peoples R China.
EM simonxv@sohu.com
OI Wang, Honglei/0000-0002-8107-0283
CR Antonov A, 2018, WORLD NEUROSURG, V109, pE835, DOI 10.1016/j.wneu.2017.10.108
   ASARI S, 1986, Neurological Surgery, V14, P587
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Cekirge HS, 2000, ACTA RADIOL, V41, P111
   Chung Jaehwan, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P262, DOI 10.7461/jcen.2014.16.3.262
   DRAKE CG, 1984, J NEUROSURG, V61, P848, DOI 10.3171/jns.1984.61.5.0848
   Forsting M, 1996, J NEUROSURG, V85, P966, DOI 10.3171/jns.1996.85.5.0966
   Huang DZ, 2017, ONCOTARGET, V8, P33676, DOI 10.18632/oncotarget.16897
   Ishikawa M, 2000, ATHEROSCLEROSIS, V152, P97, DOI 10.1016/S0021-9150(99)00455-4
   Kono K, 2014, INT J NUMER METH BIO, V30, P942, DOI 10.1002/cnm.2637
   Kono K, 2013, NEUROSURGERY, V73, pE1080, DOI 10.1227/NEU.0000000000000065
   LIN T, 1989, J NEUROSURG, V70, P556, DOI 10.3171/jns.1989.70.4.0556
   Marbacher S, 2019, NEUROSURG REV, V42, P49, DOI 10.1007/s10143-017-0892-2
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Okada Takeshi, 2016, Surg Neurol Int, V7, pS40, DOI 10.4103/2152-7806.173570
   Oya Shigeru, 2018, No Shinkei Geka, V46, P27, DOI 10.11477/mf.1436203670
   Pokorski R J, 1997, J Insur Med, V29, P11
   Sakamoto Shigeyuki, 2003, Hiroshima Journal of Medical Sciences, V52, P15
   Sakata N, 2001, HISTOPATHOLOGY, V38, P325, DOI 10.1046/j.1365-2559.2001.01081.x
   Samano Abenamar, 2011, Surg Neurol Int, V2, P35, DOI 10.4103/2152-7806.78243
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wermer MJH, 2008, NEUROLOGY, V70, P2053, DOI 10.1212/01.wnl.0000304372.01248.02
   Wermer MJH, 2005, BRAIN, V128, P2421, DOI 10.1093/brain/awh587
   Zhao JJ, 2018, ANGIOLOGY, V69, P17, DOI 10.1177/0003319717700503
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 28
EP 32
DI 10.1016/j.wneu.2018.09.088
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000125
PM 30261388
DA 2020-05-12
ER

PT J
AU Rajadurai, S
   Muthukumaraswamy, S
   Hussain, Z
AF Rajadurai, Samuel
   Muthukumaraswamy, Sabaratnam
   Hussain, Zakier
TI Endovascular Treatment of Vertebral-Venous Fistula with Flow-Diverting
   Stent
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flow-diverting stent; Pulsatile tinnitus; VVF; VV-AVF;
   Vertebral-vertebral arteriovenous fistula; Vertebral-venous;
   Vertebrovenous fistula
ID ARTERIOVENOUS-FISTULA
AB BACKGROUND: Vertebral-venous fistulas (VVFs) are a rare vascular condition and are commonly associated with trauma but may also be idiopathic, spontaneous, or congenital. A current literature review reveals there is no level 1 evidence or established guidelines on optimal treatment for VVF. Diagnosis is often confirmed by catheter cerebral angiogram. Treatment goals are complete occlusion of the fistula, which can be achieved by both endovascular closure and/or surgical ligation treatment. Telescopic Pipeline flow-diversion stents are a common treatment modality for aneurysms and have also been described to successfully treat different types of cranial arteriovenous fistulas including carotid-cavernous fistulas. There is, however, no English literature available regarding its use in the management of VVFs, which are rare entities.
   CASE DESCRIPTION: The authors present a case of VVF, which is the first reported case to their knowledge whereby a Pipeline flow-diverting stent has been used to successfully treat a VVF while preserving the parent vertebral artery. The authors describe both the advantages and limitations of this approach.
   CONCLUSIONS: This case report highlights the potential of flow-diversion stents in the treatment of VVF. This technique was shown to be a safe and effective method of treatment for VVF. Important limitations, however, need to be considered before this form of treatment for VVF, including the need for multiple devices, extended duration of treatment, and associated increased costs involved.
C1 [Rajadurai, Samuel; Hussain, Zakier] Waikato Hosp, Dept Neurosurg, Hamilton, New Zealand.
   [Muthukumaraswamy, Sabaratnam] Waikato Hosp, Dept Diagnost & Intervent Radiol, Hamilton, New Zealand.
RP Rajadurai, S (reprint author), Waikato Hosp, Dept Neurosurg, Hamilton, New Zealand.
EM samuel.rajadurai01@gmail.com
CR Amuluru K, 2016, INTERV NEURORADIOL, V22, P569, DOI 10.1177/1591019916653255
   Asai J, 2002, CLIN NEUROL NEUROSUR, V104, P146, DOI 10.1016/S0303-8467(01)00194-9
   Aymard A, 1999, INTERV NEURORADIOL, P180
   Berguer R, 1999, J VASC SURG, V30, P344, DOI 10.1016/S0741-5214(99)70146-1
   Briganti F, 2013, NEURORADIOL J, V26, P339, DOI 10.1177/197140091302600315
   Brouillard AM, 2016, CUREUS, V8, DOI 10.7759/cureus.472
   Edwards MK, 2017, CASE REP EMERG MED, V2017
   Hofmann E, 2013, DTSCH ARZTEBL INT, V110, P451, DOI 10.3238/arztebl.2013.0451
   Modi M, 2010, CARDIOVASC INTER RAD, V33, P1253, DOI 10.1007/s00270-009-9708-2
   Nadarajah M, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010000
   Narayana Randhi Venkata, 2015, Indian J Radiol Imaging, V25, P18, DOI 10.4103/0971-3026.150132
   Sadato A, 2003, NEUROL MED-CHIR, V43, P250, DOI 10.2176/nmc.43.250
   Sfyroeras GS, 2012, J VASC SURG, V56, P839, DOI 10.1016/j.jvs.2012.04.020
   Yeh CH, 2014, INTERV NEURORADIOL, V20, P766, DOI 10.15274/INR-2014-10072
NR 14
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 33
EP 36
DI 10.1016/j.wneu.2018.09.168
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000126
PM 30273720
DA 2020-05-12
ER

PT J
AU Chachan, S
   Bae, J
   Lee, SH
   Suk, JW
   Shin, SH
AF Chachan, Sourabh
   Bae, Junseok
   Lee, Sang-Ho
   Suk, Ju-Wan
   Shin, Sang-Ha
TI Microscopic Anterior Neural Decompression Combined with Oblique Lumbar
   Interbody Fusion - A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct neural decompression; Microscopic decompression; Oblique lumbar
   interbody fusion
ID MANAGEMENT; OUTCOMES
AB BACKGROUND: Minimally invasive oblique lumbar interbody fusion (OLIF) techniques generally rely on deformity correction to achieve indirect neural decompression. However, indirect neural decompression will not always be sufficient. Thus, a second procedure, such as posterior direct decompression, will be added for full decompression, increasing the surgical morbidity and healthcare costs. We have described a technique of direct anterior microscopic neural decompression combined with OLIF.
   METHODS: We report our surgical technique of anterior lumbar neural microscopic decompression with OLIF with patients in the lateral position. We also report the cases of 3 patients treated from March 2018 to June 2018.
   RESULTS: Three patients underwent anterior microscopic neural decompression combined with OLIF in the lateral position. All 3 patients achieved clinically and radiologically significant neural decompression and deformity correction. No perioperative complications developed.
   CONCLUSION: Direct anterior microscopic neural decompression is feasible and safe in selected patients undergoing OLIF.
C1 [Chachan, Sourabh; Bae, Junseok; Lee, Sang-Ho; Suk, Ju-Wan; Shin, Sang-Ha] Spine Hlth Wooridul Hosp, Dept Spine Surg, Seoul, South Korea.
RP Bae, J (reprint author), Spine Hlth Wooridul Hosp, Dept Spine Surg, Seoul, South Korea.
EM jsbaemd@gmail.com
CR Covaro A, 2016, EFORT OPEN REV, V1, P267, DOI 10.1302/2058-5241.1.000030
   Eck JC, 2007, J AM ACAD ORTHOP SUR, V15, P321, DOI 10.5435/00124635-200706000-00001
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17196
   Lee N, 2017, WORLD NEUROSURG, V101, P216, DOI 10.1016/j.wneu.2017.01.114
   Lee YC, 2016, ASIAN SPINE J, V10, P801, DOI 10.4184/asj.2016.10.4.801
   Li JXJ, 2017, WORLD NEUROSURG, V98, P113, DOI 10.1016/j.wneu.2016.10.074
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Pannell WC, 2015, SPINE J, V15, P1719, DOI 10.1016/j.spinee.2013.10.014
   Ravindra VM, 2018, GLOB SPINE J, V8, P784, DOI 10.1177/2192568218770769
   Shin SH, 2013, SPINE J, V13, P1190, DOI 10.1016/j.spinee.2013.07.458
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Teng I, 2017, J CLIN NEUROSCI, V44, P11, DOI 10.1016/j.jocn.2017.06.013
   Yoshihara H, 2017, J CLIN NEUROSCI, V44, P63, DOI 10.1016/j.jocn.2017.06.061
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 37
EP 43
DI 10.1016/j.wneu.2018.09.146
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000127
PM 30268557
DA 2020-05-12
ER

PT J
AU Liu, XW
   Wu, ZF
   Liu, G
   Sun, GJ
   Kang, ZL
   Zhao, JN
   Xu, B
AF Liu, Xiaowei
   Wu, Zhenfang
   Liu, Gang
   Sun, Guojing
   Kang, Zhili
   Zhao, Jianning
   Xu, Bin
TI Partial Vertebrae Resection Laterally to Harvest Supplemental Autograft
   Bone for Anterior Cervical Discectomy and Fusion: A Technical Note and
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; Partial vertebrae resection;
   Supplemental autograft bone
ID STAND-ALONE-CAGE; INTERBODY FUSION; GRAFT; ALLOGRAFT; SUBSIDENCE;
   SURGERY; RATES; PAIN; BODY
AB PURPOSE: To evaluate the safety and effectiveness of partial vertebrae resection laterally through intervertebral space to harvest supplemental autograft bone for anterior cervical discectomy and fusion (ACDF).
   METHODS: Patients who accepted 1-segment (n = 19, 38.2 months follow-up) or 2-segment (n = 17, 40.4 months follow-up) ACDF with supplemental autograft bone were included. Cervical lordosis (CL), segmental lordosis (SL), anterior segment height (ASH), and posterior segment height (PSH) on neutrally lateral radiography, and intervertebral fusion rate on computed tomography were measured. The operation time, intraoperative blood loss, Japanese Orthopedic Association score, visual analog scale around the neck or arm, Neck Disability Index, and complications were also recorded.
   RESULTS: Mean operation time was 86.2 and 115.6 minutes, and the intraoperative blood loss was 41.7 and 79.4 mL in cases with 1-segment and 2-segment ACDF, respectively. At the final visit, the visual analog scale score and Neck Disability Index significantly decreased, and the Japanese Orthopedic Association score significantly increased. Significant increases were observed in the ASH, PSH, CL, and SL after 2-segment ACDF. Significant increases were observed in the CL and SL after 1-segment ACDF, but not in the ASH and PSH. All the ASH, PSH, CL, and SL kept unchanged at the final visit. All cases acquired definite intervertebral fusion, and the incidence of cage subsidence was 5.3% after 1-segment and 17.6% after 2-segment ACDF at the final visit.
   CONCLUSIONS: Partial vertebrae resection laterally through the intervertebral space was a safe and effective method to harvest supplemental autograft bone for the ACDF.
C1 [Liu, Xiaowei; Wu, Zhenfang; Liu, Gang; Sun, Guojing; Kang, Zhili; Zhao, Jianning; Xu, Bin] Nanjing Univ, Jinling Hosp, Med Coll, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
RP Xu, B (reprint author), Nanjing Univ, Jinling Hosp, Med Coll, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
EM xubinnz@163.com
CR Arlet V, 2006, EUR SPINE J, V15, P1352, DOI 10.1007/s00586-006-0100-5
   Armaghani SJ, 2016, SPINE, V41, pE191, DOI 10.1097/BRS.0000000000001201
   Buser Z, 2016, J NEUROSURG-SPINE, V25, P509, DOI 10.3171/2016.1.SPINE151005
   Chau AMT, 2009, EUR SPINE J, V18, P449, DOI 10.1007/s00586-008-0878-4
   Chen Y, 2008, J SPINAL DISORD TECH, V21, P489, DOI 10.1097/BSD.0b013e318158de22
   Cheng CC, 2007, SPINE, V32, P1852, DOI 10.1097/BRS.0b013e31811ece5a
   Dang L, 2017, BRIT J NEUROSURG, V31, P33, DOI 10.1080/02688697.2016.1208805
   Fowler B L, 1995, Am J Orthop (Belle Mead NJ), V24, P895
   Iwasaki K, 2014, J NEUROSURG-SPINE, V21, P761, DOI 10.3171/2014.7.SPINE131000
   Joaquim AF, 2014, SPINE J, V14, P2246, DOI 10.1016/j.spinee.2014.03.030
   Karikari IO, 2014, J SPINAL DISORD TECH, V27, P1, DOI 10.1097/BSD.0b013e31825bd26d
   Lee CH, 2013, J SPINAL DISORD TECH, V26, P112, DOI 10.1097/BSD.0b013e318274148e
   Lee YS, 2015, SPINE, V40, pE563, DOI 10.1097/BRS.0000000000000864
   Liao JC, 2008, INT ORTHOP, V32, P643, DOI 10.1007/s00264-007-0378-x
   Ma Z, 2017, EUR SPINE J, V26, P998, DOI 10.1007/s00586-016-4779-7
   MCGUIRE RA, 1994, J SPINAL DISORD, V7, P499, DOI 10.1097/00002517-199412000-00006
   Miller LE, 2011, SPINE, V36, P2045, DOI 10.1097/BRS.0b013e3181ff37eb
   Nambiar M, 2017, EUR SPINE J, V26, P2258, DOI 10.1007/s00586-017-5015-9
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Park JI, 2013, J KOREAN NEUROSURG S, V54, P189, DOI 10.3340/jkns.2013.54.3.189
   Pitzen T, 2006, ZBL NEUROCHIR, V67, P8, DOI 10.1055/s-2006-921404
   Pollock R, 2008, EUR SPINE J, V17, P845, DOI 10.1007/s00586-008-0648-3
   Shad A, 2005, J NEUROSURG-SPINE, V2, P116, DOI 10.3171/spi.2005.2.2.0116
   Shriver MF, 2015, SPINE J, V15, P2016, DOI 10.1016/j.spinee.2015.05.010
   Simoes J, 2017, DYSPHAGIA, V32, P123, DOI 10.1007/s00455-016-9764-0
   Tabaraee E, 2017, CLIN SPINE SURG, V30, pE1201, DOI 10.1097/BSD.0000000000000341
   WANG T, 2016, MEDICINE, V95, DOI DOI 10.1097/MD.0000000000005437
   Yao JH, 2014, COMPUT MED IMAG GRAP, V38, P628, DOI 10.1016/j.compmedimag.2014.04.001
   YOUNG WF, 1993, SPINE, V18, P1123, DOI 10.1097/00007632-199307000-00002
   Zadegan SA, 2017, EUR SPINE J, V26, P958, DOI 10.1007/s00586-016-4858-9
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 44
EP 50
DI 10.1016/j.wneu.2018.09.141
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000128
PM 30267944
DA 2020-05-12
ER

PT J
AU Al-Mufti, F
   Kamal, N
   Damodara, N
   Nuoman, R
   Gupta, R
   Alotaibi, NM
   Alkanaq, A
   El-Ghanem, M
   Keller, IA
   Schonfeld, S
   Gupta, G
   Roychowdhury, S
AF Al-Mufti, Fawaz
   Kamal, Naveed
   Damodara, Nitesh
   Nuoman, Rolla
   Gupta, Raghav
   Alotaibi, Naif M.
   Alkanaq, Ahmed
   El-Ghanem, Mohammad
   Keller, Irwin A.
   Schonfeld, Steven
   Gupta, Gaurav
   Roychowdhury, Sudipta
TI Updates in the Management of Cerebral Infarctions and Subarachnoid
   Hemorrhage Secondary to Intracranial Arterial Dissection: A Systematic
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Dissection; Hemorrhage; Intracranial; Ischemia
ID INTERNAL CAROTID-ARTERY; INFERIOR CEREBELLAR ARTERY; VERTEBRAL ARTERY;
   ENDOVASCULAR TREATMENT; POSTERIOR CIRCULATION; FOLLOW-UP;
   VERTEBROBASILAR DISSECTION; SURGICAL-TREATMENT; CLINICAL-OUTCOMES; STENT
   PLACEMENT
AB OBJECTIVE: Intracranial arterial dissection (IAD) is a rare cerebrovascular disease that is likely underdiagnosed because of the inherent difficulty of visualizing the subtle radiographic signs of the pathologic small intracranial arteries. No widespread consensus exists on the treatment of IAD, and thus it is often managed empirically because of the absence of major randomized controlled trials. In this study, we conducted a systematic review to evaluate the management and treatment options for IAD.
   METHODS: We performed a systematic review in accordance with the PRISMA guidelines using the following databases: MEDLINE (PubMed) and Cochrane Library. Included studies were limited to human patients with dissections in intracranial vessels only.
   RESULTS: A total of 82 studies were included in this systematic review. The most common complications of IAD were cerebral infarction and subarachnoid hemorrhage, and thus, patients with IAD can be subdivided into those presenting with either ischemia or hemorrhage, respectively. Those with ischemia were predominantly managed with antiplatelet therapy, whereas patients presenting with hemorrhage often were amenable to treatment with endovascular techniques.
   CONCLUSIONS: Given these findings, clinicians should prescribe antiplatelet therapy for patients with IAD presenting with ischemia and consider endovascular treatment for those presenting with hemorrhage. However, further investigation is required given the heterogeneity of methods and reporting outcomes in the investigated studies.
C1 [Al-Mufti, Fawaz] New York Med Coll, Westchester Med Ctr, Dept Neurol & Neurosurg, Valhalla, NY 10595 USA.
   [Al-Mufti, Fawaz; Alkanaq, Ahmed] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.
   [Gupta, Gaurav] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ USA.
   [Keller, Irwin A.; Schonfeld, Steven; Roychowdhury, Sudipta] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Radiol, New Brunswick, NJ USA.
   [Al-Mufti, Fawaz; Kamal, Naveed; Damodara, Nitesh; Gupta, Raghav] Rutgers State Univ, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 08901 USA.
   [Nuoman, Rolla] Rutgers State Univ, New Jersey Med Sch, Dept Neurol, Newark, NJ USA.
   [Alotaibi, Naif M.] Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
   [El-Ghanem, Mohammad] Univ Arizona, Dept Neurol, Banner Univ Med Ctr, Tucson, AZ USA.
RP Al-Mufti, F (reprint author), New York Med Coll, Westchester Med Ctr, Dept Neurol & Neurosurg, Valhalla, NY 10595 USA.; Al-Mufti, F (reprint author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.; Al-Mufti, F (reprint author), Rutgers State Univ, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 08901 USA.
EM fawazalmufti@outlook.com
RI Gupta, Gaurav/AAL-3349-2020
OI Gupta, Gaurav/0000-0002-9442-6007; Al-Mufti, Fawaz/0000-0003-4461-7005;
   Alotaibi, Naif/0000-0002-8227-347X; Alkanaq, Ahmed N/0000-0002-2616-8288
CR Ahn JY, 2006, AM J NEURORADIOL, V27, P1514
   Albuquerque Felipe C, 2005, Neurosurg Focus, V18, pE3
   Amlie-Lefond C, 2009, CIRCULATION, V119, P1417, DOI 10.1161/CIRCULATIONAHA.108.806307
   Ansari SA, 2008, NEUROSURGERY, V62, P636, DOI 10.1227/01.NEU.0000311350.25281.6B
   Arauz A, 2013, EUR J NEUROL, V20, P167, DOI 10.1111/j.1468-1331.2012.03825.x
   Arnold M, 2006, STROKE, V37, P2499, DOI 10.1161/01.STR.0000240493.88473.39
   Balik V, 2017, J NEUROL SURG PART A, V78, P67, DOI 10.1055/s-0036-1588064
   Caplan LR, 2008, NAT CLIN PRACT NEURO, V4, P34, DOI 10.1038/ncpneuro0683
   Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475
   Caplan LR, 2006, CEREBROVASC DIS, V21, P145, DOI 10.1159/000090791
   Chaves C, 2002, ARCH NEUROL-CHICAGO, V59, P977, DOI 10.1001/archneur.59.6.977
   Chen YA, 2013, INTERV NEURORADIOL, V19, P479, DOI 10.1177/159101991301900412
   Chuang MJ, 2012, ASIAN J SURG, V35, P42, DOI 10.1016/j.asjsur.2012.04.007
   Chung Y, 2017, WORLD NEUROSURG, V99, P79, DOI 10.1016/j.wneu.2016.11.118
   Czabanka M, 2011, J NEUROSURG, V114, P1074, DOI 10.3171/2010.5.JNS091435
   Faria MD, 2011, AM J NEURORADIOL, V32, P2192, DOI 10.3174/ajnr.A2671
   deBray JM, 1997, J NEUROL NEUROSUR PS, V63, P46, DOI 10.1136/jnnp.63.1.46
   Doijiri R, 2012, J STROKE CEREBROVASC, V21, DOI 10.1016/j.jstrokecerebrovasdis.2012.02.003
   Fang YB, 2017, CLIN NEURORADIOL, V27, P345, DOI 10.1007/s00062-015-0494-8
   Fujimoto M, 2012, BMJ CASE REP, V2012
   Garber ST, 2011, ACTA NEUROCHIR, V153, P2461, DOI 10.1007/s00701-011-1201-4
   Grove EL, 2010, THROMB HAEMOSTASIS, V103, P1245, DOI 10.1160/TH09-08-0527
   Guillon B, 1998, J NEUROL SCI, V153, P146, DOI 10.1016/S0022-510X(97)00287-6
   Guo LM, 2014, J CRANIOFAC SURG, V25, P674, DOI 10.1097/SCS.0000000000000484
   Hamada J, 2003, J NEUROSURG, V99, P960, DOI 10.3171/jns.2003.99.6.0960
   He M, 2009, J NEUROSURG, V110, P418, DOI 10.3171/2008.3.17470
   Hosoya T, 1999, STROKE, V30, P1083, DOI 10.1161/01.STR.30.5.1083
   Huang YC, 2009, SURG NEUROL, V72, P20, DOI 10.1016/j.surneu.2008.10.002
   Iihara K, 2002, J NEUROSURG, V97, P259, DOI 10.3171/jns.2002.97.2.0259
   Islam MS, 2004, MINIM INVAS NEUROSUR, V47, P165, DOI 10.1055/s-2004-818490
   Jiang C, 2014, CARDIOVASC INTER RAD, V37, P646, DOI 10.1007/s00270-013-0737-5
   Jin SC, 2009, AM J NEURORADIOL, V30, P1518, DOI 10.3174/ajnr.A1621
   Joo JY, 2005, CARDIOVASC INTER RAD, V28, P595, DOI 10.1007/s00270-004-0199-x
   Kakino S, 2004, SURG NEUROL, V61, P185, DOI 10.1016/j.surneu.2003.06.001
   Kashiwazaki D, 2013, NEURORADIOLOGY, V55, P201, DOI 10.1007/s00234-012-1114-9
   Kim BM, 2011, NEUROLOGY, V76, P1735, DOI 10.1212/WNL.0b013e31821a7d94
   Kim BM, 2008, AM J NEURORADIOL, V29, P1937, DOI 10.3174/ajnr.A1243
   Kim BM, 2011, STROKE, V42, P2425, DOI 10.1161/STROKEAHA.111.617381
   Kim CH, 2006, ACTA NEUROCHIR, V148, P395, DOI 10.1007/s00701-006-0742-4
   Kim TW, 2013, CEREBROVASC DIS, V36, P292, DOI 10.1159/000354811
   Kocaeli H, 2009, SKULL BASE-INTERD AP, V19, P209, DOI 10.1055/s-0028-1114296
   Krings T, 2010, INTERV NEURORADIOL, V16, P151, DOI 10.1177/159101991001600206
   Kudo T, 2007, Interv Neuroradiol, V13 Suppl 1, P157
   Kurata A, 2001, AM J NEURORADIOL, V22, P11
   Kwak Jae Hyuk, 2011, Neurointervention, V6, P78, DOI 10.5469/neuroint.2011.6.2.78
   Lazinski D, 2000, NEURORADIOLOGY, V42, P128, DOI 10.1007/s002340050031
   Lee JM, 2010, ACTA NEUROCHIR, V152, P1455, DOI 10.1007/s00701-010-0683-9
   LEE RMKW, 1995, PHARMACOL THERAPEUT, V66, P149, DOI 10.1016/0163-7258(94)00071-A
   Lim SH, 2015, J KOREAN NEUROSURG S, V58, P175, DOI 10.3340/jkns.2015.58.3.175
   Lin CH, 2005, J NEUROL SCI, V235, P37, DOI 10.1016/j.jns.2005.03.047
   Luo Chao-Bao, 2005, J Chin Med Assoc, V68, P578
   Lv N, 2016, INTERV NEURORADIOL, V22, P12, DOI 10.1177/1591019915617317
   Lv X, 2010, AM J NEURORADIOL, V31, P1232, DOI 10.3174/ajnr.A2087
   Lylyk P, 2001, J NEUROSURG, V94, P427, DOI 10.3171/jns.2001.94.3.0427
   Malek AM, 2000, J TRAUMA, V48, P143, DOI 10.1097/00005373-200001000-00027
   Malinin A, 2007, THROMB RES, V119, P277, DOI 10.1016/j.thromres.2006.01.019
   Mazur MD, 2016, J NEUROINTERV SURG, V8, P1041, DOI 10.1136/neurintsurg-2015-012040
   Mehta B, 2003, AM J NEURORADIOL, V24, P1814
   Metso TM, 2007, STROKE, V38, P1837, DOI 10.1161/STROKEAHA.106.479501
   Miyamoto N, 2009, SURG CEREB STROKE, V37, P184
   Mizutani T, 2011, J NEUROSURG, V114, P1037, DOI 10.3171/2010.9.JNS10668
   Moon Y, 2012, NEUROLOGIST, V18, P136, DOI 10.1097/NRL.0b013e318253f8dc
   Mori K, 2002, BRIT J NEUROSURG, V16, P158, DOI 10.1080/02688690220131787
   Mourand I, 2010, NEURORADIOLOGY, V52, P135, DOI 10.1007/s00234-009-0597-5
   Naito I, 2004, INTERV NEURORADIOL, V10, P181, DOI 10.1177/15910199040100S131
   Naito I, 2002, NEUROSURGERY, V51, P930, DOI 10.1227/01.NEU.0000027636.42239.8E
   Nakazawa T, 2011, NEURORADIOL J, V24, P699, DOI 10.1177/197140091102400506
   Nam Dong Hyuk, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P108, DOI 10.7461/jcen.2015.17.2.108
   Nam KH, 2015, J NEUROINTERV SURG, V7, P829, DOI 10.1136/neurintsurg-2014-011366
   Narata AP, 2012, NEUROSURGERY, V70, P982, DOI 10.1227/NEU.0b013e318236715e
   Nonaka S, 2012, JNET, V6, P98, DOI [10.5797/jnet.6.98, DOI 10.5797/JNET.6.98]
   Ogiwara H, 2005, NEUROL MED-CHIR, V45, P148, DOI 10.2176/nmc.45.148
   Oh DC, 2012, J NEUROINTERV SURG, V4, P31, DOI 10.1136/jnis.2011.004952
   Ohkuma H, 2003, NEURORADIOLOGY, V45, P143, DOI 10.1007/s00234-002-0919-3
   Ohkuma H, 2002, STROKE, V33, P941, DOI 10.1161/01.STR.0000013564.73522.05
   Ono Hideaki, 2017, Surg Neurol Int, V8, P157, DOI 10.4103/sni.sni_154_17
   Ono H, 2013, STROKE, V44, P126, DOI 10.1161/STROKEAHA.112.670745
   Oran I, 2009, DIAGN INTERV RADIOL, V15, P159
   Park SI, 2009, AM J NEURORADIOL, V30, P1351, DOI 10.3174/ajnr.A1561
   Peluso JPP, 2008, AM J NEURORADIOL, V29, P102, DOI 10.3174/ajnr.A0771
   Prasad V, 2013, BMJ CASE REPORTS, V2013
   Purkayastha S, 2006, J NEURORADIOLOGY, V33, P329, DOI 10.1016/S0150-9861(06)77290-X
   Rabinov JD, 2003, AM J NEURORADIOL, V24, P1421
   Rahme RJ, 2013, NEUROIMAG CLIN N AM, V23, P661, DOI 10.1016/j.nic.2013.03.013
   Ramgren B, 2005, NEURORADIOLOGY, V47, P97, DOI 10.1007/s00234-005-1346-z
   Saito A, 2014, NEUROL MED-CHIR, V54, P196, DOI 10.2176/nmc.cr2012-0251
   Sakamoto S, 2002, NEUROL MED-CHIR, V42, P250, DOI 10.2176/nmc.42.250
   Santos-Franco JA, 2008, NEUROSURG REV, V31, P131, DOI 10.1007/s10143-008-0124-x
   SCHIEVINK WI, 1994, NEW ENGL J MED, V330, P393, DOI 10.1056/NEJM199402103300604
   Shin Gi Won, 2015, Neurointervention, V10, P14, DOI 10.5469/neuroint.2015.10.1.14
   Sikkema T, 2014, EUR J NEUROL, V21, P820, DOI 10.1111/ene.12384
   Sonmez O, 2015, AM J NEURORADIOL, V36, P1293, DOI 10.3174/ajnr.A4360
   Su WD, 2011, J CLIN NEUROSCI, V18, P1639, DOI 10.1016/j.jocn.2011.03.034
   Sugiu K, 2005, NEURORADIOLOGY, V47, P158, DOI 10.1007/s00234-005-1341-4
   Surdell DL, 2009, SURG NEUROL, V71, P604, DOI 10.1016/j.surneu.2007.11.021
   Suzuki S, 2008, MINIM INVAS NEUROSUR, V51, P193, DOI 10.1055/s-2008-1073172
   Takaba M, 1998, ACTA NEUROCHIR, V140, P411, DOI 10.1007/s007010050118
   Takagi T, 2007, NEUROSURG REV, V30, P32, DOI 10.1007/s10143-006-0049-1
   Tawk RG, 2003, NEUROSURG REV, V26, P180, DOI 10.1007/s10143-002-0231-z
   Tsuura M, 1999, Interv Neuroradiol, V5 Suppl 1, P203
   Wakabayashi Y, 2000, NEUROL MED-CHIR, V40, P624, DOI 10.2176/nmc.40.624
   Wakhloo AK, 2008, STROKE, V39, P3288, DOI 10.1161/STROKEAHA.107.512996
   Walmsley JG, 2008, J VASC RES, V16, P43
   Wang J, 2013, TURK NEUROSURG, V23, P323, DOI 10.5137/1019-5149.JTN.6513-12.1
   WILKINSON IM, 1972, ARCH NEUROL-CHICAGO, V27, P392, DOI 10.1001/archneur.1972.00490170024004
   Wong George Kwok Chu, 2010, Surg Neurol Int, V1, P84, DOI 10.4103/2152-7806.74145
   Yamada M, 2004, J NEUROSURG, V101, P25, DOI 10.3171/jns.2004.101.1.0025
   YAMAURA A, 1990, J NEUROSURG, V72, P183, DOI 10.3171/jns.1990.72.2.0183
   YONAS H, 1977, SURG NEUROL, V8, P407
   Yoon WK, 2010, ACTA NEUROCHIR, V152, P1477, DOI 10.1007/s00701-010-0693-7
   Yoon W, 2007, EUR RADIOL, V17, P983, DOI 10.1007/s00330-006-0272-8
   Yoshimoto Y, 1997, STROKE, V28, P370, DOI 10.1161/01.STR.28.2.370
   Yuki I, 2005, J NEUROSURG, V103, P649, DOI 10.3171/jns.2005.103.4.0649
   Zenteno M, 2006, SURG NEUROL, V66, P603, DOI 10.1016/j.surneu.2006.05.058
   Zenteno MA, 2008, J NEUROSURG, V108, P1104, DOI 10.3171/JNS/2008/108/6/1104
   Zhao KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067169
   Zhao WY, 2007, ACTA NEUROCHIR, V149, P585, DOI 10.1007/s00701-007-1161-x
   Zhao WY, 2016, INTERV NEURORADIOL, V22, P138, DOI 10.1177/1591019915617325
NR 118
TC 0
Z9 1
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 51
EP 58
DI 10.1016/j.wneu.2018.09.153
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000129
PM 30268550
DA 2020-05-12
ER

PT J
AU Malik, P
   Salunke, P
   Kataria, M
   Karthigeyan, M
   Ray, N
AF Malik, Puneet
   Salunke, Pravin
   Kataria, Mandeep
   Karthigeyan, Madhivanan
   Ray, Nirmalya
TI Anomalous V3 Segment Aneurysm Associated with Congenital Atlantoaxial
   Dislocation: Case Report and Discussing the Challenges in Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anomalous vertebral artery; Congenital atlantoaxial dislocation;
   Management; Vertebral artery aneurysm
ID VERTEBRAL ARTERY
AB BACKGROUND: An anomalous vertebral artery is not a deterrent for posterior C1-C2 joint manipulation and reduction of atlantoaxial dislocation (AAD). However, presence of an incidental aneurysm in the aberrant segment of artery with concurrent AAD adds to the surgical challenge.
   CASE DESCRIPTION: A 30-year-old woman presented with neck pain and spastic quadriparesis. Her imaging revealed atlantoaxial dislocation and bony segmentation defects. Three-dimensional computed tomography angiography showed bilateral anomalous vertebral arteries (V3 segment) and an incidental aneurysm on the arterial segment that crossed the right C1-C2 joint posteriorly. Because the artery bearing the aneurysm was nondominant, it was ligated and successful C1-C2 posterior reduction and fusion could be performed.
   CONCLUSION: The association of an incidental aneurysm with an anomalous vertebral artery in congenital AAD is unusual. The etiology could be an underlying collagen defect or repeated shearing trauma to the vessel wall due to C1C2 instability. It would be less risky to proceed with endovascular embolization followed by occipitocervical fusion without opening the joints in case the aneurysm is present on the dominant aberrant V3 segment. Ventral decompression can be supplemented for irreducible AAD. On the contrary, if the aneurysm is present on the nondominant aberrant V3 segment, the C1-2 joint can be opened and manipulated following an initial endovascular treatment of the aneurysm. If the circumstances demand, the nondominant artery can be ligated and sacrificed, although there is a small risk of formation of stump aneurysm.
C1 [Malik, Puneet; Salunke, Pravin; Kataria, Mandeep; Karthigeyan, Madhivanan] PGIMER, Dept Neurosurg, Chandigarh, India.
   [Ray, Nirmalya] PGIMER, Dept Radiodiag, Chandigarh, India.
RP Salunke, P (reprint author), PGIMER, Dept Neurosurg, Chandigarh, India.
EM drpravin_salunke@yahoo.co.uk
CR Anderson Tsang Chun On, 2018, Neurointervention, V13, P62, DOI 10.5469/neuroint.2018.13.1.62
   Isaji T, 2018, J NEUROSURG-SPINE, V28, P154, DOI 10.3171/2017.5.SPINE161286
   RIFKINSONMANN S, 1986, J VASC SURG, V4, P288, DOI 10.1067/mva.1986.avs0040288
   Salunke P, 2016, WORLD NEUROSURG, V95, P156, DOI 10.1016/j.wneu.2016.07.097
   Salunke P, 2015, J NEUROSURG-SPINE, V23, P294, DOI 10.3171/2014.12.SPINE14310
   Salunke P, 2015, CLIN NEUROL NEUROSUR, V131, P47, DOI 10.1016/j.clineuro.2015.01.025
   Salunke Pravin, 2014, Surg Neurol Int, V5, P82, DOI 10.4103/2152-7806.133642
   Salunke P, 2014, J NEUROSURG-SPINE, V20, P5, DOI 10.3171/2013.9.SPINE13491
   Sawlani V, 2006, SURG NEUROL, V66, P298, DOI 10.1016/j.surneu.2006.02.032
   Tanaka Y, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.09.124
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 59
EP 61
DI 10.1016/j.wneu.2018.09.231
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000130
PM 30312814
DA 2020-05-12
ER

PT J
AU Schar, RT
   Wilson, JR
   Ginsberg, HJ
AF Schar, Ralph T.
   Wilson, Jefferson R.
   Ginsberg, Howard J.
TI Intraoperative Ultrasound-Guided Posterior Cervical Laminectomy for
   Degenerative Cervical Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical fusion; Cervical laminectomy; Degenerative cervical myelopathy;
   Intraoperative ultrasound
ID SPINAL-CORD; DECOMPRESSION; OSSIFICATION; LAMINOPLASTY; SURGERY
AB OBJECTIVE: We present our experience with routine intraoperative ultrasound (IOUS)-guided posterior cervical laminectomy (PCL) in patients with degenerative cervical myelopathy (DCM), describe the technique used, and describe relevant IOUS findings that may impact the surgical procedure.
   METHODS: Three illustrative cases are presented of patients (age range, 67-79 years) who underwent PCL with IOUS guidance and instrumented fusion for DCM. Intraoperative standard B-mode images were obtained with a linear array 6.6- to 13.3-MHz transducer.
   RESULTS: Excellent high-resolution IOUS view of the spinal cord and nerve roots was obtained in every case after laminectomy. IOUS had a relevant intraoperative impact in all cases, leading to extended decompression of focal residual compression, confirmation of posterior shift of the spinal cord from anteriorly located structures, and final confirmation of sufficient decompression by visualization of symmetric and rhythmic cord pulsations.
   CONCLUSIONS: IOUS is a poorly described yet easy-to-use and very effective tool for guidance and confirmation of adequate posterior decompression of the cervical spinal cord and nerve roots during PCL. Routinely using IOUS-guided decompression for PCL in patients with myelopathy will help avoid residual compression of neural elements and might be beneficial for functional outcome.
C1 [Schar, Ralph T.; Wilson, Jefferson R.; Ginsberg, Howard J.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.
RP Schar, RT (reprint author), Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.
EM ralph.schaer@insel.ch
RI Schar, Ralph/C-5289-2017; Schar, Ralph T./P-3895-2019
OI Schar, Ralph/0000-0001-8998-9668; Schar, Ralph T./0000-0001-8998-9668
CR DOHRMANN GJ, 1982, SURG NEUROL, V18, P395, DOI 10.1016/0090-3019(82)90169-0
   Epstein N, 2002, SURG NEUROL, V58, P194, DOI 10.1016/S0090-3019(02)00819-4
   Fehlings MG, 2017, SPINE J, V17, P102, DOI 10.1016/j.spinee.2016.08.019
   JOKICH PM, 1984, J NEUROSURG, V60, P707, DOI 10.3171/jns.1984.60.4.0707
   Juthani RG, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0358-0
   Kato S, 2017, J BONE JOINT SURG AM, V99, P1013, DOI 10.2106/JBJS.16.00882
   Kimura A, 2012, EUR SPINE J, V21, P2450, DOI 10.1007/s00586-012-2430-9
   Kristof RA, 2009, EUR SPINE J, V18, P1951, DOI 10.1007/s00586-009-1110-x
   Kumar VGR, 1999, NEUROSURGERY, V44, P771, DOI 10.1097/00006123-199904000-00046
   Laratta JL, 2018, SPINE, V43, pE531, DOI 10.1097/BRS.0000000000002416
   Lazennec JY, 1998, UNFALLCHIRURG, V101, P353, DOI 10.1007/s001130050280
   Mayer M, 2015, EUR SPINE J, V24, pS168, DOI 10.1007/s00586-013-2838-x
   MONTALVO BM, 1986, NEURORADIOLOGY, V28, P551, DOI 10.1007/BF00344106
   Nishimura Y, 2014, J NEUROSURG-SPINE, V21, P568, DOI 10.3171/2014.6.SPINE13682
   RAYMOND CA, 1986, JAMA-J AM MED ASSOC, V255, P2258, DOI 10.1001/jama.255.17.2258
   RUBIN JM, 1985, RADIOLOGY, V155, P197, DOI 10.1148/radiology.155.1.3883416
   Seichi A, 2010, J NEUROSURG-SPINE, V13, P47, DOI 10.3171/2010.3.SPINE09680
   Vasudeva VS, 2017, GLOB SPINE J, V7, P648, DOI 10.1177/2192568217700100
   Wilson JR, 2017, NEUROSURGERY, V80, pS33, DOI 10.1093/neuros/nyw083
NR 19
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 62
EP 70
DI 10.1016/j.wneu.2018.09.217
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000131
PM 30312813
DA 2020-05-12
ER

PT J
AU Ravindra, VM
   Gozal, YM
   Palmer, C
   Couldwell, WT
AF Ravindra, Vijay M.
   Gozal, Yair M.
   Palmer, Cheryl
   Couldwell, William T.
TI Hemorrhagic Atypical Planum Sphenoidale Meningioma with Intermittent
   Vision Loss-Rare Presentation of Apoplexy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoplexy; Hemorrhage; Meningioma; Planum sphenoidale; Vision loss
ID MIMICKING PITUITARY APOPLEXY; MICROSURGICAL ANATOMY; WING MENINGIOMAS;
   SELLAR; TUMORS
AB BACKGROUND: Symptoms that mimic pituitary apoplexy may be encountered with other neoplastic or infectious lesions.
   CASE DESCRIPTION: This 38-year-old man presented with severe sudden-onset headache and relapsing and remitting vision loss. Radiographic imaging studies demonstrated radiographic features of a hyperdense, hemorrhagic mass in the sellar region. Magnetic resonance imaging (MRI) revealed a 4-cm mass abutting the optic chiasm and compressing the pituitary. After 4-week follow-up, surveillance MRI demonstrated near-complete resolution of the previously identified planum sphenoidale and suprasellar mass. The patient re-presented 13 months later with recurrent symptoms. MRI demonstrated recurrence of the mass. Given the broad differential diagnosis, an endoscopic endonasal biopsy was obtained; the findings were suggestive of a high-grade meningioma. The patient underwent elective resection of the extraaxial lesion via a frontotemporal approach. The lesion was identified as a hemorrhagic suprasellar atypical planum sphenoidale meningioma. Postoperatively, the patient's headaches improved significantly and his right-sided visual changes resolved. After adjuvant radiotherapy (5400 cGy in 30 fractions) to the surgical cavity 3 months later, at last follow-up 5 months postoperatively, the patient was at his neurologic baseline and denied any headaches or visual sequelae.
   CONCLUSIONS: As the most common benign intracranial tumors, meningiomas should remain in the differential for patients presenting with apoplectiform symptoms.
C1 [Ravindra, Vijay M.; Gozal, Yair M.; Couldwell, William T.] Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
   [Palmer, Cheryl] Univ Utah, Dept Pathol, Salt Lake City, UT USA.
   [Ravindra, Vijay M.] Texas Childrens Hosp, Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Gozal, Yair M.] Mayfield Clin, Cincinnati, OH USA.
RP Couldwell, WT (reprint author), Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
EM neuropub@hsc.utah.edu
CR Abele TA, 2012, CLIN RADIOL, V67, P821, DOI 10.1016/j.crad.2012.01.001
   Arunkumar MJ, 2001, NEUROL INDIA, V49, P407
   Avninder S, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-3
   BERGLAND R, 1969, J NEUROSURG, V31, P327, DOI 10.3171/jns.1969.31.3.0327
   BLANKENSTEIN MA, 1989, J STEROID BIOCHEM, V34, P419, DOI 10.1016/0022-4731(89)90119-2
   Bleibtreu L, 1905, MUNCHENER MEDIZINISC, V52, P2079
   BODSCH W, 1987, J NEUROSURG, V67, P250, DOI 10.3171/jns.1987.67.2.0250
   BROUGHAM M, 1950, J NEUROSURG, V7, P421, DOI 10.3171/jns.1950.7.5.0421
   Dietrich Jorg, 2011, Expert Rev Clin Pharmacol, V4, P233, DOI 10.1586/ecp.11.1
   EL-BANHAWY A, 1962, Acta Neurochir (Wien), V10, P194, DOI 10.1007/BF01406544
   GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560
   GORAN A, 1965, ARCH NEUROL-CHICAGO, V13, P65, DOI 10.1001/archneur.1965.00470010069009
   HELLE TL, 1980, J NEUROL NEUROSUR PS, V43, P725, DOI 10.1136/jnnp.43.8.725
   HORSTER A, 1961, Dtsch Z Nervenheilkd, V182, P288
   Huang Benjamin Y, 2005, Top Magn Reson Imaging, V16, P289, DOI 10.1097/01.rmr.0000224685.83629.18
   Khor WB, 2009, NEURO-OPHTHALMOLOGY, V33, P73, DOI 10.1080/01658100902717082
   Kudo H, 1997, SURG NEUROL, V48, P374, DOI 10.1016/S0090-3019(97)00003-7
   Kwancharoen R, 2014, PITUITARY, V17, P342, DOI 10.1007/s11102-013-0507-z
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2007, WHO CLASSIFICATION T
   MARANO SR, 1984, NEUROSURGERY, V15, P859, DOI 10.1227/00006123-198412000-00016
   MUTLU N, 1963, ARCH NEUROL-CHICAGO, V8, P644, DOI 10.1001/archneur.1963.00460060074008
   Orakdogen M, 2004, ACTA NEUROCHIR, V146, P511, DOI 10.1007/s00701-004-0239-y
   PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259
   Roser F, 2005, SURG NEUROL, V64, P37, DOI 10.1016/j.surneu.2004.08.092
   SAUTNER D, 1993, EXP CLIN ENDOCRINOL, V101, P283, DOI 10.1055/s-0029-1211245
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sughrue ME, 2013, J NEUROSURG, V119, P86, DOI 10.3171/2012.12.JNS11539
   YU ZY, 1981, J NEUROSURG, V55, P757, DOI 10.3171/jns.1981.55.5.0757
   Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006
   Zhou PZ, 2016, ONCOL LETT, V11, P1073, DOI 10.3892/ol.2015.4027
   ZIMMERMAN HM, 1949, NEW YORK STATE J MED, V49, P2153
   Zulch KJ, 1957, BRAIN TUMORS THEIR B
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 71
EP 76
DI 10.1016/j.wneu.2018.09.200
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000132
PM 30292661
DA 2020-05-12
ER

PT J
AU Park, H
   Nakagawa, I
   Yokoyama, S
   Wada, T
   Motoyama, Y
   Kichikawa, K
   Nakase, H
AF Park, Hunsoo
   Nakagawa, Ichiro
   Yokoyama, Shohei
   Wada, Takeshi
   Motoyama, Yasushi
   Kichikawa, Kimihiko
   Nakase, Hiroyuki
TI Central Retinal Artery Thromboembolism without Ophthalmic Artery
   Occlusion During Stent-Assisted Coil Embolization of Ophthalmic Artery
   Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blindness; Embolic complication; Ophthalmic aneurysm; Retinal infarct
ID ENDOVASCULAR TREATMENT; INTRACRANIAL ANEURYSMS; PARACLINOID ANEURYSMS;
   VISUAL OUTCOMES; EXPERIENCE; COMPLICATIONS; VISION
AB BACKGROUND: Recent reports have described that endovascular treatment of coil embolization of opththalmic artery (OphA) aneurysms has a relative risk of visual disruption caused by thromboembolic infarction of the central retinal artery (CRA), especially the OphA when it originates within the body of the aneurysm. Patent microthrombus in the OphA might also cause retinal infarction that affects visual acuity. We describe stent-assisted coil embolization of an OphA aneurysm complicated with a severe visual disturbance, although normal flow was scrupulously maintained in the OphA during the procedure. The visual disturbance was recovered by early treatment.
   CASE DESCRIPTION: A 40-year-old woman who presented with an intracranial aneurysm arising from the right OphA underwent stent-assisted coil embolization under general anesthesia. Although the area around the origin of the OphA was intentionally avoided and anterograde flow in the OphA was monitored by repeated angiography during this procedure, sight in the right eye was lost immediately thereafter. The immediate application of ocular massage and intraarterial fibrinolysis improved vision in the right eye to essentially normal status after discharge.
   CONCLUSIONS: Despite good anterograde flow in the OphA during aneurysm embolization, the procedural risk of a visual disturbance due to thromboembolic complications of CRA occlusion cannot be avoided. Anterograde flow in the OphA and retinochoroidal blush should be monitored by repeated angiography during coil embolization to prevent vision loss. Should vision be lost, a rapid response including ocular massage and intraarterial fibrinolysis is required for recovery.
C1 [Park, Hunsoo; Nakagawa, Ichiro; Yokoyama, Shohei; Motoyama, Yasushi; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Narashino, Chiba, Japan.
   [Wada, Takeshi; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Narashino, Chiba, Japan.
RP Nakagawa, I (reprint author), Nara Med Univ, Dept Neurosurg, Narashino, Chiba, Japan.
EM memepakusan@hotmail.com
CR Ahn JH, 2014, AM J NEURORADIOL, V35, P2146, DOI 10.3174/ajnr.A3999
   Arnold M, 2005, J NEUROL NEUROSUR PS, V76, P196, DOI 10.1136/jnnp.2004.037135
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Castillo B, 2000, ARCH OPHTHALMOL-CHIC, V118, P851
   Cugati S, 2013, CURR TREAT OPTION NE, V15, P63, DOI 10.1007/s11940-012-0202-9
   Drake CG, 1968, J NEUROSURG, V34, P544
   Durst CR, 2014, AM J NEURORADIOL, V35, P2140, DOI 10.3174/ajnr.A4032
   Duxbury Oliver, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-207943
   Elkordy Alaa Mohammed, 2016, NMC Case Rep J, V3, P71, DOI 10.2176/nmccrj.cr.2015-0243
   Ferrell AS, 2012, WORLD NEUROSURG, V78, P289, DOI 10.1016/j.wneu.2011.12.003
   Fulkerson DH, 2009, NEUROSURGERY, V64, P218, DOI 10.1227/01.NEU.0000337127.73667.80
   Heller RS, 2014, J NEUROSURG, V121, P18, DOI 10.3171/2014.3.JNS131493
   Hoh BL, 2001, NEUROSURGERY, V48, P78, DOI 10.1097/00006123-200101000-00014
   Kikuta Ken-Ichiro, 2016, Acta Neurochir Suppl, V123, P41, DOI 10.1007/978-3-319-29887-0_6
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321
   Park HK, 2003, NEUROSURGERY, V53, P14, DOI 10.1227/01.NEU.0000068789.08955.1C
   Rouchaud A, 2015, AM J NEURORADIOL, V36, P330, DOI 10.3174/ajnr.A4129
   Schmidt GW, 2007, AM J NEURORADIOL, V28, P1882, DOI 10.3174/ajnr.A0690
   Sherif C, 2009, J NEUROL NEUROSUR PS, V80, P1261, DOI 10.1136/jnnp.2008.170860
   Shimizu T, 2015, ACTA NEUROCHIR, V157, P13, DOI 10.1007/s00701-014-2251-1
   Silva MA, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1718
   Touze R, 2018, J NEUROINTERV SURG, V0, P1
   Turner RD, 2008, NEUROSURGERY, V63, P469, DOI 10.1227/01.NEU.0000324730.37144.4B
   Yadla S, 2011, NEUROSURGERY, V68, P1434, DOI 10.1227/NEU.0b013e31820b4f85
NR 25
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 77
EP 82
DI 10.1016/j.wneu.2018.09.184
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000133
PM 30292035
DA 2020-05-12
ER

PT J
AU Ohshima, T
   Miyachi, S
   Isaji, T
   Matsuo, N
   Kawaguchi, R
   Takayasu, M
AF Ohshima, Tomotaka
   Miyachi, Shigeru
   Isaji, Taiki
   Matsuo, Naoki
   Kawaguchi, Reo
   Takayasu, Masakazu
TI Bilateral Vertebral Artery Dissection and Unilateral Carotid Artery
   Dissection in Case of Ehlers-Danlos Syndrome Type IV
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery dissection; Ehlers-Danlos syndrome; Endovascular
   treatment; Vertebral artery dissection
ID SPECTRUM
AB BACKGROUND: Ehlers-Danlos syndrome (EDS) is a rare genetic connective tissue disorders, but the vascular type (type IV) typically poses the greatest risk to patients. We report a case of multiple cranial artery dissection, which was successfully treated with carotid artery stenting.
   CASE DESCRIPTION: A 50-year-old woman presented with recurrent severe headaches caused by bilateral vertebral artery dissections that were treated conservatively at our hospital. However, she developed right cervical pain and dizziness at 3 days after admission, and a magnetic resonance angiogram revealed dissection of the right internal carotid artery. Because the dissected portion of the artery had narrowed, a stent was placed. The pearl and string formations in the bilateral vertebral arteries then improved spontaneously. Subsequently, the patient was diagnosed with EDS type IV via a skin biopsy, and review of her family history revealed that multiple family members had suffered from subarachnoid hemorrhages. No neurologic deficits were observed, and the patient was discharged without further events at 30 days after admission.
   CONCLUSIONS: It is extremely rare for multiple artery dissections to occur at the same time. EDS type IV should be considered as an important differential diagnosis in similar cases, even in adult patients without a known history of connective tissue disease or vascular complications.
C1 [Ohshima, Tomotaka; Miyachi, Shigeru] Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
   [Isaji, Taiki; Matsuo, Naoki; Kawaguchi, Reo; Takayasu, Masakazu] Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
RP Ohshima, T (reprint author), Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
EM tmtkoh@gmail.com
CR Abe A, 2016, J STROKE CEREBROVASC, V25, pE114, DOI 10.1016/j.jstrokecerebrovasdis.2016.04.027
   Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O
   Bergqvist D, 2013, ANN SURG, V258, P257, DOI 10.1097/SLA.0b013e31829c7a59
   Bobrie G, 1998, NEPHROL DIAL TRANSPL, V13, P2138, DOI 10.1093/ndt/13.8.2138
   Brooke BS, 2010, J VASC SURG, V51, P131, DOI 10.1016/j.jvs.2009.08.019
   Dohle C, 2012, J NEUROL SCI, V318, P168, DOI 10.1016/j.jns.2012.04.005
   Fuentes K, 2007, CEREBROVASC DIS, V24, P543, DOI 10.1159/000111221
   Gallerini S, 2006, NEUROL SCI, V27, P291, DOI 10.1007/s10072-006-0688-6
   Hassan AE, 2013, J STROKE CEREBROVASC, V22, P42, DOI 10.1016/j.jstrokecerebrovasdis.2011.06.004
   JENNETT B, 1975, LANCET, V1, P480
   Kato Y, 2017, J STROKE CEREBROVASC, V26, pE43, DOI 10.1016/j.jstrokecerebrovasdis.2016.12.012
   Kolukisa M, 2017, CASE REP NEUROL MED, DOI 10.1155/2017/8520961
   Lee VH, 2006, NEUROLOGY, V67, P1809, DOI 10.1212/01.wnl.0000244486.30455.71
   Oderich GS, 2005, J VASC SURG, V42, P98, DOI 10.1016/j.jvs.2005.03.053
   Otawara Y, 2002, NEUROSURGERY, V50, P1372
   Pezzini A, 2002, EUR NEUROL, V47, P201, DOI 10.1159/000057899
   Pope FM, 1996, BRIT J DERMATOL, V135, P163, DOI 10.1046/j.1365-2133.1996.d01-971.x
   Vanacker P, 2009, CEREBROVASC DIS, V27, P309, DOI 10.1159/000201559
NR 18
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 83
EP 87
DI 10.1016/j.wneu.2018.09.236
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000134
PM 30315974
DA 2020-05-12
ER

PT J
AU Busch, CM
   Prickett, JT
   Stein, R
   Cuoco, JA
   Marvin, EA
   Witcher, MR
AF Busch, Christopher M.
   Prickett, Joshua T.
   Stein, Rachel
   Cuoco, Joshua A.
   Marvin, Eric A.
   Witcher, Mark R.
TI Meckel Cave Epidermoid Cyst Presenting as Multiple Cranial Nerve
   Deficits Due to Indirect Tumoral Compression of the Cavernous Sinus: A
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous sinus; Cholesteatoma; Epidermoid cyst; Meckel cave; Skull
   base; Trigeminal neuralgia
ID TRIGEMINAL NEURALGIA; OCULOMOTOR NERVE; PTOSIS; PALSY; CT
AB BACKGROUND: Epidermoid cysts in Meckel cave are exceedingly rare. Since 1971, only 17 cases have been reported in the literature, with most patients presenting with trigeminal hypesthesia. However, outgrowth of these lesions from Meckel cave can rarely lead to compression of the proximate cavernous sinus and the neurovascular structures contained within. To date, 2 cases have reported a Meckel cave epidermoid cyst presenting clinically as an intracavernous cranial nerve palsy, presumably a clinical manifestation of cavernous sinus compression from the lesion.
   CASE DESCRIPTION: We describe a case involving a 51-year-old woman presenting with unilateral refractory trigeminal neuralgia, facial hypesthesia, abducens palsy, plus new-onset partial ptosis. Magnetic resonance imaging revealed a mass in the left Meckel cave that was T1 hypointense, T2 hyperintense, peripherally enhancing, and restricting diffusion. A stereotactic left subtemporal extradural approach was used to resect the lesion, which alleviated most of the patient's symptomatology except for minimal intermittent left-sided facial hypesthesia that remained at her 1-year postoperative visit.
   CONCLUSIONS: This is a unique report depicting an epidermoid cyst in the Meckel cave causing numerous cranial nerve deficits because of indirect tumoral compression of cranial nerves within the cavernous sinus.
C1 [Busch, Christopher M.; Prickett, Joshua T.; Marvin, Eric A.; Witcher, Mark R.] Caril Clin, Sect Neurosurg, Roanoke, VA 24014 USA.
   [Busch, Christopher M.; Prickett, Joshua T.; Marvin, Eric A.; Witcher, Mark R.] Virginia Tech, Caril Sch Med, Roanoke, VA 24016 USA.
   [Busch, Christopher M.; Prickett, Joshua T.; Marvin, Eric A.; Witcher, Mark R.] Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.
   [Busch, Christopher M.; Prickett, Joshua T.; Stein, Rachel; Marvin, Eric A.] Edward Via Coll Osteopath Med, Blacksburg, VA USA.
   [Cuoco, Joshua A.] New York Inst Technol, Coll Osteopath Med, New York, NY USA.
RP Witcher, MR (reprint author), Caril Clin, Sect Neurosurg, Roanoke, VA 24014 USA.; Witcher, MR (reprint author), Virginia Tech, Caril Sch Med, Roanoke, VA 24016 USA.; Witcher, MR (reprint author), Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.
EM mrwitcher@carilionclinic.org
CR Arai A, 2010, NEUROL MED-CHIR, V50, P701, DOI 10.2176/nmc.50.701
   Arslan M, 2012, TURK NEUROSURG, V22, P317, DOI 10.5137/1019-5149.JTN.5213-11.1
   BECK DW, 1987, J NEUROSURG, V67, P684, DOI 10.3171/jns.1987.67.5.0684
   BERGER MS, 1985, J NEUROSURG, V62, P214, DOI 10.3171/jns.1985.62.2.0214
   CANTU RC, 1968, J NEUROL NEUROSUR PS, V31, P73, DOI 10.1136/jnnp.31.1.73
   Chowdhury Forhad Hossain, 2013, Asian J Neurosurg, V8, P21, DOI 10.4103/1793-5482.110276
   CHUI M, 1985, NEURORADIOLOGY, V27, P403, DOI 10.1007/BF00327603
   Fukushima Y, 2014, NEUROL MED-CHIR, V54, P214, DOI 10.2176/nmc.cr2012-0383
   Furtada SV, 2009, SKULL BASE-INTERD AP, V19, P353, DOI 10.1055/s-0029-1220201
   GOOD EF, 1990, J CLIN NEURO-OPHTHAL, V10, P59
   Hu YY, 2017, INTERDISCIP NEUROSUR, V8, P78, DOI 10.1016/j.inat.2016.01.005
   Kanzara T, 2014, CASE REP OTOLARYNGOL, DOI 10.1155/2014/184230
   KAPILA A, 1984, J COMPUT ASSIST TOMO, V8, P1172, DOI 10.1097/00004728-198412000-00027
   Lan Q, 2014, INDIAN J NEUROSURG, V3, P50, DOI 10.4103/2277-9167.132008
   MEHTA DS, 1971, J NEUROSURG, V34, P572, DOI 10.3171/jns.1971.34.4.0572
   Miyasaka Y, 1976, No Shinkei Geka, V4, P483
   MIYAZAWA N, 1989, NEUROSURGERY, V25, P951, DOI 10.1227/00006123-198912000-00016
   Nadkarni T, 2000, NEUROL MED-CHIR, V40, P74, DOI 10.2176/nmc.40.74
   Ohta H, 1997, NEUROL SURG TOKYO, V25, P943
   Pampliega-Perez A, 2003, REV NEUROLOGIA, V37, P221, DOI 10.33588/rn.3703.2003114
   Podeur P, 2015, Rev Laryngol Otol Rhinol (Bord), V136, P159
   Sabanci PA, 2011, WORLD NEUROSURG, V76, P335, DOI 10.1016/j.wneu.2011.03.037
   Samii M, 1996, J NEUROSURG, V84, P14, DOI 10.3171/jns.1996.84.1.0014
   Sun DQ, 2018, OTOL NEUROTOL, V39, P82, DOI 10.1097/MAO.0000000000001602
   Tsuda H, 2006, INTERNAL MED, V45, P851, DOI 10.2169/internalmedicine.45.1598
   YUH WTC, 1988, AM J ROENTGENOL, V151, P577, DOI 10.2214/ajr.151.3.577
NR 26
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 88
EP 94
DI 10.1016/j.wneu.2018.09.206
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000135
PM 30308341
DA 2020-05-12
ER

PT J
AU Gupta, VK
   Seth, A
AF Gupta, Vipin Kumar
   Seth, Abhinav
TI "Swirl Sign" in Extradural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extradural hematoma; Head trauma; Swirl sign
AB "Swirl sign" is a relatively uncommon sign, seen on noncontrast CT scan in patients of head trauma who develop extradural hematoma. It has 2 components: hyperacute, which represents ongoing active intracranial bleed, and acute, which comprises surrounding hyperattenuated clotted blood. The importance of early identification of this sign by surgeons and aggressive surgical management might have a bearing on the prognosis and survival of the patients, as emphasized here by 2 clinical scenarios. The clinical implication is that identification of the swirl sign suggests expanding extradural hematoma with ongoing active bleed, warranting aggressive surgical management.
C1 [Gupta, Vipin Kumar; Seth, Abhinav] Govt Med Coll & Hosp, Sector 32, Chandigarh, India.
   [Gupta, Vipin Kumar] Govt Med Coll & Hosp, Dept Neurosurg, Sector 32, Chandigarh 160032, India.
   [Seth, Abhinav] Postgrad Inst Med Educ & Res, Dept Renal Transplant Surg, Sector 12, Chandigarh 160012, India.
RP Seth, A (reprint author), Govt Med Coll & Hosp, Sector 32, Chandigarh, India.; Seth, A (reprint author), Postgrad Inst Med Educ & Res, Dept Renal Transplant Surg, Sector 12, Chandigarh 160012, India.
EM drabhinavseth@gmail.com
CR Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433
   GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008
   Guo C, 2017, NEUROL SCI, V38, P2111, DOI 10.1007/s10072-017-3121-4
   NEW PFJ, 1976, RADIOLOGY, V121, P635, DOI 10.1148/121.3.635
   ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 95
EP 96
DI 10.1016/j.wneu.2018.10.010
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000136
PM 30315986
DA 2020-05-12
ER

PT J
AU Parr, M
   Carminucci, A
   Al-Mufti, F
   Roychowdhury, S
   Gupta, G
AF Parr, Matthew
   Carminucci, Arthur
   Al-Mufti, Fawaz
   Roychowdhury, Sudipta
   Gupta, Gaurav
TI Isolated Abducens Nerve Palsy Associated with Ruptured Posterior
   Inferior Cerebellar Artery Aneurysm: Rare Neurologic Finding
SO WORLD NEUROSURGERY
LA English
DT Article
DE CN VI palsy; PICA aneurysm; Subarachnoid hemorrhage
ID SIGN
AB BACKGROUND: Isolated abducens nerve palsy can be the presenting sign of a ruptured PICA aneurysm. Few cases have been reported in the literature. In the majority of cases, cranial nerve VI resolved following microsurgical clipping.
   CASE DESCRIPTION: Here, we report a 56-year-old female who presented with a ruptured 4 mm 3 3 mm left PICA aneurysm associated with a left abducens nerve palsy. The patient underwent endovascular coil embolization of the aneurysm and had complete resolution of her abducens nerve palsy.
   CONCLUSIONS: Here, we present the first case of an abducens nerve palsy associated with a ruptured PICA aneurysm to completely resolve following endovascular coil embolization. The direction and amount of subarachnoid hemorrhage extravasation from the ruptured aneurysm are most likely responsible for cranial nerve palsy.
C1 [Parr, Matthew; Carminucci, Arthur; Gupta, Gaurav] Rutgers, Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 07102 USA.
   [Al-Mufti, Fawaz] Rutgers, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ USA.
   [Roychowdhury, Sudipta] Rutgers, Robert Wood Johnson Med Sch, Dept Radiol, New Brunswick, NJ USA.
RP Gupta, G (reprint author), Rutgers, Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 07102 USA.
EM guptaga@rwjms.rutgers.edu
RI Gupta, Gaurav/AAL-3349-2020
OI Gupta, Gaurav/0000-0002-9442-6007
CR Bhat DI, 2011, BRIT J NEUROSURG, V25, P644, DOI 10.3109/02688697.2010.544782
   Burkhardt JK, 2018, J NEUROSURG, V128, P1830, DOI 10.3171/2017.2.JNS162951
   DAY AL, 1990, J NEUROSURG, V72, P677, DOI 10.3171/jns.1990.72.5.0677
   DUMAS S, 1982, J CLIN NEURO-OPHTHAL, V2, P55
   Guresir E, 2011, NEUROSURGERY, V68, P1527, DOI 10.1227/NEU.0b013e31820edd82
   Koskela E, 2015, WORLD NEUROSURG, V83, P362, DOI 10.1016/j.wneu.2014.04.059
   Meling TR, 2014, J NEUROL SURG REP, V75, pE230, DOI 10.1055/s-0034-1387187
   MORIOKA T, 1992, J CLIN NEURO-OPHTHAL, V12, P263
   Peluso JP, 2008, AM J NEURORADIOL, V29, P86, DOI 10.3174/ajnr.A0758
   Tan HB, 2015, NEUROSURGERY, V76, P687, DOI 10.1227/NEU.0000000000000703
   Wang TL, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1560-z
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 97
EP 99
DI 10.1016/j.wneu.2018.09.096
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000137
PM 30266698
DA 2020-05-12
ER

PT J
AU Robles, LA
   Mundis, GM
AF Robles, Luis A.
   Mundis, Greg M.
TI Retro-Odontoid Pseudotumor without Radiologic Atlantoaxial Instability:
   A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlantoaxial instability; Periodontoid mass; Retro-odontoid pseudotumor
ID PYROPHOSPHATE DIHYDRATE DEPOSITION; SPINAL-CORD COMPRESSION; FORAMEN
   MAGNUM SYNDROME; TRANSVERSE LIGAMENT; CERVICAL MYELOPATHY; CRYSTAL
   DEPOSITION; CRANIOCERVICAL JUNCTION; DISC HERNIA; MASS; DISAPPEARANCE
AB BACKGROUND: Retro-odontoid pseudotumor (RP) can be caused by several diseases, especially rheumatoid arthritis, and is usually associated with the presence of atlantoaxial instability. On the other hand, a different group of patients have been identified in whom RP is observed without radiologic findings of atlantoaxial instability. The pathophysiology, clinical characteristics, and prognosis of this latter group of patients are not well described in the literature.
   METHODS: A PubMed and Scopus search adhering to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines was performed to include studies reporting patients with RP without radiologic instability (RPWRI). The data gathered from this review were analyzed to characterize RPWRI.
   RESULTS: The search yielded 36 articles with a total of 62 patients. All studies were case reports and small case series. Different characteristics of RPWRI are described, including causes, pathophysiology, and treatment.
   CONCLUSIONS: The results of this review show that RPWRI has different causes such as hypermobility, deposition of substances, and perhaps disc herniation. Depending on the cause of RPWRI, the pathophysiologic mechanism is different. Treatment should be tailored based on the primary cause of RP and the degree of compression of the cervicomedullary junction. Different degrees of improvement are usually observed after surgical treatment in these patients regardless of the treatment used, but a higher rate of mass regression was observed in those patients in whom the atlantoaxial joint was stabilized.
C1 [Robles, Luis A.] Hospiten, Sect Neurosurg, Puerto Vallarta, Mexico.
   [Mundis, Greg M.] San Diego Ctr Spinal Disorders, La Jolla, CA USA.
RP Robles, LA (reprint author), Hospiten, Sect Neurosurg, Puerto Vallarta, Mexico.
EM larob@prodigy.net.mx
CR Assaker R, 2001, SPINE, V26, P1396, DOI 10.1097/00007632-200106150-00027
   Barbagallo GMV, 2013, EUR SPINE J, V22, pS879, DOI 10.1007/s00586-013-3004-1
   Brent Alexander, 2010, BMJ Case Rep, V2010, DOI 10.1136/bcr.04.2010.2910
   Cai CY, 2001, J SPINAL DISORD, V14, P84, DOI 10.1097/00002517-200102000-00014
   Castro-Castro J, 2014, NEUROCIRUGIA, V25, P25, DOI 10.1016/j.neucir.2013.01.001
   Chang H, 2000, SPINE, V25, P2777, DOI 10.1097/00007632-200011010-00010
   Chen TY, 1997, SPINE, V22, P920, DOI 10.1097/00007632-199704150-00017
   Chikuda H, 2009, SPINE, V34, pE110, DOI 10.1097/BRS.0b013e31818acd27
   CIRICILLO SF, 1989, J NEUROSURG, V71, P141, DOI 10.3171/jns.1989.71.1.0141
   CROCKARD HA, 1991, J NEUROL NEUROSUR PS, V54, P817, DOI 10.1136/jnnp.54.9.817
   Doita M, 2007, SKELETAL RADIOL, V36, P699, DOI 10.1007/s00256-006-0273-3
   Fenoy AJ, 2008, J NEUROSURG-SPINE, V8, P22, DOI 10.3171/SPI-08/01/022
   Fujiwara Y, 2015, J SPINAL DISORD TECH, V28, P363, DOI 10.1097/BSD.0000000000000335
   Goel A, 2004, NEUROL MED-CHIR, V44, P603, DOI 10.2176/nmc.44.603
   Goel A, 2008, J NEUROSURG-SPINE, V9, P273, DOI 10.3171/SPI/2008/9/9/273
   Grob D, 1997, SPINE, V22, P1580, DOI 10.1097/00007632-199707150-00010
   Hasegawa H, 2000, NEUROL MED-CHIR, V40, P387, DOI 10.2176/nmc.40.387
   Ishchenko A, 2015, LUPUS, V24, P760, DOI 10.1177/0961203314567752
   Jun Byung-Yoon, 2002, Spine (Phila Pa 1976), V27, pE266, DOI 10.1097/00007632-200205150-00024
   Kakutani K, 2013, EUR SPINE J, V22, P1119, DOI 10.1007/s00586-013-2681-0
   Klineberg Eric, 2014, Evid Based Spine Care J, V5, P63, DOI 10.1055/s-0034-1370897
   Kobayashi K, 2018, EUR SPINE J, V27, P3105, DOI 10.1007/s00586-018-5573-5
   Lin SH, 2006, SPINAL CORD, V44, P692, DOI 10.1038/sj.sc.3101890
   Matsumoto Tomoyuki, 2006, Spine J, V6, P228, DOI 10.1016/j.spinee.2005.08.010
   Matsuno A, 2004, NEUROSURGERY, V54, P1015, DOI 10.1227/01.NEU.0000114869.89056.BE
   Moonis G, 1999, CLIN IMAG, V23, P11, DOI 10.1016/S0899-7071(98)00093-X
   Mulleman D, 2004, EUR SPINE J, V13, P244, DOI 10.1007/s00586-003-0589-9
   Nishizawa S, 1996, NEUROSURGERY, V39, P1256, DOI 10.1097/00006123-199612000-00042
   ROSENBERG WS, 1991, J NEUROSURG, V75, P954, DOI 10.3171/jns.1991.75.6.0954
   ROUSSELIN B, 1990, ARTHRITIS RHEUM, V33, P1567, DOI 10.1002/art.1780331015
   Sanders FH, 2017, CHILD NERV SYST, V33, P1415, DOI 10.1007/s00381-017-3459-1
   Shah A, 2016, WORLD NEUROSURG, V91, P419, DOI 10.1016/j.wneu.2016.04.050
   Sono T, 2014, J SPINAL DISORD TECH, V27, pE193, DOI 10.1097/BSD.0b013e318299f4d8
   Storch MJ, 2008, EUR SPINE J, V17, pS243, DOI 10.1007/s00586-007-0508-6
   Suetsuna F, 2006, J NEUROSURG-SPINE, V5, P455, DOI 10.3171/spi.2006.5.5.455
   Takemoto M, 2016, CLIN SPINE SURG, V29, pE514
   Takeshima Yasuhiro, 2012, Eur Spine J, V21 Suppl 4, pS463, DOI 10.1007/s00586-011-2084-z
   Tanaka S, 2010, J CLIN NEUROSCI, V17, P649, DOI 10.1016/j.jocn.2009.07.116
   Taschner CA, 2016, CLIN NEURORADIOL, V26, P121, DOI 10.1007/s00062-016-0503-6
   Tominaga Hiroyuki, 2016, Spinal Cord Ser Cases, V2, P16025, DOI 10.1038/scsandc.2016.25
   Wada K, 2015, ASIAN SPINE J, V9, P699, DOI 10.4184/asj.2015.9.5.699
   Werner BC, 2013, SPINE J, V13, pE1, DOI 10.1016/j.spinee.2013.04.003
   Yamaguchi I, 2006, J NEUROSURG-SPINE, V5, P156, DOI 10.3171/spi.2006.5.2.156
   Zunkeler B, 1996, J NEUROSURG, V85, P803, DOI 10.3171/jns.1996.85.5.0803
NR 44
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 100
EP 110
DI 10.1016/j.wneu.2018.10.011
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000138
PM 30315972
DA 2020-05-12
ER

PT J
AU Perier, F
   Couffin, S
   Martin, M
   Bardon, J
   Cook, F
   Mounier, R
AF Perier, Francois
   Couffin, Severine
   Martin, Mathieu
   Bardon, Jean
   Cook, Fabrice
   Mounier, Roman
TI Multidrug-Resistant Acinetobacter baumannii Ventriculostomy-Related
   Infection, Treated by a Colistin, Tigecycline, and Intraventricular
   Fibrinolysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acinetobacter baumannii; Intraventricular fibrinolysis;
   Ventriculostomy-related infection
ID MUTANT PREVENTION CONCENTRATION; CEREBROSPINAL-FLUID; BIOFILM FORMATION;
   MENINGITIS; MANAGEMENT; METHANESULFONATE; SERUM
AB BACKGROUND: Acinetobacter baumannii meningitis and ventriculitis are difficult issues, because of the low diffusion of antibiotics in the cerebrospinal fluid and bacterial multidrug resistance. The presence of an infected intraventricular hematoma, constituting an equivalent of undrained abscess, may promote biofilm formation and failure of medical treatment.
   CASE DESCRIPTION: In this case of ventriculostomy-related infection after ventricular hemorrhage, Acinetobacter baumannii was sensitive only to colistin and tigecycline. Despite a combination therapy involving intraventricular injections of colistin, we observed clinical and bacteriologic failure. Therefore, at day 4 of antibiotic therapy, we performed intraventricular fibrinolysis, which dissolved the clot, enabling sterilization of the cerebrospinal fluid after 48 hours.
   CONCLUSION: This clinical case suggests the usefulness of intraventricular fibrinolysis to lyse the clot and optimize the action of antibiotics.
C1 [Perier, Francois; Couffin, Severine; Martin, Mathieu; Bardon, Jean; Cook, Fabrice; Mounier, Roman] Henri Mondor Univ Hosp Paris, Paris Sch Med 12, Dept Anesthesia & Surg Intens Care, Creteil, France.
RP Perier, F (reprint author), Henri Mondor Univ Hosp Paris, Paris Sch Med 12, Dept Anesthesia & Surg Intens Care, Creteil, France.
EM francoisperier@aphp.fr
CR Antachopoulos C, 2010, ANTIMICROB AGENTS CH, V54, P3985, DOI 10.1128/AAC.01799-09
   Bardbari AM, 2017, MICROB PATHOGENESIS, V108, P122, DOI 10.1016/j.micpath.2017.04.039
   Cai Y, 2012, INT J ANTIMICROB AG, V40, P477, DOI 10.1016/j.ijantimicag.2012.06.018
   Cai Y, 2010, ANTIMICROB AGENTS CH, V54, P3998, DOI 10.1128/AAC.00264-10
   Cheah SE, 2015, J ANTIMICROB CHEMOTH, V70, P3291, DOI 10.1093/jac/dkv267
   De Bonis P, 2016, EUR J NEUROL, V23, P68, DOI 10.1111/ene.12789
   Falagas ME, 2007, INT J ANTIMICROB AG, V29, P9, DOI 10.1016/j.ijantimicag.2006.08.024
   Giamarellou H, 2008, INT J ANTIMICROB AG, V32, P106, DOI 10.1016/j.ijantimicag.2008.02.013
   Gobin P, 2010, ANTIMICROB AGENTS CH, V54, P1941, DOI 10.1128/AAC.01367-09
   Imberti R, 2012, ANTIMICROB AGENTS CH, V56, P4416, DOI 10.1128/AAC.00231-12
   Karaiskos I, 2013, INT J ANTIMICROB AG, V41, P499, DOI 10.1016/j.ijantimicag.2013.02.006
   Kim BN, 2009, LANCET INFECT DIS, V9, P245, DOI 10.1016/S1473-3099(09)70055-6
   Kooli I, 2016, J GLOB ANTIMICROB RE, V5, P62, DOI 10.1016/j.jgar.2015.12.003
   Lauretti L, 2017, J NEUROSURG, V127, P370, DOI 10.3171/2016.6.JNS16352
   Lebeaux D, 2014, MICROBIOL MOL BIOL R, V78, P510, DOI 10.1128/MMBR.00013-14
   Li J, 2006, LANCET INFECT DIS, V6, P589, DOI 10.1016/S1473-3099(06)70580-1
   Longo F, 2014, NEW MICROBIOL, V37, P119
   Maltezou HC, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.09.003
   MAMELAK AN, 1995, NEUROSURGERY, V36, P76, DOI 10.1227/00006123-199501000-00010
   Markantonis SL, 2009, ANTIMICROB AGENTS CH, V53, P4907, DOI 10.1128/AAC.00345-09
   Ray L, 2010, ANN PHARMACOTHER, V44, P582, DOI 10.1345/aph.1M480
   Rodvold KA, 2006, J ANTIMICROB CHEMOTH, V58, P1221, DOI 10.1093/jac/dkl403
   Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368
   Wadi JA, 2008, ANN SAUDI MED, V27, P456
   Wu YX, 2018, J CHEMOTHERAPY, V30, P49, DOI 10.1080/1120009X.2017.1338846
   Ziaka M, 2013, ANTIMICROB AGENTS CH, V57, P1938, DOI 10.1128/AAC.01461-12
NR 26
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 111
EP 116
DI 10.1016/j.wneu.2018.09.218
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000139
PM 30312816
DA 2020-05-12
ER

PT J
AU Buchanan, IA
   Ravina, K
   Strickland, B
   Fredrickson, V
   She, R
   Mathew, A
   Rennert, R
   Russin, JJ
AF Buchanan, Ian A.
   Ravina, Kristine
   Strickland, Ben
   Fredrickson, Vance
   She, Rosemary
   Mathew, Anna
   Rennert, Robert
   Russin, Jonathan J.
TI Multiple Intracranial Aneurysms from Coccidioidal Meningitis: Case
   Report Featuring Aneurysm Formation and Spontaneous Thrombosis with
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral aneurysm; Coccidioidal meningitis; Coccidioidomycosis; Mycotic
   aneurysm; Subarachnoid hemorrhage
ID VASCULITIS
AB BACKGROUND: Coccidioidal meningitis can progress to vasculitis with aneurysm formation. Although aneurysmogenesis is rare, it carries exceptionally high mortality. Except in one instance, prior case reports have documented universally fatal consequences.
   CASE DESCRIPTION: A 26-year-old man developed disseminated coccidioidomycosis with formation of multiple aneurysms throughout the anterior intracranial vasculature bilaterally. This report is unique in that it chronicles the formation and subsequent spontaneous thrombosis of several aneurysms over a 4-week period. In total 10 aneurysms were documented in the same patient-the highest reported to date. The patient was eventually discharged from the hospital for what has heretofore been a universally fatal disease process. Neurologic examination and vascular imaging 1 month after discharge demonstrated stable findings.
   CONCLUSIONS: Coccidioidal aneurysms carry a high mortality. The mainstay of therapy remains lifelong triazole antifungal therapy with the addition of liposomal amphotericin in cases of treatment failure. Steroid use is controversial but should be considered whenever there is vascular involvement. Although watchful waiting is reasonable in light of the possibility of spontaneous thrombosis with medical management, dynamic changes in aneurysm size or configuration should prompt timely endovascular or operative interventions.
C1 [Buchanan, Ian A.; Ravina, Kristine; Strickland, Ben; Fredrickson, Vance; Russin, Jonathan J.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
   [She, Rosemary; Mathew, Anna] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Rennert, Robert] Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA.
RP Buchanan, IA (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
EM ianbuchanan07@gmail.com
OI Ravina, Kristine/0000-0002-0927-5719
CR Ampel NM, 2009, CLIN CHEST MED, V30, P241, DOI 10.1016/j.ccm.2009.02.004
   Arsura EL, 2005, CLIN INFECT DIS, V40, P624, DOI 10.1086/427215
   Brown Jennifer, 2013, Clin Epidemiol, V5, P185, DOI 10.2147/CLEP.S34434
   CARVALHO CAD, 1980, HUM PATHOL, V11, P293, DOI 10.1016/S0046-8177(80)80013-X
   Ducruet AF, 2010, NEUROSURG REV, V33, P37, DOI 10.1007/s10143-009-0233-1
   Erly WK, 1999, AM J NEURORADIOL, V20, P1605
   Fusco DJ, 2013, WORLD NEUROSURG, V79
   Galgiani JN, 2005, CLIN INFECT DIS, V41, P1217, DOI 10.1086/496991
   HADLEY MN, 1987, J NEUROSURG, V66, P453, DOI 10.3171/jns.1987.66.3.0453
   Johnson RH, 2006, CLIN INFECT DIS, V42, P103, DOI 10.1086/497596
   KOBAYASHI RM, 1977, ANN NEUROL, V1, P281, DOI 10.1002/ana.410010315
   MISCHEL PS, 1995, CLIN INFECT DIS, V20, P400, DOI 10.1093/clinids/20.2.400
   Romeo JH, 2000, NEUROSURGERY, V47, P773, DOI 10.1097/00006123-200009000-00051
   Stockamp NW, 2016, INFECT DIS CLIN N AM, V30, P229, DOI 10.1016/j.idc.2015.10.008
   Thompson GR, 2017, CLIN INFECT DIS, V65, P338, DOI 10.1093/cid/cix318
   VINCENT T, 1993, CLIN INFECT DIS, V16, P247, DOI 10.1093/clind/16.2.247
   Williams PL, 2007, ANN NY ACAD SCI, V1111, P377, DOI 10.1196/annals.1406.037
NR 17
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 117
EP 123
DI 10.1016/j.wneu.2018.08.220
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000140
PM 30201579
DA 2020-05-12
ER

PT J
AU Teles, AR
   Montgomery, S
   Thomas, KC
AF Teles, Alisson R.
   Montgomery, Spencer
   Thomas, Kenneth C.
TI Necrotizing Fasciitis Involving Spine: Unusual Medical Emergency for
   Spine Surgeon
SO WORLD NEUROSURGERY
LA English
DT Article
DE Klebsiella pneumoniae; Necrotizing fasciitis; Sepsis; Spinal column;
   Spine
ID MANAGEMENT; DIAGNOSIS
AB BACKGROUND: Necrotizing fasciitis (NF) is a surgical diagnosis characterized by a rapidly progressive soft tissue infection, widespread tissue necrosis, and associated systemic illness. Friability of the superficial fascia, dishwatergray exudate, and absence of pus are surgical characteristics of this diagnosis. Due to rapid progression of the infection, early recognition and aggressive surgical debridement are crucial to reduce mortality. Despite being commonly seen by general, plastic, and orthopedic surgeons, NF is an extremely rare spine surgery emergency. Our objective is to report on a case of NF involving the spine and highlight this unusual surgical emergency for the spine surgeon.
   CASE DESCRIPTION: We present a rare case of a 61-year-old woman who presented to the emergency department in septic shock. She had a 1-week history of increasing back pain before presenting to us. Computed tomography revealed extensive soft tissue emphysema with involvement of the L3 vertebral body and spina canal. She underwent emergency surgical debridement. Despite maximal medical and surgical therapies, the patient died secondary to multisystem organ failure within 36 hours of initial presentation.
   CONCLUSIONS: To the best of our knowledge, the literature presents only 1 previous case reported involving the spine. Necrotizing fasciitis is an unusual surgical spine surgery emergency. Spine surgeons should be aware of this diagnosis in order to provide timely aggressive surgical debridement.
C1 [Teles, Alisson R.] McGill Univ, McGill Scoliosis & Spine Grp, Montreal, PQ, Canada.
   [Montgomery, Spencer; Thomas, Kenneth C.] Univ Calgary, Dept Surg, Sect Orthoped Surg, Calgary, AB, Canada.
RP Teles, AR (reprint author), McGill Univ, McGill Scoliosis & Spine Grp, Montreal, PQ, Canada.
EM alisson.r.teles@gmail.com
CR Bonne SL, 2017, INFECT DIS CLIN N AM, V31, P497, DOI 10.1016/j.idc.2017.05.011
   Bucca K, 2013, ANZ J SURG, V83, P365, DOI 10.1111/j.1445-2197.2012.06251.x
   Cheng NC, 2012, CLIN INFECT DIS, V55, P930, DOI 10.1093/cid/cis565
   Factor SH, 2003, EMERG INFECT DIS, V9, P970
   Hadeed George J, 2016, J Emerg Trauma Shock, V9, P22, DOI 10.4103/0974-2700.173868
   Jabbour G, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0097-y
   Olsen RJ, 2010, ANNU REV PATHOL-MECH, V5, P1, DOI 10.1146/annurev-pathol-121808-102135
   Sartelli M, 2014, WORLD J EMERG SURG, V9, DOI 10.1186/1749-7922-9-57
   Spock CR, 2006, SPINE, V31, pE342, DOI 10.1097/01.brs.0000217631.73632.37
   Stevens DL, 2017, NEW ENGL J MED, V377, P2253, DOI 10.1056/NEJMra1600673
   Stevens DL, 2005, CLIN INFECT DIS, V41, P1373, DOI 10.1086/497143
   van Stigt SFL, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0080-7
   Wall DB, 2000, AM J SURG, V179, P17, DOI 10.1016/S0002-9610(99)00259-7
NR 13
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 124
EP 126
DI 10.1016/j.wneu.2018.10.031
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000141
PM 30321674
DA 2020-05-12
ER

PT J
AU Kim, M
   Rybkin, I
   Smith, H
   Cooper, J
   Tobias, M
AF Kim, Michael
   Rybkin, Ilya
   Smith, Harrison
   Cooper, Jared
   Tobias, Michael
TI Bone Overgrowth Causing Proximal Ventriculoperitoneal Shunt Malfunction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Ventriculoperitoneal shunt; Ventriculoperitoneal shunt
   malfunction
ID PEDIATRIC HYDROCEPHALUS; KNOT FORMATION; REVISION RATE; CATHETER;
   CHILDREN
AB BACKGROUND: Hydrocephalus is an international disease process that is commonly treated surgically with a ventriculoperitoneal shunt. This device may be prone to malfunction, most commonly from obstruction, disconnection, or infection.
   CASE DESCRIPTION: A 35-year-old female with hydrocephalus and a ventriculoperitoneal shunt presented with altered mental status and imaging concerning for a shunt malfunction. Intraoperatively, she was found to have bone growing over and compressing the proximal occluder of the shunt valve, causing a mechanical obstruction. Removal of the bone allowed for egress of cerebrospinal fluid and return of proper shunt function. The patient did well postoperatively.
   CONCLUSION: Hydrocephalus, ventriculoperitoneal shunts, and shunt revisions represent a significant health burden and cost. Here we present an unusual cause of a shunt malfunction caused by bony overgrowth.
C1 [Kim, Michael; Cooper, Jared; Tobias, Michael] Westchester Med Ctr, Dept Neurosurg, Valhalla, NY 10595 USA.
   [Rybkin, Ilya; Smith, Harrison] New York Med Coll, Valhalla, NY 10595 USA.
RP Kim, M (reprint author), Westchester Med Ctr, Dept Neurosurg, Valhalla, NY 10595 USA.
EM Michael.Kim@wmchealth.org
OI Kim, Michael/0000-0003-3798-9409
CR Dave P, 2019, NEUROSURGERY, V84, P788, DOI 10.1093/neuros/nyy263
   Eftekhar B, 2008, J NEUROS-PEDIATR, V1, P142, DOI 10.3171/PED/2008/1/2/142
   Flannery AM, 2014, J NEUROSURG-PEDIATR, V14, P3, DOI 10.3171/2014.7.PEDS14321
   Gan YC, 2006, J NEUROSURG, V105, P153, DOI 10.3171/ped.2006.105.2.153
   Ghritlaharey RK, 2016, J CLIN DIAGN RES, V10, pPE1, DOI 10.7860/JCDR/2016/23372.8920
   Grossman R, 2004, J NEUROSURG, V100, P530, DOI 10.3171/ped.2004.100.5.0530
   Hasan A, 2002, J PEDIAT NEUROSCI, V13, P8
   Joshi KC, 2015, CHILD NERV SYST, V31, P2207, DOI 10.1007/s00381-015-2791-6
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Morais BA, 2018, J NEUROSURG-PEDIATR, V22, P147, DOI 10.3171/2018.2.PEDS17574
   Powers CJ, 2006, J NEUROSURG, V105, P227, DOI 10.3171/ped.2006.105.3.227
   Riccardello GJ, 2016, J NEUROSURG-PEDIATR, V18, P325, DOI 10.3171/2016.3.PEDS15572
   Riva-Cambrin J, 2016, J NEUROSURG-PEDIATR, V17, P382, DOI 10.3171/2015.6.PEDS14670
   Sato TS, 2009, AM J NEURORADIOL, V30, P635, DOI 10.3174/ajnr.A1320
   Simon TD, 2008, J NEUROS-PEDIATR, V1, P131, DOI 10.3171/PED/2008/1/2/131
   Stone JJ, 2013, J NEUROSURG-PEDIATR, V11, P15, DOI 10.3171/2012.9.PEDS1298
   Tubbs RS, 2005, J NEUROSURG, V102, P221
   Venable GT, 2016, J NEUROSURG-PEDIATR, V18, P7, DOI 10.3171/2015.12.PEDS15388
   Woerdeman PA, 2006, J NEUROSURG, V105, P231, DOI 10.3171/ped.2006.105.3.231
   Yang X, 2019, IEEE T NEUR NET LEAR, V30, P2987, DOI 10.1109/TNNLS.2018.2861991
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 127
EP 130
DI 10.1016/j.wneu.2018.10.030
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000142
PM 30321672
DA 2020-05-12
ER

PT J
AU Ravindra, VM
   Griauzde, J
   Scoville, JP
   Kilburg, CJ
   Wilkinson, DA
   Christensen, C
   Couldwell, WT
   Taussky, P
AF Ravindra, Vijay M.
   Griauzde, Julius
   Scoville, Jonathan P.
   Kilburg, Craig J.
   Wilkinson, D. Andrew
   Christensen, Clint
   Couldwell, William T.
   Taussky, Philipp
TI Moderate Sedation for Pipeline Embolization of Posterior Circulation
   Disease: Technical Note from a Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anesthesia; Aneurysm; Flow diversion; Moderate sedation; Neurologic
   deficit; Pipeline embolization device; Posterior circulation
ID INTRACRANIAL ANEURYSMS; CENTER EXPERIENCE; DEVICE; RECONSTRUCTION;
   INTUBATION
AB OBJECTIVE: Flow diversion has been an important addition to endovascular neurosurgery, but its use in the posterior circulation remains controversial. Our goal is to describe the safety and efficacy of moderate sedation during flow diversion for posterior circulation lesions (aneurysms or dissecting pseudoaneurysms).
   METHODS: The authors retrospectively reviewed the medical records of all patients who underwent placement of a Pipeline embolization device for a posterior circulation lesion using moderate sedation at a single institution from August 2012 through November 2017. Clinical data and outcomes were evaluated.
   RESULTS: Fifteen consecutive patients were identified: 8 female, 7 male (mean age 52.2 +/- 16.3 years, range 15-81). Eleven lesions were located in the vertebral artery, 1 in the posterior inferior cerebellar artery, 2 in the posterior cerebral artery, and 1 in the basilar artery. All patients underwent flow diversion with Pipeline embolization devices. One patient experienced an acute occlusion of the basilar artery during the procedure that required revascularization. Mean fluoroscopy time was 35.6 +/- 16.5 minutes (range 15.5-75). Mean follow-up time was 12.7 +/- 8.8 months (range 3-36). No patient had new neurologic deficits in the perioperative or postoperative period. Conversion to general anesthesia was not required in any case.
   CONCLUSIONS: Moderate sedation is safe and feasible in patients undergoing flow diversion for posterior circulation lesions. In addition, its use may allow for more rapid identification of procedural complications, facilitating emergent treatment and decreasing procedure-related morbidity.
C1 [Ravindra, Vijay M.; Scoville, Jonathan P.; Kilburg, Craig J.; Couldwell, William T.; Taussky, Philipp] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA.
   [Christensen, Clint] Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT USA.
   [Griauzde, Julius; Wilkinson, D. Andrew] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Taussky, P (reprint author), Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA.
EM neuropub@hsc.utah.edu
CR Albuquerque FC, 2015, J NEUROINTERV SURG, V7, P641, DOI 10.1136/neurintsurg-2014-011340
   ASA Committee on Quality Management and Departmental Administration, CONT DEPTH SED DEF G
   ASA Standards and Practice Parameters Committee, STAND BAS AN MON APP
   Chalouhi N, 2013, NEUROSURGERY, V72, P883, DOI 10.1227/NEU.0b013e31828ba984
   Chitale R, 2012, NEUROSURGERY, V71, P679, DOI 10.1227/NEU.0b013e318260fe86
   Hassan AE, 2012, NEUROCRIT CARE, V16, P246, DOI 10.1007/s12028-011-9638-0
   Jadhav AP, 2017, JAMA NEUROL, V74, P704, DOI 10.1001/jamaneurol.2017.0192
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kiyofuji S, 2018, J NEUROINTERV SURG, V10, P500, DOI 10.1136/neurintsurg-2017-013312
   Lylyk P, 2009, NEUROSURGERY, V64, P632, DOI 10.1227/01.NEU.0000339109.98070.65
   McAuliffe W, 2012, AM J NEURORADIOL, V33, P164, DOI 10.3174/ajnr.A2727
   Munich SA, 2014, J NEUROSURG, V121, P1077, DOI 10.3171/2014.7.JNS132595
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Phillips TJ, 2012, AM J NEURORADIOL, V33, P1225, DOI 10.3174/ajnr.A3166
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Searls DE, 2012, ARCH NEUROL-CHICAGO, V69, P346, DOI 10.1001/archneurol.2011.2083
   Srinivasan VM, 2018, J NEUROINTERV SURG, V10, P666, DOI 10.1136/neurintsurg-2017-013427
   Wang MY, 2017, J NEUROSURG-SPINE, V26, P411, DOI 10.3171/2016.9.SPINE16375
   Zumofen DW, 2015, AM J NEURORADIOL, V36, P1299, DOI 10.3174/ajnr.A4261
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 131
EP 136
DI 10.1016/j.wneu.2018.09.167
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000143
PM 30273722
DA 2020-05-12
ER

PT J
AU Zanaty, M
   Samaniego, EA
   Teferi, N
   Kung, DK
   Nakagawa, D
   Hudson, J
   Ortega-Gutierrez, S
   Allan, L
   Jabbour, P
   Hasan, DM
AF Zanaty, Mario
   Samaniego, Edgar A.
   Teferi, Nahom
   Kung, David K.
   Nakagawa, Daichi
   Hudson, Joseph
   Ortega-Gutierrez, Santiago
   Allan, Lauren
   Jabbour, Pascal
   Hasan, David M.
TI Hybrid Surgery for Internal Carotid Artery Revascularization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Complete internal carotid artery occlusion; Endarterectomy;
   Endovascular; Hybrid; Stenting; Stroke; Total occlusion of carotid
   artery
ID ENDOVASCULAR RECANALIZATION; OCCLUSION; SUBACUTE; BYPASS
AB OBJECTIVE: The management of chronic complete internal carotid artery (ICA) occlusion (COICA) has been challenging. Endovascular procedures have been performed with variable success and risks, depending on the type of occlusion and distal revascularization. We present a novel hybrid procedure to recanalize the ICA when previous endovascular interventions have failed or been deemed too risky.
   METHODS: Two patients presented with symptomatic COICA after maximal medical management. They were deemed at high risk of endovascular intervention and/or previous endovascular attempts had failed. Thus, they had indications for a hybrid procedure.
   RESULTS: A hybrid technique was used to create a stump by surgical endarterectomy, followed by recanalization using an endovascular approach via femoral access. We have described the technique in detail. Postoperative computed tomography perfusion scanning showed normalization of the mean transient time, cerebral blood volume, and cerebral blood flow compared with the preoperative findings. Cerebral angiography showed successful recanalization of the ICA. Neither patient experienced any complications.
   CONCLUSION: A hybrid technique is feasible and should be considered for patients with COICA in whom maximal medical management has failed and who have a high-risk profile for endovascular intervention or in whom previous endovascular attempts have failed.
C1 [Zanaty, Mario; Samaniego, Edgar A.; Teferi, Nahom; Nakagawa, Daichi; Hudson, Joseph; Ortega-Gutierrez, Santiago; Hasan, David M.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Samaniego, Edgar A.; Ortega-Gutierrez, Santiago] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
   [Samaniego, Edgar A.; Ortega-Gutierrez, Santiago] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
   [Allan, Lauren] Univ Iowa Hosp & Clin, Dept Surg, Iowa City, IA 52242 USA.
   [Kung, David K.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Nakagawa, Daichi] Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
   [Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
RP Hasan, DM (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM david-hasan@uiowa.edu
OI Ortega-Gutierrez, Santiago/0000-0002-3408-1297; Samaniego,
   Edgar/0000-0003-2764-2268
CR BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Binning MJ, 2009, J CLIN NEUROSCI, V16, P1244, DOI 10.1016/j.jocn.2008.11.018
   Chen YH, 2016, JACC-CARDIOVASC INTE, V9, P1825, DOI 10.1016/j.jcin.2016.06.015
   Fan YL, 2014, VASC ENDOVASC SURG, V48, P305, DOI 10.1177/1538574414525863
   Galkin P, 2017, J NEUROSURG SCI, V61, P22, DOI 10.23736/S0390-5616.16.03234-3
   Hasan D, 2019, J NEUROSURG, V130, P1468, DOI 10.3171/2018.1.JNS172858
   Kanamaru K, 2011, ACTA NEUROCHIR SUPPL, V112, P55, DOI 10.1007/978-3-7091-0661-7_10
   Kao HL, 2007, J AM COLL CARDIOL, V49, P765, DOI 10.1016/j.jacc.2006.11.029
   Kim Won Ho, 2010, Korean Circ J, V40, P288, DOI 10.4070/kcj.2010.40.6.288
   Lin MS, 2011, STROKE, V42, P2850, DOI 10.1161/STROKEAHA.111.613133
   Lin MS, 2008, CIRC-CARDIOVASC INTE, V1, P119, DOI 10.1161/CIRCINTERVENTIONS.108.772350
   Namba K, 2012, INTERV NEURORADIOL, V18, P288, DOI 10.1177/159101991201800307
   Persoon S, 2011, J NEUROL NEUROSUR PS, V82, P521, DOI 10.1136/jnnp.2010.208330
   Persoon S, 2009, J NEUROL, V256, P1728, DOI 10.1007/s00415-009-5194-3
   Shih YT, 2013, NEUROSURGERY, V73, P117, DOI 10.1227/NEU.0b013e31827fca6c
   Terada T, 2010, J NEUROSURG, V112, P563, DOI 10.3171/2009.6.JNS09125
   Thomas AJ, 2007, AM J NEURORADIOL, V28, P168
   Yue XY, 2011, J THROMB THROMBOLYS, V31, P64, DOI 10.1007/s11239-010-0472-6
NR 18
TC 4
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 137
EP 144
DI 10.1016/j.wneu.2018.09.230
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000144
PM 30312821
DA 2020-05-12
ER

PT J
AU Ishihara, E
   Toda, M
   Sasao, R
   Ozawa, H
   Saito, S
   Ogawa, K
   Yoshida, K
AF Ishihara, Eriko
   Toda, Masahiro
   Sasao, Ryota
   Ozawa, Hiroyuki
   Saito, Shin
   Ogawa, Kaoru
   Yoshida, Kazunari
TI Endonasal Chiasmapexy Using Autologous Cartilage/Bone for Empty Sella
   Syndrome After Cabergoline Therapy for Prolactinoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autologous cartilage/bone; Cabergoline therapy; Empty sella syndrome;
   Endonasal chiasmapexy; Prolactinoma
ID ENDOSCOPIC TRANSSPHENOIDAL CHIASMAPEXY; DETERIORATION
AB BACKGROUND: Visual field deterioration caused by secondary empty sella after cabergoline therapy for prolactinoma is a rare event. Chiasmapexy is performed to treat empty sella syndrome. Although various materials have been used for the elevation of the optic chasm, the most appropriate material remains to be established. Here, we describe the efficiency of chiasmapexy for empty sella syndrome following dopamine agonist treatment and the utility of septal cartilage and sphenoidal sinus bone as materials for chiasmapexy.
   CASE DESCRIPTION: A 35-year-old male with a history of cabergoline therapy for prolactinoma presented with visual deterioration. His magnetic resonance imaging revealed optic chiasm herniation into the empty sella. Endoscopic endonasal transsphenoidal chiasmapexy was performed using septal cartilage and sphenoidal sinus bone as materials for elevating the chiasm. Visual function improved immediately after operation.
   CONCLUSIONS: Chiasmapexy is an effective surgical method for treating visual deterioration caused by empty sella after cabergoline treatment. Endoscopic endonasal chiasmapexy with septal cartilage and sphenoidal sinus bone is a considerable option because it is minimally invasive and involves decreased risk of infection.
C1 [Ishihara, Eriko; Toda, Masahiro; Sasao, Ryota; Yoshida, Kazunari] Keio Univ, Sch Med, Sinjuku ku, Dept Neurosurg, Tokyo, Japan.
   [Ozawa, Hiroyuki; Saito, Shin; Ogawa, Kaoru] Keio Univ, Sch Med, Sinjuku ku, Dept Otolaryngol, Tokyo, Japan.
RP Ishihara, E (reprint author), Keio Univ, Sch Med, Sinjuku ku, Dept Neurosurg, Tokyo, Japan.
EM searoad@mail.goo.ne.jp
OI Toda, Masahiro/0000-0003-2700-1620
CR Barzaghi LR, 2018, PITUITARY, V21, P98, DOI 10.1007/s11102-017-0842-6
   Berastegui GRA, 2016, J NEUROSURG, V124, P1025, DOI 10.3171/2015.2.JNS142015
   BUSCH W, 1951, Virchows Arch Pathol Anat Physiol Klin Med, V320, P437, DOI 10.1007/BF00957474
   Cobb MIPH, 2018, WORLD NEUROSURG, V112, P250, DOI 10.1016/j.wneu.2018.01.202
   Czech T, 1999, ACTA NEUROCHIR, V141, P45, DOI 10.1007/s007010050265
   Dhanwal DK, 2011, PITUITARY, V14, P384, DOI 10.1007/s11102-009-0179-x
   Gkekas N, 2013, ACTA NEUROCHIR, V155, P495, DOI 10.1007/s00701-012-1613-9
   Hamlyn P J, 1988, Br J Neurosurg, V2, P277, DOI 10.3109/02688698808992681
   HUDGINS WR, 1981, NEUROSURGERY, V8, P231
   Jones SE, 2000, CLIN ENDOCRINOL, V53, P529, DOI 10.1046/j.1365-2265.2000.01039.x
   Kubo S, 2005, NEUROL MED-CHIR, V45, P428, DOI 10.2176/nmc.45.428
   MOSTER ML, 1985, OPHTHALMOLOGY, V92, P1332
   OLSON DR, 1972, J NEUROSURG, V37, P533, DOI 10.3171/jns.1972.37.5.0533
   Raverot G, 2009, CLIN ENDOCRINOL, V70, P588, DOI 10.1111/j.1365-2265.2008.03364.x
   Tsukiyama A, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.080
   WELCH K, 1971, J NEUROSURG, V35, P760, DOI 10.3171/jns.1971.35.6.0760
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 145
EP 148
DI 10.1016/j.wneu.2018.10.012
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000145
PM 30315973
DA 2020-05-12
ER

PT J
AU Entezami, P
   Paul, A
   Adamo, MA
   Boulos, AS
AF Entezami, Pouya
   Paul, Alexandra
   Adamo, Matthew A.
   Boulos, Alan S.
TI Transient Episode of Alice in Wonderland Syndrome After Ventriculoatrial
   Shunt Revision
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alice in Wonderland; Cerebrospinal fluid (CSF); Hydrocephalus;
   Somesthetic hallucinations; Ventriculoatrial shunt; Visual
   misperceptions
ID CHILDREN
AB BACKGROUND: Visual misperceptions as a result of neurosurgical disorders are well documented. Alice in Wonderland syndrome (AWS) typically is reported in neurologic and psychiatric disorders. We present a patient who developed symptoms of AWS postoperatively.
   CASE DESCRIPTION: A 48-year-old man presented in shunt failure, attributed to a proximal catheter occlusion. Operative revision with replacement of the proximal catheter was performed without incident. Postoperatively, he complained of visual disturbances, including the perception that people had small heads on full-sized bodies. Symptoms resolved postoperatively. The patient's symptoms were diagnosed as a transient episode of AWS. This was attributed to manipulation of the parieto-occipital cortex during the revision. The local inflammatory response from manipulation of that area is thought to have caused our patient's symptoms.
   CONCLUSIONS: Visual disturbances caused by lesions along the optic radiations are common findings for neurosurgery patients, although AWS after surgical intervention has not been reported previously.
C1 [Entezami, Pouya; Paul, Alexandra; Adamo, Matthew A.; Boulos, Alan S.] Albany Med Coll, Dept Neurosurg, Albany, NY 12208 USA.
RP Entezami, P (reprint author), Albany Med Coll, Dept Neurosurg, Albany, NY 12208 USA.
EM entezap@mail.amc.edu
OI Paul, Alexandra/0000-0002-8315-5870
CR Blom JD, 2016, NEUROL-CLIN PRACT, V6, P259, DOI 10.1212/CPJ.0000000000000251
   Brumm K, 2010, J AAPOS, V14, P317, DOI 10.1016/j.jaapos.2010.03.007
   Kuo YT, 1998, PEDIATR NEUROL, V19, P105, DOI 10.1016/S0887-8994(98)00037-X
   Lahat E, 1999, J CHILD NEUROL, V14, P732, DOI 10.1177/088307389901401109
   LIPPMAN CW, 1952, J NERV MENT DIS, V116, P346, DOI 10.1097/00005053-195210000-00009
   Liu AM, 2014, PEDIATR NEUROL, V51, P317, DOI 10.1016/j.pediatrneurol.2014.04.007
   Mastria G, 2016, BIOMED RES INT, DOI 10.1155/2016/8243145
   O'Toole P, 2017, BRAIN DEV-JPN, V39, P470, DOI 10.1016/j.braindev.2017.01.004
   Perdices M, 2018, NEUROPSYCHOL REHABIL, V28, P189, DOI 10.1080/09602011.2016.1224191
   TODD J, 1955, Can Med Assoc J, V73, P701
   Weidenfeld A, 2011, CHILD NERV SYST, V27, P893, DOI 10.1007/s00381-011-1400-6
NR 11
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 149
EP 151
DI 10.1016/j.wneu.2018.10.041
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000146
PM 30326315
DA 2020-05-12
ER

PT J
AU Aronov, M
   Mokin, M
   Zelenkov, A
   Popugaev, K
   Tsarikaev, A
   Reutov, A
AF Aronov, Moisey
   Mokin, Maxim
   Zelenkov, Alexander
   Popugaev, Konstantin
   Tsarikaev, Alan
   Reutov, Andrey
TI Endovascular Coiling of Ruptured Very Small Dissecting Fusiform Aneurysm
   of Posterior Inferior Cerebellar Artery with Parent Artery Preservation
   by Microcatheter Auto-Assistance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coiling; Parent artery preservation; PICA aneurysm
ID BLISTER-LIKE ANEURYSMS; INTRACRANIAL BYPASS; CENTER EXPERIENCE;
   DIAGNOSIS
AB BACKGROUND: Aneurysmal subarachnoid hemorrhage secondary to ruptured small dissecting fusiform aneurysms of the posterior inferior cerebellar artery (PICA) is rare and particularly challenging. Different treatment strategies have been reported in these rare cases. We report 2 patients treated with a novel endovascular approach.
   CASE DESCRIPTION: Two patients presented with subarachnoid hemorrhage secondary to very small (3 mm and 4 mm) ruptured fusiform aneurysms of the proximal section of the PICA trunk. Both patients were treated by coil embolization combined with parent artery preservation by microcatheter autoassistance. Both coiling procedures were uneventful, and the patients remained asymptomatic. Long-term follow-up angiography in both patients showed complete occlusion of aneurysms with patency of PICA.
   CONCLUSIONS: There is no single treatment strategy suitable for all PICA aneurysms. Our proposed method may be best applied to small dissecting fusiform aneurysms located on a small (<= 1 mm in diameter) PICA distally to its origin.
C1 [Aronov, Moisey] State Res Ctr Burnasyan FMBC FMBA Russia, Endovasc Div, Moscow, Russia.
   [Zelenkov, Alexander] State Res Ctr Burnasyan FMBC FMBA Russia, Dept Neurosurg, Moscow, Russia.
   [Popugaev, Konstantin] State Res Ctr Burnasyan FMBC FMBA Russia, Neuro ICU, Moscow, Russia.
   [Tsarikaev, Alan; Reutov, Andrey] Business Presidential Adm President Russian Feder, FSBI CCH Outpatient Hlth Ctr, Neurosurg Dept, Moscow, Russia.
   [Mokin, Maxim] Univ S Florida, Dept Neurosurg, Tampa, FL USA.
RP Aronov, M (reprint author), State Res Ctr Burnasyan FMBC FMBA Russia, Endovasc Div, Moscow, Russia.
EM moiseyaronov@me.com
RI Aronov, Moisey/M-3916-2019
OI Aronov, Moisey/0000-0003-1216-4566; Reutov, Andrey/0000-0003-4641-2652
CR Abla AA, 2016, J NEUROSURG, V124, P1275, DOI 10.3171/2015.5.JNS15368
   ANDREWS BT, 1986, NEUROSURGERY, V18, P204, DOI 10.1227/00006123-198602000-00017
   Bonda DJ, 2017, OPER NEUROSURG, V13, P586, DOI 10.1093/ons/opx064
   Chen Z, 2014, AFR HEALTH SCI, V14, P89, DOI 10.4314/ahs.v14i1.14
   Jeon Se-Il, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P223, DOI 10.7461/jcen.2012.14.3.223
   Lim SM, 2010, AM J NEURORADIOL, V31, P1118, DOI 10.3174/ajnr.A2014
   Linfante I, 2017, J NEUROINTERV SURG, V9, P29, DOI 10.1136/neurintsurg-2016-012287
   NAKAGAWA F, 1986, J NEUROSURG, V65, P303, DOI 10.3171/jns.1986.65.3.0303
   Peitz GW, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1751
   Peschillo S, 2016, AM J NEURORADIOL, V37, P856, DOI 10.3174/ajnr.A4606
   Peschillo S, 2015, WORLD NEUROSURG, V84, P1070, DOI 10.1016/j.wneu.2015.05.077
   Peschillo S, 2015, NEUROSURG REV, V38, P197, DOI 10.1007/s10143-014-0581-3
   Rasskazoff S, 2010, INTERV NEURORADIOL, V16, P255, DOI 10.1177/159101991001600304
   Samaniego EA, 2016, J NEUROINTERV SURG, V8, P1030, DOI 10.1136/neurintsurg-2015-012070
   Srinivasan VM, 2018, J NEUROINTERV SURG, V10, P666, DOI 10.1136/neurintsurg-2017-013427
   Taylor AG, 2001, INTERV NEURORADIOL, V7, P253, DOI 10.1177/159101990100700312
   YAMAURA A, 1988, J NEUROSURG, V69, P345, DOI 10.3171/jns.1988.69.3.0345
NR 17
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 152
EP 155
DI 10.1016/j.wneu.2018.10.049
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000147
PM 30326306
DA 2020-05-12
ER

PT J
AU Chen, KY
   Osorio, J
   Rivera, J
   Chou, D
AF Chen, Kai-Yuan
   Osorio, Joseph
   Rivera, Joshua
   Chou, Dean
TI Intramedullary and Extramedullary Thoracic Spinal Lipomas Without Spinal
   Dysraphism: Clinical Presentation and Surgical Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carbon dioxide laser; Intramedullary lipoma; Surgery; Thoracic spinal
   lipoma
ID INTRADURAL LIPOMAS; CORD; DIAGNOSIS; TUMORS
AB BACKGROUND: Intradural intramedullary lipomas without dysraphism are rare tumors. Although they appear extramedullary on imaging, they invade into the intramedullary substance of the spinal cord. We present 2 cases and discuss their clinical presentation, radiologic findings, and surgical management.
   CASE DESCRIPTION: Case 1 is a 21-year-old woman who presented with upper back pain from recurrent lipoma. She had undergone partial excision in 2008 at an outside hospital. Physical examination revealed full strength but hyperreflexia in the legs. Magnetic resonance imaging (MRI) revealed a recurrent thoracic spinal tumor with spinal cord compression. Surgery was performed, and it was found that the tumor was both extramedullary and intramedullary, with an obscure delineation between tumor and cord. Subtotal excision was performed, and the patient remained neurologically intact. Case 2 is a 47-year-old woman who presented with leg weakness, difficulty in walking, and foot drop. Physical examination revealed 4/5 in the lower extremities. MRI demonstrated a spinal lipoma with thoracic cord compression. Even though the tumor appeared to be an extramedullary lesion by MRI, intraoperatively, the tumor became intramedullary with loss of distinction between the spinal cord and tumor. Subtotal excision was performed, and the patient regained her strength to 5/5 postoperatively.
   CONCLUSIONS: Intramedullary thoracic spinal lipomas without spinal dysraphism are rare. Although these tumors may appear completely extramedullary on imaging, extreme care should be taken during surgery because the lesions eventually become intramedullary, intercalating within the substance of the spinal cord, precluding gross total resection.
C1 [Chen, Kai-Yuan; Osorio, Joseph; Chou, Dean] Univ San Francisco, Dept Neurol Surg, San Francisco, CA 94117 USA.
   [Chen, Kai-Yuan] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Chen, Kai-Yuan] Taichung Vet Gen Hosp, Dept Surg, Puli Branch, Nantou, Taiwan.
   [Rivera, Joshua] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RP Chen, KY (reprint author), Univ San Francisco, Dept Neurol Surg, San Francisco, CA 94117 USA.; Chen, KY (reprint author), Taichung Vet Gen Hosp, Dept Neurosurg, Taichung, Taiwan.; Chen, KY (reprint author), Taichung Vet Gen Hosp, Dept Surg, Puli Branch, Nantou, Taiwan.
EM kaiyuan.chen419@gmail.com
CR AMMERMAN BJ, 1976, J NEUROSURG, V44, P331, DOI 10.3171/jns.1976.44.3.0331
   CARAM PC, 1957, J NEUROSURG, V14, P28, DOI 10.3171/jns.1957.14.1.0028
   DYCK P, 1992, SPINE, V17, P979, DOI 10.1097/00007632-199208000-00021
   Elsberg CA, 1925, ANN SURG, V81, P1057, DOI 10.1097/00000658-192506010-00003
   Erdogan B, 2002, TURKISH NEUROSURGERY, V12, P46
   FUJIWARA F, 1995, NEUROSURGERY, V37, P1212, DOI 10.1227/00006123-199512000-00024
   Giuffre R, 1966, Acta Neurochir (Wien), V14, P69, DOI 10.1007/BF01401892
   HERRMANN HD, 1988, NEUROSURGERY, V22, P518, DOI 10.1227/00006123-198803000-00011
   LANTOS G, 1987, NEUROSURGERY, V20, P469, DOI 10.1227/00006123-198703000-00020
   LEE M, 1995, J NEUROSURG, V82, P394, DOI 10.3171/jns.1995.82.3.0394
   MAIRA G, 1986, Neurological Research, V8, P225
   MCLONE DG, 1986, NEUROSURGERY, V18, P611, DOI 10.1227/00006123-198605000-00016
   MORI K, 1986, J NEUROSURG, V64, P974, DOI 10.3171/jns.1986.64.6.0974
   Nittner K, 1976, HDB CLIN NEUROLOGY, P177
   Xu QW, 1996, SURG NEUROL, V46, P322, DOI 10.1016/S0090-3019(96)00040-7
NR 15
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 156
EP 159
DI 10.1016/j.wneu.2018.09.156
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000148
PM 30315981
DA 2020-05-12
ER

PT J
AU Fricia, M
   Nicolosi, F
   Ganau, M
   Cebula, H
   Todeschi, J
   Santin, MD
   Nannavecchia, B
   Morselli, C
   Chibbaro, S
AF Fricia, Marco
   Nicolosi, Federico
   Ganau, Mario
   Cebula, Helene
   Todeschi, Julien
   Santin, Marie des Neiges
   Nannavecchia, Benny
   Morselli, Carlotta
   Chibbaro, Salvatore
TI Cranioplasty with Porous Hydroxyapatite Custom-Made Bone Flap: Results
   from a Multicenter Study Enrolling 149 Patients Over 15 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Cranioplasty; Decompressive craniectomy; Hydroxyapatite;
   Heterologous
ID MIDDLE-CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS
   CRANIOPLASTY; TITANIUM; HEMICRANIECTOMY; RECONSTRUCTION; IMPLANTS;
   SURGERY; REPAIR; TRIAL
AB BACKGROUND: Despite the mixed evidence regarding the effect of decompressive craniectomy in terms of outcome, a tremendous increase in related reports has been observed in the last years. Cranioplasty plays a key role in restoring function and anatomy of the cranial vault. Considering that cranioplasty is not exempt from risks, the identification of the safest technique becomes crucial to achieve better patients' recovery. Porous hydroxyapatite (PHA) has received growing attention for its potential in bony integration. Here we report a multicenter prospective follow-up analysis of 149 patients who underwent cranioplasty with PHA prostheses. In particular, we focus on the incidence of adverse events and implant removal.
   METHOD: From January 2001 to December 2015 we conducted a prospective multicenter study of 149 patients who underwent cranioplasty with custom-made PHA flaps after decompressive craniectomy for several reasons. The endpoints were the incidence of adverse events after cranioplasty and of related implant removal.
   RESULTS: 66 patients (44%) were treated within 6 months from decompression, and only 2 patients had a bifrontal bilateral reconstruction. Of those, 25 patients reported complications (16.8%), and 9 of them (6% of the whole case series) required removal of the prosthesis. The only significant factor predicting cranioplasty removal was a previous infection.
   CONCLUSION: Hydroxyapatite for cranial implants is fully comparable to other heterologous materials. It has a biologic potential of bony integration. The risk of explants seems to be significantly higher in second-line patients, data not shown in previous studies.
C1 [Fricia, Marco] Cannizzaro Hosp, Dept Neurosurg, Catania, Italy.
   [Nicolosi, Federico; Morselli, Carlotta] Humanitas Clin & Res Ctr, Dept Neurosurg, Rozzano, Italy.
   [Ganau, Mario; Cebula, Helene; Todeschi, Julien; Santin, Marie des Neiges; Nannavecchia, Benny; Chibbaro, Salvatore] Strasbourg Univ Hosp, Dept Neurosurg, Strasbourg, France.
RP Nicolosi, F (reprint author), Humanitas Clin & Res Ctr, Dept Neurosurg, Rozzano, Italy.
EM Federico.nicolosi@humanitas.it
RI Chibbaro, Salvatore/AAI-6368-2020
CR Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4
   Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133
   Chibarro S, 2012, INDIAN J NEUROSURG, V1, P17
   Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016
   Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020
   Chistolini P, 1999, J MATER SCI-MATER M, V10, P739, DOI 10.1023/A:1008939524807
   De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116
   Fricia M, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.027
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Iaccarino C, 2015, J ORAL MAXIL SURG, V73, P2375, DOI 10.1016/j.joms.2015.07.008
   Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367
   Kim Sung Hoon, 2017, Korean J Neurotrauma, V13, P15, DOI 10.13004/kjnt.2017.13.1.15
   Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655
   Kon E, 2000, J BIOMED MATER RES, V49, P328
   Lang J, 2016, IDEGGYOGY SZEMLE, V69, P227, DOI 10.18071/isz.69.0227
   Lindner D, 2017, J NEUROSURG, V126, P175, DOI 10.3171/2015.10.JNS151245
   Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699
   Moles A, 2018, WORLD NEUROSURG, V111, pE388, DOI 10.1016/j.wneu.2017.12.082
   Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735
   NUMEROW LM, 1994, CLIN NUCL MED, V19, P9, DOI 10.1097/00003072-199401000-00003
   Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268
   Salvatore C, 2013, J NEUROSCI RURAL PRA, V4, P421, DOI 10.4103/0976-3147.120244
   Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543
   Satyarthee GD, 2018, WORLD NEUROSURG, V112, P302, DOI 10.1016/j.wneu.2017.11.136
   Servadei F, 2015, WORLD NEUROSURG, V83, P133, DOI 10.1016/j.wneu.2014.08.031
   Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055
   Sprio S, 2016, J APPL BIOMATER FUNC, V14, pE470, DOI 10.5301/jabfm.5000293
   Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9
   Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290
   Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026
   Thien A, 2015, WORLD NEUROSURG, V83, P176, DOI 10.1016/j.wneu.2014.06.003
   Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4
   Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626
   Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3
   Zanaty Mario, 2014, ScientificWorldJournal, V2014, P356042, DOI 10.1155/2014/356042
   Zheng F, 2018, J INT MED RES, V46, P2503, DOI 10.1177/0300060518755148
NR 38
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 160
EP 165
DI 10.1016/j.wneu.2018.09.199
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000149
PM 30315976
DA 2020-05-12
ER

PT J
AU Weisberg, SD
   Houten, JK
AF Weisberg, Sarah D.
   Houten, John K.
TI An Unusual Presentation of Chronic Subdural Hematoma with Isolated
   Footdrop
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Footdrop; Neurologic examination; Subdural hematoma; Surgery
AB BACKGROUND: Patients with chronic subdural hematoma (CSDH) typically present with symptoms of increased intracranial pressure, including headache, nausea/ vomiting, and somnolence, or with contralateral weakness. Compression of the convexity cerebral cortex usually causes motor deficit that is more readily appreciated in the upper extremity rather than in the leg, and very subtle deficit may be detected only by looking for pronator drift. The precise pattern of signs and symptoms in CSDH may vary from case to case depending on the specific anatomy of compression, but isolated lower extremity weakness is rare.
   CASE DESCRIPTION: A 79-year-old woman presented with isolated footdrop. CSDH overlying the cerebral convexity was detected on computed tomography. The foot weakness resolved on surgical drainage.
   CONCLUSIONS: CSDH overlying the cerebral convexity may manifest with isolated foot weakness. Awareness of the potential for this unusual presentation of CSDH may be useful to the clinician assessing a patient with otherwise unexplained foot weakness.
C1 [Weisberg, Sarah D.] Maimonides Hosp, Div Neurosurg, Brooklyn, NY 11219 USA.
   [Houten, John K.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Hempstead, NY USA.
RP Houten, JK (reprint author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Hempstead, NY USA.
EM jkhmd@yahoo.com
OI /0000-0002-4295-9434
CR Andersen-Ranberg NC, 2017, J NEUROSURG, V126, P1905, DOI 10.3171/2016.4.JNS152642
   Baysefer A, 1998, MINIM INVAS NEUROSUR, V41, P97, DOI 10.1055/s-2008-1052025
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   De Bonis P, 2018, CLIN NEUROL NEUROSUR, V170, P88, DOI 10.1016/j.clineuro.2018.05.002
   Houten JK, 2008, J NEUROSURG-SPINE, V9, P237, DOI 10.3171/SPI/2008/9/9/237
   Jaramillo SPI, 2014, J NEUROL SCI, V343, P66, DOI 10.1016/j.jns.2014.05.028
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Narenthiran Ganesalingam, 2011, Surg Neurol Int, V2, P27, DOI 10.4103/2152-7806.77594
   NATHAN PW, 1955, J NEUROL NEUROSUR PS, V18, P250, DOI 10.1136/jnnp.18.4.250
   SCHNEIDER R, 1994, BRAIN, V117, P347, DOI 10.1093/brain/117.2.347
   Sengupta SK, 2013, NEUROL INDIA, V61, P199, DOI 10.4103/0028-3886.111159
   Weaver DF, 2000, NEUROLOGY, V54, P531, DOI 10.1212/WNL.54.2.531
NR 12
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 166
EP 168
DI 10.1016/j.wneu.2018.10.042
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000150
PM 30326314
DA 2020-05-12
ER

PT J
AU Tsoucalas, G
AF Tsoucalas, Gregory
TI The Siberian Lancet: One More Possible Innovative Example of Scalpel's
   Contribution to the Evolution of Surgical Anatomy and Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bronze knifes; Lancet; Neurosurgery; Siberia
ID SCYTHIAN TREPANATIONS
AB BACKGROUND: Several primitive scalpels were used since the eve of surgical procedures. Numerous bronze knifes discovered in the Altai mountains region from the Xiongnu-Xianbei-Rouran period mold a hypotheses for a possible medical use.
   METHODS: On-sight archaeologic excavation brought into light the tools in question.
   RESULTS: Knifes, similar to modern lancets, were unearthed alongside with a series of skulls demonstrating signs of trepanation.
   CONCLUSIONS: Strong indications imply that those cutting tools, except for domestic usage, were one more example of scalpel's contribution to the evolution of surgical anatomy and neurosurgery.
C1 [Tsoucalas, Gregory] Democritus Univ Thrace, Med Sch, Anat Dept, Hist Med, Alexandroupolis, Greece.
RP Tsoucalas, G (reprint author), Democritus Univ Thrace, Med Sch, Anat Dept, Hist Med, Alexandroupolis, Greece.
EM gregorytsoucalas@yahoo.gr
OI Tsoucalas, Gregory/0000-0002-2595-9686
CR Arnott R, 2003, TREPANATION
   Aruz J., 2000, GOLDEN DEER EURASIA
   Bakay K., 1971, SCYTHIAN RATTLES CAR
   Burton R., 1824, ANATOMY MELANCHOLY
   Center for Comparative Studies of Ancient Civilizations, 1995, ANCIENT CIVILIZATION, V2
   Denko CW, 2016, ARCH MED, V8, P4
   Faria MA, 2015, WORLD NEUROSURG, V84, P1174, DOI 10.1016/j.wneu.2015.05.014
   Grmek M, 1998, MALADIES ART ANTIQUE
   Herodotus, 1862, HIST HERODOTUS, V4
   Krivoshapkin AL, 2014, WORLD NEUROSURG, V82, pE649, DOI 10.1016/j.wneu.2014.06.045
   Minns EH, 2011, SCYTHIANS GREEKS SUR
   Moutrey S., 2017, FUNDAMENTALS SURG IN
   Murphy EM, 2003, BRIT ARCHAEOLOGICAL, V1152, P1
   Niebhr BG, 1852, LECT ANCIENT HIST EA, V1
   Oleszczak ., 2018, EURASIAN PREHISTORY, V14, P153
   Pollak K., 2007, MED ANTIQUITE
   Tsoucalas G, 2017, WORLD NEUROSURG, V103, P501, DOI 10.1016/j.wneu.2017.04.022
NR 17
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 169
EP 172
DI 10.1016/j.wneu.2018.10.057
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000151
PM 30336297
DA 2020-05-12
ER

PT J
AU Kuga, D
   Toda, M
   Ozawa, H
   Ogawa, K
   Yoshida, K
AF Kuga, Daisuke
   Toda, Masahiro
   Ozawa, Hiroyuki
   Ogawa, Kaoru
   Yoshida, Kazunari
TI Endoscopic Endonasal Approach Combined with a Simultaneous Transcranial
   Approach for Giant Pituitary Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Pituitary adenoma; Pterional surgery; Transsphenoidal
   surgery; Tumor
ID TRANSSPHENOIDAL SURGERY; SUPRASELLAR EXTENSIONS; SURGICAL-TREATMENT;
   ADENOMAS; STRATEGIES; MANAGEMENT; SERIES; RESECTION
AB BACKGROUND: The endoscopic endonasal approach is widely used for treating giant pituitary adenomas. However, a small subset of tumors is still challenging to treat, and the risk of complications increases when an endoscopic endonasal approach alone is used. The simultaneous combined endoscopic endonasal and transcranial approach is a surgical option for such difficult adenomas; however, very few studies have described the technical nuances and benefits of this approach.
   METHODS: We treated 3 patients with giant pituitary adenoma and 1 patient with pituicytoma. Radiologic findings and clinical outcomes were retrospectively reviewed.
   RESULTS: All patients had preoperative visual disturbances. A pterional approach was combined with an endoscopic endonasal approach to treat all the patients. Near-total and subtotal tumor removal was accomplished in 3 patients; however, only partial tumor removal was possible in 1 patient. Postoperative visual function improved in 3 patients, but there were no changes in 1 patient. There were no major complications; however, each patient developed either adrenocorticotropic hormone (ACTH) and thyroid-stimulating hormone deficiency or ACTH deficiency and persistent diabetes. Importantly, no cerebrospinal fluid leakage was observed in the patients.
   CONCLUSIONS: Our simultaneous combined endoscopic and transcranial approach offers safe tumor resection and a low rate of complications. In this procedure, it is important that tumor debulking be performed by the main surgeon via a single surgical route and not by 2 surgeons using the simultaneous endonasal and transcranial approach, to avoid interference in the surgical field. This approach may be considered as a surgical option for carefully selected tumors in the sellar region.
C1 [Kuga, Daisuke; Toda, Masahiro; Yoshida, Kazunari] Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
   [Ozawa, Hiroyuki; Ogawa, Kaoru] Keio Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Shinjuku Ku, Tokyo, Japan.
RP Toda, M (reprint author), Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
EM todam@keio.jp
OI Toda, Masahiro/0000-0003-2700-1620
CR Alleyne CH, 2002, SURG NEUROL, V57, P380, DOI 10.1016/S0090-3019(02)00705-X
   Cappabianca P, 2015, NEUROSURG CLIN N AM, V26, P323, DOI 10.1016/j.nec.2015.03.007
   Chacko G, 2009, J CLIN NEUROSCI, V16, P660, DOI 10.1016/j.jocn.2008.08.018
   D'Ambrosio AL, 2009, PITUITARY, V12, P217, DOI 10.1007/s11102-009-0171-5
   Goel A, 2004, SURG NEUROL, V61, P436, DOI 10.1016/j.surneu.2003.08.036
   GOEL A, 1995, BRIT J NEUROSURG, V9, P37
   Gondim JA, 2014, WORLD NEUROSURG, V82, pE281, DOI 10.1016/j.wneu.2013.08.028
   Han S, 2017, J NEURO-ONCOL, V132, P313, DOI 10.1007/s11060-017-2371-6
   Islamian AP, 2012, PITUITARY, V15, P227, DOI 10.1007/s11102-011-0317-0
   Jane JA, 2001, J AM COLL SURGEONS, V193, P651
   Juraschka K, 2014, J NEUROSURG, V121, P75, DOI 10.3171/2014.3.JNS131679
   Komotar RJ, 2012, PITUITARY, V15, P150, DOI 10.1007/s11102-011-0359-3
   Koutourousiou M, 2013, J NEUROSURG, V118, P621, DOI 10.3171/2012.11.JNS121190
   Kuo CH, 2016, WORLD NEUROSURG, V91, P121, DOI 10.1016/j.wneu.2016.03.092
   Leung GKK, 2011, ACTA NEUROCHIR, V153, P1401, DOI 10.1007/s00701-011-1029-y
   Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z
   Mortini P, 2005, NEUROSURGERY, V56, P1222, DOI 10.1227/01.NEU.0000159647.64275.9D
   Mortini P, 2007, NEUROSURGERY, V60, P993, DOI 10.1227/01.NEU.0000255459.14764.BA
   Nagata Y, 2018, J NEUROSURG, V128, P685, DOI 10.3171/2016.11.JNS161833
   Nakao N, 2011, J CLIN NEUROSCI, V18, P71, DOI 10.1016/j.jocn.2010.04.049
   Ogiwara Hideki, 2011, Surg Neurol Int, V2, P116, DOI 10.4103/2152-7806.83932
   SAITO K, 1995, NEUROSURGERY, V36, P668, DOI 10.1227/00006123-199504000-00005
   Teti C, 2015, PITUITARY, V18, P592, DOI 10.1007/s11102-014-0612-7
   Youssef AS, 2005, NEUROSURGERY, V57, P168, DOI 10.1227/01.NEU.0000163602.05663.86
   Zhang X, 1999, SURG NEUROL, V52, P380, DOI 10.1016/S0090-3019(99)00120-2
NR 25
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 173
EP 179
DI 10.1016/j.wneu.2018.10.047
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000152
PM 30336293
DA 2020-05-12
ER

PT J
AU de Quintana-Schmidt, C
   Leidinger, A
   Teixido, JM
   Bertran, GC
AF de Quintana-Schmidt, Cristian
   Leidinger, Andreas
   Molet Teixido, Joan
   Conesa Bertran, Gerardo
TI Application of a Thrombin-Gelatin Matrix in the Management of
   Intractable Hemorrhage During Stereotactic Biopsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Floseal; Intractable hemorrhage; Intraoperative
   hemorrhage; Management hemorrhage; Stereotactic brain biopsy;
   Thrombin-gelatin matrix
ID HEMOSTATIC SEALANT; RISK-FACTORS; BRAIN; COMPLICATIONS; NEUROSURGERY
AB BACKGROUND: Few studies have been published about percutaneous techniques for management of surgical bed hemorrhage during a stereotactic biopsy, a serious complication that may affect patient outcome. We describe the injection of a thrombin-gelatin matrix through the biopsy cannula as an effective method to arrest surgical bed bleeding that does not respond to conventional methods of hemostasis.
   METHODS: We prospectively documented image-guided stereotactic brain biopsy procedures in 30 awake patients between July 2014 and July 2017 at our center. Among patients presenting with intractable surgical bed bleeding, a thrombin-gelatin matrix injection through the biopsy cannula was performed. Details of the injection technique, surgical outcome, and complications were recorded.
   RESULTS: Among 30 documented stereotactic brain biopsies, 3 (10%) had intractable surgical bed bleeding during the procedure. In all 3 cases, thrombin-gelatin matrix was injected, and an immediate arrest of hemorrhage was achieved. None of the patients required a craniotomy or further invasive measure to achieve hemostasis. No postoperative complications were recorded.
   CONCLUSIONS: Our preliminary results suggest that thrombin-gelatin matrix injection is a simple, safe, and effective stereotactic practice to manage persistent surgical bed bleeding that cannot be arrested by standard, conventional hemostatic methods.
C1 [de Quintana-Schmidt, Cristian; Leidinger, Andreas; Molet Teixido, Joan; Conesa Bertran, Gerardo] Hosp Santa Creu & Sant Pau, Dept Neurosurg, Barcelona, Spain.
RP de Quintana-Schmidt, C (reprint author), Hosp Santa Creu & Sant Pau, Dept Neurosurg, Barcelona, Spain.
EM cquintana@santpau.cat
CR APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019
   Ben-Haim S, 2009, NEUROSURGERY, V64, P754, DOI 10.1227/01.NEU.0000339173.77240.34
   BERNSTEIN M, 1994, J NEUROSURG, V81, P165, DOI 10.3171/jns.1994.81.2.0165
   Binder DK, 2005, NEUROSURGERY, V56, P722, DOI 10.1227/01.NEU.0000156473.57196.7E
   CHAN KH, 1989, J NEUROSURG, V71, P38, DOI 10.3171/jns.1989.71.1.0038
   CHIMOWITZ MI, 1991, J NEUROSURG, V74, P301, DOI 10.3171/jns.1991.74.2.0301
   Ellegala DB, 2002, NEUROSURGERY, V51, P513, DOI 10.1097/00006123-200208000-00041
   Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545
   Gazzeri R, 2011, ACTA NEUROCHIR, V153, P148, DOI 10.1007/s00701-010-0762-y
   Gazzeri R, 2009, J NEUROSURG, V110, P939, DOI 10.3171/2008.8.JNS17642
   Kutlay M, 2010, NEUROSURGERY, V66, pONSE334, DOI 10.1227/01.NEU.0000369655.96692.C5
   Lapierre F, 2009, NEUROCHIRURGIE, V55, P40
   Renkes KL, 2001, SPINE, V26, P15
   WHITE RP, 1985, NEUROSURGERY, V16, P27, DOI 10.1227/00006123-198501000-00007
   Zrinzo L, 2012, J NEUROSURG, V116, P84, DOI 10.3171/2011.8.JNS101407
NR 15
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 180
EP 185
DI 10.1016/j.wneu.2018.10.053
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000153
PM 30326309
DA 2020-05-12
ER

PT J
AU Stein, SC
AF Stein, Sherman C.
TI The Evolution of Modern Treatment for Depressed Skull Fractures
SO WORLD NEUROSURGERY
LA English
DT Review
DE Compound skull fracture; Depressed skull fracture; Ping-pong skull
   fracture; Skull fracture elevation
ID PRIMARY RECONSTRUCTION; COMPUTED-TOMOGRAPHY; TITANIUM CLAMPS; BONE
   FRAGMENTS; FRONTAL-SINUS; MANAGEMENT; REPAIR; INFECTION; BRAIN;
   ELEVATION
AB Surgery for depressed skull fractures has developed over centuries to attain the consensus approaches currently used. This review outlines the last 200 years of development of surgical approaches to closed and open depressed skull fractures, fractures involving dural venous sinuses and ping-pong fractures involving infants. Early reports often dealt with only closed and open depressed skull fractures. However, experience has shown that each fracture category merits its own management strategies. Accepted approaches are based on observation only; there is little to no scientific evidence to support treatment for any fracture type.
C1 [Stein, Sherman C.] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Stein, SC (reprint author), Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM sherman.stein@uphs.upenn.edu
CR AbdelFatah MA, 2016, ACTA NEUROCHIR, V158, P2341, DOI 10.1007/s00701-016-2976-0
   Adeloye A., 1993, Central African Journal of Medicine, V39, P70
   Ahmad S, 2018, PAK J MED SCI, V34, P130, DOI 10.12669/pjms.341.13184
   Akram M, 2007, JCPSP-J COLL PHYSICI, V17, P744, DOI 12.2007/JCPSP.744748
   Al-Haddad SA, 2002, ANN ROY COLL SURG, V84, P196
   Ali B, 2002, EMERG MED J, V19, P552, DOI 10.1136/emj.19.6.552
   Ali M, 2011, J POSTGRAD MED I, V17, P116
   Avery N C, 1998, J Craniomaxillofac Trauma, V4, P42
   AXTON JHM, 1965, BRIT MED J, V1, P1644, DOI 10.1136/bmj.1.5451.1644
   BENARI Y, 1986, EUR J OBSTET GYN R B, V22, P249, DOI 10.1016/0028-2243(86)90073-0
   BEYERS N, 1978, S AFR MED J, V54, P830
   BLANKENSHIP JB, 1991, PEDIATR NEUROSURG, V16, P297
   BRAAKMAN R, 1972, J NEUROL NEUROSUR PS, V35, P395, DOI 10.1136/jnnp.35.3.395
   Browder J., 1960, INJURIES BRAIN SPINA, P52
   BROWN EM, 1994, LANCET, V344, P1547
   Bullock M Ross, 2006, Neurosurgery, V58, pS56
   Bullock MR, 2006, NEUROSURGERY S, V58
   BYRNES DP, 1974, J IRISH MED ASSOC, V67, P337
   CARRINGTON KW, 1960, SURG GYNECOL OBSTET, V110, P203
   Chiarelli PA, 2018, PRINCIPLES NEUROLOGI, P445
   Cho SM, 2018, WORLD NEUROSURG, V109, pE305, DOI 10.1016/j.wneu.2017.09.168
   Cisse B, 2017, COMMON NEUROSURGICAL, P27
   Cooper PR, 1993, HEAD INJURY
   Coulon RA, 1983, CONCEPTS PEDIATR NEU, V4, P253
   Crandon LRG, 1906, ANN SURG, V44, P823, DOI 10.1097/00000658-190612000-00002
   Curry DJ, 1999, PEDIATR NEUROSURG, V31, P294, DOI 10.1159/000028878
   Cushing H, 1918, BRIT J SURG, V5, P558
   Cushing H., 1907, NY MED J, V85, P97
   Davis L, 1963, PRINCIPLES NEUROLOGI
   Delaney SW, 2016, J PLAST RECONSTR AES, V69, P1037, DOI 10.1016/j.bjps.2016.06.006
   Desault PJ, 1814, SURG WORKS STATEMENT, V1
   Ebel H, 2000, MINIM INVAS NEUROSUR, V43, P212, DOI 10.1055/s-2000-11380
   Ersahin Y, 1996, CHILD NERV SYST, V12, P323, DOI 10.1007/BF00301021
   Finger S, 2001, NEUROSURGERY, V48, P911, DOI 10.1097/00006123-200104000-00045
   Flannigan C, 2011, BMJ CASE REP, V2011
   Gamgee S, 1876, Br Med J, V2, P37
   Ganz JC, 2014, J HIST NEUROSCI, V23, P233, DOI 10.1080/0964704X.2013.823267
   Gillingham FJ, 1947, BR J SURG S, V1, P81
   Grassberger M, 2011, FORENSIC SCI INT, V207, pE19, DOI 10.1016/j.forsciint.2010.11.014
   GUHARAY DK, 1976, J REPROD MED, V16, P321
   Harrison M, 2002, EMERG MED J, V19, P329, DOI 10.1136/emj.19.4.329
   HEALY JF, 1982, COMPUT RADIOL, V6, P323, DOI 10.1016/0730-4862(82)90002-6
   HEARY RF, 1993, J TRAUMA, V35, P441, DOI 10.1097/00005373-199309000-00018
   HEISKANEN O, 1973, ACTA CHIR SCAND, V139, P605
   HEKMATPA.J, 1973, SURG CLIN N AM, V53, P47
   Hendrick EB, 1971, ANN M C NEUR SURG OC
   Hoffmann G T, 1968, Ariz Med, V25, P175
   Holt W L, 1910, Cal State J Med, V8, P347
   Hopkins W B, 1885, Ann Surg, V2, P65, DOI 10.1097/00000658-188507000-00005
   Horsley V, 1890, Br Med J, V2, P1286
   Hudson R S, 1877, Br Med J, V2, P75
   Hung KL, 2005, J NEUROSURG, V103, P69, DOI 10.3171/ped.2005.103.1.0069
   Ingraham FD, 1954, NEUROSURGERY INFANCY
   Jackson IJ, 1959, PEDIAT NEUROLOGY
   JAMIESON KG, 1972, J NEUROSURG, V37, P150, DOI 10.3171/jns.1972.37.2.0150
   JENNETT B, 1972, J NEUROSURG, V36, P333, DOI 10.3171/jns.1972.36.3.0333
   JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208
   Kaptigau WM, 2007, PAPUA NEW GUINEA MED, V50, P58
   Katikar DB, 2014, MEDPULSE INT MED J, V1, P689
   KNORINGER P, 1979, NEUROCHIRURGIA, V22, P18
   KRISS F C, 1969, Journal of Neurosurgery, V30, P698, DOI 10.3171/jns.1969.30.6.0698
   Kumar A, 2010, J CLIN NEUROSCI, V17, P178, DOI 10.1016/j.jocn.2009.05.011
   LeFeuvre D, 2004, SURG NEUROL, V62, P121, DOI 10.1016/j.surneu.2003.10.048
   Lerch KD, 1999, NEUROSURGERY, V44, P902, DOI 10.1097/00006123-199904000-00137
   Li XW, 2013, J CRANIOFAC SURG, V24, P247, DOI 10.1097/SCS.0b013e3182701226
   Li ZD, 2015, FORENSIC SCI INT, V255, P106, DOI 10.1016/j.forsciint.2015.07.012
   LYERLY J G, 1957, Am Surg, V23, P1115
   Macewen W, 1888, Br Med J, V2, P302
   Marbacher S, 2008, J CRANIOFAC SURG, V19, P490, DOI 10.1097/SCS.0b013e3181534ae8
   Mastrapa TL, 2007, CHILD NERV SYST, V23, P787, DOI 10.1007/s00381-007-0354-1
   Matson DD, 1969, NEUROSURGERY INFANCY
   Matson DD, 1948, TREATMENT ACUTE CRAN, P26
   MCFADDEN JT, 1977, SURG GYNECOL OBSTET, V144, P414
   Mendelow A D, 1983, J R Coll Surg Edinb, V28, P80
   Menon DK, 2017, HAND CLINIC, V140, P239, DOI 10.1016/B978-0-444-63600-3.00014-3
   MILLER JD, 1968, LANCET, V2, P991
   Mock HE, 1942, J AMER MED ASSOC, V120, P498, DOI 10.1001/jama.1942.02830420006002
   Mock HE, 1950, SKULL FRACTURES BRAI
   Moore CH, 1942, ANN SURG, V115, P513
   Muhammad Gul, 2017, J Ayub Med Coll Abbottabad, V29, P311
   Mukherjee KK, 2015, ACTA NEUROCHIR, V157, P305, DOI 10.1007/s00701-014-2296-1
   Mumtaz A, 2003, J POSTGRADUATE MED I, V17, P46
   Munro D, 1943, NEW ENGL J MED, V228, P737, DOI 10.1056/NEJM194306102282301
   NADELL J, 1974, J NEUROSURG, V41, P200, DOI 10.3171/jns.1974.41.2.0200
   Nayak PK, 2008, INDIAN J NEUROTRAUM, V5, P35, DOI 10.1016/S0973-0508(08)80026-3
   Neville IS, 2014, BIOMED RES INT, DOI 10.1155/2014/879286
   Nnadi M O N, 2014, Niger Postgrad Med J, V21, P311
   Ozer FD, 2005, J EMERG MED, V29, P137, DOI 10.1016/j.jemermed.2005.03.006
   Pendleton C, 2014, J NEUROL SURG PART B, V75, P27, DOI 10.1055/s-0033-1353361
   Phelps C, 1909, ANN SURG, V49, P449, DOI 10.1097/00000658-190904000-00001
   Phelps C., 1897, TRAUMATIC INJURIES B
   Piek J, 2011, CENT EUR NEUROSURG, V72, P42, DOI 10.1055/s-0029-1246133
   Pirigoff N., 1864, GRUNDZUGE ALLGEMEINE
   Plese J P, 1981, Arq Neuropsiquiatr, V39, P286
   Pollak L, 1999, J PAEDIATR CHILD H, V35, P96, DOI 10.1046/j.1440-1754.1999.00327.x
   Prakash Anand, 2018, Asian J Neurosurg, V13, P222, DOI 10.4103/ajns.AJNS_168_16
   Ransohoff J, 1910, ANN SURG, V51, P796, DOI 10.1097/00000658-191006000-00005
   RAWL A E, 1957, J S C Med Assoc, V53, P44
   Rawling LB, 1904, LANCET, V1, P1034
   Rawling LB, 1904, LANCET, V1, P973
   Rawling LB, 1904, LANCET, V1, P1097
   RAYNOR R, 1968, J PEDIATR-US, V72, P262, DOI 10.1016/S0022-3476(68)80321-X
   Rehman L, 2007, JCPSP-J COLL PHYSICI, V17, P140
   Richter AG, 1789, ANFANGSGRUNDE WUNDAR, V2
   Roberts JB, 1916, TREATISE FRACTURES, P161
   ROGERS L, 1953, BRIT MED J, V1, P1431, DOI 10.1136/bmj.1.4825.1431
   Rolekar NG, 2014, INT J MED SCI PUBLIC, V3, P1540, DOI [10.5455/ijmsph.2014.271020141, DOI 10.5455/IJMSPH.2014.271020141]
   Rowbotham GF, 1964, ACUTE INJURIES HEAD, p[280, 312]
   ROWE SN, 1945, J NEUROSURG, V2, P391, DOI 10.3171/jns.1945.2.5.0391
   Salia SM, 2018, WORLD NEUROSURG, V114, pE833, DOI 10.1016/j.wneu.2018.03.095
   SANDE GM, 1980, SCOT MED J, V25, P227, DOI 10.1177/003693308002500308
   Satardey Ritesh S, 2018, Asian J Neurosurg, V13, P341, DOI 10.4103/ajns.AJNS_117_16
   SCHORSTEIN J, 1947, Br J Surg, V55, P256
   Sharpe W, 1916, J AMER MED ASSOC, V66, P1536
   Sheppard John P, 2018, Brain Tumor Res Treat, V6, P1, DOI 10.14791/btrt.2018.6.e4
   Shokouhi G, 2014, NEUROSURG QUART, V24, P84
   STEINBOK P, 1987, J NEUROSURG, V66, P506, DOI 10.3171/jns.1987.66.4.0506
   Strong T H Jr, 1990, Obstet Gynecol Surv, V45, P284, DOI 10.1097/00006254-199005000-00002
   SUBCZYNSKI JA, 1977, J TRAUMA, V17, P467, DOI 10.1097/00005373-197706000-00009
   TODD EM, 1967, AM J SURG, V113, P479, DOI 10.1016/0002-9610(67)90190-0
   VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186
   Walker AE, 1967, HIST NEUROLOGICAL SU
   Wan YF, 2013, J CRANIOFAC SURG, V24, P589, DOI 10.1097/SCS.0b013e3182801bae
   Wilensky AO, 1919, ANN SURG, V70, P404, DOI 10.1097/00000658-191910000-00005
   Worner B, 2001, NEUROSURG REV, V24, P83, DOI 10.1007/PL00014586
   Wylen EL, 1999, SURG NEUROL, V51, P452, DOI 10.1016/S0090-3019(98)00040-8
   Zalatimo O, 2012, J NEUROSURG-PEDIATR, V9, P676, DOI 10.3171/2012.2.PEDS11304
NR 127
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 186
EP 192
DI 10.1016/j.wneu.2018.10.045
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000154
PM 30326316
OA Bronze
DA 2020-05-12
ER

PT J
AU Horisawa, S
   Nanke, M
   Kawamata, T
   Taira, T
AF Horisawa, Shiro
   Nanke, Magi
   Kawamata, Takakazu
   Taira, Takaomi
TI Pallidothalamic Tractotomy for Parkinson Disease with 1-Year Follow-Up:
   A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Campotomy; Pallidothalamic tract; Parkinson disease
ID THALAMOTOMY
AB BACKGROUND: The pallidothalamic tract connects the globus pallidus internus and the ventrolateral portion of the thalamus, and ablation of the pallidothalamic tract (pallidothalamic tractotomy [PTT]) reportedly exerts antiparkinsonian effects. However, the detailed clinical course has not yet been elucidated. Here, we present the first single case report of PTT performed in a patient with Parkinson disease, with 1-year follow-up.
   CASE DESCRIPTION: The patient was a 68-year-old woman with Parkinson disease. After 14 years of receiving oral medication, she experienced the "wearing-off" phenomenon. Levodopa (300 mg/day) was required to maintain daily activities. Rigidity and peak-dose dyskinesia were predominantly observed in the right side of her body. In addition, she demonstrated right foot dystonia with pain. The preoperative Unified Parkinson Disease Rating Scale part 1, 2 (off medication/on medication), 3 (off medication/on medication), and 4 scores were 7, 26/4, 41/23, and 13, respectively. Further, the preoperative Unified Dyskinesia Rating Scale and Parkinson Disease Questionnaire-39 scores were 102 and 46, respectively. She underwent left-sided PTT, and no perioperative complications were observed. At 1 year postoperatively, daily administration of levodopa (200 mg) was maintained without an "off" condition all day. The 1-year Unified Parkinson Disease Rating Scale part 1, 2, 3, and 4 scores were 5, 9/1, 20/12, and 5, respectively. In addition, the 1-year Unified Dyskinesia Rating Scale and Parkinson Disease Questionnaire-39 scores were 20 and 20, respectively.
   CONCLUSIONS: We present a rare case of PTT performed in a patient with Parkinson disease. PTT might be useful in patients who do not desire device implantation.
C1 [Horisawa, Shiro; Kawamata, Takakazu; Taira, Takaomi] Tokyo Womens Med Univ, Neurol Inst, Dept Neurosurg, Tokyo, Japan.
   [Nanke, Magi] Tokyo Womens Med Univ, Sch Med, Tokyo, Japan.
RP Horisawa, S (reprint author), Tokyo Womens Med Univ, Neurol Inst, Dept Neurosurg, Tokyo, Japan.
EM neurosurgery21@yahoo.co.jp
OI horisawa, shiro/0000-0002-3016-3244
CR Aufenberg Christoph, 2005, Thalamus & Related Systems, V3, P121, DOI 10.1017/S147292880700012X
   Horisawa S, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.05.017
   Iacono R P, 1995, J Image Guid Surg, V1, P133, DOI 10.1002/(SICI)1522-712X(1995)1:3<133::AID-IGS2>3.3.CO;2-9
   Lang AE, 1999, J NEUROL, V246, P28, DOI 10.1007/BF03161079
   Magara A, 2014, J THER ULTRASOUND, V2, DOI 10.1186/2050-5736-2-11
   NAGASEKI Y, 1986, J NEUROSURG, V65, P296, DOI 10.3171/jns.1986.65.3.0296
   Niranjan A, 2017, J NEUROSURG, P1
   SCOTT RM, 1970, J NEUROSURG, V32, P286, DOI 10.3171/jns.1970.32.3.0286
   SPEAKMAN TJ, 1963, CAN MED ASSOC J, V89, P652
   SPIEGEL EA, 1963, J NEUROSURG, V20, P871, DOI 10.3171/jns.1963.20.10.0871
   Young RF, 2014, TRANSL CANCER RES, V3, P525, DOI 10.3978/j.issn.2218-676X.2014.11.01
NR 11
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 193
EP 195
DI 10.1016/j.wneu.2018.10.055
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000155
PM 30336294
DA 2020-05-12
ER

PT J
AU Deng, ZD
   Pan, YX
   Li, DY
   Zhang, CC
   Jin, HY
   Wang, T
   Zhan, SK
   Sun, BM
AF Deng, Zhengdao
   Pan, Yixin
   Li, Dianyou
   Zhang, Chencheng
   Jin, Haiyan
   Wang, Tao
   Zhan, Shikun
   Sun, Bomin
TI Effect of Bilateral Anterior Cingulotomy on Chronic Neuropathic Pain
   with Severe Depression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cingulotomy; Depression; Neuropathic pain
ID DEEP BRAIN-STIMULATION; INTRATHECAL DRUG-DELIVERY; CINGULATE;
   MODULATION; MANAGEMENT; EFFICACY
AB BACKGROUND: The presence of neuropathic pain can severely impinge on emotional regulation and activities of daily living including social activities, resulting in diminished life satisfaction. Unfortunately, the majority of patients with neuropathic pain do not experience an amelioration of symptoms from conventional therapies, even when multimodal therapies are used. Chronic refractory neuropathic pain is usually accompanied by severe depression that is prone to incur suicidal events; thus clinical management of chronic neuropathic pain and depression presents a serious challenge for clinicians and patients.
   CASE DESCRIPTION: Two patients presented at our institution with neuropathic pain and severe depression. The patients had different pain symptoms emerging a few months after central or peripheral nervous system impairment. These symptoms were associated with the development of severe depression, social isolation, and a gradual inability to perform daily activities. Both patients were referred to our treatment center for bilateral anterior cingulotomy. After surgery, both patients showed significant progressive improvements in perceived pain, mental health status, and daily functioning.
   CONCLUSIONS: Bilateral anterior cingulotomy may serve as an alternative treatment for medically refractory neuropathic pain, especially for patients who also experience depression.
C1 [Deng, Zhengdao; Pan, Yixin; Li, Dianyou; Zhang, Chencheng; Wang, Tao; Zhan, Shikun; Sun, Bomin] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Funct Neurosurg, Sch Med, Shanghai, Peoples R China.
   [Jin, Haiyan] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Psychiat, Sch Med, Shanghai, Peoples R China.
RP Li, DY (reprint author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Funct Neurosurg, Sch Med, Shanghai, Peoples R China.
EM ldy11483@rjh.com.cn
RI Zhang, ChenCheng/AAK-6096-2020
OI Zhang, ChenCheng/0000-0003-4472-4134; Deng, Zhengdao/0000-0001-9247-5780
FU National Key Research and Development Program of China [2017YFC0803607];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81471387, 81271518, 81771482]
FX This work was supported by National Key Research and Development Program
   of China Grant 2017YFC0803607 (to DYL) and the National Natural Science
   Foundation of China (81471387, 81271518, 81771482 to BMS).
CR Abreu V, 2017, NEUROMODULATION, V20, P504, DOI 10.1111/ner.12620
   Al-Shaiji TF, 2018, NEUROMODULATION, V21, P805, DOI 10.1111/ner.12745
   Bingel U, 2007, CURR OPIN NEUROL, V20, P424, DOI 10.1097/WCO.0b013e328259c34d
   Bingel U, 2008, PHYSIOLOGY, V23, P371, DOI 10.1152/physiol.00024.2008
   Boccard SGJ, 2017, WORLD NEUROSURG, V106, P625, DOI 10.1016/j.wneu.2017.06.173
   Boccard SGJ, 2014, NEUROSURGERY, V74, P628, DOI 10.1227/NEU.0000000000000321
   Bronstein JM, 2011, ARCH NEUROL-CHICAGO, V68, P165, DOI 10.1001/archneurol.2010.260
   Brotis AG, 2009, STEREOT FUNCT NEUROS, V87, P271, DOI 10.1159/000226669
   Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2
   Coffey RJ, 2002, NEUROSURGERY, V50, P78, DOI 10.1097/00006123-200201000-00014
   Czernicki M, 2015, J CLIN MONIT COMPUT, V29, P241, DOI 10.1007/s10877-014-9607-1
   De Felice M, 2016, PAIN MANAG, V6, P111, DOI 10.2217/pmt.15.63
   Deer TR, 2011, PAIN PHYSICIAN, V14, pE283
   Deng ZD, 2018, STEREOT FUNCT NEUROS, V96, P204, DOI 10.1159/000489946
   Ebmeier KP, 2006, LANCET, V367, P153, DOI 10.1016/S0140-6736(06)67964-6
   Edwards RR, 2006, ARTHRIT RHEUM-ARTHR, V55, P325, DOI 10.1002/art.21865
   Follett KA, 2000, J PAIN SYMPTOM MANAG, V19, P209, DOI 10.1016/S0885-3924(99)00153-0
   FOLTZ EL, 1968, INT J NEUROL, V6, P353
   Jones RCW, 2012, PAIN MANAG, V2, P55, DOI [10.2217/PMT.11.76, 10.2217/pmt.11.76]
   Kim MS, 2017, J NEUROL SCI, V383, P135, DOI 10.1016/j.jns.2017.10.031
   Melzack R, 1999, PAIN, pS121
   Muller R, 2017, J REHABIL MED, V49, P489, DOI 10.2340/16501977-2241
   Olson KA, 1998, NEUROMODULATION, V1, P6, DOI 10.1111/j.1525-1403.1998.tb00025.x
   Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968
   Redlich R, 2018, NEUROPSYCHOPHARMACOL, V43, P546, DOI 10.1038/npp.2017.246
   Russo JF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1543
   Steele JD, 2008, BIOL PSYCHIAT, V63, P670, DOI 10.1016/j.biopsych.2007.07.019
   Yen CP, 2009, J CLIN NEUROSCI, V16, P214, DOI 10.1016/j.jocn.2008.04.008
   Yen CP, 2005, J CLIN NEUROSCI, V12, P886, DOI 10.1016/j.jocn.2004.11.018
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 196
EP 200
DI 10.1016/j.wneu.2018.10.008
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000156
PM 30315971
DA 2020-05-12
ER

PT J
AU Crisman, C
   Ward, M
   Majmundar, N
   Damodara, N
   Hsueh, WD
   Eloy, JA
   Liu, JK
AF Crisman, Celina
   Ward, Max
   Majmundar, Neil
   Damodara, Nitesh
   Hsueh, Wayne D.
   Eloy, Jean Anderson
   Liu, James K.
TI Pituitary Apoplexy Following Endoscopic Retrograde
   Cholangiopancreatography
SO WORLD NEUROSURGERY
LA English
DT Article
DE CO2 insufflation; Endoscopic retrograde cholangiopancreatography; ERCP;
   Laparoscopy; Pituitary apoplexy
ID PREVALENCE; MANAGEMENT
AB BACKGROUND: Pituitary apoplexy is an uncommon neurosurgical emergency that may be the initial presentation of undiagnosed pituitary adenomas. Though the exact pathogenesis is unclear, there appears to be an association between pituitary apoplexy and medical interventions that disturb the blood supply and venous drainage of the abnormal sellar region. We present the first case of pituitary apoplexy occurring after an endoscopic retrograde cholangiopancreatography (ERCP).
   CASE DESCRIPTION: A 43-year-old male who was several hours status post ERCP presented with a severe headache, bilateral ptosis, and multidirectional ophthalmoplegia. Computed tomography scan and magnetic resonance imaging of the brain revealed a hemorrhagic and necrotic sellar mass with suprasellar extension compressing the optic chiasm and bilateral extension displacing the cavernous carotid arteries laterally. The patient underwent emergent endoscopic endonasal transsphenoidal resection of the underlying pituitary tumor apoplexy with eventual resolution of his cranial nerve palsies.
   CONCLUSIONS: Although pituitary apoplexy has been recognized as a sequela of surgical and laparoscopic procedures, it should also be considered in less invasive gastrointestinal procedures which may alter the intraabdominal pressures, such as ERCP. Early detection of this unusual complication allows for rapid diagnosis and timely surgical intervention in select cases to prevent debilitating cranial nerve palsies, preserve visual function, and retain normal pituitary function.
C1 [Crisman, Celina; Ward, Max; Majmundar, Neil; Damodara, Nitesh; Eloy, Jean Anderson; Liu, James K.] Rutgerse New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Hsueh, Wayne D.; Eloy, Jean Anderson; Liu, James K.] Rutgerse New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
RP Liu, JK (reprint author), Rutgerse New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.; Liu, JK (reprint author), Rutgerse New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
EM james.liu.md@rutgers.edu
RI Majmundar, Neil/AAH-9695-2020
OI Majmundar, Neil/0000-0001-5910-6094; WARD, MAX/0000-0003-1279-4920
CR Ahmed SK, 2008, ACTA NEUROCHIR, V150, P1193, DOI 10.1007/s00701-008-0130-3
   Arita K, 2001, J NEUROSURG, V95, P897, DOI 10.3171/jns.2001.95.5.0897
   Bailey P, 1898, PHILA MED J, V1, P789
   Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042
   BROUGHAM M, 1950, J NEUROSURG, V7, P421, DOI 10.3171/jns.1950.7.5.0421
   Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412
   Huang TY, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-254
   Kim SJ, 2011, KOREAN J ANESTHESIOL, V61, P225, DOI 10.4097/kjae.2011.61.3.225
   Kobayashi J, 2013, J STROKE CEREBROVASC, V22, pE643, DOI 10.1016/j.jstrokecerebrovasdis.2013.03.030
   Liu JK, 2006, J NEUROSURG, V104, P892, DOI 10.3171/jns.2006.104.6.892
   Liu JK, 2001, ACTA NEUROCHIR, V143, P303, DOI 10.1007/s007010170111
   Liu JK, 2003, CONT NEUROSURG, V25, P12
   Madhusudhan S, 2011, J MED CASE REP, V5
   Marinis A, 2010, CRIT CARE, V14, DOI 10.1186/cc8908
   Mura P, 2014, EUR REV MED PHARMACO, V18, P3524
   Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x
   Ranabir Salam, 2011, Indian J Endocrinol Metab, V15 Suppl 3, pS188, DOI 10.4103/2230-8210.84862
   Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x
   ROSENBAUM TJ, 1977, J NEUROSURG, V47, P599, DOI 10.3171/jns.1977.47.4.0599
   Sarwar KN, 2013, J CLIN ENDOCR METAB, V98, P2362, DOI 10.1210/jc.2013-1249
   Semple PL, 2007, NEUROSURGERY, V61, P956, DOI 10.1227/01.neu.0000303191.57178.2a
   Swearingen B, 2008, CONT ENDOCRINOL, P357
   Tan SK, 2014, ENDOCR PRACT, V20, pE58, DOI 10.4158/EP13319.CR
   WAKAI S, 1981, J NEUROSURG, V55, P187, DOI 10.3171/jns.1981.55.2.0187
   Waqar M, 2017, PITUITARY, V20, P441, DOI 10.1007/s11102-017-0804-z
   Yang SH, 2008, J KOREAN MED SCI, V23, P1113, DOI 10.3346/jkms.2008.23.6.1113
NR 26
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 201
EP 204
DI 10.1016/j.wneu.2018.09.183
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000157
PM 30292038
DA 2020-05-12
ER

PT J
AU Matsuda, R
   Tamura, K
   Nishimura, F
   Nakagawa, I
   Motoyama, Y
AF Matsuda, Ryosuke
   Tamura, Kentaro
   Nishimura, Fumihiko
   Nakagawa, Ichiro
   Motoyama, Yasushi
TI Subcortical Calculation Mapping During Parietal Glioma Surgery in the
   Dominant Hemisphere: A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake surgery; Calculation center; Glioma; Intraoperative electrical
   stimulation mapping
ID LOW-GRADE GLIOMA; RESECTION; MULTIPLICATION; EXTENT
AB BACKGROUND: To avoid permanent neurologic deficits and preserve brain function in and near the eloquent area, intraoperative electrical stimulation mapping (IESM) is necessary. However, little is known about how these subcortical regions are involved in calculation processing function in patients with glioma.
   CASE DESCRIPTION: We report the case of a 56-year-old, right-handed woman working at a primary school as a teacher who had recurrent left parietal glioma. She underwent initial surgical resection for a low-grade glioma present in the left parietal lobe 14 months before recurrence. The latest magnetic resonance imaging results revealed an enhancing lesion in the cavity of the initial resection with an infiltrating tumor in the parietal lobe. Preserving language function and calculation processing was critical; therefore, she underwent awake surgery using IESM. Thus, the calculation site was elicited by subcortical electrical stimulation at the bottom of the tumor cavity during second resection. At the same point, she could speak normally but could not calculate repeatedly when stimulated. Therefore, we stopped tumor resection. After diagnosing anaplastic astrocytoma, she underwent radiation therapy and chemotherapy. She resumed her normal life as a teacher with preserved language and calculation processing. Eventually, 31 months later, she died from disease progression.
   CONCLUSIONS: In this report, IESM performed during awake surgery in a subcortical site demonstrated a crucial role played by the dominant parietal lobe in calculation.
C1 [Matsuda, Ryosuke; Tamura, Kentaro; Nishimura, Fumihiko; Nakagawa, Ichiro; Motoyama, Yasushi] Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
RP Matsuda, R (reprint author), Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
EM cak93500@pop02.odn.ne.jp
CR Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Della Puppa A, 2015, J NEUROSURG, V122, P1038, DOI 10.3171/2014.10.JNS14261
   Della Puppa A, 2013, J NEUROSURG, V119, P1107, DOI 10.3171/2013.6.JNS122445
   Duffau H, 2002, J NEUROL NEUROSUR PS, V73, P733, DOI 10.1136/jnnp.73.6.733
   Coello AF, 2013, J NEUROSURG, V119, P1380, DOI 10.3171/2013.6.JNS122470
   Ius T, 2012, J NEUROSURG, V117, P1039, DOI 10.3171/2012.8.JNS12393
   Kurimoto M, 2006, NEUROL MED-CHIR, V46, P46, DOI 10.2176/nmc.46.46
   Maldonado IL, 2011, J NEUROSURG, V115, P770, DOI 10.3171/2011.5.JNS112
   Matsuda R, 2014, ACTA NEUROCHIR, V156, P661, DOI 10.1007/s00701-014-2003-2
   Matsuda R, 2012, J NEUROSURG, V117, P1076, DOI 10.3171/2012.9.JNS12662
   Pu S, 2011, STEREOT FUNCT NEUROS, V89, P42, DOI 10.1159/000321186
   Roux FE, 2003, J NEUROSURG, V99, P716, DOI 10.3171/jns.2003.99.4.0716
   Roux FE, 2009, J NEUROSURG, V110, P1291, DOI 10.3171/2008.8.JNS17649
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 205
EP 210
DI 10.1016/j.wneu.2018.10.046
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000158
PM 30326305
DA 2020-05-12
ER

PT J
AU Snyder, R
   Fayed, I
   Dowlati, E
   Seager, A
   Mason, RB
AF Snyder, Rita
   Fayed, Islam
   Dowlati, Ehsan
   Seager, Adair
   Mason, Robert B.
TI Pituitary Adenoma and Craniopharyngioma Collision Tumor: Diagnostic,
   Treatment Considerations, and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Collision tumor; Craniopharyngioma; Neuroimaging diagnostics; Pituitary
   adenoma; Sellar lesions
ID LYMPHOMA
AB BACKGROUND: Different diseases may occur within the same anatomic space and invade one another. Lesions of this nature are described as collision tumors. Collision tumors of the sella are rare, with pituitary adenomacraniopharyngiomas having been described in only 15 cases. We discuss common and rare lesions of the sellar region, their neurodiagnostic qualities, and treatment considerations.
   CASE DESCRIPTION: We present the case of a 49-year-old woman presenting with symptoms of headache and blurred vision who underwent a 2-stage procedure and was found to have a craniopharyngioma and corticotrophic pituitary adenoma in collision. We review the literature on various combinations of sellar collision lesions, noting diagnostic and treatment considerations. Neuroimaging, intraoperative pathology, and histologic review help to provide optimum treatment when unusual conditions of the sella arise.
   CONCLUSIONS: Many mechanisms for the development of collision lesions have been theorized, and further investigation may provide definitive answers regarding the origin of these neoplastic entities.
C1 [Snyder, Rita; Fayed, Islam; Dowlati, Ehsan] Medstar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
   [Seager, Adair] Medstar Washington Hosp Ctr, Dept Pathol, Washington, DC USA.
   [Mason, Robert B.] Medstar Washington Hosp Ctr, Dept Neurosurg, Washington, DC USA.
RP Dowlati, E (reprint author), Medstar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
EM edowlati@gmail.com
OI Fayed, Islam/0000-0002-4183-4744; Dowlati, Ehsan/0000-0001-6739-0793
CR Albuquerque F C, 1999, Pituitary, V1, P279, DOI 10.1023/A:1009962627216
   Almefty KK, 2017, ONCOLOGY YOUMANS WIN, V7
   Bakhit MS, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.03.142
   Ban VS, 2017, NEUROSURGERY, V80, pE170, DOI 10.1093/neuros/nyw003
   BANIK S, 1984, HISTOPATHOLOGY, V8, P135, DOI 10.1111/j.1365-2559.1984.tb02328.x
   Bhatoe HS, 2016, BRAIN DISORD THER, V5, P207
   Chaudhry NS, 2016, J CLIN NEUROSCI, V33, P247, DOI 10.1016/j.jocn.2016.05.018
   Coire CI, 1998, NEUROSURGERY, V42, P650, DOI 10.1097/00006123-199803000-00039
   Cossu G, 2016, CLIN NEUROL NEUROSUR, V149, P122, DOI 10.1016/j.clineuro.2016.08.002
   CUSIMANO MD, 1988, J NEUROSURG, V69, P620, DOI 10.3171/jns.1988.69.4.0620
   Finzi G, 2014, PITUITARY, V17, P53, DOI 10.1007/s11102-013-0465-5
   Gao MT, 2016, J CRANIOFAC SURG, V27, pE128, DOI 10.1097/SCS.0000000000002371
   Glezer A, 2008, ENDOCRIN METAB CLIN, V37, P195, DOI 10.1016/j.ecl.2007.10.003
   Guaraldi F, 2013, ENDOCRINE, V44, P59, DOI 10.1007/s12020-013-9892-3
   Heng L, 2017, WORLD NEUROSURG, V106
   Jin GS, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-178
   Jukes A, 2016, J CLIN NEUROSCI, V31, P202, DOI 10.1016/j.jocn.2016.02.024
   Kochanski Ryan B, 2016, Surg Neurol Int, V7, P21, DOI 10.4103/2152-7806.176674
   Muzumdar D, 2016, INT J SURG CASE REP, V19, P75, DOI 10.1016/j.ijscr.2015.12.005
   Roberts S, 2016, PITUITARY, V19, P472, DOI 10.1007/s11102-016-0727-0
   Sahli R, 2011, PITUITARY, V14, P405, DOI 10.1007/s11102-009-0199-6
   Syro LV, 2000, J ENDOCRINOL INVEST, V23, P37, DOI 10.1007/BF03343674
   Theodosopoulos PV, 2012, SURG MANAGEMENT BRAI, V1, P292
   Valdez R, 2002, HUM PATHOL, V33, P1044, DOI 10.1053/hupa.2002.128063
   Zhang DD, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0436-6
NR 25
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 211
EP 216
DI 10.1016/j.wneu.2018.10.048
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000159
PM 30326307
DA 2020-05-12
ER

PT J
AU Chicoine, NH
   Yaacoub, AP
   Jea, A
   Raskin, JS
AF Chicoine, Nicole H.
   Yaacoub, Alan P.
   Jea, Andrew
   Raskin, Jeffrey S.
TI Surgical Management of Trigeminal Neuralgia in Children
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microvascular decompression in children; Pediatric facial pain;
   Trigeminal neuralgia
ID MICROVASCULAR DECOMPRESSION; COMPRESSION; PROGRAM; NERVE; BOY; 2ND
AB BACKGROUND: Trigeminal neuralgia (TN) is a well-recognized facial pain syndrome. Discrete forms with disparate pain symptoms include classic and atypical. However, atypical facial pain includes neuralgiform pain along a spectrum. Most cases of TN are diagnosed in the adult population. Case reports and series of children have presented TN as a similar entity, with treatment similar to that for adults. We reviewed the pertinent data and present 2 pediatric TN cases successfully treated with microvascular decompression (MVD).
   CASE DESCRIPTION: Two pediatric patients (age 12 and 15 years) with TN refractory to previous medical therapy were identified. Both patients were deemed appropriate surgical candidates and underwent MVD to manage their TN. TN compression was arterial in both cases and involved portions of the anterior inferior cerebellar artery. Patient 1 was pain free 6 months after the procedure. Patient 2 was pain free immediately after the procedure and had been weaned off preoperative symptomatic management at the latest follow-up visit. The most recent follow-up examination was 12 and 8 months for patients 1 and 2, respectively, with both experiencing continued freedom from pain.
   CONCLUSIONS: Few studies have reported on the effectiveness of MVD in the pediatric population for the management of TN. The supporting data and our 2 cases have demonstrated that MVD is effective for pediatric patients to treat their TN. Furthermore, the side effects appear to be minimal, with excellent pain relief after MVD in this patient population.
C1 [Chicoine, Nicole H.] Marian Univ, Coll Osteopath Med, Sch Med, Indianapolis, IN USA.
   [Yaacoub, Alan P.; Jea, Andrew; Raskin, Jeffrey S.] Indiana Univ, Goodman Campbell Brain & Spine, Riley Hosp Children, Dept Neurol Surg,Sect Pediat Neurosurg,Sch Med, Indianapolis, IN 46204 USA.
RP Raskin, JS (reprint author), Indiana Univ, Goodman Campbell Brain & Spine, Riley Hosp Children, Dept Neurol Surg,Sect Pediat Neurosurg,Sch Med, Indianapolis, IN 46204 USA.
EM jraskin@goodmancampbell.com
CR Baabor MG, 2011, ACTA NEUROCHIR SUPPL, V108, P251, DOI 10.1007/978-3-211-99370-5_39
   Bahgat D, 2011, J NEUROSURG, V114, P1306, DOI 10.3171/2010.10.JNS10781
   Barclay JH, 1921, BRIT J SURG, V9, P306, DOI 10.1002/bjs.1800093427
   Bender MT, 2011, CHILD NERV SYST, V27, P2123, DOI 10.1007/s00381-011-1593-8
   Bendtsen L, 2012, J HEADACHE PAIN, V13, pS1, DOI 10.1007/s10194-011-0402-9
   Bennetto L, 2007, BMJ-BRIT MED J, V334, P201, DOI 10.1136/bmj.39085.614792.BE
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Bova FJ, 2001, MED PHYS, V28, P1839, DOI 10.1118/1.1398561
   Childs AM, 2000, ARCH DIS CHILD, V82, P311, DOI 10.1136/adc.82.4.311
   de Siqueira Silvia Regina Dowgan Tesseroli, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V102, pe39
   Dubey A, 2012, Kathmandu Univ Med J (KUMJ), V10, P74
   Eboli P, 2009, NEUROSURGERY, V64, P1183, DOI 10.1227/01.NEU.0000339412.44397.76
   Figueiredo P C, 1989, Arq Neuropsiquiatr, V47, P61
   Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04
   Harris W, 1943, Br Med J, V2, P39
   HILTON DA, 1994, NEUROSURGERY, V35, P299, DOI 10.1227/00006123-199408000-00017
   Ildan F, 1996, NEUROSURG REV, V19, P43, DOI 10.1007/BF00346609
   KATUSIC S, 1991, NEUROEPIDEMIOLOGY, V10, P276, DOI 10.1159/000110284
   Konigsmaier H, 1998, ACTA NEUROCHIR, V140, P1110
   LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001
   Lopez BC, 2004, NEUROSURGERY, V54, P973, DOI 10.1227/01.NEU.0000114867.98896.F0
   Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347
   Love S, 1998, BRAIN PATHOL, V8, P1
   MASON W E, 1991, Journal of Craniomandibular Disorders, V5, P213
   Matthies C, 1997, NEUROSURGERY, V40, P1
   MITTAL B, 1986, J NEUROL NEUROSUR PS, V49, P932, DOI 10.1136/jnnp.49.8.932
   Raieli V, 2001, HEADACHE, V41, P720, DOI 10.1046/j.1526-4610.2001.041007720.x
   Resnick DK, 1998, NEUROSURGERY, V43, P804, DOI 10.1097/00006123-199810000-00047
   ROSKI RA, 1982, J NEUROSURG, V56, P424, DOI 10.3171/jns.1982.56.3.0424
   Solth A, 2008, CHILD NERV SYST, V24, P763, DOI 10.1007/s00381-008-0581-0
   Suh JH, 1999, STEREOT FUNCT NEUROS, V72, P159, DOI 10.1159/000056452
   Yue WL, 2004, INT J PEDIATR OTORHI, V68, P37, DOI 10.1016/j.ijporl.2003.09.003
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 217
EP 221
DI 10.1016/j.wneu.2018.10.074
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000160
PM 30347302
DA 2020-05-12
ER

PT J
AU Yagnick, NS
   Singh, R
   Tripathi, M
   Mohindra, S
   Deora, H
   Suri, A
   Gupta, SK
AF Yagnick, Nishant S.
   Singh, Ramandeep
   Tripathi, Manjul
   Mohindra, Sandeep
   Deora, Harsh
   Suri, Ashish
   Gupta, Sunil K.
TI Need for Grass Root Innovation in Developing Countries: Case for
   Stationary Binder Clips in Scalp Hemostasis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clips; Cost; Hemostasis; History; Raney; Scalp
AB OBJECTIVE: The primary training in any surgical practice starts with tissue handling and effective hemostasis. Neurosurgical procedures start with an incision in the scalp and require summative use of mechanical hemostats and bipolar coagulation to achieve hemostasis. Though Raney clips are the most popular and effective in maintaining hemostasis, their high cost and nonreusability become deterrents for routine use in resource-stricken environments. -
   METHODS: We have compared stationery binder clips of different sizes with Raney clips on the parameters of effectiveness, availability, and cost. Binder clips were also used in intraoperative settings for scalp hemostasis. The comparative efficacy, additional usage of cautery, and need for sterilization are also discussed.
   RESULTS: We describe our experience with simple stationery metal binder clips in maintaining effective hemostasis in a cost-effective manner. The 25-mm size binder clip exerts same force as a Raney clip without any tissue injury. Practical application revealed effective scalp hemostasis up to blood pressure of 150 mm Hg.
   CONCLUSIONS: Stationery binder clips are a cost-effective, ready-to-use alternative for standard Raney clips.
C1 [Yagnick, Nishant S.; Tripathi, Manjul; Mohindra, Sandeep; Gupta, Sunil K.] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
   [Singh, Ramandeep; Suri, Ashish] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
   [Deora, Harsh] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Tripathi, M (reprint author), Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
EM drmanjultripathi@gmail.com
RI Tripathi, Manjul/AAE-7128-2019; DEORA, HARSH/A-5817-2019
OI Tripathi, Manjul/0000-0002-5679-3439; DEORA, HARSH/0000-0003-3247-1117
CR Chivukula S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13565
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 222
EP 226
DI 10.1016/j.wneu.2018.09.182
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000161
PM 30292660
DA 2020-05-12
ER

PT J
AU Sgreccia, A
   Caragliano, A
   Sanfilippo, G
   Campa, S
   Trignani, R
   Giannoni, M
   De Nicola, M
   Consoli, A
   Rodesch, G
   Polonara, G
AF Sgreccia, Alessandro
   Caragliano, Antonio
   Sanfilippo, Giuseppina
   Campa, Serena
   Trignani, Roberto
   Giannoni, Mirko
   De Nicola, Maurizio
   Consoli, Arturo
   Rodesch, Georges
   Polonara, Gabriele
TI Rare and Symptomatic Cavernous Donut-Shaped Aneurysm Treated by Flow
   Diverter Deployment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cavernous; Central; Donut; Flow diverter; Thrombus
ID PIPELINE EMBOLIZATION DEVICE; INTRACRANIAL ANEURYSMS
AB BACKGROUND: We describe the case of a 62-year-old woman who was admitted to our center for acute diplopia secondary to a left III cranial nerve palsy, left eyelid swelling and ptosis, and mild ipsilateral retroorbital pain. No other motor or sensitive deficits were observed.
   CASE DESCRIPTION: Computed tomography angiography and digital subtraction angiography were performed, showing a 25-mm left intracavernous aneurysm with a central intrasaccular thrombus, an intrasaccular "swirling" flow with a donut-shape appearance. A flow-diverter stent was deployed bridging the aneurysmal neck.
   CONCLUSIONS: Twelve months after the procedure the aneurysm was completely occluded, and the patient had totally recovered the cavernous syndrome. A careful literature review has been performed, and the different endovascular approaches have been analyzed.
C1 [Sgreccia, Alessandro; Campa, Serena] AOU Osped Riuniti, Dept Radiol, Ancona, Italy.
   [Giannoni, Mirko; De Nicola, Maurizio; Polonara, Gabriele] AOU Osped Riuniti, Dept Neuroradiol, Ancona, Italy.
   [Trignani, Roberto] AOU Osped Riuniti, Hosp Neurosurg, Ancona, Italy.
   [Caragliano, Antonio] Univ Messina, Dept Sci Biomed & Immagini Funz & Morfol, Neuroradiol Unit, Messina, Italy.
   [Sanfilippo, Giuseppina] IRCCS Fdn Policlin San Matteo, Unit Intervent Radiol & Neuroradiol, Pavia, Italy.
   [Consoli, Arturo; Rodesch, Georges] Hop Foch, Dept Diagnost & Therapeut Neuroradiol, Suresnes, France.
RP Sgreccia, A (reprint author), AOU Osped Riuniti, Dept Radiol, Ancona, Italy.
EM a.sgreccia@hotmail.it
RI Sgreccia, Alessandro/AAD-3751-2019
OI Sgreccia, Alessandro/0000-0002-0834-644X; POLONARA,
   GABRIELE/0000-0002-2866-2749
CR Bijlenga P, 2017, STROKE, V48, P2105, DOI 10.1161/STROKEAHA.117.017391
   Cholet C, 2017, WORLD NEUROSURG, V103, DOI 10.1016/j.wneu.2017.04.088
   Eddleman CS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0920
   Fiorella D, 2009, J NEUROINTERV SURG, V1, P56, DOI 10.1136/jnis.2009.000083
   Ito H, 2016, SURG NEUROL INT, V7, P1069
   Ito Yoshiro, 2013, No Shinkei Geka, V41, P415
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Krings T, 2007, INTERV NEURORADIOL, V13, P117, DOI 10.1177/159101990701300201
   Lee CH, 2017, ACTA NEUROCHIR, V159, P721, DOI 10.1007/s00701-017-3110-7
   Luzzi S, 2018, ACTA NEUROCHIR SUPPL, V129, P25, DOI 10.1007/978-3-319-73739-3_4
   Maingard J, 2016, INTERV NEURORADIOL, V22, P266, DOI 10.1177/1591019915626918
   Mohlenbruch MA, 2015, AM J NEURORADIOL, V36, P1155, DOI 10.3174/ajnr.A4251
   Roccatagliata L, 2010, ACTA NEUROCHIR, V152, P2133, DOI 10.1007/s00701-010-0772-9
   Rosta L, 1988, Acta Neurochir Suppl (Wien), V42, P53
   Takeuchi S, 2012, ACTA NEUROL BELG, V112, P231, DOI 10.1007/s13760-012-0043-z
   Van Rooij SB, 2014, INTERV NEURORADIOL, V20, P55, DOI 10.15274/INR-2014-10009
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 227
EP 231
DI 10.1016/j.wneu.2018.09.219
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000162
PM 30312811
DA 2020-05-12
ER

PT J
AU Rahimizadeh, A
AF Rahimizadeh, Abolfazl
TI Intracranial Migration of a Broken Rod After Orbitocranial Injury in an
   Adult
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniocerebral penetrating injuries; Foreign body; Orbitocranial
ID CAROTID-CAVERNOUS FISTULA; PENETRATING HEAD-INJURY; WOODEN
   FOREIGN-BODIES; CRANIOCEREBRAL INJURIES; SPONTANEOUS MOVEMENT; CRANIAL
   INJURY; STAB WOUNDS; BRAIN; BODY; ABSCESS
AB BACKGROUND: Craniocerebral injuries due to the induction of sharp objects are relatively rare and are nearly always observed in the pediatric rather than the adult population. Orbitocranial injuries involving a piece of smooth steel rod are extremely rare and to our knowledge have yet to be reported in previous publications. When this particular category of injury does occur, the invading intracranial foreign body usually remains lodged within its entry position. This is most often near the entry point and within the frontal lobe after penetrating the orbit. Migration of the penetrating object far from the initial entry point is quite rare and has been historically confined to low-velocity bullet wounds.
   CASE DESCRIPTION: An adult man was injured on the right eyelid by a section of steel rod. The rod had entered the cranium through the right orbital roof and was lodged within the corresponding right frontal lobe. An initial plain radiograph showed that the rod was within the right frontal lobe. However, computed tomographic angiography of the brain performed during the second day of admission demonstrated displacement of the rod to the left hemisphere. This finding was clearly demonstrated through subsequent imaging. As a result of the migration, the rod could be distracted fairly easily through a left parasagittal and interhemispheric approach. Postoperatively, the patient made a full recovery.
   CONCLUSIONS: Migration of traumatically introduced intracranial foreign bodies far from their initial entry places should be suspected in objects possessing sufficient weight and a smooth surface. This means that a correct assessment of the final position of such objects is necessary before surgery, even while the patient is on the operating table.
C1 [Rahimizadeh, Abolfazl] Iran Univ Med Sci, Pars Adv & Minimally Invas Med Manners Res Ctr, Tehran, Iran.
RP Rahimizadeh, A (reprint author), Iran Univ Med Sci, Pars Adv & Minimally Invas Med Manners Res Ctr, Tehran, Iran.
EM a_rahimizadeh@hotmail.com
RI Center, Pars Advanced and Minimally Invasive Medical Manners
   Research/W-4583-2019
OI Rahimizadeh, Abolfazl/0000-0003-0366-5465
CR Abdulbaki A, 2012, CASE REP OPHTHALMOL, DOI 10.1155/2012/742186
   ALBERT DM, 1965, AM J OPHTHALMOL, V60, P1109, DOI 10.1016/0002-9394(65)92825-4
   Bilotta F, 2007, AM J EMERG MED, V25, P198, DOI 10.1016/j.ajem.2006.05.029
   BULLOCK R, 1985, SURG NEUROL, V24, P555, DOI 10.1016/0090-3019(85)90273-3
   CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151
   Cosan T E, 2001, Eur J Emerg Med, V8, P51, DOI 10.1097/00063110-200103000-00010
   Davis GA, 2000, J CLIN NEUROSCI, V7, P545, DOI 10.1054/jocn.2000.0692
   Davis NL, 2004, AM J FOREN MED PATH, V25, P259, DOI 10.1097/01.paf.0000127388.00255.85
   Di Roio C, 2000, CHILD NERV SYST, V16, P503, DOI 10.1007/s003810000291
   Dinakaran S, 1998, J ACCID EMERG MED, V15, P274
   DOOLING JA, 1967, J NEUROSURG, V26, P636, DOI 10.3171/jns.1967.26.6.0636
   Doron Y, 1982, Neurosurg Rev, V5, P35, DOI 10.1007/BF01793629
   Duffy GP, 1996, BRIT J SURG, V56, P685
   Duman H, 2002, NEUROL MED-CHIR, V42, P332, DOI 10.2176/nmc.42.332
   Erkutlu I, 2011, ULUS TRAVMA ACIL CER, V17, P79, DOI 10.5505/tjtes.2011.49092
   Evans RJ, 1996, AM J FOREN MED PATH, V17, P70, DOI 10.1097/00000433-199603000-00013
   FALLON M J, 1992, Journal of Emergency Medicine, V10, P439, DOI 10.1016/0736-4679(92)90273-V
   GINSBERG LE, 1993, AM J NEURORADIOL, V14, P892
   Grant GA, 2012, WORLD NEUROSURG, V77, P479, DOI 10.1016/j.wneu.2011.08.005
   Gupta A, 2011, PEDIATR NEUROSURG, V47, P307, DOI 10.1159/000336882
   HANSEN JE, 1988, J NEUROSURG, V68, P752, DOI 10.3171/jns.1988.68.5.0752
   HERRING CJ, 1988, NEUROSURGERY, V23, P658, DOI 10.1227/00006123-198811000-00022
   James G, 2006, EMERG MED J, V23, DOI 10.1136/emj.2005.032284
   JOOMA R, 1984, SURG NEUROL, V21, P236, DOI 10.1016/0090-3019(84)90193-9
   KAISER MC, 1983, NEURORADIOLOGY, V24, P229, DOI 10.1007/BF00399777
   Kamenski Robert S, 2008, J Trauma, V65, pE13, DOI 10.1097/01.ta.0000224219.64266.4c
   Karabagli H, 2005, PEDIATR NEUROSURG, V41, P148, DOI 10.1159/000085873
   KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042
   Kumar A, 2011, TURK NEUROSURG, V21, P413, DOI 10.5137/1019-5149.JTN.2838-09.3
   Kuntzman J., 1936, STRASBOURG MED J, V98, P154
   KUROIWA T, 1995, SURG NEUROL, V43, P68, DOI 10.1016/0090-3019(95)80042-F
   Liu WK, 2009, NEUROL INDIA, V57, P208, DOI 10.4103/0028-3886.51299
   MILHORAT TH, 1993, NEUROSURGERY, V32, P140
   Moehrlen U, 2004, J TRAUMA, V57, P396, DOI 10.1097/01.TA.0000042170.26772.BB
   MONO J, 1986, ANN EMERG MED, V15, P589, DOI 10.1016/S0196-0644(86)80998-2
   Nishio Y, 2004, ACTA NEUROCHIR, V146, P847, DOI 10.1007/s00701-004-0283-7
   Olumide A A, 1976, Surg Neurol, V6, P306
   ONEILL OR, 1994, SURG NEUROL, V42, P494, DOI 10.1016/0090-3019(94)90079-5
   Orszagh M, 2009, FORENSIC SCI INT, V193, P47, DOI 10.1016/j.forsciint.2009.09.001
   Ozer S, 2010, EUR ARCH OTO-RHINO-L, V267, P155, DOI 10.1007/s00405-009-1118-1
   Ozkan U, 2006, CLIN NEUROL NEUROSUR, V108, P573, DOI 10.1016/j.clineuro.2005.03.002
   RAHIMIZADEH A, 1988, NEUROSURGERY, V22, P160, DOI 10.1097/00006123-198801010-00031
   RAHIMIZADEH A, 1987, NEUROSURGERY, V21, P427
   RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831
   RAHIMIZADEH A, 1987, NEUROSURGERY, V20, P666, DOI 10.1097/00006123-198704000-00030
   Rahimizadeh A, 2018, J SPINE NEUROSURG, V7, P3
   Salar G, 2004, J NEUROSURG, V100, P963, DOI 10.3171/jns.2004.100.5.0963
   Seex K, 1997, J CRANIO MAXILL SURG, V25, P353, DOI 10.1016/S1010-5182(97)80038-8
   Shih TY, 2002, PEDIATR NEUROSURG, V37, P35, DOI 10.1159/000065100
   Shin TH, 2012, J KOREAN NEUROSURG S, V52, P414, DOI 10.3340/jkns.2012.52.4.414
   Slaughter H, 1944, AM J OPHTHALMOL, V27, P617
   SOLOMON KD, 1993, J TRAUMA, V34, P285, DOI 10.1097/00005373-199302000-00020
   SPECHT CS, 1992, SURV OPHTHALMOL, V36, P341, DOI 10.1016/0039-6257(92)90110-F
   Spennato P, 2005, SURG NEUROL, V64, P368, DOI 10.1016/j.surneu.2004.12.003
   Taniura S, 2004, AM J NEURORADIOL, V25, P871
   TIWARI SM, 1978, SURG NEUROL, V9, P267
   Turbin RE, 2006, SURV OPHTHALMOL, V51, P449, DOI 10.1016/j.survophthal.2006.06.008
   YAMAMOTO I, 1985, SURG NEUROL, V23, P396, DOI 10.1016/0090-3019(85)90215-0
NR 59
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 232
EP 238
DI 10.1016/j.wneu.2018.09.185
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000163
PM 30292033
DA 2020-05-12
ER

PT J
AU Pusat, S
   Erbas, YC
   Gocmen, S
   Kocaoglu, M
   Erdogan, E
AF Pusat, Serhat
   Erbas, Yahya Cem
   Gocmen, Selcuk
   Kocaoglu, Murat
   Erdogan, Ersin
TI Natural Course of Myxopapillary Ependymoma: Unusual Case Report and
   Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intradural; Magnetic resonance imaging; Myxopapillary ependymoma; Spinal
   cord tumor
ID SPINAL-CORD TUMORS; FEATURES; SERIES
AB BACKGROUND: Spinal cord ependymomas are the most frequent primary intramedullary tumors of the cord in middle age (40-60 years of age). Myxopapillary ependymomas are low-incidence tumors and occur in the cauda equina and conus medullaris. They are typically described as fleshy, sausage-shaped, vascular lesions.
   CASE DESCRIPTION: In this report, we present a 36-year-old woman who was seen in another hospital with complaints of back pain radiating into both legs 5 years ago. Magnetic resonance imaging (MRI) examinations revealed a lesion releated to the spinal cord. At that point, the patient refused the proposed surgical treatment. Five years later, the patient was referred to our clinic with advancement of the complaint to paraparesis. The new MRI showed an intradural mass at the level of T11 and S1. We performed a total intradural tumor resection. Histopathologic examination revealed a myxopapillary ependymoma.
   CONCLUSIONS: Myxopapillary ependymomas grow slowly and are well defined by MRI. Advancements in radiologic technology and surgical equipment have allowed this tumor type to be treated successfully. Unfortunately, if untreated, these lesions have poor prognosis and result in clinical symptoms such as paraparesis. Surgical treatment of these lesions using total resection was performed total resection and was associated with an excellent postoperative outcome. We highlight the natural course of myxopapillary ependymomas.
C1 [Pusat, Serhat] Sultan Abdulhamid Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Erbas, Yahya Cem; Erdogan, Ersin] Craniospinal Surg Ctr, Ankara, Turkey.
   [Gocmen, Selcuk] Anadolu Med Ctr Hosp, Dept Neurosurg, Kocaeli, Turkey.
   [Kocaoglu, Murat] Pamukkale Univ Hosp, Dept Neurosurg, Denizli, Turkey.
RP Pusat, S (reprint author), Sultan Abdulhamid Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM pusatserhat@yahoo.com
RI Kocaoglu, Murat/AAF-5204-2020
CR Choi JY, 2002, KOREAN J RADIOL, V3, P219, DOI 10.3348/kjr.2002.3.4.219
   Elsberg CA, 1911, AM J MED SCI, V142, P636
   Ertan Y, 2006, EGE TIP DERGISI, V45, P13
   Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3
   Greenberg MS, 2013, NOROSIRURJI KITABI
   GREENWOOD J, 1954, J NEUROSURG, V11, P616, DOI 10.3171/jns.1954.11.6.0616
   Grimm S, 2009, EXPERT REV NEUROTHER, V9, P1487, DOI 10.1586/ERN.09.101
   Hanbali F, 2002, NEUROSURGERY, V51, P1162, DOI 10.1097/00006123-200211000-00010
   Huang YH, 2013, CLIN NEUROL NEUROSUR, V115, P2130, DOI 10.1016/j.clineuro.2013.08.007
   Karabagli H, 2010, J NEUROL SCI-TURK, V27, P244
   Li J, 2012, J NEUROL SCI-TURK, V29, P794
   Nakamura M, 2008, SPINAL CORD, V46, P282, DOI 10.1038/sj.sc.3102130
   Ngo Trung P, 2013, J Can Chiropr Assoc, V57, P150
   Raco A, 2005, NEUROSURGERY, V56, P972, DOI 10.1227/01.NEU.0000158318.66568.CC
   Sakai Y, 2009, SPINE, V34, P1619, DOI 10.1097/BRS.0b013e3181a983d8
   Sun B, 2003, J NEUROIMAGING, V13, P346, DOI 10.1177/1051228403257619
   Volpp PB, 2007, INT J RADIAT ONCOL, V69, P1199, DOI 10.1016/j.ijrobp.2007.04.058
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 239
EP 242
DI 10.1016/j.wneu.2018.10.028
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000164
PM 30321682
DA 2020-05-12
ER

PT J
AU Jiang, LD
   Qi, M
   Ye, M
   Li, M
   Bao, YH
   Liang, JT
AF Jiang, Lidan
   Qi, Meng
   Ye, Ming
   Li, Meng
   Bao, Yuhai
   Liang, Jiantao
TI Recurrent Secondary Trigeminal Neuralgia Caused by Obliterated Tentorial
   Dural Arteriovenous Fistula Cured with Surgical Resection: Case Report
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dilated vein; Embolization; Surgical resection; Tentorial dural
   arteriovenous fistula; Trigeminal neuralgia
ID MALFORMATION; EMBOLIZATION
AB BACKGROUND: Trigeminal neuralgia (TN) caused by a tentorial dural arteriovenous fistula (TDAVF) is quite rare. To date, only 10 cases and 2 small case series have been reported in this regard, and most were treated with either embolization or surgery. Here, we report a unique case of a TDAVF presented as TN, which was embolized with Onyx first and resected later.
   CASE DESCRIPTION: A 57-year-old male presented with right-sided TN. Magnetic resonance imaging revealed a variceal venous dilation occupying the right lateral pontine cistern and multiple venous flow void signals adjacent to the right trigeminal nerve root entry zone. Digital subtraction angiography revealed the right TDAVF, which was completely embolized with transarterial Onyx later. The patient remained symptom free for 1 year before TN recurred. Digital subtraction angiography did not exhibit the recurrence of fistula. After resection of embolized dilated veins, the symptom alleviated and the patient remained symptom free for the 5-month follow-up to date.
   CONCLUSIONS: Even complete obliteration of fistula could cause the recurrence of neuralgia, and resection of embolized dilated veins might be effective for the treatment of TN in such recurrent cases.
C1 [Jiang, Lidan; Qi, Meng; Ye, Ming; Li, Meng; Bao, Yuhai; Liang, Jiantao] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Liang, JT (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM liangjt0001@163.com
OI YE, Ming/0000-0001-8148-8201
CR Akhaddar A, 2010, HEADACHE, V50, P861, DOI 10.1111/j.1526-4610.2009.01555.x
   Cannizzaro D, 2015, AM J NEURORADIOL, V36, P1905, DOI 10.3174/ajnr.A4394
   Ge HJ, 2016, INTERV NEURORADIOL, V22, P600, DOI 10.1177/1591019916654430
   Ito M, 1996, SURG NEUROL, V45, P370, DOI 10.1016/0090-3019(95)00438-6
   Matsushige T, 2006, SURG NEUROL, V66, P519, DOI 10.1016/j.surneu.2006.01.022
   MENDELOWITSCH A, 1990, EUR NEUROL, V30, P338, DOI 10.1159/000117368
   Mendes GAC, 2016, CLIN NEURORADIOL, V26, P117, DOI 10.1007/s00062-015-0417-8
   OTT D, 1993, HEADACHE, V33, P503, DOI 10.1111/j.1526-4610.1993.hed3309503.x
   Prasad S, 2009, NEUROLOGIST, V15, P87, DOI 10.1097/NRL.0b013e3181775ac3
   Rahme R, 2007, ACTA NEUROCHIR, V149, P937, DOI 10.1007/s00701-007-1251-9
   Robert T, 2015, CLIN NEUROL NEUROSUR, V138, P83, DOI 10.1016/j.clineuro.2015.08.004
   Tomak PR, 2003, NEUROSURGERY, V52, P750, DOI 10.1227/01.NEU.0000053221.22954.85
   Wakuta N, 2013, MED BULL FUKUOKA UNI, V40, P61
   X Lu, 2013, CHINA SCI WORLD J, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0057657
NR 14
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 243
EP 248
DI 10.1016/j.wneu.2018.08.176
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000165
PM 30176399
DA 2020-05-12
ER

PT J
AU Hitti, FL
   Gonzalez-Alegre, P
   Lucas, TH
AF Hitti, Frederick L.
   Gonzalez-Alegre, Pedro
   Lucas, Timothy H.
TI Gene Therapy for Neurologic Disease: A Neurosurgical Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Clinical trials; Gene therapy; Neurosurgical gene delivery; Review;
   Viral vector
ID PHASE-I TRIAL; TYPE-1 THYMIDINE KINASE; DEEP-BRAIN-STIMULATION;
   HUMAN-MALIGNANT GLIOMA; RECURRENT GLIOBLASTOMA-MULTIFORME; MEDIATED
   CYTOTOXIC IMMUNOTHERAPY; PARKINSONS-DISEASE; OPEN-LABEL; SURGICAL
   RESECTION; ADENOVIRAL VECTOR
AB Recent approval of unprecedented gene therapies has signaled the beginning of a new era in modern medicine. This rapidly changing landscape underscores the importance of neurosurgeons developing a fundamental understanding of gene therapy, because many neurologic disorders are caused by derangements in gene expression. Gene therapy, the transfer of genetic material to alter endogenous gene expression or introduce exogenous genes, has emerged as a novel therapeutic approach to treat a wide range of diseases. There are several methods to transfer genetic material to the nervous system through viral transduction. Here, we synthesize the latest developments in gene therapy for neurologic disorders and the neurosurgical approaches to treat them.
C1 [Hitti, Frederick L.; Lucas, Timothy H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Gonzalez-Alegre, Pedro] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
RP Hitti, FL (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM Frederick.Hitti@uphs.upenn.edu
OI Hitti, Frederick/0000-0002-5308-9817
FU Spark Therapeutics; Teva Pharmaceuticals; U.S. National Institutes of
   Health/National Institute of Neurological Disorders and StrokeUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [UH3-NS094355-01]
FX P.G.A. received licensing fees from Spark Therapeutics and consulting
   fees from Teva Pharmaceuticals and receives funding from the U.S.
   National Institutes of Health/National Institute of Neurological
   Disorders and Stroke (UH3-NS094355-01).
CR Al-Chalabi A, 2017, NAT REV NEUROL, V13, P96, DOI 10.1038/nrneurol.2016.182
   Alavi JB, 2001, EXPERT OPIN BIOL TH, V1, P239, DOI 10.1517/14712598.1.2.239
   Bjartmarz H, 2007, STEREOT FUNCT NEUROS, V85, P235, DOI 10.1159/000103262
   Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525
   Canter RG, 2016, NATURE, V539, P187, DOI 10.1038/nature20412
   Chiocca EA, 2008, MOL THER, V16, P618, DOI 10.1038/sj.mt.6300396
   Chiocca EA, 2011, J CLIN ONCOL, V29, P3611, DOI 10.1200/JCO.2011.35.5222
   Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021
   Chittiboina P, 2015, J NEUROSURG, V122, P1173, DOI 10.3171/2014.11.JNS131888
   Christine CW, 2009, NEUROLOGY, V73, P1662, DOI 10.1212/WNL.0b013e3181c29356
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D
   Fink DJ, 2011, ANN NEUROL, V70, P207, DOI 10.1002/ana.22446
   Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752
   Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403
   Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016
   FREEMAN SM, 1995, CANCER LETT, V92, P167, DOI 10.1016/0304-3835(95)03771-N
   Gagandeep S, 1996, CANCER GENE THER, V3, P83
   Germano IM, 2003, J NEURO-ONCOL, V65, P279, DOI 10.1023/B:NEON.0000003657.95085.56
   Hirsch ML, 2016, METHODS MOL BIOL, V1382, P21, DOI 10.1007/978-1-4939-3271-9_2
   Ho AL, 2018, J NEUROSURG, V128, P1165, DOI 10.3171/2017.1.JNS162046
   Holloway KL, 2005, J NEUROSURG, V103, P404, DOI 10.3171/jns.2005.103.3.0404
   Immonen A, 2004, MOL THER, V10, P967, DOI 10.1016/j.ymthe.2004.08.002
   Izquierdo M, 1996, GENE THER, V3, P491
   Jackson R.J., 2013, COLD SPRING HARB PER, P5
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Katz ML, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac6191
   Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/10430349850019436
   Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508
   Latchman DS, 2001, GENE, V264, P1, DOI 10.1016/S0378-1119(01)00322-5
   Leone P, 2000, ANN NEUROL, V48, P27, DOI 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6
   Leone P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003454
   LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4
   Lonser RR, 2015, J NEUROSURG, V122, P697, DOI 10.3171/2014.10.JNS14229
   MACIUNAS RJ, 1994, NEUROSURGERY, V35, P682, DOI 10.1227/00006123-199410000-00015
   Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205
   Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6
   Marks WJ, 2010, LANCET NEUROL, V9, P1164, DOI 10.1016/S1474-4422(10)70254-4
   Mastakov MY, 2001, MOL THER, V3, P225, DOI 10.1006/mthe.2001.0246
   Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866
   McCarty DM, 2008, MOL THER, V16, P1648, DOI 10.1038/mt.2008.171
   Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504
   Mesulam MM, 2013, J COMP NEUROL, V521, P4124, DOI 10.1002/cne.23415
   Muramatsu S, 2010, MOL THER, V18, P1731, DOI 10.1038/mt.2010.135
   Nagatsu T, 2009, PARKINSONISM RELAT D, V15, pS3, DOI 10.1016/S1353-8020(09)70004-5
   Obeso JA, 2000, NEUROLOGY, V55, pS7
   Olanow CW, 2004, ANNU REV MED, V55, P41, DOI 10.1146/annurev.med.55.091902.104422
   Ostrem JL, 2016, J NEUROSURG, V124, P908, DOI 10.3171/2015.4.JNS15173
   Palu G, 1999, GENE THER, V6, P330, DOI 10.1038/sj.gt.3300805
   Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664
   Prados MD, 2003, J NEURO-ONCOL, V65, P269, DOI 10.1023/B:NEON.0000003588.18644.9c
   Rahman M, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.7.FOCUS09118
   Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499
   Rajasethupathy P, 2016, CELL, V165, P524, DOI 10.1016/j.cell.2016.03.047
   Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354
   Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184
   Raper SE, 2002, HUM GENE THER, V13, P163, DOI 10.1089/10430340152712719
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Salegio EA, 2016, METHODS MOL BIOL, V1382, P217, DOI 10.1007/978-1-4939-3271-9_15
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Sandmair AM, 2000, HUM GENE THER, V11, P2197, DOI 10.1089/104303400750035726
   Saraiva J, 2016, J CONTROL RELEASE, V241, P94, DOI 10.1016/j.jconrel.2016.09.011
   Schulz A, 2018, NEW ENGL J MED, V378, P1898, DOI 10.1056/NEJMoa1712649
   Sengupta R, 2016, BIOL PROCED ONLINE, V18, DOI 10.1186/s12575-016-0044-z
   Shand N, 1999, HUM GENE THER, V10, P2325, DOI 10.1089/10430349950016979
   Smitt PS, 2003, MOL THER, V7, P851, DOI 10.1016/S1525-0016(03)00100-X
   SPIEGEL EA, 1947, SCIENCE, V106, P349, DOI 10.1126/science.106.2754.349
   Srivastava A, 2016, CURR OPIN VIROL, V21, P75, DOI 10.1016/j.coviro.2016.08.003
   Tai CH, 2010, EUR J NEUROL, V17, P1377, DOI 10.1111/j.1468-1331.2010.03035.x
   Tardieu M, 2014, HUM GENE THER, V25, P506, DOI 10.1089/hum.2013.238
   Trask TW, 2000, MOL THER, V1, P195, DOI 10.1006/mthe.2000.0030
   Tuszynski MH, 2015, JAMA NEUROL, V72, P1139, DOI 10.1001/jamaneurol.2015.1807
   Vakulskas CA, 2018, NAT MED, V24, P1216, DOI 10.1038/s41591-018-0137-0
   Warrington KH, 2006, HUM GENET, V119, P571, DOI 10.1007/s00439-006-0165-6
   Watowich SS, 2010, IMMUNOL REV, V238, P76, DOI 10.1111/j.1600-065X.2010.00949.x
   Wheeler LA, 2016, NEURO-ONCOLOGY, V18, P1137, DOI 10.1093/neuonc/now002
   Wilson JM, 2014, HUM GENE THER, V25, P257, DOI 10.1089/hum.2014.2511
   Wilson JM, 2009, MOL GENET METAB, V96, P151, DOI 10.1016/j.ymgme.2008.12.016
   Worgall S, 2008, HUM GENE THER, V19, P463, DOI 10.1089/hum.2008.022
NR 79
TC 2
Z9 2
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 261
EP 273
DI 10.1016/j.wneu.2018.09.097
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000171
PM 30253990
DA 2020-05-12
ER

PT J
AU Bustillo, MA
   Lien, CA
   Mack, PF
   Kopman, DJ
   Safavynia, SA
   Rubin, L
   Stein, D
   Hartl, R
   Stieg, PE
   Hernandez, RN
   Goldstein, PA
AF Bustillo, Maria A.
   Lien, Cynthia A.
   Mack, Patricia Fogarty
   Kopman, David J.
   Safavynia, Seyed A.
   Rubin, Lori
   Stein, David
   Hartl, Roger
   Stieg, Philip E.
   Hernandez, R. Nick
   Goldstein, Peter A.
TI Optimizing Patient Access During an Emergency While Using Intraoperative
   Computed Tomography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Education; Intraoperative imaging; Operating room safety; Patient
   safety; Quality improvement; Resuscitation; Spine
AB BACKGROUND: As minimally invasive spine surgery evolves, spine surgeons increasingly rely on advanced intraoperative computed tomography (iCT). iCT provides rapid acquisition of high-resolution images, reduces radiation exposure, improves surgical accuracy, and decreases operative time. However, all iCT systems currently available pose a patient safety risk as their physical space requirements limit patient access in the event of an emergency, particularly when patients are in the prone position. After a near-cardiac arrest at our institution during posterior cervical spine surgery, it was apparent that the presence of the iCT complicated the ability to rapidly reposition the patient in order to provide appropriate resuscitation.
   METHODS: To ensure our ability to provide timely care during an emergency, we determined that a process which included all members of the operating room (OR) team was required. We held an initial planning meeting where a detailed plan-of-action was created, reviewed, and revised in response to feedback from all stakeholders. We then simulated a cardiac arrest to test our resuscitation plan with all members of the neurosurgery team. A mannequin was positioned prone on an OR table within the iCT, and a resuscitation plan was created.
   RESULTS: The team orchestrated the mock resuscitation, and the time of cardiac arrest in the prone position to supine repositioning required 110 seconds. The simulation was recorded for post-"code" performance review. Application of the protocol during an actual cardiac arrest was associated with successful restoration of spontaneous circulation and full recovery.
   CONCLUSIONS: The development and rehearsal of an emergency plan of action greatly facilitated the timely responsiveness of the neurosurgical OR team during a simulated cardiac arrest and was an effective way to identify and address key logistical issues regarding the use of an iCT system.
C1 [Bustillo, Maria A.; Lien, Cynthia A.; Mack, Patricia Fogarty; Kopman, David J.; Safavynia, Seyed A.; Rubin, Lori; Stein, David; Goldstein, Peter A.] Weill Cornell Med Coll, Div Neuroanesthesiol, Dept Anesthesiol, New York, NY 10065 USA.
   [Bustillo, Maria A.; Hartl, Roger; Stieg, Philip E.; Hernandez, R. Nick] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10065 USA.
   [Goldstein, Peter A.] Weill Cornell Med Coll, Div Med Eth, Dept Med, New York, NY USA.
   [Lien, Cynthia A.] Med Coll Wisconsin, Dept Anesthesiol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
   [Hernandez, R. Nick] Rutgers Med Sch, Dept Neurosurg, 185 W S Orange Ave, Newark, NJ 07103 USA.
RP Bustillo, MA (reprint author), Weill Cornell Med Coll, Div Neuroanesthesiol, Dept Anesthesiol, New York, NY 10065 USA.; Bustillo, MA (reprint author), Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10065 USA.
EM bustilo@med.cornell.edu
OI Safavynia, Seyed A./0000-0002-3598-368X
FU Department of Anesthesiology, Weill Cornell Medical College, New York,
   New York
FX This work was supported by the Department of Anesthesiology, Weill
   Cornell Medical College, New York, New York.
CR Atkinson M C, 2000, Crit Care Resusc, V2, P188
   Bhatnagar V, 2018, J EMERG TRAUMA SHOCK, V11, P31, DOI 10.4103/JETS.JETS_58_17
   Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467
   Cox T, 2015, SURG CLIN N AM, V95, P827, DOI 10.1016/j.suc.2015.03.005
   Hecht N, 2016, EUR SPINE J, V25, P716, DOI 10.1007/s00586-015-3814-4
   Kim TT, 2016, BIOMED RES INT, DOI 10.1155/2016/5716235
   Kwon MJ, 2017, ANESTH ANALG, V124, P520, DOI 10.1213/ANE.0000000000001369
   Lian XF, 2016, BIOMED RES INT, DOI 10.1155/2016/5027340
   Murray WB, 2000, J CLIN ANESTH, V12, P633, DOI 10.1016/S0952-8180(00)00223-3
   Slomczykowski M, 1999, SPINE, V24, P975, DOI 10.1097/00007632-199905150-00009
   Su AW, 2016, J PEDIATR ORTHOPED, V36, P621, DOI 10.1097/BPO.0000000000000504
NR 11
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP 274
EP +
DI 10.1016/j.wneu.2018.09.134
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000172
PM 30266700
DA 2020-05-12
ER

PT J
AU Adin, ME
   Ozmen, CA
   Aygun, N
AF Adin, Mehmet Emin
   Ozmen, Cihan Akgul
   Aygun, Nafi
TI Utility of the Vidian Canal in Endoscopic Skull Base Surgery: Detailed
   Anatomy and Relationship to the Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomic variation; Endoscopic surgery; Multidetector computed
   tomography; Skull-base; Sphenoid sinus; Vidian canal
ID EXPANDED ENDONASAL APPROACH; SPHENOID SINUS; CT
AB OBJECTIVE: To investigate key anatomic features of the vidian canal that have a critical role in planning and performing endoscopic skull base surgeries.
   METHODS: We reviewed skull base computed tomographic images of 640 consecutive subjects. Studies were analyzed in axial, coronal and sagittal planes.
   RESULTS: The mean (+/- SD) length of the vidian canal was 15.4 +/- 2.0 mm in female subjects and 16.6 +/- 1.7 mm in male subjects, and the difference between genders was statistically significant (P<0.001). The most common rostral-caudal course of the vidian canal was medial to lateral and was followed by the straight course, tortuous course, and lateral-to-medial course. The frequency of pneumatization pattern from most common to least common was types 0, III, II and I. Of 342 evaluated sides, the vidian canal was located below the level of the anterior genu of petrous ICA in 303 (89%) sides, at same level with the anterior genu of petrous ICA in twenty-five(7%) sides, and above the level of the anterior genu of petrous ICA in fourteen(4.1%) sides.
   CONCLUSIONS: A variety of previously undefined features of the vidian canal that can alter the course of surgical procedure were defined. The position of the vidian canal with respect to the petrous internal carotid artery (ICA) was extensively described. From a surgical standpoint, a working room inferior and medial to the vidian canal might not always be a safe approach, because the vidian canal could be located superior to the level of the anterior genu of petrous ICA according to our findings in the present study.
C1 [Adin, Mehmet Emin] Tatvan Can Hosp, Dept Radiol, Bitlis, Turkey.
   [Ozmen, Cihan Akgul] Dicle Univ, Sch Med, Dept Radiol, Diyarbakir, Turkey.
   [Aygun, Nafi] Johns Hopkins Univ, Sch Med, Div Neuroradiol, Russel H Morgan Dept Radiol, Baltimore, MD USA.
RP Adin, ME (reprint author), Tatvan Can Hosp, Dept Radiol, Bitlis, Turkey.
EM emin.adin@gmail.com
FU Scientific and Technological Research Council of TurkeyTurkiye Bilimsel
   ve Teknolojik Arastirma Kurumu (TUBITAK)
FX Mehmet Emin Adin thanks The Scientific and Technological Research
   Council of Turkey for their support.
CR Adin ME, 2015, MINIMAL ACCESS SKULL, P8
   Aygun N., 2017, RADIOL CLIN N AM, V55, P13
   Davoodi M, 2009, Pak J Biol Sci, V12, P522, DOI 10.3923/pjbs.2009.522.525
   Gao Z, 2015, J NEUROL SURG PART B, V76, P176, DOI 10.1055/s-0034-1395488
   Hewaidi GH, 2008, LIBYAN J MED, V3, P128, DOI 10.4176/080307
   Jane John A Jr, 2005, Neurosurg Focus, V19, pE2
   Kassam AB, 2008, J NEUROSURG, V108, P177, DOI 10.3171/JNS/2008/108/01/0177
   Kim HS, 1996, NEURORADIOLOGY, V38, pS120, DOI 10.1007/s002340050936
   Lin SC, 2010, ARCH OTOLARYNGOL, V136, P595, DOI 10.1001/archoto.2010.72
   Mason EC, 2018, OPER NEUROSURG, V15, P577, DOI 10.1093/ons/opx305
   Mato D, 2015, NEUROL MED-CHIR, V55, P71, DOI 10.2176/nmc.oa.2014-0173
   Mohebbi A, 2017, BRAZ J OTORHINOLAR, V83, P381, DOI 10.1016/j.bjorl.2016.04.013
   Osawa S, 2009, NEUROSURGERY, V64, P385, DOI 10.1227/01.NEU.0000338945.54863.D9
   Padhye V, 2014, INT ARCH OTORHINOLAR, V18, pS173, DOI 10.1055/s-0034-1395266
   PANDOLFO I, 1987, AM J NEURORADIOL, V8, P479
   Prevedello DM, 2007, J NEUROSURG, V107, P206, DOI 10.3171/JNS-07/07/0206
   Priyadarshini D, 2015, TURK NEUROSURG, V25, P289, DOI 10.5137/1019-5149.JTN.10638-14.0
   Rumboldt Z, 2002, AM J ROENTGENOL, V179, P267, DOI 10.2214/ajr.179.1.1790267
   Snyderman Carl H., 2009, Keio Journal of Medicine, V58, P152
   Spaeth J, 1997, INT J PEDIATR OTORHI, V39, P25, DOI 10.1016/S0165-5876(96)01458-9
   Unal B, 2006, SURG RADIOL ANAT, V28, P195, DOI 10.1007/s00276-005-0073-9
   Vaezi A, 2015, LARYNGOSCOPE, V125, P577, DOI 10.1002/lary.24989
   Vescan AD, 2007, LARYNGOSCOPE, V117, P1338, DOI 10.1097/MLG.0b013e31806146cd
   Wang XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091444
   Yazar F, 2007, CLIN ANAT, V20, P751, DOI 10.1002/ca.20496
   Yegin Y, 2017, TURK ARCH OTORHINOL, V55, P22, DOI 10.5152/tao.2017.2038
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E132
EP E138
DI 10.1016/j.wneu.2018.09.048
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000019
PM 30240854
DA 2020-05-12
ER

PT J
AU Adogwa, O
   Davison, MA
   Vuong, VD
   Desai, SA
   Lilly, DT
   Moreno, J
   Cheng, J
   Bagley, C
AF Adogwa, Owoicho
   Davison, Mark A.
   Vuong, Victoria D.
   Desai, Shyam A.
   Lilly, Daniel T.
   Moreno, Jessica
   Cheng, Joseph
   Bagley, Carlos
TI Regional Variation in Opioid Use After Lumbar Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar decompression; Lumbar spondylolisthesis; Lumbar stenosis; Lumbar
   surgery; Opioid use; Regional variation; Symptomatic lower back pain
ID GEOGRAPHIC-VARIATION; NAIVE PATIENTS; UNITED-STATES; BACK-PAIN; TRENDS;
   RISK
AB OBJECTIVE: The aim of this study was to investigate regional variations in use of opioids after lumbar decompression and fusion surgery for patients with symptomatic lumbar stenosis or spondylolisthesis.
   METHODS: An insurance database, including private/commercially insured and Medicare Advantage beneficiaries, was queried for patients undergoing 1-level, 2-level, or 3-level index lumbar decompression and fusion procedures between 2007 and 2016. Research records were searchable by International Classification of Diseases diagnosis and procedure codes, and generic drug codes specific to Humana. Opioid use 6 months before index surgery to 2 years after surgery was assessed.
   RESULTS: Of the 13,257 patients included in the study, 63.1% were from the South, 24.3% from the Midwest, 10.5% from the West, and 2.1% from the Northeast. Of patients, 57.8% had a history of opioid use before index surgery, of whom 64.4% were from the South and 23.0% from the Midwest. Over the 6-month preoperative period, 51.6 opioid pills were billed by opioid users monthly (Midwest, 52.7 pills/patient/month; Northeast, 64.9 pills/patient/month; South, 50.6 pills/patient/month; West, 52.2 pills/patient/month). During the 2-year period after surgery, an average of 33.6 opioid pills were billed by opioid users monthly (Midwest, 32.9 pills/patient/month; Northeast, 35.4 pills/patient/month; South, 33.9 pills/patient/month; West, 32.9 pills/patient/month). In a multivariate logistic regression analysis, receiving treatment in the South (odds ratio, 1.18; 95% confidence interval, 1.07-1.29) or West (odds ratio, 1.26; 95% confidence interval, 1.10-1.45) was independently associated with prolonged (> 1 year) opioid use after index surgery.
   CONCLUSIONS: Our study suggests that regional variations may exist in the use of opioids after lumbar decompression and fusion surgery for patients with symptomatic lumbar stenosis or spondylolisthesis.
C1 [Adogwa, Owoicho; Davison, Mark A.; Vuong, Victoria D.; Desai, Shyam A.; Lilly, Daniel T.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   [Moreno, Jessica; Bagley, Carlos] Univ Texas Southwestern Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA.
   [Cheng, Joseph] Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA.
RP Adogwa, O (reprint author), Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
EM owoicho.adogwa@gmail.com
OI Desai, Shyam/0000-0001-5823-8546
CR Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827
   Brat GA, 2018, BMJ-BRIT MED J, V360, P5790
   Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006
   Clarke H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1251
   Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4
   Johnson SP, 2016, J HAND SURG-AM, V41, P947, DOI 10.1016/j.jhsa.2016.07.113
   Luo XM, 2004, SPINE, V29, P884, DOI 10.1097/00007632-200404150-00012
   McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007
   Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183
   Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563
   Raebel MA, 2013, JAMA-J AM MED ASSOC, V310, P1369, DOI 10.1001/jama.2013.278344
   Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb
   Sun EC, 2016, JAMA INTERN MED, V176, P1286, DOI 10.1001/jamainternmed.2016.3298
   Webster BS, 2009, AM J IND MED, V52, P162, DOI 10.1002/ajim.20655
   Xu Jiaquan, 2016, NCHS Data Brief, P1
   Zerzan JT, 2006, MED CARE, V44, P1005, DOI 10.1097/01.mlr.0000228025.04535.25
   Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E691
EP E699
DI 10.1016/j.wneu.2018.09.192
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000085
PM 30292669
DA 2020-05-12
ER

PT J
AU Alattar, AA
   Carroll, KT
   Bryant, AK
   Hirshman, B
   Joshi, R
   Carter, BS
   Harismendy, O
   Chen, CC
AF Alattar, Ali A.
   Carroll, Kate T.
   Bryant, Alex K.
   Hirshman, Brian
   Joshi, Rushikesh
   Carter, Bob S.
   Harismendy, Olivier
   Chen, Clark C.
TI Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade
   II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and
   the Surveillance, Epidemiology, and End Results Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Glioma; Gross total resection; IDH; Tumor location; WHO grade
ID GLIOBLASTOMA; IDH1; RESECTION; MUTATION; DISTINCT; GLIOMAS
AB BACKGROUND: Previous work in anaplastic astrocytoma (AA) demonstrated that the survival benefit from gross total resection (GTR) is modified by age and tumor location. Here, we determined the influence of age and tumor location on survival benefit from GTR in diffuse astrocytoma (DA).
   METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) database (1999e2010). We used KaplanMeier curves and Cox survival models to determine the survival benefit from GTR in populations stratified by age and tumor location. We determined the prevalence of the mutated isocitrate dehydrogenase (mIDH) using The Cancer Genome Atlas (TCGA).
   RESULTS: We identified 1980 patients with DA. For frontal DAs, GTR resulted in improved survival relative to subtotal resection in all ages (age <= 50 years hazard ratio [HR], 0.56; P = 0.002; age > 50 years HR, 0.41; P < 0.001). For nonfrontal DAs, only patients <= 50 years experienced improved survival with GTR (age <= 50 years HR, 0.55; P = 0.002; age > 50 years HR, 0.78; P = 0.114). For patients <= 50 years with frontal tumors, survival was comparable between DA and AA after GTR (75% survival DA: 80 months, AA: 89 months, P = 0.973). In TCGA, these tumors were nearly uniformly mIDH (DA: 98%; AA: 90%, P = 0.11). However, for patients <= 50 years with nonfrontal tumors, there was a survival difference after GTR (75% survival DA: 80 months, AA: 30 months, P = 0.001) despite comparable mIDH prevalence (DA: 82%, AA: 75%, P = 0.49).
   CONCLUSIONS: Age and tumor location modify the survival benefit derived from GTR in DA. Survival patterns in SEER imperfectly correlated with mIDH prevalence in TCGA, suggesting that tumor grade and mIDH status convey nonredundant prognostic information in select clinical contexts.
C1 [Alattar, Ali A.; Carroll, Kate T.; Bryant, Alex K.; Joshi, Rushikesh] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
   [Hirshman, Brian; Chen, Clark C.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.
   [Harismendy, Olivier; Chen, Clark C.] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.
   [Carter, Bob S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
   [Hirshman, Brian] Carnegie Mellon Univ, Sch Comp Sci, Ctr Computat Anal Social & Org Syst, Pittsburgh, PA 15213 USA.
   [Chen, Clark C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Chen, CC (reprint author), Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.; Chen, CC (reprint author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.; Chen, CC (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM ccchen@umn.edu
OI Joshi, Rushikesh/0000-0001-5251-5856
FU UC San Diego School of Medicine
FX This study was supported by a Clinical Research Fellowship awarded to A.
   A. Alattar from the UC San Diego School of Medicine.
CR Alattar AA, 2018, J NEUROSURG, V128, P1076, DOI 10.3171/2016.11.JNS161974
   Beiko J, 2014, NEURO-ONCOLOGY, V16, P81, DOI 10.1093/neuonc/not159
   Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121
   Carroll KT, 2018, WORLD NEUROSURG, V111, pE790, DOI 10.1016/j.wneu.2017.12.165
   Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9
   Kawaguchi T, 2016, J NEURO-ONCOL, V129, P505, DOI 10.1007/s11060-016-2201-2
   Kim W, 2012, NEUROSURG CLIN N AM, V23, P471, DOI 10.1016/j.nec.2012.04.009
   Lai A, 2011, J CLIN ONCOL, V29, P4482, DOI 10.1200/JCO.2010.33.8715
   Nathan H, 2008, ANN SURG ONCOL, V15, P415, DOI 10.1245/s10434-007-9658-3
   National Cancer Institute, 1973, SEER INC DAT 1973 20
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Pace A, 2003, ANN ONCOL, V14, P1722, DOI 10.1093/annonc/mdg502
   Paldor I, 2016, J CLIN NEUROSCI, V34, P128, DOI 10.1016/j.jocn.2016.05.017
   Paldor I, 2016, J CLIN NEUROSCI, V34, P117, DOI 10.1016/j.jocn.2016.05.016
   Sonoda Y, 2015, BRAIN TUMOR PATHOL, V32, P99, DOI 10.1007/s10014-014-0211-3
   Wessels PH, 2003, LANCET NEUROL, V2, P395, DOI 10.1016/S1474-4422(03)00434-4
   Zada G, 2012, WORLD NEUROSURG, V77, P518, DOI 10.1016/j.wneu.2011.05.051
   Zhang CB, 2014, J CANCER RES CLIN, V140, P45, DOI 10.1007/s00432-013-1519-9
NR 18
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E411
EP E418
DI 10.1016/j.wneu.2018.09.124
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000051
PM 30266697
DA 2020-05-12
ER

PT J
AU Ali, SMA
   Mirza, Y
   Ahmad, Z
   Zahid, N
   Enam, SA
AF Ali, Syed Muhammad Adnan
   Mirza, Yumna
   Ahmad, Zubair
   Zahid, Nida
   Enam, Syed Ather
TI Human Papillomavirus and Human Cytomegalovirus Infection and Association
   with Prognosis in Patients with Primary Glioblastoma in Pakistan
SO WORLD NEUROSURGERY
LA English
DT Article
DE CNS tumors; Infectious oncology; Survival; Viruses
ID CANCER; EXPRESSION; BRAIN; WOMEN; SEROPREVALENCE; PREVENTION; GLIOMA;
   TIME
AB OBJECTIVE: Glioblastoma multiforme (GBM) is the most common adult primary brain tumor. Human cytomegalovirus (HCMV) has been studied for the past decade, and conflicting results have been reported with no conclusive role established yet. Human papillomavirus (HPV) is involved in the pathogenesis of many cancers and has a high prevalence in patients with cervical and oral cancer in Pakistan. The objective of our study was to identify the prevalence of HCMV and HPV in Pakistani patients with primary GBM.
   METHODS: In total, 112 primary GBM biopsies were analyzed. HCMV and HPV infection was investigated using nested and conventional polymerase chain reaction, respectively. Positive HPV samples were further confirmed through sequencing. HPV status was correlated with histology and expression of other frequently mutated GBM molecular markers.
   RESULTS: Our study comprised of 68% male and 32% female patients. HCMV was detected in only 1 patient whereas HPV infection was present in 28% of patients with no cases of HPV and HCMV coinfection. We report for the first time that a majority of HPV-positive patients with GBM harbored types 16 and 18 both. Among them, 16% were HPV-type 16 and 20% were HPV-type 18. Patients infected with HPV had longer survival times, but this was not statistically significant. The most commonly overexpressed molecular marker in HPV-positive patients was cyclo-oxygenase-2, and no histologic changes were seen in HPV-positive GBM cases.
   CONCLUSIONS: The presence of a single HCMV positive is intriguing. In addition, we discovered a substantially high 28% prevalence of HPV in GBM patients. The role of viruses in gliomagenesis warrants further investigation.
C1 [Ali, Syed Muhammad Adnan; Mirza, Yumna; Zahid, Nida] Off Acad & Res Surg, Dept Surg, Karachi, Pakistan.
   [Ahmad, Zubair] Dept Pathol & Lab Med, Sect Histopathol, Karachi, Pakistan.
   [Enam, Syed Ather] Aga Khan Univ, Dept Surg, Sect Neurosurg, Karachi, Pakistan.
RP Ali, SMA (reprint author), Off Acad & Res Surg, Dept Surg, Karachi, Pakistan.
EM syed.adnan@aku.edu
RI Zahid, Nida/M-2696-2019
OI Zahid, Nida/0000-0001-8812-9463
FU Departmental of Surgery, Aga Khan University
FX This work was supported by funds of the Departmental of Surgery, Aga
   Khan University, awarded to Dr. S. M. Adnan Ali.
CR Ahsan Javaria, 2015, J Ayub Med Coll Abbottabad, V27, P81
   Ali SM, 2008, ORAL SURG, V1, P96, DOI [10.1111/j.1752-248X.2008.00015.x, DOI 10.1111/J.1752-248X.2008.00015.X]
   Ali SMA, 2010, ORAL SURG, V3, P83
   Anjum K, 2017, BIOMED PHARMACOTHER, V92, P681, DOI 10.1016/j.biopha.2017.05.125
   Baay MFD, 1996, J CLIN MICROBIOL, V34, P745, DOI 10.1128/JCM.34.3.745-747.1996
   Bruni L, 2017, ICO INFORM CTR HPV C
   Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596
   Chen TM, 1996, J CANCER RES CLIN, V122, P504, DOI 10.1007/BF01187164
   Cobbs CS, 2002, CANCER RES, V62, P3347
   Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
   Dziurzynski K, 2012, NEURO-ONCOLOGY, V14, P246, DOI 10.1093/neuonc/nor227
   Gillison ML, 2008, CANCER-AM CANCER SOC, V113, P3036, DOI 10.1002/cncr.23764
   Harden ME, 2017, MUTAT RES-REV MUTAT, V772, P3, DOI 10.1016/j.mrrev.2016.07.002
   Hashida Y, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/1750-9378-10-3
   Herbein G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00230
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]
   Ibrahim S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3772-8
   Jin YL, 2016, NEUROCHEM RES, V41, P1723, DOI 10.1007/s11064-016-1888-y
   Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016/j.ijid.2006.06.007
   Klingelhutz AJ, 2012, VIROLOGY, V424, P77, DOI 10.1016/j.virol.2011.12.018
   KUHN JE, 1995, J MED VIROL, V47, P70, DOI 10.1002/jmv.1890470114
   Lau SK, 2005, MODERN PATHOL, V18, P838, DOI 10.1038/modpathol.3800352
   Lucas KG, 2011, J NEURO-ONCOL, V103, P231, DOI 10.1007/s11060-010-0383-6
   Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178
   Mikaelsdottir EK, 2003, GYNECOL ONCOL, V89, P22, DOI 10.1016/S0090-8258(03)00053-2
   Mirza Y, 2018, ONCOMEDICINE, V3, P28
   Mujtaba G, 2016, J PAK MED ASSOC, V66, P1009
   Nobre RJ, 2009, J VIROL, V83, P2907, DOI 10.1128/JVI.02490-08
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Piltti K, 2006, ONCOGENE, V25, P4880, DOI 10.1038/sj.onc.1209492
   Prayson Richard A, 2002, Ann Diagn Pathol, V6, P148, DOI 10.1053/adpa.2002.33900
   Properzi F, 2008, EUR J NEUROSCI, V27, P593, DOI 10.1111/j.1460-9568.2008.06042.x
   Ranganathan P, 2012, J VIROL, V86, P854, DOI 10.1128/JVI.06097-11
   Ray S, 2014, AM HEALTH DRUG BENEF, V7, P140
   Reeves M, 2008, CURR TOP MICROBIOL, V325, P297
   Siddiqui AR, 2017, J PAK MED ASSOC, V67, P827
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Surviladze Z, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002519
   Szostek S, 2009, ACTA BIOCHIM POL, V56, P337
   Tan Ping-Guo, 2004, Ai Zheng, V23, P63
   Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275
   Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017
   Varnum SM, 2004, J VIROL, V78, P10960, DOI 10.1128/JVI.78.20.10960-10966.2004
   Vidone M, 2014, NEURO-ONCOLOGY, V16, P298, DOI 10.1093/neuonc/not140
   Wick W, 2014, NEURO-ONCOLOGY, V16, P332, DOI 10.1093/neuonc/nou002
   Xu HS, 2017, ONCOL LETT, V14, P512, DOI 10.3892/ol.2017.6221
   Yamashita Y, 2014, MODERN PATHOL, V27, P922, DOI 10.1038/modpathol.2013.219
NR 47
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E931
EP E939
DI 10.1016/j.wneu.2018.10.018
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000115
PM 30321676
DA 2020-05-12
ER

PT J
AU Altafulla, JJ
   Rai, R
   Shrager, S
   Voin, V
   Iwanaga, J
   Litvack, Z
   Loukas, M
   Tubbs, RS
AF Altafulla, Juan J.
   Rai, Rabjot
   Shrager, Sebastian
   Voin, Vlad
   Iwanaga, Joe
   Litvack, Zachary
   Loukas, Marios
   Tubbs, R. Shane
TI Transclival Venous Circulation: Anatomic Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Clival diploic veins; Clivus; Emissary veins; Transclival veins
AB INTRODUCTION: The clivus is a small, central area of the basal cranium with limited surgical access and high morbidity associated with pathologies of its surrounding structures. Therefore thorough knowledge and understanding of the anatomy in this region are crucial for the success of treatments and interpretation of imaging. As to our knowledge, there is no extant cadaveric examination of the transclival veins, so the present study was performed.
   METHODS: Fifteen lightly embalmed adult heads underwent blue latex injection of the left and right internal jugular veins. Special attention was given to the presence or absence of transclival vessels. When transclival veins were identified, their intracranial source, point of penetration of the clivus and anterior connections were documented.
   RESULTS: Ten (66.7%) specimens were found to have transclival veins. These connected the basilar venous plexus to the retropharyngeal venous plexus on all specimens. Eight of the 10 specimens had multiple transclival veins, and 2 had only 1 vessel. The majority of the transclival veins were found penetrating the clivus at its lower one third. However, 2 specimens also had transclival veins that pierced the clivus at its upper one third.
   CONCLUSIONS: An improved understanding of the skull base and its venous drainage can assist clinicians and surgeons in better understanding normal, pathologic, and variant anatomy in this region.
C1 [Altafulla, Juan J.; Voin, Vlad; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Altafulla, Juan J.; Litvack, Zachary] Swedish Neurosci Inst, Seattle, WA USA.
   [Rai, Rabjot; Shrager, Sebastian; Loukas, Marios; Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, True Blue Point, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.
EM joei@seattlesciencefoundation.org
CR Aktas U, 2013, J CRANIO MAXILL SURG, V41, P457, DOI 10.1016/j.jcms.2012.11.011
   Al-Mefty O, 2008, J NEUROSURG, V109, P783, DOI 10.3171/JNS/2008/109/11/0783
   Arias AV, 2015, ARQ NEURO-PSIQUIAT, V73, P194, DOI 10.1590/0004-282X20140237
   Hayes M, 1999, J NEUROL NEUROSUR PS, V66, P357, DOI 10.1136/jnnp.66.3.357
   Hofmann E, 2012, CLIN NEURORADIOL, V22, P123, DOI 10.1007/s00062-011-0083-4
   Inal M, 2015, J CRANIOFAC SURG, V26, P1382, DOI [10.1097/SCS.0000000000001597, 10.1097/SCS.0000000000002129]
   Jalsovec D, 1999, EUR ARCH OTO-RHINO-L, V256, P160, DOI 10.1007/s004050050132
   Lang J., 2001, SKULL BASE RELATED S, P257
   Lang J, 1986, NEURO-ORTHOPEDICS, V1, P67
   Mitsuhashi Y, 2016, NEUROL MED-CHIR, V56, P326, DOI 10.2176/nmc.ra.2015-0346
   Mizutani K, 2017, NEURORADIOLOGY, V59, P213, DOI 10.1007/s00234-017-1784-4
   Mortazavi MM, 2012, NEUROSURGERY, V70, P1312, DOI 10.1227/NEU.0b013e31824388f8
   Nayak S R, 2007, Rom J Morphol Embryol, V48, P427
   Paraskevas GK, 2013, ACTA NEUROCHIR, V155, P139, DOI 10.1007/s00701-012-1570-3
   SCHEUER L., 2000, DEV JUVENILE OSTEOLO, P36
   Schultz AH, 1918, ANAT REC, V15, P225
   Sheikh S, 2017, CUREUS, V9, DOI 10.7759/cureus.1299
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Tubbs RS, 2010, CHILD NERV SYST, V26, P1207, DOI 10.1007/s00381-010-1100-7
   Tubbs RS, 2010, NEUROSURGERY, V67, P404, DOI 10.1227/01.NEU.0000372085.70895.E7
   ZHANG WH, 1987, ACTA ANAT, V128, P63
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E128
EP E131
DI 10.1016/j.wneu.2018.09.038
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000018
PM 30236809
DA 2020-05-12
ER

PT J
AU Alvi, MA
   Wahood, W
   Huang, AE
   Kerezoudis, P
   Lachance, DH
   Bydon, M
AF Alvi, Mohammed Ali
   Wahood, Waseem
   Huang, Alice E.
   Kerezoudis, Panagiotis
   Lachance, Daniel Honore
   Bydon, Mohamad
TI Beyond Science: Effect of Marital Status and Socioeconomic Index on
   Outcomes of Spinal Cord Tumors: Analysis From a National Cancer Registry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Marital status; SEER; Socioeconomic status; Spinal tumors; Survival
ID SURVIVAL; HEALTH; MORTALITY; EPIDEMIOLOGY; SURVEILLANCE; STAGE;
   INEQUALITIES; DIAGNOSIS; MARRIAGE; IMPACT
AB BACKGROUND: The effect of marital status and living arrangements on health through modified health behaviors and social networks has been well-established in reported studies, with many experts claiming a "protective" effect from married life for individuals. We sought to study the effect of marital and socioeconomic status (SES) on the outcomes of patients with spinal cord tumors.
   METHODS: The Surveillance, Epidemiology, and End Results program was queried for patients with spinal cord tumors from 2004 to 2014. Patients were separated into 4 groups according to their marital status: single/never married, married/living together, divorced/separated, and widowed. SES was calculated using a validated method. Kaplan-Meier curves and multivariable logistic and Cox regression analyses were used to investigate the relationship between marital status and SES and the mortality rate of patients with available follow-up information.
   RESULTS: Of the 1188 patients identified (683 women [57.5%] and 505 men [42.5%]), 241 (20.3%) were in the single group, 732 (61.6%) in the married/living together, 109 (9.2%) in the divorced/separated, and 106 (8.9%) in the widowed group. Compared with married patients, divorced/separated and widowed patients had a greater mortality rate (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.1-2.9; P=0.02; HR, 2.01; 95% CI, 1.3-3.1; P = 0.001, respectively). Male sex compared with female was associated with lower survival (HR, 1.42; 95% CI, 1.03-1.9; P = 0.03). Patients with greater SES had a lower mortality rate (HR, 0.77; 95% CI, 0.55-1.08; P = 0.143).
   CONCLUSION: Unmarried and widowed status, lower SES, and male sex resulted in a greater risk of mortality. These factors should be considered when tailoring the treatment plan for such patients.
C1 [Alvi, Mohammed Ali; Wahood, Waseem; Kerezoudis, Panagiotis; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.
   [Alvi, Mohammed Ali; Wahood, Waseem; Kerezoudis, Panagiotis; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Lachance, Daniel Honore] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Huang, Alice E.] Mayo Clin, Sch Med, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM Bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Wahood,
   Waseem/0000-0002-2963-4096
CR Agency for Healthcare Research and Quality Archive, REF CREAT NEW RAC ET
   Aizer AA, 2013, J CLIN ONCOL, V31, P3869, DOI 10.1200/JCO.2013.49.6489
   Aizer AA, 2012, J CLIN ONCOL, V30, P3071, DOI 10.1200/JCO.2012.42.8466
   American Joint Committee on Cancer, CANC STAG SYST
   Anderson N.B., 2004, RACE ETHNICITY SOCIO
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Baine MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017014
   BENSHLOMO Y, 1993, J EPIDEMIOL COMMUN H, V47, P200, DOI 10.1136/jech.47.3.200
   BROWMAN GP, 1993, NEW ENGL J MED, V328, P159, DOI 10.1056/NEJM199301213280302
   CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500
   Clegg LX, 2009, CANCER CAUSE CONTROL, V20, P417, DOI 10.1007/s10552-008-9256-0
   Cohen SD, 2007, ADV CHRONIC KIDNEY D, V14, P335, DOI 10.1053/j.ackd.2007.04.007
   Duffy SA, 2009, J CLIN ONCOL, V27, P1969, DOI 10.1200/JCO.2008.18.2188
   Farr W., 1859, INFLUENCE MARRIAGE M
   Fossa SD, 2011, J CLIN ONCOL, V29, P963, DOI 10.1200/JCO.2010.32.3204
   GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125
   GOVE WR, 1973, AM J SOCIOL, V79, P45, DOI 10.1086/225505
   Gritz ER, 2009, J CLIN ONCOL, V27, P1930, DOI 10.1200/JCO.2008.21.3769
   Hankey BF, 1999, CANCER EPIDEM BIOMAR, V8, P1117
   HU YR, 1990, DEMOGRAPHY, V27, P233, DOI 10.2307/2061451
   Joung IMA, 1998, SOC SCI MED, V46, P425, DOI 10.1016/S0277-9536(97)00186-X
   Krieger N, 2005, AM J PUBLIC HEALTH, V95, P312, DOI 10.2105/AJPH.2003.032482
   Krieger N, 2003, PUBLIC HEALTH REP, V118, P240, DOI 10.1093/phr/118.3.240
   Krieger N, 2003, J EPIDEMIOL COMMUN H, V57, P186, DOI 10.1136/jech.57.3.186
   Krieger N, 2002, AM J PUBLIC HEALTH, V92, P1100, DOI 10.2105/AJPH.92.7.1100
   Krieger N, 2001, AM J PUBLIC HEALTH, V91, P1114, DOI 10.2105/AJPH.91.7.1114
   Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068
   Krongrad A, 1996, J UROLOGY, V156, P1696, DOI 10.1016/S0022-5347(01)65485-5
   Lai H, 1999, INT J BEHAV MED, V6, P150, DOI 10.1207/s15327558ijbm0602_4
   Mahdi H, 2013, PSYCHO-ONCOLOGY, V22, P83, DOI 10.1002/pon.2058
   Manzoli L, 2007, SOC SCI MED, V64, P77, DOI 10.1016/j.socscimed.2006.08.031
   Martikainen P, 2005, POP STUD-J DEMOG, V59, P99, DOI 10.1080/0032472052000332737
   Miller PM, 2006, ALCOHOL ALCOHOLISM, V41, P140, DOI 10.1093/alcalc/agh245
   Nelles JL, 2009, UROL ONCOL-SEMIN ORI, V27, P263, DOI 10.1016/j.urolonc.2008.04.016
   Ortiz CAR, 2007, J GERONTOL A-BIOL, V62, P892
   Osborne C, 2005, BREAST CANCER RES TR, V93, P41, DOI 10.1007/s10549-005-3702-4
   Rendall MS, 2011, DEMOGRAPHY, V48, P481, DOI 10.1007/s13524-011-0032-5
   Robards J, 2012, MATURITAS, V73, P295, DOI 10.1016/j.maturitas.2012.08.007
   Sammon JD, 2012, BJU INT, V110, P1301, DOI 10.1111/j.1464-410X.2012.10993.x
   Schellinger KA, 2008, J NEURO-ONCOL, V87, P173, DOI 10.1007/s11060-007-9507-z
   VERBRUGGE LM, 1979, J MARRIAGE FAM, V41, P267, DOI 10.2307/351696
   Wang L, 2011, CANCER EPIDEMIOL, V35, P417, DOI 10.1016/j.canep.2011.02.004
NR 42
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E333
EP E343
DI 10.1016/j.wneu.2018.09.103
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000041
PM 30261382
DA 2020-05-12
ER

PT J
AU Aoun, SG
   Welch, BG
   Cortes, M
   Stutzman, SE
   MacAllister, MC
   El Ahmadieh, TY
   Osman, M
   Figueroa, SA
   White, JA
   Batjer, HH
   Olson, DM
AF Aoun, Salah G.
   Welch, Babu G.
   Cortes, Michaela
   Stutzman, Sonja E.
   MacAllister, Matthew C.
   El Ahmadieh, Tarek Y.
   Osman, Mohamed
   Figueroa, Stephen A.
   White, Jonathan A.
   Batjer, Hunt H.
   Olson, Daiwai M.
TI Objective Pupillometry as an Adjunct to Prediction and Assessment for
   Oculomotor Nerve Injury and Recovery: Potential for Practical
   Applications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurological assessment tool; Neurological pupil index; Objective
   pupillometry; Prognostic neurological tool; Pupillometer; Third nerve
   palsy recovery
ID RELIABILITY; CARE
AB BACKGROUND: Pupillary light reflex examinations are intrinsic to any good neurological examination. Consistent evidence has shown that automated pupillometry assessments provide superior accuracy and interrater correlation compared with bedside eye examinations. Pupillary indexes such as the neurological pupil index (NPI) can also provide several hours of warning before the advent of herniation syndromes or third nerve palsy.
   METHODS: We determined the unique temporal relationship between NPI changes and third nerve palsy occurrence and recovery in an initially neurologically intact hospitalized patient. A 53-year-old woman presented with aneurysmal subarachnoid hemorrhage and headaches. Her aneurysm was treated surgically without complications. After lumbar drainage for hydrocephalus, she developed isolated left third nerve palsy that slowly recovered over the following weeks. Pupilometer data were obtained throughout her hospital stay.
   RESULTS: A total of 121 pupillary measurement sets were obtained. The NPI had decreased to an abnormal level (< 3) 12 hours before she became symptomatic. The NPI also started improving 24 hours before improvement in her clinical examination. The patient did not display signs of neurological dysfunction related to vasospasm during her stay.
   CONCLUSION: The NPI seems to reliably correlate with third nerve function and appears to possess predictive temporal properties that could allow practitioners to anticipate neurological injury and recovery. These findings could affect the fields of neurosciences, trauma, military medicine, critical care, and ophthalmology.
C1 [Aoun, Salah G.; Welch, Babu G.; Cortes, Michaela; Stutzman, Sonja E.; MacAllister, Matthew C.; El Ahmadieh, Tarek Y.; Figueroa, Stephen A.; White, Jonathan A.; Batjer, Hunt H.; Olson, Daiwai M.] Univ Texas Southwestern Med Ctr, Dept Neurol Surg, Houston, TX 77030 USA.
   [Stutzman, Sonja E.; Olson, Daiwai M.] Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Houston, TX USA.
   [Stutzman, Sonja E.; Osman, Mohamed; Figueroa, Stephen A.] Univ Texas Southwestern Med Ctr, Div Neurocrit Care, Houston, TX USA.
RP Aoun, SG (reprint author), Univ Texas Southwestern Med Ctr, Dept Neurol Surg, Houston, TX 77030 USA.
EM Salah.aoun@phhs.org
RI Olson, DaiWai/I-5932-2019; Aoun, Salah G./J-2406-2019
OI Olson, DaiWai/0000-0002-9280-078X; Aoun, Salah G./0000-0003-3499-7569;
   El Ahmadieh, Tarek/0000-0002-7122-4349
CR Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248
   Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548
   Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z
   Kerr RG, 2016, AM J CRIT CARE, V25, P213, DOI 10.4037/ajcc2016554
   Kim TJ, 2018, ACUTE CRIT CARE, V33, P57, DOI 10.4266/acc.2017.00213
   McNett M, 2017, J NEUROSCI NURS, V49, P229, DOI 10.1097/JNN.0000000000000290
   Mease L, 2018, MIL MED, V183, pE291, DOI 10.1093/milmed/usy011
   Olson DM, 2017, J NEUROSCI NURS, V49, P251, DOI 10.1097/JNN.0000000000000296
   Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1
   Papangelou A, 2018, MIL MED, V183, pE113, DOI 10.1093/milmed/usx018
   Truong JQ, 2016, MIL MED, V181, P1382, DOI 10.7205/MILMED-D-15-00587
   Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012
   Zhao WD, 2016, J CLIN NEUROSCI, V33, P79, DOI 10.1016/j.jocn.2016.01.039
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E475
EP E480
DI 10.1016/j.wneu.2018.09.140
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000059
PM 30267943
DA 2020-05-12
ER

PT J
AU Behmanesh, B
   Keil, F
   Dubinski, D
   Won, SY
   Quick-Weller, J
   Seifert, V
   Gessler, F
AF Behmanesh, Bedjan
   Keil, Fee
   Dubinski, Daniel
   Won, Sae-Yeon
   Quick-Weller, Johanna
   Seifert, Volker
   Gessler, Florian
TI The Value of Computed Tomography Imaging of the Head After
   Ventriculoperitoneal Shunt Surgery in Adults
SO WORLD NEUROSURGERY
LA English
DT Article
DE Costs and cost analysis; Head CT scan; Radiation protection;
   Ventriculoperitoneal shunt
ID RADIATION-EXPOSURE; CANCER-RISKS; CT SCANS; CHILDHOOD
AB BACKGROUND: Patients with a ventriculoperitoneal shunt for hydrocephalus often undergo multiple follow-up computed tomography (CT) scans of the head, increasing the risk for long-term effects of ionizing radiation. The purpose of our study was to evaluate the necessity as a routine diagnostic procedure and cost analysis of routine postoperative CT scan of the head after ventriculoperitoneal shunt surgery.
   METHODS: In this study, we comprised adults with ventriculoperitoneal shunt operations who underwent early CT scans within 48 hours postoperatively. We reviewed the correlation between revision surgery rate and the experience of surgeons who performed surgery and provided a cost analysis.
   RESULTS: In total, 479 surgeries were performed in 439 patients. Early revision surgery was performed in 11 (2.3%) patients. Reason for revision surgery was malposition in 9 cases and intracerebral hemorrhage in 2 patients. There was no significant correlation between the surgeon's experience and the rate of revision surgery. Placement of the ventricular catheter via an approach other than a standard right or left frontal burr hole resulted in risk of need for surgical shunt revision (P >= 0.002, odds ratio 54, confidence interval 13.5-223). A total of 468 CT scans of the head revealed a normal finding; thus, similar to$ 562,000 could be saved by omitting postoperative head CT scans.
   CONCLUSIONS: Routine postoperative head CT scans after fentriculoperitoneal shunting are not necessary in all cases. The reduction of exposure to ionization radiation and the beneficial economic factor are main advantages.
C1 [Behmanesh, Bedjan; Dubinski, Daniel; Won, Sae-Yeon; Quick-Weller, Johanna; Seifert, Volker; Gessler, Florian] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Neurosurg, Frankfurt, Germany.
   [Keil, Fee] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Inst Neuroradiol, Frankfurt, Germany.
RP Behmanesh, B (reprint author), Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Neurosurg, Frankfurt, Germany.
EM bedjan.behmanesh@gmail.com
RI Won, Sae-Yeon/AAK-3408-2020
CR Antonucci MC, 2017, J PEDIATR-US, V182, P210, DOI 10.1016/j.jpeds.2016.11.051
   Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0
   Bondurant CP, 1995, PEDIATR NEUROSURG, V23, P254, DOI 10.1159/000120968
   Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
   Dutzmann S, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12219
   Gessler F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124534
   Joswig H, 2017, WORLD NEUROSURG, V102, P117, DOI 10.1016/j.wneu.2017.02.128
   Kameda M, 2017, ACTA NEUROCHIR, V159, P995, DOI 10.1007/s00701-017-3115-2
   Kim KP, 2012, RADIAT PROT DOSIM, V150, P415, DOI 10.1093/rpd/ncr429
   Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Mills DM, 2006, AM J OPHTHALMOL, V142, P1046, DOI 10.1016/j.ajo.2006.08.024
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Qian ZQ, 2017, WORLD NEUROSURG, V107, P846, DOI 10.1016/j.wneu.2017.08.098
   Reddy GK, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.10.034
   Rice HE, 2007, J PEDIATR SURG, V42, P603, DOI 10.1016/j.jpedsurg.2006.12.009
   Schar RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153499
   Shuryak I, 2010, JNCI-J NATL CANCER I, V102, P1628, DOI 10.1093/jnci/djq346
   Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427
   Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296
   STEINBOK P, 1995, PEDIATR NEUROSURG, V22, P141, DOI 10.1159/000120892
   Vassilyadi M, 2010, J NEUROSURG-PEDIATR, V6, P468, DOI 10.3171/2010.8.PEDS09557
   Yim B, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15583
NR 23
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E151
EP E156
DI 10.1016/j.wneu.2018.09.063
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000022
PM 30244187
DA 2020-05-12
ER

PT J
AU Bhimani, AD
   Rosinski, CL
   Denyer, S
   Hobbs, JG
   Patel, S
   Shah, K
   Mudreac, A
   Diamond, R
   Behbahani, M
   Mehta, AI
AF Bhimani, Abhiraj D.
   Rosinski, Clayton L.
   Denyer, Steven
   Hobbs, Jonathan G.
   Patel, Saavan
   Shah, Koral
   Mudreac, Andrew
   Diamond, Ryne
   Behbahani, Mandana
   Mehta, Ankit I.
TI Acute Surgical Risk Profile of Intramedullary Spinal Cord Tumor
   Resection in Pediatric Patients: A Pediatric National Surgical Quality
   Improvement Program Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Intramedullary spinal cord tumor; Pediatric; Reoperation;
   Spine; Surgical resection
ID CHILDREN; ASTROCYTOMAS; IRRADIATION; AGE
AB OBJECTIVE: The purpose of the present study was to characterize the acute (30-day) surgical risk profile of pediatric patients undergoing surgical resection of intramedullary spinal cord tumors (IMSCTs).
   METHODS: Preoperative factors were collected from the Pediatric American College of Surgeons National Surgical Quality Improvement Program database for patients identified by Current Procedural Terminology codes for laminectomy and International Classification of Diseases codes for IMSCTs from 2012 to 2016. The postoperative outcomes were compared by tumor location and type.
   RESULTS: The mean age of the 139 patients meeting all inclusion criteria was 8.7 years, with a male predominance (58.7%). The cervical and thoracic IMSCT populations had worst preoperative health status, as indicated by American Society of Anesthesiologists class, and a greater proportion of malignant tumors compared with the lumbar IMSCT population. No patient died; 8.6% of the patients were readmitted, and 6.5% required reoperation. Of the 12 read-missions, 8 were required for patients with malignant tumors. The patients with cervical IMSCTs returned to the operating room at a significantly greater rate than did the thoracic and lumbar IMSCT populations. Two common reasons for reoperation in the cervical population were issues related to respiration and hydrocephalus management. The complications included 13 cases of infection, 6 of urinary tract infection, and 5 cases of surgical site infection.
   CONCLUSIONS: Resection of IMSCTs in the pediatric population is a relatively low-risk procedure in terms of acute surgical complications. However, surgeons operating in the cervical spine should be aware of the increased risk of reoperation, in particular as it pertains to respiratory issues and hydrocephalus.
C1 [Bhimani, Abhiraj D.; Rosinski, Clayton L.; Denyer, Steven; Patel, Saavan; Shah, Koral; Mudreac, Andrew; Diamond, Ryne; Behbahani, Mandana; Mehta, Ankit I.] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
   [Hobbs, Jonathan G.] Univ Chicago, Pritzker Sch Med, Sect Neurosurg, Chicago, IL 60637 USA.
RP Mehta, AI (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM ankitm@uic.edu
RI Mehta, Ankit/AAL-3851-2020
OI Denyer, Steven/0000-0001-5631-8788; behbahani,
   mandana/0000-0003-3882-8658
CR Abu-Bonsrah N, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17313
   Ahmed R, 2014, J NEUROSURG-PEDIATR, V13, P600, DOI [10.3171/2014.1.PEDS13317, 10.3171/2014.1.PEDS13316]
   Auguste KI, 2006, NEUROSURG CLIN N AM, V17, P51, DOI 10.1016/j.nec.2005.10.004
   Clayton P E, 1991, Clin Oncol (R Coll Radiol), V3, P220, DOI 10.1016/S0936-6555(05)81206-3
   Constantini S, 1996, J NEUROSURG, V85, P1036, DOI 10.3171/jns.1996.85.6.1036
   DESOUSA AL, 1979, J NEUROSURG, V51, P437, DOI 10.3171/jns.1979.51.4.0437
   DIRKS PB, 1994, NEUROSURGERY, V34, P68
   EPSTEIN F, 1981, J NEUROSURG, V54, P829, DOI 10.3171/jns.1981.54.6.0829
   EPSTEIN F, 1982, J NEUROSURG, V57, P685, DOI 10.3171/jns.1982.57.5.0685
   GOLDWEIN JW, 1991, CANCER-AM CANCER SOC, V67, P2766, DOI 10.1002/1097-0142(19910601)67:11<2766::AID-CNCR2820671109>3.0.CO;2-#
   HARDISON HH, 1987, CHILD NERV SYST, V3, P89, DOI 10.1007/BF00271131
   Innocenzi G, 1996, CHILD NERV SYST, V12, P776
   Jallo GI, 2003, CHILD NERV SYST, V19, P641, DOI 10.1007/s00381-003-0820-3
   KLOTZ U, 1977, INT J CLIN PHARM BI, V15, P332
   Kushel' Iu V, 2014, Zh Vopr Neirokhir Im N N Burdenko, V78, P37, DOI 10.17116/neiro201478637-42
   Kutluk T, 2015, EUR J PAEDIATR NEURO, V19, P41, DOI 10.1016/j.ejpn.2014.09.007
   MARCUS RB, 1990, INT J RADIAT ONCOL, V19, P3, DOI 10.1016/0360-3016(90)90126-5
   Nadkarni TD, 1999, CHILD NERV SYST, V15, P17, DOI 10.1007/s003810050321
   OSULLIVAN C, 1994, J NEUROSURG, V81, P507, DOI 10.3171/jns.1994.81.4.0507
   Ryan SL, 2014, J NEUROSURG-PEDIATR, V14, P259, DOI 10.3171/2014.5.PEDS1448
   Samartzis D, 2016, GLOB SPINE J, V6, P176, DOI 10.1055/s-0035-1550086
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E389
EP E397
DI 10.1016/j.wneu.2018.09.113
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000048
PM 30266692
DA 2020-05-12
ER

PT J
AU Bhimani, AD
   Selner, AN
   Esfahani, DR
   Chiu, RG
   Rosinski, CL
   Rosenberg, D
   Mudreac, A
   Diamond, RJ
   Almadidy, Z
   Mehta, AI
AF Bhimani, Abhiraj D.
   Selner, Ashley N.
   Esfahani, Darian R.
   Chiu, Ryan G.
   Rosinski, Clayton L.
   Rosenberg, David
   Mudreac, Andrew
   Diamond, Ryne J.
   Almadidy, Zayed
   Mehta, Ankit I.
TI Intracranial Electrode Placement for Seizures Before Temporal Lobectomy:
   A Risk-Benefit Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior temporal lobectomy; Electrode implant; NSQIP; Outcomes;
   Temporal lobectomy; Temporal lobe epilepsy
ID LOBE EPILEPSY; INTRAOPERATIVE ELECTROCORTICOGRAPHY; SURGERY;
   COMPLICATIONS; EEG; MORBIDITY; MORTALITY; OUTCOMES
AB BACKGROUND AND OBJECTIVE: Anterior temporal lobectomy (ATL) is the most common surgical procedure for refractory temporal lobe epilepsy. When scalp electroencephalography cannot adequately identify an epileptogenic site, electrode implantation may be used to monitor epileptic activity and localize a target focus before surgical resection. Whether the advantage of improved seizure localization justifies the added risk of electrode placement remains unclear. : The present study uses an international surgical database to explore whether a 2wo-stage approach, electrode implant followed by ATL, has a reasonable safety profile and is clinically worthwhile versus ATL alone.
   METHODS: Data from the American College of Surgeons National Surgical Quality Improvement Program for 2005 to 2016 were queried to identify patients undergoing ATL or electrode implant for epilepsy. The 30-day postoperative outcomes were analyzed for the electrode implant and ATL groups, and individual and combined risk profiles were determined.
   RESULTS: Patients undergoing electrode implant followed by ATL had a predicted reoperation rate of 7.6%, readmission rate of 14.6%, and a 30-day mortality rate of 1.2%. The combined rate of patients having >= 1 medical complication for 2-staged procedures was higher, at 14.7%. The most common complications encountered were urinary tract infection (2.7%) and sepsis (2.7%).
   CONCLUSIONS: Intracranial electrode placement increases the risk of complications when added to ATL. The severity of complications from electrode placement are mild, however, and as intracranial electrode recording provides a potentially large reduction in the surgical failure risk, electrode placement may be advisable for all but the most convincing seizure foci.
C1 [Bhimani, Abhiraj D.; Selner, Ashley N.; Esfahani, Darian R.; Chiu, Ryan G.; Rosinski, Clayton L.; Rosenberg, David; Mudreac, Andrew; Diamond, Ryne J.; Almadidy, Zayed; Mehta, Ankit I.] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
RP Mehta, AI (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM ankitm@uic.edu
RI Mehta, Ankit/AAL-3851-2020
OI Rosenberg, David/0000-0003-4914-3195; Selner, Ashley/0000-0002-5687-8862
CR Alarcon G, 2006, J NEUROL NEUROSUR PS, V77, P474, DOI 10.1136/jnnp.2005.077289
   Anyanwu C, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040049
   Arnone Gregory D, 2017, Surg Neurol Int, V8, P268, DOI 10.4103/sni.sni_325_17
   Asadi-Pooya AA, 2017, WORLD NEUROSURG, V99, P662, DOI 10.1016/j.wneu.2016.12.074
   Attiah MA, 2015, EPILEPSY RES, V115, P1, DOI 10.1016/j.eplepsyres.2015.05.007
   Bulacio JC, 2012, EPILEPSIA, V53, P1722, DOI 10.1111/j.1528-1167.2012.03633.x
   Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410
   Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea
   Fisch B, 2011, EPILEPSY CURR, V11, P186, DOI 10.5698/1535-7511-11.6.186
   Fountas KN, 2011, NEUROSURG CLIN N AM, V22, P519, DOI 10.1016/j.nec.2011.07.009
   Gonzalez-Martinez Jorge, 2015, Neurosurgery, V62 Suppl 1, P117, DOI 10.1227/NEU.0000000000000787
   Hader WJ, 2013, EPILEPSIA, V54, P840, DOI 10.1111/epi.12161
   Hu WH, 2013, J NEUROSURG, V119, P1089, DOI 10.3171/2013.8.JNS121854
   Ives-Deliperi VL, 2012, EPILEPSY BEHAV, V24, P194, DOI 10.1016/j.yebeh.2012.04.115
   Kale R, 1997, BRIT MED J, V315, P2, DOI 10.1136/bmj.315.7099.2
   Kerezoudis P, 2018, J NEUROSURG, V128, P1158, DOI 10.3171/2016.12.JNS162096
   Luther N, 2011, EPILEPSIA, V52, P941, DOI 10.1111/j.1528-1167.2011.03061.x
   Lyu YE, 2018, INT J SURG, V51, P174, DOI 10.1016/j.ijsu.2018.01.007
   Mathon B, 2017, WORLD NEUROSURG, V102, P639, DOI 10.1016/j.wneu.2017.03.128
   McClelland S, 2011, ARCH NEUROL-CHICAGO, V68, P725, DOI 10.1001/archneurol.2011.7
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495
   Pondal-Sordo M, 2007, EPILEPSY RES, V74, P176, DOI 10.1016/j.eplepsyres.2007.03.011
   Reed CM, 2017, CLIN NEUROL NEUROSUR, V163, P110, DOI 10.1016/j.clineuro.2017.10.023
   Rolston JD, 2016, EPILEPSY RES, V122, P26, DOI 10.1016/j.eplepsyres.2016.02.004
   Schiller Y, 1998, EPILEPSIA, V39, P1302, DOI 10.1111/j.1528-1157.1998.tb01328.x
   Schmeiser B, 2017, NEUROSURGERY, V81, P992, DOI 10.1093/neuros/nyx138
   Shah AK, 2014, ANN INDIAN ACAD NEUR, V17, pS89, DOI 10.4103/0972-2327.128668
   Tebo CC, 2014, J NEUROSURG, V120, P1415, DOI 10.3171/2014.1.JNS131694
   Tellez-Zenteno Jose F, 2012, Epilepsy Res Treat, V2012, P630853, DOI 10.1155/2012/630853
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Willems LM, 2019, EPILEPSY BEHAV, V91, P30, DOI 10.1016/j.yebeh.2018.05.012
   Wong C, 2009, ACTA NEUROCHIR, V151, P37, DOI 10.1007/s00701-008-0171-7
   Yang T, 2014, EPILEPTIC DISORD, V16, P271, DOI 10.1684/epd.2014.0675
NR 33
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E207
EP E214
DI 10.1016/j.wneu.2018.09.079
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000029
PM 30261395
DA 2020-05-12
ER

PT J
AU Brito, A
   Tsang, ACO
   Hilditch, C
   Nicholson, P
   Krings, T
   Brinjikji, W
AF Brito, Arnaldo
   Tsang, Anderson Chun On
   Hilditch, Christopher
   Nicholson, Patrick
   Krings, Timo
   Brinjikji, Waleed
TI Intracranial Dural Arteriovenous Fistula as a Reversible Cause of
   Dementia: Case Series and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cortical venous reflux; Dementia; Dural arteriovenous fistula; Venous
   hypertension
ID POSTERIOR-FOSSA; MALFORMATION; ISCHEMIA; PATIENT
AB OBJECTIVE: Intracranial dural arteriovenous fistulas (DAVFs) can manifest with a reversible form of dementia and parkinsonism that may be related to medullary venous hypertension and impaired cortical venous drainage. We report a consecutive case series of patients with DAVFs who presented with cognitive decline and report angioarchitecture and outcomes of treatment.
   METHODS: From a prospectively collected database of 389 cranial DAVFs, we identified patients who presented with progressive dementia. Data collected included demographic characteristics, other presenting symptoms, fistula location and type, preoperative and postoperative imaging findings, and treatment outcomes. Descriptive statisticswere reported.
   RESULTS: Of 389 patients with DAVF, 6 patients with progressive dementia (1.4%) were identified. All patients were male. Mean patient age was 68.6 years. Four patients had superior sagittal sinus DAVFs, 1 patient had a tentorialDAVF, and 1 patient had a transverse sinus DAVF. All patients had evidence of medullary venous hypertension on imaging with either reflux and arterialization of the transmedullary veins or venous congestion of the transmedullary veins. All patients underwent endovascular treatment and had reversal of dementia-related symptoms after a mean follow-up of 6.2 months.
   CONCLUSIONS: Cognitive decline is a rare but reversible manifestation of DAVFs that have impaired venous drainage of the transmedullary veins and associated medullary venous hypertension.
C1 [Brito, Arnaldo] Fdn Univ Sanitas, Dept Radiol, Clin Colsanitas, Bogota, Colombia.
   [Tsang, Anderson Chun On; Hilditch, Christopher; Nicholson, Patrick; Krings, Timo; Brinjikji, Waleed] Univ Toronto, Joint Dept Med Imaging, Div Neuroradiol, Toronto, ON, Canada.
   [Tsang, Anderson Chun On] Univ Hong Kong, Dept Surg, Div Neurosurg, Hong Kong, Peoples R China.
RP Brito, A (reprint author), Fdn Univ Sanitas, Dept Radiol, Clin Colsanitas, Bogota, Colombia.
EM aa.britoa@unisanitas.edu.co
RI Brito, Arnaldo/AAH-1007-2019; Nicholson, Patrick/I-2048-2019;
   /E-1487-2011
OI Brito, Arnaldo/0000-0002-0624-6103; Nicholson,
   Patrick/0000-0001-7182-5112; /0000-0003-2758-3253
FU Andreae Holt Hornsby Vascular Dementia Research Unit of the Toronto
   Western Hospital
FX This study received support from the Andreae Holt Hornsby Vascular
   Dementia Research Unit of the Toronto Western Hospital.
CR Bernstein R, 2003, LANCET, V361, P392, DOI 10.1016/S0140-6736(03)12394-X
   Bhogal P, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918764090
   Chaichana KL, 2012, NEUROSURG CLIN N AM, V23, P7, DOI 10.1016/j.nec.2011.09.001
   Dehdashti AR, 2010, CAN J NEUROL SCI, V37, P532, DOI 10.1017/S0317167100010611
   Ebinu JO, 2011, INTERV NEURORADIOL, V17, P212, DOI 10.1177/159101991101700212
   Fujii Hiroki, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-203921
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Geraldes R, 2012, J STROKE CEREBROVASC, V21, DOI 10.1016/j.jstrokecerebrovasdis.2011.01.002
   Goncalves MB, 2008, ARQ NEURO-PSIQUIAT, V66, P264, DOI 10.1590/S0004-282X2008000200028
   Greenough GP, 1999, AM J NEURORADIOL, V20, P145
   Holekamp TF, 2016, J NEUROSURG, V124, P1752, DOI 10.3171/2015.5.JNS15473
   Hurst RW, 1998, AM J NEURORADIOL, V19, P1267
   Hwang Heewon, 2017, Neurointervention, V12, P50, DOI 10.5469/neuroint.2017.12.1.50
   Imazeki Ryoko, 2015, Tokai J Exp Clin Med, V40, P22
   ITO M, 1995, NEUROSURGERY, V37, P1187, DOI 10.1227/00006123-199512000-00019
   LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724
   Matsumura A, 2008, NEUROLOGY, V71, P1553, DOI 10.1212/01.wnl.0000334403.46553.85
   NAKADA T, 1985, NEUROSURGERY, V17, P653, DOI 10.1227/00006123-198510000-00021
   NENCINI P, 1993, J NEUROL NEUROSUR PS, V56, P929, DOI 10.1136/jnnp.56.8.929
   Racine CA, 2008, NEUROCASE, V14, P231, DOI 10.1080/13554790802232677
   Santillan A, 2011, J NEUROL NEUROSUR PS, V82, P749, DOI 10.1136/jnnp.2010.231969
   Sugrue PA, 2009, CLIN NEUROL NEUROSUR, V111, P629, DOI 10.1016/j.clineuro.2009.05.004
   Tamamoto F, 2003, ANN NUCL MED, V17, P239, DOI 10.1007/BF02990028
   Tanaka K, 1999, SURG NEUROL, V51, P489, DOI 10.1016/S0090-3019(98)00020-2
   Tominaga T, 2003, J NEUROSURG, V98, P617, DOI 10.3171/jns.2003.98.3.0617
   van Dijk JMC, 2003, NEUROIMAG CLIN N AM, V13, P55, DOI 10.1016/S1052-5149(02)00063-1
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   WILLINSKY R, 1990, SURG NEUROL, V34, P118, DOI 10.1016/0090-3019(90)90107-Z
   Willinsky R, 1999, AM J NEURORADIOL, V20, P1031
   Wilson M, 2008, Pract Neurol, V8, P362, DOI 10.1136/jnnp.2008.162008
   Yamamoto Takahiro, 2010, Rinsho Shinkeigaku, V50, P718
   ZEIDMAN SM, 1995, AM J NEURORADIOL, V16, P1080
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E543
EP E553
DI 10.1016/j.wneu.2018.09.161
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000067
PM 30268554
DA 2020-05-12
ER

PT J
AU Buchmann, N
   Gempt, J
   Ryang, YM
   Pyka, T
   Kirschke, JS
   Meyer, B
   Ringel, F
AF Buchmann, Niels
   Gempt, Jens
   Ryang, Yu-Mi
   Pyka, Thomas
   Kirschke, Jan S.
   Meyer, Bernhard
   Ringel, Florian
TI Can Early Postoperative O-(2-(18F)Fluoroethyl)-L-Tyrosine Positron
   Emission Tomography After Resection of Glioblastoma Predict the Location
   of Later Tumor Recurrence?
SO WORLD NEUROSURGERY
LA English
DT Article
DE FET-PET; Glioblastoma; Location of recurrence; Positron emission
   tomography; Prediction; Surgery
ID RESPONSE ASSESSMENT; FET-PET; SURVIVAL; DIAGNOSIS; GLIOMAS; VOLUME
AB OBJECTIVE: Glioblastoma inevitably recurs despite aggressive therapy. Therefore, it would be helpful to predict the location of tumor recurrence from postoperative imaging to customize further treatment. O-(2-(18)Ffluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) might be a helpful technique, because tumor tissue can be differentiated from normal brain tissue with high specificity.
   METHODS: Thirty-two consecutive patients with perioperative and follow-up imaging data available were included. On postoperative FET-PET, the tumor/normal brain (TTB) ratio around the resection cavity borders was measured. Increased TTB ratios were recorded and anatomically correlated with the site of later tumor recurrence. On postoperative magnetic resonance imaging (MRI), residual contrast-enhancing tumor correlated with the site of later tumor recurrence.
   RESULTS: Location of progression was predictable using MRI alone in 42% of patients by residual tumor on postoperative MRI. FET-PET was predictive in 25 patients by a clear hot spot at the site of later tumor recurrence. In 3 patients, it was partially predictive and in 4 was not predictive of the tumor recurrence location. One patient without any tracer uptake was recurrence free at the last follow-up examination. In contrast to the postoperative MRI results, tumor recurrence was found in 79% at a site of elevated TTB ratio on postoperative FET-PET. Therefore, the predictability of the tumor recurrence location using postoperative FET-PET was greater than that with MRI, and all cases predictable using MRI could have been predicted using FET-PET.
   CONCLUSIONS: Postoperative FET-PET can be helpful for planning subsequent therapy, such as repeat resection or radiotherapy, because tumor recurrence can be predicted with relatively greater sensitivity than with MRI alone.
C1 [Buchmann, Niels; Gempt, Jens; Ryang, Yu-Mi; Meyer, Bernhard; Ringel, Florian] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, Munich, Germany.
   [Pyka, Thomas] Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, Munich, Germany.
   [Pyka, Thomas; Kirschke, Jan S.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, Munich, Germany.
   [Ringel, Florian] Johannes Gutenberg Univ Mainz, Dept Neurosurg, Univ Med, Mainz, Germany.
RP Buchmann, N (reprint author), Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, Munich, Germany.
EM niels.buchmann@tum.de
RI Ringel, Florian/E-4933-2014; Ryang, Yu-Mi/Q-8373-2016; Kirschke,
   Jan/E-2550-2012; Meyer, Bernhard/AAH-3329-2019
OI Ryang, Yu-Mi/0000-0002-9045-5038; Kirschke, Jan/0000-0002-7557-0003; 
CR Albert NL, 2016, NEURO-ONCOLOGY, V18, P1199, DOI 10.1093/neuonc/now058
   Bette S, 2016, WORLD NEUROSURG, V91, P524, DOI 10.1016/j.wneu.2016.02.094
   Buchmann N, 2016, WORLD NEUROSURG, V89, P420, DOI 10.1016/j.wneu.2016.02.032
   Chang PD, 2017, AM J ROENTGENOL, V208, P57, DOI 10.2214/AJR.16.16234
   Lopez WOC, 2015, ONCOTARGETS THER, V8, P3803, DOI 10.2147/OTT.S87126
   Galldiks N, 2013, EUR J NUCL MED MOL I, V40, P22, DOI 10.1007/s00259-012-2251-4
   Galldiks N, 2012, J NUCL MED, V53, P1048, DOI 10.2967/jnumed.111.098590
   Gempt J, 2015, EUR J RADIOL, V84, P955, DOI 10.1016/j.ejrad.2015.01.022
   Gempta J, 2014, EUR J RADIOL, V83, P829, DOI 10.1016/j.ejrad.2014.02.006
   Kebir S, 2016, CLIN CANCER RES, V22, P2190, DOI 10.1158/1078-0432.CCR-15-1334
   Klasner B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141153
   Mehrkens JH, 2008, J NEURO-ONCOL, V88, P27, DOI 10.1007/s11060-008-9526-4
   Oppitz U, 1999, RADIOTHER ONCOL, V53, P53, DOI 10.1016/S0167-8140(99)00117-6
   Pauleit D, 2005, BRAIN, V128, P678, DOI 10.1093/brain/awh399
   Piroth MD, 2011, RADIOTHER ONCOL, V99, P218, DOI 10.1016/j.radonc.2011.03.006
   Popperl G, 2004, EUR J NUCL MED MOL I, V31, P1464, DOI 10.1007/s00259-004-1590-1
   Pyka T, 2016, EUR J NUCL MED MOL I, V43, P133, DOI 10.1007/s00259-015-3140-4
   Smets T, 2013, EUR RADIOL, V23, P1467, DOI 10.1007/s00330-012-2762-1
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Suchorska B, 2016, NEURO-ONCOLOGY, V18, P549, DOI 10.1093/neuonc/nov326
   Suchorska B, 2015, NEUROLOGY, V84, P710, DOI 10.1212/WNL.0000000000001262
NR 21
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E467
EP E474
DI 10.1016/j.wneu.2018.09.139
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000058
PM 30267942
DA 2020-05-12
ER

PT J
AU Buell, TJ
   Chen, CJ
   Quinn, JC
   Buchholz, AL
   Mazur, MD
   Mullin, JP
   Nguyen, JH
   Taylor, DG
   Bess, S
   Line, BG
   Ames, CP
   Schwab, FJ
   Lafage, V
   Shaffrey, CI
   Smith, JS
AF Buell, Thomas J.
   Chen, Ching-Jen
   Quinn, John C.
   Buchholz, Avery L.
   Mazur, Marcus D.
   Mullin, Jeffrey P.
   Nguyen, James H.
   Taylor, Davis G.
   Bess, Shay
   Line, Breton G.
   Ames, Christopher P.
   Schwab, Frank J.
   Lafage, Virginie
   Shaffrey, Christopher I.
   Smith, Justin S.
TI Alignment Risk Factors for Proximal Junctional Kyphosis and the Effect
   of Lower Thoracic Junctional Tethers for Adult Spinal Deformity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; Adult spinal deformity; Complication; Proximal
   junctional kyphosis; Scoliosis; Spinal fusion; Tethers
ID UPPER INSTRUMENTED VERTEBRAE; PEDICLE SCREW CONSTRUCTS; NONOPERATIVE
   TREATMENT; CLINICAL-OUTCOMES; FUSION; SURGERY; MULTICENTER; SCOLIOSIS;
   SEGMENT; PREVALENCE
AB OBJECTIVE: The aims of this retrospective cohort study were to 1) identify new alignment risk factors for proximal junctional kyphosis (PJK) in adult spinal deformity (ASD) patients with lower thoracic upper instrumented vertebra (UIV) and 2) determine the effect of junctional tethers on PJK and UIV alignment.
   METHODS: We analyzed consecutive ASD patients who underwent posterior instrumented fusion with lower thoracic UIV (T9-T11). Posteriorly anchored junctional tethers were used more recently for ligamentous augmentation to prevent PJK. In addition to regional and global parameters, upper segmental lumbar lordosis (ULL) versus lower segmental lumbar lordosis and UIV angle (measured from UIV inferior endplate to horizontal) were assessed. Primary outcome of PJK was defined as proximal junctional angle > 10 degrees and > 10 degrees greater than the corresponding preoperative measurement. Univariable and multivariable analyses were performed.
   RESULTS: The study cohort comprised 120 ASD patients (mean age, 67 years) with minimum 1-year follow-up. Preoperative ULL (P = 0.034) and UIV angle (P = 0.026) were associated with PJK. No independent preoperative alignment risk factors of PJK were identified in multivariable analysis. Tether use was protective against PJK (odds ratio, 0.063 [0.016-0.247]; P < 0.001). PJK in tethered patients was more common with greater postoperative ULL (P = 0.047) and UIV angle (P = 0.026).
   CONCLUSIONS: Junctional tethers significantly reduced PJK in ASD patients with lower thoracic UIV. In tethered patients, PJK was more common with greater postoperative lordosis of the upper lumbar spine and greater UIV angle. This finding suggests potential benefit of tethers to mitigate effects of segmental lumbar and focal UIV malalignment that may occur after deformity surgery.
C1 [Buell, Thomas J.; Chen, Ching-Jen; Mazur, Marcus D.; Mullin, Jeffrey P.; Nguyen, James H.; Taylor, Davis G.; Shaffrey, Christopher I.; Smith, Justin S.] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.
   [Quinn, John C.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol Surg, Houston, TX 77030 USA.
   [Buchholz, Avery L.] Med Univ South Carolina, Dept Neurol Surg, Charleston, SC USA.
   [Bess, Shay; Line, Breton G.] Presbyterian St Lukes Rocky Mt Hosp Children, Denver Int Spine Ctr, Denver, CO USA.
   [Ames, Christopher P.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
   [Schwab, Frank J.; Lafage, Virginie] Hosp Special Surg, Dept Orthopaed Surg, 535 E 70th St, New York, NY 10021 USA.
RP Buell, TJ (reprint author), Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.
EM tjb4p@hscmail.mcc.virginia.edu
RI Chen, Ching-Jen/F-5976-2013; Lafage, Virginie/E-7747-2010
OI Chen, Ching-Jen/0000-0002-7830-9273; bess, shay/0000-0002-9697-8999;
   Lafage, Virginie/0000-0002-0119-7111
CR Been E, 2010, SPINE, V35, pE1014, DOI 10.1097/BRS.0b013e3181ddd433
   Bess S, 2017, J NEUROSURG-SPINE, V26, P125, DOI 10.3171/2016.6.SPINE151477
   Bridwell KH, 2013, NEUROSURGERY, V72, P899, DOI 10.1227/NEU.0b013e31828bacd8
   Bridwell KH, 2010, SPINE, V35, P1849, DOI 10.1097/BRS.0b013e3181efa06a
   Bridwell KH, 2009, SPINE, V34, P2171, DOI 10.1097/BRS.0b013e3181a8fdc8
   Buell TJ, 2018, J NEUROSURG-SPINE, V29, P610, DOI 10.3171/2018.5.SPINE18636
   Buell TJ, 2019, OPER NEUROSURG, V16, P256, DOI 10.1093/ons/opy065
   Facchinello Y, 2015, CLIN BIOMECH, V30, P1026, DOI 10.1016/j.clinbiomech.2015.09.011
   Facchinello Y, 2014, IEEE ENG MED BIO, P6605, DOI 10.1109/EMBC.2014.6945142
   Faundez AA, 2018, EUR SPINE J, V27, pS139, DOI 10.1007/s00586-017-5426-7
   FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141
   Fujimori T, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13541
   Ghobrial GM, 2017, SPINE J, V17, P1499, DOI 10.1016/j.spinee.2017.05.015
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Glattes RC, 2005, SPINE, V30, P1643, DOI 10.1097/01.brs.0000169451.76359.49
   Ha Y, 2013, J NEUROSURG-SPINE, V19, P360, DOI 10.3171/2013.5.SPINE12737
   Helgeson MD, 2010, SPINE, V35, P177, DOI 10.1097/BRS.0b013e3181c77f8c
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Kim HJ, 2014, SPINE, V39, pE795, DOI 10.1097/BRS.0000000000000339
   Kim HJ, 2012, CLIN ORTHOP RELAT R, V470, P1633, DOI 10.1007/s11999-011-2179-1
   Kim YJ, 2008, SPINE, V33, P2179, DOI 10.1097/BRS.0b013e31817c0428
   Kim YJ, 2006, SPINE, V31, P2359, DOI 10.1097/01.brs.0000238969.59928.73
   Lafage R, 2017, SPINE, V42, P1570, DOI 10.1097/BRS.0000000000002191
   Lafage R, 2017, SPINE, V42, pE1119, DOI 10.1097/BRS.0000000000002116
   Lange T, 2017, SPINE J, V17, P1148, DOI 10.1016/j.spinee.2017.03.021
   Lee GA, 1999, SPINE, V24, P795, DOI 10.1097/00007632-199904150-00011
   Lonner BS, 2017, SPINE DEFORM, V5, P181, DOI DOI 10.1016/J.JSPD.2016.10.003
   Luo M, 2017, WORLD NEUROSURG, V102, P200, DOI 10.1016/j.wneu.2017.02.126
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   Mendoza-Lattes Sergio, 2011, Iowa Orthop J, V31, P199
   Metzger MF, 2016, GLOB SPINE J, V6, P335, DOI 10.1055/s-0035-1563611
   O'Leary PT, 2009, SPINE, V34, P2134, DOI 10.1097/BRS.0b013e3181b2e17e
   Reames Davis L, 2015, J Spinal Disord Tech, V28, pE106, DOI 10.1097/BSD.0000000000000158
   Sandquist Lee, 2015, Surg Neurol Int, V6, P112, DOI 10.4103/2152-7806.159383
   Scheer JK, 2015, EUR SPINE J, V24, pS121, DOI 10.1007/s00586-014-3391-y
   Schwab F, 2005, SPINE, V30, P1082, DOI 10.1097/01.brs.0000160842.43482.cd
   Smith JS, 2009, NEUROSURGERY, V65, P93, DOI DOI 10.1227/01.NEU.0000347005.35282.6C
   Smith JS, 2016, J NEUROSURG-SPINE, V25, P1, DOI 10.3171/2015.11.SPINE151036
   Smith JS, 2016, NEUROSURGERY, V78, P851, DOI 10.1227/NEU.0000000000001116
   Smith JS, 2009, SPINE, V34, P1693, DOI 10.1097/BRS.0b013e3181ac5fcd
   Smith JS, 2009, NEUROSURGERY, V65, P86, DOI 10.1227/01.NEU.0000347005.35282.6C
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Teles AR, 2017, GLOB SPINE J, V7, P170, DOI 10.1177/2192568217699182
   Thawrani DP, 2014, SPINE, V39, pE826, DOI 10.1097/BRS.0000000000000367
   Watanabe K, 2010, SPINE, V35, P138, DOI 10.1097/BRS.0b013e3181c8f35d
   Yagi M, 2011, SPINE, V36, pE60, DOI 10.1097/BRS.0b013e3181eeaee2
NR 46
TC 4
Z9 5
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E238
EP E245
DI 10.1016/j.wneu.2018.08.242
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000033
PM 30217780
DA 2020-05-12
ER

PT J
AU Byun, J
   Kim, YH
   Nam, SJ
   Park, JE
   Cho, YH
   Kim, HS
   Hong, SH
   Kim, JH
   Kim, SJ
   Kim, CJ
AF Byun, Joonho
   Kim, Young-Hoon
   Nam, Soo Jung
   Park, Ji Eun
   Cho, Young Hyun
   Kim, Ho Sung
   Hong, Seok Ho
   Kim, Jeong Hoon
   Kim, Sang Joon
   Kim, Chang Jin
TI Comparison of Survival Outcomes Between Partial Resection and Biopsy for
   Primary Glioblastoma: A Propensity Score-Matched Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biopsy; Glioblastoma; Partial resection; Survival
ID GROSS TOTAL RESECTION; EXTENT; MULTIFORME; SURGERY; GLIOMAS;
   TEMOZOLOMIDE; VOLUME
AB OBJECTIVES: Gross total resection for glioblastoma (GBM) has been associated with better prognosis. However, it is not always feasible, and the threshold for the extent of resection required for better prognosis has been controversial. Therefore, we compared the survival and clinical outcomes of patients with GBM who had undergone partial resection (PR) or biopsy.
   METHODS: Of the 110 patients, 32 and 78, who had undergone PR and biopsy, respectively, were enrolled to identify any differences in clinical outcomes. No differences were found in patient demographics between the 2 groups, except for tumor location and mean tumor volume (P = 0.02 and P < 0.01, respectively). Propensity score matching between the PR and biopsy groups was performed, in which 20 patients each in the PR and biopsy groups were matched.
   RESULTS: The overall survival (OS) and progression-free survival (PFS) did not differ significantly between the PR and biopsy groups (P = 0.84 and P = 0.48, respectively). After propensity score matching, the differences in OS and PFS between the 2 groups were still not statistically significant (P = 0.51 and P = 0.75, respectively). The hazard ratios for OS and PFS for the PR group compared with biopsy were 0.98 and 0.73, respectively; however, the difference was not statistically significant (P = 0.96 and P = 0.39, respectively). The surgical complication rate was greater in the PR group (14 of 32; 43.7%) than in the biopsy group (9 of 78; 11.5%; P < 0.01).
   CONCLUSIONS: PR failed to improve survival compared with biopsy for patients with GBM. Moreover, the surgical complication rate in the PR group was greater than that in the biopsy group.
C1 [Byun, Joonho; Kim, Young-Hoon; Cho, Young Hyun; Hong, Seok Ho; Kim, Jeong Hoon; Kim, Chang Jin] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol Surg, Seoul, South Korea.
   [Nam, Soo Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea.
   [Park, Ji Eun; Kim, Ho Sung; Kim, Sang Joon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea.
RP Kim, YH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol Surg, Seoul, South Korea.
EM justin527@hanmail.net
OI Kim, Young-Hoon/0000-0002-8852-6503; Byun, Joonho/0000-0003-0687-3286;
   Cho, Young Hyun/0000-0002-3274-5096
CR Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Chaichana KL, 2014, WORLD NEUROSURG, V82, pE257, DOI 10.1016/j.wneu.2014.01.019
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081
   Chaichana KL, 2011, ANN SURG ONCOL, V18, P239, DOI 10.1245/s10434-010-1242-6
   CIRIC I, 1987, NEUROSURGERY, V21, P21, DOI 10.1227/00006123-198707000-00005
   De la Garza-Ramos R, 2016, CLIN NEUROL NEUROSUR, V140, P6, DOI 10.1016/j.clineuro.2015.11.005
   Duffau H, 2014, WORLD NEUROSURG, V82, pE101, DOI 10.1016/j.wneu.2014.02.015
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Hirose Y, 2013, BRAIN TUMOR PATHOL, V30, P203, DOI 10.1007/s10014-013-0148-y
   Hrabalek L, 2015, BIOMED PAP, V159, P150, DOI 10.5507/bp.2013.052
   Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4
   Kreth FW, 2013, ANN ONCOL, V24, P3117, DOI 10.1093/annonc/mdt388
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Ludwig K, 2017, J NEURO-ONCOL, V134, P505, DOI 10.1007/s11060-017-2379-y
   Orringer D, 2012, J NEUROSURG, V117, P851, DOI 10.3171/2012.8.JNS12234
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Roux A, 2017, J NEURO-ONCOL, V135, P83, DOI 10.1007/s11060-017-2551-4
   Salvati M, 2012, J NEUROSURG, V117, P204, DOI 10.3171/2012.4.JNS101702
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Warnick RE, 2016, YOUMANS WINN NEUROLO, P4310
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
NR 25
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E858
EP E866
DI 10.1016/j.wneu.2018.09.237
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000106
PM 30315970
DA 2020-05-12
ER

PT J
AU Cappelletti, M
   Ruggeri, AG
   Spizzichino, L
   D'Amico, A
   D'avella, E
   Delfini, R
AF Cappelletti, Martina
   Ruggeri, Andrea Gennaro
   Spizzichino, Lorenzo
   D'Amico, Alberto
   D'avella, Elena
   Delfini, Roberto
TI Fibrous Pituitary Macroadenomas: Predictive Role of Preoperative
   Radiologic Investigations for Proper Surgical Planning in a Cohort of 66
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Expanded endoscopic approach; Extent of resection; Extracapsular
   dissection; Fibrous pituitary adenoma; Sellar approach; Surgical
   planning
ID ENDOSCOPIC TRANSSPHENOIDAL SURGERY; ADENOMAS; CONSISTENCY; MANAGEMENT;
   MRI; COMPLICATIONS; MICROSURGERY; RESECTION; EFFICACY
AB OBJECTIVE: The endoscopic technique is in many cases the technique of choice for the removal of pituitary adenomas. Extended endoscopic approaches make it possible to remove lesions with suprasellar and parasellar extension and fibrous consistency. We identify some characteristics that might point to the adoption of an expanded approach in the preoperative phase.
   METHODS: We considered 66 consecutive cases treated for pituitary macroadenomas. All patients underwent preoperative magnetic resonance imaging and computed tomography, as well as postoperative magnetic resonance imaging. From the analysis of surgical reports and preoperative radiologic investigations, we extracted data related to size, extension, morphologic characteristics, consistency, and type of approach used (sellar or expanded). The degree of removal was judged to be total, near total, subtotal, or partial.
   RESULTS: The data showed that in some cases it is possible to assume in advance that there is a need for an expanded endoscopic approach. The features that led to an extended approach for extracapsular dissection of the lesion were the size of the tumor; an hourglass/dumbbell shape; lateral extension to the suprasellar carotid artery; Knosp degree 3 or 4; contrast enhancement heterogeneity; intratumoral hemorrhage, erosion, or discontinuity of the sellar floor; and increased sellar depth, which predicts increased thickness.
   CONCLUSIONS: The ability to predict the consistency of pituitary adenomas allows the surgeon to design a surgical procedure tailored to the patient. This approach has advantages concerning the extent of resection and allows a radical strategy with a single surgical procedure to be pursued.
C1 [Cappelletti, Martina; Ruggeri, Andrea Gennaro; Delfini, Roberto] Sapienza Univ Rome, Dept Neurol & Psychiat, Neurosurg Unit, Rome, Italy.
   [Spizzichino, Lorenzo] Minist Hlth, Gen Direct Prevent, Rome, Italy.
   [D'Amico, Alberto] Univ Hosp, Inst Neurosurg, Verona, Italy.
   [D'avella, Elena] Univ Padua, Dept Neurosci, Padua, Italy.
RP Cappelletti, M (reprint author), Sapienza Univ Rome, Dept Neurol & Psychiat, Neurosurg Unit, Rome, Italy.
EM cappelletti.marty@gmail.com
CR Alimohamadi M, 2014, ACTA NEUROCHIR, V156, P2245, DOI 10.1007/s00701-014-2259-6
   Cappabianca P, 2002, J NEUROSURG, V97, P293, DOI 10.3171/jns.2002.97.2.0293
   Cappabianca P, 2014, ACTA NEUROCHIR, V156, P2217, DOI 10.1007/s00701-014-2213-7
   Chanson P, 2015, ANN ENDOCRINOL-PARIS, V76, P239, DOI 10.1016/j.ando.2015.04.002
   Chen S, 2017, BIOMED RES INT, V2017
   Chuang CC, 2017, SCI REP-UK, V7, DOI 10.1038/srep40792
   Cortet-Rudelli C, 2015, ANN ENDOCRINOL-PARIS, V76, P228, DOI 10.1016/j.ando.2015.04.003
   D'Haens J, 2009, SURG NEUROL, V72, P336, DOI 10.1016/j.surneu.2009.04.012
   Dallapiazza RF, 2015, ENDOCRIN METAB CLIN, V44, P105, DOI 10.1016/j.ecl.2014.10.010
   Di Maio S, 2011, J NEUROSURG, V114, P345, DOI 10.3171/2010.9.JNS10262
   Goel A, 2010, J NEUROSURG, V112, P1341, DOI 10.3171/2009.11.JNS091083
   Gondim JA, 2014, WORLD NEUROSURG, V82, pE281, DOI 10.1016/j.wneu.2013.08.028
   Gondim JA, 2011, PITUITARY, V14, P174, DOI 10.1007/s11102-010-0280-1
   Hughes JD, 2016, PITUITARY, V19, P286, DOI 10.1007/s11102-016-0706-5
   Jane John A Jr, 2005, Neurosurg Focus, V19, pE2
   Koutourousiou M, 2013, J NEUROSURG, V118, P621, DOI 10.3171/2012.11.JNS121190
   Leung GKK, 2012, PITUITARY, V15, P237, DOI 10.1007/s11102-011-0319-y
   Ma ZY, 2016, NEURORADIOLOGY, V58, P51, DOI 10.1007/s00234-015-1591-8
   Micko ASG, 2015, J NEUROSURG, V122, P803, DOI 10.3171/2014.12.JNS141083
   Ojha BK, 2009, ACTA NEUROCHIR, V151, P843, DOI 10.1007/s00701-009-0336-z
   Paluzzi A, 2014, PITUITARY, V17, P307, DOI 10.1007/s11102-013-0502-4
   Pierallini A, 2006, RADIOLOGY, V239, P223, DOI 10.1148/radiol.2383042204
   Pratheesh R, 2013, PITUITARY, V16, P419, DOI 10.1007/s11102-012-0439-z
   Smith KA, 2015, J NEUROL SURG PART B, V76, P340, DOI 10.1055/s-0035-1549005
   Strychowsky J, 2011, J OTOLARYNGOL-HEAD N, V40, P175, DOI 10.2310/7070.2011.100118
   Wang SS, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-59
   Wei LF, 2015, INT J CLIN EXP MED, V8, P12898
   Yano S, 2017, WORLD NEUROSURG, V99, P533, DOI 10.1016/j.wneu.2016.12.068
NR 28
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E449
EP E457
DI 10.1016/j.wneu.2018.09.137
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000056
PM 30267949
DA 2020-05-12
ER

PT J
AU Catanese, L
   Gupta, R
   Griessenauer, CJ
   Moore, JM
   Adeeb, N
   Enriquez-Marulanda, A
   Alturki, AY
   Ascanio, LC
   Lioutas, V
   Shoamanesh, A
   Cohen, W
   Kumar, S
   Selim, M
   Thomas, AJ
   Ogilvy, CS
AF Catanese, Luciana
   Gupta, Raghav
   Griessenauer, Christoph J.
   Moore, Justin M.
   Adeeb, Nimer
   Enriquez-Marulanda, Alejandro
   Alturki, Abdulrahman Y.
   Ascanio, Luis C.
   Lioutas, Vasileios
   Shoamanesh, Ashkan
   Cohen, Wendy
   Kumar, Sandeep
   Selim, Magdy
   Thomas, Ajith J.
   Ogilvy, Christopher S.
TI Patterns of Stroke Transfers and Identification of Predictors for
   Thrombectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Neuroimaging; Patient transfer; Stroke; Stroke
   network
ID ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; ENDOVASCULAR
   TREATMENT; CT ANGIOGRAPHY; INTERVENTIONAL MANAGEMENT; SCORE; SCALE;
   PERFUSION; ASSOCIATION; VALIDATION
AB BACKGROUND: Interhospital transfers for endovascular thrombectomy (EVT) evaluation have increased since the publication of landmark neuroendovascular stroke trials in 2015. The lack of guidelines to select potential EVT candidates prior to transfer can lead to instances where, despite considerable costs and transport risks, transferred patients do not ultimately undergo EVT. Our aim was to characterize the patterns and identify predictors for EVT on transfer.
   METHODS: In this observational cohort study, we retrospectively analyzed patients with acute ischemic stroke (AIS) transferred to our institution for EVT evaluation from January 2015 to March 2016. Clinical and radiographic predictors for EVT on transfer were determined with multivariable logistic regression analysis.
   RESULTS: A total of 103 transfer patients with AIS were included in the study, and 52% were women. A higher collateral score (P < 0.01), a higher National Institutes of Health Stroke Scale (NIHSS) score (P < 0.01), computed tomography angiography (CTA) at referring hospital (P < 0.01), and large vessel occlusion on arrival CTA (P < 0.01) were significant in patients who underwent EVT on univariable analysis. More than half (61.1%) of transfers were futile and primarily related to absence of large vessel occlusion on arrival. A higher collateral score (P = 0.02), a higher NIHSS score (P = 0.006), and having undergone a CTA at the referring center (P = 0.002) remained the independent predictors of EVT. The C statistic for the model was 0.94.
   CONCLUSIONS: A higher collateral score, the acquisition of CTA imaging at the referring centers, and a higher NIHSS score independently predicted EVT on transfer.
C1 [Catanese, Luciana; Lioutas, Vasileios; Cohen, Wendy; Kumar, Sandeep; Selim, Magdy] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA.
   [Gupta, Raghav; Moore, Justin M.; Enriquez-Marulanda, Alejandro; Alturki, Abdulrahman Y.; Ascanio, Luis C.; Thomas, Ajith J.; Ogilvy, Christopher S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurosurg Serv, Boston, MA 02115 USA.
   [Griessenauer, Christoph J.] Geisinger Hlth Syst, Dept Neurosurg, Danville, PA USA.
   [Catanese, Luciana; Shoamanesh, Ashkan] McMaster Univ, Med Sch, Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Adeeb, Nimer] Louisiana State Univ, Dept Neurosurg, Shreveport, LA 71105 USA.
RP Ogilvy, CS (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurosurg Serv, Boston, MA 02115 USA.
EM cogilvy@bidmc.harvard.edu
OI Griessenauer, Christoph/0000-0002-2952-3812; Enriquez-Marulanda,
   Alejandro/0000-0001-6091-390X; Ascanio, Luis/0000-0001-9914-1599
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Aleccia J., 2014, AIR AMBULANCE LEAVE
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Cho Suck Ju, 2012, Chonnam Med J, V48, P169, DOI 10.4068/cmj.2012.48.3.169
   Fischer U, 2005, STROKE, V36, P2121, DOI 10.1161/01.STR.0000182099.04994.fc
   Fuentes B, 2015, STROKE, V46, P2156, DOI 10.1161/STROKEAHA.115.009282
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2014, CIRCULATION, V130, P265, DOI 10.1161/CIRCULATIONAHA.113.007826
   Heldner MR, 2013, STROKE, V44, P1153, DOI 10.1161/STROKEAHA.111.000604
   Higashida R, 2013, STROKE, V44, P2961, DOI 10.1161/STR.0b013e3182a6d2b2
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Katz BS, 2015, STROKE, V46, P1508, DOI 10.1161/STROKEAHA.115.008804
   Kim JJ, 2004, STROKE, V35, P1340, DOI 10.1161/01.STR.0000126043.83777.3a
   Menon BK, 2011, AM J NEURORADIOL, V32, P1640, DOI 10.3174/ajnr.A2564
   Menon BK, 2015, STROKE, V46, P1453, DOI 10.1161/STROKEAHA.115.009160
   Nazliel B, 2008, STROKE, V39, P2264, DOI 10.1161/STROKEAHA.107.508127
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   de la Ossa NP, 2014, STROKE, V45, P87, DOI 10.1161/STROKEAHA.113.003071
   Pexman JHW, 2001, AM J NEURORADIOL, V22, P1534
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schwamm LH, 2005, STROKE, V36, P690, DOI 10.1161/01.STR.0000158165.42884.4F
   Tan IYL, 2009, AM J NEURORADIOL, V30, P525, DOI 10.3174/ajnr.A1408
   Vagal A, 2016, STROKE, V47, P535, DOI 10.1161/STROKEAHA.115.011461
   van Seeters T, 2015, CEREBROVASC DIS, V40, P258, DOI 10.1159/000441088
   Vanacker P, 2016, STROKE, V47, P1844, DOI 10.1161/STROKEAHA.115.012577
   Verro P, 2002, STROKE, V33, P276, DOI 10.1161/hs0102.101223
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E675
EP E683
DI 10.1016/j.wneu.2018.09.189
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000083
PM 30296622
DA 2020-05-12
ER

PT J
AU Cavalcanti, DD
   Figueiredo, EG
   Preul, MC
   Spetzler, RF
AF Cavalcanti, Daniel D.
   Figueiredo, Eberval G.
   Preul, Mark C.
   Spetzler, Robert F.
TI Anatomical and Objective Evaluation of the Main Surgical Approaches to
   Pontine Intra-Axial Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brainstem; Cavernous malformation; Microsurgery; Safe entry zones;
   Surgical anatomy; Surgical approaches
ID SAFE ENTRY ZONES; BRAIN-STEM GLIOMAS; CAVERNOUS MALFORMATIONS;
   MICROSURGICAL ANATOMY; RHOMBOID FOSSA; MANAGEMENT; TUMORS;
   4TH-VENTRICLE; RESECTION; SURGERY
AB OBJECTIVE: Apparently similar intra-axial pontine lesions may demand distinct surgical approaches. Selecting the optimal approach reduces unnecessary manipulation of tracts and nuclei. This study aims to reveal a quantitative analysis of main surgical corridors dealing with intrinsic pontine pathology.
   METHODS: Six approaches were performed repeatedly in 10 cadaveric heads: 1) retrosigmoid, 2) retrolabyrinthine, 3) subtemporal transtentorial, 4) anterior petrosectomy, 5) combined petrosal approach, and 6) suboccipital telovelar. Six safe entry zones were studied: peritrigeminal, supratrigeminal, lateral pontine, supracollicular, infracollicular, and median sulcus of fourth ventricle. A neuronavigation device was used to collect 3-dimensional coordinates from fixed points over the edge of craniotomies and brainstem surface; 4 variables were studied: 1) angles of attack; 2) areas of exposure; 3) lengths of exposure; and 4) trajectories.
   RESULTS: The mean area of exposure generated by the retrosigmoid approach over the brainstem was 538.6 +/- 161.0 mm(2), whereas that yielded by the retrolabyrinthine was 475.0 +/- 173.4 mm(2). There were no significant differences between both when considering areas of exposure and angles. Adding a tentorial cut to the subtemporal approach exposed the superior part of the lateral surface of pons; the area of exposure increased a mean of 33% (P < 0.001).
   CONCLUSIONS: In addition to producing similar areas and angles of attack, the retrolabyrinthine yields a more orthogonal trajectory to lateral pons than the retrosigmoid approach. Adding a tentorial cut and anterior petrosectomy significantly increased areas and lengths of exposure of a regular subtemporal approach. The combined approach significantly increased angles of attack to both the supratrigeminal and lateral pontine safe zones.
C1 [Cavalcanti, Daniel D.; Preul, Mark C.; Spetzler, Robert F.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Figueiredo, Eberval G.] Univ Sao Paulo, Div Neurol Surg, Sao Paulo, SP, Brazil.
RP Cavalcanti, DD (reprint author), Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM danieldc.neuro@gmail.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
OI Cavalcanti, Daniel/0000-0002-2284-9297
CR Abla AA, 2014, OPER NEUROSURG, V10, P472, DOI 10.1227/NEU.0000000000000389
   Abla AA, 2011, NEUROSURGERY, V68, P403, DOI 10.1227/NEU.0b013e3181ff9cde
   Akers A, 2017, NEUROSURGERY, V80, P665, DOI 10.1093/neuros/nyx091
   Alphin TH, 1944, J COMP NEUROL, V80, P65, DOI 10.1002/cne.900800106
   Amin-Hanjani S, 1998, NEUROSURGERY, V42, P1229, DOI 10.1097/00006123-199806000-00013
   Amin-Hanjani S, 1998, NEUROSURGERY, V42, P1236
   BAGHAI P, 1982, NEUROSURGERY, V10, P574, DOI 10.1227/00006123-198205000-00005
   Bailey P, 1939, INTRACRANIAL TUMORS
   Bricolo A, 1995, Adv Tech Stand Neurosurg, V22, P261
   Brown AP, 1996, BNI Q, V12, P20
   Cantore G, 1999, SURG NEUROL, V52, P84, DOI 10.1016/S0090-3019(99)00036-1
   Cavalcanti DD, 2016, J NEUROSURG, V124, P1359, DOI 10.3171/2015.4.JNS141945
   Cavalcanti DD, 2010, NEUROSURGERY, V66, pONS205, DOI 10.1227/01.NEU.0000369948.37233.70
   Cavalheiro S, 2015, CHILD NERV SYST, V31, P1815, DOI 10.1007/s00381-015-2799-y
   Dandy WE, 1962, SPECIAL TUMORS BRAIN
   Doglietto F, 2016, NEUROSURG REV, V39, P357, DOI 10.1007/s10143-015-0694-3
   Essayed WI, 2017, J NEUROSURG, V127, P1139, DOI 10.3171/2016.9.JNS161503
   Figueiredo Eberval Gadelha, 2005, Neurosurgery, V56, P397, DOI 10.1227/01.NEU.0000156549.96185.6D
   Gonzalez LF, 2002, NEUROSURGERY, V50, P550, DOI 10.1097/00006123-200203000-00023
   Gross BA, 2009, NEUROSURGERY, V64, P805, DOI [10.1227/01.NEU.0000343667.14177.72, 10.1227/01.NEU.0000343668.44288.18]
   Hebb MO, 2010, NEUROSURGERY, V66, P26, DOI 10.1227/01.NEU.0000350865.85697.18
   Kalani MYS, 2016, J NEUROSURG, V125, P1596, DOI 10.3171/2016.6.JNS161043
   Kalani MYS, 2016, WORLD NEUROSURG, V87, P235, DOI 10.1016/j.wneu.2015.11.025
   KYOSHIMA K, 1993, J NEUROSURG, V78, P987, DOI 10.3171/jns.1993.78.6.0987
   LANG J, 1991, ACTA NEUROCHIR, V113, P84, DOI 10.1007/BF01402120
   Lanman TH, 1999, J NEUROSURG, V90, P617, DOI 10.3171/jns.1999.90.4.0617
   Li D, 2014, J NEUROSURG-PEDIATR, V13, P484, DOI 10.3171/2014.2.PEDS13536
   Gomez-Amador JL, 2017, J NEUROSURG, V127, P553, DOI 10.3171/2016.8.JNS161137
   Mare Pandurang B, 2014, Asian J Neurosurg, V9, P243, DOI 10.4103/1793-5482.146649
   Matson DD, 1969, NEUROSURGERY INFANCY
   Mehta VS, 2009, NEUROL INDIA, V57, P274, DOI 10.4103/0028-3886.53272
   Mussi ACM, 2000, J NEUROSURG, V92, P812, DOI 10.3171/jns.2000.92.5.0812
   Recalde RJ, 2008, NEUROSURGERY, V63, P9, DOI [10.1227/01.neu.0000317368.69523.40, 10.1227/01.NEU.0000297062.52433.3F]
   Recinos PF, 2007, PEDIATR NEUROSURG, V43, P192, DOI 10.1159/000098831
   Rhoton AL, 2000, NEUROSURGERY, V47, pS7, DOI 10.1097/00006123-200009001-00007
   Samii M, 2001, J NEUROSURG, V95, P825, DOI 10.3171/jns.2001.95.5.0825
   Strauss C, 1997, J NEUROSURG, V87, P893, DOI 10.3171/jns.1997.87.6.0893
   Tanriover N, 2004, J NEUROSURG, V101, P484, DOI 10.3171/jns.2004.101.3.0484
   Teo C, 2008, CHILD NERV SYST, V24, P1307, DOI 10.1007/s00381-008-0647-z
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
   Wilkinson H, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.09.006
   Yagmurlu K, 2017, J NEUROSURG, V127, P1134, DOI 10.3171/2016.8.JNS16947
   Zaidi HA, 2017, NEUROSURGERY, V81, P620, DOI 10.1093/neuros/nyw139
   Zhou LF, 2005, SURG NEUROL, V63, P307, DOI 10.1016/j.surneu.2004.07.038
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E199
EP E206
DI 10.1016/j.wneu.2018.09.077
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000028
PM 30261378
DA 2020-05-12
ER

PT J
AU Chang, CW
   Tsai, TT
   Niu, CC
   Fu, TS
   Lai, PL
   Chen, LH
   Chen, WJ
AF Chang, Chia-Wei
   Tsai, Tsung-Ting
   Niu, Chi-Chien
   Fu, Tsai-Sheng
   Lai, Po-Liang
   Chen, Lih-Huei
   Chen, Wen-Jer
TI Transforaminal Interbody Debridement and Fusion to Manage Postdiscectomy
   Discitis in Lumbar Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Infection clearance; Postoperative discitis; Quality of life; Surgical
   debridement; Transforaminal lumbar interbody debridement and fusion
ID POSTOPERATIVE SPONDYLODISCITIS; VERTEBRAL OSTEOMYELITIS; INTERVERTEBRAL
   DISKS; INFECTION; DISKECTOMY; INSTRUMENTATION; DIAGNOSIS; ETIOLOGY
AB BACKGROUND: Traditionally, nonoperative management with long-term antibiotics and bed rest has been recommended as first-line treatment for most patients with postoperative discitis. A recent trend in treatment under a limited range of indications has been to perform surgical debridement followed by long-term administration of antibiotics. This descriptive study investigated whether transforaminal lumbar interbody debridement and fusion (TLIDF) combined with intravenous antibiotics is appropriate to manage postdiscectomy discitis.
   METHODS: This study retrospectively analyzed demographic data, laboratory data, and radiography and magnetic resonance imaging of 10 patients with postoperative discitis who underwent surgical TLIDF followed by antibiotic treatment. Preoperative and postoperative spine sagittal alignment, visual analog scale scores, and KirkaldyWillis criteria for functional outcomes were evaluated.
   RESULTS: An infection clearance rate of 100% was ultimately achieved for the patients who underwent TLIDF with short posterior instrumentation. TLIDF yielded better outcomes than traditional conservative treatment in terms of spine alignment correction, functional outcomes, and quality of life.
   CONCLUSIONS: Based on previously reported data and the findings of this study, we suggest that surgical intervention should be used in certain cases, as it can achieve better outcomes than conservative treatment. We recommend a novel single posterior approach with TLIDF and posterior pedicle screw instrumentation for management of postdiscectomy discitis.
C1 [Chang, Chia-Wei; Tsai, Tsung-Ting; Niu, Chi-Chien; Fu, Tsai-Sheng; Lai, Po-Liang; Chen, Lih-Huei; Chen, Wen-Jer] Chang Gung Mem Hosp, Spine Sect, Dept Orthopaed Surg, Bone & Joint Res Ctr, Taoyuan, Taiwan.
   [Chang, Chia-Wei; Tsai, Tsung-Ting; Niu, Chi-Chien; Fu, Tsai-Sheng; Lai, Po-Liang; Chen, Lih-Huei; Chen, Wen-Jer] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Chang, Chia-Wei; Fu, Tsai-Sheng] Chang Gung Mem Hosp, Dept Orthopaed Surg, Keelung, Taiwan.
RP Tsai, TT (reprint author), Chang Gung Mem Hosp, Spine Sect, Dept Orthopaed Surg, Bone & Joint Res Ctr, Taoyuan, Taiwan.; Tsai, TT (reprint author), Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
EM tsai1129@gmail.com
OI Tsai, Tsung-Ting/0000-0002-7776-7627
CR Ahn Y, 2012, BRIT J NEUROSURG, V26, P482, DOI 10.3109/02688697.2011.650739
   Basu S, 2012, INDIAN J ORTHOP, V46, P427, DOI 10.4103/0019-5413.98831
   BIRCHER MD, 1988, SPINE, V13, P88
   Chelsom J, 1998, SCAND J INFECT DIS, V30, P147, DOI 10.1080/003655498750003537
   Chen SH, 2018, CLIN SPINE SURG, V31, P225, DOI 10.1097/BSD.0000000000000633
   Chen SH, 2015, EUR SPINE J, V24, P561, DOI 10.1007/s00586-014-3636-9
   Chen WJ, 2002, CLIN ORTHOP RELAT R, P50
   ELGINDI S, 1976, J BONE JOINT SURG BR, V58, P114
   FORD L T, 1955, South Med J, V48, P1295
   Goode AP, 2011, SPINE, V36, P752, DOI 10.1097/BRS.0b013e3181e030b3
   Hadjipavlou AG, 2004, EUR SPINE J, V13, P707, DOI 10.1007/s00586-004-0699-z
   Hamdan TA, 2012, INT ORTHOP, V36, P445, DOI 10.1007/s00264-011-1430-4
   Jimenez-Mejias ME, 1999, CLIN INFECT DIS, V29, P339, DOI 10.1086/520212
   Lee JS, 2006, J BONE JOINT SURG BR, V88B, P765, DOI 10.1302/0301-620X.88B6
   Lee JS, 2015, ASIAN SPINE J, V9, P841, DOI 10.4184/asj.2015.9.6.841
   Lu ML, 2015, EUR SPINE J, V24, P555, DOI 10.1007/s00586-014-3585-3
   Man WY, 2016, CELL TISSUE BANK, V17, P269, DOI 10.1007/s10561-016-9547-8
   Moon MS, 2012, J ORTHOP SURG-HONG K, V20, P11, DOI 10.1177/230949901202000103
   Murphy ME, J NEUROSURG SCI
   OSTI OL, 1990, J BONE JOINT SURG BR, V72, P271
   Ozuna RM, 1996, ORTHOP CLIN N AM, V27, P87
   Rayes M, 2010, J NEUROSURG-SPINE, V12, P647, DOI 10.3171/2009.12.SPINE09428
   Rohde V, 1998, SPINE, V23, P615, DOI 10.1097/00007632-199803010-00016
   SCHERBEL AL, 1960, JAMA-J AM MED ASSOC, V174, P370, DOI 10.1001/jama.1960.03030040024007
   SCHULITZ KP, 1994, SPINE, V19, P1172, DOI 10.1097/00007632-199405001-00016
   Sheha AF, 2011, LIFE SCI J, V84, P1
   Tanaka S, 2009, J BONE JOINT SURG BR, V91B, P1237, DOI 10.1302/0301-620X.91B9.22051
   TRONNIER V, 1992, ACTA NEUROCHIR, V117, P149, DOI 10.1007/BF01400612
   Tsai TT, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1533-1
   TURNBULL F, 1953, J NEUROSURG, V10, P469, DOI 10.3171/jns.1953.10.5.0469
   Yan DL, 2008, EUR SPINE J, V17, P1311, DOI 10.1007/s00586-008-0739-1
NR 31
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E755
EP E760
DI 10.1016/j.wneu.2018.09.211
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000093
PM 30308339
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chen, SH
   Sprau, A
   Chieng, L
   Buttrick, S
   Alam, ES
   Ali, SC
   Madhavan, K
   Sargi, ZB
   Komotar, R
AF Chen, Stephanie H.
   Sprau, Annelise
   Chieng, Leon
   Buttrick, Simon
   Alam, Elie S.
   Ali, Sheikh C.
   Madhavan, Karthik
   Sargi, Zoukaa B.
   Komotar, Ricardo
TI Transsphenoidal Approach for Pituitary Adenomas in Elderly Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Outcomes; Pituitary tumor; Transsphenoidal
ID SURGICAL-TREATMENT; SURGERY; TUMORS; COMPLICATIONS; MANAGEMENT; OUTCOMES
AB INTRODUCTION: With a rapidly expanding elderly population in the United States, the incidence of pituitary adenomas in elderly will continue to rise. In this study, we aim to evaluate the safety and efficacy of transsphenoidal endoscopic endonasal resection for pituitary adenomas in the elderly population.
   METHODS: A retrospective review of 131 consecutive patients who underwent transsphenoidal endoscopic endonasal resection for pituitary adenomas at the University of Miami Hospital between 2012 and 2016 was performed. Preoperative, intraoperative, and surgical outcomes were analyzed in elderly (> 70 years) versus nonelderly (< 70 years) patients.
   RESULTS: Of the 131 patients, 23 of them were > 70 years (18%), of which 14 were septuagenarians and 9 were octogenarians. Elderly patients were more likely to present with vision loss (80.8% vs. 56.6%; P = 0.013) and larger tumors on imaging (2.7 +/- 1.0 cm vs. 2.4 +/- 1.3 cm; P = 0.042). Overall surgical and endocrinologic outcomes between the 2 groups were similar. However, patients < 70 years old were more likely to have a gross total resection (86.7% vs. 65.4%; P = 0.011), as well as transient diabetes insipidus (54.3% vs. 26.9% P = 0.012) and intraoperative cerebrospinal fluid leak (83.5% vs. 58.5%; P = 0.013). However, permanent postoperative complication rates were similar including rate of permanent diabetes insipidus (4.3% elderly vs. 12.1% adult), cerebrospinal fluid leak (8.7% elderly vs. 8.4% adult), and meningitis (4.3% elderly vs. 2.8% adult). There were no medical complications or deaths in our cohort.
   CONCLUSION: The transsphenoidal endoscopic endonasal approach can be a safe and effective technique for resection of pituitary adenomas in patients > 70 years old with appropriate patient selection.
C1 [Chen, Stephanie H.; Sprau, Annelise; Chieng, Leon; Buttrick, Simon; Alam, Elie S.; Ali, Sheikh C.; Madhavan, Karthik; Sargi, Zoukaa B.; Komotar, Ricardo] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Chen, SH (reprint author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM stephanie.chen@jhsmiami.org
CR Benbow SJ, 1997, CLIN ENDOCRINOL, V46, P657, DOI 10.1046/j.1365-2265.1997.1180933.x
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   COHEN DL, 1989, AGE AGEING, V18, P247, DOI 10.1093/ageing/18.4.247
   Etzioni DA, 2003, ANN SURG, V238, P170, DOI 10.1097/01.SLA.0000081085.98792.3d
   Feldkamp J, 1999, CLIN ENDOCRINOL, V51, P109, DOI 10.1046/j.1365-2265.1999.00748.x
   Ferrante L, 2002, J NEURO-ONCOL, V60, P185, DOI 10.1023/A:1020652604014
   Fujimoto Kenji, 2017, Surg Neurol Int, V8, P213, DOI 10.4103/sni.sni_189_17
   Gondim JA, 2010, PITUITARY, V13, P68, DOI 10.1007/s11102-009-0195-x
   Grossman R, 2010, CLIN ENDOCRINOL, V73, P361, DOI 10.1111/j.1365-2265.2010.03813.x
   Hong JF, 2008, J CLIN NEUROSCI, V15, P1091, DOI 10.1016/j.jocn.2007.11.003
   Kurosaki M, 2000, NEUROSURGERY, V47, P843, DOI 10.1097/00006123-200010000-00009
   Leach P, 2010, NEUROSURGERY, V67, P1205, DOI 10.1227/NEU.0b013e3181ef25c5
   Liu JF, 2015, J AM GERIATR SOC, V63, P1924, DOI 10.1111/jgs.13590
   Memel Z, 2019, OPER NEUROSURG, V16, P302, DOI 10.1093/ons/opy109
   Mortini P, 2014, ENDOCRINE, V47, P415, DOI 10.1007/s12020-014-0365-0
   Ntali G, 2018, PITUITARY, V21, P111, DOI 10.1007/s11102-018-0869-3
   Turner HE, 1999, EUR J ENDOCRINOL, V140, P383, DOI 10.1530/eje.0.1400383
   US Census Bureau, AN AG NAT
   Zhan RC, 2015, WORLD NEUROSURG, V84, P1572, DOI 10.1016/j.wneu.2015.08.035
NR 19
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E670
EP E674
DI 10.1016/j.wneu.2018.09.187
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000082
PM 30292662
DA 2020-05-12
ER

PT J
AU Cho, DY
   Choi, JH
   Kim, BS
   Shin, YS
AF Cho, Dong Young
   Choi, Jai Ho
   Kim, Bum Soo
   Shin, Yong Sam
TI Comparison of Clinical and Radiologic Outcomes of Diverse Endovascular
   Treatments in Vertebral Artery Dissecting Aneurysm Involving the Origin
   of PICA
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular procedure; PICA; Vertebral artery dissection
ID INFERIOR CEREBELLAR ARTERY; STENT PLACEMENT; FOLLOW-UP; VERTEBROBASILAR
   DISSECTION
AB OBJECTIVE: To determine clinical and radiologic outcomes of vertebral artery dissecting aneurysms involving posterior inferior cerebellar artery according to different types of endovascular treatment.
   METHODS: This study included 18 vertebral artery dissecting aneurysms (6 ruptured and 12 unruptured) involving posterior inferior cerebellar artery treated from January 2009 to December 2016. Treatments were multiple stenting, stent-assisted coil embolization, vertebral artery trapping with vertebral artery-posterior inferior cerebellar artery stenting, and Pipeline embolization. Clinical and radiologic information were obtained from retrospective chart review and radiologic review.
   RESULTS: Subarachnoid hemorrhage was diagnosed initially in 6 of 18 patients, and infarction was diagnosed initially in 2 patients. Multiple stenting was performed in 4 patients, including 1 (25%) who had cerebellar infarction and 1 (25%) who had recurrence. Stent-assisted coil embolization was performed in 8 patients, including 1 (12.5%) who had postoperative cerebellar infarction and 2 (25%) who had recurrence. Vertebral artery trapping with vertebral artery-posterior inferior cerebellar artery stenting was performed in 4 patients, including 1 (25%) who had postoperative cerebellar infarction. There was no recurrence (0%). Pipeline embolization was performed in 2 patients, including 1 (50%) who had recurrence. There was no postoperative infarction (0%). No subarachnoid hemorrhage occurred during follow-up. Deterioration in modified Rankin Scale score was found only in the stent-assisted coil embolization group (1/8; 12.5%).
   CONCLUSIONS: Vertebral artery trapping with vertebral artery-posterior inferior cerebellar artery stenting showed the lowest rate of aneurysm recurrence with high rate of minor infarction and favorable neurologic outcome. Stent-assisted coil embolization showed high recurrence rates with possible fatal disabling infarction.
C1 [Cho, Dong Young; Choi, Jai Ho; Shin, Yong Sam] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Kim, Bum Soo] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Radiol, Seoul, South Korea.
RP Shin, YS (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM nsshin@gmail.com
RI KIM, Bum-soo/F-3086-2018
OI KIM, Bum-soo/0000-0002-3870-6813; Cho, Dong Young/0000-0002-2535-4273
CR Ahn JY, 2006, AM J NEURORADIOL, V27, P1514
   Ahn SS, 2012, RADIOLOGY, V264, P196, DOI 10.1148/radiol.12112331
   Aihara M, 2018, J NEUROSURG, V129, P107, DOI 10.3171/2017.2.JNS162916
   Chen YA, 2013, INTERV NEURORADIOL, V19, P479, DOI 10.1177/159101991301900412
   Chung J, 2010, ACTA NEUROCHIR, V152, P1489, DOI 10.1007/s00701-010-0725-3
   Fukuda Kenji, 2015, No Shinkei Geka, V43, P331, DOI 10.11477/mf.1436203016
   Hijikata Takamichi, 2018, J Clin Med Res, V10, P527, DOI 10.14740/jocmr3397w
   Iihara K, 2002, J NEUROSURG, V97, P259, DOI 10.3171/jns.2002.97.2.0259
   Kanematsu Y, 2018, NEUROL MED-CHIR, V58, P341, DOI 10.2176/nmc.oa.2018-0076
   Kuhn AL, 2016, J NEUROINTERV SURG, V8, P1048, DOI 10.1136/neurintsurg-2015-012028
   Lim YC, 2018, WORLD NEUROSURG, V117, P203, DOI 10.1016/j.wneu.2018.06.029
   Lv X, 2010, AM J NEURORADIOL, V31, P1232, DOI 10.3174/ajnr.A2087
   Lylyk P, 2001, J NEUROSURG, V94, P427, DOI 10.3171/jns.2001.94.3.0427
   Masuo O, 2005, AM J NEURORADIOL, V26, P543
   Mizutani T, 2004, NEUROSURGERY, V54, P342, DOI 10.1227/01.NEU.0000103449.80484.7E
   Moteki Y, 2018, WORLD NEUROSURG, V116, pE505, DOI 10.1016/j.wneu.2018.05.021
   Nakagawa K, 2000, J NEUROSURG, V93, P19, DOI 10.3171/jns.2000.93.1.0019
   Ogasawara K, 2006, J NEUROSURG, V105, P781, DOI 10.3171/jns.2006.105.5.781
   Park SI, 2009, AM J NEURORADIOL, V30, P1351, DOI 10.3174/ajnr.A1561
   Shi L, 2016, INT J MED SCI, V13, P540, DOI 10.7150/ijms.15233
   Shin YS, 2007, NEURORADIOLOGY, V49, P149, DOI 10.1007/s00234-006-0169-x
   Wang K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00482
   Yeung TW, 2012, J NEUROSURG, V116, P882, DOI 10.3171/2011.12.JNS111514
   Zhao KJ, 2014, EUR RADIOL, V24, P2088, DOI 10.1007/s00330-014-3225-7
NR 24
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E22
EP E31
DI 10.1016/j.wneu.2018.08.184
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000005
PM 30189304
DA 2020-05-12
ER

PT J
AU da Silva, SA
   Yamaki, VN
   Solla, DJF
   de Andrade, AF
   Teixeira, MJ
   Spetzler, RF
   Preul, MC
   Figueiredo, EG
AF da Silva, Saul Almeida
   Yamaki, Vitor Nagai
   Fontoura Solla, Davi Jorge
   de Andrade, Almir Ferreira
   Teixeira, Manoel Jacobsen
   Spetzler, Robert F.
   Preul, Mark C.
   Figueiredo, Eberval Gadelha
TI Pterional, Pretemporal, and Orbitozygomatic Approaches: Anatomic and
   Comparative Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Orbitozygomatic; Pretemporal; Pterional; Surgical technique
ID QUANTIFICATION; CRANIOTOMY
AB OBJECTIVE: Although pterional craniotomy and its variants are the most used approaches in neurosurgery, few studies have evaluated their precise indications. We evaluate the pterional (PT), pretemporal (PreT), and orbitozygomatic (OZ) approaches through quantitative measurements of area, linear, and angular exposures of the major intracranial vascular structures.
   METHODS: Eight fresh, adult cadavers were operated with the PT, followed by the PreT, and ending with the OZ approach. The working area, angular exposure of vascular structures and linear exposure of the basilar artery were measured.
   RESULTS: The OZ approach presented a wider area (1301.3 +/- 215.9 mm(2)) with an increase of 456.7 mm(2) compared with the PT and of 167.4 mm(2) to the PreT (P = 0.011). The extension from PT to PreT and OZ increases linear exposure of the basilar artery. When comparing the PreT and OZ, we found an increase in the horizontal and vertical angle to the bifurcation of the ipsilateral middle cerebral artery (P = 0.005 and P = 0.032, respectively), horizontal angle to the basilar artery tip (P = 0.02), and horizontal angle to the contralateral ICA bifurcation (P = 0.048).
   CONCLUSIONS: The OZ approach offered notable surgical advantages compared with the traditional PT and PreT regarding to the area of exposure and linear exposure to basilar artery. Regarding angle of attack, the orbital rim and zygomatic arch removal provided quantitatively wider exposure and increased surgical freedom. A detailed anatomic study for each patient and surgeon experience must be considered for individualized surgical approach indication.
C1 [da Silva, Saul Almeida; Yamaki, Vitor Nagai; Fontoura Solla, Davi Jorge; de Andrade, Almir Ferreira; Teixeira, Manoel Jacobsen; Figueiredo, Eberval Gadelha] Univ Sao Paulo, Div Neurol Surg, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Spetzler, Robert F.; Preul, Mark C.] St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ USA.
RP Figueiredo, EG (reprint author), Univ Sao Paulo, Div Neurol Surg, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
EM ebgadelha@yahoo.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
OI Solla, Davi/0000-0002-5092-6595
CR ALMEFTY O, 1990, J NEUROSURG, V73, P668, DOI 10.3171/jns.1990.73.5.0668
   ALMEFTY O, 1987, NEUROSURGERY, V21, P474, DOI 10.1227/00006123-198710000-00006
   Becker D, 1991, Acta Neurochir Suppl (Wien), V53, P89
   Chaddad-Neto F, 2014, ARQ NEURO-PSIQUIAT, V72, P145, DOI 10.1590/0004-282X20130202
   DEOLIVEIRA E, 1995, ACTA NEUROCHIR, V136, P204, DOI 10.1007/BF01410627
   Deshmukh VR, 2006, NEUROSURGERY, V58, P202, DOI 10.1227/01.NEU.0000207373.26614.BF
   Drake C G, 1979, Clin Neurosurg, V26, P96
   Dzierianowski J., 2008, Folia Morphologica, V67, P267
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2010, NEUROSURG REV, V33, P129, DOI 10.1007/s10143-009-0231-3
   Figueiredo EG, 2008, NEUROSURGERY, V62, P1361, DOI [10.1227/01.NEU.0000233691.23208.9C, 10.1227/01.neu.0000333801.51962.2f]
   Figueiredo EG, 2016, WORLD NEUROSURG, V87, P584, DOI 10.1016/j.wneu.2015.10.063
   Gonzalez LF, 2002, NEUROSURGERY, V50, P550, DOI 10.1097/00006123-200203000-00023
   HAKUBA A, 1986, SURG NEUROL, V26, P271, DOI 10.1016/0090-3019(86)90161-8
   HEUER GJ, 1918, J HOPKINS HOSP B, V29, P154
   PELLERIN P, 1984, NEUROSURGERY, V15, P715, DOI 10.1227/00006123-198411000-00016
   Sano K, 1980, Neurol Res, V2, P361
   Schwartz MS, 1999, J NEUROSURG, V91, P1020, DOI 10.3171/jns.1999.91.6.1020
   Araujo JLV, 2017, J NEUROSURG, V127, P209, DOI 10.3171/2016.8.JNS16403
   WEN HT, 2001, OPER TECH NEUROSURG, V4, P73
   Wen HT, 2001, OPERATIVE TECHNIQUE, V4, P60, DOI DOI 10.1053/OTNS.2001.25567
   Yasargil M G, 1976, Surg Neurol, V6, P83
   Zabramski JM, 1998, J NEUROSURG, V89, P336, DOI 10.3171/jns.1998.89.2.0336
   Zador Z, 2010, NEUROSURGERY, V66, P92, DOI 10.1227/01.NEU.0000362034.81037.FC
NR 24
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E398
EP E403
DI 10.1016/j.wneu.2018.09.120
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000049
PM 30266695
DA 2020-05-12
ER

PT J
AU Dash, C
   Moorthy, S
   Garg, K
   Singh, PK
   Kumar, A
   Gurjar, H
   Chandra, PS
   Kale, SS
AF Dash, Chinmaya
   Moorthy, Skanda
   Garg, Kanwaljeet
   Singh, Pankaj Kumar
   Kumar, Amandeep
   Gurjar, Hitesh
   Chandra, P. Sarat
   Kale, Sasank Sarad
TI Management of Choroid Plexus Tumors in Infants and Young Children Up to
   4 Years of Age: An Institutional Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Choroid plexus tumors; Intraventricular; Young age
ID BLOOD-LOSS; CARCINOMA; SURVIVAL
AB BACKGROUND: Choroid plexus tumors (CPTs) are rare tumors characterized by papillary and intraventricular growth. The young age of presentation of such tumors, especially in infants, and the lack of consensus on adjuvant therapy in case of atypical choroid plexus papilloma (aCPP) and choroid plexus carcinoma (CPC) create dilemma for the management of such tumors. We discuss the presentation, management, complications, and outcome in 15 patients (children 4 years of age and younger) and review pertinent literature.
   METHODS: We retrospectively analyzed the case records of all patients with CPTs who were operated in our institute from January 2010 to March 2018. We found 15 patients in the age group of 0-4 years of age. The variables analyzed include age, sex, presentation, location, surgical approach, extent of resection, intraoperative blood loss, percentage of blood loss, blood transfused, histopathology, postoperative complications, and outcome. Images were obtained from picture archiving and communication system, and patient details and follow-up were obtained from discharge summary, operative notes, and hospital records.
   RESULTS: Ten patients had choroid plexus papilloma (CPP), 2 patients had aCPP, and 3 patients had CPC. The mean age was 15.2 months, whereas the median age was 8 months (range, 40 dayse4 years). The mean blood loss was 329 mL, whereas the median blood loss was 175 mL. There were a total of 5 deaths, including 3 patients with CPC and 1 each with aCPP and CPP.
   CONCLUSIONS: CPTs are challenging tumors in infants and very young children because of the potential for massive blood loss. CPP is associated with lesser blood loss and favorable outcome compared with aCPP and CPC. Massive blood loss in CPC and aCPP can be life threatening as has been shown in our series. CPC has a rapid proliferation potential as shown in one of our cases. Attempts at decreasing vascularization of such tumors should be made by various methods, including preoperative embolization and neoadjuvant chemotherapy; however, a consensus on this is lacking.
C1 [Dash, Chinmaya; Moorthy, Skanda; Garg, Kanwaljeet; Singh, Pankaj Kumar; Kumar, Amandeep; Gurjar, Hitesh; Chandra, P. Sarat; Kale, Sasank Sarad] AIIMS, Dept Neurosurg, New Delhi, India.
RP Singh, PK (reprint author), AIIMS, Dept Neurosurg, New Delhi, India.
EM drpankajsingh11@gmail.com
CR Bahar M, 2017, J NEURO-ONCOL, V132, P427, DOI 10.1007/s11060-017-2384-1
   Chef T, 2008, RADIAT RES, V170, P553, DOI 10.1667/RR1393.1
   DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P1841, DOI 10.1002/1097-0142(19851001)56:7+<1841::AID-CNCR2820561325>3.0.CO;2-C
   Haliasos N, 2013, CHILD NERV SYST, V29, P65, DOI 10.1007/s00381-012-1912-8
   Judkins AR, 2005, J NEUROPATH EXP NEUR, V64, P391, DOI 10.1093/jnen/64.5.391
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Menon G, 2010, NEUROL INDIA, V58, P429, DOI 10.4103/0028-3886.66455
   Meyers SP, 2004, NEURORADIOLOGY, V46, P770, DOI 10.1007/s00234-004-1238-7
   Mishra A, 2012, J PEDIATR NEUROSCI, V7, P71, DOI 10.4103/1817-1745.97633
   Ogiwara H, 2012, BRIT J NEUROSURG, V26, P32, DOI 10.3109/02688697.2011.601820
   PACKER RJ, 1992, CANCER, V69, P580, DOI 10.1002/1097-0142(19920115)69:2<580::AID-CNCR2820690250>3.0.CO;2-O
   Pencalet P, 1998, J NEUROSURG, V88, P521, DOI 10.3171/jns.1998.88.3.0521
   Piastra M, 2007, J CLIN ANESTH, V19, P192, DOI 10.1016/j.jclinane.2006.10.010
   Schneider C, 2015, J NEUROSURG-PEDIATR, V16, P126, DOI 10.3171/2014.12.PEDS14372
   Siegfried A, 2017, J NEURO-ONCOL, V135, P151, DOI 10.1007/s11060-017-2561-2
   Strojan P, 2004, NEOPLASMA, V51, P306
   Wolff JEA, 1999, LANCET, V353, P2126, DOI 10.1016/S0140-6736(99)01744-4
   Wrede B, 2007, J NEURO-ONCOL, V85, P345, DOI 10.1007/s11060-007-9428-x
   Zaky W, 2015, PEDIATR BLOOD CANCER, V62, P784, DOI 10.1002/pbc.25436
NR 19
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E229
EP E237
DI 10.1016/j.wneu.2018.09.089
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000032
PM 30261376
DA 2020-05-12
ER

PT J
AU Debono, B
   Lotterie, JA
   Sol, JC
   Bousquet, P
   Duthil, P
   Monfraix, S
   Lazorthes, Y
   Sabatier, J
   Latorzeff, I
AF Debono, Bertrand
   Lotterie, Jean-Albert
   Sol, Jean-Christophe
   Bousquet, Philippe
   Duthil, Pierre
   Monfraix, Sylvie
   Lazorthes, Yves
   Sabatier, Jean
   Latorzeff, Igor
TI Dedicated Linear Accelerator Radiosurgery for Classic Trigeminal
   Neuralgia: A Single-Center Experience with Long-Term Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Linear accelerator; Pain; Radiosurgery; Trigeminal neuralgia
ID GAMMA-KNIFE RADIOSURGERY; QUALITY-OF-LIFE; ROOT ENTRY ZONE; STEREOTACTIC
   RADIOSURGERY; MICROVASCULAR DECOMPRESSION; CLINICAL-OUTCOMES; PAIN
   RESPONSE; SURGERY; NERVE; TARGET
AB BACKGROUND: During the past decades, stereotactic radiosurgery, and Gamma Knife in particular, has proved its safety and efficacy for drug-resistant classic trigeminal neuralgia. However, few large series exist using linear accelerator (LINAC) reporting long-term follow-up.
   METHODS: Between 2006 and 2015, 301 patients were treated by LINAC at our institution. The prescribed radiation dose was 90 Gy at the far anterior target. Clinical response was defined using the Barrow Neurological Institute scale. We considered grades I and IIIa as a successful response. Mean duration of follow-up was 54.6 months (range, 12-132 months).
   RESULTS: Two hundred and seventy-three patients (90.7%) were initially pain free, and 28 patients (9.3%) were unchanged. The actuarial probabilities of maintaining pain relief with or without medication (Barrow Neurological Institute grade I and IIIa) at 0.5, 1, 2, 4, 5, and 10 years were 88.7%, 85.0%, 76.1%, 68.8%, 65.8%, and 48.1%, respectively. Hypesthesia was present in only 26.2% of patients (very bothersome, 0.3%). No anesthesia dolorosa was reported. The actuarial probabilities of maintaining pain relief without further surgery at 0.5, 1, 2, 4, and 5 years were 99.3%, 98.3%, 95.8%, 91.0%, and 89.7%, respectively. Among all treated patients, 86.5% were satisfied by the procedure and would undergo stereotactic radiosurgery again.
   CONCLUSIONS: Stereotactic radiosurgery with dedicated LINAC is associated with high rates of long-term pain relief, with minimal invasiveness and rare complications. LINAC is a possible therapeutic alternative for drug-resistant trigeminal neuralgia and could be proposed to selected patients as the first intention therapy, among other surgical solutions.
C1 [Debono, Bertrand; Bousquet, Philippe] Capio Clin Cedres, Dept Neurosurg, Toulouse, France.
   [Debono, Bertrand; Lotterie, Jean-Albert; Sol, Jean-Christophe; Duthil, Pierre; Monfraix, Sylvie; Lazorthes, Yves; Sabatier, Jean; Latorzeff, Igor] Toulouse Univ Hosp, Dept Stereotact Radiosurg, Toulouse, France.
   [Sol, Jean-Christophe; Sabatier, Jean] Toulouse Univ Hosp, Dept Neurosurg, Toulouse, France.
   [Latorzeff, Igor] Clin Pasteur, Dept Radiotherapy, Grp ONCORAD Garonne, Toulouse, France.
RP Debono, B (reprint author), Capio Clin Cedres, Dept Neurosurg, Toulouse, France.; Debono, B (reprint author), Toulouse Univ Hosp, Dept Stereotact Radiosurg, Toulouse, France.
EM bdebono@gmail.com
RI Debono, Bertrand/P-5715-2019
OI Debono, Bertrand/0000-0003-4638-1075
CR Akram H, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.6.FOCUS13213
   Alexander E, 1993, STEREOTACTIC RADIOSU, P221
   dos Santos MA, 2011, STEREOT FUNCT NEUROS, V89, P220, DOI 10.1159/000325672
   Azar M, 2009, CLIN NEUROL NEUROSUR, V111, P174, DOI 10.1016/j.clineuro.2008.09.020
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Brisman R, 2002, NEUROSURGERY, V50, P1261, DOI 10.1097/00006123-200206000-00015
   Broggi G, 2000, J NEUROL NEUROSUR PS, V68, P59, DOI 10.1136/jnnp.68.1.59
   Burchiel KJ, 2003, NEUROSURGERY, V53, P1164, DOI 10.1227/01.NEU.0000088806.11659.D8
   Chang CS, 2018, J CLIN NEUROSCI, V47, P174, DOI 10.1016/j.jocn.2017.09.016
   Chen JC, 2008, NEUROSURGERY, V62, pA60
   Chen JCT, 2004, J NEUROSURG, V101, P346, DOI 10.3171/sup.2004.101.supplement3.0346
   Cole Chad D, 2005, Neurosurg Focus, V18, pE4
   Dellaretti M, 2008, J NEUROSURG, V109, P173, DOI 10.3171/JNS/2008/109/12/S26
   Dhople AA, 2009, J NEUROSURG, V111, P351, DOI 10.3171/2009.2.JNS08977
   Donnet A, 2017, REV NEUROL-FRANCE, V173, P131, DOI 10.1016/j.neurol.2016.12.033
   Eller Jorge L, 2005, Neurosurg Focus, V18, pE3
   Erbay SH, 2006, NEURORADIOLOGY, V48, P26, DOI 10.1007/s00234-005-0008-5
   Goss BW, 2003, NEUROSURGERY, V53, P823, DOI 10.1227/01.NEU.0000083550.03928.D8
   Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04
   Han JH, 2009, INT J RADIAT ONCOL, V75, P822, DOI 10.1016/j.ijrobp.2008.11.046
   Jannetta PJ, 2007, J NEUROSURG, V107, P216, DOI 10.3171/JNS-07/07/0216
   Jung HH, 2017, WORLD NEUROSURG, V104, P687, DOI 10.1016/j.wneu.2017.05.058
   Kitt CA, 2000, PAIN, V85, P3, DOI 10.1016/S0304-3959(99)00310-3
   Kondziolka D, 1996, J NEUROSURG, V84, P940, DOI 10.3171/jns.1996.84.6.0940
   Kondziolka D, 2010, J NEUROSURG, V112, P758, DOI 10.3171/2009.7.JNS09694
   Kubicek GJ, 2004, STEREOT FUNCT NEUROS, V82, P244, DOI 10.1159/000083176
   Latorzeff I, 2012, CANCER RADIOTHER, V16, pS57, DOI 10.1016/j.canrad.2012.01.007
   LEKSELL L, 1971, ACTA CHIR SCAND, V137, P311
   LINDQUIST C, 1991, STEREOT FUNCT NEUROS, V57, P72, DOI 10.1159/000099557
   Little AS, 2008, NEUROSURGERY, V63, P915, DOI 10.1227/01.NEU.0000327689.05823.28
   Lopez BC, 2004, NEUROSURGERY, V54, P973, DOI 10.1227/01.NEU.0000114867.98896.F0
   Lorenzoni JG, 2008, NEUROSURGERY, V62, P368, DOI 10.1227/01.neu.0000316003.80893.81
   Maesawa S, 2001, J NEUROSURG, V94, P14, DOI 10.3171/jns.2001.94.1.0014
   Marshall K, 2012, NEUROSURGERY, V70, P566, DOI 10.1227/NEU.0b013e3182320d36
   Moreno NEM, 2016, NEUROSURGERY, V79, P879, DOI 10.1227/NEU.0000000000001404
   Massager N, 2004, J NEUROSURG, V100, P597, DOI 10.3171/jns.2004.100.4.0597
   Massager N, 2007, NEUROSURGERY, V60, P681, DOI 10.1227/01.NEU.0000255393.77538.75
   Pan HC, 2010, J NEUROSURG, V113, P191, DOI 10.3171/2010.8.GKS10879
   Petit JH, 2003, INT J RADIAT ONCOL, V56, P1147, DOI 10.1016/S0360-3016(03)00264-5
   Pokhrel D, 2017, J APPL CLIN MED PHYS, V18, P136, DOI 10.1002/acm2.12057
   Pollock BE, 2001, NEUROSURGERY, V49, P58
   Pollock BE, 2006, J NEUROSURG, V105, P103, DOI 10.3171/sup.2006.105.7.103
   Pollock BE, 2010, NEUROSURGERY, V67, P633, DOI 10.1227/01.NEU.0000377861.14650.98
   REGIS J, 1995, STEREOT FUNCT NEUROS, V64, P182, DOI 10.1159/000098778
   Regis J, 2016, J NEUROSURG, V124, P1079, DOI 10.3171/2015.2.JNS142144
   Regis J, 2011, J NEUROSURG, V115, P2, DOI 10.3171/2011.12.GKSeditorial
   Regis J, 2006, J NEUROSURG, V104, P913, DOI 10.3171/jns.2006.104.6.913
   Richards GM, 2005, NEUROSURGERY, V57, P1193, DOI 10.1227/01.NEU.0000186015.01179.70
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Sharim J, 2017, PRACT RADIAT ONCOL, V7, P221, DOI 10.1016/j.prro.2016.12.006
   Sheehan J, 2005, J NEUROSURG, V102, P434, DOI 10.3171/jns.2005.102.3.0434
   Sindou M, 2008, NEUROSURGERY, V63, P341, DOI 10.1227/01.NEU.0000327022.79171.D6
   Smith ZA, 2011, INT J RADIAT ONCOL, V81, P225, DOI 10.1016/j.ijrobp.2010.05.058
   Taich ZJ, 2016, WORLD NEUROSURG, V90, P604, DOI 10.1016/j.wneu.2016.02.067
   Tuleasca C, 2012, J NEUROSURG, V117, P181, DOI 10.3171/2012.8.GKS121015
   Varela-Lema L, 2015, PAIN PHYSICIAN, V18, P15
   Verheul JB, 2010, J NEUROSURG, V113, P160, DOI 10.3171/2010.7.GKS10978
   Young B, 2013, J NEUROSURG, V119, P1166, DOI 10.3171/2013.1.JNS12875
   Zakrzewska JM, 2003, NEUROSURGERY, V53, P110, DOI 10.1227/01.NEU.0000068862.78930.EE
   Zakrzewska JM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007312.pub2
   Zerris VA, 2005, J NEUROSURG, V102, P107, DOI 10.3171/jns.2005.102.s_supplement.0107
   Zhao HY, 2018, WORLD NEUROSURG, V109, pE531, DOI 10.1016/j.wneu.2017.10.014
NR 63
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E775
EP E785
DI 10.1016/j.wneu.2018.09.222
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000096
PM 30312817
DA 2020-05-12
ER

PT J
AU Deng, YM
   Jia, BX
   Huo, XC
   Peng, Y
   Cao, YB
   Chen, SL
   Zhang, M
   Jiang, CC
   Peng, XX
   Song, CF
   Wei, LP
   Zhu, QY
   Guo, ZY
   Liu, L
   Lin, H
   Yang, H
   Wu, W
   Liang, H
   Xu, AD
   Chen, KN
   Liebeskind, DS
   Zhao, XQ
   Wang, AX
   Liu, LP
   Wang, YL
   Wang, YJ
   Gao, F
   Sun, X
   Liu, L
   Mo, DP
   Ma, N
   Song, LG
   Miao, ZR
AF Deng, Yiming
   Jia, Baixue
   Huo, Xiaochuan
   Peng, Ya
   Cao, Yibin
   Chen, Shengli
   Zhang, Meng
   Jiang, Changchun
   Peng, Xiaoxiang
   Song, Cunfeng
   Wei, Liping
   Zhu, Qiyi
   Guo, Zaiyu
   Liu, Li
   Lin, Hang
   Yang, Hua
   Wu, Wei
   Liang, Hui
   Xu, Anding
   Chen, Kangning
   Liebeskind, David S.
   Zhao, Xingquan
   Wang, Anxin
   Liu, Liping
   Wang, Yilong
   Wang, Yongjun
   Gao, Feng
   Sun, Xuan
   Liu, Lian
   Mo, Dapeng
   Ma, Ning
   Song, Ligang
   Miao, Zhongrong
CA EAST Investigators
TI Association of Cardioembolism and Intracranial Arterial Stenosis with
   Outcomes of Mechanical Thrombectomy in Acute Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Cardioembolism; Intracranial arterial stenosis;
   Mechanical thrombectomy
ID ENDOVASCULAR TREATMENT; OCCLUSION; RECANALIZATION; ETIOLOGY; THERAPY
AB OBJECTIVE: To estimate the association of different etiologies of cardioembolism (CE), intracranial arterial stenosis (ICAS), or the combination of these conditions with outcomes of mechanical thrombectomy in acute ischemic stroke.
   METHODS: Data from the intervention group of the Endovascular therapy for Acute ischemic Stroke Trial (EAST) were analyzed. In 140 patients, the presence of CE, ICAS, neither CE nor ICAS, or both conditions was assessed. The primary outcome was a favorable outcome at 90 days (modified Rankin Scale score 0-2); secondary outcomes included successful reperfusion (modified Thrombolysis In Cerebral Infarction grade 2b-3), symptomatic intracerebral hemorrhage, and 90-day mortality.
   RESULTS: Of 140 patients, 47 had neither CE nor ICAS, 35 had ICAS but not CE, 46 had CE but not ICAS, and 12 had both CE and ICAS. The rate of favorable outcome was 67.1% in the no CE and no ICAS group, 74.3% in the ICAS without CE group, 41.3% in the CE without ICAS group, and 33.3% in the CE and ICAS group. The CE and ICAS group had poor outcomes (odds ratio =0.20 after adjusting for age, sex, and National Institutes of Health Stroke Scale score; 95% confidence interval, 0.04-0.95; P = 0.043). No significant differences were observed in secondary outcomes.
   CONCLUSIONS: The presence of both CE and ICAS was associated with poor outcome in patients with anterior circulation large-vessel occlusion treated with endovascular thrombectomy. Future studies are warranted to further explore this association.
C1 [Deng, Yiming; Jia, Baixue; Huo, Xiaochuan; Wang, Anxin; Gao, Feng; Sun, Xuan; Liu, Lian; Mo, Dapeng; Ma, Ning; Song, Ligang; Miao, Zhongrong] Capital Med Univ, Beijing Tiantan Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Deng, Yiming; Jia, Baixue; Huo, Xiaochuan; Liu, Liping] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Neurointens Care Unit, Beijing, Peoples R China.
   [Zhao, Xingquan; Wang, Anxin; Liu, Liping; Wang, Yilong; Wang, Yongjun; Gao, Feng; Sun, Xuan; Liu, Lian; Mo, Dapeng; Ma, Ning; Song, Ligang; Miao, Zhongrong] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Deng, Yiming; Jia, Baixue; Huo, Xiaochuan; Zhao, Xingquan; Liu, Liping; Wang, Yilong; Wang, Yongjun; Gao, Feng; Sun, Xuan; Liu, Lian; Mo, Dapeng; Ma, Ning; Song, Ligang; Miao, Zhongrong] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.
   [Peng, Ya] Changzhou 1 Peoples Hosp, Dept Neurosurg, Changzhou, Peoples R China.
   [Cao, Yibin] Tangshan Gongren Hosp, Dept Neurol, Tangshan, Peoples R China.
   [Chen, Shengli] Chongqing Sanxia Cent Hosp, Dept Neurol, Chongqing, Peoples R China.
   [Zhang, Meng] Daping Hosp, Dept Neurol, Chongqing, Peoples R China.
   [Jiang, Changchun] Baotou Cent Hosp, Dept Neurol, Baotou, Peoples R China.
   [Peng, Xiaoxiang] Hubei Zhongshan Hosp, Dept Neurol, Wuhan, Hubei, Peoples R China.
   [Song, Cunfeng] Liaocheng 3rd Peoples Hosp, Dept Neurol, Liaocheng, Peoples R China.
   [Wei, Liping] Zhengzhou Univ, Luoyang Cent Hosp, Dept Neurol, Luoyang, Peoples R China.
   [Zhu, Qiyi] Peoples Hosp Linyi City, Dept Neurol, Linyi, Peoples R China.
   [Guo, Zaiyu] Tianjin Teda Hosp, Dept Neurol, Tianjin, Peoples R China.
   [Liu, Li] Chifeng Municipal Hosp, Dept Neurol, Chifeng, Peoples R China.
   [Lin, Hang] Fuzhou PLA Gen Hosp, Dept Neurol, Fuzhou, Fujian, Peoples R China.
   [Yang, Hua] Guiyang Med Coll, Affiliated Hosp, Dept Neurol, Guiyang, Guizhou, Peoples R China.
   [Wu, Wei] Shandong Univ, QiLu Hosp, Dept Neurol, Jinan, Shandong, Peoples R China.
   [Liang, Hui] Yantai Hill Hosp, Dept Neurol, Yantai, Peoples R China.
   [Xu, Anding] Jinan Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou, Guangdong, Peoples R China.
   [Chen, Kangning] Xinan Hosp, Dept Neurol, Chongqing, Peoples R China.
   [Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Neurovasc Imaging Res Core, Los Angeles, CA 90024 USA.
   [Zhao, Xingquan; Wang, Yilong; Wang, Yongjun] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China.
RP Miao, ZR (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Miao, ZR (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Miao, ZR (reprint author), Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.
EM zhongrongm@126.com
RI Deng, Yiming/AAE-6096-2020
CR Asif KS, 2014, J NEUROINTERV SURG, V6, P505, DOI 10.1136/neurintsurg-2013-010792
   Giray S, 2017, J NEUROL SCI, V372, P104, DOI 10.1016/j.jns.2016.11.006
   Jadhav AP, 2017, AM J NEURORADIOL, V38, P2270, DOI 10.3174/ajnr.A5406
   Jia BX, 2018, J NEUROINTERV SURG, V10, P746, DOI 10.1136/neurintsurg-2017-013489
   Kwak JH, 2014, AM J NEURORADIOL, V35, P747, DOI 10.3174/ajnr.A3747
   Lee JS, 2015, J STROKE CEREBROVASC, V24, P2074, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.003
   Miao ZR, 2016, STROKE VASC NEUROL, V1, P44, DOI 10.1136/svn-2016-000022
   Mustanoja S, 2011, STROKE, V42, P102, DOI 10.1161/STROKEAHA.110.597534
   Rebello LC, 2017, EUR J NEUROL, V24, P762, DOI 10.1111/ene.13287
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Seker F, 2017, AM J NEURORADIOL, V38, P1368, DOI 10.3174/ajnr.A5212
   Sivan-Hoffmann R, 2017, EUR RADIOL, V27, P247, DOI 10.1007/s00330-016-4338-y
   Tomsick T, 2012, J NEUROINTERV SURG, V4, P101, DOI 10.1136/jnis.2011.004846
   Wang XG, 2015, CNS NEUROSCI THER, V21, P657, DOI 10.1111/cns.12421
   Yoon W, 2015, NEUROSURGERY, V76, P680, DOI 10.1227/NEU.0000000000000694
NR 15
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E146
EP E150
DI 10.1016/j.wneu.2018.09.058
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000021
PM 30244073
DA 2020-05-12
ER

PT J
AU Dong, W
   Zhu, HB
   Gao, H
   Shi, WJ
   Zhang, Y
   Wang, HY
   Li, CZ
   Song, GD
   Zhang, YZ
AF Dong, Wei
   Zhu, Haibo
   Gao, Hua
   Shi, Wenjian
   Zhang, Yu
   Wang, Hongyun
   Li, Chuzhong
   Song, Guidong
   Zhang, Yazhuo
TI Expression of Cyclin E/Cdk2/p27(Kip1) in Growth Hormone Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cdk2; Cyclin E; Growth hormone adenomas; Invasion; Methylation;
   p27(Kip1)
ID DEPENDENT KINASE INHIBITORS; CDK INHIBITOR; PITUITARY-ADENOMAS;
   BREAST-CANCER; P27(KIP1); P27; PHOSPHORYLATION; DEGRADATION; TISSUE
AB OBJECTIVE: The present study was conducted to evaluate the levels of Cdk2, cyclin E, p21, and p27 in growth hormone adenomas (GHPAs) and analyze their association with clinicopathologic features.
   METHODS: We collected 46 GHPA specimens and clinical materials from March 2012 to December 2015 at Beijing Tiantan Hospital. We analyzed the expression of Cdk2, cyclin E, p21, and p27 using immunohistochemistry, quantitative real-time polymerase chain reaction, Western blot, and methylation-specific polymerase chain reaction and sequencing.
   RESULTS: The levels of cyclin E and Cdk2 were much greater in the invasive group than in the noninvasive group (P < 0.05). Significant differences were found between cyclin E and p21 and tumor size (P < 0.05) and between cyclin E expression and invasion (P < 0.05). Tumors were more likely to require whole resection in patients with low cyclin E expression (P < 0.05). The high-level p27 group had better progression-free survival than did the low-level p27 group (P < 0.01). Quantitative real-time polymerase chain reaction and Western blot analysis revealed a similar trend for Cdk2, cyclin E, p21, and p27 protein levels in growth hormone specimens (P < 0.01). An average of 33 CpG sites per sample were analyzed using matrix-assisted laser desorption ionization time-of-flight mass array, and in 7 of the 33 CpG sites, the methylation levels of p27 were > 50%. Statistically significant differences were found in 4 CpG sites between the invasive and noninvasive specimens (P < 0.01).
   CONCLUSIONS: Overexpression of cyclin E/Cdk2 and loss of p27 appears to be associated with a poor prognosis and might play a role in the treatment of GHPAs in the future.
C1 [Dong, Wei; Zhu, Haibo; Gao, Hua; Wang, Hongyun; Li, Chuzhong; Song, Guidong; Zhang, Yazhuo] Capital Med Univ, Beijing Neurosurg Inst, Key Lab Cent Nervous Syst Injury Res, Beijing, Peoples R China.
   [Dong, Wei; Shi, Wenjian; Zhang, Yu] Tangshan Peoples Hosp, Dept Neurosurg, Tangshan, Hebei, Peoples R China.
RP Zhang, YZ (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Key Lab Cent Nervous Syst Injury Res, Beijing, Peoples R China.
EM zyz2004520@yeah.net
FU Beijing Natural Science Foundation of ChinaBeijing Natural Science
   Foundation [7162035]; Beijing high level program [2015-3-040]; National
   High Technology Research and Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [2015AA020504]
FX This work was supported by Beijing Natural Science Foundation of China
   (7162035), and Beijing high level program (2015-3-040) and the National
   High Technology Research and Development Program of China (863 Program)
   (2015AA020504).
CR Andersen M, 2014, EUR J ENDOCRINOL, V170, pR31, DOI 10.1530/EJE-13-0532
   Bilodeau S, 2009, MOL CELL BIOL, V29, P1895, DOI 10.1128/MCB.01885-08
   Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6
   Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863
   Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6
   Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453
   Caimari F, 2016, CLIN CANCER RES, V22, P5030, DOI 10.1158/1078-0432.CCR-16-0452
   Ceccato F, 2018, ACTA NEUROCHIR, V160, P49, DOI 10.1007/s00701-017-3396-5
   Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571
   Chesnokova V, 2007, CANCER RES, V67, P10564, DOI 10.1158/0008-5472.CAN-07-0974
   Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645
   Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000
   Gao H, 2017, MOL CELL ENDOCRINOL, V443, P32, DOI 10.1016/j.mce.2016.12.029
   Hubina E, 2006, EUR J ENDOCRINOL, V155, P371, DOI 10.1530/eje.1.02213
   Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707
   Jordan S, 2000, EUR J ENDOCRINOL, V143, pR1, DOI 10.1530/eje.0.143R001
   Kalemi TG, 2007, ANTICANCER RES, V27, P913
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Langlois F, 2017, ENDOCRINOL METAB, V32, P162, DOI 10.3803/EnM.2017.32.2.162
   Liu CH, 2016, INT J CLIN EXP PATHO, V9, P3245
   Lu CL, 2016, J HEPATOL, V64, P342, DOI 10.1016/j.jhep.2015.08.036
   Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065
   Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40
   MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0
   Musat M, 2004, FRONT HORM RES, V32, P34
   Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.3.CO;2-4
   Nishioka Hiroshi, 2014, J Neurosurg, V121, P505, DOI 10.3171/2014.3.JNS132214
   POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9
   Quereda V, 2009, J MOL ENDOCRINOL, V42, P75, DOI 10.1677/JME-08-0146
   Ronchi CL, 2016, EUR J ENDOCRINOL, V174, P363, DOI 10.1530/EJE-15-1064
   Roussel-Gervais A, 2010, MOL ENDOCRINOL, V24, P1835, DOI 10.1210/me.2010-0091
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   Spruck CH, 1999, NATURE, V401, P297
   Valimaki N, 2015, J CLIN ENDOCR METAB, V100, P3918, DOI 10.1210/jc.2015-3129
   Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762
   Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334
   WILSON CB, 1984, J NEUROSURG, V61, P814, DOI 10.3171/jns.1984.61.5.0814
   Wingate H, 2009, CELL CYCLE, V8, P1062, DOI 10.4161/cc.8.7.8119
   Young Lee S, 2017, ENDOCRINOL J, V65, P33
NR 40
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E45
EP E53
DI 10.1016/j.wneu.2018.08.209
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000008
PM 30196178
DA 2020-05-12
ER

PT J
AU El Refaee, E
   Langner, S
   Marx, S
   Rosenstengel, C
   Baldauf, J
   Schroeder, HWS
AF El Refaee, Ehab
   Langner, Soenke
   Marx, Sascha
   Rosenstengel, Christian
   Baldauf, Joerg
   Schroeder, Henry W. S.
TI Endoscope-Assisted Microvascular Decompression for the Management of
   Hemifacial Spasm Caused by Vertebrobasilar Dolichoectasia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dolichoectasia; Endoscope assisted; Hemifacial spasm; Microvascular
   decompression
ID NEUROVASCULAR COMPRESSION; TRIGEMINAL NEURALGIA; VERTEBRAL ARTERY;
   SECONDARY; SURGERY; PATIENT; NERVE; RISK
AB OBJECTIVE: Vertebrobasilar dolichoectasia (VBD) is a rare cause of hemifacial spasm. The ectatic vessel hinders microscopic visualization of the root exit zone. The aim of this study was to evaluate the benefit of endoscopic visualization during microvascular decompression (MVD) in managing this type of neurovascular compression.
   METHODS: Retrospective evaluation of patients with VBD treated by endoscope-assisted MVD for hemifacial spasm between 2007 and 2016 was performed. A prospectively maintained database of all patients treated by MVD for hemifacial spasm was screened for vascular compression. Magnetic resonance imaging was evaluated to detect patients who had VBD according to defined criteria. The value of endoscopic inspection to detect offending vessels was analyzed, and clinical outcome was evaluated.
   RESULTS: VBD was detected in 11 of 290 patients (incidence 3.8%). In these patients, 12 MVD procedures were performed. The endoscope was useful in identifying the offending vessels and adjacent perforators without any brain retraction in all patients. At last clinical follow-up, all patients had almost complete to complete resolution of clinical symptoms. The interposing technique alone was effective with excellent results in 8 patients. Three patients required an additional transposition-fixation technique to achieve sufficient decompression.
   CONCLUSIONS: VBD is a rare cause of hemifacial spasm. Because of the large diameter of the offending vessel, MVD is technically more demanding. Endoscopic inspection with a 45 degrees endoscope enables accurate visualization of the root exit zone, offending vessels, and perforating arteries. Furthermore, accurate placement of the Teflon pledgets can be confirmed leading to a favorable outcome.
C1 [El Refaee, Ehab; Marx, Sascha; Rosenstengel, Christian; Baldauf, Joerg; Schroeder, Henry W. S.] Ernst Moritz Arndt Univ Greifswald, Greifswald Med Sch, Dept Neurosurg, Greifswald, Germany.
   [Langner, Soenke] Ernst Moritz Arndt Univ Greifswald, Greifswald Med Sch, Inst Radiol & Neuroradiol, Greifswald, Germany.
   [El Refaee, Ehab] Cairo Univ, Fac Med, Dept Neurosurg, Giza, Egypt.
RP El Refaee, E (reprint author), Ernst Moritz Arndt Univ Greifswald, Greifswald Med Sch, Dept Neurosurg, Greifswald, Germany.; El Refaee, E (reprint author), Cairo Univ, Fac Med, Dept Neurosurg, Giza, Egypt.
EM e.elrefaee@googlemail.com
RI Refaee, Ehab El/AAI-7128-2020
CR Alam A, 2003, Med J Armed Forces India, V59, P163, DOI 10.1016/S0377-1237(03)80072-2
   Attabib N, 2007, J NEUROSURG, V106, P929, DOI 10.3171/jns.2007.106.5.929
   AUGER RG, 1990, ARCH NEUROL-CHICAGO, V47, P1233, DOI 10.1001/archneur.1990.00530110095023
   BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Bejjani GK, 1997, J NEUROSURG, V86, P728, DOI 10.3171/jns.1997.86.4.0728
   Bigder MG, 2016, J NEUROSURG, V124, P90, DOI 10.3171/2015.1.JNS142714
   de Pablo-Fernandez E, 2012, J CLIN NEUROSCI, V19, P1046, DOI 10.1016/j.jocn.2011.05.033
   Di Stadio A, 2018, WORLD NEUROSURG, V113, P232, DOI 10.1016/j.wneu.2018.02.105
   Dubey A, 2018, WORLD NEUROSURG, V113, pE612, DOI 10.1016/j.wneu.2018.02.108
   El Damaty A, 2016, NEUROSURG REV, V39, P455, DOI 10.1007/s10143-016-0708-9
   El Refaee E, 2018, OPER NEUROSURG, V14, P121, DOI 10.1093/ons/opx105
   El Refaee E, 2013, NEUROSURGERY, V73, P58, DOI 10.1227/01.neu.0000429838.38342.e2
   El-Ghandour NMF, 2010, NEUROSURGERY, V67, P330, DOI 10.1227/01.NEU.0000371978.86528.60
   Ferreira M, 2011, J NEUROSURG, V114, P1800, DOI 10.3171/2010.12.JNS10891
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   Ikeda K, 2010, CEREBROVASC DIS, V30, P23, DOI 10.1159/000313440
   Kang JH, 2012, J KOREAN NEUROSURG S, V52, P85, DOI 10.3340/jkns.2012.52.2.85
   Kansal R, 2011, J NEUROSCI RURAL PRA, V2, P62, DOI 10.4103/0976-3147.80106
   Kim KJ, 2017, PARKINSONISM RELAT D, V38, P98, DOI 10.1016/j.parkreldis.2017.02.022
   Kimura T, 2018, WORLD NEUROSURG, V114, P435, DOI 10.1016/j.wneu.2018.03.064
   Komatsu F, 2018, ACTA NEUROCHIR, V160, P157, DOI 10.1007/s00701-017-3392-9
   Kondo A, 2012, ACTA NEUROCHIR, V154, P773, DOI 10.1007/s00701-012-1277-5
   Kurucz P, 2017, NEUROSURG REV, V40, P427, DOI 10.1007/s10143-016-0800-1
   Leal PRL, 2011, NEUROSURGERY, V69, P15, DOI 10.1227/NEU.0b013e318212bafa
   Leal PRL, 2010, ACTA NEUROCHIR, V152, P817, DOI 10.1007/s00701-009-0588-7
   Lin CF, 2012, CLIN NEUROL NEUROSUR, V114, P951, DOI 10.1016/j.clineuro.2012.02.021
   Papapetropoulos S, 2009, CEREBROVASC DIS, V27, P413, DOI 10.1159/000209243
   Passero SG, 2008, NEUROLOGY, V70, P66, DOI 10.1212/01.wnl.0000286947.89193.f3
   Pereira AD, 2008, ARQ NEURO-PSIQUIAT, V66, P408, DOI 10.1590/S0004-282X2008000300026
   Perlmutter DH, 2010, NEUROSURGERY, V66, pE1212, DOI 10.1227/01.NEU.0000369518.49077.D7
   Rak R, 2004, NEUROSURGERY, V54, P876, DOI 10.1227/01.NEU.0000115151.52925.37
   Rehder R, 2017, WORLD NEUROSURG, V103, P114, DOI 10.1016/j.wneu.2017.02.054
   Ricci G, 2019, BRAZ J OTORHINOLAR, V85, P465, DOI 10.1016/j.bjorl.2018.03.015
   Samim M, 2016, RADIOGRAPHICS, V36, P1129, DOI 10.1148/rg.2016150032
   Sarikaya S, 2008, NEUROLOGY, V71, P1460, DOI 10.1212/01.wnl.0000338448.84851.de
   Siddiqui A, 2008, Br J Radiol, V81, pe123, DOI 10.1259/bjr/27603660
   SMOKER WRK, 1986, AM J NEURORADIOL, V7, P61
   Spengos K, 2005, J NEUROL NEUROSUR PS, V76, P1500, DOI 10.1136/jnnp.2005.064147
   Thiex R, 2006, SURG NEUROL, V65, P199, DOI 10.1016/j.surneu.2005.04.041
   Ubogu EE, 2004, J NEUROL NEUROSUR PS, V75, P22
   Vasovic L, 2012, ACTA NEUROCHIR, V154, P1477, DOI 10.1007/s00701-012-1400-7
   Vieco PT, 1997, AM J NEURORADIOL, V18, P1385
   Zaidi HA, 2015, J CLIN NEUROSCI, V22, P62, DOI 10.1016/j.jocn.2014.09.008
   Zhang X, 2018, WORLD NEUROSURG, V110, pE473, DOI 10.1016/j.wneu.2017.11.022
NR 44
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E566
EP E575
DI 10.1016/j.wneu.2018.09.166
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000069
PM 30278293
DA 2020-05-12
ER

PT J
AU Felbaum, DR
   Maxwell, C
   Naydin, S
   Ringer, A
   Hanel, RA
   Sauvageau, E
   Aghaebrahim, A
   Aguilar-Salinas, P
   Veznedaroglu, E
   Liebman, K
   Hakma, Z
   Hedayat, H
   Kan, P
   Srinivasan, V
   Binning, MJ
AF Felbaum, Daniel R.
   Maxwell, Christina
   Naydin, Stan
   Ringer, Andrew
   Hanel, Ricardo A.
   Sauvageau, Eric
   Aghaebrahim, Amin
   Aguilar-Salinas, Pedro
   Veznedaroglu, Erol
   Liebman, Kenneth
   Hakma, Zakaria
   Hedayat, Hirad
   Kan, Peter
   Srinivasan, Visish
   Binning, Mandy J.
TI Carotid Stenosis: Utility of Diagnostic Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Carotid imaging; Carotid stenosis
ID RANDOMIZED TRIAL; ENDARTERECTOMY; ANGIOPLASTY; COMPLICATIONS
AB OBJECTIVE: Carotid artery stenosis is frequently diagnosed through screening tests with noninvasive imaging. Because of differences noted between the various modalities, we sought to investigate our experience comparing noninvasive imaging (ultrasound, computed tomography angiography, magnetic resonance angiography) with invasive imaging (digital subtraction angiography).
   METHODS: In a multicenter retrospective analysis, 249 carotid vessels were reviewed based on angiography with the associated noninvasive imaging.
   RESULTS: Overall, medical or surgical decision management was changed in 43% (107/243) of cases investigated with digital subtraction angiography owing to a discrepancy between the measured percentage stenosis. In patients with potentially treatable carotid stenosis, angiography revealed nonsignificant stenosis 25.7% of the time.
   CONCLUSIONS: Angiography should be considered the confirmatory test for degree of stenosis in certain patients before definitive surgical treatment.
C1 [Felbaum, Daniel R.; Maxwell, Christina; Naydin, Stan; Veznedaroglu, Erol; Liebman, Kenneth; Hakma, Zakaria; Hedayat, Hirad; Binning, Mandy J.] Global Neurosci Inst, Dept Neurosurg, Philadelphia, PA 19102 USA.
   [Ringer, Andrew] Good Samaritan Hosp, Mayfield Clin, TriHlth Hosp Syst, Dept Neurosurg, Cincinnati, OH USA.
   [Hanel, Ricardo A.; Sauvageau, Eric; Aghaebrahim, Amin; Aguilar-Salinas, Pedro] Baptist Neurol Inst, Lyerly Neurosurg, Jacksonville, FL USA.
   [Kan, Peter; Srinivasan, Visish] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Binning, MJ (reprint author), Global Neurosci Inst, Dept Neurosurg, Philadelphia, PA 19102 USA.
EM mbinning@gnineuro.org
RI Aguilar-Salinas, Pedro/AAJ-4444-2020
OI Aguilar-Salinas, Pedro/0000-0002-5268-6548
CR Alberts MJ, 2001, STROKE, V32, P325
   Anderson GB, 2000, STROKE, V31, P2168, DOI 10.1161/01.STR.31.9.2168
   Arakawa Y, 1999, NEUROL SURG TOKYO, V27, P817
   BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711
   Britt PM, 2000, AM J NEURORADIOL, V21, P55
   Brooks WH, 2001, J AM COLL CARDIOL, V38, P1589, DOI 10.1016/S0735-1097(01)01595-9
   Brott TG, 2011, J AM COLL CARDIOL, V57, P1002, DOI 10.1016/j.jacc.2010.11.005
   Brown MM, 2001, LANCET, V357, P1729
   Diethrich EB, 2011, CAROTID SUPRA AORTIC, P335
   Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0
   Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5
   Gurm HS, 2008, NEW ENGL J MED, V358, P1572, DOI 10.1056/NEJMoa0708028
   HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401
   Howard VJ, 2017, INT J STROKE, V12, P770, DOI 10.1177/1747493017706238
   Johnston DCC, 2001, NEUROLOGY, V56, P1009, DOI 10.1212/WNL.56.8.1009
   Kaufmann TJ, 2007, RADIOLOGY, V243, P812, DOI 10.1148/radiol.2433060536
   Koelemay MJW, 2004, STROKE, V35, P2306, DOI 10.1161/01.STR.0000141426.63959.cc
   Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752
   Sabeti S, 2004, RADIOLOGY, V232, P431, DOI 10.1148/radiol.2321030791
   Wardlaw JM, 2006, HLTH TECHNOL ASSESS, V10
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yucel EK, 1999, CIRCULATION, V100, P2284, DOI 10.1161/01.CIR.100.22.2284
   Zarins CK, 2009, J ENDOVASC THER, V16, P397, DOI 10.1583/08-2685.1
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E962
EP E966
DI 10.1016/j.wneu.2018.10.054
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000119
PM 30336298
DA 2020-05-12
ER

PT J
AU Feng, JT
   Yang, XG
   Wang, F
   Hua, KC
   Liu, YH
   Hu, YC
   Zhang, H
   Yang, L
   Xu, MY
   Zhang, HR
AF Feng, Jiang-tao
   Yang, Xiong-gang
   Wang, Feng
   Hua, Kun-chi
   Liu, Yong-heng
   Hu, Yong-cheng
   Zhang, Hao
   Yang, Li
   Xu, Ming-you
   Zhang, Hao-ran
TI Prognostic Discrepancy on Overall Survival Between Ambulatory and
   Nonambulatory Patients with Metastatic Spinal Cord Compression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ambulatory status; Metastatic spinal cord compression; Overall survival;
   Prognostic factor
ID PREOPERATIVE EVALUATION; SCORING SYSTEM; CANCER; SEX
AB BACKGROUND: Contradictory results have been reported regarding the prognostic effect of ambulatory status in patients with metastatic spinal cord compression (MSCC). The aim of this study was to investigate whether ambulatory status is a significant predictor of overall survival in patients with MSCC and to distinguish the differences of predictors between patients who were ambulatory and those who were not ambulatory before operation.
   METHODS: Three clinical centers were retrospectively reviewed to identify patients operated on for MSCC between 2005 and 2015. Fourteen prognostic factors were analyzed using Kaplan-Meier survival curves, univariate log-rank test, and multivariate Cox hazard regression model for the whole cohort and the subgroups of ambulatory and nonambulatory patients.
   RESULTS: In all, 169 patients were consecutively enrolled. Their mean age was 59.6 +/- 10.5 years (range, 18-84 years). The median survival time in the whole cohort was 7.0 +/- 0.5 months, whereas it was 7.0 +/- 0.8 months and 5.0 +/- 1.3 months in ambulatory and nonambulatory patients, respectively. Multivariate Cox regression analysis showed that ambulatory status was not a significant predictor of overall survival (P = 0.266), but primary tumor type and Karnofsky performance status were independent predictors of overall survival for the whole cohort. Primary tumor and metastatic site were significantly associated with survival in ambulatory patients. Gender and Karnofsky performance status were associated with survival in nonambulatory patients.
   CONCLUSIONS: Ambulatory status was not shown to predict the prognosis of patients with MSCC. prognostic factors should be distinguished between ambulatory and nonambulatory patients when choosing a therapeutic modality.
C1 [Feng, Jiang-tao; Yang, Xiong-gang; Wang, Feng; Hua, Kun-chi; Liu, Yong-heng; Zhang, Hao; Yang, Li; Xu, Ming-you; Zhang, Hao-ran] Tianjin Med Univ, Tianjin, Peoples R China.
   [Hu, Yong-cheng] Tianjin Hosp, Dept Bone Tumors, Tianjin, Peoples R China.
RP Hu, YC (reprint author), Tianjin Hosp, Dept Bone Tumors, Tianjin, Peoples R China.
EM yongchenghu@126.com
CR ATANASIU JP, 1993, SPINE, V18, P1279, DOI 10.1097/00007632-199308000-00006
   BARRON KD, 1959, NEUROLOGY, V9, P91, DOI 10.1212/WNL.9.2.91
   Bartels RHMA, 2007, CANCER-AM CANCER SOC, V110, P2042, DOI 10.1002/cncr.23002
   Bollen L, 2014, NEURO-ONCOLOGY, V16, P991, DOI 10.1093/neuonc/not318
   BYRNE TN, 1992, NEW ENGL J MED, V327, P614
   Chen YJ, 2007, SPINE, V32, pE413, DOI 10.1097/BRS.0b013e318074d6c7
   Enkaoua EA, 1997, SPINE, V22, P2293, DOI 10.1097/00007632-199710010-00020
   Innos K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1080-9
   Jacobs W B, 2001, Neurosurg Focus, V11, pe10
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Pitz MW, 2013, CAN RESPIR J, V20, P30, DOI 10.1155/2013/618691
   Rades D, 2006, J CLIN ONCOL, V24, P3388, DOI 10.1200/JCO.2005.05.0542
   Rades D, 2014, ANTICANCER RES, V34, P2503
   Rades D, 2013, CANCER-AM CANCER SOC, V119, P897, DOI 10.1002/cncr.27849
   Rades D, 2011, INT J RADIAT ONCOL, V81, pE861, DOI 10.1016/j.ijrobp.2010.11.056
   Sakurai H, 2010, J THORAC ONCOL, V5, P1594, DOI 10.1097/JTO.0b013e3181f1923b
   SCHABERG J, 1985, SPINE, V10, P19, DOI 10.1097/00007632-198501000-00003
   Sciubba DM, 2007, EUR SPINE J, V16, P1659, DOI 10.1007/s00586-007-0380-4
   SIOUTOS PJ, 1995, CANCER, V76, P1453, DOI 10.1002/1097-0142(19951015)76:8<1453::AID-CNCR2820760824>3.0.CO;2-T
   SUNDARESAN N, 1991, NEUROSURGERY, V29, P645, DOI 10.1227/00006123-199111000-00001
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   TOKUHASHI Y, 1990, SPINE, V15, P1110, DOI 10.1097/00007632-199011010-00005
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   van der Linden YM, 2005, CANCER-AM CANCER SOC, V103, P320, DOI 10.1002/cncr.20756
   White BD, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2538
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E322
EP E332
DI 10.1016/j.wneu.2018.09.102
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000040
PM 30261374
DA 2020-05-12
ER

PT J
AU Frati, A
   Pesce, A
   Palmieri, M
   Iasanzaniro, M
   Familiari, P
   Angelini, A
   Salvati, M
   Rocco, M
   Raco, A
AF Frati, Alessandro
   Pesce, Alessandro
   Palmieri, Mauro
   Iasanzaniro, Manuela
   Familiari, Pietro
   Angelini, Albina
   Salvati, Maurizio
   Rocco, Monica
   Raco, Antonino
TI Hypnosis-Aided Awake Surgery for the Management of Intrinsic Brain
   Tumors versus Standard Awake-Asleep-Awake Protocol: A Preliminary,
   Promising Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake surgery; Brain tumors; Glioma; Hypnosis; Intrinsic
ID EVENT SCALE; PSYCHOMETRIC PROPERTIES; GLIOMA SURGERY; CRANIOTOMY;
   IMPACT; ANESTHESIA; RESECTION; SATISFACTION; CHILDREN
AB BACKGROUND: Hypnosis is a technique that could aid awake surgery protocols. The aim of the present study is to describe the results of a preliminary experience of a cohort of patients operated on with an original protocol of hypnosis-aided awake surgery (HAS).
   METHODS: All patients were operated on with the aid of HAS and their data were retrospectively reviewed. A thorough literature review was conducted to compare the results of HAS with the standard awake surgery protocol regarding 1) the incidence of intraoperative pain; 2) the overall incidence of complications; 3) the length of time in which the patients were suitable for intraoperative neuropsychological testing; and 4) the incidence of gross total resection. The comparison presented a notably high statistical impact (1-beta - 0.90-0.93 for alpha - 0.05; effect size, 0.5).
   RESULTS: The final cohort comprised 6 patients from our institution and 43 records retrieved in the relevant literature underwent HAS for intrinsic brain tumor treatment. This cohort was compared with cohorts of patients who were considered eligible through a literature review. HAS showed a statistically significant superiority in the first 3 outcome variables, whereas the incidence of gross total resection favored the standard awake approaches.
   CONCLUSIONS: According to the results, hypnosisaided resection of intrinsic brain tumor located in eloquent areas is safe and effective, although dissociation phenomena deserve further investigation to be completely understood.
C1 [Frati, Alessandro; Salvati, Maurizio] IRCCS, Neuromed Neurosurg Dept, Rome, Italy.
   [Pesce, Alessandro; Palmieri, Mauro; Familiari, Pietro; Raco, Antonino] Sapienza Univ, NESMOS Dept, Neurosurg Dept, Rome, Italy.
   [Pesce, Alessandro; Palmieri, Mauro; Iasanzaniro, Manuela; Familiari, Pietro; Angelini, Albina; Rocco, Monica; Raco, Antonino] Azienda Univ Ospedaliera St Andrea, Rome, Italy.
   [Iasanzaniro, Manuela; Angelini, Albina; Rocco, Monica] Sapienza Univ, Anesthesia & Intens Care Unit, Rome, Italy.
RP Palmieri, M (reprint author), Sapienza Univ, NESMOS Dept, Neurosurg Dept, Rome, Italy.; Palmieri, M (reprint author), Azienda Univ Ospedaliera St Andrea, Rome, Italy.
EM mauro.palmieri10@gmail.com
RI Frati, Alessandro/AAC-2204-2020; Pesce, Alessandro/AAC-2223-2020
OI Palmieri, Mauro/0000-0001-5131-1392; FAMILIARI,
   PIETRO/0000-0003-0513-2312
CR Auroy Y, 2009, ANAESTHESIA, V64, P366, DOI 10.1111/j.1365-2044.2008.05792.x
   Auroy Y, 2009, ANN FR ANESTH, V28, P200, DOI 10.1016/j.annfar.2008.12.018
   Beez T, 2013, ACTA NEUROCHIR, V155, P1301, DOI 10.1007/s00701-013-1759-0
   BERGER MS, 1989, NEUROSURGERY, V25, P786, DOI 10.1227/00006123-198911000-00015
   Bilotta F, 2009, CURR OPIN ANESTHESIO, V22, P560, DOI 10.1097/ACO.0b013e3283302339
   Brennum J, 2018, ACTA NEUROCHIR, V160, P1043, DOI 10.1007/s00701-018-3521-0
   Briere J, 1998, ASSESSMENT, V5, P171, DOI 10.1177/107319119800500207
   Craparo G, 2013, NEUROPSYCH DIS TREAT, V9, P1427, DOI 10.2147/NDT.S51793
   Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010
   Danks AR, 1998, PATIENT TOLERANCE CR, P34
   Danks RA, 1998, NEUROSURGERY, V42, P28, DOI 10.1097/00006123-199801000-00006
   Delion M, 2015, WORLD NEUROSURG, V84, P1645, DOI 10.1016/j.wneu.2015.06.073
   Deras P, 2012, NEUROSURGERY, V71, P764, DOI 10.1227/NEU.0b013e3182647ab8
   Duffau H, 2007, NEUROPHYSIOL CLIN, V37, P373, DOI 10.1016/j.neucli.2007.09.003
   Erickson MH, 1979, HYPNOTHERAPY EXPLORA
   Coello AF, 2013, J NEUROSURG, V119, P1380, DOI 10.3171/2013.6.JNS122470
   Ferracci FX, 2018, EXPERT REV NEUROTHER, V18, P333, DOI 10.1080/14737175.2018.1451329
   Goebel S, 2010, NEUROSURGERY, V67, P594, DOI 10.1227/01.NEU.0000374870.46963.BB
   Hamer PCD, 2012, J CLIN ONCOL, V30, P2559, DOI 10.1200/JCO.2011.38.4818
   Hansen E, 2013, ACTA NEUROCHIR, V155, P1417, DOI 10.1007/s00701-013-1801-2
   Hervey-Jumper SL, 2015, J NEUROSURG SCI, V59, P351
   HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004
   Kanno A, 2015, NEUROL MED-CHIR, V55, P367, DOI 10.2176/nmc.ra.2014-0395
   Keifer JC, 2005, ANESTH ANALG, V101, P502, DOI 10.1213/01.ANE.0000160533.51420.44
   Keles GE, 2004, J NEUROSURG, V100, P369, DOI 10.3171/jns.2004.100.3.0369
   Khu KJ, 2010, J NEUROSURG, V112, P1056, DOI 10.3171/2009.6.JNS09716
   Malinauskiene Vilija, 2016, Acta Med Litu, V23, P185, DOI 10.6001/actamedica.v23i3.3384
   Manchella S, 2011, BRIT J NEUROSURG, V25, P391, DOI 10.3109/02688697.2011.568640
   Mandonnet E, 2010, ACTA NEUROCHIR, V152, P185, DOI 10.1007/s00701-009-0469-0
   Manninen PH, 2006, ANESTH ANALG, V102, P237, DOI 10.1213/01.ANE.0000181287.86811.5C
   Miceli G, 1994, BATTERIA ANALISI DEF
   Palese A, 2008, CANCER NURS, V31, P166, DOI 10.1097/01.NCC.0000305699.97625.dc
   Pesce A, 2016, WORLD NEUROSURG, V91, P238, DOI 10.1016/j.wneu.2016.03.064
   Raco A, 2017, WORLD NEUROSURG, V103, P748, DOI 10.1016/j.wneu.2017.04.063
   See JJ, 2007, ANN ACAD MED SINGAP, V36, P319
   Sinha PK, 2007, NEUROL INDIA, V55, P376, DOI 10.4103/0028-3886.33308
   Southwell DG, 2018, J NEUROSURG, V129, P567, DOI 10.3171/2017.5.JNS17166
   Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205
   Surbeck W, 2015, ACTA NEUROCHIR, V157, P77, DOI 10.1007/s00701-014-2249-8
   Sveen J, 2010, J BURN CARE RES, V31, P310, DOI 10.1097/BCR.0b013e3181d0f523
   Tate MC, 2015, CANCER TREAT RES, V163, P31, DOI 10.1007/978-3-319-12048-5_3
   Wahab SS, 2011, BRIT J NEUROSURG, V25, P606, DOI 10.3109/02688697.2011.568642
   Weiss Daniel S., 1997, P399
   Whittle IR, 2005, ACTA NEUROCHIR, V147, P275, DOI 10.1007/s00701-004-0445-7
   Zemmoura I, 2016, NEUROSURGERY, V78, P53, DOI 10.1227/NEU.0000000000000993
NR 45
TC 8
Z9 8
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E882
EP E891
DI 10.1016/j.wneu.2018.10.004
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000109
PM 30315969
DA 2020-05-12
ER

PT J
AU Gibelli, D
   Cellina, M
   Gibelli, S
   Belloni, E
   Oliva, AG
   Termine, G
   Dolci, C
   Sforza, C
AF Gibelli, Daniele
   Cellina, Michaela
   Gibelli, Stefano
   Belloni, Elena
   Oliva, Antonio Giancarlo
   Termine, Giovanni
   Dolci, Claudia
   Sforza, Chiarella
TI Anatomic Characteristics of Intrapetrous Carotid Artery: A 3-Dimensional
   Segmentation Study on Head Computed Tomography Scan
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D Segmentation; Anatomic variants; CT scan; Intrapetrous carotid artery
   (IPCA); Radiology
ID RETROSIGMOID APPROACH; SURGICAL EXPOSURE; PETROUS PORTION; AGE
AB BACKGROUND: The intrapetrous carotid artery (IPCA) is one of the most unexplored anatomic regions, and its 3-dimensional reconstruction in living subjects is still missing. This study aims to describe the IPCA on 3D models extracted from head computed tomography (CT) scans.
   METHODS: The intrapetrous carotid artery was manually segmented on head CT scans of 100 healthy patients free from vascular and neurologic pathologies (50 men and 50 women; age range, 18-91 years). Angles of the posterior and anterior genu, diameter and length of the horizontal portion, and volume of the entire canal were calculated through 3D analysis software. Statistically significant differences according to sex and side were assessed through 2-way analysis of variance (P < 0.05). Correlation of each measurement with age was calculated as well.
   RESULTS: On average, the angles of the posterior and anterior genu were 120.1 degrees +/- 10.4 degrees and 118.0 degrees +/- 10.0 degrees in men and 119.5 degrees +/- 9.2 degrees and 117.6 degrees +/- 10.3 degrees in women, respectively, without statistically significant differences according to sex or side (P > 0.05). The average length and diameter of the horizontal part were, respectively, 25.5 degrees 2.9 and 5.8 +/- 0.8 mm in men and 24.0 +/- 2.3 and 5.3 +/- 0.8 mm in women. The volume of the IPCA was 0.941 +/- 0.215 cm(3) in men and 0.752 +/- 0.159 cm(3) in women. The length and diameter of the horizontal portion and the volume of the IPCA showed statistically significant differences according to sex (P < 0.05). No correlation with age was found.
   CONCLUSIONS: This study provides data concerning not only linear and angular measurements, but also volumes of the IPCA, which are useful in planning surgical interventions of the cranial base.
C1 [Gibelli, Daniele; Dolci, Claudia; Sforza, Chiarella] Univ Milan, Dipartimento Sci Biomed Salute, Milan, Italy.
   [Cellina, Michaela; Oliva, Antonio Giancarlo] ASST Fatebenefratelli Sacco, Osped Fatebenefratelli, Reparto Radiol, Milan, Italy.
   [Gibelli, Stefano; Termine, Giovanni] ASST Fatebenefratelli Sacco, Osped Fatebenefratelli, Reparto Otorinolaringoiatria, Milan, Italy.
   [Belloni, Elena] Civil Hosp, Dept Radiol, Vigevano, Italy.
RP Gibelli, D (reprint author), Univ Milan, Dipartimento Sci Biomed Salute, Milan, Italy.
EM daniele.gibelli@unimi.it
RI Cellina, Michaela/AAI-2011-2019; Oliva, Antonio/K-1105-2018; Sforza,
   Chiarella/C-3008-2015; Dolci, Claudia/L-1993-2016; Gibelli,
   Daniele/L-1468-2016
OI Cellina, Michaela/0000-0002-7401-1971; Sforza,
   Chiarella/0000-0001-6532-6464; Dolci, Claudia/0000-0002-3060-4097;
   Gibelli, Daniele/0000-0002-9591-1047; Belloni, Elena/0000-0002-6544-6252
CR Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001
   Colasanti R, 2015, OPER NEUROSURG, V11, P329, DOI 10.1227/NEU.0000000000000749
   Crossland GJ, 2005, J LARYNGOL OTOL, V119, P479, DOI 10.1258/0022215054273214
   Dew LA, 1997, LARYNGOSCOPE, V107, P967, DOI 10.1097/00005537-199707000-00026
   Gao Z, 2012, SURG RADIOL ANAT, V34, P695, DOI 10.1007/s00276-011-0874-y
   Gibelli D, 2018, SURG RADIOL ANAT, V40, P193, DOI 10.1007/s00276-017-1949-1
   HANSEN F, 1995, ULTRASOUND MED BIOL, V21, P1, DOI 10.1016/0301-5629(94)00090-5
   Hassan K, 2016, STUD HEALTH TECHNOL, V220, P130, DOI 10.3233/978-1-61499-625-5-130
   Hearst MJ, 2008, OTOL NEUROTOL, V29, P1001, DOI 10.1097/MAO.0b013e31818599ea
   Huang YC, 2007, J NEUROL SCI, V253, P90, DOI 10.1016/j.jns.2006.11.019
   Jiang Y, 2015, J CRANIOFAC SURG, V26, P2180, DOI 10.1097/SCS.0000000000000207
   Kane AG, 1996, AM J NEURORADIOL, V17, P1295
   LEONETTI JP, 1990, OTOLARYNG HEAD NECK, V102, P3, DOI 10.1177/019459989010200102
   Liu JK, 2006, NEUROSURGERY, V59, P309, DOI 10.1227/01.NEU.0000232638.96933.A0
   Mason E, 2014, LARYNGOSCOPE, V124, P1988, DOI 10.1002/lary.24594
   Moore KL, 2006, CLIN ORIENTED ANATOM
   Mujagic Svjetlana, 2016, Acta Med Acad, V45, P1, DOI 10.5644/ama2006-124.150
   Naggara O, 2008, EUR RADIOL, V18, P1038, DOI 10.1007/s00330-007-0835-3
   Osawa S, 2008, NEUROSURGERY, V63, P210, DOI 10.1227/01.NEU.0000327037.75571.10
   PAULLUS WS, 1977, J NEUROSURG, V47, P713, DOI 10.3171/jns.1977.47.5.0713
   Perini Talita Adão, 2005, Rev Bras Med Esporte, V11, P81, DOI 10.1590/S1517-86922005000100009
   Samijo SK, 1998, CARDIOVASC RES, V39, P515, DOI 10.1016/S0008-6363(98)00074-1
   Scerrati A, 2016, WORLD NEUROSURG, V91, P443, DOI 10.1016/j.wneu.2016.04.064
   Spiessberger A, 2018, WORLD NEUROSURG, V114, pE1174, DOI 10.1016/j.wneu.2018.03.172
   Standering S., 2005, GRAYS ANATOMY ANATOM
   Stojanovic N, 2015, VOJNOSANIT PREGL, V72, P356, DOI 10.2298/VSP1504356S
   Takegoshi H, 2007, AURIS NASUS LARYNX, V34, P297, DOI 10.1016/j.anl.2007.01.007
   Vidya CS, 2015, J CLIN DIAGN RES, V9, pAC16, DOI 10.7860/JCDR/2015/10497.5590
   Vijaywargiya M, 2017, ANAT CELL BIOL, V50, P163, DOI 10.5115/acb.2017.50.3.163
   Villavicencio AT, 2001, NEUROSURGERY, V49, P342, DOI 10.1097/00006123-200108000-00016
   Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015
NR 31
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E419
EP E425
DI 10.1016/j.wneu.2018.09.125
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000052
PM 30266708
DA 2020-05-12
ER

PT J
AU Giulioni, M
   Marucci, G
   Cossu, M
   Tassi, L
   Bramerio, M
   Barba, C
   Buccoliero, AM
   Vornetti, G
   Zenesini, C
   Consales, A
   De Palma, L
   Villani, F
   Di Gennaro, G
   Vatti, G
   Zamponi, N
   Colicchio, G
   Marras, CE
AF Giulioni, Marco
   Marucci, Gianluca
   Cossu, Massimo
   Tassi, Laura
   Bramerio, Manuela
   Barba, Carmen
   Buccoliero, Anna Maria
   Vornetti, Gianfranco
   Zenesini, Corrado
   Consales, Alessandro
   De Palma, Luca
   Villani, Flavio
   Di Gennaro, Giancarlo
   Vatti, Giampaolo
   Zamponi, Nelia
   Colicchio, Gabriella
   Marras, Carlo Efisio
TI CD34 Expression in Low-Grade Epilepsy-Associated Tumors: Relationships
   with Clinicopathologic Features
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epilepsy surgery; Focal cortical dysplasia; Glioneuronal tumors;
   Immunohistochemistry; Progenitor cells
ID FOCAL CORTICAL DYSPLASIA; TEMPORAL-LOBE EPILEPSY; TASK-FORCE REPORT;
   ILAE COMMISSION; PLEOMORPHIC XANTHOASTROCYTOMA; CONSENSUS
   CLASSIFICATION; NEUROEPITHELIAL TUMORS; SURGICAL-TREATMENT;
   BRAIN-TISSUE; SEIZURE
AB OBJECTIVE: To analyze relationships between CD34 expression and several demographic, clinical, and pathologic features in patients with histopathologic evidence of low-grade epilepsy-associated tumors who underwent epilepsy surgery.
   METHODS: A retrospective study enrolling 187 patients with low-grade epilepsy-associated tumors who underwent surgery between January 2009 and June 2015 at 8 Italian epilepsy surgery centers was conducted. All cases were histologically diagnosed according to the World Health Organization classification of central nervous system tumors. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.
   RESULTS: Of 187 patients, 95 (50.8%) were CD34 positive. Tumor type and duration of epilepsy were independently associated with CD34 expression on multivariate analysis. Ganglioglioma and pleomorphic xanthoastrocytoma were the histologic types with the strongest association with CD34 positivity with an odds ratio of 9.2 and 10.4, respectively, compared with dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy > 10 years had a significantly greater likelihood to show CD34 expression, with an odds ratio of 2.8 compared with patients with a duration of epilepsy < 2 years. On univariate analysis, CD34 expression appeared to be significantly related to older age at surgery, higher antiepileptic drug intake, and female sex.
   CONCLUSIONS: CD34 expression holds promise as a useful biomolecular marker for patients with low-grade epilepsy-associated tumors with evidence of a link with clinicopathologic features. This study confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with longer duration of epilepsy, independent of histology.
C1 [Giulioni, Marco; Vornetti, Gianfranco] IRCCS Ist Sci Neurol Bologna, UOC Neurochirurg, Bologna, Italy.
   [Zenesini, Corrado] IRCCS Ist Sci Neurol Bologna, Unita Epidemiol & Biostat, Bologna, Italy.
   [Marucci, Gianluca] Azienda Unita Sanit Locale Bologna, Anat Pathol Unit, Bologna, Italy.
   [Marucci, Gianluca] Fdn IRCCS, Ist Neurol C Besta, Neuropathol Unit, Milan, Italy.
   [Villani, Flavio] Fdn IRCCS, Ist Neurol C Besta, Clin Epileptol & Expt Neurophysiol Unit, Milan, Italy.
   [Cossu, Massimo; Tassi, Laura] ASST Grande Osped Metropolitano Niguarda, Claudio Munari Ctr Epilepsy Surg, Milan, Italy.
   [Bramerio, Manuela] ASST Grande Osped Metropolitano Niguarda, Serv Pathol, Milan, Italy.
   [Barba, Carmen] Univ Florence, Childrens Hosp A Meyer, Pediat Neurol Unit, Neurosci Dept, Florence, Italy.
   [Buccoliero, Anna Maria] Univ Florence, Childrens Hosp A Meyer, Pathol Unit, Florence, Italy.
   [Consales, Alessandro] Ist Giannina Gaslini, Dept Pediat Neurosurg, Genoa, Italy.
   [De Palma, Luca] Bambino Gesu Childrens Hosp IRCCS, Dept Neurosci, Div Neurol, Rome, Italy.
   [Marras, Carlo Efisio] Bambino Gesu Childrens Hosp IRCCS, Dept Neurosci, Neurosurg Unit, Rome, Italy.
   [Di Gennaro, Giancarlo] IRCCS Neuromed, Epilepsy Surg Unit, Pozzilli, Italy.
   [Vatti, Giampaolo] Univ Siena, Dept Neurol, Siena, Italy.
   [Zamponi, Nelia] Univ Ancona, Childrens Hosp G Salesi, Child Neurol & Psychiat Unit, Ancona, Italy.
   [Colicchio, Gabriella] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.
RP Giulioni, M (reprint author), IRCCS Ist Sci Neurol Bologna, UOC Neurochirurg, Bologna, Italy.
EM giulioni.m@tiscali.it
RI Di Gennaro, Giancarlo/J-2794-2018; Marras, Carlo Efisio/AAA-4964-2020;
   Cossu, Massimo/K-2133-2018; Zenesini, Corrado/AAB-6649-2020; De Palma,
   Luca/O-8661-2019; Marucci, Gianluca/F-1426-2019
OI Di Gennaro, Giancarlo/0000-0003-3446-0788; Marras, Carlo
   Efisio/0000-0003-0790-8903; Cossu, Massimo/0000-0002-1891-7648; De
   Palma, Luca/0000-0002-0714-8230; Marucci, Gianluca/0000-0003-4508-3359
CR Al-Hajri A, 2017, J NEUROPATH EXP NEUR, V76, P1023, DOI 10.1093/jnen/nlx090
   Aronica E, 2014, NEUROTHERAPEUTICS, V11, P251, DOI 10.1007/s13311-013-0251-0
   Babini M, 2013, J NEUROSURG-PEDIATR, V11, P214, DOI 10.3171/2012.11.PEDS12137
   Blumcke I, 2016, NAT REV NEUROL, V12, P732, DOI 10.1038/nrneurol.2016.173
   Blumcke I, 2016, EPILEPSIA, V57, P348, DOI 10.1111/epi.13319
   Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Blumcke I, 2017, NEW ENGL J MED, V377, P1648, DOI 10.1056/NEJMoa1703784
   Blumcke I, 2002, J NEUROPATH EXP NEUR, V61, P575
   Blumcke I, 1999, ACTA NEUROPATHOL, V97, P481, DOI 10.1007/s004010051017
   Blumcke I, 2014, ACTA NEUROPATHOL, V128, P39, DOI 10.1007/s00401-014-1288-9
   Consales A, 2013, MINERVA PEDIATR, V65, P609
   Cossu M, 2013, EPILEPSIA, V54, P115, DOI 10.1111/epi.12455
   Deb P, 2006, NEUROPATH APPL NEURO, V32, P461, DOI 10.1111/j.1365-2990.2006.00734.x
   Engel Jr J., 1993, SURG TREATMENT EPILE, P609
   Fauser S, 2004, ACTA NEUROPATHOL, V108, P272, DOI 10.1007/s00401-004-0889-0
   Giulioni M, 2017, EPILEPSIA, V58, P1832, DOI 10.1111/epi.13866
   Giulioni Marco, 2014, World J Clin Cases, V2, P623, DOI 10.12998/wjcc.v2.i11.623
   Giulioni M, 2009, J NEUROSURG, V111, P1275, DOI 10.3171/2009.3.JNS081350
   Guerrini R, 2013, EPILEPSIA, V54, P84, DOI 10.1111/epi.12450
   Hirose T, 2001, ULTRASTRUCT PATHOL, V25, P469, DOI 10.1080/019131201753343502
   Holthausen H, 2016, EPILEPTIC DISORD, V18, P240, DOI 10.1684/epd.2016.0851
   Huse JT, 2017, ACTA NEUROPATHOL, V133, P417, DOI 10.1007/s00401-016-1639-9
   Huse JT, 2013, BRAIN PATHOL, V23, P515, DOI 10.1111/bpa.12035
   Jessberger S, 2015, COLD SPRING HARB PER, V7, P1
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Liubinas SV, 2014, EPILEPSIA, V55, P1438, DOI 10.1111/epi.12662
   Louis DN, 2016, WHO CLASSIFICATION T
   Marucci G, 2014, ANN CLIN TRANSL NEUR, V1, P130, DOI 10.1002/acn3.31
   Marucci G, 2013, CLIN NEUROL NEUROSUR, V115, P187, DOI 10.1016/j.clineuro.2012.05.012
   Marucci G, 2013, APMIS, V121, P22, DOI 10.1111/j.1600-0463.2012.02938.x
   Nagaishi M, 2011, NEUROPATHOLOGY, V31, P468, DOI 10.1111/j.1440-1789.2010.01188.x
   Ortiz-Gonzalez XR, 2013, EPILEPSY BEHAV, V27, P121, DOI 10.1016/j.yebeh.2012.12.035
   Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699
   Pelliccia V, 2017, J NEUROSURG, V127, P1147, DOI 10.3171/2016.9.JNS161176
   Powell SZ, 1996, AM J SURG PATHOL, V20, P80, DOI 10.1097/00000478-199601000-00009
   Reifenberger G, 2003, ACTA NEUROPATHOL, V105, P358, DOI 10.1007/s00401-002-0652-3
   Rossini L, 2017, ANN NEUROL, V82, P331, DOI 10.1002/ana.25005
   Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661
   Stockhammer F, 2012, SEIZURE-EUR J EPILEP, V21, P194, DOI 10.1016/j.seizure.2011.12.007
   Stone TJ, 2018, ACTA NEUROPATHOL, V135, P115, DOI 10.1007/s00401-017-1773-z
   Thom M, 2018, BRAIN PATHOL, V28, P155, DOI 10.1111/bpa.12555
   Thom M, 2012, BRAIN PATHOL, V22, P350, DOI 10.1111/j.1750-3639.2012.00582.x
   Vornetti G, 2017, J CLIN NEUROSCI, V44, P158, DOI 10.1016/j.jocn.2017.06.022
   You G, 2012, EUR J NEUROL, V19, P298, DOI 10.1111/j.1468-1331.2011.03509.x
NR 45
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E761
EP E768
DI 10.1016/j.wneu.2018.09.212
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000094
PM 30308344
DA 2020-05-12
ER

PT J
AU Godzik, J
   Hlubek, RJ
   Pereira, BD
   Xu, DS
   Walker, CT
   Farber, SH
   Turner, JD
   Mundis, G
   Uribe, JS
AF Godzik, Jakub
   Hlubek, Randy J.
   Pereira, Bernardo de Andrada
   Xu, David S.
   Walker, Corey T.
   Farber, S. Harrison
   Turner, Jay D.
   Mundis, Gregory
   Uribe, Juan S.
TI Combined Lateral Transpsoas Anterior Column Realignment with Pedicle
   Subtraction Osteotomy to Treat Severe Sagittal Plane Deformity:
   Cadaveric Feasibility Study and Early Clinical Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior column realignment; Combined open minimally invasive spine
   surgery technique; Deformity correction; Minimally invasive spine
   surgery; Pedicle screw osteotomy
ID ADULT SPINAL DEFORMITY; ROD FRACTURE; SURGERY; COMPLICATIONS; ACR
AB BACKGROUND: Traditional open approaches to correct lumbar spine deformities include 3-column osteotomies, such as a pedicle subtraction osteotomy (PSO). Minimally invasive surgical (MIS) techniques have been developed for lateral transpsoas anterior column realignment (ACR). These 2 techniques have not previously been combined. Our objective was to investigate the cadaveric feasibility of a combined hybrid MIS ACR-PSO technique for deformity correction and to review early clinical experience.
   METHODS: The feasibility of the combined ACR-PSO technique was evaluated in 4 fresh cadaveric specimens. The operative experience, complications, and early clinical outcomes in patients treated with the combined approach to correct global sagittal imbalance were reviewed.
   RESULTS: In the cadaveric study, the combined ACR-PSO resulted in a mean 46.0 degrees increase in lordosis (P < 0.001). Nine patients treated with ACR-PSO were evaluated (mean age, 65.2 years; 33.3% female). Most patients (6/9; 66.7%) underwent ACR at L1/2 or L3/4; 8 (88.8%) had PSO at L3 or L4. On average, 10.6 +/- 3.8 levels were fused. Significant decreases in mean pelvic tilt (P=0.01), spinopelvic mismatch (P < 0.001), and T1 spinopelvic inclination (P=0.03) were observed postoperatively; mean lumbar lordosis (P=0.007), intradiscal angle (P=0.001), and thoracic kyphosis (P=0.04) significantly increased. The overall complication rate was 55.6% (5/9).
   CONCLUSIONS: Our early experience suggests that a combined ACR-PSO with posterior fixation allows for significant correction of segmental lordosis and global imbalance. This combined approach may maximize results attainable with hybrid MIS-open surgical techniques and represents a complementary option to PSO and other posterior approaches.
C1 [Godzik, Jakub; Hlubek, Randy J.; Pereira, Bernardo de Andrada; Xu, David S.; Walker, Corey T.; Farber, S. Harrison; Turner, Jay D.; Uribe, Juan S.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Mundis, Gregory] Scripps Clin, San Diego Spine Fdn, Div Orthoped Surg, La Jolla, CA 92037 USA.
RP Uribe, JS (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Farber, S. Harrison/0000-0002-0171-6516
CR Akbarnia BA, 2014, J SPINAL DISORD TECH, V27, P29, DOI 10.1097/BSD.0b013e318287bdc1
   Berjano P, 2015, EUR SPINE J, V24, pS433, DOI 10.1007/s00586-015-3930-1
   Bridwell KH, 2006, SPINE, V31, pS171, DOI 10.1097/01.brs.0000231963.72810.38
   Diebo BG, 2018, NEUROSURGERY, V83, P69, DOI 10.1093/neuros/nyx338
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Hassanzadeh H, 2013, SPINE, V38, P726, DOI 10.1097/BRS.0b013e31827c2415
   Kanter AS, 2016, SPINE, V41, pS59, DOI 10.1097/BRS.0000000000001481
   Lapp MA, 2001, SPINE, V26, P973, DOI 10.1097/00007632-200104150-00025
   Leveque JC, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17195
   Luca A, 2017, EUR SPINE J, V26, P764, DOI 10.1007/s00586-016-4859-8
   Mundis GM, 2017, WORLD NEUROSURG, V105, P249, DOI 10.1016/j.wneu.2017.05.122
   Mundis Jr GM, 2017, SPINE DEFORM, V5, P265, DOI DOI 10.1016/j.jspd.2017.01.010
   Murray G, 2015, EUR SPINE J, V24, pS397, DOI 10.1007/s00586-015-3894-1
   Park P, 2015, J NEUROSURG-SPINE, V22, P374, DOI 10.3171/2014.9.SPINE131004
   Saigal R, 2016, SPINE, V41, pS66, DOI 10.1097/BRS.0000000000001483
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Smith JS, 2014, J NEUROSURG-SPINE, V21, P994, DOI 10.3171/2014.9.SPINE131176
   Smith JS, 2012, NEUROSURGERY, V71, P862, DOI 10.1227/NEU.0b013e3182672aab
   Turner JD, 2015, EUR SPINE J, V24, pS427, DOI 10.1007/s00586-015-3842-0
   Wang MY, 2016, J NEUROSURG-SPINE, V24, P769, DOI 10.3171/2015.7.SPINE15188
NR 20
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E589
EP E595
DI 10.1016/j.wneu.2018.09.173
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000072
PM 30292028
DA 2020-05-12
ER

PT J
AU Godzik, J
   Hool, N
   Dalton, JF
   Whiting, AC
   Newcomb, AGUS
   Kelly, BP
   Crawford, NR
AF Godzik, Jakub
   Hool, Nick
   Dalton, Jonathan F.
   Whiting, Alexander C.
   Newcomb, Anna G. U. S.
   Kelly, Brian P.
   Crawford, Neil R.
TI Impact of Connector Placement and Design on Bending Stiffness of Spinal
   Constructs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bending stiffness; Biomechanics; Cervical spine; Component testing;
   Instrumentation; Spinal fixation implant
ID ANTERIOR CERVICAL DECOMPRESSION; SCREW FIXATION; INSTRUMENTATION;
   ARTHRODESIS; STABILIZATION; STABILITY
AB OBJECTIVE: To evaluate the stability of multiple rod-connector construct designs using a mechanical 4-point bending testing frame.
   METHODS: A mechanical study was used to evaluate the bending stiffness of 3 connectors across 12 different configurations of rod-connector-rod constructs. Stability was evaluated in flexion-extension and lateral bending. Combinations of rods having 1 of 3 diameters (4.0 mm, 5.5 mm, and 6.0 mm) connected by 1 of 3 connector types (parallel open, snap-on, and hinged) were compared. Configurations with single connectors and with double connectors with variable spacing were also compared to simulate revision surgery conditions.
   RESULTS: Constructs consisting of 4.0-mm rods connected to 4.0-mm rods were significantly less stiff as the total number of connectors used in a series exceeded 2. When single-connector configurations were compared, parallel open rod connectors demonstrated greater stiffness in flexion-extension than hinged open connectors, whereas hinged open connectors demonstrated greater stiffness in lateral bending. Using double connectors increased stiffness of 4.0- to 4.0-mm rod configurations in flexion-extension and lateral bending, 4.0- to 6.0-mm rod configurations in flexion-extension, and 5.5- to 6.0-mm rod configurations in lateral bending. Spacing the double connectors significantly improved lateral bending stiffness of 4.0- to 4.0-mm and 5.5- to 6.0-mm rod configurations.
   CONCLUSIONS: Our data indicate that the design, number, and placement of rod connectors have a significant impact on the bending stiffness of a surgical construct. Such mechanical data may influence construct design in primary and revision surgeries of the cervical spine and cervicothoracic junction.
C1 [Godzik, Jakub; Whiting, Alexander C.] St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ USA.
   [Hool, Nick; Newcomb, Anna G. U. S.; Kelly, Brian P.; Crawford, Neil R.] St Josephs Hosp, Spinal Biomech Lab, Dept Neurosurg Res, Phoenix, AZ 85013 USA.
   [Dalton, Jonathan F.] Washington Univ, Med Sch, St Louis, MO USA.
RP Kelly, BP (reprint author), St Josephs Hosp, Spinal Biomech Lab, Dept Neurosurg Res, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219
CR AN HS, 1994, SPINE, V19, P2557, DOI 10.1097/00007632-199411001-00011
   BUEFF HU, 1995, SPINE, V20, P1789, DOI 10.1097/00007632-199508150-00007
   Cheng JS, 2003, SEMIN NEUROSURG, V14, P49
   Dick JC, 2001, SPINE, V26, P1668, DOI 10.1097/00007632-200108010-00008
   Eleraky M, 2010, J NEUROSURG-SPINE, V13, P622, DOI 10.3171/2010.5.SPINE09848
   Emery SE, 1998, J BONE JOINT SURG AM, V80A, P941, DOI 10.2106/00004623-199807000-00002
   Grubb MR, 1997, SPINE, V22, P1948, DOI 10.1097/00007632-199709010-00002
   Hilibrand AS, 2002, SPINE, V27, P146, DOI 10.1097/00007632-200201150-00005
   Kok D, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-269
   KOTANI Y, 1994, SPINE, V19, P2529, DOI 10.1097/00007632-199411001-00007
   Kuklo TR, 2008, SPINE, V33, pE482, DOI 10.1097/BRS.0b013e31817c64d5
   Lynn G, 1997, SPINE, V22, P1568, DOI 10.1097/00007632-199707150-00007
   Mahar AT, 2008, SPINE J, V8, P933, DOI 10.1016/j.spinee.2007.10.031
   OBrien J, 2005, CURR OPIN ORTHOP, V16, P184
   Peolsson A, 2003, EUR SPINE J, V12, P274, DOI 10.1007/s00586-003-0530-2
   Robinson ST, 2015, COMPARATIVE MED, V65, P46
   Shaw MN, 2011, J NEUROSURG-SPINE, V14, P719, DOI 10.3171/2011.1.SPINE10411
   SHINOMIYA K, 1993, J SPINAL DISORD, V6, P277, DOI 10.1097/00002517-199306040-00001
   Stambough JL, 1998, J SPINAL DISORD, V11, P221
   Tatsumi RL, 2007, SPINE, V32, P1072, DOI 10.1097/01.brs.0000261490.90956.2b
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E89
EP E95
DI 10.1016/j.wneu.2018.08.235
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000013
PM 30217782
DA 2020-05-12
ER

PT J
AU Goel, A
   Dharurkar, P
   Shah, A
   Gore, S
   Bakale, N
   Vaja, T
AF Goel, Atul
   Dharurkar, Pralhad
   Shah, Abhidha
   Gore, Sandeep
   Bakale, Nilesh
   Vaja, Tejas
TI Facetal Fixation Arthrodesis as Treatment of Cervical Radiculopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disc herniation; Cervical spondylosis; Osteophyte; Radiculopathy
ID DISTRACTION; SINGLE; DISC; INSTABILITY; MYELOPATHY; TRACTION; SURGERY;
   SPACERS; POINT
AB OBJECTIVE: We assessed the efficacy of "only fixation" as treatment for cervical radiculopathy.
   METHODS: From 2012 to December 2017, 21 patients who had presented with primary symptoms related to cervical radiculopathy, including radiating pain, tingling paresthesia, numbness, weakness, and wasting were treated by facetal stabilization surgery aimed at achieving segmental arthrodesis. No decompression by removal of bone, disc material, or osteophyte was performed. The age of the patients ranged from 27 to 59 years. Of the 21 patients, 19 were men and 2 were women. The imaging findings showed a herniated disc in 4, a disc bulge in 12, and osteophyte-related foraminal stenosis in 5 patients. Transarticular screw fixation was deployed for surgery. The levels of cervical fixation were guided by the clinical and radiological information and determined by direct observation of the facet morphology and stability by manual manipulation of the bones in the region.
   RESULTS: All the patients experienced "remarkable" relief of the presenting radicular symptoms in the "immediate" postoperative period. The visual analog scale and neck disability index scores were used to assess the patients before and after surgical treatment. During the follow-up period, which ranged from 6 to 64 months, all the patients continued to experience satisfactory symptomatic relief.
   CONCLUSIONS: Instability of the spinal segment is the nodal point of pathogenesis and the primary cause of symptoms related to degenerative spondylotic radiculopathy. The treatment is spinal stabilization. No direct bone or soft tissue decompression is necessary.
C1 [Goel, Atul; Dharurkar, Pralhad; Shah, Abhidha; Gore, Sandeep; Bakale, Nilesh; Vaja, Tejas] King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.
   [Goel, Atul; Dharurkar, Pralhad; Shah, Abhidha; Gore, Sandeep; Bakale, Nilesh; Vaja, Tejas] Seth GS Med Coll, Dept Neurosurg, Bombay, Maharashtra, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
RP Goel, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.; Goel, A (reprint author), Seth GS Med Coll, Dept Neurosurg, Bombay, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Badhiwala JH, 2019, NEUROSURGERY, V84, P890, DOI 10.1093/neuros/nyy133
   Burkhardt BW, 2018, NEUROSURG REV, V41, P473, DOI 10.1007/s10143-017-0872-6
   Cardoso MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS1031
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   Faldini C, 2017, EUR SPINE J, V26, P423, DOI 10.1007/s00586-017-5271-8
   Faldini C, 2010, J ORTHOP TRAUMATOL, V11, P99, DOI 10.1007/s10195-010-0093-z
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P305, DOI 10.4103/jcvjs.JCVJS_137_17
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P88, DOI 10.4103/jcvjs.JCVJS_50_17
   Goel A, 2016, WORLD NEUROSURG, V94, P339, DOI 10.1016/j.wneu.2016.07.020
   Goel A, 2016, NEUROL INDIA, V64, P837, DOI 10.4103/0028-3886.185379
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P47, DOI 10.4103/0974-8237.156031
   Goel A, 2013, J NEUROSURG-SPINE, V19, P672, DOI 10.3171/2011.8.SPINE11249
   Goel A, 2011, J NEUROSURG-SPINE, V14, P689, DOI 10.3171/2011.2.SPINE10601
   Goel A, 2010, J CRANIOVERTEBRAL JU, V1, P65, DOI 10.4103/0974-8237.77669
   Goel A, 2011, J CRANIOVERTEBRAL JU, V2, P1, DOI [10.4103/0974-8237.85306, 10.4103/0974-8237.65474]
   Goet A, 2011, J CRANIOVERTEBRAL JU, V2, P55, DOI 10.4103/0974-8237.100049
   HENDERSON CM, 1983, NEUROSURGERY, V13, P504, DOI 10.1227/00006123-198311000-00004
   HUSKISSON EC, 1982, J RHEUMATOL, V9, P768
   Lafuente J, 2005, J BONE JOINT SURG BR, V87B, P508, DOI 10.1302/0301-620X.87B4
   McCormack BM, 2013, J NEUROSURG-SPINE, V18, P245, DOI 10.3171/2012.12.SPINE12477
   Moustafa IM, 2014, J CHIROPR MED, V13, P157, DOI 10.1016/j.jcm.2014.07.003
   Narotam PK, 2003, J NEUROSURG, V99, P172, DOI 10.3171/spi.2003.99.2.0172
   Ozturk B, 2006, RHEUMATOL INT, V26, P622, DOI 10.1007/s00296-005-0035-x
   ROYCAMILLE R, 1972, NOUV PRESSE MED, V1, P2484
   Shah A, 2014, J CRANIOVERTEBRAL JU, V5, P9, DOI 10.4103/0974-8237.135208
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
NR 26
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E875
EP E881
DI 10.1016/j.wneu.2018.10.003
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000108
PM 30315982
DA 2020-05-12
ER

PT J
AU Goel, A
   Dhar, A
   Shah, A
   Jadhav, D
   Bakale, N
   Vaja, T
   Jadhav, N
AF Goel, Atul
   Dhar, Arjun
   Shah, Abhidha
   Jadhav, Dikpal
   Bakale, Nilesh
   Vaja, Tejas
   Jadhav, Neha
TI Central or Axial Atlantoaxial Dislocation as a Cause of Cervical
   Myelopathy: A Report of Outcome of 5 Cases Treated by Atlantoaxial
   Stabilization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central atlantoaxial instability; Facet alignment; Spastic quadriparesis
ID CANAL STENOSIS REPORT; BASILAR INVAGINATION; FACETAL INSTABILITY;
   SURGICAL-TREATMENT; FIXATION; EXPERIENCE; DISTRACTION; SINGLE; PLATE
AB OBJECTIVE: The implications of diagnosis and treatment of central or axial atlantoaxial dislocation (CAAD) as a cause of symptoms of cervical myelopathy are evaluated.
   METHODS: This is a report of a series of 5 patients who presented with the primary symptoms of spasticity and motor weakness and paresthesias in all the limbs. There was no evidence of any significant compression of the dural tube or neural structures at the craniovertebral junction. There was no craniovertebral junction instability when assessed by classically described radiologic parameters. CAAD was diagnosed based on our recently discussed parameter of facetal alignment, corroborative clinical and radiologic evidence, and direct observation of atlantoaxial instability by manual manipulation of the bones of the region. All patients underwent atlantoaxial fixation.
   RESULTS: There was remarkable improvement in the clinical symptoms in the immediate postoperative period and during the follow-up period of 12-24 months (average, 16 months). All patients have continued to have progressive clinical recovery. Clinical assessments were done using Goel clinical evaluation scale, Japanese Orthopedic Association score, and visual analog scale.
   CONCLUSIONS: Identification and treatment of CAAD can have a significant management impact on patients where the cause of spastic quadriparesis is otherwise undiagnosed.
C1 [Goel, Atul; Shah, Abhidha; Jadhav, Dikpal; Bakale, Nilesh; Vaja, Tejas; Jadhav, Neha] King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.
   [Goel, Atul; Shah, Abhidha; Jadhav, Dikpal; Bakale, Nilesh; Vaja, Tejas; Jadhav, Neha] Seth GS Med Coll, Bombay, Maharashtra, India.
   [Goel, Atul; Dhar, Arjun] Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
RP Goel, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.; Goel, A (reprint author), Seth GS Med Coll, Bombay, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
EM atulgoel62@hotmail.com
OI Dhar, Arjun/0000-0003-2044-8796
CR Fujiwara A, 2003, SPINE, V28, P1601, DOI 10.1097/00007632-200307150-00023
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   GOEL A, 1995, BRIT J NEUROSURG, V9, P67, DOI 10.1080/02688699550041773
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A., 2018, PRINCIPLES NEUROLOGI, P532
   Goel A, 2018, WORLD NEUROSURG, V110, P533, DOI 10.1016/j.wneu.2017.07.007
   Goel A, 2017, WORLD NEUROSURG, V101, P702, DOI 10.1016/j.wneu.2017.02.063
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   Goel A, 2017, WORLD NEUROSURG, V99, P164, DOI 10.1016/j.wneu.2016.11.093
   Goel A, 2016, WORLD NEUROSURG, V95, P375, DOI 10.1016/j.wneu.2016.08.026
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P69, DOI 10.4103/0974-8237.181823
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P20, DOI 10.4103/0974-8237.176613
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P1, DOI 10.4103/0974-8237.176602
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P141, DOI 10.4103/0974-8237.167850
   Goel A, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.017
   Goel A, 2015, NEUROSURGERY, V77, P296, DOI 10.1227/NEU.0000000000000761
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P51, DOI 10.4103/0974-8237.156039
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P47, DOI 10.4103/0974-8237.156031
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P15, DOI 10.4103/0974-8237.135210
   Goel A, 2013, J NEUROSURG-SPINE, V19, P672, DOI 10.3171/2011.8.SPINE11249
   Goel A, 2012, J CRANIOVERTEBRAL JU, V3, P1, DOI 10.4103/0974-8237.110115
   Goel A, 2011, J NEUROSURG-SPINE, V14, P689, DOI 10.3171/2011.2.SPINE10601
   Goel A, 2011, J NEUROSURG-SPINE, V14, P3, DOI 10.3171/2010.9.SPINE1010
   Goel A, 2010, ACTA NEUROCHIR, V152, P709, DOI 10.1007/s00701-009-0467-2
   Goel A, 2009, J NEUROSURG-SPINE, V11, P9, DOI 10.3171/2009.3.SPINE08927
   Goel A, 2009, J NEUROSURG-SPINE, V10, P220, DOI 10.3171/2008.12.SPINE08499
   Goet A, 2011, J CRANIOVERTEBRAL JU, V2, P55, DOI 10.4103/0974-8237.100049
   HUSKISSON EC, 1982, J RHEUMATOL, V9, P768
   Occiput Goel A., 2017, YOUMANS WINN NEUROLO, P2643
   Shah A, 2017, J CRANIOVERTEBRAL JU, V8, P15, DOI 10.4103/0974-8237.199878
NR 33
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E908
EP E916
DI 10.1016/j.wneu.2018.10.009
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000112
PM 30315979
DA 2020-05-12
ER

PT J
AU Goel, A
   Prasad, A
   Shah, A
   Gore, S
   Dharurkar, P
AF Goel, Atul
   Prasad, Apurva
   Shah, Abhidha
   Gore, Sandeep
   Dharurkar, Pralhad
TI Voice Quality Affection as a Symptom of Chiari Formation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apnea; Atlantoaxial instability; Atlantoaxial stabilization; Breathing;
   Chiari formation; Speech; Syringomyelia
ID ATLANTOAXIAL FIXATION; I MALFORMATION; SURGERY; APNEA; PLATE
AB OBJECTIVE: Voice alteration as a presenting symptom in cases with Chiari formation is analyzed, as well as outcome after atlantoaxial fixation.
   METHODS: During the period January 2016 to June 2017, 25 cases of Chiari formation presented with associated or a major presenting symptom of voice or speech quality alteration related to inadequate breathing efforts. All patients underwent atlantoaxial fixation. No foramen magnum decompression was done.
   RESULTS: In all patients, the voice quality and volume and breathing disturbances improved in the immediate postoperative period after recovering from anesthesia. During the period of follow-up that ranged from 12 to 25 months, all patients continued to improve in their speech function.
   CONCLUSIONS: Such critical symptoms of voice disturbance and inadequate breathing and the possibility of rapid postoperative recovery have not been recorded earlier in the literature.
C1 [Goel, Atul; Shah, Abhidha; Gore, Sandeep; Dharurkar, Pralhad] King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.
   [Goel, Atul; Shah, Abhidha; Gore, Sandeep; Dharurkar, Pralhad] Seth GS Med Coll, Bombay, Maharashtra, India.
   [Goel, Atul; Prasad, Apurva] Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
RP Goel, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.; Goel, A (reprint author), Seth GS Med Coll, Bombay, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Dept Neurosurg, Bombay, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Aarts LAM, 2011, EUR J PEDIATR, V170, P1349, DOI 10.1007/s00431-011-1500-z
   Becker HF, 2005, NEUROSURG REV, V28, P177, DOI 10.1007/s10143-005-0401-x
   Botelho RV, 2010, J NEUROSURG, V112, P800, DOI 10.3171/2009.7.JNS09174
   Botelho RV, 2000, NEUROSURG REV, V23, P151, DOI 10.1007/PL00011947
   Botelho RV, 2005, NEUROSURG REV, V28, P169, DOI 10.1007/s10143-005-0400-y
   Ferre A, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx069
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A, 2018, WORLD NEUROSURG, V111, pE668, DOI 10.1016/j.wneu.2017.12.137
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P1, DOI 10.4103/0974-8237.199881
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P49, DOI 10.4103/0974-8237.156037
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P107, DOI 10.4103/0974-8237.142302
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P15, DOI 10.4103/0974-8237.135210
   Ludlow CL, 2005, RESP PHYSIOL NEUROBI, V147, P205, DOI 10.1016/j.resp.2005.04.015
   Miyamoto M, 1998, PSYCHIAT CLIN NEUROS, V52, P212, DOI 10.1111/j.1440-1819.1998.tb01037.x
   Murray C, 2006, ARCH DIS CHILD, V91, P342, DOI 10.1136/adc.2005.085324
NR 17
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E296
EP E301
DI 10.1016/j.wneu.2018.09.099
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000038
PM 30253991
DA 2020-05-12
ER

PT J
AU Gopinath, M
   Malik, V
   Sarma, PS
   Rajan, JE
   Kannath, SK
AF Gopinath, Manoj
   Malik, Virender
   Sarma, P. Sankara
   Rajan, Jayadevan Enakshy
   Kannath, Santhosh Kumar
TI Results of Endovascular-First Approach for Treatment of Scalp
   Arteriovenous Malformations and the Effect of Simplified Angiographic
   Classification in Therapeutic Decision-Making and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular embolization; Liquid EVOH; n-BCA; Scalp arteriovenous
   malformation
ID VASCULAR MALFORMATIONS; EMBOLIZATION; NECK; HEAD
AB BACKGROUND: Scalp arteriovenous malformation (SAVM) is primarily treated by surgery and reports on endovascular treatment are scarce. We report the results of an endovascular-first approach in the treatment of SAVM. We also have proposed a simple dichotomized classification using the angiographically determined morphology findings and discussed its effect on therapeutic decisionmaking and outcomes.
   METHODS: A consecutive series of 25 patients with SAVM treated by initial or endovascular-only methods were included in the final analysis. The SAVM was categorized as a plexiform or fistulous type according to the angiographic morphology. The demographic data, treatment variables, and final clinical outcomes were analyzed and correlated with the proposed classification.
   RESULTS: Of the 25 patients, 21 were treated with n-butyl cyanoacrylate (n-BCA) and 3 with liquid ethylene vinyl alcohol. One patient had been treated initially with polyvinyl alcohol particles and later with n-BCA. Overall, complete or near complete obliteration (> 90%) was achieved in 72%. Surgical excision was performed in 76%, most often after n-BCA embolization. Fistulous-type SAVMs required greater n-BCA concentrations (median, 33% vs. 20%; P = 0.024) and achieved greater rates of complete or near-complete obliteration (90% vs. 63%). Two patients with fistulous-type SAVMs treated with liquid ethylene vinyl alcohol showed complete resolution, and further treatment was not necessary. Overall, regardless of the embolic material used, the fistulous type demonstrated a significantly greater rate of complete obliteration (75% vs. 33%; P = 0.041) compared with plexiform type.
   CONCLUSION: High rates of complete and durable obliteration of SAVM are achievable with endovascular embolization. The proposed simplified classification is easy to implement and can aid in choosing the appropriate embolic agent and predicting the therapeutic outcome.
C1 [Gopinath, Manoj; Malik, Virender; Rajan, Jayadevan Enakshy] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Imaging Sci & Intervent Radiol, Trivandrum, Kerala, India.
   [Sarma, P. Sankara; Kannath, Santhosh Kumar] Sree Chitra Tirunal Inst Med Sci & Technol, Achuta Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India.
RP Kannath, SK (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Achuta Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India.
EM drsanthoshkannath@gmail.com
CR Arat A, 2007, AM J NEURORADIOL, V28, P1409, DOI 10.3174/ajnr.A0547
   Dabus G, 2014, J NEUROINTERV SURG, V6, P405, DOI 10.1136/neurintsurg-2013-010724
   Dalyai RTZ, 2011, ACTA NEUROCHIR, V153, P1285, DOI 10.1007/s00701-011-0998-1
   Dmytriw AA, 2014, NEURORADIOLOGY, V56, P227, DOI 10.1007/s00234-014-1328-0
   Duncan IC, 2003, AM J NEURORADIOL, V24, P1453
   Gupta AK, 2008, NEUROL INDIA, V56, P167, DOI 10.4103/0028-3886.41995
   Kohout MP, 1998, PLAST RECONSTR SURG, V102, P643, DOI 10.1097/00006534-199809030-00006
   Kumar R, 2012, BRIT J NEUROSURG, V26, P371, DOI 10.3109/02688697.2012.654838
   Liu AS, 2010, PLAST RECONSTR SURG, V125, P1185, DOI 10.1097/PRS.0b013e3181d18070
   Matsushige T, 2004, SURG NEUROL, V62, P253, DOI 10.1016/j.surneu.2003.09.033
   Nishijima I, 2012, J VASC SURG, V55, P833, DOI 10.1016/j.jvs.2011.08.013
   RAPPAPORT I, 1973, ARCH OTOLARYNGOL, V97, P350
   Ryu CW, 2007, AM J NEURORADIOL, V28, P528
   Shenoy SN, 2004, NEUROL INDIA, V52, P478
   Wei N, 2017, WORLD NEUROSURG, V107, P692
   Yokouchi T, 1999, INTERVENTIONAL NEU S, V5, P115
NR 16
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E277
EP E286
DI 10.1016/j.wneu.2018.09.092
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000036
PM 30261380
DA 2020-05-12
ER

PT J
AU Guo, H
   Liu, R
   Sun, ZS
   Liu, B
   Xiang, Y
   Mao, JH
   Li, GJ
   Zhang, MZ
AF Guo, Hong
   Liu, Raynald
   Sun, Zhaosheng
   Liu, Bing
   Xiang, Yi
   Mao, Jianhui
   Li, Guangjie
   Zhang, Mingzhe
TI Evaluation of Prognosis in Patients with Severe Traumatic Brain Injury
   Using Resting-State Functional Magnetic Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Default mode network; Prognosis; Resting-state fMRI; Severe traumatic
   brain injury
ID DEFAULT-MODE NETWORK; CONNECTIVITY; MRI
AB BACKGROUND: We investigate the change of the default mode network (DMN) by using amplitude of low-frequency fluctuation (ALFF) and functional connectivity (FC) methods in acute phase patients after severe traumatic brain injury (sTBI) and correlate these changes with prognosis.
   METHODS: Twenty-one patients with sTBI were included. Twenty-one healthy sex-, age-, and education-matched control subjects were recruited for the control group. Of the 21 patients with sTBI, 12 patients regained consciousness (Glasgow Outcome Scale [GOS] score > 2) and 9 patients remained unconscious (GOS score < 2). FC and ALFF values were measured in the DMN and compared between the groups. We further assessed and compared the FC and ALFF values in both groups.
   RESULTS: Patients with sTBI showed significantly decreased FC and ALFF values in the DMN. However, patients with a better prognosis showed a significant increase in FC and ALFF values in the DMN. The conscious subgroup showed significantly enhanced FC in the medial superior frontal gyrus, left temporal gyrus, anterior cingulate gyrus, precuneus, posterior cingulate gyrus, and parietal cortex compared with the coma subgroup. Increased ALFF values in the right frontal gyrus, right temporal gyrus, and right inferior parietal gyrus were significant in the conscious subgroup compared with the coma subgroup.
   CONCLUSIONS: Increases in FC and ALFF values in the DMN are related to better prognosis in patients with sTBI.
C1 [Guo, Hong; Sun, Zhaosheng; Liu, Bing; Xiang, Yi; Mao, Jianhui; Li, Guangjie; Zhang, Mingzhe] Hebei Med Univ, Harrison Int Peace Hosp, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
   [Liu, Raynald] Capital Med Univ, Beiijing Neurosurg Inst, Beijing, Peoples R China.
RP Zhang, MZ (reprint author), Hebei Med Univ, Harrison Int Peace Hosp, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
EM 66364321@qq.com
FU Key Science and Technology Research Program of Hebei Provincial Health
   Department [ZD2014043]
FX This research was supported by the Key Science and Technology Research
   Program of Hebei Provincial Health Department (ZD2014043).
CR Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011
   Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048
   Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349
   Faul M, 2010, INJ PREV S1, V16, pA1
   Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100
   Huang ZR, 2014, HUM BRAIN MAPP, V35, P1997, DOI 10.1002/hbm.22308
   Koenig MA, 2014, NEUROCRIT CARE, V20, P348, DOI 10.1007/s12028-014-9953-3
   Kondziella D, 2017, NEUROCRIT CARE, V27, P401, DOI 10.1007/s12028-017-0407-6
   Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61
   Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25
   Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676
   Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175
   Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748
NR 13
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E630
EP E639
DI 10.1016/j.wneu.2018.09.178
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000077
PM 30292041
DA 2020-05-12
ER

PT J
AU Guo, HZ
   Tang, YC
   Li, YX
   Yuan, K
   Guo, DQ
   Mo, GY
   Luo, PJ
   Zhou, TP
   Zhang, SC
   Liang, D
AF Guo, Hui-Zhi
   Tang, Yong-Chao
   Li, Yong-Xian
   Yuan, Kai
   Guo, Dan-Qing
   Mo, Guo-Ye
   Luo, Pei-Jie
   Zhou, Ten-Peng
   Zhang, Shun-Cong
   Liang, De
TI The Effect and Safety of Polymethylmethacrylate-Augmented Sacral Pedicle
   Screws Applied in Osteoporotic Spine with Lumbosacral Degenerative
   Disease: A 2-Year Follow-up of 25 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cement augmentation; Lumbosacral degenerative disease; Osteoporosis;
   Sacral screw
ID SPINOPELVIC PARAMETERS; FIXATION; ALIGNMENT; FUSION; S1
AB BACKGROUND: A high rate of instrumentation failure is frequently seen in osteoporotic spines, especially at the sacral segment because of the great shear stress. Several techniques of sacral pedicle screw placement, such as bicortical and tricortical fixation, have been developed; however, the problems of loosening and pulling out of the screws are still a concern. Recently, the polymethylmethacrylate (PMMA)-augmented pedicle screws have been shown to strengthen the purchase in osteoporotic spine, but there are few reports on the effect of S1 pedicle screw with PMMA augmentation.
   METHODS: Seventy-five patients receiving cement-augmented pedicle screws at lumbosacral vertebra were enrolled and divided into 3 groups by different patterns of S1 pedicle screw placement: S1 pedicle screw with PMMA augmentation (group A, 25 patients), S1 bicortical pedicle screw fixation (group B, 25 patients), and S1 tricortical pedicle screw fixation (group C, 25 patients). The Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) scores were assessed preoperatively and at the last follow-up. Besides, the complications, loosening rate, and fusion rate were recorded.
   RESULTS: The VAS and ODI scores at the last follow-up were significantly improved in the 3 groups compared with preoperative results. Better pain relief and functional improvement at the last follow-up was seen in group A compared with the other 2 groups; however, no significant difference was detected between groups B and C. Although the lowest screws loosening rates and the highest fusion rate were found in group A, no significant difference among these 3 groups. Furthermore, longer fusion segments and larger postoperative pelvic incidence-lumbar lordosis (PL-LL) were found as risks related to S1 screw loosening without cement augmentation.
   CONCLUSIONS: The S1 pedicle screws with PMMA augmentation achieved better stability with less screw loosening in the osteoporotic spine with lumbosacral degenerative diseases compared with bicortical/tricortical fixation at S1. This procedure is especially recommended for patients with long segment fixation and large postoperative PI-LL, but there is also a risk of bone cement leakage and a learning curve.
C1 [Guo, Hui-Zhi; Li, Yong-Xian; Mo, Guo-Ye; Luo, Pei-Jie; Zhou, Ten-Peng; Zhang, Shun-Cong] Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou, Guangdong, Peoples R China.
   [Guo, Hui-Zhi; Tang, Yong-Chao; Li, Yong-Xian; Yuan, Kai; Guo, Dan-Qing; Mo, Guo-Ye; Luo, Pei-Jie; Zhou, Ten-Peng; Zhang, Shun-Cong; Liang, De] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Zhang, SC (reprint author), Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou, Guangdong, Peoples R China.; Zhang, SC (reprint author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM 18122436960@163.com
OI GUO, HuiZhi/0000-0003-3952-0030
CR Baek SW, 2013, INT ORTHOP, V37, P1973, DOI 10.1007/s00264-013-2000-8
   Bostelmann Richard, 2015, Eur Spine J, V24, P2098, DOI 10.1007/s00586-015-4001-3
   Chen YL, 2014, MED ENG PHYS, V36, P1416, DOI 10.1016/j.medengphy.2014.05.003
   Dakhil-Jerew F, 2009, EUR SPINE J, V18, P1486, DOI 10.1007/s00586-009-1071-0
   Dubory A, 2015, EUR SPINE J, V24, P2580, DOI 10.1007/s00586-015-4155-z
   DUVALBEAUPERE G, 1992, ANN BIOMED ENG, V20, P451, DOI 10.1007/BF02368136
   El Saman A, 2013, EUR J TRAUMA EMERG S, V39, P455, DOI 10.1007/s00068-013-0310-6
   Funao H, 2012, EUR SPINE J, V21, P2181, DOI 10.1007/s00586-012-2374-0
   Galbusera F, 2015, EUR SPINE J, V24, P1005, DOI 10.1007/s00586-015-3768-6
   Kim JB, 2015, J KOREAN NEUROSURG S, V58, P357, DOI 10.3340/jkns.2015.58.4.357
   Lee NJ, 2018, SPINE, V43, P316, DOI 10.1097/BRS.0000000000001477
   McLachlin SD, 2011, SPINE, V36, pE699, DOI 10.1097/BRS.0b013e3181fb73ea
   Mehta VA, 2012, NEUROSURGERY, V70, P707, DOI 10.1227/NEU.0b013e31823262ea
   Moon BJ, 2009, J KOREAN NEUROSURG S, V46, P305, DOI 10.3340/jkns.2009.46.4.305
   Ngu BB, 2006, SPINE, V31, pE166, DOI 10.1097/01.brs.0000202747.90508.0d
   Rihn JA, 2015, J BONE JOINT SURG AM, V97A, P177, DOI 10.2106/JBJS.N.00313
   Tu CW, 2014, J SURG RES, V192, P112, DOI 10.1016/j.jss.2014.05.034
   Wahnert D, 2013, INT ORTHOP, V37, P1147, DOI 10.1007/s00264-013-1875-8
   Wu ZX, 2012, ARCH ORTHOP TRAUM SU, V132, P471, DOI 10.1007/s00402-011-1439-6
   Yilmaz C, 2006, J SPINAL DISORD TECH, V19, P373, DOI 10.1097/01.bsd.0000210115.94273.76
   Yoshihara Hiroyuki, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS73, DOI 10.1007/s00590-013-1282-2
   Zhuang XM, 2010, SPINE, V35, pE925, DOI 10.1097/BRS.0b013e3181c5fb21
NR 22
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E404
EP E410
DI 10.1016/j.wneu.2018.09.121
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000050
PM 30266711
DA 2020-05-12
ER

PT J
AU Guppy, KH
   Lee, DJ
   Harris, J
   Brara, HS
AF Guppy, Kern H.
   Lee, Darin J.
   Harris, Jessica
   Brara, Harsimran S.
TI Reoperation for Symptomatic Nonunions in Atlantoaxial (C1-C2) Fusions
   with and without Bone Morphogenetic Protein: A Cohort of 108 Patients
   with > 2 Years Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Allograft; Autograft; Bone morphogenetic protein (BMP); C1-C2; Iliac
   crest graft; Nonunion; Polyaxial screws
ID TRANSARTICULAR SCREW FIXATION; POSTERIOR CERVICAL FUSION; INTERLAMINAR
   CLAMP; SPINAL STENOSIS; ROD CONSTRUCTS; ANTERIOR; ARTHRODESIS;
   ALLOGRAFT; PEDICLE; RATES
AB OBJECTIVE: To determine if there is a difference in reoperation rates for symptomatic nonunions in atlantoaxial (C1-C2) fusions with or without bone morphogenetic protein (BMP) using data from a national spine registry and to analyze the different types of bone grafts used in the non-BMP group.
   METHODS: Data from the Kaiser Permanente spine registry were used to identify patients with C1-C2 fusions with > 2 years follow-up. Patient characteristics, diagnosis, operative times, length of stay, and reoperations were extracted from the registry. The data set was divided into patients with and without BMP. Further analysis was made of the different types of non-BMP grafts as well as the instrumentation used.
   RESULTS: In our cohort, we found 58 patients (53.7%) with BMP and 50 patients (46.3%) without with an average follow-up time of 5 years (interquartile range, 2.04-8.49). The BMP versus non-BMP groups differed in admitting diagnosis, operative times, length of stay, and follow-up times. There were no reoperations for symptomatic nonunions in both groups. The non-BMP group included iliac crest graft (with or without allograft [D/L] allograft); lamina (D/L allograft); and allograft alone.
   CONCLUSIONS: Using one of the largest retrospective studies on C1-C2 fusions with and without BMP, we found no difference in reoperation rates for symptomatic nonunions. For the non-BMP group, we found that lamina (D/L allograft) or allograft alone may also be just as effective as iliac crest graft (D/L allograft) in having no reoperations for symptomatic nonunions.
C1 [Guppy, Kern H.] Kaiser Permanente Med Grp, Dept Neurosurg, Sacramento, CA 95825 USA.
   [Lee, Darin J.] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA.
   [Harris, Jessica] Kaiser Permanente, Surg Outcomes & Anal Unit Clin Anal, San Diego, CA USA.
   [Brara, Harsimran S.] Kaiser Permanente Southern Calif, Dept Neurosurg, Los Angeles, CA USA.
RP Guppy, KH (reprint author), Kaiser Permanente Med Grp, Dept Neurosurg, Sacramento, CA 95825 USA.
EM kguppy@yahoo.com
CR Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623-200205000-00003
   ALDRICH EF, 1993, J NEUROSURG, V78, P702, DOI 10.3171/jns.1993.78.5.0702
   AN HS, 1995, J SPINAL DISORD, V8, P131
   Aryan HE, 2008, J NEUROSURG-SPINE, V8, P222, DOI 10.3171/SPI/2008/8/3/222
   Benzel EC, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.12.079
   Bishop RC, 1996, J NEUROSURG, V85, P206, DOI 10.3171/jns.1996.85.2.0206
   Boden SD, 2000, SPINE, V25, P376, DOI 10.1097/00007632-200002010-00020
   BROOKS AL, 1978, J BONE JOINT SURG AM, V60, P279, DOI 10.2106/00004623-197860030-00001
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720-200210000-00001
   Cahill KS, 2011, SPINE, V36, P2354, DOI 10.1097/BRS.0b013e31820bc9e5
   Chen JF, 2005, J NEUROSURG-SPINE, V2, P386, DOI 10.3171/spi.2005.2.3.0386
   Dawson E, 2009, J BONE JOINT SURG AM, V91A, P1604, DOI 10.2106/JBJS.G.01157
   Derman PB, 2016, SPINE, V41, P1586, DOI 10.1097/BRS.0000000000001603
   DICKMAN CA, 1991, J NEUROSURG, V74, P190, DOI 10.3171/jns.1991.74.2.0190
   Dorward IG, 2016, CLIN SPINE SURG, V29, pE276, DOI 10.1097/BSD.0b013e318286fa7e
   Du JY, 2015, J NEUROSURG-SPINE, V22, P151, DOI 10.3171/2014.10.SPINE13805
   Elliott RE, 2014, J SPINAL DISORD TECH, V27, P11, DOI 10.1097/BSD.0b013e318277da19
   Elliott RE, 2013, WORLD NEUROSURG, V80, P627, DOI 10.1016/j.wneu.2012.03.012
   Elliott RE, 2012, WORLD NEUROSURG, V78, P326, DOI 10.1016/j.wneu.2011.12.083
   Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003
   Gallie WE, 1939, AM J SURG, V46, P495, DOI DOI 10.1016/S0002-9610(39)90309-0
   Gluf WM, 2005, J NEUROSURG-SPINE, V2, P155, DOI 10.3171/spi.2005.2.2.0155
   Guppy KH, 2016, J NEUROSURG-SPINE, V25, P309, DOI 10.3171/2016.1.SPINE151330
   Guppy KH, 2016, J NEUROSURG-SPINE, V24, P556, DOI 10.3171/2015.7.SPINE15353
   Guppy KH, 2015, SPINE, V40, P1632, DOI 10.1097/BRS.0000000000001085
   Guppy KH, 2014, SPINE, V39, P1831, DOI 10.1097/BRS.0000000000000534
   Haid RW, 2001, NEUROSURGERY, V49, P65, DOI 10.1097/00006123-200107000-00010
   Hamilton DK, 2011, NEUROSURGERY, V69, P103, DOI 10.1227/NEU.0b013e318214a9b1
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hillard VH, 2009, J NEUROSURG-SPINE, V11, P396, DOI 10.3171/2009.5.SPINE08662
   Hodges SD, 2012, ORTHOPEDICS, V35, pE895, DOI 10.3928/01477447-20120525-30
   Holly LT, 2010, NEUROSURGERY, V66, pA193, DOI 10.1227/01.NEU.0000366107.69895.74
   HOLNESS RO, 1984, NEUROSURGERY, V14, P318, DOI 10.1227/00006123-198403000-00010
   Hood B, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.01.083
   JEANNERET B, 1992, J SPINAL DISORD, V5, P464, DOI 10.1097/00002517-199212000-00012
   Kang MM, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.07.010
   Katz JN, 1997, SPINE, V22, P1123, DOI 10.1097/00007632-199705150-00012
   Lehman RA, 2008, SPINE, V33, P960, DOI 10.1097/BRS.0b013e31816c915b
   Lu DC, 2007, J NEUROSURG, V106, P480, DOI 10.3171/ped.2007.106.6.480
   Mummaneni PV, 2005, NEUROL INDIA, V53, P408, DOI 10.4103/0028-3886.22606
   Oluigbo CO, 2008, PEDIATR NEUROSURG, V44, P393, DOI 10.1159/000149907
   Parker SL, 2009, NEUROSURGERY, V64, P343, DOI 10.1227/01.NEU.0000338955.36649.4F
   Paxton Elizabeth W, 2012, Perm J, V16, P36
   PENNING L, 1987, SPINE, V12, P732, DOI 10.1097/00007632-198710000-00003
   Simsek S, 2009, SURG NEUROL, V72, P676, DOI 10.1016/j.surneu.2009.06.015
   Singh K, 2012, SPINE J, V12, P372, DOI 10.1016/j.spinee.2012.02.005
   Stein BE, 2014, SPINE, V39, P1178, DOI 10.1097/BRS.0000000000000376
   Stulik J, 2007, EUR SPINE J, V16, P479, DOI 10.1007/s00586-006-0241-6
   Thomas JA, 2010, J NEUROSURG-SPINE, V12, P337, DOI 10.3171/2009.10.SPINE08541
   Vaccaro Alexander R, 2002, Spine J, V2, P206, DOI 10.1016/S1529-9430(02)00180-8
   WHITE AA, 1990, CLIN BIOMECHANICS SP
   Wright NM, 2004, J SPINAL DISORD TECH, V17, P158, DOI 10.1097/00024720-200404000-00014
   Yanni DS, 2016, NEUROSURGERY, V66, P147
NR 53
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E458
EP E466
DI 10.1016/j.wneu.2018.09.138
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000057
PM 30267948
DA 2020-05-12
ER

PT J
AU Gupta, S
   Ahmed, AK
   Bi, WL
   Dawood, HY
   Iorgulescu, JB
   Corrales, CE
   Dunn, IF
   Smith, TR
AF Gupta, Saksham
   Ahmed, Abdul-Kareem
   Bi, Wenya Linda
   Dawood, Hassan Y.
   Iorgulescu, J. Bryan
   Corrales, C. Eduardo
   Dunn, Ian F.
   Smith, Timothy R.
TI Predicting Readmission and Reoperation for Benign Cranial Nerve
   Neoplasms: A Nationwide Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE NSQIP; Postoperative complications; Readmission; Reoperation; Vestibular
   schwannoma
ID VESTIBULAR SCHWANNOMA SURGERY; PREOPERATIVE STEROID USE; RISK-FACTORS;
   VENOUS THROMBOEMBOLISM; ACOUSTIC NEUROMAS; MORBIDITY; COMPLICATIONS;
   OUTCOMES; QUALITY; NSQIP
AB OBJECTIVE: Readmission and reoperation are risks in the resection of benign cranial nerve tumors (BCNTs). This report analyzes the impact of patient-level and surgical factors on these adverse outcomes.
   METHODS: This retrospective cohort review comprised patients with a diagnosis of BCNT enrolled in the American College of Surgeons National Surgical Quality Improvement Program registry from 2011 to 2015. Multivariate logistic regression was used to determine the impact of select medical and operative factors on the primary outcomes of readmission and reoperation within 30 days, adjusted for relevant covariates.
   RESULTS: We identified 996 patients who underwent resection of a BCNT. The most frequent major complications were readmission (11%), reoperation (8%), surgical site infections (2.6%), and venous thromboembolism (1.5%). The most frequent indications for readmission were management of infection (2.5%), cerebrospinal fluid leak (2.3%), and hydrocephalus (0.5%). Repair of cranial and meningeal defects (3.0%), correction of lagophthalmos (1.2%), and repair of middle ear defects (1.0%) were the most common indications for reoperation. Logistic regression revealed that extremes of age were associated with readmission, whereas preoperative steroid usage, long operative time, and postoperative length of stay > 3 days were associated with reoperation (P < 0.05). Obesity trended toward an association with readmission and reoperation.
   CONCLUSIONS: Extremes of age were associated with readmission; preoperative steroid use, long operative time, and postoperative length of stay > 3 days were associated with reoperation. Surgeons should consider these factors when assessing risk of postoperative complications for BCNTs.
C1 [Gupta, Saksham; Dawood, Hassan Y.; Iorgulescu, J. Bryan; Smith, Timothy R.] Harvard Med Sch, Brigham & Womens Hosp, Computat Neurosci Outcomes Ctr, Boston, MA USA.
   [Bi, Wenya Linda; Dunn, Ian F.; Smith, Timothy R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Ctr Skull Base & Pituitary Surg, Boston, MA USA.
   [Iorgulescu, J. Bryan] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA.
   [Corrales, C. Eduardo] Harvard Med Sch, Brigham & Womens Hosp, Dept Otolaryngol, Boston, MA USA.
   [Ahmed, Abdul-Kareem] Univ Maryland, Med Coll, Dept Neurosurg, Baltimore, MD 21201 USA.
RP Smith, TR (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Computat Neurosci Outcomes Ctr, Boston, MA USA.; Smith, TR (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Ctr Skull Base & Pituitary Surg, Boston, MA USA.
EM trsmith@partners.org
OI Iorgulescu, J. Bryan/0000-0003-1405-3667
CR Abt NB, 2014, J CLIN NEUROSCI, V21, P1895, DOI 10.1016/j.jocn.2014.05.010
   Aghi MK, 2007, NEUROSURGERY, V61, P754, DOI 10.1227/01.NEU.0000298903.63635.E3
   Alan N, 2014, J NEUROSURG, V120, P764, DOI 10.3171/2013.10.JNS131028
   Ansari SF, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12163
   Bekelis K, 2017, NEUROSURGERY, V80, P787, DOI 10.1093/neuros/nyw129
   Bekelis K, 2014, SPINE J, V14, P1247, DOI 10.1016/j.spinee.2013.08.009
   Bekelis K, 2013, J NEURO-ONCOL, V113, P57, DOI 10.1007/s11060-013-1089-3
   Bekelis K, 2013, STROKE, V44, P1085, DOI 10.1161/STROKEAHA.111.674358
   Bi WL, J NEUROL SURG B
   Buerba RA, 2014, SPINE J, V14, P1643, DOI 10.1016/j.spinee.2013.09.054
   Bydon M, 2015, J NEUROSURG, V122, P955, DOI 10.3171/2014.11.JNS14890
   Bydon Mohamad, 2014, Surg Neurol Int, V5, P156, DOI 10.4103/2152-7806.143754
   Cole T, 2015, CUREUS, V7, DOI 10.7759/cureus.369
   Copeland WR, 2015, J NEUROSURG, V122, P312, DOI 10.3171/2014.10.JNS14432
   Cote DJ, 2016, ACTA NEUROCHIR, V158, P1639, DOI 10.1007/s00701-016-2871-8
   Fitz-Henry J, 2011, ANN ROY COLL SURG, V93, P185, DOI 10.1308/rcsann.2011.93.3.185a
   Forouzanfar MH, 2015, LANCET, V386, P2287, DOI 10.1016/S0140-6736(15)00128-2
   Harun A, 2012, OTOL NEUROTOL, V33, P1604, DOI 10.1097/MAO.0b013e31826dba9e
   Hein PN, 2015, J CLIN NEUROSCI, V22, P998, DOI 10.1016/j.jocn.2015.01.005
   Ismael H, 2011, AM J SURG, V201, P305, DOI 10.1016/j.amjsurg.2010.09.018
   Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563
   Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122
   Karhade AV, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16168
   Khuri SF, 2005, SURGERY, V138, P837, DOI 10.1016/j.surg.2005.08.016
   Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632
   Kimmell KT, 2014, J NEURO-ONCOL, V120, P567, DOI 10.1007/s11060-014-1587-y
   Konovalov AN, 1996, ACTA NEUROCHIR, V138, P1027, DOI 10.1007/BF01412304
   Li H, 2015, ACTA NEUROCHIR, V157, P1983, DOI 10.1007/s00701-015-2542-1
   McCutcheon BA, 2015, SPINE, V40, P1122, DOI 10.1097/BRS.0000000000000599
   Merkler AE, 2014, NEUROHOSPITALIST, V4, P80, DOI 10.1177/1941874413510920
   Murphy M, 2016, J NEUROL SURG PART B, V77, P350, DOI 10.1055/s-0036-1572508
   Murphy ME, 2016, CLIN NEUROL NEUROSUR, V148, P105, DOI 10.1016/j.clineuro.2016.06.020
   Propp JM, 2006, NEURO-ONCOLOGY, V8, P1, DOI 10.1215/S1522851704001097
   Roehm PC, 2007, OTOL NEUROTOL, V28, P708, DOI 10.1097/01.mao.0000281805.44197.ec
   Rolston JD, 2014, J NEUROSURG, V121, P908, DOI 10.3171/2014.6.JNS131419
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Samii M, 1997, NEUROSURGERY, V40, P11, DOI 10.1097/00006123-199701000-00002
   Samii M, 1997, NEUROSURGERY, V40, P29
   Sarma S, 2002, NEUROSURGERY, V50, P437, DOI 10.1097/00006123-200203000-00002
   Seicean A, 2013, CANCER-AM CANCER SOC, V119, P1058, DOI 10.1002/cncr.27851
   Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604
   Skolnik AD, 2016, RADIOGRAPHICS, V36, P1463, DOI 10.1148/rg.2016150199
   Sughrue ME, 2011, J NEUROSURG, V114, P367, DOI 10.3171/2009.10.JNS091203
   Sylvester MJ, 2017, OTOLARYNG HEAD NECK, V156, P166, DOI 10.1177/0194599816677522
   Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118
   Yashar P, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12206
NR 46
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E215
EP E221
DI 10.1016/j.wneu.2018.09.081
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000030
PM 30261394
DA 2020-05-12
ER

PT J
AU Hafez, A
   Huhtakangas, J
   Muhammad, S
   Lawton, MT
   Tanikawa, R
   Niemela, M
AF Hafez, Ahmad
   Huhtakangas, Justiina
   Muhammad, Sajjad
   Lawton, Michael T.
   Tanikawa, Rokuya
   Niemela, Mika
TI The Identification of Factors That Influence the Quality of Bypass
   Anastomosis and an Evaluation of the Usefulness of an Experimental
   Practical Scale in This Regard
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anastomosis; Bypass; Practical scale
ID MICROVASCULAR ANASTOMOSIS; SUTURE
AB BACKGROUND: Several factors associated with interrupted and continuous suturing techniques affect the quality of bypass anastomosis. It is difficult to determine the impact of these factors during surgery. The primary objective of this study was to evaluate factors with the potential to influence the quality of bypass anastomosis using either interrupted or continuous suturing. A secondary objective was to evaluate the usefulness of a practical scale when comparing interrupted and continuous suturing techniques to improve bypass anastomosis.
   METHODS: Interrupted (n = 100) and continuous (n = 100) suturing techniques were used in 200 end-to-side bypasses to a depth of 3 cm and were assessed by 5 neurosurgeons.
   RESULTS: Vessel closing time (P < 0.001), stitch distribution (P < 0.001), intima-intima attachment (P < 0.001), and size of the orifice (P < 0.001) had a significant impact on the quality of the bypass regardless of the suturing technique used. The suturing technique used (interrupted or continuous) and positioning of the recipient vessel (vertical or horizontal) did not significantly influence the quality of anastomosis. Using multivariate analysis, the highest statistical significance with regard to bypass quality was attributed to the large size of the orifice and intimal attachment.
   CONCLUSIONS: There were advantages and disadvantages to both suturing techniques. The scale was a practical way to measure and improve performance.
C1 [Hafez, Ahmad; Huhtakangas, Justiina; Muhammad, Sajjad; Niemela, Mika] Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
   [Hafez, Ahmad; Huhtakangas, Justiina; Muhammad, Sajjad; Niemela, Mika] Helsinki Univ Hosp, Helsinki, Finland.
   [Lawton, Michael T.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Tanikawa, Rokuya] Sapporo Teishinkai Hosp, Brain Dis Inst, Sapporo Stroke Ctr Hiroyasu Kamiyama, Sapporo, Hokkaido, Japan.
RP Hafez, A (reprint author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.; Hafez, A (reprint author), Helsinki Univ Hosp, Helsinki, Finland.
EM ext-ahmad.hafez@hus.fi
CR Abla AA, 2014, WORLD NEUROSURG, V82, P586, DOI 10.1016/j.wneu.2014.08.032
   Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   Aboud E, 2015, J NEUROSURG, V123, P1339, DOI 10.3171/2014.12.JNS141551
   Alghoul MS, 2011, MICROSURG, V31, P72, DOI 10.1002/micr.20813
   Anderson DA, 2001, INT J NEUROSCI, V111, P221, DOI 10.3109/00207450108994233
   Arnone GD, 2019, OPER NEUROSURG, V16, P112, DOI 10.1093/ons/opy091
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Burkhardt JK, 2018, WORLD NEUROSURG, V109, pE476, DOI 10.1016/j.wneu.2017.10.005
   CHEN L, 1986, Microsurgery, V7, P72, DOI 10.1002/micr.1920070205
   Eivazi S, 2017, ACTA NEUROCHIR, V159, P959, DOI 10.1007/s00701-017-3185-1
   Hafez Ahmad, 2017, Surg Neurol Int, V8, P295, DOI 10.4103/sni.sni_322_17
   Harada K, 2015, WORLD NEUROSURG, V84, P964, DOI 10.1016/j.wneu.2015.05.033
   Hernesniemi J, 2005, SURG NEUROL, V64, P195, DOI 10.1016/j.surneu.2005.04.031
   Higurashi M, 2014, J CLIN NEUROSCI, V21, P554, DOI 10.1016/j.jocn.2013.07.029
   Hino A, 2003, NEUROSURGERY, V52, P1495, DOI 10.1227/01.NEU.0000065174.83840.62
   Huotarinen Antti, 2018, Surg Neurol Int, V9, P71, DOI 10.4103/sni.sni_427_17
   Indo M, 2011, WORLD NEUROSURG, V75, P87, DOI 10.1016/j.wneu.2010.07.030
   Kazumata K, 2018, WORLD NEUROSURG, V114, pE388, DOI 10.1016/j.wneu.2018.02.190
   Mokhtari P, 2017, WORLD NEUROSURG, V108, P230, DOI 10.1016/j.wneu.2017.08.132
   de Barros RSM, 2017, ACTA CIR BRAS, V32, P691, DOI 10.1590/s0102-865020170090000001
   MORRIS DJ, 1992, MICROSURG, V13, P103, DOI 10.1002/micr.1920130211
   Rennert RC, 2018, OPER NEUROSURG, V15, P412, DOI 10.1093/ons/opx263
   Russell SM, 2006, SURG NEUROL, V66, P285, DOI 10.1016/j.surneu.2006.03.029
   Smith AF, 2009, BRIT J ANAESTH, V103, P623, DOI 10.1093/bja/aep273
   van der Zwan A, 2014, ACTA NEUROCHIR SUPPL, V119, P71, DOI 10.1007/978-3-319-02411-0_12
   Wain RAJ, 2016, MICROVASC RES, V105, P141, DOI 10.1016/j.mvr.2016.02.003
   Wanzel KR, 2002, LANCET, V359, P230, DOI 10.1016/S0140-6736(02)07441-X
   Yadav YR, 2016, J NEUROL SURG PART A, V77, P146, DOI 10.1055/s-0034-1376190
   Yoon S, 2019, J NEUROSURG, V131, P80, DOI 10.3171/2018.3.JNS172158
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E111
EP E120
DI 10.1016/j.wneu.2018.09.031
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000016
PM 30218800
OA Green Published
DA 2020-05-12
ER

PT J
AU Hanimoglu, H
   Cevik, S
   Yilmaz, H
   Kaplan, A
   Calis, F
   Katar, S
   Evran, S
   Akkaya, E
   Karaca, O
AF Hanimoglu, Hakan
   Cevik, Serdar
   Yilmaz, Hakan
   Kaplan, Atilla
   Calis, Fatih
   Katar, Salim
   Evran, Sevket
   Akkaya, Enes
   Karaca, Onur
TI Effects of Modic Type 1 Changes in the Vertebrae on Low Back Pain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disc degeneration; Disc height; Erector spinae; Low back pain; Magnetic
   resonance imaging; Modic changes; Multifidus; Psoas; Quadratus lumborum;
   Schmorl's nodes
ID ISSLS PRIZE WINNER; END-PLATE; INTERVERTEBRAL DISC; LUMBAR SPINE;
   ASSOCIATION; PREVALENCE; INNERVATION; SYMPTOMS; DISEASE; MARROW
AB OBJECTIVE: The present study examined the physical extent of Modic type 1 (MT1) changes and other phenotypic magnetic resonance imaging (MRI) findings in the vertebrae of patients with low back pain (LBP) and MT1 changes. We also identified any correlations of these findings with the severity of pain and the Oswestry Disability Index (ODI). The relationship between the presence of pain and MT1 changes has been examined in several studies. However, to the best of our knowledge, no study has assessed the relationships between pain severity and ODI and the total vertebral area of MT1 involvement.
   METHODS: After excluding any patient with MT2 or MT3 changes, 49 patients with a diagnosis of LBP and MT1 changes demonstrated on MRI were included. MT1 involvement area, disc height, number of Schmorl's nodes, disc degeneration (Pfirrmann grade), and cross-sectional area of the lumbar muscles were obtained via MRI. Additionally, patient demographic data, body mass index, physical activity level, and disability (ODI) scores were assessed.
   RESULTS: The total vertebral area of MT1 involvement correlated significantly and positively with the ODI (P = 0.001). In the multivariate linear regression model, with ODI as the dependent variable and age, mean Pfirrmann grade, total vertebral area of MT1 involvement, and sex as independent variables, only the total vertebral area of MT1 involvement was significantly associated with the ODI.
   CONCLUSIONS: A significant positive correlation was noted between the vertebral MT1 involvement extent and changes in the ODI. Other MRI features of patients with LBP were not related to pain severity or ODI.
C1 [Hanimoglu, Hakan] Koc Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Cevik, Serdar] Istininye Univ, Liv Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Yilmaz, Hakan; Kaplan, Atilla] Agri State Hosp, Dept Radiol, Agri, Turkey.
   [Calis, Fatih] Doc Dr Yasxar Eryilmaz State Hosp, Dept Neurosurg, Agri, Turkey.
   [Katar, Salim] Selahaddin Eyyubi State Hosp, Dept Neurosurg, Diyarbakir, Turkey.
   [Evran, Sevket] Bahcelievler State Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Akkaya, Enes] Arnavutkoy State Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Karaca, Onur] Aksaray Univ, Aksaray Educ & Res Hosp, Dept Anesthesiol & Intens Care, Aksaray, Turkey.
RP Cevik, S (reprint author), Istininye Univ, Liv Hosp, Dept Neurosurg, Istanbul, Turkey.
EM dr.serdarcevik@gmail.com
RI akkaya, enes/AAA-2182-2020; Cevik, Serdar/G-7161-2018; EVRAN,
   Sevket/AAG-3284-2019
OI , ATILLA/0000-0003-3275-6446; Calis, Fatih/0000-0003-2637-1152
CR Albert HB, 2013, EUR SPINE J, V22, P697, DOI 10.1007/s00586-013-2675-y
   Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4
   Bailly F, 2014, EUR SPINE J, V23, P493, DOI 10.1007/s00586-013-3036-6
   Brown MF, 1997, J BONE JOINT SURG BR, V79B, P147, DOI 10.1302/0301-620X.79B1.6814
   Choo V, 2002, LANCET, V360, P235, DOI 10.1016/S0140-6736(02)09512-0
   Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508
   Fagan A, 2003, SPINE, V28, P2570, DOI 10.1097/01.BRS.0000096942.29660.B1
   Fairbank J C, 1980, Physiotherapy, V66, P271
   Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776
   Hills Andrew P, 2014, Front Nutr, V1, P5, DOI 10.3389/fnut.2014.00005
   Jarvinen J, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0540-3
   Jensen OK, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0827-4
   Jensen RK, 2012, EUR SPINE J, V21, P2271, DOI 10.1007/s00586-012-2309-9
   Jensen TS, 2008, EUR SPINE J, V17, P1407, DOI 10.1007/s00586-008-0770-2
   Kaapa E, 2012, SPINE, V37, P134, DOI 10.1097/BRS.0b013e3182188a90
   Karchevsky M, 2005, SKELETAL RADIOL, V34, P125, DOI 10.1007/s00256-004-0886-3
   Kjaer P, 2005, SPINE, V30, P1173, DOI 10.1097/01.brs.0000162396.97739.76
   Kjaer P, 2006, EUR SPINE J, V15, P1312, DOI 10.1007/s00586-006-0185-x
   Kuisma M, 2007, SPINE, V32, P1116, DOI 10.1097/01.brs.0000261561.12944.ff
   Kuisma M, 2006, SPINE, V31, P1714, DOI 10.1097/01.brs.0000224167.18483.14
   Mitra D, 2004, EUR RADIOL, V14, P1574, DOI 10.1007/s00330-004-2314-4
   MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089
   MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678
   Mok FPS, 2010, SPINE, V35, P1944, DOI 10.1097/BRS.0b013e3181d534f3
   Ohtori S, 2006, SPINE, V31, P1026, DOI 10.1097/01.brs.0000215027.87102.7c
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Rannou F, 2007, ARTHRIT RHEUM-ARTHR, V57, P1311, DOI 10.1002/art.22985
   Vangeneugden T, 2005, BIOMETRICS, V61, P295, DOI 10.1111/j.0006-341X.2005.031040.x
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E426
EP E432
DI 10.1016/j.wneu.2018.09.132
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000053
PM 30267950
DA 2020-05-12
ER

PT J
AU Hu, BW
   Yang, X
   Lyu, QN
   Wang, LN
   Liu, LM
   Zhu, C
   Zhou, CG
   Song, YM
AF Hu, Bowen
   Yang, Xi
   Lyu, Qiunan
   Wang, Linnan
   Liu, Limin
   Zhu, Ce
   Zhou, Chunguang
   Song, Yueming
TI Comparison of Extending Fusion to Thoracic Curve Versus
   Thoracolumbar/Lumbar Fusion in Posterior Fusion of Patients with Lenke
   5C: Variation in Upper End Vertebrae Tilt Affected Coronal Balance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Coronal balance; Lenke classification
   5C; Thoracolumbar/lumbar curve
ID ADOLESCENT IDIOPATHIC SCOLIOSIS; SELECTIVE ANTERIOR FUSION; INSTRUMENTED
   VERTEBRAE; SCREW INSTRUMENTATION; LUMBAR; SEGMENTS; FLEXIBILITY
AB BACKGROUND: Extended fusion can be performed in patients with Lenke 5C adolescent idiopathic scoliosis (AIS) with a large and relatively rigid thoracic curve. Progression of the thoracic curve is related to coronal imbalance. We aimed to determine the correlation between the upper instrumented vertebra choice and coronal balance in patients with Lenke 5C AIS.
   METHODS: A total of 61 patients with Lenke 5C AIS underwent posterior fusion from 2009 to 2015 in a single institution with >= 2 years of follow-up data available. The extended fusion group (n = 32) and thoracolumbar/lumbar (TL/L) fusion group (n = 29) were compared for the correction rates for the main TL/L and thoracic curves, coronal balance, upper end vertebra (UEV) tilt, and Scoliosis Research Society-22 questionnaire score.
   RESULTS: Both groups had excellent correction of the main TL/L curve, and the extended fusion group had a significantly greater correction rate of the thoracic curve than the TL/L fusion group (70.2% vs. 57.3%). The incidence of coronal imbalance was similar in both groups. The spontaneous change in UEV tilt was associated with the change in coronal balance from the first to the final followup examination. In the TL/L fusion group, the increase in UEV tilt from the first to final follow-up visit resulted in improved coronal balance at the final follow-up examination. Both groups had similar Scoliosis Research Society22 questionnaire scores at 2 years postoperatively.
   CONCLUSIONS: In patients with Lenke 5C AIS, thoracic curve fusion results in better correction of the thoracic curve but no improvement in coronal balance. With TL/L fusion, a postoperative UEV tilt > 5 degrees leads to better coronal balance.
C1 [Hu, Bowen; Yang, Xi; Lyu, Qiunan; Wang, Linnan; Liu, Limin; Zhu, Ce; Zhou, Chunguang; Song, Yueming] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Sichuan, Peoples R China.
RP Song, YM (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped Surg, Sichuan, Peoples R China.
EM sym_cd@163.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities
FX We are grateful to the Fundamental Research Funds for the Central
   Universities for supporting our study.
CR Bao H, 2016, BONE JOINT J, V98B, P1227, DOI [10.1302/0301-620X.9889.37273, 10.1302/0301-620X.98B9.37273]
   Dong YL, 2016, NEUROSURGERY, V78, P324, DOI 10.1227/NEU.0000000000001055
   Fischer CR, 2011, EUR SPINE J, V20, P1048, DOI 10.1007/s00586-011-1730-9
   Geck MJ, 2009, SPINE, V34, P1942, DOI 10.1097/BRS.0b013e3181a3c777
   Hee HT, 2007, SPINE, V32, P1533, DOI 10.1097/BRS.0b013e318067dc3d
   Ilgenfritz RM, 2013, SPINE, V38, P650, DOI 10.1097/BRS.0b013e3182793092
   Koller H, 2014, EUR SPINE J, V23, P2658, DOI 10.1007/s00586-014-3405-9
   Kwan MK, 2018, SPINE J, V18, P53, DOI 10.1016/j.spinee.2017.06.020
   Lark RK, 2013, SPINE, V38, P195, DOI 10.1097/BRS.0b013e3182634c85
   Lenke LG, 2003, SPINE, V28, pS199, DOI 10.1097/01.BRS.0000092216.16155.33
   Lenke LG, 2001, J BONE JOINT SURG AM, V83A, P1169, DOI 10.2106/00004623-200108000-00006
   Li JF, 2011, SPINE, V36, P1673, DOI 10.1097/BRS.0b013e3182091fba
   Li M, 2009, SPINE, V34, P1162, DOI 10.1097/BRS.0b013e31819e2b16
   Liu Y, 2009, INT ORTHOP, V33, P191, DOI 10.1007/s00264-007-0489-4
   Liu Z, 2013, EUR SPINE J, V22, P2392, DOI 10.1007/s00586-013-2808-3
   Min K, 2007, EUR SPINE J, V16, P65, DOI 10.1007/s00586-006-0075-2
   Roberts SB, 2014, BONE JOINT J, V96B, P1082, DOI 10.1302/0301-620X.96B8.33837
   Sanders AE, 2003, SPINE, V28, P706, DOI 10.1097/00007632-200304010-00015
   Senkoylu A, 2014, SPINE J, V14, P1117, DOI 10.1016/j.spinee.2013.07.467
   Shufflebarger HL, 2004, SPINE, V29, P269, DOI 10.1097/01.BRS.0000109881.63411.48
   Sudo Hideki, 2013, J Bone Joint Surg Am, V95, pe49, DOI 10.2106/JBJS.L.00781
   Sun ZJ, 2014, SPINE, V39, P2042, DOI 10.1097/BRS.0000000000000602
   Wang T, 2008, EUR SPINE J, V17, P1012, DOI 10.1007/s00586-007-0510-z
   Wang Y, 2013, SPINE, V38, pE894, DOI 10.1097/BRS.0b013e31829537be
   Wang Y, 2012, INT ORTHOP, V36, P795, DOI 10.1007/s00264-011-1331-6
   Zhang YB, 2016, SPINE, V41, P1731, DOI 10.1097/BRS.0000000000001760
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E827
EP E835
DI 10.1016/j.wneu.2018.09.232
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000102
PM 30312815
DA 2020-05-12
ER

PT J
AU Huang, ZF
   Yang, JF
   Sui, WY
   Fan, HW
   Deng, YL
   Yang, JL
AF Huang, Zi-fang
   Yang, Jing-fan
   Sui, Wen-yuan
   Fan, Heng-wei
   Deng, Yao-long
   Yang, Jun-lin
TI Surgical Outcome Comparison of Posterior Vertebral Column Resection with
   or without Anterior Column Support in Treatment of Yang's Type A Severe
   Thoracic Spinal Deformity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior column support; Neuromonitoring; Osteotomy; Posterior vertebral
   column resection; Spinal deformity
ID NEUROLOGIC DEFICITS; CORD; COMPLICATIONS; OSTEOTOMY
AB BACKGROUND: The use of posterior vertebral column resection (PVCR) has extended the treatment of severe spinal deformity. However, the practice guidelines for anterior column support in patients treated by PVCR remain ill defined. The objective of the present study was to compare the clinical and radiographic outcomes of severe thoracic spinal deformity treated by PVCR with and without anterior column support (ACS).
   METHODS: We performed a prospective study of 57 patients with severe thoracic deformity (classified as Yang's A type) treated by PVCR with or without anterior column support from January 2010 to April 2015. The patient characteristics, radiographic parameters, intraoperative data, and complications were analyzed to clarify these 2 clinical series.
   RESULTS: The sex, age, diagnosis, curve magnitude, and curve type were similar between the PVCR with ACS group (n = 21) and non-ACS group (n = 36) preoperatively. Evaluation of the radiographic parameters, intraoperative data, and complications found no statistically significant intergroup differences, except for the osteotomy distance (non-ACS group, 4.0 cm; ACS group, 5.3 cm; P < 0.001) and shortening distance of the osteotomy gap (non-ACS group, 4.0 cm; ACS group, 3.5 cm; P = 0.005).
   CONCLUSIONS: The results of the present study have shown that PVCR without ACS seems to be a safe and effective technique for Yang's A type severe thoracic spinal deformity correction compared with PVCR with ACS. PVCR without ACS requires a relatively smaller osteotomy range and could potentially decrease the risk of implant failure due to bone to bone fusion.
C1 [Huang, Zi-fang; Yang, Jun-lin] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
   [Yang, Jing-fan; Sui, Wen-yuan; Fan, Heng-wei; Deng, Yao-long; Yang, Jun-lin] Shanghai Jiao Tong Univ, Xinhua Hosp, Spine Ctr, Sch Med, Shanghai, Peoples R China.
RP Yang, JL (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.; Yang, JL (reprint author), Shanghai Jiao Tong Univ, Xinhua Hosp, Spine Ctr, Sch Med, Shanghai, Peoples R China.
EM yangjunlin@xinhuamed.com.cn
CR Alemdaroglu KB, 2007, EUR SPINE J, V16, P1451, DOI 10.1007/s00586-007-0325-y
   Bradford DS, 1987, ORTHOP T, V11, P502
   Fan Y, 2014, EXP THER MED, V8, P1539, DOI 10.3892/etm.2014.1929
   Grob D, 2005, EUR SPINE J, V14, P211, DOI 10.1007/s00586-004-0748-7
   Hamzaoglu A, 2011, SPINE, V36, P340
   Hyun SJ, 2014, SPINE, V39, P1899, DOI 10.1097/BRS.0000000000000556
   Kawahara N, 2005, SPINE, V30, P613, DOI 10.1097/01.brs.0000155407.87439.a2
   Kawahara N, 2001, SPINE, V26, P391, DOI 10.1097/00007632-200102150-00016
   Kim SS, 2012, ASIAN SPINE J, V6, P257, DOI 10.4184/asj.2012.6.4.257
   Kim YJ, 2006, SPINE, V31, P2329, DOI 10.1097/01.brs.0000238968.82799.d9
   LEATHERMAN KD, 1979, J BONE JOINT SURG BR, V61, P324
   Lenke LG, 2013, SPINE, V38, P119, DOI 10.1097/BRS.0b013e318269fab1
   Lenke LG, 2010, CLIN ORTHOP RELAT R, V468, P687, DOI 10.1007/s11999-009-1037-x
   Lenke LG, 2009, SPINE, V34, P2213, DOI 10.1097/BRS.0b013e3181b53cba
   LONSTEIN JE, 1980, SPINE, V5, P331, DOI 10.1097/00007632-198007000-00007
   MacLennan A., 1922, BMJ-BRIT MED J, V2, P865
   Qiu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127624
   Sui WY, 2017, WORLD NEUROSURG, V104, P723, DOI 10.1016/j.wneu.2017.05.063
   Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/00007632-200211010-00012
   Suk SI, 2005, SPINE, V30, P1682, DOI 10.1097/01.brs.0000170590.21071.c1
   Xie JM, 2014, EUR SPINE J, V23, P149, DOI 10.1007/s00586-013-2793-6
   Yang JL, 2016, EUR SPINE J, V25, P1821, DOI 10.1007/s00586-015-4367-2
   YAU ACMC, 1974, J BONE JOINT SURG AM, VA 56, P1419, DOI 10.2106/00004623-197456070-00010
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E433
EP E440
DI 10.1016/j.wneu.2018.09.135
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000054
PM 30267947
DA 2020-05-12
ER

PT J
AU Ibbett, I
   Schembri, G
   Cook, R
   Parkinson, J
AF Ibbett, Imogen
   Schembri, Geoff
   Cook, Raymond
   Parkinson, Jonathon
TI Role of F-18-fluoro-ethyl-tyrosine Positron Emission Tomography in
   Investigation and Management of Suspected Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioma; F-18-fluoro-ethyl-tyrosine; Positron emission tomography
ID DIFFERENTIAL-DIAGNOSIS; F-18-FET PET; PERFORMANCE
AB BACKGROUND: This study aims to investigate the utility of F-18-fluoro-ethyl-tyrosine (F-18-FET) positron emission tomography in surgical decision making in suspected glioma.
   METHODS: A retrospective review of patients undergoing F-18-FET positron emission tomography was performed. Previously published thresholds for maximum tumor background ratios (TBRs) were used for quantitative analysis. Forty-seven patients were included in the study, of whom 15 had confirmed glioma and 7 had a confirmed alternative diagnosis.
   RESULTS: F-18-FET showed significantly higher uptake in high-grade glioma than in nonglioma.
   CONCLUSIONS: Lesions with TBRmax > 2.5 should be considered suspicious for glioma and biopsy considered. Threshold TBRmax > 3.0 is useful for differentiating highgrade glioma from low-grade glioma. This may be a particularly useful tool for directing management in eloquent areas, such as brainstem glioma.
C1 [Ibbett, Imogen; Cook, Raymond; Parkinson, Jonathon] Royal North Shore Hosp, Dept Neurosurg, St Leonards, NSW, Australia.
   [Schembri, Geoff] Royal North Shore Hosp, Dept Nucl Med, St Leonards, NSW, Australia.
RP Ibbett, I (reprint author), Royal North Shore Hosp, Dept Neurosurg, St Leonards, NSW, Australia.
EM imogen84@gmail.com
RI Schembri, Geoffrey/O-8310-2019
OI Schembri, Geoffrey/0000-0002-6814-3636
CR Aghi MK, 2015, J NEURO-ONCOL, V125, P503, DOI 10.1007/s11060-015-1867-1
   Albert NL, 2016, NEURO-ONCOLOGY, V18, P1199, DOI 10.1093/neuonc/now058
   Chae SY, 2016, J NUCL MED, V57, P67, DOI 10.2967/jnumed.115.164020
   Dankbaar JW, 2015, J NEURO-ONCOL, V125, P167, DOI 10.1007/s11060-015-1883-1
   Dunet V, 2016, NEURO-ONCOLOGY, V18, P426, DOI 10.1093/neuonc/nov148
   Dunet V, 2012, J NUCL MED, V53, P207, DOI 10.2967/jnumed.111.096859
   Guidry C, 2016, RADIOL CLIN N AM, V54, P519, DOI 10.1016/j.rcl.2015.12.009
   Klasner BD, 2010, EXPERT REV ANTICANC, V10, P609, DOI 10.1586/ERA.10.37
   Prasse A, 2016, DTSCH ARZTEBL INT, V113, P565, DOI 10.3238/arztebl.2016.0565
   Rapp M, 2013, J NUCL MED, V54, P229, DOI 10.2967/jnumed.112.109603
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E712
EP E715
DI 10.1016/j.wneu.2018.09.194
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000087
PM 30300714
DA 2020-05-12
ER

PT J
AU Jakobsson, M
   Brisby, H
   Gutke, A
   Hagg, O
   Lotzke, H
   Smeets, R
   Lundberg, M
AF Jakobsson, Max
   Brisby, Helena
   Gutke, Annelie
   Hagg, Olle
   Lotzke, Hanna
   Smeets, Rob
   Lundberg, Mari
TI Prediction of Objectively Measured Physical Activity and Self-Reported
   Disability Following Lumbar Fusion Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disability; Lumbar fusion surgery; Pain catastrophizing; Physical
   activity; Predictors; Prognosis; Self-efficacy
ID LOW-BACK-PAIN; PSYCHOLOGICAL PREDICTORS; HOSPITAL ANXIETY; SPINAL
   STENOSIS; RISK-FACTOR; RELIABILITY; MANAGEMENT; INTENSITY; EFFICACY;
   VALIDITY
AB OBJECTIVE: To investigate the predictive value of preoperative fear-avoidance factors (self-efficacy for exercise, pain catastrophizing, kinesiophobia, and depression), walking capacity, and traditional predictor variables for predicting postoperative changes in physical activity level and disability 6 months after lumbar fusion surgery in patients with chronic low back pain (LBP).
   METHODS: We prospectively enrolled 118 patients scheduled for lumbar fusion surgery for motion-elicited chronic LBP with degenerative changes in 1-3 segments of the lumbar spine. Associations between the predictors and the dependent variables were investigated with multiple linear regression analysis. Dependent variables were physical activity level as objectively measured with a triaxial accelerometer and disability as measured with the Oswestry Disability Index.
   RESULTS: Preoperative physical activity level (beta = -0.349; P<0.001) and self-efficacy for exercise (beta = 0.176; P = 0.021) were significant predictors of the postoperative change in physical activity. Preoperative disability (beta = -0.790; P<0.001), self-efficacy for exercise (beta = 0.152; P = 0.024), and pain catastrophizing (beta = 0.383; P = 0.033) were significant predictors for the change in the Oswestry Disability Index.
   CONCLUSIONS: Patients with low levels of preoperative physical activity were more likely to increase their level of physical activity after lumbar fusion surgery, especially when their self-efficacy for exercise was high. However, most of these patients still had low levels of physical activity after surgery, and they may therefore need extra support in increasing their postoperative physical activity levels.
C1 [Jakobsson, Max; Brisby, Helena; Hagg, Olle; Lotzke, Hanna; Lundberg, Mari] Univ Gothenburg, Dept Orthopaed, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden.
   [Gutke, Annelie; Lundberg, Mari] Univ Gothenburg, Div Physiotherapy, Dept Hlth & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden.
   [Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, Gothenburg, Sweden.
   [Jakobsson, Max] Dept Nursing & Care Elderly, Div Home Med Care, Boras Stad, Boras, Sweden.
   [Hagg, Olle; Lotzke, Hanna] Spine Ctr Goteborg, Vastra Frolunda, Sweden.
   [Smeets, Rob] Maastricht Univ, Res Sch CAPRHI, Dept Rehabil Med, Maastricht, Netherlands.
   [Smeets, Rob] CIR Revalidatie, Eindhoven, Netherlands.
   [Lundberg, Mari] Karolinska Inst, Div Physiotherapy, Dept Neurobiol, Care Sci & Soc NVS, Stockholm, Sweden.
RP Jakobsson, M (reprint author), Back Mot Res Grp, Stockholm, Sweden.
EM max.jakobsson@gu.se
RI Smeets, Rob JEM/D-1522-2011
OI Smeets, Rob JEM/0000-0002-9503-366X; Lundberg, Mari/0000-0001-7123-0362;
   Jakobsson, Max/0000-0001-5629-5627
FU AFA [120216]; Eurospine Research Grants [TFR 8-2014]; Swedish Research
   Council (VR)Swedish Research Council [2015-02511]; Health and Medical
   Care Executive Board of the Vastra Gotaland Region (VGR)
FX The study was supported with grants from AFA Research Funding (No.
   120216), the Eurospine Research Grants (No. TFR 8-2014), the Swedish
   Research Council (VR) (No. 2015-02511), and the Health and Medical Care
   Executive Board of the Vastra Gotaland Region (VGR).
CR Abbott AD, 2011, EUR SPINE J, V20, P1626, DOI 10.1007/s00586-011-1709-6
   Blain H, 2010, J NUTR HEALTH AGING, V14, P595, DOI 10.1007/s12603-010-0111-0
   Buchbinder R, 2018, LANCET, V391, P2384, DOI 10.1016/S0140-6736(18)30488-4
   Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17
   CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X
   Carreon LY, 2009, SPINE, V34, P725, DOI 10.1097/BRS.0b013e318198cae4
   Chiarotto A, 2016, PHYS THER, V96, P1620, DOI 10.2522/ptj.20150420
   Choi L, 2012, MED SCI SPORT EXER, V44, P2009, DOI 10.1249/MSS.0b013e318258cb36
   Soriano JC, 2010, EUR SPINE J, V19, P1841, DOI [10.1007/s00586.010.1284.2, 10.1007/s00586-010-1284-2]
   den Boer JJ, 2006, PAIN, V123, P45, DOI 10.1016/j.pain.2006.02.008
   Everhart JS, 2015, KNEE SURG SPORT TR A, V23, P752, DOI 10.1007/s00167-013-2699-1
   Fairbank J C, 1980, Physiotherapy, V66, P271
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Fritzell P, SWEDISH SPINE REGIST
   Granot M, 2005, CLIN J PAIN, V21, P439, DOI 10.1097/01.ajp.0000135236.12705.2d
   Grosen K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090185
   Gunzburg R, 2003, EUR SPINE J, V12, P197, DOI 10.1007/s00586-002-0479-6
   Hagg O, 2003, EUR SPINE J, V12, P22, DOI 10.1007/s00586-002-0465-z
   Hagstromer M, 2010, AM J EPIDEMIOL, V171, P1055, DOI 10.1093/aje/kwq069
   Ham SA, 2007, MED SCI SPORT EXER, V39, P52, DOI 10.1249/01.mss.0000235886.17229.42
   Johansson AC, 2010, DISABIL REHABIL, V32, P521, DOI 10.3109/09638280903177243
   Kasl S. V., 2003, HDB OCCUPATIONAL HLT, P379, DOI DOI 10.1037/10474-018
   Kemani MK, 2019, ACTA ANAESTH SCAND, V63, P259, DOI 10.1111/aas.13246
   Khan RS, 2012, PAIN MED, V13, P820, DOI 10.1111/j.1526-4637.2012.01386.x
   LaCaille Rick A, 2005, Spine J, V5, P71, DOI 10.1016/j.spinee.2004.08.004
   Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
   Lisspers J, 1997, ACTA PSYCHIAT SCAND, V96, P281, DOI 10.1111/j.1600-0447.1997.tb10164.x
   Lotzke H, 2018, PERSON CTR PREOPERAT
   Lotzke H, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2274-5
   Lotzke H, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1203-8
   Lundberg Mari K. E., 2004, Physiotherapy Theory and Practice, V20, P121, DOI 10.1080/09593980490453002
   Mannion AF, 2006, EUR SPINE J, V15, pS93, DOI 10.1007/s00586-005-1045-9
   Mannion AF, 2013, SPINE J, V13, P1438, DOI 10.1016/j.spinee.2013.06.101
   Montero-Odasso M, 2005, J GERONTOL A-BIOL, V60, P1304, DOI 10.1093/gerona/60.10.1304
   Oppong-Yeboah B, 2014, PHYSIOTHER RES INT, V19, P222, DOI 10.1002/pri.1586
   Ostir GV, 2007, AM J EPIDEMIOL, V166, P599, DOI 10.1093/aje/kwm121
   Papaioannou M, 2009, PAIN MED, V10, P1452, DOI 10.1111/j.1526-4637.2009.00730.x
   Pavlin DJ, 2005, CLIN J PAIN, V21, P83, DOI 10.1097/00002508-200501000-00010
   Pieber K, 2016, EUR SPINE J, V25, P3520, DOI 10.1007/s00586-016-4700-4
   Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56
   Riddle DL, 2010, CLIN ORTHOP RELAT R, V468, P798, DOI 10.1007/s11999-009-0963-y
   Rydwik E, 2014, PHYSIOTHER THEOR PR, V30, P131, DOI 10.3109/09593985.2013.838614
   Simmonds MJ, 1998, SPINE, V23, P2412, DOI 10.1097/00007632-199811150-00011
   Slootmaker SM, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-17
   Smuck M, 2018, SPINE J, V18, P15, DOI 10.1016/j.spinee.2017.08.262
   Sullivan MJL, 2006, PHYS THER, V86, P8, DOI 10.1093/ptj/86.1.8
   Tabue-Teguo M, 2015, J NUTR HEALTH AGING, V19, P468, DOI 10.1007/s12603-014-0560-y
   Tcherny-Lessenot S, 2003, J PAIN SYMPTOM MANAG, V25, P539, DOI 10.1016/S0885-3924(03)00147-7
   Trief PM, 2000, SPINE, V25, P2616, DOI 10.1097/00007632-200010150-00012
   Trief PM, 2006, SPINE, V31, P823, DOI 10.1097/01.brs.0000206362.03950.5b
   Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3
   Trost SG, 2005, MED SCI SPORT EXER, V37, pS531, DOI 10.1249/01.mss.0000185657.86065.98
   U.S. Department of Health and Human Services, 2008, PHYS ACT GUID AM
   van den Akker-Scheek I, 2007, PATIENT EDUC COUNS, V66, P92, DOI 10.1016/j.pec.2006.10.012
   VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N
   WHO, GLOB REC PHYS ACT HL
   Woby SR, 2007, EUR J PAIN, V11, P711, DOI 10.1016/j.ejpain.2006.10.009
   World Health Organization, 2009, GLOB HLTH RISKS EM B
   Wylde V, 2012, MUSCULOSKELET CARE, V10, P110, DOI 10.1002/msc.1008
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 60
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E77
EP E88
DI 10.1016/j.wneu.2018.08.229
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000012
PM 30213672
OA Other Gold
DA 2020-05-12
ER

PT J
AU Jean, WC
   Felbaum, DR
AF Jean, Walter C.
   Felbaum, Daniel R.
TI Impact of Training and Practice Environment on Academic Productivity of
   Early Career Academic Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic neurosurgery; Early career; h-index; Impact; Scholarly
   environment
ID H-INDEX; PLACEMENT; FACULTY
AB BACKGROUND: Factors affecting academic productivity of neurosurgeons are increasingly being studied. In the current investigation, we retrospectively reviewed a cohort of early career neurosurgeons to determine if their medical education, residency training, or academic employer had the most influence on a young academician's productivity.
   METHODS: We studied early career neurosurgeons who completed residency in U.S.-based neurosurgical training programs between 2010 and 2014. The ranking of an individual subject's medical school, residency, and current academic employer were analyzed for correlation with his or her current h-index.
   RESULTS: The neurosurgeons with the highest h-indexes are more likely to have attended elite medical schools, have trained in high-ranking residency programs, and work for prestigious university departments (P < 0.0001). Furthermore, we identified a positive correlation between the subjects' academic productivity and the ranking of all the institutions throughout their medical education, training, and current employment. The strongest correlation was with the rank of their residency program (r = 0.52).
   CONCLUSIONS: There is a correlation between the early career academic neurosurgeons' h-indexes and the ranking of all the institutions throughout their education, training, and current employment, but the strongest correlation was with the academic productivity of their residency program.
C1 [Jean, Walter C.] George Washington Univ, Dept Neurosurg, Washington, DC 20052 USA.
   [Felbaum, Daniel R.] Medstar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC USA.
RP Jean, WC (reprint author), George Washington Univ, Dept Neurosurg, Washington, DC 20052 USA.
EM wjean@mfa.gwu.edu
RI Jean, Walter/L-2780-2019
OI Jean, Walter/0000-0001-6774-2066
CR Aoun SG, 2013, WORLD NEUROSURG, V80, pE85, DOI 10.1016/j.wneu.2012.01.052
   Bean JR, 2017, WORLD NEUROSURG, V101, P766, DOI 10.1016/j.wneu.2017.02.078
   Campbell PG, 2011, J NEUROSURG, V115, P380, DOI 10.3171/2011.3.JNS101176
   Conley JP, 2013, VANDERBILT U DEP EC
   Crowley RW, 2012, NEUROSURGERY, V70, P1024, DOI 10.1227/NEU.0b013e3182367143
   Daniels M, 2017, WORLD NEUROSURG, V101, P350, DOI 10.1016/j.wneu.2017.02.028
   Gladwell M., 2009, NEW YORKER
   Gladwell M., 2013, DAVID GOLIATH UNDERD
   Kashkoush A, 2017, WORLD NEUROSURG, V105, P341, DOI 10.1016/j.wneu.2017.05.129
   Khan NR, 2019, NEUROSURGERY, V84, P857, DOI 10.1093/neuros/nyy217
   Khan NR, 2017, WORLD NEUROSURG, V101, P746, DOI 10.1016/j.wneu.2017.03.049
   Khan NR, 2014, J NEUROSURG, V120, P746, DOI 10.3171/2013.11.JNS131708
   Lee J, 2009, J NEUROSURG, V111, P387, DOI 10.3171/2008.10.JNS08978
   Lee RP, 2016, WORLD NEUROSURG, V95, P565, DOI 10.1016/j.wneu.2016.07.006
   Leschke JM, 2018, WORLD NEUROSURG, V113, pE529, DOI 10.1016/j.wneu.2018.02.082
   Ponce FA, 2010, J NEUROSURG, V113, P447, DOI 10.3171/2010.3.JNS1032
   Sarkiss CA, 2017, NEUROSURGERY, V80, P975, DOI 10.1093/neuros/nyx071
   Spearman CM, 2010, J NEUROSURG, V113, P929, DOI 10.3171/2010.4.JNS091842
   Taylor DR, 2015, J NEUROSURG, V123, P547, DOI 10.3171/2014.10.JNS141025
   Zusman EE, 2017, WORLD NEUROSURG, V105, P988, DOI 10.1016/j.wneu.2017.04.090
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E892
EP E897
DI 10.1016/j.wneu.2018.10.005
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000110
PM 30315984
DA 2020-05-12
ER

PT J
AU Joo, C
   Park, E
   Min, JW
   Kang, H
   Yoo, DS
   Jung, HJ
AF Joo, Chunghee
   Park, Eunhye
   Min, Joo-Won
   Kang, Hyun
   Yoo, Do-Sung
   Jung, Hyun Ju
TI Contrast Media-Induced Nephropathy in Patients with Unruptured Cerebral
   Aneurysm After Coiling Endovascular Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral angiography; Contrast media; Intracranial aneurysm; Nephropathy
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE KIDNEY INJURY; CT ANGIOGRAPHY;
   RENAL-FUNCTION; RISK; PERFUSION; PREVENTION; EMERGENCY; FAILURE; STROKE
AB BACKGROUND: The endovascular coiling procedure to treat cerebral aneurysms using contrast media has become more popular. However, studies of the incidence of, and risk factors for, contrast media-induced nephropathy (CIN) after coiling procedures have been limited. Thus, we evaluated the incidence and risk factors for CIN in patients who had undergone cerebral aneurysmal coiling procedures.
   METHODS: We retrospectively reviewed the electric medical records of 380 patients who had undergone cerebral aneurysmal coiling treatment under general anesthesia. CIN was defined as an absolute increase in serum creatinine (>= 0.5 mg/dL) or a relative increase (>= 25%) in the baseline serum creatinine value at 48-72 hours after exposure to a contrast agent.
   RESULTS: Elective cerebral aneurysmal coiling procedures were performed in 230 patients. Of the 230 patients, CIN developed in 13 (5.6%). The presence of diabetes mellitus (30.8% vs. 9.7%; P = 0.040) and patient age > 75 years (30.8% vs. 6.5%; P = 0.012) were risk factors for CIN.
   CONCLUSIONS: Our study has demonstrated that the incidence of CIN in patients undergoing elective cerebral aneurysmal coiling procedures is similar to 6.0%. We also identified underlying diabetes mellitus and advanced age (>= 75 years) as potential risk factors.
C1 [Joo, Chunghee] Catholic Univ Korea, Incheon St Marys Hosp, Dept Anesthesia & Pain Med, Coll Med, Seoul, South Korea.
   [Park, Eunhye; Jung, Hyun Ju] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Anesthesia & Pain Med, Seoul, South Korea.
   [Yoo, Do-Sung] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Min, Joo-Won] Seonam Univ, Coll Med, Myongji Hosp, Div Pulm & Crit Care Med,Dept Internal Med, Goyang Si, South Korea.
   [Kang, Hyun] Chung Ang Univ, Dept Anesthesia & Pain Med, Coll Med, Seoul, South Korea.
RP Jung, HJ (reprint author), Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Anesthesia & Pain Med, Seoul, South Korea.
EM anedoc@catholic.ac.kr
RI Kang, Hyun/AAE-7872-2020
OI Kang, Hyun/0000-0003-2844-5880
CR Abe D, 2014, CIRC J, V78, P85, DOI 10.1253/circj.CJ-13-0574
   Aoun J, 2018, CURR OPIN NEPHROL HY, V27, P121, DOI 10.1097/MNH.0000000000000389
   Brown JR, 2010, CIRC-CARDIOVASC INTE, V3, P346, DOI 10.1161/CIRCINTERVENTIONS.109.910638
   Chavakula V, 2013, NEUROCRIT CARE, V19, P157, DOI 10.1007/s12028-013-9843-0
   Dangas G, 2005, AM J CARDIOL, V95, P13, DOI 10.1016/j.amjcard.2004.08.056
   Dittrich R, 2007, J NEUROL, V254, P1491, DOI 10.1007/s00415-007-0528-5
   Harjai KJ, 2008, AM J CARDIOL, V101, P812, DOI 10.1016/j.amjcard.2007.10.051
   Heinrich MC, 2005, RADIOLOGY, V235, P843, DOI 10.1148/radiol.2353040726
   Heyman SN, 2013, BIOMED RES INT, DOI 10.1155/2013/123589
   Hopyan JJ, 2008, AM J NEURORADIOL, V29, P1826, DOI 10.3174/ajnr.A1257
   Josephson SA, 2005, NEUROLOGY, V64, P1805, DOI 10.1212/01.WNL.0000161845.69114.62
   Kang H, 2013, KOREAN J ANESTHESIOL, V64, P402, DOI 10.4097/kjae.2013.64.5.402
   Lee HC, 2012, J NEPHROL, V25, P56, DOI 10.5301/JN.2011.7741
   Loh Y, 2010, AM J NEURORADIOL, V31, P1584, DOI 10.3174/ajnr.A2136
   Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068
   Morcos SK, 1999, EUR RADIOL, V9, P1602, DOI 10.1007/s003300050894
   Parakh K, 2008, AM J MED, V121, P1015, DOI 10.1016/j.amjmed.2008.06.020
   PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303
   Persson PB, 2005, KIDNEY INT, V68, P14, DOI 10.1111/j.1523-1755.2005.00377.x
   Prasad V, 2014, RADIOLOGY, V273, P853, DOI 10.1148/radiol.14131104
   Ray B, 2013, NEUROCRIT CARE, V19, P150, DOI 10.1007/s12028-013-9850-1
   Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33
   Sharma J, 2013, J NEUROINTERV SURG, V5, P543, DOI 10.1136/neurintsurg-2012-010520
   Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304
   Toprak O, 2006, KIDNEY BLOOD PRESS R, V29, P84, DOI 10.1159/000093381
   Wang XC, 2011, CHINESE MED J-PEKING, V124, P892, DOI 10.3760/cma.j.issn.0366-6999.2011.06.016
   Webster AC, 2017, LANCET, V389, P1238, DOI 10.1016/S0140-6736(16)32064-5
   Yamamoto M, 2013, JACC-CARDIOVASC INTE, V6, P479, DOI 10.1016/j.jcin.2013.02.007
NR 28
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E39
EP E44
DI 10.1016/j.wneu.2018.08.206
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000007
PM 30196168
DA 2020-05-12
ER

PT J
AU Joshi, RS
   Hirshman, BR
   Ali, MA
   Alattar, A
   Carroll, K
   Nagano, O
   Aiyama, H
   Serizawa, T
   Yamamoto, M
   Chen, CC
AF Joshi, Rushikesh S.
   Hirshman, Brian R.
   Ali, Mir Amaan
   Alattar, Ali
   Carroll, Kate
   Nagano, Osamu
   Aiyama, Hitoshi
   Serizawa, Toru
   Yamamoto, Masaaki
   Chen, Clark C.
TI Prognostic Importance of Cumulative Intracranial Tumor Volume in
   Patients with Gastrointestinal Brain Metastasis Treated with
   Stereotactic Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Cumulative intracranial tumor volume; Disease-specific
   Graded Prognostic Assessment; GI cancer; Prognostic model; Stereotactic
   radiosurgery
ID RECURSIVE PARTITIONING ANALYSIS; SURVIVAL; MANAGEMENT; OUTCOMES; CANCER;
   NUMBER; SCORE
AB BACKGROUND: The disease-specific Graded Prognostic Assessment (ds-GPA) for patients with gastrointestinal (GI) tract cancer brain metastases (BM) suggests Karnofsky Performance Status (KPS) as the only pertinent prognostic factor. We evaluated the prognostic importance of cumulative intracranial tumor volume (CITV).
   METHODS: KPS, CITV, and overall survivalwere collected from consecutive patients with stereotactic radiosurgerye treated GI BM. Patients were grouped into 2 independent cohorts for development and validation of the model (termed "exploratory" and "validation" cohorts). Analyses were performed using logistic regression, Cox proportional hazards models, Net Reclassification Index (NRI > 0), integrated discrimination improvement (IDI > 0), and Akaike information criterion.
   RESULTS: In univariable logistic regression models, both CITV and KPS were independently associated with patient survival. The association between CITV and overall survival remained robust after controlling for KPS (P < 0.001) in a multivariable Cox proportional hazards model. Based on NRI analysis of the exploratory cohort, we found that a CITV cutoff of 12 cm(3) best augments the prognostic accuracy of GI-ds-GPA. In this analysis, incorporation of CITV (as < or >= 12 cm(3)) improved prognostication of the GIspecific GPA model by NRI > 0 of 0.397 (95% confidence interval [CI], 0.165-0.630; P < 0.001) and IDI of 0.019 (95% CI, 0.004-0.033; P = 0.013). We confirmed the prognostic usefulness of the CITV-incorporated GI-ds-GPA in an independent validation cohort, in which CITV incorporation improved prognostic usefulness with an NRI > 0 of 0.478 (95% CI, 0.257-0.699; P < 0.001) and IDI of 0.028 (95% CI, 0.014-0.043; P < 0.001).
   CONCLUSIONS: CITV is an important prognostic variable in patients with stereotactic radiosurgeryetreated GI BMand augments the prognostic accuracy of the GI-ds-GPA index.
C1 [Joshi, Rushikesh S.; Ali, Mir Amaan; Alattar, Ali; Carroll, Kate] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Hirshman, Brian R.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.
   [Nagano, Osamu; Yamamoto, Masaaki] Chiba Cerebral & Cardiovasc Ctr, Gamma Knife House, Ichihara, Chiba, Japan.
   [Aiyama, Hitoshi] Katsuta Hosp Mito Gamma House, Hitachinaka, Ibaraki, Japan.
   [Serizawa, Toru] Tokyo Gamma Unit Ctr, Tsukiji Neurol Clin, Tokyo, Japan.
   [Chen, Clark C.] Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Chen, CC (reprint author), Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM ccchen@umn.edu
OI Joshi, Rushikesh/0000-0001-5251-5856
CR Ali MA, 2017, WORLD NEUROSURG, V108, P151, DOI 10.1016/j.wneu.2017.07.109
   Ali MA, 2017, WORLD NEUROSURG, V107, P944, DOI 10.1016/j.wneu.2017.07.062
   Bartelt S, 2004, WORLD J GASTROENTERO, V10, P3345, DOI 10.3748/wjg.v10.i22.3345
   Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0
   Go PH, 2011, CANCER-AM CANCER SOC, V117, P3630, DOI 10.1002/cncr.25940
   Gonda DD, 2014, EUR J CANCER, V50, P1148, DOI 10.1016/j.ejca.2014.01.001
   Hasegawa T, 2003, SURG NEUROL, V60, P506, DOI 10.1016/S0090-3019(03)00356-2
   Hirshman BR, 2018, NEUROSURGERY, V83, P237, DOI 10.1093/neuros/nyx380
   LEKSELL L, 1983, J NEUROL NEUROSUR PS, V46, P797, DOI 10.1136/jnnp.46.9.797
   Lemke J, 2014, INT J MOL SCI, V15, P16816, DOI 10.3390/ijms150916816
   Likhacheva A, 2012, J NEUROSURG, V117, P38, DOI 10.3171/2012.3.GKS1289
   LOH KWJ, 2014, J CLIN ONCOL S, V32
   Marcus LP, 2016, NEUROSURGERY, V79, P246, DOI 10.1227/NEU.0000000000001123
   Marshall DC, 2016, J NEURO-ONCOL, V128, P119, DOI 10.1007/s11060-016-2084-2
   Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413
   Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y
   Nieder C, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-155
   Nieder C, 2012, MED SCI MONITOR, V18, pCR450, DOI 10.12659/MSM.883213
   Oh Y, 2009, CANCER, V115, P2930, DOI 10.1002/cncr.24333
   Patchell RA, 2003, CANCER TREAT REV, V29, P533, DOI 10.1016/S0305-7372(03)00105-1
   Pencina MJ, 2012, AM J EPIDEMIOL, V176, P473, DOI 10.1093/aje/kws207
   Serizawa T, 2014, J NEUROSURG, V121, P35, DOI 10.3171/2014.7.GKS14980
   Shaw E, 2000, INT J RADIAT ONCOL, V47, P291, DOI 10.1016/S0360-3016(99)00507-6
   Soffietti R, 2008, CURR OPIN ONCOL, V20, P676, DOI 10.1097/CCO.0b013e32831186fe
   Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527
   Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025
   Taghipour M, 2016, AM J ROENTGENOL, V206, P846, DOI 10.2214/AJR.15.15106
   Wang CC, 2012, J NEURO-ONCOL, V106, P601, DOI 10.1007/s11060-011-0697-z
NR 28
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E747
EP E754
DI 10.1016/j.wneu.2018.09.209
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000092
PM 30308343
DA 2020-05-12
ER

PT J
AU Kashiwazaki, D
   Shiraishi, K
   Yamamoto, S
   Kamo, T
   Uchino, H
   Saito, H
   Akioka, N
   Kuwayama, N
   Noguchi, K
   Kuroda, S
AF Kashiwazaki, Daina
   Shiraishi, Keitaro
   Yamamoto, Shusuke
   Kamo, Tetsuhiro
   Uchino, Haruto
   Saito, Hisayasu
   Akioka, Naoki
   Kuwayama, Naoya
   Noguchi, Kyo
   Kuroda, Satoshi
TI Efficacy of Carotid Endarterectomy for Mild (< 50%) Symptomatic Carotid
   Stenosis with Unstable Plaque
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Carotid stenosis; Mild stenosis; MRI; Unstable
   plaque
ID ARTERY STENOSIS; INTRAPLAQUE HEMORRHAGE; MICROEMBOLIC SIGNALS; STROKE;
   RISK; FEATURES; HYPOXIA; GROWTH
AB BACKGROUND: Carotid endarterectomy (CEA) is known to reduce stroke risk in patients with symptomatic, moderate to severe carotid stenosis but has no apparent impact in patients with symptomatic, mild (less than 50%) carotid stenosis. However, recent development of noninvasive imaging modalities has shown that a certain subgroup of patients are at high risk for further ischemic events despite antiplatelet therapy. This study, therefore, aimed to clarify the patients' clinical features and explore the impact of CEA for them.
   METHODS: This prospective cohort study included 74 patients who underwent CEA for symptomatic carotid stenosis between April 2012 and December 2016. Of these, 16 (22%) had mild (less than 50%) carotid stenosis. Their demographic, radiologic, intraoperative, and pathologic findings were precisely analyzed, and their outcome after CEA was examined for 38.5 +/- 13.3 months.
   RESULTS: Of these 16 patients, 12 had already been treated with antiplatelets against previous ischemic cerebrovascular or coronary artery diseases. Plaque magnetic resonance imaging revealed that all patients had vulnerable plaque, including lipid-rich plaque (n = 6) and intraplaque hemorrhage (n = 10). Intraoperative observations confirmed this. Histologic analysis revealed that inflammatory cells and fragile angiogenesis were widely found in the specimens. Only 1 patient experienced transient (less than 30 days) neurologic deficit after CEA, and none of them repeated cerebrovascular events during the follow-up period.
   -CONCLUSIONS: It is not rare the patients who are at high risk for subsequent ischemic events because of vulnerable plaque despite mild (less than 50%) carotid stenosis. Magnetic resonance imaging is quite useful to noninvasively detect such vulnerable plaque. CEA is a promising procedure to treat these patients.
C1 [Kashiwazaki, Daina] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
   Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Radiol, Toyama, Japan.
RP Kashiwazaki, D (reprint author), Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
EM dkashiwa@med.u-toyama.ac.jp
RI Uchino, Haruto/L-6627-2019
OI Uchino, Haruto/0000-0001-6567-8136
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16K10712]
FX This study was funded by the Japan Society for the Promotion of Science
   Grants-in-Aid for Scientific Research (16K10712).
CR Akioka Naoki, 2016, No Shinkei Geka, V44, P31, DOI 10.11477/mf.1436203204
   Altaf N, 2008, J VASC SURG, V47, P337, DOI 10.1016/j.jvs.2007.09.064
   Barben M, 2018, ADV EXP MED BIOL, V1074, P177, DOI 10.1007/978-3-319-75402-4_22
   Brinjikji W, 2016, J NEUROSURG, V124, P27, DOI 10.3171/2015.1.JNS142452
   Cho KY, 2013, J STROKE CEREBROVASC, V22, P910, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.020
   Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218
   Dieleman N, 2016, STROKE, V47, P1797, DOI 10.1161/STROKEAHA.116.013007
   Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1
   Gijsen FJH, 2015, STROKE, V46, P2124, DOI 10.1161/STROKEAHA.115.009707
   Hasegawa H, 2016, ATHEROSCLEROSIS, V250, P133, DOI 10.1016/j.atherosclerosis.2016.05.021
   Hatsukami TS, 2000, CIRCULATION, V102, P959, DOI 10.1161/01.CIR.102.9.959
   Hokari M, 2011, J NEUROIMAGING, V21, P348, DOI 10.1111/j.1552-6569.2010.00552.x
   Hyafil F, 2016, EUR J NUCL MED MOL I, V43, P270, DOI 10.1007/s00259-015-3201-8
   Iwasaki M, 2011, J STROKE CEREBROVASC, V20, P55, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.001
   Karlsson L, 2016, EUR J VASC ENDOVASC, V52, P287, DOI 10.1016/j.ejvs.2016.05.014
   Kashiwazaki D, 2016, J NEUROSURG, V125, P1549, DOI 10.3171/2015.10.JNS151500
   Kashiwazaki D, 2015, NEUROSURGERY, V76, P427, DOI 10.1227/NEU.0000000000000655
   Kashiwazaki D, 2012, J NEUROSURG, V117, P574, DOI 10.3171/2012.6.JNS111922
   Khurana D, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00027
   Lepedda AJ, 2009, ATHEROSCLEROSIS, V203, P112, DOI 10.1016/j.atherosclerosis.2008.07.001
   Lindsay AC, 2012, JACC-CARDIOVASC IMAG, V5, P388, DOI 10.1016/j.jcmg.2011.10.007
   Narumi S, 2013, AM J NEURORADIOL, V34, P191, DOI 10.3174/ajnr.A3249
   Parathath S, 2011, CIRC RES, V109, P1141, DOI 10.1161/CIRCRESAHA.111.246363
   Perez W, 2015, J CLIN MONIT COMPUT, V29, P713, DOI 10.1007/s10877-014-9657-4
   Purushothaman M, 2012, ARTERIOSCL THROM VAS, V32, P2769, DOI 10.1161/ATVBAHA.112.252122
   Saito H, 2013, CEREBROVASC DIS, V35, P370, DOI 10.1159/000348846
   Sato Y, 2016, AM J NEURORADIOL, V37, P1146, DOI 10.3174/ajnr.A4674
   Silvennoinen HM, 2007, AM J NEURORADIOL, V28, P97
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   Tekabe Y, 2018, MOL IMAGING BIOL, V20, P85, DOI 10.1007/s11307-017-1045-2
   Truijman MTB, 2014, STROKE, V45, P3423, DOI 10.1161/STROKEAHA.114.006800
   Uchino H, 2012, WORLD NEUROSURG, V78, P651, DOI 10.1016/j.wneu.2011.10.039
   Yoshida K, 2012, NEUROSURGERY, V70, P1143, DOI 10.1227/NEU.0b013e31823fe50b
NR 33
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E60
EP E69
DI 10.1016/j.wneu.2018.09.013
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000010
PM 30244188
DA 2020-05-12
ER

PT J
AU Keser, N
   Kuskucu, A
   Is, M
   Celikoglu, E
AF Keser, Nese
   Kuskucu, Aysegul
   Is, Merih
   Celikoglu, Erhan
TI Familial Chiari Type 1: A Molecular Karyotyping Study in a Turkish
   Family and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Array comparative genomic hybridization; Chiari type1 malformation;
   Familial; Molecular karyotyping; Posterior fossa; Suboccipital
   craniectomy; Syringomyelia
ID POSTERIOR-FOSSA DECOMPRESSION; MALFORMATION TYPE-I; SURGICAL-TREATMENT;
   2 SIBLINGS; ARRAY CGH; SYRINGOMYELIA; DURAPLASTY; EXPERIENCE;
   TONSILLECTOMY; METAANALYSIS
AB BACKGROUND: The etiology of Chiari I malformation (CMI) has not been fully elucidated. Therefore, we performed a genetic study of a Turkish family in which 3 sisters had a diagnosis of CMI with or without syringomyelia.
   METHODS: In a family with 7 children, 4 daughters complained of occipital headaches. In 2 of these daughters, CMI had been diagnosed during their 30s, and CMI plus syrinx had been diagnosed in the other daughter in her 40s. Cranial magnetic resonance imaging of the fourth daughter who had developed headaches during her 30s showed normal findings. Because the other siblings in the family were asymptomatic, radiological examinations were not performed. The family had a history of distant consanguineous marriage between parents. Additionally, the father had died, and the mother was asymptomatic, with radiologically normal findings. Array comparative genome hybridization studies were performed for 12 persons from 3 generations of this family.
   RESULTS: None of the 12 cases examined harbored copy number variations.
   CONCLUSIONS: This family with 3 sisters having CMI suggested a possible autosomal recessive single-gene etiology. Cases of familial CMI are unusual but important to study because they could reveal the specific genes involved in posterior fossa/foramen magnum structure and function and provide insights into the cause of sporadic cases.
C1 [Keser, Nese; Is, Merih; Celikoglu, Erhan] TR Univ Hlth Sci, Istanbul Fatih Sultan Mehmet Educ & Res Hosp, Dept Neurol Surg, Istanbul, Turkey.
   [Kuskucu, Aysegul] Yeditepe Univ, Fac Med, Dept Genet, Istanbul, Turkey.
RP Keser, N (reprint author), TR Univ Hlth Sci, Istanbul Fatih Sultan Mehmet Educ & Res Hosp, Dept Neurol Surg, Istanbul, Turkey.
EM nskeser@gmail.com
CR Alkuraya FS, 2013, CLIN GENET, V84, P203, DOI 10.1111/cge.12131
   Atkinson JLD, 1998, NEUROSURGERY, V42, P401, DOI 10.1097/00006123-199802000-00129
   Batzdorf U, 2013, J NEUROSURG, V118, P232, DOI 10.3171/2012.10.JNS12305
   Bayrakli F, 2010, CLIN GENET, V77, P499, DOI 10.1111/j.1399-0004.2010.01411.x
   Bejjani GK, 2001, CONT NEUROSURG, V23, P1
   Boyles AL, 2006, AM J MED GENET A, V140A, P2776, DOI 10.1002/ajmg.a.31546
   Caldarelli M, 2007, J NEUROSURG, V106, P187, DOI 10.3171/ped.2007.106.3.187
   Castiglione A, 2013, CYTOGENET GENOME RES, V141, P243, DOI 10.1159/000353846
   Chai Z, 2018, WORLD NEUROSURG, V113, P357, DOI 10.1016/j.wneu.2018.02.092
   Chauvet D, 2009, NEUROSURG REV, V32, P465, DOI 10.1007/s10143-009-0214-4
   Chotai S, 2018, PEDIATR NEUROSURG, V53, P108, DOI 10.1159/000485254
   Chotai S, 2014, CLIN NEUROL NEUROSUR, V125, P182, DOI 10.1016/j.clineuro.2014.07.027
   COLOMBO A, 1993, ITAL J NEUROL SCI, V14, P637, DOI 10.1007/BF02339249
   CORIA F, 1983, J NEUROL SCI, V62, P147, DOI 10.1016/0022-510X(83)90195-8
   Doberstein Cody A, 2017, R I Med J (2013), V100, P47
   Erdogan E, 2010, TURK NEUROSURG, V20, P303, DOI 10.5137/1019-5149.JTN.2648-09.2
   Forander P, 2014, CLIN NEUROL NEUROSUR, V125, P58, DOI 10.1016/j.clineuro.2014.07.019
   Fujisawa H, 2002, J NEUROSURG, V97, P396, DOI 10.3171/jns.2002.97.2.0396
   Fujita K, 2009, AM J NEURORADIOL, V30, P629, DOI 10.3174/ajnr.A1380
   Genitori L, 2000, CHILD NERV SYST, V16, P707, DOI 10.1007/s003810000338
   George S, 2006, EYE, V20, P400, DOI 10.1038/sj.eye.6701887
   GIMENEZROLDAN S, 1978, J NEUROL SCI, V36, P135, DOI 10.1016/0022-510X(78)90167-3
   da Silva JAG, 2011, ARQ NEURO-PSIQUIAT, V69, P817, DOI 10.1590/S0004-282X2011000600018
   Gripp KW, 1997, SKELETAL RADIOL, V26, P131, DOI 10.1007/s002560050207
   Gurbuz MS, 2015, TURK NEUROSURG, V25, P419, DOI 10.5137/1019-5149.JTN.11235-14.1
   HERMAN MD, 1991, PEDIATR NEUROSURG, V16, P183, DOI 10.1159/000120522
   Jeong JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003155
   Karagoz F, 2002, ACTA NEUROCHIR, V144, P165, DOI 10.1007/s007010200020
   Katsanis SH, 2013, NAT REV GENET, V14, P415, DOI 10.1038/nrg3493
   Koyanagi I, 2010, NEUROSURG REV, V33, P271, DOI 10.1007/s10143-010-0266-5
   Limonadi FM, 2004, J NEUROSURG, V101, P184, DOI 10.3171/ped.2004.101.2.0184
   Ma JP, 2012, TURK NEUROSURG, V22, P274, DOI 10.5137/1019-5149.JTN.4634-11.1
   Markunas CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061521
   Mavinkurve GG, 2005, CHILD NERV SYST, V21, P955, DOI 10.1007/s00381-005-1146-0
   Mesiwala AH, 2001, J NEUROSURG, V95, P1034, DOI 10.3171/jns.2001.95.6.1034
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   Murphy RL, 2006, CHILD NERV SYST, V22, P632, DOI 10.1007/s00381-005-0041-z
   Mutchnick IS, 2010, J NEUROSURG-PEDIATR, V5, P474, DOI 10.3171/2010.1.PEDS09218
   Nagy L, 2016, TURK NEUROSURG, V26, P315, DOI 10.5137/1019-5149.JTN.10471-14.1
   Noudel R, 2009, J NEUROSURG, V111, P1046, DOI 10.3171/2009.2.JNS08284
   Rusbridge C, 2006, J VET INTERN MED, V20, P469, DOI 10.1892/0891-6640(2006)20[469:SCCIPD]2.0.CO;2
   Sagoo GS, 2009, GENET MED, V11, P139, DOI 10.1097/GIM.0b013e318194ee8f
   Sanlaville D, 2005, EUR J MED GENET, V48, P214, DOI 10.1016/j.ejmg.2005.04.013
   Schanker BD, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.6.FOCUS11104
   Schimmenti LA, 1999, HUM MUTAT, V14, P369, DOI 10.1002/(SICI)1098-1004(199911)14:5<369::AID-HUMU2>3.0.CO;2-E
   Shimojima K, 2015, AM J MED GENET A, V167, P724, DOI 10.1002/ajmg.a.36959
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P202, DOI 10.1002/ca.22939
   Solth A, 2010, BRIT J NEUROSURG, V24, P607, DOI 10.3109/02688697.2010.495173
   Speer M C, 2000, Neurosurg Focus, V8, pE12
   Speer Marcy C, 2003, J Genet Couns, V12, P297, DOI 10.1023/A:1023948921381
   STOVNER LJ, 1995, EUR NEUROL, V35, P149
   STOVNER LJ, 1992, ANN NEUROL, V31, P220, DOI 10.1002/ana.410310213
   Szewka AJ, 2006, PEDIATR NEUROL, V34, P481, DOI 10.1016/j.pediatrneurol.2005.09.008
   Tubbs RS, 2008, J NEUROSURG-PEDIATR, V1, P21, DOI 10.3171/PED-08/01/021
   Tubbs RS, 2011, J NEUROSURG-PEDIATR, V7, P248, DOI 10.3171/2010.12.PEDS10379
   Turgut M, 2001, BRIT J NEUROSURG, V15, P279, DOI 10.1080/026886901750353773
   Urbizu A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057241
   Vermeesch JR, 2005, J HISTOCHEM CYTOCHEM, V53, P413, DOI 10.1369/jhc.4A6436.2005
   Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977
   Weisfeld-Adams JD, 2007, PEDIATR NEUROSURG, V43, P533, DOI 10.1159/000108803
   Welsch M, 2013, CHILD NERV SYST, V29, P1193, DOI 10.1007/s00381-013-2056-1
   Yabe I, 2002, CLIN NEUROL NEUROSUR, V105, P69, DOI 10.1016/S0303-8467(02)00091-4
   Yilmaz A, 2011, WORLD NEUROSURG, V75, P307, DOI 10.1016/j.wneu.2010.09.005
   ZAKERI A, 1995, SURG NEUROL, V44, P48, DOI 10.1016/0090-3019(96)85515-7
NR 65
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E852
EP E857
DI 10.1016/j.wneu.2018.09.235
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000105
PM 30315983
DA 2020-05-12
ER

PT J
AU Kimura, H
   Taniguchi, M
   Hayashi, K
   Fujimoto, Y
   Fujita, Y
   Sasayama, T
   Tomiyama, A
   Kohmura, E
AF Kimura, Hidehito
   Taniguchi, Masaaki
   Hayashi, Kosuke
   Fujimoto, Yosuke
   Fujita, Youichi
   Sasayama, Takashi
   Tomiyama, Akio
   Kohmura, Eiji
TI Clear Detection of Thin-Walled Regions in Unruptured Cerebral Aneurysms
   by Using Computational Fluid Dynamics
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Computational fluid dynamics; Visualization; Wall
   shear stress vector cycle variation; Wall thinning
ID INTRACRANIAL ANEURYSMS; SHEAR-STRESS; BIFURCATION; RUPTURE;
   HEMODYNAMICS; RISK; FLOW
AB OBJECTIVE: Thin-walled regions (TIWRs) within cerebral aneurysms have a high risk of rupture during surgical manipulation. Previous reports have demonstrated specific changes in the parameters of computational fluid dynamics in TIWRs; however, they have not been fully evaluated. We identified and investigated a novel parameter, wall shear stress vector cycle variation (WSSVV), with user-friendly software that could predict TIWRs.
   METHODS: Twelve unruptured cerebral aneurysms were analyzed. TIWRs were defined as reddish areas compared with the normal-colored parent artery on intraoperative views. The position and orientation of these clinical images were adjusted to match the WSSVV color maps. TIWRs and thick-walled regions (TKWRs) were marked and compared with the corresponding regions on WSSVV maps. The default images obtained from WSSVV imaging required appropriate maximum color bar value (MCBV) adjustment for predicting TIWRs. Sensitivity and specificity analyses were performed by changing the MCBV from 300 to 700 at intervals of 100. With the optimal MCBV, the WSSVV values were quantitatively compared.
   RESULTS: All of the selected 18 TIWRs and 16 TKWRs corresponded to low-and high-value regions of the WSSVV color maps at the adjusted MCBV, respectively. The mean optimal MCBVwas 483.3 +/- 167.50 (range, 300-700). According to receiver operating characteristic analysis, the best MCBV for predicting TIWRs was 500 (highest sensitivity, 0.89; specificity, 0.94). Under this condition, the quantitative values of the computational fluid dynamics color maps for TIWRs and TKWRs were significantly different (P < 0.01).
   CONCLUSIONS: Low WSSVV values may indicate TIWRs within cerebral aneurysms.
C1 [Kimura, Hidehito; Taniguchi, Masaaki; Fujimoto, Yosuke; Fujita, Youichi; Sasayama, Takashi; Kohmura, Eiji] Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
   [Hayashi, Kosuke; Tomiyama, Akio] Kobe Univ, Dept Mech Engn, Grad Sch Engn, Kobe, Hyogo, Japan.
RP Kimura, H (reprint author), Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
EM hkimura@med.kobe-u.ac.jp
RI Taniguchi, Masaaki/AAM-4198-2020
OI Taniguchi, Masaaki/0000-0003-4678-2573; Sasayama,
   Takashi/0000-0002-5593-9045
CR Aburakawa D, 2017, NEUROSURG REV, V40, P517, DOI 10.1007/s10143-017-0866-4
   Cebral JR, 2011, AM J NEURORADIOL, V32, P264, DOI 10.3174/ajnr.A2274
   Chen SF, 2016, J CLIN NEUROSCI, V34, P63, DOI 10.1016/j.jocn.2016.01.045
   Chen XL, 2017, WORLD NEUROSURG, V101, P149, DOI 10.1016/j.wneu.2017.01.097
   Chen ZY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01906-x
   De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094
   Edjlali M, 2014, STROKE, V45, P3704, DOI 10.1161/STROKEAHA.114.006626
   Furukawa H, 2014, PROG CI, V36, P73
   Furukawa K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191287
   Hayakawa M, 2011, NEUROSURGERY, V69, P843, DOI 10.1227/NEU.0b013e318225b2d3
   Hsu CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151805
   Kadasi LM, 2013, J NEUROSURG, V119, P172, DOI 10.3171/2013.2.JNS12968
   Kadasi LM, 2013, J NEUROINTERV SURG, V5, P201, DOI 10.1136/neurintsurg-2012-010285
   Kolega J, 2011, J VASC RES, V48, P429, DOI 10.1159/000324840
   KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293
   Lu X, 2004, J PHYSIOL-LONDON, V561, P575, DOI 10.1113/jphysiol.2004.075218
   Marzo A, 2011, ANN BIOMED ENG, V39, P884, DOI 10.1007/s10439-010-0187-z
   Park YK, 2018, WORLD NEUROSURG, V114, pE605, DOI 10.1016/j.wneu.2018.03.040
   Rashad S, 2018, J NEUROSURG, V128, P723, DOI 10.3171/2016.10.JNS161695
   Russell JH, 2013, NEUROSURGERY, V73, P1061, DOI 10.1227/NEU.0000000000000137
   Song J, 2015, NEUROL SCI, V36, P907, DOI 10.1007/s10072-015-2101-9
   Stapleton CJ, 2015, J NEUROSURG, V122, P128, DOI 10.3171/2014.9.JNS14616
   Sugiyama S, 2016, COMPUT MATH METHOD M, DOI 10.1155/2016/2386031
   Sugiyama S, 2013, NEUROSURGERY, V73, P767, DOI 10.1227/NEU.0000000000000096
   Suzuki D., 2015, J BIOMECH SCI ENG, V10, P1
   Suzuki T, 2016, NEUROSURGERY, V79, P589, DOI 10.1227/NEU.0000000000001232
   Talari S, ASIAN J
   van Wyk S, 2014, COMPUT BIOL MED, V50, P56, DOI 10.1016/j.compbiomed.2014.03.006
   Yagi T, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.1031
   Zhang Y, 2011, EUR NEUROL, V66, P359, DOI 10.1159/000332814
NR 30
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E287
EP E295
DI 10.1016/j.wneu.2018.09.098
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000037
PM 30253995
OA Green Published
DA 2020-05-12
ER

PT J
AU Kinali, B
   Senoglu, M
   Karadag, FK
   Karadag, A
   Middlebrooks, EH
   Oksuz, P
   Sandal, E
   Turk, C
   Diniz, G
AF Kinali, Burak
   Senoglu, Mehmet
   Karadag, Fatma Keklik
   Karadag, Ali
   Middlebrooks, Erik H.
   Oksuz, Pinar
   Sandal, Evren
   Turk, Caglar
   Diniz, Gulden
TI Hypoxia-Inducible Factor 1 alpha and AT-Rich Interactive
   Domain-Containing Protein 1A Expression in Pituitary Adenomas:
   Association with Pathological, Clinical, and Radiological Features
SO WORLD NEUROSURGERY
LA English
DT Article
DE ARID1A; Hypoxia-inducible factor 1; alpha-subunit; Immunohistochemistry;
   Pituitary adenoma
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; CLEAR-CELL CARCINOMA;
   ARID1A EXPRESSION; O-2 HOMEOSTASIS; POOR-PROGNOSIS; BREAST; HIF-1-ALPHA;
   APOPTOSIS; CANCER
AB BACKGROUND: Hypoxia-inducible factor (HIF) plays a major role in tumorigenesis and cancer progression. In hypoxic conditions, HIF is upregulated and has been shown to activate multiple genes required for cells to adapt to hypoxia. AT-rich interactive domain-containing protein 1A (ARID1A), a SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling gene has context-dependent tumorsuppressive and oncogenic roles in cancer. We assessed the correlations between the expression and mutations of HIF1A and ARID1A in histopathologically confirmed pituitary adenomas.
   METHODS: We performed a retrospective analysis of 71 patients who had undergone surgery for pituitary adenoma. Patient demographic, radiological, and histopathological features were correlated with HIF1A and ARID1A expression.
   RESULTS: Most cases were HIF1A positive (62%). No significant correlation was found between HIF1A expression and age, gender, tumor size, bone erosion, hemorrhage, or Ki-67 index. An inverse correlation was demonstrated between HIF1A and cavernous sinus invasion (P = 0.035). ARID1A loss was found in 28.2% of pituitary adenomas. No significant correlation was found between ARID1A and any of the assessed variables.
   CONCLUSIONS: In our patient cohort, we found that most pituitary adenomas expressed HIF1A. To the best of our knowledge, we are the first to assess the presence of ARID1A loss in pituitary adenomas, which occurred in 28.2% of cases. No individual demographic, imaging, or histopathological feature was predictive of ARID1A. Likewise, with the exception of an increased incidence of cavernous sinus invasion, no correlation was found with HIF1A. Given the prognostic value of these markers in other malignancies, their frequency in pituitary adenomas warrants further exploration of their potential role in pituitary adenoma treatment and outcome.
C1 [Kinali, Burak; Senoglu, Mehmet; Karadag, Ali; Sandal, Evren; Turk, Caglar] Univ Hlth Sci, Tepecik Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
   [Oksuz, Pinar; Diniz, Gulden] Univ Hlth Sci, Tepecik Res & Training Hosp, Dept Pathol, Izmir, Turkey.
   [Karadag, Fatma Keklik] Ege Univ, Med Fac Hosp, Dept Hematol, Izmir, Turkey.
   [Middlebrooks, Erik H.] Mayo Clin, Dept Radiol, Jacksonville, FL 32224 USA.
   [Middlebrooks, Erik H.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
RP Senoglu, M (reprint author), Univ Hlth Sci, Tepecik Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
EM mehmetsenoglu@hotmail.com
RI Middlebrooks, Erik/Q-9389-2019
OI Middlebrooks, Erik/0000-0002-4418-9605; KINALI,
   BURAK/0000-0002-1124-6888
CR Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144
   Bunn HF, 1996, PHYSIOL REV, V76, P839
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339
   Dai S, 2003, INT J RADIAT ONCOL, V55, P1027, DOI 10.1016/S0360-3016(02)04507-8
   Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35
   Goda N, 2003, ANTIOXID REDOX SIGN, V5, P467, DOI 10.1089/152308603768295212
   Heckl M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192881
   Iida T, 2002, GENES CELLS, V7, P143, DOI 10.1046/j.1356-9597.2001.00512.x
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Kim K, 2005, ENDOCR PATHOL, V16, P115, DOI 10.1385/EP:16:2:115
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Kouroupi M, 2018, IN VIVO, V32, P185, DOI 10.21873/invivo.11223
   Kristof RA, 2003, NEUROSURGERY, V53, P880, DOI 10.1227/01.NEU.0000083604.09901.F6
   Kun Zhang, 2016, Technol Cancer Res Treat, V15, pNP95
   Lee SY, 2015, ONCOLOGY-BASEL, V88, P234, DOI 10.1159/000369140
   Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200
   Li JH, 2016, HUM PATHOL, V55, P17, DOI 10.1016/j.humpath.2016.04.006
   Liu Wei, 2012, Int J Biochem Mol Biol, V3, P165
   Luchini C, 2015, ONCOTARGET, V6, P39088, DOI 10.18632/oncotarget.5142
   Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386
   Nagymanyoki Z, 2015, CANCER CYTOPATHOL, V123, P253, DOI 10.1002/cncy.21514
   Nishikimi K, 2015, HISTOPATHOLOGY, V67, P866, DOI 10.1111/his.12721
   Onder S, 2017, BREAST J, V23, P638, DOI 10.1111/tbj.12823
   Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200
   Sausen M, 2013, NAT GENET, V45, P12, DOI 10.1038/ng.2493
   Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79
   Takao C, 2017, J CANCER, V8, P1, DOI 10.7150/jca.16602
   Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3
   Vidal S, 2003, HISTOL HISTOPATHOL, V18, P679, DOI 10.14670/HH-18.679
   Wang DH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039920
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wei XL, 2014, WORLD J GASTROENTERO, V20, P18404, DOI 10.3748/wjg.v20.i48.18404
   Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911
   Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361
   Xu N, 2019, PATHOL ONCOL RES, V25, P875, DOI 10.1007/s12253-017-0338-8
   Yamamoto S, 2012, VIRCHOWS ARCH, V460, P77, DOI 10.1007/s00428-011-1169-8
   Yokoyama Y, 2014, J GYNECOL ONCOL, V25, P58, DOI 10.3802/jgo.2014.25.1.58
   Yoshida D, 2006, J NEURO-ONCOL, V78, P217, DOI 10.1007/s11060-005-9017-9
   Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.3.CO;2-N
   Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhu YP, 2018, HUM PATHOL, V78, P28, DOI 10.1016/j.humpath.2018.04.003
   Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51
NR 47
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E716
EP E722
DI 10.1016/j.wneu.2018.09.196
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000088
PM 30292665
DA 2020-05-12
ER

PT J
AU Kotowski, M
   Farzin, B
   Fahed, R
   Guilbert, F
   Chagnon, M
   Darsaut, TE
   Daniel, RT
   Raymond, J
AF Kotowski, Marc
   Farzin, Behzad
   Fahed, Robert
   Guilbert, Francois
   Chagnon, Miguel
   Darsaut, Tim E.
   Daniel, Roy T.
   Raymond, Jean
TI Residual Cerebral Aneurysms After Microsurgical Clipping: A New Scale,
   an Agreement Study, and a Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Agreement; Classification; Reliability; Residual aneurysm; Surgical
   clipping
ID UNRUPTURED INTRACRANIAL ANEURYSMS; DIGITAL-SUBTRACTION-ANGIOGRAPHY;
   COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ENDOVASCULAR TREATMENT;
   SURGICAL-TREATMENT; FOLLOW-UP; POSTOPERATIVE ANGIOGRAPHY; ARTERY
   ANEURYSMS; INTRAOPERATIVE ANGIOGRAPHY; CONSECUTIVE SERIES
AB OBJECTIVE: The surgical repair of a cerebral aneurysm does not always lead to complete occlusion. A standardized repeatable method of reporting results of surgical clipping is desirable. Our purpose was to systematically review methods of classifying aneurysm remnants, provide a new scale with precise definitions of categories, and perform an agreement study to assess the variability in adjudicating remnants after aneurysm clipping.
   METHODS: A systematic review was performed to identify ways to report angiographic results of surgical clipping between 1963 and 2017. Postclipping angiographic results of 43 patients were also independently evaluated by 10 raters of various experience and backgrounds using a new 4-category scale. Agreement between responses were analyzed using k statistics.
   RESULTS: The systematic review yielded 63 articleswith 37 different nomenclatures using 2-6 categories. The reliability of judging the presence of an aneurysm remnant on catheter angiography was studied only twice, with only 2 raters each time, with contradictory results. Interobserver agreement using the new 4-category scale was moderate (k = 0.52; 95% confidence interval, 0.43-0.62) for all observers, but improved to substantial (k = 0.62; 95% confidence interval, 0.47-0.76) when results were dichotomized (grade 0/1 vs. 2/3).
   CONCLUSIONS: Various classification schemes to evaluate angiographic results after surgical clipping exist in the literature, but they lack standardization. Adjudication using fewer, better defined categories may yield more reliable agreement.
C1 [Kotowski, Marc; Farzin, Behzad; Fahed, Robert; Guilbert, Francois; Raymond, Jean] CHUM, Dept Radiol, Montreal, PQ, Canada.
   [Kotowski, Marc; Daniel, Roy T.] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.
   [Fahed, Robert] Fondati Rothschild Hosp, Intervent Neuroradiol Unit, Paris, France.
   [Chagnon, Miguel] Univ Montreal, Dept Math & Stat, Montreal, PQ, Canada.
   [Darsaut, Tim E.] Univ Alberta Hosp, Div Neurosurg, Dept Surg, Mackenzie Hlth Sci Ctr, Edmonton, AB, Canada.
   [Daniel, Roy T.] CHU Vaudois, Dept Clin Neurosci, NeurosurgUnit, Lausanne, Switzerland.
RP Raymond, J (reprint author), CHUM, Dept Radiol, Montreal, PQ, Canada.
EM jean.raymond@umontreal.ca
OI Guilbert, Francois/0000-0002-7866-0493
CR Acevedo JC, 1997, NEUROCHIRURGIE, V43, P275
   Aghakhani N, 2008, NEUROSURGERY, V62, P1227, DOI 10.1227/01.neu.0000333294.52115.28
   Akyuz M, 2004, ACTA NEUROCHIR, V146, P245, DOI 10.1007/s00701-003-0206-z
   Al-Schameri AR, 2015, AM J NEURORADIOL, V36, P1704, DOI 10.3174/ajnr.A4399
   ALLCOCK JM, 1963, J NEUROSURG, V20, P752, DOI 10.3171/jns.1963.20.9.0752
   ALLCOCK JM, 1965, J NEUROSURG, V22, P21, DOI 10.3171/jns.1965.22.1.0021
   AUSMAN JI, 1989, SURG NEUROL, V32, P21, DOI 10.1016/0090-3019(89)90031-1
   Bernat AL, 2017, J NEURORADIOLOGY, V44, P298, DOI 10.1016/j.neurad.2017.05.003
   Bharatha A, 2010, J COMPUT ASSIST TOMO, V34, P440, DOI 10.1097/RCT.0b013e3181d27393
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Cho WS, 2017, WORLD NEUROSURG, V100, P316, DOI 10.1016/j.wneu.2017.01.042
   Choi Seung Won, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P289, DOI 10.7461/jcen.2012.14.4.289
   CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M
   Cloft HJ, 2011, AM J NEURORADIOL, V32, P219, DOI 10.3174/ajnr.A2432
   D'Angelo V, 1998, J Neurosurg Sci, V42, P93
   Dandy WE, 1938, ANN SURG, V107, P654, DOI 10.1097/00000658-193805000-00003
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   David CA, 1999, J NEUROSURG, V91, P396, DOI 10.3171/jns.1999.91.3.0396
   Dehdashti AR, 2016, WORLD NEUROSURG, V91, P34, DOI 10.1016/j.wneu.2016.03.051
   Dehdashti AR, 2006, J NEUROSURG, V104, P395, DOI 10.3171/jns.2006.104.3.395
   Dolati P, 2015, WORLD NEUROSURG, V84, P1362, DOI 10.1016/j.wneu.2015.06.027
   Dong QL, 2016, INT J SURG, V32, P129, DOI 10.1016/j.ijsu.2016.07.004
   DRAKE CG, 1967, J NEUROSURG, V27, P226, DOI 10.3171/jns.1967.27.3.0226
   DRAKE CG, 1973, J NEUROSURG, V39, P683, DOI 10.3171/jns.1973.39.6.0683
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   FEUERBERG I, 1987, J NEUROSURG, V66, P30, DOI 10.3171/jns.1987.66.1.0030
   Fiehler J, 2009, CURR OPIN NEUROL, V22, P103, DOI 10.1097/WCO.0b013e32831af1c1
   Futami K, 2004, NEUROL MED-CHIR, V44, P6, DOI 10.2176/nmc.44.6
   Gerardin E, 2010, ACTA NEUROCHIR, V152, P793, DOI 10.1007/s00701-009-0465-4
   Golitz P, 2014, NEUROSURGERY, V74, P606, DOI 10.1227/NEU.0000000000000326
   Golitz P, 2012, J NEUROSURG, V117, P29, DOI 10.3171/2012.3.JNS111895
   Goksu E, 2015, TURK NEUROSURG, V25, P404, DOI 10.5137/1019-5149.JTN.10299-14.3
   Hallout S, 2015, WORLD NEUROSURG, V84, P972, DOI 10.1016/j.wneu.2015.05.069
   Han MH, 2007, J KOREAN NEUROSURG S, V42, P103
   Hauck EF, 2008, J NEUROSURG, V109, P1012, DOI 10.3171/JNS.2008.109.12.1012
   Ihm EH, 2010, J KOREAN NEUROSURG S, V48, P330, DOI 10.3340/jkns.2010.48.4.330
   Jabbarli R, 2016, J NEUROSURG, V125, P1249, DOI 10.3171/2015.10.JNS151536
   Jamali S, 2016, AM J NEURORADIOL, V37, P879, DOI 10.3174/ajnr.A4609
   Jin SC, 2009, J KOREAN NEUROSURG S, V45, P224, DOI 10.3340/jkns.2009.45.4.224
   Kakucs C, 2017, WORLD NEUROSURG, V105, P406, DOI 10.1016/j.wneu.2017.05.172
   Kang HS, 2004, AM J NEURORADIOL, V25, P1463
   Kim LJ, 2014, NEUROSURGERY, V74, P51, DOI 10.1227/NEU.0000000000000192
   Kivisaari RP, 2004, NEUROSURGERY, V55, P1015, DOI 10.1227/01.NEU.0000141043.07303.60
   Klompenhouwer EG, 2011, AM J NEURORADIOL, V32, P570, DOI 10.3174/ajnr.A2326
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Konczalla J, 2015, NEUROSURGERY, V76, P540, DOI 10.1227/NEU.0000000000000672
   Kotowski M, 2013, J NEUROL NEUROSUR PS, V84, P42, DOI 10.1136/jnnp-2011-302068
   Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002
   Kumar Subhash, 2014, ISRN Radiol, V2014, P935280, DOI 10.1155/2014/935280
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LIN T, 1989, J NEUROSURG, V70, P556, DOI 10.3171/jns.1989.70.4.0556
   Lubicz B, 2004, NEURORADIOLOGY, V46, P318, DOI 10.1007/s00234-004-1165-7
   Macdonald RL, 2015, J NEUROSURG, V123, P605, DOI 10.3171/2014.11.JNS142261
   MCKISSOCK W, 1965, J NEUROSURG, V23, P547, DOI 10.3171/jns.1965.23.5.0547
   Meyer B, 2004, ZBL NEUROCHIR, V65, P49
   Mielke D, 2014, OPER NEUROSURG, V10, P418, DOI 10.1227/NEU.0000000000000345
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Murphy M, 2005, BRIT J NEUROSURG, V19, P225, DOI 10.1080/02688690500202067
   Nanda A, 2002, SURG NEUROL, V58, P309, DOI 10.1016/S0090-3019(02)00884-4
   Natarajan SK, 2008, AM J NEURORADIOL, V29, P753, DOI 10.3174/ajnr.A0895
   Nossek E, 2016, NEUROSURG REV, V39, P225, DOI 10.1007/s10143-015-0677-4
   Ogilvy CS, 2002, NEUROSURGERY, V51, P14, DOI 10.1097/00006123-200207000-00003
   Ota Nakao, 2015, Surg Neurol Int, V6, pS553, DOI 10.4103/2152-7806.168072
   Ozgiray E, 2013, CLIN NEUROL NEUROSUR, V115, P870, DOI 10.1016/j.clineuro.2012.08.027
   Park J, 2011, NEUROSURGERY, V68, P300, DOI 10.1227/NEU.0b013e3182124810
   Pechlivanis I, 2008, ACTA NEUROCHIR, V150, P669, DOI 10.1007/s00701-008-1515-z
   Popadic A, 2001, NEURORADIOLOGY, V43, P466, DOI 10.1007/s002340000506
   Psychogios MN, 2011, AM J NEURORADIOL, V32, P1956, DOI 10.3174/ajnr.A2611
   Rabinstein AA, 2002, STROKE, V33, P1809, DOI 10.1161/01.STR.0000019600.39315.D0
   Raco A, 2008, J NEUROSURG, V108, P1200, DOI 10.3171/JNS/2008/108/6/1200
   Raymond J, 1997, J NEUROSURG, V86, P211, DOI 10.3171/jns.1997.86.2.0211
   Raymond J, 2007, AM J NEURORADIOL, V28, P501
   Rodriguez-Hernandez A, 2017, NEUROSURGERY, V80, P908, DOI 10.1093/neuros/nyw111
   Rodriguez-Hernandez A, 2013, NEUROSURGERY, V72, P415, DOI 10.1227/NEU.0b013e3182804aa2
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Sakuma I, 2006, CLIN RADIOL, V61, P505, DOI 10.1016/j.crad.2006.01.011
   Sanai N, 2010, CHILD NERV SYST, V26, P1319, DOI 10.1007/s00381-010-1210-2
   Seifert V, 2008, DTSCH ARZTEBL INT, V105, P449, DOI 10.3238/arztebl.2008.0449
   Sindou R, 1998, ACTA NEUROCHIR, V140, P1153, DOI 10.1007/s007010050230
   Sughrue ME, 2011, NEUROSURGERY, V69, P1261, DOI 10.1227/NEU.0b013e31822bb8a6
   Suzuki S, 2011, INTERV NEURORADIOL, V17, P49, DOI 10.1177/159101991101700108
   Taniguchi R, 1999, J NEUROSURG, V91, P231, DOI 10.3171/jns.1999.91.2.0231
   Thines L, 2012, CAN J NEUROL SCI, V39, P174, DOI 10.1017/S0317167100013184
   Thines L, 2010, NEUROSURGERY, V67, P844, DOI 10.1227/01.NEU.0000374684.10920.A2
   Tollard E, 2012, AM J NEURORADIOL, V33, P626, DOI 10.3174/ajnr.A2848
   Tsutsumi K, 2001, STROKE, V32, P1191, DOI 10.1161/01.STR.32.5.1191
   Uysal E, 2009, ACTA NEUROCHIR, V151, P131, DOI 10.1007/s00701-009-0184-x
   Wachter D, 2010, CENT EUR NEUROSURG, V71, P121, DOI 10.1055/s-0030-1261946
   Yadla S, 2011, NEUROSURGERY, V68, P1434, DOI 10.1227/NEU.0b013e31820b4f85
   Yamakawa Hiroyasu, 1997, Neurologia Medico-Chirurgica, V37, P380, DOI 10.2176/nmc.37.380
NR 93
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E302
EP E321
DI 10.1016/j.wneu.2018.09.100
PG 20
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000039
PM 30261387
DA 2020-05-12
ER

PT J
AU Kuo, CH
   Feroze, AH
   Poliachik, SL
   Hauptman, JS
   Novotny, EJ
   Ojemann, JG
AF Kuo, Chao-Hung
   Feroze, Abdullah H.
   Poliachik, Sandra L.
   Hauptman, Jason S.
   Novotny, Edward J., Jr.
   Ojemann, Jeffrey G.
TI Laser Ablation Therapy for Pediatric Patients with Intracranial Lesions
   in Eloquent Areas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Epilepsy; Laser ablation; LITT; Pediatric
ID INTERSTITIAL THERMAL THERAPY; GUIDED RADIOFREQUENCY THERMOCOAGULATION;
   GRADE GLIOMAS; AMYGDALOHIPPOCAMPOTOMY; EPILEPSY; PHYSICS
AB BACKGROUND: Laser interstitial thermal therapy (LITT) is an alternative, less-invasive, and, in some circumstances, effective treatment for patients with intracranial pathology including epilepsy and some tumors. For intracranial lesions in eloquent areas, resection by conventional craniotomy proves often to be a challenge, including in the care of pediatric patients. Herein, we reviewed our experience with magnetic resonance imaging (MRI)-guided LITTas treatment for pediatric patients with intracranial lesions in eloquent areas and evaluate neurologic function and clinical outcomes.
   METHODS: We retrospectively reviewed consecutive patients with intracranial lesions in eloquent speech and motor areas who underwent MRI-guided LITT. Clinical evaluation, including neurologic function and neuropsychological testing, was conducted according to clinical considerations. MRI pre-and postoperative imaging was reviewed to compare the change of lesion size.
   RESULTS: Five pediatric patients received MRI-guided LITT of intracranial lesions in eloquent cortex. One patient experienced complications secondary to MRI-guided LITT, but neither was discharged with a neurologic deficit.
   CONCLUSIONS: For intracranial lesions in the eloquent cortex, conventional craniotomy with surgical resection is a challenge for neurosurgeons, especially pediatric patients. MRI-guided LITT provides a less-invasive and potentially effective option for treatment in the management of pediatric epilepsy and tumors.
C1 [Kuo, Chao-Hung; Feroze, Abdullah H.; Hauptman, Jason S.; Ojemann, Jeffrey G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Novotny, Edward J., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
   [Kuo, Chao-Hung] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
   [Kuo, Chao-Hung] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Poliachik, Sandra L.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA.
   [Poliachik, Sandra L.; Novotny, Edward J., Jr.] Seattle Childrens Hosp, Dept Neurol, Seattle, WA USA.
   [Hauptman, Jason S.; Ojemann, Jeffrey G.] Seattle Childrens Hosp, Div Neurosurg, Seattle, WA USA.
RP Kuo, CH (reprint author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.; Kuo, CH (reprint author), Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.; Kuo, CH (reprint author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
EM chaohungk@gmail.com
OI Kuo, Chao-Hung/0000-0001-5528-204X
CR Ashraf O, 2018, WORLD NEUROSURG, V112, P166, DOI [10.1016/j.wneu.2018.01.123, 10.1016/J.WNEU.2018.01.123]
   Attiah MA, 2015, EPILEPSY RES, V115, P1, DOI 10.1016/j.eplepsyres.2015.05.007
   Bettag M, 1991, Acta Neurochir Suppl (Wien), V52, P81
   Bourdillon P, 2017, EPILEPSIA, V58, P85, DOI 10.1111/epi.13616
   Buckley RT, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16236
   Cossu M, 2015, J NEUROSURG, V123, P1358, DOI 10.3171/2014.12.JNS141968
   Drane DL, 2015, EPILEPSIA, V56, P101, DOI 10.1111/epi.12860
   Franck P, 2016, CLIN PLAST SURG, V43, P505, DOI 10.1016/j.cps.2016.03.007
   Gross RE, 2016, NEUROSURG CLIN N AM, V27, P37, DOI 10.1016/j.nec.2015.08.004
   Iyer A, 2016, CUREUS, V8, DOI 10.7759/cureus.919
   Karsy Michael, 2018, Neurosurg Focus, V44, pV2, DOI 10.3171/2018.4.FocusVid.17721
   LaRiviere MJ, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00064
   Lewis EC, 2015, EPILEPSIA, V56, P1590, DOI 10.1111/epi.13106
   Mohammadi AM, 2014, CANCER MED-US, V3, P971, DOI 10.1002/cam4.266
   Moles A, 2018, J NEUROL, V265, P1998, DOI 10.1007/s00415-018-8958-9
   Patel NV, 2016, NEUROSURGERY, V79, pS8, DOI 10.1227/NEU.0000000000001440
   Perry MS, 2017, J NEUROSURG-PEDIATR, V20, P575, DOI 10.3171/2017.6.PEDS17158
   Prince E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0772-8
   Pruitt R, 2017, J NEUROSURG, V126, P1238, DOI 10.3171/2016.3.JNS152147
   Rodriguez A, 2016, NEUROSURGERY, V79, pS35, DOI 10.1227/NEU.0000000000001442
   Smith CJ, 2016, NEUROSURGERY, V79, pS59, DOI 10.1227/NEU.0000000000001438
   SUGIYAMA K, 1990, STEREOT FUNCT NEUROS, V54-5, P501, DOI 10.1159/000100263
   Tatsui CE, 2016, NEUROSURGERY, V79, pS73, DOI 10.1227/NEU.0000000000001444
   Thomas JG, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16234
   Tovar-Spinoza Z, 2016, CHILD NERV SYST, V32, P1947, DOI 10.1007/s00381-016-3193-0
   Tovar-Spinoza Z, 2016, J NEUROSURG-PEDIATR, V17, P723, DOI 10.3171/2015.11.PEDS15242
   Wei PH, 2018, WORLD NEUROSURG, V114, pE1073, DOI 10.1016/j.wneu.2018.03.148
   Wicks RT, 2016, NEUROSURGERY, V79, pS83, DOI 10.1227/NEU.0000000000001439
   Willie JT, 2014, NEUROSURGERY, V74, P569, DOI 10.1227/NEU.0000000000000343
   Xu DS, 2018, NEUROSURGERY, V83, P1183, DOI 10.1093/neuros/nyx604
NR 30
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E183
EP E191
DI 10.1016/j.wneu.2018.09.074
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000026
PM 30261370
DA 2020-05-12
ER

PT J
AU Kwon, SM
   Chun, HJ
   Yi, HJ
   Kim, YS
   Kim, KD
AF Kwon, Sae Min
   Chun, Hyoung-Joon
   Yi, Hyeong-Joong
   Kim, Young-Soo
   Kim, Kee D.
TI Computed Tomographic Assessment of Sagittal Plane Alignment of the
   Thoracolumbar Junction in a Young Adult Korean Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cobb angle; Kyphosis; Radiographic analysis; Sagittal alignment;
   Thoracolumbar junction
ID LUMBAR LORDOSIS; THORACIC KYPHOSIS; FRACTURE KYPHOSIS; BURST FRACTURES;
   SPINE; MANAGEMENT; INTRAOBSERVER; INTEROBSERVER; PARAMETERS; ANGULATION
AB OBJECTIVE: The purpose of this study was to determine reference values for the sagittal plane alignment of the thoracolumbar junction (TLJ) in a young adult Korean population.
   METHODS: Thoracolumbar computed tomography (CT) scans of 1000 individuals (age range, 20-39 years; 500 men and 500 women) from Hanyang University Health Care Center were reviewed. All subjects had no spinal pathology or a history of previous spinal surgery. The segmental (each level from T11 to L2) and global (T11-L1 and T11-L2) Cobb angles of the TLJ of the spine were measured in midsagittal CT scans. Moreover, comparisons between the 2 age groups (20s and 30s) and sexes were performed.
   RESULTS: The segmental Cobb angles of T11, T12, L1, and L2 were 6.5 degrees +/- 3.9 degrees, 5.5 degrees +/- 4.1 degrees, 2.2 degrees +/- 4.7 degrees, and L3.3 degrees +/- 5.3 degrees, respectively. The global Cobb angles of T11-L1 and T11-L2 were 6.5 degrees +/- 5.2 degrees and 0.5 degrees +/- 6.1 degrees, respectively. There were no differences in the sagittal alignment between the 2 age groups. Women presented less kyphotic and more lordotic alignment in the lumbar spine (L1 and L2) than men; however, the thoracic spine (T11 and T12) alignment was not different between the 2 groups.
   CONCLUSIONS: This study provides reference values with a wide physiologic range for the sagittal alignment of the TLJ of the spine in a young adult Korean population.
C1 [Kwon, Sae Min] Univ Ulsan, Dept Neurol Surg, Asan Med Ctr, Coll Med, Seoul, South Korea.
   [Chun, Hyoung-Joon; Yi, Hyeong-Joong; Kim, Young-Soo] Hanyang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Kim, Kee D.] Univ Calif Davis, Neurol Surg, Sacramento, CA 95817 USA.
RP Yi, HJ (reprint author), Hanyang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM tdy815@hanyang.ac.kr
OI Kwon, Sae Min/0000-0001-9720-6037
CR Abdel MP, 2012, SPINE, V37, P340, DOI 10.1097/BRS.0b013e31821946d1
   Asai Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178697
   Bartynski WS, 2005, AM J NEURORADIOL, V26, P2077
   BERNHARDT M, 1989, SPINE, V14, P717, DOI 10.1097/00007632-198907000-00012
   Borg-Stein J, 2005, AM J PHYS MED REHAB, V84, P180, DOI 10.1097/01.PHM.0000156970.96219.48
   Cahueque M, 2016, J ORTHOP, V13, P278, DOI 10.1016/j.jor.2016.06.007
   Crawford MB, 2009, AM J ROENTGENOL, V193, pW33, DOI 10.2214/AJR.08.2026
   D'Amico M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179619
   Dai LY, 2008, SPINE, V33, P2536, DOI 10.1097/BRS.0b013e3181851bc2
   DIACINTI D, 1995, CALCIFIED TISSUE INT, V57, P426, DOI 10.1007/BF00301945
   FARCY JPC, 1990, SPINE, V15, P958, DOI 10.1097/00007632-199009000-00022
   FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979
   Iyer S, 2016, SPINE, V41, P1826, DOI 10.1097/BRS.0000000000001642
   Janssen MMA, 2009, SPINE, V34, pE826, DOI 10.1097/BRS.0b013e3181a9fd85
   Jiang SD, 2012, ARCH ORTHOP TRAUM SU, V132, P221, DOI 10.1007/s00402-011-1394-2
   Keynan O, 2006, SPINE, V31, pE156, DOI 10.1097/01.brs.0000201261.94907.0d
   Kuklo TR, 2001, SPINE, V26, P61, DOI 10.1097/00007632-200101010-00012
   Lee CS, 2011, SPINE, V36, pE1648, DOI 10.1097/BRS.0b013e318216b0fd
   Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591
   Masharawi Y, 2010, EUR SPINE J, V19, P768, DOI 10.1007/s00586-009-1256-6
   Nourbakhsh MR, 2001, J SPINAL DISORD, V14, P283, DOI 10.1097/00002517-200108000-00002
   Polly DW, 1996, SPINE, V21, P1530, DOI 10.1097/00007632-199607010-00008
   Prescher A, 1998, EUR J RADIOL, V27, P181, DOI 10.1016/S0720-048X(97)00165-4
   Sadiqi S, 2017, EUR SPINE J, V26, P1483, DOI 10.1007/s00586-016-4716-9
   STAGNARA P, 1982, SPINE, V7, P335, DOI 10.1097/00007632-198207000-00003
   Ulmar B, 2010, ARCH ORTHOP TRAUM SU, V130, P1533, DOI 10.1007/s00402-010-1104-5
   Vedantam R, 1998, SPINE, V23, P211, DOI 10.1097/00007632-199801150-00012
   Vialle R, 2005, J BONE JOINT SURG AM, V87A, P260, DOI 10.2106/JBJS.D.02043
   Watanabe Satoshi, 2006, Legal Medicine, V8, P156, DOI 10.1016/j.legalmed.2006.01.001
   Whitcome KK, 2007, NATURE, V450, P1075, DOI 10.1038/nature06342
   Wood KB, 1996, J SPINAL DISORD, V9, P165
   Wood KB, 2014, SPINE J, V14, P145, DOI 10.1016/j.spinee.2012.10.041
   Zhu ZZ, 2014, SPINE, V39, pE1, DOI 10.1097/BRS.0000000000000022
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E351
EP E357
DI 10.1016/j.wneu.2018.09.105
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000043
PM 30261381
DA 2020-05-12
ER

PT J
AU Leidinger, A
   Piquer, J
   Kim, EE
   Nahonda, H
   Qureshi, MM
   Young, PH
AF Leidinger, Andreas
   Piquer, Jose
   Kim, Eliana E.
   Nahonda, Hadia
   Qureshi, Mahmood M.
   Young, Paul H.
TI Experience in the Early Surgical Management of Myelomeningocele in
   Zanzibar
SO WORLD NEUROSURGERY
LA English
DT Article
DE East Africa; Myelomeningocele; Neonatal surgery; Neural tube defect;
   Spina bifida; Zanzibar
ID SPINA-BIFIDA; CHILDREN
AB BACKGROUND: Neural tube defects are a large health burden for East African countries. Health strategies in the prevention of this disease include nutritional prophylaxis, prenatal diagnosis, and availability of early neonatal neurosurgery. The main objective of this study is to describe our experience in the early surgical management of neural tube defects in the Zanzibar archipelago.
   METHODS: From December 2016 to December 2017, we prospectively collected data on all patients admitted with the diagnosis of myelomeningocele. We collected variables regarding demographics, maternal health, preoperative imaging, surgical procedures, and complications at follow-up.
   RESULTS: We collected data on 19 patients. Mean age was 9.8 +/- 18.7 days. Of these patients, 52.6% were male and 47.3% were female; 47.3% patients were from Unguja, 42.0% from Pemba, and 5.2% from mainland Tanzania; 68.4% of all mothers were found to have undergone prenatal ultrasonography and 89.5% of all patients received surgery. Surgical wound infection was present in 29.4% of all surgical patients and 52.9% developed secondary hydrocephalus.
   CONCLUSIONS: Neural tube defects are a prevailing condition in East Africa. We believe that more health initiatives should address its prevention, mainly through maternal nutrition. On the basis of our findings, we consider early neonatal neurosurgery as the most important factor in reducing immediate morbidity and mortality.
C1 [Leidinger, Andreas; Piquer, Jose; Kim, Eliana E.] NED Fdn, Valencia, Spain.
   [Leidinger, Andreas; Nahonda, Hadia] Mnazi Mmoja Hosp, NED Inst, Stonetown, Tanzania.
   [Piquer, Jose] Vithas CEU Univ, Chair Neurosci, Valencia, Spain.
   [Qureshi, Mahmood M.] Aga Khan Univ, Nairobi, Kenya.
   [Young, Paul H.] St Louis Univ, Dept Surg, Sect Neurosurg, St Louis, MO 63103 USA.
RP Leidinger, A (reprint author), NED Fdn, Valencia, Spain.; Leidinger, A (reprint author), Mnazi Mmoja Hosp, NED Inst, Stonetown, Tanzania.
EM andreas_leidinger@hotmail.com
FU NED Foundation
FX We are profoundly grateful to Mrs. Marina Costa for her many
   contributions to this study, to Mohammed A. Haji, A.M.O., Said Simai,
   M.D., and Said Idrissa Ahmada, M.D. for their support and effort in the
   coordination of international surgical camps at the NED Institute, and
   to the NED Foundation, which funds the NED Institute.
CR Abdullahi Hala, 2014, BMC Res Notes, V7, P498, DOI 10.1186/1756-0500-7-498
   Adeleye AO, 2015, NEUROL RES, V37, P125, DOI 10.1179/1743132814Y.0000000425
   Afidra R, 2018, FOOD FORTIFICATION I
   [Anonymous], 2012, COUNTR PROF TANZ
   [Anonymous], 2014, TANZANIA POPULATION
   Au KS, 2010, DEV DISABIL RES REV, V16, P6, DOI 10.1002/ddrr.93
   Burton A, 2017, LANCET NEUROL, V16, P499, DOI [10.1016/S1474-4422(17)30246-6, 10.1016/S1474-4422(17)30164-3, 10.1016/S1474-4422(17)30087-X]
   Chakraborty A, 2008, J NEUROSURG-PEDIATR, V1, P361, DOI 10.3171/PED/2008/1/5/361
   Ekenze SO, 2015, LANCET, V385, P35
   Grimes CE, 2011, WORLD J SURG, V35, P941, DOI 10.1007/s00268-011-1010-1
   Lazareff JA, 2011, NEURAL TUBE DEFECTS
   Leidinger A, 2018, WORLD NEUROSURG, V117, pE450, DOI 10.1016/j.wneu.2018.06.050
   McGuire M, 2010, HUM REPROD, V25, P535, DOI 10.1093/humrep/dep398
   Ogundipe O, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-481
   Plotkin M, 2012, QUALITY MATERNAL NEW
   Rabiu TB, 2013, CHILD NERV SYST, V29, P1533, DOI 10.1007/s00381-013-2126-4
   Rasmussen LB, 1998, DAN MED BULL, V45, P213
   Rendeli C, 2006, CHILD NERV SYST, V22, P28, DOI 10.1007/s00381-004-1110-4
   Rofail D, 2012, NEUROL THER, V1, DOI 10.1007/s40120-012-0004-8
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Sims-Williams HJ, 2017, ARCH DIS CHILD, V102, P1057, DOI 10.1136/archdischild-2016-312307
   Sims-Williams HJ, 2017, J NEUROSURG-PEDIATR, V19, P70, DOI 10.3171/2016.7.PEDS16296
   Verhoef M, 2006, DEV MED CHILD NEUROL, V48, P114, DOI 10.1017/S0012162206000259
   Wallingford JB, 2013, SCIENCE, V339, P1011, DOI 10.1126/science.1222002
   Zaganjor I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151586
NR 25
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E493
EP E499
DI 10.1016/j.wneu.2018.09.145
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000061
PM 30268549
DA 2020-05-12
ER

PT J
AU Lenski, M
   Biczok, A
   Huge, V
   Forbrig, R
   Briegel, J
   Tonn, JC
   Thon, N
AF Lenski, Markus
   Biczok, Annamaria
   Huge, Volker
   Forbrig, Robert
   Briegel, Josef
   Tonn, Joerg-Christian
   Thon, Niklas
TI Role of Cerebrospinal Fluid Markers for Predicting Shunt-Dependent
   Hydrocephalus in Patients with Subarachnoid Hemorrhage and External
   Ventricular Drain Placement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomarker; Cerebrospinal fluid; Chronic hydrocephalus; Shunt dependency;
   Subarachnoid hemorrhage; Total protein
ID RUPTURED INTRACRANIAL ANEURYSMS; INDEPENDENT PREDICTORS; SCORING SYSTEM;
   INSERTION; RISK; VALIDATION; VASOSPASM; COILING; IMPACT
AB OBJECTIVE: We sought to identify potential risk factors for the development of shunt-dependent chronic hydrocephalus after aneurysmal subarachnoid hemorrhage (SAH) and external ventricular drain (EVD) insertion. In particular, the role of inflammatory markers within the cerebrospinal fluid (CSF) was assessed.
   METHODS: For this single-center analysis, data were generated from consecutive patients with SAH and the need for EVD implantation treated on our neurosurgical intensive care unit between 2013 and 2015. Parameters were patient characteristics (age, sex, comorbidity), severity of SAH (according to the World Federation of Neurological Society score), imaging findings (intraventricular hemorrhage, diameter of the third ventricle, location of the ruptured aneurysm), and acute course of disease (cerebral infarction, vasospasm). Moreover, the impact of EVD drainage volume and CSF markers (total protein [CSFTP], red blood cell count [CSFRBC], interleukin-6 [CSFIL-6], and glucose [CSFGlc]) was assessed. Statistics including receiver-operating-curve with corresponding area-underthe-curve (AUC) analysis were calculated using SPSS.
   RESULTS: Overall, 63 patients (21 males, mean age 55.2 years) were included. Twenty-one patients (30%) developed a shunt-dependent hydrocephalus. Significant risk factors for shunt dependency were the World Federation of Neurological Society score, cerebral infarction, and diameter of the third ventricle (P < 0.05). Moreover, CSF markers associated with shunt-dependent hydrocephalus included increased levels of CSFTP on days 5 (AUC [0.72)/11 (AUC=0.97)/14 (AUC [0.98), CSFIL-6 on day 14 (AUC =0.81), and CSFRBC on day 15 (AUC[0.83). The EVD drainage volume was not prognostic.
   CONCLUSIONS: The time course of selected inflammatory markers in CSF may support management considerations in the early phase after SAH and critical impairment of CSF circulation.
C1 [Lenski, Markus; Biczok, Annamaria; Tonn, Joerg-Christian; Thon, Niklas] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Neurochirurg Klin & Poliklin, Munich, Germany.
   [Huge, Volker; Briegel, Josef] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Klin Anasthesiol, Munich, Germany.
   [Forbrig, Robert] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Klin Neuroradiol, Munich, Germany.
RP Lenski, M (reprint author), Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Neurochirurg Klin & Poliklin, Munich, Germany.
EM markus.lenski@med.uni-muenchen.de
RI Forbrig, Robert/AAE-2365-2020; Briegel, Josef/AAG-3774-2019
CR Aboul-Ela HM, 2018, EGYPT J NEUROL PSYCH, V54, DOI 10.1186/s41983-018-0015-1
   Adams H, 2016, STROKE, V47, P2488, DOI 10.1161/STROKEAHA.116.013739
   Bae In-Seok, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P78, DOI 10.7461/jcen.2014.16.2.78
   BLASBERG R, 1981, NEUROSURGERY, V9, P686, DOI 10.1227/00006123-198112000-00012
   Brandner S, 2012, Acta Neurochir Suppl, V114, P217, DOI 10.1007/978-3-7091-0956-4_42
   Chan M, 2009, J NEUROSURG, V110, P44, DOI 10.3171/2008.5.17560
   Chang SI, 2018, TURK NEUROSURG, V28, P36, DOI 10.5137/1019-5149.JTN.18752-16.1
   Chung DY, 2017, NEUROCRIT CARE, V26, P356, DOI 10.1007/s12028-016-0352-9
   Cinibulak Z, 2016, ACTA NEUROCHIR, V158, P847, DOI 10.1007/s00701-016-2747-y
   Collins GS, 2016, EUR J NEUROL, V23, pE41, DOI 10.1111/ene.13036
   Czorlich P, 2015, ACTA NEUROCHIR, V157, P409, DOI 10.1007/s00701-014-2334-z
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Dehdashti AR, 2004, J NEUROSURG, V101, P402, DOI 10.3171/jns.2004.101.3.0402
   Diesing Dominik, 2018, J Neurosurg, V128, P1273, DOI 10.3171/2016.12.JNS162400
   Dorai Z, 2003, NEUROSURGERY, V52, P763, DOI 10.1227/01.NEU.0000053222.74852.2D
   ELLINGTON E, 1969, Journal of Neurosurgery, V30, P651, DOI 10.3171/jns.1969.30.6.0651
   Erixon HO, 2014, ACTA NEUROCHIR, V156, P2059, DOI 10.1007/s00701-014-2200-z
   Esposito Domenic P, 2011, Surg Neurol Int, V2, P117, DOI 10.4103/2152-7806.84241
   Gruber A, 1999, NEUROSURGERY, V44, P503, DOI 10.1097/00006123-199903000-00039
   Gupta R, 2018, WORLD NEUROSURG, V109, pE210, DOI 10.1016/j.wneu.2017.09.140
   Hayek MA, 2017, J NEUROL SURG PART A, V78, P227, DOI 10.1055/s-0036-1584813
   Hirashima Y, 2003, CEREBROVASC DIS, V16, P205, DOI 10.1159/000071117
   Jabbarli R, 2016, EUR J NEUROL, V23, P912, DOI 10.1111/ene.12962
   Jabbarli R, 2018, OPER NEUROSURG, V15, P498, DOI 10.1093/ons/opy009
   Lai L, 2013, J CLIN NEUROSCI, V20, P1134, DOI 10.1016/j.jocn.2012.09.033
   Lenski M, 2017, WORLD NEUROSURG, V99, P132, DOI 10.1016/j.wneu.2016.11.131
   Lewis A, 2015, BRIT J NEUROSURG, V29, P219, DOI 10.3109/02688697.2014.967753
   Motiei-Langroudi R, 2017, WORLD NEUROSURG, V98, P421, DOI 10.1016/j.wneu.2016.11.092
   O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881
   Peters SR, 2017, J STROKE CEREBROVASC, V26, P2120, DOI 10.1016/j.jstrokecerebrovasdis.2017.04.033
   Ray B, 2017, WORLD NEUROSURG, V100, P208, DOI 10.1016/j.wneu.2017.01.008
   Rincon F, 2010, J NEUROSURG, V113, P774, DOI 10.3171/2010.2.JNS09376
   Safiri S, 2018, WORLD NEUROSURG, V109, P510, DOI 10.1016/j.wneu.2017.10.032
   Schebesch KM, 2017, J NEUROSURG ANESTH, V29, P312, DOI 10.1097/ANA.0000000000000333
   Sheehan JP, 1999, NEUROSURGERY, V45, P1120, DOI 10.1097/00006123-199911000-00021
   Shigematsu H, 2016, NEUROL RES, V38, P600, DOI 10.1080/01616412.2016.1199184
   Suarez-Rivera O, 1998, SURG NEUROL, V49, P563, DOI 10.1016/S0090-3019(97)00342-X
   Sugawara T, 2016, J NEUROSURG SCI, V60, P154
   Vale FL, 1997, J NEUROSURG, V86, P462, DOI 10.3171/jns.1997.86.3.0462
   Varelas P, 2006, NEUROCRIT CARE, V4, P223, DOI 10.1385/NCC:4:3:223
   Wang YM, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-12
   Widenka D C, 2000, Neurol Neurochir Pol, V34, P56
   Wilson CD, 2017, J NEUROSURG, V126, P586, DOI 10.3171/2015.11.JNS152094
   Wilson DA, 2012, NEUROSURGERY, V71, P869, DOI 10.1227/NEU.0b013e318267360f
   Woernle CM, 2013, J CLIN NEUROSCI, V20, P824, DOI 10.1016/j.jocn.2012.07.015
   Wostrack M, 2014, NEUROCRIT CARE, V21, P78, DOI 10.1007/s12028-014-9991-x
   Xie ZY, 2017, WORLD NEUROSURG, V106, P844, DOI 10.1016/j.wneu.2017.06.119
   Yamada S, 2012, J STROKE CEREBROVASC, V21, P493, DOI 10.1016/j.jstrokecerebrovasdis.2010.11.010
   Yang TC, 2013, EUR NEUROL, V69, P296, DOI 10.1159/000346119
   Yoshioka H, 2000, SURG NEUROL, V53, P119, DOI 10.1016/S0090-3019(99)00185-8
   Zaidi HA, 2015, NEUROSURGERY, V76, P608, DOI 10.1227/NEU.0000000000000677
NR 51
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E535
EP E542
DI 10.1016/j.wneu.2018.09.159
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000066
PM 30268545
DA 2020-05-12
ER

PT J
AU Li, CH
   Gao, BL
   Wang, JW
   Liu, JF
   Li, H
   Yang, ST
AF Li, Cong-Hui
   Gao, Bu-Lang
   Wang, Ji-Wei
   Liu, Jian-Feng
   Li, Hui
   Yang, Song-Tao
TI Hemodynamic Factors Affecting Carotid Sinus Atherosclerotic Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerosis; Carotid sinus; Computational fluid dynamics;
   Hemodynamics; Stenosis
ID FLUID DYNAMIC CHARACTERIZATION; ADHESION MOLECULE EXPRESSION; INDUCED
   ARTERIAL ENLARGEMENT; SHEAR-STRESS; BIFURCATION STENOSIS; FLOW;
   LOCALIZATION; STRETCH; SUPPRESSION
AB PURPOSE: Carotid atherosclerotic plaque occurs predominantly at the outer wall of the carotid sinus, and computational fluid dynamics (CFD) plays an important role in explaining plaque formation. The present study investigated the hemodynamic factors affecting carotid atherosclerotic stenosis.
   METHODS: Sixteen patients with normal carotid arteries and 16 with symptomatic stenotic carotid sinus underwent 3-dimensional angiographic imaging evaluations and were studied with CFD to simulate the complete 3-dimensional blood flow and hemodynamic parameter distribution in the carotid bifurcations. The hemodynamic parameters, including wall shear stress (WSS), dynamic and total pressure, total pressure gradient, strain rate, velocity, and velocity angle, were investigated.
   RESULTS: The atherosclerosis-prone outer lateral walls of the carotid sinus and the external carotid artery at its start had significantly (P < 0.05) low dynamic pressure, WSS, strain rate, and total pressure gradient but high static pressure. The blood flow near these walls with flow separation had significantly (P < 0.05) decreased velocity and dynamic pressures but a high velocity angle. The carotid divider had significantly (P < 0.05) elevated dynamic and total pressure, WSS, strain rate, and total pressure gradient but reduced static pressure. Additional stenosis occurred at the downstream area of stenosis with significantly (P < 0.05) decreased dynamic pressure, WSS, strain rate, and total pressure gradient similar to the wall at the sinus and the start of the external carotid artery.
   CONCLUSION: Significantly decreased vascular WSS, dynamic pressure, strain rate, and total pressure gradient are key to atherosclerotic plaque formation at the carotid sinus.
C1 [Li, Cong-Hui; Gao, Bu-Lang; Wang, Ji-Wei; Liu, Jian-Feng; Li, Hui; Yang, Song-Tao] Hebei Med Univ, Hosp 1, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
   [Gao, Bu-Lang] Hebei Med Univ, Shijiazhuang Hosp 1, Dept Med Res, Shijiazhuang, Hebei, Peoples R China.
RP Li, CH (reprint author), Hebei Med Univ, Hosp 1, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
EM 13363880072@163.com
RI Gao, Bu-Lang/N-3669-2015
OI Gao, Bu-Lang/0000-0003-4668-0737
CR Alexander JJ, 1997, SURGERY, V122, P279
   Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532
   Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006
   Chiu JJ, 2003, BLOOD, V101, P2667, DOI 10.1182/blood-2002-08-2560
   COLANGELO S, 1994, CELL TISSUE RES, V278, P235, DOI 10.1007/BF00414165
   Dardik A, 2005, J VASC SURG, V41, P321, DOI 10.1016/j.jvs.2004.11.016
   Davies PF, 1995, J BIOMECH, V28, P1553, DOI 10.1016/0021-9290(95)00102-6
   Dewey CF, 2002, BIORHEOLOGY, V39, P541
   Frangos SG, 1999, ARCH SURG-CHICAGO, V134, P1142, DOI 10.1001/archsurg.134.10.1142
   FRIEDMAN MH, 1981, J BIOMECH ENG-T ASME, V103, P204, DOI 10.1115/1.3138279
   FRY DL, 1968, CIRC RES, V22, P165, DOI 10.1161/01.RES.22.2.165
   Fu X, 2018, J STROKE CEREBROVASC, V27, P2993, DOI 10.1016/j.jstrokecerebrovasdis.2018.06.033
   GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431
   GIDDENS DP, 1993, J BIOMECH ENG-T ASME, V115, P588, DOI 10.1115/1.2895545
   GLAGOV S, 1995, SURG CLIN N AM, V75, P545, DOI 10.1016/S0039-6109(16)46680-6
   Guzman RJ, 1997, SURGERY, V122, P273, DOI 10.1016/S0039-6060(97)90018-0
   HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0
   Huang WY, 2018, J STROKE CEREBROVASC, V27, P3365, DOI 10.1016/j.jstrokecerebrovasdis.2018.07.042
   Hyun S, 2003, J VASC SURG, V37, P1248, DOI 10.1016/S0741-5214(02)75326-3
   Inoue N, 1998, AM J PHYSIOL-HEART C, V274, pH1928
   KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293
   Lu DS, 2011, J R SOC INTERFACE, V8, P1379, DOI 10.1098/rsif.2011.0177
   Milei J, 2009, CAN J CARDIOL, V25, pE6, DOI 10.1016/S0828-282X(09)70023-6
   RINDT CCM, 1990, J BIOMECH, V23, P461, DOI 10.1016/0021-9290(90)90302-J
   Schirmer CM, 2012, J NEUROINTERV SURG, V4, P448, DOI 10.1136/neurintsurg-2011-010070
   Schirmer CM, 2012, BRAIN BEHAV, V2, P42, DOI 10.1002/brb3.25
   Schirmer CM, 2010, NEUROSURGERY, V67, P1692, DOI 10.1227/NEU.0b013e3181f9a93b
   Schulz UGR, 2001, STROKE, V32, P1525, DOI 10.1161/01.STR.32.7.1525
   SUMPIO BE, 1990, J SURG RES, V48, P415, DOI 10.1016/0022-4804(90)90005-M
   Sweeney NV, 2004, CARDIOVASC RES, V63, P625, DOI 10.1016/j.cardiores.2004.05.008
   TAYLOR KE, 1989, ARTERIOSCLEROSIS, V9, P881, DOI 10.1161/01.ATV.9.6.881
   Wakhloo Ajay K, 2004, J Vasc Interv Radiol, V15, pS111
   ZARINS CK, 1987, J VASC SURG, V5, P413, DOI 10.1067/mva.1987.avs0050413
   ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502
   Zhao YH, 2002, PHYSIOL GENOMICS, V12, P1, DOI 10.1152/physiolgenomics.00024.2002
NR 35
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E262
EP E276
DI 10.1016/j.wneu.2018.09.091
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000035
PM 30261386
DA 2020-05-12
ER

PT J
AU Li, TF
   Shi, GD
   Shi, L
   Miao, JH
   Chen, DY
   Chen, Y
AF Li, Tiefeng
   Shi, Guodong
   Shi, Lei
   Miao, Jinhao
   Chen, Deyu
   Chen, Yu
TI Clinical Features and Long-Term Surgical Outcomes of Patients with
   Cervical Spondylotic Amyotrophy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior decompression; Cervical spondylotic amyotrophy; Follow up;
   Long-term; Prognostic factor
ID DISSOCIATED MOTOR LOSS; UPPER EXTREMITY; SURGERY
AB BACKGROUND: Cervical spondylotic amyotrophy (CSA) is not common. The clinical features and long-term surgical outcomes of patients with CSA are also unclear. We sought to summarize clinical features, assess long-term surgical outcomes, and determine the prognostic factors relevant for patients with CSA.
   METHODS: A total of 136 patients with CSA who underwent anterior or posterior decompression during January 2001 to December 2012 were included. Their clinical and radiologic data were collected. The surgical outcome was evaluated using manual muscle test and improvements in the muscle strength. Correlations between the surgical outcome and various factors also were analyzed.
   RESULTS: In total, 128 patients underwent anterior decompression and 8 patients underwent posterior decompression. At the final follow-up, the surgical outcome was significantly better after anterior decompression compared with that after posterior decompression. Statistical analyses showed the type of CSA, duration of symptoms, and association with ossification of the posterior longitudinal ligament were associated with a poor outcome after anterior surgery (P < 0.05).
   CONCLUSIONS: Besides significant muscular atrophy in one upper extremity, CSA also occasionally presents with mild atrophy in the other upper extremity, sensory disturbance in the upper extremities, or hyperflexia in the lower extremities. Anterior decompression is generally effective in the treatment of patients with CSA. Preoperative duration of symptoms, type of CSA, and ossification of the posterior longitudinal ligament are important predictors for the surgical outcome.
C1 [Li, Tiefeng; Shi, Guodong; Shi, Lei; Miao, Jinhao; Chen, Deyu; Chen, Yu] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Spine Ctr, Shanghai, Peoples R China.
RP Chen, Y (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Spine Ctr, Shanghai, Peoples R China.
EM cysine@smmu.edu.cn
CR Ahdab R, 2009, CLIN NEUROL NEUROSUR, V111, P874, DOI 10.1016/j.clineuro.2009.07.005
   Akiyama N, 1980, Nihon Seikeigeka Gakkai Zasshi, V54, P303
   BRAIN WR, 1952, BRAIN, V75, P187, DOI 10.1093/brain/75.2.187
   CRANDALL PH, 1966, J NEUROSURG, V25, P57, DOI 10.3171/jns.1966.25.1.0057
   EBARA S, 1988, SPINE, V13, P785, DOI 10.1097/00007632-198807000-00013
   Fujiwara Y, 2006, SPINE, V31, pE728, DOI 10.1097/01.brs.0000240207.00747.82
   Gebere-Michael SG, 2010, J NEUROL SCI, V290, P142, DOI 10.1016/j.jns.2009.12.009
   Holman PJ, 2005, SPINE SURG, P136
   Imajo Y, 2012, SPINE, V37, pE1444, DOI 10.1097/BRS.0b013e31826e2ead
   Inui Y, 2011, SPINE, V36, P794, DOI 10.1097/BRS.0b013e3181e531a1
   Jiang SD, 2011, EUR SPINE J, V20, P351, DOI 10.1007/s00586-010-1544-1
   Kaneko K, 2004, SPINE, V29, pE185, DOI 10.1097/00007632-200405010-00022
   KEEGAN JJ, 1965, J NEUROSURG, V23, P528, DOI 10.3171/jns.1965.23.5.0528
   Matsumoto M, 1996, J SPINAL DISORD, V9, P317
   MATSUNAGA S, 1993, SPINE, V18, P1964, DOI 10.1097/00007632-199310001-00007
   SHINOMIYA K, 1994, SPINE, V19, P21, DOI 10.1097/00007632-199401000-00005
   Sobue I, 1975, RINSHO SEIKEIGEKA, V10, P999
   Srinivasa Rao Nooti Venkata, 2009, J Neurosurg Spine, V10, P374, DOI 10.3171/2008.12.SPINE08526
   Tauchi R, 2013, EUR SPINE J, V22, P156, DOI 10.1007/s00586-012-2506-6
   Tsuboi Y, 1995, Rinsho Shinkeigaku, V35, P147
   Uchida K, 2005, J ORTHOP SCI, V10, P564, DOI 10.1007/s00776-005-0953-1
   Uchida K, 2009, J NEUROSURG-SPINE, V11, P330, DOI 10.3171/2009.3.SPINE08635
   Wang HL, 2014, INDIAN J ORTHOP, V48, P511, DOI 10.4103/0019-5413.139875
   Zhang JT, 2016, SCI REP-UK, V6, DOI 10.1038/srep39512
NR 24
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E164
EP E172
DI 10.1016/j.wneu.2018.09.072
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000024
PM 30261401
DA 2020-05-12
ER

PT J
AU Li, XQ
   Wu, W
   Miao, Q
   He, M
   Zhang, S
   Zhang, ZY
   Lu, B
   Yang, YH
   Shou, XF
   Li, YM
   Wang, YF
   Ye, HY
AF Li, Xiaoqing
   Wu, Wei
   Miao, Qing
   He, Min
   Zhang, Shuo
   Zhang, Zhaoyun
   Lu, Bin
   Yang, Yehong
   Shou, Xuefei
   Li, Yiming
   Wang, Yongfei
   Ye, Hongying
TI Endocrine and Metabolic Outcomes After Transcranial and Endoscopic
   Endonasal Approaches for Primary Resection of Craniopharyngiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngioma; Endocrine outcomes; Endoscopic endonasal approach;
   Metabolic outcomes; Transcranial approach
ID SURGICAL-TREATMENT; CHINESE ADULTS; RISK-FACTORS; MANAGEMENT; MORBIDITY;
   MORTALITY; DIAGNOSIS; CHILDREN; DISEASE; PATTERN
AB OBJECTIVE: Craniopharyngiomas have traditionally been resected through the transcranial approaches (TCA). The endoscopic endonasal approach (EEA) has recently been developed as an alternative for surgeons, but controversy remains regarding which approach has better outcomes. We compared the endocrine and metabolic outcomes of TCA and EEA in patients who underwent primary resection of craniopharyngiomas.
   METHODS: A retrospective analysis was conducted of patients with craniopharyngioma who were treated by the department of endocrinology and metabolism at our institution between 2011 and 2015.
   RESULTS: Of 43 patients assessed, 26 underwent TCA and 17 underwent EEA. After surgery, 29.4% (5/17) of patients in the EEA group had normal anterior pituitary function, whereas none in the TCA group had complete anterior pituitary function. Higher prevalences of corticotropic deficiency (92.3% vs. 52.9%, P = 0.009), thyrotrophic deficiency (96.2% vs. 52.9%, P = 0.003), and hypogonadotropic hypogonadism (100% vs. 70.6%, P=0.014) were found in the TCA group. The TCA group showed a trend toward having more patients with at least 3 anterior pituitary deficits (88.5% vs. 58.8%, P = 0.060). The mean body mass index at last follow-up tended to be lower in the EEA group (24.13 +/- 3.16 kg/m(2) vs. 26.79 +/- 4.5 kg/m(2), P=0.079), and the preoperative body mass index was comparable between groups. Similar prevalences of overweight/obesity, hypertension, hyperglycemia, and metabolic syndrome were detected in the 2 groups. Moreover, no significant differences were observed in the rates of cerebrospinal fluid leakage and intracranial infection between the 2 groups.
   CONCLUSIONS: EEA may provide the same gross total resection rate for craniopharyngioma as TCA while providing better protection of anterior pituitary function.
C1 [Li, Xiaoqing; Wu, Wei; Miao, Qing; He, Min; Zhang, Shuo; Zhang, Zhaoyun; Lu, Bin; Yang, Yehong; Li, Yiming; Ye, Hongying] Fudan Univ, Huashan Hosp, Dept Endocrinol & Metab, Shanghai, Peoples R China.
   [Shou, Xuefei; Wang, Yongfei] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Li, Xiaoqing] First Peoples Hosp Shangqiu, Dept Endocrinol & Metab, Shangqiu 476000, Henan, Peoples R China.
RP Ye, HY (reprint author), Fudan Univ, Huashan Hosp, Dept Endocrinol & Metab, Shanghai, Peoples R China.; Wang, YF (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM eamns@hotmail.com; yehongying@huashan.org.cn
CR Ahmet A, 2006, J PEDIATR ENDOCR MET, V19, P121
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Campbell PG, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09292
   Cavallo LM, 2014, WORLD NEUROSURG, V82, pS32, DOI 10.1016/j.wneu.2014.07.023
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Chakrabarti I, 2005, J NEUROSURG, V102, P650, DOI 10.3171/jns.2005.102.4.0650
   Conger AR, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14364
   Crowley RK, 2010, CLIN ENDOCRINOL, V73, P516, DOI 10.1111/j.1365-2265.2010.03838.x
   Duff JM, 2000, NEUROSURGERY, V46, P291, DOI 10.1097/00006123-200002000-00007
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Fernandez-Miranda JC, 2012, HEAD NECK-J SCI SPEC, V34, P1036, DOI 10.1002/hed.21771
   Fleseriu M, 2016, J CLIN ENDOCR METAB, V101, P3888, DOI 10.1210/jc.2016-2118
   Gautier A, 2012, J CLIN ENDOCR METAB, V97, P1258, DOI 10.1210/jc.2011-2817
   Gotto AM, 2004, J AM COLL CARDIOL, V43, P717, DOI 10.1016/j.jacc.2003.08.061
   Iannalfi A, 2013, CLIN ONCOL-UK, V25, P654, DOI 10.1016/j.clon.2013.07.005
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Liu JK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16284
   Liu James K, 2005, Neurosurg Focus, V18, pE9, DOI 10.3171/foc.2005.18.6.10
   MAIRA G, 1995, NEUROSURGERY, V36, P715, DOI 10.1227/00006123-199504000-00012
   Pascual JM, 2013, J NEUROSURG, V119, P381, DOI 10.3171/2013.1.JNS111722
   Ming J, 2014, CLIN CHIM ACTA, V430, P115, DOI 10.1016/j.cca.2014.01.004
   Mortini P, 2011, J NEUROSURG, V114, P1350, DOI 10.3171/2010.11.JNS10670
   Moussazadeh N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16299
   Muller HL, 2014, EXPERT REV NEUROTHER, V14, P187, DOI 10.1586/14737175.2014.875470
   Muller HL, 2006, KLIN PADIATR, V218, P315, DOI 10.1055/s-2006-942249
   Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P467, DOI 10.1210/jc.2014-3525
   Park SW, 2013, J NEURO-ONCOL, V113, P417, DOI 10.1007/s11060-013-1128-0
   Pereira AM, 2005, CLIN ENDOCRINOL, V62, P197, DOI 10.1111/j.1365-2265.2004.02196.x
   Prieto R, 2017, AM J NEURORADIOL, V38, P2073, DOI 10.3174/ajnr.A5361
   Prieto R, 2015, WORLD NEUROSURG, V83, P500, DOI 10.1016/j.wneu.2014.10.002
   Sahakitrungruang T, 2011, EUR J PEDIATR, V170, P763, DOI 10.1007/s00431-010-1347-8
   Simoneau-Roy J, 2010, CLIN ENDOCRINOL, V72, P364, DOI 10.1111/j.1365-2265.2009.03639.x
   Solari D, 2016, J NEUROSURG SCI, V60, P454
   Song QB, 2015, DIABETES VASC DIS RE, V12, P189, DOI 10.1177/1479164114562410
   Srinivasan S, 2004, J CLIN ENDOCR METAB, V89, P81, DOI 10.1210/jc.2003-030442
   Stripp DCH, 2004, INT J RADIAT ONCOL, V58, P714, DOI 10.1016/S0360-3016(03)01570-0
   Van Effenterre R, 2002, J NEUROSURG, V97, P3, DOI 10.3171/jns.2002.97.1.0003
   Van Gompel JJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09303
   Wannemuehler TJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16314
   Yang I, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09307
   YASARGIL MG, 1990, J NEUROSURG, V73, P3, DOI 10.3171/jns.1990.73.1.0003
   Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83
NR 44
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E8
EP E14
DI 10.1016/j.wneu.2018.08.092
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000003
PM 30266691
DA 2020-05-12
ER

PT J
AU Li, ZW
   Li, ZQ
   Tang, BM
   Ren, R
   Zhang, Y
   Li, CL
   Zhang, XB
AF Li, Zhao-Wei
   Li, Ze-Qing
   Tang, Bao-Ming
   Ren, Rong
   Zhang, Yuan
   Li, Chun-Liang
   Zhang, Xue-Bin
TI Efficacy of One-Stage Posterior Debridement and Bone Grafting with
   Internal Fixation in the Treatment of Monosegmental Thoracolumbar
   Tuberculosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone grafting; Internal fixation; One-stage posterior debridement;
   Thoracolumbar tuberculosis
ID LUMBAR INTERBODY FUSION; SPINAL TUBERCULOSIS; SURGICAL-MANAGEMENT;
   ANTERIOR DEBRIDEMENT; INSTRUMENTATION; DECOMPRESSION
AB BACKGROUND: We explored the clinical effect of one-stage posterior debridement and bone grafting with internal fixation for the treatment of monosegmental thoracolumbar tuberculosis (TB).
   METHODS: The data from 90 patients with thoracolumbar TB, who had undergone one-stage posterior debridement and bone grafting with internal fixation, were retrospectively reviewed. Data on the operative time, blood loss, length of hospital stay, erythrocyte sedimentation rate, C-reactive protein, improvement of neurological function, visual analog scale score, vertebral Cobb angle, bone healing, and complications were collected.
   RESULTS: A total of 88 patients were finally included in the present retrospective study, included 42 men and 46 women. The mean patient age was 45.4 +/- 12.3 years (range, 27-70), and the mean duration of disease until treatment was 11 +/- 4.5 months (range, 3-19). The mean operative time was 167.0 minutes (range, 130-210), and the mean blood loss was 767.4 mL (range, 500-1150). At the final follow-up examination, the correction in the Cobb angle was 19 degrees, the visual analog scale score had decreased to 3 +/- 1.72, the neurologic deficits using the Frankel grade had improved, and the erythrocyte sedimentation rate and C-reactive protein level had returned to normal levels.
   CONCLUSION: One-stage posterior debridement and bone grafting with internal fixation might be a better choice for treating patients with monosegment thoracolumbar TB.
C1 [Li, Zhao-Wei; Li, Ze-Qing; Tang, Bao-Ming; Ren, Rong; Zhang, Yuan] Qinghai Univ, Affiliated Hosp, Dept Trauma Orthoped, Xining, Qinghai, Peoples R China.
   [Li, Chun-Liang] Qinghai Prov Peoples Hosp, Department Trauma Orthoped, Xining, Qinghai, Peoples R China.
   [Zhang, Xue-Bin] Hebei Med Univ, Hosp 3, Trauma Emergency Ctr, Shijiazhuang, Hebei, Peoples R China.
RP Zhang, XB (reprint author), Hebei Med Univ, Hosp 3, Trauma Emergency Ctr, Shijiazhuang, Hebei, Peoples R China.
EM xuebinzhangto@163.com
FU  [2018-ZJ-943Q]
FX The present study was funded by the project of "molecular biological
   mechanism and feasibility of platelet rich plasma in anoxic New Zealand
   rabbits with osteonecrosis of femoral head" (grant 2018-ZJ-943Q).
CR Bezer M, 2005, J SPINAL DISORD TECH, V18, P425, DOI 10.1097/01.bsd.0000171627.11171.6f
   Dai LY, 2005, SPINE, V30, P2342, DOI 10.1097/01.brs.0000182109.36973.93
   Dupuy DE, 2000, AM J ROENTGENOL, V175, P1263, DOI 10.2214/ajr.175.5.1751263
   Jin DD, 2004, EUR SPINE J, V13, P114, DOI 10.1007/s00586-003-0661-5
   Kaloostian PE, 2013, WORLD NEUROSURG, V80, P64, DOI [10.1016/j.wneu.2013.01.120, 10.1016/j.wneu.2011.03.018]
   Lan X, 2011, INT SURG, V96, P358, DOI 10.9738/CC62.1
   LEE CK, 1995, SPINE, V20, P356, DOI 10.1097/00007632-199502000-00018
   Lee SH, 2006, J SPINAL DISORD TECH, V19, P595, DOI 10.1097/01.bsd.0000211241.06588.7b
   Lee TC, 1999, J NEUROSURG, V91, P163, DOI 10.3171/spi.1999.91.2.0163
   Lesic AR, 2010, INT J TUBERC LUNG D, V14, P1181
   Li WW, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0310-2
   LOUW JA, 1990, J BONE JOINT SURG BR, V72, P686
   Pang XY, 2013, ARCH ORTHOP TRAUM SU, V133, P765, DOI 10.1007/s00402-013-1722-9
   Rajasekaran S, 2015, UNFALLCHIRURG, V118, pS19, DOI 10.1007/s00113-015-0093-9
   Tosun B, 2014, EUR SPINE J, V23, P2299, DOI 10.1007/s00586-014-3565-7
   Turgut M, 2001, NEUROSURG REV, V24, P8, DOI 10.1007/PL00011973
   Wang XY, 2014, EUR SPINE J, V23, P830, DOI 10.1007/s00586-013-3051-7
   Wang ZL, 2012, INT ORTHOP, V36, P325, DOI 10.1007/s00264-011-1475-4
   Zaveri GR, 2009, J SPINAL DISORD TECH, V22, P257, DOI 10.1097/BSD.0b013e31818859d0
   Zeng H, 2015, ACTA ORTHOP TRAUMATO, V49, P513, DOI 10.3944/AOTT.2015.14.0037
   Zhang HQ, 2013, ARCH ORTHOP TRAUM SU, V133, P333, DOI 10.1007/s00402-012-1669-2
   Zhang QH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008574
   Zou MX, 2014, CLIN NEUROL NEUROSUR, V125, P1, DOI 10.1016/j.clineuro.2014.06.037
NR 23
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E843
EP E851
DI 10.1016/j.wneu.2018.09.234
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000104
PM 30312822
DA 2020-05-12
ER

PT J
AU Liao, CX
   Chen, WL
   Wang, JS
AF Liao, Chuangxin
   Chen, Wenli
   Wang, Jinshan
TI MicroRNA-20a Regulates Glioma Cell Proliferation, Invasion, and
   Apoptosis by Targeting CUGBP Elav-Like Family Member 2
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; CELF2; Glioma; MicroRNA; Migration; Proliferation
ID CANCER; METASTASIS; MANAGEMENT
AB OBJECTIVE: MicroRNAs (miRNAs) are a class of small noncoding RNAs that play important roles in tumor development and progression. miR-20a acts as an oncogene in many cancers; however, the underlying role of miR-20a in human glioma remains unknown.
   METHODS: Glioma tissue samples were obtained from 32 patients with primary glioma who had undergone surgery at the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Twenty-two normal brain tissue samples used as controls were obtained by internal decompression in patients who had undergone surgery for cerebral injury and cerebral hemorrhage at the same hospital.
   RESULTS: Quantitative reverse transcription polymerase chain reaction showed upregulation of miR-20a in glioma tissues and cell lines compared with normal brain tissue and normal human astrocytes. Functional assays showed that miR-20a promotes proliferation and invasion and inhibits apoptosis in glioma cells. The bioinformatic analysis showed that CELF2 (CUGBP Elav-like family member 2) is a direct target gene of miR-20a, which was confirmed using a luciferase reporter assay. Downregulation of CELF2 reversed the effects of inhibiting miR-20a expression.
   CONCLUSIONS: Collectively, these results suggest a critical role for miR-20a in glioma cell apoptosis, proliferation, and invasion via the direct targeting of CELF2 and indicate its potential application in cancer therapy.
C1 [Liao, Chuangxin; Chen, Wenli; Wang, Jinshan] Sun Yat Sen Univ, Eastern Dist Affiliated Hosp 1, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
RP Liao, CX (reprint author), Sun Yat Sen Univ, Eastern Dist Affiliated Hosp 1, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM lcxsl@126.com
FU Guangdong Science Foundation of Guangdong Province [2013B021800123]
FX This work was supported by the Guangdong Science Foundation of Guangdong
   Province (grant 2013B021800123), China.
CR Babu KR, 2016, J MOL MED, V94, P347, DOI 10.1007/s00109-015-1362-3
   Blakeley JO, 2016, NEURO-ONCOLOGY, V18, P13, DOI 10.1093/neuonc/nov291
   Chen YK, 2016, ONCOL REP, V36, P3379, DOI 10.3892/or.2016.5144
   Cheng DT, 2016, ONCOTARGET, V7, P45199, DOI 10.18632/oncotarget.9900
   Devi KP, 2017, SEMIN CANCER BIOL, V46, P146, DOI 10.1016/j.semcancer.2017.02.001
   Jackson Christina, 2016, Handb Clin Neurol, V134, P201, DOI 10.1016/B978-0-12-802997-8.00012-8
   Jafri MA, 2017, SEMIN CANCER BIOL, V44, P117, DOI 10.1016/j.semcancer.2017.02.004
   Jakstaite A, 2016, LANGENBECK ARCH SURG, V401, P99, DOI 10.1007/s00423-015-1364-1
   Khan MN, 2016, CURR ONCOL, V23, pE383, DOI 10.3747/co.23.3082
   Liao CX, 2013, ONCOL RES, V21, P129, DOI 10.3727/096504013X13832473329999
   Ramalingam S, 2008, AM J PHYSIOL-GASTR L, V294, pG971, DOI 10.1152/ajpgi.00540.2007
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Suzuki H, 2012, BMC BIOCHEM, V13, DOI 10.1186/1471-2091-13-6
   Xiong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096103
   Zhou Q, 2018, CANCER SCI, V109, P2651, DOI 10.1111/cas.13714
   Zhu YG, 2016, AM J TRANSL RES, V8, P1482
NR 16
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E519
EP E527
DI 10.1016/j.wneu.2018.09.155
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000064
PM 30268547
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lin, HY
   Hasegawa, H
   Mundil, N
   Samuel, M
   Ashkan, K
AF Lin, Hsin Ying
   Hasegawa, Harutomo
   Mundil, Nilesh
   Samuel, Michael
   Ashkan, Keyoumars
TI Patients' Expectations and Satisfaction in Subthalamic Nucleus Deep
   Brain Stimulation for Parkinson Disease: 6-Year Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Expectations; Parkinson disease; Satisfaction;
   Subthalamic nucleus
ID QUALITY-OF-LIFE; SURGERY
AB OBJECTIVE: Patients' expectations are considered to play an important role in subthalamic nucleus (STN) deep brain stimulation (DBS). We explored the relationship among expectations, satisfaction, and outcome 6 years after surgery.
   METHODS: Fifteen patients with Parkinson disease (9 males, mean age 60.5 +/- 6.4 years) undergoing STN DBS completed a modified PDQ-39 questionnaire (incorporating an assessment of patients' expected changes in addition to the standard quality of life items) preoperatively and at 6 years postoperatively. A satisfaction questionnaire accompanied the postoperative questionnaire.
   RESULTS: At 6 years' follow-up, PDQ-39 scores were unchanged from preoperative scores except in the stigma domain, which showed significant improvement. There was no significant difference between the postoperatively rated expected PDQ-39 summary score and the postoperative actual PDQ-39 summary score. However, there was a significant difference between the preoperatively rated expected PDQ-39 summary score and the postoperative actual PDQ-39 summary score. Patients remained highly satisfied with the outcome of surgery (mean satisfaction score 83%). Satisfaction did not correlate with PDQ-39 summary scores, domain scores, or fulfilment of expectations. The more satisfied patients (satisfaction >= 80%) changed their expectations so that their postoperatively rated expectations reflected a less favorable condition, whereas no such change was seen in the less satisfied (satisfaction < 80%) patients.
   CONCLUSIONS: Patients remain highly satisfied with STN DBS 6 years after surgery, although quality of life assessed by the PDQ-39 may return to baseline levels. Patients' expectations change over time and may influence patient satisfaction. Managing expectations before and after surgery plays an essential role in STN DBS.
C1 [Lin, Hsin Ying] Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan.
   [Lin, Hsin Ying] Taipei Med Univ, Coll Publ Hlth & Nutr, Grad Inst Injury Prevent & Control, Taipei, Taiwan.
   [Hasegawa, Harutomo; Mundil, Nilesh; Ashkan, Keyoumars] Kings Coll Hosp NHS Fdn Trust, Kings Hlth Partners, Dept Neurosurg, London, England.
   [Samuel, Michael] Kings Coll Hosp London, Kings Hlth Partners, Natl Parkinson Fdn, Int Ctr Excellence,Dept Neurol, London, England.
   [Hasegawa, Harutomo; Ashkan, Keyoumars] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
RP Hasegawa, H (reprint author), Kings Coll Hosp NHS Fdn Trust, Kings Hlth Partners, Dept Neurosurg, London, England.; Hasegawa, H (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
EM h.hasegawa@nhs.net
CR Alomar S, 2017, MOVEMENT DISORD, V32, P53, DOI 10.1002/mds.26924
   Aviles-Olmos I, 2014, J NEUROL NEUROSUR PS, V85, P1419, DOI 10.1136/jnnp-2013-306907
   Dafsari HS, 2018, MOVEMENT DISORD, V33, P421, DOI 10.1002/mds.27283
   Daniels C, 2011, MOVEMENT DISORD, V26, P2516, DOI 10.1002/mds.23907
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Graham B, 2016, J HAND SURG-AM, V41, P929, DOI 10.1016/j.jhsa.2016.07.109
   Graham B, 2015, J BONE JOINT SURG AM, V97A, P80, DOI 10.2106/JBJS.N.00811
   Haanstra TM, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-152
   Hariz M., 2013, WORLD NEUROSURG, V82, P1037
   Hasegawa H, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.02.001
   Jenkinson C, 1998, PARKINSONS DIS QUEST
   Lezcano E, 2016, J NEUROL, V263, P895, DOI 10.1007/s00415-016-8077-4
   Lyons KE, 2005, J NEUROSURG, V103, P252, DOI 10.3171/jns.2005.103.2.0252
   Maier F, 2016, PARKINSONISM RELAT D, V24, P41, DOI 10.1016/j.parkreldis.2016.01.019
   Maier F, 2013, J NEUROL NEUROSUR PS, V84, P1273, DOI 10.1136/jnnp-2012-303670
   Mannion AF, 2009, SPINE, V34, P1590, DOI 10.1097/BRS.0b013e31819fcd52
   McGregor AH, 2013, EUR SPINE J, V22, P2836, DOI 10.1007/s00586-013-2971-6
   Mestre TA, 2016, MOVEMENT DISORD, V31, P290, DOI 10.1002/mds.26500
   Morselli PG, 2016, AESTHET PLAST SURG, V40, P592, DOI 10.1007/s00266-016-0655-4
   Pager CK, 2004, ARCH OPHTHALMOL-CHIC, V122, P1788, DOI 10.1001/archopht.122.12.1788
   Reddy P, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-11
   Siderowf A, 2006, MOVEMENT DISORD, V21, P746, DOI 10.1002/mds.20786
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   Zywiel MG, 2013, CLIN ORTHOP RELAT R, V471, P3446, DOI 10.1007/s11999-013-3013-8
NR 24
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E654
EP E660
DI 10.1016/j.wneu.2018.09.181
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000080
PM 30292658
DA 2020-05-12
ER

PT J
AU Lin, JZ
   Zhang, Y
   Peng, RY
   Ji, X
   Luo, GX
   Luo, WS
   Wang, M
   Zhu, MH
   Sun, XH
   Zhang, Y
AF Lin, Jinzhi
   Zhang, Yang
   Peng, Ruoyu
   Ji, Xiao
   Luo, Guoxuan
   Luo, Weishi
   Wang, Mo
   Zhu, Minghua
   Sun, Xiaohui
   Zhang, Yong
TI Preoperative Imaging and Microscopic Navigation During Surgery Can Avoid
   Unnecessarily Opening the Mastoid Air Cells Through Craniotomy Using the
   Retrosigmoid Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mastoid air cells; Microscopic navigation; Preoperative imaging;
   Retrosigmoid approach
ID MICROVASCULAR DECOMPRESSION; VESTIBULAR SCHWANNOMAS; COMPLICATIONS;
   RECONSTRUCTION; REMOVAL; LEAKAGE
AB OBJECTIVE: To analyze treatment of microvascular decompression using the retrosigmoid approach (RA) in primary trigeminal neuralgia and hemifacial spasm using preoperative images combined with intraoperative microscopic navigation to avoid unnecessarily opening the mastoid air cells (MACs).
   METHODS: Ten patients with primary trigeminal neuralgia and 20 patients with hemifacial spasm (test group) were treated using RA for microvascular decompression. Preoperative head magnetic resonance angiography and temporal bone computed tomography were performed and the images registered using SPM12 and fused with MRI-cron to determine the relationship between MACs and sigmoid sinuses. An O-arm was used for navigation, and the transverse sigmoid sinus was projected under a microscope to guide RA. A control group comprised 139 patients who had the same surgical procedure as the test group but without image processing or intraoperative navigation.
   RESULTS: The relationship between MACs and the ipsilateral sigmoid sinus was classified as follows: I, MACs did not exceed the lateral edge of the ipsilateral sigmoid sinus (10/60); II, MACs exceeded the ipsilateral lateral edge of the sigmoid sinus but did not exceed the medial edge (42/60); and III, MACs exceeded the medial edge of the ipsilateral sigmoid sinus (8/60). Test and control groups showed significant differences in the incidences of opening MACs (P=0.003). There was no cerebrospinal fluid leakage or scalp and intracranial infection at follow-up.
   CONCLUSIONS: Image processing and intraoperative microscopic navigation can avoid unnecessarily opening MACs and might reduce postoperative cerebrospinal leakage and scalp infection after RA craniotomy.
C1 [Lin, Jinzhi; Zhang, Yang; Peng, Ruoyu; Ji, Xiao; Luo, Guoxuan; Luo, Weishi; Wang, Mo; Zhu, Minghua; Sun, Xiaohui; Zhang, Yong] Guangdong Second Prov Gen Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
RP Zhang, Y (reprint author), Guangdong Second Prov Gen Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM zhangyongsey@163.com
OI ZHANG, YONG/0000-0002-2689-5100; lin, jinzhi/0000-0002-3860-3208
FU Medical Scientific Research Foundation of Guangdong Province [B2017112];
   Science and Technology Planning Project of Guangzhou [201607010059]
FX This study received funding from the Medical Scientific Research
   Foundation of Guangdong Province (Grant No. B2017112) and Science and
   Technology Planning Project of Guangzhou (Grant No. 201607010059).
CR Ansari SF, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12163
   Becker SS, 2003, OTOL NEUROTOL, V24, P107, DOI 10.1097/00129492-200301000-00021
   da Silva EB, 2010, ACTA NEUROCHIR, V152, P905, DOI 10.1007/s00701-009-0553-5
   Date I, 1998, SKULL BASE SURG, V8, P181, DOI 10.1055/s-2008-1058180
   Kim JP, 2012, CHILD NERV SYST, V28, P933, DOI 10.1007/s00381-011-1675-7
   Li DJ, 2010, ACTA OTO-LARYNGOL, V130, P247, DOI 10.3109/00016480903092340
   Ling PY, 2014, ACTA NEUROCHIR, V156, P1879, DOI 10.1007/s00701-014-2190-x
   Matsushima K, 2014, J NEUROSURG, V121, P397, DOI 10.3171/2014.3.JNS132419
   Park JS, 2007, NEUROSURG REV, V30, P139, DOI 10.1007/s10143-006-0060-6
   Phan K, 2016, J CLIN NEUROSCI, V29, P7, DOI 10.1016/j.jocn.2015.11.027
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Stoker MA, 2012, J NEUROL SURG PART B, V73, P281, DOI 10.1055/s-0032-1312709
   Tamura R, 2019, J NEUROSURG, V130, P360, DOI 10.3171/2017.9.JNS171622
   Thevenaz P, 2000, IEEE T MED IMAGING, V19, P739, DOI 10.1109/42.875199
   UNSER M, 1993, IEEE T SIGNAL PROCES, V41, P834, DOI 10.1109/78.193221
   UNSER M, 1993, IEEE T SIGNAL PROCES, V41, P821, DOI 10.1109/78.193220
   Xu XL, 2017, WORLD NEUROSURG, pe989
   Zhao H, 2017, WORLD NEUROSURG, V102, P151, DOI 10.1016/j.wneu.2017.02.106
   Zou P, 2014, NEUROSURG REV, V37, P15, DOI 10.1007/s10143-013-0485-7
NR 19
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E15
EP E21
DI 10.1016/j.wneu.2018.08.181
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000004
PM 30189308
DA 2020-05-12
ER

PT J
AU Loewenstern, J
   Kessler, RA
   Caridi, J
AF Loewenstern, Joshua
   Kessler, Remi A.
   Caridi, John
TI Diabetes Comorbidity Increases Risk of Postoperative Complications in
   Traumatic Thoracic Vertebral Fracture Repair: A Propensity Score Matched
   Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Diabetes mellitus; Thoracic spine; Trauma; Vertebral
   fracture
ID AMERICAN-COLLEGE; FOLLOW-UP; SPINE; INFECTION; OUTCOMES; SURGERY; IMPACT
AB BACKGROUND: Thoracic vertebral fracture repair after a traumatic injury can be associated with significant risk for postoperative complications. Surgical outcomes are further complicated by patient comorbidity, particularly diabetes mellitus. This study compared outcomes and complication rates for traumatic thoracic vertebral fracture repair in a matched sample of patients with diabetes and nondiabetic control subjects.
   METHODS: Patients with a surgical repair of a traumainduced thoracic vertebral fracture treated from 2010 to 2015 were identified from the Trauma Quality Improvement Program database, yielding 5557 cases. Patients with comorbid diabetes were matched by propensity score matching (PSM) with patients without diabetes on age, race, and body type and were compared by postoperative complications and clinical outcomes.
   RESULTS: Prior to PSM, the diabetes group was older on average and had a greater proportion of patients who were obese (Ps < 0.001). After PSM, each group consisted of 544 patients (N = 1088) and no longer differed by any baseline characteristic. Comorbid diabetes was associated with longer average length of hospital stay and greater frequency of several major and minor postoperative complications (Ps < 0.05), including prolonged intensive care, pneumonia, acute renal failure, stroke, pressure ulcers, and urinary tract infections, but no differences were found in reoperation rates or in-hospital mortality.
   CONCLUSIONS: Diabetes comorbidity can significantly increase the risk of postoperative complications after traumatic thoracic vertebral fracture repair, which may lead to delayed recovery and greater health careerelated costs. This finding is an important consideration for surgical decision-making and patient counseling on treatment options with this comorbid condition.
C1 [Loewenstern, Joshua; Kessler, Remi A.; Caridi, John] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Loewenstern, J (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM joshua.loewenstern@icahn.mssm.edu
OI Caridi, John/0000-0003-2841-585X
CR Ardisson Korat Andres V, 2014, Curr Nutr Rep, V3, P345
   Bekelis K, 2014, SPINE J, V14, P1247, DOI 10.1016/j.spinee.2013.08.009
   Bhattacharya S, 2015, INDIAN J PLAST SURG, V48, P4, DOI 10.4103/0970-0358.155260
   Bohl DD, 2015, SPINE, V40, P1785, DOI 10.1097/BRS.0000000000001003
   Browne JA, 2007, SPINE, V32, P2214, DOI 10.1097/BRS.0b013e31814b1bc0
   Burden A, 2017, PRAGMAT OBS RES, V8, P15, DOI 10.2147/POR.S122563
   Centres for Disease Control and Prevention, 2017, NAT DIAB STAT REP
   CHEN KW, 1995, DIABETES CARE, V18, P747, DOI 10.2337/diacare.18.6.747
   Chen L, 2012, NAT REV ENDOCRINOL, V8, P228, DOI 10.1038/nrendo.2011.183
   Freedman MK, 2011, SPINE, V36, P290, DOI 10.1097/BRS.0b013e3181ef9d8c
   Hu R, 1996, SPINE, V21, P492, DOI 10.1097/00007632-199602150-00016
   Kheterpal S, 2007, ANESTHESIOLOGY, V107, P892, DOI 10.1097/01.anes.0000290588.29668.38
   Marre B, 2011, EUR SPINE J, V20, P1427, DOI 10.1007/s00586-011-1698-5
   McLain R F, 2001, Spine J, V1, P310, DOI 10.1016/S1529-9430(01)00101-2
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V289, P78
   Newgard CD, 2013, J AM COLL SURGEONS, V216, P147, DOI 10.1016/j.jamcollsurg.2012.08.017
   Rechtine GR, 2001, J ORTHOP TRAUMA, V15, P566, DOI 10.1097/00005131-200111000-00006
   Schinkel C, 2006, J TRAUMA, V61, P156, DOI 10.1097/01.ta.0000222669.09582.ec
   Schneider ALC, 2013, DIABETIC MED, V30, P926, DOI 10.1111/dme.12187
   Shai I, 2006, DIABETES CARE, V29, P1585, DOI 10.2337/dc06-0057
   Stadhouder A, 2008, SPINE, V33, P1006, DOI 10.1097/BRS.0b013e31816c8b32
   Stearne MR, 1998, BRIT MED J, V317, P713
   Vialle LR, 2005, INJURY, V36, P65, DOI 10.1016/j.injury.2005.06.016
   Weinberg DS, 2017, SPINE J, V17, P1449, DOI 10.1016/j.spinee.2017.05.008
NR 24
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E792
EP E797
DI 10.1016/j.wneu.2018.09.225
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000098
PM 30312819
DA 2020-05-12
ER

PT J
AU Lyu, QN
   Zhou, CG
   Song, YM
   Liu, LM
   Hu, BW
   Feng, GJ
   Zhou, ZJ
   Yang, X
AF Lyu, Qiunan
   Zhou, Chunguang
   Song, Yueming
   Liu, Limin
   Hu, Bowen
   Feng, Ganjun
   Zhou, Zhongjie
   Yang, Xi
TI The Efficacy of Hemivertebra Resection for Hemimetameric Segmental Shift
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balanced hemivertebrae; Congenital scoliosis; Hemimetameric segmental
   shift; Hemivertebra resection; Posterior approach
ID CONGENITAL SCOLIOSIS; NATURAL-HISTORY; CHILDREN; FUSION;
   INSTRUMENTATION; KYPHOSIS; OUTCOMES; PATIENT
AB BACKGROUND: Hemimetameric segmental shift (HMMS) is defined as >= 2 contralateral hemivertebrae (HV) that are separated by at least 1 normal vertebra. Theoretically, the 2 HV tend to balance each other to produce minor spine deformities. However, curve progression has still been observed in HMMS. No research has yet specifically studied its surgical treatment. This study aimed to report efficacy of HV resection for HMMS.
   METHODS: From 2009 to 2015, 15 patients (5 male and 10 female) with HMMS underwent HV resection in our department. Average age at the time of surgery was 10.5 +/- 4.7 years, and mean length of follow-up was 38.5 +/- 7.1 months. Clinical outcomes and related complications were assessed by reviewing the medical records, operative notes, radiographic data, and scores on the Scoliosis Research Society-22 questionnaire.
   RESULTS: The segmental curve was 45.1 degrees +/- 10.6 degrees preoperatively, 14.3 degrees +/- 7.8 degrees postoperatively, and 15.3 degrees +/- 7.6 degrees at the latest follow-up. The cranial compensatory curve was 17.1 degrees +/- 11.9 degrees, 8.9 degrees +/- 6.3 degrees, and 7.8 degrees +/- 6.5 degrees. The caudal compensatory curve was 12.0 degrees +/- 11.0 degrees, 4.5 degrees +/- 4.8 degrees, and 4.3 degrees +/- 5.0 degrees. Spinal balance was significantly improved in both coronal and sagittal planes and remained stable until the latest followup. Three domains of the Scoliosis Research Society-22 questionnaire, including general self-image, mental health, and satisfaction, were significantly improved at the latest follow-up compared with preoperative status.
   CONCLUSIONS: HV resection is a safe and effective treatment for HMMS that causes progressive or severe deformity.
C1 [Lyu, Qiunan; Zhou, Chunguang; Song, Yueming; Liu, Limin; Hu, Bowen; Feng, Ganjun; Zhou, Zhongjie; Yang, Xi] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
RP Zhou, CG (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
EM hx_zhouchunguang@163.com
OI Feng, Ganjun/0000-0002-9967-9249
CR Asher M, 2003, SPINE, V28, P63, DOI 10.1097/00007632-200301010-00015
   Baulesh DM, 2012, J PEDIATR ORTHOPED, V32, P658, DOI 10.1097/BPO.0b013e318269c438
   Bollini G, 2006, SPINE, V31, P1232, DOI 10.1097/01.brs.0000217616.17692.a0
   Bollini GR, 2006, J BONE JOINT SURG AM, V88A, P1043, DOI 10.2106/JBJS.E.00530
   Chang DG, 2015, SPINE, V40, pE484, DOI 10.1097/BRS.0000000000000809
   Flynn JM, 2013, J BONE JOINT SURG AM, V95A, P1745, DOI 10.2106/JBJS.L.01386
   Halm H, 2011, EUR SPINE J, V20, P993, DOI 10.1007/s00586-011-1806-6
   Hedequist D, 2004, J AM ACAD ORTHOP SUR, V12, P266, DOI 10.5435/00124635-200407000-00007
   Hedequist D, 2007, J PEDIATR ORTHOPED, V27, P106, DOI 10.1097/BPO.0b013e31802b4993
   Hedequist DJ, 2004, SPINE, V29, P2081, DOI 10.1097/01.brs.0000138305.12790.de
   Jalanko T, 2011, SPINE, V36, P41, DOI 10.1097/BRS.0b013e3181ccafd4
   Karol LA, 2008, J BONE JOINT SURG AM, V90A, P1272, DOI 10.2106/JBJS.G.00184
   Kesling KL, 2003, SPINE, V28, P267, DOI 10.1097/00007632-200302010-00012
   McMaster MJ, 1999, J BONE JOINT SURG AM, V81A, P1367, DOI 10.2106/00004623-199910000-00002
   MCMASTER MJ, 1986, J BONE JOINT SURG BR, V68, P588
   Mladenov K, 2012, EUR SPINE J, V21, P506, DOI 10.1007/s00586-011-2010-4
   Noordeen MHH, 2009, SPINE, V34, P1808, DOI 10.1097/BRS.0b013e3181ab6307
   Ruf M, 2003, SPINE, V28, P2132, DOI 10.1097/01.BRS.0000084627.57308.4A
   Saito T, 2018, J PEDIATR ORTHOPED, V38, P217, DOI 10.1097/BPO.0000000000000784
   Shawen Scott B, 2002, Spine (Phila Pa 1976), V27, pE539
   Shono Y, 2001, SPINE, V26, P752, DOI 10.1097/00007632-200104010-00011
   THOMPSON AG, 1995, SPINE, V20, P1380, DOI 10.1097/00007632-199506000-00009
   Wang SR, 2013, EUR SPINE J, V22, P387, DOI 10.1007/s00586-012-2577-4
   WINTER RB, 1968, J BONE JOINT SURG AM, VA 50, P1
   WINTER RB, 1973, J BONE JOINT SURG AM, VA 55, P223, DOI 10.2106/00004623-197355020-00001
   Yang X, 2016, SPINE J, V16, P1214, DOI 10.1016/j.spinee.2016.06.006
   Zhang JG, 2011, EUR SPINE J, V20, P1692, DOI 10.1007/s00586-011-1710-0
   Zhang YP, 2017, EUR SPINE J, V26, P1577, DOI 10.1007/s00586-017-4960-7
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E528
EP E534
DI 10.1016/j.wneu.2018.09.158
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000065
PM 30268555
DA 2020-05-12
ER

PT J
AU Malik, AT
   Kim, J
   Yu, E
   Khan, SN
AF Malik, Azeem Tariq
   Kim, Jeffery
   Yu, Elizabeth
   Khan, Safdar N.
TI Fixation to Pelvis in Pediatric Spine Deformity-An Analysis of 30-Day
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE 30-day outcomes; Complications; NSQIP; Pediatric spine; Pelvic fixation;
   Posterior spinal fusion
ID SCOLIOSIS SURGERY; FUSION; COMPLICATIONS; MORBIDITY; PATIENT; TRENDS
AB OBJECTIVE: To assess the impact of fixation to pelvis on 30-day outcomes after posterior spinal fusions in pediatric spine deformities.
   METHODS: The 2012-2016 American College of Surgeons-National Surgical Quality Improvement Program pediatric database was queried using Current Procedural Terminology codes for patients undergoing posterior spinal fusions (22800, 22802, and 22804). Patients undergoing concurrent anterior fusion/combined fusion and anterior-only fusions were removed from the study. Patients undergoing additional fixation to pelvis were identified by code 22848.
   RESULTS: Of a total of 13,398 patients, 1092 (8.2%) patients underwent a fixation to the pelvis. After adjustment for differences in baseline characteristics, patients undergoing fixation to pelvis had a longer length of stay (odds ratio [OR] 1.24; 95% confidence interval [CI] 1.04-1.48]), greater odds of any 30-day complication (OR 1.26; CI 1.03-1.55), pneumonia (OR 1.85; CI 1.26-2.70), renal insufficiency (OR 6.87; CI 2.02-23.40), acute renal failure (OR 14.23; CI 2.36-84.51), urinary tract infection (OR 1.99; CI 1.23-3.23), cardiac arrest (OR 2.98; CI 1.10-8.06), sepsis (OR 2.25; CI 1.35-3.74), bleeding (OR 1.51; CI 1.25-1.82), 30-day read-missions (OR 1.39; CI 1.07-1.81), and 30-day reoperations (OR 1.37; CI 1.06-1.76).
   CONCLUSIONS: In contrast to adult spinal deformity literature, pediatric patients undergoing a fixation to pelvis are at a greater risk of experiencing adverse outcomes within 30 days of surgery. Providers should use these data for preoperative counseling and/or risk-stratification to improve quality-of-care in the acute postoperative period in these patients.
C1 [Malik, Azeem Tariq; Kim, Jeffery; Yu, Elizabeth; Khan, Safdar N.] Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Khan, SN (reprint author), Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Safdar.Khan@osumc.edu
CR American College of Surgeons, ACS NSQIP PED DAT
   Basques BA, 2015, SPINE, V40, P1910, DOI 10.1097/BRS.0000000000001093
   Basques BA, 2015, CLIN ORTHOP RELAT R, V473, P286, DOI 10.1007/s11999-014-3911-4
   Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Kothari P, 2017, GLOB SPINE J, V7, P39, DOI 10.1055/s-0036-1583946
   Lee MC, 2018, SPINE J, V18, P648, DOI 10.1016/j.spinee.2017.08.253
   MACLEAN WE, 1989, J PEDIATR ORTHOPED, V9, P257
   Montero Carlos Segundo, 2017, J Spine Surg, V3, P519, DOI 10.21037/jss.2017.08.15
   Ramos RD, 2016, J NEUROSURG-PEDIATR, V18, P730, DOI 10.3171/2016.6.PEDS16200
   Rumalla K, 2016, J NEUROSURG-SPINE, V25, P500, DOI 10.3171/2016.2.SPINE151377
   Sullivan DJ, 2014, PEDIATR ANESTH, V24, P406, DOI 10.1111/pan.12338
   Theologis AA, 2017, SPINE DEFORM, V5, P56, DOI DOI 10.1016/J.JSPD.2016.09.001
   Vigneswaran HT, 2015, J NEUROSURG-PEDIATR, V16, P322, DOI 10.3171/2015.3.PEDS14649
   von Heideken J, 2018, EUR SPINE J, V27, P286, DOI 10.1007/s00586-017-5346-6
NR 15
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E344
EP E350
DI 10.1016/j.wneu.2018.09.104
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000042
PM 30261372
DA 2020-05-12
ER

PT J
AU Maragkos, GA
   Enriquez-Marulanda, A
   Salem, MM
   Ascanio, LC
   Chida, K
   Gupta, R
   Alturki, AY
   Kicielinski, KP
   Ogilvy, CS
   Moore, JM
   Thomas, AJ
AF Maragkos, Georgios A.
   Enriquez-Marulanda, Alejandro
   Salem, Mohamed M.
   Ascanio, Luis C.
   Chida, Kohei
   Gupta, Raghav
   Alturki, Abdulrahman Y.
   Kicielinski, Kimberly P.
   Ogilvy, Christopher S.
   Moore, Justin M.
   Thomas, Ajith J.
TI Proposal of a Grading System for Predicting Discharge Mortality and
   Functional Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Grading system; Intracranial aneurysm; Morbidity; Mortality;
   Subarachnoid hemorrhage
ID SYMPTOMATIC VASOSPASM; CEREBRAL INFARCTION; WORLD-FEDERATION; SCALES;
   VARIABILITY; HESS; HUNT
AB BACKGROUND: Several outcome prediction systems have been developed to evaluate aneurysmal subarachnoid hemorrhage (aSAH). However, they can be difficult to use and can contain subjective elements. We sought to identify the predictors of aSAH outcomes at discharge to provide an accurate and reliable scoring system.
   METHODS: A retrospective cohort study of patients with aSAH at an academic institution from 2007 to 2016 was conducted. The primary outcome measure was the modified Rankin scale (mRS) score at discharge, with mRS scores of 0-2 considered favorable and mRS scores of 3-6 considered unfavorable. Factors significant on multivariate regression were used to develop a scale, which was compared with other established grading systems using receiver operating characteristic curves.
   RESULTS: We identified 279 patients with aSAH, 37.3% of whom had unfavorable outcomes. The proposed scale assigns 2 points for postresuscitation Glasgow coma scale score of <= 8, 1 point for age >= 70 years, 1 for antiplatelet therapy on admission, and 1 for SAH thickness of >= 10 mm, with a total score of 0-5. The proposed, Subarachnoid Hemorrhage International Trialists, and Hunt and Hess scales had similar areas under the curve (85.2%, 84.8%, and 80.6%, respectively; P > 0.05) but were significantly better than the World Federation of Neurological Surgeons (78.5%; P = 0.001) and modified Fisher (60.8%; P < 0.001) scales.
   CONCLUSION: We propose a grading scale to predict discharge mortality and functional outcomes in patients with aSAH. The proposed scale outperformed most other outcome prediction scales. The proposed scale contains objective elements, is easy to apply by memory, and can be a useful and effective measure to predict aSAH outcomes.
C1 [Maragkos, Georgios A.; Enriquez-Marulanda, Alejandro; Salem, Mohamed M.; Ascanio, Luis C.; Chida, Kohei; Gupta, Raghav; Kicielinski, Kimberly P.; Ogilvy, Christopher S.; Moore, Justin M.; Thomas, Ajith J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
   [Alturki, Abdulrahman Y.] King Fahad Med Ctr, Natl Neurosci Inst, Dept Neurosurg, Riyadh, Saudi Arabia.
RP Thomas, AJ (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
EM athomas6@bidmc.harvard.edu
OI Maragkos, Georgios/0000-0003-2156-7391; Ascanio,
   Luis/0000-0001-9914-1599; Enriquez-Marulanda,
   Alejandro/0000-0001-6091-390X
CR Degen LAR, 2011, STROKE, V42, P1546, DOI 10.1161/STROKEAHA.110.601211
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Dengler NF, 2018, EUR J NEUROL, V25, P111, DOI 10.1111/ene.13471
   Dengler NF, 2017, NEUROSURGERY, V81, P341, DOI 10.1093/neuros/nyw141
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Jaja BNR, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5745
   Lagares A, 2005, ACTA NEUROCHIR, V147, P5, DOI 10.1007/s00701-004-0417-y
   LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057
   Lo Benjamin W Y, 2015, Surg Neurol Int, V6, P135, DOI 10.4103/2152-7806.162676
   Ogilvy CS, 1998, NEUROSURGERY, V42, P959, DOI 10.1097/00006123-199805000-00001
   Oshiro EM, 1997, NEUROSURGERY, V41, P140, DOI 10.1097/00006123-199707000-00029
   Quinn TJ, 2009, STROKE, V40, P762, DOI [10.1161/STROKEAHA.108.522516, 10.1161/STROKEAHA.109.557256]
   Rosen DS, 2005, NEUROCRIT CARE, V2, P110, DOI 10.1385/NCC:2:2:110
   VANGIJN J, 1994, STROKE, V25, P1623, DOI 10.1161/01.STR.25.8.1623
   Weir RU, 2003, AM J NEURORADIOL, V24, P585
   Wilson DA, 2012, NEUROSURGERY, V71, P869, DOI 10.1227/NEU.0b013e318267360f
NR 19
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E500
EP E510
DI 10.1016/j.wneu.2018.09.148
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000062
PM 30268551
DA 2020-05-12
ER

PT J
AU Morgan, TM
   Zaenger, D
   Switchenko, JM
   Eaton, BR
   Crocker, IR
   Ali, AN
   Shu, HKG
AF Morgan, Tiffany M.
   Zaenger, David
   Switchenko, Jeffrey M.
   Eaton, Bree R.
   Crocker, Ian R.
   Ali, Arif N.
   Shu, Hui-Kuo G.
TI Fractionated Radiotherapy Is Associated with Lower Rates of
   Treatment-Related Edema than Stereotactic Radiosurgery in Magnetic
   Resonance Imaging-Defined Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain edema; Magnetic resonance imaging; Meningioma; Radiosurgery;
   Radiotherapy
ID ASYMPTOMATIC MENINGIOMAS; NATURAL-HISTORY
AB OBJECTIVE: Both stereotactic radiosurgery (SRS) and fractionated radiation therapy (FRT) techniques are used for treatment of intracranial meningiomas with excellent local control (LC) rates. Although SRS techniques are convenient, toxicity including treatment-related edema can significantly impact patient quality of life. The long-term clinical outcomes of patients with magnetic resonance imaging (MRI)-defined meningiomas treated with radiation therapy (RT) alone are reported.
   METHODS: The charts of 211 patients with meningiomas diagnosed by contrast-enhanced MRI treated with either SRS or FRT between 1991 and 2012 at a single institution were reviewed. Actuarial rates for LC and development of treatment-related radiographic edema (TRE) were determined by the Kaplan-Meier method.
   RESULTS: There were 211 patients who received radiation therapy for 223 lesions. Median follow-up was 5.7 years. Eleven patients experienced a local failure; of these, 2 were ultimately found to have pathologically proven metastatic carcinoma. Two-and 5-year LC was 97.8% and 94.6%, respectively, with no significant difference based on modality of therapy. Actuarial rate for development of TRE at 1 and 2 years was 30.1% and 34.6% for the SRS group and 1.6% and 2.5% for the FRT group, respectively (P < 0.001).
   CONCLUSIONS: RT alone using a limited margin is an effective treatment option for MRI-defined meningiomas and should be considered even without biopsy if surgery will present significant morbidity. Although LC with SRS versus FRT was comparable, FRT was associated with a significantly decreased risk of TRE.
C1 [Morgan, Tiffany M.; Zaenger, David; Eaton, Bree R.; Crocker, Ian R.; Ali, Arif N.; Shu, Hui-Kuo G.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Switchenko, Jeffrey M.] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
   [Morgan, Tiffany M.; Zaenger, David; Switchenko, Jeffrey M.; Eaton, Bree R.; Crocker, Ian R.; Ali, Arif N.; Shu, Hui-Kuo G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
RP Morgan, TM (reprint author), Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.; Morgan, TM (reprint author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
EM tiffany.morgan2@emory.edu
FU Biostatistics and Bioinformatics Shared Resource of Winship Cancer
   Institute of Emory University; NIH/NCIUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P30CA138292]
FX This research was supported in part by the Biostatistics and
   Bioinformatics Shared Resource of Winship Cancer Institute of Emory
   University and the NIH/NCI (P30CA138292). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Cai RS, 2010, NEUROSURGERY, V66, P513, DOI 10.1227/01.NEU.0000365366.53337.88
   Claus EB, 2005, NEUROSURGERY, V57, P1088, DOI 10.1227/01.NEU.0000188281.91351.B9
   Conti A, 2016, CUREUS, V8, DOI 10.7759/cureus.605
   Flickinger JC, 2003, INT J RADIAT ONCOL, V56, P801, DOI 10.1016/S0360-3016(03)00126-3
   Go RS, 1998, NEUROLOGY, V51, P1718, DOI 10.1212/WNL.51.6.1718
   GOLDSHER D, 1990, RADIOLOGY, V176, P447, DOI 10.1148/radiology.176.2.2367659
   Hasegawa T, 2011, J NEUROSURG, V114, P1392, DOI 10.3171/2010.11.JNS10112
   Korah MP, 2010, INT J RADIAT ONCOL, V76, P181, DOI 10.1016/j.ijrobp.2009.01.066
   Marosi C, 2008, CRIT REV ONCOL HEMAT, V67, P153, DOI 10.1016/j.critrevonc.2008.01.010
   Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Pieper DR, 1999, NEUROSURGERY, V44, P742, DOI 10.1097/00006123-199904000-00028
   Pollock BE, 2012, INT J RADIAT ONCOL, V83, P1414, DOI 10.1016/j.ijrobp.2011.10.033
   Rokni-Yazdi H, 2006, EUR J RADIOL, V60, P42, DOI 10.1016/j.ejrad.2006.04.003
   WILMS G, 1989, J COMPUT ASSIST TOMO, V13, P763, DOI 10.1097/00004728-198909000-00003
   Yano S, 2006, J NEUROSURG, V105, P538, DOI 10.3171/jns.2006.105.4.538
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E640
EP E646
DI 10.1016/j.wneu.2018.09.179
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000078
PM 30292026
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Nagamoto, Y
   Okuda, S
   Matsumoto, T
   Sugiura, T
   Takahashi, Y
   Iwasaki, M
AF Nagamoto, Yukitaka
   Okuda, Shinya
   Matsumoto, Tomiya
   Sugiura, Tsuyoshi
   Takahashi, Yoshifumi
   Iwasaki, Motoki
TI Multiple-Repeated Adjacent Segment Disease After Posterior Lumbar
   Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; Complication; Iatrogenic flatback; Lumbar
   fusion; Posterior lumbar interbody fusion; Sagittal imbalance
ID SURGICAL OUTCOMES; TOTAL FACETECTOMY; RISK-FACTORS; DEGENERATION;
   SURGERY; SPONDYLOLISTHESIS; STENOSIS; MINIMUM; LEVEL
AB BACKGROUND: Although posterior lumbar interbody fusion (PLIF) has provided satisfactory clinical outcomes, adjacent segment disease (ASD) is one of the most important complications affecting long-term results. However, according to ASD studies, few have described repeat surgery. The purpose of this study was to elucidate incidence, time period, and clinical features of multiplerepeated ASD after PLIF.
   METHODS: Subjects comprised 1112 consecutive patients (502 men, 610 women) who underwent 1-level PLIF for degenerative lumbar diseases. The mean age of patients was 66 years (range, 15-89). The mean follow-up period was 6.4 years (range, 0.5-21.1). The incidence and the time period of multiple-repeated ASD were investigated. To elucidate clinical features of the multiple-repeated ASD, all 4 cases were shown as the case description including radiographic parameters.
   RESULTS: Four (0.4%) developed multiple-repeated ASD: 3 women and 1 man. Primary PLIF was performed at L3-4 in 1 patient and at L4-5 in 3 patients. Two patients underwent adjacent segment decompression simultaneously. All patients required at least 3 additional surgeries due to newly occurred ASD after each PLIF. All patients developed iatrogenic flatback as ASD was repeated. As a result, corrective surgeries were required (thoracolumbar, 2; spinopelvic, 2).
   CONCLUSIONS: Multiple-repeated ASD was observed in 0.4% of the patients. All patients developed iatrogenic flatback as a result of repeated ASD, and corrective surgeries were required for these patients.
C1 [Nagamoto, Yukitaka; Okuda, Shinya; Matsumoto, Tomiya; Sugiura, Tsuyoshi; Takahashi, Yoshifumi; Iwasaki, Motoki] Osaka Rosai Hosp, Dept Orthopaed Surg, Sakai, Osaka, Japan.
RP Nagamoto, Y (reprint author), Osaka Rosai Hosp, Dept Orthopaed Surg, Sakai, Osaka, Japan.
EM 7gam0to@gmail.com
OI Nagamoto, Yukitaka/0000-0002-7993-3959
CR Chen W J, 2001, Spine (Phila Pa 1976), V26, pE519, DOI 10.1097/00007632-200111150-00024
   Di Martino A, 2014, EUR SPINE J, V23, pS693, DOI 10.1007/s00586-014-3551-0
   Djurasovic M, 2008, ORTHOPEDICS, V31
   Ekman P, 2009, EUR SPINE J, V18, P1175, DOI 10.1007/s00586-009-0947-3
   Ghiselli G, 2004, J BONE JOINT SURG AM, V86A, P1497, DOI 10.2106/00004623-200407000-00020
   Heo Y, 2015, EUR SPINE J, V24, P2474, DOI 10.1007/s00586-015-4188-3
   Kim KH, 2010, SPINE, V35, P625, DOI 10.1097/BRS.0b013e3181bb8168
   Kumar MN, 2001, EUR SPINE J, V10, P314, DOI 10.1007/s005860000239
   Lai PL, 2004, SPINE, V29, P2527, DOI 10.1097/01.brs.0000144408.02918.20
   Lee CS, 2009, EUR SPINE J, V18, P1637, DOI 10.1007/s00586-009-1060-3
   Lee JC, 2014, SPINE, V39, pE339, DOI 10.1097/BRS.0000000000000164
   Matsumoto T, 2017, J NEUROSURG-SPINE, V26, P435, DOI 10.3171/2016.9.SPINE16232
   Miwa T, 2013, EUR SPINE J, V22, P2864, DOI 10.1007/s00586-013-2863-9
   Miyagi M, 2013, EUR SPINE J, V22, P1877, DOI 10.1007/s00586-013-2694-8
   Nakashima H, 2015, SPINE, V40, pE831, DOI 10.1097/BRS.0000000000000917
   Okuda S, 2006, J NEUROSURG-SPINE, V4, P304, DOI 10.3171/spi.2006.4.4.304
   Okuda S, 2006, J BONE JOINT SURG AM, V88A, P2714, DOI 10.2106/JBJS.F.00186
   Okuda Shinya, 2007, J Bone Joint Surg Am, V89 Suppl 2 Pt.2, P310, DOI 10.2106/JBJS.G.00307
   Okuda S, 2016, SPINE, V41, pE148, DOI 10.1097/BRS.0000000000001188
   Okuda S, 2014, J NEUROSURG-SPINE, V21, P171, DOI 10.3171/2014.4.SPINE13925
   Osterman H, 2003, SPINE, V28, P621, DOI 10.1097/00007632-200303150-00019
   Phillips FM, 2000, J SPINAL DISORD, V13, P432, DOI 10.1097/00002517-200010000-00011
   Rothenfluh DA, 2015, EUR SPINE J, V24, P1251, DOI 10.1007/s00586-014-3454-0
   Sears WR, 2011, SPINE J, V11, P11, DOI 10.1016/j.spinee.2010.09.026
   Senteler M, 2014, EUR SPINE J, V23, P1384, DOI 10.1007/s00586-013-3132-7
   Trouillier Hans, 2006, Acta Orthop Belg, V72, P460
   Wang MY, 2014, J NEUROSURG-SPINE, V21, P861, DOI 10.3171/2014.8.SPINE13841
   WHITECLOUD TS, 1994, SPINE, V19, P531, DOI 10.1097/00007632-199403000-00007
   Yamamoto T, 1998, J MUS RES, V2, P181
NR 29
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E808
EP E816
DI 10.1016/j.wneu.2018.09.227
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000100
PM 30315977
DA 2020-05-12
ER

PT J
AU Navone, SE
   Guarnaccia, L
   Locatelli, M
   Rampini, P
   Caroli, M
   La Verde, N
   Gaudino, C
   Bettinardi, N
   Riboni, L
   Marfia, G
   Campanella, R
AF Navone, Stefania Elena
   Guarnaccia, Laura
   Locatelli, Marco
   Rampini, Paolo
   Caroli, Manuela
   La Verde, Nicla
   Gaudino, Chiara
   Bettinardi, Nora
   Riboni, Laura
   Marfia, Giovanni
   Campanella, Rolando
TI Significance and Prognostic Value of The Coagulation Profile in Patients
   with Glioblastoma: Implications for Personalized Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE aPTT; Coagulation; D-dimer; Fibrinogen; GBM; PT; VWF
ID EXPRESSION; TISSUE
AB BACKGROUND: Coagulation is an important aspect of the vascular microenvironment in which brain tumors evolve. Patients with tumor often show aberrant coagulation and fibrinolysis activation. In particular, glioblastoma (GBM), the most aggressive primary brain tumor, is associated with a state of hypercoagulability, and venous thromboembolism is a common complication of this cancer and its treatment. Our study aims to investigate the clinical and prognostic significance of routine laboratory tests to assess the coagulative state of patients with brain tumors, to identify potential new prognostic factors and targets for personalized therapy.
   METHODS: Blood samples were collected from patients with GBM (n = 58) and patients with meningioma (MNG, n = 22), before any treatment. The parameters analyzed were prothrombin time (PT), activated partial thromboplastin time (aPTT), D dimer (DD), fibrinogen, von Willebrand factor (VWF), leukocyte count, and hemoglobin levels.
   RESULTS: Plasma levels of PT and aPTT were significantly reduced in GBMs compared with MNGs (P < 0.05), whereas DD, VWF: Ag levels, and leukocyte count were significantly higher in GBMs than in MNGs (P < 0.01). Furthermore, we observed that patients with GBM with reduced PT and aPTT and high levels of DD and VWF, defined as hypercoagulable patients, showed reduced overall survival (P < 0.05) compared with nonhypercoagulable patients.
   CONCLUSIONS: Our data support the assumption that patients with GBM show a plasma hypercoagulable profile and that coagulation profile is related to adverse outcome in patients with GBM. If confirmed, hypercoagulability could play an important role as a prognostic factor of the disease and in the decision of an antithrombotic prophylaxis.
C1 [Navone, Stefania Elena; Guarnaccia, Laura; Locatelli, Marco; Rampini, Paolo; Caroli, Manuela; Marfia, Giovanni; Campanella, Rolando] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosurg Unit, Lab Expt Neurosurg & Cell Therapy, Milan, Italy.
   [Gaudino, Chiara] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neuroradiol, Milan, Italy.
   [La Verde, Nicla] Fatebenefratelli & Oftalm Hosp, Oncol Unit, Milan, Italy.
   [Bettinardi, Nora] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cent Lab, Milan, Italy.
   [Riboni, Laura] Univ Milan, LITA Segrate, Dept Med Biotechnol & Translat Med, Milan, Italy.
RP Marfia, G (reprint author), Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosurg Unit, Lab Expt Neurosurg & Cell Therapy, Milan, Italy.
EM giovanni.marfia@unimi.it
RI navone, stefania/Y-4779-2019; Caroli, Manuela/AAB-9019-2019; Marfia,
   Giovanni/AAB-8702-2020; Campanella, Rolando/AAB-8998-2019; navone,
   stefania elena/K-7264-2016; Guarnaccia, Laura/K-7854-2016
OI Marfia, Giovanni/0000-0002-5849-7000; navone, stefania
   elena/0000-0002-0097-9146; Guarnaccia, Laura/0000-0002-5909-0165
FU Italian Ministry of HealthMinistry of Health, Italy [RC-2017-2018];
   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
FX The study was partially supported by Italian Ministry of Health
   (RC-2017-2018) and Fondazione IRCCS Ca' Granda Ospedale Maggiore
   Policlinico.
CR Bohm M, 2003, THROMB RES, V111, P33, DOI 10.1016/j.thromres.2003.08.018
   D'Asti E, 2014, RAMBAM MAIMONIDES ME, V5, DOI 10.5041/RMMJ.10164
   Di Vito C, 2017, PLATELETS, V28, P585, DOI 10.1080/09537104.2016.1247208
   Edwin NC, 2016, THROMB RES, V137, P184, DOI 10.1016/j.thromres.2015.11.027
   GABAZZA EC, 1993, CHEST, V103, P196, DOI 10.1378/chest.103.1.196
   Guan M, 2002, CLIN BIOCHEM, V35, P321, DOI 10.1016/S0009-9120(02)00312-0
   Gurrieri L, 2018, FUTURE ONCOL, V14, P699, DOI 10.2217/fon-2017-0437
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hoke M, 2011, WIEN KLIN WOCHENSCHR, V123, P199, DOI 10.1007/s00508-011-1556-9
   Hua Y, 2005, J THROMB HAEMOST, V3, P1917, DOI 10.1111/j.1538-7836.2005.01446.x
   Iqbal S, 2000, BREAST, V9, P264, DOI 10.1054/brst.2000.0186
   Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204
   Lee S, 2017, ONCOL LETT, V13, P4669, DOI 10.3892/ol.2017.6058
   Luo YL, 2015, TUMOR BIOL, V36, P8903, DOI 10.1007/s13277-015-3650-5
   Marfia G, 2016, CANCER MED-US, V5, P1783, DOI 10.1002/cam4.747
   Metcalf DJ, 2008, J CELL SCI, V121, P19, DOI 10.1242/jcs.03494
   Qian CF, 2016, THROMB RES, V137, P58, DOI 10.1016/j.thromres.2015.11.018
   Rak J, 2014, NEURO ONCOL S3, V16, piii1
   Streiff MB, 2015, J NEURO-ONCOL, V124, P299, DOI 10.1007/s11060-015-1840-z
   Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669
   SWEENEY JD, 1990, CANCER, V66, P2387, DOI 10.1002/1097-0142(19901201)66:11<2387::AID-CNCR2820661123>3.0.CO;2-U
   Tas F, 2013, RESP MED, V107, P451, DOI 10.1016/j.rmed.2012.11.007
   Unsal E, 2004, RESP MED, V98, P93, DOI 10.1016/j.rmed.2003.07.001
   Walter J, 2012, J CANCER RES CLIN, V138, P141, DOI 10.1007/s00432-011-1078-x
   Wang XP, 2017, J CANCER, V8, P2079, DOI 10.7150/jca.19181
   Wipfler Kristin, 2018, Oncotarget, V9, P28421, DOI 10.18632/oncotarget.25420
   Yu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165390
NR 27
TC 2
Z9 2
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E621
EP E629
DI 10.1016/j.wneu.2018.09.177
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000076
PM 30292037
DA 2020-05-12
ER

PT J
AU Ohshima, T
   Kawaguchi, R
   Nagano, Y
   Miyachi, S
   Matsuo, N
   Takayasu, M
AF Ohshima, Tomotaka
   Kawaguchi, Reo
   Nagano, Yoshitaka
   Miyachi, Shigeru
   Matsuo, Naoki
   Takayasu, Masakazu
TI Experimental Direct Measurement of Clot-Capturing Ability of Stent
   Retrievers
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Endovascular treatment; Experiment; Stent clot
   retriever; Technique
ID INDIVIDUAL PATIENT DATA; ISCHEMIC-STROKE; THROMBECTOMY; METAANALYSIS;
   TREVO
AB BACKGROUND: Stent retrievers (SRs) can be used to perform mechanical thrombectomy for the treatment of acute major arterial occlusion. Recanalization is faster, and outcomes are better with treatment involving these devices than with internal treatment. Although several SRs are available, their clot-capturing abilities are unclear. Therefore in the present study, we numerically evaluated the clot-capturing abilities of SRs in an experimental vascular model.
   METHODS: A sham clot (urethane foam) was fixed with sutures at the middle of a vascular model (polyvinyl chloride tube). One end of the tube was connected to a measuring instrument. From the other end, an SR was inserted and deployed over the sham clot. The delivery wire of the stent was then withdrawn at a constant velocity using an automatic withdrawal machine. The maximum frictional force before the stent left the clot was measured. Five stents (Trevo ProVue [2 sizes], Revive, and Solitaire [2 sizes]) and three stent-deployment techniques (standard, push-and-fluff, and wire-push techniques) were evaluated.
   RESULTS: The clot-capturing ability (maximum withdrawing force [N: newton]) was greater for large-diameter stents than for small-diameter stents (mean 0.39 +/- 0.11 vs. 0.56 +/- 0.18). For Trevo and Revive, the clot-capturing ability was highest with the push and fluff technique (mean 0.43 +/- 0.05). For Solitaire, the ability was the highest with the simple wire-push technique (mean 0.705 +/- 0.16).
   CONCLUSIONS: We successfully numerically evaluated the clot-capturing abilities of SRs. The clot-capturing ability differed among SRs and among stent-deployment techniques.
C1 [Ohshima, Tomotaka; Miyachi, Shigeru] Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
   [Kawaguchi, Reo; Matsuo, Naoki; Takayasu, Masakazu] Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
   [Nagano, Yoshitaka] Aichi Univ Technol, Dept Elect Control & Robot Engn, Nishihasama Cho, Gamagori, Aichi, Japan.
RP Ohshima, T (reprint author), Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
EM tmtkoh@gmail.com
CR Arai D, 2016, J NEUROINTERV SURG, V8, P992, DOI 10.1136/neurintsurg-2015-011968
   Binning MJ, 2014, NEUROSURGERY, V75, P584, DOI 10.1227/NEU.0000000000000523
   Campbell BCV, 2016, STROKE, V47, P798, DOI 10.1161/STROKEAHA.115.012360
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Haussen DC, 2015, STROKE, V46, P2838, DOI 10.1161/STROKEAHA.115.010044
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Ohshima T, 2017, NAGOYA J MED SCI, V79, P401, DOI 10.18999/nagjms.79.3.401
   Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24
   Serrone JC, 2014, NEUROSURGERY, V74, pS133, DOI 10.1227/NEU.0000000000000224
NR 9
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E358
EP E363
DI 10.1016/j.wneu.2018.09.106
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000044
PM 30266710
DA 2020-05-12
ER

PT J
AU Pala, A
   Pawlikowski, A
   Brand, C
   Schmitz, B
   Wirtz, CR
   Konig, R
   Kapapa, T
AF Pala, Andrej
   Pawlikowski, Alexandra
   Brand, Christine
   Schmitz, Bernd
   Wirtz, Christian Rainer
   Koenig, Ralph
   Kapapa, Thomas
TI Quality of Life After Treatment of Unruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic illness; Coiling; Quality of life; Short Form Health Survey;
   Surgical clipping; Unruptured intracranial aneurysm
ID NATURAL-HISTORY; MANAGEMENT
AB OBJECTIVE: Quality of life is an important factor in the decision making for the treatment of unruptured intracranial aneurysms (UIA). The data dealing with QoL in patients after the treatment are spare. We have evaluated QoL of patients after endovascular or surgical treatment of incidental intracranial aneurysm.
   METHODS: We performed a prospective analysis of retrospectively collected data. All patients received 36-Item Short Form Health Survey (SF-36), Hospital Anxiety and Depression Scale (HADS), German questionnaire for self-perceived deficits in attention (FEDA) and not standardized questionnaire analyzing personal job-related situation, family circumstances and chronic illnesses.
   RESULTS: 177 patients were treated during the evaluated period. 79 (44.6%) patients responded. In this cohort, 62.03% of patients underwent coiling. Complications were noted in 13.9% of patients. Stroke was the most common complication (7.6%). All SF-36 related data except for pain showed significant lower mean, if compared to the standard German population (p < 0.01). For both genders, anxiety (males, P = 0.003 and females, P = 0.002) but not depression was more common than in the standard population. According to the FEDA test, treated patients showed significant difference only for fatigue in comparison to healthy population (P < 0.001). 54.4% of patients suffered from chronic illnesses, and among them only 1 patient (1.3%) had aneurysm associated chronic disease. No significant differences were found between treatment modalities.
   CONCLUSIONS: The risk for depression and pain is not significantly increased after elective treatment of UIA. According to our results, decreased QoL is common in this cohort of patients but often related to factors not associated with aneurysm treatment.
C1 [Pala, Andrej; Pawlikowski, Alexandra; Brand, Christine; Wirtz, Christian Rainer; Koenig, Ralph] Univ Ulm, Bezirkskrankenhaus Gunzburg, Dept Neurosurg, Gunzburg, Germany.
   [Schmitz, Bernd] Univ Ulm, Sect Neuroradiol, Gunzburg, Germany.
   [Wirtz, Christian Rainer; Kapapa, Thomas] Univ Ulm, Dept Neurosurg, Ulm, Germany.
RP Pala, A (reprint author), Univ Ulm, Bezirkskrankenhaus Gunzburg, Dept Neurosurg, Gunzburg, Germany.
EM andrej.pala@uni-ulm.de
CR Backes D, 2015, STROKE, V46, P1607, DOI 10.1161/STROKEAHA.115.008795
   Brilstra EH, 2004, CEREBROVASC DIS, V17, P44, DOI 10.1159/000073897
   Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1149, DOI 10.1016/S0895-4356(98)00106-1
   Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838
   Malhotra A, 2018, JAMA NEUROL, V75, P27, DOI 10.1001/jamaneurol.2017.3232
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Rodriguez-Regent C, 2014, DIAGN INTERV IMAG, V95, P1163, DOI 10.1016/j.diii.2014.10.005
   Solheim O, 2006, ACTA NEUROCHIR, V148, P821, DOI 10.1007/s00701-006-0804-7
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Tjahjadi M, 2013, WORLD NEUROSURG, V79, P296, DOI 10.1016/j.wneu.2012.10.009
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yamashiro S, 2007, J NEUROSURG, V107, P1086, DOI 10.3171/JNS-07/12/1086
   Yamashiro S, 2007, J NEUROL NEUROSUR PS, V78, P497, DOI 10.1136/jnnp.2006.098871
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 15
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E54
EP E59
DI 10.1016/j.wneu.2018.09.010
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000009
PM 30244183
DA 2020-05-12
ER

PT J
AU Park, J
   Kim, JH
   Suk, K
   Han, HS
   Ohk, B
   Kim, DG
AF Park, Jaechan
   Kim, Jong-Heon
   Suk, Kyoungho
   Han, Hyung Soo
   Ohk, Boram
   Kim, Dong Gyu
TI Selective Brain Hypothermia Augmenting Neuroprotective Effects of
   Decompressive Craniectomy for Permanent Middle Cerebral Artery
   Infarction in a Rat Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral infarction; Craniectomy; Hypothermia; Middle cerebral artery;
   Rat
ID MILD HYPOTHERMIA; FOCAL ISCHEMIA; MALIGNANT INFARCTION; MODERATE
   HYPOTHERMIA; MULTICENTER; STROKE; HEMICRANIECTOMY; EDEMA; TRIAL;
   COMBINATION
AB OBJECTIVE: To evaluate the combined effects of a decompressive craniectomy and prolonged selective brain hypothermia on large hemispheric infarction in a rat model.
   METHODS: Permanent middle cerebral artery infarction using an endovascular occlusion technique was created in rats assigned to 4 groups. Normothermia was maintained without a craniectomy in group A (n = 20) as the control, prolonged (> 44 hours), selective brain hypothermic treatment was performed on group B (n = 20), a craniectomy was performed on group C (n = 18), and prolonged, selective brain hypothermic treatment using a cooling coil implanted in the craniectomy site was combined with a craniectomy for group D (n = 18).
   RESULTS: Group B and C exhibited a significantly reduced infarct volume when compared with the control. Furthermore, group D showed a significantly reduced infarct volume when compared with group C, plus a significantly improved neurologic score. These results for group D were associated with an increased neuronal cell count and reduced hyperactive microglia and hypertrophic astrocytes in the cortical penumbra (P < 0.01). Moreover, a greater preservation of normal-appearing axonal bundles and the bloodebrain barrier was observed in the core infarct region at the caudoputamen.
   CONCLUSIONS: A decompressive craniectomy reduced the infarct volume and improved the neurologic outcomes in a rat model of middle cerebral artery infarction. Furthermore, when combined with prolonged selective brain hypothermia, significant additional benefits were observed for the neurologic outcomes, infarct volume, and degree of neuroinflammation.
C1 [Park, Jaechan] Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Daegu, South Korea.
   [Kim, Jong-Heon; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Daegu, South Korea.
   [Han, Hyung Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, Daegu, South Korea.
   [Ohk, Boram] Kyungpook Natl Univ Hosp, Clin Trial Ctr, Daegu, South Korea.
   [Kim, Dong Gyu] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
RP Park, J (reprint author), Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Daegu, South Korea.; Kim, DG (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
EM jparkmd@hotmail.com
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health and Welfare, Republic
   of Korea [HI15C0001]; Korea Healthcare Technology R & D Project,
   Ministry of Health and Welfare, Republic of Korea [A100870]
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea
   (HI15C0001), in addition to a grant from the Korea Healthcare Technology
   R & D Project, Ministry of Health and Welfare (A100870), Republic of
   Korea.
CR Allahtavakoli M, 2014, IRAN J BASIC MED SCI, V17, P476
   Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616
   Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625
   Bian JY, 2006, NEUROSURG REV, V29, P168, DOI 10.1007/s10143-005-0010-8
   Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327
   Doerfler A, 2001, STROKE, V32, P2675, DOI 10.1161/hs1101.098369
   Forte LV, 2009, ARQ NEURO-PSIQUIAT, V67, P480, DOI 10.1590/S0004-282X2009000300019
   Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9
   Gerriets T, 2004, STROKE, V35, P566, DOI 10.1161/01.STR.0000113692.38574.57
   Han HS, 2012, THERAPEUTIC HYPOTHER, P16
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Jiang MQ, 2017, BRAIN PATHOL, V27, P480, DOI 10.1111/bpa.12425
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kim JH, 2013, CURR NEUROVASC RES, V10, P134, DOI 10.2174/1567202611310020006
   Kollmar R, 2009, STROKE, V40, P1907, DOI 10.1161/STROKEAHA.108.530410
   Kollmar R, 2009, J NEUROTRAUM, V26, P377, DOI 10.1089/neu.2008.0564
   KULUZ JW, 1993, AM J PHYSIOL, V265, pH824
   Kurisu K, 2018, NEUROPHARMACOLOGY, V134, P302, DOI 10.1016/j.neuropharm.2017.08.025
   Markarian GZ, 1996, NEUROSURGERY, V38, P542
   Milhaud D, 2005, J NEUROSURG ANESTH, V17, P49
   OGURA K, 1991, J NEUROSURG, V75, P433, DOI 10.3171/jns.1991.75.3.0433
   Park HS, 2018, J KOREAN NEUROSURG S, V61, P267, DOI 10.3340/jkns.2016.1111.002
   Park J, 2009, J NEUROSURG, V110, P101, DOI 10.3171/2008.4.17540
   Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043
   Shimamura N, 2006, J NEUROSCI METH, V156, P161, DOI 10.1016/j.jneumeth.2006.02.017
   SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47
   Szczygielski J, 2010, ACTA NEUROCHIR SUPPL, V106, P225, DOI 10.1007/978-3-211-98811-4_42
   Takano T, 2009, STROKE, V40, pS8, DOI 10.1161/STROKEAHA.108.533166
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4
   van der Worp HB, 2014, INT J STROKE, V9, P642, DOI 10.1111/ijs.12294
   Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272
   Zhao YX, 2010, NEUROTHERAPEUTICS, V7, P439, DOI 10.1016/j.nurt.2010.07.004
NR 33
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E173
EP E182
DI 10.1016/j.wneu.2018.09.073
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000025
PM 30261392
DA 2020-05-12
ER

PT J
AU Post, AF
   Li, AY
   Dai, JB
   Maniya, AY
   Haider, S
   Sobotka, S
   Choudhri, TF
AF Post, Alexander F.
   Li, Adam Y.
   Dai, Jennifer B.
   Maniya, Akbar Y.
   Haider, Syed
   Sobotka, Stanislaw
   Choudhri, Tanvir F.
TI Academic Productivity of Spine Surgeons at United States Neurological
   Surgery and Orthopedic Surgery Training Programs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic neurosurgery; Academic orthopedic surgery; Bibliometrics; h
   Index; Spine surgery
ID H-INDEX; SCHOLARLY IMPACT; NEUROSURGERY; ASSOCIATION
AB OBJECTIVE: Spinal surgery is taught and practiced within 2 different surgical disciplines, neurological surgery and orthopedic surgery. We have provided a unified analysis of academic productivity measured using the h-index attributable to spine-focused faculty at U.S. residency programs.
   METHODS: A total of 278 Accreditation Council for Graduate Medical Education training programs were assessed to identify 923 full-time faculty members with a spinal surgery designation, as defined by spine fellowship training or case volume > 75% in spine surgery. The faculty were assessed with respect to academic rank, duration of practice in years, and academic productivity (h-index).
   RESULTS: The comparison showed a significantly greater mean h-index for neurological spine surgeons. The mean h-index for both disciplines increased significantly as faculty rank increased. Within the academic ranks of assistant and associate professor, neurological spine surgeons had significantly greater mean h-indexes. Neurological spine surgeons had a significantly lower practice duration. At all ranks except for assistant professor, the mean practice duration was not significantly different statistically between the neurological spine and orthopedic spine surgeons. A positive correlation between the h-index and practice duration was found for both spine surgical disciplines. The proportional odds models for neurological and orthopedic spine surgeons were moderately successful at predicting faculty rank according to the h-index.
   CONCLUSIONS: We present a unified view of academic productivity as measured by the h-index among neurosurgical and orthopedic surgery spine faculty, with some noticeable differences. These results can be used for benchmark purposes to assess the relative productivity of its faculty and could be of interest to those pursuing academic opportunities in spine surgery.
C1 [Post, Alexander F.; Li, Adam Y.; Dai, Jennifer B.; Maniya, Akbar Y.; Haider, Syed; Sobotka, Stanislaw; Choudhri, Tanvir F.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Post, AF (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM alexander.farber.post@gmail.com
OI Li, Adam/0000-0001-7654-1469
CR Bastian S, 2017, J BONE JOINT SURG AM, V99, DOI 10.2106/JBJS.15.01354
   Batista PD, 2006, SCIENTOMETRICS, V68, P179, DOI 10.1007/s11192-006-0090-4
   Campbell PG, 2011, J NEUROSURG, V115, P380, DOI 10.3171/2011.3.JNS101176
   Cvetanovich GL, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116679393
   Ence AK, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.00757
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Kalra RR, 2013, J NEUROSURG-PEDIATR, V12, P262, DOI 10.3171/2013.6.PEDS13112
   Khan AZ, 2017, ARTHROPLAST TODAY, V3, P298
   Khan NR, 2014, J NEUROSURG, V120, P746, DOI 10.3171/2013.11.JNS131708
   Lee J, 2009, J NEUROSURG, V111, P387, DOI 10.3171/2008.10.JNS08978
   Lopez J, 2015, J HAND SURG-AM, V40, P1434, DOI 10.1016/j.jhsa.2015.03.026
   Milone Michael T, 2016, Am J Orthop (Belle Mead NJ), V45, pE119
   Ponce FA, 2010, J NEUROSURG, V113, P447, DOI 10.3171/2010.3.JNS1032
   Spearman CM, 2010, J NEUROSURG, V113, P929, DOI 10.3171/2010.4.JNS091842
   Svider PF, 2013, LARYNGOSCOPE, V123, P884, DOI 10.1002/lary.23951
   Vitzthum K, 2009, SCOLIOSIS SPINAL DIS, V4, DOI 10.1186/1748-7161-4-15
   Zhu EY, 2017, BULL HOSP JT DIS, V75, P257
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E511
EP E518
DI 10.1016/j.wneu.2018.09.150
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000063
PM 30268556
DA 2020-05-12
ER

PT J
AU Razmkon, A
   Yousefi, O
   Rezaei, R
   Salehi, S
   Petramfar, P
   Mani, A
   Rahmati, H
   Vaidyanathan, J
   Ilami, G
   Amirmoezzi, Y
AF Razmkon, Ali
   Yousefi, Omid
   Rezaei, Raziyeh
   Salehi, Sina
   Petramfar, Peyman
   Mani, Arash
   Rahmati, Hashem
   Vaidyanathan, Janardan
   Ilami, Ghazal
   Amirmoezzi, Yalda
TI Initial Results of Bilateral Subthalamic Nucleus Stimulation for
   Parkinson Disease in a Newly Established Center in a Developing Country:
   Shiraz, Southern Iran
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Developing country; Parkinson disease;
   Subthalamic nucleus
ID DEEP-BRAIN-STIMULATION; HARDWARE-RELATED COMPLICATIONS; BODY-WEIGHT
   GAIN; FOLLOW-UP
AB OBJECTIVE: To report the establishment of a new center for deep brain stimulation (DBS) as a surgical treatment for Parkinson disease and the surgical outcomes, from 2014 to 2017 in Shiraz, Southern Iran.
   METHODS: A new treatment program was established in Shiraz through a multidisciplinary team in 2014. Thirty-four patients underwent implantation of subthalamic nucleus (STN) electrodes during the last 3 years. Twenty-five patients fulfilled the minimum 6-month follow-up criteria. The baseline Unified Parkinson Disease Rating Scale (UPDRS) was assessed 1 month before surgery in both off-medication and on-medication states by a movement disorder neurologist. To evaluate the outcomes, subscores of the UPDRS were assessed in all patients before surgery and at least 6 months after the operation.
   RESULTS: All 25 patients had advanced Parkinson disease categorized as stage 3 or 4 using the Hoehn and Yahr scale. STN DBS resulted in a dramatic improvement in motor function of most patients. A reduction in dopaminergic medication dosage (average 60% reduction) was observed. The mean improvement was 40% in UPDRS II and 67% in UPDRS III. No surgical or hardware complications were observed. Stimulation-related adverse effects, including increased falling and worsening of speech, occurred in a few patients after surgery. Most of the patients experienced weight gain after surgery.
   CONCLUSIONS: Bilateral STN DBS is a satisfactory and safe treatment for carefully selected patients with advanced Parkinson disease. According to the results, the procedure can be performed safely and with comparable results in developing countries around the world.
C1 [Razmkon, Ali; Yousefi, Omid; Rezaei, Raziyeh; Ilami, Ghazal; Amirmoezzi, Yalda] Kowsar Hosp, Res Ctr Neuromodulat & Pain, Shiraz, Iran.
   [Salehi, Sina] Shiraz Univ Med Sci, Shiraz Neurosci Res Ctr, Shiraz, Iran.
   [Petramfar, Peyman] Shiraz Univ Med Sci, Dept Neurol, Shiraz, Iran.
   [Mani, Arash] Shiraz Univ Med Sci, Res Ctr Psychiat & Behav Sci, Shiraz, Iran.
   [Rahmati, Hashem] Shiraz Univ Med Sci, Community Based Psychiat Care Res Ctr, Shiraz, Iran.
   [Vaidyanathan, Janardan] Medtronic, Mumbai, Maharashtra, India.
RP Razmkon, A (reprint author), Kowsar Hosp, Res Ctr Neuromodulat & Pain, Shiraz, Iran.
EM ali.razmkon@gmail.com
RI Petramfar, Peyman/Y-7215-2019; salehi, sina/F-2703-2013
OI Petramfar, Peyman/0000-0001-8191-4637; salehi, sina/0000-0001-8027-6944
CR Alegret M, 2001, ARCH NEUROL-CHICAGO, V58, P1223, DOI 10.1001/archneur.58.8.1223
   Barichella M, 2003, MOVEMENT DISORD, V18, P1337, DOI 10.1002/mds.10543
   BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600
   Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6
   Beric A, 2001, STEREOT FUNCT NEUROS, V77, P73, DOI 10.1159/000064600
   Chan DTM, 2016, WORLD NEUROSURG, V93, P229, DOI 10.1016/j.wneu.2016.06.002
   Charles PD, 2002, NEUROLOGY, V59, P932, DOI 10.1212/WNL.59.6.932
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Fereshtehnejad S.-M., 2015, NEUROEPIDEMIOLOGY PA
   Fereshtehnejad SM, 2015, NEUROPSYCH DIS TREAT, V11, P321, DOI 10.2147/NDT.S77391
   Fraix V, 2006, J NEUROL NEUROSUR PS, V77, P443, DOI 10.1136/jnnp.2005.077677
   Gentil M, 2003, BRAIN LANG, V85, P190, DOI 10.1016/S0093-934X(02)00590-4
   Goodman RR, 2006, J NEUROL NEUROSUR PS, V77, P12, DOI 10.1136/jnnp.2005.069161
   Hamani C, 2006, STEREOT FUNCT NEUROS, V84, P248, DOI 10.1159/000096499
   Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045
   Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962
   Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275
   Krack P, 1997, LANCET, V350, P1676, DOI 10.1016/S0140-6736(05)64273-0
   Lezcano E, 2004, EUR J NEUROL, V11, P451, DOI 10.1111/j.1468-1331.2004.00804.x
   Lopiano L, 2001, NEUROLOGY, V56, P552, DOI 10.1212/WNL.56.4.552
   Lyons KE, 2004, NEUROLOGY, V63, P612, DOI 10.1212/01.WNL.0000134650.91974.1A
   Mehrdad R, 2009, INT MED COMMUNICATIO, V52, P69
   Moreau C, 2008, NEUROLOGY, V71, P80, DOI 10.1212/01.wnl.0000303972.16279.46
   Odekerken VJJ, 2016, NEUROLOGY, V86, P755, DOI 10.1212/WNL.0000000000002401
   Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8
   Oh MY, 2002, NEUROSURGERY, V50, P1268
   Okun MS, 2005, ARCH NEUROL-CHICAGO, V62, P1250, DOI 10.1001/archneur.62.8.noc40425
   Ostergaard K, 2002, MOVEMENT DISORD, V17, P693, DOI 10.1002/mds.10188
   Pahwa R, 2003, J NEUROSURG, V99, P71, DOI 10.3171/jns.2003.99.1.0071
   Rieu I, 2011, J NEUROL SCI, V310, P267, DOI 10.1016/j.jns.2011.06.055
   Tuite PJ, 2005, PARKINSONISM RELAT D, V11, P247, DOI 10.1016/j.parkreldis.2005.01.006
   Volkmann J, 2001, NEUROLOGY, V56, P548, DOI 10.1212/WNL.56.4.548
   Walter BL, 2004, LANCET NEUROL, V3, P719, DOI 10.1016/S1474-4422(04)00934-2
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E121
EP E127
DI 10.1016/j.wneu.2018.09.035
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000017
PM 30236810
DA 2020-05-12
ER

PT J
AU Robison, TR
   Heyer, EJ
   Wang, S
   Caccappolo, E
   Mergeche, JL
   Shah, SS
   Connolly, ES
AF Robison, Trae R.
   Heyer, Eric J.
   Wang, Shuang
   Caccappolo, Elise
   Mergeche, Joanna L.
   Shah, Sohum S.
   Connolly, Edward Sander, Jr.
TI Easily Screenable Characteristics Associated with Cognitive Improvement
   and Dysfunction After Carotid Endarterectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Carotid stenosis; Cognitive impairment;
   Neuropsychometric assessment
ID NEUROPSYCHOLOGICAL DYSFUNCTION; MANAGEMENT; DECLINE; ABSENCE; STROKE
AB BACKGROUND: Carotid endarterectomy (CEA) is an effective treatment for the prevention of stroke in patients with carotid artery stenosis. We aimed to clarify the incidence and risk factors for early cognitive dysfunction (eCD) and early cognitive improvement (eCI), defined as change in cognitive performance <= 24 hours after surgery, using a battery of neuropsychometric tests.
   METHODS: In total, 585 patients undergoing CEA were tested with neuropsychometric tests before and after surgery; 155 patients undergoing "simple" spine surgery were the reference group. Patient performance for each test was evaluated by z scores. Cognitive change was defined as eCD (or eCI) if: 1) patients had a z score <= -2 (or >= 2) in >= 2 cognitive domains or 2) patients had mean z scores across all domains <= -1.5 (or >= 1.5). Associations between the categorical cognitive outcomes and variables of interest were modeled using the proportional odds model.
   RESULTS: Of the 585 subjects, 24% had eCD, 6% had eCI, and 70% had "no change." Patients who had eCD were more likely to be statin naive (odds ratio [OR] 1.23 [1.03-1.48], P [0.02) or women (OR 1.27 [1.06-1.53], P = 0.02). Those with eCI were less likely to have less formal education (OR 0.95 [0.90-1.00], P = 0.04) and less likely to have diabetes mellitus (OR 0.8 [0.65-0.99], P = 0.04).
   CONCLUSIONS: Patients having CEA may develop eCD or eCI postoperatively. Medications likely to be associated with less eCD are statins and aspirin, which correlate most strongly in asymptomatic patients. In addition to confirming previous findings, we found that women were more likely than men to develop eCD. More sex-specific studies and analysis are needed to better explore these findings.
C1 [Robison, Trae R.; Heyer, Eric J.; Shah, Sohum S.; Connolly, Edward Sander, Jr.] Columbia Univ, Coll Phys & Surg, Dept Neurol Surg, New York, NY 10027 USA.
   [Heyer, Eric J.; Caccappolo, Elise; Connolly, Edward Sander, Jr.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   [Heyer, Eric J.; Mergeche, Joanna L.] Columbia Univ, Coll Phys & Surg, Dept Anesthesia, New York, NY USA.
   [Wang, Shuang] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA.
RP Robison, TR (reprint author), Columbia Univ, Coll Phys & Surg, Dept Neurol Surg, New York, NY 10027 USA.
EM trr2116@cumc.columbia.edu
FU National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01-AG050819]
FX Partial salary support for Joanna L. Mergeche, Eric J. Heyer, and E.
   Sander Connolly was obtained from grant R01-AG17604 from the National
   Institute on Aging and for Eric J. Heyer and E. Sander Connolly from
   grant R01-AG050819 from the National Institute on Aging.
CR Aharon-Peretz J, 2003, EUR J NEUROL, V10, P525, DOI 10.1046/j.1468-1331.2003.00633.x
   Brott TG, 2011, J AM COLL CARDIOL, V57, P1002, DOI 10.1016/j.jacc.2010.11.005
   Connolly ES, 2001, NEUROSURGERY, V49, P1076, DOI 10.1097/00006123-200111000-00010
   Connolly Jr ES, 2001, NEUROSURGERY, V49, P82
   ENGELTER S, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001458
   GREIFFENSTEIN MF, 1988, CORTEX, V24, P223, DOI 10.1016/S0010-9452(88)80031-5
   Halazun HJ, 2014, J VASC SURG, V59, P768, DOI 10.1016/j.jvs.2013.08.095
   Heyer EJ, 2006, NEUROSURGERY, V58, P474, DOI 10.1227/01.NEU.0000197123.09972.EA
   Heyer EJ, 2002, ARCH NEUROL-CHICAGO, V59, P217, DOI 10.1001/archneur.59.2.217
   Heyer EJ, 1998, STROKE, V29, P1110, DOI 10.1161/01.STR.29.6.1110
   Heyer EJ, 2015, NEUROSURGERY, V77, P880, DOI 10.1227/NEU.0000000000000904
   Heyer EJ, 2015, J NEUROSURG, V122, P101, DOI 10.3171/2014.8.JNS1459
   Heyer EJ, 2014, NEUROSURGERY, V74, P245, DOI 10.1227/NEU.0000000000000256
   Heyer EJ, 2014, J CLIN NEUROSCI, V21, P236, DOI 10.1016/j.jocn.2013.04.009
   Heyer EJ, 2014, J NEUROSURG, V120, P126, DOI 10.3171/2013.8.JNS13931
   Heyer EJ, 2013, DIABETES CARE, V36, P3283, DOI 10.2337/dc12-2507
   Heyer EJ, 2013, J NEUROSURG, V119, P648, DOI 10.3171/2013.4.JNS1368
   Heyer EJ, 2013, STROKE, V44, P1150, DOI 10.1161/STROKEAHA.111.000362
   Hitchner E, 2016, J VASC SURG, V64, P1719, DOI 10.1016/j.jvs.2016.06.104
   Lezak M. D., 2012, NEUROPSYCHOLOGICAL A
   Marulanda-Londono E, 2016, STROKE VASC NEUROL, V1, P192, DOI 10.1136/svn-2016-000043
   Mocco J, 2006, NEUROSURGERY, V58, P844, DOI 10.1227/01.NEU.0000209638.62401.7E
   MONONEN H, 1990, EUR NEUROL, V30, P328, DOI 10.1159/000117366
   Monteiro R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/615917
   Orrapin S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001081.pub3
   Picchetto L, 2013, CARDIOVASC PSYCHIAT
   Shi GM, 2016, CURR NEUROVASC RES, V13, P39, DOI 10.2174/1567202613666151116143757
   Simonoff JS, 2003, REGRESSION MODELS MU, P427
   Stelagowski M, 2017, ADV CLIN EXP MED, V26, P1225, DOI 10.17219/acem/68270
   Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6
   Sussman ES, 2014, J NEUROSURG, V121, P593, DOI 10.3171/2014.5.JNS131736
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   Vogten JM, 2008, VASCULAR, V16, P154, DOI 10.2310/6670.2008.00027
   Wang Q, 2015, EUR J VASC ENDOVASC, V50, P5, DOI 10.1016/j.ejvs.2015.03.032
   Yoshida K, 2012, NEUROL MED-CHIR, V52, P154, DOI 10.2176/nmc.52.154
   Zhang HP, 2016, TURK NEUROSURG, V26, P833, DOI 10.5137/1019-5149.JTN.13382-14.1
   Zhou W, 2012, J VASC SURG, V56, P1571, DOI 10.1016/j.jvs.2012.05.092
NR 37
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E192
EP E198
DI 10.1016/j.wneu.2018.09.076
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000027
PM 30261391
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Ryu, SM
   Kim, SK
   Park, JH
   Lee, SH
   Eoh, W
   Kim, ES
AF Ryu, Sung Mo
   Kim, Seung-Kook
   Park, Jong-Hyeok
   Lee, Sun-Ho
   Eoh, Whan
   Kim, Eun-Sang
TI Subtotal Resection of Cervical Dumbbell Schwannomas: Radiographic
   Predictors for Surgical Considerations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical; Dumbbell; Resectability; Schwannoma; Signal intensity;
   Vertebral artery
ID NERVE SHEATH TUMORS; RETROSPECTIVE ANALYSIS; VERTEBRAL ARTERY;
   GROWTH-RATE; NEURINOMAS; MENINGIOMAS; MANAGEMENT; REMOVAL; SERIES
AB OBJECTIVE: Currently, radiologic predictors for the resectability of cervical dumbbell schwannomas remain unknown. To identify radiologic predictors for resectability, we retrospectively reviewed data from 72 patients.
   METHODS: From January 1995 to June 2017, 72 patients who underwent surgical treatment for cervical dumbbell schwannomas were enrolled. We focused on the relationship between preoperative magnetic resonance imaging (MRI) features and the extent of tumor removal. The MRI features evaluated were tumor size, tumor level, Eden classification, degree of vertebral artery (VA) involvement, and signal intensity (SI) on T2-weighted images (WIs).
   RESULTS: Among the 72 patients, gross total resection (GTR) and subtotal resection (STR) were achieved in 37 (51.4%) and 35 (48.6%) patients, respectively. Mean maximal tumor size (P = 0.011), mean size of foraminal and extraforaminal portion (P = 0.017), tumor level (P < 0.001), VA involvement (P < 0.001), and SI on T2-WIs (P = 0.006) were significantly different between the GTR and STR groups. Univariate analyses demonstrated that maximal tumor size (odds ratio [OR]: 0.93, P = 0.012), high cervical level (OR: 11.37, P < 0.001), pushed VA (OR: 0.11, P = 0.002), encased VA (OR: 0.02, P < 0.001), and hyper-SI on T2-WIs (OR: 12.46, P = 0.020) were significant predictors for GTR. In the multivariate analysis, only high cervical level (OR: 5.48, P = 0.033) and encased VA (OR: 0.07, P = 0.014) were significant predictors for GTR.
   CONCLUSIONS: The resectability of cervical dumbbell schwannomas may be predicted by MRI features, including tumor size, tumor level, and degree of VA involvement.
C1 [Ryu, Sung Mo; Lee, Sun-Ho; Eoh, Whan; Kim, Eun-Sang] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Kim, Seung-Kook] Himchan Hosp, Dept Spine Ctr, Incheon, South Korea.
   [Park, Jong-Hyeok] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
RP Kim, ES (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea.
EM est.kim@samsung.com
CR Conti P, 2004, SURG NEUROL, V61, P34, DOI 10.1016/S0090-3019(03)00537-8
   Dehcordi SR, 2012, EUR SPINE J, V21, P887, DOI 10.1007/s00586-011-2118-6
   GEORGE B, 1985, NEUROSURGERY, V16, P591, DOI 10.1227/00006123-198505000-00001
   GEORGE B, 1995, J NEUROSURG, V82, P917, DOI 10.3171/jns.1995.82.6.0917
   George B, 1999, CRIT REV NEUROSURG, V9, P156, DOI 10.1007/s003290050125
   Goel A, 2008, J NEUROSURG-SPINE, V8, P129, DOI 10.3171/SPI/2008/8/2/129
   Gu BS, 2015, EUR SPINE J, V24, P2114, DOI 10.1007/s00586-014-3458-9
   HAKUBA A, 1984, J NEUROSURG, V61, P1100, DOI 10.3171/jns.1984.61.6.1100
   Ito K, 2014, BRIT J NEUROSURG, V28, P324, DOI 10.3109/02688697.2013.835372
   Iwasaki Y, 1999, NEUROL MED-CHIR, V39, P835, DOI 10.2176/nmc.39.835
   Jiang L, 2009, SPINE, V34, P1307, DOI 10.1097/BRS.0b013e3181a27a32
   KAMEYAMA S, 1994, ACTA NEUROCHIR, V129, P127, DOI 10.1007/BF01406491
   Kyoshima K, 2003, NEUROSURGERY, V53, P436, DOI 10.1227/01.NEU.0000073992.97761.88
   LAASONEN EM, 1986, NEURORADIOLOGY, V28, P203, DOI 10.1007/BF00548193
   Maiuri F, 1999, EUR J RADIOL, V31, P69, DOI 10.1016/S0720-048X(98)00083-7
   Ozawa H, 2007, J NEUROSURG-SPINE, V7, P587, DOI 10.3171/SPI-07/12/587
   Rizk AR, 2017, WORLD NEUROSURG, V99, P159, DOI 10.1016/j.wneu.2016.11.082
   ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0
   SEN C, 1995, NEUROSURGERY, V36, P106
   SEPPALA MT, 1995, J NEUROSURG, V83, P621, DOI 10.3171/jns.1995.83.4.0621
   Sitthinamsuwan B, 2012, ACTA NEUROCHIR, V154, P1383, DOI 10.1007/s00701-012-1427-9
   SUZUKI Y, 1994, ACTA NEUROCHIR, V129, P39, DOI 10.1007/BF01400871
   Wang ZW, 2016, CLIN NEUROL NEUROSUR, V151, P96, DOI 10.1016/j.clineuro.2016.10.016
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E661
EP E669
DI 10.1016/j.wneu.2018.09.186
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000081
PM 30292040
DA 2020-05-12
ER

PT J
AU Samanci, MY
   Calendo, G
   Baker, ST
   Erkmen, K
   Weaver, MW
   Wolfson, MR
AF Samanci, Mustafa Yavuz
   Calendo, Gennaro
   Baker, Sandy T.
   Erkmen, Kadir
   Weaver, Michael W.
   Wolfson, Marla R.
TI Neuroprotective Effects of Nasopharyngeal Perfluorochemical Cooling in a
   Rat Model of Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain temperature; Hypothermia; Neuroprotection; Perfluorochemical;
   Subarachnoid hemorrhage
ID CEREBRAL-ARTERY OCCLUSION; BRAIN TEMPERATURE; MILD HYPOTHERMIA;
   BLOOD-FLOW; SPONTANEOUS HYPERTHERMIA; THERAPEUTIC HYPOTHERMIA; TISSUE
   OXYGENATION; TIME-COURSE; ISCHEMIA; COMPLICATIONS
AB OBJECTIVE: Subarachnoid hemorrhage (SAH) frequently results in severe morbidity, even mortality. Hypothermia is known to have a neuroprotective effect in ischemic injuries. The aim of this study was to determine whether nasopharyngeal (NP) perfluorochemical (PFC) cooling could be used in a rat model of SAH model for neuroprotection.
   METHODS: SAH was induced in 16 male SpragueDawley rats by cisterna magna injection of 0.3 mL autologous blood. Vital signs, temperatures, cerebral blood flow (CBF), and brain histology were assessed. Brain cooling was performed on the treatment group using the NP-PFC method starting from 20 minutes after SAH.
   RESULTS: No SAH-related deaths were observed in either group. SAH caused an immediate decrease in mean arterial pressure (17.0% +/- 4.90% below baseline values). SAH induction caused a significant and rapid decrease in CBF from baseline (approximately -65%, ranging from -32% to -85%) in both hemispheres. In the left hemisphere, cooling facilitated the return of CBF to baseline values within 20 minutes of treatment with further increase in CBF that stabilized by the 2 hours after injury time point. Quantitative immunohistochemistry showed that there were significantly more NeuN-positive cells in the cortex and significantly fewer IBA-1-positive microglia and glial fibrillary acidic proteinepositive astrocytes cells in both cortex and hippocampus in the animals that received NP-PFC cooling compared with no treatment, reflecting preserved neuronal integrity and reduced inflammation.
   CONCLUSIONS: The data from this study indicate that local hypothermia by NP-PFC cooling supports return of CBF and neuronal integrity and suppresses the inflammatory response in SAH, suggestive of a promising neuroprotective approach in management of SAH.
C1 [Samanci, Mustafa Yavuz; Erkmen, Kadir; Weaver, Michael W.] Temple Univ, Dept Neurosurg, Temple Neurosci Ctr, Philadelphia, PA 19122 USA.
   [Samanci, Mustafa Yavuz; Calendo, Gennaro; Baker, Sandy T.; Wolfson, Marla R.] Temple Univ, Dept Physiol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Wolfson, Marla R.] Temple Univ, Dept Pediat, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Calendo, Gennaro; Baker, Sandy T.; Wolfson, Marla R.] Temple Univ, Dept Thorac Med & Surg, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Calendo, Gennaro; Baker, Sandy T.; Wolfson, Marla R.] Temple Univ, Lewis Katz Sch Med, Ctr Inflammat Translat & Clin Lung Res, Philadelphia, PA 19122 USA.
RP Samanci, MY (reprint author), Temple Univ, Dept Neurosurg, Temple Neurosci Ctr, Philadelphia, PA 19122 USA.; Samanci, MY (reprint author), Temple Univ, Dept Physiol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
EM mysamanci@hotmail.com
RI Samanci, Yavuz/I-1408-2016
OI Samanci, Yavuz/0000-0001-8952-6866
CR Abou-Chebl A, 2011, STROKE, V42, P2164, DOI 10.1161/STROKEAHA.110.613000
   Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975
   Aronowski J, 1999, J CEREBR BLOOD F MET, V19, P652, DOI 10.1097/00004647-199906000-00008
   Ayer R, 2010, TURK NEUROSURG, V20, P159, DOI 10.5137/1019-5149.JTN.2714-09.0
   BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438
   Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091
   Boller M, 2010, RESUSCITATION, V81, P1025, DOI 10.1016/j.resuscitation.2010.04.005
   Brambrink AM, 1999, J NEUROSCI METH, V92, P111, DOI 10.1016/S0165-0270(99)00100-4
   BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342
   Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x
   Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F
   Costello TG, 2007, J CLIN NEUROSCI, V14, P322, DOI 10.1016/j.jocn.2006.01.018
   Cottrell JE, 2004, J NEUROSURG ANESTH, V16, P113, DOI 10.1097/00008506-200404000-00001
   Critchley GR, 2003, NEUROL RES, V25, P451, DOI 10.1179/016164103101201841
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2
   Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6
   Fay T, 1945, ASS RES NERV MENT DI, V24, P611
   Fridriksson S, 2002, J NEUROSURG, V96, P515, DOI 10.3171/jns.2002.96.3.0515
   Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529
   GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017
   Hartung J, 2005, J NEUROSURG ANESTH, V17, P63, DOI 10.1097/00008506-200504000-00001
   He Z, 1999, STROKE, V30, P2743, DOI 10.1161/01.STR.30.12.2743
   Holzer M, 2002, NEW ENGL J MED, V346, P549
   JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140
   Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43
   Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011
   Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C
   Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464
   Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090
   MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C
   MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552
   MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758
   Noor R, 2005, STROKE, V36, P665, DOI 10.1161/01.STR.0000155684.20864.58
   Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002
   Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299
   Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241
   Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022
   Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A
   Ramirez SWJ, 2013, PED AC SOC ANN M MAY
   Reglodi D, 2000, EXP NEUROL, V163, P399, DOI 10.1006/exnr.2000.7367
   Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032
   Sehba FA, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/615154
   Sinclair HL, 2010, CRIT CARE, V14, DOI 10.1186/cc8220
   Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2
   Sobey CG, 2001, CLIN EXP PHARMACOL P, V28, P926, DOI 10.1046/j.1440-1681.2001.03550.x
   SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58
   Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004
   Thal SC, 2009, J NEUROSURG, V111, P988, DOI 10.3171/2009.3.JNS08412
   Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975
   Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013
   van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44
   Wang CX, 2009, INT J STROKE, V4, P274, DOI 10.1111/j.1747-4949.2009.00317.x
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   Westermaier T, 2009, J CEREBR BLOOD F MET, V29, P771, DOI 10.1038/jcbfm.2008.169
   Wolfson MR, 2008, NEUROCRIT CARE, V8, P437, DOI 10.1007/s12028-008-9064-0
   Yu T, 2010, CRIT CARE MED, V38, P916, DOI 10.1097/CCM.0b013e3181cd1291
   Zausinger S, 2003, STROKE, V34, P2246, DOI 10.1161/01.STR.0000083622.65684.21
   Zhang Sai, 2002, Chin J Traumatol, V5, P43
   ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5
NR 60
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E481
EP E492
DI 10.1016/j.wneu.2018.09.142
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000060
PM 30267945
DA 2020-05-12
ER

PT J
AU Sarica, C
   Ziyal, MI
AF Sarica, Can
   Ziyal, M. Ibrahim
TI Retroclival Arachnoid Cysts: Case Series, Literature Review, and New
   Classification Proposal
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arachnoid cyst; Classification; Clivus surgery; Interpeduncular;
   Prepontine; Retroclival; Suprasellar
ID ENDOSCOPIC TREATMENT; NATURAL-HISTORY; CHILDREN; PREVALENCE; HEMORRHAGE;
   MEMBRANE; JUNCTION; ANATOMY; CLIVUS
AB BACKGROUND: The retroclival region is among the rarest locations for an arachnoid cyst (AC), with only a few reported cases. No accepted classification system is available for these rare cysts. Such a classification system would solve the nomenclature problem and could result in easier and more systematic management. We reviewed and analyzed data from databases and reported studies of retroclival ACs (RACs) and have proposed a classification system.
   METHODS: A retrospective review of RACs was conducted in Marmara and Adiyaman University Hospitals, Turkey. Cysts in the prepontine and/or premedullary cisterns that spared the chiasmatic cistern were included. Additionally, the reported data were searched for relevant studies on cysts. The findings were analyzed to establish a clear nomenclature and classification system, and the clinical presentations, treatment strategies, and surgical approaches were reviewed.
   RESULTS: We identified 1 adult and 1 pediatric patient, and only the adult had undergone surgery. Additional data searches yielded 14 patients with RACs. The cysts were classified as type 1 if they had extended superiorly beyond the borders of the diencephalic leaf of the Liliequist membrane. If they had not extended, they were classified as type 2. Finally, type 2 cysts that had extended to the anterior spinal cistern were classified as type 3.
   CONCLUSIONS: RACs can be more easily and systematically managed using a simple clinical classification system. Together with the previously proposed suprasellar AC classification, our proposed RAC classification should be adequate to classify all ACs in the ventral midline cistern, which could solve the nomenclature problem.
C1 [Sarica, Can] Adiyaman Univ, Educ & Res Hosp, Dept Neurosurg, Adiyaman, Turkey.
   [Ziyal, M. Ibrahim] Marmara Univ, Dept Neurosurg, Istanbul, Turkey.
RP Sarica, C (reprint author), Adiyaman Univ, Educ & Res Hosp, Dept Neurosurg, Adiyaman, Turkey.
EM can.sarica@gmail.com
RI SARICA, CAN/F-8604-2018
OI SARICA, CAN/0000-0001-8419-7426
FU Turkish Neurosurgical Society
FX Preparation for the publication of our report was partly supported by
   the Turkish Neurosurgical Society. The authors declare that the article
   content was composed in the absence of any commercial or financial
   relationships that could be construed as a potential conflict of
   interest.
CR Akyuz M, 2010, ACTA NEUROCHIR, V152, P161, DOI 10.1007/s00701-009-0381-7
   Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464
   Andre A, 2016, NEUROSURGERY, V78, P370, DOI 10.1227/NEU.0000000000001049
   Anik I, 2011, ACTA NEUROCHIR, V153, P1701, DOI 10.1007/s00701-011-0978-5
   Ayberk G, 2011, TURK NEUROSURG, V21, P372, DOI 10.5137/1019-5149.JTN.3913-10.1
   Bonde V, 2008, SINGAP MED J, V49, pE281
   BOUREKAS EC, 1992, AM J NEURORADIOL, V13, P353
   Cavallo LM, 2007, CHILD NERV SYST, V23, P665, DOI 10.1007/s00381-007-0332-7
   Chagla AS, 2011, TURK NEUROSURG, V21, P443, DOI 10.5137/1019-5149.JTN.3019-10.1
   Ersahin Y, 2008, CHILD NERV SYST, V24, P1013, DOI 10.1007/s00381-008-0615-7
   Fitzpatrick MO, 2001, BRIT J NEUROSURG, V15, P234, DOI 10.1080/02688690120057745
   FOX JL, 1980, NEUROSURGERY, V7, P615, DOI 10.1227/00006123-198012000-00016
   Froelich SC, 2008, NEUROSURGERY, V63, P1, DOI 10.1227/01.neu.0000335004.22628.ee
   Fujiwara Y, 2018, CLIN SPINE SURG, V31, P58, DOI 10.1097/BSD.0000000000000569
   Genc E, 2008, HEADACHE, V48, P1525, DOI 10.1111/j.1526-4610.2008.01147.x
   Goel A, 2007, NEUROL INDIA, V55, P388, DOI 10.4103/0028-3886.37097
   HASSOUNAH MI, 1994, J NEUROSURG, V81, P126, DOI 10.3171/jns.1994.81.1.0126
   IACONO RP, 1990, NEUROSURGERY, V27, P130, DOI 10.1097/00006123-199007000-00020
   Ikeda H, 2000, ACTA NEUROCHIR, V142, P1317, DOI 10.1007/s007010070033
   Kumar CVR, 2001, SKULL BASE-INTERD AP, V11, P265
   Lyu J, 2014, WORLD NEUROSURG, V82, pE570, DOI 10.1016/j.wneu.2014.05.020
   Marlin E, 2010, J NEUROS-PEDIATR, V5, P310, DOI 10.3171/2009.2.PEDS0915
   MATSUNO H, 1988, NEUROSURGERY, V23, P58, DOI 10.1227/00006123-198807000-00012
   Mattox A, 2010, SURG INNOV, V17, P206, DOI 10.1177/1553350610377212
   Miyajima M, 2000, J NEUROSURG, V93, P62, DOI 10.3171/jns.2000.93.1.0062
   Mohindra S, 2007, SURG NEUROL, V68, P85, DOI 10.1016/j.surneu.2006.07.024
   Mohyeldin A, 2014, INT ARCH OTORHINOLAR, V18, pS157, DOI 10.1055/s-0034-1395267
   OBERBAUER RW, 1992, CHILD NERV SYST, V8, P281, DOI 10.1007/BF00300797
   Ozek MM, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.011
   Petscavage Jonelle M, 2010, Radiol Case Rep, V5, P435, DOI 10.2484/rcr.v5i2.435
   Preuss M, 2015, CHILD NERV SYST, V31, P347, DOI 10.1007/s00381-014-2518-0
   RAIMONDI AJ, 1980, CHILD BRAIN, V7, P57
   RENGACHARY SS, 1981, J NEUROPATH EXP NEUR, V40, P61
   Rezaee Omidvar, 2017, Surg Neurol Int, V8, P289, DOI 10.4103/sni.sni_247_17
   Schroeder HWS, 1997, NEUROSURGERY, V40, P198, DOI 10.1097/00006123-199701000-00045
   Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P261, DOI 10.1016/S0895-6111(97)00013-X
   Shim KW, 2009, CHILD NERV SYST, V25, P1459, DOI 10.1007/s00381-009-0930-7
   Shimoji K, 2009, J NEUROSURG, V110, P376, DOI 10.3171/2007.12.17287
   SWEASEY TA, 1989, PEDIATR NEUROSCI, V15, P44, DOI 10.1159/000120441
NR 40
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E898
EP E907
DI 10.1016/j.wneu.2018.10.006
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000111
PM 30315978
DA 2020-05-12
ER

PT J
AU Sellin, JN
   Brusko, GD
   Levi, AD
AF Sellin, Jonathan N.
   Brusko, G. Damian
   Levi, Allan D.
TI Lateral Lumbar Interbody Fusion Revisited: Complication Avoidance and
   Outcomes with the Mini-Open Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication avoidance; Lateral lumbar interbody fusion; Mini-open
   technique; Motor and sensory outcomes
ID TRANSPSOAS APPROACH; NERVE INJURY
AB OBJECTIVE: To discuss lessons learned from an initial lateral lumbar interbody fusion (LLIF) experience with a focus on evolving surgical technique, complication avoidance, and new motor and sensory outcomes after implementation of a modified surgical approach.
   METHODS: A retrospective analysis of a prospectively collected series of all patients undergoing LLIF by the senior author (A.D.L.) from January 2010 to January 2018 after implementation of a modified surgical mini-open technique, compared with previously reported institutional results with the originally recommended percutaneous technique. LLIF-specific complications examined included groin/thigh sensory dysfunction, flank bulge/pseudohernia, psoas-pattern weakness, and femoral nerve injury.
   RESULTS: The incidence (19%, n = 98 patients) of groin/thigh sensory dysfunction in our cohort was significantly lower than that of the historical control (60%, n = 59) (P < 0.0001). The incidence of abdominal flank bulge/pseudohernia (2.0%, n = 98 patients) in our cohort was improved but not significantly lower than that of the historical control (4.2%, n = 118) (P = 0.36). The incidence of psoas-pattern weakness (3.1%, n = 98) in our cohort was significantly lower than that of the historical control (23.7%, n = 59) (P = 0.0001). The incidence of femoral nerve injury (0%, n = 98 patients) in our cohort was improved but was not significantly lower than that of the historical control (1.7%, n = 118) (P = 0.20).
   CONCLUSIONS: The adoption of an exclusive mini-open muscle-splitting approach with first-look inspection of the lumbosacral plexus nerve elements may improve motor and sensory outcomes in general and the incidence of postoperative groin/thigh sensory dysfunction and psoas-pattern weakness in particular.
C1 [Sellin, Jonathan N.; Brusko, G. Damian; Levi, Allan D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Levi, AD (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM ALevi@med.miami.edu
CR Acosta FL, 2011, J NEUROSURG-SPINE, V15, P92, DOI 10.3171/2011.3.SPINE10425
   Aghayev K, 2013, EUR SPINE J, V22, P2113, DOI 10.1007/s00586-013-2931-1
   Ahmadian A, 2013, J NEUROSURG-SPINE, V18, P289, DOI 10.3171/2012.11.SPINE12755
   Aichmair A, 2013, SPINE, V38, pE1483, DOI 10.1097/BRS.0b013e3182a3d1b4
   Beckman JM, 2017, J NEUROSURG-SPINE, V26, P50, DOI 10.3171/2016.4.SPINE151040
   Benglis DM, 2008, NEUROSURGERY, V63, pA191, DOI 10.1227/01.NEU.0000325487.49020.91
   Cahill KS, 2012, J NEUROSURG-SPINE, V17, P227, DOI 10.3171/2012.5.SPINE1288
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Dakwar E, 2011, J NEUROSURG-SPINE, V14, P290, DOI 10.3171/2010.10.SPINE10395
   Dakwar E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09282
   Dandaleh NS, 2014, NEUROSURG CLIN N AM, V25, P353, DOI 10.1016/j.nec.2013.12.013
   Epstein Nancy E, 2016, Surg Neurol Int, V7, pS652
   Fahim DK, 2011, J NEUROSURG-SPINE, V15, P532, DOI 10.3171/2011.7.SPINE10887
   Houten JK, 2011, J NEUROSURG-SPINE, V15, P280, DOI 10.3171/2011.4.SPINE1127
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Kwon B, 2016, J AM ACAD ORTHOP SUR, V24, P96, DOI 10.5435/JAAOS-D-14-00208
   Le TV, 2013, SPINE, V38, pE13, DOI 10.1097/BRS.0b013e318278417c
   Lykissas MG, 2014, SPINE J, V14, P749, DOI 10.1016/j.spinee.2013.06.066
   Moller DJ, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11137
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Phan K, 2015, J CLIN NEUROSCI, V22, P1714, DOI 10.1016/j.jocn.2015.03.050
   Pumberger M, 2012, EUR SPINE J, V21, P1192, DOI 10.1007/s00586-011-2087-9
   Tempel ZJ, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13368
   Tormenti MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09263
   Yuan PS, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-20
NR 26
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E647
EP E653
DI 10.1016/j.wneu.2018.09.180
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000079
PM 30292030
DA 2020-05-12
ER

PT J
AU Selner, AN
   Rosinski, CL
   Chiu, RG
   Rosenberg, D
   Chaker, AN
   Drammeh, H
   Esfahani, DR
   Mehta, AI
AF Selner, Ashley N.
   Rosinski, Clayton L.
   Chiu, Ryan G.
   Rosenberg, David
   Chaker, Anisse N.
   Drammeh, Hamidou
   Esfahani, Darian R.
   Mehta, Ankit I.
TI Vagal Nerve Stimulation for Epilepsy in Adults: A Database Risk Analysis
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Electrical stimulation; Epilepsy; Outcome; Refractory epilepsy; Seizure;
   Vagus nerve stimulation therapy
ID DRUG-RESISTANT EPILEPSY; UNITED-STATES; BOTULINUM TOXIN; COMPLICATIONS;
   SURGERY; METAANALYSIS
AB BACKGROUND: Epilepsy is one of the most common neurologic disorders and often remains refractory despite pharmacologic treatment. In patients who are not amenable to surgical resection of seizure foci, vagal nerve stimulation (VNS) may be beneficial. Multiple case series have attempted to construct a risk profile for VNS, but they are largely confined to pediatric or single-center populations. We aimed to compile a risk profile for adults undergoing VNS, using multicenter patient data from an international database.
   METHODS: The 30-day outcomes of adults undergoing VNS from 2005 to 2016 were collected from the American College of Surgeons National Surgical Quality Improvement Program database. Readmission rates, reoperation rates, length of hospital stay, operative time, and complications were assessed. A comprehensive literature search was performed to identify historically reported complication rates.
   RESULTS: Inclusion and exclusion criteria were met by 77 patients. A 30-day risk profile revealed low readmission (6.2%), reoperation (1.3%), and postoperative infection (1.3%) rates. Mean operative time was 81.7 minutes, and average length of stay was 0.27 days. Most (87.0%) patients were discharged on the day of operation.
   CONCLUSIONS: This study provides a current snapshot of risks and outcomes in VNS, revealing a safe 30-day risk profile. Greater use of VNS may be beneficial in this fragile population.
C1 [Selner, Ashley N.; Rosinski, Clayton L.; Chiu, Ryan G.; Rosenberg, David; Chaker, Anisse N.; Drammeh, Hamidou; Esfahani, Darian R.; Mehta, Ankit I.] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
RP Mehta, AI (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM ankitm@uic.edu
RI Mehta, Ankit/AAL-3851-2020
OI Rosenberg, David/0000-0003-4914-3195; Selner,
   Ashley/0000-0002-5687-8862; Chiu, Ryan/0000-0001-8666-9001
CR Air EL, 2009, J NEUROSURG-PEDIATR, V3, P73, DOI 10.3171/2008.10.PEDS08294
   Andrade Filho Pedro A, 2004, J Voice, V18, P254, DOI 10.1016/j.jvoice.2003.05.002
   Charous SJ, 2001, LARYNGOSCOPE, V111, P2028, DOI 10.1097/00005537-200111000-00030
   COHEN SR, 1987, ANN OTO RHINOL LARYN, V96, P534, DOI 10.1177/000348948709600512
   Elliott RE, 2011, J NEUROSURG-PEDIATR, V7, P491, DOI 10.3171/2011.2.PEDS10505
   Elliott RE, 2011, EPILEPSY BEHAV, V20, P57, DOI 10.1016/j.yebeh.2010.10.017
   Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea
   Englot DJ, 2011, J NEUROSURG, V115, P1248, DOI 10.3171/2011.7.JNS11977
   Fiest KM, 2017, NEUROLOGY, V88, P296, DOI 10.1212/WNL.0000000000003509
   Garamendi-Ruiz I, 2019, CLIN AUTON RES, V29, P183, DOI 10.1007/s10286-017-0477-8
   Garcia-Navarrete E, 2013, SEIZURE-EUR J EPILEP, V22, P9, DOI 10.1016/j.seizure.2012.09.008
   Giordano F, 2017, EPILEPSIA, V58, P85, DOI 10.1111/epi.13678
   Hermann B, 2009, EPILEPSY BEHAV, V15, pS11, DOI 10.1016/j.yebeh.2009.03.029
   Horowitz G, 2013, EUR ARCH OTO-RHINO-L, V270, P355, DOI 10.1007/s00405-012-2118-0
   Kahlow H, 2013, SEIZURE-EUR J EPILEP, V22, P827, DOI 10.1016/j.seizure.2013.06.011
   Kaiboriboon K, 2015, EPILEPSY RES, V116, P105, DOI 10.1016/j.eplepsyres.2015.07.007
   Knight EMP, 2015, EPILEPSIA, V56, P375, DOI 10.1111/epi.12912
   Ko CY, 2015, JT COMM J QUAL PATIE, V41, P199, DOI 10.1016/S1553-7250(15)41026-8
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Morris GL, 2013, NEUROLOGY, V81, P1453, DOI 10.1212/WNL.0b013e3182a393d1
   Revesz D, 2016, J NEUROSURG-PEDIATR, V18, P97, DOI 10.3171/2016.1.PEDS15534
   Roldan P, 2013, NEUROCIRUGIA, V24, P204, DOI 10.1016/j.neucir.2013.04.003
   Rontal E, 1999, J VOICE, V13, P274, DOI 10.1016/S0892-1997(99)80032-0
   Shimogawa Takafumi, 2014, No Shinkei Geka, V42, P419
   Smyth MD, 2003, J NEUROSURG, V99, P500, DOI 10.3171/jns.2003.99.3.0500
   Spuck S, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f88867
   Spuck S, 2008, EPILEPSY RES, V82, P232, DOI 10.1016/j.eplepsyres.2008.08.003
   Wozniak SE, 2011, J NEUROSURG-PEDIATR, V7, P671, DOI 10.3171/2011.4.PEDS10556
NR 28
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E947
EP E953
DI 10.1016/j.wneu.2018.10.043
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000117
PM 30326313
DA 2020-05-12
ER

PT J
AU Shah, AH
   Kuchakulla, M
   Ibrahim, GM
   Dadheech, E
   Komotar, RJ
   Gultekin, SH
   Ivan, ME
AF Shah, Ashish H.
   Kuchakulla, Manish
   Ibrahim, George M.
   Dadheech, Eesh
   Komotar, Ricardo J.
   Gultekin, Sakir H.
   Ivan, Michael E.
TI Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active
   Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Histology; Tumor fraction perfusion; Glioblastoma; Metastasis;
   Recurrence
ID BRAIN METASTASES; PROGRESSION; SPECTROSCOPY; GLIOMAS; PET;
   DIFFERENTIATION; DIAGNOSIS; SURVIVAL; MRI
AB BACKGROUND: Ancillary criteria to identify tumor recurrence such as the McDonald criteria or Response Assessment in Neuro-Oncology criteria can provide false diagnoses. Magnetic resonance perfusion (MRP) imaging has been proposed to differentiate post-treatment changes from recurrence. We investigated the utility of MRP to quantify the histological fraction of active tumor (AT), treatment-related changes, and radiation necrosis in recurrent post-treatment intracranial tumors.
   METHODS: We conducted an exploratory single-blind study of patients with intracranial glioblastoma or metastases with previous radiation therapy and MRP before surgery. Biopsy specimens (n = 19) were analyzed for the percentage of AT, radiation necrosis, and treatment effect. Nonparametric Spearman's rho analysis and multivariable analysis of covariance were performed to assess the correlation between quantitative MRP and AT histological fraction.
   RESULTS: The mean patient age was 58 +/- 11.5 years. The mean relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF) were 1.33 +/- 0.71 and 1.34 +/- 0.73, respectively. On analysis of covariance, significant associations were identified between increased rCBF (P = 0.0004) and increased rCBV (P = 0.007) and percentage of AT. A significant interaction was identified between rCBF and rCBV and tumor histological features (glioblastoma vs. metastases; P = 0.003 and P = 0.03, respectively). An rCBF > 1 predicted a mean AT fraction of >= 53% for all intracranial tumors and 74% for glioblastoma.
   CONCLUSION: MRP can help quantitatively predict tumor recurrence and/or progression for glioblastomas. The AT histological fraction correlated with quantitative radiologic measurements, including rCBV and rCBF. For metastases, MRP might not be as useful in predicting the AT fraction. Clinicians must be judicious with their use of MRP in predicting tumor recurrence and radiation necrosis.
C1 [Shah, Ashish H.; Kuchakulla, Manish; Dadheech, Eesh; Komotar, Ricardo J.; Ivan, Michael E.] Univ Miami, Dept Neurosurg, Miami, FL 33146 USA.
   [Gultekin, Sakir H.] Univ Miami, Dept Pathol, Miami, FL USA.
   [Ibrahim, George M.] Sick Childrens Hosp, Dept Neurosurg, Toronto, ON, Canada.
RP Shah, AH (reprint author), Univ Miami, Dept Neurosurg, Miami, FL 33146 USA.
EM ashah@med.miami.edu
OI Ivan, Michael/0000-0002-4798-4989
CR Amin A, 2012, J NEURO-ONCOL, V106, P579, DOI 10.1007/s11060-011-0694-2
   Cha S, 2007, AM J NEURORADIOL, V28, P1078, DOI 10.3174/ajnr.A0484
   Chuang MT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0141438
   Cicone F, 2015, EUR J NUCL MED MOL I, V42, P103, DOI 10.1007/s00259-014-2886-4
   Detsky JS, 2017, J NEURO-ONCOL, V134, P433, DOI 10.1007/s11060-017-2545-2
   Filss CP, 2017, CLIN TRANSL IMAGING, V5, P209, DOI 10.1007/s40336-017-0225-z
   Guo L, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0702-y
   Hu LS, 2012, NEURO-ONCOLOGY, V14, P919, DOI 10.1093/neuonc/nos112
   Huang J, 2011, MAGN RESON IMAGING, V29, P993, DOI 10.1016/j.mri.2011.04.004
   Kerkhof M, 2018, J NEURO-ONCOL, V138, P133, DOI 10.1007/s11060-018-2779-7
   Kim YH, 2010, CLIN NEUROL NEUROSUR, V112, P758, DOI 10.1016/j.clineuro.2010.06.005
   Law M, 2008, RADIOLOGY, V247, P490, DOI 10.1148/radiol.2472070898
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277
   Miyatake SI, 2015, NEUROL MED-CHIR, V55, P50, DOI 10.2176/nmc.ra.2014-0188
   Muto M, 2018, RADIOL MED, V123, P545, DOI 10.1007/s11547-018-0866-7
   Nakajima T, 2009, NEUROL MED-CHIR, V49, P394, DOI 10.2176/nmc.49.394
   Rock JP, 2002, NEUROSURGERY, V51, P912, DOI 10.1097/00006123-200210000-00010
   Shah AH, 2013, J NEURO-ONCOL, V112, P141, DOI 10.1007/s11060-013-1059-9
   Snelling B, 2017, J KOREAN NEUROSURG S, V60, P15, DOI 10.3340/jkns.2016.0102.001
   Sugahara T, 2000, AM J NEURORADIOL, V21, P901
   van den Bent MJ, 2011, LANCET ONCOL, V12, P583, DOI 10.1016/S1470-2045(11)70057-2
   Verma N, 2013, NEURO-ONCOLOGY, V15, P515, DOI 10.1093/neuonc/nos307
   Woodworth GF, 2013, J NEURO-ONCOL, V113, P485, DOI 10.1007/s11060-013-1141-3
NR 24
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E836
EP E842
DI 10.1016/j.wneu.2018.09.233
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000103
PM 30312826
DA 2020-05-12
ER

PT J
AU Shi, L
   Shen, K
   Chu, L
   Yu, KX
   Yu, QS
   Deng, R
   Deng, ZL
AF Shi, Lei
   Shen, Kai
   Chu, Lei
   Yu, Ke-Xiao
   Yu, Qing-Shuai
   Deng, Rui
   Deng, Zhong-Liang
TI Biomechanical Study of Novel Unilateral Fixation Combining Unilateral
   Pedicle and Contralateral Translaminar Screws in the Subaxial Cervical
   Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanical study; Pullout strength; Range of motion; Subaxial
   cervical spine; Translaminar screw; Unilateral fixation
ID LATERAL MASS SCREWS; VERTEBRAL ARTERY; COMPUTED-TOMOGRAPHY; FEASIBILITY;
   PLACEMENT; OCCLUSION; INJURIES; ANATOMY
AB INTRODUCTION: In several situations, the stability of the subaxial cervical spine is damaged and involves the lateral mass of 1 side; in these cases, a pedicle screw (PS) or lateral mass screw (LMS) may not be suitable for placement on the affected side. Therefore, salvage shortsegment fixation with satisfactory stability is needed when bilateral fixation is not feasible.
   METHODS: Seven fresh-frozen human cervical spine specimens were used to test the 3-plane range of motion (ROM) of the C4-C5 segment. Quasistatic 2-Nm flexibility testing was performed in the following sequence: 1) intact; 2) destabilization (using 3-column injury models) treated with bilateral mass screws (BMSs); 3) destabilization treated with a unilateral PS combined with a contralateral translaminar screw (UPSDCTLS); and 4) destabilization treated with bilateral PSs (BPSs). Then, a pullout strength test was performed for the PSs, LMSs, and translaminar screws (TLSs) using 7 isolated C4 and C5 vertebrae.
   RESULTS: The UPSDCTLS group showed no significant difference from the BMS group in the 3-plane ROM or from the BPS group in the axial rotation or flexion-extension ROM but showed a significantly greater lateral bending ROM than did the BPS group. The pullout strength test showed that both C4 and C5 TLSs had strength similar to that of LMSs but poorer than that of PSs.
   CONCLUSIONS: Fixation with the hybrid UPSDCTLS construct performed as well as BMS fixation in our biomechanical tests and may play a clinical role when BPS or BMS placement is not feasible for short-segment fixation.
C1 [Shi, Lei; Shen, Kai; Chu, Lei; Yu, Ke-Xiao; Yu, Qing-Shuai; Deng, Rui; Deng, Zhong-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped, Chongqing, Peoples R China.
RP Deng, ZL (reprint author), Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped, Chongqing, Peoples R China.
EM zhongliang.deng@yahoo.com
OI Yu, Qingshuai/0000-0002-9721-1300; Yu, Ke-Xiao/0000-0002-6221-144X
FU Special Foundation for the Social Safeguard and Scientific Innovation of
   Chongqing [cstc2016shms-ztzx10001-6]; Chongqing Research and Innovation
   Project of Graduate Students [YB17112]
FX This study was supported by the Special Foundation for the Social
   Safeguard and Scientific Innovation of Chongqing (number
   cstc2016shms-ztzx10001-6) and the Chongqing Research and Innovation
   Project of Graduate Students (number YB17112).
CR Alvin MD, 2012, SPINE, V37, pE745, DOI 10.1097/BRS.0b013e31824c70ef
   Ando K, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-2
   Bhatia N, 2017, GLOB SPINE J, V7, P239, DOI 10.1177/2192568217694152
   Bozkus H, 2005, SPINE, V30, P915, DOI 10.1097/01.brs.0000158949.37281.d7
   Cho W, 2017, CLIN SPINE SURG, V30, pE535, DOI 10.1097/BSD.0000000000000159
   Cho W, 2015, SPINE J, V15, P309, DOI 10.1016/j.spinee.2014.09.013
   Dorward IG, 2011, NEUROSURGERY, V68, P1491, DOI 10.1227/NEU.0b013e318212a4d7
   Du SY, 2017, WORLD NEUROSURG, V97, P86, DOI 10.1016/j.wneu.2016.09.090
   Guan Q, 2017, WORLD NEUROSURG, V106, P715, DOI 10.1016/j.wneu.2017.07.027
   Guo-Xin J, 2015, J NEUROSURG-SPINE, P1
   Hong JT, 2008, SPINE J, V8, p116S
   Jea A, 2008, SPINE J, V8, P656, DOI 10.1016/j.spinee.2007.06.008
   Jea A, 2008, J NEUROS-PEDIATR, V2, P386, DOI 10.3171/PED.2008.2.12.386
   Ji GY, 2015, YONSEI MED J, V56, P159, DOI 10.3349/ymj.2015.56.1.159
   Jones EL, 1997, SPINE, V22, P977, DOI 10.1097/00007632-199705010-00009
   Karaikovic EE, 2000, J SPINAL DISORD, V13, P63, DOI 10.1097/00002517-200002000-00013
   Klekamp JW, 2000, J SPINAL DISORD, V13, P515, DOI 10.1097/00002517-200012000-00009
   Kothe R, 2004, SPINE, V29, P1869, DOI 10.1097/01.brs.0000137287.67388.0b
   Kretzer RM, 2010, SPINE, V35, pE948, DOI 10.1097/BRS.0b013e3181c9f56c
   Matsubara T, 2007, SPINE, V32, pE30, DOI 10.1097/01.brs.0000250994.24462.ec
   Riesenburger RI, 2012, J NEUROSURG-SPINE, V16, P251, DOI 10.3171/2011.11.SPINE11458
   Shen K, 2017, ARCH ORTHOP TRAUM SU, V137, P1349, DOI 10.1007/s00402-017-2781-0
   Shin SI, 2012, SPINE J, V12, P577, DOI 10.1016/j.spinee.2012.07.010
   Taneichi H, 2005, SPINE, V30, P1955, DOI 10.1097/01.brs.0000176186.64276.d4
   Tong J, 2016, EUR SPINE J, V25, P1787, DOI 10.1007/s00586-015-4305-3
   Wang MY, 2006, NEUROSURGERY, V58, P907, DOI 10.1227/01.NEU.0000209929.38213.72
   Wright NM, 2004, J SPINAL DISORD TECH, V17, P158, DOI 10.1097/00024720-200404000-00014
   Xu RS, 2010, J NEUROSURG-SPINE, V13, P688, DOI 10.3171/2010.5.SPINE09712
   Yoshihara H, 2013, J NEUROSURG-SPINE, V19, P614, DOI 10.3171/2013.8.SPINE13136
   Yusof MI, 2012, SURG RADIOL ANAT, V34, P203, DOI 10.1007/s00276-011-0869-8
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E684
EP E690
DI 10.1016/j.wneu.2018.09.191
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000084
PM 30292663
DA 2020-05-12
ER

PT J
AU Shields, LBE
   Shields, CB
   Yao, TL
   Plato, BM
   Zhang, YP
   Dashti, SR
AF Shields, Lisa B. E.
   Shields, Christopher B.
   Yao, Tom L.
   Plato, Brian M.
   Zhang, Yi Ping
   Dashti, Shervin R.
TI Endovascular Treatment for Venous Sinus Stenosis in Idiopathic
   Intracranial Hypertension: An Observational Study of Clinical
   Indications, Surgical Technique, and Long-Term Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular; Idiopathic intracranial hypertension; Neurosurgery;
   Pseudotumor cerebri; Stent; Venous sinus stenosis
ID PRESSURE; PATHOPHYSIOLOGY; ANGIOPLASTY
AB BACKGROUND: Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure. IIH causes significant morbidity marked by incapacitating headaches and visual disturbances. This study investigated the long-term outcomes of venous sinus stenting in a large group of patients with IIH.
   METHODS: We retrospectively reviewed all patients at our institution who underwent venous sinus stenting for IIH over 6 years (July 1, 2012-June 30, 2018). A particular focus was dedicated to collecting demographic, clinical, radiologic, and outcomes data. All patients had failed medical management.
   RESULTS: Of the 110 patients evaluated for IIH, 42 underwent venous sinus stenting, with a mean follow-up of 25.6 months (range, 8.7-60.7 months). The mean age was 32 years (range, 15-52 years), 38 (90%) were women, and the mean body mass index was 35.6 kg/m(2) (range, 18.6-47.5 kg/m(2)). Prior to the stenting procedure, all patients had headaches, visual disturbances, and papilledema. Of the 39 patients who had an ophthalmologic evaluation poststenting, 29 (74%) had resolution of their papilledema. Eighteen patients (43%) had complete resolution of their headaches after the stenting procedure, whereas 22 patients (52%) remained under a neurologist's care for chronic migraine and other types of headaches. Two patients underwent a restenting procedure for disease progression, and 1 patient experienced an in-stent thrombosis.
   CONCLUSIONS: A multidisciplinary approach involving neurosurgeons, ophthalmologists, radiologists, and neurologists is integral in the management of patients with IIH to prevent the complications of papilledema. Venous sinus stenting offers a safe and effective means of treating IIH.
C1 [Shields, Lisa B. E.; Shields, Christopher B.; Yao, Tom L.; Plato, Brian M.; Zhang, Yi Ping; Dashti, Shervin R.] Norton Healthcare, Norton Neurosci Inst, Louisville, KY 40202 USA.
   [Shields, Christopher B.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA.
RP Dashti, SR (reprint author), Norton Healthcare, Norton Neurosci Inst, Louisville, KY 40202 USA.
EM Shervin.Dashti@nortonhealthcare.org
CR Aguilar-Perez M, 2017, NEURORADIOLOGY, V59, P277, DOI 10.1007/s00234-017-1783-5
   Ahmed RM, 2011, AM J NEURORADIOL, V32, P1408, DOI 10.3174/ajnr.A2575
   Albuquerque FC, 2011, WORLD NEUROSURG, V75, P648, DOI 10.1016/j.wneu.2010.11.012
   Ball AK, 2011, J NEUROL, V258, P874, DOI 10.1007/s00415-010-5861-4
   Bidot S, 2015, J NEURO-OPHTHALMOL, V35, P400, DOI 10.1097/WNO.0000000000000303
   Biousse V, 2012, J NEUROL NEUROSUR PS, V83, P488, DOI 10.1136/jnnp-2011-302029
   Bussiere M, 2010, AM J NEURORADIOL, V31, P645, DOI 10.3174/ajnr.A1890
   Butros SR, 2012, ACTA RADIOL, V53, P682, DOI 10.1258/ar.2012.110705
   D'Amico D, 2012, NEUROL SCI, V33, pS189, DOI 10.1007/s10072-012-1065-2
   Donnet A, 2008, NEUROLOGY, V70, P641, DOI 10.1212/01.wnl.0000299894.30700.d2
   Ducruet AF, 2014, J NEUROINTERV SURG, V6, P238, DOI 10.1136/neurintsurg-2013-010691
   Fields JD, 2013, J NEUROINTERV SURG, V5, P62, DOI 10.1136/neurintsurg-2011-010156
   Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17
   Higgins JNP, 2003, J NEUROL NEUROSUR PS, V74, P1662, DOI 10.1136/jnnp.74.12.1662
   Kumpe DA, 2012, J NEUROSURG, V116, P538, DOI 10.3171/2011.10.JNS101410
   Liu KC, 2017, J NEUROSURG, V127, P1126, DOI 10.3171/2016.8.JNS16879
   McGeeney BE, 2014, HEADACHE, V54, P445, DOI 10.1111/head.12291
   Mollan SP, 2016, J NEUROL NEUROSUR PS, V87, P982, DOI 10.1136/jnnp-2015-311302
   Radvany MG, 2013, J NEURO-OPHTHALMOL, V33, P117, DOI 10.1097/WNO.0b013e31827f18eb
   Satti SR, 2015, AM J NEURORADIOL, V36, P1899, DOI 10.3174/ajnr.A4377
   Satti SR, 2017, INTERV NEURORADIOL, V23, P186, DOI 10.1177/1591019916680110
   Sinclair AJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c2701
   Starke Robert M, 2015, ScientificWorldJournal, V2015, P140408, DOI 10.1155/2015/140408
   Sugerman HJ, 1997, NEUROLOGY, V49, P507, DOI 10.1212/WNL.49.2.507
   Teleb MS, 2013, INTERV NEUROL, V2, P132, DOI 10.1159/000357503
   Teleb MS, 2015, J NEUROIMAGING, V25, P72, DOI 10.1111/jon.12072
NR 26
TC 9
Z9 9
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E157
EP E163
DI 10.1016/j.wneu.2018.09.070
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000023
PM 30248468
DA 2020-05-12
ER

PT J
AU Shkarubo, AN
   Koval, KV
   Chernov, IV
   Andreev, DN
   Panteleyev, AA
AF Shkarubo, Alexey N.
   Koval, Konstantin V.
   Chernov, Ilia V.
   Andreev, Dmitry N.
   Panteleyev, Andrey A.
TI Endoscopic Endonasal Transclival Approach to Tumors of the Clivus and
   Anterior Region of the Posterior Cranial Fossa (Results of Surgical
   Treatment of 136 Patients)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma of the clivus; Clivus; Endoscopic endonasal surgery of the
   skull base; Endoscopic endonasal transclival approach; Monitoring of
   cranial nerves; Posterior cranial fossa; Skull base anatomy
ID TRANSSPHENOIDAL APPROACH; BASE CHORDOMAS; COMPLICATIONS; MANAGEMENT;
   RESECTION; SURGERY
AB INTRODUCTION: With the introduction into the neurosurgical practice of minimally invasive methods using endoscopic techniques, it became possible to effectively remove hard-to-reach tumors, including central tumors of the anterior region of the posterior cranial fossa.
   OBJECTIVE: To analyze the results of surgical treatment of patients with various centrally located tumors of the base of the skull that extend into the anterior region of the posterior cranial fossa using the endoscopic endonasal transclival approach.
   METHODS: The personal surgical experience of the first author is 136 patients with various tumors (e.g., chordomas, meningiomas, pituitary adenomas, and fibrous dysplasia).
   RESULTS: Radicality of tumor removal was total 61.03%; subtotal 25%; partial 13.23%; and insufficient removal 0.74%. Postoperative cerebrospinal fluid leaks occurred in 9 cases (6.62%) and meningitis in 13 cases (9.56%). In 2 cases, surgical treatment had a lethal outcome (1.47%).
   CONCLUSIONS: The endoscopic endonasal transclival approach can be used to obtain access to centrally located skull base tumors. This approach allows for a radical and low-risk removal of various skull base tumors of central localization that, until recently, were considered to be almost inoperable.
C1 [Shkarubo, Alexey N.; Koval, Konstantin V.; Chernov, Ilia V.; Andreev, Dmitry N.] Minist Hlth Russian Federat NN Burdenko NMRCN, Fed State Autonomous Inst, Dept Neurooncol, NN Burdenko Natl Med Res Ctr Neurosurg, Moscow, Russia.
   [Panteleyev, Andrey A.] NN Priorov Cent Inst Traumatol & Orthoped, Dept Spine Pathol, Moscow, Russia.
RP Chernov, IV (reprint author), Minist Hlth Russian Federat NN Burdenko NMRCN, Fed State Autonomous Inst, Dept Neurooncol, NN Burdenko Natl Med Res Ctr Neurosurg, Moscow, Russia.
EM ilch@list.ru
CR Al-Mefty O, 2008, J NEUROSURG, V109, P783, DOI 10.3171/JNS/2008/109/11/0783
   Couldwell WT, 2004, NEUROSURGERY, V55, P539, DOI 10.1227/01.NEU.0000134287.19377.A2
   de Notaris M, 2009, NEUROSURGERY, V65, P42, DOI [10.1227/01.NEU.000034/001.62158.57, 10.1227/01.NEU.0000347001.62158.57]
   Forander P, 2017, ACTA NEUROCHIR, V159, P1857, DOI 10.1007/s00701-017-3266-1
   Frank G, 2003, ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL SURGERY, P159
   Frank G, 2006, NEUROSURGERY, V59, P50, DOI 10.1227/01.NEU.0000219914.17221.55
   Funaki T, 2013, NEUROSURGERY, V73, P155, DOI 10.1227/01.neu.0000431469.82215.93
   Jagersberg M, 2017, ACTA NEUROCHIR, V159, P1815, DOI 10.1007/s00701-017-3163-7
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P16, DOI 10.1088/s-2004-818347
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Konovalov A N, 1998, Zh Vopr Neirokhir Im N N Burdenko, P3
   Koutourousiou M, 2012, NEUROSURGERY, V71, P614, DOI 10.1227/NEU.0b013e31825ea3e0
   Ibanez FAL, 2011, WORLD NEUROSURG, V75, P709, DOI 10.1016/j.wneu.2010.11.010
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Morera VA, 2010, NEUROSURGERY, V66, pONS211, DOI 10.1227/01.NEU.0000369926.01891.5D
   Ramm-Pettersen J, 2017, ACTA NEUROCHIR, V159, P1849, DOI 10.1007/s00701-017-3236-7
   Sanmillan JL, 2016, WORLD NEUROSURG, V89, P368, DOI 10.1016/j.wneu.2016.01.081
   Sen C, 2010, J NEUROSURG, V113, P1059, DOI 10.3171/2009.9.JNS08596
   Shimony N, 2017, ACTA NEUROCHIR, V159, P1835, DOI 10.1007/s00701-016-3032-9
   Shkarubo A N, 2016, Zh Vopr Neirokhir Im N N Burdenko, V80, P35, DOI 10.17116/neiro201680335-49
   Shkarubo AN, 2017, WORLD NEUROSURG, V98, P230, DOI 10.1016/j.wneu.2016.10.089
   Shkarubo AN, 2000, Russian patent for invention number, Patent No. 2144326
   Shkarubo AN, 2001, Russian patent for invention number, Patent No. 2173959
   Shkarubo AN, 2001, Russian patent for invention number, Patent No. 2174825
   Shkarubo AN, 2017, Russian patent for invention number, Patent No. 2621421
   Sidorkin D V, 2009, Zh Vopr Neirokhir Im N N Burdenko, P14
   Sidorkin D V, 2009, Zh Vopr Neirokhir Im N N Burdenko, P15
   Vellutini EDS, 2014, WORLD NEUROSURG, V82, pS106, DOI 10.1016/j.wneu.2014.07.031
   Snyderman C, 2014, MASTER TECHNIQUES OT
   Stamm AC, TRANSNASAL ENDOSCOPI
   Stippler M, 2009, NEUROSURGERY, V64, P268, DOI 10.1227/01.NEU.0000338071.01241.E2
   Tamura Takamitsu, 2015, Fukushima J Med Sci, V61, P131, DOI 10.5387/fms.2015-12
   Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091
   Wang K, 2016, J CLIN NEUROSCI, V27, P147, DOI 10.1016/j.jocn.2015.05.073
   Wang L, 2017, J NEUROSURG, V127, P1257, DOI 10.3171/2016.9.JNS16559
   Wang L, 2017, ACTA NEUROCHIR, V159, P1803, DOI 10.1007/s00701-017-3261-6
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P419, DOI 10.1016/j.wneu.2015.10.004
NR 38
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E246
EP E261
DI 10.1016/j.wneu.2018.09.090
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000034
PM 30261397
DA 2020-05-12
ER

PT J
AU Sorimachi, T
   Yokota, K
   Hirayama, A
   Shigematsu, H
   Hayashi, N
   Osada, T
   Srivatanakul, K
   Matsumae, M
AF Sorimachi, Takatoshi
   Yokota, Kazuma
   Hirayama, Akihiro
   Shigematsu, Hideaki
   Hayashi, Naokazu
   Osada, Takahiro
   Srivatanakul, Kittipong
   Matsumae, Mitsunori
TI Hemiparesis without Responsible Hematomas in Patients with Subarachnoid
   Hemorrhage Undergoing Early Aneurysmal Repair
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Hemiparesis; Outcomes; Subarachnoid hemorrhage
ID SEIZURES; ONSET; COMMITTEE; VASOSPASM; SCALE
AB OBJECTIVE: The presence of hemiparesis on arrival in patients with subarachnoid hemorrhage (SAH) is presumed to affect prognosis; intracranial hematomas with mass effect responsible for hemiparesis are frequently observed in these patients. The aim of this study was to clarify characteristics and outcomes of patients who presented with hemiparesis on arrival with no responsible hematomas (hemiparesis without hematoma) having mass effect demonstrated on computed tomography.
   METHODS: Consecutive patients with SAH treated with surgery for ruptured cerebral aneurysms within 5 days of onset between 2003 and 2015 were retrospectively reviewed.
   RESULTS: Hemiparesis without hematoma was present in 25 of 858 surgically treated patients (2.9%). Internal carotid artery aneurysms were significantly more common in patients with hemiparesis without hematoma than in the other patients (P < 0.05). In 19 of 21 surviving patients (90.5%) with hemiparesis without hematoma on arrival, the hemiparesis improved at discharge. Favorable outcomes were achieved in 16 of 25 patients with hemiparesis without hematoma (64%) and in 13 of 59 patients with hemiparesis with hematomas (22.0%); this difference was significant (P < 0.05).
   CONCLUSIONS: Hemiparesis can be expected to improve in patients with SAH with hemiparesis without hematoma, and such patients appear to have a better prognosis than patients with SAH with hemiparesis and responsible hematomas. A possible major mechanism of hemiparesis without hematoma based on the characteristics identified is a combination of transient ipsilateral hemispheric functional failure caused by the impact of aneurysmal rupture and transient ischemia of the perforators originating from the internal carotid artery.
C1 [Sorimachi, Takatoshi; Yokota, Kazuma; Hirayama, Akihiro; Shigematsu, Hideaki; Hayashi, Naokazu; Osada, Takahiro; Srivatanakul, Kittipong; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
RP Sorimachi, T (reprint author), Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
EM sorimachi@tokai-u.jp
CR Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf
   Bar B, 2016, NEUROCRIT CARE, V24, P180, DOI 10.1007/s12028-015-0177-y
   Behrouz R, 2016, J STROKE CEREBROVASC, V25, P2644, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.009
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   Fukuda H, 2015, J NEUROSURG, V123, P686, DOI 10.3171/2014.10.JNS141658
   Fung C, 2015, J NEUROSURG, V122, P408, DOI 10.3171/2014.10.JNS14163
   Galea JP, 2017, STROKE, V48, P2958, DOI 10.1161/STROKEAHA.117.017777
   GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560
   Giraldo EA, 2012, J NEUROSURG, V117, P15, DOI 10.3171/2012.3.JNS11706
   Huang APH, 2010, NEUROSURGERY, V67, P964, DOI 10.1227/NEU.0b013e3181ee359c
   Lin CL, 2003, J NEUROSURG, V99, P978, DOI 10.3171/jns.2003.99.6.0978
   Mahaney KB, 2012, J NEUROSURG, V116, P1267, DOI 10.3171/2012.1.JNS111277
   Phan K, 2017, WORLD NEUROSURG, V102, P632, DOI 10.1016/j.wneu.2017.03.057
   Pinto AN, 1996, J NEUROL, V243, P161, DOI 10.1007/BF02444009
   Raper DMS, 2013, WORLD NEUROSURG, V79, P682, DOI 10.1016/j.wneu.2012.08.006
   Rosen DS, 2005, NEUROCRIT CARE, V2, P110, DOI 10.1385/NCC:2:2:110
   Rosen DS, 2004, NEUROSURGERY, V54, P566, DOI 10.1227/01.NEU.0000108862.32404.A5
   Sano H, 2015, WORLD NEUROSURG, V83, P801, DOI 10.1016/j.wneu.2014.12.032
   Shimoda M, 1997, J NEUROSURG, V87, P170, DOI 10.3171/jns.1997.87.2.0170
   TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457
   van Donkelaar CE, 2017, J NEUROSURG, V126, P52, DOI 10.3171/2016.1.JNS152136
   Wang A, 2015, WORLD NEUROSURG, V83, P734, DOI 10.1016/j.wneu.2015.01.048
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E614
EP E620
DI 10.1016/j.wneu.2018.09.176
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000075
PM 30292036
DA 2020-05-12
ER

PT J
AU Steinberg, JA
   Rennert, RC
   Levy, M
   Khalessi, AA
AF Steinberg, Jeffrey A.
   Rennert, Robert C.
   Levy, Michael
   Khalessi, Alexander A.
TI A Practical Cadaveric Model for Intracranial Bypass Training
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver; Intracranial bypass; Microanastomosis; Simulation; Training
ID ANASTOMOSIS
AB BACKGROUND: Intracranial bypass is technically challenging and difficult to learn owing to its relative rarity and complexity. Although multiple training models for intracranial bypass exist, a detailed depiction of the use and fidelity of cadaveric specimens for bypass training is lacking in the literature. This study describes use of preserved cadaveric specimens as a practical training model for performance of multiple intracranial bypasses and discusses the surgical setup for a cadaveric bypass laboratory.
   METHODS: Using a cadaveric specimen and basic microneurosurgical instruments and supplies, 5 intracranial bypasses were performed (superficial temporal artery [STA]-to-middle cerebral artery [MCA], MCA-to-MCA, STA-to-posterior cerebral artery [PCA], anterior cerebral artery-to-anterior cerebral artery, and posterior inferior cerebellar artery-to-posterior inferior cerebellar artery) using pterional, subtemporal, interhemispheric, and suboccipital approach. Bypass integrity was assessed by direct fluid injection into the adjacent vessel segment. All procedures were recorded.
   RESULTS: Procedural steps mirrored actual bypass surgery and included vessel marking, performance of arteriotomy, and completion of an end-to-end, end-to-side, or side-to-side anastomosis. Simulations included anatomically appropriate exposures of common intracranial (MCA, PCA, posterior inferior cerebellar artery, anterior cerebral artery) and extracranial (STA) vessels encountered during cerebral bypass surgery and high-fidelity recreations of the operative corridors associated with deeper anastomoses, such as STA-to-PCA bypass. Vessel diameters were 1.5-2.1 mm, and anastomosis times were 20-40 minutes. Immediate feedback on anastomotic integrity was achieved via direct fluid injection adjacent to the anastomosis site.
   CONCLUSIONS: The cadaveric specimen trainee model is a relatively simple yet high-fidelity approach for learning intracranial bypass.
C1 [Steinberg, Jeffrey A.; Rennert, Robert C.; Levy, Michael; Khalessi, Alexander A.] Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA.
RP Steinberg, JA (reprint author), Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA.
EM j1steinberg@ucsd.edu
RI Levy, Michael/AAL-4647-2020
CR Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   Chung SB, 2017, WORLD NEUROSURG, V105, P369, DOI 10.1016/j.wneu.2017.05.174
   Higurashi M, 2014, J CLIN NEUROSCI, V21, P554, DOI 10.1016/j.jocn.2013.07.029
   Hwang G, 2010, J KOREAN NEUROSURG S, V47, P287, DOI 10.3340/jkns.2010.47.4.287
   Inoue T, 2006, SURG NEUROL, V66, P638, DOI 10.1016/j.surneu.2006.03.035
   MacDonald JD, 2005, SKULL BASE-INTERD AP, V15, P229, DOI 10.1055/s-2005-872598
   Mokhtari P, 2017, WORLD NEUROSURG, V108, P230, DOI 10.1016/j.wneu.2017.08.132
   Olabe J, 2009, SURG NEUROL, V72, P700, DOI 10.1016/j.surneu.2009.02.028
   Russin JJ, 2012, NEUROSURGERY, V71, P315, DOI 10.1227/NEU.0b013e318266e7c6
   Sekhar LN, 2008, NEUROSURGERY, V62, P1373, DOI [10.1227/01.NEU.0000315873.41953.74, 10.1227/01.neu.0000333803.97703.c6]
   Sekhar LN, 2008, NEUROSURGERY, V62, P1440
   Srinivasan J, 2001, NEUROSURG CLIN N AM, V12, P509, DOI 10.1016/S1042-3680(18)30040-8
   Surdell Daniel L, 2008, Neurosurg Focus, V24, pE21, DOI 10.3171/FOC.2008.25.2.E21
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E576
EP E583
DI 10.1016/j.wneu.2018.09.170
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000070
PM 30278290
DA 2020-05-12
ER

PT J
AU Storey, C
   Barry, J
   Adkins, W
   Nanda, A
   Saenz-Cuellar, H
AF Storey, Christopher
   Barry, James
   Adkins, William
   Nanda, Anil
   Saenz-Cuellar, Hugo
TI A Morphometric Analysis for the Feasibility of Percutaneous Translacerum
   Access of the Internal Carotid Artery Based on Computed Tomography
   Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct petrous internal carotid access; Foramen lacerum; Percutaneous;
   Tortuous carotid artery; Translacerum
ID ENDOVASCULAR TREATMENT; SURGICAL EXPOSURE; DISTAL EMBOLI; ANGIOPLASTY;
   THROMBECTOMY; CIRCULATION; EXPERIENCE; PUNCTURE; ANATOMY
AB BACKGROUND: The increasing frequency of elderly patients with severe tortuous anatomy, especially when combined with fibromuscular dysplasia, can make intracranial canalization severely difficult or impossible. Computed tomography angiography was used to determine the feasibility of accessing the internal carotid artery (ICA) via a percutaneous translacerum approach.
   METHODS: Twenty consecutive stroke activations with CT angiography were reconstructed in three-dimensional models to take measurements to assess if currently available technologies could safely provide access. We assessed the diameter of the foramen lacerum and ICA. Entry points and angulations were measured based on trajectory. Our trajectory was based on anatomic observations that provided a safe corridor from the angle of the jaw to the foramen lacerum.
   RESULTS: Based on the 40 carotid arteries from 20 patients, 77.5% had a large enough foramen lacerum to provide access to the ICA. Although there were no traversals of the pharynx, we noted a 20% traversal of the eustachian tube and 5% traversal of a small maxillary artery branch. There was no large-vessel traversal by the trajectory. All patients with bilateral stenotic foramen lacerum were African-American women; 44% of African-American women had bilateral stenotic foramen lacerum. The diameter of the ICA and foramen lacerum would not be prohibitive of sheath placement in patients without stenosis with adequate canalized length of sheath necessary for stability.
   CONCLUSIONS: Access of the ICA via the foramen lacerum can be safely performed with currently available technologies.
C1 [Storey, Christopher; Barry, James; Adkins, William; Nanda, Anil; Saenz-Cuellar, Hugo] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Neurosurg, Shreveport, LA 71105 USA.
RP Storey, C (reprint author), Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Neurosurg, Shreveport, LA 71105 USA.
EM dr.christopher.storey.md.phd@gmail.com
OI Storey, Christopher/0000-0002-7665-8920; Cuellar,
   Hugo/0000-0002-8348-4535
CR BAUER J, 1980, J NEUROSURG, V52, P525, DOI 10.3171/jns.1980.52.4.0525
   Bergeron P, 2015, J ENDOVASC THER, V22, P135, DOI 10.1177/1526602814564362
   Blanc R, 2006, NEURORADIOLOGY, V48, P925, DOI 10.1007/s00234-006-0157-1
   Chueh JY, 2017, J NEUROINTERV SURG, V9, P183, DOI 10.1136/neurintsurg-2015-012256
   Chueh JY, 2016, J NEUROINTERV SURG, V8, P197, DOI 10.1136/neurintsurg-2014-011491
   Chueh JY, 2013, STROKE, V44, P1396, DOI 10.1161/STROKEAHA.111.670463
   Diethrich EB, 1996, J ENDOVASC SURG, V3, P42, DOI 10.1583/1074-6218(1996)003<0042:SITCAI>2.0.CO;2
   Dorfer C, 2012, WORLD NEUROSURG, V77, P192, DOI 10.1016/j.wneu.2010.11.007
   Fargen KM, 2016, J NEUROINTERV SURG, V8, P66, DOI 10.1136/neurintsurg-2014-011432
   Liu JF, 2014, LARYNGOSCOPE, V124, P2655, DOI 10.1002/lary.24808
   Mathieu X, 2009, J CARDIOVASC SURG, V50, P677
   MENEZES AH, 1988, J NEUROSURG, V69, P895, DOI 10.3171/jns.1988.69.6.0895
   Nii K, 2006, AM J NEURORADIOL, V27, P1502
   Osawa S, 2008, NEUROSURGERY, V63, P210, DOI 10.1227/01.NEU.0000327037.75571.10
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Ross IB, 2006, SURG NEUROL, V65, P207, DOI 10.1016/j.surneu.2005.06.023
   Taha MM, 2007, SURG NEUROL, V68, P431, DOI 10.1016/j.surneu.2006.11.036
   Taniguchi M, 2016, J NEUROSURG, V124, P1032, DOI 10.3171/2015.1.JNS142526
   Ziyal IM, 1998, ACTA NEUROCHIR, V140, P201, DOI 10.1007/s007010050086
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E925
EP E930
DI 10.1016/j.wneu.2018.10.017
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000114
PM 30321677
DA 2020-05-12
ER

PT J
AU Suner, HI
   Kurt, G
   Yildirim, Z
   Bulduk, EB
   Borcek, AO
   Demirci, H
   Kartal, B
   Kaplanoglu, GT
AF Suner, Halil Ibrahim
   Kurt, Gokhan
   Yildirim, Zuhal
   Bulduk, Erkut Baha
   Borcek, Alp Ozgun
   Demirci, Harun
   Kartal, Bahar
   Kaplanoglu, Gulnur Take
TI Investigation of the Effect of Alemtuzumab in an Experimental Spinal
   Cord Trauma Model in Rats
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alemtuzumab; Anti-inflammatory; Antioxidants; Oxidative stress; Spinal
   cord injury
ID ISCHEMIA-REPERFUSION INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS;
   METHYLPREDNISOLONE; NEUROPROTECTION; INFLIXIMAB; MECHANISM; EMPHASIS;
   RECOVERY; BREAST
AB OBJECTIVE: Spinal cord injuries generate the most negative response to medical treatment among all general body injuries. This important morbidity is thought to be caused by a complex secondary damage mechanism. In the present study, we examined the neuroprotective effects of alemtuzumab in a spinal cord trauma model.
   METHODS: We divided 24 Long-Evans male rats into 4 groups (n = 6 per group). Laminectomy was performed at T5-T8 in all groups. Trauma was applied using the Yasargil temporary aneurysm clip for 60 seconds at these spinal cord levels in all groups, except for group 1. Next, 1 mg/kg of alemtuzumab was administered to each rat in groups 3 and 4. A functional evaluation was performed on days 1, 3, and 5 in groups 1, 2, and 4, and the rats were then sacrificed. The rats in group 3 were sacrificed on the third postoperative day to observe the early effects of alemtuzumab. The biochemical examination findings of malondialdehyde and glutathione in plasma and tissue samples and histopathological findings of the spinal cord were evaluated and compared by statistical analysis.
   RESULTS: The inflammatory findings in the trauma group were not seen in either group treated with alemtuzumab. The clinical motor examination and inclined plane test results were also significantly better in these groups.
   CONCLUSION: Our results have shown that alemtuzumab might prevent spinal cord injury after trauma and is a histopathologically and biochemically strong antiinflammatory, antioxidant, and neuroprotective agent.
C1 [Suner, Halil Ibrahim; Kurt, Gokhan; Borcek, Alp Ozgun; Demirci, Harun] Gazi Univ, Fac Med, Dept Neurosurg, Ankara, Turkey.
   [Kartal, Bahar; Kaplanoglu, Gulnur Take] Gazi Univ, Fac Med, Dept Histol & Embryol, Ankara, Turkey.
   [Yildirim, Zuhal] Etimesgut Publ Hlth Lab, Ankara, Turkey.
   [Bulduk, Erkut Baha] Eskisehir Govt Hosp, Dept Neurosurg, Eskisehir, Turkey.
RP Yildirim, Z (reprint author), Etimesgut Publ Hlth Lab, Ankara, Turkey.
EM zyildirim2004@yahoo.com
RI Borcek, Alp Ozgun/O-6840-2017
OI Borcek, Alp Ozgun/0000-0002-6222-382X; BULDUK, ERKUT
   BAHA/0000-0002-8812-1290
CR Alinari L, 2007, ONCOGENE, V26, P3644, DOI 10.1038/sj.onc.1210380
   AYKAC G, 1985, TOXICOLOGY, V36, P71, DOI 10.1016/0300-483X(85)90008-3
   CASINI AF, 1986, AM J PATHOL, V123, P520
   Cayli SR, 2006, INT J DEV NEUROSCI, V24, P233, DOI 10.1016/j.ijdevneu.2006.04.003
   Celik H, 2016, TURK NEUROSURG, V26, P622, DOI 10.5137/1019-5149.JTN.13210-14.1
   CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625
   Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Emmez H, 2010, ACTA NEUROCHIR, V152, P1591, DOI 10.1007/s00701-010-0703-9
   Fehlings MG, 2001, SPINE, V26, pS101, DOI 10.1097/00007632-200112151-00017
   Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88
   Golay J, 2004, HAEMATOLOGICA, V89, P1476
   Gonenc A, 2001, J CLIN PHARM THER, V26, P141, DOI 10.1046/j.1365-2710.2001.00334.x
   Guven C, 2010, J CLIN NEUROSCI, V17, P1563, DOI 10.1016/j.jocn.2010.04.027
   Ha KY, 2008, EUR SPINE J, V17, P864, DOI 10.1007/s00586-008-0653-6
   Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x
   Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992
   Kale A, 2011, J NEUROSURG-SPINE, V15, P228, DOI 10.3171/2011.4.SPINE10583
   Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077
   Kaptanoglu E, 2003, NEUROSURG REV, V26, P283, DOI 10.1007/s10143-003-0272-y
   Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y
   Kumbasar U, 2018, TURK THORAC CARDIOVA, V26, P1
   Kurt G, 2015, NEUROSURG QUART, V25, P189
   Kurt G, 2009, SURG NEUROL, V71, P332, DOI 10.1016/j.surneu.2008.01.038
   Kurt G, 2014, J NEUROSURG-SPINE, V20, P464, DOI 10.3171/2013.12.SPINE1312
   KURTEL H, 1992, AM J PHYSIOL, V263, pG573
   Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1
   Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281
   Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8
   Ray G, 2000, BREAST CANCER RES TR, V59, P163, DOI 10.1023/A:1006357330486
   Reiff A, 2005, HEMATOLOGY, V10, P79, DOI 10.1080/10245330400026139
   RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577
   Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001
   Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8
   Suzer T, 1999, SPINAL CORD, V37, P480, DOI 10.1038/sj.sc.3100874
   Tas N, 2010, INJURY, V41, P1068, DOI 10.1016/j.injury.2010.05.027
   TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015
   Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955
   Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007
   Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yildirim Z, 2009, BIOL TRACE ELEM RES, V128, P135, DOI 10.1007/s12011-008-8258-9
   YOSHIOKA T, 1979, AM J OBSTET GYNECOL, V135, P372, DOI 10.1016/0002-9378(79)90708-7
   Young W, 1987, Cent Nerv Syst Trauma, V4, P27
   Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085
   Zent CS, 2008, LEUKEMIA RES, V32, P1849, DOI 10.1016/j.leukres.2008.05.014
NR 46
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E723
EP E730
DI 10.1016/j.wneu.2018.09.197
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000089
PM 30292667
DA 2020-05-12
ER

PT J
AU Sutovsky, J
   Sutovska, M
   Kocmalova, M
   Kazimierova, I
   Pappova, L
   Benco, M
   Grendar, M
   Bredvold, HH
   Miklusica, J
   Franova, S
AF Sutovsky, Juraj
   Sutovska, Martina
   Kocmalova, Michaela
   Kazimierova, Ivana
   Pappova, Lenka
   Benco, Martin
   Grendar, Marian
   Bredvold, Harald H.
   Miklusica, Juraj
   Franova, Sona
TI Degenerative Lumbar Spondylolisthesis: Biochemical Aspects and
   Evaluation of Stabilization Surgery Extent in Terms of Adjacent Segment
   Disease Theory
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cytokines; Degenerative spondylolisthesis; Fusion; Pain; Remodeling;
   Stabilization
ID CHRONIC LOW-BACK; SAGITTAL ALIGNMENT; DIAGNOSIS; FUSION; CYTOKINE;
   ALPHA; PAIN
AB OBJECTIVE: In lumbar degenerative spondylolisthesis (DSL), the criteria and extent of surgical treatment have not been strictly defined owing to the adjacent segment disease theory and unclear molecular pathogenesis. The present study analyzed the clinical and radiographic findings of patients after lower lumbar fusion surgery with single and 2-level DSL and explored the inflammatory mediator's role in DSL evolution and symptoms.
   METHODS: The prospective follow-up of patients with DSL, stratified by the stabilization extent (L4-L5, L5-S1, and L4-S1), included the Back Illness Pain and Disability 9-item questionnaire and native and dynamic radiographs to evaluate the intervertebral disc height and adjacent segments' angular motion. Follow-up examinations were performed at 3, 12, and 24 months. The pathological cytokine concentrations in the intervertebral disc and facet joints of the subchondral bone were assessed using the BioPlex assay in perioperatively collected patient samples and compared with those of control subjects obtained during multiorgan procurement. These findings were correlated with pain localization and severity.
   RESULTS: Statistical analysis of the questionnaire data revealed significant postoperative improvement in all patients, in particular, the L4-L5 group. Also, we found radiographic evidence of angular motion reduction in both adjacent segments near the limits of statistical significance and a meaningful correlation with subjective status improvement at 24 months. BioPlex analysis revealed platelet-derived growth factor 2 B subunits, interleukin-6, interleukin-8, and tumor necrosis factor-alpha were elevated in spinal unit segments and the interleukin-1 beta levels correlated significantly with the intensity of low backache.
   CONCLUSIONS: Our findings did not support the adjacent segment disease theory. However, later development of these changes could not be excluded. The cytokines, chemokines, and growth factors play a significant role in DSL pathogenesis and symptoms.
C1 [Sutovsky, Juraj; Benco, Martin; Bredvold, Harald H.] Martin Univ Hosp, Neurosurg Clin, Martin, Slovakia.
   [Miklusica, Juraj] Martin Univ Hosp, Transplant & Vasc Surg Clin, Martin, Slovakia.
   [Sutovska, Martina; Kocmalova, Michaela; Kazimierova, Ivana; Pappova, Lenka; Franova, Sona] Comenius Univ, Dept Pharmacol, Martin, Slovakia.
   [Kocmalova, Michaela; Kazimierova, Ivana; Grendar, Marian] Comenius Univ, Jessenius Fac Med, Martins Biomed Ctr, BioMed, Martin, Slovakia.
RP Sutovska, M (reprint author), Comenius Univ, Dept Pharmacol, Martin, Slovakia.
EM martinka.sutovska@gmail.com
RI Grendar, Marian/X-6032-2018; Grendar, Marian/R-5424-2019; Franova,
   sona/X-5984-2018
OI Grendar, Marian/0000-0002-6712-3457; Grendar,
   Marian/0000-0002-6712-3457; Franova, sona/0000-0001-8429-092X
FU "BioMed" project (ITMS) [26220220187]; EC sources; VEGAVedecka grantova
   agentura MSVVaS SR a SAV (VEGA) [1/0163/16]
FX The present study was supported by the "BioMed" project (ITMS code
   26220220187), which was co-financed by EC sources, and VEGA (grant
   1/0163/16).
CR Cohen SP, 2007, ANESTHESIOLOGY, V106, P591, DOI 10.1097/00000542-200703000-00024
   Cunha JM, 2000, BRIT J PHARMACOL, V130, P1418, DOI 10.1038/sj.bjp.0703434
   Fox J., 2011, R COMPANION APPL REG
   Frymoyer JW, 1991, SPINAL DEGENERATION, P611
   Fujii K, 2015, SPINE, V40, P703, DOI 10.1097/BRS.0000000000000708
   Haun DW, 2005, J CHIROPR MED, V4, P206, DOI 10.1016/S0899-3467(07)60153-0
   Hayes AM, 2013, J ORTHOP SPORT PHYS, V43, P674, DOI 10.2519/jospt.2013.0417
   Igarashi A, 2007, J ORTHOP SCI, V12, P154, DOI 10.1007/s00776-006-1105-y
   Jacobsen S, 2007, SPINE, V32, P120, DOI 10.1097/01.brs.0000250979.12398.96
   Jeon CH, 2015, SPINE, V40, pE279, DOI 10.1097/BRS.0000000000000745
   Kalichman L, 2008, EUR SPINE J, V17, P327, DOI 10.1007/s00586-007-0543-3
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kornblum MB, 2004, SPINE, V29, P726, DOI 10.1097/01.BRS.0000119398.22620.92
   Le Maitre CL, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2275
   Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069
   Lee JY, 2011, SPINE, V36, pE203, DOI 10.1097/BRS.0b013e3181df8063
   Liu H, 2014, SPINE, V39, pB52, DOI 10.1097/BRS.0000000000000500
   Longo UG, 2010, BRIT MED BULL, V94, P81, DOI 10.1093/bmb/ldp052
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maruenda JI, 2016, EUR SPINE J, V25, P1550, DOI 10.1007/s00586-016-4469-5
   Masuda K, 2008, EUR SPINE J, V17, pS441, DOI 10.1007/s00586-008-0749-z
   Meyerding HW, 1932, SURG GYNECOL OBSTET, V54, P371
   Modic MT, 2007, RADIOLOGY, V245, P43, DOI 10.1148/radiol.2451051706
   Moreau PE, 2016, ORTHOP TRAUMATOL-SUR, V102, P759, DOI 10.1016/j.otsr.2016.03.012
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Phan KH, 2015, SPINE J, V15, P230, DOI 10.1016/j.spinee.2014.08.453
   Qazi BS, 2011, INT J INFLAMM, DOI 10.4061/2011/908468
   R Core Team, 2016, R LANG ENV STAT COMP
   Ren Chunpeng, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS245, DOI 10.1007/s00590-014-1445-9
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Singh K, 2005, SEMIN SPINE SURG, V17, P128, DOI DOI 10.1053/J.SEMSS.2005.06.001
   Sutovsky J, 2017, INT J SURG, V43, P163, DOI 10.1016/j.ijsu.2017.06.024
   Tsuchida AI, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0441-0
   Wang H, 2008, CLIN J PAIN, V24, P273, DOI 10.1097/AJP.0b013e31816111d3
   Whatley BR, 2012, MAT SCI ENG C-MATER, V32, P61, DOI 10.1016/j.msec.2011.10.011
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Wuertz K, 2013, GLOB SPINE J, V3, P175, DOI 10.1055/s-0033-1347299
   Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018
   Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957
NR 40
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E554
EP E565
DI 10.1016/j.wneu.2018.09.163
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000068
PM 30278292
DA 2020-05-12
ER

PT J
AU Tacconi, L
   Spinelli, R
   Signorelli, F
AF Tacconi, Leonello
   Spinelli, Roberto
   Signorelli, Francesco
TI Skin Glue for Wounds Closure in Brain Surgery: Our Updated Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain; Cosmetic; Cyanoacrylate; Infection; Polymer; Wound
ID PROSPECTIVE RANDOMIZED-TRIAL; TISSUE ADHESIVE; CYANOACRYLATE;
   OCTYLCYANOACRYLATE; SUTURES; LACERATIONS; INCISIONS; REPAIR; HEAD
AB BACKGROUND: Traditional wound closure techniques include skin sutures and metal clips. Cyanoacrylate has good neovascularization, epithelialization, and antimicrobial activity properties and a fast application procedure. This study presents our long-term experience.
   METHODS: We retrospectively selected 362 patients who underwent brain surgery from January 2007 to March 2017. Exclusion criteria were applied for repeat surgeries, emergency/posttraumatic procedures, wound infections, wounds longer than 16 cm, skull base cases, and postoperative patients who stayed in the intensive care unit more than 1 day. We collected data from 250 cases of supratentorial procedures and 112 cases of infratentorial procedures. The median wound length was 11 cm (range, 4-15 cm); the median age was 51 years. We followed-up all patients for 1, 3, and 12 months focusing on wound complications, cosmetic results, based on the Hollander Wound Evaluation Scale (HWES), and patient satisfaction using a visual analog scale.
   RESULTS: Cosmetic results were very good (HWES score of 5-6) in 99.5% of cases at 12 months. Patient satisfaction reached almost 100% at 12 months. We experienced 2 cases of wound dehiscence and 2 others with poor cosmetic results. The main complaint was a feeling of discomfort, during the first 2 weeks after surgery, because of the dried glue along the wound's edges.
   CONCLUSIONS: With additional research, we can confirm that cyanoacrylate glue may be a valid and useful alternative to traditional techniques for wound closure in brain surgery, carrying several advantages. However, a randomized controlled trial with a large number of patients is warranted to confirm our findings.
C1 [Tacconi, Leonello; Spinelli, Roberto] Azienda Osped Univ Integrata, Neurosurg Unit, Trieste, Italy.
   [Signorelli, Francesco] Azienda Osped Univ, Neurosurg Unit, Bari, Italy.
RP Tacconi, L (reprint author), Azienda Osped Univ Integrata, Neurosurg Unit, Trieste, Italy.
EM leonello.tacconi@asuits.sanita.fvg.it
RI Signorelli, Francesco/AAF-7550-2019
OI Signorelli, Francesco/0000-0002-5040-1916; tacconi,
   leonello/0000-0003-3915-5635
CR Arunachalam P, 2003, PEDIATR SURG INT, V19, P18, DOI 10.1007/s00383-002-0893-1
   Bozkurt MK, 2008, EUR ARCH OTO-RHINO-L, V265, P331, DOI 10.1007/s00405-007-0454-2
   Chibbaro S, 2009, J CLIN NEUROSCI, V16, P535, DOI 10.1016/j.jocn.2008.08.004
   COOVER HN, 1959, SPECIAL TECHNICAL PA, V5, P413
   EIFERMAN RA, 1983, ARCH OPHTHALMOL-CHIC, V101, P958
   Eymann R, 2010, ACT NEUR S, V106, P87, DOI 10.1007/978-3-211-98811-4_14
   Gennari R, 2004, SURGERY, V136, P593, DOI 10.1016/j.surg.2004.02.015
   Greene D, 1999, Arch Facial Plast Surg, V1, P292, DOI 10.1001/archfaci.1.4.292
   HOLLANDER JE, 1995, ANN EMERG MED, V25, P675, DOI 10.1016/S0196-0644(95)70183-4
   Jallali N, 2004, J LAPAROENDOSC ADV A, V14, P209, DOI 10.1089/1092642041802056
   JANDINSKI J, 1971, J DENT RES, V50, P1557, DOI 10.1177/00220345710500063301
   Laccourreye O, 2005, ANN CHIR, V130, P624, DOI 10.1016/j.anchir.2005.10.003
   Maartense S, 2002, BRIT J SURG, V89, P1370, DOI 10.1046/j.1365-2168.2002.02235.x
   Matin SF, 2003, J AM COLL SURGEONS, V196, P845, DOI 10.1016/S1072-7515(03)00119-4
   Ong CCP, 2002, PEDIATR SURG INT, V18, P553, DOI 10.1007/s00383-002-0728-0
   Petratos PB, 2002, J UROLOGY, V167, P677, DOI 10.1016/S0022-5347(01)69123-7
   Quinn James V., 1995, Journal of Emergency Medicine, V13, P581, DOI 10.1016/0736-4679(95)80025-5
   QUINN JV, 1993, ANN EMERG MED, V22, P1130, DOI 10.1016/S0196-0644(05)80977-1
   Qureshi A, 1997, ANN ROY COLL SURG, V79, P414
   REFOJO MF, 1968, ARCH OPHTHALMOL-CHIC, V80, P645
   Romero IL, 2009, INDIAN J OPHTHALMOL, V57, P341, DOI 10.4103/0301-4738.55065
   Rosin D, 2001, J LAPAROENDOSC ADV A, V11, P157, DOI 10.1089/10926420152389305
   Sabol F, 2010, EUR SURG RES, V45, P321, DOI 10.1159/000320837
   Sebesta MJ, 2003, J ENDOUROL, V17, P899, DOI 10.1089/089277903772036235
   Shapiro AJ, 2001, AM SURGEON, V67, P1113
   Singer AJ, 2002, SURGERY, V131, P270, DOI 10.1067/msy.2002.121377
   Singer AJ, 2001, ACAD EMERG MED, V18, P538
   Sinha S, 2001, J HAND SURG-BRIT EUR, V26, P264, DOI 10.1054/jhsb.2000.0572
   Sultan A, 2017, TURK NEUROSURG, V1, P1
   Tacconi L, 2018, OPEN ACCESS J NEUROL, V7
   Thacoor A, 2018, J CRANIOFAC SURG, V29, P202, DOI 10.1097/SCS.0000000000004069
   Toriumi DM, 1998, PLAST RECONSTR SURG, V102, P2209, DOI 10.1097/00006534-199811000-00062
   Zempsky WT, 2004, PEDIATR EMERG CARE, V20, P519, DOI 10.1097/01.pec.0000136068.45198.ae
   Zhou YJ, 2016, MED SCI MONITOR, V22, P3689, DOI 10.12659/MSM.896982
NR 34
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E940
EP E946
DI 10.1016/j.wneu.2018.10.023
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000116
PM 30336296
DA 2020-05-12
ER

PT J
AU Takai, K
   Niimura, M
   Hongo, H
   Umekawa, M
   Teranishi, A
   Kayahara, T
   Taniguchi, M
AF Takai, Keisuke
   Niimura, Manabu
   Hongo, Hiroki
   Umekawa, Motoyuki
   Teranishi, Akio
   Kayahara, Tomomichi
   Taniguchi, Makoto
TI Disturbed Consciousness and Coma: Diagnosis and Management of
   Intracranial Hypotension Caused by a Spinal Cerebrospinal Fluid Leak
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coma; CSF leakage; Dural tear; Epidural blood patch; Intracranial
   hypovolemia; Myelographic CT; Subdural hematoma
ID EPIDURAL BLOOD PATCH; SUBDURAL-HEMATOMA; CSF LEAK; HEMORRHAGE; SYSTEM
AB OBJECTIVE: The diagnosis and treatment of intracranial hypotension associated with a spinal cerebrospinal fluid (CSF) leak, especially in comatose patients, have yet to be established.
   METHODS: Clinical manifestations, neuroimaging findings, and treatment outcomes in 11 patients (Glasgow Coma Scale score 10 +/- 4) were described and compared with 36 patients with normal consciousness.
   RESULTS: Patients with disturbed consciousness were diagnosed at a significantly older age (55 +/- 11 years; P < 0.001) than those without (42 +/- 8.8 years). Neuroimaging findings in patients with disturbed consciousness were characterized by a smaller midbrainepons angle (7.8 +/- 10 degrees; P < 0.001), brainstem swelling (122%; P = 0.002), and thicker subdural hematomas (16 +/ 7.0 mm degrees; P < 0.001). Epidural blood patch (EBP) alone did not achieve sustained improvements in patients with disturbed consciousness but did in most patients without (94%; P = 0.001). Over the treatment course, 5 patients progressed to coma, which correlated with a high signal intensity on T2-weighted magnetic resonance imaging in the brainstem. Hematoma drainage before EBP caused neurologic deterioration in 2 patients. Simultaneous EBP after hematoma drainage achieved sustained improvements in 5 of 6 patients. Simultaneous microsurgical dural repair after hematoma drainage achieved more rapid improvements in 3 of 3 patients.
   CONCLUSIONS: Among patients with intracranial hypotension caused by a spinal CSF leak, disturbed consciousness may occur in elderly patients because of severe diencephalic-mesencephalic deformities. Simultaneous EBP after safe hematoma drainage is indicated for these patients. Alternatively, dural repair is indicated for patients for whom the spinal level of dural disease has been identified. Hematoma drainage before EBP is not recommended because it caused deterioration.
C1 [Takai, Keisuke; Niimura, Manabu; Hongo, Hiroki; Umekawa, Motoyuki; Teranishi, Akio; Kayahara, Tomomichi; Taniguchi, Makoto] Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Fuchu, Tokyo, Japan.
RP Takai, K (reprint author), Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Fuchu, Tokyo, Japan.
EM takai-nsu@umin.ac.jp
CR Akkawi N, 2006, NEUROL SCI, V27, P63, DOI 10.1007/s10072-006-0566-2
   Beck CE, 1998, J NEUROSURG, V89, P470, DOI 10.3171/jns.1998.89.3.0470
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Binder DK, 2002, NEUROSURGERY, V51, P830, DOI 10.1227/01.NEU.0000024286.95876.2F
   Chaudhary N, 2011, CAN J NEUROL SCI, V38, P54, DOI 10.1017/S0317167100011070
   Chi NF, 2007, CEPHALALGIA, V27, P279, DOI 10.1111/j.1468-2982.2007.01259.x
   Collange O, 2016, A A CASE REP, V7, P207, DOI 10.1213/XAA.0000000000000385
   Davidson B, 2017, WORLD NEUROSURG, V101, P343, DOI 10.1016/j.wneu.2017.01.123
   Dhillon AK, 2010, NEUROCRIT CARE, V12, P390, DOI 10.1007/s12028-009-9323-8
   Ferrante E, 2009, CLIN NEUROL NEUROSUR, V111, P699, DOI 10.1016/j.clineuro.2009.06.001
   Ghavanini AA, 2013, CEPHALALGIA, V33, P43, DOI 10.1177/0333102412466963
   Inamasu J, 2015, CASE REP NEUROL, V7, P71, DOI 10.1159/000381667
   Koch KK, 2015, MIL MED, V180, pE369, DOI 10.7205/MILMED-D-14-00141
   Lasboo AA, 2008, AM J NEURORADIOL, V29, P1627, DOI 10.3174/ajnr.A1157
   Loya JJ, 2012, J NEUROSURG, V117, P615, DOI 10.3171/2012.4.JNS112030
   Savoiardo M, 2007, BRAIN, V130, P1884, DOI 10.1093/brain/awm101
   Sayer FT, 2006, NEUROSURGERY, V59, P204, DOI 10.1227/01.NEU.0000129843.34356.EE
   Schievink WI, 2008, AM J NEURORADIOL, V29, P853, DOI 10.3174/ajnr.A0956
   Schievink WI, 2016, NEUROLOGY, V87, P673, DOI 10.1212/WNL.0000000000002986
   Schievink WI, 2013, NEUROCRIT CARE, V18, P248, DOI 10.1007/s12028-012-9800-3
   Shah LM, 2013, AM J ROENTGENOL, V200, P400, DOI 10.2214/AJR.12.8611
   Shin HS, 2016, J KOREAN NEUROSURG S, V59, P69, DOI 10.3340/jkns.2016.59.1.69
   Takahashi K, 2016, NEUROL MED-CHIR, V56, P69, DOI 10.2176/nmc.oa.2015-0032
   Takai K, 2018, WORLD NEUROSURG, V118, P269, DOI 10.1016/j.wneu.2018.07.148
   Takai K, 2017, WORLD NEUROSURG, V107, P351, DOI 10.1016/j.wneu.2017.07.168
   Takai K, 2017, J NEUROSURG-SPINE, V26, P751, DOI 10.3171/2016.11.SPINE16488
   Terajima K, 2002, ANESTH ANALG, V94, P959, DOI 10.1097/00000539-200204000-00034
   Whiteley W, 2003, BRIT J NEUROSURG, V17, P456, DOI 10.1080/02688690310001611251
   Yoshida H, 2014, J NEUROSURG-SPINE, V21, P432, DOI 10.3171/2014.5.SPINE13549
   Zada G, 2007, J NEUROSURG, V106, P1089, DOI 10.3171/jns.2007.106.6.1089
NR 30
TC 5
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E700
EP E711
DI 10.1016/j.wneu.2018.09.193
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000086
PM 30292664
DA 2020-05-12
ER

PT J
AU Trevisi, G
   Vigo, V
   Morena, MG
   Grieco, DL
   Rigante, M
   Anile, C
   Mangiola, A
AF Trevisi, Gianluca
   Vigo, Vera
   Morena, Maria Grazia
   Grieco, Domenico Luca
   Rigante, Mario
   Anile, Carmelo
   Mangiola, Annunziato
TI Comparison of Endoscopic Versus Microsurgical Resection of Pituitary
   Adenomas with Parasellar Extension and Evaluation of the Predictive
   Value of a Simple 4-Quadrant Radiologic Classification
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Endoscopy; Gross total resection; Knosp classification;
   Microsurgery; Pituitary adenoma; Quadrants
ID CAVERNOUS SINUS INVASION; RESONANCE-IMAGING CRITERIA; TRANSSPHENOIDAL
   SURGERY; CONCURRENT SERIES; SPACE; MACROADENOMAS; EFFICACY
AB BACKGROUND: The amount of parasellar extension is a known limitation for gross total resection (GTR) of pituitary adenomas. Endoscopic technique seems to improve resection of adenomas extending laterally. Knosp classification is used to evaluate the extent of parasellar invasion: increasing Knosp grades correspond with lower rates of GTR. The 4-quadrant method could help to estimate the risk of partial resection in adenomas with parasellar extension. The objective of this study was to compare the rate of GTR between microsurgical and endoscopic techniques in pituitary adenomas with parasellar extension. The secondary aim was to compare the predictive value of Knosp classification and of the 4-quadrant classification regarding GTR.
   METHODS: This was a retrospective comparison of GTR in different Knosp grades and per quadrant in 55 consecutive patients who underwent microsurgical (n = 28, 2001-2008) or endoscopic (n = 27, 2008-2016) resection of a pituitary adenoma with parasellar extension.
   RESULTS: The endoscopic group (19/27 patients) had a significant higher rate of GTR than the microsurgical group (8/28 patients) (P = 0.005). This was evident in all patients but those with Knosp grade 4. Using the quadrant classification, the endoscopic group had a significantly higher rate of GTR than the microsurgical group in all but the inferolateral quadrant. The 2 classifications showed similar sensitivity in predicting subtotal resection (78% quadrant vs. 82% Knosp), with limited specificity (both 25%).
   CONCLUSIONS: GTR of macroadenomas with parasellar extension is significantly enhanced by the endoscopic approach. The 4-quadrant classification appears as sensitive as the Knosp classification and could be a simple adjunct to predict surgical radicality, in particular in cases of inferolateral quadrant invasion.
C1 [Trevisi, Gianluca; Vigo, Vera; Morena, Maria Grazia; Anile, Carmelo] Univ Cattolica Sacro Cuore, Dept Neurosurg, Rome, Italy.
   [Grieco, Domenico Luca] Univ Cattolica Sacro Cuore, Dept Anesthesiol & Intens Care Med, Rome, Italy.
   [Rigante, Mario] Univ Cattolica Sacro Cuore, Dept Otolaryngol, Rome, Italy.
   [Trevisi, Gianluca; Vigo, Vera; Morena, Maria Grazia; Anile, Carmelo] Fdn Policlin Univ A Gemelli IRCCS, Dept Neurosurg, Rome, Italy.
   [Grieco, Domenico Luca] Fdn Policlin Univ A Gemelli IRCCS, Dept Anesthesia Emergency & Intens Care Med, Rome, Italy.
   [Rigante, Mario] Fdn Policlin Univ A Gemelli IRCCS, Dept Otolaryngol, Rome, Italy.
   [Mangiola, Annunziato] Univ G DAnnunzio, Dept Neurosurg, Pescara, Italy.
RP Vigo, V (reprint author), Univ Cattolica Sacro Cuore, Dept Neurosurg, Rome, Italy.; Vigo, V (reprint author), Fdn Policlin Univ A Gemelli IRCCS, Dept Neurosurg, Rome, Italy.
EM vera.vigo@gmail.com
RI , Rigante/T-6879-2019; Grieco, Domenico Luca/D-9706-2018; Trevisi,
   Gianluca/K-9664-2016
OI , Rigante/0000-0002-6111-0786; Grieco, Domenico
   Luca/0000-0002-4557-6308; Trevisi, Gianluca/0000-0002-2879-8451
CR Anik I, 2017, WORLD NEUROSURG, V108, P278, DOI 10.1016/j.wneu.2017.08.182
   Briceno V, 2017, NEUROL RES, V39, P387, DOI 10.1080/01616412.2017.1296653
   Connor SEJ, 2014, J NEUROL SURG PART B, V75, P41, DOI 10.1055/s-0033-1353362
   Cottier JP, 2000, RADIOLOGY, V215, P463, DOI 10.1148/radiology.215.2.r00ap18463
   Dallapiazza R, 2014, J NEUROSURG, V121, P511, DOI 10.3171/2014.6.JNS131321
   Dhandapani S, 2016, WORLD NEUROSURG, V96, P36, DOI 10.1016/j.wneu.2016.08.088
   Diao YL, 2013, NEUROSURGERY, V73, P106, DOI 10.1227/NEU.0b013e3182889f2b
   Fernandez-Miranda JC, 2018, J NEUROSURG, V129, P430, DOI 10.3171/2017.2.JNS162214
   Goncalves MB, 2012, NEUROSURG REV, V35, P147, DOI 10.1007/s10143-011-0360-3
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Lofrese G, 2018, J CLIN NEUROSCI, V47, P299, DOI 10.1016/j.jocn.2017.09.011
   Mattogno PP, 2017, ACTA NEUROCHIR SUPPL, V124, P101, DOI 10.1007/978-3-319-39546-3_16
   Micko ASG, 2015, J NEUROSURG, V122, P803, DOI 10.3171/2014.12.JNS141083
   Moreau L, 1998, J RADIOL, V79, P241
   Starke RM, 2013, J CLIN ENDOCR METAB, V98, P3190, DOI 10.1210/jc.2013-1036
   Tong T, 2015, J COMPUT ASSIST TOMO, V39, P222, DOI 10.1097/RCT.0000000000000191
   Vieira JO, 2006, SURG NEUROL, V65, P130, DOI 10.1016/j.surneu.2005.05.021
   Zoli M, 2016, J NEUROSURG SCI, V60, P485
NR 18
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E769
EP E774
DI 10.1016/j.wneu.2018.09.215
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000095
PM 30312824
DA 2020-05-12
ER

PT J
AU Vidal, CHF
   Brainer-Lima, AM
   Valenca, MM
   Farias, RD
AF Vidal, Claudio H. F.
   Brainer-Lima, Alessandra M.
   Valenca, Marcelo M.
   Farias, Ronald de Lucena
TI Chiari 1 Malformation Surgery: Comparing Non-violation of the Arachnoid
   versus Arachnoid Opening and Thermocoagulation of the Tonsils
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arnold-Chiari malformation; Cerebellum; Foramen magnum; Neurologic
   examination
ID POSTERIOR-FOSSA DECOMPRESSION; I-MALFORMATION; FORAMEN MAGNUM;
   CRANIOCERVICAL DECOMPRESSION; SYRINGOMYELIA COMPLEX; MANAGEMENT; CSF;
   CHILDREN; MR; VELOCITIES
AB OBJECTIVE: Evidence is lacking concerning the myriad surgical techniques for type 1 Chiari malformation. This study evaluated the impact of arachnoid violation with tonsil thermocoagulation during surgical craniovertebral junction decompression.
   METHODS: The evaluation included aspects of the neurologic examination and parameters of cerebrospinal fluid flow on magnetic resonance imaging during preoperative and postoperative periods. All patients underwent craniovertebral junction decompression and opening of the dura mater. Patients were divided into 2 study groups. Patients in group 1 did not undergo arachnoid violation. Patients in group 2 underwent tonsil manipulation and systematic opening of the fourth ventricle outlet.
   RESULTS: There were 16 patients enrolled in each group (total of 32 patients). Regarding clinical improvement, there were no significant differences between groups in the postoperative period. Group 2 had more adverse events (relative risk 2.45, 95% confidence interval 1.55-3.86). In terms of cerebrospinal fluid flow parameter analyses, patients in group 1 achieved better results (P < 0.05).
   CONCLUSIONS: For treatment of symptomatic type 1 Chiari malformation, craniovertebral junction decompression with arachnoid preservation (i.e., without tonsillar manipulation) seems more suitable than the addition of arachnoid opening and thermocoagulation of the tonsils.
C1 [Vidal, Claudio H. F.] Getulio Vargas Hosp, Dept Neurosurg, Recife, PE, Brazil.
   [Brainer-Lima, Alessandra M.] Imaging Clin SIR Diagnost, Recife, PE, Brazil.
   [Valenca, Marcelo M.] Univ Fed Pernambuco, Hlth Sci Ctr, Dept Neurosurg, Recife, PE, Brazil.
   [Farias, Ronald de Lucena] Univ Fed Paraiba, Dept Anat, Joao Pessoa, Paraiba, Brazil.
RP Vidal, CHF (reprint author), Getulio Vargas Hosp, Dept Neurosurg, Recife, PE, Brazil.
EM chfvidalncr@gmail.com
RI Valenca, Marcelo/A-4302-2013
OI Valenca, Marcelo/0000-0003-0678-3782
CR Abla AA, 2010, J CRANIOVERTEBRAL JU, V1, P29, DOI 10.4103/0974-8237.65479
   ALDEEB SM, 1991, J NEUROL SCI, V103, P144, DOI 10.1016/0022-510X(91)90157-3
   Alden T D, 2001, Neurosurg Focus, V11, pE2
   Alzate J C, 2001, Neurosurg Focus, V11, pE3
   ARMONDA RA, 1994, NEUROSURGERY, V35, P214, DOI 10.1227/00006123-199408000-00006
   ASKENASY JJM, 1992, EUR NEUROL, V32, P159, DOI 10.1159/000116815
   Bejjani G K, 2001, Neurosurg Focus, V11, pE1
   Chang Yung-Yee, 1993, Journal of the Formosan Medical Association, V92, P926
   DAUSER RC, 1988, PEDIATR NEUROSCI, V14, P184, DOI 10.1159/000120386
   DILORENZO N, 1995, SPINE, V20, P2479, DOI 10.1097/00007632-199512000-00001
   Dolar MT, 2004, AM J NEURORADIOL, V25, P142
   DYSTE GN, 1989, J NEUROSURG, V71, P159, DOI 10.3171/jns.1989.71.2.0159
   Ellenbogen R G, 2000, Neurosurg Focus, V8, pE6
   Feldstein NA, 1999, PEDIATR NEUROSURG, V31, P143, DOI 10.1159/000028850
   FISCHER EG, 1995, CHILD NERV SYST, V11, P625, DOI 10.1007/BF00300718
   Genitori L, 2000, CHILD NERV SYST, V16, P707, DOI 10.1007/s003810000338
   Ghanem IB, 1997, SPINE, V22, P1313, DOI 10.1097/00007632-199706150-00006
   Guyotat J, 1998, ACTA NEUROCHIR, V140, P745, DOI 10.1007/s007010050175
   Haughton VM, 2003, AM J NEURORADIOL, V24, P169
   Hayhurst C, 2008, BRIT J NEUROSURG, V22, P86, DOI 10.1080/02688690701779525
   Hofmann E, 2000, AM J NEURORADIOL, V21, P151
   Iskandar BJ, 2005, J NEUROSURG, V103, P508, DOI 10.3171/ped.2005.103.6.0508
   Klekamp J, 1996, ACTA NEUROCHIR, V138, P788, DOI 10.1007/BF01411256
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Lazareff JA, 2002, J NEUROSURG, V97, P1018, DOI 10.3171/jns.2002.97.5.1018
   Levine DN, 2004, J NEUROL SCI, V220, P3, DOI 10.1016/j.jns.2004.01.014
   MARSOTDUPUCH K, 1995, AM J NEURORADIOL, V16, P2093
   Mauer UM, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11105
   McGirt MJ, 2006, NEUROSURGERY, V59, P140, DOI 10.1227/01.NEU.0000219841.73999.B3
   Menezes AH, 1995, PEDIATR NEUROSURG, V23, P260, DOI 10.1159/000120969
   Munshi I, 2000, NEUROSURGERY, V46, P1384, DOI 10.1097/00006123-200006000-00018
   OHARA S, 1988, J NEUROSURG, V69, P675, DOI 10.3171/jns.1988.69.5.0675
   Oldfield EH, 2002, J NEUROSURG, V97, P1009, DOI 10.3171/jns.2002.97.5.1009
   Park JK, 1997, PEDIATR NEUROSURG, V26, P190, DOI 10.1159/000121190
   Parker SR, 2011, J NEUROSURG-PEDIATR, V8, P177, DOI 10.3171/2011.5.PEDS10362
   SAHUQUILLO J, 1994, NEUROSURGERY, V35, P874, DOI 10.1227/00006123-199411000-00011
   Sindou M, 2002, ACTA NEUROCHIR, V144, P1005, DOI 10.1007/s00701-002-1004-8
   Tubbs RS, 2004, J NEUROSURG, V100, P460, DOI 10.3171/ped.2004.100.5.0460
   Tubbs RS, 2003, J NEUROSURG, V99, P291, DOI 10.3171/jns.2003.99.2.0291
   Ward B A, 1994, J Neuroimaging, V4, P164
   Weinberg JS, 1998, PEDIATR NEUROSURG, V29, P14, DOI 10.1159/000028678
   Yeh DD, 2006, J NEUROSURG, V105, P26, DOI 10.3171/ped.2006.105.1.26
NR 42
TC 6
Z9 6
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E605
EP E613
DI 10.1016/j.wneu.2018.09.175
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000074
PM 30292659
DA 2020-05-12
ER

PT J
AU Vulcu, S
   Wagner, F
   Santos, AF
   Reitmeir, R
   Soll, N
   Schoni, D
   Fung, C
   Wiest, R
   Raabe, A
   Beck, J
   Z'Graggen, WJ
AF Vulcu, Sonja
   Wagner, Franca
   Santos, Ana Fernandes
   Reitmeir, Ralcua
   Soll, Nicole
   Schoni, Daniel
   Fung, Christian
   Wiest, Roland
   Raabe, Andreas
   Beck, Jurgen
   Z'Graggen, Werner J.
TI Repetitive Computed Tomography Perfusion for Detection of Cerebral
   Vasospasm-Related Hypoperfusion in Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral vasospasm; CT perfusion parameters; Delayed cerebral ischemia;
   Misery perfusion; Subarachnoid hemorrhage
ID CT PERFUSION; TRANSCRANIAL DOPPLER; ISCHEMIA; DIAGNOSIS; ANGIOGRAPHY;
   TISSUE; MANAGEMENT; DIFFUSION
AB BACKGROUND: Delayed cerebral infarction after aneurysmal subarachnoid hemorrhage (aSAH) still remains the leading cause of disability in patients that survive the initial ictus. It has been shown that computed tomography perfusion (CTP) imaging can detect hypoperfused brain areas. The aim of this study was to evaluate if a single acute CTP examination at time of neurologic deterioration is sufficient or if an additional baseline CTP increases diagnostic accuracy.
   METHODS: Retrospective analysis of acute and baseline (within 24 hours after aneurysm treatment) CTP examinations of patients with neurologic deterioration because of vasospasm-related hypoperfusion. Patients without clinical deterioration during the vasospasm period served as control subjects. The following CTP parameters were analyzed for predefined brain regions: time to drain (TTD), mean transit time, time to peak, cerebral blood flow, and volume.
   RESULTS: Thirty-three patients with and 23 without neurologic deterioration were included. Baseline CTP examination did not ameliorate diagnostic accuracy of the acute CTP examination in symptomatic patients. The same was true for interhemispheric comparison of perfusion parameters of the acute examination. The CTP parameter with the highest diagnostic yield was TTD of the symptomatic brain region (threshold value, 4.7 seconds; sensitivity, 97%; specificity, 96%).
   CONCLUSIONS: Acute CTP examination in case of suspected vasospasm-induced neurologic deterioration after aSAH has the highest diagnostic accuracy to detect misery perfusion. Additional baseline CTP is not needed. The most sensitive parameter to detect critically perfused brain areas is TTD.
C1 [Vulcu, Sonja; Santos, Ana Fernandes; Reitmeir, Ralcua; Soll, Nicole; Schoni, Daniel; Fung, Christian; Raabe, Andreas; Beck, Jurgen; Z'Graggen, Werner J.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Neurosurg, Bern, Switzerland.
   [Wagner, Franca; Wiest, Roland] Univ Bern, Bern Univ Hosp, Inselspital, Inst Diagnost & Intervent Neuroradiol, Bern, Switzerland.
RP Z'Graggen, WJ (reprint author), Univ Bern, Bern Univ Hosp, Inselspital, Dept Neurosurg, Bern, Switzerland.
EM werner.zgraggen@insel.ch
OI Schoni, Daniel/0000-0003-0625-5445
CR Abels B, 2010, AM J NEURORADIOL, V31, P1690, DOI 10.3174/ajnr.A2151
   Adamczyk P, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/462491
   American Association of Physicists in Medicine, 2016, AD BRAIN PERF CT PRO
   Beck J, 2004, J NEUROL NEUROSUR PS, V75, P1779, DOI 10.1136/jnnp.2004.036921
   Brathwaite S, 2014, TRANSL STROKE RES, V5, P207, DOI 10.1007/s12975-013-0316-8
   Cremers CHP, 2014, J CEREBR BLOOD F MET, V34, P200, DOI 10.1038/jcbfm.2013.208
   Dankbaar JW, 2010, STROKE, V41, P1927, DOI 10.1161/STROKEAHA.109.574392
   Dankbaar JW, 2009, STROKE, V40, P3493, DOI 10.1161/STROKEAHA.109.559013
   Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045
   Dolatowski K, 2014, EUR J RADIOL, V83, P1881, DOI 10.1016/j.ejrad.2014.06.020
   Etminan N, 2013, STROKE, V44, P1260, DOI 10.1161/STROKEAHA.111.675975
   Faust K, 2014, CLIN NEUROL NEUROSUR, V125, P36, DOI 10.1016/j.clineuro.2014.06.023
   Fontana J, 2015, CLIN NEUROL NEUROSUR, V137, P22, DOI 10.1016/j.clineuro.2015.06.014
   Greenberg ED, 2010, AM J NEURORADIOL, V31, P1853, DOI 10.3174/ajnr.A2246
   Hertel F, 2005, NEUROSURGERY, V56, P28, DOI 10.1227/01.NEU.0000144866.28101.6D
   Hoang JK, 2013, AM J ROENTGENOL, V201, pW730, DOI 10.2214/AJR.12.10031
   Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108
   Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823
   Mir DIA, 2014, AM J NEURORADIOL, V35, P866, DOI 10.3174/ajnr.A3787
   Othman AE, 2016, NEURORADIOLOGY, V58, P787, DOI 10.1007/s00234-016-1695-9
   Rabinstein AA, 2004, STROKE, V35, P1862, DOI 10.1161/01.STR.0000133132.76983.8e
   Rordorf G, 1999, STROKE, V30, P599, DOI 10.1161/01.STR.30.3.599
   Sanelli PC, 2011, NEURORADIOLOGY, V53, P425, DOI 10.1007/s00234-010-0752-z
   SLOAN MA, 1989, NEUROLOGY, V39, P1514, DOI 10.1212/WNL.39.11.1514
   Sviri GE, 2006, NEUROSURGERY, V59, P319, DOI 10.1227/01.NEU.0000222819.18834.33
   Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265
   Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   Voigt Louis P, 2009, J Intensive Care Med, V24, P108, DOI 10.1177/0885066608329946
   Waydhas C, 1999, CRIT CARE, V3, pR83, DOI 10.1186/cc362
   Weidauer S, 2007, STROKE, V38, P1831, DOI 10.1161/STROKEAHA.106.477976
   Wilson CD, 2014, CAN J NEUROL SCI, V41, P314, DOI 10.1017/S031716710001725X
   Wintermark M, 2006, AM J NEURORADIOL, V27, P26
NR 33
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E739
EP E746
DI 10.1016/j.wneu.2018.09.208
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000091
PM 30308346
OA Green Published
DA 2020-05-12
ER

PT J
AU Wallace, AN
   Kayan, Y
   Almandoz, JED
   Fease, JL
   Milner, AA
   Scholz, JM
AF Wallace, Adam N.
   Kayan, Yasha
   Almandoz, Josser E. Delgado
   Fease, Jennifer L.
   Milner, Anna A.
   Scholz, Jill M.
TI Endovascular Treatment of Wide-Necked Intracranial Aneurysms with the
   Scepter XC Balloon Catheter, with Low-Profile Visualized Intraluminal
   Support (LVIS) Jr. Deployment as a "Bailout" Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Balloon; Hemorrhage; LVIS; Scepter; Stent; Stroke
ID STENT-ASSISTED COILING; EMBOLIZATION; OCCLUSION; EFFICACY; DEVICE;
   SAFETY
AB BACKGROUND: The Scepter XC balloon catheter can be used for balloon-assisted coiling (BAC) of cerebral aneurysms but also accommodates delivery of a low-profile visible intraluminal stent (LVIS Jr.). We assessed the safety and effectiveness of BAC using the Scepter XC, with LVIS Jr. stent-assisted coiling (SAC) as a bailout option.
   METHODS: A single-institution prospectively maintained neurointerventional database was reviewed for wide-necked (neck width >= 4 mm or dome/neck ratio < 2) saccular aneurysms treated using the Scepter XC. Complication and angiographic occlusion rates of BAC and SAC procedures were compared. Multivariate logistic regression was used to identify variables predictive of complete aneurysm occlusion.
   RESULTS: The cohort included 141 wide-necked saccular intracranial aneurysms treated in 135 procedures. SAC was used to treat 30% of aneurysms by deploying the LVIS Jr. through the Scepter XC. The overall procedural complication rate was 8.9%, including a 1.5% rate of symptomatic thromboembolic events and 3.0% rate of hemorrhagic complications, with no significant differences in complications between BAC and SAC procedures (P = 0.27). The overall complete or near-complete aneurysm occlusion rate was 96%, with trends toward higher complete aneurysm occlusion and lower retreatment rates with SAC (78 vs. 57%; P = 0.13; 0 vs. 8.4%, P = 0.13). Multivariate logistic regression identified aneurysm size, procedure technique (BAC or SAC), and duration of follow-up as independent predictors of complete aneurysm occlusion.
   CONCLUSIONS: Use of the Scepter XC for BAC, with LVIS Jr. SAC as a bailout option, shows acceptable angiographic and clinical results.
C1 [Wallace, Adam N.; Kayan, Yasha; Almandoz, Josser E. Delgado; Fease, Jennifer L.; Milner, Anna A.; Scholz, Jill M.] Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.
   [Wallace, Adam N.] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
RP Wallace, AN (reprint author), Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.; Wallace, AN (reprint author), Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
EM adam.wallace@crlmed.com
CR Amenta PS, 2012, NEUROSURGERY, V70, P1415, DOI 10.1227/NEU.0b013e318246a4b1
   Bodily KD, 2011, AM J NEURORADIOL, V32, P1232, DOI 10.3174/ajnr.A2478
   Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470
   Cekirge HS, 2011, J NEUROSURG, V114, P944, DOI 10.3171/2010.3.JNS081131
   Chalouhi N, 2013, AM J NEURORADIOL, V34, P1987, DOI 10.3174/ajnr.A3538
   Feng ZZ, 2016, J NEUROINTERV SURG, V8, P1192, DOI 10.1136/neurintsurg-2015-012090
   Fiorella D, 2016, J NEUROINTERV SURG, V8, P894, DOI 10.1136/neurintsurg-2015-011937
   Grossberg JA, 2017, J NEUROINTERV SURG, V9, P1098, DOI 10.1136/neurintsurg-2016-012687
   Iosif C, 2018, J NEUROINTERV SURG, V10, P675, DOI 10.1136/neurintsurg-2017-013375
   Kayan Y, 2017, J NEUROINTERV SURG, V9, P792, DOI 10.1136/neurintsurg-2016-012409
   Lawson MF, 2011, NEUROSURGERY, V69, P598, DOI 10.1227/NEU.0b013e3182181c2b
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Mocco J, 2009, J NEUROSURG, V110, P35, DOI 10.3171/2008.7.JNS08322
   Pierot L, 2012, AM J NEURORADIOL, V33, P1475, DOI 10.3174/ajnr.A3003
   Piotin M, 2010, STROKE, V41, P110, DOI 10.1161/STROKEAHA.109.558114
   Ross IB, 2006, SURG NEUROL, V66, P593, DOI 10.1016/j.surneu.2006.03.050
   Wang F, 2016, J NEUROL SCI, V364, P160, DOI 10.1016/j.jns.2016.03.041
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E798
EP E807
DI 10.1016/j.wneu.2018.09.226
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000099
PM 30312823
DA 2020-05-12
ER

PT J
AU Wang, HW
   Yin, YH
   Jin, YZ
   Zong, R
   Li, T
   Yu, XG
   Qiao, GY
AF Wang, Hua-wei
   Yin, Yi-heng
   Jin, Ya-zhou
   Zong, Rui
   Li, Teng
   Yu, Xin-guang
   Qiao, Guang-yu
TI Morphometric Measurements of the C1 Lateral Mass with Congenital
   Occipitalization of the Atlas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Atlantoaxial dislocation; C1 lateral mass; Computed tomography;
   Craniocervical junction; Occipitalization of the atlas
ID IRREDUCIBLE ATLANTOAXIAL DISLOCATION; ANOMALOUS VERTEBRAL ARTERY; DIRECT
   POSTERIOR REDUCTION; BASILAR INVAGINATION; CRANIOVERTEBRAL JUNCTION;
   SCREW PLACEMENT; CLASSIFICATION; FIXATION; REALIGNMENT; NUANCES
AB OBJECTIVE: Unfamiliarity with the morphometry of the assimilated C1 lateral mass (C1LM) could make screw placement dangerous. In the present study, we defined the morphometric dimensions of the occipitalized C1LM to provide surgeons with valuable information for preoperative planning.
   METHODS: Thin-slice computed tomography scanning data from 131 patients with occipitalization of the atlas (OA) and 50 control cases were imported into Mimics software for analysis. The widths and heights of the C1LM were fully measured in the different planes. The ideal inward angulation and the safe maximum cephalic angulation of C1 screw trajectory were evaluated.
   RESULTS: Except for the medial height, all the widths and heights of C1LM were significantly shorter in the OA group than those in the control group. The ideal inward angle (alpha) was significantly larger in the OA group (23.8 degrees +/- 8.3 degrees) than that (15.3 degrees +/- 3.8 degrees) in the control group; the corresponding screw length was also significantly longer in the OA group (20.9 +/- 2.9 mm). The safe maximum cephalic angles (beta) of the screw trajectory did not reach a significant difference between the 2 groups. All the widths and heights were shorter in the females than those in the males. The a angle also did not reach a significant difference between the sexes; however, the b angles in the males (35.9 degrees +/- 10.4 degrees) was significantly larger than that in the females (32.0 degrees +/- 9.4 degrees).
   CONCLUSIONS: Although the hypoplastic C1LM brings limitations to screw insertion to some extent, it is still broad enough to accommodate a screw safely in both female and male patients. Considering the irregularity of the C1LM in patients with OA, the preoperative imaging assessment is critical, and C1LM screw placement should be performed individually.
C1 [Wang, Hua-wei; Yin, Yi-heng; Jin, Ya-zhou; Zong, Rui; Li, Teng; Yu, Xin-guang; Qiao, Guang-yu] Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Yu, XG (reprint author), Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xinguang_yu@263.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571350]; Beijing Science and Technology Nova
   Program Project [Z171100001117106]
FX This research was supported by the National Natural Science Foundation
   of China (grant 81571350) and the Beijing Science and Technology Nova
   Program Project (grant Z171100001117106).
CR Chandra PS, 2016, NEUROSURGERY, V78, P400
   Chandra PS, 2014, OPER NEUROSURG, V10, P621, DOI 10.1227/NEU.0000000000000470
   CHANDRARAJ S, 1992, SPINE, V17, P1249, DOI 10.1097/00007632-199210000-00021
   Currier BL, 2008, SPINE, V33, P635, DOI 10.1097/BRS.0b013e318166e083
   Ebraheim NA, 2000, SURG NEUROL, V53, P208, DOI 10.1016/S0090-3019(00)00160-9
   Gholve PA, 2007, J BONE JOINT SURG AM, V89A, P571, DOI 10.2106/JBJS.F.00527
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Goel A, 2004, SPINE, V29, pE520, DOI 10.1097/01.brs.0000144827.17054.35
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A, 2009, J NEUROSURG-SPINE, V10, P220, DOI 10.3171/2008.12.SPINE08499
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hong JT, 2011, NEUROL MED-CHIR, V51, P701, DOI 10.2176/nmc.51.701
   Jian FZ, 2012, CLIN NEUROL NEUROSUR, V114, P590, DOI 10.1016/j.clineuro.2011.12.017
   Jian FZ, 2010, NEUROSURGERY, V66, P678, DOI 10.1227/01.NEU.0000367632.45384.5A
   Lu DC, 2010, NEUROSURGERY, V66, pA141, DOI 10.1227/01.NEU.0000365744.54102.B9
   Menezes AH, 2008, CHILD NERV SYST, V24, P1109, DOI 10.1007/s00381-008-0600-1
   Menezes AH, 2008, CHILD NERV SYST, V24, P1101, DOI 10.1007/s00381-008-0605-9
   Salunke P, 2016, CLIN NEUROL NEUROSUR, V145, P19, DOI 10.1016/j.clineuro.2016.04.001
   Salunke P, 2015, CLIN NEUROL NEUROSUR, V131, P47, DOI 10.1016/j.clineuro.2015.01.025
   Salunke P, 2014, J NEUROSURG-SPINE, V20, P5, DOI 10.3171/2013.9.SPINE13491
   Simsek S, 2009, EUR SPINE J, V18, P1321, DOI 10.1007/s00586-009-1105-7
   Wang SL, 2013, SPINE, V38, pE1348, DOI 10.1097/BRS.0b013e3182a1e5e4
   Wang SL, 2009, SPINE, V34, P2838, DOI 10.1097/BRS.0b013e3181b4fb8b
   Yin YH, 2016, NEUROSURGERY, V78, P391, DOI 10.1227/NEU.0000000000001026
   Yin YH, 2014, SPINE, V39, P2013, DOI 10.1097/BRS.0000000000000611
   Yin YH, 2013, SPINE J, V13, P1864, DOI 10.1016/j.spinee.2013.08.014
   Yin YH, 2012, SPINE, V37, pE170, DOI 10.1097/BRS.0b013e318227efe7
   Zong R, 2017, WORLD NEUROSURG, V99, P96, DOI 10.1016/j.wneu.2016.11.062
NR 30
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E1
EP E7
DI 10.1016/j.wneu.2018.08.016
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000002
PM 30107247
DA 2020-05-12
ER

PT J
AU Wee, HY
   Ho, CH
   Chang, CH
   Chio, CC
   Wang, JJ
   Wang, CC
   Kuo, JR
AF Wee, Hsiao-Yue
   Ho, Chung-Han
   Chang, Ching-Hung
   Chio, Chung-Ching
   Wang, Jhi-Joung
   Wang, Che-Chuan
   Kuo, Jinn-Rung
TI Probability of New-Onset Cancer Between Patients with Traumatic Brain
   Injury and a Comparison General Population Cohort
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Cancer; Comorbidity; Gender; Mortality; Traumatic brain injury
ID SUBSEQUENT RISK; EPIDEMIOLOGY; BURDEN
AB BACKGROUND: Traumatic brain injury (TBI) has been reported as a risk factor for the development of brain tumors. However, whether TBI affects systemic cancer remains to be determined. We investigated the incidence and factors associated with cancer development in patients with TBI.
   METHODS: A propensity score (age, gender, and comorbidity)-matched longitudinal cohort study of 34,556 patients with pre-existing TBI and 69,112 patients without TBI from January 2000 to December 2015 was presented using the Taiwan's National Health Insurance Research Database. The Cox proportional hazard regression model was used to estimate the hazard ratio of developing cancer adjusted by the potential confounding factors. The stratified analysis of age, gender, and comorbidities for each cancer type was evaluated using forest plot analysis
   RESULTS: The cancer incidence rate in the patients with TBI (4.38%) was greater than that in patients without TBI (3.88%). The interval to cancer development in those with TBI (5.65 +/- 3.58 years) was shorter than that in those without TBI (6.02 +/- 3.65 years). The cancer risk in those with TBI was increased 1.27-fold compared with that in the general population. Of the patients with TBI, age < 55 years and male gender indicated a greater incidence of cancer than that of the general population. The patients with TBI had greater cancer frequencies in the head and neck structures compared with those in the general population.
   CONCLUSIONS: TBI is a risk factor for cancer development, especially in males and those aged < 55 years. We hope this information will remind physicians to consider the long-term effects of TBI on cancer development.
C1 [Wee, Hsiao-Yue] Dept Neurosurg, Liouying, Taiwan.
   [Ho, Chung-Han; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.
   [Chang, Ching-Hung; Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.
   [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan.
   [Wang, Che-Chuan] South Taiwan Univ Sci & Technol, Ctr Gen Educ, Tainan, Taiwan.
   [Kuo, Jinn-Rung] South Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
RP Kuo, JR (reprint author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.; Kuo, JR (reprint author), South Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
EM kuojinnrung@gmail.com
OI Ho, Chung-Han/0000-0001-5925-8477
CR Alaranta H, 2000, Wien Med Wochenschr, V150, P444
   Chen CW, 2017, ONCOTARGET, V8, P108989, DOI 10.18632/oncotarget.22480
   Chen CY, 2013, INT J NEUROSCI, V123, P724, DOI 10.3109/00207454.2013.796552
   Chen YH, 2012, J NEUROTRAUM, V29, P1328, DOI 10.1089/neu.2011.2235
   Chiang CJ, 2010, JPN J CLIN ONCOL, V40, P897, DOI 10.1093/jjco/hyq057
   Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793
   Francois P, 2010, ACTA NEUROCHIR, V152, P1755, DOI 10.1007/s00701-010-0730-6
   Kirkman MA, 2012, J NEUROTRAUM, V29, P2365, DOI 10.1089/neu.2012.2485
   Krishnamoorthy V, 2016, CHEST, V149, P1325, DOI 10.1016/j.chest.2015.12.014
   Lamminpaa A, 2002, EUR J CLIN PHARMACOL, V58, P137, DOI 10.1007/s00228-002-0429-6
   Lim SW, 2017, NEUROCRIT CARE, V26, P122, DOI 10.1007/s12028-016-0290-6
   Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070
   Luebeck EG, 2013, CANCER RES, V73, P1086, DOI 10.1158/0008-5472.CAN-12-2198
   Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358
   Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8
   MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944
   Nygren C, 2001, CANCER CAUSE CONTROL, V12, P733, DOI 10.1023/A:1011227617256
   Ostrom QT, 2011, CURR NEUROL NEUROSCI, V11, P329, DOI 10.1007/s11910-011-0189-8
   PARSONS LS, 2004, SAS USERS GROUP INT, V29, P1
   Salibi PN, 2014, AM J ROENTGENOL, V202, P397, DOI 10.2214/AJR.12.10294
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y
   Tang WC, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1457-6
   Tyagi Vineet, 2016, Surg Neurol Int, V7, P78, DOI 10.4103/2152-7806.189296
   Wu S, 2016, NATURE, V529, P43, DOI 10.1038/nature16166
NR 25
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E817
EP E826
DI 10.1016/j.wneu.2018.09.229
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000101
PM 30312818
DA 2020-05-12
ER

PT J
AU Whiting, AC
   Sutton, EF
   Walker, CT
   Godzik, J
   Catapano, JS
   Oh, MY
   Tomycz, ND
   Ravussin, E
   Whiting, DM
AF Whiting, Alexander C.
   Sutton, Elizabeth F.
   Walker, Corey T.
   Godzik, Jakub
   Catapano, Joshua S.
   Oh, Michael Y.
   Tomycz, Nestor D.
   Ravussin, Eric
   Whiting, Donald M.
TI Deep Brain Stimulation of the Hypothalamus Leads to Increased Metabolic
   Rate in Refractory Obesity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Functional neurosurgery; Lateral hypothalamus;
   Neuromodulation; Obesity
ID BODY-WEIGHT; ENERGY-EXPENDITURE; DISEASE BURDEN; PREVALENCE; OVERWEIGHT;
   SURGERY; TRENDS; ADULTS; RISKS
AB OBJECTIVE: Obesity has become a worldwide epidemic, with very few long-term successful treatment options for refractory disease. Deep brain stimulation (DBS) of the bilateral lateral hypothalamus (LH) in refractory obesity has been performed safely. However, questions remain regarding the optimal settings and its effects on metabolic rate. The goals of our experiment were to determine the optimal DBS settings and the actual effect of optimal stimulation on energy expenditure.
   METHODS: After bilateral LH DBS implantation, 2 subjects with treatment refractory obesity underwent 4 days of metabolic testing. The subjects slept overnight in a respiratory chamber to measure their baseline sleep energy expenditure, followed by 4 consecutive days of resting metabolic rate (RMR) testing at different stimulation settings. On day 4, the optimized DBS settings were used, and sleep energy expenditure was measured again overnight in the room calorimeter.
   RESULTS: During daily testing, the RMR fluctuated acutely with changes in stimulation settings and returned to baseline immediately after turning off the stimulation. Optimal stimulation settings selected for participants showed a 20% and 16% increase in RMR for the 2 participants. Overnight sleep energy expenditure measurements at these optimized settings on day 4 yielded a 10.4% and 4.8% increase over the baseline measurements for the 2 participants.
   CONCLUSIONS: These findings have demonstrated the efficacy of optimized DBS of the LH on increasing the RMR acutely and maintaining this increase during overnight sleep. These promising preliminary findings have laid the groundwork for the possible treatment of refractory obesity with DBS.
C1 [Whiting, Alexander C.; Walker, Corey T.; Godzik, Jakub; Catapano, Joshua S.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Sutton, Elizabeth F.; Ravussin, Eric] Pennington Biomed Res Ctr, Div Clin Sci, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
   [Oh, Michael Y.; Tomycz, Nestor D.; Whiting, Donald M.] Allegheny Hlth Network, Dept Neurosurg, Pittsburgh, PA 15212 USA.
RP Whiting, DM (reprint author), Allegheny Hlth Network, Dept Neurosurg, Pittsburgh, PA 15212 USA.
EM Donald.Whiting@ahn.org
OI Whiting, Alexander/0000-0002-4585-5219
CR Bandini LG, 2004, AM J CLIN NUTR, V80, P1262
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Chang SH, 2014, JAMA SURG, V149, P275, DOI 10.1001/jamasurg.2013.3654
   Chen T, 2017, J NEUROSURG, V127, P360, DOI 10.3171/2016.6.JNS152946
   Christou NV, 2006, ANN SURG, V244, P734, DOI 10.1097/01.sla.0000217592.04061.d5
   Compher C, 2006, J AM DIET ASSOC, V106, P881, DOI 10.1016/j.jada.2006.02.009
   Fenoy AJ, 2014, J NEUROSURG, V120, P132, DOI 10.3171/2013.10.JNS131225
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   Gloy VL, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5934
   Gobbi DG, 2003, COMPUT MED IMAG GRAP, V27, P255, DOI 10.1016/S0895-6111(02)00091-5
   Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165
   Halpern CH, 2013, J NEUROSCI, V33, P7122, DOI 10.1523/JNEUROSCI.3237-12.2013
   HARRELL LE, 1975, PHYSIOL BEHAV, V15, P133, DOI 10.1016/0031-9384(75)90292-9
   HERBERG LJ, 1967, SCIENCE, V155, P349, DOI 10.1126/science.155.3760.349
   KEESEY RE, 1973, AM J PHYSIOL, V224, P970
   Kupsch A, 2006, NEW ENGL J MED, V355, P1978, DOI 10.1056/NEJMoa063618
   Lam YY, 2017, EUR J CLIN NUTR, V71, P318, DOI 10.1038/ejcn.2016.220
   Lam YY, 2014, AM J CLIN NUTR, V99, P834, DOI 10.3945/ajcn.113.079566
   Mai K. M., 2004, ATLAS HUMAN BRAIN
   Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Nowicki EM, 2003, MIL MED, V168, P252
   Ogden CL, 2016, JAMA-J AM MED ASSOC, V315, P2292, DOI 10.1001/jama.2016.6361
   RAVUSSIN E, 1993, INT J OBESITY, V17, pS28
   RAVUSSIN E, 1993, INT J OBES RELAT S3, V17, pS41
   Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309
   REINHOLD RB, 1982, SURG GYNECOL OBSTET, V155, P385
   Rosenbaum M, 1988, Adv Pediatr, V35, P73
   Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606
   Rui LY, 2013, REV ENDOCR METAB DIS, V14, P387, DOI 10.1007/s11154-013-9261-9
   Sani S, 2007, J NEUROSURG, V107, P809, DOI 10.3171/JNS-07/10/0809
   Torres N, 2012, INT J OBESITY, V36, P1537, DOI 10.1038/ijo.2011.271
   WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Whiting DM, 2013, J NEUROSURG, V119, P56, DOI 10.3171/2013.2.JNS12903
NR 37
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E867
EP E874
DI 10.1016/j.wneu.2018.10.002
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000107
PM 30315980
DA 2020-05-12
ER

PT J
AU Wu, XH
   Zhang, S
   Cheng, ZH
   Aung, TT
   Fang, YJ
   Li, CG
AF Wu, Xiaohua
   Zhang, Sheng
   Cheng, Zhonghao
   Aung, Tin Tun
   Fang, Yuanjian
   Li, Chenguang
TI Comparison of Supraorbital and Pterional Keyhole Approach for Clipping
   Middle Cerebral Artery Aneurysm: A Chinese Population-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Efficacy; Keyhole approach; Middle cerebral artery aneurysm;
   Safety
ID SURGICAL-TREATMENT; RISK-FACTORS; RUPTURE
AB OBJECTIVE: Keyhole craniotomy is a minimally invasive approach for the treatment of middle cerebral artery (MCA) aneurysms. The aim of this study was to compare the clinical outcome between supraorbital keyhole approach and pterional keyhole approach (PKA) in Chinese patients with MCA aneurysm.
   METHODS: Consecutive patients with MCA aneurysms were reviewed between January 2013 and December 2017. Efficacy and safety between PKA and supraorbital keyhole approach were compared. Poor outcome was defined as modified Rankin Scale score of 3-6 at discharge.
   RESULTS: This study enrolled 260 patients; 222 (85.4%) had ruptured aneurysm, and 183 (70.4%) received PKA. The distribution of PKA in unruptured and ruptured aneurysms showed no significant difference (P > 0.05). In subgroup analyses, PKA was more likely associated with poor outcome at discharge in patients with unruptured aneurysms (odds ratio = 5.500, 95% confidence interval = 1.013-29.850, P = 0.048), whereas approach selection was not an independent factor predicting poor outcome in patients with ruptured aneurysms (P > 0.05).
   CONCLUSIONS: In a Chinese population, supraorbital keyhole approach was superior to PKA in improving outcome in patients with unruptured MCA aneurysms, but the 2 approaches showed comparable outcomes at discharge in patients with ruptured aneurysms.
C1 [Wu, Xiaohua; Cheng, Zhonghao; Fang, Yuanjian; Li, Chenguang] Zhejiang Univ, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Sheng] Peoples Hosp Hangzhou, Zhejiang Prov Peoples Hosp, Med Coll, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
   [Aung, Tin Tun] Univ Med 1, Dept Neurol, Yangon, Myanmar.
RP Li, CG (reprint author), Zhejiang Univ, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
EM 2315084@zju.edu.cn
RI , 方远坚/AAH-1971-2020
OI Fang, Yuanjian/0000-0002-0035-6045
CR Avdic T, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007618
   Cha KC, 2012, J KOREAN NEUROSURG S, V51, P334, DOI 10.3340/jkns.2012.51.6.334
   Chalouhi N, 2013, NEUROSURGERY, P441
   Chalouhi N, 2013, NEUROSURGERY, V72, P437, DOI 10.1227/NEU.0b013e3182804e9c
   Choi YJ, 2016, J KOREAN NEUROSURG S, V59, P564, DOI 10.3340/jkns.2016.59.6.564
   de Vos LC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012584
   Dua MM, 2010, SURGERY, V148, P429, DOI 10.1016/j.surg.2010.05.014
   Elsharkawy A, 2013, NEUROSURGERY, V73, P94, DOI 10.1227/01.neu.0000429842.61213.d5
   Golledge J, 2008, EUR HEART J, V29, P665, DOI 10.1093/eurheartj/ehm557
   Inagawa T, 2010, WORLD NEUROSURG, V73, P155, DOI 10.1016/j.surneu.2009.03.007
   Lan Q, 2017, WORLD NEUROSURG, V102, P350, DOI 10.1016/j.wneu.2017.02.025
   Nussbaum ES, 2019, J NEUROSURG, V130, P1498, DOI 10.3171/2018.1.JNS172466
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Perneczky A, 1998, NEUROSURGERY, V42, P24
   Tada Y, 2014, STROKE, V45, P579, DOI 10.1161/STROKEAHA.113.003072
   Tanaka T, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003062
   Tang C, 2013, TURK NEUROSURG, V23, P434, DOI 10.5137/1019-5149.JTN.6160-12.1
   Wang GX, 2018, INDIAN J MED RES, V147, P51, DOI 10.4103/ijmr.IJMR_1665_15
   Yamahata H, 2014, NEUROSURG REV, V37, P629, DOI 10.1007/s10143-014-0562-6
   Zhang QH, 2015, RESTOR NEUROL NEUROS, V33, P771, DOI 10.3233/RNN-150531
NR 20
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E596
EP E604
DI 10.1016/j.wneu.2018.09.174
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000073
PM 30292031
DA 2020-05-12
ER

PT J
AU Xu, CP
   Yu, T
   Zhang, GJ
   Wang, YP
   Li, YJ
AF Xu, Cuiping
   Yu, Tao
   Zhang, Guojun
   Wang, Yuping
   Li, Yongjie
TI Prognostic Factors and Longitudinal Change in Long-Term Outcome of
   Frontal Lobe Epilepsy Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute postoperative seizure; Epilepsy surgery; Frontal lobe epilepsy;
   Seizure outcome
ID CLINICAL CHARACTERISTICS; EEG; PREDICTS; SEIZURES; CHILDREN
AB OBJECTIVE: We aimed to investigate the possible predictive factors and longitudinal change in long-term surgical outcome after refractory frontal lobe epilepsy surgery.
   METHODS: We retrospectively reviewed 82 patients who underwent frontal lobe resection. Invasive monitoring was performed in 43 patients. All patients were followed-up for a minimum of 3 years after surgery. Univariate and multivariate analyses were used to evaluate the predictors. The Kaplan-Meier survival curve showed the estimated probability of complete seizure freedom, and a favorable outcome was defined as Engel class I at the last follow-up.
   RESULTS: The estimated probability of complete seizure freedom was 57.3% at 1 year postoperatively, 51.2% at 2 years, and 50.0% at 5 years. Factors predictive of worse long-term outcome were lack of a lesion in the frontal lobe on magnetic resonance imaging, generalized/nonlocalized ictal discharge, use of subdural grids, and acute postoperative seizure (APOS). After the surgery, 44 patients (53.7%) had seizures at any time during the first 2 years. Five of 44 patients had seizure freedom at the last follow-up. After a seizure-free period of at least 6 months, seizure recurred in 6 patients by 6 months to 1 year (early recurrence) and in 9 patients by 1-3 years (late recurrence). Eight of 43 (18.6%) seizure-free patients had discontinued drugs.
   CONCLUSIONS: The overall seizure outcome after surgery changed most during the first 2 years. The presence of frontal focal lesions and ictal frontal rhythm predicted favorable outcome. However, APOS was predictive of early epilepsy recurrence.
C1 [Xu, Cuiping; Yu, Tao; Zhang, Guojun; Li, Yongjie] Capital Med Univ, Xuanwu Hosp, Dept Funct Neurosurg, Beijing, Peoples R China.
   [Wang, Yuping] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.
   [Xu, Cuiping; Yu, Tao; Zhang, Guojun; Li, Yongjie] Capital Med Univ, Beijing Inst Funct Neurosurg, Xuanwu Hosp, Beijing, Peoples R China.
RP Yu, T (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Funct Neurosurg, Beijing, Peoples R China.; Yu, T (reprint author), Capital Med Univ, Beijing Inst Funct Neurosurg, Xuanwu Hosp, Beijing, Peoples R China.
EM yutaoly@sina.com
FU National Scientific Foundation of ChinaNational Natural Science
   Foundation of China [81771395]
FX This work was supported by the National Scientific Foundation of China
   (81771395).
CR Bautista RED, 1998, NEUROLOGY, V50, P1765
   Boesebeck F, 2002, BRAIN, V125, P2320, DOI 10.1093/brain/awf236
   Chung CK, 2005, EPILEPSIA, V46, P25, DOI 10.1111/j.0013-9580.2005.461008.x
   Elsharkawy AE, 2008, EPILEPSY RES, V81, P97, DOI 10.1016/j.eplepsyres.2008.04.017
   ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P949, DOI 10.1136/jnnp.54.11.949
   Engel Jr J., 1993, SURG TREATMENT EPILE, P609
   Englot DJ, 2012, J NEUROSURG, V116, P1042, DOI 10.3171/2012.1.JNS111620
   FISH DR, 1993, EPILEPSIA, V34, P244, DOI 10.1111/j.1528-1157.1993.tb02405.x
   Holtkamp M, 2012, EPILEPSIA, V53, P1739, DOI 10.1111/j.1528-1167.2012.03600.x
   Janszky J, 2000, NEUROLOGY, V54, P1470, DOI 10.1212/WNL.54.7.1470
   Jeha LE, 2006, NEUROLOGY, V66, P1938, DOI 10.1212/01.wnl.0000219810.71010.9b
   Jeha LE, 2007, BRAIN, V130, P574, DOI 10.1093/brain/awl364
   Jobst BC, 2000, EPILEPSIA, V41, P1139, DOI 10.1111/j.1528-1157.2000.tb00319.x
   Kim CH, 2010, NEUROSURGERY, V67, P1222, DOI 10.1227/NEU.0b013e3181f2380b
   Kral T, 2001, CHILD NERV SYST, V17, P595, DOI 10.1007/s003810100497
   Lazow SP, 2012, EPILEPSIA, V53, P1746, DOI 10.1111/j.1528-1167.2012.03582.x
   Lee JJ, 2008, SEIZURE-EUR J EPILEP, V17, P514, DOI 10.1016/j.seizure.2008.01.007
   Luders H, 1998, EPILEPSIA, V39, P1006, DOI 10.1111/j.1528-1157.1998.tb01452.x
   Mosewich RK, 2000, EPILEPSIA, V41, P843, DOI 10.1111/j.1528-1157.2000.tb00251.x
   Norden AD, 2002, EPILEPSY BEHAV, V3, P219, DOI 10.1016/S1525-5050(02)00029-X
   Pinheiro-Martins AP, 2012, EPILEPSY RES, V99, P55, DOI 10.1016/j.eplepsyres.2011.10.008
   RASMUSSEN T, 1991, CAN J NEUROL SCI, V18, P606, DOI 10.1017/S0317167100032819
   Schramm J, 2002, NEUROSURGERY, V51, P644, DOI 10.1097/00006123-200209000-00008
   Simasathien T, 2013, ANN NEUROL, V73, P646, DOI 10.1002/ana.23862
   Sperling MR, 2003, CURRENT PRACTICE CLI, P639
   Tigaran S, 2003, EPILEPSIA, V44, P831, DOI 10.1046/j.1528-1157.2003.56402.x
   WIESER HG, 1995, ADV NEUROL, V66, P297
   Worrell GA, 2002, EPILEPSIA, V43, P277, DOI 10.1046/j.1528-1157.2002.37501.x
   Yun CH, 2006, EPILEPSIA, V47, P574, DOI 10.1111/j.1528-1167.2006.00470.x
NR 29
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E32
EP E38
DI 10.1016/j.wneu.2018.08.192
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000006
PM 30189301
DA 2020-05-12
ER

PT J
AU Xu, F
   Gu, JJ
   Ni, W
   Xu, Q
   Gu, YX
   Leng, B
AF Xu, Feng
   Gu, Jianjun
   Ni, Wei
   Xu, Qiang
   Gu, Yuxiang
   Leng, Bing
TI Endovascular Treatment of Transverse-Sigmoid Sinus Dural Arteriovenous
   Fistulas: A Single-Center Experience with Long-Term Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon; Dural arteriovenous fistula; Embolization; Endovascular;
   Transvenous; Transverse-sigmoid sinus
ID TRANSARTERIAL ONYX EMBOLIZATION; MANAGEMENT; BALLOON
AB BACKGROUND: Endovascular treatment of transversee sigmoid sinus dural arteriovenous fistulas (TSDAVFs) remains challenging because of their complex anatomic factors. The aim of our study was to evaluate the long-term efficacy and safety of endovascular treatment of TSDAVFs.
   METHODS: From January 2008 to December 2014, 44 patients with TSDAVFs were treated endovascularly at our institution. The clinical and angiographic data were retrospectively collected, and the occlusion rate, complications, and clinical outcomes were analyzed.
   RESULTS: Overall, 44 patients (26 males and 18 females) were identified, with a mean age of 47 years (range, 13-68 years). Of the 44 patients, 5 presented with Cognard type I fistula, 12 with type IIa, 6 with type IIb, 13 with type IIaDIIb, 2 with type III, and 6 with type IV. Complete (n = 29) or nearcomplete (n = 7) occlusion of the fistula was achieved in 36 patients (82%). Two patients experienced a transient neurological deficit (cranial nerve VII). In 31 patients with angiographic follow-up (range, 2-40 months) data available, the occlusion remained in 25, 2 previously minimal residual fistulas were completely occluded, 3 residual fistulas were unchanged, and 1 fistula recurred. Two patients with cortical venous reflux who had received incomplete treatment died of intracranial hemorrhage during the followup period. Of the 37 patients with clinical follow-up (mean, 33.6 months) data available, clinical cure was achieved in 29, residual symptoms remained unchanged in 7, and symptoms had deteriorated in 1.
   CONCLUSIONS: Favorable and durable outcomes were achieved with endovascular treatment of TSDAVFs. TSDAVFs with cortical venous reflux carry a high risk of hemorrhage and require curative treatment.
C1 [Xu, Feng; Ni, Wei; Gu, Yuxiang; Leng, Bing] Fudan Univ, Huashan Hosp, Shanghai Med Sch, Dept Neurosurg, Shanghai, Peoples R China.
   [Xu, Qiang] Fudan Univ, Huashan Hosp, Shanghai Med Sch, Dept Radiol, Shanghai, Peoples R China.
   [Xu, Feng] Kashgar Prefecture Second Peoples Hosp, Dept Neurosurg, Kashgar, Peoples R China.
   [Gu, Jianjun] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
RP Gu, YX (reprint author), Fudan Univ, Huashan Hosp, Shanghai Med Sch, Dept Neurosurg, Shanghai, Peoples R China.
EM guyuxiang1972@126.com
OI Gu, Yuxiang/0000-0002-4580-2205
FU National Ministry of Science and Technology [2016YFC1301704]
FX The present study was supported by the National Ministry of Science and
   Technology (grant 2016YFC1301704).
CR Alturki AY, 2018, WORLD NEUROSURG, V109, P398, DOI 10.1016/j.wneu.2017.10.083
   Ambekar S, 2016, J NEUROSURG, V124, P1123, DOI 10.3171/2015.3.JNS1558
   Bink A, 2011, NEURORADIOLOGY, V53, P493, DOI 10.1007/s00234-010-0754-x
   Carlson AP, 2013, J NEUROINTERV SURG, V5, P566, DOI 10.1136/neurintsurg-2012-010497
   Chandra RV, 2014, AM J NEURORADIOL, V35, P1793, DOI 10.3174/ajnr.A3938
   Choi BJ, 2009, NEUROSURGERY, V65, P994, DOI 10.1227/01.NEU.0000351772.45417.92
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Dawson RC, 1998, AM J NEURORADIOL, V19, P571
   de Paula Lucas C, 2007, NEUROSURGERY, V61, P293, DOI 10.1227/01.neu.0000303981.34622.39
   Duffau H, 1999, J NEUROSURG, V90, P78, DOI 10.3171/jns.1999.90.1.0078
   Eftekhar B, 2013, J CLIN NEUROSCI, V20, P532, DOI 10.1016/j.jocn.2012.05.035
   Endo S, 1998, J NEUROSURG, V88, P449, DOI 10.3171/jns.1998.88.3.0449
   Ertl Lorenz, 2017, J Neurosurg, V126, P360, DOI 10.3171/2016.2.JNS152081
   GOBIN YP, 1993, AM J NEURORADIOL, V14, P1102
   Gross BA, 2017, J NEUROSURG, V126, P1884, DOI 10.3171/2016.5.JNS16331
   Guo F, 2018, WORLD NEUROSURG, V116, pE203, DOI 10.1016/j.wneu.2018.04.163
   HALBACH VV, 1989, AM J NEURORADIOL, V10, P385
   Irie K, 2001, J CLIN NEUROSCI, V8, P92, DOI 10.1054/jocn.2001.0886
   Jittapiromsak P, 2013, NEURORADIOLOGY, V55, P345, DOI 10.1007/s00234-012-1107-8
   Kerolus MG, 2018, J NEUROSURG, V129, P922, DOI 10.3171/2017.5.JNS17287
   Kim MS, 2002, J CLIN NEUROSCI, V9, P147, DOI 10.1054/jocn.2001.1029
   Kirsch M, 2009, NEURORADIOLOGY, V51, P477, DOI 10.1007/s00234-009-0524-9
   Komiyama M, 2002, ACTA NEUROCHIR, V144, P1041, DOI 10.1007/s00701-002-0997-3
   Liebig T, 2005, NEURORADIOLOGY, V47, P543, DOI 10.1007/s00234-005-1377-5
   Lv XL, 2010, WORLD NEUROSURG, V74, P297, DOI 10.1016/j.wneu.2010.02.063
   Lv XL, 2008, NEURORADIOL J, V21, P579, DOI 10.1177/197140090802100418
   Mantilla D, 2018, J NEUROINTERV SURG, V10, P958, DOI 10.1136/neurintsurg-2017-013476
   Naito I, 2001, NEURORADIOLOGY, V43, P672, DOI 10.1007/s002340100550
   OlteanuNerbe V, 1997, ACTA NEUROCHIR, V139, P307, DOI 10.1007/BF01808826
   Piechowiak E, 2017, AM J NEURORADIOL, V38, P1984, DOI 10.3174/ajnr.A5333
   Rangel-Castilla L, 2014, J NEUROINTERV SURG, V6, P607, DOI 10.1136/neurintsurg-2013-010894
   Sadeh-Gonike U, 2018, NEUROSURGERY, V82, P854, DOI 10.1093/neuros/nyx309
   Satomi J, 2002, J NEUROSURG, V97, P767, DOI 10.3171/jns.2002.97.4.0767
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Wong GKC, 2007, ACTA NEUROCHIR, V149, P929, DOI 10.1007/s00701-007-1264-4
   Xu B, 2012, CHIN J CEREBROVASC D, V9, P206
   Zipfel GJ, 2009, NEUROSURG FOCUS, V26, pE9
NR 37
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E441
EP E448
DI 10.1016/j.wneu.2018.09.136
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000055
PM 30267946
DA 2020-05-12
ER

PT J
AU Xu, KH
   Lou, Y
   Sun, R
   Liu, YJ
   Li, B
   Li, JL
   Huang, Q
   Wan, W
   Xiao, JR
AF Xu, Kehan
   Lou, Yan
   Sun, Rui
   Liu, Yujie
   Li, Bo
   Li, Jialin
   Huang, Quan
   Wan, Wei
   Xiao, Jianru
TI Establishment of a Nomogram-Based Model for Predicting the Prognostic
   Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in
   Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE D-dimer; Ewing's sarcoma family tumors; Inflammatory biomarker;
   Nomogram; Prognosis; Spinal
ID COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; SURVIVAL; FIBRINOGEN; RISK
AB BACKGROUND: Ewing's sarcoma family tumors (ESFTs) are the second most common malignancy in children and adolescents. The purpose of the present retrospective study was to evaluate the prognostic role of inflammatory biomarkers and preoperative D-dimer levels in patients with spinal ESFTs.
   METHODS: The neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, albumin/globulin ratio, C-reactive protein/albumin ratio (CAR), preoperative D-dimer level, and clinical parameters were evaluated and analyzed. Univariate and multivariate analyses for disease-free survival (DFS) and overall survival (OS) were performed using the log-rank test and Cox regression analysis, respectively. The DFS and OS rates were calculated using the Kaplan-Meier method. Nomograms were established to predict DFS and OS quantitatively.
   RESULTS: The optimal cutoff values for D-dimer, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, CAR, and albumin/globulin ratio were 0.3, 3.2, 168, 2.2, 1.5, and 1.4, respectively. The patients were stratified into 2 groups according to the cutoff values. Multivariate analysis revealed that age, resection mode, and D-dimer level were favorable prognostic factors for DFS and OS (P < 0.05). Metastasis and CAR < 1.5 were significantly associated with OS (P < 0.05). Nomograms with all significant factors were established to predict DFS and OS.
   CONCLUSIONS: Our results have indicated that the preoperative D-dimer level is an effective prognostic factor with discriminatory ability for DFS and OS, superior to other indicators. Also, CAR was favorable prognostic factor for OS. Nomograms of DFS and OS can be recommended as practical models to evaluate the prognosis for patients with spinal ESFTs.
C1 [Xu, Kehan; Lou, Yan; Liu, Yujie; Li, Bo; Li, Jialin; Huang, Quan; Wan, Wei; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China.
   [Sun, Rui] Nanjing Med Univ, Dept Neurol, Jinling Clin Coll, Nanjing, Jiangsu, Peoples R China.
RP Xiao, JR (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China.
EM jianruxiao83@smmu.edu.cn
CR Ahmed SK, 2017, INT J RADIAT ONCOL, V99, P1286, DOI 10.1016/j.ijrobp.2017.08.020
   Arpaci E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0469-z
   Batschauer APB, 2010, ANN ONCOL, V21, P1267, DOI 10.1093/annonc/mdp474
   Bobdey S, 2016, HEAD NECK-J SCI SPEC, V38, P1826, DOI 10.1002/hed.24507
   Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96
   Caceres S, 2016, BIOMED RES INT, DOI 10.1155/2016/8909878
   Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108, DOI 10.1200/JCO.2000.18.17.3108
   Dihge L, 2017, BRIT J SURG, V104, P1494, DOI 10.1002/bjs.10583
   Frankel H L, 1969, Paraplegia, V7, P179
   Galyfos G, 2016, INDIAN J SURG, V78, P49, DOI 10.1007/s12262-015-1399-0
   Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256
   Gu LY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23846
   He CB, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4240-x
   Hirahara N, 2016, BMC SURG, V16, DOI 10.1186/s12893-016-0179-5
   Hobusch GM, 2014, CLIN ORTHOP RELAT R, V472, P3471, DOI 10.1007/s11999-014-3777-5
   Hong TT, 2017, CANCER BIOMARK, V19, P103, DOI 10.3233/CBM-160510
   Ilaslan H, 2004, SKELETAL RADIOL, V33, P506, DOI 10.1007/s00256-004-0810-x
   Jess T, 2012, GASTROENTEROLOGY, V143, P375, DOI 10.1053/j.gastro.2012.04.016
   Kaseda K, 2017, J CARDIOTHORAC SURG, V12, DOI 10.1186/s13019-017-0676-3
   Lee CY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003830
   Li JXJL, 2017, WORLD NEUROSURG, V104, P628, DOI 10.1016/j.wneu.2017.05.071
   Li JL, 2017, ONCOTARGET, V8, P86934, DOI 10.18632/oncotarget.21168
   Li YQ, 2016, INT J CANCER, V139, P220, DOI 10.1002/ijc.30071
   Li YJ, 2017, CANCER MANAG RES, V9, P443, DOI 10.2147/CMAR.S146827
   Liu ZK, 2017, HEPATOL RES, V47, P1108, DOI 10.1111/hepr.12848
   Mbeutcha A, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.05.013
   McCourt M, 2001, EUR J SURG ONCOL, V27, P396, DOI 10.1053/ejso.2001.1133
   Raj SD, 2012, AM J CLIN ONCOL-CANC, V35, P462, DOI 10.1097/COC.0b013e31821d4529
   Samartzis D, 2005, SPINE, V30, P831, DOI 10.1097/01.brs.0000158226.49729.6c
   Shen JY, 2017, GUT LIVER, V11, P684, DOI 10.5009/gnl16465
   Song SH, 2016, EUR RADIOL, V26, P1538, DOI 10.1007/s00330-015-4029-0
   Suega Ketut, 2011, Acta Med Indones, V43, P162
   Tomas I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06674-2
   Venkateswaran L, 2001, MED PEDIATR ONCOL, V37, P30, DOI 10.1002/mpo.1159
   Wan W, 2017, J NEURO-ONCOL, V131, P313, DOI 10.1007/s11060-016-2295-6
   Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984
   Watanabe A, 2016, ANN SURG ONCOL, V23, pS886, DOI 10.1245/s10434-016-5422-x
   Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703
NR 38
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E96
EP E104
DI 10.1016/j.wneu.2018.09.022
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000014
PM 30218803
DA 2020-05-12
ER

PT J
AU Yamada, E
   Ishikawa, E
   Watanabe, R
   Matsumura, H
   Sakamoto, N
   Ishii, A
   Tamaoka, A
   Hattori, K
   Obara, N
   Chiba, S
   Nakamagoe, K
   Matsuda, M
   Tsurubuchi, T
   Tomidokoro, Y
   Akutsu, H
   Zaboronok, A
   Shibuya, M
   Takano, S
   Matsumura, A
AF Yamada, Erika
   Ishikawa, Eiichi
   Watanabe, Rei
   Matsumura, Hideaki
   Sakamoto, Noriaki
   Ishii, Akiko
   Tamaoka, Akira
   Hattori, Keiichiro
   Obara, Naoshi
   Chiba, Shigeru
   Nakamagoe, Kiyotaka
   Matsuda, Masahide
   Tsurubuchi, Takao
   Tomidokoro, Yasushi
   Akutsu, Hiroyoshi
   Zaboronok, Alexander
   Shibuya, Makoto
   Takano, Shingo
   Matsumura, Akira
TI Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell
   Lymphoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intravascular large B-cell lymphoma; Plasma soluble interleukin-2
   receptor; Random skin biopsies
ID MANAGEMENT
AB OBJECTIVE: To evaluate effectiveness of random skin biopsies for intravascular large B-cell lymphoma (IVLBCL) with or without central nervous system (CNS) involvement.
   METHODS: Data from 21 patients with suspected IVLBCL (7 with CNS involvement and 14 without CNS involvement) who underwent single (4 patients), double (1 patient), and random (16 patients) skin biopsies were retrospectively analyzed.
   RESULTS: IVLBCL was diagnosed in 16 patients (including 6 with CNS involvement). Sensitivity, specificity, and positive predictive value of random skin biopsies were 75%, 100%, and 100%. Ratio of tumor-positive biopsy samples to plasma soluble interleukin-2 receptor (sIL-2R) values was significantly correlated in cases with data on both variables. sIL-2R values in the 6 tumor-negative skin samples (median, 1415 U/mL; range, 487-3200 U/mL) were significantly lower than in tumor-positive skin samples (median, 3550 U/mL; range, 595-8700 U/mL) with at least 1 skin specimen obtained. Mean ratio of tumor-positive biopsy samples in IVLBCL cases with low sIL-2R (< 3000 U/mL) was only 45%, indicating a requirement for 3-site multiple sampling. No differences in median sIL-2 values between cases of IVLBCL with and without CNS involvement were found (2795 U/mL vs. 3550 U/mL). Steroids administered before diagnosis yielded false-negative results in 3 of 5 IVLBCL cases (all false-negative cases were IVLBCL with CNS involvement), whereas none of 11 IVLBCL cases without steroid administration yielded false-negative results.
   CONCLUSIONS: Random skin biopsies before brain biopsy are recommended in patients with suspected IVLBCL regardless of CNS involvement, but low sIL-2R values and steroids may yield false-negative results.
C1 [Yamada, Erika; Ishikawa, Eiichi; Matsumura, Hideaki; Matsuda, Masahide; Tsurubuchi, Takao; Akutsu, Hiroyoshi; Zaboronok, Alexander; Takano, Shingo; Matsumura, Akira] Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
   [Watanabe, Rei] Univ Tsukuba, Dept Dermatol, Fac Med, Tsukuba, Ibaraki, Japan.
   [Sakamoto, Noriaki] Univ Tsukuba, Dept Diagnost Pathol, Fac Med, Tsukuba, Ibaraki, Japan.
   [Ishii, Akiko; Tamaoka, Akira; Nakamagoe, Kiyotaka; Tomidokoro, Yasushi] Univ Tsukuba, Dept Neurol, Fac Med, Tsukuba, Ibaraki, Japan.
   [Hattori, Keiichiro; Obara, Naoshi; Chiba, Shigeru] Univ Tsukuba, Dept Hematol, Fac Med, Tsukuba, Ibaraki, Japan.
   [Shibuya, Makoto] Tokyo Med Univ, Cent Lab, Hachioji Med Ctr, Tokyo, Japan.
RP Ishikawa, E (reprint author), Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
EM e-ishikawa@md.tsukuba.ac.jp
RI Zaboronok, Alexander/W-4119-2019
OI ying ming, song cun/0000-0002-1638-9415
CR Kraus MD, 1999, AM J MED, V107, P169, DOI 10.1016/S0002-9343(99)00191-6
   Matsue K, 2011, ANN HEMATOL, V90, P417, DOI 10.1007/s00277-010-1101-3
   Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253
   Orwat DE, 2012, ARCH PATHOL LAB MED, V136, P333, DOI 10.5858/arpa.2010-0747-RS
   PFLEGER L, 1959, Hautarzt, V10, P359
   Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313
   Shimada K, 2008, J CLIN ONCOL, V26, P3189, DOI 10.1200/JCO.2007.15.4278
   Shimada K, 2009, LANCET ONCOL, V10, P895, DOI 10.1016/S1470-2045(09)70140-8
   Suehara Y, 2018, HAEMATOLOGICA, V103, pE241, DOI 10.3324/haematol.2017.178830
   Williams RL, 1998, AM J NEURORADIOL, V19, P427
NR 10
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E364
EP E369
DI 10.1016/j.wneu.2018.09.110
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000045
PM 30261371
DA 2020-05-12
ER

PT J
AU Yamahata, H
   Sugata, J
   Mori, M
   Niiro, T
   Yonenaga, M
   Yamaguchi, S
   Hiwatari, T
   Okada, T
   Arita, K
   Yoshimoto, K
AF Yamahata, Hitoshi
   Sugata, Jun
   Mori, Masanao
   Niiro, Tadaaki
   Yonenaga, Masanori
   Yamaguchi, Satoshi
   Hiwatari, Takaaki
   Okada, Tomohisa
   Arita, Kazunori
   Yoshimoto, Koji
TI Measurement of Cervical Sagittal Alignment Parameters on X-Ray Films of
   Adults without Severe Spinal Deformity Whose Shoulder Hides the Lower
   Cervical Column
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical alignment; Cobb angle; Endplate; Measurement
ID T1 SLOPE; BALANCE; AGE
AB OBJECTIVE: The Cobb angle between the lower endplate of C2 and C7 (C2L-C7L angle) is a traditional parameter used for the assessment of the cervical alignment. However, when the lower cervical column is masked by the shoulder, measurements are difficult. In the present study, we inspected 191 X-ray films, measured the Cobb angle between C2L and the endplates at the several levels of the lower cervical column, and assessed their usefulness of such measurements for the determination of cervical sagittal alignment.
   METHODS: We obtained X-ray films on 191 patients ranging in age from 20 to 93 years. The Cobb angle between C2L and the C7 upper (C7U), the C6 lower (C6L), the C6 upper (C6U), and the C5 lower endplate (C5L) was measured and compared with the C2L-C7L angle.
   RESULTS: C7L was identified in 116 of 191 patients (60.7%). Except for C2L-C7U angle (P = 0.55), the difference in the mean between C2L-C7L angle and the angle between C2L and the other endplates was statistically significant (P < 0.05). There was a very strong correlation between C2L-C7L angle and C2L-C7U angle (r = 0.99), C2L-C6L angle (r = 0.96), C2L-C6U angle (r = 0.94), and C2L-C5L angle (r = 0.86).
   CONCLUSIONS: To measure the C2L-C7L angle on unclear X-ray films, C7U can be substituted for C7L. Our measurement data for the C6 and C5 endplates were statistically different; however, the correlation between the C2L-C7L angle and C2L-C6U angle, C2L-C6L angle or C2L-C5L angle was very strong. In patients with unclear lower vertebral bodies, cervical sagittal alignment can be predicted by using adjacent endplates.
C1 [Yamahata, Hitoshi; Sugata, Jun; Mori, Masanao; Niiro, Tadaaki; Yonenaga, Masanori; Hiwatari, Takaaki; Okada, Tomohisa; Arita, Kazunori; Yoshimoto, Koji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
   [Yamaguchi, Satoshi] Hiroshima Univ, Dept Neurosurg, Grad Sch Biomed Sci, Hiroshima, Japan.
RP Yamahata, H (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
EM yamahata-nsu@umin.net
RI Okada, Tomohisa/C-5939-2008
OI Yamaguchi, Satoshi/0000-0001-9670-005X
CR Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Harrison DE, 2000, SPINE, V25, P2072, DOI 10.1097/00007632-200008150-00011
   Hey HWD, 2017, SPINE J, V17, P799, DOI 10.1016/j.spinee.2016.03.056
   Jun HS, 2015, SPINE, V40, pE220, DOI 10.1097/BRS.0000000000000722
   Jun HS, 2014, SPINE, V39, pE630, DOI 10.1097/BRS.0000000000000281
   Knott PT, 2010, SPINE J, V10, P994, DOI 10.1016/j.spinee.2010.08.031
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Liu W, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008194
   Nunez-Pereira S, 2015, J NEUROSURG-SPINE, V23, P16, DOI 10.3171/2014.11.SPINE14368
   Oe S, 2015, SPINE, V40, P1487, DOI 10.1097/BRS.0000000000001071
   Park JH, 2013, J KOREAN NEUROSURG S, V53, P356, DOI 10.3340/jkns.2013.53.6.356
   Park MS, 2013, SPINE, V38, pE458, DOI 10.1097/BRS.0b013e31828802c2
   Rajshekhar V, 2003, NEUROSURGERY, V52, P799, DOI 10.1227/01.NEU.0000054218.50113.40
   Roussouly Pierre, 2011, Eur Spine J, V20 Suppl 5, P609, DOI 10.1007/s00586-011-1928-x
   Roussouly Pierre, 2011, Eur Spine J, V20 Suppl 5, P578, DOI 10.1007/s00586-011-1924-1
   Sasaki T, 1998, NEUROL MED-CHIR, V38, P83, DOI 10.2176/nmc.38.83
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Silber JS, 2004, J SPINAL DISORD TECH, V17, P301, DOI 10.1097/01.bsd.0000095824.98982.53
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
   Uchida K, 2009, J NEUROSURG-SPINE, V11, P521, DOI 10.3171/2009.2.SPINE08385
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E139
EP E145
DI 10.1016/j.wneu.2018.09.051
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000020
PM 30240860
DA 2020-05-12
ER

PT J
AU Yamakami, I
   Kubota, S
   Higuchi, Y
   Ito, S
AF Yamakami, Iwao
   Kubota, Shunsuke
   Higuchi, Yoshinori
   Ito, Seiro
TI Challenging Anterior Inferior Cerebellar Artery in Retrosigmoid
   Vestibular Schwannoma Removal
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Cerebellopontine angle;
   Complication; Tumor removal; Vestibular schwannoma
ID HEARING PRESERVATION; SUBARCUATE FOSSA; MIDDLE FOSSA; SURGERY; ORIGIN
AB OBJECTIVE: Referring to the anterior inferior cerebellar artery (AICA) traversing a cerebellopontine angle tumor during retrosigmoid vestibular schwannoma (VS) removal as a challenging AICA (c-AICA), we describe incidence, anatomic characteristics, mechanism of development of c-AICA, and surgical techniques used to remove VS while preserving the AICA.
   METHODS: Review of surgical records and videos of 150 patients who underwent retrosigmoid VS removal revealed 10 patients (7%) with c-AICAs. Retrospective analysis of these 10 patients was performed.
   RESULTS: Surgical findings classified c-AICAs as c-AICAs with subarcuate artery (SAA) and c-AICAs without SAA. In c-AICAs with SAA (7/10), the SAA had an anchoring effect in the development of the c-AICA. The most challenging c-AICAs (i.e., c-AICAs reaching the porus acusticus, entering the internal auditory canal, and adhering to the dura) were associated with short cisternal SAAs (4/7). We preserved the most challenging c-AICA with the surrounding dura by drilling the posterior wall to preserve the posterior wall dura. AICAs adhering to the porus acusticus dura were not associated with long cisternal SAAs. Sacrificing the SAA caused no neurologic deficits. c-AICAs were preserved in all patients, and tumors were removed with no complications related to AICAs.
   CONCLUSIONS: c-AICAs occur more often than expected. The anatomy of the SAA is related to the development and characteristics of c-AICAs. Although preserving a c-AICA is challenging and necessitates a complex dissecting technique, understanding of anatomic characteristics and appropriate surgical management of c-AICAs enable VS removal while preserving the AICA.
C1 [Yamakami, Iwao; Kubota, Shunsuke] Seikei Kai Chiba Med Ctr, Dept Neurosurg, Chiba, Japan.
   [Yamakami, Iwao] Chiba Cent Med Ctr, Dept Neurosurg, Chiba, Japan.
   [Higuchi, Yoshinori] Chiba Univ, Dept Neurosurg, Postgrad Sch Med, Chiba, Japan.
   [Ito, Seiro] Chiba Rosai Hosp, Dept Neurosurg, Ichihara, Chiba, Japan.
RP Yamakami, I (reprint author), Seikei Kai Chiba Med Ctr, Dept Neurosurg, Chiba, Japan.; Yamakami, I (reprint author), Chiba Cent Med Ctr, Dept Neurosurg, Chiba, Japan.
EM yamakami@seikeikai-cmc.jp
OI Higuchi, Yoshinori/0000-0001-5689-3416
CR ATKINSON WJ, 1949, J NEUROL NEUROSUR PS, V12, P137, DOI 10.1136/jnnp.12.2.137
   ECKERMEIER L, 1979, ARCH OHREN NASEN KEH, V222, P1, DOI 10.1007/BF00456332
   GOEL A, 1991, J NEUROSURG, V75, P985, DOI 10.3171/jns.1991.75.6.0985
   Hegarty JL, 2002, OTOL NEUROTOL, V23, P560, DOI 10.1097/00129492-200207000-00028
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   Kania RE, 2004, AURIS NASUS LARYNX, V31, P69, DOI 10.1016/j.anl.2003.09.007
   Malis L., 1998, ACOUSTIC NEUROMA
   MARTIN RG, 1980, NEUROSURGERY, V6, P483, DOI 10.1227/00006123-198005000-00001
   MAZZONI A, 1969, ANN OTO RHINOL LARYN, V78, P797, DOI 10.1177/000348946907800413
   MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P179
   Noudel R, 2009, ACTA NEUROCHIR, V151, P935, DOI 10.1007/s00701-009-0344-z
   RHOTON AL, 1968, J NEUROSURG, V29, P609, DOI 10.3171/jns.1968.29.6.0609
   Roosli C, 2012, AUDIOL NEURO-OTOL, V17, P121, DOI 10.1159/000331394
   Sameshima T, 2010, NEUROSURGERY, V67, P640, DOI 10.1227/01.NEU.0000374853.97891.FB
   Sampath P, 2000, J NEUROSURG, V92, P70, DOI 10.3171/jns.2000.92.1.0070
   STERKERS JM, 1987, ACTA OTO-LARYNGOL, V103, P427
   Tanriover N, 2005, NEUROSURGERY, V57, P314, DOI 10.1227/01.NEU.0000166677.70797.5E
   Tekdemir I, 1999, ANN ANAT, V181, P207, DOI 10.1016/S0940-9602(99)80009-0
   Warren DT, 2010, NEUROSURGERY, V66, pONS199, DOI 10.1227/01.NEU.0000369661.83373.33
   Yamakami I, 2000, NEUROL MED-CHIR, V40, P597, DOI 10.2176/nmc.40.597
   Yamakami I, 2009, J NEUROL NEUROSUR PS, V80, P218, DOI 10.1136/jnnp.2008.156919
   Yamakami I, 2014, J NEUROSURG, V121, P554, DOI 10.3171/2014.6.JNS132471
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E370
EP E378
DI 10.1016/j.wneu.2018.09.111
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000046
PM 30261396
DA 2020-05-12
ER

PT J
AU Yang, HS
   Xu, XM
   Shi, JG
   Guo, YF
   Sun, JC
   Shi, GD
   Wang, Y
AF Yang, Haisong
   Xu, Ximing
   Shi, Jiangang
   Guo, Yongfei
   Sun, Jingchuan
   Shi, Guodong
   Wang, Yuan
TI Anterior Controllable Antedisplacement Fusion as a Choice for
   Ossification of Posterior Longitudinal Ligament and Degenerative
   Kyphosis and Stenosis: Postoperative Morphology of Dura Mater and
   Probability Analysis of Epidural Hematoma Based on 63 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACAF; Anterior controllable antedisplacement fusion; Complications;
   Degenerative kyphosis and stenosis; DKS; Dura mater; Epidural hematoma;
   OPLL; Ossification of the posterior longitudinal ligament
ID 3 RECONSTRUCTIVE TECHNIQUES; SURGICAL-MANAGEMENT; CORPECTOMY; RISK;
   DECOMPRESSION; MYELOPATHY; STRATEGY
AB OBJECTIVE: We studied the postoperative morphology of the dura mater and analyzed the probability of epidural hematoma (EH) after anterior controllable antedisplacement and fusion (ACAF).
   METHODS: A total of 63 patients with a diagnosis of ossification of the posterior longitudinal ligament (OPLL) and degenerative kyphosis and stenosis (DKS) had undergone ACAF from 2016 to 2017. All these patients had undergone cervical plain films, computed tomography, and magnetic resonance imaging (MRI). The operation duration, blood loss, and hospital stay were estimated. Radiological assessments included the occupying rate, OPLL type and extent, kyphotic angle, decompression width, and postoperative area of the spinal canal. On sagittal MRI, the postoperative morphology of dura mater was observed. The Japanese Orthopaedic Association scoring system was used to evaluate neurological status. EH and other surgery-related complications were recorded.
   RESULTS: Of the 63 patients, 39 had OPLL and 24 had DKS. All the patients were followed up for 3-18 months (average, 12.5). The mean decompression width and postoperative spinal canal area were 18.7 +/- 1.1 mm and 167.7 +/- 34.6 mm(2) in the OPLL group and 17.9 +/- 0.9 mm and 263.1 +/- 46.9 mm(2) in the DKS group, respectively. On sagittal MRI, the dura mater was classified into 4 types according to its morphology (dune, ladder, wave, and mixed type), protecting the spinal cord as would a suspensory tent. No patient presented with EH. The mean postoperative Japanese Orthopaedic Association score at the last follow-up examination was significantly better than preoperatively.
   CONCLUSIONS: The dura mater can protect the spinal cord like a suspensory tent after ACAF. The occurrence of EH is rare when ACAF is used to treat OPLL and DKS.
C1 [Yang, Haisong; Xu, Ximing; Shi, Jiangang; Guo, Yongfei; Sun, Jingchuan; Shi, Guodong; Wang, Yuan] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM chzhshijg@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81650031]
FX The present study was supported by a grant from the National Natural
   Science Foundation of China (grant 81650031).
CR Al-Mutair A, 2010, J AM ACAD ORTHOP SUR, V18, P494, DOI 10.5435/00124635-201008000-00006
   An HS, 2014, J AM ACAD ORTHOP SUR, V22, P420, DOI 10.5435/JAAOS-22-07-420
   Awad JN, 2005, J BONE JOINT SURG BR, V87B, P1248, DOI 10.1302/0301-620X.87B9.16518
   Cardoso MJ, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10278
   Chen Y, 2011, J SPINAL DISORD TECH, V24, P24, DOI 10.1097/BSD.0b013e3181c7e91e
   Chen Y, 2009, INT ORTHOP, V33, P477, DOI 10.1007/s00264-008-0542-y
   Chen ZH, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS15596
   Grosso MJ, 2013, J NEUROSURG-SPINE, V18, P537, DOI 10.3171/2013.2.SPINE12525
   Guo QF, 2011, EUR SPINE J, V20, P1539, DOI 10.1007/s00586-011-1735-4
   Hou Y, 2017, ORTHOP TRAUMATOL-SUR, V103, P733, DOI 10.1016/j.otsr.2017.05.011
   Iwasaki M, 2007, SPINE, V32, P654, DOI 10.1097/01.brs.0000257566.91177.cb
   Kebaish KM, 2004, NEUROSURG FOCUS, V16, P1
   Kim B, 2015, SPINE J, V15, P875, DOI 10.1016/j.spinee.2015.01.028
   LAWTON MT, 1995, J NEUROSURG, V83, P1, DOI 10.3171/jns.1995.83.1.0001
   Li Z, 2017, SPINE, V42, pE575, DOI 10.1097/BRS.0000000000001907
   Liao CC, 2004, J NEUROSURG, V100, P38, DOI 10.3171/spi.2004.100.1.0038
   Lin QS, 2012, EUR SPINE J, V21, P474, DOI 10.1007/s00586-011-1961-9
   Liu WJ, 2016, THER CLIN RISK MANAG, V12, P675, DOI 10.2147/TCRM.S100046
   Liu Y, 2012, SPINE, V37, pE1450, DOI 10.1097/BRS.0b013e31826c72b4
   Matsunaga S, 2004, J NEUROSURG, V100, P245, DOI 10.3171/spi.2004.100.3.0245
   Mayr MT, 2002, J NEUROSURG, V96, P10, DOI 10.3171/spi.2002.96.1.0010
   Ozgen S, 2004, ACTA NEUROCHIR, V146, P1099, DOI 10.1007/s00701-004-0327-z
   Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10273
   Saetia K, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.11.FOCUS10276
   Sarkar S, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1638
   Sun JC, 2018, WORLD NEUROSURG, V113, pE101, DOI 10.1016/j.wneu.2018.01.181
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006421
   WHITE AA, 1990, CLIN BIOMECHANICS SP
   Wu JC, 2012, J NEUROTRAUM, V29, P462, DOI 10.1089/neu.2011.2095
   Yang HS, 2018, WORLD NEUROSURG, V118, pE562, DOI 10.1016/j.wneu.2018.06.239
   Yang HS, 2018, J CLIN NEUROSCI, V56, P21, DOI 10.1016/j.jocn.2018.08.014
   Yang HS, 2018, WORLD NEUROSURG, V115, pE501, DOI 10.1016/j.wneu.2018.04.078
   Yeh KT, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0280-y
   Yi S, 2006, YONSEI MED J, V47, P326, DOI 10.3349/ymj.2006.47.3.326
NR 34
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E954
EP E961
DI 10.1016/j.wneu.2018.10.052
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000118
PM 30326317
DA 2020-05-12
ER

PT J
AU Yi, JL
   Porucznik, CA
   Gren, LH
   Guan, J
   Joyce, E
   Brodke, DS
   Dailey, AT
   Mahan, MA
   Hood, RS
   Lawrence, BD
   Spiker, WR
   Spina, NT
   Bisson, EF
AF Yi, Juneyoung L.
   Porucznik, Christina A.
   Gren, Lisa H.
   Guan, Jian
   Joyce, Evan
   Brodke, Darrel S.
   Dailey, Andrew T.
   Mahan, Mark A.
   Hood, Robert S.
   Lawrence, Brandon D.
   Spiker, William R.
   Spina, Nicholas T.
   Bisson, Erica F.
TI The Impact of Preoperative Mindfulness-Based Stress Reduction on
   Postoperative Patient-Reported Pain, Disability, Quality of Life, and
   Prescription Opioid Use in Lumbar Spine Degenerative Disease: A Pilot
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative disease; Lumbar spine surgery; Mindfulness-based stress
   reduction; Patient-reported outcomes; Prescription opioids
ID LOW-BACK-PAIN; COGNITIVE-BEHAVIORAL THERAPY; MIND-BODY PROGRAM;
   UNITED-STATES; OLDER-ADULTS; ORGAN TRANSPLANT; NATIONAL TRENDS; FUSION
   SURGERY; DISC DISEASE; CARE
AB BACKGROUND: Prescription opioid medications negatively affect postoperative outcomes after lumbar spine surgery. Furthermore, opioid-related overdose death rates in the United States increased by 200% between 2000 and 2014. Thus, alternatives are imperative. Mindfulness-based stress reduction (MBSR), a mind-body therapy, has been associated with improved activity and mood in opioidusing patients with chronic pain. This study assessed whether preoperative MBSR is an effective adjunct to standard postoperative care in adult patients undergoing lumbar spine surgery for degenerative disease.
   METHODS: The intervention group underwent a preoperative online MBSR course. The comparison group was matched retrospectively in a 1: 1 ratio by age, sex, type of surgery, and preoperative opioid use. Prescription opioid use during hospital admission and at 30 days postoperatively were compared with preoperative use. Thirty-day postoperative patient-reported outcomes for pain, disability, and quality of life were compared with preoperative patient-reported outcomes. Dose-response effect of mindfulness courses was assessed using Mindful Attention Awareness Scale scores.
   RESULTS: In this pilot study, 24 participants were included in each group. Most intervention patients (70.83%) completed 1 session, and the mean Mindful Attention Awareness Scale score was 4.28 +/- 0.71 during hospital admission. At 30 days, mean visual analog scale back pain score was lower in the intervention group (P = 0.004) but other patient-reported outcomes did not differ.
   CONCLUSIONS: During hospital admission, no significant dose-response effect of mindfulness techniques was found. At 30 days postoperatively, MBSR use was associated with less back pain. Further research is needed to assess the effectiveness of preoperative MBSR on postoperative outcomes in lumbar spine surgery for degenerative disease.
C1 [Yi, Juneyoung L.; Guan, Jian; Joyce, Evan; Dailey, Andrew T.; Mahan, Mark A.; Hood, Robert S.; Bisson, Erica F.] Univ Utah, Hlth Sci Ctr, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
   [Brodke, Darrel S.; Lawrence, Brandon D.; Spiker, William R.; Spina, Nicholas T.] Univ Utah, Hlth Sci Ctr, Dept Orthopaed Surg, Salt Lake City, UT USA.
   [Porucznik, Christina A.; Gren, Lisa H.] Univ Utah, Sch Med, Dept Family & Prevent Med, Div Publ Hlth, Salt Lake City, UT 84112 USA.
RP Yi, JL (reprint author), Univ Utah, Hlth Sci Ctr, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
EM June.Yi@hsc.utah.edu
OI Guan, Jian/0000-0002-4762-7113; Porucznik, Christy/0000-0003-1973-2917
CR Anderson JT, 2015, SPINE, V40, P1775, DOI 10.1097/BRS.0000000000001054
   Bergen-Cico D, 2014, MED CARE, V52, pS25, DOI 10.1097/MLR.0000000000000224
   Cherkin DC, 2016, JAMA-J AM MED ASSOC, V315, P1240, DOI 10.1001/jama.2016.2323
   Day MA, 2014, COMPLEMENT THER MED, V22, P278, DOI 10.1016/j.ctim.2013.12.018
   Deyo RA, 2005, SPINE, V30, P1441, DOI 10.1097/01.brs.0000166503.37969.8a
   Dowd H, 2015, CLIN J PAIN, V31, P517, DOI 10.1097/AJP.0000000000000201
   Drozd F, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2570
   Esmer G, 2010, J AM OSTEOPATH ASSOC, V110, P646
   Garland EL, 2014, J PAIN SYMPTOM MANAG, V48, P1091, DOI 10.1016/j.jpainsymman.2014.03.006
   Gluck TM, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-175
   Gross CR, 2004, ALTERN THER HEALTH M, V10, P58
   Gross CR, 2010, ALTERN THER HEALTH M, V16, P30
   Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016
   Kabat-Zinn J., 2013, FULL CATASTROPHE LIV
   Kepler CK, 2014, SPINE, V39, P1584, DOI 10.1097/BRS.0000000000000486
   Lee Dennis, 2014, J Bone Joint Surg Am, V96, pe89
   Lengacher CA, 2009, PSYCHO-ONCOLOGY, V18, P1261, DOI 10.1002/pon.1529
   McCormick JD, 2013, J AM ACAD ORTHOP SUR, V21, P99, DOI 10.5435/JAAOS-21-02-99
   Morone NE, 2008, J PAIN, V9, P841, DOI 10.1016/j.jpain.2008.04.003
   Morone NE, 2016, JAMA INTERN MED, V176, P329, DOI 10.1001/jamainternmed.2015.8033
   Morone NE, 2009, PAIN MED, V10, P1395, DOI 10.1111/j.1526-4637.2009.00746.x
   NORTH RB, 1991, NEUROSURGERY, V28, P685, DOI 10.1227/00006123-199105000-00008
   O'Lynnger TM, 2015, NEUROSURGERY, V77, pS136, DOI 10.1227/NEU.0000000000000945
   Park T, 2013, QUAL LIFE RES, V22, P2639, DOI 10.1007/s11136-013-0395-8
   Radcliff K, 2013, SPINE, V38, pE849, DOI 10.1097/BRS.0b013e3182959e4e
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   Schmidt S, 2015, FORSCH KOMPLEMENTMED, V22, P298, DOI 10.1159/000440687
   Smith JE, 2005, J ADV NURS, V52, P315, DOI 10.1111/j.1365-2648.2005.03592.x
   Sullivan MD, 2010, PAIN, V150, P332, DOI 10.1016/j.pain.2010.05.020
   Yoshihara H, 2015, SPINE J, V15, P265, DOI 10.1016/j.spinee.2014.09.026
   Zernicke KA, 2014, PSYCHOSOM MED, V76, P257, DOI 10.1097/PSY.0000000000000053
   Zgierska AE, 2016, PAIN MED, V17, P1865, DOI 10.1093/pm/pnw006
NR 32
TC 2
Z9 2
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E786
EP E791
DI 10.1016/j.wneu.2018.09.223
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000097
PM 30312812
DA 2020-05-12
ER

PT J
AU Yu, ZY
   Zheng, J
   Li, M
   Wang, XZ
   Guo, R
   Ma, L
   You, C
   Li, H
AF Yu, Zhiyuan
   Zheng, Jun
   Li, Mou
   Wang, Xiaoze
   Guo, Rui
   Ma, Lu
   You, Chao
   Li, Hao
TI Determining the Optimal Shape-Related Indicator on Noncontrast Computed
   Tomography for Predicting Hematoma Expansion in Spontaneous
   Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hematoma expansion; Island sign; Satellite sign; Shape irregularity;
   Spontaneous intracerebral hemorrhage
ID ANGIOGRAPHY SPOT SIGN; SATELLITE SIGN; GROWTH; GUIDELINES; MANAGEMENT;
   MORTALITY; DENSITY
AB OBJECTIVE: Among several novel predictors on non-contrast computed tomography (CT) for hematoma expansion in spontaneous intracerebral hemorrhage (sICH), shape irregularity grade, satellite sign, and island sign are all related to irregular shape of hematoma. This study is aimed to compare the accuracy of these imaging markers for predicting hematoma expansion in the same cohort of sICH patients.
   METHODS: This retrospective study enrolled sICH patients who underwent diagnostic computed tomography (CT) scans within 6 hours after onset and another follow-up CT scan within 24 hours after initial CT scan. Shape irregularity grade, satellite sign, and island sign were assessed according to the definitions in previous studies. The accuracy of these imaging indicators for predicting hematoma expansion was analyzed using receiver operator analysis.
   RESULTS: Finally, a total of 196 patients were included. Shape irregularity grade >= 3 was found in 87 (44.39%) patients, satellite sign was identified in 76 (38.78%) patients, and island sign was shown in only 41 (20.92%) patients. Only island sign remained an independent predictor for hematoma expansion in multivariate logistic regression. The sensitivity values of shape irregularity grade >= 3, satellite sign, and island sign were 0.52, 0.63, and 0.48, respectively. By contrast, the specificity values of these 3 predictors were 0.58, 0.69, and 0.85, respectively. Shape irregularity grade >= 3 had the smallest area under the curve (0.597), and island sign had the largest (0.676).
   CONCLUSIONS: Island sign seems to be the optimal shape-related predictor for hematoma expansion in sICH patients and could be included in the future predictive model for hematoma expansion.
C1 [Yu, Zhiyuan; Zheng, Jun; Guo, Rui; Ma, Lu; You, Chao; Li, Hao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Li, Mou; Wang, Xiaoze] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
RP Li, H (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM ns_lihao@126.com
FU Outstanding Subject Development 135 Project of West China Hospital,
   Sichuan University [ZY2016102]
FX This work was supported by Outstanding Subject Development 135 Project
   of West China Hospital, Sichuan University (grant number ZY2016102).
CR Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Blacquiere D, 2015, STROKE, V46, P3111, DOI 10.1161/STROKEAHA.115.010566
   Boulouis G, 2016, JAMA NEUROL, V73, P961, DOI 10.1001/jamaneurol.2016.1218
   Boulouis G, 2014, STROKE, V45, P1154, DOI 10.1161/STROKEAHA.114.004844
   Brouwers HB, 2014, JAMA NEUROL, V71, P158, DOI 10.1001/jamaneurol.2013.5433
   Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Du FZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115777
   Han JH, 2014, J KOREAN NEUROSURG S, V56, P303, DOI 10.3340/jkns.2014.56.4.303
   Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Morotti A, 2018, STROKE, V49, P1163, DOI 10.1161/STROKEAHA.117.020138
   Morotti A, 2017, NEUROLOGY, V89, P548, DOI 10.1212/WNL.0000000000004210
   Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Shimoda Y, 2017, CEREBROVASC DIS, V44, P105, DOI 10.1159/000477179
   Steiner T, 2014, INT J STROKE, V9, P840, DOI 10.1111/ijs.12309
   Takeda R, 2013, CLIN NEUROL NEUROSUR, V115, P1028, DOI 10.1016/j.clineuro.2012.10.016
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Yu ZY, 2017, WORLD NEUROSURG, V108, P347, DOI 10.1016/j.wneu.2017.09.022
   Yu ZY, 2017, CLIN NEUROL NEUROSUR, V162, P67, DOI 10.1016/j.clineuro.2017.09.008
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E584
EP E588
DI 10.1016/j.wneu.2018.09.172
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000071
PM 30292034
DA 2020-05-12
ER

PT J
AU Zeng, JP
   Qin, LP
   Wang, DB
   Gong, JB
   Pan, JW
   Zhu, Y
   Sun, TF
   Xu, KL
   Zhan, RY
AF Zeng, JianPing
   Qin, LiPing
   Wang, DuanBu
   Gong, JiangBiao
   Pan, JianWei
   Zhu, Yu
   Sun, TianFu
   Xu, KangLi
   Zhan, RenYa
TI Comparing the Risk of Shunt-Dependent Hydrocephalus in Patients with
   Ruptured Intracranial Aneurysms Treated by Endovascular Coiling or
   Surgical Clipping: An Updated Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coiling; Clipping; Meta-analysis; Shunt-dependent hydrocephalus; Update
ID SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; CEREBRAL ANEURYSMS;
   EMBOLIZATION; PREDICTORS; OUTCOMES; QUALITY
AB BACKGROUND: This meta-analysis aimed to evaluate the risk of shunt-dependent hydrocephalus among patients with ruptured intracranial aneurysms treated with either coil placement or clipping.
   METHODS: A systematic literature search of Embase, PubMed, Web of Science, and the Cochrane Library was performed to confirm relevant studies. The scientific literature was screened in accordance with the predetermined inclusion and exclusion criteria. After quality assessment and data extraction from the eligible studies, a metaanalysis was conducted using the STATA 12.0 software (Stata corporation, College Station, Texas, USA).
   RESULTS: Thirteen studies met all inclusion criteria and were included in the analysis. In total, these studies included 13,751 patients. Of the patients, 8444 of them underwent neurosurgical clipping, and 5307 underwent endovascular coiling. The overall result of a pooled estimate revealed there was no statistically significant risk of shunt dependency difference between the clipping and coiling groups (11.4% vs. 12.0%, respectively; relative risk [RR], 0.92; 95% confidence interval = CI], 0.84-1.01). Six prospective studies (n = 1373) reported shunt-dependent hydrocephalus revealed no significant difference between clipping and coiling (23.3% vs. 20.1%, respectively; RR, 1.12; 95% CI, 0.91-1.38). Seven retrospective studies (n=12,378) reported shunt-dependent hydrocephalus found statistical significance between the surgical and endovascular treatment groups (10.0% vs. 11.1%, respectively; RR, 0.88; 95% CI, 0.79-0.98).
   CONCLUSIONS: Microsurgical clipping and endovascular coiling of ruptured cerebral aneurysms are associated with similar incidences of ventricular shunt placement for hydrocephalus. The risk of shunt-dependent hydrocephalus is not higher after coiling than after clipping of ruptured intracranial aneurysms.
C1 [Zeng, JianPing; Wang, DuanBu; Gong, JiangBiao; Pan, JianWei; Zhu, Yu; Sun, TianFu; Xu, KangLi; Zhan, RenYa] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Qin, LiPing] Hangzhou Normal Univ, Sch Med, Inst Aging Res, Hangzhou, Zhejiang, Peoples R China.
RP Zhan, RY (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
EM 1196057@zju.edu.cn
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81371371]; International Cooperation Project of Zhejiang
   Provincial Science and Technology Department [2015C34007]
FX This work was supported by the Natural Science Foundation of China
   (81371371) and the International Cooperation Project of Zhejiang
   Provincial Science and Technology Department (2015C34007).
CR Bae In-Seok, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P78, DOI 10.7461/jcen.2014.16.2.78
   Bech RA, 1997, NEUROSURGERY, V40, P497, DOI 10.1097/00006123-199703000-00013
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Dehdashti AR, 2004, J NEUROSURG, V101, P402, DOI 10.3171/jns.2004.101.3.0402
   Dorai Z, 2003, NEUROSURGERY, V52, P763, DOI 10.1227/01.NEU.0000053222.74852.2D
   Douglas MR, 2009, J NEUROL NEUROSUR PS, V80, P545, DOI 10.1136/jnnp.2008.155671
   ELLINGTON E, 1969, Journal of Neurosurgery, V30, P651, DOI 10.3171/jns.1969.30.6.0651
   Greitz D, 1996, AM J NEURORADIOL, V17, P431
   Gruber A, 1999, NEUROSURGERY, V44, P503, DOI 10.1097/00006123-199903000-00039
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Hirashima Y, 2003, CEREBROVASC DIS, V16, P205, DOI 10.1159/000071117
   Hoh BL, 2011, WORLD NEUROSURG, V76, P548, DOI 10.1016/j.wneu.2011.05.054
   Hui FK, 2011, J NEUROINTERV SURG, V3, P319, DOI 10.1136/jnis.2011.004770
   KIBLER RF, 1961, BRAIN, V84, P45, DOI 10.1093/brain/84.1.45
   Li XF, 2007, NEUROSCI LETT, V413, P141, DOI 10.1016/j.neulet.2006.11.039
   MCCOMB JG, 1983, J NEUROSURG, V59, P369, DOI 10.3171/jns.1983.59.3.0369
   Moher D, 2000, ONKOLOGIE, V23, P597, DOI 10.1159/000055014
   Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873
   Nam KH, 2010, J KOREAN NEUROSURG S, V48, P313, DOI 10.3340/jkns.2010.48.4.313
   Natarajan SK, 2008, AM J NEURORADIOL, V29, P753, DOI 10.3174/ajnr.A0895
   Proust F, 2003, J NEUROSURG, V99, P3, DOI 10.3171/jns.2003.99.1.0003
   Sethi H, 2000, J NEUROSURG, V92, P991, DOI 10.3171/jns.2000.92.6.0991
   Sheehan JP, 1999, NEUROSURGERY, V45, P1120, DOI 10.1097/00006123-199911000-00021
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taha MA, 2006, SURG NEUROL, V66, P277, DOI 10.1016/j.surneu.2005.12.031
   Vale FL, 1997, J NEUROSURG, V86, P462, DOI 10.3171/jns.1997.86.3.0462
   Vanninen R, 1999, RADIOLOGY, V211, P325, DOI 10.1148/radiology.211.2.r99ap06325
   Varelas P, 2006, NEUROCRIT CARE, V4, P223, DOI 10.1385/NCC:4:3:223
   Xia ZW, 2017, WORLD NEUROSURG, V98, P411, DOI 10.1016/j.wneu.2016.11.032
   Yoshioka H, 2000, SURG NEUROL, V53, P119, DOI 10.1016/S0090-3019(99)00185-8
   Zaidi HA, 2015, NEUROSURGERY, V76, P608, DOI 10.1227/NEU.0000000000000677
NR 32
TC 0
Z9 0
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E731
EP E738
DI 10.1016/j.wneu.2018.09.207
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000090
PM 30308338
DA 2020-05-12
ER

PT J
AU Zhang, JX
   Liu, H
   Bou, EH
   Jiang, WM
   Zhou, F
   He, F
   Yang, HL
   Liu, T
AF Zhang, Junxin
   Liu, Hao
   Bou, Emily Hong
   Jiang, Weimin
   Zhou, Feng
   He, Fan
   Yang, Huilin
   Liu, Tao
TI Comparative Study Between Anterior Cervical Discectomy and Fusion with
   ROI-C Cage and Laminoplasty for Multilevel Cervical Spondylotic
   Myelopathy without Spinal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Laminoplasty; Multilevel cervical spondylotic myelopathy; ROI-C;
   Sagittal balance
ID PROFILE ANCHORED SPACER; ZERO-PROFILE; POSTERIOR LAMINOPLASTY;
   FOLLOW-UP; DECOMPRESSION; COHORT; LAMINECTOMY; CORPECTOMY; DYSPHAGIA;
   PLATE
AB BACKGROUND: Selection of anterior versus posterior surgery for multilevel (>= 3) cervical spondylotic myelopathy (MCSM) continues to be controversial. A comparison between anterior cervical discectomy and fusion (ACDF) with ROI-C cage and laminoplasty was made to determine the better treatment for MCSM.
   METHODS: Between 2012 and 2017, 57 patients received either ACDF with ROI-C or laminoplasty (LMP) treatment. Clinical and radiologic outcomes between the 2 groups were compared.
   RESULTS: In total, 24 patients underwent ACDF with ROIC cage (ACDF group) and 33 patients underwent LMP (LMP group). They were studied with a median follow-up of 22 months. Less operative blood loss (136.7 +/- 60.8 vs. 316.7 +/- 139.6 mL, P < 0.001) and a shorter hospital stay (7.8 +/- 1.6 vs. 9.9 +/- 3.3 days, P < 0.01) were notable for ACDF. The Japanese Orthopedic Association score showed that ACDF and LMP improved similarly (recovery rate, 55.3 +/- 19.2% vs. 58.9 +/- 18.1%, P > 0.05). Preoperative occupying rate and JOA score significantly affected the operation result (P < 0.01). The cervical lordosis, segmental cervical lordosis, and T1 slope were all larger in the ACDF group. The cervical range of motion decreased 10.6 degrees in the ACDF group and 4.8 degrees in the LMP group (P = 0.01). No significant differences were found between complication rates.
   CONCLUSIONS: ACDF with ROI-C cage has a similar clinical efficacy to LMP for patients with MCSM. There was less blood loss, shorter hospital stays, and improved sagittal balance when ACDF was used. However, a greater decrease in range of motion was observed after ACDF. Preoperative occupying ratio and Japanese Orthopaedic Association score are potential risk factors for different outcomes.
C1 [Zhang, Junxin; Liu, Hao; Jiang, Weimin; Zhou, Feng; Yang, Huilin; Liu, Tao] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Suzhou, Jiangsu, Peoples R China.
   [Bou, Emily Hong] Univ Waterloo, Biochem Dept, Waterloo, ON, Canada.
   [He, Fan] Soochow Univ, Orthoped Inst, Suzhou, Jiangsu, Peoples R China.
RP Liu, T (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Suzhou, Jiangsu, Peoples R China.
EM sudalt@126.com
CR Agha RA, 2017, INT J SURG, V46, P198, DOI 10.1016/j.ijsu.2017.08.586
   Anakwenze OA, 2009, SPINE, V34, P2001, DOI 10.1097/BRS.0b013e3181b03fe6
   Blizzard DJ, 2017, EUR SPINE J, V26, P85, DOI 10.1007/s00586-016-4746-3
   BOIJSEN E, 1954, ACTA RADIOL, V42, P101, DOI 10.3109/00016925409175101
   Chen GD, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0715-3
   Fang Z, 2016, CLIN SPINE SURG, V29, pE21, DOI 10.1097/BSD.0000000000000074
   Farrokhi MR, 2016, WORLD NEUROSURG, V94, P97, DOI 10.1016/j.wneu.2016.06.109
   Fehlings MG, 2013, SPINE, V38, P2247, DOI 10.1097/BRS.0000000000000047
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Grasso G, 2014, EUR SPINE J, V23, pS650, DOI 10.1007/s00586-014-3553-y
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   HIRABAYASHI K, 1988, SPINE, V13, P870, DOI 10.1097/00007632-198807000-00032
   Hofstetter CP, 2015, J SPINAL DISORD TECH, V28, pE284, DOI 10.1097/BSD.0b013e31828873ed
   Kawaguchi Y, 2016, SPINE, V41, P1570, DOI 10.1097/BRS.0000000000001579
   LEE HM, 1995, SPINE, V20, P1679, DOI 10.1097/00007632-199508000-00006
   Lee SH, 2018, NEUROSPINE, V15, P91, DOI 10.14245/ns.1834864.432
   Li ZH, 2017, EUR SPINE J, V26, P1129, DOI 10.1007/s00586-016-4739-2
   Lin JH, 2016, SPINE J, V16, P1428, DOI 10.1016/j.spinee.2016.08.017
   Liu T, 2011, J SPINAL DISORD TECH, V24, P213, DOI 10.1097/BSD.0b013e3181e9f294
   Liu XZ, 2014, EUR SPINE J, V23, P362, DOI 10.1007/s00586-013-3043-7
   Liu YJ, 2016, EUR SPINE J, V25, P1881, DOI 10.1007/s00586-016-4500-x
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   PENNING L, 1978, AM J ROENTGENOL, V130, P317, DOI 10.2214/ajr.130.2.317
   Phan K, 2017, EUR SPINE J, V26, P94, DOI 10.1007/s00586-016-4671-5
   Scholz M, 2015, SPINE, V40, pE375, DOI 10.1097/BRS.0000000000000768
   Seng CS, 2013, SPINE J, V13, P723, DOI 10.1016/j.spinee.2013.02.038
   Shi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159761
   Sun YF, 2015, CLIN NEUROL NEUROSUR, V134, P28, DOI 10.1016/j.clineuro.2015.04.011
   Yang L, 2017, SPINE, V42, P903, DOI 10.1097/BRS.0000000000001941
   Yang Y, 2016, DYSPHAGIA, V31, P134, DOI 10.1007/s00455-015-9681-7
   Yu HF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004863
   Zhang YJ, 2018, INT ORTHOP, V42, P1877, DOI 10.1007/s00264-018-3804-3
   Zhu B, 2013, EUR SPINE J, V22, P1583, DOI 10.1007/s00586-013-2817-2
NR 33
TC 2
Z9 2
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E917
EP E924
DI 10.1016/j.wneu.2018.10.016
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000113
PM 30321683
DA 2020-05-12
ER

PT J
AU Zhang, XJ
   Li, CH
   Hao, WL
   Zhang, DH
   Gao, BL
AF Zhang, Xue-Jing
   Li, Cong-Hui
   Hao, Wei-Li
   Zhang, Dong-Hai
   Gao, Bu-Lang
TI The Optimality Principle Decreases Hemodynamic Stresses for Aneurysm
   Initiation at Anterior Cerebral Artery Bifurcations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cerebral artery; Cerebral aneurysm; Hemodynamic stress;
   Optimality principle; Vascular bifurcation
ID SMOOTH-MUSCLE-CELLS; WALL SHEAR-STRESS; ADAPTIVE REGULATION;
   ENLARGEMENT; MATRIX; INHIBITION; APOPTOSIS; BIOMECHANICS; ASSOCIATION;
   SUPPRESSION
AB OBJECTIVE: To investigate hemodynamic stresses on anterior cerebral artery bifurcation apex and possible mechanism of the optimality principle in protecting bifurcation wall from supercharged hemodynamic stresses.
   METHODS: Three-dimensional angiographic datasets of 122 patients with anterior communicating artery (Acom) aneurysms, 21 patients with non-Acom aneurysms, and 220 control subjects with no aneurysms were used. Radii of parent (r(0)) and daughter branches (r(1) and r(2)) were measured, and bifurcations obeying the optimality principle required optimal caliber control of r(0)(n) = r(1)(n) + r(2)(n), with the junction exponent n approximating 3. Radius ratio = r(0)(3)/(r(1)(3) + r(2)(3)) and n were compared between aneurysmal and control bifurcations. Blood flow was simulated for analysis of hemodynamic stresses.
   RESULTS: Acom bifurcations in subjects without Acom aneurysms displayed optimal caliber radius, with mean radius ratio of 0.99 and n of 3.25, whereas Acom aneurysmal bifurcations had significantly lower radius ratio, 0.62 (P < 0.05), but higher n, 4.23 (P < 0.05). Peak wall shear stress and corresponding total pressure were significantly smaller for bifurcations obeying than disobeying the optimality principle (P < 0.001 and P < 0.05, respectively). Total pressures in the direct impinging center, peak wall shear stress distance, and anterior cerebral artery bifurcation angle all were significantly smaller for bifurcations obeying than disobeying the optimality principle (P < 0.05 and P < 0.001, respectively).
   CONCLUSIONS: Normal anterior cerebral artery bifurcations obey the optimality principle whereas bifurcations with Acom aneurysms do not. Disobeying the optimality principle presents significantly enhanced hemodynamic stresses to possibly damage the bifurcation wall for aneurysm initiation.
C1 [Zhang, Xue-Jing; Li, Cong-Hui; Gao, Bu-Lang] Hebei Med Univ, Dept Neurosurg, Hosp 1, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Xue-Jing; Hao, Wei-Li; Gao, Bu-Lang] Hebei Med Univ, Dept Med Res, Shijiazhuang Hosp 1, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Dong-Hai] Henan Balance Med Lab, Zhengzhou, Henan, Peoples R China.
RP Gao, BL (reprint author), Hebei Med Univ, Dept Neurosurg, Hosp 1, Shijiazhuang, Hebei, Peoples R China.; Gao, BL (reprint author), Hebei Med Univ, Dept Med Res, Shijiazhuang Hosp 1, Shijiazhuang, Hebei, Peoples R China.
EM browngao@163.com
RI Gao, Bu-Lang/N-3669-2015
OI Gao, Bu-Lang/0000-0003-4668-0737
FU Hebei Provincial 100-Talents Program [E2014100010]; China National
   Natural Scientific Funding [81271575]
FX This study was supported by Hebei Provincial 100-Talents Program (grant
   number E2014100010) and was partly supported by China National Natural
   Scientific Funding (grant number 81271575).
CR Abbruzzese TA, 1998, SURGERY, V124, P328, DOI 10.1067/msy.1998.91338
   Alexander JJ, 1997, SURGERY, V122, P279
   Alnaes MS, 2007, STROKE, V38, P2500, DOI 10.1161/STROKEAHA.107.482471
   Aoki T, 2008, STROKE, V39, P2603, DOI 10.1161/STROKEAHA.107.513648
   Baharoglu MI, 2014, J BIOMECH, V47, P3318, DOI 10.1016/j.jbiomech.2014.08.012
   Bruno G, 1998, J NEUROSURG, V89, P431, DOI 10.3171/jns.1998.89.3.0431
   Canham PB, 2004, STROKE, V35, P1153, DOI 10.1161/01.STR.0000124926.76836.df
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006
   COLANGELO S, 1994, CELL TISSUE RES, V278, P235, DOI 10.1007/BF00414165
   Davies PF, 1995, J BIOMECH, V28, P1553, DOI 10.1016/0021-9290(95)00102-6
   Davis V, 1998, ARTERIOSCL THROM VAS, V18, P1625, DOI 10.1161/01.ATV.18.10.1625
   Gao BL, 2013, NEUROSURGERY, V72, P739, DOI 10.1227/NEU.0b013e318286fab3
   Guzman RJ, 1997, SURGERY, V122, P273, DOI 10.1016/S0039-6060(97)90018-0
   HASHIMOTO N, 1987, J NEUROSURG, V67, P903, DOI 10.3171/jns.1987.67.6.0903
   HASHIMOTO N, 1978, SURG NEUROL, V10, P3
   Henderson EL, 1999, CIRCULATION, V99, P96, DOI 10.1161/01.CIR.99.1.96
   Ingebrigtsen T, 2004, J NEUROSURG, V101, P108, DOI 10.3171/jns.2004.101.1.0108
   Jayaraman T, 2008, VASC HEALTH RISK MAN, V4, P805, DOI 10.2147/VHRM.S2700
   KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5
   KAMIYA A, 1980, AM J PHYSIOL, V239, pH14
   Kasuya H, 1999, NEUROSURGERY, V45, P89, DOI 10.1097/00006123-199907000-00021
   Kim SC, 1997, NEUROSURGERY, V41, P642, DOI 10.1097/00006123-199709000-00027
   Kondo S, 1998, STROKE, V29, P181, DOI 10.1161/01.STR.29.1.181
   Lasheras JC, 2007, ANNU REV FLUID MECH, V39, P293, DOI 10.1146/annurev.fluid.39.050905.110128
   Masuda Hirotake, 1993, Frontiers of Medical and Biological Engineering, V5, P57
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   OKA S, 1987, BIORHEOLOGY, V24, P737
   Painter PR, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-31
   Rojas HA, 2018, CLIN BIOCHEM, V55, P63, DOI 10.1016/j.clinbiochem.2018.03.005
   ROSSITTI S, 1993, STROKE, V24, P371, DOI 10.1161/01.STR.24.3.371
   Rowe AJ, 2003, J VASC RES, V40, P406, DOI 10.1159/000072831
   Sakaki T, 1997, ACTA NEUROCHIR, V139, P469, DOI 10.1007/BF01808885
   Sakaki T, 1997, ACTA NEUROCHIR, V139, P475
   Sho E, 2002, EXP MOL PATHOL, V73, P142, DOI 10.1006/exmp.2002.2457
   SUMPIO BE, 1990, J SURG RES, V48, P415, DOI 10.1016/0022-4804(90)90005-M
   Sweeney NV, 2004, CARDIOVASC RES, V63, P625, DOI 10.1016/j.cardiores.2004.05.008
   Thompson RW, 1998, SURGERY, V124, P334
   Tutuncu F, 2014, J NEUROSURG, V121, P1401, DOI 10.3171/2014.8.JNS1447
   ZAMIR M, 1984, J THEOR BIOL, V109, P401, DOI 10.1016/S0022-5193(84)80089-2
   ZAMIR M, 1976, J THEOR BIOL, V62, P227, DOI 10.1016/0022-5193(76)90058-8
   ZARINS CK, 1987, J VASC SURG, V5, P413, DOI 10.1067/mva.1987.avs0050413
NR 42
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E379
EP E388
DI 10.1016/j.wneu.2018.09.112
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000047
PM 30266713
DA 2020-05-12
ER

PT J
AU Zhu, Y
   Wu, P
   Luo, W
   Zhao, ZH
   Ou, YS
AF Zhu, Yong
   Wu, Peng
   Luo, Wei
   Zhao, Zenghui
   Ou, Yunsheng
TI Single-Stage Posterior Instrumentation and Unilateral Transpedicular
   Debridement for the Treatment of Thoracolumbar Tuberculosis: Three Years
   of Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Single-stage posterior instrumentation; Thoracolumbar tuberculosis;
   Traditional posterior operation; Unilateral transpedicular debridement
ID ANTERIOR INTERBODY FUSION; SPINAL TUBERCULOSIS; SURGICAL-TREATMENT;
   DECOMPRESSION; STABILIZATION; SPONDYLITIS; KYPHOSIS; SURGERY; SCALES;
   PAIN
AB OBJECTIVE: The present study compared the efficacy and safety of single-stage posterior instrumentation and unilateral transpedicular debridement with the traditional posterior operation for the treatment of thoracolumbar tuberculosis.
   METHODS: Of the 97 included patients, 53 had undergone posterior unilateral transpedicular debridement and pedicle screw fixation (group A) and 44 had undergone the traditional posterior operation (group B). We compared the outcomes, including correction of kyphosis (Cobb angle), bone fusion rate, visual analog scale score, Frankel classification, and short-form 12-item health survey between the 2 groups.
   RESULTS: All patients obtained intervertebral bone fusion. The mean interval to bone graft fusion was 4.1 months (range, 3e8 months). The patients in the 2 groups showed significant improvement in kyphosis correction, short-form 12-item health survey score, and nerve function. In addition, single-stage posterior instrumentation and unilateral transpedicular debridement resulted in comparable clinical outcomes for the treatment of thoracolumbar tuberculosis. However, the patients experienced less trauma, greater spinal stability, and better functional recovery compared with the traditional posterior operation group.
   CONCLUSIONS: Our results suggest that single-stage posterior instrumentation and unilateral transpedicular debridement can be considered an effective and safe therapy for spinal tuberculosis with single-level and/ or bilevel segments.
C1 [Zhu, Yong; Wu, Peng; Luo, Wei; Zhao, Zenghui; Ou, Yunsheng] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing, Peoples R China.
RP Ou, YS (reprint author), Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing, Peoples R China.
EM ouyunsheng2001@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572634]
FX Yunsheng Ou was supported by the National Natural Science Foundation of
   China (grant 81572634). The remaining authors declare that the article
   content was composed in the absence of any commercial or financial
   relationships that could be construed as a potential conflict of
   interest.
CR Almeida A, 2005, EUR J RADIOL, V55, P193, DOI 10.1016/j.ejrad.2005.04.018
   Benli IT, 2007, CLIN ORTHOP RELAT R, P108, DOI 10.1097/BLO.0b013e318065b70d
   Briggs M, 1999, J PAIN SYMPTOM MANAG, V18, P438, DOI 10.1016/S0885-3924(99)00092-5
   Broner FA, 1996, ORTHOP CLIN N AM, V27, P37
   Flamme CH, 2005, SPINE, V30, pE352, DOI 10.1097/01.brs.0000168551.60385.b3
   Frankel H L, 1969, Paraplegia, V7, P179
   Fukuta S, 2003, SPINE, V28, pE302, DOI 10.1097/00007632-200308010-00025
   Gong K, 2011, ARCH ORTHOP TRAUM SU, V131, P217, DOI 10.1007/s00402-010-1138-8
   He B, 2012, ARCH ORTHOP TRAUM SU, V132, P1407, DOI 10.1007/s00402-012-1565-9
   Hee HT, 2002, J SPINAL DISORD TECH, V15, P149, DOI 10.1097/00024720-200204000-00010
   HODGSON AR, 1960, BRIT J SURG, V48, P172, DOI 10.1002/bjs.18004820819
   Issack PS, 2012, INT ORTHOP, V36, P353, DOI 10.1007/s00264-011-1292-9
   Jain AK, 2008, J BONE JOINT SURG BR, V90B, P1477, DOI 10.1302/0301-620X.90B11.20972
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P905, DOI 10.1302/0301-620X.92B7.24668
   Jin WD, 2014, SPINE J, V14, P964, DOI 10.1016/j.spinee.2013.07.466
   Korovessis P, 2006, SPINE, V31, P1014, DOI 10.1097/01.brs.0000215049.08622.9d
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185
   LEE CK, 1995, SPINE, V20, P356, DOI 10.1097/00007632-199502000-00018
   Lee SH, 2006, J SPINAL DISORD TECH, V19, P595, DOI 10.1097/01.bsd.0000211241.06588.7b
   Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013
   Parthasarathy R, 1999, J BONE JOINT SURG BR, V81B, P464, DOI 10.1302/0301-620X.81B3.9043
   SHIPLEY JA, 1993, SPINE, V18, P397
   Talu U, 2006, J SPINAL DISORD TECH, V19, P554, DOI 10.1097/01.bsd.0000211202.93125.c7
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   World Health Organization, GLOB TUB REP 2010
   World Health Organization, 2004, WHO GLOB STAT REP AL, P22
   Zeng H, 2015, ACTA ORTHOP TRAUMATO, V49, P513, DOI 10.3944/AOTT.2015.14.0037
   Zhang HQ, 2012, INT ORTHOP, V36, P293, DOI 10.1007/s00264-011-1449-6
   Zhao J, 2007, INT ORTHOP, V31, P859, DOI 10.1007/s00264-006-0253-1
NR 30
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E222
EP E228
DI 10.1016/j.wneu.2018.09.085
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000031
PM 30261383
DA 2020-05-12
ER

PT J
AU Ziechmann, R
   Hoffman, H
   Chin, LS
AF Ziechmann, Robert
   Hoffman, Haydn
   Chin, Lawrence S.
TI Academic Genealogy of Neurosurgery via Department Chair
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic; Chair; Genealogy; Neurosurgery
ID NEUROLOGICAL SURGERY; UNIVERSITY; HISTORY; CLEVELAND
AB BACKGROUND: An academic genealogy describes mentoring relationships in an academic discipline. In this study, we outline an academic genealogy of neurosurgery department chairs in the United States beginning with the founding members of the field.
   METHODS: The biographic information provided by the Society for Neurological Surgery provided the basis for our genealogy. We also performed a literature review with PubMed using the term neurosurgery department history. Our data was manually uploaded to an online database called Academic Tree. Within this platform, mentor and trainee relationships were indicated to produce an academic genealogy.
   RESULTS: Our search yielded a total of 377 chairs and 368 mentoring relationships across 98 neurosurgery departments. The largest family tree in our academic genealogy was that of Harvey Cushing, with 177 department chairs. Harvey Cushing was also the individual who trained the most number of department chairs (22). The institution that trained the most department chairs was Brigham and Women's Hospital (26). Only 23.6% of department chairs completed residency training at the same institution where they became chair.
   CONCLUSIONS: The academic genealogy in this study allows for any neurosurgeon trained in the United States to put his or her training into historical context. It also provides a reference for bibliographic research to quantitatively describe the influence of individuals and institutions on the field.
C1 [Ziechmann, Robert; Hoffman, Haydn; Chin, Lawrence S.] SUNY Upstate, Dept Neurosurg, Syracuse, NY 13210 USA.
RP Ziechmann, R (reprint author), SUNY Upstate, Dept Neurosurg, Syracuse, NY 13210 USA.
EM rcziechmann@gmail.com
CR Alberga L, 2017, J NEUROSURG, V126, P1285, DOI 10.3171/2016.4.JNS152356
   Boockvar JA, 2000, NEUROSURGERY, V46, P1223, DOI 10.1097/00006123-200005000-00040
   Chalouhi N, 2013, NEUROSURGERY, V73, P709, DOI 10.1227/01.neu.0000430299.02714.46
   Chowdhry SA, 2014, NEUROSURGERY, V74, pS198, DOI 10.1227/NEU.0000000000000225
   David SV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046608
   Flanigan PM, 2018, J NEUROSURG, V129, P1342, DOI 10.3171/2017.7.JNS17567
   Foreman PM, 2014, NEUROSURGERY, V75, P483, DOI 10.1227/NEU.0000000000000464
   Haines SJ, 2014, NEUROSURGERY, V74, P553, DOI 10.1227/NEU.0000000000000311
   Hirshman BR, 2016, ANN NEUROL, V79, P169, DOI 10.1002/ana.24569
   HLAVIN ML, 1995, J NEUROSURG, V83, P750, DOI 10.3171/jns.1995.83.4.0750
   HOFF JT, 1992, J NEUROSURG, V77, P962, DOI 10.3171/jns.1992.77.6.0962
   House PA, 2010, NEUROSURGERY, V67, P781, DOI 10.1227/01.NEU.0000374766.52631.0C
   Kole MK, 2001, NEUROSURGERY, V48, P412
   Krishna V, 2011, NEUROSURGERY, V69, P145, DOI 10.1227/NEU.0b013e3182137384
   LONG DM, 1989, J NEUROSURG, V71, P635, DOI 10.3171/jns.1989.71.5.0635
   OPPENHEIM JS, 1994, J NEUROSURG, V80, P935, DOI 10.3171/jns.1994.80.5.0935
   Ponce FA, 2010, J NEUROSURG, V113, P447, DOI 10.3171/2010.3.JNS1032
   Quest DO, 2010, NEUROSURGERY, V66, P590, DOI 10.1227/01.NEU.0000364997.62303.E7
   Rocque BG, 2010, NEUROSURGERY, V67, P424, DOI 10.1227/01.NEU.0000372084.38520.9B
   SCHNEIDER JH, 1993, J NEUROSURG, V79, P145, DOI 10.3171/jns.1993.79.1.0145
   Shillito J, 2008, NEUROSURGERY, V63, P579, DOI 10.1227/01.NEU.0000325262.13402.38
   Spinner RJ, 2001, NEUROSURGERY, V49, P438, DOI 10.1097/00006123-200108000-00032
   Spiotta AM, 2009, NEUROSURGERY, V64, P164, DOI 10.1227/01.NEU.0000334412.64433.9D
   Tumialan LM, 2008, NEUROSURGERY, V62, P1361, DOI 10.1227/01.neu.0000333309.10426.74
NR 24
TC 0
Z9 0
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E105
EP E110
DI 10.1016/j.wneu.2018.09.023
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000015
PM 30218804
DA 2020-05-12
ER

PT J
AU Zong, R
   Li, T
   Lu, LNA
   Qiao, GY
   Yu, XG
AF Zong, Rui
   Li, Teng
   Lu, Lenian
   Qiao, Guangyu
   Yu, Xinguang
TI Posterior C2 Fixation Using Trans-C2 Inferior Articular Process Screws:
   A Case Series and Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocation; Atlantoaxial instability; C1 lateral mass
   screw; C2 pedicle screw; Congenital craniovertebral anomalies; Trans-C2
   inferior articular process screw; Vertebral artery injury
ID ATLANTOAXIAL DISLOCATION; BASILAR INVAGINATION; VERTEBRAL ARTERY; C1-C2
   SCREW; REDUCTION; PLACEMENT; OCCIPITALIZATION; FUSION
AB OBJECTIVE: Upper cervical fixation with C2 pedicle screw insertion may predispose patients to vertebral artery injury, in particular, patients with craniovertebral junction anomalies. The aim of this study was to describe an alternative technique with trans-C2 inferior articular process screw (C2IAPS) insertion for rigid C2 fixation, which can be used to anchor the C2 vertebra for upper cervical fixation.
   METHODS: Records of 19 patients who underwent posterior atlantoaxial fixation using C2IAPS combined with C1 lateral mass screw were retrospectively reviewed. Efficacy was assessed by postoperative imaging and Japanese Orthopaedic Association scores.
   RESULTS: There were 22 C2IAPSs successfully implanted (3 on both sides and 16 on 1 side). With the exception of 2 screws that had intruded into the outlet of the intervertebral foramen, all screws were safely implanted. Average Japanese Orthopaedic Association scores improved from 11.8 +/- 1.9 preoperatively to 15.3 +/- 1.3 postoperatively. Bony fusion rate was 100%.
   CONCLUSIONS: For patients who are not eligible for C2 pedicle screw fixation, C2IAPS fixation can be considered as an alternative technique for upper cervical fixation of C2.
C1 [Zong, Rui; Li, Teng; Qiao, Guangyu; Yu, Xinguang] Gen Hosp Peoples Liberat Army, Dept Neurosurg, Beijing, Peoples R China.
   [Lu, Lenian] First Peoples Hosp Shunde, Dept Neurosurg, Foshan, Guangdong, Peoples R China.
RP Yu, XG (reprint author), Gen Hosp Peoples Liberat Army, Dept Neurosurg, Beijing, Peoples R China.
EM xinguang_yu@263.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81301274, 81571350]; Capital Characteristic
   Clinical Application Research Funding [Z151100004015009]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81301274 and 81571350 to X.Y.) and Capital
   Characteristic Clinical Application Research Funding (grant number
   Z151100004015009 to X.Y.).
CR Ahmed R, 2013, NEUROSURGERY S, V72
   Ahmed R, 2013, NEUROSURGERY S, V72
   Anderst WJ, 2015, SPINE J, V15, P2538, DOI 10.1016/j.spinee.2015.08.042
   Aoyama T, 2014, J NEUROSURG-SPINE, V21, P732, DOI 10.3171/2014.7.SPINE131087
   Cassinelli EH, 2006, SPINE, V31, P2767, DOI 10.1097/01.brs.0000245869.85276.f4
   Chun DH, 2018, SPINE, V43, pE891, DOI 10.1097/BRS.0000000000002584
   Du JY, 2015, J NEUROSURG-SPINE, V22, P151, DOI 10.3171/2014.10.SPINE13805
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Guo SL, 2014, EUR SPINE J, V23, P1666, DOI 10.1007/s00586-014-3409-5
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Huang DG, 2015, SPINE J, V15, P2271, DOI 10.1016/j.spinee.2015.07.008
   Liu GY, 2014, INDIAN J ORTHOP, V48, P550, DOI 10.4103/0019-5413.144212
   Matsubara T, 2007, SPINE, V32, pE30, DOI 10.1097/01.brs.0000250994.24462.ec
   Meyer D, 2012, NEUROSURG REV, V35, P255, DOI 10.1007/s10143-011-0358-x
   Moon BJ, 2018, J CLIN NEUROSCI, V53, P147, DOI 10.1016/j.jocn.2018.04.058
   Morita T, 2015, J NEUROSURG-SPINE, V23, P254, DOI 10.3171/2014.11.SPINE14624
   Nagata K, 2013, BMJ CASE REP, V2013
   Ould-Slimane M, 2014, SURG RADIOL ANAT, V36, P537, DOI 10.1007/s00276-013-1233-y
   Robertson PA, 2012, SPINE J, V12, P136, DOI 10.1016/j.spinee.2012.01.004
   Sim HB, 2011, SPINE, V36, pE401, DOI 10.1097/BRS.0b013e31820611ba
   Takigawa T, 2016, EUR SPINE J, V25, P1655, DOI 10.1007/s00586-015-4343-x
   Wang JH, 2013, EUR SPINE J, V22, P1547, DOI 10.1007/s00586-013-2779-4
   Wang SL, 2012, NEUROSURGERY, V71, P976, DOI 10.1227/NEU.0b013e31826cdd3b
   Wang SL, 2010, EUR SPINE J, V19, P1306, DOI 10.1007/s00586-010-1418-6
   Wright NM, 2004, J SPINAL DISORD TECH, V17, P158, DOI 10.1097/00024720-200404000-00014
   Xiu P, 2014, EUR SPINE J, V23, P1730, DOI 10.1007/s00586-014-3397-5
   Yin YH, 2016, NEUROSURGERY, V78, P391, DOI 10.1227/NEU.0000000000001026
   Yin YH, 2014, SPINE, V39, P2013, DOI 10.1097/BRS.0000000000000611
   Yin YH, 2013, SPINE J, V13, P1864, DOI 10.1016/j.spinee.2013.08.014
   Yoshida M, 2006, SPINE, V31, pE513, DOI 10.1097/01.brs.0000224516.29747.52
   Zhou FJ, 2010, ARCH ORTHOP TRAUM SU, V130, P1505, DOI 10.1007/s00402-010-1069-4
NR 31
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2019
VL 121
BP E70
EP E76
DI 10.1016/j.wneu.2018.09.014
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HD9QJ
UT WOS:000452897000011
PM 30213673
DA 2020-05-12
ER

PT J
AU Bryan-Quiros, W
   Fernandez, J
   Gutierrez, JM
   Lewin, MR
   Lomonte, B
AF Bryan-Quiros, Wendy
   Fernandez, Julian
   Gutierrez, Jose Maria
   Lewin, Matthew R.
   Lomonte, Bruno
TI Neutralizing properties of LY315920 toward snake venom group I and II
   myotoxic phospholipases A(2)
SO TOXICON
LA English
DT Article
DE LY315920; Varespladib; Snake venom; Phospholipase A(2); Myotoxin
ID BOTHROPS-ASPER VENOM; ANTIINFLAMMATORY DRUGS; CRYSTAL-STRUCTURE; MUSCLE;
   DAMAGE; INHIBITION; CROTOXIN; METALLOPROTEINASE; MECHANISMS; STABILITY
AB A need exists to develop specific and clinically useful inhibitors of toxic enzymes present in snake venoms, responsible for severe tissue damage and life-threatening effects occurring in thousands of people suffering envenomations globally. LY315920 (Varespladib, S-5920, A-001), a low molecular weight drug developed to inhibit several human secreted phospholipases A(2) (PLA(2)s), was recently shown to also inhibit PLA(2)s in whole snake venoms with high potency, yet no studies have examined its direct effect on purified snake venom PLA(2)s. This work evaluated the ability of LY315920 to neutralize the enzymatic and toxic activities of three isolated PLA(2) toxins of structural groups I (pseudexin) and II (crotoxin B and myotoxin I), and their corresponding whole venoms. In vitro, LY315920 inhibited the catalytic activity of these three enzymes upon a synthetic substrate. The drug also blocked their cytotoxic effect on cultured murine myotubes. In mice, preincubation of the toxins or venoms with LY315920, followed by their intramuscular injection, resulted in significant inhibition of muscle damage. Finally, immediate, independent injection of LY315920 at the site of toxin or venom inoculation also resulted in a large reduction of myonecrosis in the case of pseudexin and myotoxin-I, and of Pseudechis colletti and Bothrops asper whole venoms, suggesting a possible method of drug delivery in emergency situations. Present findings add evidence to suggest the possibility of using LY315920 as a field antidote in snakebites, aiming to limit the myonecrosis induced by many venom PLA2s in the clinical setting.
C1 [Bryan-Quiros, Wendy; Fernandez, Julian; Gutierrez, Jose Maria; Lomonte, Bruno] Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose 11501, Costa Rica.
   [Lewin, Matthew R.] Calif Acad Sci, Ctr Explorat & Travel Hlth, San Francisco, CA 94118 USA.
RP Lomonte, B (reprint author), Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose 11501, Costa Rica.
EM bruno.lomonte@ucr.ac.cr
RI Lomonte, Bruno/B-8862-2019
OI Lomonte, Bruno/0000-0003-2419-6469; Gutierrez, Jose
   Maria/0000-0001-8385-3081
FU Vicerrectoria de Investigacion, Universidad de Costa Rica
   [VI-741-B5-602]
FX We thank Vicerrectoria de Investigacion, Universidad de Costa Rica, for
   partial support to this project through grant (VI-741-B5-602) and a
   scholarship to W.B.-Q. Prof. Ivan Kaiser and Ophirex, Inc. are
   acknowledged for kindly providing materials. This work was performed in
   partial fulfillment of the requirements for the M.Sc. degree of W.
   Bryan-Quirds at Universidad de Costa Rica.
CR Pereanez JA, 2014, CHEM-BIOL INTERACT, V220, P94, DOI 10.1016/j.cbi.2014.06.015
   Azofeifa K, 2008, TOXICON, V51, P373, DOI 10.1016/j.toxicon.2007.10.008
   Bucaretchi F, 2010, CLIN TOXICOL, V48, P57, DOI 10.3109/15563650903356201
   Calvete JJ, 2018, TOXICON, V148, P107, DOI 10.1016/j.toxicon.2018.04.015
   Calvete JJ, 2017, BIOCHEM J, V474, P611, DOI 10.1042/BCJ20160577
   Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515
   Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
   Dixon RW, 1999, AM J PATHOL, V154, P447, DOI 10.1016/S0002-9440(10)65291-1
   Escalante T, 2000, BIOCHEM PHARMACOL, V60, P269, DOI 10.1016/S0006-2952(00)00302-6
   FAURE G, 1993, EUR J BIOCHEM, V214, P491, DOI 10.1111/j.1432-1033.1993.tb17946.x
   Faure G, 2011, J MOL BIOL, V412, P176, DOI 10.1016/j.jmb.2011.07.027
   Fernandez J, 2011, J PROTEOME RES, V10, P1816, DOI 10.1021/pr101091a
   FLOWERS HERSCHEL H., 1965, TOXICON, V2, P221, DOI 10.1016/0041-0101(65)90020-6
   GUTIERREZ JM, 1986, COMP BIOCHEM PHYS C, V84, P159, DOI 10.1016/0742-8413(86)90183-0
   GUTIERREZ JM, 1984, TOXICON, V22, P115, DOI 10.1016/0041-0101(84)90144-2
   Gutierrez JM, 2008, TOXICON, V51, P80, DOI 10.1016/j.toxicon.2007.08.007
   Harrison RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000569
   Herzel BJ, 2018, AM J TROP MED HYG, V99, P404, DOI 10.4269/ajtmh.17-0922
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Lewin M, 2016, TOXINS, V8, DOI 10.3390/toxins8090248
   LOMONTE B, 1994, TOXICON, V32, P41, DOI 10.1016/0041-0101(94)90020-5
   Lomonte B, 2011, ACTA CHIM SLOV, V58, P647
   Longbottom J., 2018, LANCET, V18, P31224
   MELO PA, 1993, TOXICON, V31, P285, DOI 10.1016/0041-0101(93)90146-A
   Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2
   Milani R, 1997, QJM-MON J ASSOC PHYS, V90, P323, DOI 10.1093/qjmed/90.5.323
   Mohapatra B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001018
   Montecucco C, 2008, CELL MOL LIFE SCI, V65, P2897, DOI 10.1007/s00018-008-8113-3
   Mora-Obando D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109846
   Mora-Obando D, 2014, PEERJ, V2, DOI 10.7717/peerj.569
   Nicholls SJ, 2012, CARDIOVASC DRUG THER, V26, P71, DOI 10.1007/s10557-011-6358-9
   O'Brien J, 2016, J AM CHEM SOC, V138, P16604, DOI 10.1021/jacs.6b10950
   RUBSAMEN K, 1971, N-S ARCH PHARMAKOL, V270, P274
   Rucavado A, 1996, TOXICON, V34, P567, DOI 10.1016/0041-0101(95)00162-X
   Salvador GHM, 2017, BIOCHIMIE, V133, P95, DOI 10.1016/j.biochi.2016.12.015
   Sampaio SC, 2010, TOXICON, V55, P1045, DOI 10.1016/j.toxicon.2010.01.011
   SELLAHEWA KH, 1995, AM J TROP MED HYG, V53, P260, DOI 10.4269/ajtmh.1995.53.260
   Arias AS, 2017, TOXICON, V132, P40, DOI 10.1016/j.toxicon.2017.04.001
   Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117
   Swethakumar B, 2018, BBA-GEN SUBJECTS, V1862, P1115, DOI 10.1016/j.bbagen.2018.02.003
   Tonello F, 2017, TOXINOLOGY, P49, DOI 10.1007/978-94-007-6410-1_26
   Urs ANN, 2015, TOXICON, V93, P68, DOI 10.1016/j.toxicon.2014.11.224
   Wang YD, 2018, MOLECULES, V23, DOI 10.3390/molecules23020391
   WEINSTEIN SA, 1992, TOXICON, V30, P171, DOI 10.1016/0041-0101(92)90470-P
   Weinstein SA, 2018, TOXICON, V142, P34, DOI 10.1016/j.toxicon.2017.12.047
NR 45
TC 6
Z9 6
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 1
EP 7
DI 10.1016/j.toxicon.2018.11.292
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300001
PM 30447275
DA 2020-05-12
ER

PT J
AU Salinas, LM
   Balseiro, A
   Jiron, W
   Peralta, A
   Munoz, D
   Fajardo, J
   Gayo, E
   Martinez, IZ
   Riet-Correa, F
   Gardner, DR
   Marin, JFG
AF Manuel Salinas, Luis
   Balseiro, Ana
   Jiron, William
   Peralta, Alan
   Munoz, David
   Fajardo, Jorge
   Gayo, Elena
   Zorhaya Martinez, Ileana
   Riet-Correa, Franklin
   Gardner, Dale R.
   Garcia Marin, Juan Francisco
TI Neurological syndrome in goats associated with Ipomoea trifida and
   Ipomoea carnea containing calystegines
SO TOXICON
LA English
DT Article
DE Goat; Poisoning; Ipomoea trifida; Ipomoea cornea; Calystegines;
   Nicaragua
ID STORAGE DISEASE; SWAINSONINE; SOLANUM; DEGENERATION; INTOXICATION;
   ALKALOIDS; PLANTS
AB A disease characterized by ataxia, tremors and nystagmus had been observed in goats in Nicaragua. The main histologic lesions were loss and neuronal vacuolation of Purkinje cells and Wallerian-like degeneration mainly in the cerebellum, suggesting a glycoprotein storage disease. Ipomoea cornea and Ipomoea trifida found in the paddocks were negative for swainsonine, but contained calystegines at 0.02% and 0.06% suggesting that the disease was caused by these substances, which are competitive inhibitors of beta-glucosidase and alpha-galactosidase activities.
C1 [Manuel Salinas, Luis] Univ Int Antonio Valdivieso UNIAV, Rivas, Nicaragua.
   [Balseiro, Ana] Ctr Biotecnol Anim, Serv Reg Invest & Desarrollo Agroalimentario SERI, Gijon, Asturias, Spain.
   [Jiron, William; Peralta, Alan; Munoz, David; Fajardo, Jorge] Univ Nacl Autonoma Nicaragua, Leon, Nicaragua.
   [Manuel Salinas, Luis; Gayo, Elena; Zorhaya Martinez, Ileana; Garcia Marin, Juan Francisco] Univ Leon, Fac Vet, Campus Vegazana, Leon, Spain.
   [Zorhaya Martinez, Ileana] Univ Popular Autonoma Estado Puebla, Puebla, Mexico.
   [Riet-Correa, Franklin] Inst Nacl Invest Agr, La Estanzuela, Colonia, Uruguay.
   [Gardner, Dale R.] Poisonous Plant Res Lab, Logan, UT USA.
RP Balseiro, A (reprint author), Ctr Biotecnol Anim, Serv Reg Invest & Desarrollo Agroalimentario, SERIDA, Gijon 33394, Asturias, Spain.
EM abalseiro@serida.org
RI Balseiro, Ana/O-1794-2019
OI Balseiro, Ana/0000-0002-5121-7264; Peralta-Ramirez,
   Alan/0000-0002-3253-4731; Jiron Toruno, William/0000-0002-5778-5721
FU Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria
   (INIA, Spain) (FEDER) [E-RTA2013-00013-004-04]
FX This work was partially supported by a grant from Instituto Nacional de
   Investigacion y Tecnologia Agraria y Alimentaria (INIA, Spain),
   reference number E-RTA2013-00013-004-04 (FEDER co-funded).
CR Aguirre M., 2009, FLORA ARBUSTIVA RAST
   [Anonymous], 2018, CLIMATE DATA
   Armien AG, 2007, VET PATHOL, V44, P170, DOI 10.1354/vp.44-2-170
   Asano N, 1997, GLYCOBIOLOGY, V7, P1085, DOI 10.1093/glycob/7.8.1085
   Barbosa RC, 2006, TOXICON, V47, P371, DOI 10.1016/j.toxicon.2005.11.010
   Cantile C., 2016, JUBB KENNEDY PALMERS, P250, DOI DOI 10.1016/B978-0-7020-5317-7.00004-7
   de Lucena KFC, 2014, TOXICON, V92, P129, DOI 10.1016/j.toxicon.2014.10.019
   Cook D, 2015, TOXICON, V95, P62, DOI 10.1016/j.toxicon.2015.01.002
   Cook D, 2014, J AGR FOOD CHEM, V62, P7326, DOI 10.1021/jf501674r
   Cook D, 2013, J AGR FOOD CHEM, V61, P3797, DOI 10.1021/jf4008423
   de Balogh KKIM, 1999, J VET DIAGN INVEST, V11, P266, DOI 10.1177/104063879901100310
   DEBARROS SS, 1987, PESQUISA VET BRASIL, V7, P1
   Gardner DR, 2001, J AGR FOOD CHEM, V49, P4573, DOI 10.1021/jf010596p
   Gotardo AT, 2016, TOXINS, V8, DOI 10.3390/toxins8030074
   Hueza IM, 2005, EXP TOXICOL PATHOL, V57, P53, DOI 10.1016/j.etp.2005.02.004
   Ikeda K, 2003, J AGR FOOD CHEM, V51, P7642, DOI 10.1021/jf035003k
   Lee ST, 2017, J AGR FOOD CHEM, V65, P5266, DOI [10.1021/acs.jafc.7b01834, 10.1021/acs.jafc.7b03237]
   Lima DDCC, 2013, PESQUI VET BRASIL, V33, P867, DOI 10.1590/S0100-736X2013000700007
   Mayhew I. G., 2009, LARGE ANIMAL NEUROLO
   NASH RJ, 1993, PHYTOCHEMISTRY, V34, P1281, DOI 10.1016/0031-9422(91)80016-T
   Radostits O.M., 1999, VET MED TXB DIS CATT, P501
   RIETCORREA F, 1983, CORNELL VET, V73, P240
   Schumaher Henrique B., 2003, VET RES COMMUN, V27, P311
   Scott PR, 2004, VET CLIN N AM-FOOD A, V20, P215, DOI 10.1016/j.cvfa.2004.02.004
   Stegelmeier BL, 1999, J VET DIAGN INVEST, V11, P448, DOI 10.1177/104063879901100510
   TOKARNIA CARLOS HUBINGER, 1960, ARQ INST BIOL ANIMAL, V3, P59
   van der Lugt JJ, 2010, VET J, V185, P225, DOI 10.1016/j.tvjl.2009.04.012
NR 27
TC 1
Z9 1
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 8
EP 11
DI 10.1016/j.toxicon.2018.11.291
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300002
PM 30447273
DA 2020-05-12
ER

PT J
AU Brandehoff, N
   Smith, CF
   Buchanan, JA
   Mackessy, SP
   Bonney, CF
AF Brandehoff, Nicklaus
   Smith, Cara F.
   Buchanan, Jennie A.
   Mackessy, Stephen P.
   Bonney, Caitlin F.
TI First reported case of thrombocytopenia from a Heterodon nasicus
   envenomation
SO TOXICON
LA English
DT Review
DE Envenomation; Colubridae; Heterodon nasicus
ID SNAKE-BITES; VENOM; PSEUDECHETOXIN
AB Context The vast majority of the 2.5 million annual worldwide venomous snakebites are attributed to Viperidae or Elapidae envenomations. Of the nearly 2000 Colubridae species described, only a handful are known to cause medically significant envenomations. Considered medically insignificant, Heterodon nasicus (Western Hognose Snake) is a North American rear-fanged colubrid common in the legal pet trading industry. Previously reported cases of envenomations describe local pain, swelling, edema, and blistering. However, there are no reported cases of systemic or hematologic toxicity.
   Case details: A 20-year-old female sustained a bite while feeding a captive H. nasicus causing local symptoms and thrombocytopenia. On day three after envenomation, the patient was seen in the emergency department for persistent pain, swelling, and blistering. At that time, she was found to have a platelet count of 90 x 10(9)/L. Previous routine platelet counts ranged from 315 to 373 x 10(9)/L during the prior two years. Local symptoms peaked on day seven post envenomation. Her local symptoms and thrombocytopenia improved on evaluation four months after envenomation.
   Discussion: We report the first Heterodon nasicus envenomation causing both local toxicity and thrombocytopenia. Potential mechanisms based on H. nasicus venom composition are discussed in detail. Treatment is largely supportive. Bites by H. nascius should be evaluated by a toxicologist familiar with Colubridae species. This represents the first reported case of hematologic toxicity from envenomation by a North American colubrid snake.
C1 [Brandehoff, Nicklaus; Buchanan, Jennie A.; Bonney, Caitlin F.] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO USA.
   [Smith, Cara F.; Mackessy, Stephen P.] Univ Northern Colorado, Sch Biol Sci, Greeley, CO 80639 USA.
   [Brandehoff, Nicklaus] Univ Calif San Francisco, Fresno, CA USA.
RP Brandehoff, N (reprint author), UCSF Fresno, Dept Emergency Med, 155 N Fresno St, Fresno, CA 93701 USA.
EM nick.brandehoff@me.com
OI Mackessy, Stephen/0000-0003-4515-2545; Brandehoff,
   Nicklaus/0000-0002-6140-5963
CR Aird SD, 2005, COMP BIOCHEM PHYS B, V140, P109, DOI 10.1016/j.cbpc.2004.09.020
   Aird SD, 2002, TOXICON, V40, P335, DOI 10.1016/S0041-0101(01)00232-X
   Bragg A. N., 1960, Herpetologica, V16, P121
   Brown RL, 2003, J GEN PHYSIOL, V122, P749, DOI 10.1085/jgp.200308823
   Brown RL, 1999, P NATL ACAD SCI USA, V96, P754, DOI 10.1073/pnas.96.2.754
   Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515
   de Medeiros CR, 2008, TOXICON, V51, P672, DOI 10.1016/j.toxicon.2007.11.022
   Dhananjaya Bhadrapura L., 2010, P155
   GROGAN W L JR, 1974, Herpetologica, V30, P248
   Gutierrez JM, 2005, TOXICON, V45, P997, DOI 10.1016/j.toxicon.2005.02.029
   Gutierrez Jose Maria, 2010, P115
   Heyborne William H., 2010, P325
   Hill RE, 2000, TOXICON, V38, P1663, DOI 10.1016/S0041-0101(00)00091-X
   HOGAN DE, 1990, ANN EMERG MED, V19, P814, DOI 10.1016/S0196-0644(05)81710-X
   Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7
   KROLL J C, 1976, Southwestern Naturalist, V20, P537, DOI 10.2307/3669870
   Lavonas EJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-2
   Mackessy SP, 2016, INTEGR COMP BIOL, V56, P1004, DOI 10.1093/icb/icw110
   Gutierrez JM, 2010, TOXICON, V56, P1223, DOI 10.1016/j.toxicon.2009.11.020
   MORRIS MA, 1985, HERPETOLOGICA, V41, P361
   MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8
   Mowry JB, 2013, CLIN TOXICOL, V51, P949, DOI 10.3109/15563650.2013.863906
   Offerman SR, 2003, J EMERG MED, V24, P289, DOI 10.1016/S0736-4679(02)00763-1
   Phillips S., 1997, Journal of Toxicology Clinical Toxicology, V35, P532
   Reimers AR, 2000, CLIN EXP ALLERGY, V30, P276
   RUSSELL FINDLAY E., 1963, TOXICON, V1, P99, DOI 10.1016/0041-0101(63)90070-9
   Smith CF, 2016, TOXICON, V120, P110, DOI 10.1016/j.toxicon.2016.08.001
   Warrell D.A., 2004, VENOMOUS REPTILES W, P709
   Weinstein SA, 2009, TOXICON, V54, P354, DOI 10.1016/j.toxicon.2009.04.015
   White J, 2005, TOXICON, V45, P951, DOI 10.1016/j.toxicon.2005.02.030
   WHO, 2018, 71 WORLD HLTH ASS
   Yamazaki Y, 2004, TOXICON, V44, P227, DOI 10.1016/j.toxicon.2004.05.023
   Yamazaki Y, 2002, BIOCHEMISTRY-US, V41, P11331, DOI 10.1021/bi026132h
NR 33
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 12
EP 17
DI 10.1016/j.toxicon.2018.11.295
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300003
PM 30465776
DA 2020-05-12
ER

PT J
AU Chernova, E
   Sidelev, S
   Russkikh, I
   Voyakina, E
   Zhakovskaya, Z
AF Chernova, Ekaterina
   Sidelev, Sergey
   Russkikh, Iana
   Voyakina, Ekaterina
   Zhakovskaya, Zoya
TI First observation of microcystin- and anatoxin-a-producing cyanobacteria
   in the easternmost part of the Gulf of Finland (the Baltic Sea)
SO TOXICON
LA English
DT Article
DE Cyanotoxins; Toxin-producing cyanobacteria; Aphanizomenon flos-aquae;
   Planktothrix agardhii; Microcystis aeruginosa
ID NODULARIA-SPUMIGENA; GENETIC DIVERSITY; ANABAENA-STRAINS; APHANIZOMENON;
   BLOOMS; TOXIN; PCR; IDENTIFICATION; PHYTOPLANKTON; ASSOCIATIONS
AB The aim of this study was to obtain the first data on the occurrence and distribution of potentially toxic cyanobacteria and cyanotoxins in the Russian Easternmost part of the Gulf of Finland of the Baltic Sea. Studied samples were collected from 2012 to 2017 and three independent approaches - HPLC-HRMS, PCR and light microscopy were applied for cyanotoxins analysis and detection of toxigenic cyanobacteria. Aphanizomenon flosaquae Ralfs ex Born. et Flah., Planktothrix agardhii (Gom.) Anag. et Kom., Microcystis aeruginosa (Kiltz.) Katz. and Dolichospermum spp. dominated among cyanobacteria in collected samples. In 2012-2013 during research cruises, microcystins concentrations varied from below detection levels to low (0.01-0.6 mu g L-1) values. In the autumn of 2015 and 2017, during cyanobacterial bloom events very high concentrations of microcystins (dissolved up to 49 mu g L-1, intracellular up to 466 mu g g(-1)) and dissolved anatoxin-a (1.4 mu g L-1) were detected. The evaluated toxin profile was represented by most common arginine-containing variants of microcystins (MC-LR, MC-RR, MC-YR) and their desmethylated forms. Leucine-containing congeners (MC-LF; MC-LY; MC-LW for the biomass sample from the coast of Komarovo, 2015) were found at low concentrations. In environmental DNA from bloom samples, we identified mcy genes regions responsible for MC biosynthesis that are specific for Dolichospermum, Microcystis, and Planktothrix. This study is the first molecular evidence the ability of Microcystis aeruginosa and Planktothrix agardhii from the Gulf of Finland to produce microcystins. On the basis of the obtained data of genus-specific PCR and microscopy, we suppose the presence of anatoxin-a-producing Apanizomenon flos-aquae population in the phytoplankton of Russian part of the Gulf of Finland.
C1 [Chernova, Ekaterina; Russkikh, Iana; Voyakina, Ekaterina; Zhakovskaya, Zoya] Inst Russian Acad Sci Russia, St Petersburg Sci Res Ctr Ecol Safety, Korpusnaya Str 18, St Petersburg 197110, Russia.
   [Sidelev, Sergey] Yaroslavl State Univ, Reg Ctr Water Resources Safety, Matrosova 9, Yaroslavl 150057, Russia.
RP Chernova, E (reprint author), Inst Russian Acad Sci Russia, St Petersburg Sci Res Ctr Ecol Safety, Korpusnaya Str 18, St Petersburg 197110, Russia.
EM s3561389@yandex.ru; sidelev@mail.ru; yanarussk@gmail.com;
   katerina.voyakina@gmail.com; zazhak@hotmail.com
OI Russkikh, Iana/0000-0003-1762-3055; Chernova,
   Ekaterina/0000-0002-2135-4540; Voyakina, Ekaterina/0000-0003-4620-5864;
   Sidelev, Sergey/0000-0003-3052-1352; Zhakovskaya,
   Zoya/0000-0002-5620-1317
FU Russian Foundation for Basic Research (RFBR)Russian Foundation for Basic
   Research (RFBR) [N 18-04-01069 A]
FX This work was supported by the Russian Foundation for Basic Research
   (RFBR) "Ecology and metabolic activity of cyanobacteria of different
   types of water bodies in the European part of Russia" [grant number N
   18-04-01069 A].
CR Andreeva I., 2016, SEASONAL INTERANNUAL, P38
   Ballot A, 2010, TOXICON, V56, P964, DOI 10.1016/j.toxicon.2010.06.021
   Barker GLA, 2000, J PHYCOL, V36, P947, DOI 10.1046/j.1529-8817.2000.99146.x
   Belykh OI, 2013, OCEANOLOGY+, V53, P71, DOI 10.1134/S0001437013010025
   Bukowska A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08701-8
   Chernova E, 2017, TOXICON, V130, P47, DOI 10.1016/j.toxicon.2017.02.016
   Chernova E, 2016, OCEANOL HYDROBIOL ST, V45, P466, DOI 10.1515/ohs-2016-0040
   Cires S, 2016, HARMFUL ALGAE, V54, P21, DOI 10.1016/j.hal.2015.09.007
   Dimitrakopoulos IK, 2010, ANAL BIOANAL CHEM, V397, P2245, DOI 10.1007/s00216-010-3727-3
   Fewer DP, 2009, ENVIRON MICROBIOL, V11, P855, DOI 10.1111/j.1462-2920.2008.01806.x
   Gugger M, 2005, APPL ENVIRON MICROB, V71, P1097, DOI 10.1128/AEM.71.2.1097-1100.2005
   Halinen K, 2007, APPL ENVIRON MICROB, V73, P6543, DOI 10.1128/AEM.01377-07
   Karlsson KM, 2005, HARMFUL ALGAE, V4, P163, DOI 10.1016/j.hal.2004.02.002
   Kobos J, 2013, OCEANOL HYDROBIOL ST, V42, P358, DOI 10.2478/s13545-013-0093-8
   Kokocinski M, 2011, ANN LIMNOL-INT J LIM, V47, P363, DOI 10.1051/limn/2011046
   Komarek J, 1998, SUSSWASSERFLORA MITT, V19, P1
   Komarek J, 2013, SUSSWASSERFLORA MITT, V19, P1130, DOI 10.1007/978-3-8274-2737-3
   Komarek J., 2005, SUSSWASSER FLORA MIT, V19, P759
   Laamanen MJ, 2002, APPL ENVIRON MICROB, V68, P5296, DOI 10.1128/AEM.68.11.5296-5303.2002
   Luckas B, 2005, ENVIRON TOXICOL, V20, P1, DOI 10.1002/tox.20072
   Lyra C, 2001, INT J SYST EVOL MICR, V51, P513, DOI 10.1099/00207713-51-2-513
   Mazur H, 2003, OCEANOLOGIA, V45, P305
   MAZUR H., 2003, OCEANOL HYDROBIOL ST, V32, P15
   Ngwa FF, 2014, J APPL PHYCOL, V26, P1675, DOI 10.1007/s10811-013-0199-9
   Olenina I, 2006, BALT SEA ENV P, V106, P1
   Osswald J, 2009, ECOTOXICOLOGY, V18, P1110, DOI 10.1007/s10646-009-0375-5
   Ostermaier V, 2009, MICROB ECOL, V58, P323, DOI 10.1007/s00248-009-9484-1
   Ouahid Y, 2005, ENVIRON TOXICOL, V20, P235, DOI 10.1002/tox.20103
   Pawlik-Skowronska B, 2004, POL J ECOL, V52, P479
   Purvina S., 2008, ACTA U LATV B, V745, P63
   Rantala A, 2006, APPL ENVIRON MICROB, V72, P6101, DOI 10.1128/AEM.01058-06
   Rantala-Ylinen A, 2011, APPL ENVIRON MICROB, V77, P7271, DOI 10.1128/AEM.06022-11
   RAPALA J, 1993, J APPL PHYCOL, V5, P581, DOI 10.1007/BF02184637
   Repka S, 2004, MICROB ECOL, V47, P350, DOI 10.1007/s00248-003-2010-y
   Semenova AS, 2017, BIOL BULL+, V44, P538, DOI 10.1134/S1062359017050156
   Sidelev SI, 2015, MICROBIOLOGY+, V84, P828, DOI 10.1134/S0026261715060120
   SIVONEN K, 1989, APPL ENVIRON MICROB, V55, P1990, DOI 10.1128/AEM.55.8.1990-1995.1989
   SIVONEN K, 1989, TOXIC ASSESS, V4, P339, DOI 10.1002/tox.2540040310
   SIVONEN K, 1999, TOXIC CYANOBACTERIA, P41, DOI DOI 10.4324/9780203478073
   Sivonen K, 2007, AMBIO, V36, P180, DOI 10.1579/0044-7447(2007)36[180:BDAFIT]2.0.CO;2
   Spoof L, 2003, J CHROMATOGR A, V1020, P105, DOI 10.1016/S0021-9673(03)00428-X
   Stal LJ, 2003, CONT SHELF RES, V23, P1695, DOI 10.1016/j.csr.2003.06.001
   Vaitomaa J, 2003, APPL ENVIRON MICROB, V69, P7289, DOI 10.1128/AEM.69.12.7289-7297.2003
   Viaggiu E, 2004, ENVIRON TOXICOL, V19, P191, DOI 10.1002/tox.20011
   WHO, 2003, COAST FRESH WAT, V1
NR 45
TC 3
Z9 3
U1 1
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 18
EP 24
DI 10.1016/j.toxicon.2018.11.005
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300004
PM 30448287
DA 2020-05-12
ER

PT J
AU El Golli-Bennour, E
   Timoumi, R
   Koroit, M
   Bacha, H
   Abid-Essefi, S
AF El Golli-Bennour, Emna
   Timoumi, Rim
   Koroit, Meriam
   Bacha, Hassen
   Abid-Essefi, Salwa
TI Protective effects of kefir against zearalenone toxicity mediated by
   oxidative stress in cultured HCT-116 cells
SO TOXICON
LA English
DT Article
DE Kefir; Zearalenone; Cell viability; Hsp70; Oxidative stress
ID FICUS-INDICA CLADODES; CHROMOSOME-ABERRATIONS; HEAT-SHOCK;
   LACTOBACILLUS-ACIDOPHILUS; MYCOTOXIN ZEARALENONE; PREVENTIVE ROLE; FREE
   FRACTION; BONE-MARROW; VERO CELLS; IN-VITRO
AB Kefir is a fermented milk with numerous health favors counting restorative properties of bacterial flora, reduction of the symptoms of lactose intolerance, immune system stimulation, cholesterol reduction, as well as anti-mutagenic and anti-tumor properties. Zearalenone (ZEN) is a mycotoxin produced by some Fusariwn species. ZEN often occurs as a contaminant in cereal grains and animal feeds. Human exposure occurs by ingestion of mycotoxin-contaminated products and can cause serious health problems.
   This study aimed to assess the preventive effect of kefir against ZEN toxicity in cultured HCT-116 colorectal carcinoma cells; by the evaluation of cell viability, oxidative stress status and the initiation of apoptotic cell death pathway.
   Our results demonstrated that ZEN inhibits cell proliferation which was accompanied by an increase in the generation of free radicals as measured by fluorescent 2,7-dichlorofluorescein (DCF) and Malondialdehyde (MDA). As an adaptive response to this redox status, we showed an induction of heat shock protein expression (Hsp 70) and an activation of antioxidant enzymes; catalase and Superoxide Dismutase (SOD). Moreover, a loss of mitochondrial membrane potential (Atpm) was observed. The co-treatment as well as the pre-treatment by kefir showed a reduction of ZEN induced damages for all tested markers. However, the pre-treatment seems to be the most efficient, it prevented almost all ZEN hazards. Consequently, oxidative damage appears to be a key determinant of ZEN induced toxicity in cultured HCT-116 cells. In conclusion, we showed that kefir may better exert its virtue on preventive mode rather than on curative one. By this way, kefir as a beverage with highly antioxidant properties could be relevant particularly with the emergent demand for natural products which may counteract the detrimental effects of oxidative stress and therefore prevent multiple human diseases.
C1 [El Golli-Bennour, Emna; Timoumi, Rim; Koroit, Meriam; Bacha, Hassen; Abid-Essefi, Salwa] Fac Dent, Lab Res Biol Compatible Cpds, Monastir, Tunisia.
RP El Golli-Bennour, E (reprint author), Fac Dent, Lab Res Biol Compatible Cpds, Monastir, Tunisia.
EM emnagol@yahoo.fr
FU "Le Ministere Tunisien de l'Enseignement Superieur et de la Recherche
   Scientifique"; through the Laboratoire de Recherche sur les Substances
   Biologiquement Compatible
FX This research was supported by "Le Ministere Tunisien de l'Enseignement
   Superieur et de la Recherche Scientifique"; through the Laboratoire de
   Recherche sur les Substances Biologiquement Compatible.
CR Abbes S, 2007, MUTAT RES-GEN TOX EN, V631, P85, DOI 10.1016/j.mrgentox.2007.01.012
   Abbes S, 2006, INT IMMUNOPHARMACOL, V6, P1251, DOI 10.1016/j.intimp.2006.03.012
   Abid-Essefi S, 2004, TOXICOL IN VITRO, V18, P467, DOI 10.1016/j.tiv.2003.12.011
   Abid-Essefi S, 2012, EXP TOXICOL PATHOL, V64, P689, DOI 10.1016/j.etp.2010.12.012
   Abid-Essefi S, 2003, TOXICOLOGY, V192, P237, DOI 10.1016/S0300-483X(03)00329-9
   AYEDBOUSSEMA I, 2007, [No title captured], V639, P85
   BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8
   Ben Salah-Abbes J, 2009, TOXICON, V53, P525, DOI 10.1016/j.toxicon.2009.01.013
   Bennour EEG, 2009, ENVIRON TOXICOL, V24, P538, DOI 10.1002/tox.20449
   Bensmira M, 2010, LWT-FOOD SCI TECHNOL, V43, P1180, DOI 10.1016/j.lwt.2010.04.005
   Bouaziz C, 2008, TOXICOLOGY, V254, P19, DOI 10.1016/j.tox.2008.08.020
   Calabrese V, 2004, ANTIOXID REDOX SIGN, V6, P895, DOI 10.1089/ars.2004.6.895
   Cao J, 2007, FREE RADICAL BIO MED, V43, P968, DOI 10.1016/j.freeradbiomed.2007.06.006
   CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1
   CEVIKBAS A, 1994, PHYTOTHER RES, V8, P78, DOI 10.1002/ptr.2650080205
   Chen YP, 2013, J DAIRY SCI, V96, P7467, DOI 10.3168/jds.2013-7015
   Chen ZN, 2015, INT DAIRY J, V43, P15, DOI 10.1016/j.idairyj.2014.10.004
   CLAIBORNE A, 1985, CRC HDB METHODS OXYG, P283
   Conkova E, 2001, TOXICOL LETT, V121, P145, DOI 10.1016/S0378-4274(01)00312-5
   Corthesy B, 2007, J NUTR, V137, p781S, DOI 10.1093/jn/137.3.781S
   Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P642
   Diniz RO, 2003, PHARMACOL RES, V47, P49, DOI 10.1016/S1043-6618(02)00240-2
   Donmez-Altuntas H, 2007, J APPL TOXICOL, V27, P337, DOI 10.1002/jat.1209
   Durackova Z, 2010, PHYSIOL RES, V59, P459
   El Golli E, 2006, TOXICOL LETT, V166, P122, DOI 10.1016/j.toxlet.2006.06.004
   El Golli-Bennour E, 2011, TOXICOLOGY, V287, P1, DOI 10.1016/j.tox.2011.06.002
   Eriksen G. S., 1998, CEREALS RISK ASSESSM, V502, P7
   Farnworth E. R., 2005, Food Science and Technology Bulletin:  Functional Foods, V2, P1, DOI 10.1616/1476-2137.13938
   Farnworth ER, 2008, FUNCT FOOD NUTRA SER, P89
   Fehrenbach E, 2001, EXERC IMMUNOL REV, V7, P66
   Gao J, 2013, INT DAIRY J, V30, P14, DOI 10.1016/j.idairyj.2012.11.011
   Gao J, 2012, J FOOD SCI, V77, pM425, DOI 10.1111/j.1750-3841.2012.02805.x
   Garrote G. L., 2010, BIOTECHNOLOGY LACTIC, P327, DOI DOI 10.1002/9780813820866.CH18
   Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003
   GREEN ML, 1990, J ANIM SCI, V68, P171
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   Hassen W., 2005, TOXICOLOGY, V25, P203
   Hassen W, 2007, TOXICOLOGY, V232, P294, DOI 10.1016/j.tox.2007.01.015
   Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66
   Hoeschen RJ, 1997, CAN J CARDIOL, V13, P1021
   Kakisu E, 2013, J DAIRY RES, V80, P64, DOI 10.1017/S0022029912000659
   Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X
   Kim IH, 2003, TOXICOL LETT, V138, P185, DOI 10.1016/S0378-4274(02)00405-8
   Kullisaar T, 2002, INT J FOOD MICROBIOL, V72, P215, DOI 10.1016/S0168-1605(01)00674-2
   Le Guevel R, 2001, HUM REPROD, V16, P1030, DOI 10.1093/humrep/16.5.1030
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Lee MY, 2007, IMMUNOBIOLOGY, V212, P647, DOI 10.1016/j.imbio.2007.05.004
   Lin MY, 2000, DIGEST DIS SCI, V45, P1617, DOI 10.1023/A:1005577330695
   Lioi MB, 2004, MUTAT RES-GEN TOX EN, V557, P19, DOI 10.1016/j.mrgentox.2003.09.009
   Maaroufi K, 1996, TOXICON, V34, P535, DOI 10.1016/0041-0101(96)00008-6
   Mahapatra Subhadip, 2013, Microbiol Insights, V6, P1, DOI 10.4137/MBI.S10957
   MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1
   Mohamad N, 2005, BIOCELL, V29, P149
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Barboza KRM, 2018, LIFE SCI, V209, P370, DOI 10.1016/j.lfs.2018.08.035
   Murata H, 2003, VET HUM TOXICOL, V45, P18
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Ouanes Z, 2005, MUTAT RES-GEN TOX EN, V565, P139, DOI 10.1016/j.mrgentox.2004.10.005
   Phillips TD, 1999, TOXICOL SCI, V52, P118, DOI 10.1093/toxsci/52.2.118
   Quiros A, 2005, J DAIRY SCI, V88, P3480, DOI 10.3168/jds.S0022-0302(05)73032-0
   Rattray F, 2011, ENCY DAIRY SCI, V2, P518
   Rizk S, 2009, CLIN LYMPHOMA MYELOM, V9, pS198, DOI 10.3816/CLM.2009.s.012
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   Salminen WF, 1998, J PHARMACOL EXP THER, V286, P519
   Santos A, 2003, SYST APPL MICROBIOL, V26, P434, DOI 10.1078/072320203322497464
   Satir G, 2016, SMALL RUMINANT RES, V134, P1, DOI 10.1016/j.smallrumres.2015.10.022
   Savini M, 2010, NUTRIENTS, V2, P330, DOI 10.3390/nu2030330
   Servin AL, 2004, FEMS MICROBIOL REV, V28, P405, DOI 10.1016/j.femsre.2004.01.003
   Songisepp E, 2004, J DAIRY SCI, V87, P2017, DOI 10.3168/jds.S0022-0302(04)70019-3
   Tamime A. Y., 2006, PRODUCTION KEFIR KOU, P174
   Vinderola CG, 2005, J DAIRY RES, V72, P195, DOI 10.1017/S0022029905000828
   Wang W, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/10/105103
   Wang YC, 2006, FOOD MICROBIOL, V23, P128, DOI 10.1016/j.fm.2005.01.020
   West JD, 2006, CHEM RES TOXICOL, V19, P173, DOI 10.1021/tx050321u
   Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229, DOI 10.1016/S1081-1206(10)63007-4
   WOOD GE, 1992, J ANIM SCI, V70, P3941
   Yilmaz-Ersan L, 2018, J DAIRY SCI, V101, P3788, DOI 10.3168/jds.2017-13871
   Zorgui L, 2009, FOOD CHEM TOXICOL, V47, P662, DOI 10.1016/j.fct.2008.12.031
   Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2
   Zourgui L, 2008, FOOD CHEM TOXICOL, V46, P1817, DOI 10.1016/j.fct.2008.01.023
NR 80
TC 1
Z9 1
U1 6
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 25
EP 34
DI 10.1016/j.toxicon.2018.11.296
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300005
PM 30448289
DA 2020-05-12
ER

PT J
AU Xie, YL
   Wang, W
   Zhang, SJ
AF Xie, Yanli
   Wang, Wei
   Zhang, Shujie
TI Purification and identification of an aflatoxin B-1 degradation enzyme
   from Pantoea sp. T6
SO TOXICON
LA English
DT Article
DE Aflatoxin B-1; Aflatoxin-degrading enzyme; Pantoea sp.; Purification
ID LACTIC-ACID BACTERIA; DAIRY STRAINS; DETOXIFICATION; BINDING; ABILITY;
   CONTAMINATION; PROTEINS; OZONE; FEED; FOOD
AB Aflatoxin B-1 (AFB(1)) is a secondary metabolite produced by Aspergillus fiavus and other fungi. Soil, crops, food, feed, etc. were susceptible to aflatoxin B-1 contamination, which caused adverse economic and health consequences. It is necessary to search for microorganisms or microbial enzymes that can degrade AFB(1). The degradation activity of AFB(1) by cell-free supernatant (68.30%) of isolate Pantoea sp. T6 was significantly higher (P < 0.05) than viable bacterial cells (4.87%) and intracellular cell extracts (3.68%). The supernatant's AFB(1) degradation activity was reduced from 68.30% to 5.33% in treatment with protease K and sodium dodecyl sulphate (SDS). An extracellular enzyme from the supernatant was secreted by Pantoea sp. T6 and was named as Pantoea aflatoxin degradation enzyme (PADE), which was obtained using Diethylaminoethanol (DEAE)Sepharose chromatography. PADE was further purified by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The PADE, outer membrane protein A, was identified by mass spectrometry and molecular mass was 38180.1Da. The optimum temperature and pH for the reaction of PADE with AFBI were 40 degrees C and 7.0, respectively. These finding showing that the PADE, which was isolated from the supernatant of Pantoea sp. T6, has the ability to degrade AFB(1), and may have potential application for aflatoxin B-1 reduction in the food and feed industry.
C1 [Xie, Yanli; Wang, Wei] Henan Univ Technol, Sch Food Sci & Technol, Henan Key Lab Cereal & Oil Food Safety Inspect &, Zhengzhou 450001, Henan, Peoples R China.
   [Zhang, Shujie] Henan Normal Univ, Coll Life Sci, Xinxiang 453007, Henan, Peoples R China.
RP Xie, YL (reprint author), Henan Univ Technol, Sch Food Sci & Technol, Henan Key Lab Cereal & Oil Food Safety Inspect &, Zhengzhou 450001, Henan, Peoples R China.
EM ylxie@haut.edu.cn; wangwei20160801@163.com; sjzhang2016@hotmail.com
OI Xie, Yanli/0000-0002-3895-5959
FU Science and Technology Project of Science and Technology Department of
   Henan Province, China [162102310084]; Emerging Industry Research Project
   of Zhengzhou City, China [20150503]
FX This work was supported by the Science and Technology Project of Science
   and Technology Department of Henan Province, China (No. 162102310084)
   and Emerging Industry Research Project of Zhengzhou City, China (No.
   20150503).
CR Adebo OA, 2017, CRIT REV FOOD SCI, V57, P3208, DOI 10.1080/10408398.2015.1106440
   Adebo OA, 2016, FOOD CONTROL, V68, P92, DOI 10.1016/j.foodcont.2016.03.021
   Alberts JF, 2009, INT J FOOD MICROBIOL, V135, P47, DOI 10.1016/j.ijfoodmicro.2009.07.022
   Amaike S, 2011, ANNU REV PHYTOPATHOL, V49, P107, DOI 10.1146/annurev-phyto-072910-095221
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BULLERMAN LB, 1977, J FOOD SCI, V42, P1107, DOI 10.1111/j.1365-2621.1977.tb12677.x
   BUONFIGLIO V, 1993, FEMS MICROBIOL REV, V11, P43, DOI 10.1111/j.1574-6976.1993.tb00265.x
   Cao H, 2011, MICROBIOL RES, V166, P475, DOI 10.1016/j.micres.2010.09.002
   Chen R, 2014, FOOD CHEM, V146, P284, DOI 10.1016/j.foodchem.2013.09.059
   Diaz DE, 2004, MYCOPATHOLOGIA, V157, P233, DOI 10.1023/B:MYCO.0000020587.93872.59
   DIENER UL, 1987, ANNU REV PHYTOPATHOL, V25, P249, DOI 10.1146/annurev.py.25.090187.001341
   Dogi CA, 2011, FOOD ADDIT CONTAM A, V28, P1705, DOI 10.1080/19440049.2011.605771
   El-Nezami H, 1998, FOOD CHEM TOXICOL, V36, P321, DOI 10.1016/S0278-6915(97)00160-9
   Farzaneh M, 2012, FOOD CONTROL, V23, P100, DOI 10.1016/j.foodcont.2011.06.018
   Juri MGF, 2015, J APPL MICROBIOL, V118, P574, DOI 10.1111/jam.12726
   Ghanem I, 2008, BRAZ J MICROBIOL, V39, P787, DOI [10.1590/S1517-83822008000400035, 10.1590/S1517-838220080004000035]
   Guan S, 2008, INT J MOL SCI, V9, P1489, DOI 10.3390/ijms9081489
   Hanson KG, 1997, CURR MICROBIOL, V35, P191, DOI 10.1007/s002849900237
   Hormisch D, 2004, SYST APPL MICROBIOL, V27, P653, DOI 10.1078/0723202042369866
   Jin JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017027
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Larsen AN, 2006, FEBS J, V273, P47, DOI 10.1111/j.1742-4658.2005.05044.x
   Luo XH, 2014, FOOD CONTROL, V37, P171, DOI 10.1016/j.foodcont.2013.09.043
   Moerck K. E., 1980, J FOOD PROTECT, V182, P4077
   Motomura M, 2003, MICROBIOL RES, V158, P237, DOI 10.1078/0944-5013-00199
   Peltonen K, 2001, J DAIRY SCI, V84, P2152, DOI 10.3168/jds.S0022-0302(01)74660-7
   Petchkongkaew A, 2008, J APPL MICROBIOL, V104, P1495, DOI 10.1111/j.1365-2672.2007.03700.x
   Rao KR, 2017, FOOD CONTROL, V71, P234, DOI 10.1016/j.foodcont.2016.06.040
   Rastegar H, 2017, FOOD CONTROL, V71, P279, DOI 10.1016/j.foodcont.2016.06.045
   Reddy KRN, 2010, TOXIN REV, V29, P3, DOI 10.3109/15569541003598553
   Shao S, 2016, FOOD SCI BIOTECHNOL, V25, P1789, DOI 10.1007/s10068-016-0272-7
   Smiley RD, 2000, J FOOD PROTECT, V63, P415, DOI 10.4315/0362-028X-63.3.415
   Taylor MC, 2010, MOL MICROBIOL, V78, P561, DOI 10.1111/j.1365-2958.2010.07356.x
   Teniola OD, 2005, INT J FOOD MICROBIOL, V105, P111, DOI 10.1016/j.ijfoodmicro.2005.05.004
   Tripathi S., 2009, INT J FOOD SAF NUTR, V2, P325
   Trucksess MW, 2000, OFFICIAL METHODS ANA
   Verheecke C, 2014, LETT APPL MICROBIOL, V58, P597, DOI 10.1111/lam.12233
   Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2
   Walzer G, 2006, ENVIRON MICROBIOL, V8, P1026, DOI 10.1111/j.1462-2920.2006.00994.x
   Wang JQ, 2011, FEMS MICROBIOL LETT, V314, P164, DOI 10.1111/j.1574-6968.2010.02158.x
   Wang SQ, 2015, EUR FOOD RES TECHNOL, V241, P103, DOI 10.1007/s00217-015-2439-5
   Xu L, 2017, TOXINS, V9, DOI 10.3390/toxins9010036
   Zhao HF, 2016, FOOD CHEM TOXICOL, V97, P40, DOI 10.1016/j.fct.2016.08.028
   Zhao LH, 2011, J APPL MICROBIOL, V110, P147, DOI 10.1111/j.1365-2672.2010.04867.x
   Zhu Y, 2016, ANIM FEED SCI TECH, V216, P19, DOI 10.1016/j.anifeedsci.2016.03.030
   Zjalic S, 2006, INT J FOOD MICROBIOL, V107, P243, DOI 10.1016/j.ijfoodmicro.2005.10.003
NR 46
TC 3
Z9 3
U1 10
U2 61
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 35
EP 42
DI 10.1016/j.toxicon.2018.11.290
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300006
PM 30447276
DA 2020-05-12
ER

PT J
AU Gaikwad, S
   Pawar, Y
   Banerjee, S
   Kulkarni, S
AF Gaikwad, Sujay
   Pawar, Yogita
   Banerjee, Sharmila
   Kulkarni, Savita
TI Potential immunomodulatory effect of allelochemical juglone in mice
   vaccinated with BCG
SO TOXICON
LA English
DT Article
DE Juglone; Immunomodulation; BCG vaccine; Immune response; Cytokine ratio;
   IgG2a/IgG1 ratio
ID CELL-CYCLE; T-CELLS; IN-VIVO; ENERGY-METABOLISM; IFN-GAMMA; PIN1;
   EFFICACY; CANCER; RESPONSES; IL-10
AB Juglone, a naphthoquinone is a known phytotoxic and cytotoxic allelochemical. Various anticancer studies suggest that pharmacological ROS insult and enzymes inhibited by juglone could be of therapeutic utility. In this study, we show that juglone induces immunomodulation in BCG-vaccinated mice. We have shown that juglone treatment leads to the generation of Th1 cytokines which develops an M1 phenotype in splenic macrophages. These findings were supported by a decrease in Treg population in BCG-vaccinated mice treated with juglone. Additionally, we observed juglone significantly increases CD8(+) and T-helper memory population in BCG-vaccinated mice under immunomodulation. Further, BCG-challenge test showed that juglone enhances effector immune functions. Our finding was demonstrated by estimating ex-vivo Th1 and Th2 cytokines, flow cytometric analysis of Treg, T-helper memory, and CD8(+) cells and determining serum IgG2a/IgG1 titer shift in BCG-vaccinated animals treated with juglone. Collectively, our findings provide evidence that juglone may act as immunomodulator when used at a low dose, metronomically.
C1 [Gaikwad, Sujay; Pawar, Yogita; Banerjee, Sharmila; Kulkarni, Savita] Bhabha Atom Res Ctr, Radiat Med Ctr, Bombay, Maharashtra, India.
   [Gaikwad, Sujay; Kulkarni, Savita] Homi Bhabha Natl Inst, Bombay, Maharashtra, India.
RP Kulkarni, S (reprint author), Bhabha Atom Res Ctr, Tata Mem Ctr Annex, E Borges Marg, Bombay 400012, Maharashtra, India.
EM savitapk@barc.gov.in
FU Bhabha Atomic Research Centre; Department of Atomic Energy (DAE),
   Government of IndiaDepartment of Atomic Energy (DAE)
FX This work was funded by Bhabha Atomic Research Centre which is part of
   Department of Atomic Energy (DAE), Government of India.
CR Aithal KB, 2012, INTEGR CANCER THER, V11, P68, DOI 10.1177/1534735411403477
   Bais HP, 2006, ANNU REV PLANT BIOL, V57, P233, DOI 10.1146/annurev.arplant.57.032905.105159
   Bali P, 2015, IMMUNOTHERAPY-UK, V7, P945, DOI 10.2217/imt.15.60
   Bettini ML, 2010, ANN NY ACAD SCI, V1183, P1, DOI 10.1111/j.1749-6632.2009.05129.x
   Brode S, 2008, CRIT REV IMMUNOL, V28, P109, DOI 10.1615/CritRevImmunol.v28.i2.20
   Cao ZY, 2014, ONCOL LETT, V7, P1260, DOI 10.3892/ol.2014.1856
   Casares N, 2010, J IMMUNOL, V185, P5150, DOI 10.4049/jimmunol.1001114
   Chae JI, 2012, INT J MOL MED, V30, P8, DOI 10.3892/ijmm.2012.969
   Choi JH, 2016, J EUR ACAD DERMATOL, V30, P13
   Cobos C, 2014, INT REV IMMUNOL, V33, P383, DOI 10.3109/08830185.2014.911857
   Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
   da Silva CCC, 2008, AGING CELL, V7, P552, DOI 10.1111/j.1474-9726.2008.00407.x
   Dai CS, 2016, FOOD CHEM TOXICOL, V95, P52, DOI 10.1016/j.fct.2016.06.025
   Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947
   de Biasi AR, 2014, CLIN CANCER RES, V20, P5384, DOI 10.1158/1078-0432.CCR-14-1298
   ELSE KJ, 1993, PARASITE IMMUNOL, V15, P595
   Esnault S, 2008, CRIT REV IMMUNOL, V28, P45, DOI 10.1615/CritRevImmunol.v28.i1.30
   Fang F, 2015, IRAN J BASIC MED SCI, V18, P544
   Fila C, 2008, J BIOL CHEM, V283, P21714, DOI 10.1074/jbc.M710264200
   Fischer K, 2002, J IMMUNOL, V168, P2689, DOI 10.4049/jimmunol.168.6.2689
   Grifka-Walk HM, 2015, EUR J IMMUNOL, V45, P2780, DOI 10.1002/eji.201545800
   Nguyen HV, 2012, BLOOD, V119, P4174, DOI 10.1182/blood-2011-09-378182
   Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552
   Hsieh CH, 2009, AM J PATHOL, V175, P1504, DOI 10.2353/ajpath.2009.081174
   Hwang SA, 2009, TUBERCULOSIS, V89, pS49, DOI 10.1016/S1472-9792(09)70012-5
   Inoue S, 2014, EXP THER MED, V7, P703, DOI 10.3892/etm.2014.1489
   Jin X, 2016, INT J PHARMACEUT, V515, P359, DOI 10.1016/j.ijpharm.2016.10.027
   Karki N., 2016, ANTIANGIOGENIC ANTIM
   Kaveh DA, 2014, VACCINE, V32, P6911, DOI 10.1016/j.vaccine.2014.10.041
   Krawczyk E, 2005, J PHARM PHARMACOL, V57, P791, DOI 10.1211/0022357056235
   Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906
   Lee TH, 2009, NAT CELL BIOL, V11, P97, DOI 10.1038/ncb1818
   Li L, 2007, TUBERCULOSIS, V87, P526, DOI 10.1016/j.tube.2007.07.004
   Li L, 2011, IMMUNOBIOLOGY, V216, P477, DOI 10.1016/j.imbio.2010.09.003
   LI WJ, 2015, CLIN GASTROENTEROL H, V13, pE92
   Lin CH, 2015, EXP BIOL MED, V240, P403, DOI 10.1177/1535370215570829
   Liu X, 2016, BIOCHEM BIOPH RES CO, V479, P109, DOI 10.1016/j.bbrc.2016.09.050
   Lv L, 2013, J CELL MOL MED, V17, P989, DOI 10.1111/jcmm.12082
   Macallan DC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010005
   Machiels JPH, 2001, CANCER RES, V61, P3689
   Masihi KN, 2001, EXPERT OPIN BIOL TH, V1, P641, DOI 10.1517/14712598.1.4.641
   Matar P, 2002, CANCER IMMUNOL IMMUN, V50, P588, DOI 10.1007/s00262-001-0237-3
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nandakumar S., 2016, MYCOBACT TUBERC SCI, V6
   Nars MS, 2013, INT J CANCER, V132, P2471, DOI 10.1002/ijc.27801
   Orr MT, 2015, J INFECT DIS, V212, P495, DOI 10.1093/infdis/jiv055
   Paulsen MT, 2005, TOXICOL APPL PHARM, V209, P1, DOI 10.1016/j.taap.2005.03.005
   Pektas M.B., 2018, CAN J PHYSL PHARM, P1
   Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061
   Rohas LM, 2007, P NATL ACAD SCI USA, V104, P7933, DOI 10.1073/pnas.0702683104
   Sabado RL, 2010, IMMUNOTHERAPY-UK, V2, P37, DOI 10.2217/IMT.09.43
   Saling SC, 2011, TOXICOL APPL PHARM, V257, P319, DOI 10.1016/j.taap.2011.09.004
   Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012
   Shankaranarayanan JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep32062
   Shen E., 2013, CELL BIOL INT, V35, P705
   Siddiqui KF, 2015, CLIN EXP IMMUNOL, V181, P286, DOI 10.1111/cei.12634
   Singh DK, 2016, J INFECT DIS, V214, P1456, DOI 10.1093/infdis/jiw395
   Sistigu A, 2011, SEMIN IMMUNOPATHOL, V33, P369, DOI 10.1007/s00281-011-0245-0
   Song M, 2017, ANTON LEEUW INT J G, V110, P1069, DOI 10.1007/s10482-017-0880-0
   Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517
   Varga Z, 1996, BIOCHEM BIOPH RES CO, V218, P828, DOI 10.1006/bbrc.1996.0147
   von Kiparski GR, 2007, J ENVIRON QUAL, V36, P709, DOI 10.2134/jeq2006.0231
   Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200
   Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107
   You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037
   Young S, 2002, IMMUNOL CELL BIOL, V80, P209, DOI 10.1046/j.1440-1711.2002.01078.x
   Zagozdzon R, 2001, INT J ONCOL, V18, P417
   Zhang W, 2012, CAN J PHYSIOL PHARM, V90, P1553, DOI 10.1139/y2012-134
NR 68
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 43
EP 52
DI 10.1016/j.toxicon.2018.11.003
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300007
PM 30419248
DA 2020-05-12
ER

PT J
AU White, J
   Weinstein, SA
   De Haro, L
   Bedry, R
   Schaper, A
   Rumack, BH
   Zilker, T
AF White, Julian
   Weinstein, Scott A.
   De Haro, Luc
   Bedry, Regis
   Schaper, Andreas
   Rumack, Barry H.
   Zilker, Thomas
TI Mushroom poisoning: A proposed new clinical classification
SO TOXICON
LA English
DT Review
DE Mushrooms; Mushroom poisoning; Poisonous mushrooms; Diagnostic
   algorithm; Hepatotoxicity; Renal failure; Rhabdomyolysis
ID FULMINANT HEPATIC-FAILURE; MYSTICAL-TYPE EXPERIENCES;
   ACUTE-RENAL-FAILURE; CASE SERIES; MUSCARINIC SYNDROME; INGESTION;
   CONSUMPTION; IDENTIFICATION; INTOXICATION; PSILOCYBIN
AB Mushroom poisoning is a significant and increasing form of toxin-induced-disease. Existing classifications of mushroom poisoning do not include more recently described new syndromes of mushroom poisoning and this can impede the diagnostic process. We reviewed the literature on mushroom poisoning, concentrating on the period since the current major classification published in 1994, to identify all new syndromes of poisoning and organise them into a new integrated classification, supported by a new diagnostic algorithm. New syndromes were eligible for inclusion if there was sufficient detail about both causation and clinical descriptions. Criteria included: identity of mushrooms, clinical profile, epidemiology, and the distinctive features of poisoning in comparison with previously documented syndromes. We propose 6 major groups based on key clinical features relevant in distinguishing between poisoning syndromes. Some clinical features, notably gastrointestinal symptoms, are common to many mushroom poisoning syndromes. Group 1 - Cytotoxic mushroom poisoning. Syndromes with specific major internal organ pathology: (Subgroup 1.1; Primary hepatotoxicity); 1A, primary hepatotoxicity (amatoxins); (Subgroup 1.2; Primary nephrotoxicity); 1B, early primary nephrotoxicity (amino hexadienoic acid; AHDA); 1C, delayed primary nephrotoxicity (orellanines). Group 2 - Neurotoxic mushroom poisoning. Syndromes with primary neurotoxicity: 2A, hallucinogenic mushrooms (psilocybins and related toxins); 2B, autonomic-toxicity mushrooms (muscarines); 2C, CNS-toxicity mushrooms (ibotenic acid/muscimol); 2D, morel neurologic syndrome (Morchella spp.). Group 3 - Myotoxic mushroom poisoning. Syndromes with rhabdomyolysis as the primary feature: 3A, rapid onset (Russula spp.); 3B, delayed onset (Tricholoma spp.). Group 4 - Metabolic, endocrine and related toxicity mushroom poisoning. Syndromes with a variety of clinical presentations affecting metabolic and/or endocrine processes: 4A, GABA-blocking mushroom poisoning (gyromitrins); 4B, disulfiram-like (coprines); 4C, polyporic mushroom poisoning (polyporic acid); 4D, trichothecene mushroom poisoning (Podostroma spp.); 4E, hypoglycaemic mushroom poisoning (Trogia venenata); 4F, hyperprocalcitoninemia mushroom poisoning (Boletus satanas); 4G, pancytopenic mushroom poisoning (Ganoderma neojaponicum). Group 5 - Gastrointestinal irritant mushroom poisoning. This group includes a wide variety of mushrooms that cause gastrointestinal effects without causing other clinically significant effects. Group 6 - Miscellaneous adverse reactions to mushrooms. Syndromes which do not fit within the previous 5 groups: 6A, Shiitake mushroom dermatitis; 6B, erythromelagic mushrooms (Clitocybe acromelagia); 6C, Paxillus syndrome (Paxillus involutus); 6D, encephalopathy syndrome (Pleurocybella porrigens).
C1 [White, Julian; Weinstein, Scott A.] Womens & Childrens Hosp, Toxinol Dept, 72 King William Rd, Adelaide, SA 5006, Australia.
   [De Haro, Luc] Hop St Marguerite, Marseille Poison Ctr, Marseille, France.
   [Bedry, Regis] Pellegrin Univ Hosp, Hosp Secure Unit, Bordeaux, France.
   [Schaper, Andreas] Univ Med Ctr Goettingen, GIZ Nord Poisons Ctr, Gottingen, Germany.
   [Rumack, Barry H.] Univ Colorado, Sch Med, Dept Emergency Med & Pediat, Aurora, CO USA.
   [Zilker, Thomas] Tech Univ Munich, Med Klin, Dept Clin Toxicol 2, Munich, Germany.
RP White, J (reprint author), Womens & Childrens Hosp, Toxinol Dept, 72 King William Rd, Adelaide, SA 5006, Australia.
EM julian.white@adelaide.edu.au
OI de Haro, Luc/0000-0003-2250-6312
CR Ahn JY, 2013, YONSEI MED J, V54, P265, DOI 10.3349/ymj.2013.54.1.265
   Anand Jacek Sein, 2009, Przegl Lek, V66, P339
   Bedry R, 2001, NEW ENGL J MED, V345, P798, DOI 10.1056/NEJMoa010581
   Bedry R, 2009, REV MED INTERNE, V30, P640, DOI 10.1016/j.revmed.2009.03.017
   Bedry R, 2002, REANIMATION, V11, P524
   Ben Khelil M, 2010, ANN BIOL CLIN-PARIS, V68, P561, DOI 10.1684/abc.2010.0467
   Besancon A, 2012, ANN FR ANESTH, V31, P466, DOI 10.1016/j.annfar.2012.01.021
   Bonacini M, 2017, CLIN GASTROENTEROL H, V15, P776, DOI 10.1016/j.cgh.2016.11.039
   BOUGET J, 1990, INTENS CARE MED, V16, P506, DOI 10.1007/BF01709401
   BUDMIGER H, 1982, SCHWEIZ MED WSCHR, V112, P1179
   Carlvik B, 2017, CLIN TOXICOL, V55, P374
   Cho JT, 2016, J KOREAN MED SCI, V31, P1164, DOI 10.3346/jkms.2016.31.7.1164
   Chu EY, 2013, CUTIS, V91, P287
   Chwaluk Pawel, 2013, Przegl Lek, V70, P684
   DADPOUR B, 2017, [No title captured], V5
   Danel VC, 2001, TOXICON, V39, P1053, DOI 10.1016/S0041-0101(00)00248-8
   De Haro L, 1999, PRESSE MED, V28, P1069
   Diaz JH, 2018, WILD ENVIRON MED, V29, P111, DOI 10.1016/j.wem.2017.10.002
   Diaz JH, 2005, CRIT CARE MED, V33, P419, DOI 10.1097/01.CCM.0000153530.32162.B7
   FANTOZZI R, 1986, KLIN WOCHENSCHR, V64, P38, DOI 10.1007/BF01721579
   Flammer Rene, 2009, Ther Umsch, V66, P357, DOI 10.1024/0040-5930.66.5.357
   Frank H, 2009, CLIN NEPHROL, V71, P557
   Frimlova G, 2017, CLIN TOXICOL, V55, P373
   Gawlikowski T, 2015, HUM EXP TOXICOL, V34, P718, DOI 10.1177/0960327114557901
   Gejyo F, 2005, KIDNEY INT, V68, P188, DOI 10.1111/j.1523-1755.2005.00393.x
   Golob N, 2017, CLIN TOXICOL, V55, P375
   Gonmori Kunio, 2009, Chudoku Kenkyu, V22, P61
   Grebe SO, 2013, RENAL FAILURE, V35, P1436, DOI 10.3109/0886022X.2013.826110
   Griffiths RR, 2008, J PSYCHOPHARMACOL, V22, P621, DOI 10.1177/0269881108094300
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5
   Haberl B, 2011, CLIN TOXICOL, V49, P113, DOI 10.3109/15563650.2011.554840
   Hiroshima Y, 2010, THER APHER DIAL, V14, P483, DOI 10.1111/j.1744-9987.2010.00862.x
   Hori K, 2008, INT J SURG PATHOL, V16, P62, DOI 10.1177/1066896907306883
   Horn S, 1997, AM J KIDNEY DIS, V30, P282, DOI 10.1016/S0272-6386(97)90066-4
   Hu JS, 2012, J SCI FOOD AGR, V92, P2664, DOI 10.1002/jsfa.5685
   Huang Liang, 2009, BMJ Case Rep, V2009, DOI 10.1136/bcr.06.2008.0327
   [黄文丽 Huang Wenli], 2007, [中华流行病学杂志, Chinese Journal of Epidemiology], V28, P233
   Jang J, 2013, TUBERC RESPIR DIS, V75, P264, DOI 10.4046/trd.2013.75.6.264
   Johnson MW, 2012, DRUG ALCOHOL DEPEN, V123, P132, DOI 10.1016/j.drugalcdep.2011.10.029
   Dinis-Oliveira RJ, 2016, HUM EXP TOXICOL, V35, P1016, DOI 10.1177/0960327115613845
   Kang E, 2015, KIDNEY RES CLIN PRAC, V34, P233, DOI 10.1016/j.krcp.2015.05.007
   Karahan S, 2016, J INVESTIG MED HIGH, V4, P1
   Kervegant M, 2013, WILD ENVIRON MED, V24, P170, DOI 10.1016/j.wem.2012.11.002
   Kim HN, 2016, CLIN EXP EMERG MED, V3, P186, DOI 10.15441/ceem.15.028
   Kim So Yeon, 2018, Korean J Gastroenterol, V71, P94, DOI 10.4166/kjg.2018.71.2.94
   Kirchmair M, 2012, NEPHROL DIAL TRANSPL, V27, P1380, DOI 10.1093/ndt/gfr511
   Klan J, 1993, Cas Lek Cesk, V132, P449
   Lang NN, 2016, J DTSCH DERMATOL GES, V14, P303, DOI 10.1111/ddg.12769
   Latha SS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00090
   Laubner Gabija, 2016, Acta Med Litu, V23, P193, DOI 10.6001/actamedica.v23i3.3385
   Lin SD, 2015, WILD ENVIRON MED, V26, P380, DOI 10.1016/j.wem.2015.03.027
   Lurie Y, 2009, CLIN TOXICOL, V47, P562, DOI 10.1080/15563650903008448
   Madhok M, 2006, PEDIATR EMERG CARE, V22, P177, DOI 10.1097/01.pec.0000202459.49731.33
   Madhok Manu, 2007, Minn Med, V90, P48
   Matsuura M, 2016, CHEM PHARM BULL, V64, P602, DOI 10.1248/cpb.c15-01033
   Matsuura M, 2009, NAT CHEM BIOL, V5, P465, DOI 10.1038/nchembio.179
   Merlet A, 2012, CLIN INFECT DIS, V54, DOI 10.1093/cid/cir845
   Mikaszewska-Sokolewicz MA, 2016, ACTA BIOCHIM POL, V63, P181, DOI 10.18388/abp.2015_1170
   Minami T., 2009, BRIT J PHARMACOL, V142, P679
   Mottram AR, 2010, J MED TOXICOL, V6, P155, DOI 10.1007/s13181-010-0062-1
   Nakajima N, 2013, CLIN TOXICOL, V51, P451, DOI 10.3109/15563650.2013.792933
   Nishizawa Masatoyo, 2005, Rinsho Shinkeigaku, V45, P818
   Nomoto Tatsuya, 2007, Journal of Nippon Medical School, V74, P261, DOI 10.1272/jnms.74.261
   Nummela-Salo U., 2005, SUOMEN HELTTASIENTEN, V769, P33
   Obara K, 2008, NEUROPATHOLOGY, V28, P151, DOI 10.1111/j.1440-1789.2007.00819.x
   Parnmen S, 2016, J TOXICOL SCI, V41, P65, DOI 10.2131/jts.41.65
   Pauli JL, 2005, MED J AUSTRALIA, V182, P294, DOI 10.5694/j.1326-5377.2005.tb06705.x
   Pfab R, 2008, CLIN TOXICOL, V46, P259, DOI 10.1080/15563650701206715
   RAMIREZ P, 1993, J HEPATOL, V19, P51, DOI 10.1016/S0168-8278(05)80175-8
   Ren Cheng-shan, 2007, Zhonghua Nei Ke Za Zhi, V46, P229
   Rogart JN, 2008, J CLIN GASTROENTEROL, V42, P662, DOI 10.1097/MCG.0b013e3181595b7c
   Roux X, 2008, ANN FR ANESTH, V27, P450, DOI 10.1016/j.annfar.2008.03.003
   Satora Leszek, 2005, Przegl Lek, V62, P394
   Saviuc Philippe, 2006, Toxicol Rev, V25, P199, DOI 10.2165/00139709-200625030-00004
   Saviuc P, 2010, CLIN TOXICOL, V48, P365, DOI 10.3109/15563651003698034
   Schenk-Jager KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162314
   Shi GQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035894
   Shi Guo-qing, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P96
   Shi GQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038712
   Spoerke DG, 1994, HDB MUSHROOM POISONI
   Sun J, 2018, HUM EXP TOXICOL, V37, P665, DOI 10.1177/0960327117721960
   Suzuki Masayuki, 2002, Chudoku Kenkyu, V15, P177
   Taguchi T, 2009, NEUROSCI LETT, V456, P69, DOI 10.1016/j.neulet.2009.03.102
   Trestrail III J., 1994, HDB MUSHROOM POISONI, P279
   van Amsterdam J, 2011, REGUL TOXICOL PHARM, V59, P423, DOI 10.1016/j.yrtph.2011.01.006
   Vendramin A, 2014, TOXICON, V90, P269, DOI 10.1016/j.toxicon.2014.08.067
   Villa AF, 2013, CLIN TOXICOL, V51, P798, DOI 10.3109/15563650.2013.827708
   Vo KT, 2017, MMWR-MORBID MORTAL W, V66, P549, DOI 10.15585/mmwr.mm6621a1
   Wang Audrey S, 2013, Dermatol Online J, V19, P5
   Wanmuang Harirak, 2007, Journal of the Medical Association of Thailand, V90, P179
   Ward J, 2013, J EMERG MED, V44, P116, DOI 10.1016/j.jemermed.2012.02.020
   West PL, 2009, J MED TOXICOL, V5, P32, DOI 10.1007/BF03160979
   Xiang H, 2018, CLIN TOXICOL, V56, P365, DOI 10.1080/15563650.2017.1388386
   Yang L, 2008, J PREVENTIVE MED INF, V12, P110
   Yang ZL, 2012, MYCOL PROG, V11, P937, DOI 10.1007/s11557-012-0809-y
   Yarze JC, 2012, AM J GASTROENTEROL, V107, P790, DOI 10.1038/ajg.2012.29
   Yin W, 1993, Zhonghua Nei Ke Za Zhi, V32, P810
   Yin X, 2014, CHEM-EUR J, V20, P7001, DOI 10.1002/chem.201400226
   Yoon YH, 2011, CLIN TOXICOL, V49, P115, DOI 10.3109/15563650.2011.553834
   Zhou ZY, 2012, ANGEW CHEM INT EDIT, V51, P2368, DOI 10.1002/anie.201106502
   2004, NO TO SHINKEI, V56, P999
NR 102
TC 10
Z9 10
U1 7
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 53
EP 65
DI 10.1016/j.toxicon.2018.11.007
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300008
PM 30439442
DA 2020-05-12
ER

PT J
AU Correa, AL
   Oliveira, AP
   Ruppelt, BM
   de Araujo, ERD
   Santos, MG
   Caldas, GR
   Muylaert, FF
   Amendoeira, FC
   Ferraris, FK
   de Souza, CMV
   Fuly, AL
   Rocha, L
AF Correa, Arthur Luiz
   Oliveira, Adriana Passos
   Ruppelt, Bettina Monika
   de Azevedo de Araujo, Erica Ribeiro
   Santos, Marcelo Guerra
   Caldas, Gabriel Rocha
   Muylaert, Flavia Fontenelle
   Amendoeira, Fabio Coelho
   Ferraris, Fausto Klabund
   Vieira de Souza, Claudio Mauricio
   Fuly, Andre Lopes
   Rocha, Leandro
TI Protective effect of Myrsine parvifolia plant extract against the
   inflammatory process induced by Bothrops jararaca snake venom
SO TOXICON
LA English
DT Article
DE Myrsine parvifolia; Bothrops jararaca; anti-inflammatory; Medicinal
   plant
ID ANTIINFLAMMATORY COMPOUNDS; ANTIOXIDANT ACTIVITY; PAW EDEMA;
   NEUTRALIZATION; PERMEABILITY; SEGUINII; MEDICINE; ORIGIN
AB Accidents involving snakes from the genus Bothrops sp. constitute the most important cause of snake envenomation in Brazil. The Myrsine genus has been reported to be used in folk medicine against snakebites. In this work, the phytochemical profiles and ability of extracts from Myrsine parvifolia leaves to reduce the inflammatory process (edema, vascular permeability increase and leukocyte migration) induced by Bothrops jararaca venom were investigated in vivo. Chemical compounds were identified by chromatographic and spectroscopy techniques. Total polyphenol, tannin, and flavonoid contents were determined by spectrophotometric methods. Swiss male mice received an oral administration of extracts (100 mg/kg) in different protocols. Paw edema, intraperitoneal vascular permeability and pleurisy models in mice were used to evaluate the antiophidic potential of the extracts. Paw edema was induced by subplantar injection of B. jararaca venom and quantified as the increase in paw volume. Changes in vascular permeability were assessed by measuring the amount of Evans blue dye extravasation. Leukocyte migration was assessed by total and differential counts in the pleural cavity washes. Myricetin, myricetin-3-O-beta-arabinopyranoside, quercetin and kaempferol were isolated from the ethyl acetate extract and identified as the primary compounds of the dichloromethane extract. Terpenes and fatty acids were identified in the hexane and dichloromethane extracts. The pretreated group with hydroethanolic and dichloromethane extract reduced total edema (40 and 52%, respectively), vascular permeability increase (32.4 and 32.2%, respectively) and leukocyte influx into the pleural cavity (42 and 39%, respectively), while the group treated with hexane extract showed only reduced edema (37%) induced by B. jararaca venom. The hydroethanolic extract showed better results in all of the tests performed and was also administered by the protocol of post-poisoning, showing maintenance of paw edema reduction and cell migration. These data indicate a potential anti-inflammatory activity of M. parvifolia in poisoning by B. jararaca, especially to reduce local poison effects.
C1 [Correa, Arthur Luiz; Ruppelt, Bettina Monika; de Azevedo de Araujo, Erica Ribeiro; Caldas, Gabriel Rocha; Rocha, Leandro] Univ Fed Fluminense, Dept Tecnol Farmaceut, Lab Tecnol Prod Nat, Niteroi, RJ, Brazil.
   [Oliveira, Adriana Passos] Univ Fed Rio de Janeiro, Fac Farm, Dept Farmacos & Med, Rio De Janeiro, RJ, Brazil.
   [Santos, Marcelo Guerra] Estadual Rio de Janeiro, Fac Formacao Professores, Dept Ciencias, Rio De Janeiro, Brazil.
   [Muylaert, Flavia Fontenelle; Amendoeira, Fabio Coelho; Ferraris, Fausto Klabund] Fundacao Oswaldo Cruz, Inst Nacl Controle Qualidade Saude, Dept Farmacol & Toxicol, Lab Farmacol, Rio De Janeiro, RJ, Brazil.
   [Vieira de Souza, Claudio Mauricio] Inst Vital Brazil, Lab Artropodos, Niteroi, RJ, Brazil.
   [Fuly, Andre Lopes] Univ Fed Fluminense, Inst Biol, Niteroi, RJ, Brazil.
RP Correa, AL (reprint author), Univ Fed Fluminense, Dept Tecnol Farmaceut, Lab Tecnol Prod Nat, Niteroi, RJ, Brazil.
EM arthur_farm@yahoo.com.br; adrianapassos@pharma.ufrj.br
RI Rocha, Leandro M./N-4088-2013
OI Rocha, Leandro/0000-0003-0484-1918
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologic (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This work was supported by the Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologic (CNPq).
CR Abbhi V., 2011, INT J PHARM PHARM SC, V3, P427
   Ainooson GK, 2012, AFR J TRADIT COMPLEM, V9, P8, DOI 10.4314/ajtcam.v9i1.2
   Almeida F. B., 2015, PHCOG MAG, V11, P533
   Amendoeira FC, 2005, PHYTOMEDICINE, V12, P78, DOI 10.1016/j.phymed.2003.09.002
   Anesini C, 2008, J AGR FOOD CHEM, V56, P9225, DOI 10.1021/jf8022782
   [Anonymous], 2010, FARMACOPEIA BRASILEI
   Araujo SD, 2007, INFLAMM RES, V56, P409, DOI 10.1007/s00011-007-7054-x
   Arot LOM, 1996, PHYTOCHEMISTRY, V43, P1107
   Assafim Mariane, 2011, J Venom Res, V2, P11
   BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L
   Burigo AC, 1996, J PHARM PHARMACOL, V48, P106, DOI 10.1111/j.2042-7158.1996.tb05887.x
   Calixto JB, 2004, PLANTA MED, V70, P93, DOI 10.1055/s-2004-815483
   Calixto JB, 2003, PLANTA MED, V69, P973, DOI 10.1055/s-2003-45141
   Carvalho BMA, 2013, BIOMED RES INT, DOI 10.1155/2013/153045
   Chandra V, 2002, J MOL BIOL, V320, P215, DOI 10.1016/S0022-2836(02)00473-4
   Chibli LA, 2014, J ETHNOPHARMACOL, V154, P330, DOI 10.1016/j.jep.2014.03.035
   Claudino MM, 2014, J APPL PHYCOL, V26, P2047, DOI 10.1007/s10811-014-0266-x
   Correa AL, 2017, REC NAT PROD, V11, P82
   de Araujo AL, 2000, TOXICON, V38, P209, DOI 10.1016/S0041-0101(99)00145-2
   Picanco LCD, 2016, PHARM BIOL, V54, P2103, DOI 10.3109/13880209.2016.1145703
   El-Fishawy A., 2011, Journal of Natural Products (India), V4, P184
   Esteves I., 2011, INT J PHARM SCI REV, V7, P28
   Farias JAC, 2012, INFLAMMATION, V35, P764, DOI 10.1007/s10753-011-9372-y
   Felix-Silva J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104952
   Fernandes JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168658
   Fernandes RS, 2011, J VENOM ANIM TOXINS, V17, P85, DOI 10.1590/S1678-91992011000100011
   Franca H, 2011, BIOCHEM SYST ECOL, V39, P885, DOI 10.1016/j.bse.2011.06.022
   [FUNASA Fundacao Nacional de Saude (FUNASA)], 2001, MAN DIAGN TRAT AC AN
   Furtado RA, 2015, BIOMED RES INT, DOI 10.1155/2015/913152
   GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211
   Hedge V. R., 1995, J NAT PRODUCTS, V58, P184
   Hirota M, 2002, BIOSCI BIOTECH BIOCH, V66, P655, DOI 10.1271/bbb.66.655
   Jorge M. T., 1997, Journal of Venomous Animals and Toxins, V3, P264
   Macedo Jessica Marques, 2013, Revista de Ciencias Farmaceuticas Basica e Aplicada, V34, P585
   Magalhaes A, 2011, J ETHNOPHARMACOL, V134, P82, DOI 10.1016/j.jep.2010.11.062
   Makabe H, 2003, BIOSCI BIOTECH BIOCH, V67, P2038, DOI 10.1271/bbb.67.2038
   Gutierrez JM, 2009, TOXICON, V54, P958, DOI 10.1016/j.toxicon.2009.01.038
   Mizushina Y, 2000, BBA-GEN SUBJECTS, V1475, P1, DOI 10.1016/S0304-4165(00)00052-0
   Mosa R. A., 2011, Journal of Natural Products (India), V4, P136
   Nishijima CM, 2009, MOLECULES, V14, P1072, DOI 10.3390/molecules14031072
   Nunez V, 2004, BRAZ J MED BIOL RES, V37, P969, DOI 10.1590/S0100-879X2004000700005
   Okoli CO, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-27
   Oliveira AP, 2010, B LATINOAM CARIBE PL, V9, P206
   Olivo RD, 2007, TOXICON, V49, P670, DOI 10.1016/j.toxicon.2006.11.006
   Patrao-Neto FC, 2013, TOXICON, V69, P55, DOI 10.1016/j.toxicon.2013.01.023
   Prakash C. V. S., 2012, Research Journal of Pharmaceutical Sciences, V1, P23
   Prasain JK, 2007, MOL PHARMACEUT, V4, P846, DOI 10.1021/mp700116u
   Reis FP, 2014, J ETHNOPHARMACOL, V158, P352, DOI 10.1016/j.jep.2014.10.045
   RUPPELT BM, 1991, MEM I OSWALDO CRUZ, V86, P203, DOI 10.1590/S0074-02761991000600046
   SCHEPPELE SE, 1972, LIPIDS, V7, P297, DOI 10.1007/BF02532647
   Scherer R, 2009, FOOD CHEM, V112, P654, DOI 10.1016/j.foodchem.2008.06.026
   Sinan, 2016, ACIDENTES ANIMALS PE
   Sunitha K, 2015, TOXICON, V98, P89, DOI 10.1016/j.toxicon.2015.02.014
   Teixeira C. C. C., 2016, PHARMACOGN J, V8, P264
   TREBIEN HA, 1989, AGENTS ACTIONS, V26, P292, DOI 10.1007/BF01967293
   Vasquez J, 2015, J ETHNOPHARMACOL, V170, P158, DOI 10.1016/j.jep.2015.04.059
   WAGNER H, 1995, PLANT DRUG ANAL THIN
   Whistler R L, 1976, Adv Carbohydr Chem Biochem, V32, P235
   WHITTLE BA, 1964, BRIT J PHARM CHEMOTH, V22, P246, DOI 10.1111/j.1476-5381.1964.tb02030.x
   WHO, 2007, HLTH ORG MOD LIST ES
   Yang WS, 2014, J ETHNOPHARMACOL, V151, P1165, DOI 10.1016/j.jep.2013.12.033
NR 61
TC 3
Z9 3
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 66
EP 76
DI 10.1016/j.toxicon.2018.11.289
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300009
PM 30447274
DA 2020-05-12
ER

PT J
AU Dissanayake, PV
   Muthukumarana, TGW
   Aslam, WAM
   Chaminda, SAA
   Munasinghe, TS
   Kularatne, SAM
AF Dissanayake, P. V.
   Muthukumarana, T. G. W.
   Aslam, W. A. M.
   Chaminda, S. A. A.
   Munasinghe, T. S.
   Kularatne, S. A. M.
TI An unusual case of gross myoglobinuria in a child following Russell's
   viper (Daboia russelii) envenomation
SO TOXICON
LA English
DT Review
DE Russell's viper; Myotoxicity; Gross myoglobinuria; Sri Lanka
ID TIGER SNAKE NOTECHIS; VENOM; MYOTOXICITY; SIAMENSIS; HEMOLYSIS
AB Overt myoglobinuria associated with myotoxicity is a classic feature of sea snake envenomation. Russell's viper bites usually result in coagulopathy, neurotoxicity and nephrotoxicity but rarely myotoxicity has been reported, especially in the Sri Lankan variety (Daboia russelii). All those studies have demonstrated mild degree myotoxicity with microscopic level myoglobinuria. We report what is probably the first case of gross myoglobinuria in a child following a Russell's viper bite with biochemical evidence of significant myotoxicity well beyond the levels that have been previously reported.
C1 [Dissanayake, P. V.] Univ Peradeniya, Dept Pediat, Fac Med, Peradeniya 20400, Sri Lanka.
   [Muthukumarana, T. G. W.; Aslam, W. A. M.; Chaminda, S. A. A.] Teaching Hosp, Peradeniya 20400, Sri Lanka.
   [Munasinghe, T. S.] Univ Peradeniya, Fac Med, Peradeniya 20400, Sri Lanka.
   [Kularatne, S. A. M.] Univ Peradeniya, Fac Med, Dept Med, Peradeniya 20400, Sri Lanka.
RP Dissanayake, PV (reprint author), Univ Peradeniya, Dept Pediat, Fac Med, Peradeniya 20400, Sri Lanka.
EM pa_th_um@yahoo.com
OI Dissanayake, Pathum/0000-0001-5254-4390; Munasinghe,
   Thilini/0000-0002-9621-2555
CR CUPO P, 1988, T ROY SOC TROP MED H, V82, P924, DOI 10.1016/0035-9203(88)90044-2
   de Roodt A, 2018, TOXICON, V148, P143, DOI 10.1016/j.toxicon.2018.04.026
   Gopalan G, 2007, ACTA CRYSTALLOGR D, V63, P722, DOI 10.1107/S0907444907016204
   Isbister GK, 2012, MED J AUSTRALIA, V197, P173, DOI 10.5694/mja11.11300
   Johnston CI, 2013, CLIN TOXICOL, V51, P417, DOI 10.3109/15563650.2013.787535
   Kularatne S A M, 2003, Southeast Asian J Trop Med Public Health, V34, P855
   Kularatne S. A. M., 2013, SNAKES SNAKEBITE ENV, P41
   Kularatne SAM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090198
   LEONARDI TM, 1979, TOXICON, V17, P549, DOI 10.1016/0041-0101(79)90229-0
   Lomonte B, 2012, J PROTEOMICS, V75, P1675, DOI 10.1016/j.jprot.2011.12.016
   PHILLIPS RE, 1988, Q J MED, V68, P691
   Arias SP, 2017, TOXINS, V9, DOI 10.3390/toxins9110342
   REID HA, 1961, BMJ-BRIT MED J, V1, P1284, DOI 10.1136/bmj.1.5235.1284
   Saha K, 2017, INDIAN J EXP BIOL, V55, P7
   Silva A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005172
   SUTHERLAND SK, 1977, MED J AUSTRALIA, V2, P177, DOI 10.5694/j.1326-5377.1977.tb114543.x
   Tan KY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25955-y
   THWIN MM, 1995, TOXICON, V33, P63, DOI 10.1016/0041-0101(94)00133-S
   Vikrant Sanjay, 2017, World J Nephrol, V6, P150, DOI 10.5527/wjn.v6.i3.150
NR 19
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 77
EP 79
DI 10.1016/j.toxicon.2018.11.299
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300010
PM 30448288
DA 2020-05-12
ER

PT J
AU Micheloud, JF
   Caro, LAC
   Cholich, LA
   Martinez, OG
   Gimeno, EJ
AF Micheloud, Juan F.
   Colque Caro, Luis A.
   Cholich, Luciana A.
   Martinez, Olga G.
   Gimeno, Eduardo J.
TI Suspected poisoning in beef cattle from ingestion of Prosopis nigra pods
   in north-western Argentina
SO TOXICON
LA English
DT Review
DE Cattle; Mesquite pods; Neuronal damage; Nervous signs; Prosopis
   poisoning
ID JULIFLORA PODS; JULIPROSOPINE; VACUOLATION; LEAVES
AB The aim of this paper was to present the first report of Prosopis nigra poisoning of cattle in Argentina. Outbreaks occurred in five farms located in Salta and Santiago del Estero provinces. All animals were examined, euthanized and necropsied. Clinical signs included tongue protrusion, twitches and tremors of muscles of mastication, weight loss and lethargy. Severe atrophy of the masseter, buccinator and lingual muscles was observed, along with neuronal vacuolation in the nuclei of the trigeminal, facial, and hypoglossus nerves. These findings and the clinical signs are consistent with results obtained in animals, spontaneously and experimentally intoxicated with Prosopis juliflora in previous studies. Several species of this genus are native to Argentina. Farmers should be warned about the suspected toxicity by Prosopis nigra, since this species has wide geographical distribution in the country.
C1 [Micheloud, Juan F.; Colque Caro, Luis A.] Area Sanidad Anim IIACS INTA, Grp Trabajo Patol Epidemiol & Invest Diagnost, Salta, Argentina.
   [Micheloud, Juan F.] UCASAL, Fac Ciencias Vet & Agr, Salta, Argentina.
   [Cholich, Luciana A.] UNNE, Fac Ciencias Vet, Corrientes, Argentina.
   [Martinez, Olga G.] Univ Nacl Salta, Catedra Diversidad Plantas, Corrientes, Argentina.
   [Gimeno, Eduardo J.] Univ Nacl La Plata, Fac Ciencias Vet, Catedra Patol Gen, Bs As, Argentina.
   [Cholich, Luciana A.; Gimeno, Eduardo J.] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
RP Micheloud, JF (reprint author), Area Sanidad Anim IIACS INTA, Grp Trabajo Patol Epidemiol & Invest Diagnost, Salta, Argentina.
EM micheloud.juan@inta.gob.ar
OI Colque Caro, Luis Adrian/0000-0002-3821-4683
FU INTA (Instituto Nacional de Tecnologia Agropecuaria); Consejo de
   Investigacion de la Universidad Catolica de Salta
FX This study was supported by grants from INTA (Instituto Nacional de
   Tecnologia Agropecuaria) and Consejo de Investigacion de la Universidad
   Catolica de Salta. LACH and EJG are members of CONICET (Consejo Nacional
   e Investigaciones Cientificas y Tecnicas). We thank Dr Ruben Bravo and
   Dr Rafael Piedrasanta for their contribution to field work during
   outbreaks.
CR AHMAD A, 1986, PLANTA MED, P285, DOI 10.1055/s-2007-969153
   AHMAD VU, 1989, J NAT PROD, V52, P497, DOI 10.1021/np50063a005
   Almeida VM, 2017, PESQUI VET BRASIL, V37, P110, DOI 10.1590/s0100-736x2017000200003
   Assis TS, 2009, PESQUI VET BRASIL, V29, P919, DOI 10.1590/S0100-736X2009001100010
   Camara ACL, 2009, PESQUI VET BRASIL, V29, P233, DOI 10.1590/S0100-736X2009000300008
   da Silva DM, 2006, PESQUI VET BRASIL, V26, P223, DOI 10.1590/S0100-736X2006000400007
   Figueiredo L. J. C., 1995, ARQ ESC MED VET UFBA, V18, P175
   Flora Argentina, 2017, PLANT VASC REP ARG
   Jubb K.V.F., 2007, PATHOLOGY DOMESTIC A
   Kingsbury J. M., 1964, POISONOUS PLANTS US, P349
   LIMA E, 2004, [No title captured], V24, P36
   Maioli MA, 2012, TOXICON, V60, P1355, DOI 10.1016/j.toxicon.2012.09.012
   Micheloud JF, 2018, TROP ANIM HEALTH PRO, V50, P441, DOI 10.1007/s11250-017-1422-5
   Pasiecznick N. M., 2001, MONOGRAPH HDRA, P162
   Riet-Correa F, 2012, PESQUI VET BRASIL, V32, P987, DOI 10.1590/S0100-736X2012001000006
   Silva A. M., 1990, VET ZOOTECNICA, V2, P9
   Silva D. S., 1981, SUBSTITUICAO PROGR F
   Silva VDA, 2013, CHEM RES TOXICOL, V26, P1810, DOI 10.1021/tx4001573
   Tabosa IM, 2006, VET PATHOL, V43, P695, DOI 10.1354/vp.43-5-695
   Tabosa I. M., 2004, TOXIC PLANTS OTHER N, P341
   Tabosa IM, 2000, VET HUM TOXICOL, V42, P155
   Valberg S. J., 2010, MED INTERNA GRANDES, P1388
   Verga A., 2009, Quebracho (Santiago del Estero), V17, P31
   Washburn KE, 2002, J AM VET MED ASSOC, V220, P1837, DOI 10.2460/javma.2002.220.1837
NR 24
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 80
EP 83
DI 10.1016/j.toxicon.2018.11.302
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300011
PM 30468757
DA 2020-05-12
ER

PT J
AU Martinez, A
   Lauroua, C
   Borrelli, LB
   Gardner, DR
   Robles, CA
AF Martinez, Agustin
   Lauroua, Catalina
   Borrelli, Laura B.
   Gardner, Dale R.
   Robles, Carlos A.
TI Spontaneous outbreak of Astragalus pehuenches (Fabaceae) poisoning in
   cattle in Argentina
SO TOXICON
LA English
DT Article
DE Astragalus pehuenches; Poisoning; Cattle; Swainsonine; Patagonia
AB This is the first report of a spontaneous outbreak of Astragalus pehuenches poisoning on a farm in Argentine Patagonia, where 63 out of 70 cattle died. The main clinical signs of affected animals were ataxia, balance loss and progressive emaciation. Purkinje cells presented vacuolation and marginalization of the nucleus. Astragalus pehuenches was detected in the paddock as well as in the ruminal content and fecal matter samples of the affected animals. Swainsonine concentrations in Astragalus specimens were found to be as high as 0.096%.
C1 [Martinez, Agustin; Robles, Carlos A.] Inst Nacl Tecnol Agr, Grp Salud Anim, Modesta Victoria 4450, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina.
   [Lauroua, Catalina] Univ Nacl Ctr Prov Buenos Aires, Residencia Estudiantil, Tandil, Argentina.
   [Borrelli, Laura B.] INTA Bariloche, Lab Microhistol, San Carlos De Bariloche, Rio Negro, Argentina.
   [Gardner, Dale R.] ARS USDA, Poisonous Plant Res Lab, Washington, DC USA.
RP Martinez, A (reprint author), Inst Nacl Tecnol Agr, Grp Salud Anim, Modesta Victoria 4450, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina.
EM martinez.agustin@inta.gob.ar
OI Martinez, Agustin/0000-0002-1917-1104
FU National Institute for Agricultural Technology (INTA), Argentina;
   Regional Animal Health System -SIRSA- INTA Bariloche [1281102, 1115054]
FX We thank Mr. Nelson Botte for allowing us to work in his farms. This
   work was supported by the National Institute for Agricultural Technology
   (INTA), Argentina, with funds from the Regional Animal Health System
   -SIRSA- INTA Bariloche; Regional Project 1281102 "Development of the
   semiarid region of Rio Negro province" and National Project 1115054
   "Diagnosis and surveillance of complex and emerging diseases".
CR Bran D., 2000, REGIONES ECOLOGICAS, V59, P8
   Driemeier D, 2000, VET PATHOL, V37, P153, DOI 10.1354/vp.37-2-153
   Furlan FH, 2009, VET PATHOL, V46, P343, DOI 10.1354/vp.46-2-343
   Gardner DR, 2011, PHYTOCHEM ANALYSIS, V22, P124, DOI 10.1002/pca.1257
   HARRIES WN, 1972, CANADIAN VET J, V13, P141
   Jolly RD, 1997, VET PATHOL, V34, P527, DOI 10.1177/030098589703400601
   Kauffer F., 1984, INFORME TECNICO PROD, P54
   Martinez A., 2018, REV INVESTIGACIONES
   Micheloud J. F., 2017, INT J POISONOUS PLAN, V5, P34
   Molyneux R. J., 1994, PLANT ASS TOXINS AGR
   Robles C. A., 2000, Revista de Medicina Veterinaria (Buenos Aires), V81, P380
   Schudel A. A., 1997, SCRAPIE RISK FACTORS
   SPARKS DR, 1968, J RANGE MANAGE, V21, P264, DOI 10.2307/3895829
   Takeda S, 2014, J VET MED SCI, V76, P839, DOI 10.1292/jvms.14-0023
NR 14
TC 1
Z9 1
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 84
EP 86
DI 10.1016/j.toxicon.2018.11.303
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300012
PM 30468758
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Carcamo-Noriega, EN
   Possani, LD
   Ortiz, E
AF Norberto Carcamo-Noriega, Edson
   Domingos Possani, Lourival
   Ortiz, Ernesto
TI Venom content and toxicity regeneration after venom gland depletion by
   electrostimulation in the scorpion Centruroides limpidus
SO TOXICON
LA English
DT Article
DE Centruroides limpidus; Milking by electrostimulation; Scorpion;
   Toxicity; Venom regeneration
ID EXTRACTION; PARABUTHUS; BUTHIDAE; MAINTENANCE; ACTIVATION; CAPTIVITY;
   CHANNELS; PEPTIDE; PROFILE; COST
AB The scorpion venom is a cocktail of many components. Its composition can exhibit a level of plasticity in response to different behavioral and environmental factors, leading to intraspecific variation. The toxicity and specificity of scorpion venoms appear to be taxon-dependent, due to a co-evolutionary interaction with prey and predators, which shaped the composition at the molecular level. The venom regeneration by the venom glands is an asynchronous process, in which particular components are expressed at different stages and at different rates. According to this, it can be reasonably assumed that the regeneration of toxicity in the venom is also asynchronous. In this work, we studied the toxicity regeneration dynamics by the scorpion Centruroides limpidus after full venom depletion by electrical stimulation. For this, we evaluated the toxicity of venom samples extracted at different days post depletion, against insects (crickets) and mammals (humans, by assessing the venom activity on the human voltage-dependent Na+ channel Nav1.6). The regeneration of toxicity against humans lagged behind that against crickets (13 vs 10 days, respectively). Thirteen days after depletion the venom seems to be replenished. Our results show asynchrony in the regeneration of species-specific toxic activity in the venom of Centruroides limpidus. The understanding of the venom regeneration kinetics for the different scorpion species will help to design venom extraction protocols that could maximize the yield and quality of the collected venoms.
C1 [Norberto Carcamo-Noriega, Edson; Domingos Possani, Lourival; Ortiz, Ernesto] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.
RP Possani, LD; Ortiz, E (reprint author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.
EM possani@ibt.unam.mx; erne@ibt.unam.mx
FU DGAPA-UNAMUniversidad Nacional Autonoma de Mexico [IN203416]
FX This work was inspired by the inquisitiveness of 5th grade students that
   took part in a Science Fair in the Ocachicualli College in Cuernavaca
   city: Bruno Mier Fenoglio, Maria Jose Tejedor Gutierrez, Regina Santana
   Miranda, Estefania Quintero Rodriguez and Leonardo Alfonso Sanchez
   Martinez. We thank Biol. Cipriano Balderas Altamirano for technical
   assistance with scorpion manipulation and Dr. Rita Restano Cassulini for
   her help in the analysis of the electrophysiology data. This work was
   supported by grant DGAPA-UNAM number IN203416 awarded to LDP.
CR BOEVE JL, 1995, TOXICON, V33, P1347, DOI 10.1016/0041-0101(95)00066-U
   Brenes E, 2016, REV BIOL TROP, V64, P1019, DOI 10.15517/rbt.v64i3.21138
   Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Cooper AM, 2014, ZOOLOGY, V117, P398, DOI 10.1016/j.zool.2014.06.007
   du Plessis JL, 2005, TOXICON, V45, P681, DOI 10.1016/j.toxicon.2004.12.013
   Estrada-Gomez S, 2014, TOXINS, V6, P2082, DOI 10.3390/toxins6072082
   Gangur AN, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/rspb.2017.1364
   Gao B, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00320
   KOCHVA E, 1960, AM J TROP MED HYG, V9, P381, DOI 10.4269/ajtmh.1960.9.381
   Nagaraj SK, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0053-4
   Nisani Z, 2007, COMP BIOCHEM PHYS A, V147, P509, DOI 10.1016/j.cbpa.2007.01.027
   Nisani Z, 2012, TOXICON, V60, P315, DOI 10.1016/j.toxicon.2012.04.343
   Olamendi-Portugal T, 2017, PEPTIDES, V87, P34, DOI 10.1016/j.peptides.2016.11.008
   Ortiz E, 2015, TOXICON, V93, P125, DOI 10.1016/j.toxicon.2014.11.233
   Oukkache N, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-5
   Ozkan O, 2010, J VENOM ANIM TOXINS, V16, P505, DOI 10.1590/S1678-91992010000300017
   Pimenta AMC, 2003, RAPID COMMUN MASS SP, V17, P413, DOI 10.1002/rcm.934
   Pucca MB, 2014, TOXICON, V90, P326, DOI 10.1016/j.toxicon.2014.08.064
   Quintero-Hernandez V, 2013, TOXICON, V76, P328, DOI 10.1016/j.toxicon.2013.07.012
   Rodriguez-Rodriguez ER, 2016, TOXICON, V119, P52, DOI 10.1016/j.toxicon.2016.05.011
   Restano-Cassulini R, 2017, TOXINS, V9, DOI 10.3390/toxins9030074
   Riano-Umbarila L, 2013, TOXICON, V76, P370, DOI 10.1016/j.toxicon.2013.09.016
   Riano-Umbarila L, 2011, J BIOL CHEM, V286, P6143, DOI 10.1074/jbc.M110.189175
   Santibanez-Lopez CE, 2016, TOXINS, V8, DOI 10.3390/toxins8010002
   Santussi WM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00984
   Schaffrath S, 2018, TOXICON, V144, P83, DOI 10.1016/j.toxicon.2018.02.004
   Schiavon E, 2012, TOXICON, V59, P283, DOI 10.1016/j.toxicon.2011.12.003
   Tanner MR, 2018, J PHARMACOL EXP THER, V365, P227, DOI 10.1124/jpet.117.245118
   WILLEMSE GT, 1979, TOXICON, V17, P37, DOI 10.1016/0041-0101(79)90253-8
   Yacioob R, 2016, PAK J ZOOL, V48, P265
   Zhao RM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-452
NR 32
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 87
EP 92
DI 10.1016/j.toxicon.2018.11.305
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300013
PM 30468759
DA 2020-05-12
ER

PT J
AU Aranda-Souza, MA
   de Lorena, VMB
   Correia, MTD
   Pereira-Neves, A
   de Figueiredo, RCBQ
AF Aranda-Souza, Mary Angela
   Barros de Lorena, Virginia Maria
   dos Santos Correia, Maria Tereza
   Pereira-Neves, Antonio
   Bressan Queiroz de Figueiredo, Regina Celia
TI A C-type lectin from Bothrops leucurus snake venom forms amyloid-like
   aggregates in RPMI medium and are efficiently phagocytosed by peritoneal
   macrophages
SO TOXICON
LA English
DT Article
DE Lectin; Aggregation; Amyloid-like fibrils; Macrophage; Immunomodulation
ID ALZHEIMERS-DISEASE; PROTEIN; RECEPTORS; INFLAMMASOME; EVOLUTION;
   PROMOTES; FIBRILS; CELLS; GAMMA
AB Lectins are carbohydrate-binding proteins that play important roles in the immune system. Under specific conditions, lectins can form amyloids, proteinaceous aggregates rich in cross beta-strand structures. A Ca++ dependent lectin, isolated from Bothrops leucurus snake venom (BLL) has demonstrated relevant biological activities such as antibacterial and antitumor activity. In this work, we aimed to study the interaction of BLL with macrophages. The formation of amyloid structures by BLL in a cell culture medium, the effects of the lectin on macrophage morphology and cytokine production were investigated. BLL amyloid-like fibrils in RMPI medium, pH 7.2, at 37 degrees C was confirmed by binding of Congo Red, Thioflavin T and electron microscopy. Neither binding of amyloid markers nor fibrillar structures were found when the lectin was incubated in RPMI plus galactose, the specific BLL-binding carbohydrate. Several phagocytic compartments containing fibrillar structures were observed in BLL-treated macrophages in RPMI medium for 24 h; these compartments showed an apple-green birefringence after Congo Red staining and were positive for thioflavin S and anti-amyloid antibody, indicating the presence of amyloid-like fibrils. No fibrillar material and no labeling were observed when the macrophages were treated with BLL plus galactose or cytochalasin B, an inhibitor of phagocytosis. BLL did not affect the viability of the cells. A significant release of proinflammatory (TNF-alpha, IL-6, INF-gamma and IL-1 beta) and regulatory (IL-10) cytokines was observed in BLL-treated macrophages. Taken together, our results shed light on the structural organization of BLL, improving knowledge about the interaction of lectin with macrophages. The phagocytosis of amyloid-like aggregates together with the proinflammatory response induced by BLL may open new perspectives for the use of this lectin as an interesting model to study cytokines and the production of other mediators as well as understand the mechanisms occurring in human immune cells during amyloid protein deposition.
C1 [Aranda-Souza, Mary Angela; Pereira-Neves, Antonio; Bressan Queiroz de Figueiredo, Regina Celia] Inst Aggeu Magalhaes IAM FIOCRUZ, Dept Microbiol, Av Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
   [Barros de Lorena, Virginia Maria] Inst Aggeu Magalhaes IAM FIOCRUZ, Dept Imunol, Av Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
   [dos Santos Correia, Maria Tereza] Univ Fed Pernambuco UFPE, Dept Bioquim, Av Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
RP Aranda-Souza, MA (reprint author), Inst Aggeu Magalhaes FIOCRUZ, Dept Microbiol, Av Moraes Rego S-N,Campus UFPE Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM profmaryaranda@gmail.com
RI FIGUEIREDO, REGINA CBQ/N-2800-2013
OI FIGUEIREDO, REGINA/0000-0001-5806-0944; Pereira-Neves,
   Antonio/0000-0001-6629-568X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado de Pernambuco
   [APQ/FACEPE 0584-2.13/15]; FIOCRUZ
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) and the Fundacao de Amparo a Pesquisa
   do Estado de Pernambuco (APQ/FACEPE 0584-2.13/15). Aranda-Souza is a PhD
   student supported by the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) in cooperation with FIOCRUZ with a Brasil sem
   Miseria fellowship.
CR Aaron Y. L., 2012, FUTURE NEUROL, V7, P165
   Aranda-Souza MA, 2014, TOXICON, V82, P97, DOI 10.1016/j.toxicon.2014.02.018
   Aranda-Souza MA, 2018, INT J BIOL MACROMOL, V120, P431, DOI 10.1016/j.ijbiomac.2018.08.064
   Bemporad F, 2017, INT REV CEL MOL BIO, V329, P1, DOI 10.1016/bs.ircmb.2016.08.008
   Boldrini-Franca J, 2017, BBA-GEN SUBJECTS, V1861, P824, DOI 10.1016/j.bbagen.2016.12.022
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Buell AK, 2017, INT REV CEL MOL BIO, V329, P187, DOI 10.1016/bs.ircmb.2016.08.014
   Caproni P, 2009, J VENOM ANIM TOXINS, V15, P216, DOI 10.1590/S1678-91992009000200005
   Carrotta R, 2012, J PHYS CHEM B, V116, P14700, DOI 10.1021/jp307417x
   Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754
   Chiffoleau E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00227
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Araujo LCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081973
   Cummings R. D., 2009, ESSENTIALS GLYCOBIOL
   Darwich L, 2009, IMMUNOLOGY, V126, P386, DOI 10.1111/j.1365-2567.2008.02905.x
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Doley R, 2009, CELL MOL LIFE SCI, V66, P2851, DOI 10.1007/s00018-009-0050-2
   Drickamer K, 2015, CURR OPIN STRUC BIOL, V34, P26, DOI 10.1016/j.sbi.2015.06.003
   Fry BG, 2008, MOL CELL PROTEOMICS, V7, P215, DOI 10.1074/mcp.M700094-MCP200
   Guillot-Sestier MV, 2016, JOVE-J VIS EXP, DOI 10.3791/54868
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Jones S, 2014, VACCINE, V32, P4234, DOI 10.1016/j.vaccine.2013.09.061
   Khan MV, 2018, J BIOMOL STRUCT DYN, V36, P1261, DOI 10.1080/07391102.2017.1318718
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312
   Mizuno Tetsuya, 2012, Int J Alzheimers Dis, V2012, P737846, DOI 10.1155/2012/737846
   Mizwicki MT, 2012, J ALZHEIMERS DIS, V29, P51, DOI 10.3233/JAD-2012-110560
   Morgan D, 2008, BEHAV NEUROSCI, V122, P730, DOI 10.1037/0735-7044.122.3.730
   Nowick JS, 2008, ACCOUNTS CHEM RES, V41, P1319, DOI 10.1021/ar800064f
   Nunes ED, 2011, COMP BIOCHEM PHYS B, V159, P57, DOI 10.1016/j.cbpb.2011.02.001
   Nunes ES, 2012, TOXICON, V59, P667, DOI 10.1016/j.toxicon.2012.03.002
   Okada T, 2007, J MOL BIOL, V371, P481, DOI 10.1016/j.jmb.2007.05.069
   Oleszycka E, 2016, FEBS J, V283, P9, DOI 10.1111/febs.13546
   Paouri E, 2017, J NEUROSCI, V37, P5155, DOI 10.1523/JNEUROSCI.2484-16.2017
   Patin EC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00861
   Pham CLL, 2014, ESSAYS BIOCHEM, V56, P207, DOI [10.1042/BSE0560207, 10.1042/bse0560207]
   Rapsinski GJ, 2015, INFECT IMMUN, V83, P693, DOI 10.1128/IAI.02370-14
   Sartim MA, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0038-3
   Savchenko E, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00279
   Shiokawa M, 2017, CURR OPIN MICROBIOL, V40, P123, DOI 10.1016/j.mib.2017.11.004
   Sulatskaya AI, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092486
   TAKAHASHI M, 1989, VIRCHOWS ARCH A, V415, P411, DOI 10.1007/BF00747742
   Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008
   van den Berg LM, 2012, ANN NY ACAD SCI, V1253, P149, DOI 10.1111/j.1749-6632.2011.06392.x
   Vautier S, 2012, CYTOKINE, V58, P89, DOI 10.1016/j.cyto.2011.08.031
   Verbeeck C., 2017, AM J PATHOL, V9440, P30493, DOI [10.1016/j.ajpath.2017.08.010.15, DOI 10.1016/J.AJPATH.2017.08.010.15]
   Vetri V, 2011, BIOPHYS J, V100, P774, DOI 10.1016/j.bpj.2010.11.089
   Vetri V, 2010, BBA-PROTEINS PROTEOM, V1804, P173, DOI 10.1016/j.bbapap.2009.09.013
NR 49
TC 2
Z9 2
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 93
EP 100
DI 10.1016/j.toxicon.2018.11.309
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300014
PM 30471382
DA 2020-05-12
ER

PT J
AU Zhao, YH
   Chen, ZY
   Cao, ZJ
   Li, WX
   Wu, YL
AF Zhao, Yonghui
   Chen, Zongyun
   Cao, Zhijian
   Li, Wenxin
   Wu, Yingliang
TI Defensins, a novel type of animal toxin-like potassium channel inhibitor
SO TOXICON
LA English
DT Review
DE Animal toxin; Defensin; Inhibitor; Modifier; Blocker; Potassium channel
ID KV1.3 CHANNEL; K+-CHANNEL; CHEMICAL-SYNTHESIS; STRUCTURAL BASIS;
   MOLECULAR-BASIS; DENDROTOXIN-I; SHK TOXIN; PEPTIDE; BINDING; PORE
AB The classical potassium channel inhibitors are toxin peptides from venomous animals, and whether there are peptide inhibitors from other species is an open question. Due to both the independent and interdependent relationships between the spear (peptide inhibitors) and the shield (potassium channels), human defensins were first identified by our group as endogenous potassium channel inhibitors. Encouraged by the discovery of human defensins as potassium channel inhibitors, defensins from invertebrates and fungi were successively found by our group to be potassium channel inhibitors. In addition, a plant defensin was reported to be a potassium channel inhibitor. Since defensins are widely produced by vertebrate, invertebrate, plant and fungi species, the recent work established a new research field on defensin-potassium channel interactions. Here, we review the current work on defensins from vertebrate, invertebrate, plant and fungi species as inhibitors of potassium channels and discuss future work in this research field.
C1 [Zhao, Yonghui; Chen, Zongyun; Cao, Zhijian; Li, Wenxin; Wu, Yingliang] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Hubei, Peoples R China.
   [Chen, Zongyun] Hubei Univ Med, Coll Basic Med, Dept Biochem & Mol Biol, Shiyan, Hubei, Peoples R China.
   [Cao, Zhijian; Li, Wenxin; Wu, Yingliang] Wuhan Univ, Biodrug Res Ctr, Wuhan 430072, Hubei, Peoples R China.
RP Wu, YL (reprint author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Biodrug Res Ctr, Wuhan 430072, Hubei, Peoples R China.
EM ylwu@whu.edu.cn
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [81630091, 31670840, 81773746]; State Key Project of
   Research and Development Plan [2016YFE0122800]; Hubei Natural Sciences
   Foundation [2016CFA018]
FX This work was supported by grants from the National Natural Sciences
   Foundation of China (Nos. 81630091, 31670840 and 81773746), The State
   Key Project of Research and Development Plan (No. 2016YFE0122800) and
   the Hubei Natural Sciences Foundation (No. 2016CFA018).
CR Banerjee A, 2013, ELIFE, V2, DOI 10.7554/eLife.00594
   Chen ZY, 2012, J BIOL CHEM, V287, P13813, DOI 10.1074/jbc.M112.343996
   Chen ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09881
   Chen ZY, 2014, BIOCHEM BIOPH RES CO, V447, P70, DOI 10.1016/j.bbrc.2014.03.101
   Esmaielbeiki R, 2012, PROTEIN PEPTIDE LETT, V19, P458, DOI 10.2174/092986612799789341
   Feng J, 2016, TOXICON, V113, P1, DOI 10.1016/j.toxicon.2016.02.007
   Feng J, 2015, J BIOL CHEM, V290, P15487, DOI 10.1074/jbc.M115.639500
   Gan GL, 2008, J BIOL CHEM, V283, P24177, DOI 10.1074/jbc.M800179200
   Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200
   Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4
   Han S, 2008, J BIOL CHEM, V283, P19058, DOI 10.1074/jbc.M802054200
   Han S, 2010, J PROTEOME RES, V9, P3118, DOI 10.1021/pr100027k
   Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200
   Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200
   Housley DM, 2017, NEUROPHARMACOLOGY, V127, P46, DOI 10.1016/j.neuropharm.2016.10.004
   Huang XQ, 2005, J AM CHEM SOC, V127, P6836, DOI 10.1021/ja042641q
   Jin L, 2007, J CHEM INF MODEL, V47, P1967, DOI 10.1021/ci700178w
   LAMBERT P, 1990, BIOCHEM BIOPH RES CO, V170, P684, DOI 10.1016/0006-291X(90)92145-P
   Lanigan MD, 2001, BIOCHEMISTRY-US, V40, P15528, DOI 10.1021/bi011300b
   Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535
   MASSEFSKI W, 1990, SCIENCE, V249, P521, DOI 10.1126/science.1696395
   Meng LX, 2016, J BIOL CHEM, V291, P7097, DOI 10.1074/jbc.M115.680611
   Nishio H, 1998, J PEPT RES, V51, P355
   Nishio H, 1999, BIOCHEM BIOPH RES CO, V262, P319, DOI 10.1006/bbrc.1999.1198
   PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002
   PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E
   PENNINGTON MW, 1995, INT J PEPT PROT RES, V46, P354
   Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g
   Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873
   Qiu S, 2009, J CHEM INF MODEL, V49, P1831, DOI 10.1021/ci900025n
   REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919
   Renisio JG, 2000, PROTEINS, V38, P70, DOI 10.1002/(SICI)1097-0134(20000101)38:1&lt;70::AID-PROT8&gt;3.0.CO;2-5
   Shen BZ, 2017, EXPERT OPIN BIOL TH, V17, P1065, DOI 10.1080/14712598.2017.1346606
   Swartz KJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00873
   SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1
   Tu JB, 2015, EVOL BIOINFORM, V11, DOI 10.4137/EBO.S25580
   Vriens K, 2016, SCI REP-UK, V6, DOI 10.1038/srep32121
   Wommack AJ, 2012, BIOCHEMISTRY-US, V51, P9624, DOI 10.1021/bi301255u
   Wu JJ, 2014, PHARMACEUTICALS, V7, P866, DOI 10.3390/ph7080866
   Wu YL, 2004, BIOPHYS J, V87, P105, DOI 10.1529/biophysj.103.039156
   Xiang F, 2015, TOXINS, V7, P34, DOI 10.3390/toxins7010034
   Xie ZL, 2015, FASEB J, V29, P4324, DOI 10.1096/fj.15-274787
   Yang WS, 2015, CELL MOL LIFE SCI, V72, P845, DOI 10.1007/s00018-014-1715-z
   Yi H, 2007, J PROTEOME RES, V6, P611, DOI 10.1021/pr060368g
   Zhang CG, 2016, BIOCHEM J, V473, P1257, DOI 10.1042/BCJ20160178
   Zhang M, 2007, MOL PHARMACOL, V72, P259, DOI 10.1124/mol.107.035840
   Zhang Y., 2018, MOUSE BETA DEFENSIN
   Zhao Y, 2018, ENGINEERING-PRC, V4, P3, DOI 10.1016/j.eng.2017.12.011
   Zhu SY, 2014, MOL BIOL EVOL, V31, P546, DOI 10.1093/molbev/msu038
NR 49
TC 1
Z9 1
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN
PY 2019
VL 157
BP 101
EP 105
DI 10.1016/j.toxicon.2018.11.304
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HJ1EI
UT WOS:000456904300015
PM 30472109
DA 2020-05-12
ER

PT J
AU Ben-Shimol, S
   Givon-Lavi, N
   Leibovitz, E
   Greenberg, D
   Dagan, R
AF Ben-Shimol, Shalom
   Givon-Lavi, Noga
   Leibovitz, Eugene
   Greenberg, David
   Dagan, Ron
TI Studying PCV impact on clinical presentation of otitis media helps to
   understand its pathogenesis
SO VACCINE
LA English
DT Article
DE Complicated otitis media; PCV - pneumococcal conjugate vaccine;
   Spontaneous otorrhea; Tympanocentesis; Dynamics; Children; Surveillance
ID PNEUMOCOCCAL CONJUGATE VACCINE; CARRIAGE; EFFICACY; CHILDREN; MECHANISMS
AB Background: Complex otitis media (OM) may present with intact tympanic membrane or spontaneous otorrhea. We compared dynamics of intact tympanic membrane and spontaneous otorrhea OM following 7- and 13-valent conjugated vaccines (PCV7, PCV13) implementation, since differences in dynamics may imply different underlying mechanisms.
   Methods: A prospective, population-based, active surveillance. Episodes with middle-ear fluid cultures in children < 3 years were included. Defined sub-periods were: pre-pneumococcal conjugated vaccines (PCV) (2004-2008); PCV7 (2009-2011); PCV13 (2014-2016). Results: Of 7705 episodes, 57.2% had intact tympanic membrane, 16.8% spontaneous otorrhea, 26.0% unknown.
   In the pre-PCV period, the spontaneous otorrhea group was older and had higher proportions of factors associated with recurrence/chronicity.
   During the PCV7 period, spontaneous otorrhea and intact tympanic membrane episodes caused by PCV13 serotypes decreased significantly (43% and 51%, respectively) and those caused by non-PCV13 serotypes and culture-negative episodes increased significantly. However, rates increases were steeper in the spontaneous otorrhea group for both non-PCV13 serotypes (117% vs. 38%) and culture-negative (720% vs. 69%). In the spontaneous otorrhea group, nontypeable Haemophilus influenzae rates increased non-significantly by 10% and all-cause OM rates increased significantly by 56%, while in the intact tympanic membrane group the respective rates decreased significantly by 22% and 11%. These trends were especially pronounced in ages 24-35 months.
   Despite these differences, after PCV13 introduction, both spontaneous otorrhea and intact tympanic membrane rates declined for all outcomes.
   Conclusions: Spontaneous otorrhea was associated with older age, frequent history of complex OM and delayed PCV impact, suggesting a higher proportion of advanced-stage complex OM. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ben-Shimol, Shalom; Givon-Lavi, Noga; Leibovitz, Eugene; Greenberg, David] Soroka Univ, Med Ctr, Pediat Infect Dis Unit, Beer Sheva, Israel.
   [Ben-Shimol, Shalom; Givon-Lavi, Noga; Leibovitz, Eugene; Greenberg, David; Dagan, Ron] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
RP Dagan, R (reprint author), Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
EM rdagan@bgu.ac.il
RI Ben-Shimol, Shalom/G-3368-2015
OI Ben-Shimol, Shalom/0000-0002-7690-0991
FU PfizerPfizer [0887X1-4603]
FX The study was funded in part by a grant from Pfizer [grant no.
   0887X1-4603].
CR Armbruster CE, 2010, EXPERT REV ANTI-INFE, V8, P1067, DOI [10.1586/eri.10.109, 10.1586/ERI.10.109]
   Ben-Shimol S, 2016, CLIN INFECT DIS, V63, P611, DOI 10.1093/cid/ciw347
   Ben-Shimol S, 2016, HUM VACC IMMUNOTHER, V12, P268, DOI 10.1080/21645515.2015.1095414
   Ben-Shimol S, 2014, CLIN INFECT DIS, V59, P1724, DOI 10.1093/cid/ciu683
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Central Bureau of Statistics, 2012, STAT ABSTR ISR NO 63
   Cilveti R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170316
   Dagan R, 2000, ANTIMICROB AGENTS CH, V44, P43, DOI 10.1128/AAC.44.1.43-50.2000
   Dagan R, 2016, LANCET INFECT DIS, V16, P480, DOI 10.1016/S1473-3099(15)00549-6
   Dagan R, 2015, J INFECT DIS, V211, P1144, DOI 10.1093/infdis/jiu576
   Dagan R, 2013, J INFECT DIS, V208, P1152, DOI 10.1093/infdis/jit289
   Domenech M, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01992-16
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Garcia-Cobos S, 2014, J ANTIMICROB CHEMOTH, V69, P2394, DOI 10.1093/jac/dku158
   Hoberman A, 2011, NEW ENGL J MED, V364, P105, DOI 10.1056/NEJMoa0912254
   Jokinen J, 2012, CLIN INFECT DIS, V55, P1673, DOI 10.1093/cid/cis799
   Klugman KP, 2014, LANCET GLOB HEALTH, V2, pE365, DOI 10.1016/S2214-109X(14)70241-4
   Leibovitz E, 2009, PEDIATR INFECT DIS J, V28, P381, DOI 10.1097/INF.0b013e318194e783
   Lewnard JA, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00727-17, 10.1128/iai.00727-17]
   Marchisio P, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2017.01.010
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 1
EP 6
DI 10.1016/j.vaccine.2018.11.054
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100001
PM 30497832
DA 2020-05-12
ER

PT J
AU Pike, J
   Leidner, AJ
   MacNeil, JR
   Cohn, AC
AF Pike, Jamison
   Leidner, Andrew J.
   MacNeil, Jessica R.
   Cohn, Amanda C.
TI Review of the economic evidence presented to the United States Advisory
   Committee on Immunization Practices, 2012-2016
SO VACCINE
LA English
DT Review
DE Advisory Committee on Immunization; Practices; Economics;
   Cost-effectiveness; Immunization
ID PNEUMOCOCCAL CONJUGATE VACCINE; COST-EFFECTIVENESS; PREVENTABLE
   DISEASES; ADULTS; IMPACT; OLDER
AB We identified 16 Advisory Committee on Immunization Practices (ACIP) presentations from 2012 to 2016 that indicated 'cost' or 'economic' content. Characteristics were reviewed, abstracted, and tabulated to quantify and assess the transparency and consistency of economic evidence presented to ACIP. To assess transparency, we documented if each study identified author affiliation, conflicts of interest, study limitations, a clearly described model structure and other model attributes. To assess consistency, we identified the frequency of specific modeling choices, including the perspective, types of health outcomes considered, inclusion of specific types of costs, discount rate, and use of sensitivity analyses. Our results indicate that the content in these presentations appear to be transparent overall and consistent in several important areas, such as study perspective and health outcomes. However, we find the inclusion of particular types of direct costs, indirect costs, program costs, and sensitivity analyses are areas that could improve consistency. Published by Elsevier Ltd.
C1 [Pike, Jamison; MacNeil, Jessica R.; Cohn, Amanda C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,MS A-19, Atlanta, GA 30333 USA.
   [Leidner, Andrew J.] Berry Technol Solut, Atlanta, GA USA.
RP Pike, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,MS A-19, Atlanta, GA 30333 USA.
EM jpike@cdc.gov
OI Leidner, Andrew/0000-0001-8869-5561; Pike, Jamison/0000-0002-3442-5627
FU Intramural CDC HHS [CC999999]
CR Advisory Committee on Immunization Practices, 2012, CHART ADV COMM IMM P
   [Anonymous], 2016, MOD METH PRED EP HLT
   Berwick DM, 2012, JAMA-J AM MED ASSOC, V307, P1513, DOI 10.1001/jama.2012.362
   Brisson M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv282
   Chesson HW, 2016, HUM VACC IMMUNOTHER, V12, P1363, DOI 10.1080/21645515.2016.1140288
   Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2
   Cho BH, 2013, VACCINE, V31, P6011, DOI 10.1016/j.vaccine.2013.10.024
   Control CfD Prevention. Measles-United States, 2011, MMWR-MORBID MORTAL W, V61, P253
   Council SF, 1999, DTUCH GUID PHARM RES
   de Trabajo Criterios G., 2011, TRABAJO CRITERIOS G
   Drugs CM, 2006, GUID EC EV HLTH TECH
   Hoerger TJ, 2014, INFECT CONT HOSP EP, V35, P845, DOI 10.1086/676865
   Kamiya H, 2016, VACCINE, V34, P1832, DOI 10.1016/j.vaccine.2016.02.027
   Laprise JF, 2016, J INFECT DIS, V214, P685, DOI 10.1093/infdis/jiw227
   Lieu T, 2007, GUIDANCE HLTH EC STU
   Mahamud A, 2012, VACCINE, V30, P6444, DOI 10.1016/j.vaccine.2012.08.001
   McGarry LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0072723
   Porteous GH, 2016, ANESTH ANALG, V122, P1450, DOI 10.1213/ANE.0000000000001196
   Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155
   Smith JC, 2010, VACCINE, V28, pA68, DOI 10.1016/j.vaccine.2010.02.037
   Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0
   Stoecker C, 2013, PEDIATRICS, V132, pE324, DOI 10.1542/peds.2012-3350
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 7
EP 10
DI 10.1016/j.vaccine.2018.11.055
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100002
PM 30473183
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Campbell, ZA
   Otieno, L
   Shirima, GM
   Marsh, TL
   Palmer, GH
AF Campbell, Zoe A.
   Otieno, Linus
   Shirima, Gabriel M.
   Marsh, Thomas L.
   Palmer, Guy H.
TI Drivers of vaccination preferences to protect a low-value livestock
   resource: Willingness to pay for Newcastle disease vaccines by
   smallholder households
SO VACCINE
LA English
DT Article
DE Vaccination decision; Contingent valuation; Willingness to pay;
   Veterinary vaccines; Poultry; Food security
AB Vaccination can be an effective risk management approach to minimize the burden of disease and increase livestock productivity for smallholder households in low income countries. In contrast to vaccination of cattle, a high-value smallholder asset, there is a significant knowledge gap for the drivers of vaccine adoption of smallholder poultry. Newcastle disease virus (NDV) causes high mortality in chickens and is one of the greatest constraints to East African poultry production. To determine preferences and willingness to pay for NDV vaccines by chicken-owning households in Tanzania, we administered a survey with a contingent valuation activity to 535 households across six villages in Arusha, Singida, and Mbeya regions. Given the low current vaccination rate, we tested the null hypothesis that smallholder households do not value NDV vaccines and found overwhelming evidence that smallholders do value NDV vaccines. The willingness to pay (WTP) estimate was 5853 Tanzanian shillings ($2.64) to vaccinate ten chickens given the vaccine was protective for a period of three months. This estimate is about twice the market price reported by households in the study areas suggesting chicken-owning households value and benefit from NDV vaccines, but face other barriers to vaccination. Previous vaccination had the largest positive effect size on WTP suggesting smallholders observe benefits from vaccinating. In contrast to studies of vaccination of higher-cost cattle where off-farm income sources often drive willingness to pay, on-farm income was a driver of WTP for NDV vaccines suggesting different drivers affect protection of low-value livestock assets as compared to high-value assets. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
C1 [Campbell, Zoe A.; Shirima, Gabriel M.; Marsh, Thomas L.; Palmer, Guy H.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, POB 647090, Pullman, WA 99164 USA.
   [Otieno, Linus] Kenya Govt Med Res Ctr, Kisumu, Kenya.
   [Campbell, Zoe A.; Shirima, Gabriel M.; Palmer, Guy H.] Nelson Mandela African Inst Sci & Technol, Arusha, Tanzania.
   [Marsh, Thomas L.] Washington State Univ, Sch Econ Sci, Pullman, WA 99164 USA.
RP Campbell, ZA (reprint author), Washington State Univ, Paul G Allen Sch Global Anim Hlth, POB 647090, Pullman, WA 99164 USA.
EM zoe.campbell@wsu.edu
OI Campbell, Zoe/0000-0002-4759-9976
FU Bill & Melinda Gates Foundation, Seattle, WA through the Program for
   Enhancing Health and Productivity of Livestock (PEHPL) [OPP1083453]
FX This research was funded by the Bill & Melinda Gates Foundation,
   Seattle, WA (grant #OPP1083453) through the Program for Enhancing Health
   and Productivity of Livestock (PEHPL). The findings and conclusions
   contained are those of the authors and do not necessarily reflect
   positions or policies of the Bill & Melinda Gates Foundation.
CR Armbruster W, 2005, EC IMPACTS ANIMAL DI
   Bernard H.R., 2006, RES METHODS ANTHR QU
   Brown TC, 2003, INTRO STATED PREFERE, P99, DOI [10.1007/978-94-007-0826-6_4, DOI 10.1007/978-94-007-0826-6_4]
   Campbell ZA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206058
   Delgado C, 1999, FOOD AGR ENV, V28, P1, DOI 10.5367/000000001101293427
   Dixon J., 2004, FRAMEWORK ANAL IMPAC
   FAO, 2000, APPL CONT VAL METH D
   FAO, 2012, END FARMS CLIM CHANG
   Fisher H, 2014, NEWCASTLE DIS CONTRO
   HANEMANN M, 1991, AM J AGR ECON, V73, P1255, DOI 10.2307/1242453
   Herrero M, 2013, ANIMAL, V7, P3, DOI 10.1017/S1751731112001954
   Holden S, 1999, REV SCI TECH OIE, V18, P425, DOI 10.20506/rst.18.2.1166
   Kairu-Wanyoike SW, 2014, PREV VET MED, V115, P130, DOI 10.1016/j.prevetmed.2014.03.028
   Karanja-Lumumba T., 2015, East African Agricultural and Forestry Journal, V81, P34
   Kryger K. N, 2010, SMALLHOLDER POULTRY
   Lopez-Feldman A., 2012, INTRO CONTINGENT VAL, DOI [10.1258/095646202760029804, DOI 10.1258/095646202760029804]
   Marsh TL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601410
   Musa U., 2010, Nigerian Veterinary Journal, V31, P46
   OIE World Organisation for Animal Health, 2016, NEWCASTLE DIS
   OTTE MJ, 2002, CATTLE SMALL RUMINAN
   Pound Sterling Live, 2017, HIST RAT USD TZS CUR
   Railey AF, 2018, VACCINE, V36, P5077, DOI [10.1016/j.vaccine.2018.06.069, 10.1016/j.va]
   Randall A, 1997, AM J AGR ECON, V79, P1489, DOI 10.2307/1244369
   Tanzania Ministry of Agriculture, 2012, UN REP TANZ NAT SAMP, P3
   Terfa ZG, 2015, FOOD SECUR, V7, P905, DOI 10.1007/s12571-015-0482-5
   WHO, 2016, NAT IMM COV SCOR EST
NR 26
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 11
EP 18
DI 10.1016/j.vaccine.2018.11.058
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100003
PM 30478006
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Verma, SK
   Gupta, A
   Batra, L
   Tuteja, U
AF Verma, Shailendra K.
   Gupta, Ankit
   Batra, Lalit
   Tuteja, Urmil
TI Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi
   improved the protective efficacy of YopE against plague infection
SO VACCINE
LA English
DT Article
DE Recombinant YopE; Plague; Subunit vaccine; Yersinia pestis; Flagellin C;
   Salmonella Typhi
ID YERSINIA-PESTIS; IMMUNE-RESPONSE; MOUSE MODELS; INDUCE; TLR5; DEFENSE;
   VACCINE
AB In the current antibiotic resistance scenario, vaccines may provide best defense against lethal bacterial diseases. So far, there is no ideal vaccine available against plague. Despite providing complete protection in small animal models, F1/LcrV based vaccine failed to provide ideal protection in non human primates. Here, we cloned, expressed and purified YopE of Yersinia pestis and flagellin C (FIiC) of Salmonella Typhi. However the best possible protection needs the significant induction of IFN-gamma and TNF-alpha. To determine the protective potential of the recombinant YopE alone or in formulation with FliC, Balb/C mice were immunized subcutaneously. The formulations were prepared with alum, a human compatible adjuvant. In our studies, the combination of YopE + FIiC induced significantly strong humoral and cellular immune responses. A combination of YopE + FliC provided 83% protection whereas YopE alone provided only 50% against 1 OOLD50 of Y. pestis in a mouse model. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Verma, Shailendra K.; Gupta, Ankit; Batra, Lalit; Tuteja, Urmil] Def Res & Dev Estab, Microbiol Div, Jhansi Rd, Gwalior 474002, India.
RP Verma, SK (reprint author), Def Res & Dev Estab, Microbiol Div, Jhansi Rd, Gwalior 474002, India.
EM vermask@drde.drdo.in
OI BATRA, LALIT/0000-0002-4375-9004
CR Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x
   Bashaw J, 2007, CLIN VACCINE IMMUNOL, V14, P605, DOI 10.1128/CVI.00398-06
   Batra L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003322
   Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077
   Diepold A, 2012, MOL MICROBIOL, V85, P878, DOI 10.1111/j.1365-2958.2012.08146.x
   Elvin SJ, 2004, MICROB PATHOGENESIS, V37, P177, DOI 10.1016/j.micpath.2004.06.009
   Feodorova VA, 2009, EXPERT REV VACCINES, V8, P1721, DOI 10.1586/ERV.09.129
   Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004
   Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882
   Hajam IA, 2013, RES VET SCI, V95, P936, DOI 10.1016/j.rvsc.2013.07.021
   Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006
   Honko AN, 2004, INFECT IMMUN, V72, P6676, DOI 10.1128/IAI.72.11.6676-6679.2004
   Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281
   Lin JS, 2010, VACCINE, V29, P357, DOI 10.1016/j.vaccine.2010.08.099
   Liu G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020928
   Murthy KGK, 2004, J BIOL CHEM, V279, P5667, DOI 10.1074/jbc.M307759200
   Pawel-Rammingen V, 2000, MOL MICROBIOL, V36, P73
   Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35
   RUSSELL P, 1995, VACCINE, V13, P1551, DOI 10.1016/0264-410X(95)00090-N
   Skountzou I, 2010, VACCINE, V28, P4103, DOI 10.1016/j.vaccine.2009.07.058
   Smiley ST, 2008, IMMUNOL REV, V225, P256, DOI 10.1111/j.1600-065X.2008.00674.x
   Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209
   Szaba FM, 2009, INFECT IMMUN, V77, P4295, DOI 10.1128/IAI.00273-09
   Taylor DN, 2011, VACCINE, V29, P4897, DOI 10.1016/j.vaccine.2011.05.001
   Tedla N, 1998, J IMMUNOL, V161, P5663
   Tsujimoto H, 2005, J LEUKOCYTE BIOL, V78, P888, DOI 10.1189/jlb.0105051
   Verma S. K., 2013, Journal of Clinical and Cellular Immunology, V4, P1000151
   Verma SK, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01053
   Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602
   Vicente-Suarez I, 2009, IMMUNOL LETT, V125, P114, DOI 10.1016/j.imlet.2009.06.007
   Welkos S, 2002, VACCINE, V20, P2206, DOI 10.1016/S0264-410X(02)00119-6
   Wren BW, 2003, NAT REV MICROBIOL, V1, P55, DOI 10.1038/nrmicro730
NR 32
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 19
EP 24
DI 10.1016/j.vaccine.2018.11.057
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100004
PM 30497835
DA 2020-05-12
ER

PT J
AU McMorrow, ML
   Tempia, S
   Walaza, S
   Treurnicht, FK
   Ramkrishna, W
   Azziz-Baumgartner, E
   Madhi, SA
   Cohen, C
AF McMorrow, Meredith L.
   Tempia, Stefano
   Walaza, Sibongile
   Treurnicht, Florette K.
   Ramkrishna, Wayne
   Azziz-Baumgartner, Eduardo
   Madhi, Shabir A.
   Cohen, Cheryl
TI Prioritization of risk groups for influenza vaccination in resource
   limited settings - A case study from South Africa
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine policy; Hospitalization; Mortality; South Africa
ID PANDEMIC INFLUENZA; RESPIRATORY ILLNESS; MATERNAL INFLUENZA; SEASONAL
   INFLUENZA; YOUNG-CHILDREN; GLOBAL BURDEN; AGE; PREVALENCE; MORTALITY;
   VACCINES
AB Background: Due to competing health priorities, low- and middle-income countries (LMIC) may need to prioritize between different influenza vaccine risk groups. Risk group prioritization may differ in LMIC based upon programmatic feasibility, country-specific prevalence of risk conditions and influenza associated morbidity and mortality.
   Methods: In South Africa, we collected local disease burden data (both published and unpublished) and published vaccine efficacy data in risk groups and healthy adults. We used these data to aid policy makers with risk group prioritization for influenza vaccination. We used the following formula to assess potential vaccine averted disease in each risk group: rate of influenza-associated hospitalization (or death) per 100,000 population * influenza vaccine efficacy (VE). We further estimated the cost per hospital day averted and the cost per year of life saved by influenza vaccination.
   Results: Pregnant women, HIV-infected adults, and adults and children with tuberculosis disease had among the highest estimates of hospitalizations averted per 100,000 vaccinated and adults aged 65 years and older had the highest estimated deaths averted per 100,000 vaccinated. However, when assessing both the cost per hospital day averted (range: USD148-1,344) and the cost per year of life saved (range: USD112-1,230); adults and children with TB disease, HIV-infected adults and pregnant women had the lowest cost per outcome averted.
   Discussion: An assessment of the potential disease outcomes averted and associated costs may aid policymakers in risk group prioritization for influenza vaccination. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
C1 [McMorrow, Meredith L.; Tempia, Stefano; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [McMorrow, Meredith L.; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa.
   [McMorrow, Meredith L.; Azziz-Baumgartner, Eduardo] US PHS, Rockville, MD USA.
   [Tempia, Stefano; Walaza, Sibongile; Treurnicht, Florette K.; Cohen, Cheryl] Natl Hlth Lab Serv, Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis, Johannesburg, South Africa.
   [Walaza, Sibongile; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [Ramkrishna, Wayne] Natl Dept Hlth, Communicable Dis Cluster, Pretoria, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
RP McMorrow, ML (reprint author), US Ctr Dis Control & Prevent, 100 Totius St, ZA-0181 Pretoria, Gauteng, South Africa.; Tempia, S (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa.
EM mmcmorrow@cdc.gov; stefanot@nicd.ac.za
OI McMorrow, Meredith/0000-0001-6363-4033; Cohen,
   Cheryl/0000-0003-0376-2302
FU NCIRD CDC HHS [U01 IP001048]; Intramural CDC HHS [CC999999]
CR Abadom TR, 2016, VACCINE, V34, P5649, DOI 10.1016/j.vaccine.2016.09.011
   [Anonymous], 2014, VACCINES PREVENTING
   [Anonymous], 2016, STAT RELEASE P0302 M
   Black SB, 2004, AM J PERINAT, V21, P333, DOI 10.1055/s-2004-831888
   Case A, 2005, HLTH SEEKING BEHAV N
   Cohen C, 2017, CLIN INFECT DIS
   Cohen C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118884
   Cohen C, 2013, EMERG INFECT DIS, V19, P1766, DOI 10.3201/eid1911.130546
   Cohen C, 2012, CLIN INFECT DIS, V55, P996, DOI 10.1093/cid/cis549
   Darvishian M, 2014, LANCET INFECT DIS, V14, P1228, DOI 10.1016/S1473-3099(14)70960-0
   Fell DB, 2017, BJOG-INT J OBSTET GY, V124, P48, DOI 10.1111/1471-0528.14143
   Fischer WA, 2014, GLOB HEART, V9, P325, DOI 10.1016/j.gheart.2014.08.004
   Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014
   Health Professions Council of South Africa, SUMM REG PERS 2016
   Hoberman A, 2003, JAMA-J AM MED ASSOC, V290, P1608, DOI 10.1001/jama.290.12.1608
   Horton KC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180954
   Jefferson T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub4
   Johnson LF, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30314
   Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Lawn SD, 2006, CLIN INFECT DIS, V42, P1040, DOI 10.1086/501018
   Lee BY, 2010, VACCINE, V28, P4875, DOI 10.1016/j.vaccine.2010.05.002
   Madhi SA, 2011, CLIN INFECT DIS, V52, P128, DOI 10.1093/cid/ciq004
   McGrath LJ, 2012, ARCH INTERN MED, V172, P548, DOI 10.1001/archinternmed.2011.2238
   McMorrow ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189623
   McMorrow ML, 2018, CLIN INFECT DIS
   Meeting of the Strategic Advisory Group of Experts on Immunization, 2012, WEEKLY EPIDEMIOLOGIC, P1
   Meeting of the Strategic Advisory Group of Experts on Immunization, 2015, WKLY EPIDEMIOL REC, V90, P261
   Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061
   Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008
   Miller MA, 2008, J INFECT DIS, V198, P305, DOI 10.1086/589716
   Moro PL, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.050
   Mylius SD, 2008, VACCINE, V26, P3742, DOI 10.1016/j.vaccine.2008.04.043
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704
   Pan American Health Organization, 2016, EXP PROGR IMM VACC P
   Pretorius MA, 2012, J INFECT DIS, V206, pS159, DOI 10.1093/infdis/jis538
   Radin JM, 2012, J INFECT DIS, V206, pS14, DOI 10.1093/infdis/jis606
   Ramkrishna W., 2016, OPTIONS 9 CONTROL IN
   Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Shisana O, 2004, SAMJ S AFR MED J, V94, P846
   Shisana O., 2014, S AFRICAN NATL HLTH
   South Africa Nursing Council, 2015, REG LIST QUAL CAL YE
   Steinhoff MC, 2012, CAN MED ASSOC J, V184, P645, DOI 10.1503/cmaj.110754
   Tamma PD, 2009, AM J OBSTET GYNECOL, V201, P547, DOI 10.1016/j.ajog.2009.09.034
   Tapia MD, 2016, LANCET INFECT DIS
   Tempia S, 2017, INFLUENZA OTHER RESP
   Tempia S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1198-z
   Tempia S, 2015, CLIN INFECT DIS, V61, P1063, DOI 10.1093/cid/civ448
   Tempia S, 2015, EMERG INFECT DIS, V21, P600, DOI 10.3201/eid2104.141033
   Tempia S, 2014, CLIN INFECT DIS, V58, P1241, DOI 10.1093/cid/ciu095
   Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053
   Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331
   Walaza S, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx116
   Walaza S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129173
   World Health Organization, GLOB HLTH OBS 2015
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 58
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 25
EP 33
DI 10.1016/j.vaccine.2018.11.048
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100005
PM 30471956
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Bollaerts, K
   Verstraeten, T
   Cohet, C
AF Bollaerts, Kaatje
   Verstraeten, Thomas
   Cohet, Catherine
TI Observational studies of non-specific effects of
   Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing
   the potential impact of study characteristics, bias and confounding
   through meta-regression
SO VACCINE
LA English
DT Article
DE Vaccine; Whole-cell Diphtheria-Tetanus-Pertussis; Non-specific effects;
   All-cause mortality; Bias; Confounding
ID CHILD SURVIVAL; ROUTINE IMMUNIZATIONS; GUINEA-BISSAU; MORTALITY;
   VACCINATIONS; MEASLES; COHORT; HEALTH
AB Introduction: It has been suggested that some vaccines have effects beyond protection against the diseases they target, called non-specific effects (NSEs). In 2016, a systematic review by Higgins et al., commissioned by the WHO Strategic Advisory Group of Experts (SAGE) on immunization, estimated the relative risk (RR) of all-cause mortality after whole-cell Diphtheria-Tetanus-Pertussis (DTwP) vaccination to be 1.38 (95% CI: 0.92-2.08), and described these potential NSEs as inconsistent. However, the selection of studies for meta-analysis, based on their proneness to bias and confounding, was debated.
   Objective: To identify study characteristics and postulated risks of bias and confounding that might have impacted the RR of all-cause mortality after DTwP vaccination in observational studies conducted in low-income countries.
   Methods: Based on methodological considerations on study design and analysis, we systematically assessed all 17 DTwP studies from the Higgins et al. review for risk of selection bias, exposure and outcome misclassification, confounding and differential co-interventions. We used meta-regression to assess the impact of study characteristics and the postulated risks of bias and confounding on the RR estimates, and looked for outlying and influential risk estimates. Permutation tests were performed to control for false-positive findings.
   Results: The overall RR of all-cause mortality after DTwP vaccination including all but one outlying and influential study was 1.32 (95% CI: 0.83-2.08). Based on uni-variable meta-regression, we found that study location (p = 0.01), studies using the landmark approach (p = 0.015) and studies at high risk of exposure misclassification (p = 0.036) were significantly associated with increased RR estimates whereas studies at high risk of selection bias (p = 0.059) showed borderline significance. The results further suggest these effect modifiers are clustered in studies conducted in West-Africa.
   Conclusion: The increased RR of all-cause mortality after DTwP might be confined to West-African countries and/or certain postulated risks of bias might have inflated these RRs. (C) 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY license.
C1 [Bollaerts, Kaatje; Verstraeten, Thomas] P95 Epidemiol & Pharmacovigilance, B-3000 Leuven, Belgium.
   [Cohet, Catherine] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
RP Bollaerts, K (reprint author), Vlierbeeklaan 18, B-3010 Kessel Lo, Belgium.
EM Kaatje.Bollaerts@p-95.com
FU GlaxoSmithKline Biologicals S.A., BelgiumGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals S.A., Belgium.
CR Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2016, PEDIATR INFECT DIS J, V35, P1247, DOI 10.1097/INF.0000000000001269
   Aaby P, 2015, T ROY SOC TROP MED H, V109, P77, DOI 10.1093/trstmh/tru186
   Aaby P, 2012, ARCH DIS CHILD, V97, P685, DOI 10.1136/archdischild-2011-300646
   Bawah AA, 2010, SCAND J PUBLIC HEALT, V38, P95, DOI 10.1177/1403494809352532
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   Chan GJ, 2007, INT J EPIDEMIOL, V36, P1022, DOI 10.1093/ije/dym142
   Cooper WO, 2003, B WORLD HEALTH ORGAN, V81, P821
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   Fisker AB, 2014, VACCINE, V32, P598, DOI 10.1016/j.vaccine.2013.11.074
   Higgins JP, 2016, BMJ, V355, pi5170
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirve S, 2012, VACCINE, V30, P7300, DOI 10.1016/j.vaccine.2012.09.035
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Krishnan A, 2013, Trop Med Int Health, V18, P1329, DOI 10.1111/tmi.12192
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Lehmann D, 2005, INT J EPIDEMIOL, V34, P138, DOI 10.1093/ije/dyh262
   Mina MJ, 2015, SCIENCE, V348, P694, DOI 10.1126/science.aaa3662
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003
   Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282
   R Development Core Team, 2013, R LANG ENV STAT COMP
   Saadatian-Elahi M, 2016, VACCINE, V34, P3923, DOI 10.1016/j.vaccine.2016.06.020
   Shann F, 2010, ARCH DIS CHILD, V95, P662, DOI 10.1136/adc.2009.157537
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   Viechtbauer W, 2010, RES SYNTH METHODS, V1, P112, DOI 10.1002/jrsm.11
   Welaga P, 2012, TROP MED INT HEALTH, V17, P1492, DOI 10.1111/j.1365-3156.2012.03093.x
NR 36
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 34
EP 40
DI 10.1016/j.vaccine.2018.11.049
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100006
PM 30471957
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pezzotti, P
   Bellino, S
   Riccardo, F
   Lucaroni, F
   Cerquetti, M
   Pantosti, A
   Rezza, G
   Stefanelli, P
AF Pezzotti, Patrizio
   Bellino, Stefania
   Riccardo, Flavia
   Lucaroni, Francesca
   Cerquetti, Marina
   Pantosti, Annalisa
   Rezza, Giovanni
   Stefanelli, Paola
TI Vaccine preventable invasive bacterial diseases in Italy: A comparison
   between the national surveillance system and recorded hospitalizations,
   2007-2016
SO VACCINE
LA English
DT Article
DE Invasive bacterial disease; Neisseria meningitidis; Streptococcus
   pneumoniae; Haemophilus influenzae; Hospital discharge records; National
   surveillance system
ID MENINGOCOCCAL DISEASE
AB Background: Vaccine-preventable invasive bacterial diseases (IBDs) caused by Neisseria meningitidis (Nm), Streptococcus pneumoniae (Sp), and Haemophilus influenzae (Hi) have been notified in Italy since 2007 without assessing reporting completeness.
   Methods: Our study compared the number of cases of IBDs identified from the Italian Hospital Discharge Records (HDRs), using specific diagnostic ICD-9-CM codes, with those notified to the National Surveillance System (NSS) from 2007 to 2016. A multinomial logistic regression model was used to impute the aetiology of all discharges with a diagnosis of unspecified bacterial meningitis.
   Results: Over a 10-year period, 14,243 hospital discharges with diagnosis of IBD were estimated in Italy (12,671 with specified aetiology and 1,572 with imputed aetiology). Among those, 2,513 (17.6%) were caused by Nm, 10,441 (73.3%) by Sp, and 1289 (9.1%) by Hi. Most invasive meningococcal diseases were coded as meningitis (72.3%), while Hi and Sp were more frequently coded as septicaemia (51.6% and 60.4%, respectively). The highest mean annual incidence rate was found for IBD caused by Sp (1.74 per 100,000), followed by Nm (0.42 per 100,000) and by Hi (0.21 per 100,000). Comparing NSS with HDR data, we found an initially high underreporting of all IBDs, and particularly for Hi. Data from the two systems overlapped in more recent years, due to an improved reporting completeness. The increasing IBD incidence observed in NSS data was not confirmed by HDR data trends, although with pathogen-related differences with Hi cases rising in both data sources, suggesting that is mainly due to an improved disease notification rather than to a true incidence increase.
   Conclusions: Comparing surveillance data with other data sources is useful to better interpret observed trends of notifiable diseases. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pezzotti, Patrizio; Bellino, Stefania; Riccardo, Flavia; Cerquetti, Marina; Pantosti, Annalisa; Rezza, Giovanni; Stefanelli, Paola] ISS, Italian Natl Inst Hlth, Dept Infect Dis, Rome, Italy.
   [Lucaroni, Francesca] Tor Vergata Univ, Rome, Italy.
RP Pezzotti, P; Stefanelli, P (reprint author), Ist Super San, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM patrizio.pezzotti@iss.it; paola.stefanelli@iss.it
RI rezza, giovanni/D-4393-2016
OI rezza, giovanni/0000-0003-0268-6790
FU Italian Ministry of HealthMinistry of Health, Italy
FX The Italian National Surveillance System of the Invasive Bacterial
   Diseases is partially funded by the Italian Ministry of Health. The IBD
   Surveillance System was included in the Decree of the President of the
   Council of Ministers, 3rd March 2017.
CR Baldovin T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012478
   Blasi F, 2012, CLIN MICROBIOL INFEC, V18, P7, DOI 10.1111/j.1469-0691.2012.03937.x
   European Centre for Disease Prevention and Control, ANN EP REP 2015 HAEM
   European Centre for Disease Prevention and Control, INV MEN DIS ANN EP R
   European Centre for Disease Prevention and Control, INV PNEUM DIS ANN EP
   Giambi C, 2017, EUR J PEDIATR, V176, P955, DOI 10.1007/s00431-017-2935-7
   Gibbons CL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-147
   Hosmer D.W., 2013, APPL LOGISTIC REGRES
   Istituto Superiore di Sanita, DAT SORV MAL BATT IN
   Peterson LE, 2006, INT JOINT C NEUR NET
   Peterson LE, 2008, INT J APPROX REASON, V47, P17, DOI 10.1016/j.ijar.2007.03.006
   Raghunathan T. E., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186
   Rossi PG, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-13
   Stefanelli P, 2016, J INFECTION, V73, P136, DOI 10.1016/j.jinf.2016.05.003
   van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463
   Vescio F, 2015, EPIDEMIOL INFECT, V143, P1742, DOI 10.1017/S0950268814002659
NR 16
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 41
EP 48
DI 10.1016/j.vaccine.2018.11.047
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100007
PM 30478004
DA 2020-05-12
ER

PT J
AU Mahaux, O
   Bauchau, V
   Zeinoun, Z
   Van Holle, L
AF Mahaux, Olivia
   Bauchau, Vincent
   Zeinoun, Ziad
   Van Holle, Lionel
TI Tree-based scan statistic - Application in manufacturing-related safety
   signal detection
SO VACCINE
LA English
DT Article
DE Tree-based scan statistic; Safety signal detection; Manufacturing;
   Data-mining
ID RED-CELL APLASIA; ADVERSE EVENTS; DISEASE; VACCINE; PHARMACOVIGILANCE;
   INCIDENT
AB Background and objectives: Over the last decades, medicinal regulations have been put into place and have considerably improved manufacturing practices. Nevertheless, safety issues may still arise. Using the simulation described in this manuscript, our aim is to develop adequate detection methods for manufacturing-related safety signals, especially in the context of biological products.
   Methods: Pharmaceutical companies record the entire batch genealogies, from seed batches over intermediates to final product (FP) batches. We constructed a hierarchical tree based on this genealogy information and linked it to the spontaneous safety data available for the FP batch numbers. The tree-based scan statistic (TBSS) was used on simulated data as a proof of concept to locate the source that may have subsequently generated an excess of specific adverse events (AEs) within the manufacturing steps, and to evaluate the method's adjustment for multiple testing. All calculations were performed with a customized program in SAS v9.2.
   Results: The TBSS generated a close to expected number of false positive signals, demonstrating that it adjusted for multiple testing. Overall, the method detected 71% of the simulated signals at the correct production step when a 6-fold increase in reports with AEs of interest (AEOI) was applied, and 31% when a 2-fold increase was applied. The relatively low detection performance may be attributed to the higher granularity associated with the lower levels of the hierarchy, leading to a lack of power and the stringent definition criteria that were applied for a true positive result.
   Conclusion: As a data-mining method for manufacturing-related safety signal detection, the TBSS may provide advantages over other disproportionality analyses (using batch information) but may benefit from complementary methods (not relaying on batch information). While the method warrants further refinement, it may improve safety signal detection and contribute to improvements in the quality of manufacturing processes. (C) 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY license.
C1 [Mahaux, Olivia; Bauchau, Vincent; Zeinoun, Ziad; Van Holle, Lionel] GSK, Vaccine Clin Safety & Pharmacovigilance, Ave Fleming 20, B-1300 Waver, Belgium.
RP Mahaux, O (reprint author), GSK, Vaccine Clin Safety & Pharmacovigilance, Ave Fleming 20, B-1300 Waver, Belgium.
EM Olivia.x.mahaux@gsk.com
RI bauchau, vincent g/H-3710-2012
OI Mahaux, Olivia/0000-0002-9361-3118
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA was the funding source and was involved
   in all stages of the study conduct and analysis. GlaxoSmithKline
   Biologicals SA also took responsibility for all costs associated with
   the development and publishing of the present manuscript.
CR Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Bennett CL, 2014, NEW ENGL J MED, V370, P2055, DOI 10.1056/NEJMc1400883
   Boven K, 2005, KIDNEY INT, V67, P2346, DOI 10.1111/j.1523-1755.2005.00340.x
   Candore G, 2015, DRUG SAFETY, V38, P577, DOI 10.1007/s40264-015-0289-5
   Caster O, 2014, DRUG SAFETY, V37, P617, DOI 10.1007/s40264-014-0204-5
   Center for Disease Control and Prevention (CDC, HIST VACC SAF
   DuMouchel W, 2013, J BIOPHARM STAT, V23, P161, DOI 10.1080/10543406.2013.736809
   Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77
   Gentle J. E., 2003, RANDOM NUMBER GENERA
   Harpaz R, 2013, CLIN PHARMACOL THER, V93, P539, DOI 10.1038/clpt.2013.24
   Kleinman K, 2004, AM J EPIDEMIOL, V159, P217, DOI 10.1093/aje/kwh029
   Kulldorff M, 2003, BIOMETRICS, V59, P323, DOI 10.1111/1541-0420.00039
   Kulldorff M, 2001, J ROY STAT SOC A STA, V164, P61, DOI 10.1111/1467-985X.00186
   Macdougall IC, 2012, KIDNEY INT, V81, P727, DOI 10.1038/ki.2011.500
   NATHANSON N, 1995, AM J EPIDEMIOL, V142, P109, DOI 10.1093/oxfordjournals.aje.a117611
   Nathanson N, 1963, AM J EPIDEMIOL, V142, P7
   Purcell P, 2002, DRUG SAFETY, V25, P415, DOI 10.2165/00002018-200225060-00005
   Son DS, 2015, J BIOMED INFORM, V53, P355, DOI 10.1016/j.jbi.2014.12.010
   Van Holle L, 2014, DRUG SAFETY, V37, P1047, DOI 10.1007/s40264-014-0237-9
   Van Holle L, 2012, PHARMACOEPIDEM DR S, V21, P603, DOI 10.1002/pds.3226
   van Puijenbroek EP, 2010, DRUG SAFETY, V33, P1097, DOI 10.2165/11539270-000000000-00000
   Weaver JL, 2015, TOXICOL APPL PHARM, V287, P246, DOI 10.1016/j.taap.2015.06.009
   Yih WK, 2018, AM J EPIDEMIOL, V187, P1269, DOI 10.1093/aje/kwy023
NR 23
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 49
EP 55
DI 10.1016/j.vaccine.2018.11.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100008
PM 30470642
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wehbi, NK
   Wani, RJ
   Klepser, DG
   Murry, J
   Khan, AS
AF Wehbi, Nizar K.
   Wani, Rajvi J.
   Klepser, Donald G.
   Murry, Janice
   Khan, Ali S.
TI Impact of implementing a technology platform in community pharmacies to
   increase adult immunizations rates
SO VACCINE
LA English
DT Article
DE Adult immunization; Community pharmacies; Influenza vaccine;
   Pneumococcal vaccine; Herpes zoster vaccine; Pertussis vaccine
ID HERPES-ZOSTER VACCINATION; UNITED-STATES; INFLUENZA VACCINATION;
   COVERAGE; CARE
AB Over the course of this project, we utilized pharmacists at 159 community pharmacies in Nebraska and Iowa to administer vaccinations to adults 19 years of age or older with the objective of improving immunization rates in both states. We implemented a pharmacy-based technology platform and partnered with public health via the state immunization registries of both states to ensure that immunizations provided at the pharmacy were transmitted to the statewide registry, for which reporting is currently voluntary for health care providers. After using the technology platform for one year, an increase of immunization rates for influenza, herpes zoster, and pertussis vaccination rates by 37%, 12%, and 74%, respectively, was recorded in comparison to the prior year numbers. However, there was about 16% decrease in vaccination rates for pneumococcal vaccine. For the first time, the project's participating pharmacies in Nebraska reported immunization counts to their state's immunization registries. This project leveraged community pharmacies as healthcare destinations to achieve further gains in increasing immunization rates, improving the health of adults, and creating a community-wide network for prevention. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wehbi, Nizar K.] Univ Nebraska, Med Ctr, Dept Hlth Serv Res & Adm, 600 S 42nd St, Omaha, NE 68198 USA.
   [Wani, Rajvi J.] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA.
   [Klepser, Donald G.; Murry, Janice] Univ Nebraska, Med Ctr, Dept Pharm Practice, 600 S 42nd St, Omaha, NE 68198 USA.
   [Khan, Ali S.] Univ Nebraska, Med Ctr, Dept Epidemiol, 600 S 42nd St, Omaha, NE 68198 USA.
RP Wehbi, NK (reprint author), Univ Nebraska, Med Ctr, Coll Publ Hlth, Ctr Hlth Policy Hlth Serv Res & Adm, 984350 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM nizar.wehbi@unmc.edu
OI Wani, Rajvi/0000-0002-2422-7758
FU Grant Federal Award - Center for Disease Control and Prevention (CDC)
   [IH23IP000985]; CDC Grant; National Association of Chain Drug Stores
   (NACDS); CDCCentre National de la Recherche Scientifique (CNRS)United
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA; NACDS
FX This work was supported, in part, by Grant Federal Award Identification
   Number, IH23IP000985, funded by the Center for Disease Control and
   Prevention (CDC). The content of this paper is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the CDC or the Department of Health and Human Services. The underlying
   demonstration project is part of a larger initiative with three (3)
   sub-awardees spanning four (4) states to increase adult immunizations.
   The demonstration projects are supported by $800,000 funded by the CDC
   Grant with an additional $300,000 from the National Association of Chain
   Drug Stores (NACDS). Each sub-awardee received approximately 67 percent
   ($200,000) of its funding from the CDC and approximately 33 percent
   ($100,000) from NACDS to implement its demonstration project. A total of
   $1.1 million will be used to complete CDC project work, with 73 percent
   from the CDC and 27 percent from NACDS.
CR American Lung Association, 2015, WHO PNEU PNEUM PNEUM, P1
   American Pharmacist Association, 2013, PHARM ADM VACC
   [Anonymous], 2017, HLTH US 2016 CHARTB
   Bodenheimer T, 2006, NEW ENGL J MED, V355, P861, DOI 10.1056/NEJMp068155
   Burson RC, 2016, HUM VACC IMMUNOTHER, V12, P3146, DOI 10.1080/21645515.2016.1215393
   Centers for Disease control and Prevention, 2014, 2013 IISAR DAT PART
   Centers for Disease Control and Prevention, 2015, SHINGL SURV, V159
   Drozd EM, 2017, CLIN THER, V39, P1563, DOI 10.1016/j.clinthera.2017.07.004
   Duncan Ian G, 2012, Cost Eff Resour Alloc, V10, P10
   Eid Deeb D, 2015, Consult Pharm, V30, P459, DOI 10.4140/TCP.n.2015.459
   Ernst M E, 1997, J Am Pharm Assoc (Wash), VNS37, P570
   GlaxoSmithKline, 2017, GSK STAT PNEUM VACC, P7
   Grabenstein JD, 2001, MED CARE, V39, P340, DOI 10.1097/00005650-200104000-00005
   Helms C, 2011, VACCINE, V29, P3483, DOI 10.1016/j.vaccine.2011.02.056
   Iowa Department of Public Health, 2014, 2014 IOW IMM PROGR A
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005
   Kennedy ED, 2012, MARCH FLU VACCINATIO
   Lee BY, 2009, VACCINE, V27, P4252, DOI 10.1016/j.vaccine.2009.04.055
   McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3
   National Association Chain Drug Stores, 2014, COMM PHARM FILLS GAP
   National Commission on Quality Assurance, 2013, IMPR QUAL PAT EXP ST
   Nebraska Department of Health and Human Services D of PH, 2014, STAT REL PHARM PRACT
   Nevin-Woods C, 2013, PUBLIC HEALTH REP, V128, P7
   Postema A S, 2000, MMWR Recomm Rep, V49, P1
   Rolfes MA, 2016, ESTIMATED INFLUENZA
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Wang JL, 2013, J AM PHARM ASSOC, V53, P46, DOI 10.1331/JAPhA.2013.12019
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95
   Williams WW, 2014, MMWR-MORBID MORTAL W, V63, P95
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 56
EP 60
DI 10.1016/j.vaccine.2018.11.043
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100009
PM 30471954
DA 2020-05-12
ER

PT J
AU Bernstein, DI
   Pullum, DA
   Cardin, RD
   Bravo, FJ
   Dixon, DA
   Kousoulas, KG
AF Bernstein, David, I
   Pullum, Derek A.
   Cardin, Rhonda D.
   Bravo, Fernando J.
   Dixon, David A.
   Kousoulas, Konstantin G.
TI The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2
   genital infection in the guinea pig model of genital herpes
SO VACCINE
LA English
DT Article
DE Genital herpes; Herpes simplex virus; Vaccine; Guinea pigs; Live
   attenuated vaccine
ID SIMPLEX-VIRUS TYPE-1; HIV ACQUISITION; EFFICACY; MUTANT;
   HERPES-SIMPLEX-VIRUS-2; PREVALENCE; PREVENTION; PATHOGENS; TERMINUS;
   TRIAL
AB Background: Although development of an HSV vaccine is a priority there is currently no vaccine available. The recent failure of subunit vaccines suggest that presentation of more antigens via a live attenuated vaccine may be required for protection. We therefore evaluated VC2, a live attenuated HSV vaccine, engineered to be unable to enter into neuronal axons.
   Methods: VC2 pathogenesis was first evaluated in guinea pigs following intravaginal inoculation. VC2 was then evaluated as a prophylactic and therapeutic vaccine and compared protection to a gD2 vaccine adjuvanted with MPL/Alum in the guinea pig model of genital HSV-2. The guinea pig model allows evaluation of acute and recurrent disease, as well as vaginal shedding acutely and during episodes of recurrent activation.
   Results: VC2 was significantly attenuated in guinea pigs compared to the wild type strain, 17syn+. It replicated poorly at the inoculation site, did not produce any genital disease and rarely infected the neural tissue. After prophylactic vaccination, the VC2 vaccine decreased the clinical severity of acute and recurrent HSV-2 disease and shedding and decreased the quantity of virus in the DRGs. When compared to gD2+MPL/Alum, VC2 was somewhat more effective especially as it relates to neural tissue infection. VC2 was not effective as a therapeutic vaccine.
   Conclusion: The live attenuated prophylactic HSV vaccine, VC2, was effective in the guinea pig model of genital HSV-2. Its decreased ability to infect neural tissues provides advantages over other live attenuated vaccines. (C) 2018 Published by Elsevier Ltd.
C1 [Bernstein, David, I; Pullum, Derek A.; Bravo, Fernando J.; Dixon, David A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
   [Cardin, Rhonda D.; Kousoulas, Konstantin G.] Louisiana State Univ, Sch Vet Med, Baton Rouge, LA 70803 USA.
RP Bernstein, DI (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM david.bernstein@cchmc.org
OI KOUSOULAS, KONSTANTIN/0000-0001-7077-9003
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272201000008I]
FX We thank Brent Stanfield for performing the confirmatory PCR testing at
   LSU. We are grateful to Toni Cunningham for assistance with manuscript
   preparation. This work was supported by National Institute of Health
   Contract No. HHSN272201000008I to CCHMC.
CR Awasthi S, 2008, VACCINE, V26, P1195, DOI 10.1016/j.vaccine.2007.12.032
   Awasthi S, 2012, J VIROL, V86, P4586, DOI 10.1128/JVI.07203-11
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   Bernstein David I., 2015, Antiviral Chemistry & Chemotherapy, V24, P19, DOI 10.1177/2040206614566581
   Bernstein DI, 2011, VACCINE, V29, P2071, DOI 10.1016/j.vaccine.2011.01.005
   Bernstein DI, 2010, VACCINE, V28, P3748, DOI 10.1016/j.vaccine.2009.10.025
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Chouljenko VN, 2009, J VIROL, V83, P12301, DOI 10.1128/JVI.01329-09
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331
   David AT, 2008, CURR EYE RES, V33, P455, DOI 10.1080/02713680802130362
   David AT, 2012, MBIO, V3, DOI 10.1128/mBio.00144-12
   Dropulic LK, 2012, EXPERT REV VACCINES, V11, P1429, DOI [10.1586/ERV.12.129, 10.1586/erv.12.129]
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7
   Gershon AA, 2013, VIROLOGY, V435, P29, DOI 10.1016/j.virol.2012.10.006
   Halford WP, 2014, EXPERT REV VACCINES, V13, P691, DOI 10.1586/14760584.2014.910121
   Halford WP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017748
   Harris SA, 2015, J ALZHEIMERS DIS, V48, P319, DOI 10.3233/JAD-142853
   Itzhaki RF, 2018, J ALZHEIMERS DIS, V64, P363, DOI 10.3233/JAD-180266
   Iyer AV, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-317
   Johnston C, 2016, VACCINE, V34, P2948, DOI 10.1016/j.vaccine.2015.12.076
   Lee HC, 2009, J VIROL, V83, P6115, DOI 10.1128/JVI.00128-09
   Lewis DA, 2012, SEX TRANSM DIS, V39, P880, DOI 10.1097/OLQ.0b013e318269cf90
   Looker KJ, 2017, LANCET INFECT DIS, V17, P1303, DOI 10.1016/S1473-3099(17)30405-X
   Mertz GJ, 2008, J INFECT DIS, V198, P1098, DOI 10.1086/591914
   Mertz KJ, 1998, J INFECT DIS, V178, P1795, DOI 10.1086/314502
   Musarrat F., 2018, J VIROL, V92
   Richards AL, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006741
   Rider PJF, 2018, CURR CLIN MICROBIOL, V5, P55, DOI 10.1007/s40588-018-0082-1
   Sacks SL, 2004, ANTIVIR RES, V63, pS19, DOI 10.1016/j.antiviral.2004.06.004
   Saied AA, 2014, CURR EYE RES, V39, P596, DOI 10.3109/02713683.2013.855238
   Sawtell NM, 1999, J INFECT DIS, V180, P821, DOI 10.1086/314958
   Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915
   STANBERRY LR, 1991, REV INFECT DIS, V13, pS920
   STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914
   Stanfield B, 2015, CURR CLIN MICROBIOL, V2, P125, DOI 10.1007/s40588-015-0020-4
   Stanfield BA, 2018, VACCINE, V36, P2842, DOI 10.1016/j.vaccine.2018.03.075
   Stanfield BA, 2017, VACCINE, V35, P536, DOI 10.1016/j.vaccine.2016.12.018
   Stanfield BA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109890
   Tanaka M, 2003, J VIROL, V77, P1382, DOI 10.1128/JVI.77.2.1382-1391.2003
   Thompson C, 2011, ADV EXP MED BIOL, V697, P221, DOI 10.1007/978-1-4419-7185-2_15
   THOMPSON RL, 1986, MICROB PATHOGENESIS, V1, P409, DOI 10.1016/0882-4010(86)90072-0
   Visalli RJ, 2014, VACCINE, V32, P1398, DOI 10.1016/j.vaccine.2013.10.079
   Walker J, 1998, VACCINE, V16, P1, DOI 10.1016/S0264-410X(97)00164-3
   Wang KN, 2016, J VIROL, V90, P562, DOI 10.1128/JVI.01845-15
   WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201
   Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998
   Xu F., 2010, Morbidity and Mortality Weekly Report, V59, P456
NR 47
TC 6
Z9 6
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 61
EP 68
DI 10.1016/j.vaccine.2018.11.042
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100010
PM 30471955
DA 2020-05-12
ER

PT J
AU Stead, M
   Critchlow, N
   Eadie, D
   Sullivan, F
   Gravenhorst, K
   Dobbie, F
AF Stead, Martine
   Critchlow, Nathan
   Eadie, Douglas
   Sullivan, Fay
   Gravenhorst, Katja
   Dobbie, Fiona
TI Mandatory policies for influenza vaccination: Views of managers and
   healthcare workers in England
SO VACCINE
LA English
DT Article
DE Influenza; Flu; Vaccination; Policy; Attitudes
ID OCCUPATIONAL VACCINES; PREVENTABLE DISEASES; ATTITUDES; PERSONNEL;
   RATES; COVERAGE; CARROTS
AB Introduction: Mandatory policies have the potential to increase uptake of influenza ('flu') vaccination among healthcare workers (HCWs), but concerns have been expressed about their acceptability and effectiveness. We explored views on three mandatory policies (declination forms, face masks or reduced patient contact, and mandatory vaccination) among both HCWs and flu vaccination programme managers in the National Health Service (NHS) in England.
   Method: A mixed method approach was employed. An online cross-sectional survey was conducted with staff responsible for implementing influenza campaigns in NHS trusts (healthcare organisations) in England (n = 72 trusts). The survey measured perceived effectiveness of the three mandatory policies and perceived support for them among HCWs. Qualitative interviews were conducted in four trusts, with influenza campaign managers (n = 24) and with HCWs who had the opportunity to receive the influenza vaccination (n = 32). Interviews explored respondents' views of the three strategies and were analysed thematically using QSR NVivo 11 All data were collected shortly after the 2016/2017 influenza season.
   Results: In the survey, views varied on the effectiveness of the three policies and none of the interventions were thought to be strongly supported by HCWs, with particularly low levels of support perceived for mandatory vaccination and for face masks or reduced patient contact. The qualitative interviews revealed substantial concerns around the practicability and enforceability of mandatory policies and the potential discriminatory effect on HCWs who made a principled decision or had medical reasons for exemption. Additional doubts were also expressed regarding the effectiveness of face masks and their potential to worry patients, and the ethics of compelling staff to accept medical intervention.
   Discussion: Mandatory vaccination and face masks would not be strongly supported if introduced in the UK. If declination forms are adopted, they should be used in a constructive intelligence-gathering manner which avoids stigmatising HCWs. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Stead, Martine; Critchlow, Nathan; Eadie, Douglas; Dobbie, Fiona] Univ Stirling, Fac Hlth Sci & Sport, Inst Social Mkt, Stirling FK9 4LA, Scotland.
   [Sullivan, Fay] NatCen Social Res, 35 Northampton Sq, London EC1V 0AX, England.
   [Gravenhorst, Katja] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Publ Hlth Environm & Soc, 15-17 Tavistock Pl, London WC1H 9SH, England.
RP Stead, M (reprint author), Univ Stirling, Fac Hlth Sci & Sport, Inst Social Mkt, Stirling FK9 4LA, Scotland.
EM martine.stead@stir.ac.uk
RI Critchlow, Nathan/Q-9210-2019; dobbie, fiona/L-5858-2016
OI dobbie, fiona/0000-0002-8294-8203
FU Department of Health and Social Care Policy Research Programme
FX The work was undertaken by the authors as part of the Public Health
   Research Consortium. The Public Health Research Consortium is funded by
   the Department of Health and Social Care Policy Research Programme. The
   views expressed in the publication are those of the authors and not
   necessarily those of the DHSC. Information about the wider programme of
   the PHRC is available from http://phrc.lshtm.ac.uk/.
CR Carter AH, 2018, PUBLIC HEALTH, V158, P61, DOI 10.1016/j.puhe.2018.01.020
   Ajenjo MC, 2010, INFECT CONT HOSP EP, V31, P233, DOI 10.1086/650449
   Derber CJ, 2012, CURR INFECT DIS REP, V14, P627, DOI 10.1007/s11908-012-0291-3
   Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442
   Donnelly L., 2018, TELEGRAPH
   Drees M, 2015, INFECT CONT HOSP EP, V36, P717, DOI 10.1017/ice.2015.47
   Dubova A, 2015, VACCINE, V33, P2530, DOI 10.1016/j.vaccine.2015.03.048
   Edelstein M, 2014, EPIDEMIOL INFECT, V142, P438, DOI 10.1017/S095026881300112X
   Esolen LM, 2011, INFECT CONT HOSP EP, V32, P703, DOI 10.1086/660762
   Galanakis E, 2013, EUROSURVEILLANCE, V18, P23, DOI 10.2807/1560-7917.ES2013.18.45.20627
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Jamrozik E, 2016, J MED ETHICS, V42, P762, DOI 10.1136/medethics-2015-103327
   Khodyakov D, 2014, VACCINE, V32, P3082, DOI 10.1016/j.vaccine.2013.06.077
   La Torre G, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010013
   Looijmans-van den Akker I, 2009, J AM GERIATR SOC, V57, P2253, DOI 10.1111/j.1532-5415.2009.02560.x
   Lugo NR, 2007, AM J INFECT CONTROL, V35, P1, DOI 10.1016/j.ajic.2006.10.004
   Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P66, DOI 10.1016/j.ajic.2012.01.028
   Maltezou HC, 2012, PEDIATR INFECT DIS J, V31, P623, DOI 10.1097/INF.0b013e31824ddc1e
   McCartney M, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k402
   Mytton OT, 2013, OCCUP MED-OXFORD, V63, P189, DOI 10.1093/occmed/kqt002
   NICE (National Institute for Health and Care Excellence), 2017, FLU VACC INCR UPT NI
   NICE (National Institute for Health and Care Excellence), 2017, FLU VACC INCR UPT EV
   Ofstead CL, 2017, VACCINE, V35, P2390, DOI 10.1016/j.vaccine.2017.03.041
   Pereira M, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k1141
   Pereira M, 2017, CLIN MED, V17, P484, DOI 10.7861/clinmedicine.17-6-484
   Pless A, 2017, INFLUENZA OTHER RESP, V11, P247, DOI 10.1111/irv.12441
   Podczervinski S, 2015, AM J INFECT CONTROL, V43, P228, DOI 10.1016/j.ajic.2014.11.025
   Public Health England, 2018, SEAS INFL VACC UPT F
   Public Health England, 2017, SEAS INFL VACC UPT F
   Shrikrishna D, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2015-000079
   Skowronski DM, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0163586e0163586, DOI 10.1371/JOURNAL.PONE.0163586E0163586]
   Stead M, 2018, INFECT DIS HLTH, DOI [10.1016/j.jdh2018.09.082, DOI 10.1016/J.JDH2018.09.082]
   Talbot TR, 2009, CLIN INFECT DIS, V49, P773, DOI 10.1086/605554
   The King's Fund, 2018, KINGS FUND NOT BE SN
   Wang TL, 2017, CURR OPIN PEDIATR, V29, P606, DOI 10.1097/MOP.0000000000000527
   WHO (World Health Organization), 2018, IMM VACC BIOL WHO RE
   Wicker S, 2013, VACCINE, V31, P5111, DOI 10.1016/j.vaccine.2013.08.070
   Winston L, 2014, VACCINE, V32, P4786, DOI 10.1016/j.vaccine.2014.06.001
   Zimmerman RK, 2013, VACCINE, V31, P6172, DOI 10.1016/j.vaccine.2013.10.066
NR 40
TC 1
Z9 1
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 69
EP 75
DI 10.1016/j.vaccine.2018.11.033
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100011
PM 30470641
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU McClure, DL
   Jacobsen, SJ
   Klein, NP
   Naleway, AL
   Kharbanda, EO
   Glanz, JM
   Jackson, LA
   Weintraub, ES
   McLean, HQ
AF McClure, David L.
   Jacobsen, Steven J.
   Klein, Nicola P.
   Naleway, Allison L.
   Kharbanda, Elyse O.
   Glanz, Jason M.
   Jackson, Lisa A.
   Weintraub, Eric S.
   McLean, Huong Q.
TI Similar relative risks of seizures following measles containing
   vaccination in children born preterm compared to full-term without
   previous seizures or seizure-related disorders
SO VACCINE
LA English
DT Article
DE Measles containing vaccine; MMR; MMRV; Seizures; Preterm; Premature
ID FEBRILE SEIZURES; CONTAINING VACCINES; SAFETY; IMMUNIZATION; RUBELLA;
   MUMPS; RECOMMENDATIONS; DATALINK; WEIGHT; PREMATURE
AB Background: Febrile seizures are associated with the first dose of measles-containing vaccines and the risk increases with chronologic age during the second year of life. We used the Vaccine Safety Datalink (VSD) to determine if the relative increase in risk of seizures following receipt of measles-containing vaccine differs by gestational age at birth.
   Methods: Children were eligible if they received their first dose of measles-containing vaccine at age 12 through 23 months from January 2003 through September 2015. Children were excluded if they had a history of seizure or conditions strongly related to seizure prior to 12 months of age. Seizures were identified by diagnostic codes in the inpatient or emergency department settings. Using risk-interval analysis, we estimated the incidence rate ratio (IRR) for seizures in the 7 through 10 days (risk period) vs 15 through 42 days (control period) following receipt of measles-containing vaccines in children born pre term (<37 weeks gestation age) and those born full-term (>= 37 weeks).
   Results: There were 532,375 children (45,343 preterm and 487,032 full-term) who received their first dose of measles-containing vaccine at age 12 through 23 months. The IRRs of febrile seizures 7 through 10 days compared with 15 through 42 days after receipt of measles-containing vaccine were 3.9 (95% CI: 2.5-6.0) in preterm children and 3.2 (2.7-3.7) in full-term children; the ratio of IRRs: was 1.2 (0.76-1.9), p = 0.41. IRRs were also similar across gestational age groups, by vaccine type received (measles-mumps rubella [MMR] or measles-mumps-rubella-varicella [MMRV]) and age at vaccination (12-15 or 16-23 months).
   Conclusion: Vaccination with a measles-containing vaccine in the second year of life is associated with a similar relative risk of a first seizure in children born preterm as in those who were born full-term. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [McClure, David L.; McLean, Huong Q.] Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, Marshfield, WI 54449 USA.
   [Jacobsen, Steven J.] Kaiser Permanente Southern Calif, Kaiser Permanente Dept Res & Evaluat, Pasadena, CA USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
   [Naleway, Allison L.] Kaiser Permanente Northwest, Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Kharbanda, Elyse O.] Hlth Partners Inst, Minneapolis, MN USA.
   [Glanz, Jason M.] Kaiser Permanente Colorado, Kaiser Permanente Inst Hlth Res, Denver, CO USA.
   [Jackson, Lisa A.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA.
   [Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA.
RP McClure, DL (reprint author), Marshfield Clin Res Inst, 1000 North Oak Ave, Marshfield, WI 54449 USA.
EM mcclure.david@marshfieldclinic.org
OI Jacobsen, Steven/0000-0002-8174-8533; Kharbanda,
   Elyse/0000-0003-1806-6502
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2012-53587]
FX This work was supported by the Centers for Disease Control and
   Prevention [contract number 200-2012-53587].
CR Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H
   Baker MA, 2015, AM J EPIDEMIOL, V181, P608, DOI 10.1093/aje/kwu322
   Barlow WE, 2001, NEW ENGL J MED, V345, P656, DOI 10.1056/NEJMoa003077
   Davis RL, 1999, JAMA-J AM MED ASSOC, V282, P547, DOI 10.1001/jama.282.6.547
   Duffy J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0320
   Esposito S, 2012, EXPERT REV VACCINES, V11, P1199, DOI [10.1586/ERV.12.93, 10.1586/erv.12.93]
   FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9
   Gagneur A, 2015, HUM VACC IMMUNOTHER, V11, P2556, DOI 10.1080/21645515.2015.1074358
   Gayrielov-Yusim N, 2014, VACCINE, V32, P4954, DOI 10.1016/j.vaccine.2014.07.024
   GRIFFIN MR, 1991, PEDIATRICS, V88, P881
   Hambidge SJ, 2014, PEDIATRICS, V133, pE1492, DOI 10.1542/peds.2013-3429
   HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x
   Institute of Medicine, 2013, CHILDH IMM SCHED SAF
   Jacobsen SJ, 2009, VACCINE, V27, P4656, DOI 10.1016/j.vaccine.2009.05.056
   Kawai AT, 2014, PHARMACOEPIDEMIOL DR
   Klein NP, 2017, VACCINE, V35, P1615, DOI 10.1016/j.vaccine.2017.02.013
   Klein NP, 2015, PEDIATRICS, V135, pE321, DOI 10.1542/peds.2014-1822
   Klein NP, 2011, HUM VACCINES, V7, P269, DOI 10.4161/hv.7.2.13860
   Klein NP, 2010, PEDIATRICS, V126, pE1, DOI 10.1542/peds.2010-0665
   Knol MJ, 2012, INT J EPIDEMIOL, V41, P514, DOI 10.1093/ije/dyr218
   McClure DL, 2012, VACCINE, V30, P3986, DOI 10.1016/j.vaccine.2012.04.040
   McLean HQ, 2013, MMWR RECOMM REP, V62, P1
   McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073
   Mullooly J, 1999, AM J EPIDEMIOL, V149, P186
   Naleway AL, 2013, VACCINE, V31, P2898, DOI 10.1016/j.vaccine.2013.03.069
   Rowhani-Rahbar A, 2013, JAMA PEDIATR, V167, P1111, DOI 10.1001/jamapediatrics.2013.2745
   Saari TN, 2003, PEDIATRICS, V112, P193, DOI 10.1542/peds.112.1.193
   Shui IM, 2009, VACCINE, V27, P5307, DOI 10.1016/j.vaccine.2009.06.092
   Sisson H, 2017, J CLIN NURS
   Spong CY, 2013, JAMA-J AM MED ASSOC, V309, P2445, DOI 10.1001/jama.2013.6235
   Tartof SY, 2014, VACCINE, V32, P2574, DOI 10.1016/j.vaccine.2014.03.044
   Tse A, 2012, VACCINE, V30, P2024, DOI 10.1016/j.vaccine.2012.01.027
   Vestergaard M, 2002, EPIDEMIOLOGY, V13, P282, DOI 10.1097/00001648-200205000-00008
   Waruiru C, 2004, ARCH DIS CHILD, V89, P751, DOI 10.1136/adc.2003.028449
NR 34
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 76
EP 79
DI 10.1016/j.vaccine.2018.11.038
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100012
PM 30478005
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Queenan, AM
   Dowling, DJ
   Cheng, WK
   Fae, K
   Fernandez, J
   Flynn, PJ
   Joshi, S
   Brightman, SE
   Ramirez, J
   Serroyen, J
   Wiertsema, S
   Fortanier, A
   van den Dobbeisteen, G
   Levy, O
   Poolman, J
AF Queenan, Anne Marie
   Dowling, David J.
   Cheng, Wing Ki
   Fae, Kellen
   Fernandez, Jeffrey
   Flynn, Peter J.
   Joshi, Sweta
   Brightman, Spencer E.
   Ramirez, Juan
   Serroyen, Jan
   Wiertsema, Selma
   Fortanier, Alexandre
   van den Dobbeisteen, Germie
   Levy, Ofer
   Poolman, Jan
TI Increasing FIM2/3 antigen-content improves efficacy of Bordetella
   pertussis vaccines in mice in vivo without altering vaccine-induced
   human reactogenicity biomarkers in vitro
SO VACCINE
LA English
DT Article
DE Bordetella pertussis; Fimbriae; Pertactin; Acellular pertussis vaccines;
   Whole cell pertussis vaccines; Reactogenicity
ID INTRANASAL MURINE MODEL; WHOLE-CELL; CONTROLLED-TRIAL; INFECTION;
   PERTACTIN; FIMBRIAE; PROTECTION; 2-COMPONENT; ANTIBODIES; IMMUNITY
AB Current acellular-pertussis (aP) vaccines appear inadequate for long-term pertussis control because of short-lived efficacy and the increasing prevalence of pertactin-negative isolates which may negatively impact vaccine efficacy. In this study, we added fimbriae (FIM)2 and FIM3 protein to licensed 2-, 3- or 5-component aP vaccines (Pentavac (R), Boostrix (R), Adacel (R), respectively) to assess whether an aP vaccine with enhanced FIM content demonstrates enhanced efficacy. Vaccine-induced protection was assessed in an intranasal mouse challenge model. In addition, potential reactogenicity was measured by biomarkers in a human whole blood assay (WBA) in vitro and benchmarked the responses against licensed whole cell pertussis (wP) and aP vaccines including Easyfive (R), Pentavac (R) and Pentacel (R). The results show that commercial vaccines demonstrated reduced efficacy against pertactin-negative versus pertactin-positive strains. However, addition of higher amounts of FIM2/3 to aP vaccines reduced lung colonization and increased vaccine efficacy against a pertactin-negative strain in a dose-dependent manner. Improvements in efficacy were similar for FIM2 and FIM3-expressing strains. Increasing the amount of FIM2/3 proteins in aP formulations did not alter vaccine-induced biomarkers of potential reactogenicity including prostaglandin E-2, cytokines and chemokines in human newborn cord and adult peripheral blood tested in vitro. These results suggest that increasing the quantity of FIM proteins in current pertussis vaccine formulations may further enhance vaccine efficacy against B. pertussis infection without increasing the reactogenicity of the vaccine. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Queenan, Anne Marie] Janssen Res & Dev, Raritan, NJ 08869 USA.
   [Dowling, David J.; Cheng, Wing Ki; Flynn, Peter J.; Joshi, Sweta; Brightman, Spencer E.; Ramirez, Juan; Levy, Ofer] Boston Childrens Hosp, Div Infect Dis, Precis Vaccines Program, Boston, MA 02115 USA.
   [Dowling, David J.; Cheng, Wing Ki; Levy, Ofer] Harvard Med Sch, Boston, MA USA.
   [Fae, Kellen; Serroyen, Jan; Wiertsema, Selma; Fortanier, Alexandre; van den Dobbeisteen, Germie; Poolman, Jan] Janssen Vaccines & Prevent, NL-2333 CN Leiden, Netherlands.
   [Fernandez, Jeffrey] Janssen Res & Dev, Spring House, PA 19477 USA.
   [Levy, Ofer] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Wiertsema, Selma] Danone Nutricia Res, Utrecht, Netherlands.
   [Fortanier, Alexandre] Seqirus, Amsterdam, Netherlands.
RP Levy, O (reprint author), Boston Childrens Hosp, John F Enders Res Labs, Div Infect Dis, Precis Vaccines Program, Room 861-1,300 Longwood Ave, Boston, MA 02115 USA.
EM ofer.levy@childrens.harvard.edu
OI Levy, Ofer/0000-0002-5859-1945
FU Janssen Vaccines and Prevention B. V.; U.S. National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01AI100135-01, 3R01AI067353-05S1];
   National Institutes of Allergy and Infectious Diseases (NIAID), NIH
   [1U01AI124284-01]; Department of Health and Human Services, Adjuvant
   Discovery Program [HHSN272201400052C]; Adjuvant Development Program
   [HHSN272201800047C]; Crucell/Janssen Vaccines and Prevention B.V.
   Uohnson Johnson; internal Boston Children's Hospital award
FX This study was supported by Janssen Vaccines and Prevention B. V. O.L.'s
   laboratory is supported by U.S. National Institutes of Health (NIH)
   grants 1R01AI100135-01, and 3R01AI067353-05S1, 1U01AI124284-01 the
   National Institutes of Allergy and Infectious Diseases (NIAID), NIH,
   Department of Health and Human Services, Adjuvant Discovery Program
   Contract No. HHSN272201400052C and Adjuvant Development Program Contract
   No. HHSN272201800047C. The Levy Laboratory has received sponsored
   research support from Crucell/Janssen Vaccines and Prevention B.V.
   Uohnson & Johnson) and an internal Boston Children's Hospital award to
   the Precision Vaccines Program.
CR [Anonymous], 2011, GUIDE CARE USE LAB A
   Burns DL, 2014, J INFECT DIS, V209, pS32, DOI 10.1093/infdis/jit491
   DECKER MD, 1995, PEDIATRICS, V96, P557
   Denoel P, 2005, VACCINE, V23, P5333, DOI 10.1016/j.vaccine.2005.06.021
   Denoel P, 2002, VACCINE, V20, P2551, DOI 10.1016/S0264-410X(02)00158-5
   Dowling DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00562
   EDWARDS KM, 1995, PEDIATRICS, V96, P548
   Fadugba OO, 2014, CLIN VACCINE IMMUNOL, V21, P1613, DOI 10.1128/CVI.00438-14
   Godfroid F, 2004, INT J MED MICROBIOL, V294, P269, DOI 10.1016/j.ijmm.2004.07.007
   Gorringe AR, 2014, EXPERT REV VACCINES, V13, P1205, DOI 10.1586/14760584.2014.930667
   Gu XX, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00034-17
   Guiso N, 1999, VACCINE, V17, P2366, DOI 10.1016/S0264-410X(99)00037-7
   Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602
   Hallander HO, 2009, APMIS, V117, P660, DOI 10.1111/j.1600-0463.2009.02521.x
   Hegerle N, 2014, EXPERT REV VACCINES, V13, P1135, DOI 10.1586/14760584.2014.932254
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   KLEIN DL, 1995, PEDIATRICS, V96, P547
   Martin SW, 2015, CLIN INFECT DIS, V60, P223, DOI 10.1093/cid/ciu788
   MOOI FR, 1992, MICROB PATHOGENESIS, V12, P127, DOI 10.1016/0882-4010(92)90115-5
   Oh DY, 2016, MOT CELL PROTEOM MCP
   Olin P, 1997, LANCET, V350, P1569, DOI 10.1016/S0140-6736(97)06508-2
   Poolman JT, 2007, EXPERT REV VACCINES, V6, P47, DOI 10.1586/14760584.6.1.47
   Queenan AM, 2014, EXPERT REV VACCINES, V13, P1265, DOI 10.1586/14760584.2014.938642
   Queenan AM, 2013, NEW ENGL J MED, V368, P583, DOI 10.1056/NEJMc1209369
   ROBINSON A, 1989, VACCINE, V7, P321, DOI 10.1016/0264-410X(89)90193-X
   Rodriguez ME, 2006, FEMS IMMUNOL MED MIC, V46, P39, DOI 10.1111/j.1574-695X.2005.00001.x
   Ross PJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003264
   Safarchi A, 2015, VACCINE, V33, P6277, DOI 10.1016/j.vaccine.2015.09.064
   Scheller EV, 2015, MBIO, V6
   Sheridan SL, 2014, EXPERT REV VACCINES, V13, P1081, DOI 10.1586/14760584.2014.944167
   Stenger RM, 2011, CLIN VACCINE IMMUNOL, V18, P595, DOI 10.1128/CVI.00061-10
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   van Haren SD, 2016, CYTOKINE, V83, P99, DOI 10.1016/j.cyto.2016.04.001
   Warfel JM, 2013, MUCOSAL IMMUNOL, V6, P787, DOI 10.1038/mi.2012.117
   Warfel JM, 2012, INFECT IMMUN, V80, P1530, DOI 10.1128/IAI.06310-11
   World Health Organization, 2015, WKLY EPIDEMIOL REC, P433
   Zaitseva M, 2012, VACCINE, V30, P4859, DOI 10.1016/j.vaccine.2012.05.002
   ZHANG JM, 1985, INFECT IMMUN, V48, P422, DOI 10.1128/IAI.48.2.422-427.1985
NR 38
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 80
EP 89
DI 10.1016/j.vaccine.2018.11.028
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100013
PM 30478007
DA 2020-05-12
ER

PT J
AU Kim, SJ
   Seon, SH
   Luong, TT
   Ghosh, P
   Pyo, S
   Rhee, DK
AF Kim, Se-Jin
   Seon, Seung Han
   Truc Thanh Luong
   Ghosh, Prachetash
   Pyo, Suhkneung
   Rhee, Dong-Kwon
TI Immunization with attenuated non-transformable pneumococcal pep27 and
   comD mutant provides serotype-independent protection against
   pneumococcal infection
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; pep27; comD; Protection; Safety
ID LONG-TERM IMMUNITY; STREPTOCOCCUS-PNEUMONIAE; GENETIC-TRANSFORMATION;
   CONJUGATE VACCINE; HEAT-SHOCK; MUCOSAL; COMPETENCE; INDUCTION;
   PHEROMONE; EPIDEMIOLOGY
AB Streptococcus pneumoniae is a well-known pathogenic bacterium with a high mortality rate. Currently, a 23-valent pneumococcal polysaccharide vaccine (PPV23) and protein-conjugate vaccines (PCVs) are available on the market. However, both of these vaccines have limitations; specifically, PPV23 produces weak antibody responses in children younger than 2 years and PCVs only partially protect against secondary infection. Previously, we showed serotype-nonspecific protection by Delta pep27 vaccine, but the reversion of Delta pep27 to the wild type serotype during immunization cannot be excluded. To ensure the safety of the Delta pep27 vaccine, comD, an important protein that activates competence, was inactivated, and the transformability of the double mutant (Delta pep27 Delta comD)was determined. The transformation ability of this double mutant was successfully abolished. Delta pep27 Delta comD immunization significantly increased the survival time after heterologous challenge(s), and diminished colonization levels independent of serotype, including a non-typeable strain (NCC1). Moreover, the double mutant was found to be highly safe in both normal and immunocompromised mice. In conclusion, this pneumococcal Delta pep27 Delta comD vaccine appears to be a highly feasible and safe vaccine to prevent various types of pneumococcal infections. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kim, Se-Jin; Seon, Seung Han; Truc Thanh Luong; Ghosh, Prachetash; Pyo, Suhkneung; Rhee, Dong-Kwon] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.
RP Rhee, DK (reprint author), Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.
EM dkrhee@skku.edu
FU National Research Foundation, Republic of Korea [2018R1A2A1A05078102]
FX This work was supported by the National Research Foundation, Republic of
   Korea (2018R1A2A1A05078102). The authors declare there are no
   conflicting financial interests.
CR Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137
   Blanchard-Rohner G, 2011, EXPERT REV VACCINES, V10, P673, DOI 10.1586/erv.11.14
   Brown JS, 2012, CLIN MED, V12, P538, DOI 10.7861/clinmedicine.12-6-538
   Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168
   Cheng Q, 1997, MOL MICROBIOL, V23, P683, DOI 10.1046/j.1365-2958.1997.2481617.x
   Choi SY, 2013, CLIN EXP VACCINE RES, V2, P58, DOI 10.7774/cevr.2013.2.1.58
   Dockrell DH, 2003, J IMMUNOL, V171, P5380, DOI 10.4049/jimmunol.171.10.5380
   Ferreira DM, 2011, TRENDS MICROBIOL, V19, P464, DOI 10.1016/j.tim.2011.06.003
   Feunou PF, 2010, VACCINE, V28, P7047, DOI 10.1016/j.vaccine.2010.08.017
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   Gladstone RA, 2011, J MED MICROBIOL, V60, P1, DOI 10.1099/jmm.0.020016-0
   Gladstone RA, 2015, VACCINE, V33, P2015, DOI 10.1016/j.vaccine.2015.03.012
   Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879
   Havarstein LS, 1996, MOL MICROBIOL, V21, P863, DOI 10.1046/j.1365-2958.1996.521416.x
   HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140
   Hogenesch Harm, 2011, J Immune Based Ther Vaccines, V9, P5, DOI 10.1186/1476-8518-9-5
   Hvalbye BKR, 1999, INFECT IMMUN, V67, P4320, DOI 10.1128/IAI.67.9.4320-4325.1999
   Kayhty H, 2006, EXPERT REV VACCINES, V5, P651, DOI 10.1586/14760584.5.5.651
   Kim EH, 2012, VACCINE, V30, P2008, DOI 10.1016/j.vaccine.2011.11.073
   Kim GL, 2016, VACCINE, V34, P6481, DOI 10.1016/j.vaccine.2016.10.071
   Kimoto T, 2013, INFLUENZA OTHER RESP, V7, P1218, DOI 10.1111/irv.12124
   Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566
   Kwon HY, 2003, INFECT IMMUN, V71, P3757, DOI 10.1128/IAI.71.7.3757-3765.2003
   Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311
   Lee Hyunju, 2014, Korean J Pediatr, V57, P55, DOI 10.3345/kjp.2014.57.2.55
   Lesinski Gregory B., 2001, Current Drug Targets - Infectious Disorders, V1, P325, DOI 10.2174/1568005014605964
   Lottenbach KR, 1999, INFECT IMMUN, V67, P4935, DOI 10.1128/IAI.67.9.4935-4938.1999
   Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159
   Luby SP, 2009, CLIN INFECT DIS, V48, pS97, DOI 10.1086/596487
   Martin B, 2010, MOL MICROBIOL, V75, P1513, DOI 10.1111/j.1365-2958.2010.07071.x
   McEllistrem MC, 2003, J INFECT DIS, V188, P1679, DOI 10.1086/379665
   Miyaji EN, 2013, CELL MOL LIFE SCI, V70, P3303, DOI 10.1007/s00018-012-1234-8
   Moffitt KL, 2012, VACCINE, V30, P4316, DOI 10.1016/j.vaccine.2012.01.034
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   O'Brien KL, 2009, CLIN INFECT DIS, V49, P1326, DOI 10.1086/606047
   Ogunniyi AD, 2002, MICROBIOL-SGM, V148, P2045, DOI 10.1099/00221287-148-7-2045
   Oliveira MLS, 2007, EXPERT REV VACCINES, V6, P419, DOI 10.1586/14760584.6.3.419
   Paganin F, 2004, EUR RESPIR J, V24, P779, DOI 10.1183/09031936.04.00119503
   Park IH, 2012, MBIO, V3, DOI 10.1128/mBio.00035-12
   Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x
   Roche AM, 2007, INFECT IMMUN, V75, P2469, DOI 10.1128/IAI.01972-06
   Scott DA, 2007, VACCINE, V25, P6164, DOI 10.1016/j.vaccine.2007.06.004
   Seon SH, 2017, J INFECT DIS
   Tarahomjoo S, 2014, J MOL MICROB BIOTECH, V24, P215, DOI 10.1159/000365052
   Tran TDH, 2011, ANTIMICROB AGENTS CH, V55, P2714, DOI 10.1128/AAC.01383-10
   Tyrrell GJ, 2009, VACCINE, V27, P3553, DOI 10.1016/j.vaccine.2009.03.063
   World Health Organization [WHO], 2014, ANT RES GLOB REP SUR
   Wu KF, 2014, VACCINE, V32, P4179, DOI 10.1016/j.vaccine.2014.05.019
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 90
EP 98
DI 10.1016/j.vaccine.2018.11.027
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100014
PM 30467061
DA 2020-05-12
ER

PT J
AU Kovacs, E
   Sahin-Toth, J
   Tothpal, A
   Kristof, K
   van der Linden, M
   Tirczka, T
   Dobay, O
AF Kovacs, Eszter
   Sahin-Toth, Judit
   Tothpal, Adrienn
   Kristof, Katalin
   van der Linden, Mark
   Tirczka, Tunas
   Dobay, Orsolya
TI Vaccine-driven serotype-rearrangement is seen with latency in clinical
   isolates: Comparison of carried and clinical pneumococcal isolates from
   the same time period in Hungary
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal conjugated vaccines (PCVs);
   Serotypes; Carriers; Antibiotic resistance
ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; NASOPHARYNGEAL
   CARRIAGE; HEALTHY-CHILDREN; TOBACCO-SMOKE; RISK-FACTORS; COLONIZATION;
   EPIDEMIOLOGY; IDENTIFICATION; DETERMINANTS
AB Young children - the main asymptomatic carriers of pneumococcus - are often the source of pneumococcal infections. PCV13 replaced PCV7 in 2010 in Hungary and it became a mandatory vaccine in 2014. In this work we surveyed the effect of vaccination in three groups: in healthy children under 7 years; in children of the same age but infected with pneumococcus (P1); in older patients (P2) who were very likely not vaccinated.
   Nasal swabs were taken from 522 healthy children to screen pneumococcal carriage between March 2015 and May 2016. In the same time period, 146 clinical isolates were collected, mainly from mucosal infections. Serotypes, antibiotic susceptibility and clonality of the isolates was determined and compared.
   The carriage rate was 39.1%. Regarding carriage, the serotype distribution showed the total disappearance of serotypes 3 and 6A compared to former Hungarian studies. The prevalence of PCV13 serotypes was only 5.8% represented by three serotypes (19F, 19A, 9V). Of note, serotype 19A (a very resistant and invasive type) also decreased significantly. In the patient groups, PCV13 prevalence was higher: 17.5% (P1) and 32.6% (P2). Although serotype 3 was present in P1 (7.9%), the leading serotype was 23B (22.2%), a non-vaccine type (NVT). P2 showed the most diverse serotype distribution, but serotype 3 was predominant here (15.7%). Pneumococcal isolates from the patients were more resistant towards the tested antibiotics compared to those from carriers.
   PCV13 seems to be highly successful in reducing the prevalence of vaccine serotypes. The serotype-rearrangement can be seen also among clinical isolates, albeit somewhat later in time. Fortunately, the replacing serotypes are less invasive and less resistant, but, most worrisome, serotype 19F can be found again with increased frequency among carriage isolates and mucosal infections. Further surveillance is needed to carefully monitor such successful, antibiotic resistant "refugees". (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kovacs, Eszter; Sahin-Toth, Judit; Tothpal, Adrienn; Dobay, Orsolya] Semmelweis Univ, Inst Med Microbiol, Nagyvarad Ter 4, H-1089 Budapest, Hungary.
   [Kristof, Katalin] Semmelweis Univ, Inst Lab Med, Ulloi Ut 78-A, H-1082 Budapest, Hungary.
   [van der Linden, Mark] Univ Hosp RWTH Aachen, Dept Med Microbiol, German Natl Reference Ctr Streptococci, Pauwelsstr 30, D-52074 Aachen, Germany.
   [Tirczka, Tunas] Natl Publ Hlth Inst, Albert Florian Ut 2-6, H-1097 Budapest, Hungary.
RP Dobay, O (reprint author), Semmelweis Univ, Inst Med Microbiol, Nagyvarad Ter 4, H-1089 Budapest, Hungary.
EM kristof.katalin@med.semmelweis-univ.hu; mlinden@ukaachen.de;
   dobay.orsolya@med.semmelweis-univ.hu
RI van der Linden, Mark/B-9305-2009
OI van der Linden, Mark/0000-0002-6574-4313; Dobay,
   Orsolya/0000-0001-7094-2288; Tothpal, Adrienn/0000-0002-5204-9450
FU National Research, Development and Innovation Office/Hungarian
   Scientific Research Fund [K108631]
FX This work was supported by the National Research, Development and
   Innovation Office/Hungarian Scientific Research Fund [grant number
   K108631].
CR [Anonymous], 2016, ANN EP REP 2016 INV
   Arvas A, 2017, BALK MED J, V34, P362, DOI 10.4274/balkanmedj.2016.1256
   Beall B, 2006, J CLIN MICROBIOL, V44, P999, DOI 10.1128/JCM.44.3.999-1017.2006
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brito DA, 2003, J CLIN MICROBIOL, V41, P2378, DOI 10.1128/JCM.41.6.2378-2384.2003
   Centers for Disease Control and Prevention, 2014, LIST OL PRIM US 41 C
   de Lencastre H, 2002, J ANTIMICROB CHEMOTH, V50, P75, DOI 10.1093/jac/dkf511
   DiFranza JR, 2004, PEDIATRICS, V113, P1007
   Dobay O, 2005, CLIN MICROBIOL INFEC, V11, P673, DOI 10.1111/j.1469-0691.2005.01197.x
   Dobay O, 2005, INT J ANTIMICROB AG, V25, P488, DOI 10.1016/j.ijantimicag.2005.02.010
   Ercibengoa M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-69
   European Centre for Disease Prevention and Control, 2017, ANN EP REP 2015
   European Centre for Disease Prevention and Control, 2012, SURV INV BACT DIS EU
   Farrell DJ, 2005, EMERG INFECT DIS, V11, P851, DOI 10.3201/eid1106.050222
   Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083
   Gounder PP, 2018, VACCINE, V36, P691, DOI 10.1016/j.vaccine.2017.12.035
   Gounder PP, 2014, J INFECT DIS, V209, P1251, DOI 10.1093/infdis/jit642
   Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935
   Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031
   Lynch JP, 2009, SEMIN RESP CRIT CARE, V30, P189, DOI 10.1055/s-0029-1202938
   McFarland M, 2017, VACCINE, V35, P4389, DOI 10.1016/j.vaccine.2017.06.047
   Mostowy RJ, 2017, MOL BIOL EVOL, V34, P2537, DOI 10.1093/molbev/msx173
   Nagai K, 2001, J ANTIMICROB CHEMOTH, V48, P915, DOI 10.1093/jac/48.6.915
   National Bacteriological Surveillance Management Team, 2015, NBS ANN REP
   National Center for Epidemiology, 2009, EPINFO, V16, P141
   National Center for Epidemiology, 2009, EPINFO, V16, P487
   National Center for Epidemiology, 2015, MICROBIOL LETT, V15, P14
   National Center for Epidemiology, 2012, EPINFO, V19, P521
   National Center for Epidemiology, 2016, EPINFO, V23, P369
   National Center for Epidemiology, 2014, EPINFO, V21
   Neves FPG, 2017, VACCINE, V35, P2794, DOI 10.1016/j.vaccine.2017.04.019
   Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002
   Oligbu G, 2016, VACCINE, V34, P6126, DOI 10.1016/j.vaccine.2016.10.050
   Oster P, 1999, ANTIMICROB AGENTS CH, V43, P2510, DOI 10.1128/AAC.43.10.2510
   Pletz MW, 2008, INT J ANTIMICROB AG, V32, P199, DOI 10.1016/j.ijantimicag.2008.01.021
   Shi ZY, 1998, J CLIN MICROBIOL, V36, P3514, DOI 10.1128/JCM.36.12.3514-3519.1998
   Sigurdsson S, 2017, VACCINE, V35, P5242, DOI 10.1016/j.vaccine.2017.08.020
   Simoes AS, 2016, DIAGN MICR INFEC DIS, V85, P141, DOI 10.1016/j.diagmicrobio.2016.03.018
   Spijkerman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039730
   Sugimoto Naomi, 2017, BMC Res Notes, V10, P21, DOI 10.1186/s13104-016-2353-3
   Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P2562, DOI 10.1128/AAC.40.11.2562
   Tocheva AS, 2011, VACCINE, V29, P4400, DOI 10.1016/j.vaccine.2011.04.004
   Tothpal A, 2016, EPIDEMIOL INFECT, V144, P1563, DOI 10.1017/S0950268815002757
   Tothpal A, 2014, LAM, V24, P180
   Tothpal A, 2015, EUR J PEDIATR, V174, P373, DOI 10.1007/s00431-014-2408-1
   Tothpal A, 2012, ACTA MICROBIOL IMM H, V59, P423, DOI 10.1556/AMicr.59.2012.3.12
   Tothpal A, 2012, ACTA MICROBIOL IMM H, V59, P107, DOI 10.1556/AMicr.59.2012.1.11
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   Tyrrell GJ, 2011, J INFECT DIS, V203, P1345, DOI 10.1093/infdis/jir056
   Uhari M, 1996, CLIN INFECT DIS, V22, P1079, DOI 10.1093/clinids/22.6.1079
   United States Patent Application, 2015, IMM COMP COMPR CONJ
   van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039150
   Varon E, 2015, VACCINE, V33, P6178, DOI 10.1016/j.vaccine.2015.10.015
   Weinberger DM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000476
   Wouters I, 2018, VACCINE, V36, P15, DOI 10.1016/j.vaccine.2017.11.052
   Wyllie AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23809
NR 56
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 99
EP 108
DI 10.1016/j.vaccine.2018.11.026
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100015
PM 30470639
DA 2020-05-12
ER

PT J
AU Ben Fraj, I
   Smaoui, H
   Zghal, M
   Sassi, O
   Guiso, N
   Kechrid, A
AF Ben Fraj, Ikram
   Smaoui, Hanen
   Zghal, Maroua
   Sassi, Orjouane
   Guiso, Nicole
   Kechrid, Amel
TI Seroprevalence of pertussis among healthcare workers: A cross-sectional
   study from Tunisia
SO VACCINE
LA English
DT Article
DE Pertussis toxin; Bordetella; Seroprevalence; Healthcare workers
ID BORDETELLA-PERTUSSIS; VACCINATION; PROFESSIONALS; ANTIBODIES; STAFF
AB This cross-sectional study aimed to assess pertussis seroprevalence among healthy healthcare workers (HCW) of the Children's Hospital of Tunis, Tunisia. During the study period, 236 blood samples were obtained to determine HCW exposure to pertussis. Concentrations of immunoglobulin G (IgG) to pertussis toxin (PT) were measured using a commercial enzyme-linked immunosorbent assay. Cut-offs values used were 40 and 100 IU/ml, respectively indicative of an infection within the last year and a current/recent infection. Overall, seropositivity rate was 11.4% (95% CI 7.4-15.5) and 2.5% (95% Cl 0.5-4.6) of ELISA results were indicative of a current infection. Seroprevalence was significantly most important in nurses (p = 0.03) and in participants aged 21-31y (p = 0.009). Our study confirmed that pertussis is circulating in hospital settings and affecting Tunisian HCW, in close contact with infants. Therefore, a booster dose of acellular pertussis vaccine needs to be considered. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ben Fraj, Ikram; Smaoui, Hanen; Zghal, Maroua; Kechrid, Amel] Univ Tunis El Manar, Childrens Hosp Tunis, Lab Microbiol, UR12ES01, Tunis 1007, Tunisia.
   [Sassi, Orjouane] Childrens Hosp Tunis, Occupat Med Dept, Tunis 1007, Tunisia.
   [Guiso, Nicole] Inst Pasteur, Unite Prevent & Therapies Mol Malad Humaines, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.
RP Ben Fraj, I (reprint author), Univ Tunis El Manar, Childrens Hosp Tunis, Lab Microbiol, UR12ES01, Tunis 1007, Tunisia.
EM ikrambenfraj@hotmail.com
FU Tunisian Ministry of Health
FX This work was supported by the Tunisian Ministry of Health.
CR [Anonymous], 2018, CALENDRIER VACCINATI
   BARKOFF AM, 2015, PATHOG DIS, V73, DOI DOI 10.1093/FEMSPD/FRV050
   Calugar A, 2006, CLIN INFECT DIS, V42, P981, DOI 10.1086/500321
   Faruque MO, 2008, EMERG MED AUSTRALAS, V20, P45, DOI 10.1111/j.1742-6723.2007.01044.x
   Greer AL, 2009, INFECT CONT HOSP EP, V30, P1084, DOI 10.1086/644755
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Hashemi SH, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-58
   Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014
   Higa F, 2008, JPN J INFECT DIS, V61, P371
   Hoffait M, 2011, HUM VACCINES, V7, P197, DOI 10.4161/hv.7.2.13918
   Kennerknecht N, 2018, EPIDEMIOL INFECT, V146, DOI 10.1017/S0950268818001851
   Lee Sarah M., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046
   Muloiwa R, 2018, VACCINE, V36, P2385, DOI 10.1016/j.vaccine.2018.03.025
   Riffelmann M, 2010, J CLIN MICROBIOL, V48, P4459, DOI 10.1128/JCM.01371-10
   Riffelmann M, 2002, PEDIATR INFECT DIS J, V21, P381, DOI 10.1097/00006454-200205000-00006
   de la Pinta MLR, 2016, VACCINE, V34, P1109, DOI 10.1016/j.vaccine.2015.12.036
   UNICEF, 2013, MULT IND CLUST SURV
   Urbiztondo L, 2015, HUM VACC IMMUNOTHER, V11, P293, DOI 10.4161/hv.36167
   Warfel JM, 2014, EXPERT REV VACCINES, V13, P1241, DOI 10.1586/14760584.2014.946016
   WHO, 2016, VACCINE, V34, P1423, DOI 10.1016/j.vaccine.2015.10.136
   Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0
   Zepp F, 2011, LANCET INFECT DIS, V11, P557, DOI 10.1016/S1473-3099(11)70007-X
   Zouari A, 2012, DIAGN MICR INFEC DIS, V72, P303, DOI 10.1016/j.diagmicrobio.2012.01.002
NR 24
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 109
EP 112
DI 10.1016/j.vaccine.2018.11.023
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100016
PM 30459070
DA 2020-05-12
ER

PT J
AU Nakiboneka, R
   Mugaba, S
   Auma, BO
   Kintu, C
   Lindan, C
   Nanteza, MB
   Kaleebu, P
   Serwanga, J
AF Nakiboneka, Ritah
   Mugaba, Susan
   Auma, Betty O.
   Kintu, Christopher
   Lindan, Christina
   Nanteza, Mary Bridget
   Kaleebu, Pontiano
   Serwanga, Jennifer
TI Interferon gamma (IFN-gamma) negative CD4+and CD8+T-cells can produce
   immune mediators in response to viral antigens
SO VACCINE
LA English
DT Article
DE HIV-1; IFN-gamma negative T-cells; Vaccines; ELISpot assay; Flow
   cytometry; T-cell responses
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; NEF PEPTIDES; MEMORY;
   INFECTION; PERFORIN; VACCINE; VIREMIA; GAG; CYTOTOXICITY
AB Evaluation of antigen-specific T-cell responses to viral antigens is frequently performed on IFN-gamma secreting cells. However, T-cells are capable of producing many more functions than just IFN-gamma, some of which, like Perforin, are associated with immune protection in HIV-1 disease elite controllers. We evaluated the extent of missed T-cell functions when IFN-gamma secretion is used as a surrogate marker for further evaluation of T-cell functions. Intracellular cytokine staining assay and flow cytometry were used to assess peripheral blood mononuclear cells (PBMCs) from 31 HIV-infected ART-naive individuals for the extent to which gated CD4+ and CD8+ IFN-gamma producing and non-producing T-cells also secreted IL-2, Perforin, and TNF-alpha functions. Similarly, the extent of missed virus-specific responses in IFN-gamma ELISpot assay negative T-cells from 5 HIV-1 uninfected individuals was evaluated. Cells from HIV-infected individuals were stimulated with pooled consensus group M (Con M) peptides; and those from healthy individuals were stimulated with pooled adenovirus (Ad) peptides. Overall, frequencies of virus-specific IFN-gamma secreting CD4+ and CD8+ cells were low. Proportions of IFN-gamma negative CD4+ expressing IL-2, Perforin, or TNF-alpha to Con M were significantly higher (5 of 7 functional profiles) than the corresponding IFN-y positive CD4+ (0 of 7) T-cell phenotype, p = 0.02; Fisher's Exact test. Likewise, proportions of CD8+ T-cells expressing other functions were significantly higher in 4 of the 7 IFN-gamma negative CD8+ T-cells. Notably, newly stimulated Perforin, identified as Perforin co-expression with IL-2 or TNF-alpha, was significantly higher in IFN-gamma negative CD8+ T-cell than in the positive CD8+ T-cells. Using SEB, lower responses in IFN-gamma positive cells were most associated with CD4+ than CD8+ T-cells. These findings suggest that studies evaluating immunogenicity in response to HIV and Adenovirus viral antigens should not only evaluate T-cell responsiveness among IFN-gamma producing cells but also among those T-cells that do not express IFN-gamma. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Nakiboneka, Ritah; Mugaba, Susan; Auma, Betty O.; Kintu, Christopher; Nanteza, Mary Bridget; Kaleebu, Pontiano; Serwanga, Jennifer] UVRI, MRC, Plot 51-59,Nakiwogo Rd, Entebbe, Uganda.
   [Nakiboneka, Ritah; Mugaba, Susan; Auma, Betty O.; Kintu, Christopher; Nanteza, Mary Bridget; Kaleebu, Pontiano; Serwanga, Jennifer] LSHTM, Uganda Res Unit, Plot 51-59,Nakiwogo Rd, Entebbe, Uganda.
   [Lindan, Christina] UCSF, Dept Epidemiol & Biostat & Global Hlth Sci, San Francisco, CA 94143 USA.
RP Serwanga, J (reprint author), UVRI, MRC, Plot 51-59,Nakiwogo Rd, Entebbe, Uganda.; Serwanga, J (reprint author), LSHTM, Uganda Res Unit, Plot 51-59,Nakiwogo Rd, Entebbe, Uganda.
EM Jennifer.Serwanga@mrcuganda.org
FU Medical Research Council (MRC UK)Medical Research Council UK (MRC);
   Wellcome TrustWellcome Trust [087540]; International Atomic Energy
   AgencyInternational Atomic Energy Agency [RAF6/029]
FX We gratefully acknowledge all study participants and staff of The AIDS
   Support Organization and the Uganda Virus Research Institute in Entebbe.
   We thank the Medical Research Council (MRC UK) for co-funding this study
   and for enabling access to the study cohorts. Recruitment of study
   participants was funded by the International Atomic Energy Agency
   through grant RAF6/029 to the WHO/African AIDS Vaccine program.
   Flowcytometry reagents were secured using funds from The Wellcome Trust
   grant (087540) to the Training Health Researchers into Vocational
   Excellence (THRiVE) in East Africa program. HIV peptides were obtained
   through the NIH AIDS Research and Reference reagent program, Division of
   AIDS, NIAID, NIH, Adenovirus peptide pools were kindly provided by
   Professor Ertl Hildegund C. J from the Wistar Institute, Philadelphia,
   Pennsylvania, United States. All authors made substantial contributions
   to this work as follows: (i) Conceiving and designing the study: RN, JS,
   PK. Performing the flow cytometry experiments: RN, SM, BOA. Analyzing
   the data: RN, JS. Drafting and writing the manuscript: RN, JS. Revising
   and critical review of the manuscript: RN, JS, SM, BOA, CL, MBN, PK.
   Clinical evaluation, Informed consent and recruitment of study
   participants: MBN. Final approval of the version to be submitted RN, JS,
   and PK.
CR Al-Sherbiny M, 2005, AM J TROP MED HYG, V73, P44
   Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003
   Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403
   BELL SJD, 1992, CLIN EXP IMMUNOL, V90, P6
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BISWAS P, 1992, J EXP MED, V176, P739, DOI 10.1084/jem.176.3.739
   Boulet S, 2007, J IMMUNOL METHODS, V320, P18, DOI 10.1016/j.jim.2006.11.010
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Burgers WA, 2009, J IMMUNOL, V182, P4751, DOI 10.4049/jimmunol.0803801
   Cellerai C, 2010, J VIROL, V84, P3868, DOI 10.1128/JVI.02565-09
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Chen H, 2010, J VIROL, V84, P10522, DOI 10.1128/JVI.00450-10
   Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Fang M, 2012, P NATL ACAD SCI USA, V109, P9983, DOI 10.1073/pnas.1202143109
   Ford T, 2017, VACCINE, V35, P1898, DOI 10.1016/j.vaccine.2017.02.038
   Frederiksen J, 2014, CYTOM PART A, V85A, P969, DOI 10.1002/cyto.a.22510
   Freel SA, 2010, J VIROL, V84, P4998, DOI 10.1128/JVI.00138-10
   Fu TM, 2007, AIDS RES HUM RETROV, V23, P67, DOI 10.1089/aid.2006.0114
   Ghiglione Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104235
   Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Horton H, 2004, J INFECT DIS, V190, P1692, DOI 10.1086/424490
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505
   Makedonas G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000798
   Makedonas G, 2009, J IMMUNOL, V182, P5560, DOI 10.4049/jimmunol.0803945
   Malyguine Anatoli M, 2012, Cells, V1, P111, DOI 10.3390/cells1020111
   Mugaba S, 2014, VACCINE, V32, P3787, DOI 10.1016/j.vaccine.2014.05.021
   Obuku AE, 2016, AIDS RES HUM RETROV, V32, P237, DOI [10.1089/aid.2015.0157, 10.1089/AID.2015.0157]
   Reier A, 1998, BIODRUGS, V10, P215, DOI 10.2165/00063030-199810030-00005
   Richmond M, 2011, J VIROL, V85, P1275, DOI 10.1128/JVI.01707-10
   Riou C, 2014, J VIROL, V88, P1819, DOI 10.1128/JVI.02968-13
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Rutebemberwa A, 2005, AIDS, V19, P1165, DOI 10.1097/01.aids.0000176216.02743.98
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Serwanga J, 2012, AIDS RES HUM RETROV, V28, P384, DOI [10.1089/aid.2011.0175, 10.1089/AID.2011.0175]
   Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101
   Streeck H, 2009, J VIROL, V83, P7641, DOI 10.1128/JVI.00182-09
   TALLEY AK, 1995, MOL CELL BIOL, V15, P2359
   Techakriengkrai N, 2013, AIDS, V27, P17, DOI 10.1097/QAD.0b013e32835ac0e1
   Varadarajan N, 2011, J CLIN INVEST, V121, P4322, DOI 10.1172/JCI58653
NR 43
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 113
EP 122
DI 10.1016/j.vaccine.2018.11.024
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100017
PM 30459072
OA Other Gold, Green Accepted, Green Published
DA 2020-05-12
ER

PT J
AU Demeure, CE
   Derbise, A
   Guillas, C
   Gerke, C
   Cauchemez, S
   Carniel, E
   Pizarro-Cerda, J
AF Demeure, Christian E.
   Derbise, Anne
   Guillas, Chloe
   Gerke, Christiane
   Cauchemez, Simon
   Carniel, Elisabeth
   Pizarro-Cerda, Javier
TI Humoral and cellular immune correlates of protection against bubonic
   plague by a live Yersinia pseudotuberculosis vaccine
SO VACCINE
LA English
DT Article
DE Plague; Live vaccine; Yersinia pestis; Yersinia pseudotuberculosis;
   Correlates of protection; F1; IgG
ID PNEUMONIC PLAGUE; NONHUMAN-PRIMATES; MOUSE MODELS; PESTIS; LCRV;
   IMMUNIZATION; ANTIBODIES; ANTIGEN; PROTEIN; MICE
AB Immunization with the live-attenuated Yersinia pseudotuberculosis VTnF1 strain producing a Yersinia pestis F1 pseudocapsule efficiently protects mice against bubonic and pneumonic plague. In clinical trials, demonstration of a plague vaccine's efficacy in humans will not be feasible, and correlates of protection will be needed to bridge the immune response of protected animals to that of vaccinated humans. Using serum transfer and vaccination of antibody-deficient MT mice, we established that both humoral and cellular responses elicited by VTnF1 independently conferred protection against bubonic plague. Thus, correlates were searched for in both responses, using blood only. Mice were vaccinated with increasing doses of VTnF1 to provide a range of immune responses and survival outcomes. The cellular response was evaluated using an in vitro IFN gamma release assay, and IFN gamma levels were significantly associated with protection, although some survivors were negative for IFN gamma, so that IFN gamma release is not a fully satisfactory correlate. Abundant serum IgG against the F1 capsule, Yop injectable toxins, and also non-F1 Y. pestis antigens were found, but none against the LcrV antigen. All readouts correlated to survival and to each other, confirming that vaccination triggered multiple protective mechanisms developing in parallel. Anti-F1 IgG was the most stringent correlate of protection, in both inbred BALB/c mice and outbred OFI mice. This indicates that antibodies (Ab) to F1 play a dominant role for protection even in the presence of Ab to many other targets. Easy to measure, the anti-F1 IgG titer will be useful to evaluate the immune response in other animal species and in clinical trials. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Demeure, Christian E.; Derbise, Anne; Guillas, Chloe; Carniel, Elisabeth; Pizarro-Cerda, Javier] Inst Pasteur, Unite Rech Yersinia, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
   [Gerke, Christiane] Inst Pasteur, Vaccine Programs, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
   [Cauchemez, Simon] Inst Pasteur, Unite Modelisat Math Malad Infect, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
   [Cauchemez, Simon] CNRS, URA3012, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
   [Cauchemez, Simon] Ctr Bioinformat Biostat & Integrat Biol, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
   [Carniel, Elisabeth] Pasteur Ctr Cameroon, BP 1274, Yaounde, Cameroon.
RP Demeure, CE (reprint author), Inst Pasteur, Unite Rech Yersinia, 25-28 Rue Dr Roux, F-75724 Paris 15, France.
EM cdemeure@pasteur.fr; anne.derbise@pasteur.fr; chloe.guillas@pasteur.fr;
   christiane.gerke@pasteur.fr; simon.cauchemez@pasteur.fr;
   elisabeth.carniel@pasteur.fr; javier.pizarro-cerda@pasteur.fr
RI Demeure, Christian/AAD-4922-2020
FU ANR Emergence grant [ANR-12-EMMA-0011-01]; Institut Pasteur Accelerating
   Preclinical Candidates - GPF -Vaccinology 2015 grant [GPFVacc2-08]
FX The project was supported by an ANR Emergence grant
   (ANR-12-EMMA-0011-01) and an Institut Pasteur Accelerating Preclinical
   Candidates - GPF - Vaccinology 2015 grant (GPFVacc2-08). The authors
   wish to warmly thank Pierre Goossens for precious advice and support,
   Henrik Salje for help with statistical analysis, F. Guinet for advice
   and help with mu MT mice, H. Saklani for advice regarding the cell
   culture protocols and Stephanie Simon (CEA, Saclay, France) for the kind
   gift of recombinant LcrV and a mouse monoclonal anti-LcrV.
CR Anderson GW, 1997, AM J TROP MED HYG, V56, P471, DOI 10.4269/ajtmh.1997.56.471
   Bashaw J, 2007, CLIN VACCINE IMMUNOL, V14, P605, DOI 10.1128/CVI.00398-06
   Benoit C, 1996, PRESSE MED, V25, P1627
   Braciale VL, 2008, INFECT DIS-SER, P473, DOI 10.1007/978-1-59745-569-5_50
   Cavaleri M, 2016, CLIN TRIALS, V13, P101, DOI 10.1177/1740774515619860
   Chanteau S, 2003, LANCET, V361, P211, DOI 10.1016/S0140-6736(03)12270-2
   Chichester JA, 2009, VACCINE, V27, P3471, DOI 10.1016/j.vaccine.2009.01.050
   Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932
   DePaolo RW, 2008, CELL HOST MICROBE, V4, P350, DOI 10.1016/j.chom.2008.09.004
   Derbise A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004162
   Derbise A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001528
   Fellows P, 2015, CLIN VACCINE IMMUNOL, V22, P1070, DOI 10.1128/CVI.00290-15
   Fellows P, 2010, VACCINE, V28, P7748, DOI 10.1016/j.vaccine.2010.09.062
   Feodorova VA, 2016, VACCINE DESIGN METHO
   Flashner Y, 2010, FEMS IMMUNOL MED MIC, V59, P197, DOI 10.1111/j.1574-695X.2010.00687.x
   Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004
   GIRARD G., 1963, BIOL MED [PARIS], V52, P631
   Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106
   HALLETT AF, 1973, INFECT IMMUN, V8, P876, DOI 10.1128/IAI.8.6.876-881.1973
   Heath DG, 1998, VACCINE, V16, P1131, DOI 10.1016/S0264-410X(98)80110-2
   Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281
   KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0
   Kummer LW, 2008, VACCINE, V26, P6901, DOI 10.1016/j.vaccine.2008.09.063
   LAWTON WD, 1963, J IMMUNOL, V91, P179
   Levine MM, 2004, NAT IMMUNOL, V5, P460, DOI 10.1038/ni0504-460
   Li B, 2008, MICROBES INFECT, V10, P45, DOI 10.1016/j.micinf.2007.10.003
   Lin JS, 2011, J IMMUNOL, V186, P1675, DOI 10.4049/jimmunol.1003303
   Little SF, 2010, VACCINE, V28, P934, DOI 10.1016/j.vaccine.2009.10.143
   Lopez A, 2017, J AUTOIMMUN, V80, P10, DOI 10.1016/j.jaut.2017.03.011
   Mencher JS, 2004, INFECT IMMUN, V72, P5502, DOI 10.1128/IAI.72.9.5502-5505.2004
   MEYER KF, 1974, J INFECT DIS, V129, pS13, DOI 10.1093/infdis/129.Supplement_1.S13
   MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990
   Morton M, 2004, VACCINE, V22, P2524, DOI 10.1016/j.vaccine.2004.01.007
   NAKAJIMA R, 1993, INFECT IMMUN, V61, P23, DOI 10.1128/IAI.61.1.23-31.1993
   Parent MA, 2005, INFECT IMMUN, V73, P7304, DOI 10.1128/IAI.73.11.7304-7310.2005
   PITT L, 2004, PUBL WORKSH AN MOD C
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Public Health England, 2016, LIV ATT VACC AV US T
   Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x
   Quenee LE, 2008, INFECT IMMUN, V76, P2025, DOI 10.1128/IAI.00105-08
   Quenee LE, 2011, VACCINE, V29, P6572, DOI 10.1016/j.vaccine.2011.06.119
   Rasoamanana B, 1997, CLIN DIAGN LAB IMMUN, V4, P587, DOI 10.1128/CDLI.4.5.587-591.1997
   Salerno-Goncalves R, 2006, TRENDS MICROBIOL, V14, P536, DOI 10.1016/j.tim.2006.10.004
   Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209
   Sun W, 2014, INFECT IMMUN, V82, P4390, DOI 10.1128/IAI.02173-14
   Welkos S, 2002, VACCINE, V20, P2206, DOI 10.1016/S0264-410X(02)00119-6
   Williamson ED, 2012, YERSINIA: SYSTEMS BIOLOGY AND CONTROL, P123
   Williamson ED, 1999, CLIN EXP IMMUNOL, V116, P107
   WILLIAMSON ED, 1995, FEMS IMMUNOL MED MIC, V12, P223, DOI 10.1111/j.1574-695X.1995.tb00196.x
   Zauberman A, 2008, VACCINE, V26, P1616, DOI 10.1016/j.vaccine.2008.01.033
NR 50
TC 3
Z9 3
U1 4
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 123
EP 129
DI 10.1016/j.vaccine.2018.11.022
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100018
PM 30467064
DA 2020-05-12
ER

PT J
AU Deng, Y
   Cai, W
   Li, JY
   Li, Y
   Yang, XL
   Ma, Y
   Yao, YF
   Yang, LJ
   Shi, L
   Sun, MB
AF Deng, Yan
   Cai, Wei
   Li, Jinyan
   Li, Ying
   Yang, Xiaolei
   Ma, Yan
   Yao, Yufeng
   Yang, Lujie
   Shi, Li
   Sun, Mingbo
TI Evaluation of the genetic stability of Sabin strains and the consistency
   of inactivated poliomyelitis vaccine made from Sabin strains using
   direct deep-sequencing
SO VACCINE
LA English
DT Article
DE sIPV; Sabin strain; Direct deep-sequencing; Genetic stability
ID ORAL POLIOVIRUS VACCINE; NEUROVIRULENCE TEST; READ ALIGNMENT; REGION;
   GENOME
AB Inactivated poliomyelitis vaccine made from Sabin strains (sIPV) has been encouraged to introduce in the "Global Polio Eradication & Endgame Strategic Plan" and increasingly used worldwide. Attenuated Sabin strains used in manufacture of oral poliovirus vaccine (OPV) and sIPV may regain full or partial neurovirulence during growth in vaccine recipients and the vaccine manufacturing processes. Ensuring the molecular consistency of sIPV batches and that no mutation accumulates beyond the level present in past batches are important for quality control of vaccine manufacture process. Direct deep-sequencing allows the construction of a library of virus RNA and the detection of genetic mutations throughout the viral genome. In the present study, direct deep-sequencing was conducted to detect molecular mutations in virus passages, multiple sIPV monovalent lots, and virus monovalent lots from different polio type Ill strains. The results indicated that direct deep-sequencing can be used to identify and quantify small amounts of mutant viruses in vaccine preparations, trace the source of a specific virus seed, and monitor the batch-to-batch consistency of vaccines, suggesting that this technique could be suitable for the quality control and consistency monitoring of sIPV production. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Deng, Yan; Cai, Wei; Li, Jinyan; Li, Ying; Yang, Xiaolei; Ma, Yan; Yao, Yufeng; Yang, Lujie; Shi, Li; Sun, Mingbo] Chinese Acad Med Sci, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
   [Deng, Yan; Cai, Wei; Li, Jinyan; Li, Ying; Yang, Xiaolei; Ma, Yan; Yao, Yufeng; Yang, Lujie; Shi, Li; Sun, Mingbo] Peking Union Med Coll, Kunming 650118, Yunnan, Peoples R China.
   [Deng, Yan; Cai, Wei; Yang, Xiaolei; Ma, Yan; Yang, Lujie; Sun, Mingbo] Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.
RP Shi, L; Sun, MB (reprint author), Chinese Acad Med Sci, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.; Shi, L; Sun, MB (reprint author), Peking Union Med Coll, Kunming 650118, Yunnan, Peoples R China.; Sun, MB (reprint author), Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.
EM dy@imbcams.com.cn; caiwei@imbcams.com.cn; lijingyan@imbcams.com.cn;
   yingli@imbcams.com.cn; yxl@imbcams.com.cn; mayan2519@imbcams.com.cn;
   yao@imbcams.com.cn; yanglujie@imbcams.com.cn; shili@imbcams.com.cn;
   smb@imbcams.com.cn
OI Shi, Li/0000-0001-9508-7863
FU National Health Commission of the People's Republic of China
   [2015ZX09101031]; Yunnan Provincial Science and Technology Department
   [2016ZF003]; CAMS Initiative for Innovative Medicine [2016-I2M-1-019];
   Special Funds for high-level health talents of Yunnan Province
   [D-201669, L-201615]
FX This work was financially supported by a grant from the National Health
   Commission of the People's Republic of China (2015ZX09101031), Yunnan
   Provincial Science and Technology Department (2016ZF003), CAMS
   Initiative for Innovative Medicine (2016-I2M-1-019) and Special Funds
   for high-level health talents of Yunnan Province (D-201669 and
   L-201615). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2015, WHO GLOB ACT PLAN MI
   Benyesh-Melnick M, 1959, USE IN VITRO MARKERS, P179
   CANN AJ, 1984, NUCLEIC ACIDS RES, V12, P7787, DOI 10.1093/nar/12.20.7787
   CHUMAKOV KM, 1992, J VIROL, V66, P966, DOI 10.1128/JVI.66.2.966-970.1992
   CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R
   DOMINGO E, 1985, GENE, V40, P1, DOI 10.1016/0378-1119(85)90017-4
   Dragunsky E, 1996, BIOLOGICALS, V24, P77, DOI 10.1006/biol.1996.0010
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Eisen JA, 2007, PLOS BIOL, V5, P384, DOI 10.1371/journal.pbio.0050082
   EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0
   Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Levenbook I, 2000, VACCINE, V19, P163, DOI 10.1016/S0264-410X(00)00190-0
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liao GY, 2012, J INFECT DIS, V205, P237, DOI 10.1093/infdis/jir723
   Margeridon-Thermet S, 2009, J INFECT DIS, V199, P1275, DOI 10.1086/597808
   Marston DA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-444
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Neverov A, 2010, P NATL ACAD SCI USA, V107, P20063, DOI 10.1073/pnas.1012537107
   Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
   Organization WH, 2015TRS993 WHO
   Organization WH, 2014TRS980 WHO
   Rozera G, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-15
   Sarcey E, 2017, J VIROL METHODS, V246, P75, DOI 10.1016/j.jviromet.2017.04.016
   Schuster SC, 2008, NAT METHODS, V5, P16, DOI 10.1038/NMETH1156
   TORDO N, 1986, P NATL ACAD SCI USA, V83, P3914, DOI 10.1073/pnas.83.11.3914
   Victoria JG, 2010, J VIROL, V84, P6033, DOI 10.1128/JVI.02690-09
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   WHO Representative Office in China, NEW POL VACC LIC CHI
   Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155
   World Health Organization, 2013, POL ER ENDG STRAT PL, P1
NR 32
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 130
EP 136
DI 10.1016/j.vaccine.2018.11.020
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100019
PM 30467062
DA 2020-05-12
ER

PT J
AU Diamos, AG
   Larios, D
   Brown, L
   Kilbourne, J
   Kim, HS
   Saxena, D
   Palmer, KE
   Mason, HS
AF Diamos, Andrew G.
   Larios, Dalia
   Brown, Lauren
   Kilbourne, Jacquelyn
   Kim, Hyun Soon
   Saxena, Divyasha
   Palmer, Kenneth E.
   Mason, Hugh S.
TI Vaccine synergy with virus-like particle and immune complex platforms
   for delivery of human papillomavirus L2 antigen
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Minor capsid protein; Recombinant immune complex;
   Virus-like particle; Vaccine
ID CROSS-NEUTRALIZING EPITOPE; CAPSID PROTEIN L2; CORE PARTICLES;
   MONOCLONAL-ANTIBODIES; FC-RECEPTORS; EXPRESSION; PROTECTION; INFECTION;
   GLYCOSYLATION; CHALLENGE
AB Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Diamos, Andrew G.; Larios, Dalia; Brown, Lauren; Kilbourne, Jacquelyn; Mason, Hugh S.] Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst ASU, Tempe, AZ 85287 USA.
   [Diamos, Andrew G.; Larios, Dalia; Brown, Lauren; Kilbourne, Jacquelyn; Mason, Hugh S.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
   [Kim, Hyun Soon] KRIBB, Plant Syst Engn Res Ctr, Gwahang Ro 125, Daejeon 34141, South Korea.
   [Saxena, Divyasha; Palmer, Kenneth E.] Univ Louisville, Ctr Predict Med Emerging Infect Dis, Louisville, KY 40202 USA.
   [Saxena, Divyasha; Palmer, Kenneth E.] Univ Louisville, Dept Pharmacol & Toxicol, Sch Med, Louisville, KY 40202 USA.
   [Saxena, Divyasha; Palmer, Kenneth E.] Ctr Predict Med, Louisville, KY 40202 USA.
RP Mason, HS (reprint author), Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst ASU, Tempe, AZ 85287 USA.; Mason, HS (reprint author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
EM Hugh.Mason@asu.edu
OI Mason, Hugh/0000-0002-0192-6716
FU NIH-NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19-AI062150-01]; Center for Immunotherapy,
   Vaccines, and Virotherapy of the Biodesign Insitute at ASU
FX This work was supported by NIH-NIAID grant U19-AI062150-01, and funds
   provided by the Center for Immunotherapy, Vaccines, and Virotherapy of
   the Biodesign Insitute at ASU. We thank Zhong Huang, Khanrat Piensook,
   Mike Lopker, and Andrew Osahor at ASU for preliminary studies that
   supported and informed this work.
CR Alphs HH, 2008, P NATL ACAD SCI USA, V105, P5850, DOI 10.1073/pnas.0800868105
   Bajtay Z, 2006, IMMUNOL LETT, V104, P46, DOI 10.1016/j.imlet.2005.11.023
   BROWN AL, 1991, VACCINE, V9, P595, DOI 10.1016/0264-410X(91)90248-5
   Buck CB, 2007, CURRENT PROTOCOLS CE, V26, P1, DOI DOI 10.1002/0471143030.CB2601S37
   Castilho A, 2012, BIOTECHNOL J, V7, DOI 10.1002/biot.201200032
   Chargelegue D, 2005, INFECT IMMUN, V73, P5915, DOI 10.1128/IAI.73.9.5915-5922.2005
   Chen Qiang, 2016, F1000Res, V5, DOI 10.12688/f1000research.8010.1
   COUTELIER JP, 1988, J EXP MED, V168, P2373, DOI 10.1084/jem.168.6.2373
   Crow JM, 2012, NATURE, V486, pS12, DOI 10.1038/486S12a
   de Jong JMH, 2006, MOL IMMUNOL, V43, P2045, DOI 10.1016/j.molimm.2006.01.002
   Diamos AG, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00200
   Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822
   Gambhira R, 2007, J VIROL, V81, P13927, DOI 10.1128/JVI.00936-07
   Gambhira R, 2007, J VIROL, V81, P11585, DOI 10.1128/JVI.01577-07
   Gaukroger JM, 1996, J GEN VIROL, V77, P1577, DOI 10.1099/0022-1317-77-7-1577
   Gerhard W, 1997, IMMUNOL REV, V159, P95, DOI 10.1111/j.1600-065X.1997.tb01009.x
   Hiatt A, 2014, P NATL ACAD SCI USA, V111, P5992, DOI 10.1073/pnas.1402458111
   Hioe CE, 2009, VACCINE, V28, P352, DOI 10.1016/j.vaccine.2009.10.040
   Huang Z, 2004, PLANT BIOTECHNOL J, V2, P241, DOI 10.1111/j.1467-7652.2004.00068.x
   Huang Z, 2010, BIOTECHNOL BIOENG, V106, P9, DOI 10.1002/bit.22652
   Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299
   Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804
   Kawana K, 1999, J VIROL, V73, P6188, DOI 10.1128/JVI.73.7.6188-6190.1999
   Kim MY, 2018, PLANT BIOTECHNOL J, V16, P1283, DOI 10.1111/pbi.12869
   Kim MY, 2015, VACCINE, V33, P1830, DOI 10.1016/j.vaccine.2015.02.036
   Kines RC, 2009, P NATL ACAD SCI USA, V106, P20458, DOI 10.1073/pnas.0908502106
   KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180
   Kondo K, 2007, VIROLOGY, V358, P266, DOI 10.1016/j.virol.2006.08.037
   KRIEGER G, 1985, J CLIN LAB IMMUNOL, V18, P129
   Mariani L, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-105
   Markine-Goriaynoff D, 2002, J VIROL, V76, P432, DOI 10.1128/JVI.76.1.432-435.2002
   Marusic C, 2018, BIOTECHNOL BIOENG, V115, P565, DOI 10.1002/bit.26503
   Mason HS, 2016, HUM VACC IMMUNOTHER, V12, P988, DOI 10.1080/21645515.2015.1116655
   Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901
   NEUBERGER MS, 1981, EUR J IMMUNOL, V11, P1012, DOI 10.1002/eji.1830111212
   Pastrana DV, 2005, VIROLOGY, V337, P365, DOI 10.1016/j.virol.2005.04.011
   Pepponi I, 2014, PLANT BIOTECHNOL J, V12, P840, DOI 10.1111/pbi.12185
   Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751
   Phoolcharoen W, 2011, P NATL ACAD SCI USA, V108, P20695, DOI 10.1073/pnas.1117715108
   Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x
   Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037
   Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6
   Rosenthal SH, 2018, PLANT MOL BIOL, V96, P429, DOI 10.1007/s11103-018-0708-y
   Santi L, 2008, VACCINE, V26, P1846, DOI 10.1016/j.vaccine.2008.01.053
   Schellenbacher C, 2017, VIRUS RES, V231, P166, DOI 10.1016/j.virusres.2016.11.020
   SCHODEL F, 1992, J VIROL, V66, P106
   STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4
   Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x
   Strasser R, 2014, CURR OPIN BIOTECH, V30, P95, DOI 10.1016/j.copbio.2014.06.008
   TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5
   Tuse D, 2014, BIOMED RES INT, DOI 10.1155/2014/256135
   Vesikari T, 2015, PEDIATR INFECT DIS J, V34, P992, DOI 10.1097/INF.0000000000000773
   Wang JW, 2018, J VIROL, V92, DOI 10.1128/JVI.00572-18
   Webster GR, 2018, PLANT BIOTECHNOL J, V16, P1983, DOI 10.1111/pbi.12932
   Wheeler CM, 2009, J INFECT DIS, V199, P936, DOI 10.1086/597309
   Whitacre DC, 2009, EXPERT REV VACCINES, V8, P1565, DOI [10.1586/erv.09.121, 10.1586/ERV.09.121]
   Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664
   Zeitlin L, 2011, P NATL ACAD SCI USA, V108, P20690, DOI 10.1073/pnas.1108360108
NR 58
TC 4
Z9 4
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 137
EP 144
DI 10.1016/j.vaccine.2018.11.021
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100020
PM 30459071
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Nagashima, S
   Yamamoto, C
   Ko, K
   Chuon, C
   Sugiyama, A
   Ohisa, M
   Akita, T
   Katayama, K
   Yoshihara, M
   Tanaka, J
AF Nagashima, Shintaro
   Yamamoto, Chikako
   Ko, Ko
   Chuon, Channarena
   Sugiyama, Aya
   Ohisa, Masayuki
   Akita, Tomoyuki
   Katayama, Keiko
   Yoshihara, Masaharu
   Tanaka, Junko
TI Acquisition rate of antibody to hepatitis B surface antigen among
   medical and dental students in Japan after three-dose hepatitis B
   vaccination
SO VACCINE
LA English
DT Article
DE HB vaccine; HBs antibody; Antibody titre; Responders; Non-responders
ID HBV INFECTION; VIRUS; IMMUNOGENICITY; STANDARD; RISK
AB Background: Health care workers (HCWs) are at high risk of contracting blood-borne infections including hepatitis B virus (HBV) infection. In Japan, all HCWs are required to receive HB vaccination before beginning work. This study aimed to investigate the dynamics of the HB surface antibody (anti-HBs) titer after a three-dose HB vaccination in HCWs and to determine effective scheduling of HB vaccination for non responders.
   Methods: Subjects included 832 medical and dental students who had received a three-dose HB vaccination (Bimmugen (R) 0.5 ml/vial). Anti-HBs was measured three times (before the third dose and 1 and 5 months after the third dose) using the CLIA method. The cut-off value of anti-HBs acquisition was 10 mlU/mL. After booster doses (three maximum) were administered to non-responders, the anti-HBs titers were measured again.
   Results: Out of 832 students, 491 were analyzed, of which 58.9% (289) were male. Anti-HBs-positive rates before the third dose and 1 and 5 months later were 47.9%, 95.9%, and 89.0%, respectively. The relationship between the antibody titer at one month (x) and 5 months (y) was estimated by log(10)y = log(10)- x - 0.134 (P < 0.0001). Twelve non-responders were followed-up, all of which acquired a protective anti-HBs titer after revaccination with a three-dose booster.
   Conclusion: Anti-HBs titer decreases by an average of 20% within 4 months between the 1st and 5th month after the third dose. Therefore, anti-HBs titer should be measured periodically after completing the three-dose vaccination. Additionally, results suggested that booster doses are effective if administered with the same schedule as primary vaccination. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
C1 [Nagashima, Shintaro; Yamamoto, Chikako; Ko, Ko; Chuon, Channarena; Sugiyama, Aya; Ohisa, Masayuki; Akita, Tomoyuki; Katayama, Keiko; Tanaka, Junko] Hiroshima Univ, Dept Epidemiol Infect Dis Control & Prevent, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan.
   [Yoshihara, Masaharu] Hiroshima Univ, Hlth Serv Ctr, Hiroshima, Japan.
RP Tanaka, J (reprint author), Hiroshima Univ, Dept Epidemiol Infect Dis Control & Prevent, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM jun-tanaka@hiroshima-u.ac.jp
RI Tanaka, Junko/G-6166-2019
OI Tanaka, Junko/0000-0002-5669-4051
FU Japanese Ministry of Health, Labour and WelfareMinistry of Health,
   Labour and Welfare, Japan [H22-Kanen-ippan-012, H25-Kanen-ippan-010,
   H28-Kansei-japan-001]
FX A grant from the Japanese Ministry of Health, Labour and Welfare
   (H22-Kanen-ippan-012, H25-Kanen-ippan-010 and H28-Kansei-japan-001).
CR Alikasifoglu M, 2001, J TROP PEDIATRICS, V47, P60, DOI 10.1093/tropej/47.1.60
   [Anonymous], 1997, MMWR Recomm Rep, V46, P1
   Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8
   Bertino JS, 1997, J INFECT DIS, V175, P678, DOI 10.1093/infdis/175.3.678
   Floreani A, 2004, VACCINE, V22, P607, DOI 10.1016/j.vaccine.2003.09.001
   Gara N, 2015, CLIN INFECT DIS, V60, P505, DOI 10.1093/cid/ciu867
   GOLDFARB J, 1994, PEDIATR INFECT DIS J, V13, P18, DOI 10.1097/00006454-199401000-00005
   Japan Society of Infection Prevention and Control (JSIPC), 2014, GUID VACC HEALTHC WO
   Komiya Y, 2008, TRANSFUSION, V48, P286, DOI 10.1111/j.1537-2995.2007.01522.x
   Lee Sarah M., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Limited DSC, 2014, BIMM, P1
   Makvandi M, 2016, WORLD J GASTROENTERO, V22, P8720, DOI 10.3748/wjg.v22.i39.8720
   McMahon BJ, 2009, J INFECT DIS, V200, P1390, DOI 10.1086/606119
   Pan HX, 2014, VACCINE, V32, P3706, DOI 10.1016/j.vaccine.2014.02.094
   Prevention CDC, 2001, UPD US PUBL HLTH SER
   Satoshi Kitamura, 2011, JPN J PHARM HLTH CAR, V37
   Schillie S, 2013, MMWR RECOMM REP, V62, P1
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   Tabuchi A, 2008, J MED VIROL, V80, P2064, DOI 10.1002/jmv.21320
   Tanaka J, 2018, J VIRAL HEPATITIS, V25, P363, DOI 10.1111/jvh.12828
   WHO, 2017, HEP B FACT SHEET
   WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935
   World Health Organization, 2018, HEP B
   World Health Organization, 2017, INT NEGL TROP DIS GL, P1
   World Hearth Organization, 2002, WHO TECH REP SER, P1
   Yoshioka N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187661
NR 26
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 145
EP 151
DI 10.1016/j.vaccine.2018.11.019
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100021
PM 30449632
OA Other Gold
DA 2020-05-12
ER

PT J
AU Bacci, JL
   Hansen, R
   Ree, C
   Reynolds, MJ
   Stergachis, A
   Odegard, PS
AF Bacci, Jennifer L.
   Hansen, Ryan
   Ree, Christina
   Reynolds, Marci J.
   Stergachis, Andy
   Odegard, Peggy S.
TI The effects of vaccination forecasts and value-based payment on adult
   immunizations by community pharmacists
SO VACCINE
LA English
DT Article
DE Public health; Adult immunizations; Community pharmacist; Immunization
   information system; Value-based payment
ID PUBLIC-HEALTH ACHIEVEMENTS; INFLUENZA; BARRIERS; SYSTEM; CITY
AB Background: The prevalence of vaccine-preventable diseases in adults remains a significant public health issue in the United States. The objectives of this demonstration project were to increase the number of influenza, pneumococcal, pertussis, and herpes zoster immunizations administered to adults by community pharmacists, evaluate the percentage of immunizations documented in the state immunization information system (IIS), and design and pilot a value-based payment model.
   Methods: A one-year prospective, observational demonstration project was conducted in 70 community pharmacies in western Washington State from September 1, 2016 to August 31, 2017. An immunization interface was integrated into workflow at each pharmacy to enable "forecasting" of and proactive recommendation to patients about their vaccine needs and documentation of vaccines administered in the state IIS. Categorical value-based payment models were developed and implemented in a subgroup of 12 community pharmacies from March 1 to November 30, 2017. The change in the number of immunizations administered in comparison to the baseline period and the percentage of immunizations documented in the state IIS during the demonstration period were analyzed using descriptive statistics.
   Results: There was a 15% total increase in the collective number of influenza, pneumococcal, pertussis, and herpes zoster vaccines administered in the demonstration year in the 70 pharmacies, due to increases in influenza and pertussis vaccinations. Eighty-three percent of the vaccines administered were documented in the state IIS. Pneumococcal, pertussis, and herpes zoster performance appeared to be unaffected by the value-based payment models while influenza performance improved across the 12 pilot pharmacies.
   Conclusions: This work demonstrated that community pharmacists contribute to improving adult immunizations through vaccine "forecasting" and proactive recommendation. Meaningful quality measures with both positive and negative incentives could further drive adoption of best immunization practices. Further implementation and outcomes research is needed to fully examine the impact and scalability of these strategies. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bacci, Jennifer L.; Hansen, Ryan; Stergachis, Andy; Odegard, Peggy S.] Univ Washington, Sch Pharm, 1959 NE Pacific St Box 357630, Seattle, WA 98195 USA.
   [Ree, Christina] Bartell Drugs, 4025 Delridge Way SW Suite 400, Seattle, WA 98106 USA.
   [Reynolds, Marci J.] Qual Food Ctr, 10116 NE 8th St, Bellevue, WA 98004 USA.
RP Bacci, JL (reprint author), Univ Washington, Sch Pharm, 1959 NE Pacific St Box 357630, Seattle, WA 98195 USA.
EM jbacci@uw.edu
FU Center for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention -
   USA; National Association of Chain Drug Stores (NACDS); CDCCentre
   National de la Recherche Scientifique (CNRS)United States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [IH23IP000985]; CDCCentre National de la Recherche Scientifique
   (CNRS)United States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA; NACDS
FX This project was supported by the Center for Disease Control and
   Prevention (CDC) and the National Association of Chain Drug Stores
   (NACDS). The content of this publication is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   CDC or the Department of Health and Human Services. This project is part
   of a larger initiative with three (3) sub-awardees spanning four (4)
   states to increase adult immunizations. The demonstration projects are
   supported by Grant Federal Award Identification Number, IH23IP000985,
   for $800,000 funded by the CDC. NACDS contributed an additional $300,000
   to execute the demonstration projects. Given this contribution, each
   sub-awardee received approximately 67 percent ($200,000) of its funding
   from the CDC and approximately 33 percent ($100,000) from NACDS to
   implement its demonstration project. A total of $1.1 million will be
   used to complete CDC project work, with 73 percent from the CDC and 27
   percent from NACDS.
CR American Immunization Registry Association, SURV IMM REP IMM INF
   Baroy J, 2006, J AM PHARM ASSOC, V56, P418
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Bluml BM, 2018, POPUL HEALTH MANAG, V21, P55, DOI 10.1089/pop.2017.0049
   Bourdet SV, 2003, AM J HEALTH-SYST PH, V60, P1767, DOI 10.1093/ajhp/60.17.1767
   Brackett A, 2015, J AM PHARM ASSOC, V55, P182, DOI 10.1331/JAPhA.2015.14120
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brock KA, 2006, J AM PHARM ASSOC, V46, P378, DOI 10.1331/154434506777069642
   Burson RC, 2016, HUM VACC IMMUNOTHER, V12, P3146, DOI 10.1080/21645515.2016.1215393
   Centers for Disease Control and Prevention, ADULTVAXVIEW
   Centers for Disease Control and Prevention, 2018, SURV RES STAT IMM IN
   Centers for Disease Control and Prevention, 2018, 2016 IISAR DAT PART
   Centers for Disease Control and Prevention, STAND AD IMM PRACT
   Esposito S, 2014, EUR J INTERN MED, V25, P203, DOI 10.1016/j.ejim.2013.12.004
   Garcia MC, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6602a1
   Hagemann T, 2014, J AM PHARM ASSOC, V54, pe225
   Hendrickson BK, 2015, J PUBLIC HEALTH MAN, V21, P288, DOI 10.1097/PHH.0000000000000045
   Hogue MD, 2006, J AM PHARM ASSOC, V46, P168, DOI 10.1331/154434506776180621
   Jacobson Vann JC, 2018, COCHRANE DB SYST REV, V1
   Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005
   Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P814
   Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619
   Lee Ventola C, 2016, P T, V41, p[492, 502]
   Lin JL, 2018, J AM PHARM ASSOC, V58, pS94, DOI 10.1016/j.japh.2018.04.003
   Lounsbery JL, 2009, J AM PHARM ASSOC, V49, P51, DOI [10.1331/JAPhA.2009.017158, 10.1331/JAPhA.2009.07158]
   Metroka AE, 2016, PUBLIC HEALTH REP, V131, P583, DOI 10.1177/0033354916662217
   Miller WR, 1991, MOTIVATIONAL INTERVI
   Nichol KL, 1996, J GEN INTERN MED, V11, P673, DOI 10.1007/BF02600158
   Office of Disease Prevention and Health Promotion, HLTH PEOPL 2020
   Pharmacy Quality Alliance Adult Immunization Task Force, REC IMPR AD VACC RAT
   Tanzi MG, 2014, PHARM TIMES
   Wang JL, 2013, J AM PHARM ASSOC, V53, P46, DOI 10.1331/JAPhA.2013.12019
   Weaver KK, PHARM ADM IMM WHAT D
   Winston CA, 2006, J AM GERIATR SOC, V54, P303, DOI 10.1111/j.1532-5415.2005.00585.x
   Zimmerman RK, 2003, AM J MED, V114, P31, DOI 10.1016/S0002-9343(02)01421-3
NR 35
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 152
EP 159
DI 10.1016/j.vaccine.2018.11.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100022
PM 30446177
DA 2020-05-12
ER

PT J
AU Nagai, K
   Domon, H
   Maekawa, T
   Hiyoshi, T
   Tamura, H
   Yonezawa, D
   Habuka, R
   Saitoh, A
   Terao, Y
AF Nagai, Kosuke
   Domon, Hisanori
   Maekawa, Tomoki
   Hiyoshi, Takumi
   Tamura, Hikaru
   Yonezawa, Daisuke
   Habuka, Rie
   Saitoh, Akihiko
   Terao, Yutaka
TI Immunization with pneumococcal elongation factor Tu enhances
   serotype-independent protection against Streptococcus pneumoniae
   infection
SO VACCINE
LA English
DT Article
DE Elongation factor Tu; Serotype-independent protection; Streptococcus
   pneumoniae; Vaccine candidate
ID EF-TU; PROTEIN; DISEASE; VACCINE; IMMUNOGENICITY; PNEUMOLYSIN;
   COMPLEMENT; ANTIBODIES; IMMUNITY; IDENTIFICATION
AB Vaccination is an effective strategy to prevent pneumococcal diseases. Currently, licensed vaccines include the pneumococcal polysaccharide vaccine (PPSV) and the pneumococcal conjugate vaccine (PCV), which target some of the most common of the 94 serotypes of S. pneumoniae based on their capsular composition. However, it has been reported that PPSV is not effective in children aged less than 2 years old and PCV induces serotype replacement, which means that the pneumococcal population has changed following widespread introduction of these vaccines, and the non-vaccine serotypes have increased in being the cause of invasive pneumococcal disease. Therefore, it is important that there is development of novel pneumococcal vaccines to either replace or complement current polysaccharide based vaccines. Our previous study suggested that S. pneumoniae releases elongation factor Tu (EF-Tu) through autolysis followed by the induction of proinflammatory cytokines in macrophages via toll-like receptor 4, that may contribute to the development of pneumococcal diseases. In this study, we investigated the expression of EF-Tu in various S. pneumoniae strains and whether EF-Tu could be an antigen candidate for serotype-independent vaccine against pneumococcal infection. Western blotting and flow cytometry analysis revealed that EF-Tu is a common factor expressed on the surface of all pneumococcal strains tested, as well as intracellularly. In addition, we demonstrate that immunization with recombinant (r) EF-Tu induced the production of inflammatory cytokines and the IgG1 and lgG2a antibodies in mice, and increased the CD4(+) T-cells proportion in splenocytes. We also reveal that anti-EF-Tu serum increased the phagocytic activity of mouse peritoneal macrophages against S. pneumoniae infection, independent of their serotypes. Finally, our results indicate that mice immunized with rEF-Tu were significantly and non-specifically protected against lethal challenges with S. pneumoniae serotypes (2 and 15A). Therefore, pneumococcal EF-Tu could be an antigen candidate for the serotype-independent vaccine against pneumococcal infection. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nagai, Kosuke; Domon, Hisanori; Maekawa, Tomoki; Hiyoshi, Takumi; Tamura, Hikaru; Terao, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Div Microbiol & Infect Dis, Niigata, Japan.
   [Domon, Hisanori; Maekawa, Tomoki; Tamura, Hikaru; Yonezawa, Daisuke; Terao, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Res Ctr Adv Oral Sci, Niigata, Japan.
   [Maekawa, Tomoki; Hiyoshi, Takumi; Tamura, Hikaru] Niigata Univ, Grad Sch Med & Dent Sci, Div Periodontol, Niigata, Japan.
   [Yonezawa, Daisuke] Niigata Univ, Grad Sch Med & Dent Sci, Div Oral Sci Hlth Promot, Niigata, Japan.
   [Habuka, Rie; Saitoh, Akihiko] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Niigata, Japan.
RP Terao, Y (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Div Microbiol & Infect Dis, Chuo Ku, 2-5274 Gakkocho Dori, Niigata, Niigata 9518514, Japan.
EM terao@dent.niigata-u.ac.jp
RI Maekawa, Tomoki/AAA-4673-2020
OI Maekawa, Tomoki/0000-0002-4597-1316
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18K19638,
   17H04367, 16K15785, 16K11439, 16H06272]
FX This work was supported by JSPS KAKENHI grant numbers 18K19638,
   17H04367, 16K15785, 16K11439, and 16H06272.
CR Alderson MR, 2016, VACCINE, V34, P2959, DOI 10.1016/j.vaccine.2016.03.107
   ALEXANDER JE, 1994, INFECT IMMUN, V62, P5683, DOI 10.1128/IAI.62.12.5683-5688.1994
   Andersen GR, 2003, TRENDS BIOCHEM SCI, V28, P434, DOI 10.1016/S0968-0004(03)00162-2
   Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400
   Barbier M, 2013, MBIO, V4, DOI 10.1128/mBio.00207-13
   Batista-Duharte A, 2011, TOXICOL LETT, V203, P97, DOI 10.1016/j.toxlet.2011.03.001
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Chitradevi STS, 2013, VACCINE, V31, P2035, DOI 10.1016/j.vaccine.2013.02.045
   Cohen JI, 2010, J INFECT DIS, V201, P1183, DOI 10.1086/651453
   Crowe JD, 2003, MOL MICROBIOL, V47, P1637, DOI 10.1046/j.1365-2958.2003.03390.x
   Daniels CC, 2010, INFECT IMMUN, V78, P2163, DOI 10.1128/IAI.01199-09
   Darrieux M, 2015, CRIT REV MICROBIOL, V41, P190, DOI 10.3109/1040841X.2013.813902
   de Bree GJ, 2007, J INFECT DIS, V195, P1718, DOI 10.1086/517612
   Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953
   Domon H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38013
   Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006
   Greene CM, 2006, CLIN INFECT DIS, V43, P141, DOI 10.1086/505117
   Hanage WP, 2007, J INFECT DIS, V196, P1282, DOI 10.1086/521630
   Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310
   Johnson SE, 1999, J INFECT DIS, V180, P133, DOI 10.1086/314845
   Jonak J, 2007, J CHROMATOGR B, V849, P141, DOI 10.1016/j.jchromb.2006.11.053
   Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005
   Krab IM, 2002, PROG NUCLEIC ACID RE, V71, P513, DOI 10.1016/S0079-6603(02)71050-7
   Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311
   Leroux-Roels G, 2014, VACCINE, V32, P6838, DOI 10.1016/j.vaccine.2014.02.052
   Li DS, 2013, MICROBIOL MOL BIOL R, V77, P253, DOI 10.1128/MMBR.00059-12
   Lin RQ, 2017, VET PARASITOL, V243, P79, DOI 10.1016/j.vetpar.2017.06.003
   Malley R, 1998, J INFECT DIS, V178, P878, DOI 10.1086/597600
   Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, P60
   Mizukami M, 2010, CURR PHARM BIOTECHNO, V11, P251, DOI 10.2174/138920110791112031
   Moens L, 2018, HUM VACC IMMUNOTHER, V14, P1234, DOI 10.1080/21645515.2018.1430541
   Moffitt KL, 2011, CURR OPIN IMMUNOL, V23, P407, DOI 10.1016/j.coi.2011.04.002
   Mohan S, 2014, MOL IMMUNOL, V62, P249, DOI 10.1016/j.molimm.2014.06.029
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   Mureithi MW, 2009, J INFECT DIS, V200, P783, DOI 10.1086/605023
   Nagai K, 2018, J INFECT CHEMOTHER, DOI [10.1016/j.jjac.2018.08.018, DOI 10.1016/J.JJAC.2018.08.018]
   Nagai K, 2018, CELL IMMUNOL, V325, P14, DOI 10.1016/j.cellimm.2018.01.006
   Nakano S, 2018, EMERG INFECT DIS, V24, P275, DOI 10.3201/eid2402.171268
   Nakano S, 2016, VACCINE, V34, P67, DOI 10.1016/j.vaccine.2015.11.015
   Nakayama T, 2016, VACCINE, V34, P5815, DOI 10.1016/j.vaccine.2016.08.051
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Pettini E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01340
   Pichichero ME, 2009, PEDIATRICS, V124, P1633, DOI 10.1542/peds.2008-3645
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Ren B, 2012, CLIN VACCINE IMMUNOL, V19, P1574, DOI 10.1128/CVI.00393-12
   Sen G, 2005, J IMMUNOL, V175, P3084, DOI 10.4049/jimmunol.175.5.3084
   Sheppard C, 2016, EURO SURVEILL, V21
   Terpe K, 2006, APPL MICROBIOL BIOT, V72, P211, DOI 10.1007/s00253-006-0465-8
   van der Linden M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0941-9
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Yamada M, 2011, AM J RESP CRIT CARE, V183, P1391, DOI 10.1164/rccm.201004-0592OC
   Zhang QB, 2007, J INFECT DIS, V195, P1194, DOI 10.1086/512617
NR 52
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 160
EP 168
DI 10.1016/j.vaccine.2018.11.015
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100023
PM 30442480
DA 2020-05-12
ER

PT J
AU Seppala, EM
   Lopez-Perea, N
   de Mier, MDT
   Echevarria, JE
   Fernandez-Garcia, A
   Masa-Calles, J
AF Seppala, Elina Marjukka
   Lopez-Perea, Noemi
   Torres de Mier, Maria de Viarce
   Echevarria, Juan E.
   Fernandez-Garcia, Aurora
   Masa-Calles, Josefa
TI Last cases of rubella and congenital rubella syndrome in Spain,
   1997-2016: The success of a vaccination program
SO VACCINE
LA English
DT Article
DE Congenital rubella syndrome; Rubella; Rubella vaccine; Epidemiological
   surveillance; Congenital abnormalities; Disease prevention; Genetic
   testing; Emigration and immigration; Spain
ID IMMUNIZATION
AB With a highly immunized population, rubella infection in Spain is so low that the WHO has declared the elimination of rubella. Rubella in pregnant women is also very rare. The objective of this study is to describe the last cases of congenital rubella syndrome reported and recommend actions to maintain the status of the disease as eliminated.
   The CRS cases reported to the Spanish National Epidemiological Surveillance Network between 1997 and 2016 were studied, and the epidemiological, clinical, diagnostic and maternal characteristics of newborns with CRS described. The incidence of CRS was calculated using Birth Statistics from the Spanish National Statistics Agency (INE).
   Twenty-three cases of CRS were reported, 70% of which were associated with rubella outbreaks. The most common clinical conditions were heart disease (52.2%), deafness (39.1%) and cataracts (30.4%); 91.3% of cases were confirmed by laboratory testing. 70.0% were born from a non-vaccinated foreign mother, resident in Spain (cumulative rate incidence (CR): 1.1/100,000 births), with mothers coming from Africa (36.0%), Latin America (29.0%), Eastern Europe (21.0%) and Asia (14.0%). Six were born to Spanish mothers (CR: 0.08/100,000 births), the last of which were in 2005.
   The majority of CRS cases were born to unvaccinated immigrant women infected in Spain during rubella outbreaks. Universal vaccination in childhood is the most efficient strategy to prevent rubella. The limited circulation of the virus will, however, quickly lead to a loss of awareness about rubella among clinicians and epidemiologists. It is necessary to maintain protocols capable of identifying signs consistent with rubella in pregnant women and signs suggestive of congenital rubella in newborns. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
C1 [Seppala, Elina Marjukka] Tampere Univ, Arvo Ylpon Katu 34, Tampere 33520, Finland.
   [Lopez-Perea, Noemi; Torres de Mier, Maria de Viarce; Masa-Calles, Josefa] Inst Salud Carlos III, Natl Epidemiol Ctr, Av Monforte de Lemos 5, Madrid 28029, Spain.
   [Echevarria, Juan E.; Fernandez-Garcia, Aurora] Inst Salud Carlos III, Natl Microbiol Ctr, Ctra Majadahoda Pozuelo S-N, Madrid 28220, Spain.
   [Lopez-Perea, Noemi; Torres de Mier, Maria de Viarce; Echevarria, Juan E.; Fernandez-Garcia, Aurora; Masa-Calles, Josefa] Ctr Biomed Res Network CIBER Epidemiol & Publ Hlt, Madrid, Spain.
RP Lopez-Perea, N (reprint author), Inst Salud Carlos III, Natl Epidemiol Ctr, Av Monforte de Lemos 5, Madrid 28029, Spain.; Lopez-Perea, N (reprint author), Ctr Biomed Res Network CIBER Epidemiol & Publ Hlt, Madrid, Spain.
EM Seppala.Elina.M@student.uta.fi; nlopezp@isciii.es; mvtorres@isciii.es;
   jeecheva@isciii.es; aurorafg@externos.isciii.es; jmasa@isciii.es
RI Echevarria, Juan E./F-7913-2016
OI Echevarria, Juan E./0000-0001-7522-850X; MASA-CALLES,
   JOSEFA/0000-0002-2725-417X
FU Erasmus + scholarship at the National Epidemiology Centre (ISCIII)
FX This work is the result of the stay that Elina M. Seppala, a student at
   the University of Tampere (Finland) and granted an Erasmus +
   scholarship, held at the National Epidemiology Centre (ISCIII) between
   February and April 2017.
CR Albendiz MA, 1989, GAC SANIT, V3, P366
   Banatvala JE, 2004, LANCET, V363, P1127, DOI 10.1016/S0140-6736(04)15897-2
   Carnicer-Pont D, 2008, EUR J PUBLIC HEALTH, V18, P688, DOI 10.1093/eurpub/ckn098
   Echevarria JE, 2010, OPEN VACCINE J, V3, P55
   Giambi C, 2015, VACCINE, V33, P4929, DOI 10.1016/j.vaccine.2015.07.041
   Grant GB, PROGR RUBELLA CONGEN
   Hernandez Diaz R, ESTUDIO SEROPREVALEN
   ISCIII. Centro Nacional de Epidemiologia, 2008, PROT VIG RUB SINDR R
   ISCIII. Centro Nacional de Epidemiologia. Plan de Eliminacion del Sarampifin y de la Rubeola en Espana, 2002, INF AN B EP SEM
   Lazar M, 2016, EURO SURVEILL, V21
   Lemos C, 2004, Euro Surveill, V9, P9
   Martinez-Torres AO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162403
   Masa-Calles J, 2008, SISTEMA VIGILANCIA E, V13
   Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462
   Public Health England, 2016, RUB SUSC SCREEN PREG
   Red de Vigilancia Epidemiologica de la Comunidad de Madrid, 2005, EUROSURVEILLANCE, V10, DOI [10.2807/esw.10.27.02742-en, DOI 10.2807/ESW.10.27.02742-EN]
   Reef SE, 2000, CLIN INFECT DIS, V31, P85, DOI 10.1086/313928
   RENAVE. Centro Nacional de epidemiologia, 2013, PROT ENF DECL OBL 20
   Sampedro A, 2010, ENFERM INFEC MICR CL, V28, P694, DOI 10.1016/j.eimc.2010.04.007
   Scholz N, 2016, PUBLIC HLTH DIMENSIO
   Torner N, 2006, EURO SURVEILL, V11
   Vilajeliu A, 2015, VACCINE, V33, P1767, DOI 10.1016/j.vaccine.2015.02.043
   *WHO, 2005, EL MEASL RUB PREV CO
   WHO-Europe, 2017, 5 M EUR REG VER COMM
   WHO-Europe, 2013, SURV GUID MEASL RUB
   World Health Organization (WHO), WHO VACC PREV DIS MO
NR 26
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 169
EP 175
DI 10.1016/j.vaccine.2018.11.017
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100024
PM 30454948
OA Other Gold
DA 2020-05-12
ER

PT J
AU Martinez, AC
   Prymula, R
   Valdivieso, MM
   Reigada, MDO
   Arribas, JMM
   Brzostek, J
   Szenborn, L
   Ruzkova, R
   Horn, MR
   Jackowska, T
   Centeno-Malfaz, F
   Traskine, M
   Dobbelaere, K
   Borys, D
AF Carmona Martinez, Alfonso
   Prymula, Roman
   Miranda Valdivieso, Mariano
   Otero Reigada, Maria del Carmen
   Merino Arribas, Jose Manuel
   Brzostek, Jerzy
   Szenborn, Leszek
   Ruzkova, Renata
   Horn, Michael R.
   Jackowska, Teresa
   Centeno-Malfaz, Fernando
   Traskine, Magali
   Dobbelaere, Kurt
   Borys, Dorota
TI Immunogenicity and safety of 11-and 12-valent pneumococcal non-typeable
   Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV,
   12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre
   study
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; PHiD-CV; Immunogenicity;
   Non-inferiority; Safety; Infants/children
ID STREPTOCOCCUS-PNEUMONIAE; PHID-CV; CHILDREN; REACTOGENICITY;
   VACCINATION; CARRIAGE; DISEASE; IMPACT; ERA
AB Background: We assessed 2 investigational 11- and 12-valent vaccines, containing capsular polysaccharides of 10 serotypes as in the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and CRIA(197)-conjugated capsular polysaccharides of serotypes 19A (11-valent) or 19A and 6A (12-valent).
   Methods: In this phase II, partially-blind, multicentre study (NCT01204658), healthy infants were randomised (1:1:1:1) to receive 11vPHiD-CV, 12vPHiD-CV, PHiD-CV, or 13-valent CRM197-conjugate pneumococcal vaccine (PCV13), at 2, 3, and 4 (primary series), and 12-15 months of age (booster dose), co-administered with DTPa-HBV-IPV/Hib. Confirmatory objectives assessed non-inferiority of investigational vaccines to comparators (PHiD-CV for common serotypes; PCV13 for 19A and 6A), in terms of percentage of infants with pneumococcal antibody concentrations >= 0.2 mu g/mL and antibody geometric mean concentrations, post-primary vaccination. Reactogenicity and safety were assessed.
   Results: 951 children received >= 1 primary dose, 919 a booster dose. Pre-defined immunological non inferiority criteria were met simultaneously for 9/11 11vPHiD-CV serotypes (all except 23F and 19A) and 10/12 12vPHiD-CV serotypes (all except 19A and 6A); thus, non-inferiority objectives were reached.
   For each PHiD-CV serotype, percentages of children with antibody concentrations >= 0.2 AgirnL were >96.7% post-primary (except 6B [>= 75.2%] and 23F [>= 81.1%]), and >= 98.1% post-booster vaccination. For each PHiD-CV serotype except serotype 1, >= 81.0% and >= 93.9% of children had opsonophagocytic activity titres >= 8, post-primary and booster vaccination. AEs incidence was similar across all groups. SAEs were reported for 117 children (29 in the 11vPHiD-CV group, 26 in the 12vPHiD-CV group, 38 in the PHiD-CV group and 24 in the PCV13 group); 4 SAEs were considered vaccination-related. No fatal events were recorded.
   Conclusion: Addition of 19A and 6A CRM197-conjugates did not alter immunogenicity of the PHiD-CV conjugates; for both investigational vaccines post-booster immune responses to 10 common serotypes appeared similar to those elicited by PHiD-CV. Safety and reactogenicity profiles of the investigational vaccines were comparable to PHiD-CV. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
C1 [Carmona Martinez, Alfonso] Inst Hispalense Pediat, C Manuel Siurot 45, Seville 41013, Spain.
   [Prymula, Roman] Charles Univ Prague, Fac Med Hradec Kralove, Dept Social Med, Simkova 870, Hradec Kralove 50038, Czech Republic.
   [Miranda Valdivieso, Mariano] Hosp Antequera, Ave Poeta Munoz Rojas S-N, Malaga 29200, Spain.
   [Otero Reigada, Maria del Carmen] La Fe Hosp, Avinguda Fernando Abril Martorell 106, Valencia, Spain.
   [Merino Arribas, Jose Manuel] Burgos Univ Hosp, Pediat Dept, Ave Islas Baleares S-N, Burgos 09006, Spain.
   [Brzostek, Jerzy] Hlth Care Estab Debica, Infect Dis Outpatient Clin, Ul Krakowska 91, PL-39200 Debica, Poland.
   [Szenborn, Leszek] Wroclaw Med Univ, Dept Paediat Infect Dis, 2-2A Chalubinskiego, PL-50368 Wroclaw, Poland.
   [Ruzkova, Renata] Medicentrum 6 Sro, Pediat Off Dr Renato Ruzkova, Kladenska 53, Prague 16000, Czech Republic.
   [Horn, Michael R.] Pediat Off Dr Med Michael Horn, Achenweg 1, D-83471 Schonau, Germany.
   [Jackowska, Teresa] Ctr Postgrad Med Educ, Dept Pediat, Ul Marymoncka 99-103, PL-01813 Warsaw, Poland.
   [Centeno-Malfaz, Fernando] Rio Hortega Univ Hosp, Dept Pediat, Calle Dulzaina 2, Valladolid 47012, Spain.
   [Traskine, Magali; Dobbelaere, Kurt; Borys, Dorota] GSK, Av Fleming 20, B-1300 Wavre, Belgium.
RP Prymula, R (reprint author), Charles Univ Prague, Fac Med Hradec Kralove, Dept Social Med, Simkova 870, Hradec Kralove 50038, Czech Republic.
EM alfonsocarmona@ihppediatria.com; prymula@fnhk.cz;
   mariano.miranda@andaluciajunta.es; otero_car@gva.es;
   jerzy_br@poczta.onet.pl; leszek.szenborn@umed.wroc.pl;
   drruzkova@email.cz; info@drhorn.de; tjackowska@cmkp.edu.pl;
   fcentenoma@saludcastillayleon.es; magali.x.traskine@gsk.com;
   dorota.d.borys@gsk.com
RI JACKOWSKA, TERESA/X-1947-2019
OI JACKOWSKA, TERESA/0000-0003-0131-7854
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA was the funding source and was involved
   in all stages of the study conduct and analysis. GlaxoSmithKline
   Biologicals SA also took responsibility for all costs associated with
   the development and publishing of the present manuscript.
CR Alari A, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0755-7
   Alderson MR, 2016, VACCINE, V34, P2959, DOI 10.1016/j.vaccine.2016.03.107
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Bareja C, 2015, COMMUN DIS INTELL, V39, pE265
   Chalmers JD, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0242-0
   Chan KCC, 2016, VACCINE, V34, P3867, DOI 10.1016/j.vaccine.2016.05.047
   Chevallier B, 2009, PEDIATR INFECT DIS J, V28, pS109, DOI 10.1097/INF.0b013e318199f62d
   Concepcion NF, 2001, CLIN DIAGN LAB IMMUN, V8, P266, DOI 10.1128/CDLI.8.2.266-272.2001
   Dagan R, 2009, CLIN MICROBIOL INFEC, V15, P16, DOI 10.1111/j.1469-0691.2009.02726.x
   Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026
   de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736
   De Wals P, 2014, VACCINE, V32, P1501, DOI 10.1016/j.vaccine.2013.11.028
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Ginsburg AS, 2012, EXPERT REV VACCINES, V11, P279, DOI [10.1586/ERV.12.5, 10.1586/erv.12.5]
   Hausdorff WP, 2016, HUM VACC IMMUNOTHER, V12, P358, DOI 10.1080/21645515.2015.1118593
   Henckaerts I, 2007, VACCINE, V25, P2518, DOI 10.1016/j.vaccine.2006.09.029
   Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x
   Imohl M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0787-1
   IVAC, 2017, PNEUM CONJ VACC PCV
   Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290
   Kaur R, 2016, PEDIATR INFECT DIS J, V35, P901, DOI 10.1097/INF.0000000000001206
   Kawaguchiya M., 2016, New Microbes and New Infections, V9, P66, DOI 10.1016/j.nmni.2015.11.001
   Knuf M, 2009, PEDIATR INFECT DIS J, V28, pS97, DOI 10.1097/INF.0b013e318199f61b
   Lee H, 2009, CLIN VACCINE IMMUNOL, V16, P376, DOI 10.1128/CVI.00344-08
   Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031
   McFetridge R, 2015, VACCINE, V33, P2793, DOI 10.1016/j.vaccine.2015.04.025
   Odutola A, 2016, HUM VACC IMMUNOTHER, V12, P393, DOI 10.1080/21645515.2015.1111496
   Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071
   Plosker GL, 2013, PEDIATR DRUGS, V15, P403, DOI 10.1007/s40272-013-0047-z
   Poolman JT, 2010, CLIN VACCINE IMMUNOL, V17, P134, DOI 10.1128/CVI.00289-09
   Prymula R, 2017, VACCINE, V35, P4603, DOI 10.1016/j.vaccine.2017.07.008
   Prymula R, 2014, VACCINE, V32, P3025, DOI 10.1016/j.vaccine.2014.03.066
   Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113
   van den Bergh MR, 2016, PEDIATR INFECT DIS J, V35, pE206, DOI 10.1097/INF.0000000000001170
   van der Linden M, 2015, PLOS ONE, P10, DOI [10.1371/journal.pone.0131494e0131494, DOI 10.1371/JOURNAL.PONE.0131494E0131494]
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, pS66, DOI 10.1097/INF.0b013e318199f8ef
   World Health Organization Expert Committee on Biological Standardization, 2009, REC ASS QUAL SAF EFF
   Wysocki J, 2009, PEDIATR INFECT DIS J, V28, pS77, DOI 10.1097/INF.0b013e318199f609
NR 38
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 176
EP 186
DI 10.1016/j.vaccine.2018.07.023
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100025
PM 30054160
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lake, P
   Kasting, ML
   Malo, T
   Giuliano, AR
   Vadaparampil, ST
AF Lake, Paige
   Kasting, Monica L.
   Malo, Teri
   Giuliano, Anna R.
   Vadaparampil, Susan T.
TI An environmental scan to examine stakeholder perspectives on human
   papillomavirus vaccination: A mixed methods study
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccination; Cancer; Education; PRECEDE PROCEED
   model
ID HPV VACCINE; STATEWIDE SURVEY; RECOMMENDATIONS; PARENTS; GIRLS; US;
   OPPORTUNITIES; INTERVENTION; ADOLESCENTS; ACCEPTANCE
AB Purpose: Human papillomavirus (HPV) vaccine series completion rates among females and males remain low in Florida (46.4% and 34.5%, respectively). Multiple stakeholders influence vaccination uptake, including health care providers (HCPs), public health professionals (PHPs), and members of professional organizations. We examined stakeholder efforts related to increasing vaccine uptake and education among parents/adolescents and HCPs.
   Methods: We conducted an environmental scan of stakeholder efforts and identified stakeholders using our professional networks and a snowball sampling approach. Stakeholders (n = 46) completed a survey about involvement in and barriers to vaccination promotion efforts. A subset (n = 12) of stakeholders participated in follow-up interviews further exploring vaccination efforts and barriers, Survey data were analyzed using descriptive statistics. Interview data were analyzed using deductive analysis and coded using constructs from the PRECEDE-PROCEED model.
   Results: The majority of our survey sample was PHPs (50.0%) and HCPs (32.6%). Stakeholder efforts were focused on adolescent/parent/HCP education including providing: educational materials for HCPs (55.8%) and adolescents/parents (59.6%), one-on-one consultations for adolescents/parents (55.3%), and HCP education (54.7%). Lack of knowledge/understanding and education/information were barriers reported across almost all groups/areas. Office staff/HCP education and distribution of patient education materials were efforts described as important during qualitative interviews. Stakeholders also noted HCP discomfort when recommending HPV vaccine, parental perceptions that the vaccine is unnecessary, and a lack of education/understanding among parents and HCPs.
   Conclusions: Results suggest the need for parent/adolescent education, specifically targeting key areas we identified: importance and benefits of HPV vaccine, and education and skill building in vaccine communication for HCPs. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Lake, Paige; Kasting, Monica L.; Giuliano, Anna R.; Vadaparampil, Susan T.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33617 USA.
   [Kasting, Monica L.; Giuliano, Anna R.] H Lee Moffitt Canc Ctr & Res Inst, Ctr Infect Canc Res, Tampa, FL 33617 USA.
   [Vadaparampil, Susan T.] Univ S Florida, Coll Med, Tampa, FL USA.
   [Malo, Teri] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.
RP Vadaparampil, ST (reprint author), H Lee Moffitt Canc Ctr & Res Inst, MFC CRISP, 4115 East Fowler Ave, Tampa, FL 33617 USA.
EM susan.vadaparampil@moffitt.org
OI Kasting, Monica/0000-0002-9879-7235; Giuliano, Anna
   R/0000-0002-5440-8859
FU National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [3P30CA076292-16S3]; National Cancer Institute of
   the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R25-CA090314]; Center for Research in Infection
   and Cancer [K05-CA181320]
FX This project was approved by the institutional review board (protocol:
   #19784). This work was supported by a supplement from the National
   Cancer Institute (NCI) under grant number: 3P30CA076292-16S3. The
   efforts of Monica Kasting are supported by the National Cancer Institute
   of the National Institutes of Health (R25-CA090314). Dr. Kasting is
   additionally supported by the Center for Research in Infection and
   Cancer (K05-CA181320). The authors wish to thank Nazach Rodriguez for
   helping with this project by conducting a portion of our stakeholder
   interviews.
CR Allen JD, 2010, CANCER EPIDEM BIOMAR, V19, P2187, DOI 10.1158/1055-9965.EPI-10-0217
   Bynum SA, 2014, J ADOLESCENT HEALTH, V54, P190, DOI 10.1016/j.jadohealth.2013.08.006
   Cabo W, 2016, CANCER EPIDEM BIOMAR, V25, P9
   Conroy K, 2009, J WOMENS HEALTH, V18, P8
   Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x
   Etter DJZG, 2012, CURR OPIN OBSTET GYN, V24, P6
   Gerend MA, 2016, SEX TRANSM INFECT, V92, P104, DOI 10.1136/sextrans-2015-052088
   Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326
   Green L, 1999, HLTH PROMOTION PLANN, P32
   Hofman R, 2014, HEALTH EDUC RES, V29, P83, DOI 10.1093/her/cyt092
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Kahn JA, 2005, J ADOLESCENT HEALTH, V37, P502, DOI 10.1016/j.jadohealth.2005.07.014
   Kahn JA, 2009, CANCER EPIDEM BIOMAR, V18, P2325, DOI 10.1158/1055-9965.EPI-09-0184
   KASTING ML, 2017, FAMILY MED, V49, P9, DOI DOI 10.1016/J.WHI.2015.07.012
   Khurana S, 2015, VACCINE, V33, P1620, DOI 10.1016/j.vaccine.2015.01.038
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Mayne Stephanie, 2012, AMIA Annu Symp Proc, V2012, P616
   McCave E, 2010, J COMMUN HEALTH, V35, P8
   McRee A, 2014, J PEDIATR HEALTH CAR, V28, P9
   McRee AL, 2014, J PEDIATR HEALTH CAR, V28, P541, DOI 10.1016/j.pedhc.2014.05.003
   Mroz S, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160610
   National Cancer Institute, 2012, PRES CANC PAN ANN RE
   Patton M. Q., 1990, QUALITATIVE EVALUATI
   Perkins RB, 2015, VACCINE, V33, P1223, DOI 10.1016/j.vaccine.2014.11.021
   Perkins RB, 2014, PEDIATRICS, V134, pE666, DOI 10.1542/peds.2014-0442
   Perkins RB, 2010, WOMEN HEALTH ISS, V20, P420, DOI 10.1016/j.whi.2010.07.001
   Quinn GP, 2012, J PEDIATR ADOL GYNEC, V25, P254, DOI 10.1016/j.jpag.2012.02.007
   Reagan-Steiner S., 2015, MMWR MORB MORT WEEKL, P65
   Reiter PL, 2011, CANCER EPIDEM BIOMAR, V20, P2354, DOI 10.1158/1055-9965.EPI-11-0562
   Scherr CL, 2016, VACCINE, V34, P4229, DOI 10.1016/j.vaccine.2016.06.037
   Smulian EA, 2016, HUM VACC IMMUNOTHER, V12, P1566, DOI 10.1080/21645515.2015.1125055
   Staras SAS, 2014, VACCINE, V32, P6163, DOI 10.1016/j.vaccine.2014.08.054
   Sturm L, 2017, J ADOLESCENT HEALTH, V61, P246, DOI 10.1016/j.jadohealth.2017.02.006
   Thompson E, 2017, J ADOLESCENT HEALTH, V61, P6
   Tiro JA, 2007, CANCER EPIDEM BIOMAR, V16, P288, DOI 10.1158/1055-9965.EPI-06-0756
   TISSOT AM, 2008, J ADOLESCENT HEALTH, V41, P7, DOI DOI 10.1542/PEDS.2016-1537
   Vadaparampil ST, 2016, CANC EPIDEMIOL PREV
   Vadaparampil ST, 2014, AM J PREV MED, V46, P80, DOI 10.1016/j.amepre.2013.07.009
   Vadaparampil ST, 2013, CANCER-AM CANCER SOC, V119, P621, DOI 10.1002/cncr.27735
   Vadaparampil ST, 2011, VACCINE, V29, P8634, DOI 10.1016/j.vaccine.2011.09.006
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P9
   Wilburn A, 2016, PREV CHRONIC DIS ENV, P13
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 44
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 187
EP 194
DI 10.1016/j.vaccine.2018.06.073
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100026
PM 29983257
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Hechter, RC
   Qian, L
   Luo, Y
   Grant, DSL
   Baxter, R
   Klein, NP
   Nunley, KV
   Aukes, L
   Hogea, C
   Krishnarajah, G
   Patterson, BJ
   Im, TM
   Tseng, HF
AF Hechter, Rulin C.
   Qian, Lei
   Luo, Yi
   Grant, Deborah S. Ling
   Baxter, Roger
   Klein, Nicola P.
   Nunley, Karen Valdez
   Aukes, Laurie
   Hogea, Cosmina
   Krishnarajah, Girishanthy
   Patterson, Brandon J.
   Im, Theresa M.
   Tseng, Hung Fu
TI Impact of an electronic medical record reminder on hepatitis B vaccine
   initiation and completion rates among insured adults with diabetes
   mellitus
SO VACCINE
LA English
DT Article
DE Hepatitis B; Vaccination; Coverage; Electronic reminder; Compliance;
   Diabetes
ID UNITED-STATES; COVERAGE
AB Objective: The Advisory Committee on Immunization Practices recommends Hepatitis B (HepB) vaccine for previously unvaccinated adults <60 years with diabetes mellitus. This observational retrospective cohort study assessed the impact of implementing electronic provider reminders on HepB vaccine initiation and 3-dose series completion rates among insured adults with diabetes aged 19-59 years old.
   Research design and methods: Difference-in-difference (DID) analyses compared changes in vaccine initiation and completion rates (ratio of the rate ratio [RRR] and 95% confidence interval [CI]) during 12 months pre- and post-implementation between intervention and control sites. We examined trends in vaccine initiation and completion rates by plotting monthly rates during the study period. We also calculated the overall HepB vaccine coverage rates with 95% CI among all adults with diabetes aged 19-59 years old at the start and end date of the study period.
   Results: Baseline HepB vaccine initiation and completion rates were similar at both the intervention and control sites. Gender, age, and race/ethnicity distributions within both sites were similar during the 12 months pre- and post-implementation. DID analyses demonstrated statistically significant differences in the changes of the annual vaccine initiation rates (RRR: 70.7, 95% CI: 62.8-79.6) and the third dose completion rates (RRR = 18.7, 95% CI: 14.2-24.8) between the two sites. The coverage increased significantly at the intervention site while it remained low at the control site.
   Conclusions: Use of provider reminders is highly effective in increasing both HepB vaccine initiation and series completion rates among adults with diabetes. (C) 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
C1 [Hechter, Rulin C.; Qian, Lei; Luo, Yi; Grant, Deborah S. Ling; Im, Theresa M.; Tseng, Hung Fu] Kaiser Permanente Southern Calif, 100 S Los Robles,2nd Floor, Pasadena, CA 91101 USA.
   [Baxter, Roger; Klein, Nicola P.; Nunley, Karen Valdez; Aukes, Laurie] Kaiser Permanente Northern Calif, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
   [Hogea, Cosmina; Krishnarajah, Girishanthy; Patterson, Brandon J.] GSK, 5 Crescent Dr, Philadelphia, PA 19112 USA.
   [Krishnarajah, Girishanthy] CSL Behring, King Of Prussia, PA USA.
RP Tseng, HF (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles,2nd Floor, Pasadena, CA 91101 USA.
EM Rulin.C.Hechter@kp.org; Lei.X.Qian@kp.org; Yi.X.Luo@kp.org;
   Deborah.S.Ling-Grant@kp.org; nicola.klein@kp.org; Karen.V.Nunley@kp.org;
   Laurie.A.Aukes@kp.org; cosmina.s.hogea@gsk.com;
   shanthy.krishnarajah@cslbehring.com; brandon.j.patterson@gsk.com;
   theresa.m.im@kp.org; Hung-Fu.X.Tseng@kp.org
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline [HO-15-15717]
FX GlaxoSmithKline Biologicals SA funded this study (GSK study identifier:
   HO-15-15717) and was involved in all stages of study conduct, including
   analysis of the data. GlaxoSmithKline Biologicals SA also took in charge
   all costs associated with the development and publication of this
   manuscript.
CR Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1
   Baxter R, 2015, NAT FDN INF DIS 18 A
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1709
   Community Preventive Services Task Force, 2015, INCR APPR VACC PROV
   Koenig A, 2016, LIVER INT, V36, P1096, DOI 10.1111/liv.13164
   Loo TS, 2011, ARCH INTERN MED, V171, P1552, DOI 10.1001/archinternmed.2011.394
   Reilly Meredith L, 2012, J Diabetes Sci Technol, V6, P858
   Thompson Nicola D, 2009, J Diabetes Sci Technol, V3, P283
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95
   Williams WW, 2014, MMWR-MORBID MORTAL W, V63, P95
   Williams WW, 2013, MMWR-MORBID MORTAL W, V62, P66
   Younossi Z, 2017, HUM VACCIN IMMUNOTHE
NR 13
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 195
EP 201
DI 10.1016/j.vaccine.2018.06.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100027
PM 29958736
DA 2020-05-12
ER

PT J
AU Toizumi, M
   Vo, HM
   Dang, DA
   Moriuchi, H
   Yoshida, LM
AF Toizumi, Michiko
   Hien Minh Vo
   Duc Anh Dang
   Moriuchi, Hiroyuki
   Yoshida, Lay-Myint
TI Clinical manifestations of congenital rubella syndrome: A review of our
   experience in Vietnam
SO VACCINE
LA English
DT Review
DE Congenital rubella syndrome; Rubella vaccine; Clinical manifestations
ID PATENT DUCTUS-ARTERIOSUS; SYNDROME CRS; DEVELOPMENTAL DELAY; MATERNAL
   RUBELLA; CHILDREN; IMMUNIZATION; INFECTION; SEROPREVALENCE;
   EPIDEMIOLOGY; OUTBREAK
AB Rubella vaccination programs have dramatically reduced the incidence of rubella and congenital rubella syndrome (CRS) in developed countries. However, CRS prevalence is still rising in developing countries where rubella-containing vaccines (RCV) are not included in the immunization program and even in some countries where a part of the population lacks immunity to rubella despite the presence of RCV in the regular immunization program. This review aimed to summarize the clinical features of CRS using data from our studies conducted between 2011 and 2015 in Vietnam, wherein we examined clinical manifestations in Vietnamese children with CRS who were born after the large rubella outbreak of 2011; a series of studies dealing with CRS in North America and Europe after the 1960s epidemic; and those from countries before introduction of RCVS.
   This review shows that children with CRS have a variety of disabilities such as hearing, visual, developmental, behavioral, cardiac, and endocrine impairments, which have variable severity and may appear in different combinations. Some of these impairments can appear or worsen later in the lives of these children.
   Physicians should thus complete pediatric, cardiac, auditory, ophthalmologic, and neurologic examinations along with laboratory diagnostic testing soon after birth. These assessments should be repeated during follow-up if congenital rubella infection is suspected in a neonate. Timely intervention for cardiac defects can be lifesaving. Early introduction and continuation of speech, occupational, physical, and behavior therapies and training with appropriate medical interventions by a multidisciplinary team approach are required to maximize quality of life. (C) 2018 Published by Elsevier Ltd.
C1 [Toizumi, Michiko; Yoshida, Lay-Myint] Nagasaki Univ, Inst Trop Med, Dept Pediat Infect Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
   [Hien Minh Vo] Khanh Hoa Gen Hosp, Dept Pediat, Nha Trang, Vietnam.
   [Duc Anh Dang] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
   [Moriuchi, Hiroyuki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pediat, Nagasaki, Japan.
RP Yoshida, LM (reprint author), Nagasaki Univ, Inst Trop Med, Dept Pediat Infect Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM lmyoshi@nagasaki-u.ac.jp
RI Toizumi, Michiko/AAA-7450-2019
OI Toizumi, Michiko/0000-0002-8401-9344; YOSHIDA,
   LAYMYINT/0000-0002-7567-3248
FU NEK-KEN collaborative research fund (Institute of Tropical Medicine,
   Nagasaki University) [27-general-17]; AMEDJapan Agency for Medical
   Research and Development (AMED) [JP18fm0108001]
FX Authors' studies reviewed in this paper were supported by NEK-KEN
   collaborative research fund (Institute of Tropical Medicine, Nagasaki
   University) under Grant Number 27-general-17 and AMED under Grand Number
   JP18fm0108001.
CR ALI Z, 1986, J TROP PEDIATRICS, V32, P79, DOI 10.1093/tropej/32.2.79
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   ANDERSON H, 1970, ARCHIV OTOLARYNGOL, V91, P141
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   Banatvala JE, 2004, LANCET, V363, P1127, DOI 10.1016/S0140-6736(04)15897-2
   Berger BE, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-340
   BOGER WP, 1981, ARCH OPHTHALMOL-CHIC, V99, P433
   BOGER WP, 1980, OPHTHALMOLOGY, V87, P1244
   Bricker D, 1999, AGES STAGES QUESTION
   CAMPBELL M, 1961, BMJ-BRIT MED J, V1, P691, DOI 10.1136/bmj.1.5227.691
   CHESS S, 1971, J AUTISM CHILD SCHIZ, V1, P33, DOI 10.1007/BF01537741
   CLARKE WL, 1984, J PEDIATR-US, V104, P370, DOI 10.1016/S0022-3476(84)81097-5
   COOPER LZ, 1985, REV INFECT DIS, V7, pS2
   COOPER LZ, 1967, ARCH OPHTHALMOL-CHIC, V77, P434
   COOPER LZ, 1969, AM J DIS CHILD, V118, P18, DOI 10.1001/archpedi.1969.02100040020004
   Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55
   DEOWENS CS, 1989, PEDIATR INFECT DIS J, V8, P110
   DESMOND MM, 1978, J PEDIATR-US, V93, P584, DOI 10.1016/S0022-3476(78)80892-0
   Doraisingham S, 1981, Ann Acad Med Singapore, V10, P238
   DOWDLE WR, 1970, B WORLD HEALTH ORGAN, V42, P419
   Duszak RS, 2009, OPTOMETRY, V80, P36, DOI 10.1016/j.optm.2008.03.006
   Eckstein M, 1996, BRIT J OPHTHALMOL, V80, P628, DOI 10.1136/bjo.80.7.628
   FELDMAN RB, 1971, LANCET, V2, P978
   FORREST JM, 1971, LANCET, V2, P332
   FORREST JM, 1969, LANCET, V1, P1263
   FORTUIN NJ, 1971, AM J MED, V51, P134, DOI 10.1016/0002-9343(71)90330-5
   FRANKENBURG WK, 1992, PEDIATRICS, V89, P91
   GIVENS KT, 1993, BRIT J OPHTHALMOL, V77, P358, DOI 10.1136/bjo.77.6.358
   Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35
   Gunasekera DP, 1996, LANCET, V347, P1694, DOI 10.1016/S0140-6736(96)91521-4
   Johnson JL, 2005, PEDIATRICS, V116, P663, DOI 10.1542/peds.2004-1688
   Kanner L, 1943, NERV CHILD, V2, P217
   Kaplan G W, 1973, Urology, V2, P148, DOI 10.1016/0090-4295(73)90248-3
   Khandekar R, 2004, ARCH OPHTHALMOL-CHIC, V122, P541, DOI 10.1001/archopht.122.4.541
   KONO R, 1985, REV INFECT DIS, V7, pS56
   KRICHENKO A, 1989, AM J CARDIOL, V63, P877, DOI 10.1016/0002-9149(89)90064-7
   Lanzieri T., 2013, CONGENITAL RUBELLA S
   Lawn JE, 2000, AM J PUBLIC HEALTH, V90, P1555, DOI 10.2105/AJPH.90.10.1555
   Mason WH, 2011, NELSON TXB PEDIAT, P1075
   Masri S, 2015, CATHETER CARDIO INTE, V86, pE66, DOI 10.1002/ccd.25940
   MENDIS L, 1989, Ceylon Medical Journal, V34, P73
   MENSER MA, 1978, LANCET, V1, P57
   Minakami H, 2014, J INFECTION, V68, P99, DOI 10.1016/j.jinf.2013.09.002
   Miyakawa M, 2014, VACCINE, V32, P1192, DOI 10.1016/j.vaccine.2013.08.076
   Mizuno Y, 2016, PEDIATR INT, V58, P490, DOI 10.1111/ped.12830
   Oster ME, 2010, BIRTH DEFECTS RES A, V88, P1, DOI 10.1002/bdra.20621
   Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462
   PECKHAM C, 1985, REV INFECT DIS, V7, pS11
   Plotkin SA, 2001, VACCINE, V19, P3311, DOI 10.1016/S0264-410X(01)00073-1
   PREECE MA, 1977, LANCET, V2, P842
   Reef SE, 2000, CLIN INFECT DIS, V31, P85, DOI 10.1086/313928
   Reef SE, 2016, REMINGTON KLEINS INF, P894
   Reef SE, 2013, VACCINES, P688
   Reef SE, 2006, CLIN INFECT DIS, V43, pS126, DOI 10.1086/505944
   Rittler M, 2004, BIRTH DEFECTS RES A, V70, P939, DOI 10.1002/bdra.20089
   Robins DL, 2001, J AUTISM DEV DISORD, V31, P131, DOI 10.1023/A:1010738829569
   Saitoh A, 2014, VACCINE, V32, P4253, DOI 10.1016/j.vaccine.2014.06.022
   Schopler E, 2010, CHILDHOOD AUTISM RAT
   Semerikov VV, 2000, EPIDEMIOL INFECT, V125, P359, DOI 10.1017/S0950268899004343
   SEVER JL, 1985, REV INFECT DIS, V7, pS164
   Shevell M, 2003, NEUROLOGY, V60, P367, DOI 10.1212/01.WNL.0000031431.81555.16
   Smith RJH, 2005, LANCET, V365, P879, DOI 10.1016/S0140-6736(05)71047-3
   Strebel PM, 2011, J INFECT DIS, V204, pS579, DOI 10.1093/infdis/jir447
   SWAN C, 1946, Med J Aust, V2, P889
   Tan K L, 1970, J Singapore Paediatr Soc, V12, P111
   Toda K, 2015, VACCINE, V33, P3673, DOI 10.1016/j.vaccine.2015.06.035
   Toizumi M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46483
   Toizumi M, 2014, PEDIATRICS, V134, pE519, DOI 10.1542/peds.2013-4184
   TOMER Y, 1993, ENDOCR REV, V14, P107, DOI 10.1210/er.14.1.107
   UEDA K, 1978, AM J EPIDEMIOL, V107, P344, DOI 10.1093/oxfordjournals.aje.a112550
   Upreti SR, 2011, J INFECT DIS, V204, pS433, DOI 10.1093/infdis/jir078
   VERNON M, 1967, VOLTA REV, V69, P176
   Vijayalakshmi P., 2002, Indian Journal of Ophthalmology, V50, P307
   Vynnycky E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149160
   *WHO, 1994, WKLY EPIDEMIOL REC, V69, P333
   Wolff S M, 1972, Trans Am Ophthalmol Soc, V70, P577
   ZIRING PR, 1977, J PEDIATR-US, V90, P419, DOI 10.1016/S0022-3476(77)80705-1
NR 78
TC 1
Z9 2
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2019
VL 37
IS 1
BP 202
EP 209
DI 10.1016/j.vaccine.2018.11.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HF6UP
UT WOS:000454374100028
PM 30503658
OA Green Published
DA 2020-05-12
ER

PT J
CA World Hlth Org
TI Typhoid vaccines: WHO position paper, March 2018-Recommendations
SO VACCINE
LA English
DT Article
DE Vaccines; Immunization; Vaccine policy; Typhoid; Salmonella typhi
AB This article presented the World Health Organization's (WHO) recommendations on the use of Typhoid vaccines excerpted from the Typhoid vaccines: WHO position paper - March 2018 published in the Weekly Epidemiological Record (World Health Organization, 2018) [1]. This position paper replaces the 2008 WHO position paper on typhoid vaccines (WHO, 2008) [2]. It re-emphasizes the importance of vaccination to control typhoid fever and presents the WHO recommendations on the use of a new generation of typhoid conjugate vaccines.
   Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation tables. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of cholera vaccines were discussed by the Strategic Advisory Group of Experts (SAGE) in October 2017; evidence presented at these meetings can be accessed at: http://www.who.int/immunization/sage/meetings/2017/October/presentations_background_docs/en/. (C) 2018 Published by Elsevier Ltd.
C1 [World Hlth Org] WHO, Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
RP WHO, Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
FU World Health OrganizationWorld Health Organization [001]
CR [Anonymous], 2008, Wkly Epidemiol Rec, V83, P49
   [Anonymous], 2015, WEEKLY EPIDEMIOLOGIC, P505
   WHO, SURV STAND TYPH OTH
   WHO, EV REC TABL TYPH VAC
   World Health Organization, 2018, VACCINE, V13, P153
   World Health Organization, 2017, VACC AC HUM EM FRAM
NR 6
TC 26
Z9 26
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 214
EP 216
DI 10.1016/j.vaccine.2018.04.022
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300002
PM 29661581
HC Y
HP N
DA 2020-05-12
ER

PT J
CA World Hlth Org
TI Announcing the publication of the WHO immunological basis for
   immunization series module on pertussis vaccines
SO VACCINE
LA English
DT Article
DE Pertussis vaccines; Vaccine immunology; Global health; Bordetella
   pertussis
AB In 2017, the World Health Organization (WHO) published an updated document aimed at facilitating the understanding of the immunological basis of pertussis vaccines and their use. The document "The Immunological Basis for Immunization Series: Pertussis Vaccines" is freely available on the WHO website. The main purpose of the module is to provide national immunization managers and vaccination professionals with an overview of the scientific basis of vaccination against pertussis and the immunological basis for the WHO position on pertussis vaccines.
   The Immunological Basis for Immunization Series was initially developed in 1993. Since then the series was regularly updated and extended. They reflect the biological differences in immune responses to the individual pathogens and the differing strategies employed to create the best possible level of protection that can be provided by vaccination.
   We invite the immunization community to use these references, and we hope the updated pertussis vaccine module will be a valuable resource. (C) 2017 Published by Elsevier Ltd.
C1 [World Hlth Org] IVB Dept, Geneva, Switzerland.
RP IVB Dept, Geneva, Switzerland.
CR World Health Organization, 2015, WKLY EPIDEMIOL REC, P433
   World Health Organization, IMM BAS IMM SER
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 217
EP 218
DI 10.1016/j.vaccine.2017.10.110
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300003
PM 29129454
DA 2020-05-12
ER

PT J
CA World Hlth Org
TI Measles vaccines: WHO position paper, April 2017-Recommendations World
   Health Organization
SO VACCINE
LA English
DT Article
DE World Health Organization (WHO); Recommendations; Measles vaccines; WHO
   position paper; SAGE
AB This article presents the World Health Organization's (WHO) recommendations on the use of measles vaccines excerpted from the WHO position paper on Measles vaccines: WHO position paper - April 2017, published in the Weekly Epidemiological Record [1]. This position paper replaces the 2009 WHO position paper on measles vaccines [2]. The position paper summarizes the most recent developments in the field of measles and includes removal of introduction criteria for the routine second dose of measles-containing vaccine (MCV2), guidance on when to vaccinate infants from 6 months of age, and guidance on re-vaccination of HIV-infected children receiving highly active anti-retroviral therapy (HAART).
   Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of measles vaccines were discussed by SAGE in November 2013,October 2015 and October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2013/november/presentations_background_docs/en/, www.who.int/immunization/sage/meetings/2015/october/presentations_background_docs/en/ and www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/. (C) 2017 Published by Elsevier Ltd.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P97
   [Anonymous], 2009, WEEKLY EPIDEMIOLOGIC, P349
   [Anonymous], 2012, WEEKLY EPIDEMIOLOGIC, P89
   [Anonymous], 2017, WEEKLY EPIDEMIOLOGIC, P205
   Prada JM, 2017, VACCINE, V35, P1488, DOI 10.1016/j.vaccine.2017.02.008
NR 5
TC 0
Z9 0
U1 3
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 219
EP 222
DI 10.1016/j.vaccine.2017.07.066
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300004
DA 2020-05-12
ER

PT J
CA World Hlth Org
TI Hepatitis B vaccines: WHO position paper, July 2017-Recommendations
SO VACCINE
LA English
DT Article
DE Hepatitis B vaccines; Hepatitis B virus; HBV; Birth dose; Position
   paper; WHO; Immunization programmes; Health policy; OPV; BCG
AB This article presents the World Health Organization's (WHO) recommendations on the use of hepatitis B vaccines excerpted from the Hepatitis B vaccines: WHO position paper, July 2017, published in the Weekly Epidemiological Record (Hepatitis B vaccines, 2017) [1]. This position paper replaces the May 2009 WHO position paper on hepatitis B vaccines (Hepatitis B vaccines, 2009) [2].
   The position paper gives updated information on hepatitis B vaccines and their storage, transport and deployment. The recommendations concern the target groups for vaccination and the appropriate schedules. In particular, the recommendations stress the importance of vaccination of all infants at birth as the most effective intervention for the prevention of hepatitis B virus-associated disease worldwide.
   Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of hepatitis B vaccines were discussed by SAGE in October 2016; evidence presented at these meetings can be accessed at: http://www.who.int/immunization/sage/meetings/2016/October/presentations_background_docs/en/. (C) 2017 Published by Elsevier Ltd.
C1 [World Hlth Org] WHO, Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
RP WHO, Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
OI Ortiz, Justin/0000-0002-3138-5965
FU World Health OrganizationWorld Health Organization [001]
CR Hepatitis B vaccines: WHO position paper, 2009, WEEKLY EPIDEMIOLOGIC, P405
   Hepatitis B vaccines: WHO position paper, 2017, WEEKLY EPIDEMIOLOGIC, P369
   Meeting of the Strategic Advisory Group of Experts on immunization, 2016, WEEKLY EPIDEMIOLOGIC, P561
   WHO, EV REC TABL GRADE TA
NR 4
TC 26
Z9 26
U1 5
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 223
EP 225
DI 10.1016/j.vaccine.2017.07.046
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300005
PM 28743487
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Leidner, AJ
   Murthy, N
   Chesson, HW
   Biggerstaff, M
   Stoecker, C
   Harris, AM
   Acosta, A
   Dooling, K
   Bridges, CB
AF Leidner, Andrew J.
   Murthy, Neil
   Chesson, Harrell W.
   Biggerstaff, Matthew
   Stoecker, Charles
   Harris, Aaron M.
   Acosta, Anna
   Dooling, Kathleen
   Bridges, Carolyn B.
TI Cost-effectiveness of adult vaccinations: A systematic review
SO VACCINE
LA English
DT Review
DE Vaccines; Adults; Cost-effectiveness
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HEPATITIS-B VACCINATION; PREVENT
   HERPES-ZOSTER; PNEUMOCOCCAL POLYSACCHARIDE VACCINATION; RECOMMENDED
   IMMUNIZATION SCHEDULE; UNIVERSAL INFLUENZA VACCINATION; HEALTHY WORKING
   ADULTS; UNITED-STATES; ECONOMIC-EVALUATION; POSTHERPETIC NEURALGIA
AB Background: Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule.
   Methods: We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged >= 18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios.
   Results: The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of <=$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations.
   Conclusions: The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations. Published by Elsevier Ltd.
C1 [Leidner, Andrew J.; Bridges, Carolyn B.] Berry Technol Solut, Atlanta, GA 30333 USA.
   [Murthy, Neil; Biggerstaff, Matthew; Acosta, Anna; Dooling, Kathleen] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Murthy, Neil] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Chesson, Harrell W.; Harris, Aaron M.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Stoecker, Charles] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.
RP Leidner, AJ (reprint author), Berry Technol Solut, Contractor Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-19, Atlanta, GA 30333 USA.
EM aleidner@cdc.gov
OI Leidner, Andrew/0000-0001-8869-5561; Biggerstaff,
   Matthew/0000-0001-5108-8311
FU Intramural CDC HHS [CC999999]
CR Albright K, 2017, VACCINE, V35, P7292, DOI 10.1016/j.vaccine.2017.11.001
   Almario CV, 2016, AM J INFECT CONTROL, V44, P1004, DOI 10.1016/j.ajic.2016.03.064
   [Anonymous], 2017, CAN US FOR EXCH RAT
   Atkins KE, 2016, AM J EPIDEMIOL, V183, P1159, DOI 10.1093/aje/kwv347
   Avritscher EBC, 2007, CANCER-AM CANCER SOC, V109, P2357, DOI 10.1002/cncr.22670
   Bader MS, 2007, AM J MED SCI, V334, P481, DOI 10.1097/MAJ.0b013e318156b4bc
   BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616
   Beigi RH, 2009, CLIN INFECT DIS, V49, P1784, DOI 10.1086/649013
   BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009
   Bonville CA, 2017, HUM VACC IMMUNOTHER, V13, P2646, DOI 10.1080/21645515.2017.1371380
   Bridges CB, 2015, VACCINE, V33, pD114, DOI 10.1016/j.vaccine.2015.09.054
   Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655
   Brisson M, 2008, HUM VACCINES, V4, P238, DOI 10.4161/hv.4.3.5686
   Brisson M, 2007, VACCINE, V25, P5399, DOI 10.1016/j.vaccine.2007.04.086
   Bureau of Labor Statistics US Dept of Labor, 2017, ALL IT US CIT AV ALL
   Burls A, 2006, VACCINE, V24, P4212, DOI 10.1016/j.vaccine.2005.12.043
   Campbell DS, 1997, J OCCUP ENVIRON MED, V39, P408, DOI 10.1097/00043764-199705000-00006
   Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2
   Cho BH, 2013, VACCINE, V31, P6011, DOI 10.1016/j.vaccine.2013.10.024
   Coudeville L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006284
   Davis JW, 2001, MED CARE, V39, P1273, DOI 10.1097/00005650-200112000-00003
   De Graeve D, 2004, PHARMACOECONOMICS, V22, P719, DOI 10.2165/00019053-200422110-00003
   Dehmer SP, 2017, ANN FAM MED, V15, P23, DOI 10.1370/afm.2015
   Deshmukh AA, 2014, VACCINE, V32, P6941, DOI 10.1016/j.vaccine.2014.10.052
   Ding Y, 2012, OBSTET GYNECOL, V119, P306, DOI 10.1097/AOG.0b013e318242af27
   Dirmesropian S, 2016, PHARMACOECONOMICS, P1
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Elbasha EH, 2007, EMERG INFECT DIS, V13, P28, DOI 10.3201/eid1301.060438
   Elbasha EH, 2009, VALUE HEALTH, V12, P697, DOI 10.1111/j.1524-4733.2009.00512.x
   Gatwood J, 2012, DRUGS, V72, P35, DOI 10.2165/11597310-000000000-00000
   Goldman GS, 2013, VACCINE, V31, P1680, DOI 10.1016/j.vaccine.2012.05.050
   Greer AL, 2011, PEDIATRICS, V128, pE591, DOI 10.1542/peds.2010-0796
   Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165
   Haddix AC, 2003, PREVENTION EFFECTIVE
   Herman C, 1998, INFECT MED, V15
   Hoerger TJ, 2013, DIABETES CARE, V36, P63, DOI 10.2337/dc12-0759
   Holzer S, 1993, J RES PHARM EC, V5, P79
   Hornberger J, 2006, ANN INTERN MED, V145, P317, DOI 10.7326/0003-4819-145-5-200609050-00004
   Housey M, 2014, MMWR-MORBID MORTAL W, V63, P839
   Hu YQ, 2008, AM J PREV MED, V35, P25, DOI 10.1016/j.amepre.2008.03.028
   Hurley LP, 2016, PUBLIC HEALTH REP, V131, P320, DOI 10.1177/003335491613100216
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Kamiya H, 2016, VACCINE, V34, P1832, DOI 10.1016/j.vaccine.2016.02.027
   Kawai K, 2014, VACCINE, V32, P1645, DOI 10.1016/j.vaccine.2014.01.058
   Kim DK, 2017, ANN INTERN MED, V166, P209, DOI 10.7326/M16-2936
   Kim JJ, 2008, NEW ENGL J MED, V359, P821, DOI 10.1056/NEJMsa0707052
   Kim JJ, 2010, LANCET INFECT DIS, V10, P845, DOI 10.1016/S1473-3099(10)70219-X
   Kim JJ, 2009, ANN INTERN MED, V151, P538, DOI 10.7326/0003-4819-151-8-200910200-00007
   Kim SY, 2008, PHARMACOECONOMICS, V26, P191, DOI 10.2165/00019053-200826030-00004
   Kim SY, 2006, AM J PREV MED, V30, P498, DOI 10.1016/j.amepre.2006.01.017
   Koepke R, 2015, MMWR-MORBID MORTAL W, V64, P746
   La EM, 2018, HUM VACC IMMUNOTHER, V14, P430, DOI 10.1080/21645515.2017.1403697
   Lee BY, 2011, VACCINE, V29, P2149, DOI 10.1016/j.vaccine.2010.12.078
   Lee GM, 2005, PEDIATRICS, V115, P1675, DOI 10.1542/peds.2004-2509
   Lee GM, 2007, AM J PREV MED, V32, P186, DOI 10.1016/j.amepre.2006.10.016
   Lee PY, 2002, ANN INTERN MED, V137, P225, DOI 10.7326/0003-4819-137-4-200208200-00005
   Leidner A. J., ADV COMM IMM PRACT J
   Lindley MC, 2018, VACCINE, V36, P1093, DOI 10.1016/j.vaccine.2018.01.015
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Lu PJ, 2017, VACCINE, V35, P3104, DOI 10.1016/j.vaccine.2017.04.028
   Lu PJ, 2015, VACCINE, V33, pD83, DOI 10.1016/j.vaccine.2015.09.031
   Maciosek MV, 2006, AM J PREV MED, V31, P72, DOI 10.1016/j.amepre.2006.03.008
   Marra CA, 2000, CAN J PUBLIC HEALTH, V91, P334, DOI 10.1007/BF03404802
   Marra F, 2009, PHARMACOECONOMICS, V27, P127, DOI 10.2165/00019053-200927020-00004
   McGarry LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0072723
   McGarry LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067260
   McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3
   Mieczkowski TA, 2002, VACCINE, V20, P1383, DOI 10.1016/S0264-410X(01)00463-7
   Miriti MK, 2008, PUBLIC HEALTH REP, V123, P504, DOI 10.1177/003335490812300412
   Mittmann N, 2015, HEALTH REP, V26, P16
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Mukamel DB, 2001, AM J PREV MED, V21, P29, DOI 10.1016/S0749-3797(01)00312-9
   MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103
   MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008
   Myers ER, 2011, AM J OBSTET GYNECOL, V204, pS128, DOI 10.1016/j.ajog.2011.04.009
   Najafzadeh M, 2009, PHARMACOECONOMICS, V27, P991, DOI 10.2165/11314010-000000000-00000
   Neumann PJ, 2016, COST EFFECTIVENESS H
   Nichol KL, 2003, VACCINE, V21, P1769, DOI 10.1016/S0264-410X(03)00070-7
   Nichol KL, 2002, VACCINE, V20, pS21, DOI 10.1016/S0264-410X(02)00124-X
   Nichol KL, 1999, VACCINE, V17, pS67, DOI 10.1016/S0264-410X(99)00110-3
   Nichol KL, 2001, ARCH INTERN MED, V161, P749, DOI 10.1001/archinte.161.5.749
   NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206
   O'Leary ST, 2018, AM J PREV MED, V54, P205, DOI 10.1016/j.amepre.2017.10.016
   ODDONE EZ, 1993, HEALTH SERV RES, V28, P97
   [Office of Technology Assessment U. S. Congress], 1981, COST EFF INFL VACC, P1
   Ogilvie I, 2009, VACCINE, V27, P4891, DOI 10.1016/j.vaccine.2009.05.061
   Patterson BW, 2012, AM J EMERG MED, V30, P1072, DOI 10.1016/j.ajem.2011.07.007
   Pellissier JM, 2007, VACCINE, V25, P8326, DOI 10.1016/j.vaccine.2007.09.066
   Pepper PV, 2002, MED DECIS MAKING, V22, pS45, DOI 10.1177/027298902237705
   Pepper PV, 2000, CLIN INFECT DIS, V30, P157, DOI 10.1086/313601
   Le P, 2017, J GEN INTERN MED, V32, P159, DOI 10.1007/s11606-016-3844-6
   Le P, 2015, ANN INTERN MED, V163, P489, DOI 10.7326/M15-0093
   Pink J, 2016, PHARMACOECONOMICS, P1
   Pisu M, 2002, VACCINE, V21, P312, DOI 10.1016/S0264-410X(02)00457-7
   Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006
   Prosser LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022308
   Roberts S, 2006, OBSTET GYNECOL, V107, P1323, DOI 10.1097/01.AOG.0000210225.45986.99
   Robinson CL, 2018, MMWR-MORBID MORTAL W, V67, P156, DOI 10.15585/mmwr.mm6705e2
   Rossi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078548
   Rothberg MB, 2005, AM J MED, V118, P68, DOI 10.1016/j.amjmed.2004.03.044
   Rothberg MB, 2007, CLIN INFECT DIS, V44, P1280, DOI 10.1086/514342
   Rozenbaum MH, 2008, EXPERT REV VACCINES, V7, P753, DOI 10.1586/14760584.7.6.753
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Seto K, 2012, DRUGS, V72, P715, DOI 10.2165/11599470-000000000-00000
   Sharaf RN, 2013, AM J GASTROENTEROL, V108, P120, DOI 10.1038/ajg.2012.380
   Sisk JE, 2003, ANN INTERN MED, V138, P960, DOI 10.7326/0003-4819-138-12-200306170-00007
   SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79
   Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333
   Skedgel C, 2011, CAN J PUBLIC HEALTH, V102, P445, DOI 10.1007/BF03404197
   Smith KJ, 2008, VACCINE, V26, P1420, DOI 10.1016/j.vaccine.2008.01.007
   Smith KJ, 2013, VACCINE, V31, P3950, DOI 10.1016/j.vaccine.2013.06.037
   Smith KJ, 2013, AM J PREV MED, V44, P373, DOI 10.1016/j.amepre.2012.11.035
   Smith KJ, 2012, JAMA-J AM MED ASSOC, V307, P804, DOI 10.1001/jama.2012.169
   Smith KJ, 2010, VACCINE, V28, P7620, DOI 10.1016/j.vaccine.2010.09.053
   Smith KJ, 2010, AM J MANAG CARE, V16, P200
   Smith KJ, 2009, VACCINE, V27, P3159, DOI 10.1016/j.vaccine.2009.03.059
   Stack SJ, 1999, ANN EMERG MED, V33, P299, DOI 10.1016/S0196-0644(99)70366-5
   Stewart AM, 2014, VACCINE, V32, P618, DOI 10.1016/j.vaccine.2013.11.050
   Szucs TD, 2013, PHARMACOECONOMICS, V31, P125, DOI 10.1007/s40273-012-0020-7
   Tahamtan I, 2016, SCIENTOMETRICS, V107, P1195, DOI 10.1007/s11192-016-1889-2
   Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222
   Thiry N, 2003, PHARMACOECONOMICS, V21, P13, DOI 10.2165/00019053-200321010-00002
   Ting EEK, 2017, VACCINE, V35, P1828, DOI 10.1016/j.vaccine.2017.02.044
   Tully SP, 2012, VACCINE, V30, P425, DOI 10.1016/j.vaccine.2011.10.067
   U. S. Government Accountability Office, GAO REP, P12
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Xu J, 2016, VACCINE, V34, P3149, DOI 10.1016/j.vaccine.2016.04.057
   Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067
   Zimmerman B, 2017, BECKERS HOSP REV
NR 132
TC 12
Z9 12
U1 4
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 226
EP 234
DI 10.1016/j.vaccine.2018.11.056
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300006
PM 30527660
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Hakim, H
   Provencher, T
   Chambers, CT
   Driedger, SM
   Dube, E
   Gavaruzzi, T
   Giguere, AMC
   Ivers, NM
   MacDonald, S
   Paquette, JS
   Wilson, K
   Reinharz, D
   Witteman, HO
AF Hakim, Hina
   Provencher, Thierry
   Chambers, Christine T.
   Driedger, S. Michelle
   Dube, Eve
   Gavaruzzi, Teresa
   Giguere, Anik M. C.
   Ivers, Noah M.
   MacDonald, Shannon
   Paquette, Jean-Sebastien
   Wilson, Kumanan
   Reinharz, Daniel
   Witteman, Holly O.
TI Interventions to help people understand community immunity: A systematic
   review
SO VACCINE
LA English
DT Review
DE Community immunity; Herd immunity; Vaccination; Vaccine hesitancy
ID HERD-IMMUNITY; VACCINE HESITANCY; COMMUNICATION; INFORMATION;
   STRATEGIES; DECISION; CHILDREN; QUALITY; REFUSAL; IMPACT
AB Background: Herd immunity, or community immunity, occurs when susceptible people in a population are indirectly protected from infection thanks to the pervasiveness of immunity within the population. In this study, we aimed to systematically review interventions designed to communicate what community immunity is and how community immunity works to members of the general public.
   Methods: We searched PubMed, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials and Web of Science for peer-reviewed articles describing interventions with or without evaluations. We then conducted web searches with Google to identify interventions lacking associated publications. We extracted data about the target population of the interventions, the interventions themselves (e.g., did they describe what community immunity is, and how it works), any effects of evaluated interventions, and synthesized data narratively.
   Results: We identified 32 interventions: 11 interventions described in peer-reviewed articles and 21 interventions without associated articles. Of the 32 interventions, 5 described what community immunity is, 6 described the mechanisms of how community immunity occurs and 21 described both. Fourteen of the 32 addressed infectious diseases in general while the other 13 addressed one or more specific diseases. Twelve of the 32 interventions used videos, 7 used interactive simulations and 6 used questionnaires. Ten of the 11 peer-reviewed articles described studies evaluating at least one effect of the interventions. Within these 10, 4/4 reported increased knowledge, 3/5 reported shifts of attitudes in favour of vaccination, 2/5 reported increased intentions to vaccinate. Of 3 studies evaluating interventions specifically about community immunity, 2 reported increased intentions to vaccinate.
   Conclusions: A compelling benefit of vaccination exists at the population level in the form of community immunity. Identifying ways to optimally communicate about this benefit may be important, because some evidence suggests that effective communication about community immunity can increase vaccination intentions. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hakim, Hina; Giguere, Anik M. C.; Paquette, Jean-Sebastien; Witteman, Holly O.] Laval Univ, Dept Family & Emergency Med, 1050 Ave Med,Pavillon Ferdinand Vandry, Quebec City, PQ G1V 0A6, Canada.
   [Provencher, Thierry] Laval Univ, Sch Psychol, Quebec City, PQ, Canada.
   [Chambers, Christine T.] Dalhousie Univ, Dept Pediat & Psychol & Neurosci, Halifax, NS, Canada.
   [Driedger, S. Michelle] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada.
   [Dube, Eve] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada.
   [Gavaruzzi, Teresa] Univ Padua, Dept Dev Psychol & Socializat, Padua, Italy.
   [Ivers, Noah M.] Univ Toronto, Womens Coll Hosp, Dept Family & Community Med, Toronto, ON, Canada.
   [MacDonald, Shannon] Univ Alberta, Fac Nursing, Edmonton, AB, Canada.
   [Wilson, Kumanan] Univ Ottawa, Ottawa Hosp Res Inst, Dept Med, Ottawa, ON, Canada.
   [Reinharz, Daniel] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada.
RP Witteman, HO (reprint author), Laval Univ, Dept Family & Emergency Med, 1050 Ave Med,Pavillon Ferdinand Vandry, Quebec City, PQ G1V 0A6, Canada.
EM hina.hakim.1@ulaval.ca; thierry.provencher@fmed.ulaval.ca;
   christine.chambers@dal.ca; Michelle.Driedger@umanitoba.ca;
   eve.dube@inspq.qc.ca; teresa.gavaruzzi@unipd.it;
   anik.giguere@fmed.ulaval.ca; noah.ivers@utoronto.ca;
   smacdon@ualberta.ca; jean-sebastien.Paquette@fmed.ulaval.ca;
   kwilson@ohri.ca; daniel.reinharz@fmed.ulaval.ca;
   holly.witteman@fmed.ulaval.ca
RI Gavaruzzi, T/AAB-1489-2019; Paquette, Jean-Sebastien/Y-9736-2018
OI Gavaruzzi, T/0000-0001-6389-2550; MacDonald,
   Shannon/0000-0003-4675-4433; Provencher, Thierry/0000-0003-2182-7835;
   Paquette, Jean-Sebastien/0000-0002-9524-6761
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [FDN-148426, 2016-2021]; Fonds de Recherche du Quebec
   SanteFonds de la Recherche en Sante du Quebec
FX This study was funded by the Canadian Institutes of Health Research
   (grant number FDN-148426, 2016-2021, PI: Witteman). The CIHR had no role
   in determining the study design, the plans for data collection or
   analysis, the decision to publish, nor the preparation of this
   manuscript. HW receives salary support from a Research Scholar Junior 2
   Career Development Award by the Fonds de Recherche du Quebec Sante.
CR Anderson VL, 2015, JNP-J NURSE PRACT, V11, P1, DOI 10.1016/j.nurpra.2014.10.016
   [Anonymous], 2014, META BOX 4 4 0 RELEA
   [Anonymous], HERD IMM EXPL GIF
   [Anonymous], 2015, ROMINA LIBSTER SPEAK
   [Anonymous], 2013, VACC HERD IMM GUMM B
   [Anonymous], WHAT IS HERD IMM
   [Anonymous], HERD IMM COMM IMM
   [Anonymous], GAM EP PREV
   Awadh Ammar Ihsan, 2014, BMC Pediatr, V14, P254, DOI 10.1186/1471-2431-14-254
   Betsch C, 2011, EURO SURVEILL, V16
   Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056
   Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590
   Brockmann D, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0065
   Cairns G, 2012, SYSTEMATIC LIT REV E
   Carolan K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190984
   Choices N, 2018, NHS VIDEOS VACCINA 2
   Crocker-Buque T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4473-7
   Development Core R Team R, 2017, LANG ENV STAT COMP
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Editorial team, 2015, VACCINESTODAY
   Fazio-Attitude strength: Antecedents and consequences RH, 1995, ATTITUDE STRENGTH AN
   Fefferman NH, 2015, LANCET INFECT DIS, V15, P922, DOI 10.1016/S1473-3099(15)00053-5
   Garcia-Retamero R, 2011, J EXP PSYCHOL-APPL, V17, P270, DOI 10.1037/a0023677
   Gargano LM, 2014, HLTH PROMOT PRACT
   Glik D, 2004, AM J HEALTH BEHAV, V28, P487
   Hargrave DR, 2006, NEURO-ONCOLOGY, V8, P175, DOI 10.1215/15228517-2005-008
   Harris R, 2015, GUARDIAN
   Hawley ST, 2008, PATIENT EDUC COUNS, V73, P448, DOI 10.1016/j.pec.2008.07.023
   Hendrix KS, 2014, PEDIATRICS, V134, pE675, DOI 10.1542/peds.2013-4077
   Hobson-West P, 2003, HEALTH RISK SOC, V5, P273, DOI 10.1080/13698570310001606978
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jordan R, 2006, VACCINE, V24, P1047, DOI 10.1016/j.vaccine.2005.09.017
   Kahneman D, 1998, J RISK UNCERTAINTY, V16, P49, DOI 10.1023/A:1007710408413
   KAHNEMAN D, 1994, J RISK UNCERTAINTY, V9, P5, DOI 10.1007/BF01073401
   Kaufman J, 2013, COCHRANE LIB
   Kennedy A, 2008, J HEALTH COMMUN, V13, P793, DOI 10.1080/10810730802487463
   Kylstra C., 2015, 5 GIFS SHOW WHY HERD
   Lefebvre CDS, 2015, HUM VACC IMMUNOTHER, V11, P2142, DOI 10.1080/21645515.2015.1052196
   Lerner JS, 2015, ANNU REV PSYCHOL, V66, P799, DOI 10.1146/annurev-psych-010213-115043
   Lorini C, 2018, HUM VACC IMMUNOTHER, V14, P478, DOI 10.1080/21645515.2017.1392423
   Lumley Thomas, 2014, HERD IMMUNITY SIMULA
   Melton M., 2013, 141 APHA ANN M NOV 2
   Metcalf CJE, 2015, TRENDS IMMUNOL, V36, P753, DOI 10.1016/j.it.2015.10.004
   Never stop dreaming, 2016, NEVER STOP DREAMING
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Okan Y, 2015, J EXP PSYCHOL-APPL, V21, P178, DOI 10.1037/xap0000045
   Petrescu P, MOZ BLOG        1001
   Pluye P, 2009, INT J NURS STUD, V46, P529, DOI 10.1016/j.ijnurstu.2009.01.009
   Quadri-Sheriff M, 2012, PEDIATRICS, V130, P522, DOI 10.1542/peds.2012-0140
   Rashid H, 2012, CURR OPIN INFECT DIS, V25, P243, DOI 10.1097/QCO.0b013e328352f727
   Resnick Paul, 2013, P 2013 C COMP SUPP C, P95, DOI [10.1145/2441955.2441981, DOI 10.1145/2441955.2441981]
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Saeterdal I, 2014, COCHRANE LIB
   Schoeppe J, 2017, HEALTH PROMOT PRACT, V18, P654, DOI 10.1177/1524839917697303
   Slovic P, 2007, EUR J OPER RES, V177, P1333, DOI 10.1016/j.ejor.2005.04.006
   van der Marel S, 2009, INFLAMM BOWEL DIS, V15, P1891, DOI 10.1002/ibd.20976
   Vietri JT, 2012, MED DECIS MAKING, V32, P447, DOI 10.1177/0272989X11427762
   wsusignpost, 2014, SIGNPOST
NR 61
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 235
EP 247
DI 10.1016/j.vaccine.2018.11.016
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300007
PM 30528593
DA 2020-05-12
ER

PT J
AU Hegazy-Hassan, W
   Zepeda-Escobar, JA
   Ochoa-Garcia, L
   Contreras-Ortiz, JME
   Tenorio-Borroto, E
   Barbabosa-Pliego, A
   Aparicio-Burgos, JE
   Oros-Pantoja, R
   Rivas-Santiago, B
   Diaz-Albiter, H
   Garg, NJ
   Vazquez-Chagoyan, JC
AF Hegazy-Hassan, Wael
   Antonio Zepeda-Escobar, Jose
   Ochoa-Garcia, Laucel
   Eloy Contreras-Ortiz, J. M.
   Tenorio-Borroto, Esvieta
   Barbabosa-Pliego, Alberto
   Esteban Aparicio-Burgos, Jose
   Oros-Pantoja, Rigoberto
   Rivas-Santiago, Bruno
   Diaz-Albiter, Hector
   Garg, Nisha Jain
   Carlos Vazquez-Chagoyan, Juan
TI TcVac1 vaccine delivery by intradermal electroporation enhances vaccine
   induced immune protection against Trypanosoma cruzi infection in mice
SO VACCINE
LA English
DT Article
DE Trypanosoma cruzi; TcVac1; Intradermal electroporation; Intramuscular;
   Chagas disease; Mice model
ID DNA VACCINE; PLASMID DNA; IMMUNIZATION; RESPONSES; CANDIDATES; ANTIBODY;
   POTENCY; DISEASE
AB The efforts for the development and testing of vaccines against Trypanosoma cruzi infection have increased during the past years. We have designed a TcVac series of vaccines composed of T. cruzi derived, GPI-anchored membrane antigens. The TcVac vaccines have been shown to elicit humoral and cellular mediated immune responses and provide significant (but not complete) control of experimental infection in mice and dogs. Herein, we aimed to test two immunization protocols for the delivery of DNA-prime/DNA-boost vaccine (TcVac1) composed of TcG2 and TcG4 antigens in a BALB/c mouse model. Mice were immunized with TcVac1 through intradermal/electroporation (IDE) or intramuscular (IM) routes, challenged with T. cruzi, and evaluated during acute phase of infection. The humoral immune response was evaluated through the assessment of anti-TcG2 and anti-TcG4 IgG subtypes by using an ELISA. Cellular immune response was assessed through a lymphocyte proliferation assay. Finally, clinical and morphopathological aspects were evaluated for all experimental animals. Our results demonstrated that when comparing TcVac1 IDE delivery vs IM delivery, the former induced significantly higher level of antigen-specific antibody response (lgG2a + IgG2b > IgG1) and lymphocyte proliferation, which expanded in response to challenge infection. Histological evaluation after challenge infection showed infiltration of inflammatory cells (macrophages and lymphocytes) in the heart and skeletal tissue of all infected mice. However, the largest increase in inflammatory infiltrate was observed in TcVac1_IDE/Tc mice when compared with TcVac1_IM/Tc or non-vaccinated/infected mice. The extent of tissue inflammatory infiltrate was directly associated with the control of tissue amastigote nests in vaccinated/infected (vs. non-vaccinated/infected) mice. Our results suggest that IDE delivery improves the protective efficacy of TcVac1 vaccine against T. cruzi infection in mice when compared with IM delivery of the vaccine. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Hegazy-Hassan, Wael; Antonio Zepeda-Escobar, Jose; Ochoa-Garcia, Laucel; Eloy Contreras-Ortiz, J. M.; Tenorio-Borroto, Esvieta; Barbabosa-Pliego, Alberto; Carlos Vazquez-Chagoyan, Juan] Univ Autonoma Estado Mexico, Fac Med Vet & Zootecnia, Ctr Invest & Estudios Avanzados Salud Anim, Km 15-5 Carretera Panamer Toluca Atlacomulco, Toluca 50200, Estado De Mexic, Mexico.
   [Ochoa-Garcia, Laucel] Inst Salud Estado Mexico, Lab Estatal Salud Publ, Independencia Oriente 1310 Colonia, Toluca 50070, Estado De Mexic, Mexico.
   [Esteban Aparicio-Burgos, Jose] Univ Autonoma Estado Hidalgo, Escuela Super Apan, Carretera Apan Calpulalpan,Km 8, Apan 43920, Hidalgo, Mexico.
   [Oros-Pantoja, Rigoberto] Univ Autonoma Estado Mexico, Fac Med, Dept Neurociencias, Tollocan Esq Jesus Carranza S-N, Toluca 50180, Estado De Mexic, Mexico.
   [Rivas-Santiago, Bruno] Unidad Invest Med Zacatecas IMSS, Interior Alameda 45, Zacatecas 98000, Mexico.
   [Diaz-Albiter, Hector] Univ Glasgow, Wellcome Trust Ctr Mol Parasitol, Univ Pl, Glasgow G12 8TA, Lanark, Scotland.
   [Diaz-Albiter, Hector] Colegio Frontera Sur, Carretera Villahermosa Reforma Km 15-5,Secc 2, Villahermosa 86280, Tabasco, Mexico.
   [Garg, Nisha Jain] Univ Texas Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Garg, Nisha Jain] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA.
RP Vazquez-Chagoyan, JC (reprint author), Univ Autonoma Estado Mexico, Fac Med Vet & Zootecnia, Ctr Invest & Estudios Avanzados Salud Anim, Km 15-5 Carretera Panamer Toluca Atlacomulco, Toluca 50200, Estado De Mexic, Mexico.
EM jcvch@yahoo.com
RI Chagoyan, Juan Carlos Vazquez/B-1603-2016; Burgos, Jose Esteban
   Aparicio/P-3464-2019; Rivas-Santiago, Bruno/AAJ-1885-2020; Oros-Pantoja,
   Rigoberto/B-3370-2016
OI Burgos, Jose Esteban Aparicio/0000-0002-7611-7825; Rivas-Santiago,
   Bruno/0000-0002-1521-1519; Oros-Pantoja, Rigoberto/0000-0001-5441-0863;
   Diaz-Albiter, Hector/0000-0003-2937-0569
FU Universidad Autonoma de Estado de Mexico [3326/2012C]; Consejo Nacional
   de Ciencia y Tecnologia (CONACYT)Consejo Nacional de Ciencia y
   Tecnologia (CONACyT) [156701]; Consejo Nacional de Ciencia y
   TecnologiaConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [518232/291117]
FX The authors thank the Universidad Autonoma de Estado de Mexico (Grant
   No. 3326/2012C) and the Consejo Nacional de Ciencia y Tecnologia
   (CONACYT No. 156701) for the financial support awarded to this project.
   M.Sc. Wael Hegazy Hassan Moustafa would like to thank Consejo Nacional
   de Ciencia y Tecnologia (Scholarship No. 518232/291117) for the
   scholarship awarded for postgraduate studies at the Universidad Autonoma
   del Estado de Mexico.
CR Aparicio-Burgos JE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003625
   Aparicio-Burgos JE, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001050
   Barbabosa-Pliego A, 2009, AM J TROP MED HYG, V81, P390, DOI 10.4269/ajtmh.2009.81.390
   Best SR, 2009, VACCINE, V27, P5450, DOI 10.1016/j.vaccine.2009.07.005
   Bhatia V, 2004, INFECT IMMUN, V72, P6245, DOI 10.1128/IAI.72.11.6245-6254.2004
   Bhatia V, 2008, CLIN VACCINE IMMUNOL, V15, P1158, DOI 10.1128/CVI.00144-08
   Bhatia V, 2005, EXPERT REV VACCINES, V4, P867, DOI 10.1586/14760584.4.6.867
   Bolhassani A, 2011, NON TRADITIONAL REF, DOI [10.5772/18021, DOI 10.5772/18021]
   Brave A, 2011, IMMUNOL CELL BIOL, V89, P492, DOI 10.1038/icb.2010.109
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   BRODSKYN CI, 1989, IMMUNOL CELL BIOL, V67, P343, DOI 10.1038/icb.1989.50
   Cazorla SI, 2008, INFECT IMMUN, V76, P324, DOI 10.1128/IAI.01163-07
   Cazorla SI, 2009, EXPERT REV VACCINES, V8, P921, DOI [10.1586/erv.09.45, 10.1586/ERV.09.45]
   Chagas C., 1909, Memorias do Instituto Oswaldo Cruz, V1
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Daemi A, 2012, IMMUNOL LETT, V148, P117, DOI 10.1016/j.imlet.2012.10.003
   Faurie C, 2005, ENG LIFE SCI, V5, P179, DOI 10.1002/elsc.200420068
   Garg N, 2002, INFECT IMMUN, V70, P5547, DOI 10.1128/IAI.70.10.5547-5555.2002
   Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099
   Gupta S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004828
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059434
   Gupta S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000797
   Hirao LA, 2008, VACCINE, V26, P440, DOI 10.1016/j.vaccine.2007.10.041
   Hotez PJ, 2006, VACCINE, V24, P5787, DOI 10.1016/j.vaccine.2006.05.008
   Kumar S, 1998, PARASITE IMMUNOL, V20, P207, DOI 10.1046/j.1365-3024.1998.00154.x
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lin F, 2012, HUM GENE THER METHOD, V23, P157, DOI 10.1089/hgtb.2011.209
   Liu MA, 2005, ADV GENET, V55, P25, DOI 10.1016/S0065-2660(05)55002-8
   Manning-Cela R, 2001, INFECT IMMUN, V69, P3916, DOI 10.1128/IAI.69.6.3916-3923.2001
   Marinho CRF, 2004, INFECT IMMUN, V72, P2350, DOI 10.1128/IAI.72.4.2350-2357.2004
   Miyahira Y, 2005, INFECT IMMUN, V73, P7356, DOI 10.1128/IAI.73.11.7356-7365.2005
   Monie A, 2009, EXPERT REV VACCINES, V8, P1221, DOI 10.1586/ERV.09.76
   Mumper RJ, 2001, MOL BIOTECHNOL, V19, P79, DOI 10.1385/MB:19:1:079
   Ochoa L., 1999, NON TRADITIONAL REF, P1
   Parasuraman S, 2010, J PHARMACOL PHARMACO, V1, P87, DOI 10.4103/0976-500X.72350
   Pereira-Chioccola VL, 1999, PARASITE IMMUNOL, V21, P103, DOI 10.1046/j.1365-3024.1999.00201.x
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519
   Ribeirao M, 2000, PARASITE IMMUNOL, V22, P49, DOI 10.1046/j.1365-3024.2000.00260.x
   Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
   Slauson DO, 2002, NON TRADITIONAL REF
   Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008
   Special Programme for Research and Training in Tropical Diseases, 1993, SPEC PROGR RES TRAIN
   Steel RGD, 1997, PRINCIPLES PROCEDURE
   Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635
   Zhou Y, 2008, INTERVIROLOGY, V51, P241, DOI 10.1159/000156483
NR 45
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 248
EP 257
DI 10.1016/j.vaccine.2018.11.041
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300008
PM 30497833
OA Other Gold
DA 2020-05-12
ER

PT J
AU Vajo, Z
   Kalabay, L
   Vajo, P
   Balaton, G
   Rozsa, N
   Torzsa, P
AF Vajo, Zoltan
   Kalabay, Laszlo
   Vajo, Peter
   Balaton, Gergely
   Rozsa, Noemi
   Torzsa, Peter
TI Licensing the first reduced, mu g dose whole virion, aluminum adjuvanted
   seasonal influenza vaccine - A randomized-controlled multicenter trial
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Trial; Dose
ID ELDERLY-PATIENTS; SAFETY; VIRUS; ADULT
AB Introduction: Shortages of vaccine supplies repeatedly occur, limiting our abilities to prevent influenza. Therefore, increasing production volume remains a priority. The presently licensed seasonal influenza vaccines contain 15 fig of viral hemagglutinin per strain in adult, and up to 60 mu g in elderly patients. Decreasing the amount of viral parts while maintaining efficacy is one way of increasing production capacity.
   Methods: This was multicenter, stratified (18-60 years and >60 years of age), prospective, randomized, double-blind, active-controlled, parallel-arm, non-inferiority clinical trial, conducted in the European Union, involving 1206 patients. We used hemagglutination inhibition assay to assess the immunogenicity of a newly developed, whole virion, seasonal trivalent influenza vaccine, containing 6 mu g hemagglutinin per strain (FluArt, Hungary) and to assess whether it is non-inferior to the presently licensed vaccine containing 15 mu g hemagglutinin per strain. Safety and tolerability of both vaccines were assessed based on EMEA guidelines.
   Results: The reduced dose vaccine containing 6 mu g of hemagglutinin per strain was safe and non-inferior to the currently licensed 15 mu g vaccine, not only in adult, but also in elderly patients, according to the immunogenicity criteria by the FDA and EMEA (seroconversion, seroprotection and post/pre vaccination GMT ratios), and it fulfilled all applicable licensing requirements for both age groups.
   Conclusions: Based on the results, the reduced dose vaccine was licensed in the EU member state Hungary and safely administered in over 1.5 million cases so far. The amount of viral hemagglutinin needed can be reduced by using a whole virion vaccine with aluminum phosphate adjuvants.
   Registration: This study was registered by the European Clinical Trials Database, EudraCT, number: 2011-003314-16. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Vajo, Zoltan; Kalabay, Laszlo; Balaton, Gergely; Rozsa, Noemi; Torzsa, Peter] Semmelweis Univ, Dept Family Med, Budapest, Hungary.
   [Vajo, Peter] Univ Debrecen, Debrecen, Hungary.
RP Vajo, Z (reprint author), Semmelweis Univ, Dept Family Med, Budapest, Hungary.
EM zoltanvajo@gmail.com
RI Torzsa, Peter/K-5150-2017
OI Vajo, Zoltan/0000-0003-1049-1694
CR [Anonymous], 2011, WHO GLOBAL INFLUENZA, P59
   Ansaldi F, 2012, EXPERT REV VACCINES, V11, P17, DOI [10.1586/ERV.11.154, 10.1586/erv.11.154]
   Centers for Disease Control and Prevention, INFL VACC US
   Chow SC, 2001, J PHARMACOKINET PHAR, V28, P155, DOI 10.1023/A:1011503032353
   Committee for Medicinal Products for Human use. BWP ad  hoc influenza Working Group, 2011, EU REC SEAS INFL VAC
   Couch RB, 2007, VACCINE, V25, P7656, DOI 10.1016/j.vaccine.2007.08.042
   European Committee for Proprietary Medicinal Products, 1997, CPMPBWP21496
   European Directoriate for the Quality of Medicines and Health Care, 2007, EUR PHARM
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Kempe A, 2007, AM J PREV MED, V33, P486, DOI 10.1016/j.amepre.2007.07.038
   Klimov A, 2003, SEROLOGIC DIAGNOSIS, P71
   Kurupati R, 2016, ONCOTARGET, V7, P62898, DOI 10.18632/oncotarget.11704
   Mitkus RJ, 2011, VACCINE, V29, P9538, DOI 10.1016/j.vaccine.2011.09.124
   Rolfes MA, 2016, ESTIMATED INFLUENZA
   Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023
   Trogstad L, 2017, VACCINE, V35, P1879, DOI 10.1016/j.vaccine.2017.02.053
   US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE
   Vajo P, 2017, ORVOSI HETILAP, V158, P1953, DOI 10.1556/650.2017.30877
   Vajo Z, 2008, INFLUENZA OTHER RESP, V2, P221, DOI 10.1111/j.1750-2659.2008.00055.x
   Vajo Z, 2017, BRIT J CLIN PHARMACO, V83, P1912, DOI 10.1111/bcp.13289
   Vajo Z, 2012, CLIN VACCINE IMMUNOL, V19, P313, DOI 10.1128/CVI.05619-11
   Vajo Z, 2010, LANCET, V375, P49, DOI 10.1016/S0140-6736(09)62039-0
   Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
NR 25
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 258
EP 264
DI 10.1016/j.vaccine.2018.11.039
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300009
PM 30497837
DA 2020-05-12
ER

PT J
AU Faber, MT
   Duun-Henriksen, AK
   Dehlendorff, C
   Tatla, MK
   Munk, C
   Kjaer, SK
AF Faber, Mette Tuxen
   Duun-Henriksen, Anne Katrine
   Dehlendorff, Christian
   Tatla, Manrinder Kaur
   Munk, Christian
   Kjaer, Susanne K.
TI Adverse pregnancy outcomes and infant mortality after quadrivalent HPV
   vaccination during pregnancy
SO VACCINE
LA English
DT Article
DE HPV vaccination; Spontaneous abortion; Stillbirth; Infant mortality;
   Pregnancy outcomes
ID HUMAN-PAPILLOMAVIRUS; DANISH; RISK
AB Background: Few studies have studied the association between unintended human papillomavirus (HPV) vaccination and adverse pregnancy outcomes. This study set out to determine the association between HPV vaccination during pregnancy and subsequent risk of spontaneous abortion, stillbirth, and one-year infant mortality.
   Methods: Population-based study including all pregnancies in Denmark (October 2006-December 2014) among women born 1975-1992. From nationwide health registries using the personal identification numbers, we obtained information on HPV vaccination, pregnancy outcomes, and infant mortality. The exposure window went from four weeks before conception date until 22 weeks of gestation for the outcome spontaneous abortion, and until birth for stillbirth and infant mortality outcomes. In the analyses of spontaneous abortion, we used time to event models, for stillbirth logistic regression models, and for infant mortality Cox regression was applied.
   Results: We included 522,705 pregnancies for the outcome spontaneous abortion (7487 exposed to at least one dose during pregnancy); 351,878 births (5262 exposed to at least one dose during pregnancy) for the stillbirth; and 350,739 live births (5245 exposed to at least one dose during pregnancy) for infant mortality. No significantly increased rate of spontaneous abortion among women vaccinated during pregnancy compared with unvaccinated women was found. In addition, we found no association between HPV vaccination during pregnancy and stillbirth (adjusted odds ratio = 0.96 [95% CI: 0.57-1.611), or infant mortality (adjusted hazard ratio = 0.94 [95% CI: 0.53-1.67]). A secondary analysis showed no association between number of doses and timing of administration (i.e. vaccination before or during pregnancy) and an increased risk of spontaneous abortion.
   Conclusion: We found no increased risk of spontaneous abortion, stillbirth, or infant mortality following unintended HPV vaccination during pregnancy. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Faber, Mette Tuxen; Tatla, Manrinder Kaur; Munk, Christian; Kjaer, Susanne K.] Danish Canc Soc Res Ctr, Virus Lifestyle & Genes, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Duun-Henriksen, Anne Katrine; Dehlendorff, Christian] Danish Canc Soc Res Ctr, Stat & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Kjaer, Susanne K.] Univ Copenhagen, Rigshosp, Dept Gynecol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
RP Kjaer, SK (reprint author), Danish Canc Soc Res Ctr, Virus Lifestyle & Genes, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
EM susanne@cancer.dk
RI Dehlendorff, Christian/AAG-9421-2019
OI Dehlendorff, Christian/0000-0001-6161-4565
FU Mermaid project (Mermaid 11)
FX Financial support for the study was provided by the Mermaid project
   (Mermaid 11). The project had no role in the study or in the decision to
   submit the paper for publication.
CR Andersen JS, 2011, SCAND J PUBLIC HEALT, V39, P34, DOI 10.1177/1403494810394718
   Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P466, DOI 10.1002/pds.3554
   Baril L, 2015, VACCINE, V33, P6884, DOI 10.1016/j.vaccine.2015.07.024
   Bartlett JW, 2015, STAT METHODS MED RES, V24, P462, DOI 10.1177/0962280214521348
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Goss MA, 2015, VACCINE, V33, P3422, DOI 10.1016/j.vaccine.2015.04.014
   Harrell Jr FE, 2015, SPRINGER SER STAT, DOI DOI 10.1007/978-3-319-19425-7
   Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717
   Knudsen LB, 1998, DAN MED BULL, V45, P320
   Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Panagiotou OA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4358
   Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965
   PRENTICE RL, 1978, BIOMETRICS, V34, P57, DOI 10.2307/2529588
   Scheller NM, 2017, NEW ENGL J MED, V376, P1223, DOI 10.1056/NEJMoa1612296
   Therneau TM, 2000, STAT BIOL HEALTH
NR 17
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 265
EP 271
DI 10.1016/j.vaccine.2018.11.030
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300010
PM 30503078
DA 2020-05-12
ER

PT J
AU O'Neill, J
   Newall, F
   Antolovich, G
   Lima, S
   Danchin, M
AF O'Neill, Jenny
   Newall, Fiona
   Antolovich, Giuliana
   Lima, Sally
   Danchin, Margie
TI The uptake of adolescent vaccinations through the School Immunisation
   Program in specialist schools in Victoria, Australia
SO VACCINE
LA English
DT Article
DE Adolescent immunisation; Disability; Immunisation uptake
ID HPV VACCINATION; CHILDREN; COVERAGE; TIMELINESS; PREVALENCE
AB Background: As part of the National Immunisation Program (NIP) students in Australia receive adolescent immunisations through the School Immunisation Program at 12 to 13 years. For children with disabilities attending specialist schools, no vaccine uptake data is collected at this time point. We aimed to determine uptake of diphtheria-tetanus-pertussis (dTpa) and Human Papillomavirus (HPV) immunisations amongst young people with disabilities in specialist schools in Victoria.
   Methods: A prospective cohort study was conducted in Victoria, Australia. Data was collected on immunisation days in the 2017 school year from specialist schools in Victoria. The school immunisation coordinator entered data online for eligible students for receipt of dTpa and HPV on each school immunisation day. Demographic data, motor and intellectual function of students and reasons for non-receipt of dTpa and HPV vaccine were recorded. Data were analysed using descriptive statistics.
   Results: Of 73 eligible specialist schools in Victoria, 28 (38%) participated. dTpa was received by 63% (237/374) of participating students and HPV dose 1 (HPV1) was received by 66% (76/114) females and 67% (174/260) male students respectively. Three doses of HPV were received by only 41% (100/241) of students. The main reasons for missed immunisation were absence from school, lack of consent and inability to immunise due to the student's behaviour and/or anxiety.
   Conclusion: This is the first study in Australia to report that uptake of adolescent immunisations in specialist schools for young people with a disability is significantly lower than in mainstream settings. Comparative data during the same time period for students in mainstream schools demonstrated higher uptake, at 89% for dTpa and 75% for three doses of HPV. These data highlight the inequity of receipt of school-based immunisations for this group of adolescents, the barriers to which could be more thoroughly explored through qualitative inquiry from a socio-ecological perspective. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [O'Neill, Jenny; Antolovich, Giuliana] Royal Childrens Hosp, Dept Neurodev & Disabil, Melbourne, Vic, Australia.
   [O'Neill, Jenny; Newall, Fiona; Danchin, Margie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [O'Neill, Jenny; Antolovich, Giuliana] Murdoch Childrens Res Inst, Dev Disabil & Rehabil Res Grp, Melbourne, Vic, Australia.
   [Newall, Fiona] Royal Childrens Hosp, Dept Haematol, Melbourne, Vic, Australia.
   [Newall, Fiona; Lima, Sally] Royal Childrens Hosp, Nursing Res, Melbourne, Vic, Australia.
   [Newall, Fiona] Murdoch Childrens Res Inst, Clin Haematol Res Grp, Melbourne, Vic, Australia.
   [Newall, Fiona; Lima, Sally] Univ Melbourne, Dept Nursing, Melbourne, Vic, Australia.
   [Lima, Sally] Bendigo Hlth, Clin Learning & Dev Unit, Bendigo, Vic, Australia.
   [Danchin, Margie] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia.
   [Danchin, Margie] Murdoch Childrens Res Inst, Vaccine & Immunisat Res Grp, Melbourne, Vic, Australia.
   [Danchin, Margie] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia.
RP O'Neill, J (reprint author), Royal Childrens Hosp, Flemington Rd, Melbourne, Vic, Australia.
EM jenny.oneill@rch.org.au
FU University of Melbourne, MelbourneUniversity of Melbourne; Developmental
   Disability and Rehabilitation Research Group Galli Trust through The
   Murdoch Research Institute, Melbourne; DHHS Immunisation Section,
   Victoria
FX Jenny O'Neill was funded to undertake this research as part of a PhD
   with a Research and Training Stipend through The University of
   Melbourne, Melbourne, and the Developmental Disability and
   Rehabilitation Research Group Galli Trust through The Murdoch Research
   Institute, Melbourne and a grant from DHHS Immunisation Section,
   Victoria. Funding sources did not have input into design of research,
   analysis and interpretation of the data or writing of the report.
CR [Anonymous], 2014, CLIN THER, V36, P17
   Association for Children with a Disability, 2015, GOV SPEC SCH UN
   Bernard DM, 2011, MED J AUSTRALIA, V194, P297, DOI 10.5694/j.1326-5377.2011.tb02978.x
   Brotherton JML, 2018, BEST PRACT RES CL OB, V47, P42, DOI 10.1016/j.bpobgyn.2017.08.010
   Brotherton JML, 2017, MED J AUSTRALIA, V206, P262, DOI 10.5694/mja16.00958
   Buttery JP, 2008, MED J AUSTRALIA, V189, P261, DOI 10.5694/j.1326-5377.2008.tb02018.x
   Cameron JC, 2007, ARCH DIS CHILD, V92, P1062, DOI 10.1136/adc.2007.123232
   Cheng DR, 2018, VACCINE, V36, P3681, DOI 10.1016/j.vaccine.2018.05.018
   Clements CJ, 2007, AUST NZ J PUBL HEAL, V31, P387, DOI 10.1111/j.1753-6405.2007.00101.x
   Cody PJ, 2013, J PEDIATR ADOL GYNEC, V26, P219, DOI 10.1016/j.jpag.2013.03.003
   Department of Education and Training Victoria, 2018, STUD DIS SCH POL
   Department of Education and Training Victoria, 2016, GOV SCH STUD ATT RAT
   Department of Health and Human Services Immunisation Section Victoria, 2016, SCH IMM OV ENC UNPUB
   Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012
   Evans DW, 2005, CHILD PSYCHIAT HUM D, V36, P3, DOI 10.1007/s10578-004-3619-x
   Ferrer HB, 2015, PREV MED, V81, P122, DOI 10.1016/j.ypmed.2015.08.004
   Greenwood VJ, 2013, J PAEDIATR CHILD H, V49, pE137, DOI 10.1111/jpc.12097
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   HPV Register, 2017, COV DAT NAT HPV VACC
   Jones L, 2012, LANCET, V380, P899, DOI 10.1016/S0140-6736(12)60692-8
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Mackroth MS, 2010, VACCINE, V28, P1138, DOI 10.1016/j.vaccine.2009.11.008
   MacLeod R, 2014, ARCH DIS CHILD, V99, P1068, DOI 10.1136/archdischild-2013-305919
   McCabe MP, 1999, SEX DISABIL, V17, P157, DOI 10.1023/A:1021476418440
   National Centre for Immunisation Research and Surveillance, 2014, EV NAT HUM PAP VACC, P20
   O'Neill J, 2017, J INTELLECT DEV DIS, P1
   Pandolfi E, 2012, VACCINE, V30, P5172, DOI 10.1016/j.vaccine.2011.02.099
   Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070
   RADDISH M, 1993, AM J DIS CHILD, V147, P849, DOI 10.1001/archpedi.1993.02160320051018
   Remes O, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1047
   Sachedina N, 2010, LANCET, V376, P1846, DOI 10.1016/S0140-6736(10)61195-6
   Stata. Statacorp, 2017, STAT STAT SOFTW REL
   Taddio A, 2009, CLIN THER SB, V31
   Taddio A, 2012, VACCINE, V30, P4807, DOI 10.1016/j.vaccine.2012.05.011
   Thavarajah N, 2015, INT J CHILD ADOLES H, V8, P265
   Tillmann BU, 2005, EUR J PEDIATR, V164, P320, DOI 10.1007/s00431-005-1627-x
   Tuffrey C, 2013, AUDIT LOCAL RATES PA
   Tung ILY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161846
   Vandelaer J, 2015, VACCINE, V33, P719, DOI 10.1016/j.vaccine.2014.11.037
   Ward K, 2013, COMMUN DIS INTELL, V37, pE156
   Wienholz S, 2016, SEX DISABIL, V34, P171, DOI 10.1007/s11195-016-9433-0
   Yen CF, 2012, RES DEV DISABIL, V33, P704, DOI 10.1016/j.ridd.2011.11.011
NR 42
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 272
EP 279
DI 10.1016/j.vaccine.2018.11.034
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300011
PM 30522907
DA 2020-05-12
ER

PT J
AU Duszynski, KM
   Pratt, NL
   Lynch, JW
   Berry, JG
   Gold, MS
   Gold, MS
   Braunack-Mayer, AJ
   Ryan, P
   Duszynski, KM
   Berry, JG
   Xafis, V
   Carlson, J
   Richards, B
   Taylor, LK
   Buttery, JP
   Freemantle, CJ
   McNeil, JJ
   Demos, LL
   Thomson, C
   Lawrence, GL
   Elliot, EJ
   Leask, J
   Givney, R
   Lacey, G
   Woollacott, T
   Gascoigne, C
   Koehler, A
   Watson, M
   Horgan, R
   Lawson, S
   Richmond, PC
   Tarrant, S
   Roughead, EE
AF Duszynski, Katherine M.
   Pratt, Nicole L.
   Lynch, John W.
   Berry, Jesia G.
   Gold, Michael S.
   Gold, Michael S.
   Braunack-Mayer, Annette J.
   Ryan, Philip
   Duszynski, Katherine M.
   Berry, Jesia G.
   Xafis, Vicki
   Carlson, Jillian
   Richards, Bernadette
   Taylor, Lee K.
   Buttery, Jim P.
   Freemantle, Cecily J.
   McNeil, John J.
   Demos, Lisa L.
   Thomson, Colin
   Lawrence, Glenda L.
   Elliot, Elizabeth J.
   Leask, Julie
   Givney, Rod
   Lacey, Gary
   Woollacott, Tony
   Gascoigne, Chris
   Koehler, Ann
   Watson, Maureen
   Horgan, Rebecca
   Lawson, Sarah
   Richmond, Peter C.
   Tarrant, Sean
   Roughead, Elizabeth E.
CA Vaccine Assessment Using Linked D
TI Use of different combination diphtheria-tetanus-acellular pertussis
   vaccines does not increase risk of 30-day infant mortality. A
   population-based linkage cohort study using administrative data from the
   Australian Childhood Immunisation Register and the National Death Index
SO VACCINE
LA English
DT Article
ID COVERAGE; DECISIONS; PATTERNS; CHILDREN; SAFETY; HEALTH; RATES; MMR
AB Objective: To determine whether differences in combination DTaP vaccine types at 2, 4 and 6 months of age were associated with mortality (all-cause or non-specific), within 30 days of vaccination.
   Design: Observational nationwide cohort study.
   Setting: Linked population data from the Australian Childhood Immunisation Register and National Death Index.
   Participants: Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6 months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3 million children in the 2, 4 and 6 month vaccine cohorts, respectively.
   Main outcome measures: Infants were evaluated for the primary outcome of all-cause mortality within 30 days. A secondary outcome was non-specific mortality (unknown cause of death) within 30 days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 'Sudden infant death syndrome', R96 'Other sudden death, cause unknown', R98 'Unattended death', R99 'Other ill-defined and unspecified cause of mortality' or where no cause of death was recorded.
   Results: The rate of 30 day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6 month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.
   Conclusion: Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Duszynski, Katherine M.; Berry, Jesia G.; Gold, Michael S.] Univ Adelaide, Sch Med, Discipline Paediat, Adelaide, SA, Australia.
   [Duszynski, Katherine M.; Lynch, John W.; Berry, Jesia G.] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.
   [Duszynski, Katherine M.; Berry, Jesia G.; Gold, Michael S.] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5005, Australia.
   [Pratt, Nicole L.] Univ South Australia, Sansom Inst, Qual Use Med & Pharm Res Ctr, Adelaide, SA, Australia.
   [Gold, Michael S.; Braunack-Mayer, Annette J.; Ryan, Philip; Duszynski, Katherine M.; Berry, Jesia G.; Xafis, Vicki; Carlson, Jillian; Richards, Bernadette] Univ Adelaide, Adelaide, SA, Australia.
   [Taylor, Lee K.] New South Wales Minist Hlth, Sydney, NSW, Australia.
   [Buttery, Jim P.] Royal Childrens Hosp, Melbourne, Vic, Australia.
   [Freemantle, Cecily J.] Univ Melbourne, Melbourne, Vic, Australia.
   [McNeil, John J.; Demos, Lisa L.] Monash Univ, Clayton, Vic, Australia.
   [Thomson, Colin] Univ Wollongong, Wollongong, NSW, Australia.
   [Lawrence, Glenda L.] Univ New South Wales, Sydney, NSW, Australia.
   [Elliot, Elizabeth J.; Leask, Julie] Univ Sydney, Sydney, NSW, Australia.
   [Givney, Rod] John Hunter Hosp, Lambton Hts, NSW, Australia.
   [Lacey, Gary] Therapeut Goods Adm, Symonston, ACT, Australia.
   [Woollacott, Tony; Gascoigne, Chris; Koehler, Ann; Watson, Maureen; Horgan, Rebecca; Lawson, Sarah] SA Hlth, Adelaide, SA, Australia.
   [Richmond, Peter C.] Univ Western Australia, Nedlands, WA, Australia.
   [Tarrant, Sean] Medicare Australia, Nedlands, ACT, Australia.
   [Roughead, Elizabeth E.] Univ South Australia, Adelaide, SA, Australia.
RP Duszynski, KM (reprint author), Univ Adelaide, Robinson Res Inst, Adelaide, SA 5005, Australia.
EM katherine.duszynski@adelaide.edu.au; nicole.pratt@unisa.edu.au;
   john.lynch@adelaide.edu.au; jesia.berry@adelaide.edu.au;
   michael.gold@adelaide.edu.au
RI Lynch, John W/A-4797-2008; Richmond, Peter C/G-3379-2012;
   Braunack-Mayer, Annette/AAE-7796-2019
OI Lynch, John W/0000-0003-2781-7902; Richmond, Peter
   C/0000-0001-7562-7228; Braunack-Mayer, Annette/0000-0003-4427-0224
FU Australian Research Council (ARC) Linkage Project GrantAustralian
   Research Council [LP0882394]; Vaccine Assessment Using Linked Data
   project; University of Adelaide Division of Health Sciences Postgraduate
   Scholarship
FX This project work was supported by an Australian Research Council (ARC)
   Linkage Project Grant LP0882394. Michael Gold, Philip Ryan, John McNeil,
   Jane Freemantle, Colin Thomson, Elizabeth Roughead, Lee Taylor and Jim
   Buttery are Chief Investigators on this grant. Lee Taylor, David Filby,
   Jim Buttery and Elizabeth Elliot are Partner Investigators affiliated
   with organisations who provided financial and/or in-kind support for
   this work as part of the Vaccine Assessment Using Linked Data project.
   The organisations include the South Australian Department of Health &
   Ageing, the NSW Ministry of Health, Surveillance of Adverse Events
   Following Vaccination in Victoria (SAEFVic) and the Australian
   Paediatric Surveillance Unit (APSU). The study funders had no role in
   study design and the collection, analysis, and interpretation of data,
   writing of the article or the decision to submit it for publication. KMD
   was supported by a University of Adelaide Division of Health Sciences
   Postgraduate Scholarship.
CR Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961
   [Anonymous], 2013, AUSTR IMM HDB
   Australian Bureau of Statistics, 2011, 3238 0 55 001 EST AB
   Australian Bureau of Statistics, 1998, 2033 0 55 001 CENS P
   Australian Bureau of Statistics, 2006, 2033 0 55 001 CENS P
   Australian Bureau of Statistics, 2008, 2033 0 55 001 CENS P
   Australian Bureau of Statistics, 2015, 3303 0 CAUS DEATH AU
   Australian Bureau of Statistics, 2005, 4704 0 HLTH WELF AUS
   Australian Government Department of Human Services, AIR VACC COD FORM
   Bardenheier B, 2004, ARCH PEDIAT ADOL MED, V158, P569, DOI 10.1001/archpedi.158.6.569
   Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8
   Bohensky MA, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-346
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Cassell JA, 2006, PUBLIC HEALTH, V120, P783, DOI 10.1016/j.puhe.2006.03.011
   DECKER MD, 1995, PEDIATRICS, V96, P557
   FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479
   Gellatly J, 2005, FAM PRACT, V22, P658, DOI 10.1093/fampra/cmi066
   Harron K, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-36
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hull B P, 1999, Aust Fam Physician, V28, P55
   Hull BP, 2003, AUST NZ J PUBL HEAL, V27, P533, DOI 10.1111/j.1467-842X.2003.tb00829.x
   Hull BP, 2004, AUST NZ J PUBL HEAL, V28, P47, DOI 10.1111/j.1467-842X.2004.tb00632.x
   Hull BP, 2009, VACCINE, V27, P5054, DOI 10.1016/j.vaccine.2009.06.056
   Jefferson T, 2004, LANCET INFECT DIS, V4, P84, DOI 10.1016/S1473-3099(04)00927-2
   Maman K, 2015, HUM VACC IMMUNOTHER, V11, P2132, DOI 10.1080/21645515.2015.1044180
   Marshall GS, 2007, PEDIATR INFECT DIS J, V26, P496, DOI 10.1097/INF.0b013e31805d7f17
   McCarthy NL, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2970
   McCarthy NL, 2013, AM J PREV MED, V45, P91, DOI 10.1016/j.amepre.2013.02.020
   Menzies Robert, 2008, Commun Dis Intell Q Rep, V32 Suppl, pS2
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Rank C, 2007, COMMUN DIS INTELL, V31, P283
   United Nations Children's Fund (UNICEF), 2017, INF MORT RAT
   Wilson K, 2012, VACCINE, V30, P6115, DOI 10.1016/j.vaccine.2012.06.004
   Wilson K, 2011, VACCINE, V29, P3746, DOI 10.1016/j.vaccine.2011.03.044
   Zhang LJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001478.pub6
NR 36
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 280
EP 288
DI 10.1016/j.vaccine.2018.11.025
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300012
PM 30503081
DA 2020-05-12
ER

PT J
AU Cattapan, A
   Browne, K
   Halperin, DM
   Di Castri, A
   Fullsack, P
   Graham, J
   Langley, JM
   Taylor, BA
   McNeil, SA
   Halperin, SA
AF Cattapan, A.
   Browne, K.
   Halperin, D. M.
   Di Castri, A.
   Fullsack, P.
   Graham, J.
   Langley, J. M.
   Taylor, B. A.
   McNeil, S. A.
   Halperin, S. A.
TI Motivation for participating in phase 1 vaccine trials: Comparison of an
   influenza and an Ebola randomized controlled trial
SO VACCINE
LA English
DT Article
DE Ebola vaccine; Adjuvant; Influenza vaccine; Phase 1 clinical trials;
   Participant motivation; Altruism
ID HEALTHY-VOLUNTEERS; ENROLLMENT
AB Introduction/Hypothesis: Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014-2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.
   Methods: An online survey which included participants' prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.
   Results: A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.
   Conclusions/Recommendations: Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Cattapan, A.; Browne, K.] Dalhousie Univ, Novel Tech Eth, Fac Med, Halifax, NS, Canada.
   [Cattapan, A.] Univ Saskatchewan, Johnson Shoyama Grad Sch Publ Policy, 101 Diefenbaker Pl, Saskatoon, SK S7H 0J7, Canada.
   [Browne, K.] Langara Coll, Dept Philosophy, 100 W 49th Ave, Vancouver, BC V5Y 2Z6, Canada.
   [Halperin, D. M.] St Francis Xavier Univ, Sch Nursing, Antigonish, NS, Canada.
   [Halperin, D. M.; Di Castri, A.; Fullsack, P.; Graham, J.; Langley, J. M.; Taylor, B. A.; McNeil, S. A.; Halperin, S. A.] Dalhousie Univ, IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Halperin, D. M.; Di Castri, A.; Fullsack, P.; Graham, J.; Langley, J. M.; Taylor, B. A.; McNeil, S. A.; Halperin, S. A.] Nova Scotia Hlth Author, Halifax, NS, Canada.
   [Halperin, D. M.; Graham, J.; Langley, J. M.; Taylor, B. A.; Halperin, S. A.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
   [Taylor, B. A.] Dalhousie Univ, Sch Nursing, Halifax, NS, Canada.
   [McNeil, S. A.] Dalhousie Univ, Dept Med, Halifax, NS, Canada.
RP Cattapan, A (reprint author), Univ Saskatchewan, Johnson Shoyama Grad Sch Publ Policy, 101 Diefenbaker Pl, Saskatoon, SK S7H 0J7, Canada.
EM alana.cattapan@usask.ca
RI Cattapan, Alana/AAA-9207-2019
OI Di Castri, Antonia/0000-0002-6318-5394; Langley,
   Joanne/0000-0003-3270-7345
FU Faculty of Medicine, Dalhousie University (Halifax, Nova Scotia)
FX We would like thank Francoise Baylis for initiating conversations about
   this project and for her support throughout the research process. We
   would also like to thank Angel Petropanagos for her contributions to the
   early stages of this project, Donna MacKinnon-Cameron for data
   management, and Li Li, Lingyun Ye, and Bruce Smith for statistical
   analyses and advice. We greatly appreciate the time and effort of the
   participants of both clinical trials for completing the survey. This
   study was funded by a grant from the Faculty of Medicine, Dalhousie
   University (Halifax, Nova Scotia). The authors report no conflicts of
   interest related to this study.
CR Almeida L, 2007, EUR J CLIN PHARMACOL, V63, P1085, DOI 10.1007/s00228-007-0368-3
   [Anonymous], 2014, CBC NEWS
   BIGORRA J, 1990, EUR J CLIN PHARMACOL, V38, P443, DOI 10.1007/BF02336681
   Bramstedt KA, 2007, CLIN MED RES, V5, P91, DOI 10.3121/cmr.2007.718
   Chen SC, 2017, CLIN TRIALS, V14, P537, DOI 10.1177/1740774517722131
   Costas L, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-28
   Dhalla S, 2011, AIDS CARE, V23, P1430, DOI 10.1080/09540121.2011.555750
   ElSherif MS, 2017, CAN MED ASSOC J, V189, pE819, DOI 10.1503/cmaj.170074
   European Medicines Agency, 2017, GUID STRAT ID MIT RI
   Kiberd Mb, 2009, Can J Infect Dis Med Microbiol, V20, pe124
   O'Cathain A., 2004, BMC MED RES METHODOL, V4, P1, DOI DOI 10.1186/1471-2288-4-25
   Pasqualetti G, 2010, EUR J CLIN PHARMACOL, V66, P647, DOI 10.1007/s00228-010-0827-0
   Pentz RD, 2002, J CLIN ONCOL, V20, P3785, DOI 10.1200/JCO.2002.04.084
   Sheehy Susanne, 2012, Virtual Mentor, V14, P35, DOI 10.1001/virtualmentor.2012.14.1.pfor1-1201
   Stunkel L, 2011, CONTEMP CLIN TRIALS, V32, P342, DOI 10.1016/j.cct.2010.12.003
   VANGELDEREN CEM, 1993, EUR J CLIN PHARMACOL, V45, P15, DOI 10.1007/BF00315344
NR 16
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 289
EP 295
DI 10.1016/j.vaccine.2018.11.014
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300013
PM 30528592
DA 2020-05-12
ER

PT J
AU Satzke, C
   Dunne, EM
   Choummanivong, M
   Ortika, BD
   Neal, EFG
   Pell, CL
   Nation, ML
   Fox, KK
   Nguyen, CD
   Gould, KA
   Hinds, J
   Chanthongthip, A
   Xeuatvongsa, A
   Mulholland, EK
   Sychareun, V
   Russell, FM
AF Satzke, Catherine
   Dunne, Eileen M.
   Choummanivong, Molina
   Ortika, Belinda D.
   Neal, Eleanor F. G.
   Pell, Casey L.
   Nation, Monica L.
   Fox, Kimberley K.
   Nguyen, Cattram D.
   Gould, Katherine A.
   Hinds, Jason
   Chanthongthip, Anisone
   Xeuatvongsa, Anonh
   Mulholland, E. Kim
   Sychareun, Vanphanom
   Russell, Fiona M.
TI Pneumococcal carriage in vaccine-eligible children and unvaccinated
   infants in Lao PDR two years following the introduction of the 13-valent
   pneumococcal conjugate vaccine
SO VACCINE
LA English
DT Article
DE 13-Valent pneumococcal conjugate vaccine; Vaccine impact; Nasopharyngeal
   pneumococcal carriage; Herd immunity; Lower-middle income country;
   Antimicrobial resistance
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; ANTIBIOTIC-RESISTANCE; SEROTYPE DISTRIBUTION;
   DISEASE; REPLACEMENT; DENSITY; BURDEN; IMPACT
AB Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of PCVs in lower income settings, particularly in Asia. In 2013, the Lao People's Democratic Republic (Lao PDR) introduced 13-valent PCV (PCV13) as a 3 + 0 schedule (doses at 6, 10 and 14 weeks of age) with limited catch-up vaccination. We conducted two cross-sectional carriage surveys (pre- and two years post-PCV) to assess the impact of PCV13 on nasopharyngeal pneumococcal carriage in 5-8 week old infants (n = 1000) and 12-23 month old children (n = 1010). Pneumococci were detected by quantitative real-time PCR, and molecular serotyping was performed using DNA microarray. Post PCV13, there was a 23% relative reduction in PCV13-type carriage in children aged 12-23 months (adjusted prevalence ratio [aPR] 0.77 [0.61-0.96]), and no significant change in non-PCV13 serotype carriage (aPR 1.11 [0.89-1.38]). In infants too young to be vaccinated, there was no significant change in carriage of PCV13 serotypes (aPR 0.74 [0.43-1.27]) or non-PCV13 serotypes (aPR 1.29 [0.85-1.96]), although trends were suggestive of indirect effects. Over 70% of pneumococcal-positive samples contained at least one antimicrobial resistance gene, which were more common in PCV13 serotypes (p < 0.001). In 12-23 month old children, pneumococcal density of both PCV13 serotypes and non-PCV13 serotypes was higher in PCV13-vaccinated compared with undervaccinated children (p = 0.004 and p < 0.001, respectively). This study provides evidence of PCV13 impact on carriage in a population without prior PCV7 utilisation, and provides important data from a lower-middle income setting in Asia. The reductions in PCV13 serotype carriage in vaccine eligible children are likely to result in reductions in pneumococcal transmission and disease in Lao PDR. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Satzke, Catherine; Dunne, Eileen M.; Ortika, Belinda D.; Neal, Eleanor F. G.; Pell, Casey L.; Nation, Monica L.; Nguyen, Cattram D.; Mulholland, E. Kim; Russell, Fiona M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Pneumococcal Res, Flemington Rd, Parkville, Vic, Australia.
   [Satzke, Catherine; Dunne, Eileen M.; Neal, Eleanor F. G.; Nguyen, Cattram D.; Mulholland, E. Kim; Russell, Fiona M.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Satzke, Catherine] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia.
   [Choummanivong, Molina; Sychareun, Vanphanom] Univ Hlth Sci, Viangchan, Laos.
   [Neal, Eleanor F. G.; Russell, Fiona M.] Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Parkville, Vic, Australia.
   [Fox, Kimberley K.] World Hlth Org, Reg Off Western Pacific, Expanded Programme Immunizat, Manila, Philippines.
   [Gould, Katherine A.; Hinds, Jason] St Georges Univ London, Inst Infect & Immun, London, England.
   [Gould, Katherine A.; Hinds, Jason] London Biosci Innovat Ctr, BUGS Biosci, London, England.
   [Chanthongthip, Anisone] Laos Oxford Mahosot Wellcome Trust Res Unit, Viangchan, Laos.
   [Xeuatvongsa, Anonh] Minist Hlth, Viangchan, Laos.
   [Mulholland, E. Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Fox, Kimberley K.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Satzke, C (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
EM catherine.satzke@mcri.edu.au
RI Dunne, Eileen M/M-3203-2019; Satzke, Catherine/D-6501-2013
OI Dunne, Eileen M/0000-0001-5542-0780; Neal, Eleanor/0000-0001-7998-0942;
   Satzke, Catherine/0000-0003-3164-8849; Hinds, Jason/0000-0002-2739-1908;
   Gould, Katherine/0000-0002-2528-9512
FU Vaccine Alliance; World Health Organization Western Pacific Regional
   Office; Victorian Government's Operational Infrastructure Support
   Program; NHMRC Early CareerNational Health and Medical Research Council
   of Australia; TRIP Fellowships; NHMRC Career Development
   FellowshipNational Health and Medical Research Council of Australia
   [1087957]; veski Inspiring Women Fellowship
FX The project was funded by Gavi, the Vaccine Alliance, and the World
   Health Organization Western Pacific Regional Office, with support from
   the Victorian Government's Operational Infrastructure Support Program.
   FR was supported by a NHMRC Early Career and TRIP Fellowships. CS was
   supported by a NHMRC Career Development Fellowship (1087957) and a veski
   Inspiring Women Fellowship. EFGN holds an Australian Government Research
   Training Scholarship. We thank Chansay Pathammvong and Phounphenghack
   Kongxay (Ministry of Health, Lao PDR); Alejandro Ramirez-Gonzalez and
   Rita Reyburn (World Health Organization); Jana Lai, Kathryn Bright and
   Kathryn Stanhope (MCRI).
CR [Anonymous], 2015, IND PEOPL PLANN FRAM
   Becker-Dreps S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183348
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Brugger SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011638
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Dagan R, 2017, VACCINE, V35, P945, DOI 10.1016/j.vaccine.2016.12.052
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   Dunne E.M., 2018, ISPPD 11
   Dunne E.M., LANCET GLOB HLTH
   Dunne EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195098
   Dunne EM, 2012, J CLIN MICROBIOL, V50, P1034, DOI 10.1128/JCM.06589-11
   Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015
   Ginsburg AS, 2017, LANCET GLOB HEALTH, V5, pE1176, DOI 10.1016/S2214-109X(17)30364-9
   Gladstone RA, 2015, VACCINE, V33, P2015, DOI 10.1016/j.vaccine.2015.03.012
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   Hanke CR, 2016, PEDIATR INFECT DIS J, V35, P432, DOI 10.1097/INF.0000000000001030
   Huong TTV, 2011, PEDIATR INFECT DIS J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   International Vaccine Access Center (IVAC), 2018, VIEW HUB REP GLOB VA
   Jean SS, 2011, INT J ANTIMICROB AG, V37, P291, DOI 10.1016/j.ijantimicag.2011.01.009
   Kandasamy R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114286
   Kempf M, 2015, CLIN MICROBIOL INFEC, V21, P35, DOI 10.1016/j.cmi.2014.08.009
   Kim SH, 2012, ANTIMICROB AGENTS CH, V56, P1418, DOI 10.1128/AAC.05658-11
   Lai CC, 2014, J GLOB ANTIMICROB RE, V2, P141, DOI 10.1016/j.jgar.2014.02.007
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Manna S, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.06.031
   Morpeth SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29119-w
   Mulholland K, 2012, LANCET, V379, P1387, DOI 10.1016/S0140-6736(12)60588-1
   Navne JE, 2017, INT J CIRCUMPOL HEAL, V76, DOI 10.1080/22423982.2017.1309504
   Newton R, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-88
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Olwagen CP, 2018, VACCINE, V36, P3278, DOI 10.1016/j.vaccine.2018.04.068
   Pimhidzai O, 2014, POVERTY PROFILE LAO
   Poehling KA, 2006, JAMA-J AM MED ASSOC, V295, P1668, DOI 10.1001/jama.295.14.1668
   Porter BD, 2014, JOVE-J VIS EXP, DOI 10.3791/51747
   Russell FM, 2010, CLIN VACCINE IMMUNOL, V17, P1970, DOI 10.1128/CVI.00117-10
   Salter SJ, 2012, MICROBIOL-SGM, V158, P1560, DOI 10.1099/mic.0.056580-0
   Satzke C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001903
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134
   Sigurdsson S, 2017, VACCINE, V35, P5242, DOI 10.1016/j.vaccine.2017.08.020
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Turner P, 2011, J CLIN MICROBIOL, V49, P1784, DOI 10.1128/JCM.00157-11
   Valente C, 2016, VACCINE, V34, P4072, DOI 10.1016/j.vaccine.2016.06.017
   Valente C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030235
   van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003
   von Gottberg A, 2014, NEW ENGL J MED, V371, P1889, DOI 10.1056/NEJMoa1401914
   Weinberger DM, 2013, AM J EPIDEMIOL, V178, P1488, DOI 10.1093/aje/kwt156
   Wenger JD, 2010, PEDIATR INFECT DIS J, V29, P251, DOI 10.1097/INF.0b013e3181bdbed5
   Yu JG, 2011, CLIN VACCINE IMMUNOL, V18, P1900, DOI 10.1128/CVI.05312-11
   Zafar MA, 2016, INFECT IMMUN, V84, P2714, DOI 10.1128/IAI.00416-16
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 52
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 296
EP 305
DI 10.1016/j.vaccine.2018.10.077
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300014
PM 30502068
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Rodrigues-da-Silva, RN
   Correa-Moreira, D
   Soares, IF
   de-Luca, PM
   Totino, PRR
   Morgado, FN
   Henriques, MDD
   Candea, ALP
   Singh, B
   Galinski, MR
   Moreno, A
   Oliveira-Ferreira, J
   Lima, JD
AF Rodrigues-da-Silva, Rodrigo Nunes
   Correa-Moreira, Daniely
   Soares, Isabela Ferreira
   de-Luca, Paula Melo
   Rivas Totino, Paulo Renato
   Morgado, Fernanda Nazare
   de Oliveira Henriques, Maria das Gracas
   Peixoto Candea, Andre Luis
   Singh, Balwan
   Galinski, Mary R.
   Moreno, Alberto
   Oliveira-Ferreira, Joseli
   Lima-Junior, Josue da Costa
TI Immunogenicity of synthetic peptide constructs based on
   PvMSP9(E795-A808), a linear B-cell epitope of the P. vivax Merozoite
   Surface Protein-9
SO VACCINE
LA English
DT Article
DE Malaria; Linear B-cell epitope; T-cell epitope; Peptide-based
   immunogens; Immunogenicity; Antigenicity
ID MULTIPLE ANTIGEN PEPTIDES; PLASMODIUM-VIVAX; IMMUNE-RESPONSES;
   PROTECTIVE IMMUNITY; VACCINE ADJUVANTS; HELPER EPITOPES; MALARIA;
   RECOMBINANT; FALCIPARUM; PROGRESS
AB Plasmodium vivax Merozoite Surface Protein-9 (PvMSP-9) is a malaria vaccine candidate naturally immunogenic in humans and able to induce high antibody titers in animals when delivered as a recombinant protein. Recently, we identified the sequence EAAPENAEPVHENA (PvMSP9(E795-A808)) as the main linear B-cell epitope in naturally exposed individuals. However, the potential of PvMSP9(E795-A808) as an immunogen in experimental animal models remained unexplored. Here we assess the immunogenicity of PvMSP9(E795-A808) using synthetic peptides. The peptides tested in BALB/c mice include two repeats of the sequence EAAPENAEPVHENA tested alone (peptide RII), or linked to an autologous (PvMSP9 peptide pL; pLRII) or heterologous (p2 tetanus toxin universal T cell epitope; TTRII) T cell epitope. Immune responses were evaluated by ELISA, FLUOROSPOT, and indirect immunofluorescence. We show that all of the peptide constructs tested were immunogenic eliciting specific IgG antibodies at different levels, with a prevalence of IgG1 and IgG2. Animals immunized with synthetic peptides containing T cell epitopes (pLRII or TIMID had more efficient antibody responses that resulted in higher antibody titers able to recognize the native protein by immunofluorescence. Relevantly, the frequency of IFN-gamma secreting SFC elicited by immunization with TTRII synthetic peptide was comparable to that reported to the PvMSP9-Nt recombinant protein. Taken together, our study indicates that PvMSP9(E795-A808) is highly immunogenic in mice and further studies to evaluate its value as promising vaccine target are warranted. Moreover, our study supports the critical role of CD4 T cell epitopes to enhance humoral responses induced by subunit based vaccines. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Rodrigues-da-Silva, Rodrigo Nunes; Soares, Isabela Ferreira; de-Luca, Paula Melo; Oliveira-Ferreira, Joseli; Lima-Junior, Josue da Costa] Fiocruz MS, Oswaldo Cruz Fdn, Oswaldo Cruz Inst, Lab Immunoparasitol, Rio De Janeiro, RJ, Brazil.
   [Correa-Moreira, Daniely] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Taxon Biochem & Fungi Bioprospecting, Rio De Janeiro, Brazil.
   [Rivas Totino, Paulo Renato] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Malaria Res, Rio De Janeiro, Brazil.
   [Morgado, Fernanda Nazare] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Leishmaniasis Res, Rio De Janeiro, Brazil.
   [de Oliveira Henriques, Maria das Gracas; Peixoto Candea, Andre Luis] Fundacao Oswaldo Cruz, Farmanguinhos, Lab Appl Pharmacol, Rio De Janeiro, Brazil.
   [Singh, Balwan; Galinski, Mary R.; Moreno, Alberto] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
   [Galinski, Mary R.; Moreno, Alberto] Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Div Infect Dis,Emory Vaccine Ctr, Atlanta, GA USA.
RP Lima, JD (reprint author), Fiocruz MS, Inst Oswaldo Cruz, Lab Immunoparasitol, Pavilhao Leonidas Deane,4th Floor,Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM josue@ioc.fiocruz.br
RI Correa-Moreira, Danielly/V-2834-2019; Morgado, Fernanda N/K-2527-2013;
   Henriques, Maria das Gracas/AAG-3694-2020; Oliveira-Ferreira,
   Joseli/E-7942-2014; Lima-Junior, Josue da Costa/B-1361-2014
OI Morgado, Fernanda N/0000-0002-7188-251X; Henriques, Maria das
   Gracas/0000-0003-3065-0541; Totino, Paulo/0000-0002-4790-3317; Moreno,
   Alberto/0000-0002-3031-7194; Oliveira-Ferreira,
   Joseli/0000-0002-6063-465X; Rodrigues-da-Silva, Rodrigo
   Nunes/0000-0002-9772-849X; Lima-Junior, Josue da
   Costa/0000-0002-5848-404X
FU Brazilian National Research Council -CNPq/PAPES (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/Programa de Apoio Pesquisa
   Estrategica em SaCide), Fiocruz; National Institute of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 1R01A124710]; Yerkes National
   Primate Research Center Base Grant - National Center for Research
   Resources of the National Institutes of Health [ORIP/OD P51OD011132];
   FAPERJ APQ1Carlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E-26/210.653/2015]; Jovem Cientista do
   Nosso Estado [E26/203.255/2016]; CPNq-Universal research grants
   [445150/2014-9]; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by Brazilian National Research Council
   -CNPq/PAPES (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/Programa de Apoio Pesquisa Estrategica em SaCide), Fiocruz,
   the National Institute of Health (NIH Grant #R01 1R01A124710), and the
   Yerkes National Primate Research Center Base Grant (ORIP/OD P51OD011132)
   awarded by the National Center for Research Resources of the National
   Institutes of Health. JCLJ is recipient of FAPERJ APQ1
   (E-26/210.653/2015), Jovem Cientista do Nosso Estado (E26/203.255/2016)
   and CPNq-Universal research grants (445150/2014-9), JOF and JCLJ are
   recipients of CNPq Productivity Fellowship.
CR Alexander J, 2000, J IMMUNOL, V164, P1625, DOI 10.4049/jimmunol.164.3.1625
   ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0
   ARIAS AE, 1989, TROP MED PARASITOL, V40, P21
   BALLOU WR, 1987, LANCET, V1, P1277
   Barnwell JW, 1999, EXP PARASITOL, V91, P238, DOI 10.1006/expr.1998.4372
   Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Brown GV, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P429
   Caro-Aguilar I, 2005, MICROBES INFECT, V7, P1324, DOI 10.1016/j.micinf.2005.04.020
   Caro-Aguilar I, 2002, INFECT IMMUN, V70, P3479, DOI 10.1128/IAI.70.7.3479-3492.2002
   Cespedes N, 2013, VACCINE, V31, P4923, DOI 10.1016/j.vaccine.2013.05.082
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Dembele L, 2014, NAT MED, V20, P307, DOI 10.1038/nm.3461
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753
   Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0
   Galinski MR, 2014, MALARIA VACCINE DEV
   Geleta G., 2016, MALAR RES TREAT, V2016
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   Gupta Bal Kishan, 2015, Infect Dis (Auckl), V8, P45, DOI 10.4137/IDRT.S34039
   HERRERA MA, 1994, MEM I OSWALDO CRUZ, V89, P71, DOI 10.1590/S0074-02761994000600017
   Herrera S, 2004, INT J PARASITOL, V34, P1535, DOI 10.1016/j.ijpara.2004.10.009
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   Jackson DC, 2002, CURR DRUG TARGETS, V3, P175, DOI 10.2174/1389450024605436
   Jang JI, 2012, MICROBIOL IMMUNOL, V56, P595, DOI 10.1111/j.1348-0421.2012.00480.x
   Kalaiselvan S, 2017, J CELL BIOCHEM, V118, P2320, DOI 10.1002/jcb.25887
   Kalaiselvan S, 2017, J CELL BIOCHEM, V118, P1182, DOI 10.1002/jcb.25765
   Karunajeewa HA, 2008, NEW ENGL J MED, V359, P2545, DOI 10.1056/NEJMoa0804915
   Kaumaya Pravin T. P., 1993, Journal of Molecular Recognition, V6, P81, DOI 10.1002/jmr.300060206
   Kristensen KL, 2014, SCAND J INFECT DIS, V46, P63, DOI 10.3109/00365548.2013.822093
   LAIRMORE MD, 1995, J VIROL, V69, P6077, DOI 10.1128/JVI.69.10.6077-6089.1995
   Lanier JG, 1999, VACCINE, V18, P549
   Lima JC, 2010, VACCINE, V28, P3185, DOI 10.1016/j.vaccine.2010.02.046
   Lima-Junior JC, 2008, VACCINE, V26, P6645, DOI 10.1016/j.vaccine.2008.09.029
   Lima JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036419
   Lopera-Mesa TM, 2008, VACCINE, V26, P1335, DOI 10.1016/j.vaccine.2007.12.042
   Lopez C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00126
   Mahanty S, 2003, J EXP BIOL, V206, P3781, DOI 10.1242/jeb.00646
   Malkin E, 2006, TRENDS PARASITOL, V22, P292, DOI 10.1016/j.pt.2006.05.002
   Marussig M, 1997, INT IMMUNOL, V9, P1817, DOI 10.1093/intimm/9.12.1817
   Mccoy KD, 2008, CELL HOST MICROBE, V4, P362, DOI 10.1016/j.chom.2008.08.014
   McKenzie FE, 2007, J PARASITOL, V93, P627, DOI 10.1645/GE-1052R.1
   Mitra S, 2015, J VECTOR DIS, V52, P281
   Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Nardelli B, 1995, Pharm Biotechnol, V6, P803
   Nardin EH, 1995, ADV IMMUNOL, V60, P105, DOI 10.1016/S0065-2776(08)60585-4
   Nayar JK, 1997, J PARASITOL, V83, P739, DOI 10.2307/3284254
   Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948
   Oliveira-Ferreira J, 2004, VACCINE, V22, P2023, DOI 10.1016/j.vaccine.2003.07.021
   Overholser J, 2015, VACCINES, V3, P519, DOI 10.3390/vaccines3030519
   PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209
   Patarroyo MA, 2012, EXPERT REV VACCINES, V11, P1249, DOI [10.1586/ERV.12.91, 10.1586/erv.12.91]
   Patarroyo ME, 2008, ACCOUNTS CHEM RES, V41, P377, DOI 10.1021/ar700120t
   Pourseif MM, 2017, COMPUT BIOL CHEM
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   Rodrigues-da-Silva RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146951
   Sabet LP, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.22215
   Santiago HC, 2011, J ALLERGY CLIN IMMUN, V127, P479, DOI 10.1016/j.jaci.2010.11.007
   SATTERTHWAIT AC, 1990, B WORLD HEALTH ORGAN, V68, P17
   Silva-Flannery LM, 2009, INFECT IMMUN, V77, P1798, DOI 10.1128/IAI.00470-08
   Silva-Flannery LM, 2009, MICROBES INFECT, V11, P83, DOI 10.1016/j.micinf.2008.10.009
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Stanisic DI, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002498
   Teka H, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-220
   Testa JS, 2012, FUTURE VIROL, V7, P1077, DOI 10.2217/FVL.12.108
   Tetteh KKA, 2007, BIODRUGS, V21, P357, DOI 10.2165/00063030-200721060-00004
   Thomson-Luque R, 2017, TRENDS PARASITOL
   Valero LMS, 1998, INFECT IMMUN, V66, P3925, DOI 10.1128/IAI.66.8.3925-3930.1998
   VALMORI D, 1992, J IMMUNOL, V149, P717
   Vargas-Serrato E, 2002, MOL BIOCHEM PARASIT, V120, P41, DOI 10.1016/S0166-6851(01)00433-9
   Vargas-Serrato E, 2003, INFECT GENET EVOL, V3, P67, DOI 10.1016/S1567-1348(03)00007-8
   White MT, 2014, ELIFE, V3, DOI 10.7554/eLife.04692
   Wojciechowski W, 2009, IMMUNITY, V30, P421, DOI 10.1016/j.immuni.2009.01.006
   Woof JM, 2005, SCIENCE, V310, P1442, DOI 10.1126/science.1122009
   World Health Organization, 2017, WORLD MAL REP 2017
   Xie Q, 2017, IEEE ACM T COMPUT BI
NR 79
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 306
EP 313
DI 10.1016/j.vaccine.2018.10.016
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300015
PM 30509693
OA Green Published
DA 2020-05-12
ER

PT J
AU Naili, I
   Vinot, J
   Baudner, BC
   Bernalier-Donadille, A
   Pizza, M
   Desvaux, M
   Jubelin, G
   D'Oro, U
   Buonsanti, C
AF Naili, Ilham
   Vinot, Juliette
   Baudner, Barbara C.
   Bernalier-Donadille, Annick
   Pizza, Mariagrazia
   Desvaux, Mickael
   Jubelin, Gregory
   D'Oro, Ugo
   Buonsanti, Cecilia
TI Mixed mucosal-parenteral immunizations with the broadly conserved
   pathogenic Escherichia coli antigen SslE induce a robust mucosal and
   systemic immunity without affecting the murine intestinal microbiota
SO VACCINE
LA English
DT Article
DE Immunization; Intranasal; Intramuscular; SslE; Pathogenic E. coli; Gut
   microbiota
ID GUT MICROBIOTA; RESPONSES; INFECTION; VACCINE; METALLOPROTEASE;
   EPIDEMIOLOGY; SALMONELLA; MECHANISMS; VIRULENCE; ADJUVANT
AB Emergence and dissemination of multidrug resistance among pathogenic Escherichia coli have posed a serious threat to public health across developing and developed countries. In combination with a flexible repertoire of virulence mechanisms, E. coli can cause a vast range of intestinal (InPEC) and extraintestinal (ExPEC) diseases but only a very limited number of antibiotics still remains effective against this pathogen. Hence, a broad spectrum E. coli vaccine could be a promising alternative to prevent the burden of such diseases, while offering the potential for covering against several InPEC and ExPEC at once. SslE, the Secreted and Surface-associated Lipoprotein of E. coli, is a widely distributed protein among InPEC and ExPEC. SslE functions ex vivo as a mucinase capable of degrading mucins and reaching the surface of mucus-producing epithelial cells. SslE was identified by reverse vaccinology as a protective vaccine candidate against an ExPEC murine model of sepsis, and further shown to be cross-effective against other ExPEC and InPEC models of infection. In this study, we aimed to gain insight into the immune response to antigen SslE and identify an immunization strategy suited to generate robust mucosal and systemic immune responses. We'showed, by analyzing T cell and antibody responses, that mice immunized with SsIE via an intranasal prime followed by two intramuscular boosts developed an enhanced overall immune response compared to either intranasal-only or intramuscular-only protocols. Importantly, we also report that this regimen of immunization did not impact the richness of the murine gut microbiota, and mice had a comparable cecal microbial composition, whether immunized with SslE or PBS. Collectively, our findings further support the use of SslE in future vaccination strategies to effectively target both InPEC and ExPEC while not perturbing the resident gut microbiota. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Naili, Ilham; Vinot, Juliette; Baudner, Barbara C.; Pizza, Mariagrazia; D'Oro, Ugo; Buonsanti, Cecilia] GSK, Via Fiorentina,1, I-53100 Siena, Italy.
   [Naili, Ilham; Bernalier-Donadille, Annick; Desvaux, Mickael; Jubelin, Gregory] Univ Clermont Auvergne, INRA, UMR454, MEDiS, F-63000 Clermont Ferrand, France.
RP Buonsanti, C (reprint author), GSK, Via Fiorentina,1, I-53100 Siena, Italy.; Naili, I (reprint author), INRA, Auvergne Rhone Alpes, Ctr Rech Clermont Ferrand, UMR454,MEDiS Microbiol Environm Digestif Sante, Site Theix, F-63122 St Genes Champanelle, France.
EM ilham.naili@gmail.com; cecilia.x.buonsanti@gsk.com
RI DESVAUX, Mickael/A-8333-2008
OI DESVAUX, Mickael/0000-0003-2986-6417; JUBELIN,
   Gregory/0000-0002-9902-0663
FU Marie Sklodowska-Curie Actions ITN EID DISCo [FP7-PEOPLE-607611];
   Universite Clermont-Auvergne and Universita degli studi Roma Tre
FX This study was funded by the Marie Sklodowska-Curie Actions ITN EID
   DISCo (A multidisciplinary Doctoral Industrial School on novel
   preventive strategies against E. coli infections;
   http://www.discoproject.eu/; n'FP7-PEOPLE-607611) in which GSK Vaccines
   and INRA are full partners, and Universite Clermont-Auvergne and
   Universita degli studi Roma Tre are associated partners.
CR Amezquita-Lopez BA, 2017, J MICROBIOL IMMUNOL
   Atarashi K, 2015, CELL, V163, P367, DOI 10.1016/j.cell.2015.08.058
   Baldi DL, 2012, INFECT IMMUN, V80, P2042, DOI 10.1128/IAI.06160-11
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Bonacorsi S, 2005, INT J MED MICROBIOL, V295, P373, DOI 10.1016/j.ijmm.2005.07.011
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001
   Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611
   Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035
   Crouzet L, 2013, NEUROGASTROENT MOTIL, V25, pe272, DOI 10.1111/nmo.12103
   Croxen MA, 2013, CLIN MICROBIOL REV, V26, P822, DOI 10.1128/CMR.00022-13
   Croxen MA, 2010, NAT REV MICROBIOL, V8, P26, DOI 10.1038/nrmicro2265
   Das Shibali, 2017, F1000Res, V6, P741, DOI 10.12688/f1000research.10862.1
   DeCanio MS, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-130
   Donati C, 2013, ANN NY ACAD SCI, V1285, P115, DOI 10.1111/nyas.12046
   Flores-Mireles AL, 2015, NAT REV MICROBIOL, V13, P269, DOI 10.1038/nrmicro3432
   Garcia-Angulo VA, 2013, VACCINE, V31, P3229, DOI 10.1016/j.vaccine.2013.05.013
   Girard-Madoux MJH, 2016, ONCOTARGET, V7, P32015, DOI 10.18632/oncotarget.8337
   Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802, DOI 10.1128/AEM.63.7.2802-2813.1997
   Gu SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074957
   Havelaar AH, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001923
   Hays Michael P, 2016, BMC Res Notes, V9, P401, DOI 10.1186/s13104-016-2208-y
   Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818
   Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808
   Langille MG, 2014, MICROBIOME, V2, DOI 10.1186/s40168-014-0050-9
   Lasaro MO, 2004, INFECT IMMUN, V72, P6480, DOI 10.1128/IAI.72.11.6480-6491.2004
   LAYTON GT, 1983, CLIN EXP IMMUNOL, V54, P305
   Le Bihan G, 2015, MICROBES INFECT, V17, P23, DOI 10.1016/j.micinf.2014.09.008
   LEVINE MM, 1979, INFECT IMMUN, V23, P729, DOI 10.1128/IAI.23.3.729-736.1979
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Lundberg R, 2017, SCI REP-UK, V7, DOI 10.1038/srep42245
   Luo QW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003446
   Luo QW, 2014, INFECT IMMUN, V82, P509, DOI 10.1128/IAI.01106-13
   Luo Y, 2015, VET RES, V46, DOI 10.1186/s13567-015-0264-2
   Mattsson J, 2015, MUCOSAL IMMUNOL, V8, P815, DOI 10.1038/mi.2014.111
   Mediavilla JR, 2016, MBIO, V7, DOI 10.1128/mBio.01191-16
   Mike LA, 2016, P NATL ACAD SCI USA, V113, P13468, DOI 10.1073/pnas.1606324113
   Mobley HLT, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010001
   Moriel DG, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00326-16
   Moriel DG, 2010, P NATL ACAD SCI USA, V107, P9072, DOI 10.1073/pnas.0915077107
   Nakjang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030287
   Nesta B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004124
   O'Ryan M, 2015, HUM VACC IMMUNOTHER, V11, P601, DOI 10.1080/21645515.2015.1011578
   Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004
   Pang WY, 2012, LAB ANIM-UK, V46, P231, DOI 10.1258/la.2012.011128
   PIERCE NF, 1977, J INFECT DIS, V135, P888, DOI 10.1093/infdis/135.6.888
   Pitout J. D. D., 2017, F1000RES, V6, pF1000, DOI 10.12688/f1000research.10609.1
   Pournaras S, 2016, INT J ANTIMICROB AG, V48, P11, DOI 10.1016/j.ijantimicag.2016.04.017
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Roy K, 2010, INFECT IMMUN, V78, P3027, DOI 10.1128/IAI.00264-10
   Shah RR, 2015, J PHARM SCI-US, V104, P1352, DOI 10.1002/jps.24337
   Simonsen KA, 2014, CLIN MICROBIOL REV, V27, P21, DOI 10.1128/CMR.00031-13
   Tapader R, 2017, MICROB PATHOGENESIS, V105, P96, DOI 10.1016/j.micpath.2017.02.020
   Terlizzi ME, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01566
   Thumbikat P, 2006, J IMMUNOL, V176, P3080, DOI 10.4049/jimmunol.176.5.3080
   Torres AG, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx012
   Vajdy M, 2003, IMMUNOLOGY, V110, P86, DOI 10.1046/j.1365-2567.2003.01711.x
   Vajdy M, 2007, CLIN IMMUNOL, V123, P166, DOI 10.1016/j.clim.2007.01.009
   Valeri M, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw111
   Valeri M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117486
   Xiao L, 2015, NAT BIOTECHNOL, V33, P1103, DOI 10.1038/nbt.3353
NR 63
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 314
EP 324
DI 10.1016/j.vaccine.2018.10.008
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300016
PM 30503655
OA Other Gold
DA 2020-05-12
ER

PT J
AU Frew, PM
   Murden, R
   Mehta, CC
   Chamberlain, AT
   Hinman, AR
   Nowak, G
   Mendel, J
   Aikin, A
   Randall, LA
   Hargreaves, AL
   Omer, SB
   Orenstein, WA
   Bednarczyk, RA
AF Frew, Paula M.
   Murden, Raphiel
   Mehta, C. Christina
   Chamberlain, Allison T.
   Hinman, Alan R.
   Nowak, Glen
   Mendel, Judith
   Aikin, Ann
   Randall, Laura A.
   Hargreaves, Allison L.
   Omer, Saad B.
   Orenstein, Walter A.
   Bednarczyk, Robert A.
TI Development of a US trust measure to assess and monitor parental
   confidence in the vaccine system
SO VACCINE
LA English
DT Article
DE Vaccine confidence; Vaccine measurement; Vaccine index; Immunization
   coverage; Immunization assessment
ID UNITED-STATES; AMERICAN CHILDREN; IMMUNIZATION; HESITANCY; ATTITUDES;
   VALIDATION; REFUSAL; SCALE; RISK; ASSOCIATION
AB Objective: To develop a Vaccine Confidence Index (VCI) that is capable of detecting variations in parental confidence towards childhood immunizations centered on trust and concern issues that impact vaccine confidence.
   Methods: We used a web-based national poll of 893 parents of children <7 years in 2016 to assess the measures created for the Emory VCI (EVCI). EVCI measures were developed using constructs related to vaccine confidence identified by the U.S. National Vaccine Advisory Committee (i.e., "Information Environment", "Trust", "Healthcare Provider", "Attitudes and Beliefs", and "Social Norms"). Reliability for EVCI was assessed using Cronbach's alpha. Using the variables related to each of the constructs, we calculated an overall EVCI score that was then assessed against self-reported childhood vaccine receipt using chi-square and the Cochrane-Armitage trend tests.
   Results: Respondents' EVCI scores could range from 0 to 24, and the full range of values was observed in this sample (Mean = 17.5 (SD 4.8)). EVCI scores were significantly different (p <= 0.006 for all comparisons) between parents who indicated their child(ren) received routinely recommended vaccines compared with parents who indicated they had delayed or declined recommended immunizations. There was also a significant, consistent association between higher EVCI scores and greater reported vaccine receipt.
   Conclusions: We developed EVCI to reliably measure parental vaccine confidence, with individuals' scores linked to parental vaccine-related attitudes, intentions, and behaviors. As such, EVCI may be a useful tool for future monitoring of both population and individual confidence in childhood immunization. (C) 2018 Published by Elsevier Ltd.
C1 [Frew, Paula M.; Randall, Laura A.; Hargreaves, Allison L.; Orenstein, Walter A.] Emory Univ, Sch Med, 1760 Haygood Rd, Atlanta, GA 30322 USA.
   [Frew, Paula M.; Murden, Raphiel; Mehta, C. Christina; Chamberlain, Allison T.; Randall, Laura A.; Hargreaves, Allison L.; Omer, Saad B.; Bednarczyk, Robert A.] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Hinman, Alan R.] Task Force Global Hlth, 330 West Ponce de Leon Ave, Decatur, GA 30030 USA.
   [Nowak, Glen] Univ Georgia, Grady Coll Journalism & Mass Commun, 120 Hooper St, Athens, GA 30602 USA.
   [Mendel, Judith; Aikin, Ann] Hlth & Human Serv, Natl Vaccine Program Off, Washington, DC USA.
RP Frew, PM (reprint author), Univ Nevada, Las Vegas Sch Community Hlth Sci, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.
EM paula.frew@unlv.edu
RI Bednarczyk, Robert/L-9403-2017; Chamberlain, Allison T./AAA-3835-2019
OI Bednarczyk, Robert/0000-0002-6812-0928; Chamberlain, Allison
   T./0000-0001-6009-537X; Nowak, Glen/0000-0002-9153-2189
FU National Vaccine Program Office [1VSRNV00000]; National Institute for
   Allergy and Infectious Diseases, National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [K01Al106961]
FX This research was supported in part by a grant from the National Vaccine
   Program Office (1VSRNV00000). Dr. Bednarczyk is supported by a grant
   (K01Al106961) from the National Institute for Allergy and Infectious
   Diseases, National Institutes of Health. We are grateful to Dr. Vialla
   Hartfield-Mendez and the staff of the Emory University Center for
   Faculty Development and Excellence for their support. The findings and
   conclusions in this article are those of the authors and do not
   necessarily represent the official position of the U.S. Department of
   Health and Human Services.
CR Bednarczyk RA, 2016, AM J EPIDEMIOL, V184, P148, DOI 10.1093/aje/kwv320
   Bisgard KM, 2005, PEDIATRICS, V116, pE285, DOI 10.1542/peds.2004-2759
   CDC, 2015, REC IMM CHILDR BIRTH
   Chen WW, 2017, CLIN PEDIATR, V56, P348, DOI 10.1177/0009922816660540
   Childs L, 2017, PEDIAT INFECT DIS J
   Chung YM, 2017, MATERN CHILD HLTH J, V21, P2178, DOI 10.1007/s10995-017-2336-6
   Connors JT, 2017, J PEDIATR NURS, V33, P10, DOI 10.1016/j.pedn.2016.11.002
   Copeland VC, 1996, HEALTH SOC WORK, V21, P105, DOI 10.1093/hsw/21.2.105
   Edelman, 2018, 2018 EDELMAN TRUST B
   Elam-Evans LD, 2014, MMWR-MORBID MORTAL W, V63, P741
   Frew PM, 2016, VACCINE, V34, P5840, DOI 10.1016/j.vaccine.2016.10.026
   Frew PM, 2016, VACCINE, V34, P5689, DOI 10.1016/j.vaccine.2016.08.001
   Gilkey MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159087
   Gilkey MB, 2016, ACAD PEDIATR, V16, P42, DOI 10.1016/j.acap.2015.06.007
   Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007
   Glanz JM, 2010, ARCH PEDIAT ADOL MED, V164, P66, DOI 10.1001/archpediatrics.2009.244
   Glanz JM, 2009, PEDIATRICS, V123, P1446, DOI 10.1542/peds.2008-2150
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Hill Holly A, 2016, MMWR Morb Mortal Wkly Rep, V65, P1065, DOI 10.15585/mmwr.mm6539a4
   HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023
   Kempe A, 2015, PEDIATRICS, V135, P666, DOI 10.1542/peds.2014-3474
   Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396
   Lang CW, 2009, PEDIATRICS, V124, P1143, DOI 10.1542/peds.2009-0658
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Larson HJ, 2015, PLOS CURRENTS, V7
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Measles-United States, 2013, MMWR MORB MORTAL WKL, V62, P741
   Nadeau JA, 2015, J PEDIATR-US, V166, P151, DOI 10.1016/j.jpeds.2014.09.013
   Niederhauser VP, 2010, J NURS MEAS, V18, P26, DOI 10.1891/1061-3749.18.1.26
   Oladejo O, 2016, VACCINE, V34, P4964, DOI 10.1016/j.vaccine.2016.08.046
   Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Orenstein WA, 1999, VACCINE, V17, pS19, DOI 10.1016/S0264-410X(99)00290-X
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Pearson SD, 2000, J GEN INTERN MED, V15, P509, DOI 10.1046/j.1525-1497.2000.11002.x
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Prashanth GP, 2014, LANCET INFECT DIS, V14, P187, DOI 10.1016/S1473-3099(14)70014-3
   Qualtrics, 2014, ESOMAR 28 28 QUESTIO
   Robinson CL, 2016, MMWR-MORBID MORTAL W, V65, P86
   Robison SG, 2012, PEDIATRICS, V130, P32, DOI 10.1542/peds.2011-3154
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Seither R, 2017, MMWR MORB MORTAL WKL, V66
   Smith MJ, 2015, INFECT DIS CLIN N AM, V29, P759, DOI 10.1016/j.idc.2015.07.004
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187
   Sobo EJ, 2016, MED ANTHROPOL, V35, P529, DOI 10.1080/01459740.2016.1145219
   Velan B, 2012, HUM VACC IMMUNOTHER, V8, P1272, DOI 10.4161/hv.21183
   Walsh B, 2016, HEALTH AFFAIR, V35, P356, DOI [10.1377/hlthaff.2015.1019, 10.1377/hlthaff.2015.10]
   Weinberg M, 2017, VACCINE
   Williams SE, 2014, HUM VACC IMMUNOTHER, V10, P2584, DOI 10.4161/hv.28596
   Winter K, 2014, MMWR-MORBID MORTAL W, V63, P1129
NR 55
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 325
EP 332
DI 10.1016/j.vaccine.2018.09.043
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300017
PM 30503657
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Valencia, S
   Gill, RB
   Dowdell, KC
   Wang, YM
   Hornung, R
   Bowman, JJ
   Lacayo, JC
   Cohen, JI
AF Valencia, Sarah
   Gill, Rachel B.
   Dowdell, Kennichi C.
   Wang, Yanmei
   Hornung, Ron
   Bowman, J. Jason
   Lacayo, Juan C.
   Cohen, Jeffrey I.
TI Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a
   RhCMV replication-defective virus deleted for MHC class I immune evasion
   genes in a RhCMV challenge model
SO VACCINE
LA English
DT Article
DE Cytomegalovirus; Rhesus cytomegalovirus; Replication-defective vaccine;
   Disabled infectious single cycle vaccine
ID CYTOMEGALOVIRUS GLYCOPROTEIN-B; NONHUMAN PRIMATE MODEL; INFECTION;
   VACCINES; TROPISM; LIVE
AB A human cytomegalovirus (HCMV) vaccine to prevent infection and/or reduce disease associated with congenital infection or visceral disease in transplant recipients is a high priority, but has remained elusive. We created a disabled infectious single cycle rhesus CMV (RhCMV) deleted for glycoprotein L (gL) and the MHC class I immune evasion genes Rh178 and Rh182-189, and restored its epithelial cell tropism by inserting the Rh128-131A genes. The resulting virus, RhCMVR Delta gL/178/182-189, was used to vaccinate rhesus monkeys intramuscularly and was compared with vaccination of animals with soluble RhCMV glycoprotein B (gB) in alum/monophosphoryl lipid A or with PBS as a control. At 4 weeks after the second vaccination, an increased frequency of RhCMV-specific CD8 T cells was detected in animals vaccinated with the RhCMVR Delta gL/178/182-189 vaccine compared to animals vaccinated with soluble gB. In contrast, monkeys vaccinated with soluble gB had 20-fold higher gB antibody titers than animals vaccinated with RhCMVR Delta gL/178/182-189. Titers of neutralizing antibody to RhCMV infection of fibroblasts were higher in animals vaccinated with gB compared with RhCMVR Delta gL/178/182-189. Following vaccination, monkeys were challenged subcutaneously with RhCMV UCD59, a low passage virus propagated in monkey kidney epithelial cells. All animals became infected after challenge; however, the frequency of RhCMV detection in the blood was reduced in monkeys vaccinated with soluble gB compared with those vaccinated with RhCMVR Delta gL/178/182-189. The frequency of challenge virus shedding in the urine and saliva and the RhCMV copy number shed at these sites was not different in animals vaccinated with RhCMVR Delta gL/178/182-189 or soluble gB compared with those that received PBS before challenge. Although the RhCMVR Delta gL/178/182-189 vaccine was superior in inducing cellular immunity to RhCMV, it induced lower titers of neutralizing antibody and antibody to gB than the soluble gB vaccine; after challenge, animals vaccinated with soluble gB had a lower frequency of virus detection in the blood than those vaccinated with RhCMVR Delta gL/178/182-189. Published by Elsevier Ltd.
C1 [Valencia, Sarah; Gill, Rachel B.; Dowdell, Kennichi C.; Bowman, J. Jason; Lacayo, Juan C.; Cohen, Jeffrey I.] NIAID, Med Virol Sect, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Wang, Yanmei; Hornung, Ron] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Clin Serv Program, Frederick, MD USA.
RP Cohen, JI (reprint author), NIH, Med Virol Sect, Lab Infect Dis, Bldg 50,Room 6134,50 South Dr,MSC8007, Bethesda, MD 20892 USA.
EM jcohen@niaid.nih.gov
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Cancer Institute, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [HHSN261200800001E]
FX This work was supported by the intramural research program of the
   National Institute of Allergy and Infectious Diseases. This project has
   been funded in whole or in part with federal funds from the National
   Cancer Institute, National Institutes of Health, under contract No.
   HHSN261200800001E. The content of this publication does not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. Government. We thank Peter
   Barry for Telo-RF and MKE cells, RhCMV UCD52, UCD59, RhCMV BAC 68.1,
   plasmid pND/gB Delta, and anti-RhCMV IE1 antobody, and Bill Britt for
   hybridoma cells expressing mouse anti-HCMV gB AD-1.
CR Abbate J, 2001, BIOTECHNIQUES, V31, P336, DOI 10.2144/01312st05
   Abel K, 2011, J VIROL, V85, P2878, DOI 10.1128/JVI.00883-10
   Adler SP, 2016, J INFECT DIS, V214, P1341, DOI 10.1093/infdis/jiw365
   Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980
   ALCENDOR DJ, 1993, VIROLOGY, V194, P815, DOI 10.1006/viro.1993.1323
   Andoniou CE, 2006, IMMUNOL CELL BIOL, V84, P99, DOI 10.1111/j.1440-1711.2005.01412.x
   Baraniak I, 2018, P NATL ACAD SCI USA, V115, P6273, DOI 10.1073/pnas.1800224115
   Bernstein DI, 2016, VACCINE, V34, P313, DOI 10.1016/j.vaccine.2015.11.056
   Bialas KM, 2015, P NATL ACAD SCI USA, V112, P13645, DOI 10.1073/pnas.1511526112
   Bowman JJ, 2011, J VIROL, V85, P2089, DOI 10.1128/JVI.01970-10
   Britt WJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02392-16
   Chandramouli S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9176
   FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003
   Francis SS, 2017, BLOOD, V129, P1680, DOI 10.1182/blood-2016-07-723148
   Gill RB, 2013, VIROLOGY, V447, P208, DOI 10.1016/j.virol.2013.08.026
   Griffiths PD, 2011, LANCET, V377, P1256, DOI 10.1016/S0140-6736(11)60136-0
   Horst D, 2011, CURR OPIN IMMUNOL, V23, P96, DOI 10.1016/j.coi.2010.11.005
   Itell HL, 2017, CURR OPIN VIROL, V25, P126, DOI 10.1016/j.coviro.2017.08.005
   Kabanova A, 2014, P NATL ACAD SCI USA, V111, P17965, DOI 10.1073/pnas.1415310111
   Kharfan-Dabaja MA, 2012, LANCET INFECT DIS, V12, P290, DOI 10.1016/S1473-3099(11)70344-9
   Lilja AE, 2008, P NATL ACAD SCI USA, V105, P19950, DOI 10.1073/pnas.0811063106
   Lockridge KM, 1999, J VIROL, V73, P9576, DOI 10.1128/JVI.73.11.9576-9583.1999
   Majchrzak K, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90547
   Manicklal S, 2013, CLIN MICROBIOL REV, V26, P86, DOI 10.1128/CMR.00062-12
   Mayer B.T., 2017, J VIROL, V91
   Nelson CS, 2018, P NATL ACAD SCI USA, V115, P6267, DOI 10.1073/pnas.1800177115
   Noriega V, 2012, IMMUNOL RES, V54, P140, DOI 10.1007/s12026-012-8304-8
   Odom CI, 2012, ADV VIROL, V2012, DOI 10.1155/2012/359869
   Oxford KL, 2008, VIROLOGY, V373, P181, DOI 10.1016/j.virol.2007.10.040
   Pande NT, 2005, J VIROL, V79, P5786, DOI 10.1128/JVI.79.9.5786-5798.2005
   Pass RF, 2009, J CLIN VIROL, V46, pS73, DOI 10.1016/j.jcv.2009.07.002
   Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749
   Permar SR, 2018, J VIROL, V92, DOI 10.1128/JVI.00030-18
   Powers CJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000150
   Revello MG, 2010, REV MED VIROL, V20, P136, DOI 10.1002/rmv.645
   Sashihara J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002308
   SHARP M, 1992, J INFECT DIS, V165, P852, DOI 10.1093/infdis/165.5.852
   Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102
   Wang D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9387
   Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035
   WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006
   Wussow F, 2013, J VIROL, V87, P1322, DOI 10.1128/JVI.01669-12
   Yue YJ, 2003, J GEN VIROL, V84, P3371, DOI 10.1099/vir.0.19508-0
   Yue YJ, 2008, MED MICROBIOL IMMUN, V197, P117, DOI 10.1007/s00430-008-0074-5
   Zhou MM, 2015, J VIROL, V89, P8999, DOI 10.1128/JVI.01325-15
NR 45
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 333
EP 342
DI 10.1016/j.vaccine.2018.08.043
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300018
PM 30522906
DA 2020-05-12
ER

PT J
AU Statler, VA
   Albano, FR
   Airey, J
   Sawlwin, DC
   Jones, AG
   Matassa, V
   Heijnen, E
   Edelman, J
   Marshall, GS
AF Statler, Victoria A.
   Albano, Frank R.
   Airey, Jolanta
   Sawlwin, Daphne C.
   Jones, Alison Graves
   Matassa, Vince
   Heijnen, Esther
   Edelman, Jonathan
   Marshall, Gary S.
TI Immunogenicity and safety of a quadrivalent inactivated influenza
   vaccine in children 6-59 months of age: A phase 3, randomized,
   noninferiority study
SO VACCINE
LA English
DT Article
DE Immunogenicity; Inactivated influenza vaccine; Paediatrics; Quadrivalent
   influenza vaccine; Safety
ID UNITED-STATES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SEASONAL
   INFLUENZA; RECOMMENDATIONS; PREVENTION; TRIAL
AB Background: In the Southern Hemisphere 2010 influenza season, Segirus' split-virion, trivalent inactivated influenza vaccine was associated with increased reports of fevers and febrile reactions in young children. A staged clinical development program of a quadrivalent vaccine (Seqirus IIV4 [S-IIV4]; Afluria (R) Quadrivalent/Afluria Quad (TM)/Afluria Tetrar (TM)), wherein each vaccine strain is split using a higher detergent concentration to reduce lipid content (considered the cause of the increased fevers and febrile reactions), is now complete.
   Methods: Children aged 6-59 months were randomized 3:1 and stratified by age (6-35 months/36-59 months) to receive S-IIV4 (n = 1684) or a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone Quadrivalent; n = 563) during the Northern Hemisphere 2016-2017 influenza season. The primary objective was to demonstrate noninferior immunogenicity of S-IIV4 versus C-IIV4.Immunogenicity was assessed by hemagglutination inhibition (baseline, 28 days postvaccination). Solicited, unsolicited, and serious adverse events were assessed for 7, 28, and 180 days postvaccination, respectively.
   Results: S-IIV4 met the immunogenicity criteria for noninferiority. Adjusted geometric mean titer ratios (C-IIV4/S-IIV4) for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 0.79 (95% CI: 0.72, 0.88), 1.27 (1.15, 1.42), 1.12 (1.01,1.24), and 0.97 (0.86,1.09), respectively. Corresponding values for differences in seroconversion rates (C-IIV4 minus S-IIV4) were -10.3 (-15.4, -5.1), 2.6 (-2.5, 7.8), 3.1 (-2.1, 8.2), and 0.9 (-4.2, 6.1). Solicited, unsolicited, and serious adverse events were similar between vaccines in both age cohorts, apart from fever. Fever rates were lower with S-IIV4 (5.8%) than C-IIV4 (8.4%), with no febrile convulsions reported with either vaccine during the 7 days postvaccination.
   Conclusion: S-IIV4, manufactured with a higher detergent concentration, demonstrated noninferior immunogenicity to the US -licensed C-IIV4, with similar postvaccination safety and tolerability, in children aged 6-59 months. This completes the program demonstrating the immunogenicity and safety of S-IIV4 in participants aged 6 months and older. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Statler, Victoria A.; Marshall, Gary S.] Univ Louisville, Sch Med, Div Pediat Infect Dis, Louisville, KY 40292 USA.
   [Albano, Frank R.; Airey, Jolanta; Matassa, Vince] Seqirus Pty Ltd, Clin Dev, 63 Poplar Rd, Parkville, Vic 3052, Australia.
   [Sawlwin, Daphne C.; Jones, Alison Graves] Seqirus Pty Ltd, Global Pharmacovigilance & Risk Management, Parkville, Vic, Australia.
   [Heijnen, Esther] Seqirus Netherlands BV, Clin Dev, Amsterdam, Netherlands.
   [Edelman, Jonathan] Seqirus USA Inc, Clin Dev, Cambridge, MA USA.
RP Albano, FR (reprint author), Seqirus Pty Ltd, Clin Dev, 63 Poplar Rd, Parkville, Vic 3052, Australia.
EM frank.albano@seqirus.com
FU Seqirus Pty Ltd., Australia
FX This study was sponsored by Seqirus Pty Ltd, Australia,
   manufacturer/licensee of Afluria (R) Quadrivalent/Afluria Quad
   (TM)/Afluria Tetra (TM) (trademarks of Seqirus UK Limited or its
   affiliates). Medical writing assistance was provided by Jordana
   Campbell, BSc and Justine Southby, PhD, CMPP of ProScribe - Envision
   Pharma Group, and was funded by Seqirus Pty Ltd, Australia. ProScribe's
   services complied with international guidelines for Good Publication
   Practice (GPP3).
CR Airey J, 2017, VACCINE, V35, P2745, DOI 10.1016/j.vaccine.2017.03.028
   [Anonymous], 2013, WORLD MED ASS DECL H
   Brady RC, 2014, VACCINE, V32, P7141, DOI 10.1016/j.vaccine.2014.10.024
   Centers for Disease Control and Prevention, 2015, EST INFL ILL HOSP AV
   Domachowske JB, 2013, J INFECT DIS, V207, P1878, DOI 10.1093/infdis/jit091
   Greenberg DP, 2014, PEDIATR INFECT DIS J, V33, P630, DOI 10.1097/INF.0000000000000254
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Rockman S, 2014, VACCINE, V32, P3869, DOI 10.1016/j.vaccine.2014.03.035
   Therapeutic Goods Administration, 2010, OV VACC SAF MON INV
   Therapeutic Goods Administration, 2010, INV FEBR REACT YOUNG
   Treanor JT, 2017, VACCINE, V35, P1856, DOI 10.1016/j.vaccine.2017.02.066
   U.S Food and Drug Administration, 1996, GUID IND E6 GOOD CLI
   *US FDA, 2007, GUID IND CLIN DAT NE
NR 14
TC 3
Z9 6
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 343
EP 351
DI 10.1016/j.vaccine.2018.07.036
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300019
PM 30057283
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pan, WK
   Seidman, JC
   Ali, A
   Hoest, C
   Mason, C
   Mondal, D
   Knobler, SL
   Bessong, P
   Blank, RR
   Gottlieb, M
   Knobler, SL
   Lang, DR
   Miller, MA
   Tountas, KH
   Bhutta, ZA
   Caulfield, L
   Checkley, W
   Guerrant, RL
   Houpt, E
   Kosek, MN
   Mason, CJ
   Murray-Kolb, LE
   Petri, WA
   Seidman, JC
   Ahmed, T
   Bessong, P
   Haque, R
   John, S
   Kang, G
   Lima, AAM
   Mduma, ER
   Oria, RB
   Shrestha, PS
   Shrestha, SK
   Svensen, E
   Zaidi, AKM
   Abreu, CB
   Acosta, AM
   Ahmed, I
   Ahmed, AMS
   Ali, A
   Ambikapathi, R
   Barrett, L
   Bauck, A
   Bayyo, E
   Bodhidatta, L
   Bose, A
   Carreon, JD
   Chandyo, RK
   Charu, V
   Costa, H
   Dillingham, R
   Di Moura, A
   Doan, V
   Quirino, J
   Graham, J
   Hoest, C
   Hossain, I
   Islam, M
   Jennifer, MS
   Kaki, S
   Koshy, B
   Lee, G
   Leite, AM
   Lima, NL
   Maciel, BLL
   Mahfuz, M
   Mahopo, C
   Maphula, A
   McCormick, BJJ
   McGrath, M
   Mohale, A
   Moraes, M
   Mota, FS
   Muliyil, J
   Mvungi, R
   Nayyar, G
   Nyathi, E
   Olortegui, MP
   Oria, R
   Vasquez, AO
   Pan, WK
   Pascal, J
   Patil, CL
   Pendergast, L
   Pinedo, SR
   Platts-Mills, J
   Psaki, S
   Raghava, MV
   Ramanujam, K
   Rasheed, M
   Rasmussen, ZA
   Richard, SA
   Rose, A
   Roshan, R
   Schaefer, B
   Scharf, R
   Sharma, SL
   Shrestha, B
   Shrestha, R
   Simons, S
   Soares, AM
   Mota, RMS
   Soofi, S
   Strand, T
   Tofail, F
   Thomas, RJ
   Turab, A
   Ulak, M
   Wang, V
   Yarrot, L
   Yori, PP
   Alam, D
   Amour, C
   Chavez, CB
   Babji, S
   de Burga, RR
   Flores, JT
   Gratz, J
   George, AT
   Hariraju, D
   Havt, A
   Karunakaran, P
   Lazarus, RP
   Lima, IF
   Mondal, D
   Medeiros, PHQS
   Nshama, R
   Quetz, J
   Qureshi, S
   Raju, S
   Ramachandran, A
   Ramadas, R
   Ross, AC
   Salas, MS
   Samie, A
   Schulze, K
   Sundaram, S
   Swema, BM
   Trigoso, DR
AF Pan, William K.
   Seidman, Jessica C.
   Ali, Asad
   Hoest, Christel
   Mason, Carl
   Mondal, Dinesh
   Knobler, Stacey L.
   Bessong, Pascal
   Blank, Rebecca R.
   Gottlieb, Michael
   Knobler, Stacey L.
   Lang, Dennis R.
   Miller, Mark A.
   Tountas, Karen H.
   Bhutta, Zulfiqar A.
   Caulfield, Laura
   Checkley, William
   Guerrant, Richard L.
   Houpt, Eric
   Kosek, Margaret N.
   Mason, Carl J.
   Murray-Kolb, Laura E.
   Petri, William A., Jr.
   Seidman, Jessica C.
   Ahmed, Tahmeed
   Bessong, Pascal
   Haque, Rashidul
   John, Sushil
   Kang, Gagandeep
   Lima, Aldo A. M.
   Mduma, Estomih R.
   Oria, Reinaldo B.
   Shrestha, Prakash Sunder
   Shrestha, Sanjaya Kumar
   Svensen, Erling
   Zaidi, Anita K. M.
   Abreu, Claudia B.
   Acosta, Angel Mendez
   Ahmed, Imran
   Ahmed, A. M. Shamsir
   Ali, Asad
   Ambikapathi, Ramya
   Barrett, Leah
   Bauck, Aubrey
   Bayyo, Eliwaza
   Bodhidatta, Ladaporn
   Bose, Anuradha
   Carreon, J. Daniel
   Chandyo, Ram Krishna
   Charu, Vivek
   Costa, Hilda
   Dillingham, Rebecca
   Di Moura, Alessandra
   Doan, Viyada
   Filho, Jose Quirino
   Graham, Jhanelle
   Hoest, Christel
   Hossain, Iqbal
   Islam, Munirul
   Jennifer, M. Steffi
   Kaki, Shiny
   Koshy, Beena
   Lee, Gwenyth
   Leite, Alvaro M.
   Lima, Noelia L.
   Maciel, Bruna L. L.
   Mahfuz, Mustafa
   Mahopo, Cloupas
   Maphula, Angelina
   McCormick, Benjamin J. J.
   McGrath, Monica
   Mohale, Archana
   Moraes, Milena
   Mota, Francisco S.
   Muliyil, Jayaprakash
   Mvungi, Regisiana
   Nayyar, Gaurvika
   Nyathi, Emanuel
   Olortegui, Maribel Paredes
   Oria, Reinaldo
   Vasquez, Angel Orbe
   Pan, William K.
   Pascal, John
   Patil, Crystal L.
   Pendergast, Laura
   Pinedo, Silvia Rengifo
   Platts-Mills, James
   Psaki, Stephanie
   Raghava, Mohan Venkata
   Ramanujam, Karthikeyan
   Rasheed, Muneera
   Rasmussen, Zeba A.
   Richard, Stephanie A.
   Rose, Anuradha
   Roshan, Reeba
   Schaefer, Barbara
   Scharf, Rebecca
   Sharma, Srujan L.
   Shrestha, Binob
   Shrestha, Rita
   Simons, Suzanne
   Soares, Alberto M.
   Mota, Rosa M. S.
   Soofi, Sajid
   Strand, Tor
   Tofail, Fahmida
   Thomas, Rahul J.
   Turab, Ali
   Ulak, Manjeswori
   Wang, Vivian
   Yarrot, Ladislaus
   Yori, Pablo Penataro
   Alam, Didar
   Amour, Caroline
   Chavez, Cesar Banda
   Babji, Sudhir
   de Burga, Rosa Rios
   Flores, Julian Torres
   Gratz, Jean
   George, Ajila T.
   Hariraju, Dinesh
   Havt, Alexandre
   Karunakaran, Priyadarshani
   Lazarus, Robin P.
   Lima, Ila F.
   Mondal, Dinesh
   Medeiros, Pedro H. Q. S.
   Nshama, Rosemary
   Quetz, Josiane
   Qureshi, Shahida
   Raju, Sophy
   Ramachandran, Anup
   Ramadas, Rakhi
   Ross, A. Catharine
   Salas, Mery Siguas
   Samie, Amidou
   Schulze, Kerry
   Sundaram E, Shanmuga
   Swema, Buliga Mujaga
   Trigoso, Dixner Rengifo
CA MAL-ED Network Investigators
TI Oral polio vaccine response in the MAL-ED birth cohort study:
   Considerations for polio eradication strategies
SO VACCINE
LA English
DT Article
DE Oral polio vaccination; Poliomyelitis; Enteropathogen infection; Home
   environment
ID CASH TRANSFER PROGRAMS; ANTIBODY-RESPONSE; ENVIRONMENTAL ENTEROPATHY;
   DEVELOPING-COUNTRIES; FEEDING PRACTICES; MUCOSAL IMMUNITY; GUT FUNCTION;
   FED INFANTS; CHILDREN; TRIVALENT
AB Background: Immunization programs have leveraged decades of research to maximize oral polio vaccine (OPV) response. Moving toward global poliovirus eradication, the WHO recommended phased OPV-to-IPV replacement on schedules in 2012. Using the MAL-ED prospective birth cohort data, we evaluated the influence of early life exposures impacting OPV immunization by measuring OPV response for serotypes 1 and 3.
   Methods: Polio neutralizing antibody assays were conducted at 7 and 15 months of age for serotypes 1 and 3. Analyses were conducted on children receiving >= 3 OPV doses (n = 1449). History of vaccination, feeding patterns, physical growth, home environment, diarrhea, enteropathogen detection, and gut inflammation were examined as risk factors for non-response [Log(2)(titer)< 3] and Log(2)(titer) by serotype using multivariate regression.
   Findings: Serotype 1 seroconversion was significantly higher than serotype 3 (96.6% vs. 89.6%, 15 months). Model results indicate serotypes 1 and 3 failure was minimized following four and six OPV doses, respectively; however, enteropathogen detection and poor socioeconomic conditions attenuated response in both serotypes. At three months of age, bacterial detection in stool reduced serotype 1 and 3 Log(2) titers by 0.34 (95% CI 0.14-0.54) and 0.53 (95% CI 0.29-0.77), respectively, and increased odds of serotype 3 failure by 3.0 (95% CI 1.6-5.8). Our socioeconomic index, consisting of Water, Assets, Maternal education, and Income (WAMI), was associated with a 0.79 (95% CI 0.15-1.43) and 1.23 (95% CI 034-2.12) higher serotype 1 and 3 Log(2) titer, respectively, and a 0.04 (95% CI 0.002-0.40) lower odds of serotype 3 failure. Introduction of solids, transferrin receptor, and underweight were differentially associated with serotype response. Other factors, including diarrheal frequency and breastfeeding practices, were not associated with OPV response.
   Interpretation: Under real-world conditions, improved vaccination coverage and socio-environmental conditions, and reducing early life bacterial exposures are key to improving OPV response and should inform polio eradication strategies. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Pan, William K.] Duke Univ, Duke Global Hlth Inst, Trent Hall,310 Trent Dr, Durham, NC 27710 USA.
   [Seidman, Jessica C.; Hoest, Christel; Knobler, Stacey L.; Knobler, Stacey L.; Lang, Dennis R.; Miller, Mark A.; Checkley, William; Seidman, Jessica C.; Ambikapathi, Ramya; Carreon, J. Daniel; Charu, Vivek; Doan, Viyada; Filho, Jose Quirino; Graham, Jhanelle; Hoest, Christel; McCormick, Benjamin J. J.; McGrath, Monica; Mohale, Archana; Nayyar, Gaurvika; Pan, William K.; Psaki, Stephanie; Rasmussen, Zeba A.; Richard, Stephanie A.; Schaefer, Barbara; Wang, Vivian] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Ali, Asad] Aga Khan Univ, Karachi, Pakistan.
   [Mason, Carl] Armed Forces Res Inst Med Sci, Bangkok, Thailand.
   [Mondal, Dinesh; Ahmed, Tahmeed; Haque, Rashidul; Ahmed, A. M. Shamsir; Hossain, Iqbal; Islam, Munirul; Mahfuz, Mustafa; Tofail, Fahmida; Mondal, Dinesh] ICDDR B, Dhaka, Bangladesh.
   [Bessong, Pascal; Bessong, Pascal; Mahopo, Cloupas; Maphula, Angelina; Nyathi, Emanuel; Samie, Amidou] Univ Venda, Thohoyandou, South Africa.
   [Acosta, Angel Mendez; Olortegui, Maribel Paredes; Vasquez, Angel Orbe; Pinedo, Silvia Rengifo; Chavez, Cesar Banda; de Burga, Rosa Rios; Flores, Julian Torres; Salas, Mery Siguas; Trigoso, Dixner Rengifo] AB PRISMA, Iquitos, Peru.
   [Bhutta, Zulfiqar A.; Zaidi, Anita K. M.; Ahmed, Imran; Ali, Asad; Rasheed, Muneera; Soofi, Sajid; Turab, Ali; Alam, Didar; Qureshi, Shahida] Aga Khan Univ, Karachi, Pakistan.
   [Mason, Carl J.; Bodhidatta, Ladaporn] Armed Forces Res Inst Med Sci, Bangkok, Thailand.
   [John, Sushil; Kang, Gagandeep; Bose, Anuradha; Jennifer, M. Steffi; Kaki, Shiny; Koshy, Beena; Muliyil, Jayaprakash; Raghava, Mohan Venkata; Ramanujam, Karthikeyan; Rose, Anuradha; Roshan, Reeba; Sharma, Srujan L.; Thomas, Rahul J.; Babji, Sudhir; George, Ajila T.; Hariraju, Dinesh; Karunakaran, Priyadarshani; Lazarus, Robin P.; Raju, Sophy; Ramachandran, Anup; Ramadas, Rakhi; Sundaram E, Shanmuga] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
   [Pan, William K.] Duke Univ, Durham, NC USA.
   [Blank, Rebecca R.; Gottlieb, Michael; Lang, Dennis R.; Tountas, Karen H.] Fdn NIH, Bethesda, MD USA.
   [Mduma, Estomih R.; Svensen, Erling; Bayyo, Eliwaza; Mvungi, Regisiana; Pascal, John; Yarrot, Ladislaus; Amour, Caroline; Nshama, Rosemary; Swema, Buliga Mujaga] Haydom Lutheran Hosp, Haydom, Tanzania.
   [Shrestha, Prakash Sunder; Chandyo, Ram Krishna; Shrestha, Rita; Ulak, Manjeswori] Tribhuvan Univ, Inst Med, Kathmandu, Nepal.
   [Caulfield, Laura; Checkley, William; Kosek, Margaret N.; Bauck, Aubrey; Lee, Gwenyth; Yori, Pablo Penataro; Schulze, Kerry] Johns Hopkins Univ, Baltimore, MD USA.
   [Murray-Kolb, Laura E.; Schaefer, Barbara; Simons, Suzanne; Ross, A. Catharine] Penn State Univ, University Pk, PA 16802 USA.
   [Pendergast, Laura] Temple Univ, Philadelphia, PA 19122 USA.
   [Lima, Aldo A. M.; Oria, Reinaldo B.; Abreu, Claudia B.; Costa, Hilda; Di Moura, Alessandra; Filho, Jose Quirino; Leite, Alvaro M.; Lima, Noelia L.; Maciel, Bruna L. L.; Moraes, Milena; Mota, Francisco S.; Oria, Reinaldo; Soares, Alberto M.; Mota, Rosa M. S.; Havt, Alexandre; Lima, Ila F.; Medeiros, Pedro H. Q. S.; Quetz, Josiane] Univ Fed Ceara, Fortaleza, Ceara, Brazil.
   [Strand, Tor] Univ Bergen, Bergen, Norway.
   [Patil, Crystal L.] Univ Illinois, Chicago, IL USA.
   [Guerrant, Richard L.; Houpt, Eric; Petri, William A., Jr.; Barrett, Leah; Dillingham, Rebecca; Platts-Mills, James; Scharf, Rebecca; Gratz, Jean] Univ Virginia, Charlottesville, VA USA.
   [Shrestha, Sanjaya Kumar; Shrestha, Binob; Strand, Tor] Walter Reed AFRIMS Res Unit, Kathmandu, Nepal.
   [Svensen, Erling] Haukeland Hosp, Bergen, Norway.
RP Pan, WK (reprint author), Duke Univ, Duke Global Hlth Inst, Trent Hall,310 Trent Dr, Durham, NC 27710 USA.
EM william.pan@duke.edu; rebecca.blank@gmail.com; mgottlieb@fnih.org;
   Stacey.Knobler@nih.gov; Lang4@fnih.org; Mark.Miller3@nih.gov;
   ktountas@fnih.org; zulfiqar.bhutta@aku.edu; lcaulfi1@jhu.edu;
   wcheckl1@jhmi.edu; guerrant@virginia.edu; erh6k@virginia.edu;
   mkosek@jhmi.edu; carlmason@icloud.com; lem118@psu.edu;
   wap3g@virginia.edu; Jessica.Seidman@nih.gov; tahmeed@icddrb.org;
   pascal.bessong@univen.ac.za; rhaque@icddrb.org;
   rikkisush@cmcvellore.ac.in; gkang@cmcvellore.ac.in; alima@ufc.br;
   estomih.mduma@haydom.co.tz; rbo5u@hscmail.mcc.virginia.edu;
   prakashsunder@hotmail.com; ShresthaSK@afrims.org;
   Erling.Svensen@cih.uib.no; anita.zaidi@aku.edu;
   claudia_beghini2004@yahoo.com.br; amendez@prisma.org.pe;
   imran.ahmed@aku.edu; a.ahmed@uq.net.au; asad.ali@aku.edu;
   rambikapathi@gmail.com; ljbarrett@mindspring.com; abauck1@jhu.edu;
   elb.bayo@gmail.com; ladapornb@afrims.org; abose@cmcvellore.ac.in;
   carreonj@mail.nih.gov; ram.chandyo@uib.no; vcharu@jhsph.edu;
   hildacosta@hotmail.com; rd8v@virginia.edu;
   ferrer.alessandra@yahoo.com.br; Viyada.Doan@nih.gov;
   jqf_ce@yahoo.com.br; jhalexia@gmail.com; christel.host@nih.gov;
   ihossain@icddrb.org; mislam@icddrb.org; stefjeni.11@gmail.com;
   shinykaki@gmail.com; beenakoshy1@rediffmail.com; gwenyth.lee@gmail.com;
   alvaromadeiro@yahoo.com.br; noelialima30@yahoo.com.br;
   brunalimamaciel@gmail.com; mustafa@icddrb.org; mahopotc@gmail.com;
   angelina.maphula@univen.ac.za; ben.mccormick@gmail.com;
   mcgrath.monica@gmail.com; mohalea@mail.nih.gov; milenamaia@hotmail.com;
   sulivan.mota@iprede.org.br; jpmuliyil@gmail.com; regisiana@yahoo.com;
   gaurvika@gmail.com; Emanuel.Nyathi@univen.ac.za;
   mparedeso@prisma.org.pe; rbo5u@hscmail.mcc.virginia.edu;
   angel_orbe@hotmail.com; william.pan@duke.edu;
   johnagustinopaschal@gmail.com; cpatil@uic.edu;
   laura.pendergast@temple.edu; siguase36@hotmail.com;
   jp5t@hscmail.mcc.virginia.edu; spsaki@popcouncil.org;
   venkat@cmcvellore.ac.in; karthikeyan05@yahoo.co.in;
   muneera.rasheed@aku.edu; Zeba.Rasmussen@nih.gov;
   Stephanie.Richard@nih.gov; anurose@cmcvellore.ac.in;
   reebageorge@hotmail.com; bas19@psu.edu; rebeccascharf@virginia.edu;
   srujan.sharma@gmail.com; binobs@afrims.org; ritas_12@yahoo.com;
   sxs126@psu.edu; rosa@dema.ufc.br; sajid.soofi@aku.edu; Tors@me.com;
   Tors@me.com; ftofail@icddrb.org; rj_thomas99@yahoo.com;
   turab.ali@aku.edu; manjeswori@gmail.com; aijun.wang@nih.gov;
   ladisblacy@yahoo.com; pyori@jhsph.edu; didar.alam@aku.edu;
   lyneamour@gmail.com; cebchavez@yahoo.com; sudhirbabji@cmcvellore.ac.in;
   rosaburga@gmail.com; jflores@prisma.org.pe; jean.gratz@gmail.com;
   agilatgeorge@gmail.com; dinesh85@gmail.com; ahavtbinda@gmail.com;
   priyadarshinicmc15@gmail.com; robin.lazarus@gmail.com;
   ilafarm@yahoo.com.br; din63d@icddrb.org; phquintela@hotmail.com;
   nshamarosemary@yahoo.com; jquetz@gmail.com; shahida.qureshi@aku.edu;
   sophyraju@gmail.com; anuprama@yahoo.co.uk; rakhi.ram9@gmail.com;
   Acr6@psu.edu; msiguas@prisma.org.pe; samieamidou@yahoo.com;
   kschulz1@jhu.edu; shanmugame@cmcvellore.ac.in; buligamujaga@yahoo.co.uk;
   drengifo@prisma.org.pe
RI Petri, William A./D-3639-2019; Havt, Alexandre/AAM-8585-2020; Petri,
   William/AAL-3642-2020; Bessong, Pascal/AAA-5907-2020; Mahopo,
   Tjale/W-4933-2019; Oria, Reinaldo B/D-6440-2014; Strand,
   Tor/D-9836-2016; MASON, CARL/F-3538-2010
OI Petri, William/0000-0002-7268-1218; Mahopo, Tjale/0000-0003-0186-1438;
   Strand, Tor/0000-0002-4038-151X; MASON, CARL/0000-0002-3676-2811;
   Bessong, Pascal/0000-0003-0561-272X
FU Bill AMP; Melinda Gates Foundation
FX The Bill & Melinda Gates Foundation.
CR Acosta AM, 2014, CLIN INFECT DIS, V59, pS193, DOI 10.1093/cid/ciu653
   [Anonymous], 1995, J Infect Dis, V171, P1097
   Banda K, 2007, T ROY SOC TROP MED H, V101, P1124, DOI 10.1016/j.trstmh.2007.05.004
   BHATAWDEKAR A M, 1990, Indian Pediatrics, V27, P911
   Bradley Robert, 1984, HOME ENV EARLY COGNI, P5
   Caldwell B. M., 2003, HOME OBSERVATION MEA
   Cardemil CV, 2016, VACCINE, V34, P2519, DOI 10.1016/j.vaccine.2016.03.027
   Caulfield LE, 2014, CLIN INFECT DIS, V59, pS248, DOI 10.1093/cid/ciu421
   CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19, DOI 10.1093/tropej/35.1.19
   COHENABBO A, 1995, PEDIATR INFECT DIS J, V14, P100, DOI 10.1097/00006454-199502000-00004
   DOMOK I, 1974, B WORLD HEALTH ORGAN, V51, P333
   DOMOK I, 1984, REV INFECT DIS, V6, pS413
   FADEN H, 1990, J INFECT DIS, V162, P1291, DOI 10.1093/infdis/162.6.1291
   FADEN H, 1993, J INFECT DIS, V168, P452, DOI 10.1093/infdis/168.2.452
   Fernald LCH, 2008, LANCET, V371, P828, DOI 10.1016/S0140-6736(08)60382-7
   Global Polio Eradication Initiative, 2018, POL CAS WORLDW GLOB
   Grassly NC, 2010, J INFECT DIS, V201, P1535, DOI 10.1086/651952
   Guerin N, 1998, EUR J CLIN MICROBIOL, V17, P815, DOI 10.1007/s100960050198
   Haque R, 2014, VACCINE, V32, P478, DOI 10.1016/j.vaccine.2013.11.056
   Herremans TMPT, 1999, J IMMUNOL, V162, P5011
   Hird TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002599
   Hoest C, 2016, VACCINE
   Hoest C, 2017, VACCINE, V35, P443, DOI 10.1016/j.vaccine.2016.11.075
   Hoest C, 2014, CLIN INFECT DIS, V59, pS273, DOI 10.1093/cid/ciu611
   Houpt E, 2014, CLIN INFECT DIS, V59, pS225, DOI 10.1093/cid/ciu413
   JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457
   JOHN TJ, 1976, BRIT MED J, V1, P812, DOI 10.1136/bmj.1.6013.812
   JOHN TJ, 1976, B WORLD HEALTH ORGAN, V54, P115
   Jones PC, 2017, J SCHOOL PSYCHOL, V64, P109, DOI 10.1016/j.jsp.2017.06.001
   Kabeer N, 2015, J DEV EFFECT, V7, P290, DOI 10.1080/19439342.2015.1068833
   Keusch GT, 2014, CLIN INFECT DIS, V59, pS207, DOI 10.1093/cid/ciu485
   Kew OM, 2014, MMWR-MORBID MORTAL W, V63, P1031
   Khare Shashi, 1993, Indian Journal of Pediatrics, V60, P275, DOI 10.1007/BF02822191
   Kosek M, 2014, CLIN INFECT DIS, V59, pS239, DOI 10.1093/cid/ciu457
   Kosek MN, 2017, EBIOMEDICINE, V18, P109, DOI 10.1016/j.ebiom.2017.02.024
   Lagarde M, 2007, JAMA-J AM MED ASSOC, V298, P1900, DOI 10.1001/jama.298.16.1900
   Lee GO, 2017, AM J TROP MED HYG, V97, P281, DOI 10.4269/ajtmh.16-0830
   LEPOW ML, 1961, NEW ENGL J MED, V264, P1071, DOI 10.1056/NEJM196105252642102
   McCormick BJJ, 2017, AM J TROP MED HYG, V96, P465, DOI 10.4269/ajtmh.16-0496
   Mir F, 2015, LANCET INFECT DIS, V15, P889, DOI 10.1016/S1473-3099(15)00093-6
   Murray-Kolb LE, 2014, CLIN INFECT DIS, V59, pS261, DOI 10.1093/cid/ciu437
   Myaux JA, 1996, PEDIATR INFECT DIS J, V15, P204, DOI 10.1097/00006454-199603000-00006
   Naylor C, 2015, EBIOMEDICINE
   ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1
   PATRIARCA PA, 1988, LANCET, V1, P429
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   Platts-Mills JA, 2015, LANCET GLOB HEALTH, V3, pE564, DOI 10.1016/S2214-109X(15)00151-5
   PolioEradication.Org, 2017, CIRC VACC DER POL
   POLTKIN SA, 1966, AM J DIS CHILD, V111, P27
   Posey DL, 1997, J INFECT DIS, V175, pS258, DOI 10.1093/infdis/175.Supplement_1.S258
   Prevots DR, 2004, PEDIATR INFECT DIS J, V23, P1130, DOI 10.1097/01.inf.0000143641.27336.2e
   Psaki S, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-24
   Psaki SR, 2014, POPUL HEALTH METR, V12, DOI 10.1186/1478-7954-12-8
   Raihan MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172134
   Richard SA, 2014, CLIN INFECT DIS, V59, pS220, DOI 10.1093/cid/ciu435
   SAS, 2012, SAS 9 4 X64 9 4
   SIMOES EAF, 1985, AM J DIS CHILD, V139, P977, DOI 10.1001/archpedi.1985.02140120023021
   STEWIEN KE, 1985, REV SAUDE PUBL, V19, P51, DOI 10.1590/S0034-89101985000100006
   Sutter RW, 2014, J INFECT DIS, V210, pS434, DOI 10.1093/infdis/jiu222
   Tebbens RJD, 2013, RISK ANAL, V33, P544, DOI 10.1111/j.1539-6924.2012.01864.x
   WARREN RJ, 1964, PEDIATRICS, V34, P4
   World Health Organization, 2006, WHO CHILD GROWTH STA, DOI 10.4067/S0370-41062009000400012
   World Health Organization Expanded Program on Immunization and Division of Communicable Diseases, 1990, MAN VIR INV POL GEN
NR 63
TC 2
Z9 2
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 352
EP 365
DI 10.1016/j.vaccine.2018.05.080
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300020
PM 30442479
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Nakayama, T
AF Nakayama, Tetsuo
TI Causal relationship between immunological responses and adverse
   reactions following vaccination
SO VACCINE
LA English
DT Review
DE Gelatin allergy; Anaphylaxis; Influenza vaccine; Adverse events; Adverse
   reaction
ID C MEASLES-VACCINE; AIK-C; INFLUENZA VACCINE; EDMONSTON-ZAGREB; FUSION
   PROTEIN; IMMUNIZATION; VIRUS; ANTIBODIES; SYMPTOMS; GELATIN
AB Vaccine adverse events and controversial safety issues have occurred in recent decades in Japan: aseptic meningitis following the measles-mumps-rubella combined vaccine (MMR), anaphylaxis after immunization with live virus vaccines and inactivated split influenza vaccine, an increased incidence of febrile illness following the simultaneous administration of inactivated vaccines, and chronic pain with neurological illness after immunization with the human papilloma virus vaccine (HPV). Vaccine adverse events are a matter of concern for the public as well as general practitioners; some are within the range of assumptions that adverse reactions after live attenuated vaccines are related to the nature of their parental wild-type viruses. Vaccines stimulate the innate immunity of host immunological defense mechanisms and induce the development of specific acquired immunity. Some adverse events related to autoimmune responses have been reported, such as idiopathic thrombocytopenic purpura and acute disseminated encephalomyelitis (ADEM). Although a plausible relationship was not demonstrated, the possibility of an association cannot be denied. The pathogenicity of adverse reactions was investigated for anaphylactic reactions, systemic and local reactions following vaccinations. Initial innate immune responses are essential for the development of acquired immunity and are related to adverse events from different viewpoints. (C) 2018 Published by Elsevier Ltd.
C1 [Nakayama, Tetsuo] Kitasato Inst Life Sci, Lab Viral Infect, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.
RP Nakayama, T (reprint author), Kitasato Inst Life Sci, Lab Viral Infect, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.
EM tetsuo-n@lisci.kitasato-u.ac.jp
CR [Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P1049
   BOLOTOVSKI VM, 1994, INT J EPIDEMIOL, V23, P1069, DOI 10.1093/ije/23.5.1069
   Duffy J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0320
   GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L
   GURVICH EB, 1983, ACTA VIROL, V27, P154
   Hale BG, 2010, FUTURE MICROBIOL, V5, P23, DOI [10.2217/fmb.09.108, 10.2217/FMB.09.108]
   Hara M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0777-3
   Kashiwagi Y, 2014, HUM VACC IMMUNOTHER, V10, P677, DOI 10.4161/hv.27264
   Kashiwagi Y, 2014, VACCINE, V32, P3393, DOI 10.1016/j.vaccine.2014.04.018
   Kelso JM, 2014, EXPERT REV VACCINES, V13, P1049, DOI 10.1586/14760584.2014.933079
   Kimura M, 1996, ACTA PAEDIATR JAPON, V38, P205
   Kinoshita T, 2014, INTERNAL MED, V53, P2185, DOI 10.2169/internalmedicine.53.3133
   Komase K, 2006, VACCINE, V24, P826, DOI 10.1016/j.vaccine.2005.06.036
   Kumagai T, 2000, CLIN EXP ALLERGY, V30, P1430, DOI 10.1046/j.1365-2222.2000.00940.x
   Kuno-Sakai H, 2004, BIOLOGICALS, V32, P29, DOI 10.1016/j.biologicals.2003.11.001
   Kurane Ichiro, 2005, Uirusu, V55, P307, DOI 10.2222/jsv.55.307
   Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009
   Nagai M, 2009, J MED VIROL, V81, P1094, DOI 10.1002/jmv.21372
   Nagao M, 2016, J ALLERGY CLIN IMMUN, V137, P861, DOI 10.1016/j.jaci.2015.08.001
   Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433
   Nakayama T, 2001, J GEN VIROL, V82, P2143, DOI 10.1099/0022-1317-82-9-2143
   Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7
   Nakayama T, 2007, VACCINE, V25, P570, DOI 10.1016/j.vaccine.2006.05.130
   Nakayama T, 2018, MICROBIOL IMMUNOL, V62, P124, DOI 10.1111/1348-0421.12566
   Nakayama T, 2016, VACCINE, V34, P5815, DOI 10.1016/j.vaccine.2016.08.051
   Nakayama T, 2015, VACCINE, V33, P6099, DOI 10.1016/j.vaccine.2015.05.106
   Nakayama T, 2013, J INFECT CHEMOTHER, V19, P787, DOI 10.1007/s10156-013-0641-6
   Nakayama T, 2012, VACCINE, V30, P3885, DOI 10.1016/j.vaccine.2012.04.004
   Nkrumah FK, 1998, B WORLD HEALTH ORGAN, V76, P353
   Oguchi K, 2015, J INFECT CHEMOTHER, V21, P639, DOI 10.1016/j.jiac.2015.05.006
   Olivier C, 2008, VACCINE, V26, P3142, DOI 10.1016/j.vaccine.2007.11.096
   Ozawa K, 2017, DRUG SAFETY, V40, P1219, DOI 10.1007/s40264-017-0574-6
   Rouleau I, 2012, J ALLERGY CLIN IMMUN, V130, P1423, DOI 10.1016/j.jaci.2012.07.019
   SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7
   Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6
   Sakata M, 2011, VACCINE, V29, P1107, DOI 10.1016/j.vaccine.2010.11.074
   Sato Y, 1990, LANCET, V336, P30
   Smith-Norowitz TA, 2012, J INFLAMM RES, V5, P111, DOI 10.2147/JIR.S34152
   Sugawara K, 2002, BIOLOGICALS, V30, P303, DOI 10.1006/biol.2002.0345
   Suzuki S, 2018, PAPILLOMAVIRUS RES, V5, P96, DOI 10.1016/j.pvr.2018.02.002
   Tanaka-Taya K, 2013, MMWR-MORBID MORTAL W, V62, P457
   TIDJANI O, 1989, LANCET, V2, P1357
   Yoshida N, 2010, INTERVIROLOGY, V53, P193, DOI 10.1159/000299061
NR 43
TC 2
Z9 2
U1 2
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 366
EP 371
DI 10.1016/j.vaccine.2018.11.045
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300021
PM 30503656
DA 2020-05-12
ER

PT J
AU Panozzo, CA
   Pourmalek, F
   Pernus, YB
   Pileggi, GS
   Woerner, A
   Bonhoeffer, J
   Abraham, S
   Bauwens, J
   Bonhoeffer, J
   Pernus, YB
   Caric, A
   Hudson, M
   Oleske, J
   Panozzo, C
   Pileggi, G
   Pourmalek, F
   Varricchio, F
   Velasco, C
   Woerner, A
AF Panozzo, Catherine A.
   Pourmalek, Farshad
   Pernus, Yolanda Brauchli
   Pileggi, Gecilmara S.
   Woerner, Andreas
   Bonhoeffer, Jan
   Abraham, Sonya
   Bauwens, Jorgen
   Bonhoeffer, Jan
   Pernus, Yolanda Brauchli
   Caric, Aleksandra
   Hudson, Michael
   Oleske, James
   Panozzo, Catherine
   Pileggi, Gecilmara
   Pourmalek, Farshad
   Varricchio, Frederick
   Velasco, Cesar
   Woerner, Andreas
CA Brighton Collaboration Aseptic Art
TI Arthritis and arthralgia as an adverse event following immunization: A
   systematic literature review
SO VACCINE
LA English
DT Review
DE Arthritis; Arthralgia; Vaccine; Immunization; Systematic review; Adverse
   event following immunization (AEFI)
ID RANDOMIZED DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; REACTIVE ARTHRITIS;
   ANTHRAX VACCINE; SAFETY DATA; LUPUS-ERYTHEMATOSUS; INFLUENZA VACCINE;
   CONTROLLED-TRIAL; RUBELLA VACCINE; VAERS DATABASE
AB Background: Arthritis and arthralgia are reported as adverse events following immunization with various vaccines.
   Objective: To better understand current knowledge of arthritis and arthralgia as an adverse event following immunization.
   Methods: A systematic literature review of Pubmed, Embase, and Cochrane Library was conducted. Data extraction was performed by two independent reviewers. No restrictions on dates were imposed and all types of vaccine studies with primary data were reviewed.
   Results: Of 343 included studies, there were 206 clinical trials, 90 observational studies, and 47 case reports. Influenza was the most commonly studied vaccine (n = 91, 24.4%). Of the 155 (45.2%) studies addressing causality assessment, 84 studies (54.2%) revealed the assessment method. Only seven clinical trials and 12 observational studies reported a measure of association. Four of these studies examined worsening of arthritic conditions in patients with pre-existing disease. Rigorous assessment of causality was not performed in most studies and many observational studies were prone to bias.
   Conclusions: The current evidence linking vaccination to incident arthritis or worsening of arthritic conditions is too heterogeneous and incomplete to infer a causal association. Recommendations for future studies include use of consistent, standardized case definitions and causality assessments, better control of confounding and minimization of bias, and inclusion of measures of associations. (C) 2018 Published by Elsevier Ltd.
C1 [Panozzo, Catherine A.] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Pourmalek, Farshad] Univ British Columbia, Vancouver, BC, Canada.
   [Pernus, Yolanda Brauchli; Bonhoeffer, Jan] Brighton Collaborat Fdn, Basel, Switzerland.
   [Pileggi, Gecilmara S.] Univ Sao Paulo, Sch Med Ribeirclo Preto, Sao Paulo, Brazil.
   [Woerner, Andreas; Bonhoeffer, Jan] Univ Basel, Childrens Hosp, Spitalstr 33, CH-4056 Basel, Switzerland.
RP Bonhoeffer, J (reprint author), Univ Basel, Childrens Hosp, Spitalstr 33, CH-4056 Basel, Switzerland.
EM contact@brightoncollaboration.org
FU World Health Organization (WHO)World Health Organization
   [SPHQ15-LOA-009]
FX This study was investigator driven and partially supported by the World
   Health Organization (WHO) via SPHQ15-LOA-009.
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   Agnandji ST, 2015, NEW ENGL J MED
   Aksu K, 2006, RHEUMATOL INT, V27, P209, DOI 10.1007/s00296-006-0185-5
   Bardage C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5956
   Bardenheier BH, 2016, MIL MED, V181, P1348, DOI 10.7205/MILMED-D-15-00485
   Barrett PN, 2011, LANCET, V377, P751, DOI 10.1016/S0140-6736(10)62228-3
   Barros SM, 2011, ACTA REUMATOL PORT, P65
   Bengtsson C, 2010, ANN RHEUM DIS, V69, P1831, DOI 10.1136/ard.2010.129908
   BIASI D, 1994, CLIN RHEUMATOL, V13, P645, DOI 10.1007/BF02243011
   BIASI D, 1993, CLIN EXP RHEUMATOL, V11, P215
   Bonhoeffer J, 2005, PHARMACOEPIDEM DR S, V14, P101, DOI 10.1002/pds.979
   Bonhoeffer J, 2009, VACCINE, V27, P2282, DOI 10.1016/j.vaccine.2008.11.036
   Ceners for Disease Control and Prevention, SIERR LEON TRIAL INT
   Chao C, 2012, J INTERN MED, V271, P193, DOI 10.1111/j.1365-2796.2011.02467.x
   Collet JP, 2000, B WORLD HEALTH ORGAN, V78, P178
   Del Porto F, 2006, VACCINE, V24, P3217, DOI 10.1016/j.vaccine.2006.01.028
   DUDGEON JA, 1969, BRIT MED J, V1, P271, DOI 10.1136/bmj.1.5639.271
   Embree J, 2015, CLIN VACCINE IMMUNOL, V22, P282, DOI 10.1128/CVI.00682-14
   Fisher MA, 2001, ANN EPIDEMIOL, V11, P13, DOI 10.1016/S1047-2797(00)00078-8
   Frenck RW, 2012, CLIN VACCINE IMMUNOL, V19, P1296, DOI 10.1128/CVI.00176-12
   Fulton TR, 2015, VACCINE, V33, P6453, DOI 10.1016/j.vaccine.2015.08.043
   Geier DA, 2005, AUTOIMMUNITY, V38, P295, DOI 10.1080/08916930500144484
   Geier DA, 2001, CLIN EXP RHEUMATOL, V19, P724
   Geier DA, 2015, CLIN RHEUMATOL, V34, P1225, DOI 10.1007/s10067-014-2846-1
   Geier MR, 2004, CLIN EXP RHEUMATOL, V22, P749
   HACHULLA E, 1990, J RHEUMATOL, V17, P1250
   Halperin SA, 2017, J INFECT DIS, V215, P1789, DOI 10.1093/infdis/jix189
   Heijstek MW, 2007, ANN RHEUM DIS, V66, P1384, DOI 10.1136/ard.2006.063586
   Heijstek MW, 2013, JAMA-J AM MED ASSOC, V309, P2449, DOI 10.1001/jama.2013.6768
   Heppner DG, 2017, LANCET INFECT DIS, V17, P854, DOI 10.1016/S1473-3099(17)30313-4
   Ho TY, 2012, PLOS ONE, V7
   HOLTZMAN CM, 1969, NEW ENGL J MED, V280, P111
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   KANTOR TG, 1962, ARTHRITIS RHEUM-US, V5, P378
   Kathleen Stratton, 2011, COMMITTEE REV ADVERS
   Klein NP, 2015, PEDIATRICS, V135, pE321, DOI 10.1542/peds.2014-1822
   KURLAND LT, 1984, MAYO CLIN PROC, V59, P816, DOI 10.1016/S0025-6196(12)65615-8
   La Rosa C, 2012, J INFECT DIS, V205, P1294, DOI 10.1093/infdis/jis107
   Lai Yi Chun, 2015, J Drugs Dermatol, V14, P681
   Lehtinen M, 2016, HUM VACC IMMUNOTHER, V12, P3177, DOI 10.1080/21645515.2016.1183847
   Lyons A, 2008, VACCINE, V26, P2890, DOI 10.1016/J.vaccine.2008.03.037
   Maillefert JF, 1999, RHEUMATOLOGY, V38, P978, DOI 10.1093/rheumatology/38.10.978
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Niu MT, 2009, VACCINE, V27, P290, DOI 10.1016/j.vaccine.2008.10.044
   PELTOLA H, 1986, LANCET, V1, P939
   Ray P, 2011, VACCINE, V29, P6592, DOI 10.1016/j.vaccine.2011.06.112
   ROPES MW, 1957, ANN RHEUM DIS, V16, P118, DOI 10.1136/ard.16.1.118
   Rose CD, 2001, J RHEUMATOL, V28, P2555
   Sever JL, 2004, PHARMACOEPIDEM DR S, V13, P825, DOI 10.1002/pds.936
   Sever JL, 2002, PHARMACOEPIDEM DR S, V11, P189, DOI 10.1002/pds.712
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Sibilia J, 2002, ANN RHEUM DIS, V61, P575, DOI 10.1136/ard.61.7.575
   Sikand VK, 2001, PEDIATRICS, V108, P123, DOI 10.1542/peds.108.1.123
   Smith LM, 2012, PHARMACOEPIDEM DR S, V21, P358
   Tamminga C, 2013, VACCINE, V31, P3628, DOI 10.1016/j.vaccine.2013.01.045
   The Maryland State Board of Physicians, 2011, ORD SUMM SUSP LIC PR
   Tingle AJ, 1997, LANCET, V349, P1277, DOI 10.1016/S0140-6736(96)12031-6
   US Department of Health and Human Services FaDA Center for Biologics Evaluation and Research, 2007, GUID IND TOX GRAD SC
   van't Klooster TM, 2011, VACCINE, V29, P4601, DOI 10.1016/j.vaccine.2011.04.050
   Wasserman GM, 2003, J OCCUP ENVIRON MED, V45, P222, DOI 10.1097/01.jom.0000058345.05741.6b
   WHO/HIS/EMP/QSS, 2013, CAUS ASS ADV EV FOLL
   Woerner APF, VACCINE
NR 62
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 372
EP 383
DI 10.1016/j.vaccine.2018.06.067
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300022
PM 30502066
DA 2020-05-12
ER

PT J
AU Woerner, A
   Pourmalek, F
   Panozzo, C
   Pileggi, G
   Hudson, M
   Caric, A
   Abraham, S
   Varricchio, F
   Velasco, C
   Oleske, J
   Bauwens, J
   Bonhoeffer, J
AF Woerner, Andreas
   Pourmalek, Farshad
   Panozzo, Catherine
   Pileggi, Gecilmara
   Hudson, Michael
   Caric, Aleksandra
   Abraham, Sonya
   Varricchio, Frederick
   Velasco, Cesar
   Oleske, James
   Bauwens, Jorgen
   Bonhoeffer, Jan
CA Brighton Collaboration Acute
TI Acute aseptic arthritis: Case definition & guidelines for data
   collection, analysis, and presentation of immunisation safety data
SO VACCINE
LA English
DT Article
DE Arthritis (MeSH); Aseptic arthritis; Immunisation (MeSH); Vaccine
   (MeSH); Guidelines as topic (MesH); Case definition; Adverse event;
   Adverse drug related side effects and adverse reactions (MeSH)
ID JUVENILE IDIOPATHIC ARTHRITIS; SYNOVIAL-FLUID LEUKOCYTOSIS;
   RHEUMATOID-ARTHRITIS; REACTIVE ARTHRITIS; CLASSIFICATION CRITERIA;
   BACTERIAL ARTHRITIS; SEPTIC ARTHRITIS; LABORATORY TESTS; ASSOCIATION;
   VACCINATION
C1 [Woerner, Andreas; Bonhoeffer, Jan] Univ Basel, Childrens Hosp, Basel, Switzerland.
   [Pourmalek, Farshad] Univ British Columbia, Vancouver, BC, Canada.
   [Panozzo, Catherine] Harvard Med Sch, Boston, MA USA.
   [Panozzo, Catherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
   [Pileggi, Gecilmara] Univ Sao Paulo, Sch Med Ribeirao Preto, Sao Paulo, Brazil.
   [Pileggi, Gecilmara] Univ Fed Sao Carlos, Sch Med, Sao Carlos, SP, Brazil.
   [Hudson, Michael] Publ Hlth England, London, England.
   [Caric, Aleksandra] Family Med Clin Dr Puksic Haubrih, Zagreb, Croatia.
   [Abraham, Sonya] Imperial Coll, Imperial Natl Inst Hlth Res Wellcome CRF, London, England.
   [Velasco, Cesar] Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
   [Oleske, James] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Bauwens, Jorgen] Brighton Collaborat Fdn, Basel, Switzerland.
RP Woerner, A (reprint author), Univ Basel, Childrens Hosp, Basel, Switzerland.
EM contact@brightoncollaboration.org
FU Brighton Collaboration Steering Committee
FX The authors are grateful for the support and helpful comments provided
   by Guillaume Moulis, Silvia Pessah-Eljay, Elizabeth Jamme, Robert Pless,
   the Brighton Collaboration Steering Committee (Jim Buttery, Barbara Law,
   Kathryn Edwards, Michael Gold, Miriam Sturkenboom, Steven Black, Hector
   Izurieta, Egeruan Babatunde Imoukhuede, Heidi Larson, Daniel Salmon) and
   comments received in the frame of the reference group review by:
   Graciela Alarcon, David Nalin, Sadhu Panda, Dinesh Kumar, Nisha
   Kesharybhatta, Reinaldo de Menezes Martins, Rosemary Aaron as well as
   other experts consulted as part of the process. We also thank the
   Brighton Collaboration management team, particularly, Jorgen Bauwens,
   Simone Casagrande, Viviane Seeger for administrative and technical
   support. (http://www.cioms.chiframe_current_programme.htm) for the
   review of, constructive comments on, and endorsement of this document.
CR Aksu K, 2006, RHEUMATOL INT, V27, P209, DOI 10.1007/s00296-006-0185-5
   Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Bengtsson C, 2010, ANN RHEUM DIS, V69, P1831, DOI 10.1136/ard.2010.129908
   Brannan SR, 2006, J EMERG MED, V30, P331, DOI 10.1016/j.jemermed.2005.05.029
   Brewerton D A, 1978, J Clin Pathol Suppl (R Coll Pathol), V12, P117
   Brown TD, 2006, J ORTHOP TRAUMA, V20, P739, DOI 10.1097/01.bot.0000246468.80635.ef
   Carpenter CR, 2011, ACAD EMERG MED, V18, P782, DOI [10.1111/j.1553-2712.2011.01121.x, 10.1111/j.1553-2712.2011.01096.x]
   Cassidy JT, 2005, TXB PEDIAT RHEUMATOL, pxvi
   Colebatch AN, 2013, ANN RHEUM DIS, V72, P804, DOI 10.1136/annrheumdis-2012-203158
   Colebatch-Bourn AN, 2015, ANN RHEUM DIS, V74, P1946, DOI 10.1136/annrheumdis-2015-207892
   Espinoza LR, 2013, REUMATOL CLIN, V9, P229, DOI 10.1016/j.reuma.2012.06.008
   FINK CW, 1986, CLIN RHEUM DIS, V12, P423
   Garcia-Arias M, 2011, BEST PRACT RES CL RH, V25, P407, DOI 10.1016/j.berh.2011.02.001
   GRATACOS J, 1995, J RHEUMATOL, V22, P1504
   Heijstek MW, 2007, ANN RHEUM DIS, V66, P1384, DOI 10.1136/ard.2006.063586
   Heijstek MW, 2013, JAMA-J AM MED ASSOC, V309, P2449, DOI 10.1001/jama.2013.6768
   Horowitz DL, 2011, AM FAM PHYSICIAN, V84, P653
   Jeng GW, 1997, AM J EMERG MED, V15, P626, DOI 10.1016/S0735-6757(97)90173-X
   Kingsley G, 1996, ANN RHEUM DIS, V55, P564, DOI 10.1136/ard.55.8.564
   Kohl KS, 2007, VACCINE, V25, P5671, DOI 10.1016/j.vaccine.2007.02.063
   KORTEKANGAS P, 1992, SCAND J RHEUMATOL, V21, P283, DOI 10.3109/03009749209099243
   Krabben A, 2015, ANN RHEUM DIS, V74, P506, DOI 10.1136/annrheumdis-2013-204005
   KREY PR, 1979, AM J MED, V67, P436, DOI 10.1016/0002-9343(79)90790-3
   KURLAND LT, 1984, MAYO CLIN PROC, V59, P816, DOI 10.1016/S0025-6196(12)65615-8
   Li SF, 2007, EMERG MED J, V24, P75, DOI 10.1136/emj.2006.037929
   Li SF, 2004, ACAD EMERG MED, V11, P276, DOI [10.1111/j.1553-2712.2004.tb02209.x, 10.1197/j.aem.2003.09.018]
   Ma LL, 2009, CAN MED ASSOC J, V180, P59, DOI 10.1503/cmaj.080183
   Magni-Manzoni S, 2009, ARTHRIT RHEUM-ARTHR, V61, P1497, DOI 10.1002/art.24823
   Marcy SM, 2004, VACCINE, V22, P551, DOI 10.1016/j.vaccine.2003.09.007
   Margaretten ME, 2007, JAMA-J AM MED ASSOC, V297, P1478, DOI 10.1001/jama.297.13.1478
   Martinot M, 2005, CLIN EXP RHEUMATOL, V23, P303
   Mathews CJ, 2008, CURR OPIN RHEUMATOL, V20, P457, DOI 10.1097/BOR.0b013e3283036975
   MCCUTCHAN HJ, 1990, CLIN ORTHOP RELAT R, P226
   McGillicuddy DC, 2007, AM J EMERG MED, V25, P749, DOI 10.1016/j.ajem.2006.12.001
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Nade S, 2003, BEST PRACT RES CL RH, V17, P183, DOI 10.1016/S1521-6942(02)00106-7
   Pacheco-Tena C, 1999, J RHEUMATOL, V26, P1338
   Panozzo Catherine A, 2019, VACCINE, V37, P372
   Pascual E, 2005, BEST PRACT RES CL RH, V19, P371, DOI 10.1016/j.berh.2005.01.004
   Pioro MH, 1997, RHEUM DIS CLIN N AM, V23, P239, DOI 10.1016/S0889-857X(05)70328-8
   Reese NB, 2010, JOINT RANGE MOTION M
   Ropes MW, 1953, SYNOVIAL FLUID CHANG, pxvi
   Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645
   SCHLAPBACH P, 1990, CLIN RHEUMATOL, V9, P69, DOI 10.1007/BF02030245
   Sharff KA, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0332-4
   SHMERLING RH, 1990, JAMA-J AM MED ASSOC, V264, P1009, DOI 10.1001/jama.264.8.1009
   SHMERLING RH, 1994, RHEUM DIS CLIN N AM, V20, P503
   Soderquist B, 1998, SCAND J INFECT DIS, V30, P591, DOI 10.1080/00365549850161151
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Taylor-Robinson D, 1999, BEST PRACT RES CL RH, V13, P179, DOI 10.1053/berh.1999.0013
   Trampuz A, 2004, AM J MED, V117, P556, DOI 10.1016/j.amjmed.2004.06.022
   Watts R, 2013, OXFORD TXB RHEUMATOL, pxxx
NR 53
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 7
PY 2019
VL 37
IS 2
BP 384
EP 391
DI 10.1016/j.vaccine.2017.08.087
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI3LS
UT WOS:000456352300023
PM 30342899
DA 2020-05-12
ER

PT J
AU Bahri, P
   Rago, L
   Abdoellah, SA
   Bachtiar, NW
   Bahri, P
   Balakrishnan, MR
   Bergman, U
   Chandler, R
   Chua, PG
   Darko, MD
   Dodoo, A
   Habersaat, KB
   Hartigan-Go, K
   Hugman, B
   Lindquist, M
   Santos, P
   Zuber, P
AF Bahri, Priya
   Rago, Lembit
   Abdoellah, Siti Asfijah
   Bachtiar, Novilia Working
   Bahri, Priya
   Balakrishnan, Madhav Ram
   Bergman, Ulf
   Chandler, Rebecca
   Chua, Peter Glen
   Darko, Mimi Delese
   Dodoo, Alexander
   Habersaat, Katrine Bach
   Hartigan-Go, Ken
   Hugman, Bruce
   Lindquist, Marie
   Santos, Paulo
   Zuber, Patrick
CA CIOMS Working Grp Vaccine Safety
TI CIOMS Guide To Vaccine Safety Communication - Executive summary
SO VACCINE
LA English
DT Article
DE Vaccines; Vaccine safety; Vaccine hesitancy; Pharmacovigilance; Risk
   perception; Health communication; CIOMS; WHO Global Vaccine Safety
   Initiative
ID RISK COMMUNICATION; PHARMACOVIGILANCE; HESITANCY; MODEL
AB Background: In 2018, the Council for International Organizations of Medical Sciences (CIOMS) issued their Guide to Vaccine Safety Communication. This has been built upon existing guidance and a new review of research and compilation of latest experiences, in order to fill, for the first time at global level, a specific niche for regulatory authorities in the contexts of vaccine hesitancy and informed choice. The Guide was developed by the international multi-stakeholder CIOMS Working Group on Vaccine Safety, formed to assist the Global Vaccine Safety Initiative (GVSI) of the World Health Organization (WHO).
   Summary: Besides the public health authorities responsible for immunization programmes, regulators have their own role in communicating about vaccine safety. As they are responsible for licensing vaccine products, they need to be transparent about their assessments of data on quality, safety and efficacy. Furthermore, they are responsible for continuous safety surveillance and keeping safe use advice to the public up-to-date. The Guide stresses the fundamental importance of regulatory bodies to have a system in place with defined functions and skilled persons who can efficiently run vaccine safety communication in collaboration with stakeholders. This system should take a strategic approach to communication, be integral to safety surveillance and risk assessment, and support vaccine safety communication plans (VacSCPs) adapted to vaccine types in local situations. The Guide provides recommendations and examples for the system components as well as a practical VacSCP template.
   Conclusions: While the Guide should help strengthening regulatory bodies worldwide with regard to vaccine safety communication, it is meant to help regulators in resource-limited countries in particular. It can also be of interest to other stakeholders and be leveraged to other medicinal products.
C1 [Bahri, Priya] EMA, Pharmacovigilance Dept, Surveillance & Epidemiol Serv, 30 Churchill Pl, London E14 5EU, England.
   [Rago, Lembit] CIOMS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
RP Bahri, P (reprint author), EMA, Pharmacovigilance Dept, Surveillance & Epidemiol Serv, 30 Churchill Pl, London E14 5EU, England.
EM priya.bahri@ema.europa.eu; ragol@cioms.ch
RI Rago, Lembit/AAF-4732-2019
CR Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Bahri P, 2018, BRIT J CLIN PHARMACO, V84, P1696, DOI 10.1111/bcp.13587
   Bahri P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0850-4
   Bahri P, 2015, DRUG SAFETY, V38, P621, DOI 10.1007/s40264-015-0301-0
   Bahri P, 2012, DRUG SAFETY, V35, P971, DOI 10.2165/11640990-000000000-00000
   Bahri P, 2010, DRUG SAFETY, V33, P1065, DOI 10.2165/11539040-000000000-00000
   Beckmann J, 2014, DRUG SAFETY, V37, P743, DOI 10.1007/s40264-014-0216-1
   Bystrom E, 2014, VACCINE, V32, P6752, DOI 10.1016/j.vaccine.2014.10.011
   CIOMS, 2018, CIOMS GUID VACC SAF
   CIOMS Working Group on Vaccine Safety, 2017, CIOMS GUID ACT VACC
   Council for International Organizations of Medical Sciences (CIOMS), 2018, CIOMS TEMPL STRAT VA
   Council for International Organizations of Medical Sciences (CIOMS), 2018, WORK GROUP 11 PAT IN
   Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization, 2012, DEF APPL TERMS VACC
   Darko DM, 2018, COMMUNICATION
   ECDC, 2015, RAP LIT REV MOT HES
   EMA, 2013, GUID GOOD PHARM PRAC
   European Medicines Agency (EMA) and Heads of Medicines Agencies, 2013, GUID PHARM PRACT GVP
   European Medicines Agency (EMA) and Heads of Medicines Agencies, 2013, GUID GOOD PHARM PRAC
   Feltelius N, 2015, J INTERN MED, V278, P335, DOI 10.1111/joim.12391
   Fischhoff B, 2009, COMMUNICATING RISKS
   Folkhalsomyndigheten, 2015, BARR MOT FACT MMR VA
   Health Canada, 2015, STAND HLTH PROD RISK
   Heininger U, 2017, VACCINE, V35, P3917, DOI 10.1016/j.vaccine.2017.06.033
   Hugman B., 2013, HEALTHCARE COMMUNICA
   Hugman B., 2010, EXPECTING THE WORST
   Kaliner E, 2014, EUROSURVEILLANCE, V19, P20701
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Larson H, 2017, DEV COMMUNICATION ST
   Larson H, 2012, DRUG SAFETY, V35, P1053, DOI 10.2165/11635880-000000000-00000
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Minister of Health Canada, 2006, STRAT RISK COMM FRAM
   Nakaweya G., 2016, COMMUNICATION VITAL
   Public Health England, MENB VACC PAR
   Rimon JG, 2007, STRATEGIC COMMUNICAT
   Simis MJ, 2016, PUBLIC UNDERST SCI, V25, P400, DOI 10.1177/0963662516629749
   Strategic advisory group of experts on immunization, STRAT ADV GROUP EXP
   The Health Communication Capacity Collaborative (H3C), 2013, P PROC 5 STEPS STRAT
   The Health Communication Capacity Collaborative [HC3], 2018, IMPACT
   United Nations Children's Fund (UNICEF), WHAT AR SOC EC MOD S
   WHO, 2018, IMM COV
   World Health Organization, VACC SAF NET
   World Health Organization Regional Office for Europe (WHO-EURO), 2017, VACC TRUST LIB
   World Health Organization (WHO), 2011, MAN ADV EV FOLL IMM
   World Health Organization (WHO), GLOB ADV COMM VACC S
   World Health Organization (WHO), 2018, GLOB VACC SAF IN GVS
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 401
EP 408
DI 10.1016/j.vaccine.2018.11.082
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200001
PM 30554796
DA 2020-05-12
ER

PT J
AU Khatami, A
   Randis, TM
   Tavares, L
   Gegick, M
   Suzman, E
   Ratner, AJ
AF Khatami, Ameneh
   Randis, Tara M.
   Tavares, Larissa
   Gegick, Margaret
   Suzman, Evan
   Ratner, Adam J.
TI Vaginal co-colonization with multiple Group B Streptococcus serotypes
SO VACCINE
LA English
DT Article
DE Streptococcus agalactiae; Vaginal colonization; Serotype;
   Co-colonization
ID RECTAL COLONIZATION; DISEASE WORLDWIDE
AB Group B Streptococcus (GBS) is a neonatal pathogen frequently transmitted from maternal asymptomatic vagino-rectal colonization. Co-colonization with multiple GBS serotypes, which has implications for type specific vaccination strategies, is difficult to detect with standard microbiologic techniques. We designed a nested real-time PCR assay to detect vaginal co-colonization in samples from a cohort of non-pregnant women (N = 433). 6/91 (6.6%) GBS-positive samples harbored >= 2 GBS serotypes, with over-representation of serotype V among co-colonized samples. Serotype IV GBS was more prevalent (>10%) in this cohort than in previously reported United States studies. Ongoing surveillance of GBS serotype epidemiology and co-colonization is indicated. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 NYU, Sch Med, Dept Pediat, New York, NY USA.
   NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
RP Ratner, AJ (reprint author), NYU, Sch Med, Dept Pediat, Div Pediat Infect Dis, 430 East 29th St,Room 505, New York, NY 10016 USA.; Ratner, AJ (reprint author), NYU, Sch Med, Dept Microbiol, Div Pediat Infect Dis, 430 East 29th St,Room 505, New York, NY 10016 USA.
EM Adam.Ratner@nyulangone.org
OI Randis, Tara/0000-0003-0348-6766; Ratner, Adam/0000-0003-1761-794X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R56 AI136499, K23
   HD065844, R21 A1127957]; Doris Duke Charitable FoundationDoris Duke
   Charitable Foundation (DDCF) [DDCF CSDA 2009-039]; Jack Cary Eichenbaum
   Neonatology Scholars Program at New York University School of Medicine
FX This work was supported by the National Institutes of Health [R56
   AI136499 to A.J.R.; K23 HD065844 and R21 A1127957 to T. M.R.] and the
   Doris Duke Charitable Foundation [DDCF CSDA 2009-039 to A.J.R] M.G. and
   E.S. were supported by the Jack Cary Eichenbaum Neonatology Scholars
   Program at New York University School of Medicine. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the funding bodies.
CR Anderson AL, 2017, INT SOC VACC ANN C
   ANTHONY BF, 1978, J INFECT DIS, V137, P524, DOI 10.1093/infdis/137.5.524
   BADRI MS, 1977, J INFECT DIS, V135, P308, DOI 10.1093/infdis/135.2.308
   Breeding KM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38523
   Diedrick MJ, 2010, J CLIN MICROBIOL, V48, P3100, DOI 10.1128/JCM.00277-10
   Ferrieri P, 2004, INDIAN J MED RES, V119, P208
   HOOGKAMPKORSTANJE JAA, 1982, J INFECT DIS, V145, P800, DOI 10.1093/infdis/145.6.800
   Imperi M, 2010, J MICROBIOL METH, V80, P212, DOI 10.1016/j.mimet.2009.11.010
   Khatami A, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy164
   Kobayashi Miwako, 2016, F1000Res, V5, P2355
   Kohli-Lynch M, 2017, CLIN INFECT DIS, V65, pS190, DOI 10.1093/cid/cix663
   Rosen GH, 2017, J INFECT DIS, V216, P744, DOI 10.1093/infdis/jix395
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Sheppard AE, 2016, J CLIN MICROBIOL, V54, P1388, DOI 10.1128/JCM.03142-15
   Teatero S, 2017, J CLIN MICROBIOL, V55, P412, DOI 10.1128/JCM.01615-16
   Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Whitney C G, 2004, J Matern Fetal Neonatal Med, V15, P267, DOI 10.1080/14767050410001668617
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 409
EP 411
DI 10.1016/j.vaccine.2018.12.001
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200002
PM 30528847
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Brotherton, JML
   Hawkes, D
   Sultana, F
   Malloy, MJ
   Machalek, DA
   Smith, MA
   Garland, SM
   Saville, M
AF Brotherton, Julia M. L.
   Hawkes, David
   Sultana, Farhana
   Malloy, Michael J.
   Machalek, Dorothy A.
   Smith, Megan A.
   Garland, Suzanne M.
   Saville, Marion
TI Age-specific HPV prevalence among 116,052 women in Australia's renewed
   cervical screening program: A new tool for monitoring vaccine impact
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Prevalence; Cervical screening; Australia
ID HUMAN-PAPILLOMAVIRUS PREVALENCE
AB Australia's transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25-74, 9.25% (95%CI: 9.09-9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05-2.22%) were 16/18 positive and 7.12% (95%CI: 6.97-7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25-29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Brotherton, Julia M. L.; Sultana, Farhana; Malloy, Michael J.] VCS Fdn, VCS Populat Hlth, Level 6,176 Wellington Parade, East Melbourne, Vic 3002, Australia.
   [Brotherton, Julia M. L.; Sultana, Farhana; Malloy, Michael J.; Machalek, Dorothy A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Level 3,207 Bouverie St, Carlton, Vic 3053, Australia.
   [Hawkes, David; Saville, Marion] VCS Fdn, VCS Pathol, 265 Faraday St, Carlton, Vic 3053, Australia.
   [Hawkes, David] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic 3010, Australia.
   [Machalek, Dorothy A.; Garland, Suzanne M.] Royal Womens Hosp, Ctr Womens Infect Dis, Cnr Grattan St & Flemington Rd, Parkville, Vic 3052, Australia.
   [Machalek, Dorothy A.; Garland, Suzanne M.] Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic, Australia.
   [Smith, Megan A.] Canc Council NSW, Canc Res Div, 153 Dowling St, Woolloomooloo, NSW 2011, Australia.
   [Garland, Suzanne M.; Saville, Marion] Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3010, Australia.
RP Brotherton, JML (reprint author), VCS Fdn, VCS Populat Hlth, Level 6,176 Wellington Parade, East Melbourne, Vic 3002, Australia.
EM jbrother@vcs.org.au; dhawkes@vcs.org.au; fsultana@vcs.org.au;
   mmalloy@vcs.org.au; dorothy.machalek@mcri.edu.au;
   Megan.Smith@nswcc.org.au; Suzanne.Garland@thewomens.org.au;
   msaville@vcs.org.au
OI Smith, Megan/0000-0002-0401-2653
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia [APP1135172]
FX This work was supported by the National Health and Medical Research
   Council funded Centre for Research Excellence in Cervical Cancer Control
   (APP1135172), which provides partial salary support to David Hawkes,
   Farhana Sultana, Dorothy Machalek and Megan Smith. The funder had no
   role in study design, in the collection, analysis and interpretation of
   data, in the writing of the report, or in the decision to submit the
   article for publication.
CR Arbyn M, 2016, J CLIN VIROL, V76, pS14, DOI 10.1016/j.jcv.2015.09.014
   Australian Institute of Health and Welfare, 2018, CERV SCREEN AUSTR 20
   Berecki-Gisolf J, 2009, MENOPAUSE, V16, P1021, DOI 10.1097/gme.0b013e3181a8c49f
   Brotherton JML, 2015, SEX HEALTH, V12, P353, DOI 10.1071/SH15035
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Cancer Council Australia Cervical Cancer Screening Guidelines Working Party, 2017, NAT CERV SCREEN PROG
   Drolet M, 2017, J INFECT DIS, V216, P1205, DOI 10.1093/infdis/jix476
   Garland SM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-104
   Gravitt PE, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100267
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075
   Meites E, 2013, INT J CANCER, V133, P1101, DOI 10.1002/ijc.28115
   Mercer CH, 2013, LANCET, V382, P1781, DOI 10.1016/S0140-6736(13)62035-8
   Moscicki AB, 2012, VACCINE, V30, pF24, DOI 10.1016/j.vaccine.2012.05.089
   National Pathology Accreditation Advisory Council, 2017, REQ LAB REP TESTS NA
   Sharma M, 2013, INT J CANCER, V132, P1895, DOI 10.1002/ijc.27835
NR 16
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 412
EP 416
DI 10.1016/j.vaccine.2018.11.075
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200003
PM 30551987
DA 2020-05-12
ER

PT J
AU Fisher, H
   Harding, S
   Hickman, M
   Macleod, J
   Audrey, S
AF Fisher, Harriet
   Harding, Sarah
   Hickman, Matthew
   Macleod, John
   Audrey, Suzanne
TI Barriers and enablers to adolescent self-consent for vaccination: A
   mixed-methods evidence synthesis
SO VACCINE
LA English
DT Review
DE Self-consent; Vaccination; Systematic review; Adolescents; Mixed methods
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HPV VACCINATION; IMMUNIZATION;
   PARENTS; PROGRAM; FACILITATORS; PERSPECTIVES; CHALLENGES; DELIVERY;
   COVERAGE
AB 2 Introduction: The recent global expansion of routine adolescent vaccination programmes has the potential to protect young people against infectious diseases and improve their health. Although the legal framework in many countries permits young people to consent for vaccinations if competent, lack of written parental consent can still prevent uptake. We aimed to review systematically the associated barriers and enablers to implementation of adolescent self-consent procedures.
   Methods: A comprehensive search strategy of ten databases from inception to June 2018 was undertaken to identify relevant qualitative and quantitative studies. Titles, abstracts and full texts were assessed for eligibility, and the methodological quality of eligible primary studies evaluated. Thematic synthesis methods were used to interpret and combine qualitative data, and to identify overarching themes as well as similarities and differences within themes. Quantitative data were summarised and, because the data were sufficiently similar in focus, were integrated within the qualitative framework.
   Results: Twenty-five publications related to 23 studies were included. Three themes were identified which related to the policy framework, protection, and self-determination. Despite supportive national policy frameworks, implementation of adolescent self-consent procedures can be prevented by local policies, professionals' misunderstandings of the legal framework and the context in which the vaccination programme is delivered. Motivation to protect young people's health increased acceptability of adolescent self-consent, but implementation might be prevented to protect the reputation of professionals or relationships with parents. Further, maintaining the role of parents as decision-makers for their child's healthcare was frequently prioritised over enabling young people's autonomy to consent.
   Conclusions: Barriers to the implementation of adolescent self-consent procedures have implications for young people's health and uptake of vaccination programmes. There is a need to clarify the policy framework and challenge the primacy of parental consent. (C) 2018 The Author(s). Published by Elsevier Ltd.
C1 [Fisher, Harriet; Harding, Sarah; Hickman, Matthew; Macleod, John; Audrey, Suzanne] Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Canynge Hall,Whatley Rd, Bristol BS8 2PS, Avon, England.
RP Fisher, H (reprint author), Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Canynge Hall,Whatley Rd, Bristol BS8 2PS, Avon, England.
EM Harriet.Fisher@bristol.ac.uk
RI Hickman, Matthew/Y-2400-2019
OI Hickman, Matthew/0000-0001-9864-459X; audrey,
   suzanne/0000-0002-8310-2672; Fisher, Harriet/0000-0002-5639-0955;
   Macleod, John/0000-0001-8202-1144
FU National Institute for Health Research (NIHR) under its Research for
   Patient Benefit (RfPB) ProgrammeNational Institute for Health Research
   (NIHR) [PB-PG-0416-20013]; NIHR Health Protection Research Unit in
   Evaluation of Interventions at University of Bristol; Public Health
   England (PHE); Centre for the Development and Evaluation of Complex
   Interventions for Public Health Improvement (DECIPHer); UKCRC Public
   Health Research Centre of Excellence; British Heart Foundation under UK
   Clinical Research Collaboration [MR/K0232331/1]; Cancer Research UK
   under UK Clinical Research Collaboration [MR/K0232331/1]; Medical
   Research Council under UK Clinical Research Collaboration
   [MR/K0232331/1]; Welsh Government under UK Clinical Research
   Collaboration [MR/K0232331/1]; Wellcome Trust under UK Clinical Research
   Collaboration [MR/K0232331/1]; Economic and Social Research Council
   under UK Clinical Research Collaboration [MR/K0232331/1]
FX This work presents independent research funded by the National Institute
   for Health Research (NIHR) under its Research for Patient Benefit (RfPB)
   Programme (Grant Reference Number PB-PG-0416-20013). The views expressed
   are those of the authors and not necessarily those of the NHS, the NIHR
   or the Department of Health. The work has been supported by the NIHR
   Health Protection Research Unit in Evaluation of Interventions at
   University of Bristol, in partnership with Public Health England (PHE).
   The work was also undertaken with the support of The Centre for the
   Development and Evaluation of Complex Interventions for Public Health
   Improvement (DECIPHer), a UKCRC Public Health Research Centre of
   Excellence. Joint funding (MR/K0232331/1) from the British Heart
   Foundation, Cancer Research UK, Economic and Social Research Council,
   Medical Research Council, the Welsh Government and the Wellcome Trust,
   under the auspices of the UK Clinical Research Collaboration, is
   gratefully acknowledged. The views and opinions expressed therein are
   those of the authors and do not necessarily reflect those of the NIHR
   RfPB Programme, the NHS, the Department of Health, or Public Health
   England.
CR Agrawal S, 2018, J MED ETHICS
   [Anonymous], 1986, World Health Organ Tech Rep Ser, V731, P1
   [Anonymous], 1989, UN TREAT SER, P1577
   Audrey S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021321
   Batista Ferrer H., 2014, FACTORS INFLUENCING
   Brabin L, 2009, BRIT J CANCER, V101, P1502, DOI 10.1038/sj.bjc.6605362
   Brabin L, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-20
   Braun R, 2013, CONTRACEPTION, V88, P307, DOI 10.1016/j.contraception.2013.04.015
   Brown ECF, 2010, FAM PRACT, V27, P224, DOI 10.1093/fampra/cmp087
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Carolan K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190984
   Cave E, 2014, LEGAL STUD, V34, P103, DOI 10.1111/lest.12009
   Crocker-Buque T, 2017, J EPIDEMIOL COMMUN H, V71, P87, DOI 10.1136/jech-2016-207572
   Estabrooks C. A., 1994, QUALITATIVE HLTH RES, V4, P503, DOI DOI 10.1177/104973239400400410
   Ferrer HB, 2016, J PUBLIC HEALTH-UK, V38, P569, DOI 10.1093/pubmed/fdv073
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Fisher H, 2013, INT J EPIDEMIOL, V25, P25
   Fisher H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021335
   Ford CA, 2014, J ADOLESCENT HEALTH, V54, P183, DOI 10.1016/j.jadohealth.2013.07.028
   Ford CA, 2009, J ADOLESCENT HEALTH, V44, P568, DOI 10.1016/j.jadohealth.2008.11.015
   Gottvall M, 2015, HEALTH CARE ANAL, V23, P50, DOI 10.1007/s10728-012-0237-9
   Gottvall M, 2011, VACCINE, V29, P4576, DOI 10.1016/j.vaccine.2011.04.054
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hilton S, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-226
   Humiston SG, 2009, PATIENT EDUC COUNS, V75, P121, DOI 10.1016/j.pec.2008.09.012
   Kennedy A, 2012, J ADOLESCENT HEALTH, V50, P198, DOI 10.1016/j.jadohealth.2011.04.017
   Kennedy C, 2014, INT J BEHAV MED, V21, P3, DOI 10.1007/s12529-013-9356-4
   Lee HY, 2018, ANN BEHAV MED, V52, pS15
   Marshall HS, 2014, VACCINE, V32, P2434, DOI 10.1016/j.vaccine.2014.02.098
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   National Institute for Health, 2017, QUAL ASS TOOL OBS CO
   Pope C, 2007, SYNTHESISING QUALITA
   Public Health England, 2018, TD IPV SCH LEAV BOOS
   Public Health England, 2016, GREEN BOOK
   Public Health Resource Unit, 1998, CRIT APPR SKILLS PRO
   Pyrzanowski J, 2013, CLIN PEDIATR, V52, P329, DOI 10.1177/0009922813475703
   Rand CM, 2011, VACCINE, V29, P7651, DOI 10.1016/j.vaccine.2011.08.002
   Remes P, 2012, VACCINE, V30, P5363, DOI 10.1016/j.vaccine.2012.06.025
   RYLANCE G, 1995, BRIT MED J, V311, P923, DOI 10.1136/bmj.311.7010.923
   Sandelowski Margarete, 2006, Res Sch, V13, P29
   Shah PD, 2014, J ADOLESCENT HEALTH, V54, P421, DOI 10.1016/j.jadohealth.2013.09.022
   Skiles M, 2010, J ADOLESCENT HEALTH, V46, pS71
   Stretch R, 2009, BMC PUBLIC HEALTH, P9
   Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
   Wilson SE, 2012, CAN J PUBLIC HEALTH, V103, P34, DOI 10.1007/BF03404066
   Wood F, 2011, J MED ETHICS, V37, P466, DOI 10.1136/jme.2010.038562
   World Health Organisation, 2014, CONS REG CONS VACC C
   World Health Organization, 2017, SUMM WHO POS PAP REC
NR 49
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 417
EP 429
DI 10.1016/j.vaccine.2018.12.007
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200004
PM 30573357
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU van Zandvoort, K
   Howard, N
   Mounier-Jack, S
   Jit, M
AF van Zandvoort, Kevin
   Howard, Natasha
   Mounier-Jack, Sandra
   Jit, Mark
TI Strengthening national vaccine decision-making: Assessing the impact of
   SIVAC Initiative support on national immunisation technical advisory
   group (NITAG) functionality in 77 low and middle-income countries
SO VACCINE
LA English
DT Article
DE NITAG; SIVAC; Low and middle-income countries; Vaccination; Vaccine
   policy
ID ESTABLISHMENT
AB Background: National Immunisation Technical Advisory Groups (NITAGs) are multi-disciplinary expert groups that provide policy-makers with independent, evidence-based advice on vaccination. Between 2008 and 2017, the SIVAC Initiative supported establishment and strengthening of NITAGs in low and lower-middle income countries though its impact was never assessed quantitatively.
   Aim: To quantitatively assess whether SIVAC support is associated with a faster rate at which NITAGs became functional based on six performance indicators.
   Methods: Data from the World Health Organization/Unicef Joint Reporting Form (JRF) from 77 low and lower-middle-income countries were used to examine the time delay between the start of SIVAC support and NITAG functionality using a Cox proportional hazards model.
   Results: Countries receiving SIVAC support took a mean of 2.00 (95% CI 1.40-2.60) years to reported functionality compared to 2.82 (95% CI 2.05-3.59) years for countries without SIVAC support. We found evidence that SIVAC support is associated with reduced time until NITAG functionality, and this association cannot fully be explained by GDP per capita, percentage of GDP spent on healthcare, or NITAG functionality score at the start of the study period. However, quality of JRF data for the questions used to calculate NITAG functionality were poor, particularly for countries not receiving SIVAC support.
   Conclusion: SIVAC support is likely to have enabled many countries to more rapidly achieve NITAG functionality. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [van Zandvoort, Kevin; Jit, Mark] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
   [Howard, Natasha; Mounier-Jack, Sandra] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, 14-17 Tavistock Pl, London WC1H 9SH, England.
   [Jit, Mark] Publ Hlth England, Modelling & Econ Unit, 61 Colindale Ave, London NW9 5EQ, England.
RP Jit, M (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM Kevin.Van-Zandvoort@lshtm.ac.uk; Natasha.Howard@lshtm.ac.uk;
   Sandra.Mounier-jack@lshtm.ac.uk; Mark.jit@lshtm.ac.uk
OI van Zandvoort, Kevin/0000-0002-7770-0537; Howard,
   Natasha/0000-0003-4174-7349; Jit, Mark/0000-0001-6658-8255
FU Bill & Melinda Gates Foundation (BMGF)Gates Foundation [IID46303]
FX The Bill & Melinda Gates Foundation (BMGF) provided study funding (grant
   IID46303). Views expressed are those of the authors and not necessarily
   reflective of the views of LSHTM or BMGF.
CR Adjagba A, 2015, VACCINE, V33, P588, DOI 10.1016/j.vaccine.2014.12.026
   Ba-Nguz A, 2017, J INFECT DIS, V216, pS109, DOI 10.1093/infdis/jiw601
   Bell S, 2018, VALUE EFFECTIV UNPUB
   Duclos P, 2012, VACCINE, V30, P7147, DOI 10.1016/j.vaccine.2012.04.015
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Howard N, 2018, VACCINE, V36, P5536, DOI 10.1016/j.vaccine.2018.07.063
   Howard N, 2018, HUM VACC IMMUNOTHER, V14, P1539, DOI 10.1080/21645515.2018.1444321
   Lee LA, 2013, VACCINE, V31, P1361, DOI [10.1016/i.vaccine.7017.11035, DOI 10.1016/I.VACCINE.7017.11035]
   Senouci K, 2010, VACCINE, V28, pA26, DOI 10.1016/j.vaccine.2010.02.028
   Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
NR 11
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 430
EP 434
DI 10.1016/j.vaccine.2018.11.070
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200005
PM 30545715
OA Green Accepted, Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Oshansky, CM
   Zhou, J
   Gao, Y
   Schweinle, JE
   Biscardi, K
   DeBeauchamp, J
   Pavetto, C
   Wollish, A
   Webby, RJ
   Cioce, V
   Donis, RO
   Bright, RA
   Armstrong, K
   Gibson, L
   Hylton, P
   Jackson, A
   King, J
   Little, J
   O'Hara, M
   Robinson-Wright, K
   Tresnjak-Smith, S
   Walker, R
   Yeh, B
   Yeskey, D
AF Oshansky, Christine M.
   Zhou, James
   Gao, Yonghong
   Schweinle, Jo Ellen
   Biscardi, Karen
   DeBeauchamp, Jennifer
   Pavetto, Corrina
   Wollish, Amy
   Webby, Richard J.
   Cioce, Vittoria
   Donis, Ruben O.
   Bright, Rick A.
   Armstrong, Kimberly
   Gibson, Laura
   Hylton, Penny
   Jackson, Angela
   King, James
   Little, James
   O'Hara, Michael
   Robinson-Wright, Katina
   Tresnjak-Smith, Silvija
   Walker, Robert
   Yeh, Bai
   Yeskey, Debra
CA BRITE Study Coordination Team
TI Safety and immunogenicity of influenza A(H5N1) vaccine stored up to
   twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile
   (NPIVS)
SO VACCINE
LA English
DT Article
DE NPIVS; Vaccine; Avian influenza; MF59; Stockpile
ID ADJUVANTS; VIRUSES; ADULTS; AS03
AB Background: As part of the U.S. Department of Health and Human Services (HHS) Pandemic Influenza Plan preparedness and response strategy, the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program was established by the Biomedical Advanced Research and Development Authority (BARDA) in 2005 with the goal of building and maintaining a stockpile of vaccines for influenza viruses with pandemic potential to vaccinate 20 million people in the critical workforce in the event of a pandemic. The NPIVS program continuously monitors the integrity of influenza vaccine antigens and adjuvants stored within the stockpile. In addition to monitoring physical and chemical properties in stability studies, it is important to regularly assess the safety and immunogenicity of stockpiled vaccines and adjuvants to maintain preparedness for use in the event of an influenza pandemic.
   Methods: BARDA conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10-12 years administered with or without MF59 (R) adjuvant, stored over the previous 2-7 years at the time of vaccination.
   Results: Stockpiled vaccines were well-tolerated, adverse events were generally mild, and there was no drop in immunogenicity to the oldest stockpiled A(H5N1) vaccine. Compared to unadjuvanted vaccine, greater peak antibody responses were observed in subjects who were vaccinated with MF59-adjuvanted vaccines, regardless of antigen dose. Vaccination with the A(H5N1) vaccine antigen also results in cross-reactive antibody responses to contemporary circulating strains of A(H5) influenza viruses.
   Conclusions: The frequency, type, and severity of AEs observed during this study are similar to historical clinical study data with A(H5N1) vaccines and MF59 adjuvant indicating that a stockpiled A(H5N1) vaccine appears to remain safe and tolerable. The vaccines were immunogenic when administered as a two-dose vaccine regimen in healthy adults, despite extended storage of HA antigen or MF59 adjuvant within the NPIVS. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Oshansky, Christine M.; Zhou, James; Gao, Yonghong; Schweinle, Jo Ellen; Biscardi, Karen; Pavetto, Corrina; Cioce, Vittoria; Donis, Ruben O.; Bright, Rick A.] US Dept HHS, BARDA, Off Assistant Secretary Preparedness & Response A, Washington, DC 20201 USA.
   [DeBeauchamp, Jennifer; Webby, Richard J.] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Wollish, Amy] PPD, Wilmington, NC USA.
RP Cioce, V; Donis, RO (reprint author), 330 Independence Ave SW,Room 640 G, Washington, DC 20201 USA.
EM vittoria.cioce@hhs.gov; ruben.donis@hhs.gov
FU Biomedical Advanced Research and Development Authority (BARDA)
   [HHSO1002014000031, HHSO10033002T]; ALSACAmerican Lebanese Syrian
   Associated Charities (ALSAC)
FX The authors thank the volunteers who participated in the trial and
   acknowledge the program managers, particularly Susan Red del, Karen
   Hufham, Joy Wu, and Junli Zhang of PPD, clinical site investigators,
   study nurses and technicians, and Landon Westfall (Southern Research)
   who contributed to the study. Thank you is extended to Matthew McCord,
   Michele Riggs, Jasur Ishmukhamedov, Armen Donabedian, Li-Mei Chen, Jason
   Asher, Flora Castellino, and Robin Robinson (HHS) for their support and
   helpful discussion and to Kristina Bradford and Jonathan Edelman
   (Seqirus) for critical review of the manuscript. This work was funded by
   the Biomedical Advanced Research and Development Authority (BARDA) under
   contract HHSO1002014000031, order HHSO10033002T. Cross -reactivity
   antibody response work was supported by ALSAC. Opinions, findings and
   conclusions reported by the authors are strictly their own and are in no
   way meant to represent the opinion, views, or policies of ASPR/BARDA or
   HHS.
CR [Anonymous], 2007, M TOP 1 SAF IMM H5N1
   [Anonymous], 2017, FLUAD
   [Anonymous], 2007, PACKAGE INSERT SANOF
   [Anonymous], 2017, US DEP HLTH HUM SERV
   [Anonymous], 2007, SANOFI PASTEUR VRBPA
   Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384
   Belshe RB, 2014, JAMA-J AM MED ASSOC, V312, P1420, DOI 10.1001/jama.2014.12609
   Bernstein DI, 2008, J INFECT DIS, V197, P667, DOI 10.1086/527489
   Black S, 2015, VACCINE, V33, pB3, DOI 10.1016/j.vaccine.2014.11.062
   Center for Biologics Evaluation and Research FDA US Department of Health and Human Services, 2007, GUID IND CLIN DAT NE
   Centers for Disease Control and Prevention, INFL RISK ASS TOOL I
   Chen WH, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu091
   Claes F, 2016, CURR OPIN VIROL, V16, P158, DOI 10.1016/j.coviro.2016.02.005
   Del Giudice G, 2014, INACTIVATED ADJUVANT
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Jackson LA, 2012, J INFECT DIS, V206, P811, DOI 10.1093/infdis/jis427
   Khurana S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095496
   Langley JM, 2015, VACCINE, V33, P559, DOI 10.1016/j.vaccine.2014.11.018
   Lee DH, 2017, J VET SCI, V18, P269, DOI [10.4142/jvs.2017.18.s1.269, 10.4142/jvs.2017.18.S1.269]
   Levine MZ, 2017, J INFECT DIS, V216, pS555, DOI 10.1093/infdis/jix001
   Mulligan MJ, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu102
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Stephenson I, 2008, NEW ENGL J MED, V359, P1631, DOI 10.1056/NEJMc0805274
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   [WHO] World Health Organization, 2018, CUM NUMB CONF HUM CA
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 435
EP 443
DI 10.1016/j.vaccine.2018.11.069
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200006
PM 30553570
OA Other Gold
DA 2020-05-12
ER

PT J
AU Xu, XH
   Ding, Z
   Yuan, QL
   Ding, JX
   Li, JD
   Wang, WQ
   Cong, YL
   Ouyang, W
   Wang, YS
   Qian, J
   Yin, RF
AF Xu, Xiaohong
   Ding, Zhuang
   Yuan, Qianliang
   Ding, Jiaxin
   Li, Jindou
   Wang, Weiqi
   Cong, Yanlong
   Ouyang, Wei
   Wang, Yongshan
   Qian, Jing
   Yin, Renfu
TI A genotype VII Newcastle disease virus-like particles confer full
   protection with reduced virus load and decreased virus shedding
SO VACCINE
LA English
DT Article
DE Newcastle disease; Genotype VII; Virus-like particles; Vaccine candidate
ID GENETIC DIVERSITY; VACCINATION; INFLUENZA; STRAINS; CHICKEN; CHINA;
   XVII; XIV
AB Newcastle disease (ND) is one of the most severe avian infectious disease inflicting a great loss on poultry industry worldwide. The control of ND relies on proper vaccination strategies. The vaccine strains of Newcastle disease virus (NDV) mainly belong to genotype I, II or III, which cannot fully prohibit virus shedding against the prevalent genotype VII virulent strain attack. To develop a safe, genotype matched vaccine candidate, we employed a bac-to-bac expression system and constructed a genotype VII NDV strain based virus-like particles (NDV VLPs). It was constructed with NDV M protein as the skeleton, and protective antigen F and HN proteins displayed on the surface. The NDV VLPs exhibited a similar appearance to the live NDV particles, but with denser F and HN proteins displayed on the surface. The immunization assay indicated that NDV VLPs stimulated a longer protection period, less tissue virus loading and shorter virus shedding period than the commercialized LaSota-formulated vaccine when challenged with genotype VII NDV strain. These results proposed the potential role of NDV VLPs as an alternative to current live genotype unmatched vaccine for the control and eliminate NDV in the avian flocks. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Xu, Xiaohong; Ding, Zhuang; Yuan, Qianliang; Ding, Jiaxin; Li, Jindou; Wang, Weiqi; Cong, Yanlong; Qian, Jing; Yin, Renfu] Jilin Univ, Coll Vet Med, Infect Dis Lab, Key Lab Zoonosis Res,Minist Educ, Changchun 130062, Jilin, Peoples R China.
   [Ouyang, Wei; Wang, Yongshan; Qian, Jing] Jiangsu Acad Agr Sci, Inst Vet Med, Key Lab Vet Bioprod Engn, Minist Agr, Nanjing 210014, Jiangsu, Peoples R China.
RP Qian, J; Yin, RF (reprint author), Jilin Univ, Coll Vet Med, Infect Dis Lab, Key Lab Zoonosis Res,Minist Educ, Changchun 130062, Jilin, Peoples R China.; Qian, J (reprint author), Jiangsu Acad Agr Sci, Inst Vet Med, Key Lab Vet Bioprod Engn, Minist Agr, Nanjing 210014, Jiangsu, Peoples R China.
EM Dingzhuang@jlu.edu.cn
FU National Key Research and Development Program of China [2018YFD0500100];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31772735, 31472195]; Jiangsu Provincial Natural
   Science Foundation of ChinaNatural Science Foundation of Jiangsu
   Province [BK20180299]; Key Technology Research and Development Project
   of Jilin Province [20180201021NY]
FX This work was supported by grants from the National Key Research and
   Development Program of China (Grant Nos. 2018YFD0500100), the National
   Natural Science Foundation of China (Grant Nos. 31772735, 31472195),
   Jiangsu Provincial Natural Science Foundation of China (Grant Nos.
   BK20180299), and Key Technology Research and Development Project of
   Jilin Province (Grant Nos. 20180201021NY).
CR Alexander D, 2001, BRIT POULTRY SCI, V42, P5, DOI 10.1080/713655022
   Alexander DJ, 2000, REV SCI TECH OIE, V19, P443, DOI 10.20506/rst.19.2.1231
   Cai SX, 2011, VET MICROBIOL, V152, P46, DOI 10.1016/j.vetmic.2011.04.014
   Chuan YP, 2014, BIOCHEM ENG J, V90, P255, DOI 10.1016/j.bej.2014.06.005
   Courtney SC, 2013, J CLIN MICROBIOL, V51, P508, DOI 10.1128/JCM.02393-12
   Diel DG, 2012, INFECT GENET EVOL, V12, P1770, DOI 10.1016/j.meegid.2012.07.012
   Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019
   Dimitrov KM, 2016, INFECT GENET EVOL, V39, P22, DOI 10.1016/j.meegid.2016.01.008
   Ebrahimi MM, 2012, VIRUS GENES, V45, P63, DOI 10.1007/s11262-012-0738-5
   Hu SL, 2009, VACCINE, V27, P904, DOI 10.1016/j.vaccine.2008.11.091
   Jing Q, 2017, VET MICROBIOL, V203, P158
   Liu XF, 2003, ARCH VIROL, V148, P1387, DOI 10.1007/s00705-003-0014-z
   McGinnes LW, 2010, J VIROL, V84, P4513, DOI 10.1128/JVI.01931-09
   Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017
   Miller PJ, 2015, INFECT GENET EVOL, V29, P216, DOI 10.1016/j.meegid.2014.10.032
   Miller PJ, 2009, AVIAN DIS, V53, P39, DOI 10.1637/8407-071208-Reg.1
   Office International des Epizooties, 2012, OIE MANUAL DIAGNOSTI, P555
   Pandey A, 2010, HUM VACCINES, V6, P178, DOI 10.4161/hv.6.2.9899
   Pantua HD, 2006, J VIROL, V80, P11062, DOI 10.1128/JVI.00726-06
   Park JK, 2014, CLIN VACCINE IMMUNOL, V21, P360, DOI 10.1128/CVI.00636-13
   Qian J, 2017, VIRUS GENES, V53, P555, DOI 10.1007/s11262-017-1451-1
   Qin ZM, 2008, VIRUS RES, V131, P299, DOI 10.1016/j.virusres.2007.10.001
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Shen HF, 2013, VIRUS RES, V178, P430, DOI 10.1016/j.virusres.2013.09.009
   Snoeck CJ, 2013, J CLIN MICROBIOL, V51, P2250, DOI 10.1128/JCM.00684-13
   Su Q, 2018, VET RES, V49, DOI 10.1186/s13567-018-0577-z
   Su Q, 2018, VET MICROBIOL, V218, P52, DOI 10.1016/j.vetmic.2018.03.019
   Susta L, 2015, VET PATHOL, V52, P120, DOI 10.1177/0300985814521247
   Xu M, 2008, ARCH VIROL, V153, P1281, DOI 10.1007/s00705-008-0115-9
   Xue C, 2017, VIRUS GENES, V53, P63, DOI 10.1007/s11262-016-1404-0
NR 30
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 444
EP 451
DI 10.1016/j.vaccine.2018.11.068
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200007
PM 30545716
DA 2020-05-12
ER

PT J
AU Miller, PDE
   de Silva, TI
   Leonard, H
   Anthias, C
   Hoschler, K
   Goddard, K
   Peggs, K
   Madrigal, A
   Snowden, JA
AF Miller, Paul D. E.
   de Silva, Thushan I.
   Leonard, Hayley
   Anthias, Chloe
   Hoschler, Katja
   Goddard, Kathryn
   Peggs, Karl
   Madrigal, Alejandro
   Snowden, John A.
TI A comparison of viral microneutralization and haemagglutination
   inhibition assays as measures of seasonal inactivated influenza vaccine
   immunogenicity in the first year after reduced intensity conditioning,
   lymphocyte depleted allogeneic haematopoietic stem cell transplant
SO VACCINE
LA English
DT Article
DE Haematopoietic stem cell transplant; Inactivated influenza vaccine;
   Immunogenicity
ID ANTIBODY-RESPONSE; SEROLOGIC ASSAYS; VIRUS-INFECTIONS; ETHER TREATMENT;
   UNITED-STATES; ADULT; SURVEILLANCE; SPECIFICITY; SENSITIVITY; RECIPIENTS
AB Traditionally, immune response to influenza vaccines has been measured using the haemagglutination inhibition (HAI) assay. A broader repertoire of techniques including the sensitive viral microneutralization (VMN) assay is now recommended by the European Medicines Agency (EMA). Comparing HAI and VMN, we determined immune response to a trivalent 2015-2016 seasonal inactivated influenza vaccine (SIIV) administered to 28 recipients of allogeneic haematopoietic stem cell transplant (HSCT). Vaccination was within the first-year post-transplant at a median of 78.5 (24-363) days. The proportion of patients with baseline and post-vaccination HAI titres >= 1:40 were 28.6% and 25% for A(H1N1)pdm09, 14.3% at both timepoints for A(H3N2), and 32.1% and 25% for B(Phuket). Pre and Post-vaccination geometric mean titres(GMT) were higher by VMN than HAI for A(H1N1)pdm09 and A(H3N2), but lower for B(Phuket) (p=<0.05). Geometric mean ratios(GMR) of baseline and post-vaccination titres were similar by HAI and VMN(p > 0.05) for all components. A single seroconversion to A(H1N1) was detected by ELISA-VMN. None of patient age, lymphocyte count, days from transplant to vaccination, donor type, or graft-versus-host disease (GVHD) or immunosuppressive therapy (IST) at vaccination correlated with baseline or post-vaccination titres by either assay. This absence of seroresponse to SIIV in the first-year post HSCT highlights the need for novel immunogenic vaccination formulations and schedules in this high-risk population. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Miller, Paul D. E.; Leonard, Hayley; Anthias, Chloe; Madrigal, Alejandro] Royal Free Hosp, Anthony Nolan Res Inst, Pond St, London NW3 2QU, England.
   [de Silva, Thushan I.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Infect & Trop Med, Sheffield, S Yorkshire, England.
   [Anthias, Chloe] Royal Marsden NHS Fdn Trust, Dept Haematooncol, London, England.
   [Hoschler, Katja] Publ Hlth England, Resp Virus Reference Dept, London, England.
   [Goddard, Kathryn] Rothertham NHS Fdn Trust, Dept Haematol, Rotherham, S Yorkshire, England.
   [Peggs, Karl] Univ Coll London Hosp NHS Fdn Trust, Dept Clin Haematol, London, England.
   [Snowden, John A.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Clin Haematol, Sheffield, S Yorkshire, England.
RP Miller, PDE (reprint author), Royal Free Hosp, Anthony Nolan Res Inst, Pond St, London NW3 2QU, England.
EM paul.miller@doctors.org.uk
OI Madrigal, Alejandro/0000-0001-8359-9917; de Silva,
   Thushan/0000-0002-6498-9212
FU Anthony Nolan Research Institute
FX Paul Miller is funded by the Anthony Nolan Research Institute (No grant
   number).
CR Ambati A, 2015, BONE MARROW TRANSPL, V50, P858, DOI 10.1038/bmt.2015.47
   Avetisyan G, 2008, TRANSPLANTATION, V86, P257, DOI 10.1097/TP.0b013e3181772a75
   Babor F, 2012, TRANSPL INFECT DIS, V14, P589, DOI 10.1111/tid.12013
   Barge RMY, 2006, BONE MARROW TRANSPL, V37, P1129, DOI 10.1038/sj.bmt.1705385
   Barrett PN, 2011, LANCET, V377, P751, DOI 10.1016/S0140-6736(10)62228-3
   Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662
   Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1
   European Medicines Agency, 2014, GUID APPL ART 101 TR, P44
   European Medicines Agency, 1997, NOT GUID HARM REQ IN
   FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Halasa NB, 2016, BIOL BLOOD MARROW TR, V22, P528, DOI 10.1016/j.bbmt.2015.12.003
   Harris AE, 2015, BONE MARROW TRANSPL, V50, P899, DOI 10.1038/bmt.2015.49
   Hassan IA, 2003, BONE MARROW TRANSPL, V32, P73, DOI 10.1038/sj.bmt.1704048
   Issa NC, 2011, BIOL BLOOD MARROW TR, V17, P434, DOI 10.1016/j.bbmt.2010.10.002
   Karras NA, 2013, BIOL BLOOD MARROW TR, V19, P109, DOI 10.1016/j.bbmt.2012.08.015
   Katz JM, 2011, EXPERT REV ANTI-INFE, V9, P669, DOI [10.1586/eri.11.51, 10.1586/ERI.11.51]
   KENDAL AP, 1983, J CLIN MICROBIOL, V18, P930, DOI 10.1128/JCM.18.4.930-934.1983
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Machado CM, 2005, BONE MARROW TRANSPL, V36, P897, DOI 10.1038/sj.bmt.1705159
   MANCINI G, 1983, J HYG-CAMBRIDGE, V91, P157, DOI 10.1017/S0022172400060137
   Miller PDE, 2017, BONE MARROW TRANSPL, V52, P775, DOI 10.1038/bmt.2016.362
   Mohty M, 2007, LEUKEMIA, V21, P1387, DOI 10.1038/sj.leu.2404683
   MONTO AS, 1981, J CLIN MICROBIOL, V13, P54, DOI 10.1128/JCM.13.1.54-57.1981
   MONTO AS, 1973, LANCET, V1, P623, DOI 10.1016/S0140-6736(73)92196-X
   Nichols WG, 2004, CLIN INFECT DIS, V39, P1300, DOI 10.1086/425004
   Orcurto A, 2012, TRANSPLANTATION, V94, P630, DOI 10.1097/TP.0b013e31825f7f82
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pauksen K, 2000, CLIN INFECT DIS, V30, P342, DOI 10.1086/313663
   PYHALA R, 1985, J HYG-CAMBRIDGE, V94, P341, DOI 10.1017/S002217240006157X
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574
   Veguilla V, 2011, J CLIN MICROBIOL, V49, P2210, DOI 10.1128/JCM.00229-11
   Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531
   WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437
   WHO Global Influenza Network, 2011, MAN LAB DIAGN VIR SU, P153
   World Health Organization, 1998, REC INFL VACC COMP
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
NR 42
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 452
EP 457
DI 10.1016/j.vaccine.2018.11.061
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200008
PM 30554797
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Yang, YT
   Huang, AL
   Zhao, Y
AF Yang, Yu-ting
   Huang, Ai-long
   Zhao, Yao
TI The prevalence of hepatitis B core antibody in vaccinated Chinese
   children: A hospital-based study
SO VACCINE
LA English
DT Article
DE Hepatitis B core antibody; Vaccinated children; Serosurvey
ID HBSAG-POSITIVE MOTHERS; VIRUS-INFECTION; INFANTS BORN; REACTIVATION;
   TRANSPLANTATION; LYMPHOMA
AB Background & aims: After nearly 30 years of immunization, there is little known about the prevalence of hepatitis B core antibody (anti-HBc) in Chinese children. The clinical significance of anti-HBc would be more and more important. In this study, we had tried to analyse the prevalence of anti-HBc in vaccinated Chinese children, exploring the post-immunization status based on a large sample sized investigation.
   Methods: Proportions of anti-HBc were analysed among 215,627 hospitalized Chinese children immunized with HBV vaccination in this study.
   Results: The proportions of anti-HBc were divided into 3 stages: 36.6% in 0-year-old group, followed by 1- to 10-year-old which stayed relatively stable (5.69 +/- 0.40%, [4.86-6.28%]), and significant increasing within 11- to 16-year-old (7.80 +/- 1.24%, [6.62-9.74%]), meanwhile, similar changes of HBsAg were showed in the corresponding ages, and significantly increased in children older than 9-year (1.40%, [1.00-2.04%]), comparing with 0.30% in 0-year-old, 0.55 +/- 0.13% (0.30-0.64%) in 1- to 9-year-old. The average level of anti-HBc maintains 5.99% in children aged 1- to 16-year with 0.63% for HBsAg.
   Conclusion: This is the first study of the prevalence of anti-HBc in vaccinated Chinese children: 36.6% of anti-HBc-positivity was found in 0-year-old group, which could be maternal in origin. Relatively high prevalence of anti-HBc may not be ignored in children aged 1- to 16-year-old. Strangely, our data also showed that HBV breakthrough infection would occur in immunized Chinese children older than 9-year-old, and more attention is needed on those children. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yang, Yu-ting; Zhao, Yao] Chongqing Med Univ, China Int Sci & Technol Cooperat Base Child Dev &, Minist Educ,Childrens Hosp,Res Ctr Immunol & Infe, Chongqing Key Lab Pediat,Key Lab Child Dev & Diso, Chongqing 400014, Peoples R China.
   [Huang, Ai-long] Chongqing Med Univ, Inst Viral Hepatitis, Minist Educ, Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China.
RP Zhao, Y (reprint author), Chongqing Med Univ, Ctr Child Infect & Immunol Disorders, Key Lab Child Dev & Disorders, Minist Educ,Childrens Hosp, Chongqing 400014, Peoples R China.
EM Zhaoy@cqmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371876]; Health and Family Planning Commission of
   Chongqing [[2013] 39-2013-1-025]; Chongqing Municipal Colleges and
   Universities Outstanding Talent Support Program and Outstanding Youth
   Foundation of Children's Hospital of Chongqing Medical University
FX This work was supported by the National Natural Science Foundation of
   China (No. 81371876), Health and Family Planning Commission of Chongqing
   [2013] 39-2013-1-025 and Chongqing Municipal Colleges and Universities
   Outstanding Talent Support Program and Outstanding Youth Foundation of
   Children's Hospital of Chongqing Medical University.
CR [Anonymous], 2017, GLOBAL HEPATITIS REP
   Ba Alawi F, 2013, PATHOLOGY, V45, P501, DOI 10.1097/PAT.0b013e3283631cf9
   Caviglia GP, 2018, J HEPATOL, V69, P301, DOI 10.1016/j.jhep.2018.03.021
   Chen KL, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0015-9
   Conjeevaram H, 2001, HEPATOLOGY, V34, P204, DOI 10.1053/jhep.2001.25225
   Dickson RC, 1997, GASTROENTEROLOGY, V113, P1668, DOI 10.1053/gast.1997.v113.pm9352871
   Elbedewy TA, 2015, J EGYPT NATL CANCER, V27, P11, DOI 10.1016/j.jnci.2015.01.004
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Foaud H, 2015, INFECTION, V43, P307, DOI 10.1007/s15010-015-0733-6
   Fukushima N, 2009, ANN ONCOL, V20, P2013, DOI 10.1093/annonc/mdp230
   Hourfar MK, 2009, INT J LAB HEMATOL, V31, P649, DOI 10.1111/j.1751-553X.2008.01092.x
   Hsu H, 2014, HEPATOL RES, V61, P1183
   Liang XF, 2009, VACCINE, V27, P6550, DOI 10.1016/j.vaccine.2009.08.048
   Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5
   MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425
   Ni YH, 2011, J GASTROENTEROL, V46, P1, DOI 10.1007/s00535-010-0304-7
   Pande C, 2013, J VIRAL HEPATITIS, V20, P801, DOI 10.1111/jvh.12102
   Poovorawan Y, 1997, ARCH DIS CHILD-FETAL, V77, pF47, DOI 10.1136/fn.77.1.F47
   Raimondo G, 2008, J HEPATOL, V49, P652, DOI 10.1016/j.jhep.2008.07.014
   Roushan MRH, 2016, VACCINE, V34, P4475, DOI 10.1016/j.vaccine.2016.07.044
   Sadeghi A, 2016, J VIRAL HEPATITIS, V23, P282, DOI 10.1111/jvh.12490
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Seto WK, 2017, HEPATOLOGY, V65, P1451, DOI 10.1002/hep.29022
   Shao ZJ, 2011, J MED VIROL, V83, P791, DOI 10.1002/jmv.22043
   Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   Wang FS, 2014, HEPATOLOGY, V60, P2099, DOI 10.1002/hep.27406
   Xian G, 1996, INT HEPATOL COMMON, V5, P62
   Yue X, 2018, J VIRAL HEPATITIS, V25, P373, DOI 10.1111/jvh.12818
   Zheng H, 2018, J VIRAL HEPATITIS, V25, P88, DOI 10.1111/jvh.12757
NR 30
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 458
EP 463
DI 10.1016/j.vaccine.2018.11.067
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200009
PM 30527659
DA 2020-05-12
ER

PT J
AU Dawa, J
   Chaves, SS
   Nguz, AB
   Kalani, R
   Anyango, E
   Mutie, D
   Muthoka, P
   Tabu, C
   Maritim, M
   Amukoye, E
   Were, F
   Gatheru, Z
   Wangai, K
   Githanga, D
   Ongore, D
   Gander, C
   Osano, B
   Tuet, J
   Maree, E
   Thuo, S
AF Dawa, Jeanette
   Chaves, Sandra S.
   Nguz, Antoinette Ba
   Kalani, Rosalia
   Anyango, Edwina
   Mutie, Dominic
   Muthoka, Phillip
   Tabu, Collins
   Maritim, Marybeth
   Amukoye, Evans
   Were, Fred
   Gatheru, Zipporah
   Wangai, Kiama
   Githanga, David
   Ongore, Dismas
   Gander, Christopher
   Osano, Bonface
   Tuet, Julius
   Maree, Ephantus
   Thuo, Samson
CA Kenya Natl Immunization Tech
TI Developing a seasonal influenza vaccine recommendation in Kenya: Process
   and challenges faced by the National Immunization Technical Advisory
   Group (NITAG)
SO VACCINE
LA English
DT Article
DE Immunisation; Policy; Law- and middle-income country; Influenza
   vaccination program
ID ACUTE RESPIRATORY ILLNESS; BURDEN; HOSPITALIZATION
AB Background: In 2014 the Kenya National Immunization Technical Advisory Group (KENITAG) was asked by the Ministry of Health to provide an evidence-based recommendation on whether the seasonal influenza vaccine should be introduced into the national immunization program (NIP).
   Methods: We reviewed KENITAG manuals, reports and meeting minutes generated between June 2014 and June 2016 in order to describe the process KENITAG used in arriving at that recommendation and the challenges encountered.
   Results: KENITAG developed a recommendation framework to identify critical, important and non-critical data elements that would guide deliberations on the subject. Literature searches were conducted in several databases and the quality of scientific articles obtained was assessed using the Critical Appraisal Skills Programme tool. There were significant gaps in knowledge on the national burden of influenza disease among key risk groups, i.e., pregnant women, individuals with co-morbidities, the elderly and health care workers. Insufficient funding and limited work force hindered KENITAG activities.
   In 2016 KENITAG recommended introduction of the annual seasonal influenza vaccine among children 6 to 23 months of age. However, the recommendation was contingent on implementation of a pilot study to address gaps in local data on the socio-economic impact of influenza vaccination programs, strategies for vaccine delivery, and the impact of the vaccination program on the healthcare workforce and existing immunization program. KENITAG did not recommend the influenza vaccine for any other risk group due to lack of local burden of disease data.
   Conclusion: Local data are a critical element in NITAG deliberations, however, where local data and in particular burden of disease data are lacking, there is need to adopt scientifically acceptable methods of utilizing findings from other countries to inform local decisions in a manner that is valid and acceptable to decision makers. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Dawa, Jeanette; Nguz, Antoinette Ba] Agcy Prevent Med AMP, Supporting Independent Immunizat & Vaccine Adviso, Paris, France.
   [Chaves, Sandra S.] Ctr Dis Control & Prevent, Nairobi, Kenya.
   [Chaves, Sandra S.] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Kalani, Rosalia] Minist Hlth, Dis Surveillance & Response Unit, Nairobi, Kenya.
   [Kalani, Rosalia; Anyango, Edwina; Mutie, Dominic; Muthoka, Phillip; Tabu, Collins; Maritim, Marybeth; Amukoye, Evans; Were, Fred] Kenya Natl Immunizat Tech Advisory Grp KENITAG, Nairobi, Kenya.
   [Anyango, Edwina; Mutie, Dominic; Muthoka, Phillip; Tabu, Collins] Minist Hlth, Natl Vaccines Immunizat Programme, Nairobi, Kenya.
   [Dawa, Jeanette] Washington State Univ, Global Hlth Program, Kenya Off, POB 72398-00200, Nairobi, Kenya.
RP Dawa, J (reprint author), POB 72938-00200, Nairobi, Kenya.
EM jdawa@wsuglobalhealth.org; bev8@cdc.gov
OI amukoye, Evans/0000-0003-0683-0585; Dawa, Jeanette/0000-0001-9405-148X;
   Were, Fred/0000-0001-7879-1883
FU Agency for Preventive Medicine through the Supporting Independent
   Immunization and Vaccine Advisory Committees (SIVAC) - Bill & Melinda
   Gates Foundation; Gavi, the Vaccine Alliance; Centers for Disease
   Control and PreventionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA; Government of
   Kenya [C1000454, FOA CI06-607]
FX This work was supported by the Agency for Preventive Medicine through
   the Supporting Independent Immunization and Vaccine Advisory Committees
   (SIVAC) Initiative which is funded by a grant from the Bill & Melinda
   Gates Foundation and Gavi, the Vaccine Alliance and; a grant provided by
   the Centers for Disease Control and Prevention through a Co-operative
   Agreement with the Government of Kenya (FOA CI06-607/Award number
   C1000454). Staff from AMP and CDC had a role in writing the report and
   in the decision to submit the manuscript for publication.
CR Adjagba A, 2015, VACCINE, V33, P588, DOI 10.1016/j.vaccine.2014.12.026
   Bryson M, 2010, VACCINE, P1873
   CASP, 2018, CRIT APPR SKILLS PRO
   Dawa JA, 2018, INFLUENZA OTHER RESP, V12, P30, DOI 10.1111/irv.12488
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Emukule GO, 2015, PLOS ONE, V10
   Gessner BD, 2011, LANCET INFECT DIS, V11, P223, DOI 10.1016/S1473-3099(11)70008-1
   Glassman A, 2016, VALUE HEALTH, V19, P913, DOI 10.1016/j.jval.2016.04.014
   Howard N, 2018, VACCINE, V36, P5536, DOI 10.1016/j.vaccine.2018.07.063
   Katz MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098615
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Lee VJ, 2018, INFLUENZA OTHER RESP, V12, P3, DOI 10.1111/irv.12533
   luliano A. D., LANCET
   Members of the Global NITAG Network, 2017, STRAT DOC GLOB NITAG
   Ministry of Health, 2017, KEN PRIOR UN HLTH CO
   Nohynek H, 2013, CLIN MICROBIOL INFEC, V19, P1096, DOI 10.1111/1469-0691.12315
   Nyamusore J, 2018, INFLUENZA OTHER RESP, V12, P38, DOI 10.1111/irv.12494
   Office of Director of Medical Services Ministry of Health, 2016, COMM STAK PROGR UPD
   Schoub Barry D, 2010, Expert Rev Respir Med, V4, P167, DOI 10.1586/ers.10.10
   Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) Initiative and Agency for Preventive Medicine (AMP), 2015, DRAW NITAGS INT PROC
   Theo A, 2018, INFLUENZA OTHER RESP, V12, P46, DOI 10.1111/irv.12492
   WHO, 2018, IMM VACC BIOL
   World Bank, 2015, WB UPD SAYS 10 COUNT
   World Health Organisation, 2017, SAGE M APR 2017
   World Health Organisation, 2012, VACC INFL WHO POS PA, V47, P461
   World Health Organization, 2017, EST DIS BURD COST EF
NR 26
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 464
EP 472
DI 10.1016/j.vaccine.2018.11.062
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200010
PM 30502070
OA Other Gold
DA 2020-05-12
ER

PT J
AU Aguado-Martinez, A
   Basto, AP
   Tanaka, S
   Ryser, LT
   Nunes, TP
   Ortega-Mora, LM
   Arranz-Solis, D
   Leitao, A
   Hemphill, A
AF Aguado-Martinez, Adriana
   Basto, Afonso P.
   Tanaka, Shun
   Ryser, Lorenz T.
   Nunes, Telmo P.
   Ortega-Mora, Luis-Miguel
   Arranz-Solis, David
   Leitao, Alexandre
   Hemphill, Andrew
TI Immunization with a cocktail of antigens fused with OprI reduces
   Neospora caninum vertical transmission and postnatal mortality in mice
SO VACCINE
LA English
DT Article
DE Neosporosis; Mouse model; Pregnancy; Vaccine; Dendritic cells;
   Immunomodulation; Rhoptries; Protein disulfide isomerase
ID INTRANASAL VACCINATION; EXPERIMENTAL-INFECTION; CHIMERIC ANTIGEN; MOUSE
   MODELS; PREGNANCY; PROTECTION; VIRULENT; VACCINES; COWS
AB OprI is an outer membrane lipoprotein from Pseudomonas aeruginosa, and when fused to a recombinant antigen, will exert adjuvant properties by engaging Toll-like receptor 2, leading to dendritic cell activation. Previous studies have shown that the Neospora caninum (Nc) antigens NcPDI, NcROP2 and NcROP40 are implicated in host cell interactions and are promising vaccine candidates. In two independent experiments, the efficacy of a polyvalent vaccine formulation composed of OprI-NcPDI, OprI-NcROP2 and OprI-NcROP40 (collectively named O-Ags) was assessed in non-pregnant and pregnant Balb/c mouse models challenged with tachyzoites of the high-virulence isolate Nc-Spain7. Parameters that were investigated were clinical signs, fertility, parasite burden in adult mice, humoral and cellular immune responses at different time-points prior to and after challenge infection, vertical transmission and post-natal survival of offspring mice, all to explore potential correlations with efficacy. Vaccination of mice with O-Ags induced a mixed Th1/Th2 immune response in adult mice and led to significantly increased protection against cerebral infection. Vaccination with O-Ags also resulted in reduced vertical transmission, and postnatal disease in offspring was significantly inhibited at a rate not observed in mice infected with a high-virulence isolate to date. However, O-Ags mixed with TLR ligands targeting TLR3 and TLR7, which are known to induce clear Th1-biased responses, or vaccination with OprI fused to the non-N. caninum antigen ovalbumin (OprI-OVA) did not confer protection. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Aguado-Martinez, Adriana; Basto, Afonso P.; Tanaka, Shun; Ryser, Lorenz T.; Hemphill, Andrew] Univ Bern, Inst Parasitol, Vetsuisse Fac, Langgass Str 122, CH-3012 Bern, Switzerland.
   [Nunes, Telmo P.; Leitao, Alexandre] Univ Lisbon, CIISA, Fac Med Vet, Ave Univ Tecn, P-1300977 Lisbon, Portugal.
   [Ortega-Mora, Luis-Miguel; Arranz-Solis, David] Univ Complutense Madrid, Dept Anim Hlth, SALUVET, Ciudad Univ S-N, Madrid 28040, Spain.
RP Aguado-Martinez, A; Hemphill, A (reprint author), Univ Bern, Inst Parasitol, Langgass Str 122, CH-3012 Bern, Switzerland.
EM adriana.aguado@vetsuisse.unibe.ch; andrew.hemphill@vetsuisse.unibe.ch
RI Leitao, Alexandre/M-3688-2013; Arranz-Solis, D./D-9877-2019;
   Ortega-Mora, Luis-Miguel/F-1470-2016
OI Leitao, Alexandre/0000-0002-8398-6754; Arranz-Solis,
   D./0000-0002-2647-3194; Basto, Afonso/0000-0002-4651-1338; Nunes,
   Telmo/0000-0003-4388-5366; Ortega-Mora, Luis-Miguel/0000-0002-4986-6783;
   Hemphill, Andrew/0000-0002-0622-2128
FU Swiss National Science Foundation, SwitzerlandSwiss National Science
   Foundation (SNSF) [310030_165782]
FX We are grateful to Vreni Balmer for technical assistance and help in
   cell culture, and Joachim Muller and Norbert Muller for many helpful
   pieces of advice. This work was financed by the Swiss National Science
   Foundation, Switzerland, (grant No. 310030_165782).
CR Aguado-Martinez A, 2017, INT J PARASITOL, V47, P723, DOI 10.1016/j.ijpara.2017.09.001
   Aguado-Martinez A, 2016, PARASITOLOGY, V143, P606, DOI 10.1017/S0031182016000056
   Amah-Tariah FS, 2016, INT RES J MED SCI, V4, P11
   Arranz-Solis D, 2016, VET RES, V47, DOI 10.1186/s13567-015-0290-0
   Arranz-Solis D, 2015, VET PARASITOL, V211, P133, DOI 10.1016/j.vetpar.2015.05.021
   Basto AP, 2014, J IMMUNOL RES, DOI 10.1155/2014/619410
   Basto AP, 2012, J BIOTECHNOL, V157, P50, DOI 10.1016/j.jbiotec.2011.11.006
   Bethancourt CN, 2017, CURR OPIN PEDIATR, V29, P737, DOI 10.1097/MOP.0000000000000553
   Mansilla FC, 2016, EXP PARASITOL, V160, P1, DOI 10.1016/j.exppara.2015.10.008
   Debache K, 2013, PARASITE IMMUNOL, V35, P11, DOI 10.1111/pim.12013
   Debache K, 2010, PARASITOLOGY, V137, P229, DOI 10.1017/S0031182009991259
   Debache K, 2008, INT J PARASITOL, V38, P1455, DOI 10.1016/j.ijpara.2008.04.001
   Debache K, 2009, INT J PARASITOL, V39, P1373, DOI 10.1016/j.ijpara.2009.04.006
   Dubey JP, 2017, NEOSPOROSIS ANIMALS
   Guy CS, 2001, VET REC, V149, P443, DOI 10.1136/vr.149.15.443
   Hemphill A, 2016, PARASITOLOGY, V143, P245, DOI 10.1017/S0031182015001596
   Horcajo P, 2016, PARASITE IMMUNOL, V38, P709, DOI 10.1111/pim.12342
   Jenum PA, 1997, J CLIN MICROBIOL, V35, P1972, DOI 10.1128/JCM.35.8.1972-1977.1997
   Khan IA, 1997, EXP PARASITOL, V85, P24, DOI 10.1006/expr.1996.4110
   MacHugh ND, 2011, INFECT IMMUN, V79, P2059, DOI 10.1128/IAI.01285-10
   Miller C, 2005, INT J PARASITOL, V35, P821, DOI 10.1016/j.ijpara.2005.03.006
   Monney T, 2011, VACCINE, V29, P6967, DOI 10.1016/j.vaccine.2011.07.038
   Morrison WI, 2016, PARASITE IMMUNOL, V38, P707, DOI 10.1111/pim.12398
   Muller J, 2008, EXP PARASITOL, V118, P80, DOI 10.1016/j.exppara.2007.06.008
   Muller N, 2002, J CLIN MICROBIOL, V40, P252, DOI 10.1128/JCM.40.1.252-255.2002
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Papaioannou AI, 2017, EUR J PHARMACOL, V808, P14, DOI 10.1016/j.ejphar.2016.09.033
   Pare J, 1997, J PARASITOL, V83, P82, DOI 10.2307/3284321
   Pastor-Fernandez I, 2016, PARASITOLOGY, V143, P97, DOI 10.1017/S0031182015001511
   Pastor-Fernandez I, 2015, VET PARASITOL, V207, P203, DOI 10.1016/j.vetpar.2014.12.009
   Quintanilla-Gozalo A., 2000, INT J PARASITOL, V30, P877
   Regidor-Cerrillo J, 2008, PARASITOLOGY, V135, P1651, DOI 10.1017/S003118200800509X
   Regidor-Cerrillo J, 2012, J PROTEOMICS, V75, P2306, DOI 10.1016/j.jprot.2012.01.039
   Reichel MP, 2015, VACCINE, V33, P1299, DOI 10.1016/j.vaccine.2015.01.064
   Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022
   Rettigner C, 2004, PARASITOLOGY, V128, P149, DOI 10.1017/S0031182003004402
   Rojo-Montejo S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-106
   Rojo-Montejo S, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-62
   Wang S, 2011, J IMMUNOL, V187, P141, DOI 10.4049/jimmunol.1003740
   Weber FH, 2013, CLIN VACCINE IMMUNOL, V20, P99, DOI 10.1128/CVI.00225-12
   WHITTEN MK, 1957, NATURE, V180, P1436, DOI 10.1038/1801436a0
NR 41
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 473
EP 483
DI 10.1016/j.vaccine.2018.11.060
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200011
PM 30497830
OA Green Published
DA 2020-05-12
ER

PT J
AU Jeong, JH
   Kim, EH
   Lloren, KKS
   Kwon, JJ
   Kwon, HI
   Ahn, SJ
   Kim, YI
   Choi, WS
   Si, YJ
   Lee, OJ
   Han, HJ
   Baek, YH
   Song, MS
   Choi, YK
   Kim, CJ
AF Jeong, Ju Hwan
   Kim, Eun-Ha
   Lloren, Khristine Kaith S.
   Kwon, Jin Jung
   Kwon, Hyeok-il
   Ahn, Su Jeong
   Kim, Young-Il
   Choi, Won-Suk
   Si, Young-Jae
   Lee, Ok-Jun
   Han, Hae Jung
   Baek, Yun Hee
   Song, Min-Suk
   Choi, Young Ki
   Kim, Chul-Joong
TI Preclinical evaluation of the efficacy of an H5N8 vaccine candidate
   (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness
SO VACCINE
LA English
DT Article
DE H5N8 pre-pandemic vaccine; Preclinical evaluation; Immunogenicity;
   Protective efficacy
ID AVIAN INFLUENZA-VIRUSES; UNIVERSAL VACCINE; HUMAN INFECTION; EVOLUTION
AB Because H5N1 influenza viruses continuously threaten the public health, the WHO has prepared various clades of H5N1 mock-up vaccines as one of the measures for pandemic preparedness. The recent worldwide outbreak of H5Nx virus which belongs to clade 2.3.4.4 and of which H5N6 subtype belongs and already caused human infection also increases the need of pandemic vaccine for such novel emerging viruses. In this study, we evaluated the protective efficacy and immunogenicity of an egg-based and inactivated whole-virus H5N8 (IDCDC-RG43A) developed by CDC containing HA and NA gene of the parent virus A/gyrfalcon/Washington/41088-6/2014. Mice vaccinated two times elicited low to moderate antibody titer in varying amount of antigen doses against the homologous H5N8 vaccine virus and heterologous intra-clade 23.4.4 H5N6 (A/Sichuan/26221/2014) virus. Mice immunized with at least 3.0 mu g/dose of IDCDC-RG43A with aluminum hydroxide adjuvant were completely protected from lethal challenge with the mouse-adapted H5N8 (A/Environment/Korea/ma468/2015, maH5N8) as well as cleared the viral replication in tissues including lung, brain, spleen, and kidney. Vaccinated ferrets induced high antibody titers against clade 2.3.4.4 H5N8/H5N6 viruses and the antibody showed high cross-reactivity to Glade 2.2 H5N1 but not to clade 1 and 2.3.4 viruses as measured by hemagglutinin inhibition and serum neutralization assays. Furthermore, administration of the vaccine in ferrets resulted in attenuation of clinical disease signs and virus spread to peripheral organs including lung, spleen, and kidney from high dose challenge with maH5N8 virus. The protective and immunogenic characteristic of the candidate vaccine are essential attributes to be considered for further clinical trials as a pre-pandemic vaccine for a potential pandemic virus. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Jeong, Ju Hwan; Kim, Eun-Ha; Lloren, Khristine Kaith S.; Kwon, Jin Jung; Kwon, Hyeok-il; Ahn, Su Jeong; Kim, Young-Il; Choi, Won-Suk; Si, Young-Jae; Lee, Ok-Jun; Han, Hae Jung; Baek, Yun Hee; Song, Min-Suk; Choi, Young Ki] Chungbuk Natl Univ, Coll Med, Dept Microbiol, Cheongju, South Korea.
   [Jeong, Ju Hwan; Kim, Eun-Ha; Lloren, Khristine Kaith S.; Kwon, Jin Jung; Kwon, Hyeok-il; Ahn, Su Jeong; Kim, Young-Il; Choi, Won-Suk; Si, Young-Jae; Lee, Ok-Jun; Han, Hae Jung; Baek, Yun Hee; Song, Min-Suk; Choi, Young Ki] Med Res Inst, Cheongju, South Korea.
   [Han, Hae Jung] Green Cross Co, Res & Dev Ctr, Yongin, South Korea.
   [Han, Hae Jung] Green Cross Wellbeing Corp, Res & Dev Ctr, Seongnam, South Korea.
   [Kim, Chul-Joong] Chungnam Natl Univ, Coll Vet Med, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Lloren, Khristine Kaith S.] De La Salle Araneta Univ, Coll Vet Med & Agr Sci, 303 Victoneta Ave, Malabon City 1475, Philippines.
RP Kim, CJ (reprint author), Chungnam Natl Univ, Coll Vet Med, 99 Daehak Ro, Daejeon 34134, South Korea.; Song, MS; Choi, YK (reprint author), Chungbuk Natl Univ, Coll Med, Chungdae Ro 1, Cheongju 28644, South Korea.; Song, MS; Choi, YK (reprint author), Chungbuk Natl Univ, Med Res Inst, Chungdae Ro 1, Cheongju 28644, South Korea.
EM songminsuk@chungbulc.ac.kr; choiki55@chungbuk.ac.kr; cjkim@cnu.ac.kr
OI Kim, Chul-Joong/0000-0001-8827-6332
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Korea Health Technology R&D Project through the Korea
   Health Industry Development Institute (KHIDI) - Ministry of Health &
   Welfare, Republic of Korea [HI16C1032]; Ministry of Science, ICT &
   Future Planning [NRF-2016M3A9B6918676]
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic
   of Korea [grant number: HI16C1032] and by the Ministry of Science, ICT &
   Future Planning [NRF-2016M3A9B6918676].
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Bi YH, 2016, CELL HOST MICROBE, V20, P810, DOI 10.1016/j.chom.2016.10.022
   (CDC) CfDCaP, 2014, NOV EUR HIGHL PATH A
   Choi WS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40667
   He F, 2014, ANTIVIR RES, V105, P143, DOI 10.1016/j.antiviral.2014.03.002
   Hertst S, 2018, MSPHERE, V3
   Hirst GK, 1942, J EXP MED, V75, P49, DOI 10.1084/jem.75.1.49
   Joob Beuy, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P434, DOI 10.1016/j.apjtb.2015.03.001
   Lee DH, 2017, J VET SCI, V18, P269, DOI [10.4142/jvs.2017.18.s1.269, 10.4142/jvs.2017.18.S1.269]
   Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845
   Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999
   Ohkawara A, 2017, MICROBIOL IMMUNOL, V61, P149, DOI 10.1111/1348-0421.12478
   Pan M, 2016, J INFECTION, V72, P52, DOI 10.1016/j.jinf.2015.06.009
   Pappas C, 2007, CLIN VACCINE IMMUNOL, V14, P1425, DOI 10.1128/CVI.00174-07
   Prabakaran M, 2010, J VIROL, V84, P11822, DOI 10.1128/JVI.00891-10
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rockman S, 2010, HUM VACCINES, V6, P792, DOI 10.4161/hv.6.10.12915
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Smith GJD, 2015, INFLUENZA OTHER RESP, V9, P271, DOI 10.1111/irv.12324
   Song MS, 2012, J MICROBIOL, V50, P478, DOI 10.1007/s12275-012-1573-z
   Uyeki TM, 2009, CLIN INFECT DIS, V49, P279, DOI 10.1086/600035
   WHO, 2015, EV INFL A H5 HAEM WH
   WHO, 2009, SAF PAND VACC
   World Health Organization, 2017, ANT GEN CHAR ZOON IN
   Xu WT, 2015, CLIN VACCINE IMMUNOL, V22, P327, DOI 10.1128/CVI.00662-14
   Zacour M, 2016, CLIN VACCINE IMMUNOL, V23, P236, DOI 10.1128/CVI.00613-15
   Zhang Y, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.38
NR 27
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 484
EP 493
DI 10.1016/j.vaccine.2018.11.064
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200012
PM 30502069
DA 2020-05-12
ER

PT J
AU Flaxman, A
   Yamaguchi, Y
   van Diemen, PM
   Rollier, C
   Allen, E
   Elshina, E
   Wyllie, DH
AF Flaxman, Amy
   Yamaguchi, Yuko
   van Diemen, Pauline M.
   Rollier, Christine
   Allen, Elizabeth
   Elshina, Elizaveta
   Wyllie, David H.
TI Heterogeneous early immune responses to the S-aureus EapH2 antigen
   induced by gastrointestinal tract colonisation impact the response to
   subsequent vaccination
SO VACCINE
LA English
DT Article
DE S. aureus; Vaccine; Colonisation; Mouse; EapH1; EapH2
ID NASAL CARRIERS; COMMUNITY; CARRIAGE; EVASION; IMMUNOGENICITY;
   EPIDEMIOLOGY; INFECTIONS; ANTIBODIES; MICROBIOTA; INDUCTION
AB Introduction: S. aureus is a pathogen to which individuals are exposed shortly after birth, with immune responses to S. aureus increasing during childhood. There is marked heterogeneity between the anti- S. aureus immune responses of different humans, the basis of which is not fully understood.
   Methods: To investigate development of anti-S. aureus immune responses, we studied S. aureus colonised mice under controlled conditions. Mice were either acquired colonised from breeding colonies, or experimentally colonised by exposure to a cage environment which had been sprayed with a S. aureus suspension. Colonisation was monitored by sequential stool sampling, and immunoglobulin levels against both whole fixed S. aureus and individual S. aureus antigens quantified. The immunological impact of colonisation on subsequent vaccination was investigated.
   Results: Colonised BALB/c and BL/6 mice develop serum anti- S. aureus cell surface IgG1 antibodies. Responses were proportional to the cumulative S. aureus bioburden in the mice, and were higher in BALB/c mice, which have higher colonisation levels, than in C57BL/6 animals. We observed marked variation in the induction of anti-cell surface antibodies, even in genetically identical mice experimentally colonised with the same S. aureus clone. Heterogeneity was also evident when monitoring immune responses to the secreted S. aureus protein EapH2. Approximately 50% of colonised mice developed anti-EapH2 responses (responders); in other mice, responses were not significantly different to those in uncolonised mice (non-responders). Following vaccination with a replication deficient adenovirus expressing EapH2, less anti-EapH2 antibody was generated in non-responder than responder animals.
   Conclusions: In genetically identical mice, S. aureus colonisation results in all-or-nothing antibody responses against some antigens, including EapH2. For antigens involved in colonisation success by microbes, apparently stochastic early immune responses may impact both vaccine responses and the establishment of an animal-specific microbiome. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Flaxman, Amy; Yamaguchi, Yuko; van Diemen, Pauline M.; Allen, Elizabeth; Elshina, Elizaveta; Wyllie, David H.] Univ Oxford, Jenner Inst, Ctr Cellular & Mol Physiol, Oxford, England.
   [Rollier, Christine] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Churchill Dr, Oxford, England.
   [Rollier, Christine] CCVTM, NIHR Biomed Res Ctr, Churchill Dr, Oxford, England.
   [van Diemen, Pauline M.] APHA Weybridge, Addlestone KT15 3NB, Surrey, England.
   [Elshina, Elizaveta] Univ Cambridge, Dept Pathol, Cambridge, England.
RP Wyllie, DH (reprint author), Univ Oxford, Jenner Inst, Ctr Cellular & Mol Physiol, Oxford, England.
EM david.wyllie@ndm.ox.ac.uk
OI Flaxman, Amy/0000-0001-6460-1372
FU European Union's Seventh Framework ProgrammeEuropean Union (EU)
   [601783]; National Institute for Health Research (NIHR) Oxford
   Biomedical Research CentreNational Institute for Health Research (NIHR)
FX The research leading to these results has received funding from the
   European Union's Seventh Framework Programme under the grant agreement
   no. 601783 (BELLEROPHON project). The research was supported in part by
   the National Institute for Health Research (NIHR) Oxford Biomedical
   Research Centre. CR is a Jenner Institute investigator. The views
   expressed are those of the author(s) and not necessarily those of the
   NHS, the NIHR or the Department of Health.
CR Acton DS, 2009, EUR J CLIN MICROBIOL, V28, P115, DOI 10.1007/s10096-008-0602-7
   Adhikari RP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137874
   Bode LGM, 2010, NEW ENGL J MED, V362, P9, DOI 10.1056/NEJMoa0808939
   Brown AE, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00507
   Burbelo PD, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-22
   Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850
   Dryla A, 2005, CLIN DIAGN LAB IMMUN, V12, P387, DOI 10.1128/CDLI.12.3.387-398.2005
   Elshina E, 2019, VACCINE, V37, P502, DOI 10.1016/j.vaccine.2018.11.036
   Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014
   Fitzgerald JR, 2012, TRENDS MICROBIOL, V20, P192, DOI 10.1016/j.tim.2012.01.006
   Flaxman A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12576-0
   Fritz SA, 2013, CLIN INFECT DIS, V56, P1554, DOI 10.1093/cid/cit123
   Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9
   Holtfreter S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071142
   Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848
   Kolata J, 2011, PROTEOMICS, V11, P3914, DOI 10.1002/pmic.201000760
   Lecuyer E, 2014, IMMUNITY, V40, P608, DOI 10.1016/j.immuni.2014.03.009
   Lindberg E, 2011, CLIN MICROBIOL INFEC, V17, P1209, DOI 10.1111/j.1469-0691.2010.03426.x
   Macpherson AJ, 2018, ANNU REV IMMUNOL, V36, P359, DOI 10.1146/annurev-immunol-042617-053238
   Mediavilla JR, 2012, CURR OPIN MICROBIOL, V15, P588, DOI 10.1016/j.mib.2012.08.003
   Miller RR, 2014, J INFECTION, V68, P426, DOI 10.1016/j.jinf.2013.12.013
   Mrochen D. M., 2017, INT J MED MICROBIOL
   Pauli NT, 2014, J EXP MED, V211, P2331, DOI 10.1084/jem.20141404
   Rasigade JP, 2014, INFECT GENET EVOL, V21, P510, DOI 10.1016/j.meegid.2013.08.018
   Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822
   Schulz D, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00152
   Slack E, 2014, IMMUNOL REV, V260, P50, DOI 10.1111/imr.12179
   Sollid JUE, 2014, INFECT GENET EVOL, V21, P531, DOI 10.1016/j.meegid.2013.03.020
   Stapels DAC, 2016, CELL MICROBIOL, V18, P536, DOI 10.1111/cmi.12528
   Stapels DAC, 2018, PROTEIN SCI, V27, P509, DOI 10.1002/pro.3342
   Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111
   Stentzel S, 2015, J PROTEOMICS, V128, P1, DOI 10.1016/j.jprot.2015.06.018
   Sun Y, 2018, J BACTERIOL, V200, DOI 10.1128/JB.00735-17
   Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/s1473-3099(17)30753-3, 10.1016/S1473-3099(17)30753-3]
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14
   van Belkum A, 2009, J INFECT DIS, V199, P1820, DOI 10.1086/599119
   van Diemen PM, 2013, PATHOG DIS, V68, P20, DOI 10.1111/2049-632X.12042
   Verkaik NJ, 2010, CLIN MICROBIOL INFEC, V16, P1312, DOI 10.1111/j.1469-0691.2009.03073.x
   Verkaik NJ, 2009, J INFECT DIS, V199, P625, DOI 10.1086/596743
   Whitehouse J, 2016, VACCINE, V34, P1792, DOI 10.1016/j.vaccine.2016.02.034
   Zhao F, 2015, INFECT IMMUN, V83, P3712, DOI 10.1128/IAI.00667-15
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 494
EP 501
DI 10.1016/j.vaccine.2018.11.063
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200013
PM 30503080
DA 2020-05-12
ER

PT J
AU Elshina, E
   Allen, ER
   Flaxman, A
   van Diemen, PM
   Milicic, A
   Rollier, CS
   Yamaguchi, Y
   Wyllie, DH
AF Elshina, Elizaveta
   Allen, Elizabeth R.
   Flaxman, Amy
   van Diemen, Pauline M.
   Milicic, Anita
   Rollier, Christine S.
   Yamaguchi, Yuko
   Wyllie, David H.
TI Vaccination with the Staphylococcus aureus secreted proteins EapH1 and
   EapH2 impacts both S-aureus carriage and invasive disease
SO VACCINE
LA English
DT Article
DE S. aureus; Vaccine; Colonisation; Mouse; EapH1; EapH2
ID EXTRACELLULAR ADHERENCE PROTEIN; T-CELL RESPONSES;
   METHICILLIN-RESISTANT; MONOCLONAL-ANTIBODY; ADENOVIRAL VACCINE; NASAL
   CARRIAGE; IN-VIVO; MICE; VECTORS; DECOLONIZATION
AB Introduction: There is a need for an efficacious vaccine reducing infections due to Staphylococcus aureus, a common cause of community and hospital infection. Infecting organisms originate from S. aureus populations colonising the nares and bowel. Antimicrobials are widely used to transiently reduce S. aureus colonisation prior to surgery, a practice which is selecting for resistant S. aureus isolates. S. aureus secretes multiple proteins, including the protease inhibitors extracellular adhesion protein homologue 1 and 2 (EapH1 and EapH2).
   Methods: Mice were vaccinated intramuscularly or intranasally with Adenovirus serotype 5 and Modified Vaccinia Ankara viral vectors expressing EapH1 and EapH2 proteins, or with control viruses. Using murine S. aureus colonisation models, we monitored S. aureus colonisation by sequential stool sampling. Monitoring of S. aureus invasive disease after intravenous challenge was performed using bacterial load and abscess numbers in the kidney.
   Results: Intramuscular vaccination with Adenovirus serotype 5 and Modified Vaccinia Ankara viral vectors expressing EapH1 and EapH2 proteins significantly reduces bacterial recovery in the murine renal abscess model of infection, but the magnitude of the effect is small. A single intranasal vaccination with an adenoviral vaccine expressing these proteins reduced S. aureus gastrointestinal (GI) tract colonisation.
   Conclusion: Vaccination against EapH1 / EapH2 proteins may offer an antibiotic independent way to reduce S. aureus colonisation, as well as contributing to protection against S. aureus invasive disease. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Elshina, Elizaveta; Allen, Elizabeth R.; Flaxman, Amy; van Diemen, Pauline M.; Milicic, Anita; Yamaguchi, Yuko; Wyllie, David H.] Univ Oxford, Jenner Inst, Ctr Cellular & Mol Physiol, Oxford, England.
   [Rollier, Christine S.] Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford, England.
   [Rollier, Christine S.] Univ Oxford, NIHR Oxford Biomed Res Ctr, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Elshina, Elizaveta] Univ Cambridge, Dept Pathol, Cambridge, England.
   [van Diemen, Pauline M.] APHA Weybridge, Virol, Addlestone, Surrey, England.
RP Wyllie, DH (reprint author), Univ Oxford, Jenner Inst, Ctr Cellular & Mol Physiol, Oxford, England.
EM david.wyllie@ndm.ox.ac.uk
OI Flaxman, Amy/0000-0001-6460-1372
FU European Union's Seventh Framework ProgrammeEuropean Union (EU)
   [601783]; Oxford Biomedical Research Centre
FX The research leading to these results has received funding from the
   European Union's Seventh Framework Programme under the grant agreement
   no 601783 (BELLEROPHON project). The research was supported in part by
   the Oxford Biomedical Research Centre. CR is a Jenner Institute
   investigator. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Acton DS, 2009, EUR J CLIN MICROBIOL, V28, P115, DOI 10.1007/s10096-008-0602-7
   Allen E. R., MRI BASED QUANTIFICA
   Allen ER, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154705
   Archer NK, 2013, INFECT IMMUN, V81, P2070, DOI 10.1128/IAI.00084-13
   Bagnoli F, 2015, P NATL ACAD SCI USA, V112, P3680, DOI 10.1073/pnas.1424924112
   Bauza K, 2014, INFECT IMMUN, V82, P1277, DOI 10.1128/IAI.01187-13
   Bode LGM, 2016, ANN SURG, V263, P511, DOI 10.1097/SLA.0000000000001060
   Bode LGM, 2010, NEW ENGL J MED, V362, P9, DOI 10.1056/NEJMoa0808939
   BREMELL T, 1991, INFECT IMMUN, V59, P2615, DOI 10.1128/IAI.59.8.2615-2623.1991
   Burbelo PD, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-22
   Carter GP, 2018, ANTIMICROB AGENTS CH, V62
   Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728
   Cheng AG, 2009, FASEB J, V23, P3393, DOI 10.1096/fj.09-135467
   CLAASSENWEITZ S, 2016, FRONT MICROBIOL, V7
   Cooper BS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002454
   Dasa S, 2016, P NATL ACAD SCI USA, V113, pE3101, DOI 10.1073/pnas.1520255113
   David MZ, 2014, INFECT CONT HOSP EP, V35, P1466, DOI 10.1086/678606
   Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0
   Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850
   Dupont CD, 2018, MSPHERE, V3
   Everitt RG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4956
   Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014
   Ewer KJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3836
   Flaxman A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12576-0
   Flock M, 2001, J BACTERIOL, V183, P3999, DOI 10.1128/JB.183.13.3999-4003.2001
   Fowler VG, 2013, JAMA-J AM MED ASSOC, V309, P1368, DOI 10.1001/jama.2013.3010
   French GL, 2010, INT J ANTIMICROB AG, V36, pS3, DOI 10.1016/S0924-8579(10)70003-0
   Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9
   Gomez CE, 2007, J GEN VIROL, V88, P2473, DOI 10.1099/vir.0.83018-0
   Hammel M, 2007, PROTEIN SCI, V16, P2605, DOI 10.1110/ps.073170807
   Hansen U, 2006, MATRIX BIOL, V25, P252, DOI 10.1016/j.matbio.2006.01.005
   Haut LH, 2010, EUR J IMMUNOL, V40, P3426, DOI 10.1002/eji.201040440
   Huang SS, 2013, NEW ENGL J MED, V368, P2255, DOI 10.1056/NEJMoa1207290
   Hussain M, 2001, CLIN DIAGN LAB IMMUN, V8, P1271, DOI 10.1128/CDLI.8.6.1271-1276.2001
   Hussain M, 2008, INFECT IMMUN, V76, P5615, DOI 10.1128/IAI.00480-08
   Kim HK, 2015, MBIO, V6, DOI 10.1128/mBio.02369-14
   Kim HK, 2014, VACCINE, V32, P464, DOI 10.1016/j.vaccine.2013.11.054
   Kim HK, 2012, INFECT IMMUN, V80, P3460, DOI 10.1128/IAI.00230-12
   Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]
   Lin SW, 2007, VACCINE, V25, P2187, DOI 10.1016/j.vaccine.2006.11.044
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806
   McGuinness WA, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010032
   Miller RR, 2014, J INFECTION, V68, P426, DOI 10.1016/j.jinf.2013.12.013
   Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999
   Poovelikunnel T, 2015, J ANTIMICROB CHEMOTH, V70, P2681, DOI 10.1093/jac/dkv169
   Pozzi C, 2016, STAPHYLOCOCCUS AUREU
   Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822
   Reyes-Sandoval A, 2011, J IMMUNOL, V187, P1347, DOI 10.4049/jimmunol.1100302
   Reyes-Sandoval A, 2010, INFECT IMMUN, V78, P145, DOI 10.1128/IAI.00740-09
   Schulz D, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00152
   Senn L, 2016, MBIO, V7, DOI 10.1128/mBio.02039-15
   Shinefield H, 2002, NEW ENGL J MED, V346, P491, DOI 10.1056/NEJMoa011297
   Singer AJ, 2014, NEW ENGL J MED, V370, P1039, DOI 10.1056/NEJMra1212788
   Spencer AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033555
   Stapels DAC, 2016, CELL MICROBIOL, V18, P536, DOI 10.1111/cmi.12528
   Stapels DAC, 2018, PROTEIN SCI, V27, P509, DOI 10.1002/pro.3342
   Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111
   Sun Y, 2018, J BACTERIOL, V200, DOI 10.1128/JB.00735-17
   Tatsis N, 2007, BLOOD, V110, P1916, DOI 10.1182/blood-2007-02-062117
   Thammavongsa V, 2015, NAT REV MICROBIOL, V13, P529, DOI 10.1038/nrmicro3521
   Thammavongsa V, 2015, VACCINE, V33, P523, DOI 10.1016/j.vaccine.2014.11.051
   van Belkum A, 2016, MBIO, V7, DOI 10.1128/mBio.00079-16
   van Diemen PM, 2013, PATHOG DIS, V68, P20, DOI 10.1111/2049-632X.12042
   Whitehouse J, 2016, VACCINE, V34, P1792, DOI 10.1016/j.vaccine.2016.02.034
   Whitman TJ, 2012, INFECT CONT HOSP EP, V33, P809, DOI 10.1086/666631
   Woehl JL, 2014, J IMMUNOL, V193, P6161, DOI 10.4049/jimmunol.1401600
NR 66
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 502
EP 509
DI 10.1016/j.vaccine.2018.11.036
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200014
PM 30502067
DA 2020-05-12
ER

PT J
AU Langedijk, AC
   van Aalst, M
   Meek, B
   van Leeuwen, EMM
   Zeerleder, S
   Meijer, E
   Hazenberg, MD
   Grobusch, MP
   Goorhuis, A
AF Langedijk, Annefleur C.
   van Aalst, Marielle
   Meek, Bob
   van Leeuwen, Ester M. M.
   Zeerleder, Sacha
   Meijer, Ellen
   Hazenberg, Mette D.
   Grobusch, Martin P.
   Goorhuis, Abraham
TI Long-term pneumococcal vaccine immunogenicity following allogeneic
   hematopoietic stem cell transplantation
SO VACCINE
LA English
DT Article
DE Hematopoietic stem cell transplantation; Allogeneic; Invasive
   pneumococcal disease; Pneumococcal vaccination; PCV13; PPSV23
ID PROTECTIVE ANTIBODY-RESPONSES; COMMUNITY-ACQUIRED PNEUMONIA;
   BONE-MARROW-TRANSPLANTATION; CONJUGATE VACCINE;
   STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; RECIPIENTS; DISEASE;
   POLYSACCHARIDE; INFECTIONS
AB Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3-6 months after HSCT, focuses on short-term immunogenicity while long-term immunogenicity is not well characterized. The current Dutch immunization schedule, which starts at 12 months post allo-HSCT, was developed as a result of concerns on the coverage of long-term immunogenicity in international guidelines. We recently encountered two cases of allo-HSCT recipients who developed invasive pneumococcal disease (IPD) despite adequate revaccinations, which led us to question the immunogenicity of pneumococcal vaccinations in this patient group, and whether the currently existing vaccination schedules are appropriate. We included allo-HSCT recipients, vaccinated from one year after transplantation, and tested antibody responses to pneumococcal vaccination. We also performed a systematic review. Antibody concentrations were measured in 42 of 103 (41%) patients, with a response rate of 85% to PCV13 and 62% to PPSV23-unique serotypes. In six relevant studies, protection rates varied between 64 and 98%. Antibody responses in early and late vaccination schedules were similar, but adequate antibody responses were maintained better after late vaccination. Therefore, we propose a vaccination schedule that combines the advantages of early and late vaccination. This new schedule has been introduced since March 2018 in the two academic hospitals in Amsterdam, The Netherlands. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Langedijk, Annefleur C.; van Aalst, Marielle; Grobusch, Martin P.; Goorhuis, Abraham] Univ Amsterdam, Acad Med Ctr, Div Internal Med, Ctr Trop Med & Travel Med,Dept Infect Dis, NL-1105 AZ Amsterdam, Netherlands.
   [Meek, Bob] St Antonius Hosp, Dept Med Microbiol & Immunol, NL-3435 CM Nieuwegein, Netherlands.
   [van Leeuwen, Ester M. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1100 AZ Amsterdam, Netherlands.
   [Zeerleder, Sacha; Hazenberg, Mette D.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1100 AZ Amsterdam, Netherlands.
   [Meijer, Ellen] Vrije Univ Amsterdam Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands.
RP Goorhuis, A (reprint author), Meibergdreef 9, NL-1100 AZ Amsterdam, Netherlands.
EM a.goorhuis@amc.uva.nl
OI Hazenberg, Mette/0000-0002-5113-0249
CR Antin JH, 2005, BIOL BLOOD MARROW TR, V11, P213, DOI 10.1016/j.bbmt.2004.12.330
   Avigan D, 2001, BIOL BLOOD MARROW TR, V7, P171, DOI 10.1053/bbmt.2001.v7.pm11302551
   Chen CS, 2003, BONE MARROW TRANSPL, V32, P515, DOI 10.1038/sj.bmt.1704162
   Cordonnier C, 2015, BONE MARROW TRANSPL, V50, P978, DOI 10.1038/bmt.2015.42
   Cordonnier C, 2015, CLIN INFECT DIS OFF
   Cordonnier C, 2010, VACCINE, V28, P2730, DOI 10.1016/j.vaccine.2010.01.025
   Cordonnier C, 2009, CLIN INFECT DIS, V48, P1392, DOI 10.1086/598324
   Di Sabatino A, 2011, LANCET, V378, P86, DOI 10.1016/S0140-6736(10)61493-6
   Engelhard D, 2002, BRIT J HAEMATOL, V117, P444, DOI 10.1046/j.1365-2141.2002.03457.x
   Jain N, 2013, LEUKEMIA LYMPHOMA, V54, P1242, DOI 10.3109/10428194.2012.739688
   Jeurissen A, 2007, CLIN CHEM, V53, P505, DOI 10.1373/clinchem.2006.080051
   Kennedy LB, 2017, BIOL BLOOD MARROW TR, V23, P1614, DOI 10.1016/j.bbmt.2017.06.006
   Kong Y, 2015, HUMAN VACC IMMUNOTHE
   Kulkarni S, 2000, BLOOD, V95, P3683
   Kumar D, 2008, BONE MARROW TRANSPL, V41, P743, DOI 10.1038/sj.bmt.1705964
   Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870
   Meerveld-Eggink A, 2009, BIOL BLOOD MARROW TR, V15, P1523, DOI 10.1016/j.bbmt.2009.07.020
   Meisel R, 2007, BLOOD, V109, P2322, DOI 10.1182/blood-2006-06-032284
   Mirsaeidi M, 2014, AM J MED, V127, DOI 10.1016/j.amjmed.2014.05.010
   Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832
   Nordoy T, 2001, BONE MARROW TRANSPL, V28, P681, DOI 10.1038/sj.bmt.1703228
   OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979
   Paradiso PR, 2012, CLIN INFECT DIS, V55, P259, DOI 10.1093/cid/cis359
   Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641
   Poolman J, 2011, EXPERT REV VACCINES, V10, P307, DOI [10.1586/erv.11.8, 10.1586/ERV.11.8]
   Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI 10.1093/cid/cit816
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Torda A, 2014, TRANSPL INFECT DIS, V16, P751, DOI 10.1111/tid.12268
   van der Velden AMT, 2007, VACCINE, V25, P8512, DOI 10.1016/j.vaccine.2007.10.008
   Vestjens SMT, 2017, VACCINE, V35, P4112, DOI 10.1016/j.vaccine.2017.06.049
   Wagenvoort GHJ, 2017, VACCINE, V35, P4886, DOI 10.1016/j.vaccine.2017.07.088
   Youssef S, 2007, MEDICINE, V86, P69, DOI 10.1097/md.0b013e31803eb176
NR 32
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 510
EP 515
DI 10.1016/j.vaccine.2018.11.053
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200015
PM 30502071
DA 2020-05-12
ER

PT J
AU Lakhal-Naouar, I
   Koles, N
   Rao, M
   Morrison, EB
   Childs, JM
   Alving, CR
   Aronson, NE
AF Lakhal-Naouar, Ines
   Koles, Nancy
   Rao, Mangala
   Morrison, Elaine B.
   Childs, John M.
   Alving, Carl R.
   Aronson, Naomi E.
TI Transcutaneous immunization using SLA or rLACK skews the immune response
   towards a Th1 profile but fails to protect BALB/c mice against a
   Leishmania major challenge
SO VACCINE
LA English
DT Article
DE Leishmania; Transcutaneous immunization; BALB/c; SLA; rLACK; Th1
ID NITRIC-OXIDE; CUTANEOUS LEISHMANIASIS; VACCINE DELIVERY; CHOLERA-TOXIN;
   IN-VIVO; INFECTION; SKIN; ANTIGEN; IDENTIFICATION; TETANUS
AB Leishmaniasis is an expanding health threat worldwide complicated by the absence of an effective vaccine. We investigated transcutaneous immunization (TO) as a needle-free immunization route which exploits the abundance of antigen presenting cells in the skin to induce both mucosal and systemic immunity. Leishmania (L) major soluble antigens (SLA) or recombinant Leishmania homolog of receptors for activated C-kinase (rLACK) antigens were delivered transcutaneously together with cholera toxin (CT), to BALB/c mice. Mice were immunized at weeks 1, 4, and 7 with PBS, CT, SLA/CT or rLACK/CT. Two weeks after the final boost, antigen-specific IgG titers, IFN-gamma ELISpot, and cytokine levels were assessed in half of the mice and the remainder were challenged with an intradermal (ear) injection of 5 x 10(4) L major metacyclic parasites. Mice were monitored weekly and sacrificed after 7 weeks to assess the parasite burden and to study the ear lesion immunohistopathology. Our results show that TO with SLA or rLACK yielded high levels of anti-SLA, anti-rLACK and anti-CT IgG antibodies. A Th1-type of immune response was demonstrated with a high frequency of IFN-gamma secreting cells, high levels of IFN-gamma production, and lower levels of IL-10 resulting in a high IFN-gamma/IL-10 ratio in mice immunized with SLA/CT or rLACK/CT. After parasite challenge, rLACK immunization was not associated with protection. In addition, SLA/CT immunized mice had larger ear lesions and an increased parasite load in the ear. Immunohistochemistry of ear biopsies stained for nitric oxide synthase revealed that staining intensity was diminished in the SLA/CT group compared to the control group. This finding suggested that less parasite killing occurred at the site of the infection.
   In conclusion, despite a strong Th1 type profile induced by TCI, exacerbation of infection occurred after challenge with L major. This also correlated with low induction of nitric oxide. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Lakhal-Naouar, Ines; Koles, Nancy; Aronson, Naomi E.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA.
   [Rao, Mangala; Morrison, Elaine B.; Alving, Carl R.] Walter Reed Army Inst Res, US Mil HIV Res Program, Lab Adjuvant & Antigen Res, Silver Spring, MD USA.
   [Childs, John M.] Walter Reed Natl Mil Med Ctr, Dept Pathol, Bethesda, MD USA.
RP Lakhal-Naouar, I (reprint author), Uniformed Serv Univ Hlth Sci, Room A3056,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM ines.elakhal.naouar.ctr@usuhs.edu
FU intramural Uniformed Services University (USUHS)
FX This work was supported by an intramural Uniformed Services University
   (USUHS) grant administered through the Henry M. Jackson Foundation. The
   funding agency did not have any role in study design; in the collection,
   analysis and interpretation of data; in the writing of the report; and
   in the decision to submit the article for publication.
CR Adam L, 2015, J IMMUNOL METHODS, V426, P42, DOI 10.1016/j.jim.2015.07.010
   Alexander J, 2005, IMMUNOL LETT, V99, P17, DOI 10.1016/j.imlet.2005.01.009
   Azeredo-Coutinho RBG, 2008, CLIN EXP IMMUNOL, V153, P369, DOI 10.1111/j.1365-2249.2008.03705.x
   Bal SM, 2010, J CONTROL RELEASE, V148, P266, DOI 10.1016/j.jconrel.2010.09.018
   Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497
   Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x
   Bos JD, 1997, CLIN EXP IMMUNOL, V107, P3
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   Campos-Neto A, 2005, BRAZ J MED BIOL RES, V38, P979, DOI 10.1590/S0100-879X2005000700001
   Campos-Neto A, 2002, INFECT IMMUN, V70, P2828, DOI 10.1128/IAI.70.6.2828-2836.2002
   Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
   Czerkinsky C, 2010, MUCOSAL IMMUNOL, V3, P545, DOI 10.1038/mi.2010.55
   De Luca PM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00151
   Deak E, 2010, EUR J IMMUNOL, V40, P1355, DOI 10.1002/eji.200939455
   Dey R, 2014, J IMMUNOL, V193, P3513, DOI 10.4049/jimmunol.1303145
   Duthie MS, 2017, CLIN VACCINE IMMUNOL, P24
   Gimblet C, 2017, CELL HOST MICROBE, V22, P13, DOI 10.1016/j.chom.2017.06.006
   Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797
   Glenn GM, 1998, J IMMUNOL, V161, P3211
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014
   Golali E, 2012, IRAN J BASIC MED SCI, V15, P1032
   Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]
   Gupta G, 2013, ADV APPL MICROBIOL, V82, P155, DOI 10.1016/B978-0-12-407679-2.00005-3
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001
   HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011
   Himes R, 2011, VACCINE, V29, P5393, DOI 10.1016/j.vaccine.2011.05.085
   Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007
   Hirobe S, 2012, VACCINE, V30, P1847, DOI 10.1016/j.vaccine.2011.12.130
   Kaurav M, 2016, NANOMED-NANOTECHNOL, V12, P1063, DOI 10.1016/j.nano.2015.12.372
   Khamesipour A, 2005, VACCINE, V23, P3642, DOI 10.1016/j.vaccine.2005.02.015
   Kropf P, 2007, EUR J IMMUNOL, V37, P935, DOI 10.1002/eji.200636542
   Kumar V, 2014, NUTRITION, V30, P449, DOI 10.1016/j.nut.2013.10.003
   Lakhal-Naouar I, 2008, BIOCHEM BIOPH RES CO, V375, P54, DOI 10.1016/j.bbrc.2008.07.099
   Lakhal-Naouar I, 2009, CLIN VACCINE IMMUNOL, V16, P956, DOI 10.1128/CVI.00023-09
   Levine MM, 2003, NAT MED, V9, P99, DOI 10.1038/nm0103-99
   Marshall S, 2016, HUM VACC IMMUNOTHER, V12, P2975, DOI 10.1080/21645515.2016.1171440
   Matsuo K, 2013, VACCINE, V31, P2403, DOI 10.1016/j.vaccine.2013.03.022
   Matsuo K, 2012, J CONTROL RELEASE, V160, P495, DOI 10.1016/j.jconrel.2012.04.001
   Mattsson J, 2015, MUCOSAL IMMUNOL, V8, P815, DOI 10.1038/mi.2014.111
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Modolell M, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000480
   Muller AJ, 2013, CELL HOST MICROBE, V14, P460, DOI 10.1016/j.chom.2013.09.008
   Mutiso JM, 2010, J BIOMED RES, V24, P16, DOI 10.1016/S1674-8301(10)60004-8
   Probst P, 2001, J IMMUNOL, V166, P498, DOI 10.4049/jimmunol.166.1.498
   Roberts MTM, 2005, INFECT IMMUN, V73, P7620, DOI 10.1128/IAI.73.11.7620-7628.2005
   Ronet C, 2008, J IMMUNOL, V180, P4825, DOI 10.4049/jimmunol.180.7.4825
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Scharton-Kersten T, 1999, VACCINE, V17, pS37, DOI 10.1016/S0264-410X(99)00233-9
   Schwarz T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003476
   SCOTT P, 1987, J IMMUNOL, V139, P3118
   Seid RC, 2014, CLIN VACCINE IMMUNOL, V21, P253, DOI 10.1128/CVI.00638-13
   Sharma U, 2009, INDIAN J EXP BIOL, V47, P412
   Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   Stacey KJ, 1999, INFECT IMMUN, V67, P3719, DOI 10.1128/IAI.67.8.3719-3726.1999
   Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501
   STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0
   Thalhofer CJ, 2010, J VIS EXP JOVE, DOI http://dx.doi.org/10.3791/1980
   TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x
   WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0
NR 62
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 516
EP 523
DI 10.1016/j.vaccine.2018.11.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200016
PM 30528328
OA Other Gold
DA 2020-05-12
ER

PT J
AU Shibli, R
   Rishpon, S
   Cohen-Dar, M
   Kandlik, Y
AF Shibli, Rana
   Rishpon, Shmuel
   Cohen-Dar, Michal
   Kandlik, Yael
TI What affects pediatric healthcare providers to encourage receipt of
   routine childhood vaccinations? Results from the Northern District of
   Israel, 2016
SO VACCINE
LA English
DT Article
DE Behavior; Knowledge; Attitude; Healthcare provider; Childhood
   vaccination
ID KNOWLEDGE; ATTITUDES
AB Background: Pediatric healthcare providers (HCPs) are a major resource which helps parents make decisions about their children's vaccinations. It is important to assess their behavior to encourage the receipt of routine vaccines.
   Objectives: (1) To evaluate the knowledge level of and attitudes towards routine childhood vaccinations among pediatric HCPs; (2) To assess their behavior to encourage the receipt of routine vaccinations and associated predictors; (3) To examine their willingness to receive immunization training and to improve their skills to cope with vaccine-hesitant parents.
   Study design and settings: This is a cross-sectional study among pediatric physicians and nurses working at primary clinics (curative service) and mother-child health clinics (preventive service) in Jewish localities in the Northern District of Israel.
   Methods: A structured, anonymous, self-administered questionnaire was used.
   Results: The study included 271 HCPs (response rate = 72.2%). An insufficient knowledge level about vaccines was demonstrated among participants (mean score: 5.2 +/- 0.91 and 4.71 +/- 1.21 points out of 6 in the preventive and curative services, respectively; p = 0.000). The overall attitude towards vaccinations was positive (mean score: 45.40 +/- 5.98 and 42.95 +/- 6.84 points out of 56 in the preventive and curative services, respectively; p = 0.002). The two predictors that were associated with the behavior of HCPs to encourage childhood vaccinations were workplace (preventive vs. curative service) and the number of parents encountered by the HCP who opposed or feared vaccines. No association was found between the behavior and the knowledge level and the attitudes. Of the HCPs, 79.3% were interested in immunization training and 66.1% in participating in workshops to improve their communication skills to cope with vaccine-hesitant parents.
   Conclusions: There is a need to increase the commitment of HCPs to encourage parents to vaccinate their children with routine vaccines, to improve their knowledge about vaccines, and to provide them with communication tools to deal with vaccine-hesitant parents. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shibli, Rana; Rishpon, Shmuel] Haifa Dist Hlth Off, Govt Complex,Palyam Ave 15a,POB 800, IL-31999 Haifa, Israel.
   [Rishpon, Shmuel] Univ Haifa, Sch Publ Hlth, 199 Aba Khoushy Ave, IL-349883 Haifa, Israel.
   [Cohen-Dar, Michal] Northern Dist Hlth Off, 3 Ha Melacha St,POB 744, IL-1710602 Nazareth, Israel.
   [Kandlik, Yael] Zefat Subdist Hlth Off, 100 Hehalutz St,POB 1133, IL-1311101 Safed, Israel.
RP Shibli, R (reprint author), Haifa Dist Hlth Off, Govt Complex,Palyam Ave 15a,POB 800, IL-31999 Haifa, Israel.
EM rana.shibly@lbhaifa.health.gov.il
CR Althouse LA, 1999, ADV HEALTH SCI EDUC, V4, P111, DOI 10.1023/A:1009768526142
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Gesser-Edelsburg A, 2016, J RISK RES, V19, P405, DOI 10.1080/13669877.2014.983947
   Israeli Ministry of Health, 2016, DAT COURT DIV EP ROU
   Kempe A, 2011, AM J PREV MED, V40, P548, DOI 10.1016/j.amepre.2010.12.025
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Maayan-Metzger A, 2013, ACTA PAEDIATR, V102, P1186, DOI 10.1111/apa.12397
   Mollema L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-128
   Salmon DA, 2004, PEDIATRICS, V113, pE552, DOI 10.1542/peds.113.6.e552
   Shibli R, 2017, VACCINE, V35, P633, DOI 10.1016/j.vaccine.2016.12.005
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Velan B, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0071-x
   World Health Organization, GLOB VACC ACT PLAN
   Zingg A, 2012, VACCINE, V30, P3771, DOI 10.1016/j.vaccine.2012.03.014
NR 14
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 524
EP 529
DI 10.1016/j.vaccine.2018.11.051
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200017
PM 30509694
DA 2020-05-12
ER

PT J
AU Jradi, H
   Bawazir, A
AF Jradi, Hoda
   Bawazir, Amen
TI Knowledge, attitudes, and practices among Saudi women regarding cervical
   cancer, human papillomavirus (HPV) and corresponding vaccine
SO VACCINE
LA English
DT Article
DE HPV vaccine; Barriers; Cervical cancer; Saudi Arabia
ID INFECTION; PREVALENCE; BELIEFS
AB Aim: To our knowledge there are no studies exploring Saudi women's understanding of the importance of the human papillomavirus (HPV) vaccine. In the present study, we examined the awareness of HPV and women's attitudes toward the HPV vaccine.
   Method: Nine focus groups were formed in Riyadh City, Saudi Arabia, including 77 women between the ages of 18 and 45 years old. Face-to-face interviews were conducted in 58 female healthcare providers to examine women's awareness of cervical cancer, HPV, barriers, acceptance, beliefs, and attitudes towards the HPV vaccine.
   Results: Focus group discussions revealed a lack of knowledge and awareness of cervical cancer, HPV, and the HPV vaccine. Cultural concerns regarding screening and vaccinating for a conventionally known sexually transmitted infection were an emerging theme in addition to not perceiving cervical cancer screening as necessary because women with no signs and symptoms considered themselves not at risk for developing cervical cancer. Approximately 30% of healthcare providers other than physicians were unaware of prevention methods, and 63.3% did not practice any screening methods for cervical cancer and attributed the lack of screening to "no specific reasons at all".
   Conclusion: Because of the unfavorable knowledge and attitude of HPV infection and the associated vaccine from the women in the present study, emphasis should be directed to educate and promote awareness of women to the risk factors of cervical cancer and to the need for screening programs and the administration of the vaccine. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Jradi, Hoda; Bawazir, Amen] King Saud Bin Abdulaziz Univ Hlth Sci, Publ & Environm Hlth, Coll Publ Hlth & Hlth Informat, King Abdullah Int Med Res Ctr,Natl Guard Hlth Aff, Riyadh, Saudi Arabia.
RP Bawazir, A (reprint author), King Saud bin Abdulaziz Univ Hlth Sci, Community & Environm Hlth Dept, Coll Publ Hlth & Hlth Informat, POB 3660, Riyadh 11481, Saudi Arabia.
EM bawazir56@hotmail.com
RI Bawazir, Amen/AAE-8993-2019
OI Bawazir, Amen/0000-0002-6308-3136
CR Al Khudairi H, 2017, CUREUS, V9, DOI 10.7759/cureus.984
   Al Sairafi M, 2009, MED PRIN PRACT, V18, P35, DOI 10.1159/000163044
   Al-Meer F. M., 2011, Eastern Mediterranean Health Journal, V17, P855
   Al-Muammar T, 2007, ANN SAUDI MED, V27, P1, DOI 10.4103/0256-4947.51540
   Al-nsour M, 2012, OPEN BREAST CANC J, V4, P1, DOI DOI 10.2174/18768172012040100N
   Alsbeih G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00065
   Assoumou SZ, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0193-2
   Aziza S, 2016, J NURS ED PRACT, V7, P117, DOI [10.5430/inep.v7n2p117, DOI 10.5430/INEP.V7N2P117]
   Baloch Z, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903370
   Bastani R, 2011, CANC EPIDEMIOLOGY PR, V2011, DOI [10.1177/1403494815569105cebp.0267, DOI 10.1177/1403494815569105CEBP.0267]
   Bondagji NS, 2013, ANN SAUDI MED, V33, P13, DOI 10.5144/0256-4947.2013.13
   Brown AJ, 2012, BEST PRACT RES CL OB, V26, P233, DOI 10.1016/j.bpobgyn.2011.11.001
   Brown DR, 2011, J NATL MED ASSOC, V103, P719, DOI 10.1016/S0027-9684(15)30411-9
   Elbarazi I, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00176
   Feng SW, 2012, ASIA-PAC J PUBLIC HE, V24, P522, DOI 10.1177/1010539511415838
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fishman J, 2014, PEDIATRICSPEDS, P2013, DOI [10.1542/peds.2017-1081, DOI 10.1542/PEDS.2017-1081]
   Gazzaz FS, 2009, SAUDI MED J, V30, P633
   Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485
   Hong Y, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-696
   Jaspers L, 2011, VACCINE, V29, P7785, DOI 10.1016/j.vaccine.2011.07.107
   Lacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015
   Lee-Lin F, 2007, ONCOL NURS FORUM, V34, P1203, DOI 10.1188/07.ONF.1203-1209
   Loke Alice Yuen, 2017, BMC Res Notes, V10, P390, DOI 10.1186/s13104-017-2734-2
   Miles MB, 2013, QUALITATIVE DATA ANA, P408
   Mosavel M, 2009, J CANCER EDUC, V24, P114, DOI 10.1080/08858190902854590
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Navarro-Illana P, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-490
   Nwankwo KC, 2011, EUR J CANCER CARE, V20, P362, DOI 10.1111/j.1365-2354.2009.01175.x
   Onon TS, 1999, INT J GYNECOL CANCER, V9, P265, DOI 10.1046/j.1525-1438.1999.99022.x
   Ortashi O, 2012, ASIAN PAC J CANCER P, V13, P6481, DOI 10.7314/APJCP.2012.13.12.6481
   Ramathuba DU, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i2.1002
   Rees HD, 2017, PEERJ, V5, DOI 10.7717/peerj.3871
   Richardson Lyndsay A, 2011, Expert Rev Obstet Gynecol, V6, P343
   Sait KH, 2009, SAUDI MED J, V30, P1208
   Salem Marwa Rashad, 2017, Asian Pac J Cancer Prev, V18, P969
   Sauvageau C, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-304
   Savas LS, 2012, AM J PREV MED, V43, pS490, DOI 10.1016/j.amepre.2012.09.003
   SHC/SCR, 2014, 616992 SHCSCR
   Tung ILY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161846
   Waller J, 2012, BJOG-INT J OBSTET GY, V119, P26, DOI 10.1111/j.1471-0528.2011.03030.x
   Williams M, 2013, Afr Health Sci, V13, P1054, DOI 10.4314/ahs.v13i4.28
   Yabroff KR, 2005, J RURAL HEALTH, V21, P149, DOI 10.1111/j.1748-0361.2005.tb00075.x
NR 43
TC 2
Z9 2
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2019
VL 37
IS 3
BP 530
EP 537
DI 10.1016/j.vaccine.2018.11.065
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HI9CP
UT WOS:000456753200018
PM 30503079
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wang, WW
   Liang, X
   Zhang, MZ
   Sefiane, K
AF Wang, Weiwei
   Liang, Xiao
   Zhang, Mingzhu
   Sefiane, Khellil
TI A new method for voidage correlation of gas-liquid mixture based on
   differential pressure fluctuation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid mixture; Differential pressure; Fluctuation; Voidage;
   Extreme-Point Symmetric Mode; Decomposition; Fuzzy pattern
   identification
ID 2-PHASE FLOW-THROUGH; AIR-WATER; DROP; LAMINAR; METER; TUBES; PIPE
AB Differential pressure of gas-liquid mixture contains abundant information about fluid flow and its nature. In this paper, a differential pressure across a Venturi tube is measured for a gas-liquid mixture. Trend component and fluctuation components of the differential pressure are extracted using Extreme-Point Symmetric Mode Decomposition. The analysis shows that the mean of the trend component is related to liquid flowrate, and the amplitude of the fluctuation components is correlated to voidage and flow pattern. Hence, a fluctuation coefficient based approach to access voidage is proposed. This is based on the trend and fluctuation components. Since there exists an influence of gas/liquid flowrate, fluid density and voidage on fluctuation coefficient, their qualitative relationships are analyzed to find the appropriate variables to modify the fluctuation coefficient. Experimental data are used to determine the appropriate specific modification parameters. The modified fluctuation coefficient is found to be flow pattern dependent, and hence fuzzy pattern recognition is adopted to identify flow patterns combining statistics from differential pressure. Finally, a flow pattern-based correlation is proposed to estimate the voidage. Verifications through confrontation with experimental results show that the proposed correlation is effective in estimating voidage of mixtures. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Weiwei; Liang, Xiao; Zhang, Mingzhu] China Univ Petr East China, Coll Informat & Control Engn, Qingdao 266580, Peoples R China.
   [Sefiane, Khellil] Tianjin Univ Commerce, Tianjin Key Lab Refrigerat Technol, Tianjin 300134, Peoples R China.
   [Sefiane, Khellil] Univ Edinburgh, Sch Engn, Kings Bldg, Edinburgh EH9 3FB, Midlothian, Scotland.
RP Wang, WW (reprint author), China Univ Petr East China, Coll Informat & Control Engn, Qingdao 266580, Peoples R China.
EM wangww@upc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51304231]; Open Project Funding of State Key
   Laboratory of Industrial Control Technology [ICT170338]; Shandong
   Provincial Natural Science Foundation, ChinaNatural Science Foundation
   of Shandong Province [ZR2010EQ015]
FX This work was supported by the National Natural Science Foundation of
   China (51304231), the Open Project Funding of State Key Laboratory of
   Industrial Control Technology (ICT170338), and the Shandong Provincial
   Natural Science Foundation, China (ZR2010EQ015).
CR Abdulkadir M, 2016, CHEM ENG SCI, V156, P147, DOI 10.1016/j.ces.2016.09.015
   Awad M. M., 2014, ADV MECH ENG, V2014, P3
   Azevedo GR, 2017, CHEM ENG SCI, V161, P1, DOI 10.1016/j.ces.2016.12.004
   BEATTIE DRH, 1982, INT J MULTIPHAS FLOW, V8, P83, DOI 10.1016/0301-9322(82)90009-X
   Bertoldi D, 2015, EXP THERM FLUID SCI, V64, P152, DOI 10.1016/j.expthermflusci.2015.02.011
   Chen IY, 2001, INT J MULTIPHAS FLOW, V27, P1293, DOI 10.1016/S0301-9322(01)00004-0
   Chisholm D., 1983, 2 PHASE FLOW PIPELIN
   DUKLER AE, 1964, AICHE J, V10, P38, DOI 10.1002/aic.690100117
   DUKLER AE, 1964, AICHE J, V10, P44, DOI 10.1002/aic.690100118
   Falcone G, 2009, DEV PET SCI, V54, P1
   Fang L., 2008, MATH PROBL ENG, V2008, P1
   FRIEDEL L, 1979, EUR 2 PHAS FLOW GROU
   Garcia F, 2007, INT J MULTIPHAS FLOW, V33, P1320, DOI 10.1016/j.ijmultiphaseflow.2007.06.003
   Hetsroni, 1982, HDB MULTIPHASE SYSTE
   Hosokawa S, 2013, INT J HEAT FLUID FL, V40, P97, DOI 10.1016/j.ijheatfluidflow.2013.01.004
   Kawahara A, 2009, INT J HEAT FLUID FL, V30, P831, DOI 10.1016/j.ijheatfluidflow.2009.02.017
   Li Y, 2009, ICICTA: 2009 SECOND INTERNATIONAL CONFERENCE ON INTELLIGENT COMPUTATION TECHNOLOGY AND AUTOMATION, VOL II, PROCEEDINGS, P660, DOI 10.1109/ICICTA.2009.394
   LOCKHART RW, 1949, CHEM ENG PROG, V45, P39
   Mishima K, 1996, INT J MULTIPHAS FLOW, V22, P703, DOI 10.1016/0301-9322(96)00010-9
   Sharaf S, 2011, MEAS SCI TECHNOL, V22, DOI 10.1088/0957-0233/22/10/104019
   Shippen M., 2004, MODELING MULTIPHASE
   Steven R, 2008, FLOW MEAS INSTRUM, V19, P342, DOI 10.1016/j.flowmeasinst.2008.05.004
   Steven RN, 2002, FLOW MEAS INSTRUM, V12, P361, DOI 10.1016/S0955-5986(02)00003-1
   Sun B, 2011, CHINESE J CHEM ENG, V19, P243, DOI 10.1016/S1004-9541(11)60161-4
   Tian XY, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16101584
   Wang J., 2013, ADV ADAPTIVE DATA AN, V05, P1137
   Wang Shu-guo, 2010, Journal of the Harbin Institute of Technology, V42, P1056
   [王微微 WANG Weiwei], 2006, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V20, P515
   [张宏建 ZHANG Hongjian], 2005, [化工学报, Journal of Chemical Industry and Engineering (China)], V56, P2102
   Zhang W, 2010, INT J HEAT MASS TRAN, V53, P453, DOI 10.1016/j.ijheatmasstransfer.2009.09.011
   Zhu Y, 2017, J MECH SCI TECHNOL, V31, P493, DOI 10.1007/s12206-017-0102-8
NR 31
TC 2
Z9 2
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 15
EP 26
DI 10.1016/j.ces.2018.08.058
PG 12
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800003
DA 2020-05-12
ER

PT J
AU Liu, ZP
   Hill, JC
   Fox, RO
   Passalacqua, A
   Olsen, MG
AF Liu, Zhenping
   Hill, James C.
   Fox, Rodney O.
   Passalacqua, Alberto
   Olsen, Michael G.
TI A delayed detached eddy simulation model with low Reynolds number
   correction for transitional swirling flow in a multi-inlet vortex
   nanoprecipitation reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Turbulent mixing; Detached eddy simulation; Transitional flow; Vortex
   reactor; Computational fluid dynamics
ID LOCAL VARIABLES; NANOPARTICLES; DDES
AB The objective of the presented work is to verify a delayed detached eddy simulation (DDES) model for simulating transitional swirling flow in a micro-scale multi-inlet vortex reactor (MIVR). The DDES model is a k-omega based turbulence model with a low Reynolds number correction applied to the standard k-omega model such that the Reynolds-averaged Navier-Stokes (RANS) component of the DDES model is able to account for low Reynolds number flow. By limiting the dissipation rate in the k-equation, the largeeddy simulation (LES) part of the DDES model behaves similarly to a one-equation sub-grid model. The turbulent Reynolds number is redefined to represent both modeled and resolved turbulence level so that underestimation of the RANS length scale in the LES range can be reduced. Applying the DDES model to simulate both laminar and transitional flow in the micro-scale MIVR produces an accurate prediction of mean velocity and turbulent intensity compared with experimental data. It is demonstrated that the proposed DDES model is capable of simulating transitional flow in the complex geometry of the micro-scale MIVR. These simulation results also help to understand the flow and mixing patterns in the micro-scale MIVR and provide guidances to optimize the reactor for the application of producing functional nanoparticles. (C) 2018 Published by Elsevier Ltd.
C1 [Liu, Zhenping; Passalacqua, Alberto; Olsen, Michael G.] Iowa State Univ, Dept Mech Engn, Ames, IA 50011 USA.
   [Hill, James C.; Fox, Rodney O.] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA USA.
RP Olsen, MG (reprint author), Iowa State Univ, Dept Mech Engn, Ames, IA 50011 USA.
EM mgolsen@iastate.edu
RI Passalacqua, Alberto/L-9483-2016; Olsen, Michael G/B-2118-2010
OI Passalacqua, Alberto/0000-0001-9368-9393; Fox,
   Rodney/0000-0003-1944-1861
FU National Science FoundationNational Science Foundation (NSF)
   [CBET-0932978, S12-SSE-1440443]
FX The author would like to thank Dr. Paul A. Durbin for the discussion
   about current simulations and Dr. Yanxiang Shi for providing the
   experimental data. This research is supported by Grant CBET-0932978 and
   S12-SSE-1440443 from the National Science Foundation.
CR Aguirre-Chagala YE, 2014, ACS MACRO LETT, V3, P353, DOI 10.1021/mz500047p
   Bensaid S, 2014, CHEM ENG J, V238, P66, DOI 10.1016/j.cej.2013.09.065
   Cheng JC, 2010, IND ENG CHEM RES, V49, P10651, DOI 10.1021/ie100558n
   Cheng JC, 2010, J COLLOID INTERF SCI, V351, P330, DOI 10.1016/j.jcis.2010.07.066
   Cheng JC, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3125428
   D'Addio SM, 2011, ADV DRUG DELIVER REV, V63, P417, DOI 10.1016/j.addr.2011.04.005
   Fang RH, 2012, LANGMUIR, V28, P13824, DOI 10.1021/la303012x
   Fox RO, 2003, COMPUTATIONAL MODELS, P438
   Ge X, 2014, FLOW TURBUL COMBUST, V93, P37, DOI 10.1007/s10494-014-9533-9
   Gritskevich MS, 2012, FLOW TURBUL COMBUST, V88, P431, DOI 10.1007/s10494-011-9378-4
   Jasak H., 2007, INT WORKSH COUPL MET, V1000, P1
   Langtry RB, 2006, J TURBOMACH, V128, P423, DOI 10.1115/1.2184353
   Lardeau S, 2012, FLOW TURBUL COMBUST, V88, P19, DOI 10.1007/s10494-011-9353-0
   Liu Y, 2008, PEST MANAG SCI, V64, P808, DOI 10.1002/ps.1566
   Liu Y, 2008, CHEM ENG SCI, V63, P2829, DOI 10.1016/j.ces.2007.10.020
   Liu ZP, 2016, AICHE J, V62, P2570, DOI 10.1002/aic.15230
   Liu ZP, 2015, IND ENG CHEM RES, V54, P4512, DOI 10.1021/ie5041836
   Liu ZP, 2015, J FLUID ENG-T ASME, V137, DOI 10.1115/1.4028784
   Mejia-Ariza R, 2014, J MATER CHEM B, V2, P210, DOI 10.1039/c3tb21228a
   Menter FR, 2006, J TURBOMACH, V128, P413, DOI 10.1115/1.2184352
   Reddy KR, 2014, INT J HEAT FLUID FL, V50, P103, DOI 10.1016/j.ijheatfluidflow.2014.06.002
   RHIE CM, 1983, AIAA J, V21, P1525, DOI 10.2514/3.8284
   Sayadi T., 2012, PHYS FLUIDS, V24
   Shen H, 2011, J NANOPART RES, V13, P4109, DOI 10.1007/s11051-011-0354-7
   Sheng J, 2000, CHEM ENG SCI, V55, P4423, DOI 10.1016/S0009-2509(00)00039-7
   Shi YX, 2013, J MICROMECH MICROENG, V23, DOI 10.1088/0960-1317/23/7/075005
   Shi YX, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3662042
   Spalart PR, 2006, THEOR COMP FLUID DYN, V20, P181, DOI 10.1007/s00162-006-0015-0
   Spalart PR, 2009, ANNU REV FLUID MECH, V41, P181, DOI 10.1146/annurev.fluid.010908.165130
   SWEBY PK, 1984, SIAM J NUMER ANAL, V21, P995, DOI 10.1137/0721062
   Wilcox D. C., 2006, TURBULENCE MODELING
   Yin Z, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4907746
NR 32
TC 1
Z9 1
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 66
EP 75
DI 10.1016/j.ces.2018.08.020
PG 10
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800007
DA 2020-05-12
ER

PT J
AU Hamidouche, Z
   Masi, E
   Fede, P
   Simonin, O
   Mayer, K
   Penthor, S
AF Hamidouche, Ziad
   Masi, Enrica
   Fede, Pascal
   Simonin, Olivier
   Mayer, Karl
   Penthor, Stefan
TI Unsteady three-dimensional theoretical model and numerical simulation of
   a 120-kW chemical looping combustion pilot plant
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Chemical looping combustion; Fluidized beds; Gas-solid reactions; 3D CFD
ID INTERCONNECTED FLUIDIZED-BED; OXYGEN CARRIER; FUEL REACTOR; CFD
   SIMULATION; GAS; SYSTEM; SCALE; PERFORMANCE; DESIGN; FLOW
AB In this paper, reactive unsteady three-dimensional numerical simulations of a chemical looping combustion (CLC) unit are presented. The configuration is a 120-kW pilot plant working with perovskite, CaMn0.9Mg0.1O3-delta, as the selected oxygen carrier. Numerical simulations were performed using NEPTUNE_CFD code in the frame of an Euler-Euler approach by computing both gas and solid phases in an Eulerian technique, accounting for specific closures in order to model the interphase mass, and momentum and energy transfers. Heterogeneous reduction and oxidation (gas-solid) reactions were modeled by means of a grain model to account for the competing mechanisms of the chemical reaction onto the grain surface, the gaseous diffusion through the product layer around the grain, and the external transfer through the gas mixture surrounding the particle. Results from numerical simulations were assessed against experimental measurements and analyzed in order to acquire insight on the local behavior of reactive gas-particle flow in the CLC system. The theoretical/numerical tool developed in this work can be used for the design upgrade of crucial parts of the system in the stage of scaling-up from pilot to industrial plants. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hamidouche, Ziad; Masi, Enrica; Fede, Pascal; Simonin, Olivier] Univ Toulouse, IMFT, UPS, CNRS,INPT, Toulouse, France.
   [Mayer, Karl; Penthor, Stefan] Vienna Univ Technol, Inst Chem Engn, Getreidemarkt 9-166, A-1060 Vienna, Austria.
RP Masi, E (reprint author), Univ Toulouse, IMFT, UPS, CNRS,INPT, Toulouse, France.
EM enrica.masi@imft.fr
RI Simonin, Olivier/J-5172-2012
OI Fede, Pascal/0000-0002-0368-4829; Simonin, Olivier/0000-0002-2794-7662
FU European Community through the SUCCESS project under the 7th Framework
   program [608571]
FX This work received funding from the European Community through the
   SUCCESS project under the 7th Framework program (Grant agreement No.
   608571). It reflects only the author's views, and the Community is not
   liable for any use that may be made of the information contained herein.
   This work was granted access to the HPC resources of CALMIP
   supercomputing center under allocation 2016-0111 and of CINES
   supercomputing center under allocation A0022B06012. Accordingly, CALMIP
   and CINES are gratefully acknowledged. The authors would like to thank
   Prof. Juan Adanez for productive discussions and Ing. Herve Neau for the
   numerical support with the NEPTUNE_CFD code.
CR Abad A, 2007, FUEL, V86, P1021, DOI 10.1016/j.fuel.2006.09.021
   Abad A., 2014, 11 INT C FLUID BED T, P861
   Abad A, 2018, FUEL PROCESS TECHNOL, V171, P78, DOI 10.1016/j.fuproc.2017.09.015
   Abad A, 2013, CHEM ENG SCI, V87, P277, DOI 10.1016/j.ces.2012.10.006
   Abad A, 2010, COMBUST FLAME, V157, P602, DOI 10.1016/j.combustflame.2009.10.010
   Alobaid F, 2015, ENERGY, V93, P2395, DOI 10.1016/j.energy.2015.10.107
   Bakken E, 2005, SOLID STATE IONICS, V176, P217, DOI 10.1016/j.ssi.2004.07.001
   Banerjee S., 2015, J ENERGY RES TECHNOL, V138
   Bird RB, 2007, TRANSPORT PHENOMENA
   Boelle A., 1995, GAS PARTICLE FLOWS A, V228, P9
   Bolhar-Nordenkampf J, 2009, CHEM ENG TECHNOL, V32, P410, DOI 10.1002/ceat.200800568
   Cabello A, 2016, INT J GREENH GAS CON, V52, P120, DOI 10.1016/j.ijggc.2016.06.023
   Cabello A, 2016, FUEL PROCESS TECHNOL, V148, P188, DOI 10.1016/j.fuproc.2016.03.004
   Cabello A, 2014, CHEM ENG J, V258, P265, DOI 10.1016/j.cej.2014.07.083
   Chen LM, 2017, COMPUT CHEM ENG, V99, P82, DOI 10.1016/j.compchemeng.2017.01.009
   de Diego LF, 2014, IND ENG CHEM RES, V53, P87, DOI 10.1021/ie4015765
   Deng ZY, 2008, CHEM ENG TECHNOL, V31, P1754, DOI 10.1002/ceat.200800341
   Fede P, 2016, CHEM ENG SCI, V142, P215, DOI 10.1016/j.ces.2015.11.016
   Frossling N., 1938, GERL BEITR GEOPHYS, V52, P170
   Garcia-Labiano F, 2013, CHEM ENG SCI, V87, P173, DOI 10.1016/j.ces.2012.10.007
   Gauthier T, 2017, POWDER TECHNOL, V316, P3, DOI 10.1016/j.powtec.2017.01.003
   Geng CM, 2015, POWDER TECHNOL, V276, P144, DOI 10.1016/j.powtec.2015.01.077
   Gobin A, 2003, INT J NUMER METH FL, V43, P1199, DOI 10.1002/fld.542
   Guan YJ, 2016, POWDER TECHNOL, V289, P118, DOI 10.1016/j.powtec.2015.11.043
   Guan YJ, 2014, POWDER TECHNOL, V268, P316, DOI 10.1016/j.powtec.2014.08.046
   Hallberg P, 2014, ENRGY PROCED, V63, P80, DOI 10.1016/j.egypro.2014.11.009
   Hamidouche Z, 2018, ADV CHEM ENG, V52, P51
   Hamidouche Z., 2017, THESIS
   Haus J, 2017, POWDER TECHNOL, V316, P628, DOI 10.1016/j.powtec.2016.12.022
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2012, IND ENG CHEM RES, V51, P2094, DOI 10.1021/ie2007278
   Jing DZ, 2016, MATER DESIGN, V89, P527, DOI 10.1016/j.matdes.2015.09.117
   Johansson E, 2003, POWDER TECHNOL, V134, P210, DOI 10.1016/S0032-5910(03)00125-6
   Jung JW, 2008, POWDER TECHNOL, V183, P401, DOI 10.1016/j.powtec.2008.01.019
   Kolbitsch P, 2009, ENERG FUEL, V23, P1450, DOI 10.1021/ef8008184
   Kolbitsch P, 2009, CHEM ENG TECHNOL, V32, P398, DOI 10.1002/ceat.200800378
   Konan N., 2010, P 7 INT C MULT FLOW
   Konan N., 2010, P 7 INT C MULT FLOW, P1152
   Kruggel-Emden H, 2010, CHEM ENG SCI, V65, P4732, DOI 10.1016/j.ces.2010.05.022
   Leonidova EI, 2011, J SOLID STATE ELECTR, V15, P1071, DOI 10.1007/s10008-010-1288-1
   Mahalatkar K, 2011, OIL GAS SCI TECHNOL, V66, P301, DOI 10.2516/ogst/2010021
   Mahalatkar K, 2011, CHEM ENG SCI, V66, P3617, DOI 10.1016/j.ces.2011.04.025
   Markstrom P, 2012, POWDER TECHNOL, V222, P182, DOI 10.1016/j.powtec.2012.02.041
   Marx K, 2013, ENRGY PROCED, V37, P635, DOI 10.1016/j.egypro.2013.05.151
   Mayer K, 2015, APPL ENERG, V157, P323, DOI 10.1016/j.apenergy.2015.07.053
   Neau H., 2013, ECI SERIES
   Ohlemuller P, 2015, APPL ENERG, V157, P433, DOI 10.1016/j.apenergy.2015.05.088
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Parker JM, 2014, POWDER TECHNOL, V265, P47, DOI 10.1016/j.powtec.2014.01.027
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Penthor S, 2017, ENRGY PROCED, V114, P395, DOI 10.1016/j.egypro.2017.03.1181
   Penthor S, 2016, POWDER TECHNOL, V287, P61, DOI 10.1016/j.powtec.2015.09.029
   Penthor S, 2015, APPL ENERG, V145, P52, DOI 10.1016/j.apenergy.2015.01.079
   Pishahang M, 2016, ENERGY TECHNOL-GER, V4, P1305, DOI 10.1002/ente.201600177
   Proll T, 2009, AICHE J, V55, P3255, DOI 10.1002/aic.11934
   Proll T, 2009, CHEM ENG TECHNOL, V32, P418, DOI 10.1002/ceat.200800521
   RHODES MJ, 1990, POWDER TECHNOL, V60, P27, DOI 10.1016/0032-5910(90)80101-4
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Sharma R, 2017, FUEL, V200, P435, DOI 10.1016/j.fuel.2017.03.076
   Simonin O., 2000, LECT SERIES, V6
   Su MZ, 2015, ENERG CONVERS MANAGE, V105, P1, DOI 10.1016/j.enconman.2015.07.042
   Vermorel O, 2003, J TURBUL, V4
   Wang S, 2014, CHEM ENG J, V236, P121, DOI 10.1016/j.cej.2013.09.033
   Zerobin F, 2017, POWDER TECHNOL, V316, P569, DOI 10.1016/j.powtec.2017.02.001
   Zerobin F, 2016, ENERGY TECHNOL-GER, V4, P1299, DOI 10.1002/ente.201600162
   Zhang YW, 2017, CHEM ENG J, V320, P271, DOI 10.1016/j.cej.2017.03.046
NR 66
TC 4
Z9 4
U1 2
U2 50
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 102
EP 119
DI 10.1016/j.ces.2018.08.032
PG 18
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800010
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Farizhandi, AAK
   Paclawski, A
   Szlek, J
   Mendyk, A
   Shao, YH
   Lau, R
AF Farizhandi, Amir Abbas Kazemzadeh
   Paclawski, Adam
   Szlek, Jakub
   Mendyk, Aleksander
   Shao, Yu-Hsuan
   Lau, Raymond
TI Evaluation of carrier size and surface morphology in carrier-based dry
   powder inhalation by surrogate modeling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dry powder inhalation; Emitted dose; Fine particle fraction; Surface
   roughness; Variable selection; Artificial neural network; Sensitivity
   analysis
ID ARTIFICIAL NEURAL-NETWORKS; PULMONARY DRUG-DELIVERY; POLLEN-SHAPE
   CARRIER; IN-VITRO DEPOSITION; FINE LACTOSE RATIOS; SALBUTAMOL SULFATE;
   PARTICLE-SIZE; RESPONSE-SURFACE; SALMETEROL XINAFOATE; INHALER
   FORMULATIONS
AB In this work, design parameters of carrier-based dry powder inhalation were studied using surrogate modeling technique. The surrogate models constructed were then used to evaluate the key design parameters independently, which were otherwise difficult to determine based on experimental studies alone. Artificial neural network (ANN) was chosen as the surrogate modeling technique and models were constructed based on experimental data obtained from the literature. Twenty-eight variables describing the carrier size distribution, density, surface characteristics and operating conditions of dry powder inhaler were used as the input variables and emitted dose (ED) and fine particle fraction (FPF) were used as the output variables. Carrier surface characteristics were evaluated by applying image analysis on carrier SEM images. Genetic algorithm (GA) was used for the selection of important variables to be included in the surrogate models. Sensitivity analysis was also performed to determine the key variables affecting ED and FPF. Key design criteria for carrier-based dry powder inhalation were proposed based on the surrogate models constructed. (C) 2018 Published by Elsevier Ltd.
C1 [Farizhandi, Amir Abbas Kazemzadeh; Lau, Raymond] Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
   [Paclawski, Adam; Szlek, Jakub; Mendyk, Aleksander] Jagiellonian Univ, Dept Pharmaceut Technol & Biopharmaceut, Med Coll, Med 9 St, PL-30688 Krakow, Poland.
   [Shao, Yu-Hsuan] Taipei Med Univ, Grad Inst Biomed Informat, 250 Wu Hsing St, Taipei 110, Taiwan.
RP Lau, R (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
EM wmlau@ntu.edu.sg
RI Lau, Raymond/E-6843-2010
OI Lau, Raymond/0000-0001-5967-530X; Mendyk, Aleksander/0000-0002-4394-9115
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Adi H, 2008, J PHARM SCI-US, V97, P3140, DOI 10.1002/jps.21228
   Adi H, 2007, INT J PHARM, V337, P229, DOI 10.1016/j.ijpharm.2007.01.007
   Agatonovic-Kustrin S, 1998, ANAL CHIM ACTA, V364, P265, DOI 10.1016/S0003-2670(98)00121-4
   Alexander DLJ, 2015, J CHEM INF MODEL, V55, P1316, DOI 10.1021/acs.jcim.5b00206
   Baumes L, 2004, QSAR COMB SCI, V23, P767, DOI 10.1002/qsar.200430900
   Behrisch M., 2011, SIMUL 2011, P55
   Boshhiha AM, 2009, DRUG DEV IND PHARM, V35, P904, DOI 10.1080/03639040802698794
   Bourquin J, 1998, EUR J PHARM SCI, V7, P5, DOI 10.1016/S0928-0987(97)10028-8
   Broadhurst D, 1997, ANAL CHIM ACTA, V348, P71, DOI 10.1016/S0003-2670(97)00065-2
   BYRON PR, 1986, DRUG DEV IND PHARM, V12, P993, DOI 10.3109/03639048609048053
   Chan LW, 2003, J PHARM SCI, V92, P975, DOI 10.1002/jps.10372
   Chi GY, 2012, CHEM ENG RES DES, V90, P1235, DOI 10.1016/j.cherd.2011.12.012
   Chinga G., 2003, SURFCHARJ
   Chinga G, 2007, J MICROSC-OXFORD, V227, P254, DOI 10.1111/j.1365-2818.2007.01809.x
   Concessio NM, 1999, PHARM RES-DORDR, V16, P828, DOI 10.1023/A:1018865717374
   Daberkow D.D., 2002, P 9 AIAA USFA NASA I, P4
   de Boer AH, 2005, INT J PHARMACEUT, V294, P173, DOI 10.1016/j.ijpharm.2005.01.035
   Deb Kalyanmoy, 2014, International Journal of Artificial Intelligence and Soft Computing, V4, P1, DOI 10.1504/IJAISC.2014.059280
   Donovan MJ, 2010, INT J PHARMACEUT, V402, P1, DOI 10.1016/j.ijpharm.2010.08.045
   Du P, 2014, AAPS PHARMSCITECH, V15, P1417, DOI 10.1208/s12249-014-0166-z
   Eigenvector, 2006, PLS TOOLB 4 0
   El Tabach E, 2007, MATH COMPUT MODEL, V45, P766, DOI 10.1016/j.mcm.2006.07.020
   El-Gendy N, 2012, J PHARM SCI-US, V101, P3445, DOI 10.1002/jps.23176
   Fogel D.B., 2005, THEORETICAL EMPIRICA, P105
   Fonseca DJ, 2002, ADV ENG INFORM, V16, P241, DOI 10.1016/S1474-0346(03)00005-3
   French DL, 1996, J AEROSOL SCI, V27, P769, DOI 10.1016/0021-8502(96)00021-3
   Ganderton D, 1992, ADV PHARM SCI, P165
   Giunta A. A., 1994, P 5 AIAA USAF NASA I, P1117
   Giunta A. A., 1998, COMP APPROXIMATION M
   Glover W, 2008, INT J PHARMACEUT, V349, P314, DOI 10.1016/j.ijpharm.2007.08.013
   Greenwood GW, 1997, IEEE T SPEECH AUDI P, V5, P192, DOI 10.1109/89.554781
   Guchardi R, 2008, INT J PHARM, V348, P10, DOI 10.1016/j.ijpharm.2007.06.041
   Guenette E, 2009, INT J PHARMACEUT, V380, P80, DOI 10.1016/j.ijpharm.2009.07.002
   Hadjmohammadi MR, 2008, J SEP SCI, V31, P3864, DOI 10.1002/jssc.200800343
   Hamishehkar H, 2010, POWDER TECHNOL, V201, P289, DOI 10.1016/j.powtec.2010.04.017
   Handoko A, 2009, EUR J PHARM SCI, V36, P265, DOI 10.1016/j.ejps.2008.10.001
   Harjunen P, 2003, INT J PHARM, V263, P151, DOI 10.1016/S0378-5173(03)00357-0
   Hassan MS, 2011, INT J PHARMACEUT, V413, P93, DOI 10.1016/j.ijpharm.2011.04.033
   Hassan MS, 2010, J PHARM SCI-US, V99, P1309, DOI 10.1002/jps.21913
   Hassan MS, 2010, INT J PHARMACEUT, V386, P6, DOI 10.1016/j.ijpharm.2009.10.047
   Heaton J., 2008, INTRO NEURAL NETWORK
   Heng PWS, 2000, CHEM PHARM BULL, V48, P393, DOI 10.1248/cpb.48.393
   Hickey AJ, 1997, ADV DRUG DELIVER REV, V26, P29, DOI 10.1016/S0169-409X(97)00508-5
   HICKEY AJ, 1994, PHARM TECH, V18, P58
   Holland J.H., 1992, ADAPTATION NATURAL A
   Huber KP, 1996, PERFORM EVALUATION, V27-8, P473
   Hurrion RD, 1999, J OPER RES SOC, V50, P1018
   Iida K, 2005, CHEM PHARM BULL, V53, P431, DOI 10.1248/cpb.53.431
   Iida K, 2004, CHEM PHARM BULL, V52, P350, DOI 10.1248/cpb.52.350
   Iida K, 2003, CHEM PHARM BULL, V51, P1455, DOI 10.1248/cpb.51.1455
   Islam N, 2004, PHARM RES-DORDR, V21, P492, DOI 10.1023/B:PHAM.0000019304.91412.18
   Jin R, 2003, STRUCT MULTIDISCIP O, V25, P99, DOI 10.1007/s00158-002-0277-0
   Kaialy W, 2013, PHARM RES-DORDR, V30, P458, DOI 10.1007/s11095-012-0892-4
   Kaialy W, 2012, COLLOID SURFACE B, V89, P29, DOI 10.1016/j.colsurfb.2011.08.019
   Karhu M, 2000, INT J PHARM, V196, P95, DOI 10.1016/S0378-5173(99)00450-0
   Kassem N., 1989, J PHARM PHARMACOL, V41, P13
   Kassem NM, 1989, J PHARM PHARMACOL, V41, P14
   Kawashima Y, 1998, INT J PHARM, V172, P179, DOI 10.1016/S0378-5173(98)00202-6
   Kleijnen J.P., 2004, DESIGN ANAL MONTE CA
   Koehler J., 1998, COMPUT SCI STAT, P25
   Korany MA, 2012, J ADV RES, V3, P53, DOI 10.1016/j.jare.2011.04.001
   Kou X, 2012, ADV DRUG DELIVER REV, V64, P220, DOI 10.1016/j.addr.2011.11.004
   Krajzewicz D., 2012, INT J ADV SYST MEAS, V5, P128
   KRAJZEWICZ D, 2002, P 4 MIDDL E S SIM MO, P183
   Kumon M, 2008, CHEM PHARM BULL, V56, P617, DOI 10.1248/cpb.56.617
   Larhrib H, 1999, INT J PHARM, V191, P1, DOI 10.1016/S0378-5173(99)00164-7
   Le VNP, 2012, AAPS PHARMSCITECH, V13, P477, DOI 10.1208/s12249-012-9765-8
   Li R., 2003, ASME 2003 INT DES EN, P527
   Li YF, 2010, APPL SOFT COMPUT, V10, P1257, DOI 10.1016/j.asoc.2009.11.034
   Littringer EM, 2012, EUR J PHARM BIOPHARM, V82, P194, DOI 10.1016/j.ejpb.2012.05.001
   Lopez DCC, 2013, IND ENG CHEM RES, V52, P12993, DOI 10.1021/ie4000344
   Louey MD, 2003, INT J PHARM, V252, P87, DOI 10.1016/S0378-5173(02)00621-X
   Louey MD, 2002, PHARMACEUT RES, V19, P1524, DOI 10.1023/A:1020464801786
   Lucas P, 1998, PHARMACEUT RES, V15, P562, DOI 10.1023/A:1011977826711
   Maas SG, 2010, ATOMIZATION SPRAY, V20, P763, DOI 10.1615/AtomizSpr.v20.i9.20
   Madsen JI, 2000, AIAA J, V38, P1512, DOI 10.2514/2.1160
   MADU CN, 1995, APPL MATH LETT, V8, P35, DOI 10.1016/0893-9659(95)00082-2
   Martin JD, 2005, AIAA J, V43, P853, DOI 10.2514/1.8650
   Martini A, 2000, EXPERT OPIN THER PAT, V10, P315, DOI 10.1517/13543776.10.3.315
   Mitchell JP, 2004, KONA, V22, P32, DOI DOI 10.14356/KONA.2004010
   MORRIS MD, 1993, TECHNOMETRICS, V35, P243, DOI 10.2307/1269517
   Nakayama H, 2002, OPTIM ENG, V3, P201, DOI 10.1023/A:1020971504868
   Natrella M., 2010, NIST SEMATECH E HDB
   Paclawski A, 2015, INT J NANOMED, V10, P801, DOI 10.2147/IJN.S75758
   Palmer K, 2002, CHEM ENG RES DES, V80, P760, DOI 10.1205/026387602320776830
   Palmer K, 2002, CHEM ENG RES DES, V80, P773, DOI 10.1205/026387602320776849
   Podczeck F, 1997, INT J PHARM, V149, P51, DOI 10.1016/S0378-5173(96)04850-8
   Podczeck F, 1998, J ADHES SCI TECHNOL, V12, P1323, DOI 10.1163/156856198X00461
   Podczeck F, 1999, AEROSOL SCI TECH, V31, P301, DOI 10.1080/027868299304174
   Qian ZG, 2006, J MECH DESIGN, V128, P668, DOI 10.1115/1.2179459
   Rahimpour Y, 2012, ADV PHARM BULL, V2, P183, DOI 10.5681/apb.2012.028
   Rasmussen J, 1998, STRUCT OPTIMIZATION, V15, P1, DOI 10.1007/BF01197431
   RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   SCHREIER H, 1994, STP PHARMA SCI, V4, P38
   Shao P, 2007, FOOD BIOPROD PROCESS, V85, P85, DOI 10.1205/fbp06048
   Shin YS, 2001, STRUCT MULTIDISCIP O, V22, P351, DOI 10.1007/s00158-001-0155-1
   Sibalija TV, 2012, J INTELL MANUF, V23, P1511, DOI 10.1007/s10845-010-0451-y
   Simpson TW, 2001, ENG COMPUT-GERMANY, V17, P129, DOI 10.1007/PL00007198
   STANIFORTH JN, 1982, J PHARM PHARMACOL, V34, P141, DOI 10.1111/j.2042-7158.1982.tb04210.x
   Steckel H, 1997, INT J PHARM, V154, P31, DOI 10.1016/S0378-5173(97)00115-4
   STEPHENSON PL, 1980, POWDER TECHNOL, V25, P115, DOI 10.1016/0032-5910(80)87017-3
   Tan M.J.B., 2015, PARTICLE SURFACE ROU, P199
   Tang QH, 2010, CHEM ENG J, V156, P423, DOI 10.1016/j.cej.2009.11.002
   Nguyen TQN, 2014, IND ENG CHEM RES, V53, P19943, DOI 10.1021/ie502980k
   TIMSINA MP, 1994, INT J PHARM, V101, P1, DOI 10.1016/0378-5173(94)90070-1
   TOROPOV VV, 1993, STRUCT OPTIMIZATION, V6, P7, DOI 10.1007/BF01743169
   Van Beers W.C., 2001, KRIGING INTERPOLATIO
   Van Beers W.C.M., 2004, SIM C 2004 P 2004 WI
   Wang LP, 2005, Proceedings of the ASME International Design Engineering Technical Conferences and Computers and Information in Engineering Conference, 2005, Vol 2, Pts A and B, P785
   Wang LP, 1996, INT J NUMER METH ENG, V39, P787, DOI 10.1002/(SICI)1097-0207(19960315)39:5<787::AID-NME881>3.0.CO;2-5
   Yan WJ, 2012, CHEM ENG SCI, V76, P26, DOI 10.1016/j.ces.2012.03.049
   Yan WJ, 2011, CATAL TODAY, V174, P127, DOI 10.1016/j.cattod.2011.01.039
   Yan WJ, 2011, CHEM ENG J, V166, P1095, DOI 10.1016/j.cej.2010.11.097
   Young PM, 2007, J PHARM SCI-US, V96, P1331, DOI 10.1002/jps.20933
   Young PM, 2011, INT J PHARMACEUT, V416, P129, DOI 10.1016/j.ijpharm.2011.06.020
   Zeng XM, 1998, INT J PHARMACEUT, V176, P99, DOI 10.1016/S0378-5173(98)00300-7
   Zeng XM, 2000, INT J PHARM, V197, P41, DOI 10.1016/S0378-5173(99)00400-7
   Zeng XM, 2000, J PHARM PHARMACOL, V52, P1211, DOI 10.1211/0022357001777342
   Zhang FY, 2015, MOL PHARMACEUT, V12, P223, DOI 10.1021/mp5005614
   Zhao D, 2010, STRUCT MULTIDISCIP O, V42, P923, DOI 10.1007/s00158-010-0529-3
   Zhou Q, 2012, ADV DRUG DELIVER REV, V64, P275, DOI 10.1016/j.addr.2011.07.002
NR 123
TC 1
Z9 1
U1 2
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 144
EP 155
DI 10.1016/j.ces.2018.09.007
PG 12
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800013
DA 2020-05-12
ER

PT J
AU Harouna, BM
   Benkortbi, O
   Hanini, S
   Amrane, A
AF Harouna, Bassirou Mahamadou
   Benkortbi, Othmane
   Hanini, Salah
   Amrane, Abdeltif
TI Modeling of transitional pore blockage to cake filtration and modified
   fouling index - Dynamical surface phenomena in membrane filtration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Membrane filtration; Fouling process; Blocking pore; Surface phenomena;
   Modified-fouling-index; Modeling; Optimization
ID DEAD-END FILTRATION; WASTE-WATER; CONCENTRATION POLARIZATION;
   INTERFACIAL INTERACTIONS; POTENTIAL EVALUATION; MFI MEASUREMENTS;
   CONSTANT FLUX; CFS-MFI; FLOW; ULTRAFILTRATION
AB The objective of this study was to optimize and to model the membrane fouling process. The modeling was based on two approaches, dynamical and phenomenological with the combination of surface phenomena. The established model was a transitional pore blockage model towards cake fouling through new characteristic parameters and a modified fouling index.
   The characteristic parameters developed in this study described the effect of cake restructuring, the shear, the mass of the cake, the filtered fluid recirculation according to the effective thickness Z(c) in the membrane fouling mechanism. The Modified fouling index - Dynamical surface phenomena (MFI- DSP) was developed by characteristics of multiple interactions forces ratio and mechanical forces in the transition of the regime.
   The membrane fouling was carried out according to the membrane compressibility factor m = 1, the cake n = [0-1] and the kinetics of the fouling process corresponding to the partial orders omega = [0-4]. The new model was validated based on experimental data in tangential and frontal filtration, using PES-10, UE-100 and NF-270 membranes with the prediction of the transitional blockage. Statistical analyzes at CI >= 95% showed better performance and efficiency of the new model compared to the existing models focused on the absolute relative error, the correlation coefficient, the number of characteristic parameters in the prediction, the characterization of the fouling process, as well as in the transition from pore blockage to cake filtration. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Harouna, Bassirou Mahamadou; Benkortbi, Othmane; Hanini, Salah] LBMPT Yahia Fares Univ, Fac Technol, Dept Chem Engn & Environm, Biomat & Transport Phenomena Lab, Ain Dheb Medea 26000, Algeria.
   [Amrane, Abdeltif] Univ Rennes, Ecole Natl Super Chim Rennes, CNRS, ISCR UMR6226, F-35000 Rennes, France.
RP Benkortbi, O (reprint author), LBMPT Yahia Fares Univ, Fac Technol, Dept Chem Engn & Environm, Biomat & Transport Phenomena Lab, Ain Dheb Medea 26000, Algeria.
EM benkortbi_oth@yahoo.fr
RI cai, yuanyuan/C-6301-2014; Amrane, Abdeltif/AAG-5117-2020
OI Mahamadou Harouna, Bassirou/0000-0001-7738-0759
CR Abdelrasoul A, 2013, J MEMBRANE SCI, V433, P88, DOI 10.1016/j.memsci.2013.01.003
   Albasi Claire C., 2007, MODELISATION SIMULAT
   Arukalam IO, 2016, J COLLOID INTERF SCI, V484, P220, DOI 10.1016/j.jcis.2016.08.064
   Bacchin P, 2011, ADV COLLOID INTERFAC, V164, P2, DOI 10.1016/j.cis.2010.10.005
   Bessiere Y, 2005, J MEMBRANE SCI, V264, P37, DOI 10.1016/j.memsci.2005.04.018
   Boerlage S. F. E., 2000, P C MEMBR DRINK IND, V1, P397
   Boerlage SFE, 2002, J MEMBRANE SCI, V197, P1, DOI 10.1016/S0376-7388(01)00618-4
   Bouchard C., 2004, ETUDE COM COLMATAGE, P150
   Bugge TV, 2012, WATER RES, V46, P4330, DOI 10.1016/j.watres.2012.06.015
   Cai X, 2018, J COLLOID INTERF SCI, V531, P282, DOI 10.1016/j.jcis.2018.07.030
   Cai X, 2017, J COLLOID INTERF SCI, V490, P710, DOI 10.1016/j.jcis.2016.12.005
   Chen JR, 2017, BIORESOURCE TECHNOL, V226, P220, DOI 10.1016/j.biortech.2016.12.025
   COMITI J, 1989, CHEM ENG SCI, V44, P1539, DOI 10.1016/0009-2509(89)80031-4
   Daniel RC, 2011, CHEM ENG RES DES, V89, P1094, DOI 10.1016/j.cherd.2010.09.006
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Han Q, 2017, J MEMBRANE SCI, V528, P112, DOI 10.1016/j.memsci.2017.01.026
   Harouna BM, 2017, DESALIN WATER TREAT, V74, P71, DOI 10.5004/dwt.2017.20576
   He YL, 2005, WATER RES, V39, P4110, DOI 10.1016/j.watres.2005.07.030
   HERMIA J, 1982, T I CHEM ENG-LOND, V60, P183
   Huang H, 2008, ENVIRON SCI TECHNOL, V42, P714, DOI 10.1021/es071043j
   Huang H, 2009, J MEMBRANE SCI, V334, P1, DOI 10.1016/j.memsci.2009.01.049
   Huang X, 2008, J MEMBRANE SCI, V309, P7, DOI 10.1016/j.memsci.2007.09.069
   Jaffrin MY, 1997, J MEMBRANE SCI, V124, P233, DOI 10.1016/S0376-7388(96)00241-4
   Javeed MA, 2009, DESALINATION, V238, P98, DOI 10.1016/j.desal.2008.01.040
   Jee KY, 2016, DESALINATION, V394, P131, DOI 10.1016/j.desal.2016.05.013
   Jin YX, 2017, DESALINATION, V407, P24, DOI 10.1016/j.desal.2016.12.006
   Jin Y, 2015, J MEMBRANE SCI, V490, P57, DOI 10.1016/j.memsci.2015.04.049
   Ju Y, 2015, DESALINATION, V365, P136, DOI 10.1016/j.desal.2015.02.035
   Koo CH, 2014, J WATER PROCESS ENG, V3, P151, DOI 10.1016/j.jwpe.2014.06.006
   Li HG, 2016, DESALINATION, V386, P25, DOI 10.1016/j.desal.2016.02.037
   Li N, 2016, CHEM ENG J, V304, P165, DOI 10.1016/j.cej.2016.06.088
   Li N, 2016, J MEMBRANE SCI, V514, P241, DOI 10.1016/j.memsci.2016.04.072
   Lodge B, 2004, J MEMBRANE SCI, V231, P91, DOI 10.1016/j.memsci.2003.09.026
   Marselina Y, 2009, J MEMBRANE SCI, V341, P163, DOI 10.1016/j.memsci.2009.06.001
   Maximous N, 2010, SEP PURIF TECHNOL, V73, P294, DOI 10.1016/j.seppur.2010.04.016
   Mondal S, 2010, SEP PURIF TECHNOL, V75, P222, DOI 10.1016/j.seppur.2010.07.016
   Paipuri M, 2015, DESALINATION, V365, P151, DOI 10.1016/j.desal.2015.02.022
   Pradhan M, 2014, DESALINATION, V350, P14, DOI 10.1016/j.desal.2014.07.003
   Qu XL, 2018, APPL SURF SCI, V427, P915, DOI 10.1016/j.apsusc.2017.08.013
   Robles A, 2013, J MEMBRANE SCI, V444, P139, DOI 10.1016/j.memsci.2013.05.021
   Salinas-Rodriguez SG, 2015, DESALINATION, V365, P79, DOI 10.1016/j.desal.2015.02.018
   Sampath Muthukumar, 2014, Bioengineering-Basel, V1, P260, DOI 10.3390/bioengineering1040260
   SCHIPPERS JC, 1980, DESALINATION, V32, P137, DOI 10.1016/S0011-9164(00)86014-2
   Shen LG, 2015, CHEM ENG J, V269, P328, DOI 10.1016/j.cej.2015.02.002
   Tien C, 2013, CURR OPIN CHEM ENG, V2, P245, DOI 10.1016/j.coche.2013.03.003
   Tien C, 2014, CHEM ENG SCI, V111, P421, DOI 10.1016/j.ces.2014.01.022
   Wang XM, 2012, COLLOID SURFACE A, V407, P99, DOI 10.1016/j.colsurfa.2012.05.014
   Wu J, 2011, DESALINATION, V279, P127, DOI 10.1016/j.desal.2011.05.069
   Xiao K, 2013, J MEMBRANE SCI, V427, P139, DOI 10.1016/j.memsci.2012.09.049
   Zhang MJ, 2018, WATER RES, V129, P337, DOI 10.1016/j.watres.2017.11.034
   Zhang WX, 2015, SEP PURIF TECHNOL, V141, P160, DOI 10.1016/j.seppur.2014.11.041
   Zhao CS, 2013, PROG MATER SCI, V58, P76, DOI 10.1016/j.pmatsci.2012.07.002
NR 52
TC 3
Z9 3
U1 1
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 298
EP 311
DI 10.1016/j.ces.2018.07.054
PG 14
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800026
DA 2020-05-12
ER

PT J
AU Murphy, E
   Lomboy, G
   Wang, KJ
   Sundararajan, S
   Subramaniam, S
AF Murphy, Eric
   Lomboy, Gilson
   Wang, Kejin
   Sundararajan, Sriram
   Subramaniam, Shankar
TI The rheology of slurries of athermal cohesive micro-particles immersed
   in fluid: A computational and experimental comparison
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Slurries; Granular; Rheology; Cohesion; Cement
ID DIRECT NUMERICAL-SIMULATION; CEMENTITIOUS MATERIALS; YIELD-STRESS;
   CONCRETE; SPHERES; PASTES; PERFORMANCE; SUSPENSIONS; MICROSCOPY;
   PARTICLES
AB Immersed cohesive particles that aggregate under shear are commonly encountered in chemical engineering contexts. This work concerns the rheology of a particular set of systems, cement pastes, that have been difficult to treat from first-principles. In practice, these pastes exhibit large polydispersity with micron to millimeter sized particles, complicated particle shapes, and non-trivial surface morphology and surface chemistry. Simulations presented here utilize the discrete element model, informed by microscale atomic force microscopy measurements of surface topography, surface energy, and friction, and a simplified version of Stokesian Dynamics. Using these simulations, we study simple shear of two cementitious slurries composed of Portland cement and fly ash particles. These computations are then compared with steady-state vane rheometer experiments. This first-principles approach to comparing simulation and experiment allows us to explore how the microscale and macroscale physics are linked. Both computations and experiments agree qualitatively and are well modeled as Bingham plastics. Computations also show the emergence of percolating clusters, responsible for the rheology. Finally, including the mechanisms that are responsible for frustrated particle motions, such as effects of friction and rough walls at experimental scales, are shown to help give quantitatively better comparisons between simulation and experiment. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Murphy, Eric; Subramaniam, Shankar] Iowa State Univ, Dept Mech Engn, CoMFRE Multiphase Flow Res & Educ, Ames, IA 50011 USA.
   [Lomboy, Gilson] Rowan Univ, Dept Civil & Environm Engn, Glassboro, NJ 08028 USA.
   [Wang, Kejin] Iowa State Univ, Dept Civil Construct & Environm Engn, Ames, IA 50011 USA.
   [Sundararajan, Sriram] Iowa State Univ, Dept Mech Engn, Ames, IA 50011 USA.
RP Subramaniam, S (reprint author), Iowa State Univ, Dept Mech Engn, CoMFRE Multiphase Flow Res & Educ, Ames, IA 50011 USA.
EM shankar@iastate.edu
RI ; Wang, Kejin/A-1675-2017
OI Murphy, Eric/0000-0001-8153-8889; Wang, Kejin/0000-0002-7466-3451;
   Sundararajan, Sriram/0000-0003-2234-320X
FU NSF CMMI Grant [0927660]
FX We gratefully acknowledge the support provided for this work from NSF
   CMMI Grant No. 0927660.
CR Aitcin PC, 2000, CEMENT CONCRETE RES, V30, P1349, DOI 10.1016/S0008-8846(00)00365-3
   Ando T, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4817660
   Ball RC, 1997, PHYSICA A, V247, P444, DOI 10.1016/S0378-4371(97)00412-3
   Bentz DP, 2012, CEMENT CONCRETE RES, V42, P404, DOI 10.1016/j.cemconres.2011.11.006
   Bentz DP, 1999, CEMENT CONCRETE RES, V29, P1663, DOI 10.1016/S0008-8846(99)00163-5
   Bolintineanu DS, 2014, COMPUT PART MECH, V1, P321, DOI 10.1007/s40571-014-0007-6
   BRADY JF, 1988, ANNU REV FLUID MECH, V20, P111, DOI 10.1146/annurev.fl.20.010188.000551
   Brewer DD, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.022304
   Brilliantov N.V., 2004, KINETIC THEORY GRANU
   Crow J. M., 2008, CONCRETE CONUNDRUM C
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Estelle P, 2012, APPL RHEOL, V22, DOI 10.3933/ApplRheol-22-12881
   Ferraris CF, 2001, CEMENT CONCRETE RES, V31, P245, DOI 10.1016/S0008-8846(00)00454-3
   Haecker C, 2005, CEMENT CONCRETE RES, V35, P1948, DOI 10.1016/j.cemconres.2005.05.001
   Hoornahad H, 2014, CEMENT CONCRETE COMP, V54, P80, DOI 10.1016/j.cemconcomp.2014.04.006
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   KARRILA S. J, 1991, MICROHYDRODYNAMICS P
   Kumar A., 2010, THESIS
   Kumar A, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.051401
   KUWABARA G, 1987, JPN J APPL PHYS 1, V26, P1230, DOI 10.1143/JJAP.26.1230
   Liard M, 2014, J RHEOL, V58, P1993, DOI 10.1122/1.4896896
   Lin NYC, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.228304
   Liu PY, 2016, CHEM ENG SCI, V145, P266, DOI 10.1016/j.ces.2016.02.024
   Lomboy G, 2013, CEMENT CONCRETE RES, V54, P21, DOI 10.1016/j.cemconres.2013.08.006
   Lomboy G, 2011, CEMENT CONCRETE RES, V41, P1157, DOI 10.1016/j.cemconres.2011.07.004
   Lomboy GR, 2012, POWDER TECHNOL, V229, P104, DOI 10.1016/j.powtec.2012.06.015
   Martys N., 2002, 1 N AM C DES US SELF
   Martys NS, 2012, EUR PHYS J E, V35, DOI 10.1140/epje/i2012-12020-3
   Matsunaga T, 2002, MAT SCI ENG A-STRUCT, V325, P333, DOI 10.1016/S0921-5093(01)01466-6
   Mckay W. B., 1952, BUILDING CONSTRUCTIO, VII
   Mechtcherine V, 2014, RILEM STATE ART REP, V15, P65, DOI 10.1007/978-94-017-8884-7_3
   Mehrabadi M, 2016, CHEM ENG SCI, V152, P199, DOI 10.1016/j.ces.2016.06.006
   Murphy E, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.062902
   Murphy E, 2017, POWDER TECHNOL, V305, P462, DOI 10.1016/j.powtec.2016.09.010
   Murphy E, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4916674
   Narayanan N, 2000, CEMENT CONCRETE COMP, V22, P321, DOI 10.1016/S0958-9465(00)00016-0
   Oseen C., 1927, NEUERE METHODEN ERGE
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Puri UC, 2002, J MATER CIVIL ENG, V14, P137, DOI 10.1061/(ASCE)0899-1561(2002)14:2(137)
   Rahman M, 2017, TUNN UNDERGR SP TECH, V61, P50, DOI 10.1016/j.tust.2016.09.009
   ROTNE J, 1969, J CHEM PHYS, V50, P4831, DOI 10.1063/1.1670977
   Roussel N, 2012, CEMENT CONCRETE RES, V42, P148, DOI 10.1016/j.cemconres.2011.09.004
   Roussel N, 2016, CEMENT CONCRETE RES, V79, P265, DOI 10.1016/j.cemconres.2015.09.022
   Roussel N, 2010, CEMENT CONCRETE RES, V40, P77, DOI 10.1016/j.cemconres.2009.08.026
   Schunk PR, 2012, J RHEOL, V56, P353, DOI 10.1122/1.3690105
   Shah SP, 2004, PROCEEDINGS OF THE INTERNATIONAL WORKSHOP ON SUSTAINABLE DEVELOPMENT AND CONCRETE TECHNOLOGY, P15
   Skolnick J, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4962258
   Stutzman P, 2004, CEMENT CONCRETE COMP, V26, P957, DOI 10.1016/j.cemconcomp.2004.02.043
   Svec O, 2012, J NON-NEWTON FLUID, V179, P32, DOI 10.1016/j.jnnfm.2012.05.005
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   TORQUATO S, 1995, PHYS REV LETT, V74, P2156, DOI 10.1103/PhysRevLett.74.2156
   U. N. E. P, 2012, UNEP GREEN CEM PROD
   Wang K., 2012, 0927660 NSF CBET
NR 53
TC 3
Z9 3
U1 3
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 411
EP 420
DI 10.1016/j.ces.2018.09.010
PG 10
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800035
DA 2020-05-12
ER

PT J
AU Agahzamin, S
   Pakzad, L
AF Agahzamin, Siamak
   Pakzad, Leila
TI A comprehensive CFD study on the effect of dense vertical internals on
   the hydrodynamics and population balance model in bubble columns
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble column; Dense internals; Population balance model; Interfacial
   forces; CFD
ID CHURN-TURBULENT REGIME; NUMERICAL-SIMULATION; GAS HOLDUP; FLOW; SIZE;
   COALESCENCE; DISPERSION; DYNAMICS; DISTRIBUTIONS; PARAMETERS
AB In this paper, the effects of dense vertical internals (rods) on gas holdup and local gas and liquid velocities were investigated by using the Eulerian-Eulerian model coupled with the population balance model. The inclusion of lift and wall lubrication forces was studied by applying different models. The results indicated that just by choosing the appropriate interfacial forces, the numerical model agrees well with the experimental data. A sharper gas holdup, a stronger gas velocity gradient, and a more intense liquid recirculation were observed as the important impacts of the internals. Moreover, three circular internals' arrangements were considered to study the effect of wall and core clearance distances on the bubble column hydrodynamics. The results revealed that by increasing the wall clearance distance, flatter gas holdup and velocity distributions could be achieved. Also, the turbulence parameters were used to evaluate the capability of the model in the prediction of the bubble size distribution. A modification factor for the breakage and coalescence kernels was proposed; the factor enabled the model to reach equilibrium mean diameters for bubbles. The comparison of the probability distribution function (PDF) of bubble sizes in the bubble column with and without internals showed a narrower bubble size distribution with a smaller mean diameter in the presence of internals. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Agahzamin, Siamak; Pakzad, Leila] Lakehead Univ, Dept Chem Engn, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.
RP Pakzad, L (reprint author), Lakehead Univ, Dept Chem Engn, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.
EM lpakzad@lakeheadu.ca
OI Agahzamin, Siamak/0000-0002-7304-9214
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX We gratefully acknowledge the financial support of the Natural Sciences
   and Engineering Research Council of Canada (NSERC). We gratefully
   acknowledge Compute Canada for providing hardware platforms and
   technical support.
CR Al Mesfer MK, 2017, CHEM ENG SCI, V161, P228, DOI 10.1016/j.ces.2016.12.001
   Al Mesfer MK, 2016, CHEM ENG J, V300, P317, DOI 10.1016/j.cej.2016.04.075
   ANSYS&REG;, 2017, US GUID
   ANTAL SP, 1991, INT J MULTIPHAS FLOW, V17, P635, DOI 10.1016/0301-9322(91)90029-3
   Bhole MR, 2008, CHEM ENG SCI, V63, P2267, DOI 10.1016/j.ces.2008.01.013
   Bhusare VH, 2017, CHEM ENG J, V317, P157, DOI 10.1016/j.cej.2017.01.128
   Chen JW, 1999, CHEM ENG SCI, V54, P2187, DOI 10.1016/S0009-2509(99)00003-2
   Chen P, 2005, CHEM ENG SCI, V60, P1085, DOI 10.1016/j.ces.2004.09.070
   Cokljat D., 2006, AN INT J, V6, P168
   Ekambara K, 2008, IND ENG CHEM RES, V47, P8505, DOI 10.1021/ie071393e
   Forret A, 2003, CAN J CHEM ENG, V81, P360
   FRANK T, 2004, P 3 INT S 2 PHAS MOD
   Gholamzadehdevin M, 2019, CAN J CHEM ENG, V97, P967, DOI 10.1002/cjce.23335
   Guan XP, 2017, CHEM ENG RES DES, V126, P109, DOI 10.1016/j.cherd.2017.08.019
   Guan XP, 2015, CHEM ENG RES DES, V102, P196, DOI 10.1016/j.cherd.2015.06.028
   Guan XP, 2014, IND ENG CHEM RES, V53, P16529, DOI 10.1021/ie502666y
   Guo XF, 2017, CHEM ENG SCI, V174, P311, DOI 10.1016/j.ces.2017.09.004
   Hamed M, 2012, HYDRODYNAMICS MIXING
   Hinze J. O., 1975, TURBULENCE, P218
   Jakobsen HA, 2003, INT J CHEM REACT ENG, V1, DOI 10.2202/1542-6580.1006
   Jasim A, 2016, IMPACT HEAT EXCHANGI
   Jiang XD, 2016, PARTICUOLOGY, V27, P95, DOI 10.1016/j.partic.2015.05.011
   Kagumba M, 2015, IND ENG CHEM RES, V54, P1359, DOI 10.1021/ie503490h
   Kalaga DV, 2017, CHEM ENG SCI, V170, P332, DOI 10.1016/j.ces.2017.02.022
   Krishna R, 2000, CHEM ENG J, V78, P43, DOI 10.1016/S1385-8947(99)00167-9
   Krishna R, 1999, CHEM ENG SCI, V54, P4903, DOI 10.1016/S0009-2509(99)00211-0
   Laborde-Boutet C, 2009, CHEM ENG SCI, V64, P4399, DOI 10.1016/j.ces.2009.07.009
   Larachi F, 2006, CHEM ENG SCI, V61, P4195, DOI 10.1016/j.ces.2006.01.053
   Lehr F, 2002, AICHE J, V48, P2426, DOI 10.1002/aic.690481103
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Luo H., 1993, COALESCENCE BREAKUP
   Masood RMA, 2014, INT J MULTIPHAS FLOW, V66, P11, DOI 10.1016/j.ijmultiphaseflow.2014.06.008
   McClure DD, 2017, CHEM ENG SCI, V170, P91, DOI 10.1016/j.ces.2016.12.066
   McClure DD, 2014, CHEM ENG TECHNOL, V37, P131, DOI 10.1002/ceat.201300546
   Oey RS, 2003, AICHE J, V49, P1621, DOI 10.1002/aic.690490703
   Olmos E, 2001, CHEM ENG SCI, V56, P6359, DOI 10.1016/S0009-2509(01)00204-4
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   PRADHAN AK, 1993, CAN J CHEM ENG, V71, P468, DOI 10.1002/cjce.5450710319
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Rusche H., 2003, THESIS
   SAXENA SC, 1992, CHEM ENG J BIOCH ENG, V49, P151, DOI 10.1016/0300-9467(92)80051-B
   Schiller L., 1935, Z VER DTSCH ING, V77, P318
   SHINNAR R, 1960, IND ENG CHEM, V52, P253, DOI 10.1021/ie50603a036
   Simonin C., 1990, NUMER METHODS MULTIP, V91, P65
   Simonnet M, 2008, CHEM ENG PROCESS, V47, P1726, DOI 10.1016/j.cep.2007.08.015
   Sokolichin A, 2004, AICHE J, V50, P24, DOI 10.1002/aic.10003
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   Thakre SS, 1999, CAN J CHEM ENG, V77, P826, DOI 10.1002/cjce.5450770507
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Tomiyama A, 1998, MULTIPHASE SCIENCE AND TECHNOLOGY, VOL 10 ISSUE 4 1998, P369
   Nguyen VT, 2013, INT J MULTIPHAS FLOW, V54, P31, DOI 10.1016/j.ijmultiphaseflow.2013.03.001
   Wang TF, 2005, CHEM ENG SCI, V60, P6199, DOI 10.1016/j.ces.2005.04.027
   Xu LJ, 2013, IND ENG CHEM RES, V52, P6794, DOI 10.1021/ie4005964
   YAMASHITA F, 1987, J CHEM ENG JPN, V20, P204, DOI 10.1252/jcej.20.204
   Yang N, 2017, CHEM ENG SCI, V170, P241, DOI 10.1016/j.ces.2017.01.026
   Youssef A., 2010, FLUID DYNAMICS SCALE
   Youssef AA, 2009, IND ENG CHEM RES, V48, P8007, DOI 10.1021/ie900266q
   Zhang Y., 2009, J CHEM IND ENG SOC
NR 59
TC 4
Z9 4
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 421
EP 435
DI 10.1016/j.ces.2018.08.052
PG 15
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800036
DA 2020-05-12
ER

PT J
AU Li, G
   Li, XS
   Lv, QN
   Zhang, Y
AF Li, Gang
   Li, Xiao-Sen
   Lv, Qiu-Nan
   Zhang, Yu
TI Permeability measurements of quartz sands with methane hydrate
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methane hydrate; Quartz sands; Permeability; Shape factor
AB The permeability of porous media is one of the critical parameters that determines gas recovery from natural gas hydrate reservoirs. We measured the permeability of quartz sands by injecting water at a certain flow rate. In hydrate-bearing sands, the larger the hydrate saturation, the smaller the shape factor in the presence of hydrate. A k(r) - S-H relationship with the hydrate saturation both lower and higher than 10% was obtained. Based on the experimental results, the saturation exponent n varied from 6.0 to 1.0. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Xiao-Sen] Chinese Acad Sci, Guangzhou Inst Energy Convers, Key Lab Gas Hydrate, Guangzhou 510640, Guangdong, Peoples R China.
   Chinese Acad Sci, Guangdong Prov Key Lab New & Renewable Energy Res, Guangzhou 510640, Guangdong, Peoples R China.
   Chinese Acad Sci, Guangzhou Ctr Gas Hydrate Res, Guangzhou 510640, Guangdong, Peoples R China.
   Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Li, XS (reprint author), Chinese Acad Sci, Guangzhou Inst Energy Convers, Key Lab Gas Hydrate, Guangzhou 510640, Guangdong, Peoples R China.
EM lixs@ms.giec.ac.cn
RI Li, Xiaosen/AAC-7284-2019
OI Li, Xiaosen/0000-0001-8608-0950
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51676196, 51736009, 51506203]; Key Research Program
   of Frontier Sciences, CAS [QYZDB-SSW-JSC028, QYZDJ-SSW-JSC033]; National
   Key R&D Program of China [2017YFC0307306, 2016YFC0304002]; Special
   Project for Marine Economy Development of Guangdong Province
   [GDME-2018D002]
FX This work was supported by the National Natural Science Foundation of
   China (51676196, 51736009, 51506203), Key Research Program of Frontier
   Sciences, CAS (QYZDB-SSW-JSC028, QYZDJ-SSW-JSC033), the National Key R&D
   Program of China (2017YFC0307306, 2016YFC0304002), and Special Project
   for Marine Economy Development of Guangdong Province (GDME-2018D002)
   which are gratefully acknowledged.
CR Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   Collett T, 2015, J CHEM ENG DATA, V60, P319, DOI 10.1021/je500604h
   Hearst J. R, 2000, WELL LOGGING PHYS PR
   Kleinberg RL, 2003, J GEOPHYS RES SOLID, V108, pB10
   Kozeny J., 1927, SITZUNGSBER AKAD WIS, V136, P271
   Kumar A, 2010, J PETROL SCI ENG, V70, P109, DOI 10.1016/j.petrol.2009.10.005
   Li B, 2013, ENERGIES, V6, P3622, DOI 10.3390/en6073622
   Li G, 2017, APPL ENERG, V202, P282, DOI 10.1016/j.apenergy.2017.05.147
   Li G, 2010, ENERG FUEL, V24, P6018, DOI 10.1021/ef100930m
   Minagawa H, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005403
   Sakamoto Yasuhide, 2010, Journal of Thermodynamics, DOI 10.1155/2010/452326
NR 11
TC 9
Z9 9
U1 8
U2 108
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 1
EP 5
DI 10.1016/j.ces.2018.08.055
PG 5
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800001
DA 2020-05-12
ER

PT J
AU Zhao, LHB
   Zeng, GF
   Gu, Y
   Tang, ZY
   Wang, G
   Tang, T
   Shan, Y
   Sun, YH
AF Zhao, Luhaibo
   Zeng, Gaofeng
   Gu, Yu
   Tang, Zhiyong
   Wang, Gang
   Tang, Tao
   Shan, Ying
   Sun, Yuhan
TI Nature inspired fractal tree-like photobioreactor via 3D printing for
   CO2 capture by microaglae
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bionic fractal; Photobioreactor; Algae cultivation; CO2 capture; CFD; 3D
   printing
ID FLOW DISTRIBUTION; HEAT-EXCHANGER; OPTIMIZATION; DISTRIBUTOR;
   CULTIVATION; PERFORMANCE; BIOREACTOR; MICROALGAE; PRINCIPLE; REACTORS
AB Based on the bionic fractal theory, a fractal tree-like photobioreactor (PBR) with high surface area to volume ratio is designed on the basis of bifurcation tree algorithm and manufactured via 3D printing technology. Numerical simulation and experimental results show that the fractal structure has a good flow performance and can lead to secondary flow, which is beneficial to enhance the turbulence and produce smaller bubble sizes. Chlorella culture in the fractal tree-like PBR has a higher Fv/Fm (Chlorophyll fluorescence parameter), close to 0.767, and higher efficiency of photosynthetic growth as well as CO2 capture, compared with multitubular PBR and conventional acrylic column reactors. Therefore, the fractal tree-like PBR can improve the efficiency of light energy utilization and bioreaction. Combined with 3D printing technology, fractal PBR blazes a new trail for process intensification on the microalgae cultivation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhao, Luhaibo; Zeng, Gaofeng; Gu, Yu; Tang, Zhiyong; Wang, Gang; Tang, Tao; Shan, Ying; Sun, Yuhan] Chinese Acad Sci, SARI, Key Lab Low Carbon Convers Sci & Engn, Shanghai 201210, Peoples R China.
   [Zhao, Luhaibo] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Sun, Yuhan] Shanghai Tech Univ, Sch Phys Sci & Technol, Shanghai 201210, Peoples R China.
RP Tang, ZY; Sun, YH (reprint author), Chinese Acad Sci, SARI, Key Lab Low Carbon Convers Sci & Engn, Shanghai 201210, Peoples R China.
EM tangzy@sari.ac.cn; sunyh@sari.ac.cn
FU Global Innovation Initiative (GII); Youth Innovation Promotion
   Association CAS; CAS Key Technology Talent Program; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81400658]
FX The authors are grateful for the support of the Global Innovation
   Initiative (GII), the Youth Innovation Promotion Association CAS, the
   CAS Key Technology Talent Program and the National Natural Science
   Foundation of China (No. 81400658).
CR AL-Mashhadani MKH, 2015, CHEM ENG SCI, V137, P243, DOI 10.1016/j.ces.2015.06.032
   Bejan A., 2000, SHAPE STRUCTURE ENG
   Bhargava KC, 2014, P NATL ACAD SCI USA, V111, P15013, DOI 10.1073/pnas.1414764111
   Bliss PM, 2009, CHAOS SOLITON FRACT, V42, P119, DOI 10.1016/j.chaos.2008.11.001
   Brennan L, 2010, RENEW SUST ENERG REV, V14, P557, DOI 10.1016/j.rser.2009.10.009
   Carvalho AP, 2006, BIOTECHNOL PROGR, V22, P1490, DOI 10.1021/bp060065r
   Chen XD, 2016, CHINESE J CHEM ENG, V24, P1, DOI 10.1016/j.cjche.2015.07.009
   Chisti Y, 2007, BIOTECHNOL ADV, V25, P294, DOI 10.1016/j.biotechadv.2007.02.001
   Coppens M. O., 2017, DIFFUSIVE SPREADING
   Coppens MO, 2012, CURR OPIN CHEM ENG, V1, P281, DOI 10.1016/j.coche.2012.03.002
   Fan YL, 2008, AICHE J, V54, P2796, DOI 10.1002/aic.11597
   Farrelly DJ, 2013, RENEW SUST ENERG REV, V21, P712, DOI 10.1016/j.rser.2012.12.038
   Fernandes BD, 2014, CHEM ENG SCI, V117, P445, DOI 10.1016/j.ces.2014.06.043
   Guo XF, 2014, ENERGY, V69, P728, DOI 10.1016/j.energy.2014.03.069
   [何皓 He Hao], 2013, [过程工程学报, The Chinese Journal of Process Engineering], V13, P1068
   Huang JK, 2016, BIORESOURCE TECHNOL, V222, P399, DOI 10.1016/j.biortech.2016.09.109
   Kulkarni AA, 2011, IND ENG CHEM RES, V50, P7667, DOI 10.1021/ie200301y
   Leupold M, 2013, J APPL PHYCOL, V25, P485, DOI 10.1007/s10811-012-9882-5
   Luo LG, 2015, CHEM ENG SCI, V123, P542, DOI 10.1016/j.ces.2014.11.051
   Marquis J, 2013, CHEM ENG SCI, V102, P151, DOI 10.1016/j.ces.2013.08.003
   Monzel WJ, 2015, IEEE T DIELECT EL IN, V22, P3543, DOI 10.1109/TDEI.2015.005199
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P299, DOI 10.1073/pnas.12.5.299
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Parra-Cabrera C, 2018, CHEM SOC REV, V47, P209, DOI 10.1039/c7cs00631d
   Perin G, 2016, ALGAL RES, V19, P69, DOI 10.1016/j.algal.2016.07.015
   PIRT SJ, 1983, J CHEM TECH BIOT B, V33, P35
   Posten C, 2009, ENG LIFE SCI, V9, P165, DOI 10.1002/elsc.200900003
   Richmond, 2014, HDB MICROALGAL CULTU
   Sato T, 2010, ENERG CONVERS MANAGE, V51, P1196, DOI 10.1016/j.enconman.2009.12.030
   Takeshita T, 2014, BIORESOURCE TECHNOL, V158, P127, DOI 10.1016/j.biortech.2014.01.135
   Ugwu CU, 2008, BIORESOURCE TECHNOL, V99, P4021, DOI 10.1016/j.biortech.2007.01.046
   Wang CC, 2018, BIOTECHNOL ADV, V36, P986, DOI 10.1016/j.biotechadv.2018.03.001
   West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677
   Yeo UH, 2018, BIOSYST ENG, V171, P165, DOI 10.1016/j.biosystemseng.2018.04.012
   Yu XF, 2012, INT J HEAT MASS TRAN, V55, P7499, DOI 10.1016/j.ijheatmasstransfer.2012.07.050
NR 35
TC 5
Z9 5
U1 12
U2 123
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 6
EP 14
DI 10.1016/j.ces.2018.08.057
PG 9
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800002
DA 2020-05-12
ER

PT J
AU Dou, HZ
   Jiang, B
   Xu, M
   Zhou, JH
   Sun, YL
   Zhang, LH
AF Dou, Haozhen
   Jiang, Bin
   Xu, Mi
   Zhou, Junhan
   Sun, Yongli
   Zhang, Luhong
TI Supported ionic liquid membranes with high carrier efficiency via strong
   hydrogen-bond basicity for the sustainable and effective olefin/paraffin
   separation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ionic liquids; Hydrogen bond basicity; Olefin/paraffin separations;
   Supported ionic liquid membranes; Thermodynamic analysis
ID FACILITATED OLEFIN TRANSPORT; DEEP EUTECTIC SOLVENTS; ETHYLENE/ETHANE
   SEPARATION; ABSORPTION EQUILIBRIUM; METAL-SALTS; SILVER SALT; MIXTURES;
   DISSOLUTION; MEDIA; CO2
AB Supported ionic liquid membranes (SILMs) constitute a radical advance in olefin/paraffin separation membranes. Unfortunately, the applications of SILMs are vastly hindered by low carrier efficiency. Herein, SILMs with high carrier efficiency via strong hydrogen-bond basicity were designed to carry out efficient ethylene/ethane separation. The strong hydrogen-bond basicity of ILs not only endowed the membranes with high carrier concentration, but also effectively favored for the good disassociation of carrier to form solvated free ions through coordinative interactions between IL and carrier, which greatly increased the number of carrier and enhanced the carrier efficiency. Benefiting from the high carrier efficiency, both ethylene permeability and ethylene/ethane selectivity were significantly elevated, which could reach up to 100 Barrers and 40, respectively, surpassing most of results reported in the open literature. Meanwhile, the ethylene and ethane solubility data in the carrier/ILs were measured in a pressure range from 0 to 3.5 bar at 298.15 K, a first-order equilibrium model based on the formation carrier-ethylene complex species has been developed to describe the physical and chemical dissolving behaviors of ethylene and the equilibrium constants were obtained accordingly. Moreover, the membrane separation process was optimized, confirming that ethylene permeability and ethylene/ethane selectivity increased with the increase of carrier concentration due to the combined effects of gas solubility and diffusion. It was notable that the selectivity of as-prepared SILMs was more effective at lower transmembrane pressures and operating temperatures, which contributed to designing the energy-efficient and sustainable membrane processes. This study opens a new route for the utilization of the IL properties to manipulate the carrier efficiency for developing high performance SILMs. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dou, Haozhen; Jiang, Bin; Xu, Mi; Zhou, Junhan; Sun, Yongli; Zhang, Luhong] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Dou, Haozhen; Xu, Mi; Zhou, Junhan; Sun, Yongli; Zhang, Luhong] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP Zhang, LH (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM zhanglvh@tju.edu.cn
RI cai, yuanyuan/C-6301-2014
FU National Key R&D Program of China [2016YFC0400406]
FX Thanks for the financial support from National Key R&D Program of China
   (No. 2016YFC0400406).
CR Ab Rani MA, 2011, PHYS CHEM CHEM PHYS, V13, P16831, DOI 10.1039/c1cp21262a
   Abdelrahim MYM, 2017, J MEMBRANE SCI, V528, P225, DOI 10.1016/j.memsci.2017.01.033
   Aki SNVK, 2001, CHEM COMMUN, P413, DOI 10.1039/b008039j
   Bagh FSG, 2013, IND ENG CHEM RES, V52, P11488, DOI 10.1021/ie401282y
   Bortolini O, 2015, J PHYS CHEM A, V119, P5078, DOI 10.1021/jp507437g
   Branco LC, 2002, CHEM-EUR J, V8, P3671, DOI 10.1002/1521-3765(20020816)8:16<3671::AID-CHEM3671>3.0.CO;2-9
   Cadiau A, 2016, SCIENCE, V353, P137, DOI 10.1126/science.aaf6323
   Capela EV, 2017, GREEN CHEM, V19, P1850, DOI [10.1039/c6gc03060b, 10.1039/C6GC03060B]
   Chiappe C, 2010, GREEN CHEM, V12, P77, DOI 10.1039/b919111a
   Deng R, 2017, ENERG FUEL, V31, P11146, DOI 10.1021/acs.energyfuels.7b01305
   Doherty TV, 2010, GREEN CHEM, V12, P1967, DOI 10.1039/c0gc00206b
   Dong K, 2016, CHEM COMMUN, V52, P6744, DOI 10.1039/c5cc10120d
   Dou HZ, 2018, J MEMBRANE SCI, V557, P76, DOI 10.1016/j.memsci.2018.04.015
   Dou HZ, 2018, ACS APPL MATER INTER, V10, P13963, DOI 10.1021/acsami.8b00123
   Fallanza M, 2012, SEP PURIF TECHNOL, V97, P83, DOI 10.1016/j.seppur.2012.01.044
   Fukaya Y, 2008, GREEN CHEM, V10, P44, DOI 10.1039/b713289a
   Hallett JP, 2011, CHEM REV, V111, P3508, DOI 10.1021/cr1003248
   Hong GH, 2013, CHEM ENG J, V230, P111, DOI 10.1016/j.cej.2013.06.054
   Huang K, 2014, J MEMBRANE SCI, V471, P227, DOI 10.1016/j.memsci.2014.08.022
   Hunt PA, 2006, J PHYS CHEM A, V110, P2269, DOI 10.1021/jp0547865
   Hunt PA, 2015, CHEM SOC REV, V44, P1257, DOI 10.1039/c4cs00278d
   Iarikov DD, 2011, CHEM ENG J, V166, P401, DOI 10.1016/j.cej.2010.10.060
   Ilyas A, 2017, J MEMBRANE SCI, V543, P301, DOI 10.1016/j.memsci.2017.08.071
   Jelicic A, 2009, MACROMOLECULES, V42, P8801, DOI 10.1021/ma9017907
   Jiang B, 2017, IND ENG CHEM RES, V56, P15153, DOI 10.1021/acs.iecr.7b03843
   Jiang B, 2017, ACS SUSTAIN CHEM ENG, V5, P6873, DOI 10.1021/acssuschemeng.7b01092
   Jiang B, 2017, J MEMBRANE SCI, V536, P123, DOI 10.1016/j.memsci.2017.05.004
   Jiang PW, 2016, ENERG CONVERS MANAGE, V120, P338, DOI 10.1016/j.enconman.2016.05.010
   Kang SW, 2008, CHEM MATER, V20, P1308, DOI 10.1021/cm071516l
   Kang SW, 2006, CHEM MATER, V18, P1789, DOI 10.1021/cm0522329
   Kasahara S, 2013, J MEMBRANE SCI, V431, P121, DOI 10.1016/j.memsci.2012.12.026
   Kuzmin O, 2016, PHYS CHEM CHEM PHYS, V18, P16161, DOI 10.1039/c6cp02286c
   Lee JH, 2012, J MEMBRANE SCI, V423, P159, DOI 10.1016/j.memsci.2012.08.007
   Li YF, 2015, CHEM SOC REV, V44, P103, DOI 10.1039/c4cs00215f
   Lui MY, 2011, CHEM SCI, V2, P1491, DOI 10.1039/c1sc00227a
   Malik MA, 2011, CHEM ENG J, V171, P242, DOI 10.1016/j.cej.2011.03.041
   Ortiz A, 2008, SEP PURIF TECHNOL, V63, P311, DOI 10.1016/j.seppur.2008.05.011
   Pereiro AB, 2012, CHEM COMMUN, V48, P3656, DOI 10.1039/c2cc30374d
   Pilli SR, 2014, CHEM ENG J, V257, P56, DOI 10.1016/j.cej.2014.07.019
   Pitsch F, 2012, ADV MATER, V24, P4306, DOI 10.1002/adma.201201832
   Ravanchi MT, 2010, DESALINATION, V250, P130, DOI 10.1016/j.desal.2008.09.011
   Reine TA, 2005, IND ENG CHEM RES, V44, P7505, DOI 10.1021/ie0488546
   Schade A, 2014, CHEM-EUR J, V20, P2232, DOI 10.1002/chem.201304069
   Sun YQ, 2017, ENERG CONVERS MANAGE, V132, P213, DOI 10.1016/j.enconman.2016.10.071
   Sun YL, 2017, IND ENG CHEM RES, V56, P741, DOI 10.1021/acs.iecr.6b03364
   Tsuzuki S, 2007, PHYS CHEM CHEM PHYS, V9, P4780, DOI 10.1039/b707419k
   Vijayaraghavan R, 2009, CHEM COMMUN, P6297, DOI 10.1039/b911568d
   Weingaertner H, 2008, ANGEW CHEM INT EDIT, V47, P654, DOI 10.1002/anie.200604951
   Wentink AE, 2005, IND ENG CHEM RES, V44, P4726, DOI 10.1021/ie0487890
   Yokozeki A, 2007, PHYS CHEM CHEM PHYS, V9, P5018, DOI 10.1039/b706497g
   Yu GR, 2014, IND ENG CHEM RES, V53, P13430, DOI 10.1021/ie501522m
   Zakzeski J, 2011, GREEN CHEM, V13, P671, DOI 10.1039/c0gc00437e
NR 52
TC 4
Z9 5
U1 18
U2 131
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 27
EP 37
DI 10.1016/j.ces.2018.08.060
PG 11
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800004
DA 2020-05-12
ER

PT J
AU Gumulya, M
   Joshi, JB
   Utikar, RP
   Evans, GM
   Pareek, V
AF Gumulya, M.
   Joshi, J. B.
   Utikar, R. P.
   Evans, G. M.
   Pareek, V
TI Characteristics of energy production and dissipation around a bubble
   rising in water
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble generated turbulence; Turbulence in gas-liquid flows; Bubble
   wake; Shape oscillations; Bubbly flows; Volume-of-fluid method
ID HIGH-REYNOLDS-NUMBER; ADAPTIVE SOLVER; RISE VELOCITY; LIQUID;
   TURBULENCE; FLOWS; DYNAMICS; MOTION; WAKE
AB A numerical simulation on the rise behaviour of a bubble rising in stagnant water at Re approximate to 800-1300 has been conducted. It is found that vorticity generated at the side of the bubble is transferred to the wake region, forming chains of hairpin vortices that are regularly shed and transported downstream. The resulting fluctuations in shape, trajectory, and rise velocity were found to conform well to experimental observations. The fluctuations in velocity resulting from the unsteady wakes were analysed through a fixed-frame approach about the centre of mass of the bubble. The average turbulent kinetic energy in the near wake region was found to be approximate to 1.4-4.8%with respect to the average kinetic energy of the bubble. The production of the turbulent kinetic energy was found to occur predominantly at the near wake region of the bubble, mostly as a result of normal and tangential gradients of the mean streamwise velocity. Interestingly, several regions of negative rate of energy production were identified, namely at the top and side interfaces of the bubble. Overall, the ratio of positive-to-negative production rate was found to be approximate to 2.4-3.1 resulting in a net conversion towards smaller-scale fluctuations from the mean flow. Small-scale dissipation was found to occur throughout the wake of the bubble. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gumulya, M.; Utikar, R. P.; Pareek, V] Curtin Univ, Dept Chem Engn, U1987, Perth, WA 6845, Australia.
   [Joshi, J. B.] Homi Bhabha Natl Inst, Bombay 400094, Maharashtra, India.
   [Joshi, J. B.] Inst Chem Technol, Dept Chem Engn, Bombay 400019, Maharashtra, India.
   [Evans, G. M.] Univ Newcastle, Discipline Chem Engn, Callaghan, NSW 2308, Australia.
RP Gumulya, M (reprint author), Curtin Univ, Dept Chem Engn, U1987, Perth, WA 6845, Australia.
EM m.gumulya@curtin.edu.au
OI Pareek, Vishnu/0000-0002-0848-3671
FU ARC Discovery Projects Scheme [DP140104510]; Pawsey Supercomputing
   Centre; Australian GovernmentAustralian Government; Government of
   Western Australia
FX This work was funded through the ARC Discovery Projects Scheme
   DP140104510. This work was supported by resources provided by The Pawsey
   Supercomputing Centre with funding from the Australian Government and
   the Government of Western Australia. The authors would also like to
   acknowledge the remarkable contribution of the Gerris Flow Solver
   community (http://sourceforge.net/projects/gfs/).
CR Batchelor G. K., 1967, INTRO FLUID DYNAMICS
   Besagni Giorgio, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2020013
   Bouche E, 2014, J FLUID MECH, V758, P508, DOI 10.1017/jfm.2014.544
   Brucker C, 1999, PHYS FLUIDS, V11, P1781, DOI 10.1063/1.870043
   Bunner B, 2002, J FLUID MECH, V466, P17, DOI 10.1017/S0022112002001179
   Bunner B, 2003, J FLUID MECH, V495, P77, DOI 10.1017/S0022112003006293
   Cano-Lozano JC, 2016, PHYS REV FLUIDS, V1, DOI 10.1103/PhysRevFluids.1.053604
   Cui Z, 2004, CHEM ENG SCI, V59, P1755, DOI 10.1016/j.ces.2004.01.031
   DUINEVELD PC, 1995, J FLUID MECH, V292, P325, DOI 10.1017/S0022112095001546
   Ellingsen K, 2001, J FLUID MECH, V440, P235, DOI 10.1017/S0022112001004761
   Esmaeeli A, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2056617
   Gumulya M, 2017, CHEM ENG SCI, V166, P1, DOI 10.1016/j.ces.2017.03.013
   Gumulya M, 2016, CHEM ENG SCI, V144, P298, DOI 10.1016/j.ces.2016.01.051
   JEONG J, 1995, J FLUID MECH, V285, P69, DOI 10.1017/S0022112095000462
   Joshi JB, 2017, CHEM ENG SCI, V157, P26, DOI 10.1016/j.ces.2016.03.041
   LANCE M, 1991, J FLUID MECH, V222, P95, DOI 10.1017/S0022112091001015
   Lunde K, 1998, APPL SCI RES, V58, P387
   Magnaudet J, 2000, ANNU REV FLUID MECH, V32, P659, DOI 10.1146/annurev.fluid.32.1.659
   Mercado JM, 2010, J FLUID MECH, V650, P287, DOI 10.1017/S0022112009993570
   MOORE DW, 1965, J FLUID MECH, V23, P749, DOI 10.1017/S0022112065001660
   MOORE DW, 1963, J FLUID MECH, V16, P161, DOI 10.1017/S0022112063000665
   Mudde RF, 1997, CHEM ENG SCI, V52, P4217, DOI 10.1016/S0009-2509(97)88935-X
   Popinet S, 2003, J COMPUT PHYS, V190, P572, DOI 10.1016/S0021-9991(03)00298-5
   Popinet S, 2009, J COMPUT PHYS, V228, P5838, DOI 10.1016/j.jcp.2009.04.042
   Rensen J, 2005, J FLUID MECH, V538, P153, DOI 10.1017/S0022112005005276
   Riboux G, 2010, J FLUID MECH, V643, P509, DOI 10.1017/S0022112009992084
   Takagi S, 2011, ANNU REV FLUID MECH, V43, P615, DOI 10.1146/annurev-fluid-122109-160756
   Takemura F, 2003, J FLUID MECH, V495, P235, DOI 10.1017/S0022112003006232
   Veldhuis C.H.J., 2007, LEONARDOS PARADOX PA
   Veldhuis C, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911042
NR 30
TC 2
Z9 2
U1 2
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 38
EP 52
DI 10.1016/j.ces.2018.08.059
PG 15
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800005
DA 2020-05-12
ER

PT J
AU Zhan, CJ
   Hagrot, E
   Brandt, L
   Chotteau, V
AF Zhan, Caijuan
   Hagrot, Erika
   Brandt, Luca
   Chotteau, Veronique
TI Study of hydrodynamics in wave bioreactors by computational fluid
   dynamics reveals a resonance phenomenon
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wave bioreactor; Computation Fluid Dynamics (CFD); Volume of fluid
   (VOF); Hydrodynamic; Resonance
ID HAMSTER OVARY CELLS; SERUM-FREE MEDIA; MICROCARRIER CULTURES;
   SHEAR-STRESS; INFLUENZA-VIRUS; HIGH-DENSITY; STEM-CELLS; FLOW;
   EXPANSION; SCALE
AB Culture of mammalian or human cells in Wave bioreactor is widely used for cell expansion or for biologics manufacturing. Wave bioreactor cultivation of sensitive cells such as stem cells, immune cells or anchorage-dependent cells, is recognized as an attractive option for culture in suspension or adherently on microcarriers. A systematic optimization of the mixing, oxygen transfer rate and shear stress, most favorable for the cells requires a deep understanding of the hydrodynamics inside the Wave bioreactor bag, i.e. cellbag. Numerical simulation by Computation Fluid Dynamics (CFD), is considered as an inexpensive and efficient tool for predicting the fluid behavior in many fields. In the present study, we perform numerical simulations by Ansys-FLUENT to characterize the flow conditions in a 10 L cellbag. The numerical simulations are carried out to investigate the fluid structures for nine different operating conditions of rocking speed and angle. The influence of these operating parameters on the mixing and the shear stress induced by the liquid motion are studied. We find that the mixing and shear stress increase with the cellbag angle from 4 degrees to 7 degrees but that increasing rocking speeds are not systematically associated with increasing mixing and shear stress. It is concluded that a resonance phenomenon is responsible for the fact that the lowest studied rocking speed, 15 rpm, generates the highest fluid velocity, mixing and shear stress compared to the higher speeds of 22 and 30 rpm. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Zhan, Caijuan; Hagrot, Erika; Chotteau, Veronique] KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Ind Biotechnol, Cell Technol Grp CETEG, SE-10691 Stockholm, Sweden.
   [Zhan, Caijuan; Hagrot, Erika; Chotteau, Veronique] VINNOVA Competence Ctr Adv Bioprod Continuous Pro, AdBIOPRO, Stockholm, Sweden.
   [Zhan, Caijuan; Chotteau, Veronique] Wallenberg Ctr Prot Res, SE-10691 Stockholm, Sweden.
   [Zhan, Caijuan; Brandt, Luca] Royal Inst Technol, KTH Mech, Linne FLOW Ctr, SE-10044 Stockholm, Sweden.
RP Chotteau, V (reprint author), KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Ind Biotechnol, Cell Technol Grp CETEG, SE-10691 Stockholm, Sweden.
EM chotteau@kth.se
OI Chotteau, Veronique/0000-0002-5370-4621
FU Chinese Scholarship CouncilChina Scholarship Council; Competence Centre
   for Advanced BioProduction by Continuous Processing, AdBIOPRO - Sweden's
   Innovation Agency VINNOVA [2016-05181]
FX This research was supported by the Chinese Scholarship Council and by
   the Competence Centre for Advanced BioProduction by Continuous
   Processing, AdBIOPRO, sponsored by the Sweden's Innovation Agency
   VINNOVA, diaries nr. 2016-05181. Many thanks to Swedish Orphan Biovitrum
   for providing the Wave bioreactor system and to Prof. Alper A. Oncul and
   Dominique Thevenin for generously providing their data.
CR Chalmers JJ, 2015, CURR OPIN CHEM ENG, V10, P94, DOI 10.1016/j.coche.2015.09.005
   Chen AKL, 2013, BIOTECHNOL ADV, V31, P1032, DOI 10.1016/j.biotechadv.2013.03.006
   Clincke MF, 2013, BIOTECHNOL PROGR, V29, P754, DOI 10.1002/btpr.1704
   Clincke MF, 2013, BIOTECHNOL PROGR, V29, P768, DOI 10.1002/btpr.1703
   Cormier JT, 2006, TISSUE ENG, V12, P3233, DOI 10.1089/ten.2006.12.3233
   CROUGHAN MS, 1987, BIOTECHNOL BIOENG, V29, P130, DOI 10.1002/bit.260290117
   dos Santos FF, 2013, BIOTECHNOL J, V8, P644, DOI 10.1002/biot.201200373
   Eibl R, 2009, ADV BIOCHEM ENG BIOT, V115, P55, DOI 10.1007/10_2008_15
   FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812
   GARCIABRIONES MA, 1994, BIOTECHNOL BIOENG, V44, P1089, DOI 10.1002/bit.260440910
   Genzel Y, 2006, VACCINE, V24, P6074, DOI 10.1016/j.vaccine.2006.05.023
   Gregoriades N, 2000, BIOTECHNOL BIOENG, V69, P171, DOI 10.1002/(SICI)1097-0290(20000720)69:2<171::AID-BIT6>3.0.CO;2-C
   Hundt B, 2007, VACCINE, V25, P3987, DOI 10.1016/j.vaccine.2007.02.061
   Joshi JB, 1996, CHEM ENG J BIOCH ENG, V62, P121, DOI 10.1016/0923-0467(95)03062-X
   Keane JT, 2003, BIOTECHNOL BIOENG, V81, P211, DOI 10.1002/bit.10472
   King JA, 2007, CURR OPIN CHEM BIOL, V11, P394, DOI 10.1016/j.cbpa.2007.05.034
   KUNDU PK, 1990, FLUID MECH
   KURZWEG UH, 1989, PHYS FLUIDS A-FLUID, V1, P1972, DOI 10.1063/1.857469
   Liu N, 2014, ENG LIFE SCI, V14, P4, DOI 10.1002/elsc.201300013
   Lohr V, 2009, VACCINE, V27, P4975, DOI 10.1016/j.vaccine.2009.05.083
   Ma NN, 2002, BIOTECHNOL BIOENG, V80, P428, DOI 10.1002/bit.10387
   Mollet M, 2007, BIOTECHNOL BIOENG, V98, P772, DOI 10.1002/bit.21476
   Morrow KJ, 2006, GENET ENG NEWS, V26, P42
   Motobu M, 1998, J FERMENT BIOENG, V85, P190, DOI 10.1016/S0922-338X(97)86766-9
   Noh W. F., 1976, SLIC SIMPLE LINE INT
   Oncul AA, 2010, BIOTECHNOL PROGR, V26, P101, DOI 10.1002/btpr.312
   Okonkowski J, 2007, J BIOSCI BIOENG, V103, P50, DOI 10.1263/jbb.103.50
   Romero JA, 2005, INT J HEAVY VEH SYST, V12, P121, DOI 10.1504/IJHVS.2005.006379
   Schnitzler AC, 2016, BIOCHEM ENG J, V108, P3, DOI 10.1016/j.bej.2015.08.014
   Sharma C, 2011, BIOTECHNOL PROGR, V27, P1497, DOI 10.1002/btpr.689
   Singh H., 2008, BIOREACTOR STUDIES C
   Singh V, 1999, CYTOTECHNOLOGY, V30, P149, DOI 10.1023/A:1008025016272
   Williams KA, 2002, BIOTECHNOL PROGR, V18, P951, DOI 10.1021/bp020087n
   Youn BS, 2005, BIOTECHNOL PROGR, V21, P984, DOI 10.1021/bp050059f
   ZIEGELSTEIN RC, 1992, SCIENCE, V258, P656, DOI 10.1126/science.1329207
NR 35
TC 4
Z9 4
U1 0
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 53
EP 65
DI 10.1016/j.ces.2018.08.017
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800006
OA Other Gold
DA 2020-05-12
ER

PT J
AU Li, X
   Gao, DY
   Hou, BL
   Wang, XD
AF Li, Xue
   Gao, Deyang
   Hou, Baolin
   Wang, Xiaodong
TI A mass-conserving lattice Boltzmann method for bubble behavior
   estimation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubbly flow; Lattice Boltzmann; Conservation; Closure relation
ID INCOMPRESSIBLE 2-PHASE FLOWS; NUMERICAL-SIMULATION; MULTIPHASE FLOWS;
   SURFACE-TENSION; FREE-ENERGY; PARASITIC CURRENTS; NONUNIFORM SYSTEM;
   TERMINAL VELOCITY; EQUATION METHOD; SINGLE BUBBLE
AB The Lattice Boltzmann Method (LBM) has been known as a promising approach for simulating the deformable moving interface of multiphase fluid phenomena due to its mesoscopic nature in organizing and executing distribution functions. However, LBMs are limited in simulating real gas-liquid bubbly flows, where the numerical inaccuracy and instability may significantly increase due to the high surface tension force and the large density ratio. In this paper, a mass-conserving LBM model is developed. The proposed model introduces a conserving correction step and an effective surface tension formula to improve physical accuracy, and utilizes a Multiple-Relaxation-Time (MRT) D3Q19 (three-dimensional and 19 discrete direction) operator to increase numerical stability. The proposed model was applied to estimate bubble behaviors, dimensionless parameter correlations, and drag force coefficient. The results were compared with analytical results, existing numerical results, and experimental data in literature and performed. The good agreement indicates that the proposed mass-conserving LBM model has the ability to predict bubble behaviors in the gas-liquid system. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Xue; Gao, Deyang; Hou, Baolin; Wang, Xiaodong] Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Catalysis, Dalian 116023, Peoples R China.
   [Gao, Deyang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Hou, BL; Wang, XD (reprint author), Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Catalysis, Dalian 116023, Peoples R China.
EM blhou@dicp.ac.cn; xdwang@dicp.ac.cn
OI Li, Xue/0000-0003-0500-5161
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676266, 21676269, 91645109]; DICP Fundamental
   Research Program for Clean Energy [DICP DMTO201602]
FX This work was funded by National Natural Science Foundation of China
   (Nos. 21676266, 21676269 and 91645109) and DICP Fundamental Research
   Program for Clean Energy (DICP DMTO201602).
CR Annaland MV, 2005, CHEM ENG SCI, V60, P2999, DOI 10.1016/j.ces.2005.01.031
   BHAGA D, 1981, J FLUID MECH, V105, P61, DOI 10.1017/S002211208100311X
   BHATNAGAR PL, 1954, PHYS REV, V94, P511, DOI 10.1103/PhysRev.94.511
   CAHN JW, 1958, J CHEM PHYS, V28, P258, DOI 10.1063/1.1744102
   CAHN JW, 1959, J CHEM PHYS, V31, P688, DOI 10.1063/1.1730447
   Celata GP, 2007, EXP THERM FLUID SCI, V31, P609, DOI 10.1016/j.expthermflusci.2006.06.006
   Celata GP, 2006, EXP THERM FLUID SCI, V31, P37, DOI 10.1016/j.expthermflusci.2005.08.006
   Chao JH, 2011, INT J NUMER METH FL, V66, P622, DOI 10.1002/fld.2276
   Cheng M, 2010, COMPUT FLUIDS, V39, P260, DOI 10.1016/j.compfluid.2009.09.003
   Chiappini D, 2010, COMMUN COMPUT PHYS, V7, P423, DOI 10.4208/cicp.2009.09.018
   Clift R., 1978, BUBBLES DROPS PARTIC
   Connington K, 2012, J MECH SCI TECHNOL, V26, P3857, DOI 10.1007/s12206-012-1011-5
   d'Humieres D, 2002, PHILOS T ROY SOC A, V360, P437, DOI 10.1098/rsta.2001.0955
   Dijkhuizen W, 2010, CHEM ENG SCI, V65, P1415, DOI 10.1016/j.ces.2009.10.021
   Ding H, 2007, J COMPUT PHYS, V226, P2078, DOI 10.1016/j.jcp.2007.06.028
   Fakhari A, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.036707
   Falcucci G, 2007, COMMUN COMPUT PHYS, V2, P1071
   Gong JM, 2015, J THERM SCI TECH-JPN, V10, DOI 10.1299/jtst.2015jtst0004
   GRACE JR, 1973, T I CHEM ENG-LOND, V51, P116
   GRACE JR, 1976, T I CHEM ENG-LOND, V54, P167
   GUNSTENSEN AK, 1991, PHYS REV A, V43, P4320, DOI 10.1103/PhysRevA.43.4320
   Guo ZL, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.036707
   He XY, 1998, PHYS REV E, V57, pR13, DOI 10.1103/PhysRevE.57.R13
   He XY, 1999, J COMPUT PHYS, V152, P642, DOI 10.1006/jcph.1999.6257
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Hua J, 2007, J COMPUT PHYS, V222, P769, DOI 10.1016/j.jcp.2006.08.008
   Huang H., 2015, MULTIPHASE LATTICE B
   Huang HB, 2014, J COMPUT PHYS, V269, P386, DOI 10.1016/j.jcp.2014.03.028
   Huang HB, 2011, COMPUT MATH APPL, V61, P3606, DOI 10.1016/j.camwa.2010.06.034
   Huang JJ, 2012, J ADHES SCI TECHNOL, V26, P1825, DOI 10.1163/156856111X599607
   Inamuro T, 2004, J COMPUT PHYS, V198, P628, DOI 10.1016/j.jcp.2004.01.019
   Inamuro T, 2000, COMPUT PHYS COMMUN, V129, P32, DOI 10.1016/S0010-4655(00)00090-4
   Jacqmin D, 1999, J COMPUT PHYS, V155, P96, DOI 10.1006/jcph.1999.6332
   Jamet D, 2002, J COMPUT PHYS, V182, P262, DOI 10.1006/jcph.2002.7165
   Kang QJ, 2002, PHYS FLUIDS, V14, P3203, DOI 10.1063/1.1499125
   Kim J, 2005, J COMPUT PHYS, V204, P784, DOI 10.1016/j.jcp.2004.10.032
   Lallemand P, 2000, PHYS REV E, V61, P6546, DOI 10.1103/PhysRevE.61.6546
   Leclaire S, 2015, INT J NUMER METH FL, V77, P732, DOI 10.1002/fld.4002
   Lee T, 2005, J COMPUT PHYS, V206, P16, DOI 10.1016/j.jcp.2004.12.001
   Lee T, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.056703
   Lee T, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.046709
   Liu L, 2016, EXP THERM FLUID SCI, V78, P254, DOI 10.1016/j.expthermflusci.2016.06.011
   Liu L, 2015, EXP THERM FLUID SCI, V62, P109, DOI 10.1016/j.expthermflusci.2014.11.018
   LOU Q, 2012, EPL, V99
   Luo LS, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.056710
   Martys NS, 1996, PHYS REV E, V53, P743, DOI 10.1103/PhysRevE.53.743
   McCracken ME, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.046704
   MEI RW, 1994, PHYS FLUIDS, V6, P418, DOI 10.1063/1.868039
   Osher S, 2001, J COMPUT PHYS, V169, P463, DOI 10.1006/jcph.2000.6636
   Pooley CM, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.046702
   Raymond F, 2000, CHEM ENG SCI, V55, P943, DOI 10.1016/S0009-2509(99)00385-1
   Ren F, 2016, ADV WATER RESOUR, V97, P100, DOI 10.1016/j.advwatres.2016.08.012
   Renardy Y, 2002, J COMPUT PHYS, V183, P400, DOI 10.1006/jcph.2002.7190
   Roghair I, 2011, CHEM ENG SCI, V66, P3204, DOI 10.1016/j.ces.2011.02.030
   ROTHMAN DH, 1988, J STAT PHYS, V52, P1119, DOI 10.1007/BF01019743
   Sbragaglia M, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.026702
   Scardovelli R, 1999, ANNU REV FLUID MECH, V31, P567, DOI 10.1146/annurev.fluid.31.1.567
   SHAN XW, 1995, J STAT PHYS, V81, P379, DOI 10.1007/BF02179985
   SHAN XW, 1993, PHYS REV E, V47, P1815, DOI 10.1103/PhysRevE.47.1815
   SHAN XW, 1994, PHYS REV E, V49, P2941, DOI 10.1103/PhysRevE.49.2941
   Shao JY, 2015, INT J NUMER METH FL, V77, P526, DOI 10.1002/fld.3995
   Shao JY, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.033309
   Son GH, 2001, NUMER HEAT TR B-FUND, V39, P509, DOI 10.1080/104077901750188868
   Swift MR, 1996, PHYS REV E, V54, P5041, DOI 10.1103/PhysRevE.54.5041
   SWIFT MR, 1995, PHYS REV LETT, V75, P830, DOI 10.1103/PhysRevLett.75.830
   Takada N, 2001, J NUCL SCI TECHNOL, V38, P330, DOI 10.1080/18811248.2001.9715037
   Tomiyama A, 1998, JSME INT J B-FLUID T, V41, P472, DOI 10.1299/jsmeb.41.472
   Wagner AJ, 2003, INT J MOD PHYS B, V17, P193, DOI 10.1142/S0217979203017448
   Wang Y, 2015, J COMPUT PHYS, V290, P336, DOI 10.1016/j.jcp.2015.03.005
   Yan XK, 2017, CHEM ENG J, V316, P553, DOI 10.1016/j.cej.2017.01.137
   Yu Z, 2008, CAN J CHEM ENG, V86, P267, DOI 10.1002/cjce.20048
   Yuan P, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2187070
   Zhang L, 2008, CHEM ENG SCI, V63, P2099, DOI 10.1016/j.ces.2008.01.010
   Zheng HW, 2006, J COMPUT PHYS, V218, P353, DOI 10.1016/j.jcp.2006.02.015
   Zuo YY, 2004, COLLOID SURFACE A, V250, P233, DOI 10.1016/j.colsurfa.2004.04.081
NR 75
TC 3
Z9 3
U1 9
U2 64
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 76
EP 88
DI 10.1016/j.ces.2018.08.061
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800008
DA 2020-05-12
ER

PT J
AU Arogeti, M
   Sher, E
   Bar-Kohany, T
AF Arogeti, M.
   Sher, E.
   Bar-Kohany, T.
TI Drop impact on small targets with different target-to-drop diameters
   ratio
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drop impact; Collision; Small target; Spreading; Classification
ID LIQUID; DYNAMICS; THICKNESS; SURFACES; SHEET
AB Drop impact on small cylindrical targets has been experimentally studied. Special attention has been drawn to the effect of the different target-to-drop diameters ratio on the evolution of the drop spreading after colliding with the surface. Three distinct regions have been identified as related to the ratio of the target-to-drop diameters (beta(t)  D-t/D-0), and the maximum spreading to drop diameters beta(max)  D-ma/D-0. The particular response of each type group was analyzed to define the specific spreading characteristics. The small target is an obstacle on the drop way, yet it does not stop its vertical velocity completely, as for the larger surfaces. A drop that impacts a small target continues to flow, not only radially but with some vertical velocity, in accordance with an appropriate energy balance. The analysis yielded expressions for the maximal spread of each impact type. Type-A was observed for (1 < beta(t) <= beta(max)) and demonstrated mainly a radial spread, type-B (1/2 < beta(t) <= 1) with two directional spread; radial and vertical, and type-C for (beta(t) <= 1/2) a very small obstacle which barely affects the drop flow. The present analysis yielded expressions for the maximal spread of each impact type. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Arogeti, M.] Ben Gurion Univ Negev, Dept Mech Engn, Beer Sheva, Israel.
   [Sher, E.] Technion Israel Inst Technol, Fac Aerosp Engn, Haifa, Israel.
   [Bar-Kohany, T.] Tel Aviv Univ, Sch Mech Engn, IL-6997801 Tel Aviv, Israel.
RP Bar-Kohany, T (reprint author), Univ Maryland, Dept Mech Engn, College Pk, MD 20742 USA.
EM talibk@tauex.tau.ac.il
RI Bar-Kohany, Tali/C-6644-2016
OI Bar-Kohany, Tali/0000-0002-7303-2359
CR Arogeti M, 2017, ATOMIZATION SPRAY, V27, P759, DOI 10.1615/AtomizSpr.2017019241
   Arora S, 2016, PHYS REV FLUIDS, V1, DOI 10.1103/PhysRevFluids.1.083302
   Attane P, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2408495
   Banitabaei SA, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4990088
   Bussmann M, 2000, PHYS FLUIDS, V12, P3121, DOI 10.1063/1.1321258
   CHANDRA S, 1991, P R SOC-MATH PHYS SC, V432, P13, DOI 10.1098/rspa.1991.0002
   Clanet C, 2004, J FLUID MECH, V517, P199, DOI 10.1017/S0022112004000904
   De Gennes P.-G., 2013, CAPILLARITY WETTING
   Eggers J, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3432498
   Erickson D, 2001, COLLOID SURFACE A, V182, P109, DOI 10.1016/S0927-7757(00)00834-7
   FROHN A, 2000, EXP FLUID MECH, P1
   Gu YG, 2000, COLLOID SURFACE A, V163, P239, DOI 10.1016/S0927-7757(99)00295-2
   Josserand C, 2016, ANNU REV FLUID MECH, V48, P365, DOI 10.1146/annurev-fluid-122414-034401
   Juarez G, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.026319
   Lagubeau G, 2012, J FLUID MECH, V713, P50, DOI 10.1017/jfm.2012.431
   Lee JB, 2016, J FLUID MECH, V786, DOI 10.1017/jfm.2015.620
   Mao T, 1997, AICHE J, V43, P2169, DOI 10.1002/aic.690430903
   PasandidehFard M, 1996, PHYS FLUIDS, V8, P650, DOI 10.1063/1.868850
   REIN M, 1993, FLUID DYN RES, V12, P61, DOI 10.1016/0169-5983(93)90106-K
   Rioboo R, 2002, EXP FLUIDS, V33, P112, DOI [10.1007/s00348-002-0431-X, 10.1007/s00348-002-0431-x]
   Roisman IV, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3129282
   Rozhkov A, 2006, J NON-NEWTON FLUID, V134, P44, DOI 10.1016/j.jnnfm.2005.11.006
   Rozhkov A, 2004, P ROY SOC A-MATH PHY, V460, P2681, DOI 10.1098/rspa.2004.1293
   Rozhkov A, 2003, PHYS FLUIDS, V15, P2006, DOI 10.1063/1.1580480
   Rozhkov A, 2010, P ROY SOC A-MATH PHY, V466, P2897, DOI 10.1098/rspa.2010.0015
   Rozhkov A, 2002, PHYS FLUIDS, V14, P3485, DOI 10.1063/1.1502663
   Sher E, 2013, INT J MULTIPHAS FLOW, V54, P55, DOI 10.1016/j.ijmultiphaseflow.2013.03.002
   Ukiwe C, 2005, LANGMUIR, V21, P666, DOI 10.1021/la0481288
   Vadillo DC, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3276259
   Vernay C, 2015, J FLUID MECH, V764, P428, DOI 10.1017/jfm.2014.714
   Villermaux E, 2011, J FLUID MECH, V668, P412, DOI 10.1017/S002211201000474X
   Wang Y, 2017, J FLUID MECH, V814, P510, DOI 10.1017/jfm.2017.18
   Yarin A. L., 2017, COLLISION PHENOMENA
   Yarin AL, 2006, ANNU REV FLUID MECH, V38, P159, DOI 10.1146/annurev.fluid.38.050304.092144
   Yonemoto Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02450-4
NR 35
TC 3
Z9 3
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 89
EP 101
DI 10.1016/j.ces.2018.08.013
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800009
DA 2020-05-12
ER

PT J
AU Fernandez, JR
   Abanades, JC
AF Ramon Fernandez, Jose
   Carlos Abanades, Juan
TI Experimental testing and model validation of the calcination of calcium
   carbonate by the reduction of copper oxide with CH4
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 capture; Chemical looping; Calcium looping; H-2 production; CaCO3
   calcination; CuO reduction
ID CHEMICAL-LOOPING COMBUSTION; FIXED-BED REACTOR; CAO-BASED SORBENT; CO2
   CAPTURE; HYDROGEN-PRODUCTION; CONCEPTUAL DESIGN; NATURAL-GAS; H-2
   PRODUCTION; PACKED-BEDS; OPERATION STRATEGY
AB The reduction reaction of copper oxide with CH4 is highly exothermic and can be arranged to generate sufficient heat to in-situ calcine calcium carbonate and produce a highly concentrated stream of CO2. This concept is tested at TRL4 in a packed-bed reactor operated close to adiabatic conditions. The impact of the initial solids temperature and the inlet flowrate of the gases is evaluated. A 50/50 (vol.%) mixture of methane and hydrogen (i.e., a possible composition of the PSA-off gas generated in a reforming process) has also been used as reducing gas. The presence of H2 reduces the CuO/CaCO3 proportion required in the bed and promotes the calcination at temperatures lower than 870 degrees C. The experimental measurements are well predicted by a one-dimensional fixed-bed reactor model, in which the steam methane reforming, water-gas-shift, carbon deposition and carbon gasification reactions are also considered. Different characterization techniques (i.e., SEM, XRD, N-2 adsorption, TPR) demonstrate that both commercial CuO- and CaO-based materials show good stability after successive cyclic experiments. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ramon Fernandez, Jose; Carlos Abanades, Juan] CSIC, INCAR, Spanish Res Council, Francisco Pintado Fe 26, Oviedo 33011, Spain.
RP Fernandez, JR (reprint author), CSIC, INCAR, Spanish Res Council, Francisco Pintado Fe 26, Oviedo 33011, Spain.
EM jramon@incar.csic.es
RI Abanades, Juan Carlos/P-6399-2018
OI Abanades, Juan Carlos/0000-0003-1711-6993
FU EU-FP7 ASCENT Project [608512]
FX The authors acknowledge the contribution of J.M Alarcon during the
   experimental campaign. This research was funded by the EU-FP7 ASCENT
   Project (Grant agreement number 608512).
CR Abanades JC, 2010, ENVIRON SCI TECHNOL, V44, P6901, DOI 10.1021/es101707t
   Adanez J, 2012, PROG ENERG COMBUST, V38, P215, DOI 10.1016/j.pecs.2011.09.001
   Alarcon JM, 2015, CHEM ENG SCI, V137, P254, DOI 10.1016/j.ces.2015.06.030
   Aloisi I, 2017, CHEM ENG J, V314, P570, DOI 10.1016/j.cej.2016.12.014
   Antzara A, 2016, APPL ENERG, V180, P457, DOI 10.1016/j.apenergy.2016.08.005
   Arias B, 2013, INT J GREENH GAS CON, V18, P237, DOI 10.1016/j.ijggc.2013.07.014
   BAKER EH, 1962, J CHEM SOC, P464, DOI 10.1039/jr9620000464
   Boot-Handford ME, 2014, ENERG ENVIRON SCI, V7, P130, DOI 10.1039/c3ee42350f
   Borghei M, 2010, INT J HYDROGEN ENERG, V35, P9479, DOI 10.1016/j.ijhydene.2010.05.072
   Broda M, 2013, ENVIRON SCI TECHNOL, V47, P6007, DOI 10.1021/es305113p
   Diglio G, 2018, APPL ENERG, V210, P1, DOI 10.1016/j.apenergy.2017.10.101
   EDWARDS MF, 1968, CHEM ENG SCI, V23, P109, DOI 10.1016/0009-2509(68)87056-3
   Fernandez JR, 2017, CURR OPIN CHEM ENG, V17, P1, DOI 10.1016/j.coche.2017.04.010
   Fernandez JR, 2017, INT J HYDROGEN ENERG, V42, P11023, DOI 10.1016/j.ijhydene.2017.02.141
   Fernandez JR, 2017, CHEM ENG SCI, V166, P144, DOI 10.1016/j.ces.2017.03.039
   Fernandez JR, 2014, APPL ENERG, V135, P309, DOI 10.1016/j.apenergy.2014.08.069
   Fernandez JR, 2013, CHEM ENG J, V232, P442, DOI 10.1016/j.cej.2013.07.115
   Fernandez JR, 2012, CHEM ENG SCI, V84, P12, DOI 10.1016/j.ces.2012.07.050
   Fernandez JR, 2012, CHEM ENG SCI, V84, P1, DOI 10.1016/j.ces.2012.07.039
   Fernandez JR, 2012, INT J GREENH GAS CON, V6, P126, DOI 10.1016/j.ijggc.2011.11.014
   Fernandez JR, 2017, APPL THERM ENG, V125, P811, DOI 10.1016/j.applthermaleng.2017.07.063
   Fernandez JR, 2016, IND ENG CHEM RES, V55, P5128, DOI 10.1021/acs.iecr.5b04073
   Garcia-Labiano F, 2004, IND ENG CHEM RES, V43, P8168, DOI 10.1021/ie0493311
   Garcia-Lario AL, 2015, CHEM ENG J, V264, P697, DOI 10.1016/j.cej.2014.11.116
   Garcia-Lario AL, 2013, IND ENG CHEM RES, V52, P1481, DOI 10.1021/ie3012598
   Grasa G, 2017, CHEM ENG J, V324, P266, DOI 10.1016/j.cej.2017.04.134
   GUNN DJ, 1987, CHEM ENG SCI, V42, P363, DOI 10.1016/0009-2509(87)85066-2
   GUNN DJ, 1993, INT J HEAT MASS TRAN, V36, P2209, DOI 10.1016/S0017-9310(05)80152-8
   Hamers HP, 2014, APPL ENERG, V119, P163, DOI 10.1016/j.apenergy.2013.12.053
   Han L, 2013, CHEM ENG SCI, V104, P233, DOI 10.1016/j.ces.2013.09.021
   Harrison DP, 2008, IND ENG CHEM RES, V47, P6486, DOI 10.1021/ie800298z
   Hufton JR, 1999, AICHE J, V45, P248, DOI 10.1002/aic.690450205
   IEA, 2015, HYDROGEN FUEL CELLS
   IEA, 2017, CO2 EM FUEL COMB
   Imtiaz Q, 2012, ENVIRON SCI TECHNOL, V46, P3561, DOI 10.1021/es2042788
   IPCC, 2014, CLIM CHANG 2014 MIT
   ISHIDA M, 1994, ENERGY, V19, P415, DOI 10.1016/0360-5442(94)90120-1
   Kazi SS, 2017, ENRGY PROCED, V114, P211, DOI 10.1016/j.egypro.2017.03.1163
   Kierzkowska AM, 2012, ENERG ENVIRON SCI, V5, P6061, DOI 10.1039/c2ee03079a
   KRUPICZKA R, 1967, INT CHEM ENG, V7, P122
   Lyngfelt A, 2014, APPL ENERG, V113, P1869, DOI 10.1016/j.apenergy.2013.05.043
   Lyon RK, 2000, COMBUST FLAME, V121, P249, DOI 10.1016/S0010-2180(99)00136-4
   Manovic V, 2011, ENVIRON SCI TECHNOL, V45, P10750, DOI 10.1021/es202292c
   Alarcon JM, 2017, CHEM ENG J, V325, P208, DOI 10.1016/j.cej.2017.05.070
   Martavaltzi CS, 2011, IND ENG CHEM RES, V50, P539, DOI 10.1021/ie1002284
   Martavaltzi CS, 2010, CHEM ENG SCI, V65, P4134, DOI 10.1016/j.ces.2010.04.038
   Martinez I, 2014, APPL ENERG, V114, P192, DOI 10.1016/j.apenergy.2013.09.026
   Martinez I, 2012, ENERG FUEL, V26, P1432, DOI 10.1021/ef201525k
   Martinez I, 2017, IND ENG CHEM RES, V56, P2526, DOI 10.1021/acs.iecr.6b04615
   Martinez I, 2013, AICHE J, V59, P2780, DOI 10.1002/aic.14054
   Martini M, 2017, CHEM ENG J, V328, P304, DOI 10.1016/j.cej.2017.07.048
   Martini M, 2016, CHEM ENG J, V303, P73, DOI 10.1016/j.cej.2016.05.135
   Martini M, 2017, ENRGY PROCED, V114, P104, DOI 10.1016/j.egypro.2017.03.1153
   Noorman S, 2007, IND ENG CHEM RES, V46, P4212, DOI 10.1021/ie061178i
   Qin CL, 2016, APPL ENERG, V164, P400, DOI 10.1016/j.apenergy.2015.11.059
   Rahman RA, 2015, ENERG FUEL, V29, P3808, DOI 10.1021/acs.energyfuels.5b00256
   Fernandez JR, 2016, J CLEAN PROD, V112, P1211, DOI 10.1016/j.jclepro.2015.06.010
   Fernandez JR, 2014, APPL ENERG, V113, P1945, DOI 10.1016/j.apenergy.2013.02.013
   Rostrup-Nielsen JR, 2009, CATAL TODAY, V145, P72, DOI 10.1016/j.cattod.2008.06.019
   Shimizu T, 1999, CHEM ENG RES DES, V77, P62, DOI 10.1205/026387699525882
   Snoeck JW, 2002, IND ENG CHEM RES, V41, P4252, DOI 10.1021/ie010666h
   Spallina V, 2015, INT J GREENH GAS CON, V36, P34, DOI 10.1016/j.ijggc.2015.01.025
   Strohle J, 2014, APPL ENERG, V113, P1490, DOI 10.1016/j.apenergy.2013.09.008
   Valverde JM, 2012, ENVIRON SCI TECHNOL, V46, P6401, DOI 10.1021/es3002426
   Voldsund M, 2016, INT J HYDROGEN ENERG, V41, P4969, DOI 10.1016/j.ijhydene.2016.01.009
   VORTMEYER D, 1982, AICHE J, V28, P508, DOI 10.1002/aic.690280321
   Wolf J, 2005, INT J ENERG RES, V29, P739, DOI 10.1002/er.1079
   XU JG, 1989, AICHE J, V35, P97, DOI 10.1002/aic.690350110
   Zhenissova A, 2014, CHEM ENG RES DES, V92, P727, DOI 10.1016/j.cherd.2013.11.005
   Zhou ZQ, 2013, CHEM ENG J, V233, P331, DOI 10.1016/j.cej.2013.08.025
NR 70
TC 2
Z9 2
U1 4
U2 47
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 120
EP 132
DI 10.1016/j.ces.2018.09.001
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800011
DA 2020-05-12
ER

PT J
AU Enzmann, F
   Mayer, F
   Stockl, M
   Mangold, KM
   Hommel, R
   Holtmann, D
AF Enzmann, Franziska
   Mayer, Florian
   Stoeckl, Markus
   Mangold, Klaus-Michael
   Hommel, Rolf
   Holtmann, Dirk
TI Transferring bioelectrochemical processes from H-cells to a scalable
   bubble column reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bioelectrochemistry; Bioelectrochemical systems; Electromethanogenesis;
   Reactor characterization; Bubble column reactor; Scale-up
ID MICROBIAL ELECTROLYSIS CELL; WASTE-WATER TREATMENT; FUEL-CELLS;
   SCALE-UP; MASS-TRANSFER; METHANOCOCCUS-MARIPALUDIS; SYSTEMS;
   ELECTROSYNTHESIS; REDUCTION; HYDROGEN
AB In times of energy revolution, bioelectrochemistry is a growing field of research, either for the generation of electrical energy from organic substrates or the use of electrical energy to produce various products. By now, this technology is on the turning point from lab scale to industrial applications. Unfortunately, there is still a lack of well characterized, scalable reactor systems that are capable of hosting different bioelectrochemical processes, linking lab scale research to industrial application. In this paper, we introduce a two-chamber bioelectrochemical bubble-column reactor (one liter working volume), which can be used as microbial fuel cell as well as for microbial electrosynthesis and is especially advantageous for processes with gaseous substrates. It is designed flexible in terms of electrode material and area, membrane material and area, and capable of hosting continuous processes. It is a promising replacement of lab-scale H-cells for wider screening possibilities with regard to industrial applications. We characterized the reactor by giving key values such as Ito and gas hold up, and suggest scale-up parameters. These are, for example, dimensionless numbers like Reynolds and Wagner number and different ratios that should be kept constant during scale-up. Therefore, this paper can be a guideline for the development and scale-up of bioelectrochemical systems. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Enzmann, Franziska; Mayer, Florian; Holtmann, Dirk] DECHEMA Forschungsinst, Ind Biotechnol, Theodor Heuss Allee 25, D-60486 Frankfurt, Germany.
   [Stoeckl, Markus; Mangold, Klaus-Michael] DECHEMA Forschungsinst, Elektrochem, Theodor Heuss Allee 25, D-60486 Frankfurt, Germany.
   [Hommel, Rolf] ifn FTZ GmbH, Dr Bergius Str 19, D-06729 Elsteraue, Germany.
RP Holtmann, D (reprint author), DECHEMA Forschungsinst, Ind Biotechnol, Theodor Heuss Allee 25, D-60486 Frankfurt, Germany.
EM holtmann@dechema.de
FU BMBFFederal Ministry of Education & Research (BMBF) [033RC013A]
FX The authors thank the BMBF for funding [Grant number 033RC013A, 2016].
CR Andricacos P. C, 1999, ELECTROCHEMICAL PROC
   Bajracharya S, 2015, BIORESOURCE TECHNOL, V195, P14, DOI 10.1016/j.biortech.2015.05.081
   Bensmann A, 2014, APPL ENERG, V134, P413, DOI 10.1016/j.apenergy.2014.08.047
   Blasco-Gomez R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040874
   Bretschger O, 2007, APPL ENVIRON MICROB, V73, P7003, DOI 10.1128/AEM.01087-07
   Brown RK, 2014, BIORESOURCE TECHNOL, V163, P206, DOI 10.1016/j.biortech.2014.04.044
   Chae KJ, 2008, ENERG FUEL, V22, P169, DOI 10.1021/ef700308u
   Cheng SA, 2011, BIORESOURCE TECHNOL, V102, P4468, DOI 10.1016/j.biortech.2010.12.104
   Clauwaert P., 2008, APPL MICROBIOL BIOTE
   Cusick RD, 2011, APPL MICROBIOL BIOT, V89, P2053, DOI 10.1007/s00253-011-3130-9
   Deutzmann JS, 2015, MBIO, V6, DOI 10.1128/mBio.00496-15
   Enzmann F, 2018, AMB EXPRESS, V8, DOI 10.1186/s13568-017-0531-x
   Escapa A, 2015, BIORESOURCE TECHNOL, V180, P72, DOI 10.1016/j.biortech.2014.12.096
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   Geppert F, 2016, TRENDS BIOTECHNOL, V34, P879, DOI 10.1016/j.tibtech.2016.08.010
   Giddings CGS, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00468
   Gil-Carrera L, 2013, BIORESOURCE TECHNOL, V130, P584, DOI 10.1016/j.biortech.2012.12.062
   Hara M, 2013, ENRGY PROCED, V37, P7021, DOI 10.1016/j.egypro.2013.06.637
   Harnisch F, 2010, CHEM SOC REV, V39, P4433, DOI 10.1039/c003068f
   Heidrich ES, 2014, BIORESOURCE TECHNOL, V173, P87, DOI 10.1016/j.biortech.2014.09.083
   Hintermayer S, 2016, BIOCHEM ENG J, V115, P1, DOI 10.1016/j.bej.2016.07.020
   Janicek A, 2014, BIOFUELS-UK, V5, P79, DOI [10.4155/bfs.13.69, 10.4155/BFS.13.69]
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Kougias PG, 2017, BIORESOURCE TECHNOL, V225, P429, DOI 10.1016/j.biortech.2016.11.124
   Krieg T., 2018, BIOTECHNOL BIOENG
   Krieg T, 2019, ADV BIOCHEM ENG BIOT, V167, P231, DOI 10.1007/10_2017_40
   Krieg T, 2018, ANGEW CHEM INT EDIT, V57, P1879, DOI 10.1002/anie.201711302
   Krieg T, 2017, APPL ENERG, V195, P942, DOI 10.1016/j.apenergy.2017.03.101
   Krieg T, 2014, TRENDS BIOTECHNOL, V32, P645, DOI 10.1016/j.tibtech.2014.10.004
   Kumar R, 2018, INT J ENERG RES, V42, P369, DOI 10.1002/er.3780
   Lanthier M, 2008, FEMS MICROBIOL LETT, V278, P29, DOI 10.1111/j.1574-6968.2007.00964.x
   Lienemann M, 2018, BIORESOURCE TECHNOL, V254, P278, DOI 10.1016/j.biortech.2018.01.036
   Logan BE, 2010, APPL MICROBIOL BIOT, V85, P1665, DOI 10.1007/s00253-009-2378-9
   Lohner ST, 2014, ISME J, V8, P1673, DOI 10.1038/ismej.2014.82
   Mayer F., 2018, J CHEM TECHNOL BIOTE
   Montes FJ, 1999, CHEM ENG SCI, V54, P3127, DOI 10.1016/S0009-2509(98)00314-5
   Motos PR, 2017, J CHEM TECHNOL BIOT, V92, P2817, DOI 10.1002/jctb.5353
   Oliveira VB, 2013, BIOCHEM ENG J, V73, P53, DOI 10.1016/j.bej.2013.01.012
   Patil SA, 2015, BIOTECHNOL ADV, V33, P736, DOI 10.1016/j.biotechadv.2015.03.002
   PAUSS A, 1990, APPL ENVIRON MICROB, V56, P1636, DOI 10.1128/AEM.56.6.1636-1644.1990
   Rosa LFM, 2017, ENG LIFE SCI, V17, P77, DOI 10.1002/elsc.201600105
   Schmidt FR, 2005, APPL MICROBIOL BIOT, V68, P425, DOI 10.1007/s00253-005-0003-0
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Sharma M, 2014, ELECTROCHIM ACTA, V140, P191, DOI 10.1016/j.electacta.2014.02.111
   Stockl M., 2016, ACTA, V220, P444
   Sulaymon A. H., 2012, ELECTROLYSIS
   Takors R, 2012, J BIOTECHNOL, V160, P3, DOI 10.1016/j.jbiotec.2011.12.010
   Takors R., 2014, KOMMENTIERTE FORMELS
   TRIBE LA, 1995, BIOTECHNOL BIOENG, V46, P388, DOI 10.1002/bit.260460412
   Watson VJ, 2010, BIOTECHNOL BIOENG, V105, P489, DOI 10.1002/bit.22556
   Zamora P, 2017, J POWER SOURCES, V356, P491, DOI 10.1016/j.jpowsour.2017.02.089
NR 51
TC 12
Z9 12
U1 4
U2 47
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 133
EP 143
DI 10.1016/j.ces.2018.08.056
PG 11
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800012
DA 2020-05-12
ER

PT J
AU Chen, C
   Guan, XP
   Ren, Y
   Yang, N
   Li, JH
   Kunkelman, C
   Schreiner, E
   Holtze, C
   Mulheims, K
   Sachweh, B
AF Chen, Chao
   Guan, Xiaoping
   Ren, Ying
   Yang, Ning
   Li, Jinghai
   Kunkelman, Christian
   Schreiner, Eduard
   Holtze, Christian
   Mulheims, Kerstin
   Sachweh, Bernd
TI Mesoscale modeling of emulsification in rotor-stator devices Part II: A
   model framework integrating emulsifier adsorption
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotor-stator mixers; Droplet size distribution; Surfactant mass
   transfer; Meso-scale modeling
ID DROP-SIZE DISTRIBUTIONS; BUBBLE-COLUMNS; SURFACTANT ADSORPTION;
   TURBULENT DISPERSIONS; STABILITY CONDITION; CFD SIMULATION; SOLID FLOW;
   LIQUID; PRESSURE; COALESCENCE
AB Precise and rational control of droplet size distribution (DSD) is important in emulsification for target-oriented product design. To develop a complete DSD model, crossing the two mesoscales of two different levels is of great significance, viz., the emulsifier adsorption at interfacial level (Mesoscale 1) and the droplet breakage and coalescence in turbulence in rotor-stator device level (Mesoscale 2). While the first mesoscale can be simulated by coarse-grained molecular dynamic (CGMD), the second has been investigated in computational fluid dynamics and population balance model (CFD-PBM) simulation through the Energy-Minimization Multi-Scale (EMMS) approach in Part I. We then developed a model framework in Part II, coupling CGMD and CFD-PBM simulation through surfactant transport equations in bulk phase and at interface, with source terms taking account of emulsifier adsorption parameters. The parameters including maximal adsorption amount, diffusion coefficient and adsorption/desorption kinetic constants are acquired from CGMD. The coalescence efficiency is then corrected by the interfacial area fraction not occupied by surfactant and fed into the coalescence kernel functions in PBM. Compared to traditional CFD-PBM simulation, the coupled model can greatly improve the simulation of DSD, Sauter mean diameter, median diameter and span for high dispersed phase amount (DPA), and correctly reflect the influence of DPA, surfactant concentration and rotational speed of rotor-stator (RS) devices. While the simulation cases validate and demonstrate the advantage of this new model framework, it is also promising to incorporate different types of surfactant in future. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Chao; Guan, Xiaoping; Ren, Ying; Yang, Ning; Li, Jinghai] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   [Chen, Chao] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Kunkelman, Christian; Schreiner, Eduard; Holtze, Christian; Mulheims, Kerstin] BASF SE, D-67056 Ludwigshafen, Germany.
   [Sachweh, Bernd] BASF Adv Chem Co Ltd, Shanghai 200137, Peoples R China.
RP Yang, N (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
EM nyang@ipe.ac.cn
RI Yang, Ning/K-5766-2019; Yang, Ning/F-5888-2010
OI Yang, Ning/0000-0002-7446-8568; , Jinghai/0000-0002-5026-7104
FU BASF; National Key R&D Program of China [2017YE0106500]; National Nature
   Science Foundation of ChinaNational Natural Science Foundation of China
   [91634203]; Beijing National Science Foundation [2184125]; Research
   Center for Mesoscience at Institute of Process Engineering, Chinese
   Academy of Sciences [COM2016A004]
FX This work is supported by BASF, and the authors of Chinese Academy of
   Sciences also wish to thank the long term support from the National Key
   R&D Program of China (2017YE0106500), the National Nature Science
   Foundation of China (91634203), Beijing National Science Foundation
   (2184125), and the Research Center for Mesoscience at Institute of
   Process Engineering, Chinese Academy of Sciences (Grant No.
   COM2016A004).
CR Alopaeus V, 2002, CHEM ENG SCI, V57, P1815, DOI 10.1016/S0009-2509(02)00067-2
   Chen C., CHEM ENG SCI, V193, P171
   Diamant H, 1996, J PHYS CHEM-US, V100, P13732, DOI 10.1021/jp960377k
   Gimbun J, 2009, CHEM ENG RES DES, V87, P437, DOI 10.1016/j.cherd.2008.12.017
   Hakansson A, 2009, FOOD HYDROCOLLOID, V23, P1177, DOI 10.1016/j.foodhyd.2008.10.003
   Hakansson A, 2013, CHEM ENG SCI, V91, P44, DOI 10.1016/j.ces.2013.01.011
   Hakansson A, 2009, CHEM ENG SCI, V64, P2915, DOI 10.1016/j.ces.2009.03.034
   Hall S, 2011, CHEM ENG SCI, V66, P2068, DOI 10.1016/j.ces.2011.01.054
   LAMONT JC, 1970, AICHE J, V16, P513, DOI 10.1002/aic.690160403
   Li J., 1994, PARTICLE FLUID 2 PHA, P204
   Li JH, 2016, CURR OPIN CHEM ENG, V13, P10, DOI 10.1016/j.coche.2016.07.008
   [李静海 Li Jinghai], 2014, [中国科学. 化学, Scientia Sinica Chimica], V44, P277
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Luo H., 1993, COALESCENCE BREAKUP
   Maindarkar SN, 2015, COLLOID SURFACE A, V467, P18, DOI 10.1016/j.colsurfa.2014.11.032
   Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f
   Ortona O, 2000, PHYS CHEM CHEM PHYS, V2, P1961, DOI 10.1039/b000864h
   Paria S, 2004, ADV COLLOID INTERFAC, V110, P75, DOI 10.1016/j.cis.2004.03.001
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Qin CP, 2016, CHEM ENG SCI, V155, P16, DOI 10.1016/j.ces.2016.07.034
   Raikar NB, 2011, IND ENG CHEM RES, V50, P6089, DOI 10.1021/ie101818h
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wu HS, 2014, CHEM ENG SCI, V117, P173, DOI 10.1016/j.ces.2014.06.039
   Xiao Q, 2013, CHEM ENG SCI, V100, P279, DOI 10.1016/j.ces.2013.02.027
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Yang N., 2015, ADV CHEM ENG, V46
   Yang N, 2007, CHEM ENG SCI, V62, P6978, DOI 10.1016/j.ces.2007.08.034
   Yang N, 2017, CHEM ENG SCI, V170, P241, DOI 10.1016/j.ces.2017.01.026
   Yang N, 2011, CHEM ENG SCI, V66, P3212, DOI 10.1016/j.ces.2011.02.029
   Yang N, 2010, CHEM ENG SCI, V65, P517, DOI 10.1016/j.ces.2009.06.014
   Zhou RT, 2017, POWDER TECHNOL, V314, P466, DOI 10.1016/j.powtec.2016.09.083
NR 34
TC 4
Z9 4
U1 5
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 156
EP 170
DI 10.1016/j.ces.2018.08.049
PG 15
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800014
DA 2020-05-12
ER

PT J
AU Chen, C
   Guan, XP
   Ren, Y
   Yang, N
   Li, JH
   Kunkelmann, C
   Schreiner, E
   Holtze, C
   Mulheims, K
   Sachweh, B
AF Chen, Chao
   Guan, Xiaoping
   Ren, Ying
   Yang, Ning
   Li, Jinghai
   Kunkelmann, Christian
   Schreiner, Eduard
   Holtze, Christian
   Muelheims, Kerstin
   Sachweh, Bernd
TI Mesoscale modeling of emulsification in rotor-stator devices Part I: A
   population balance model based on EMMS concept
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotor-stator; Droplet size distribution; Energy-Minimization
   Multi-Scale; Meso-scale; Emulsification
ID TURBULENT FRAGMENTING STRESSES; BUBBLE-COLUMNS; ENERGY-SPECTRUM; POWER
   CHARACTERISTICS; ISOTROPIC TURBULENCE; STABILITY CONDITION; SIZE
   DISTRIBUTION; CFD SIMULATION; LIQUID FLOW; SOLID FLOW
AB Droplet size distribution represents one of the key parameters of emulsification products and emulsification efficiency. While there is a large number of computational fluid dynamics and population balance model (CFD-PBM) simulation for droplet size distribution in various emulsification devices, fitting parameters or empirical correlations were always involved to generate the reasonable simulation. In this study, we applied the Energy-Minimization Multi-scale (EMMS) approach for the liquid-liquid flow in rotor-stator (RS) mixing devices. The so-called mesoscale energy dissipation for droplet breakage was derived to close the population balance equations through a breakage rate corrector. The correction factor was then integrated into the fully-coupled CFD-PBM simulation for a surfactant-free MCT-oil/water system. Compared to the original Alopaeus breakage model or the combination of Alopaeus model and Prince coalescence model, this new model could greatly improve the prediction of droplet size distribution, Sauter mean diameter, median diameter and span of size distribution for both the dilute and the dense systems of dispersed oil phase. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Chao; Guan, Xiaoping; Ren, Ying; Yang, Ning; Li, Jinghai] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   [Chen, Chao] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Kunkelmann, Christian; Schreiner, Eduard; Holtze, Christian; Muelheims, Kerstin] BASF SE, D-67056 Ludwigshafen, Germany.
   [Sachweh, Bernd] BASF Adv Chem Co Ltd, Shanghai 200137, Peoples R China.
RP Yang, N (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
EM nyang@ipe.ac.cn
RI Yang, Ning/F-5888-2010; Yang, Ning/K-5766-2019
OI Yang, Ning/0000-0002-7446-8568; , Jinghai/0000-0002-5026-7104
FU BASF; National Key R&D Program of China [2017YE0106500]; National Nature
   Science Foundation of ChinaNational Natural Science Foundation of China
   [91634203]; Beijing National Science Foundation [2184125]; Research
   Center for Mesoscience at Institute of Process Engineering, Chinese
   Academy of Sciences [COM2016A004]
FX This work is supported by BASF, and the authors of Chinese Academy of
   Sciences also wish to thank the long term support from the National Key
   R&D Program of China (2017YE0106500), the National Nature Science
   Foundation of China (91634203), Beijing National Science Foundation
   (2184125), and the Research Center for Mesoscience at Institute of
   Process Engineering, Chinese Academy of Sciences (Grant No.
   COM2016A004).
CR Alopaeus V, 2002, CHEM ENG SCI, V57, P1815, DOI 10.1016/S0009-2509(02)00067-2
   Baldyga J, 1998, CAN J CHEM ENG, V76, P456, DOI 10.1002/cjce.5450760316
   Calabrese R. V., 2002, P 3 WORLD C EM LYON, P1
   Chen C., CHEM ENG SCI, V193, P156
   Cooke M, 2012, AICHE J, V58, P1683, DOI 10.1002/aic.12703
   De Hert SC, 2017, CHEM ENG SCI, V172, P423, DOI 10.1016/j.ces.2017.07.002
   Dubbelboer A, 2016, CHEM ENG SCI, V148, P32, DOI 10.1016/j.ces.2016.03.014
   Hakansson A., 2016, CAN J CHEM ENG, V9999, P1
   Hakansson A, 2017, CHEM ENG SCI, V171, P638, DOI 10.1016/j.ces.2017.06.038
   Hakansson A, 2017, CHEM ENG SCI, V171, P625, DOI 10.1016/j.ces.2017.06.042
   Hakansson A, 2017, CHEM ENG PROCESS, V115, P46, DOI 10.1016/j.cep.2017.01.007
   Hakansson A, 2017, CAN J CHEM ENG, V95, P806, DOI 10.1002/cjce.22718
   Han LC, 2015, AICHE J, V61, P2147, DOI 10.1002/aic.14830
   Han LC, 2014, CHEM ENG SCI, V117, P55, DOI 10.1016/j.ces.2014.06.018
   HULBURT HM, 1964, CHEM ENG SCI, V19, P555, DOI 10.1016/0009-2509(64)85047-8
   Jasinska M, 2015, CHEM ENG PROCESS, V91, P43, DOI 10.1016/j.cep.2015.03.015
   Jasinska M, 2014, CHEM ENG PROCESS, V84, P45, DOI 10.1016/j.cep.2014.02.008
   Kostoglou M, 2005, CHEM ENG SCI, V60, P6584, DOI 10.1016/j.ces.2005.05.051
   Lehr F., 1999, 2 EUR C CHEM ENG OCT
   Li J., 1994, PARTICLE FLUID 2 PHA, P204
   Li MM, 2016, IND ENG CHEM RES, V55, P3630, DOI 10.1021/acs.iecr.5b03301
   Li YW, 2015, CHEM ENG SCI, V134, P521, DOI 10.1016/j.ces.2015.05.046
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Makino S, 2015, FLOW TURBUL COMBUST, V95, P399, DOI 10.1007/s10494-015-9619-z
   Menter F, 1993, AIAA PAPER, P93, DOI [10.2514/6.1993-2906, DOI 10.2514/6.1993-2906]
   Mortensen HH, 2018, CHEM ENG SCI, V177, P340, DOI 10.1016/j.ces.2017.11.037
   NARSIMHAN G, 1979, CHEM ENG SCI, V34, P257, DOI 10.1016/0009-2509(79)87013-X
   Ozcan-Taskin G, 2011, CAN J CHEM ENG, V89, P1005, DOI 10.1002/cjce.20553
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Qin CP, 2016, CHEM ENG SCI, V155, P16, DOI 10.1016/j.ces.2016.07.034
   Ramkrishna D., 2000, POPULATION BALANCE T
   Solsvik J, 2016, CHEM ENG SCI, V149, P249, DOI 10.1016/j.ces.2016.04.037
   Solsvik J, 2016, AICHE J, V62, P1795, DOI 10.1002/aic.15128
   Solsvik J, 2016, IND ENG CHEM RES, V55, P1449, DOI 10.1021/acs.iecr.5b04077
   Utomo AT, 2008, CHEM ENG RES DES, V86, P1397, DOI 10.1016/j.cherd.2008.07.012
   Wu HS, 2014, CHEM ENG SCI, V117, P173, DOI 10.1016/j.ces.2014.06.039
   Xiao Q, 2013, CHEM ENG SCI, V100, P279, DOI 10.1016/j.ces.2013.02.027
   Xu SQ, 2014, AICHE J, V60, P1143, DOI 10.1002/aic.14315
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Yang N., 2015, ADV CHEM ENG, V46
   Yang N, 2007, CHEM ENG SCI, V62, P6978, DOI 10.1016/j.ces.2007.08.034
   Yang N, 2017, CHEM ENG SCI, V170, P241, DOI 10.1016/j.ces.2017.01.026
   Yang N, 2011, CHEM ENG SCI, V66, P3212, DOI 10.1016/j.ces.2011.02.029
   Yang N, 2010, CHEM ENG SCI, V65, P517, DOI 10.1016/j.ces.2009.06.014
   Zhao ZM, 2016, CHEM ENG PROCESS, V109, P158, DOI 10.1016/j.cep.2016.09.007
   Zhou RT, 2017, POWDER TECHNOL, V314, P466, DOI 10.1016/j.powtec.2016.09.083
NR 49
TC 5
Z9 5
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 171
EP 183
DI 10.1016/j.ces.2018.08.048
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800015
DA 2020-05-12
ER

PT J
AU Xiao, H
   Fan, Y
   Jacob, KV
   Umbanhowar, PB
   Kodam, M
   Koch, JF
   Lueptow, RM
AF Xiao, Hongyi
   Fan, Yi
   Jacob, Karl, V
   Umbanhowar, Paul B.
   Kodam, Madhusudhan
   Koch, James F.
   Lueptow, Richard M.
TI Continuum modeling of granular segregation during hopper discharge
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hopper discharge; Segregation; Continuum modeling; Granular materials
ID PARTICLE-SIZE SEGREGATION; DISCRETE ELEMENT; BINARY-MIXTURES; FLOW;
   DENSITY; SIMULATIONS; PREDICTION; SYSTEMS; SILOS; RATES
AB Modeling segregation of size disperse granular materials during hopper discharge is important as hoppers are widely used in various industries. However, due to the complexity of segregation and hopper discharge flows, accurately modeling this process has been challenging. In this study, we apply a continuum transport model to predict segregation of size bidisperse granular material during the discharge of quasi2D hoppers. We apply Discrete Element Method (DEM) simulations to reveal that segregation occurs mainly in a surface layer where particles are transported from the sidewalls to the hopper center. Velocity profiles are also developed based on a kinematic model and DEM data. The continuum model, which captures the interplay of advection, diffusion, and segregation, is then applied to predict the particle concentration distribution in the surface layer and the bulk. The continuum model accurately predicts the segregation pattern inside the hopper during discharge and the concentration profile of the discharged materials, in agreement with DEM simulations and experiments. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Xiao, Hongyi; Fan, Yi; Jacob, Karl, V; Kodam, Madhusudhan; Koch, James F.] Dow Chem Co USA, Midland, MI 48667 USA.
   [Xiao, Hongyi; Umbanhowar, Paul B.; Lueptow, Richard M.] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA.
   [Lueptow, Richard M.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA.
   [Lueptow, Richard M.] Northwestern Univ, Northwestern Inst Complex Syst NICO, Evanston, IL 60208 USA.
RP Fan, Y (reprint author), Dow Chem Co USA, Midland, MI 48667 USA.
EM yfan5@dow.com
RI Xiao, Hongyi/AAM-5333-2020; Lueptow, Richard/B-6740-2009
OI Lueptow, Richard/0000-0002-1855-1471
FU Dow Chemical Company; National Science FoundationNational Science
   Foundation (NSF) [CBET-1511450]
FX We thank Jinhui Yan from Northwestern University for help developing the
   FEM solver. We gratefully acknowledge support from The Dow Chemical
   Company and from National Science Foundation, Grant No. CBET-1511450.
CR Anand A, 2008, CHEM ENG SCI, V63, P5821, DOI 10.1016/j.ces.2008.08.015
   ARTEAGA P, 1990, CHEM ENG SCI, V45, P205, DOI 10.1016/0009-2509(90)87093-8
   Belytschko T, 2013, NONLINEAR FINITE ELE
   Bertuola D, 2016, CHEM ENG SCI, V150, P16, DOI 10.1016/j.ces.2016.04.054
   BEVERLOO WA, 1961, CHEM ENG SCI, V15, P260, DOI 10.1016/0009-2509(61)85030-6
   BRIDGWATER J, 1985, POWDER TECHNOL, V41, P147, DOI 10.1016/0032-5910(85)87033-9
   Bridgwater J, 2012, PARTICUOLOGY, V10, P397, DOI 10.1016/j.partic.2012.06.002
   BROOKS AN, 1982, COMPUT METHOD APPL M, V32, P199, DOI 10.1016/0045-7825(82)90071-8
   Chavan PV, 2009, IND ENG CHEM RES, V48, P4592, DOI 10.1021/ie8018627
   Choi J, 2005, J PHYS-CONDENS MAT, V17, pS2533, DOI 10.1088/0953-8984/17/24/011
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Deng ZK, 2018, P ROY SOC A-MATH PHY, V474, DOI 10.1098/rspa.2017.0384
   Dhodapkar S, 2016, CHEM ENG PROG, V112, P50
   DOLGUNIN VN, 1995, POWDER TECHNOL, V83, P95, DOI 10.1016/0032-5910(94)02954-M
   DONEA J, 1982, COMPUT METHOD APPL M, V33, P689, DOI 10.1016/0045-7825(82)90128-1
   Edwards AN, 2016, PHYS REV FLUIDS, V1, DOI 10.1103/PhysRevFluids.1.064201
   Fan Y, 2017, POWDER TECHNOL, V312, P67, DOI 10.1016/j.powtec.2017.02.026
   Fan Y, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.088001
   Fan Y, 2013, P ROY SOC A-MATH PHY, V469, DOI 10.1098/rspa.2013.0235
   Fan Y, 2014, J FLUID MECH, V741, P252, DOI 10.1017/jfm.2013.680
   Fan Y, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051305
   Fry AM, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.062906
   Gajjar P, 2016, J FLUID MECH, V794, P460, DOI 10.1017/jfm.2016.170
   Gella D, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.052904
   Golick LA, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.042301
   Gray JMNT, 2006, J FLUID MECH, V569, P365, DOI 10.1017/S0022112006002977
   Gray JMNT, 2009, J FLUID MECH, V629, P387, DOI 10.1017/S0022112009006466
   Gray JMNT, 2005, P ROY SOC A-MATH PHY, V461, P1447, DOI 10.1098/rspa.2004.1420
   Gray JMNT, 1997, CONTINUUM MECH THERM, V9, P341, DOI 10.1007/s001610050075
   Gray JMNT, 2018, ANNU REV FLUID MECH, V50, P407, DOI [10.1146/annurev-fluid-122316045201, 10.1146/annurev-fluid-122316-045201]
   Hajra SK, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.061318
   Hastie D. B., 2000, IUTAM S SEGR GRAN FL, P61
   Hughes TJ, 2012, FINITE ELEMENT METHO
   Jain N, 2005, GRANUL MATTER, V7, P69, DOI 10.1007/s10035-005-0198-x
   Jenike A., 1964, B U UTAH, V123
   Jing L, 2017, PHYS REV LETT, V118, DOI 10.1103/PhysRevLett.118.118001
   Jones R.P., 2018, ARXIV180607993
   Jop P, 2006, NATURE, V441, P727, DOI 10.1038/nature04801
   Jop P, 2005, J FLUID MECH, V541, P167, DOI 10.1017/S0022112005005987
   Kalaga DV, 2014, CHEM ENG J, V245, P323, DOI 10.1016/j.cej.2014.02.038
   Kalaga DV, 2012, CHEM ENG J, V191, P475, DOI 10.1016/j.cej.2012.02.091
   Ketterhagen WR, 2008, POWDER TECHNOL, V179, P126, DOI 10.1016/j.powtec.2007.06.023
   Ketterhagen WR, 2007, CHEM ENG SCI, V62, P6423, DOI 10.1016/j.ces.2007.07.052
   Ketterhagen WR, 2009, POWDER TECHNOL, V195, P1, DOI 10.1016/j.powtec.2009.05.002
   Koivisto J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15551
   Larcher M, 2015, J FLUID MECH, V782, P405, DOI 10.1017/jfm.2015.549
   Liu SY, 2017, AICHE J, V63, P3756, DOI 10.1002/aic.15770
   Lueptow Richard M., 2017, EPJ Web of Conferences, V140, DOI 10.1051/epjconf/201714003018
   Madrid M, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.022904
   Makse HA, 1997, NATURE, V386, P379, DOI 10.1038/386379a0
   Medina A, 1998, PHYS LETT A, V250, P111, DOI 10.1016/S0375-9601(98)00795-6
   Meier SW, 2007, ADV PHYS, V56, P757, DOI 10.1080/00018730701611677
   MULLINS WW, 1974, POWDER TECHNOL, V9, P29, DOI 10.1016/0032-5910(74)80006-9
   Muzzio FJ, 2002, POWDER TECHNOL, V124, P1, DOI 10.1016/S0032-5910(01)00482-X
   NEDDERMAN RM, 1979, POWDER TECHNOL, V22, P243, DOI 10.1016/0032-5910(79)80030-3
   NEDDERMAN RM, 1982, CHEM ENG SCI, V37, P1597, DOI 10.1016/0009-2509(82)80029-8
   Ottino JM, 2000, ANNU REV FLUID MECH, V32, P55, DOI 10.1146/annurev.fluid.32.1.55
   Ristow GH, 2000, SPRINGER TRAC MOD PH, V164, P1
   Samadani A, 1999, PHYS REV E, V60, P7203, DOI 10.1103/PhysRevE.60.7203
   SAVAGE SB, 1988, J FLUID MECH, V189, P311, DOI 10.1017/S002211208800103X
   Schafer J, 1996, J PHYS I, V6, P5, DOI 10.1051/jp1:1996129
   Schlick CP, 2016, J FLUID MECH, V797, P95, DOI 10.1017/jfm.2016.260
   Schlick CP, 2015, AICHE J, V61, P1524, DOI 10.1002/aic.14780
   Schlick CP, 2015, J FLUID MECH, V765, P632, DOI 10.1017/jfm.2015.4
   Sela N, 1998, J FLUID MECH, V361, P41, DOI 10.1017/S0022112098008660
   STANDISH N, 1985, POWDER TECHNOL, V45, P43, DOI 10.1016/0032-5910(85)85059-2
   Tang Y, 2017, J ENERGY INST, V59, P1
   Thombare M.A., 2017, REV CHEM ENG
   Thornton A, 2012, INT J MOD PHYS C, V23, DOI 10.1142/S0129183112400141
   Tian T, 2018, PARTICUOLOGY, V36, P127, DOI 10.1016/j.partic.2017.04.001
   Tripathi A, 2013, J FLUID MECH, V717, P643, DOI 10.1017/jfm.2012.603
   Tunuguntla DR, 2014, J FLUID MECH, V749, P99, DOI 10.1017/jfm.2014.223
   Tunuguntla D. R., 2016, COMPUT PART MECH, V4, P1
   Utter B, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.031308
   Weinhart T, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4812809
   Wiederseiner S, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3536658
   Williams J.C., 1968, POWDER TECHNOL, V2, P13, DOI DOI 10.1016/0032-5910(68)80028-2
   Woodhouse MJ, 2012, J FLUID MECH, V709, P543, DOI 10.1017/jfm.2012.348
   Xiao HY, 2017, POWDER TECHNOL, V312, P360, DOI 10.1016/j.powtec.2017.02.050
   Xiao HY, 2016, P ROY SOC A-MATH PHY, V472, DOI 10.1098/rspa.2015.0856
   Xu J, 2017, POWDER TECHNOL, V308, P273, DOI 10.1016/j.powtec.2016.12.013
   Yan J, 2017, COMPUT FLUIDS, V158, P157, DOI 10.1016/j.compfluid.2016.06.016
   Yan J, 2016, COMPUT FLUIDS, V141, P155, DOI 10.1016/j.compfluid.2016.03.008
   Zhao Y, 2018, AICHE J, V64, P1174, DOI 10.1002/aic.16026
   Zhao YZ, 2018, AICHE J, V64, P1550, DOI 10.1002/aic.16035
   Zheng QJ, 2017, POWDER TECHNOL, V307, P63, DOI 10.1016/j.powtec.2016.11.037
   Zhou Y, 2017, J FLUID MECH, V829, P459, DOI 10.1017/jfm.2017.543
   Zhou Y, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.062204
NR 88
TC 9
Z9 9
U1 2
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 188
EP 204
DI 10.1016/j.ces.2018.08.039
PG 17
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800017
DA 2020-05-12
ER

PT J
AU Li, Y
   Zheng, Y
   Chen, YS
   Lan, Z
   Ma, XH
AF Li, Yun
   Zheng, Yi
   Chen, Yansong
   Lan, Zhong
   Ma, Xuehu
TI The exact regulation of temperature evolutions for droplet impact on
   ultrathin cold films at superhydrophilic surface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet impact; Thin film; Superhydrophilic surface; Thermal tracing
   method; Temperature distribution regulation
ID HEAT-TRANSFER; SOLID-SURFACES; DYNAMICS; WALL; SIMULATIONS; TIME
AB The present study reports a study of water droplets impacting on cold thin water films on a superhydrophilic surface. A thermal infrared imager was used to record the surface temperature distribution after the droplet impact on the liquid films. A ring-shaped high temperature zone was found after impact with the temperature first increasing and then gradually decreasing in the radial direction. Numerical simulations were then used to study the velocity distribution and the droplet motion inside the liquid film. The droplet spreading motion was restricted by liquid in the film for lower We which then reduces the heat transfer in that area and causes the formation of a ring-shaped high temperature distribution. The ring structure shape then changes with the increasing of We. This hot ring becomes wider and the temperature difference between the ring and the impact center decrease with the increasing of We. As We continues to increase, the ring-shaped temperature distribution disappears with the highest temperature at the center and the temperature in radial direction monotonically decreasing from the center to the edge. The initial film thickness also affects the temperature distribution after droplet impact. A thicker film causes the ring-shaped hot region to gradually move inward until it reaches the center and forms a hottest region in the impact center. Thus, the ring-shaped temperature distribution only occurs for lower We and thinner films. The shape and position of the temperature distribution after droplet impact on the cold, thin liquid films can then be precisely controlled by regulating the impact We and the initial film thickness. These results will greatly facilitate the design of precision spraying processes. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Yun; Zheng, Yi; Chen, Yansong; Lan, Zhong; Ma, Xuehu] Dalian Univ Technol, Inst Chem Engn, Liaoning Key Lab Clean Utilizat Chem Resources, State Key Lab Fine Chem, Dalian 116024, Peoples R China.
RP Lan, Z (reprint author), Dalian Univ Technol, Inst Chem Engn, Liaoning Key Lab Clean Utilizat Chem Resources, State Key Lab Fine Chem, Dalian 116024, Peoples R China.
EM lanzhong@dlut.edu.cn
FU National Key R&D Program of China [2017YFD0200304]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51836002, 51476018]
FX The authors are grateful for the financial support by the National Key
   R&D Program of China (No. 2017YFD0200304) and the National Natural
   Science Foundation of China (No. 51836002 and No. 51476018).
CR Agbaglah G, 2014, J FLUID MECH, V752, P485, DOI 10.1017/jfm.2014.240
   Almohammadi H, 2017, SOFT MATTER, V13, P2040, DOI 10.1039/c6sm02514e
   Bird JC, 2013, NATURE, V503, P385, DOI 10.1038/nature12740
   Bisighini A, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.036319
   Castanet G, 2009, INT J HEAT MASS TRAN, V52, P670, DOI 10.1016/j.ijheatmasstransfer.2008.07.024
   Clanet C, 2004, J FLUID MECH, V517, P199, DOI 10.1017/S0022112004000904
   Crooks R, 2001, CHEM ENG SCI, V56, P5575, DOI 10.1016/S0009-2509(01)00175-0
   Fabien G, 2011, LANGMUIR, V27, P6744, DOI 10.1021/la104962m
   Gao X, 2017, INT J HEAT MASS TRAN, V108, P1068, DOI 10.1016/j.ijheatmasstransfer.2016.12.106
   Gunjal PR, 2005, AICHE J, V51, P59, DOI 10.1002/aic.10300
   Hao CL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8986
   Herbert S, 2013, COLLOID SURFACE A, V432, P57, DOI 10.1016/j.colsurfa.2013.05.014
   Jung S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1630
   Lee JB, 2016, LANGMUIR, V32, P1279, DOI 10.1021/acs.langmuir.5b03848
   Li N, 2018, ADV MATER, V30, DOI 10.1002/adma.201703838
   Li Y, 2017, APPL PHYS LETT, V111, DOI 10.1063/1.5005837
   Liang GT, 2016, INT J HEAT MASS TRAN, V101, P577, DOI 10.1016/j.ijheatmasstransfer.2016.05.062
   Liang GT, 2016, INT J HEAT MASS TRAN, V100, P48, DOI 10.1016/j.ijheatmasstransfer.2016.04.061
   Meuler AJ, 2010, ACS NANO, V4, P7048, DOI 10.1021/nn103214q
   OGUZ HN, 1990, J FLUID MECH, V219, P143, DOI 10.1017/S0022112090002890
   Raman KA, 2016, CHEM ENG SCI, V145, P181, DOI 10.1016/j.ces.2016.02.017
   Ray B, 2013, INT J NUMER METHOD H, V23, P143, DOI 10.1108/09615531311289150
   Rioboo R, 2002, EXP FLUIDS, V33, P112, DOI [10.1007/s00348-002-0431-X, 10.1007/s00348-002-0431-x]
   Rioboo R, 2001, ATOMIZATION SPRAY, V11, P155, DOI 10.1615/atomizspr.v11.i2.40
   Schremb M, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.022805
   Silk EA, 2006, INT J HEAT MASS TRAN, V49, P4910, DOI 10.1016/j.ijheatmasstransfer.2006.05.031
   Sussman M, 2000, J COMPUT PHYS, V162, P301, DOI 10.1006/jcph.2000.6537
   Tran T, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.036101
   Vander Wal RL, 2006, EXP FLUIDS, V40, P53, DOI 10.1007/s00348-005-0045-1
   Worthington AM, 1877, P ROY SOC LONDON, V25, P261, DOI [10.1098/rspl.1876.0048, DOI 10.1098/RSPL.1876.0048]
   Xie JL, 2013, APPL THERM ENG, V59, P464, DOI 10.1016/j.applthermaleng.2013.05.047
   Yarin AL, 2006, ANNU REV FLUID MECH, V38, P159, DOI 10.1146/annurev.fluid.38.050304.092144
   YARIN AL, 1995, J FLUID MECH, V283, P141, DOI 10.1017/S0022112095002266
   Zheng Y, 2017, APPL THERM ENG, V111, P1548, DOI 10.1016/j.applthermaleng.2016.07.177
NR 34
TC 1
Z9 1
U1 2
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 205
EP 216
DI 10.1016/j.ces.2018.09.014
PG 12
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800018
DA 2020-05-12
ER

PT J
AU Ghani, NNM
   Jalil, AA
   Triwahyono, S
   Aziz, MAA
   Rahman, AFA
   Hamid, MYS
   Izan, SM
   Nawawi, MGM
AF Ghani, N. N. M.
   Jalil, A. A.
   Triwahyono, S.
   Aziz, M. A. A.
   Rahman, A. F. A.
   Hamid, M. Y. S.
   Izan, S. M.
   Nawawi, M. G. M.
TI Tailored mesoporosity and acidity of shape-selective fibrous silica beta
   zeolite for enhanced toluene co-reaction with methanol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fibrous silica beta; Urea/TEOS ratio; Mesoporosity: acidity;
   Shape-selective toluene methylation
ID SIDE-CHAIN ALKYLATION; N-HEPTANE ISOMERIZATION; PARA-XYLENE SELECTIVITY;
   NANOPARTICLES MSN; CATALYSTS; ZSM-5; HZSM-5; METHYLATION; SEPARATION;
   CONVERSION
AB Fibrous silica beta zeolite (FSB) catalysts, which are excellent catalytic materials for petrochemical processes, were prepared by a microemulsion system assisted by commercial beta zeolite (BEA) seed crystallization under different urea/tetraethyl orthosilicate (urea/TEOS) ratios, denoted as 0.5:1-FSB, 1:1-FSB and 1:0.5-FSB. The physicochemical properties of the catalysts were investigated by XRD, MP-AES, FESEM, TEM, N2 physisorption and FTIR. The characterization results revealed that the dendrimeric silica fibers surrounding the BEA core shell of FSB were improved when the urea/TEOS ratio was altered, particularly for the ratio of 1:1. The highest terminal silanol and silanol nest intensities further confirmed its highest density of dendrimeric fibers. The catalytic testing of toluene methylation at 673 K resulted in the following order of p-, o- and m-xylene production ratio: 1:1-FSB (6/2/0) > 0.5:1-FSB (6/4/4) > 1:0.5-FSB (2/1/1). The catalyst with denser dendrimeric fibers led to lower acidity and pore volumes, which assist in selectively producing p-xylene and limiting the formation of side products. The FSB with denser dendrimeric fibers was also found to have a slower internal mass transfer rate, which is directly proportional to the activation energy. Optimization by the response surface methodology showed that the reactant molar ratio and reaction temperature were significant factors in the toluene methylation. The remarkable performance of these catalysts in the toluene co-reaction with methanol highlights their potential as future catalysts in the industrial application of toluene methylation and other chemical processes. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ghani, N. N. M.; Jalil, A. A.; Aziz, M. A. A.; Rahman, A. F. A.; Hamid, M. Y. S.; Nawawi, M. G. M.] Univ Teknol Malaysia, Fac Chem & Energy Engn, Dept Chem Engn, Utm Johor Bahru 81310, Johor, Malaysia.
   [Jalil, A. A.] Inst Future Energy, Ctr Hydrogen Energy, Utm Johor Bahru 81310, Johor, Malaysia.
   [Triwahyono, S.; Izan, S. M.] Univ Teknol Malaysia, Fac Sci, Dept Chem, Utm Johor Bahru 81310, Johor, Malaysia.
RP Jalil, AA (reprint author), Univ Teknol Malaysia, Fac Chem & Energy Engn, Dept Chem Engn, Utm Johor Bahru 81310, Johor, Malaysia.
EM aishahaj@utm.my
RI ABDUL RAHMAN, ANIS FARHANA/F-7192-2019; Yusuf, Muhd/F-7181-2019
OI ABDUL RAHMAN, ANIS FARHANA/0000-0002-5514-3864; Yusuf,
   Muhd/0000-0003-4770-1392; Ab Aziz, Muhammad Arif/0000-0002-7969-7132
FU Fundamental Research Grant Scheme from the Ministry of Higher Education,
   Malaysia [02K22, 12H70]; Universiti Teknologi Malaysia
FX The authors are grateful for the financial support by the Fundamental
   Research Grant Scheme (Grant Nos. 02K22 and 12H70) from the Ministry of
   Higher Education, Malaysia and Universiti Teknologi Malaysia for their
   support.
CR Aboul-Gheit AK, 2011, J TAIWAN INST CHEM E, V42, P860, DOI 10.1016/j.jtice.2011.03.004
   Aboul-Gheit AK, 2010, CHINESE J CATAL, V31, P1209, DOI 10.1016/S1872-2067(10)60113-1
   Ahn JH, 2015, MICROPOR MESOPOR MAT, V210, P52, DOI 10.1016/j.micromeso.2015.02.018
   Ahn JH, 2014, J CATAL, V311, P271, DOI 10.1016/j.jcat.2013.12.003
   Ahn JH, 2013, ACS CATAL, V3, P817, DOI 10.1021/cs4000766
   Alabi W, 2012, CHEM ENG J, V195, P276, DOI 10.1016/j.cej.2012.04.100
   Alabi WO, 2014, CATAL TODAY, V226, P117, DOI 10.1016/j.cattod.2013.08.004
   Armaroli T, 2001, APPL CATAL A-GEN, V220, P181, DOI 10.1016/S0926-860X(01)00720-7
   Aziz MAA, 2014, APPL CATAL A-GEN, V486, P115, DOI 10.1016/j.apcata.2014.08.022
   Bakhtiary-Davijany H., 2018, CHEM ENG SCI, V66, P6350
   Bezerra MA, 2008, TALANTA, V76, P965, DOI 10.1016/j.talanta.2008.05.019
   Bi Y, 2014, CHEMCATCHEM, V6, P713, DOI 10.1002/cctc.201301072
   Cejka J, 2002, CATAL REV, V44, P375, DOI 10.1081/CR-120005741
   Dai CN, 2013, CHEM ENG SCI, V100, P342, DOI 10.1016/j.ces.2013.02.066
   Fatah NAA, 2017, CHEM ENG J, V314, P650, DOI 10.1016/j.cej.2016.12.028
   Fatah NAA, 2016, APPL CATAL A-GEN, V516, P135, DOI 10.1016/j.apcata.2016.02.026
   Fathi S, 2014, FUEL, V116, P529, DOI 10.1016/j.fuel.2013.08.036
   Febriyanti E, 2016, LANGMUIR, V32, P5802, DOI 10.1021/acs.langmuir.6b00675
   Firmansyah ML, 2016, CATAL SCI TECHNOL, V6, P5178, DOI 10.1039/c6cy00106h
   Gai SL, 2012, DALTON T, V41, P4511, DOI 10.1039/c2dt11552b
   Gamonchuang J, 2016, COLLOID SURFACE A, V511, P39, DOI 10.1016/j.colsurfa.2016.09.080
   GORDYMOVA TA, 1982, REACT KINET CATAL L, V20, P113, DOI 10.1007/BF02063594
   Guo YP, 2011, CHEM ENG J, V166, P391, DOI 10.1016/j.cej.2010.10.057
   Hasan MMF, 2017, CHEM ENG SCI, V159, P3, DOI 10.1016/j.ces.2016.10.039
   Hattori H, 2016, J MOL CATAL A-CHEM, V424, P98, DOI 10.1016/j.molcata.2016.08.015
   Hattori H, 2013, CATAL LETT, V143, P1025, DOI 10.1007/s10562-013-1049-8
   HEGDE SG, 1989, ZEOLITES, V9, P231, DOI 10.1016/0144-2449(89)90031-6
   Hodala JL, 2015, CHEM ENG SCI, V138, P396, DOI 10.1016/j.ces.2015.08.007
   Huang G, 2017, MICROPOR MESOPOR MAT, V248, P30, DOI 10.1016/j.micromeso.2017.03.060
   Ilias S, 2013, ACS CATAL, V3, P18, DOI 10.1021/cs3006583
   Janardhan HL, 2014, APPL CATAL A-GEN, V471, P12, DOI 10.1016/j.apcata.2013.11.029
   Jin YJ, 2015, MICROPOR MESOPOR MAT, V218, P180, DOI 10.1016/j.micromeso.2015.07.021
   Jusoh NWC, 2015, APPL SURF SCI, V330, P10, DOI 10.1016/j.apsusc.2014.12.192
   Kamarudin NHN, 2012, APPL CATAL A-GEN, V431, P104, DOI 10.1016/j.apcata.2012.04.020
   Li JH, 2014, CATAL SCI TECHNOL, V4, P2639, DOI 10.1039/c4cy00095a
   Lu P, 2013, APPL CATAL A-GEN, V453, P302, DOI 10.1016/j.apcata.2012.12.042
   Min HK, 2012, ACS CATAL, V2, P971, DOI 10.1021/cs300127w
   Miyake K, 2016, J CATAL, V342, P63, DOI 10.1016/j.jcat.2016.07.008
   Mohameed HA, 2007, CHEM ENG PROCESS, V46, P25, DOI 10.1016/j.cep.2006.04.002
   Muller S, 2015, J CATAL, V325, P48, DOI 10.1016/j.jcat.2015.02.013
   Odedairo T, 2011, IND ENG CHEM RES, V50, P3169, DOI 10.1021/ie1018904
   Ozbay N, 2015, J CLEAN PROD, V100, P333, DOI 10.1016/j.jclepro.2015.03.050
   Palomino GT, 2004, MATER CHEM PHYS, V85, P145, DOI 10.1016/j.mathcemphys.2003.12.020
   Polshettiwar V, 2010, ANGEW CHEM INT EDIT, V49, P9652, DOI 10.1002/anie.201003451
   Rahman AFA, 2017, J CLEAN PROD, V143, P948, DOI 10.1016/j.jclepro.2016.12.026
   Seidel C, 2018, CHEM ENG SCI, V175, P130, DOI 10.1016/j.ces.2017.09.043
   Setiabudi HD, 2012, J CATAL, V294, P128, DOI 10.1016/j.jcat.2012.07.012
   Sidik SM, 2016, J CO2 UTIL, V13, P71, DOI 10.1016/j.jcou.2015.12.004
   Simonetti DA, 2011, J CATAL, V277, P173, DOI 10.1016/j.jcat.2010.11.004
   Song LL, 2014, J BRAZIL CHEM SOC, V25, P1346, DOI 10.5935/0103-5053.20140116
   Teh LP, 2016, APPL CATAL A-GEN, V523, P200, DOI 10.1016/j.apcata.2016.05.031
   Tope BB, 2012, APPL CATAL A-GEN, V443, P214, DOI 10.1016/j.apcata.2012.08.003
   Tukur NM, 2011, CHEM ENG J, V166, P348, DOI 10.1016/j.cej.2010.11.004
   Upare PP, 2015, APPL CATAL A-GEN, V491, P127, DOI 10.1016/j.apcata.2014.12.007
   Wang CF, 2017, MOL CATAL, V433, P242, DOI 10.1016/j.mcat.2016.12.007
   WEI J, 1982, J CATAL, V76, P433, DOI 10.1016/0021-9517(82)90272-X
   Wichterlova B, 1996, MICROPOROUS MATER, V6, P405, DOI 10.1016/0927-6513(96)00042-9
   Wu W., 2018, CHEM ENG SCI, V66, P4722
   YOUNG LB, 1982, J CATAL, V76, P418, DOI 10.1016/0021-9517(82)90271-8
   Zhang JY, 2017, CHEM ENG J, V327, P278, DOI 10.1016/j.cej.2017.06.114
   Zhang JG, 2015, ACS CATAL, V5, P2982, DOI 10.1021/acscatal.5b00192
   Zhu ZR, 2006, MICROPOR MESOPOR MAT, V88, P16, DOI 10.1016/j.micromeso.2005.08.021
   Zhu ZR, 2004, CATAL TODAY, V93-5, P321, DOI 10.1016/j.cattod.2004.06.008
NR 63
TC 6
Z9 6
U1 13
U2 114
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 217
EP 229
DI 10.1016/j.ces.2018.09.009
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800019
DA 2020-05-12
ER

PT J
AU Namsaeng, J
   Punyodom, W
   Worajittiphon, P
AF Namsaeng, Janthana
   Punyodom, Winita
   Worajittiphon, Patnarin
TI Synergistic effect of welding electrospun fibers and MWCNT reinforcement
   on strength enhancement of PAN-PVC non-woven mats for water filtration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Nanofibers; Electrospinning; Mechanical properties; Carbon nanotubes;
   Filtration
ID MEMBRANES; PERFORMANCE; ULTRAFILTRATION; FABRICATION; NANOFIBERS;
   BEHAVIOR
AB Typical electrospun polymer mats exhibit poor mechanical properties, undesirable for pressure-driven water filtration. Herein, strength enhancement of polyacrylonitrile-poly(vinyl chloride) (PAN-PVC) electrospun mats is demonstrated with a synergistic approach, using solvent vapor-induced welding of the polymer fibers at their cross points and reinforcement of the fibers by unfunctionalized multiwalled carbon nanotubes (MWCNTs). Tensile strength and Young's modulus of the as-spun PAN-PVC mats are increased by 127% and 175% respectively via welding effects, and are further enhanced to 205% and 314% increments respectively, using 1 wt% MWCNTs. The post-treated composite mats achieve over four-fold the modulus predicted by the modified Halpin-Tsai model. With a slight total reduction in pure water flux (8%), water permeability is not greatly suppressed by welding the polymer fibers or by the presence of MWCNTs in the fibers. The two strength-enhancing strategies also allow recyclability of the post-treated composite mats with high particulate (25 nm-5 mu m) filtration efficiency of nearly 100% and good antifouling performance (flux recovery of >93%) throughout the 10 tested filtration cycles. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Namsaeng, Janthana; Punyodom, Winita; Worajittiphon, Patnarin] Chiang Mai Univ, Fac Sci, Dept Chem, Chiang Mai 50200, Thailand.
   [Namsaeng, Janthana] Chiang Mai Univ, Grad Sch, Chiang Mai 50200, Thailand.
   [Namsaeng, Janthana; Punyodom, Winita; Worajittiphon, Patnarin] Chiang Mai Univ, Fac Sci, Ctr Excellence Innovat Chem, Chiang Mai 50200, Thailand.
   [Punyodom, Winita; Worajittiphon, Patnarin] Chiang Mai Univ, Ctr Excellence Mat Sci & Technol, Chiang Mai 50200, Thailand.
RP Worajittiphon, P (reprint author), Chiang Mai Univ, Fac Sci, Dept Chem, Chiang Mai 50200, Thailand.
EM pworajittiphon@gmail.com
RI cai, yuanyuan/C-6301-2014; Worajittiphon, Patnarin/P-8850-2019
OI Worajittiphon, Patnarin/0000-0002-7498-8416
FU Chiang Mai University, Thailand; Center of Excellence for Innovation in
   Chemistry, Thailand (PERCH-CIC); Office of the Higher Education
   Commission, Ministry of Education, Thailand (OHEC); Center of Excellence
   in Materials Science and Technology, Chiang Mai University under the
   administration of the Materials Science Research Center, Faculty of
   Science, Chiang Mai University
FX This research project is supported by Chiang Mai University, Thailand.
   The authors wish to thank the Center of Excellence for Innovation in
   Chemistry, Thailand (PERCH-CIC), Office of the Higher Education
   Commission, Ministry of Education, Thailand (OHEC) for funding Janthana
   Namsaeng's study and research activities. We also wish to thank the
   Center of Excellence in Materials Science and Technology, Chiang Mai
   University, for the financial support under the administration of the
   Materials Science Research Center, Faculty of Science, Chiang Mai
   University. We are additionally grateful to the Graduate School, Chiang
   Mai University; and the Department of Chemistry, Faculty of Science,
   Chiang Mai University.
CR Abdelrasoul A., 2013, ADV SUSTAINABLE ENER, DOI [10.5772/52370, DOI 10.5772/52370]
   Amirilargani M, 2012, POLYM ADVAN TECHNOL, V23, P398, DOI 10.1002/pat.1888
   Arkhangelsky E, 2007, TRIBOL LETT, V28, P109, DOI 10.1007/s11249-007-9253-6
   Aussawasathien D, 2008, J MEMBRANE SCI, V315, P11, DOI 10.1016/j.memsci.2008.01.049
   Baji A, 2010, COMPOS SCI TECHNOL, V70, P1401, DOI 10.1016/j.compscitech.2010.04.020
   Bridge MJ, 2002, J MEMBRANE SCI, V195, P51, DOI 10.1016/S0376-7388(01)00523-3
   Chahal S, 2016, CHEM ENG SCI, V144, P17, DOI 10.1016/j.ces.2015.12.030
   Chailek N, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.46318
   Chou TW, 2010, COMPOS SCI TECHNOL, V70, P1, DOI 10.1016/j.compscitech.2009.10.004
   Demczyk BG, 2002, MAT SCI ENG A-STRUCT, V334, P173, DOI 10.1016/S0921-5093(01)01807-X
   Faccini M, 2015, J NANOMATER, DOI 10.1155/2015/247471
   Faibish RS, 2001, COLLOID SURFACE A, V191, P27, DOI 10.1016/S0927-7757(01)00761-0
   Gopal R, 2007, J MEMBRANE SCI, V289, P210, DOI 10.1016/j.memsci.2006.11.056
   Gopal R, 2006, J MEMBRANE SCI, V281, P581, DOI 10.1016/j.memsci.2006.04.026
   Gu JC, 2017, ACS APPL MATER INTER, V9, P5968, DOI 10.1021/acsami.6b13547
   Han L, 2013, SENSOR ACTUAT B-CHEM, V186, P52, DOI 10.1016/j.snb.2013.05.069
   Hong S, 2011, CARBOHYD POLYM, V83, P940, DOI 10.1016/j.carbpol.2010.09.002
   Huang BQ, 2017, RSC ADV, V7, P56629, DOI 10.1039/c7ra11632b
   Huang LW, 2013, J MEMBRANE SCI, V436, P213, DOI 10.1016/j.memsci.2012.12.037
   Jeong JS, 2007, THIN SOLID FILMS, V515, P5136, DOI 10.1016/j.tsf.2006.10.058
   Kang M, 2009, CURR APPL PHYS, V9, pS95, DOI 10.1016/j.cap.2008.08.014
   Li HX, 2017, MACROMOL RAPID COMM, V38, DOI 10.1002/marc.201600723
   Li L, 2013, J MEMBRANE SCI, V436, P57, DOI 10.1016/j.memsci.2013.02.037
   Li TT, 2013, FIBER POLYM, V14, P258, DOI 10.1007/s12221-013-0258-5
   Liu CL, 2016, J MEMBRANE SCI, V512, P1, DOI 10.1016/j.memsci.2016.03.062
   Lu P, 2010, ACS APPL MATER INTER, V2, P2413, DOI 10.1021/am1004128
   Mahalingam S, 2015, CHEM ENG J, V280, P344, DOI 10.1016/j.cej.2015.05.114
   Mei S, 2011, DESALINATION, V280, P378, DOI 10.1016/j.desal.2011.07.026
   Nicosia A, 2016, CHEM ENG SCI, V153, P284, DOI 10.1016/j.ces.2016.07.017
   Peng SS, 2017, RSC ADV, V7, P1852, DOI 10.1039/c6ra24801b
   Rahimpour A, 2007, J MEMBRANE SCI, V305, P299, DOI 10.1016/j.memsci.2007.08.030
   Rajendran S, 2008, J MEMBRANE SCI, V315, P67, DOI 10.1016/j.memsci.2008.02.007
   Rajendran S, 2007, J POWER SOURCES, V170, P460, DOI 10.1016/j.jpowsour.2007.04.041
   Rajzer I, 2017, MAT SCI ENG C-MATER, V77, P493, DOI 10.1016/j.msec.2017.03.306
   Ramesh S, 2011, SOLID STATE IONICS, V192, P2, DOI 10.1016/j.ssi.2010.05.045
   Saligheh O, 2013, J POLYM RES, V20, DOI 10.1007/s10965-012-0065-5
   Saligheh O, 2011, J MACROMOL SCI B, V50, P1031, DOI 10.1080/00222348.2010.497417
   Vaisman L, 2007, POLYMER, V48, P6843, DOI 10.1016/j.polymer.2007.09.032
   Wang X, 2017, LANGMUIR, V33, P12592, DOI 10.1021/acs.langmuir.7b02990
   Wang XF, 2008, MACROMOL RAPID COMM, V29, P826, DOI 10.1002/marc.200700873
   Yousefzadeh, 2010, TRANSACTION F, V17, P60
   Zha JW, 2014, J APPL PHYS, V116, DOI 10.1063/1.4897230
   Zhong Z, 2012, IONICS, V18, P853, DOI 10.1007/s11581-012-0682-3
NR 43
TC 10
Z9 10
U1 7
U2 99
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 230
EP 242
DI 10.1016/j.ces.2018.09.019
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800020
DA 2020-05-12
ER

PT J
AU Patel, HV
   Kuipers, JAM
   Peters, EAJF
AF Patel, H., V
   Kuipers, J. A. M.
   Peters, E. A. J. F.
TI Effect of flow and fluid properties on the mobility of multiphase flows
   through porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Water flooding; Porous media; Immersed boundary method (IBM); Volume of
   fluid (VOF); Contact angle; Viscous finger
ID LATTICE BOLTZMANN; NUMERICAL-SIMULATION; 2-PHASE FLOW; FREE-SURFACE;
   VOLUME; DYNAMICS; SOIL; DISPLACEMENT; COMPUTATIONS; CHANNEL
AB In this paper we quantify the effect of capillary number (Ca), contact angle (theta) and viscosity ratio (M) on the mobility of multiphase flow through porous media. The focus is mainly on oil-water flows through porous rocks observed during the water flooding process. Simulations are performed using a finite volume method employing a staggered grid formulation. Interactions between fluids and complex solid boundaries are resolved by a direct forcing, implicit and sharp interface immersed boundary method (IBM). The fluid-fluid interface is tracked by a mass conservative sharp interface volume of fluid (VOF) method. IBM and VOF are coupled by imposing the contact angle as a boundary condition at the three phase contact line. Our methodology has been verified/validated for several test cases including multiphase Poiseuille flow in a channel, a viscous finger in a channel and mesh convergence of the contact force. Two types of porous structures are considered: (i) a repeated single pore and (ii) a random multi-pore arrangement. Temporal evolution of phase pressure difference and oil saturation have been studied as viscous fingers penetrate the pores. We observed that the residual oil saturation for different capillary numbers shows exactly the opposite trend for the single and multi pore arrangement. The residual oil saturation for multi-pore shows a well defined linear trend with log Ca, theta and log M. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Patel, H., V; Kuipers, J. A. M.; Peters, E. A. J. F.] Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
RP Peters, EAJF (reprint author), Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
EM E.A.J.F.Peters@tue.nl
RI Peters, Frank/V-1293-2018
OI Peters, Frank/0000-0001-6099-3583
FU Shell Global Solutions International B.V.; SURF Cooperative
FX This work is part of the Industrial Partnership Program (IPP)
   'Computational sciences for energy research' of the Netherlands
   Organization for Scientific Research (NWO) and co-financed by Shell
   Global Solutions International B.V. This work was carried out on the
   Dutch national e-infrastructure with the support of SURF Cooperative.
CR Alvarado V, 2010, ENERGIES, V3, P1529, DOI 10.3390/en3091529
   Annaland MV, 2005, CHEM ENG SCI, V60, P2999, DOI 10.1016/j.ces.2005.01.031
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   Das S., 2016, AICHE J
   De S, 2017, J NON-NEWTON FLUID, V248, P50, DOI 10.1016/j.jnnfm.2017.08.010
   Ferrari A, 2013, ADV WATER RESOUR, V57, P19, DOI 10.1016/j.advwatres.2013.03.005
   Frenkel D., 2001, UNDERSTANDING MOL SI, V1
   Gerritsen MG, 2005, ANNU REV FLUID MECH, V37, P211, DOI 10.1146/annurev.fluid.37.061903.175748
   HALPERN D, 1994, J COMPUT PHYS, V115, P366, DOI 10.1006/jcph.1994.1202
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   HOSTMADSEN J, 1992, J HYDROL, V135, P13, DOI 10.1016/0022-1694(92)90079-B
   Huang HB, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3225144
   Huang HB, 2009, INT J NUMER METH FL, V61, P341, DOI 10.1002/fld.1972
   Jerauld G R, 2006, SPE ANN TECHN C EXH
   Kang QJ, 2004, ADV WATER RESOUR, V27, P13, DOI 10.1016/j.advwatres.2003.10.002
   Keshtkar Sadegh, 2016, Petroleum, V2, P98, DOI 10.1016/j.petlm.2015.11.002
   Kumpiene J, 2008, WASTE MANAGE, V28, P215, DOI 10.1016/j.wasman.2006.12.012
   LENORMAND R, 1988, J FLUID MECH, V189, P165, DOI 10.1017/S0022112088000953
   Li HN, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.026705
   Lv MM, 2015, RSC ADV, V5, P85373, DOI 10.1039/c5ra12136a
   Mittal R, 2005, ANNU REV FLUID MECH, V37, P239, DOI 10.1146/annurev.fluid.37.061903.175743
   Mulligan CN, 2001, ENG GEOL, V60, P371, DOI 10.1016/S0013-7952(00)00117-4
   Patel HV, 2017, CHEM ENG SCI, V166, P28, DOI 10.1016/j.ces.2017.03.012
   PRATS M, 1982, SPE MONOGRAPH SERIES
   Prosperetti A, 2002, CISM COUR L, P237
   Pyle D.L., 1972, FLUIDIZED BED REACTO
   Renardy M, 2001, J COMPUT PHYS, V171, P243, DOI 10.1006/jcph.2001.6785
   Saha AA, 2009, J COLLOID INTERF SCI, V339, P461, DOI 10.1016/j.jcis.2009.07.071
   Scardovelli R, 1999, ANNU REV FLUID MECH, V31, P567, DOI 10.1146/annurev.fluid.31.1.567
   Shah D. O., 2012, IMPROVED OIL RECOVER
   Sheng JJ, 2014, J PETROL SCI ENG, V120, P216, DOI 10.1016/j.petrol.2014.05.026
   Singer-Loginova I, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/10/106501
   Snoeijer JH, 2013, ANNU REV FLUID MECH, V45, P269, DOI 10.1146/annurev-fluid-011212-140734
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Sui Y, 2014, ANNU REV FLUID MECH, V46, P97, DOI 10.1146/annurev-fluid-010313-141338
   SUSSMAN M, 1994, J COMPUT PHYS, V114, P146, DOI 10.1006/jcph.1994.1155
   Tryggvason G, 2001, J COMPUT PHYS, V169, P708, DOI 10.1006/jcph.2000.6726
   Washino K, 2013, CHEM ENG SCI, V93, P197, DOI 10.1016/j.ces.2013.02.006
   Yang JH, 2013, COMPUT MATH APPL, V65, P882, DOI 10.1016/j.camwa.2012.11.022
   Yiotis AG, 2007, COLLOID SURFACE A, V300, P35, DOI 10.1016/j.colsurfa.2006.12.045
   Youngs D. L., 1982, NUMERICAL METHODS FL
   Zhang CY, 2011, ENERG FUEL, V25, P3493, DOI 10.1021/ef101732k
   Zhu Z., 2011, EFFICIENT SIMULATION
NR 44
TC 2
Z9 2
U1 2
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 243
EP 254
DI 10.1016/j.ces.2018.08.050
PG 12
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800021
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Gao, JD
   Sun, W
   Hu, YH
   Wang, L
   Liu, RQ
   Gao, ZY
   Chen, P
   Tang, HH
   Jiang, W
   Lyu, F
AF Gao, Jiande
   Sun, Wei
   Hu, Yuehua
   Wang, Li
   Liu, Runqing
   Gao, Zhiyong
   Chen, Pan
   Tang, Honghu
   Jiang, Wei
   Lyu, Fei
TI Propyl gallate: A novel collector for flotation separation of fluorite
   from calcite
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluorite; Calcite; Propyl gallate; Separation; Flotation
ID GALLIC ACID; SELECTIVE FLOTATION; FOOD-ADDITIVES; TANNIC-ACID; REAGENT
   SCHEME; METAL-IONS; SURFACES; WATER; ADSORPTION; SCHEELITE
AB In real flotation systems, the flotation separation of fluorite from calcite is a challenge due to the similar surface properties of these two minerals. The purpose of this paper is to develop a highly selective flotation collector for the separation. Propyl gallate (PG) was introduced as a collector for selective flotation separation of fluorite from calcite. The separation of fluorite from calcite without using any depressant can be achieved by using PG as the collector. The flotation mechanism of fluorite and calcite was studied by zeta potential measurements, adsorption, FT-IR and XPS analysis. The results indicated that phenolic hydroxyls were the functional groups of PG which can selectively adsorb on fluorite, and the adsorption amount of PG on the surface of fluorite was larger than on calcite. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gao, Jiande; Sun, Wei; Hu, Yuehua; Wang, Li; Liu, Runqing; Gao, Zhiyong; Chen, Pan; Tang, Honghu; Jiang, Wei; Lyu, Fei] Cent S Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Hunan, Peoples R China.
RP Sun, W; Hu, YH (reprint author), Cent S Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Hunan, Peoples R China.
EM sunmenghu@csu.edu.cn; hyh@csu.edu.cn
RI Lyu, Fei/Y-2467-2018
OI Lyu, Fei/0000-0002-9197-9546
FU Innovation Driven Plan of Central South University [2016zzts109,
   2015CX005]; National 111 Project [B14034]; Sublimation Scholar's
   Distinguished Professor of Central South University
FX The authors acknowledge funding from the Innovation Driven Plan of
   Central South University (No. 2016zzts109), the National 111 Project
   (No. B14034), the Sublimation Scholar's Distinguished Professor of
   Central South University and the Innovation Driven Plan of Central South
   University (No. 2015CX005).
CR Ai GH, 2017, SEP PURIF TECHNOL, V176, P59, DOI 10.1016/j.seppur.2016.11.064
   ARUOMA OI, 1990, FREE RADICAL RES COM, V10, P143, DOI 10.3109/10715769009149883
   AYHAN F. D., 2013, MIN PROC EXT MET REV, V115, P113
   Bouaziz A, 2010, J MOL CATAL B-ENZYM, V67, P242, DOI 10.1016/j.molcatb.2010.08.013
   Chen JH, 2011, INT J MINER PROCESS, V100, P54, DOI 10.1016/j.minpro.2011.04.010
   CHUNG KT, 1993, LETT APPL MICROBIOL, V17, P29, DOI 10.1111/j.1472-765X.1993.tb01428.x
   de Leeuw NH, 2000, SURF SCI, V452, P9, DOI 10.1016/S0039-6028(00)00288-0
   Deng LQ, 2016, J IND ENG CHEM, V33, P131, DOI 10.1016/j.jiec.2015.09.027
   Ding K., 2013, CANADIAN METALLURGIC, V45, P199
   Dolatabadi JEN, 2010, FOOD RES INT, V43, P1223, DOI 10.1016/j.foodres.2010.03.026
   Feng B, 2015, MINER ENG, V80, P45, DOI 10.1016/j.mineng.2015.06.017
   Filippova IV, 2014, MINER ENG, V66-68, P135, DOI 10.1016/j.mineng.2014.05.009
   Gao YS, 2018, J COLLOID INTERF SCI, V512, P39, DOI 10.1016/j.jcis.2017.10.045
   Gao YS, 2016, INT J MINER PROCESS, V154, P10, DOI 10.1016/j.minpro.2016.06.010
   Gao ZY, 2012, T NONFERR METAL SOC, V22, P1203, DOI 10.1016/S1003-6326(11)61306-X
   Guan XY, 2017, J ENVIRON CHEM ENG, V5, P479, DOI 10.1016/j.jece.2016.12.010
   Guler T, 2017, PHYSICOCHEM PROBL MI, V53, P5, DOI 10.5277/ppmp170101
   Hu YH, 2003, INT J MINER PROCESS, V72, P87, DOI 10.1016/S0301-7516(03)00089-9
   Hu YH, 2003, IND ENG CHEM RES, V42, P1641, DOI 10.1021/ie020729b
   JANG WH, 1995, LANGMUIR, V11, P3491, DOI 10.1021/la00009a035
   Kim DY, 2017, J COLLOID INTERF SCI, V494, P1, DOI 10.1016/j.jcis.2017.01.050
   Laajalehto K, 1997, INT J MINER PROCESS, V51, P163, DOI 10.1016/S0301-7516(97)00029-X
   Leeuw N. H. D., 2016, LANGMUIR, V14, P5900
   Li CW, 2017, POWDER TECHNOL, V322, P386, DOI 10.1016/j.powtec.2017.08.066
   LOPEZ GP, 1991, SURF INTERFACE ANAL, V17, P267, DOI 10.1002/sia.740170508
   Lu LL, 2009, SPECTROCHIM ACTA A, V74, P829, DOI 10.1016/j.saa.2009.08.025
   Martinez-Tome M, 2001, J FOOD PROTECT, V64, P1412, DOI 10.4315/0362-028X-64.9.1412
   Mohammadkhani M, 2011, INT J MINER PROCESS, V100, P157, DOI 10.1016/j.minpro.2011.06.001
   Nagaraj DR, 2016, MINER ENG, V96-97, P2, DOI 10.1016/j.mineng.2016.06.019
   Ni X, 2012, MINER ENG, V36-38, P111, DOI 10.1016/j.mineng.2012.03.003
   Ni X, 2012, COLLOID SURFACE A, V411, P80, DOI 10.1016/j.colsurfa.2012.07.005
   Nie GJ, 2014, PROCESS BIOCHEM, V49, P277, DOI 10.1016/j.procbio.2013.11.009
   Nie GJ, 2012, J MOL CATAL B-ENZYM, V82, P102, DOI 10.1016/j.molcatb.2012.06.003
   Pokrovsky OS, 2002, ENVIRON SCI TECHNOL, V36, P426, DOI 10.1021/es010925u
   Pokrovsky OS, 2000, LANGMUIR, V16, P2677, DOI 10.1021/la980905e
   Pradip, 2003, INT J MINER PROCESS, V72, P95, DOI 10.1016/S0301-7516(03)00090-5
   Rahaman A, 2008, J PHYS CHEM C, V112, P2109, DOI 10.1021/jp077594d
   Schaufuss AG, 1998, SURF SCI, V411, P321, DOI 10.1016/S0039-6028(98)00355-0
   Sharma RK, 2009, J HAZARD MATER, V163, P295, DOI 10.1016/j.jhazmat.2008.06.120
   Song S, 2006, MINER ENG, V19, P912, DOI 10.1016/j.mineng.2005.10.005
   SRIVASTAVA S, 1985, POLYHEDRON, V4, P409, DOI 10.1016/S0277-5387(00)87000-X
   Xie FZ, 2008, TALANTA, V74, P836, DOI 10.1016/j.talanta.2007.07.018
   Yang TS, 2017, FOOD CHEM, V228, P541, DOI 10.1016/j.foodchem.2017.02.035
   Zhang C, 2012, CHEM ENG J, V209, P464, DOI 10.1016/j.cej.2012.08.056
   Zhang Y, 2003, MINER ENG, V16, P597, DOI 10.1016/S0892-6875(03)00136-5
   Zhou WB, 2013, MINER ENG, V45, P142, DOI 10.1016/j.mineng.2013.02.017
NR 46
TC 8
Z9 8
U1 4
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 255
EP 263
DI 10.1016/j.ces.2018.09.017
PG 9
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800022
DA 2020-05-12
ER

PT J
AU Chen, SY
   Zhang, T
   Lv, L
   Chen, YX
   Yang, YC
   Tang, SW
AF Chen, Siyuan
   Zhang, Tao
   Lv, Li
   Chen, Yanxiao
   Yang, Yongchang
   Tang, Shengwei
TI Intensification of the liquid side mass transfer in double-side falling
   film microchannels by micro-mixing structures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Falling film; Microchannel; Micro-mixing structure; Mass transfer
ID DIOXIDE CO2 ABSORPTION; ELEMENTAL FLUORINE; CFD SIMULATION; FLOW;
   MICROREACTOR; REACTOR; HYDRODYNAMICS
AB The interphase mass transfer in a falling film microchannel relies on the liquid-phase mass transfer behavior. Flow in a liquid film is predominantly laminar, and the liquid mass transfer is usually controlled by molecular diffusion. Micro-mixing structures were designed and configured in a double-side falling film microchannel, and the liquid side mass transfer was enhanced by fluid mixing and surface renewal. Computational fluid dynamics approach was used to simulate the falling film flow and mass transfer behavior with and without micro-mixing structures. The impact of the micro-mixing structures on the liquid side mass transfer coefficient was systematically investigated via CO2 absorption experiments in water. The results showed that the fluid flow and mixing was improved by staggered flow mode with micro-mixing structures in the falling film microchannels. Three flow patterns are observed inside the liquid film, including direct flow, cross flow, and vortex flow when the falling liquid film crosses the micro-mixing structures. Both cross flow and vortex flow intensify the surface renewal and turbulence of the liquid film, which is the fundamental reason for the enhancement of the liquid side mass transfer. The experimental results reveal that liquid side mass transfer coefficient in double falling film microchannels with micro-mixing structures is between 3.59 x 10(5) m/s and 5.38 x 10(5) m/s, while it is between 3.35 x 10(5) m/s and 4.82 x 10(5) m/s without micro-mixing structures. The liquid side mass transfer coefficient is increased 7-14% by the configuration of micro-mixing structures. Therefore, a double-side falling film microcontactor with micro-mixing structures not only reduces the contactor size, but also effectively enhances the interphase mass transfer behavior. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Siyuan; Zhang, Tao; Lv, Li; Chen, Yanxiao; Yang, Yongchang; Tang, Shengwei] Sichuan Univ, Sch Chem Engn, Multiphase Mass Transfer & React Engn Lab, Chengdu 610065, Sichuan, Peoples R China.
RP Tang, SW (reprint author), Sichuan Univ, Sch Chem Engn, Multiphase Mass Transfer & React Engn Lab, Chengdu 610065, Sichuan, Peoples R China.
EM sychen@stu.scu.edu.cn; zhangtao@scu.edu.cn; lily@scu.edu.cn;
   yxchen@scu.edu.cn; yc.yang@stu.scu.edu.cn; tangdynasty@scu.edu.cn
OI Chen, Siyuan/0000-0002-4530-9576; Yang, Yongchang/0000-0002-7045-6885
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21576168]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 21576168).
CR Al-Rawashdeh M, 2012, CHEM ENG J, V179, P318, DOI 10.1016/j.cej.2011.11.014
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Cantu-Perez A, 2013, CHEM ENG J, V227, P34, DOI 10.1016/j.cej.2012.11.122
   Chambers RD, 2005, LAB CHIP, V5, P191, DOI 10.1039/b416400h
   Chasanis P, 2010, CHEM ENG SCI, V65, P1125, DOI 10.1016/j.ces.2009.09.067
   Gu F, 2004, CHEM ENG TECHNOL, V27, P1099, DOI 10.1002/ceat.200402018
   Hameed MS, 2003, INT J HEAT MASS TRAN, V46, P1715, DOI 10.1016/S0017-9310(02)00500-8
   Hessel V., 2005, INT S CAT MULT REACT
   Hewitt G. F., 1978, CORRELATION LIQUID E
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Ho CD, 2011, INT J HEAT MASS TRAN, V54, P3740, DOI 10.1016/j.ijheatmasstransfer.2011.03.015
   Hu JG, 2017, CHEM ENG PROCESS, V111, P46, DOI 10.1016/j.cep.2016.11.002
   Hu JG, 2014, CHEM ENG SCI, V116, P243, DOI 10.1016/j.ces.2014.05.002
   Ishikawa H, 2016, CHEM ENG SCI, V149, P104, DOI 10.1016/j.ces.2016.04.021
   Jahnisch K, 2000, J FLUORINE CHEM, V105, P117, DOI 10.1016/S0022-1139(00)00300-6
   Li QS, 2016, CHEM ENG SCI, V143, P23, DOI 10.1016/j.ces.2015.12.014
   Lokhat D, 2016, CHEM ENG SCI, V155, P38, DOI 10.1016/j.ces.2016.08.002
   Mengeaud V, 2002, ANAL CHEM, V74, P4279, DOI 10.1021/ac025642e
   Niu XF, 2010, INT J REFRIG, V33, P686, DOI 10.1016/j.ijrefrig.2009.11.014
   Raynal L, 2007, CHEM ENG SCI, V62, P7196, DOI 10.1016/j.ces.2007.08.010
   Steinfeldt N, 2007, ORG PROCESS RES DEV, V11, P1025, DOI 10.1021/op7000673
   Stroock AD, 2002, SCIENCE, V295, P647, DOI 10.1126/science.1066238
   Suryawanshi PL, 2018, CHEM ENG SCI, V189, P431, DOI 10.1016/j.ces.2018.03.026
   Tourvieille JN, 2013, CHEM ENG J, V227, P182, DOI 10.1016/j.cej.2012.07.095
   Wang D, 2019, J TAIWAN INST CHEM E, V98, P53, DOI 10.1016/j.jtice.2018.05.010
   Xie TM, 2013, IND ENG CHEM RES, V52, P3714, DOI 10.1021/ie3028763
   Xu YY, 2009, CHEM ENG TECHNOL, V32, P1227, DOI 10.1002/ceat.200900099
   Yang YC, 2019, J TAIWAN INST CHEM E, V98, P27, DOI 10.1016/j.jtice.2018.07.033
   Yeong KK, 2004, CHEM ENG SCI, V59, P3491, DOI 10.1016/j.ces.2004.04.022
   Yeong KK, 2003, CATAL TODAY, V81, P641, DOI 10.1016/S0920-5861(03)00162-7
   Zanfir M, 2005, IND ENG CHEM RES, V44, P1742, DOI 10.1021/ie049726k
   Zhang HC, 2009, AICHE J, V55, P1110, DOI 10.1002/aic.11743
   Zhu M, 2010, IND ENG CHEM RES, V49, P11724, DOI 10.1021/ie9020683
   Ziegenbalg D, 2010, CHEM ENG SCI, V65, P3557, DOI 10.1016/j.ces.2010.02.039
NR 34
TC 2
Z9 2
U1 22
U2 71
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 264
EP 275
DI 10.1016/j.ces.2018.09.016
PG 12
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800023
DA 2020-05-12
ER

PT J
AU Chen, A
   Li, SW
   Jing, D
   Xu, JH
AF Chen, An
   Li, Shao-Wei
   Jing, Dian
   Xu, Jian-Hong
TI Interactions between colliding oil drops coated with non-ionic
   surfactant determined using optical tweezers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Non-ionic surfactant; Fluorocarbon; Interaction forces; Tetradecane;
   Optical tweezers
ID ATOMIC-FORCE MICROSCOPY; IN-WATER EMULSIONS; OIL/WATER INTERFACE;
   MULTIPLE EMULSIONS; RADIATION PRESSURE; STABILITY; ADSORPTION;
   COALESCENCE; PARTICLES; DROPLETS
AB Non-ionic surfactants are widely used in many industrial applications such as detergents, oil recovery, and mineral flotation techniques. Non-ionic surfactants readily adsorb onto the oil-water interface, although they cannot dissociate in solutions like ionic surfactants can. Nonetheless, the electrostatic double-layer (EDL) repulsive force between oil drops coated with the non-ionic surfactant can still provide stability against coalescence. In this work, the interaction forces between two tetradecane drops with diameter of 6.5 mu m were measured in the presence of the non-ionic fluorocarbon-based surfactant FS-30 in various salt solutions using optical tweezers. The measured force curves were consistent with the presence of a surface charge, even though the surfactant was non-ionic in nature. The results clearly show that the EDL repulsive force is gradually screened with increasing salt concentration. It was also found that the EDL repulsive force was significantly screened in the divalent cation salt solutions (Ca2+, Ba2+) in comparison to in the monovalent cation salt solutions (Na+). In addition, the absolute value of the measured zeta potential (-xi) of emulsified tetradecane drops gradually decreased with increasing FS-30 concentration. In all experimental processes, the emulsified tetradecane drops coated with FS-30 were stable against coalescence. These findings have significant implications for the stability of emulsions used in the food, cosmetic, and detergent industries. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, An; Jing, Dian; Xu, Jian-Hong] Tsinghua Univ, Dept Chem Engn, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
   [Li, Shao-Wei] Tsinghua Univ, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China.
RP Xu, JH (reprint author), Tsinghua Univ, Dept Chem Engn, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
EM xujianhong@tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21476121, 21322604]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [2162020]; Tsinghua
   University Initiative Scientific Research Program [2014z21026]
FX The authors gratefully acknowledge the support of the National Natural
   Science Foundation of China (21476121, 21322604), the Beijing Natural
   Science Foundation (2162020), and the Tsinghua University Initiative
   Scientific Research Program (2014z21026) for this work.
CR ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156
   ASHKIN A, 1978, PHYS REV LETT, V40, P729, DOI 10.1103/PhysRevLett.40.729
   Beattie JK, 2009, FARADAY DISCUSS, V141, P31, DOI 10.1039/b805266b
   Beattie JK, 2004, ANGEW CHEM INT EDIT, V43, P3568, DOI 10.1002/anie.200453916
   Bhatt D, 2001, LANGMUIR, V17, P116, DOI 10.1021/la0009691
   Butt HJ, 2005, SURF SCI REP, V59, P1, DOI 10.1016/j.surfrep.2005.08.003
   Chan DYC, 2011, ADV COLLOID INTERFAC, V165, P70, DOI 10.1016/j.cis.2010.12.001
   Chan DYC, 2009, SOFT MATTER, V5, P2858, DOI 10.1039/b907953j
   Chan DYC, 2001, J COLLOID INTERF SCI, V236, P141, DOI 10.1006/jcis.2000.7400
   Chen A., 2018, CHEM ENG SCI, V181, P341
   Chen A, 2018, J COLLOID INTERF SCI, V532, P128, DOI 10.1016/j.jcis.2018.07.116
   Creux P, 2009, J PHYS CHEM B, V113, P14146, DOI 10.1021/jp906978v
   Dagastine RR, 2006, SCIENCE, V313, P210, DOI 10.1126/science.1125527
   Derjaguin B.V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L
   DERJAGUIN BV, 1954, DISCUSS FARADAY SOC, P24, DOI 10.1039/df9541800024
   Dong PF, 2013, CHEM ENG J, V214, P106, DOI 10.1016/j.cej.2012.10.081
   El-Ali J, 2006, NATURE, V442, P403, DOI 10.1038/nature05063
   EXEROWA D, 1979, COLLOID POLYM SCI, V257, P1089, DOI 10.1007/BF01761121
   EXEROWA D, 1969, KOLLOID Z Z POLYM, V232, P703, DOI 10.1007/BF01500168
   Fang H, 2015, RSC ADV, V5, P23578, DOI 10.1039/c4ra15401k
   Frostad JM, 2013, LANGMUIR, V29, P4715, DOI 10.1021/la304115k
   Fu E., 1992, THERMODYNAMIC STUDY
   Gallarate M, 1999, INT J PHARM, V188, P233, DOI 10.1016/S0378-5173(99)00228-8
   Ge XH, 2014, LAB CHIP, V14, P4451, DOI 10.1039/c4lc00645c
   Gillies G, 2002, LANGMUIR, V18, P1674, DOI 10.1021/la011461g
   Gillies G, 2001, LANGMUIR, V17, P7955, DOI 10.1021/la011136t
   Giribabu K, 2007, CHEM ENG SCI, V62, P3057, DOI 10.1016/j.ces.2007.03.002
   Gray-Weale A, 2009, PHYS CHEM CHEM PHYS, V11, P10994, DOI 10.1039/b901806a
   Gromer A, 2010, SOFT MATTER, V6, P3957, DOI 10.1039/c0sm00089b
   Jena KC, 2012, ANGEW CHEM INT EDIT, V51, P12938, DOI 10.1002/anie.201204662
   Jiang S, 2010, ADV MATER, V22, P1060, DOI 10.1002/adma.200904094
   Karraker KA, 2002, ADV COLLOID INTERFAC, V96, P231, DOI 10.1016/S0001-8686(01)00083-5
   Laugel C, 1998, INT J PHARM, V160, P109, DOI 10.1016/S0378-5173(97)00302-5
   Laugel C, 2000, J CONTROL RELEASE, V63, P7, DOI 10.1016/S0168-3659(99)00169-8
   Lee DH, 2002, J DISPER SCI TECHNOL, V23, P491, DOI 10.1081/DIS-120014017
   Liang Y, 2007, ADV COLLOID INTERFAC, V134-35, P151, DOI 10.1016/j.cis.2007.04.003
   LISSANT KJ, 1974, J COLLOID INTERF SCI, V47, P416, DOI 10.1016/0021-9797(74)90273-2
   MANEV ED, 1991, LANGMUIR, V7, P2253, DOI 10.1021/la00058a046
   Marinova KG, 1996, LANGMUIR, V12, P2045, DOI 10.1021/la950928i
   Mettu S, 2017, LANGMUIR, V33, P4913, DOI 10.1021/acs.langmuir.6b04632
   Muguet V, 2001, J CONTROL RELEASE, V70, P37, DOI 10.1016/S0168-3659(00)00314-X
   Nilsen-Nygaard J, 2014, RSC ADV, V4, P52220, DOI 10.1039/c4ra07140a
   Patrick HN, 1997, LANGMUIR, V13, P4349, DOI 10.1021/la9702547
   Pera-Titus M, 2015, ANGEW CHEM INT EDIT, V54, P2006, DOI 10.1002/anie.201402069
   Reichert MD, 2015, J COLLOID INTERF SCI, V449, P480, DOI 10.1016/j.jcis.2015.02.032
   Roger K, 2012, ANGEW CHEM INT EDIT, V51, P5625, DOI 10.1002/anie.201108228
   RUTLAND MW, 1993, LANGMUIR, V9, P412, DOI 10.1021/la00026a009
   SCAMEHORN JF, 1986, ACS SYM SER, V311, P1
   Shi C, 2017, LANGMUIR, V33, P1265, DOI 10.1021/acs.langmuir.6b04265
   Shi C, 2016, LANGMUIR, V32, P2302, DOI 10.1021/acs.langmuir.5b04392
   Shively M., 2002, PROTEIN DELIVERY, P199
   Stubenrauch C, 2004, LANGMUIR, V20, P4977, DOI 10.1021/la0304060
   Stubenrauch C, 2003, J PHYS-CONDENS MAT, V15, pR1197, DOI 10.1088/0953-8984/15/27/201
   Tabor RF, 2011, ANGEW CHEM INT EDIT, V50, P3454, DOI 10.1002/anie.201006552
   Tucker IM, 2012, LANGMUIR, V28, P14974, DOI 10.1021/la303563j
   UGELSTAD J, 1992, PROG POLYM SCI, V17, P87, DOI 10.1016/0079-6700(92)90017-S
   Verwey E. J. W., 1941, THEORY STABILITY LYO
   Zangi R, 2005, J AM CHEM SOC, V127, P2272, DOI 10.1021/ja044426f
   Zhou QQ, 2016, SOFT MATTER, V12, P1674, DOI 10.1039/c5sm02924d
NR 59
TC 2
Z9 2
U1 4
U2 48
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 276
EP 281
DI 10.1016/j.ces.2018.09.029
PG 6
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800024
DA 2020-05-12
ER

PT J
AU Zhu, SJ
   Liu, RZ
   Wang, T
   Niu, YJ
   Lu, HF
   Chen, XL
AF Zhu, Shi-Jie
   Liu, Run-Zhe
   Wang, Tian
   Niu, Yong-Jian
   Lu, Hai-Feng
   Chen, Xue-Li
TI Penetration time of hydrophilic micron particles impacting into an
   unconfined planar gas-liquid interface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Penetration time; Micron particle; Interface impaction; Confinement
   effect; Capillary force
ID SPHERICAL-PARTICLE; WATER ENTRY; SUBMICRON PARTICLES; CAVITY DYNAMICS;
   DETACHMENT; DROPLET; CAPTURE; SURFACE; POLLUTION; BEHAVIOR
AB The penetration time of hydrophilic micron particles during the submergence process is experimentally studied by using a high-speed camera. The effects of impact velocity (0.5 m/s <= mu(p0) <= 1.48 m/s), surface tension (44.3 mN/m <= gamma <= 73.9 mN/m) and dynamic viscosity (1.31 mPa.s <= mu <= 2.13 mPa.s) on the penetration time have been investigated. The penetration time for different fluids can be expressed as two different functions with the increase of impact velocity, which are in a good accordance with the experimental results. The results show that the penetration time exhibits a power function with particle size at lower impact velocity (mu(p0) <= 0.5 m/s), which increases with the surface tension decreasing and dynamic viscosity increasing. As the impact velocity increases, the penetration time can be expressed as a linear function of particle size. When the impact velocity exceeds the transition velocity (mu(p0) approximate to 0.74 m/s), the penetration time decreases at first and then increases with the decreasing surface tension, while changing little with the increase of dynamic viscosity. The confinement effect of cavity induced by the Marangoni stress and viscous stress has been analyzed in the different surface tension and dynamic viscosity solutions, respectively. The competitive motion of the three-phase contact line (TPCL) width and interfacial deformation width is the key factor that controls the capillary force, further influencing the penetration time. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Xue-Li] East China Univ Sci & Technol, Minist Educ, Key Lab Coal Gasificat & Energy Chem Engn, Shanghai 200237, Peoples R China.
   East China Univ Sci & Technol, Shanghai Engn Res Ctr Coal Gasificat, Shanghai 200237, Peoples R China.
RP Chen, XL (reprint author), East China Univ Sci & Technol, Minist Educ, Key Lab Coal Gasificat & Energy Chem Engn, Shanghai 200237, Peoples R China.
EM cxl@ecust.edu.cn
FU National Key Research and Development Program of China [2017YFB0602601];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [222201718003]
FX This work was supported by the National Key Research and Development
   Program of China [2017YFB0602601] and the Fundamental Research Funds for
   the Central Universities [222201718003].
CR Akers B, 2006, J NON-NEWTON FLUID, V135, P97, DOI 10.1016/j.jnnfm.2006.01.004
   Ally J, 2010, LANGMUIR, V26, P18135, DOI 10.1021/la103242e
   Ally J, 2010, LANGMUIR, V26, P11797, DOI 10.1021/la1010924
   Aristoff JM, 2009, J FLUID MECH, V619, P45, DOI 10.1017/S0022112008004382
   Chen LQ, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4737210
   Duclaux V, 2007, J FLUID MECH, V591, P1, DOI 10.1017/S0022112007007343
   Duez C, 2007, NAT PHYS, V3, P180, DOI 10.1038/nphys545
   Gao Y, 2017, CHEM ENG SCI, V172, P182, DOI 10.1016/j.ces.2017.06.018
   Geogiou D, 2017, J COLLOID INTERF SCI, V495, P149, DOI 10.1016/j.jcis.2017.02.004
   Ha S, 2014, ENVIRON RES, V134, P198, DOI 10.1016/j.envres.2014.08.002
   Ji BQ, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4991915
   Knupfer P, 2017, COLLOID SURFACE A, V513, P215, DOI 10.1016/j.colsurfa.2016.10.046
   Koch D, 2012, J AEROSOL SCI, V53, P61, DOI 10.1016/j.jaerosci.2012.05.012
   Le Goff A, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4797499
   Lee DG, 2008, LANGMUIR, V24, P142, DOI 10.1021/la702437c
   Lee DG, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3614536
   Lee JY, 2014, ATMOS ENVIRON, V89, P260, DOI 10.1016/j.atmosenv.2014.02.049
   Lee M, 1997, PHYS FLUIDS, V9, P540, DOI 10.1063/1.869472
   Liu D, 2010, ADV POWDER TECHNOL, V21, P401, DOI 10.1016/j.apt.2010.04.004
   Liu DM, 2016, CHEM ENG RES DES, V114, P52, DOI 10.1016/j.cherd.2016.08.003
   Liu DM, 2014, MINER ENG, V55, P138, DOI 10.1016/j.mineng.2013.10.001
   Liu DM, 2012, ADV MATER RES-SWITZ, V361-363, P320, DOI 10.4028/www.scientific.net/AMR.361-363.320
   Mansoor MM, 2016, J FLUID MECH, V796, DOI 10.1017/jfm.2016.229
   Mitra S, 2016, AICHE J, V62, P295, DOI 10.1002/aic.15027
   Mitra S, 2015, ADV POWDER TECHNOL, V26, P280, DOI 10.1016/j.apt.2014.10.008
   Nguyen AV, 1997, INT J MINER PROCESS, V50, P97, DOI 10.1016/S0301-7516(97)00006-9
   Nguyen AV, 2004, J COLLOID INTERF SCI, V273, P271, DOI 10.1016/j.jcis.2003.12.066
   Nguyen AV, 1997, INT J MINER PROCESS, V50, P113, DOI 10.1016/S0301-7516(97)00002-1
   Roche M, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.264501
   Shantharama, 2018, COLLOID INTERFAC SCI, V22, P5, DOI 10.1016/j.colcom.2017.11.005
   Sinn N, 2015, J COLLOID INTERF SCI, V458, P62, DOI 10.1016/j.jcis.2015.06.050
   Tammaro M, 2012, CHEM ENG SCI, V74, P124, DOI 10.1016/j.ces.2012.02.023
   Truscott TT, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3272264
   Vella D, 2006, LANGMUIR, V22, P5979, DOI 10.1021/la060606m
   Wang A, 2017, POWDER TECHNOL, V311, P408, DOI 10.1016/j.powtec.2017.02.003
   Wang A, 2016, ATMOS ENVIRON, V147, P157, DOI 10.1016/j.atmosenv.2016.10.001
   Wang A, 2015, ATMOS ENVIRON, V115, P1, DOI 10.1016/j.atmosenv.2015.05.053
   Wang JD, 2017, SCI TOTAL ENVIRON, V584, P426, DOI 10.1016/j.scitotenv.2017.01.027
   Wang J, 2011, POWDER TECHNOL, V210, P315, DOI 10.1016/j.powtec.2011.04.002
   Wang QL, 2014, POWDER TECHNOL, V256, P52, DOI 10.1016/j.powtec.2013.12.044
   Wang QL, 2013, AICHE J, V59, P2168, DOI 10.1002/aic.13967
   Winkels KG, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.055301
   Yan HM, 2009, J FLUID MECH, V641, P441, DOI 10.1017/S0022112009991558
   YE Y, 1988, COAL PREP, V5, P147, DOI DOI 10.1080/07349348808945563
   Zhao H, 2017, EXP FLUIDS, V58, DOI 10.1007/s00348-016-2296-4
   Zhao S, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/5265818
NR 46
TC 1
Z9 1
U1 3
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 282
EP 297
DI 10.1016/j.ces.2018.09.027
PG 16
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800025
DA 2020-05-12
ER

PT J
AU Soni, S
   Sharma, L
   Meena, P
   Roy, S
   Nigam, KDP
AF Soni, Surbhi
   Sharma, Loveleen
   Meena, Priya
   Roy, Shantanu
   Nigam, K. D. P.
TI Compact coiled flow inverter for process intensification
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Axial dispersion; Compact CFI; CFD; RTD
ID RESIDENCE TIME DISTRIBUTION; PRESSURE-DROP; HELICAL-COILS;
   HEAT-TRANSFER; 2-PHASE FLOW; LAMINAR-FLOW; CURVED PIPE; INVERSION;
   POLYMERIZATION; MICROREACTORS
AB The present study focuses on the intensification of flow and mixing in coiled flow inverter (CFI) geometries in order to achieve higher mixing efficiency with a lower base footprint. For this, two designs of "compact coiled flow inverter (CCFI)", namely, symmetrical compact coiled flow inverter and asymmetrical compact coiled flow inverter, are proposed within the same floor area as covered by a standard design of a conventional CFI. The design of the symmetrical CCFI is based on incorporating as many as possible 90 degrees bends, whereas the asymmetrical CCFI is based on incorporating as much as possible mixing volume.
   In order to quantify the improvements caused by proposed designs, all three geometries (two CCFIs and one standard CFI) are compared (experimentally and numerically) with each other in terms of dimensionless dispersion number (D/UL) and mixing efficiency (that measures induced radial mixing by incorporating pressure drop penalty), over laminar flow regime (10 <= N-Re <= 145). After validation of the numerical model (CFD) with experimental data, the RTD at different cross-sectional planes along the length of coiled tube is investigated. Such a study provides the relative contribution of helical turns and 90 degrees bends in reducing axial dispersion, and also provides an insight of the required length of coiled tube that is sufficient to achieve a desired reduction in the axial dispersion. The present study reveals that the symmetrical compact coiled flow inverter has the highest mixing efficiency per unit occupied floor area, and requires the least length of coiled tube in order to reduce the axial dispersion at same extent. Thus, the symmetrical CCFI has potential to save significant material and operational energy cost in the Industry. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Soni, Surbhi; Sharma, Loveleen; Meena, Priya; Roy, Shantanu; Nigam, K. D. P.] Indian Inst Technol Delhi, Dept Chem Engn, New Delhi 110016, India.
RP Nigam, KDP (reprint author), Indian Inst Technol Delhi, Dept Chem Engn, New Delhi 110016, India.
EM nigamkdp@gmail.com
CR Abe M., 2016, FLOW CHEM SOC IMRET1
   [Anonymous], Indian patent application, Patent No. 201711003181
   [Anonymous], 2008, U. S. Patent, Patent No. [US007337835B2, 007337835B2]
   [Anonymous], W. O. Patent, Patent No. 2015135844
   [Anonymous], Indian patent 159/ DEL/ 2005 and Design patent, Patent No. 198236
   Castelain C, 2000, INT J HEAT MASS TRAN, V43, P3687, DOI 10.1016/S0017-9310(99)00363-4
   Dean WR, 1928, PHILOS MAG, V5, P673
   Dean WR, 1927, PHILOS MAG, V4, P208
   Gad-el-Hak M, 2000, FLOW CONTROL PASSIVE
   Gursel IV, 2016, CHEM ENG J, V283, P855, DOI 10.1016/j.cej.2015.08.028
   Kateja N, 2016, BIOTECHNOL J, V11, P1320, DOI 10.1002/biot.201600271
   Klutz S, 2016, CHEM ENG PROCESS, V102, P88, DOI 10.1016/j.cep.2016.01.002
   Klutz S, 2015, J BIOTECHNOL, V213, P120, DOI 10.1016/j.jbiotec.2015.06.388
   Klutz S, 2015, CHEM ENG RES DES, V95, P22, DOI 10.1016/j.cherd.2015.01.003
   Kumar V, 2005, INT J HEAT MASS TRAN, V48, P4811, DOI 10.1016/j.ijheatmasstransfer.2005.05.037
   Kumar V, 2007, CHEM ENG SCI, V62, P2386, DOI 10.1016/j.ces.2007.01.032
   Kumar V, 2006, CHEM ENG SCI, V61, P4403, DOI 10.1016/j.ces.2006.01.039
   Kurnia JC, 2011, J ZHEJIANG UNIV-SC A, V12, P63, DOI 10.1631/jzus.A1000296
   Kurt S. K., 2016, P ASME 2016 SUMM HEA
   Kurt SK, 2016, CHEM ENG J, V284, P764, DOI 10.1016/j.cej.2015.08.099
   Kurt SK, 2015, CHEM ENG TECHNOL, V38, P1122, DOI 10.1002/ceat.201400515
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   [梁栋 Liang Dong], 2015, [化工学报, CIESC Journal], V66, P3036
   Mandal MM, 2010, CHEM ENG SCI, V65, P999, DOI 10.1016/j.ces.2009.09.053
   Mandal MM, 2011, IND ENG CHEM RES, V50, P13230, DOI 10.1021/ie2002473
   Mandal MM, 2011, MICROFLUID NANOFLUID, V10, P415, DOI 10.1007/s10404-010-0679-z
   Mrldha M, 2008, CHEM ENG SCI, V63, P1724, DOI 10.1016/j.ces.2007.10.028
   Parida D, 2014, MACROMOL REACT ENG, V8, P597, DOI 10.1002/mren.201400002
   Parida D, 2014, MACROMOLECULES, V47, P3282, DOI 10.1021/ma5001628
   SAXENA AK, 1984, AICHE J, V30, P363, DOI 10.1002/aic.690300303
   Sharma AK, 2016, CHEM ENG SCI, V140, P153, DOI 10.1016/j.ces.2015.10.009
   Singh J, 2016, IND ENG CHEM RES, V55, P3861, DOI 10.1021/acs.iecr.5b04865
   Singh J, 2016, CHEM ENG PROCESS, V102, P219, DOI 10.1016/j.cep.2016.02.001
   Singh J, 2014, CHEM ENG PROCESS, V86, P78, DOI 10.1016/j.cep.2014.10.013
   Singh J, 2014, CAN J CHEM ENG, V92, P2185, DOI 10.1002/cjce.22045
   Singh J, 2013, IND ENG CHEM RES, V52, P207, DOI 10.1021/ie300516w
   Slominski CG, 2011, IND ENG CHEM RES, V50, P8842, DOI 10.1021/ie102284g
   TRIVEDI RN, 1975, CHEM ENG SCI, V30, P317, DOI 10.1016/0009-2509(75)80081-9
   TRIVEDI RN, 1974, CHEM ENG SCI, V29, P2291, DOI 10.1016/0009-2509(74)80005-9
   Vashisth S, 2008, CHEM ENG PROCESS, V47, P1287, DOI 10.1016/j.cep.2007.04.008
   Vashisth S, 2008, IND ENG CHEM RES, V47, P3291, DOI 10.1021/ie701760h
   Vashisth S, 2008, IND ENG CHEM RES, V47, P3630, DOI 10.1021/ie070447h
   Vashisth S, 2007, IND ENG CHEM RES, V46, P5043, DOI 10.1021/ie061490s
NR 43
TC 5
Z9 5
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 312
EP 324
DI 10.1016/j.ces.2018.09.008
PG 13
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800027
DA 2020-05-12
ER

PT J
AU Shang, XL
   Luo, ZY
   Bai, BF
AF Shang, Xinglong
   Luo, Zhengyuan
   Bai, Bofeng
TI Numerical simulation of dynamic behavior of compound droplets on solid
   surface in shear flow by front-tracing method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Compound droplets; Dynamic behavior; Moving contact line; Detachment and
   pinch-off; Multiphase flow; Front-tracking method
ID MODERATE REYNOLDS-NUMBERS; NAVIER BOUNDARY-CONDITION; LEVEL-SET
   APPROACH; TRACKING METHOD; CONTACT-ANGLE; EMULSIONS; DEFORMATION;
   HYSTERESIS; BREAKUP; SYSTEMS
AB The dynamic behavior of compound droplets on the wall of a rectangle channel by the action of an imposed shear flow is simulated using our developed three-dimensional front-tracking method combined with generalized Navier boundary condition. The validity of the present method was confirmed by comparing results of the compound droplet spreading under gravity force with analytical solutions. To determine the physical condition required for detaching/pinching-off the compound droplet, we have performed a large number of simulations with varying capillary numbers of two interfaces and obtained a phase diagram of compound droplets on solid surface in shear flow. The deformation and motion of the compound droplet including its contact line motion are investigated. It is found that the behavior of the compound droplet is controlled by two dimensionless parameters, the capillary numbers of the outer interface and the inner interface. Moreover, we also analyze the deformation and migration of the inner droplet and discuss its effect on the compound droplet. The simulation demonstrate that the lateral migration of the small inner droplet could accelerates the pinch-off process and the large inner droplet could promote the detachment for a moderate capillary number of the outer interface. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shang, Xinglong; Luo, Zhengyuan; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
RI bai, bofeng/C-7663-2011
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2017YFE0100600];
   National Science Fund for Distinguished Young Scholars of ChinaNational
   Natural Science Foundation of ChinaNational Science Fund for
   Distinguished Young Scholars [51425603]
FX Bofeng Bai acknowledges financial support from the Ministry of Science
   and Technology of the People's Republic of China (Grant no.
   2017YFE0100600) and the National Science Fund for Distinguished Young
   Scholars of China (Grant no. 51425603).
CR BAZHLEKOV IB, 1995, J COLLOID INTERF SCI, V169, P1, DOI 10.1006/jcis.1995.1001
   Chen HS, 2011, SOFT MATTER, V7, P2345, DOI 10.1039/c0sm01100b
   COX RG, 1986, J FLUID MECH, V168, P169, DOI 10.1017/S0022112086000332
   Dimitrakopoulos P, 2007, J FLUID MECH, V580, P451, DOI 10.1017/S0022112007005721
   Dimitrakopoulos P, 1998, J FLUID MECH, V377, P189, DOI 10.1017/S0022112098002985
   Ding H, 2007, J FLUID MECH, V576, P287, DOI 10.1017/S0022112007004910
   Ding H, 2010, J FLUID MECH, V644, P217, DOI 10.1017/S0022112009992217
   Dupont JB, 2010, J COMPUT PHYS, V229, P2453, DOI 10.1016/j.jcp.2009.07.034
   EHRHARD P, 1991, J FLUID MECH, V229, P365, DOI 10.1017/S0022112091003063
   ENGEL RH, 1968, NATURE, V219, P856, DOI 10.1038/219856a0
   Esmaeeli A, 1998, J FLUID MECH, V377, P313, DOI 10.1017/S0022112098003176
   Fang C, 2008, INT J MULTIPHAS FLOW, V34, P690, DOI 10.1016/j.ijmultiphaseflow.2007.08.008
   FERMIGIER M, 1991, J COLLOID INTERF SCI, V146, P226, DOI 10.1016/0021-9797(91)90020-9
   Gao P, 2011, J FLUID MECH, V682, P415, DOI 10.1017/jfm.2011.235
   HOCHMUTH RM, 1993, BIOPHYS J, V64, P1596, DOI 10.1016/S0006-3495(93)81530-3
   Hua H, 2014, INT J HEAT FLUID FL, V50, P63, DOI 10.1016/j.ijheatfluidflow.2014.05.007
   Huang H., 2004, COMMUN MATH SCI, V2, P535, DOI DOI 10.4310/CMS.2004.V2.N4.A1
   Langer R, 1998, NATURE, V392, P5
   Li Y, 2013, COMPUT METHOD APPL M, V257, P36, DOI 10.1016/j.cma.2013.01.009
   Luo ZY, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5026874
   Luo ZY, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4965251
   Luo ZY, 2015, J FLUID MECH, V775, P77, DOI 10.1017/jfm.2015.286
   Muradoglu M, 2010, COMPUT FLUIDS, V39, P615, DOI 10.1016/j.compfluid.2009.10.009
   Ni MJ, 2003, NUMER HEAT TR B-FUND, V44, P533, DOI 10.1080/10407790390231789
   Palaniappan D, 2000, PHYS FLUIDS, V12, P2377, DOI 10.1063/1.1289775
   Park JK, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4707703
   Peskin CS, 2002, ACT NUMERIC, V11, P479, DOI 10.1017/S0962492902000077
   QIAN T, 2003, COMMUN MATH SCI, V1, P333, DOI DOI 10.4310/CMS.2003.v1.n2.a7
   Qian TZ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.016306
   Shang XL, 2018, COMPUT FLUIDS, V172, P181, DOI 10.1016/j.compfluid.2018.06.021
   Shintaku H, 2007, MICROSYST TECHNOL, V13, P951, DOI 10.1007/s00542-006-0291-z
   Smith KA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.204501
   Smith KA, 2000, PHYS REV LETT, V84, P91, DOI 10.1103/PhysRevLett.84.91
   Spelt PDM, 2005, J COMPUT PHYS, V207, P389, DOI 10.1016/j.jcp.2005.01.016
   Spelt PDM, 2006, J FLUID MECH, V561, P439, DOI 10.1017/S0022112006000954
   STONE HA, 1990, J FLUID MECH, V211, P123, DOI 10.1017/S0022112090001525
   Sugiyama K, 2008, J ENG MATH, V62, P35, DOI 10.1007/s10665-007-9185-z
   Tasoglu S, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3475527
   Tryggvason G, 2001, J COMPUT PHYS, V169, P708, DOI 10.1006/jcph.2000.6726
   Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164
   Vasudevan TV, 2002, J COLLOID INTERF SCI, V256, P208, DOI 10.1006/jcis.2002.8326
   Wang L, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.013301
   Yamamoto Y, 2014, INT J MULTIPHAS FLOW, V59, P106, DOI 10.1016/j.ijmultiphaseflow.2013.10.018
   Yamamoto Y, 2013, INT J MULTIPHAS FLOW, V51, P22, DOI 10.1016/j.ijmultiphaseflow.2012.12.002
NR 44
TC 3
Z9 3
U1 4
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 325
EP 335
DI 10.1016/j.ces.2018.09.021
PG 11
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800028
DA 2020-05-12
ER

PT J
AU Chen, S
   Liu, WW
   Li, SQ
AF Chen, Sheng
   Liu, Wenwei
   Li, Shuiqing
TI A fast adhesive discrete element method for random packings of fine
   particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Discrete element method; Reduced stiffness; Microspheres; Cohesive
   particles; Rolling resistance; Packing structure
ID COMPUTER-SIMULATION; FLUIDIZATION BEHAVIOR; DUST COAGULATION; DEM
   SIMULATIONS; LOOSE PACKINGS; CONTACT; STIFFNESS; IMPACT; MODEL;
   DEPOSITION
AB Introducing a reduced particle stiffness in discrete element method (DEM) allows for bigger time steps and therefore fewer total iterations in a simulation. Although this approach works well for dry nonadhesive particles, it has been shown that for fine particles with adhesion, system behaviors are drastically sensitive to the particle stiffness. Besides, a simple and applicable principle to set the parameters in adhesive DEM is also lacking. To solve these two problems, we first propose a fast DEM based on scaling laws to reduce particle Young's modulus, surface energy and to modify rolling and sliding resistances simultaneously in the framework of Johnson-Kendall-Roberts (JKR)-based contact theory. A novel inversion method is then presented to help users to quickly determine the damping coefficient, particle stiffness and surface energy to reproduce a prescribed experimental result. After validating this inversion method, we apply the fast adhesive DEM to packing problems of microparticles. Measures of packing fraction, averaged coordination number and distributions of local packing fraction and contact number of each particle are in good agreement with results simulated using original value of particle properties. The new method should be helpful to accelerate DEM simulations for systems associated with aggregates or agglomerates. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Sheng; Liu, Wenwei; Li, Shuiqing] Tsinghua Univ, Key Lab Thermal Sci & Power Engn, Dept Energy & Power Engn, Minist Educ, Beijing 100084, Peoples R China.
RP Li, SQ (reprint author), Tsinghua Univ, Key Lab Thermal Sci & Power Engn, Dept Energy & Power Engn, Minist Educ, Beijing 100084, Peoples R China.
EM lishuiqing@tsinghua.edu.cn
OI Li, Shuiqing/0000-0003-4443-5316; Chen, Sheng/0000-0003-0006-973X
FU National Fund for Distinguished Young Scholars of ChinaNational Natural
   Science Foundation of ChinaNational Science Fund for Distinguished Young
   Scholars [51725601]; National Natural Science Funds of ChinaNational
   Natural Science Foundation of China [51390491]
FX SQL acknowledges support from the National Fund for Distinguished Young
   Scholars of China (51725601) and the National Natural Science Funds of
   China (51390491). We are grateful to Prof. Jeff Marshall at Vermont,
   Prof. Q. Yao and Prof. Y. Zhang at Tsinghua for their useful
   suggestions.
CR BATCHELOR GK, 1977, P ROY SOC LOND A MAT, V355, P313, DOI 10.1098/rspa.1977.0100
   Baule A, 2018, REV MOD PHYS, V90, DOI 10.1103/RevModPhys.90.015006
   Blum J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.115503
   Chen S, 2018, J FLUID MECH, V835, P880, DOI 10.1017/jfm.2017.772
   Chen S, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.063108
   Chen S, 2016, SOFT MATTER, V12, P1836, DOI 10.1039/c5sm02403j
   Chen S, 2015, POWDER TECHNOL, V274, P431, DOI 10.1016/j.powtec.2015.01.051
   CHOKSHI A, 1993, ASTROPHYS J, V407, P806, DOI 10.1086/172562
   Coetzee CJ, 2017, POWDER TECHNOL, V310, P104, DOI 10.1016/j.powtec.2017.01.015
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   DAHNEKE B, 1975, J COLLOID INTERF SCI, V51, P58, DOI 10.1016/0021-9797(75)90083-1
   Dominik C, 1997, ASTROPHYS J, V480, P647, DOI 10.1086/303996
   DUNN PF, 1995, AEROSOL SCI TECH, V23, P80, DOI 10.1080/02786829508965296
   Fan Y, 2014, J FLUID MECH, V741, P252, DOI 10.1017/jfm.2013.680
   Gu YL, 2016, POWDER TECHNOL, V296, P17, DOI 10.1016/j.powtec.2015.09.037
   Haervig J, 2017, POWDER TECHNOL, V319, P472, DOI 10.1016/j.powtec.2017.07.006
   Hakim LF, 2005, POWDER TECHNOL, V160, P149, DOI 10.1016/j.powtec.2005.08.019
   Hanes DM, 2000, POWDER TECHNOL, V109, P133, DOI 10.1016/S0032-5910(99)00232-6
   Jin X, 2017, J ELECTROSTAT, V87, P217, DOI 10.1016/j.elstat.2017.04.011
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   Kim OV, 2008, J AEROSOL SCI, V39, P373, DOI 10.1016/j.jaerosci.2007.12.007
   Kobayashi T, 2013, POWDER TECHNOL, V248, P143, DOI 10.1016/j.powtec.2013.02.028
   Kolehmainen J, 2016, AICHE J, V62, P2282, DOI 10.1002/aic.15279
   Li SQ, 2007, J AEROSOL SCI, V38, P1031, DOI 10.1016/j.jaerosci.2007.08.004
   Li SQ, 2011, PROG ENERG COMBUST, V37, P633, DOI 10.1016/j.pecs.2011.02.001
   Li X, 1999, J AEROSOL SCI, V30, P439, DOI 10.1016/S0021-8502(98)00067-6
   Liu PY, 2016, CHEM ENG SCI, V145, P266, DOI 10.1016/j.ces.2016.02.024
   Liu WW, 2017, AICHE J, V63, P4296, DOI 10.1002/aic.15775
   Liu WW, 2017, SOFT MATTER, V13, P421, DOI 10.1039/c6sm02216b
   Liu WW, 2016, POWDER TECHNOL, V302, P414, DOI 10.1016/j.powtec.2016.08.068
   Liu WW, 2015, SOFT MATTER, V11, P6492, DOI 10.1039/c5sm01169h
   Lommen S, 2014, PARTICUOLOGY, V12, P107, DOI 10.1016/j.partic.2013.03.006
   Luo ZG, 2017, POWDER TECHNOL, V314, P102, DOI 10.1016/j.powtec.2016.08.053
   Marshall JS, 2009, J COMPUT PHYS, V228, P1541, DOI 10.1016/j.jcp.2008.10.035
   Marshall J.S., 2014, ADHESIVE PARTICLE FL
   Moreno-Atanasio R, 2007, CHEM ENG SCI, V62, P184, DOI 10.1016/j.ces.2006.08.036
   Moysey PA, 2005, POWDER TECHNOL, V153, P95, DOI 10.1016/j.powtec.2005.03.001
   Parteli EJR, 2014, SCI REP-UK, V4, DOI 10.1038/srep06227
   Paulick M, 2015, POWDER TECHNOL, V283, P66, DOI 10.1016/j.powtec.2015.03.040
   PAYATAKES AC, 1980, CHEM ENG SCI, V35, P1083, DOI 10.1016/0009-2509(80)85097-4
   Simons TAH, 2015, PROCEDIA ENGINEER, V102, P741, DOI 10.1016/j.proeng.2015.01.178
   Sorace CM, 2009, MECH RES COMMUN, V36, P364, DOI 10.1016/j.mechrescom.2008.10.009
   Sumer B, 2008, J ADHES SCI TECHNOL, V22, P481, DOI 10.1163/156856108X295527
   Sundaresan S., 2018, ANN REV CHEM BIOMOL
   TSUJI Y, 1992, POWDER TECHNOL, V71, P239, DOI 10.1016/0032-5910(92)88030-L
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Valverde JM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.258303
   WALL S, 1990, AEROSOL SCI TECH, V12, P926, DOI 10.1080/02786829008959404
   Washino K, 2018, POWDER TECHNOL, V325, P202, DOI 10.1016/j.powtec.2017.11.024
   Wei MZ, 2018, NUCL ENG DES, V330, P217, DOI 10.1016/j.nucengdes.2018.01.048
   Xiao HY, 2016, P ROY SOC A-MATH PHY, V472, DOI 10.1098/rspa.2015.0856
   Yang RY, 2000, PHYS REV E, V62, P3900, DOI 10.1103/PhysRevE.62.3900
   Yang SY, 2013, GRANUL MATTER, V15, P467, DOI 10.1007/s10035-013-0410-3
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
NR 54
TC 9
Z9 9
U1 8
U2 54
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 336
EP 345
DI 10.1016/j.ces.2018.09.026
PG 10
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800029
DA 2020-05-12
ER

PT J
AU Sun, H
   Li, HA
AF Sun, Hao
   Li, Huazhou Andy
TI A New Three-Phase Flash Algorithm Considering Capillary Pressure in a
   Confined Space
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Three-phase flash; P-T flash; Capillary pressure; Unconventional
   reservoir; Phase behavior
ID RELATIVE PERMEABILITY; PHASE-BEHAVIOR; OIL; EQUILIBRIUM; WETTABILITY;
   SIMULATION; RECOVERY; 2-PHASE; SYSTEMS
AB Tight/shale reservoirs are extensively containing nanopores, and the confined space in nanopores can greatly alter the phase behavior of reservoir fluids due to the strong capillarity effect. Many researches have been recently conducted to investigate the effect of capillary pressure in nanopores on altering the oleic-vapor two-phase equilibria. Few attempts have been made to describe the effect of capillarity on the aqueous-oleic-vapor three-phase equilibria. This work proposes a new algorithm for performing three-phase pressure-temperature (P-T) flash coupled with capillary effect. This algorithm considers two capillary pressures that exist across the two interfaces dividing the three phases in a nanopore. When describing the three-phase equilibria, two types of reservoir wettability are considered: waterwet formation and oil-wet formation. In each case, distribution of the three phases in a nanopore is determined based on the spreading coefficient which refers to the spreading ability of an oleic phase over the spreading ability of an aqueous phase. Example calculations are conducted to show the robustness of the new algorithm as well as to study the effect of capillarity on the three-phase equilibria. Computation results show that the three-phase P-T envelope for a given hydrocarbons/water mixture in a nanopore can be significantly altered by capillary pressure, but how the envelope moves will depend on the wettability of the nanopore and the spreading coefficient. The general trend is that both the upper branch (i.e., the oleic-aqueous/vapor-oleic-aqueous boundary) and the lower branch (i.e., the liquid-vapor/ liquid-liquid-vapor boundary) of the three-phase envelope tend to move downward. Compared to the water-wet case, the oil-wet nanopore will shift the three-phase boundaries in a much larger degree. In addition to the alteration of the three-phase envelope, the presence of capillarity will also lead to the alteration of the phase fractions and phase compositions in the nanopore. Nanofluidic experiments should be conducted in the future to verify the findings obtained from the calculations. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sun, Hao; Li, Huazhou Andy] Univ Alberta, Fac Engn, Sch Min & Petr Engn, Edmonton, AB T6G 1H9, Canada.
RP Li, HA (reprint author), Univ Alberta, Fac Engn, Sch Min & Petr Engn, Edmonton, AB T6G 1H9, Canada.
EM huazhou@ualberta.ca
RI Li, Huazhou/AAG-7565-2020
OI Li, Huazhou/0000-0002-4541-670X
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51704234]
FX The authors greatly acknowledge the financial support provided by a
   Discovery Grant from the Natural Sciences and Engineering Research
   Council of Canada (NSERC) and a Young Scientists Fund of the National
   Natural Science Foundation of China (Grant No. 51704234). The authors
   would also like to express gratitude to PVTsim for providing an academic
   license to the University of Alberta.
CR Abu Al-Rub FA, 1999, FLUID PHASE EQUILIBR, V162, P83, DOI 10.1016/S0378-3812(99)00197-1
   Brusilovsky A.I., 1992, SPE RESERV EVAL ENG, V7, P117, DOI DOI 10.2118/20180-PA
   DANESH A, 2007, [No title captured]
   Dong J., 2014, SIURO, V7, P74, DOI DOI 10.1137/13S012637
   Firincioglu T., 2012, SPE ANN TECHN C EXH, DOI [10.2118/159869-MS, DOI 10.2118/159869-MS]
   FIROOZABADI A, 1988, J CAN PETROL TECHNOL, V27, P41, DOI 10.2118/88-03-03
   Green DW, 2007, BILING-LANG COGN, V10, P1, DOI 10.1017/S1366728906002719
   Guo P., 1996, SPE GAS TECHN S CALG, DOI DOI 10.2118/35644-MS
   Hustad OS, 2010, SPE J, V15, P1009, DOI 10.2118/125429-PA
   Iwere F. O., 2012, AM UNC RES C, DOI [10.2118/154937-MS, DOI 10.2118/154937-MS]
   Jin ZH, 2016, SPE J, V21, P190, DOI 10.2118/176015-PA
   Kantzas A, 1998, J CAN PETROL TECHNOL, V37, P48
   Lapene A, 2010, FLUID PHASE EQUILIBR, V297, P121, DOI 10.1016/j.fluid.2010.06.018
   Li L, 2013, ASEE ANNU CONF EXPO
   Li RX, 2018, CAN J CHEM ENG, V96, P390, DOI 10.1002/cjce.23018
   Li X., 2008, INT PETR TECHN C, DOI [10.2523/IPTC-12303-MS, DOI 10.2523/IPTC-12303-MS]
   Li ZX, 2015, PETROL EXPLOR DEV+, V42, P241, DOI 10.1016/S1876-3804(15)30011-2
   Loucks RG, 2009, J SEDIMENT RES, V79, P848, DOI 10.2110/jsr.2009.092
   Luo SQ, 2005, SPE RESERV EVAL ENG, V8, P528, DOI 10.2118/89407-PA
   Moortgat J, 2013, SPE J, V18, P1150, DOI 10.2118/159777-PA
   Neshat SS, 2018, SPE J, V23, P1438, DOI 10.2118/187260-PA
   Nojabaei B, 2013, SPE RESERV EVAL ENG, V16, P281, DOI 10.2118/159258-PA
   OREN PE, 1994, SPE FORMATION EVAL, V9, P149, DOI 10.2118/24881-PA
   Oren PE, 1992, SPE FORMATION EVAL, DOI [10.2118/20185-PA, DOI 10.2118/20185-PA]
   Pang J., 2012, SPE CAN UNC RES C CA, DOI [10.2118/161143-MS, DOI 10.2118/161143-MS]
   Pang WY, 2017, FLUID PHASE EQUILIBR, V450, P86, DOI 10.1016/j.fluid.2017.07.010
   Passey Q.R., 2010, INT OIL GAS C EXH CH, DOI [10.2118/131350-MS, DOI 10.2118/131350-MS]
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   PENG DY, 1976, CAN J CHEM ENG, V54, P595
   Qi Z., 2007, EUROPE EAGE C EXH LO, DOI [10.2118/107315-MS, DOI 10.2118/107315-MS]
   QUAYLE OR, 1953, CHEM REV, V53, P439, DOI 10.1021/cr60166a003
   Rachford H.H., 1952, J PETROL TECHNOL, V4, P19, DOI [DOI 10.2118/952327-G, 10.2118/952327-G, 19-3]
   Robinson D. B., 1978, CHARACTERIZATION HEP
   Sandoval D., 2015, SPE ANN TECHN C EXH, DOI [10.2118/175110-MS, DOI 10.2118/175110-MS]
   Shaw JM, 2007, ASPHALTENES HEAVY OI, P489, DOI DOI 10.1007/0-387-68903-6_19
   Siripatrachai N, 2017, SPE J, V22, P1046, DOI 10.2118/179660-PA
   van Dijke MIJ, 2001, TRANSPORT POROUS MED, V44, P1, DOI 10.1023/A:1010773606657
   Wang F. P, 2009, SPE ANN TECHN C EXH, DOI [10.2118/124253-MS, DOI 10.2118/124253-MS]
   Weinaug CF, 1943, IND ENG CHEM, V35, P239, DOI 10.1021/ie50398a028
   Whitson CH, 2000, PHASE BEHAV
   Wilson G.M., 1969, 65 NAT AICHE M CLEV
   Wong S. W., 2000, 2000 SPE AAPG W REG, DOI [10.2118/62618-MS, DOI 10.2118/62618-MS]
   Wu KL, 2018, ANGEW CHEM INT EDIT, V57, P8432, DOI 10.1002/anie.201712915
   Wu KL, 2017, P NATL ACAD SCI USA, V114, P3358, DOI 10.1073/pnas.1612608114
   Wu KL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33461
   Young T., 1805, PHILOS T R SOC LONDO, V95, P65, DOI [10.1098/rst1.1805.0005, DOI 10.1098/RSTL.1805.0005]
   Zhang Y., 2016, SPE LOW PERM S DENV, DOI [10.2118/180235-MS, DOI 10.2118/180235-MS]
NR 47
TC 2
Z9 3
U1 3
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 346
EP 363
DI 10.1016/j.ces.2018.09.013
PG 18
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800030
DA 2020-05-12
ER

PT J
AU Li, X
   Wang, ZX
   Zhang, GL
   Yi, LJ
AF Li, Xia
   Wang, Zhaoxia
   Zhang, Genlin
   Yi, Lijuan
TI Improving lycopene production in Saccharomyces cerevisiae through
   optimizing pathway and chassis metabolism
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Chassis; GGPP; Lycopene; Metabolic engineering; Saccharomyces cerevisiae
ID BETA-CAROTENE PRODUCTION; ESCHERICHIA-COLI; BIOSYNTHESIS; ARTEMISININ;
   YEAST; ACID; MICROORGANISMS; MILTIRADIENE
AB Lycopene, a tetraterpenoid containing 13 double bonds, has important pharmaceutical and industrial application values. However, unstable supply of raw for extracted from natural host and residue of chemical reagents in chemically synthesized products have limited the quality of lycopene. Engineering microorganism is thus regarded as an alternative and attractive route for lycopene production. To improve the ability of engineered yeast to synthesize lycopene, here we have optimized the lycopene biosynthesis pathway and chassis metabolism. The results have verified that S. cerevisiae CEN.PK2-1C was more suitable for lycopene production because of its strong ability of synthesizing precursors of terpenoids. Compared to use inducible promoter, the use of constitutive promoter controlling pathway expression was more efficient for balancing lycopene synthesis and chassis metabolism. GGPP was identified the rate-controlling metabolite. Through expanding GGPP pool and MVA pathway, lycopene production was thus significantly increased. By citric acid fed-batch fermentation, the yield of lycopene finally reached 115.64 mg/L, 2689-folds of initial engineered yeast. These results indicated that cooptimization of heterologous pathway and chassis metabolism is a good strategy for enforcing microbial overproduction of natural products. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Xia; Wang, Zhaoxia; Zhang, Genlin; Yi, Lijuan] Shihezi Univ, Key Lab Green Proc Chem Engn Xinjiang Bingtuan, Sch Chem & Chem Engn, Shihezi 832003, Peoples R China.
RP Zhang, GL; Yi, LJ (reprint author), Shihezi Univ, Key Lab Green Proc Chem Engn Xinjiang Bingtuan, Sch Chem & Chem Engn, Shihezi 832003, Peoples R China.
EM zhgl_food@sina.com; ylj_xx@163.com
RI Zhang, genlin/O-2282-2019
FU Research Project of Youth Science and Technology Innovation Leader of
   XPCC [2017CB007]; National Nature Science Foundation of ChinaNational
   Natural Science Foundation of China [21676167]; Scientific and
   Technological Project of XPCC [2016AB009]; Research Project of
   High-Level Talents in Shihezi University [RCZX201505]
FX This work was supported by the Research Project of Youth Science and
   Technology Innovation Leader of XPCC (grant number 2017CB007), the
   National Nature Science Foundation of China (grant number. 21676167),
   Scientific and Technological Project of XPCC (grant number 2016AB009)
   and Research Project of High-Level Talents in Shihezi University grant
   numbers RCZX201505).
CR Aghajanpour M, 2017, AM J CANCER RES, V7, P740
   Ajikumar PK, 2008, MOL PHARMACEUT, V5, P167, DOI 10.1021/mp700151b
   Choudhari SM, 2008, BIORESOURCE TECHNOL, V99, P3166, DOI 10.1016/j.biortech.2007.05.051
   Dai ZB, 2012, BIOTECHNOL BIOENG, V109, P2845, DOI 10.1002/bit.24547
   Engels B, 2008, METAB ENG, V10, P201, DOI 10.1016/j.ymben.2008.03.001
   Grether-Beck S, 2017, BRIT J DERMATOL, V176, P1231, DOI 10.1111/bjd.15080
   JENSEN SYNNVE LIAAEN, 1967, PURE APPL CHEM, V14, P227
   Ledesma-Amaro R, 2016, TRENDS BIOTECHNOL, V34, P798, DOI 10.1016/j.tibtech.2016.04.010
   Levesque F, 2012, ANGEW CHEM INT EDIT, V51, P1706, DOI 10.1002/anie.201107446
   Li J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01116
   Li Q, 2013, FEMS MICROBIOL LETT, V345, P94, DOI 10.1111/1574-6968.12187
   Marienhagen J, 2013, J BIOTECHNOL, V163, P166, DOI 10.1016/j.jbiotec.2012.06.001
   Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200
   Paddon CJ, 2013, NATURE, V496, P528, DOI 10.1038/nature12051
   Saini RK, 2018, FOOD CHEM, V240, P90, DOI 10.1016/j.foodchem.2017.07.099
   Shao ZY, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn991
   Song MC, 2014, NAT PROD REP, V31, P1497, DOI 10.1039/c4np00057a
   Song TQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15005-4
   Wang CW, 2015, CHINESE J CHEM ENG, V23, P234, DOI 10.1016/j.cjche.2014.10.018
   Westfall PJ, 2012, P NATL ACAD SCI USA, V109, P111, DOI 10.1073/pnas.1110740109
   Xie WP, 2014, BIOTECHNOL BIOENG, V111, P125, DOI 10.1002/bit.25002
   YAMANO S, 1994, BIOSCI BIOTECH BIOCH, V58, P1112, DOI 10.1271/bbb.58.1112
   Yang CH, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0530-7
   Yoon SH, 2007, APPL MICROBIOL BIOT, V74, P131, DOI 10.1007/s00253-006-0623-z
   Yuan JF, 2014, BIOTECHNOL BIOENG, V111, P608, DOI 10.1002/bit.25123
   Zhang GL, 2015, AICHE J, V61, P3172, DOI 10.1002/aic.14950
   Zhou YJJ, 2012, J AM CHEM SOC, V134, P3234, DOI 10.1021/ja2114486
   Zhu FY, 2015, PROCESS BIOCHEM, V50, P341, DOI 10.1016/j.procbio.2014.12.008
   Zhu M, 2018, METAB ENG, V45, P43, DOI 10.1016/j.ymben.2017.11.009
NR 29
TC 4
Z9 4
U1 16
U2 104
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 364
EP 369
DI 10.1016/j.ces.2018.09.030
PG 6
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800031
DA 2020-05-12
ER

PT J
AU Diaz, I
   Rodriguez, M
   Gonzalez, EJ
   Gonzalez-Miquel, M
AF Diaz, Ismael
   Rodriguez, Manuel
   Gonzalez, Emilio J.
   Gonzalez-Miquel, Maria
TI A simple and reliable procedure to accurately estimate NRTL interaction
   parameters from liquid-liquid equilibrium data
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-liquid equilibrium; NRTL; Parameter estimation
ID EXCESS GIBBS ENERGY; PHASE; OPTIMIZATION; SYSTEMS; PREDICTION;
   RETRIEVAL; STABILITY; MIXTURES; MODELS
AB Fitting liquid-liquid equilibrium (LLE) data to common thermodynamic models (NRTL, UNIQUAC...) has been proved in the past to be a non trivial task. Many times it leads to inconsistent solutions where the Gibbs stability criteria is not satisfied. In this work, a simplified parameter estimation problem is formulated where the Gibbs stability criteria and the minimization of experimental and calculated phase composition distances, are simultaneously applied. This formulation is intended to be implemented in general mathematical computing software. Five isothermal ternary systems are studied and the obtained NRTL binary interaction parameters are compared with both existing published parameters and those obtained from commercial data regression tools. Results show that the combination of the proposed problem formulation with commercial non-linear programming solvers improves the quality of the ternary fittings obtained. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Diaz, Ismael; Rodriguez, Manuel; Gonzalez, Emilio J.; Gonzalez-Miquel, Maria] Univ Politecn Madrid, Dept Ingn Quim Ind & Medio Ambiente, ETSI Ind, C Jose Gutierrez Abascal 2, Madrid, Spain.
RP Diaz, I (reprint author), Univ Politecn Madrid, Dept Ingn Quim Ind & Medio Ambiente, ETSI Ind, C Jose Gutierrez Abascal 2, Madrid, Spain.
EM ismael.diaz@upm.es
RI Diaz, Ismael/N-3286-2019; Diaz, Ismael/H-1794-2012
OI Diaz, Ismael/0000-0001-6745-0960; Diaz, Ismael/0000-0001-6745-0960
FU Comunidad de MadridComunidad de Madrid [S2013-MAE-2800]
FX The authors are grateful to the Comunidad de Madrid (project
   S2013-MAE-2800) for financial support.
CR ABRAMS DS, 1975, AICHE J, V21, P116, DOI 10.1002/aic.690210115
   Arlt W., 1980, LIQUID LIQUID EQUILI
   BAKER LE, 1982, SOC PETROL ENG J, V22, P731, DOI 10.2118/9806-PA
   BRITT HI, 1973, TECHNOMETRICS, V15, P233, DOI 10.2307/1266984
   Colombo A, 1999, J CHEM ENG DATA, V44, P35, DOI 10.1021/je9702910
   DRUD A, 1985, MATH PROGRAM, V31, P153, DOI 10.1007/BF02591747
   Drud A. S., 1994, ORSA Journal on Computing, V6, P207
   Fahim MA, 1997, J CHEM ENG DATA, V42, P183, DOI 10.1021/je960215h
   Fahim MA, 1998, J CHEM ENG DATA, V43, P884, DOI 10.1021/je9800813
   Glass M, 2017, FLUID PHASE EQUILIBR, V433, P212, DOI 10.1016/j.fluid.2016.11.004
   GMEHLING J, 1980, VAPOR LIQUID EQUILIB
   MAGNUSSEN T, 1980, FLUID PHASE EQUILIBR, V4, P151, DOI 10.1016/0378-3812(80)80012-4
   Marcilla A, 2017, FLUID PHASE EQUILIBR, V433, P243, DOI 10.1016/j.fluid.2016.11.009
   Marcilla A, 2007, J CHEM ENG DATA, V52, P2538, DOI 10.1021/je700320u
   Margules M, 1895, SITZBER MN, p[104, 1243]
   MCDONALD CM, 1995, COMPUT CHEM ENG, V19, P1111, DOI 10.1016/0098-1354(94)00106-X
   McDonald CM, 1997, COMPUT CHEM ENG, V21, P1
   MICHELSEN ML, 1982, FLUID PHASE EQUILIBR, V9, P1, DOI 10.1016/0378-3812(82)85001-2
   Mitsos A, 2009, CHEM ENG SCI, V64, P548, DOI 10.1016/j.ces.2008.09.034
   Negadi L., 2002, 6 INT C DIST ABS BAD, P1
   Olaya M. M., 2007, CHEM ENG EDUC, V41, P218
   RENON H, 1968, AICHE J, V14, P135, DOI 10.1002/aic.690140124
   SORENSEN JM, 1979, FLUID PHASE EQUILIBR, V3, P47, DOI 10.1016/0378-3812(79)80027-8
   Tessier SR, 2000, CHEM ENG SCI, V55, P1785, DOI 10.1016/S0009-2509(99)00442-X
   WOHL K, 1946, T AM INST CHEM ENG, V42, P215
   Yang XG, 2015, J CHEM THERMODYN, V84, P14, DOI 10.1016/j.jct.2014.12.014
NR 26
TC 6
Z9 6
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 370
EP 378
DI 10.1016/j.ces.2018.09.015
PG 9
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800032
DA 2020-05-12
ER

PT J
AU Cervi, E
   Lorenzi, S
   Cammi, A
   Luzzi, L
AF Cervi, E.
   Lorenzi, S.
   Cammi, A.
   Luzzi, L.
TI Development of a multiphysics model for the study of fuel
   compressibility effects in the Molten Salt Fast Reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphysics; OpenFOAM; Compressible fluid dynamics; Reactor dynamics;
   Molten Salt Fast Reactor (MSFR)
ID FLOWS
AB Compressible fluid dynamics is of great practical interest in many industrial applications, ranging from chemistry to aeronautical industry, and to nuclear field as well. At the same time, modelling and simulation of compressible flows is a very complex task, requiring the development of specific approaches, in order to describe the effect of pressure on the fluid velocity field. Compressibility effects become even more important in the study of two-phase flows, due to the presence of a gaseous phase. In addition, compressibility is also expected to have a significant impact on other physics, such as chemical or nuclear reactions occurring in the mixture. In this perspective, multiphysics represents a useful approach to address this complex problem, providing a way to catch all the different physics that come into play as well as the coupling between them.
   In this work, a multiphysics model is developed for the analysis of the generation IV Molten Salt Fast Reactor (MSFR), with a specific focus on the compressibility effects of the fluid that acts as fuel in the reactor. The fuel mixture compressibility is expected to have an important effect on the system dynamics, especially in very rapid super-prompt-critical transients. In addition, the presence of a helium bubbling system used for online fission product removal could modify the fuel mixture compressibility, further affecting the system transient behaviour. Therefore, the MSFR represents an application of concrete interest, inherent to the analysis of compressibility effects and to the development of suitable modelling approaches. An OpenFOAM solver is developed to handle the fuel compressibility, the presence of gas bubbles in the reactor as well as the coupling between the system neutronics and fluid dynamics. The outcomes of this analysis point out that the fuel compressibility plays a crucial role in the evolution of fast transients, introducing delays in the expansion feedbacks that strongly affect the system dynamics. Moreover, it is found that the gas bubbles significantly alter the fuel compressibility, yielding even larger differences compared to the incompressible approximation usually adopted in the current MSFR solvers. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Cervi, E.; Lorenzi, S.; Cammi, A.; Luzzi, L.] Politecn Milan, Dept Energy, Nucl Engn Div, Via Masa 34, I-20156 Milan, Italy.
RP Luzzi, L (reprint author), Politecn Milan, Dept Energy, Nucl Engn Div, Via Masa 34, I-20156 Milan, Italy.
EM lelio.luzzi@polimi.it
OI Cammi, Antonio/0000-0003-1508-5935
FU EURATOM research and training programme 2014-2018 [661891]
FX This project has received funding from the EURATOM research and training
   programme 2014-2018 under grant agreement No. 661891.
CR Aufiero M., 2017, MONTE CARLO CFD COUP, V116
   Aufiero M., 2014, ANN NUCL ENERGY, V65, P390
   Aufiero M, 2014, CHEM ENG SCI, V111, P390, DOI 10.1016/j.ces.2014.03.003
   Cammi A, 2012, NUCL ENG DES, V246, P12, DOI 10.1016/j.nucengdes.2011.08.002
   Cammi A, 2011, ANN NUCL ENERGY, V38, P1356, DOI 10.1016/j.anucene.2011.01.037
   Cervi E., 2017, NENE 2017 26 INT C N
   Dolan TJ, 2017, WOODHEAD PUBL SER EN, P1
   Enwald H, 1996, INT J MULTIPHAS FLOW, V22, P21, DOI 10.1016/S0301-9322(96)90004-X
   Fiorina C, 2015, NUCL ENG DES, V294, P24, DOI 10.1016/j.nucengdes.2015.05.035
   Fiorina C, 2014, ANN NUCL ENERGY, V64, P485, DOI 10.1016/j.anucene.2013.08.003
   Gerardin D., 2017, INT C FAST REACT REL
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   GIF, 2016, ANN REP 2016
   Ignatiev V. V., 2012, P ICAPP 12 CHIC US J
   Koning A., 2006, JEFF 3 1 NUCL DATA L
   Lahey RT, 2005, NUCL ENG DES, V235, P1043, DOI 10.1016/j.nucengdes.2005.02.020
   Lance M, 1996, CHEM ENG COMMUN, V141, P51
   Leppanen J, 2015, ANN NUCL ENERGY, V82, P142, DOI 10.1016/j.anucene.2014.08.024
   Mimouni S, 2010, NUCL ENG DES, V240, P2260, DOI 10.1016/j.nucengdes.2009.11.018
   Moukalled F., 2016, FINITE VOLUME METHOD
   OpenFOAM, 2013, OPENFOAM DOC
   Paladino E. E., 2002, 2002 ASME INT PIP C
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Qiu S, 2016, KERNTECHNIK, V81, P149, DOI 10.3139/124.110688
   RANZ WE, 1952, CHEM ENG PROG, V48, P173
   Rusche H., 2002, THESIS
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Serp J, 2014, PROG NUCL ENERG, V77, P308, DOI 10.1016/j.pnucene.2014.02.014
   Thompson P.A., 1972, COMPRESSIBLE FLUID D
   Xiao Q, 2017, CHEM ENG J, V329, P88, DOI 10.1016/j.cej.2017.06.008
   Zhang DL, 2018, INT J ENERG RES, V42, P1834, DOI 10.1002/er.3979
NR 31
TC 7
Z9 7
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 379
EP 393
DI 10.1016/j.ces.2018.09.025
PG 15
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800033
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Shao, WM
   Ge, ZQ
   Song, ZH
AF Shao, Weiming
   Ge, Zhiqiang
   Song, Zhihuan
TI Quality variable prediction for chemical processes based on
   semisupervised Dirichlet process mixture of Gaussians
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Soft sensor; Semisupervised learning, Dirichlet process; mixture models;
   Variational inference; Nonlinear chemical processes; Non-Gaussian data
ID DRIVEN SOFT SENSORS; MAXIMUM-LIKELIHOOD; BAYESIAN-INFERENCE; MODEL;
   REGRESSION
AB Data driven soft sensors have found widespread applications in chemical processes for predicting those important yet difficult-to-measure quality variables. In the vast majority of chemical processes, relationships among primary and secondary variables are nonlinear, and process data inherently contain uncertainties and present strongly non-Gaussian characteristics. In addition, labeled samples are often scarce due to certain technical or economical difficulties. These process and data characteristics impose challenges on high-accuracy soft sensors. To deal with these issues, this paper proposes a soft sensing approach referred to as the semisupervised Dirichlet process mixture of Gaussians (SsDPMG). In the SsDPMG, a fully Bayesian model structure is first designed to enable semisupervised tasks that are suitable for regression applications. Subsequently, a Bayesian learning procedure for the SsDPMG is developed based on variational inference framework, where information contained in both labeled and unlabeled samples are extracted. Case studies are carried out on one numerical example and two real-life chemical processes to evaluate the performance of the proposed approach. The results demonstrate that the SsDPMG is an effective soft sensing approach with promising application foreground. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shao, Weiming; Ge, Zhiqiang; Song, Zhihuan] Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
RP Song, ZH (reprint author), Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
EM songzhihuan@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [61703367]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation
FX This work was supported by the National Natural Science Foundation of
   China (Grant No 61703367), and the China Postdoctoral Science
   Foundation.
CR Bishop C., 2006, PATTERN RECOGNITION
   Blei DM, 2006, BAYESIAN ANAL, V1, P121, DOI 10.1214/06-BA104
   Bouguila N, 2012, IEEE T KNOWL DATA EN, V24, P2184, DOI 10.1109/TKDE.2011.162
   Bourouis S, 2014, EXPERT SYST APPL, V41, P2329, DOI 10.1016/j.eswa.2013.09.030
   Boyed S., 2004, CONVEX OPTIMIZATION
   Broderick T., 2013, ADV NEURAL INFORM PR, V2, P1727
   Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644
   Cai LF, 2017, IEEE T NEUR NET LEAR, V28, P122, DOI 10.1109/TNNLS.2015.2505086
   Chan LLT, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.45237
   Choi SW, 2005, IND ENG CHEM RES, V44, P2316, DOI 10.1021/ie049081o
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   FERGUSON TS, 1973, ANN STAT, V1, P209, DOI 10.1214/aos/1176342360
   Ge ZQ, 2017, IEEE ACCESS, V5, P20590, DOI 10.1109/ACCESS.2017.2756872
   Ghahramani Z., 1999, 12 ADV NEURAL INFOM
   Grbic R, 2013, COMPUT CHEM ENG, V58, P84, DOI 10.1016/j.compchemeng.2013.06.014
   Kadlec P, 2009, COMPUT CHEM ENG, V33, P795, DOI 10.1016/j.compchemeng.2008.12.012
   Kaneko H, 2011, AICHE J, V57, P1506, DOI 10.1002/aic.12351
   Kimura T., 2009, IEICE TECH REP, P77
   Lai YP, 2018, NEUROCOMPUTING, V278, P23, DOI 10.1016/j.neucom.2017.07.068
   Liu JL, 2010, IND ENG CHEM RES, V49, P11530, DOI 10.1021/ie101356c
   Mei CL, 2017, CHINESE J CHEM ENG, V25, P116, DOI 10.1016/j.cjche.2016.07.005
   RASMUSSEN CE, 2000, ADV NEURAL INFORM PR
   SETHURAMAN J, 1994, STAT SINICA, V4, P639
   Shao W., 2012, CHEM ENG RES DES, V95, P113
   Souza FAA, 2016, CHEMOMETR INTELL LAB, V152, P69, DOI 10.1016/j.chemolab.2015.12.011
   Stanford DC, 2002, IEEE T PATTERN ANAL, V24, P1517, DOI 10.1109/TPAMI.2002.1046170
   Teh Y.W., 2011, ENCY MACHINE LEARNIN
   Wang D, 2010, IEEE T IND INFORM, V6, P11, DOI 10.1109/TII.2009.2025124
   Wang L, 2016, IND ENG CHEM RES, V55, P7704, DOI 10.1021/acs.iecr.6b00240
   Xie L, 2014, IEEE T CONTR SYST T, V22, P360, DOI 10.1109/TCST.2013.2248155
   Xing XL, 2013, PATTERN RECOGN LETT, V34, P2118, DOI 10.1016/j.patrec.2013.08.005
   Xiong WL, 2016, COMPUT CHEM ENG, V90, P260, DOI 10.1016/j.compchemeng.2016.04.033
   Yan HC, 2017, IEEE T INSTRUM MEAS, V66, P723, DOI 10.1109/TIM.2017.2654552
   Yan WW, 2017, IEEE T IND ELECTRON, V64, P4237, DOI 10.1109/TIE.2016.2622668
   Yan WW, 2016, IND ENG CHEM RES, V55, P7394, DOI 10.1021/acs.iecr.5b04118
   Yang F., 2017, 39 INT C IEEE ENG ME
   Yao L, 2017, CONTROL ENG PRACT, V61, P72, DOI 10.1016/j.conengprac.2017.02.002
   Yao L, 2017, IEEE T AUTOM SCI ENG, V14, P126, DOI 10.1109/TASE.2016.2608914
   Yu J, 2008, AICHE J, V54, P1811, DOI 10.1002/aic.11515
   Yu J, 2012, IND ENG CHEM RES, V51, P13227, DOI 10.1021/ie3020186
   Yu J, 2012, CHEM ENG SCI, V82, P22, DOI 10.1016/j.ces.2012.07.018
   Yuan XF, 2018, IEEE T IND ELECTRON, V65, P1508, DOI 10.1109/TIE.2017.2733443
   Yuan XF, 2017, IEEE T CONTR SYST T, V25, P1124, DOI 10.1109/TCST.2016.2579609
   Yuan XF, 2014, CHEMOMETR INTELL LAB, V138, P97, DOI 10.1016/j.chemolab.2014.07.013
   Zhou L, 2014, CHEM ENG SCI, V116, P296, DOI 10.1016/j.ces.2014.04.045
   Zhu JL, 2017, IEEE T CONTR SYST T, V25, P1092, DOI 10.1109/TCST.2016.2576999
   Zhu JL, 2015, CHEMOMETR INTELL LAB, V142, P231, DOI 10.1016/j.chemolab.2015.02.003
NR 47
TC 13
Z9 14
U1 9
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2019
VL 193
BP 394
EP 410
DI 10.1016/j.ces.2018.09.031
PG 17
WC Engineering, Chemical
SC Engineering
GA GW7TA
UT WOS:000447171800034
DA 2020-05-12
ER

PT J
AU Vojtek, I
   Buchy, P
   Doherty, TM
   Hoet, B
AF Vojtek, Ivo
   Buchy, Philippe
   Doherty, T. Mark
   Hoet, Bernard
TI Would immunization be the same without cross-reactivity?
SO VACCINE
LA English
DT Review
DE Vaccines; Cross-reactivity; Cross-protection; Adjuvants
ID INVASIVE PNEUMOCOCCAL DISEASE; MENINGOCOCCAL SEROGROUP-B; HPV-16/18
   AS04-ADJUVANTED VACCINE; HUMAN ROTAVIRUS VACCINE; HUMAN-PAPILLOMAVIRUS
   VACCINATION; NONVACCINE HPV TYPES; OF-STUDY ANALYSIS; 1ST 2 YEARS;
   INFLUENZA VACCINE; DOUBLE-BLIND
AB "Cross-reactivity" (the observed immune response against pathogen types not specifically targeted by the vaccine antigen composition) and "cross-protection" (clinical protection against related non-vaccine microorganism types) are vaccinology concepts that are attracting renewed interest in the context of disease prevention. National health authorities are collecting mounting evidence of the importance of cross reactivity. For some vaccines, this has been substantiated by cross-protection data from clinical studies and/or post-licensure data, where their introduction into immunization programmes has shown beneficial impacts on disease caused by related non-vaccine microorganisms. This knowledge has influenced the way new vaccines are designed, developed, and evaluated in real-life settings. Some of the new vaccines are now designed with the specific aim of having a greater breadth of protection. Ideal vaccine antigens therefore include epitopes with conserved homology across related pathogen types, because it is not always possible to include the antigens of all the individual types of a given pathogen species. The use of novel adjuvants with greater immunostimulatory properties can also contribute to improved overall vaccine cross-reactivity, as could the use of antigen delivery platforms. The growing body of evidence allows us to better understand the full impact of vaccines - beyond vaccine-type disease - which should be taken into consideration when assessing the full value of vaccination programmes. (C) 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Vojtek, Ivo; Doherty, T. Mark; Hoet, Bernard] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Buchy, Philippe] GSK, Singapore, Singapore.
RP Vojtek, I (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM ivo.x.vojtek@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX All costs associated with the development and publication of this
   manuscript were funded by GlaxoSmithKline Biologicals SA.
CR Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958
   Baldo V, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/517198
   Banyai K, 2012, VACCINE, V30, pA122, DOI 10.1016/j.vaccine.2011.09.111
   Bissett SL, 2017, VACCINE, V35, P3922, DOI 10.1016/j.vaccine.2017.06.028
   Brookes SM, 2005, VACCINE, V23, P4101, DOI 10.1016/j.vaccine.2005.03.037
   Brotherton JML, 2018, BEST PRACT RES CL OB, V47, P42, DOI 10.1016/j.bpobgyn.2017.08.010
   Brown DR, 2009, J INFECT DIS, V199, P926, DOI 10.1086/597307
   Camilloni B, 2015, HUM VACC IMMUNOTHER, V11, P553, DOI 10.1080/21645515.2015.1011562
   Canvin M, 2017, SEX TRANSM INFECT, V93, P125, DOI 10.1136/sextrans-2016-052626
   CDC 2009 Centers for Disease Control and Prevention, 2009, TYP INFL VIR
   Chada KE, 2017, VACCINE, V35, P3162, DOI 10.1016/j.vaccine.2017.04.029
   Chidumayo NN, 2014, MICROBIOL IMMUNOL, V58, P112, DOI 10.1111/1348-0421.12122
   Clifford G., 2006, VACCINE S3, V24, pS3
   Cowling BJ, 2012, CLIN INFECT DIS, V55, P695, DOI 10.1093/cid/cis518
   Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005
   Dennehy PH, 2008, CLIN MICROBIOL REV, V21, P198, DOI 10.1128/CMR.00029-07
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Dominguez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183191
   Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011
   Domnich A, 2014, HUM VACC IMMUNOTHER, V10, P2819, DOI 10.4161/hv.29984
   Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
   Edwards JL, 2018, CURR OPIN INFECT DIS, V31, P246, DOI [10.1097/QCO.0000000000000450, 10.1097/qco.0000000000000450]
   Feiring B, 2018, J INFECT DIS
   Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001
   Fox Christopher B, 2013, Ther Adv Vaccines, V1, P7, DOI 10.1177/2051013613480144
   FRANK SA, 2002, IMMUNOLOGY EVOLUTION
   Frosi G, 2013, VACCINE, V31, P4968, DOI 10.1016/j.vaccine.2013.08.006
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Gray J, 2008, J PEDIATR GASTR NUTR, V46, pS24, DOI 10.1097/MPG.0b013e31816f78ee
   Hanquet G, 2011, VACCINE, V29, P2856, DOI 10.1016/j.vaccine.2011.02.016
   Harboe ZB, 2010, VACCINE, V28, P2642, DOI 10.1016/j.vaccine.2010.01.017
   Herrin DM, 2014, HUM VACC IMMUNOTHER, V10, P3446, DOI 10.4161/hv.34408
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129
   Hong E, 2013, VACCINE, V31, P1113, DOI 10.1016/j.vaccine.2012.12.022
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Joint Committee on Vaccination and Immunisation (JCVI), JCVI POS STAT US BEX
   Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290
   Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1
   Kim HW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004854
   Kim JS, 2005, ANAL BIOCHEM, V347, P262, DOI 10.1016/j.ab.2005.09.022
   Kollaritsch H, BACKGROUND DOCUMENT
   Ladhani SN, 2016, EMERG INFECT DIS, V22, P309, DOI 10.3201/eid2202.150369
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8
   Leo O., 2011, PERSPECT VACCINOL, V1, P25, DOI DOI 10.1016/J.PERVAC.2011.05.002
   Leroux-Roels I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001665
   Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5
   Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109
   Linhares AC, 2008, LANCET, V371, P1181, DOI 10.1016/S0140-6736(08)60524-3
   Lobigs M, 2012, EXPERT REV VACCINES, V11, P177, DOI [10.1586/erv.11.180, 10.1586/ERV.11.180]
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Malerczyk C, 2014, HUM VACC IMMUNOTHER, V10, P2799, DOI 10.4161/21645515.2014.972741
   Malerczyk C, 2009, VACCINE, V27, P5320, DOI 10.1016/j.vaccine.2009.06.095
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Matthijnssens J, 2012, ARCH VIROL, V157, P1177, DOI 10.1007/s00705-012-1273-3
   Medini D, 2015, VACCINE, V33, P2629, DOI 10.1016/j.vaccine.2015.04.015
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI 10.1586/ERV.09.161
   Morabia A, 2018, J ROY SOC MED, V111, P255, DOI 10.1177/0141076818783658
   Orsi A, 2013, HUM VACC IMMUNOTHER, V9, P582, DOI 10.4161/hv.23239
   Park IH, 2008, J INFECT DIS, V198, P1818, DOI 10.1086/593339
   Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6
   Phua KB, 2009, VACCINE, V27, P5936, DOI 10.1016/j.vaccine.2009.07.098
   Poolman J, 2011, CLIN VACCINE IMMUNOL, V18, P327, DOI 10.1128/CVI.00402-10
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Roden RBS, 2018, NAT REV CANCER, V18, P240, DOI 10.1038/nrc.2018.13
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046
   Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448
   Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y
   Schuller E, 2008, VACCINE, V26, P6151, DOI 10.1016/j.vaccine.2008.08.056
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279
   Shirley M, 2015, BIODRUGS, V29, P353, DOI 10.1007/s40259-015-0139-0
   Siegrist CA, 2013, VACCINES, P14, DOI DOI 10.1016/B978-1-4557-0090-5.00004-5
   Steele AD, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-213
   Szarewski A, 2013, J INFECT DIS, V208, P1391, DOI 10.1093/infdis/jit360
   Takeuchi M, 2014, HUM VACC IMMUNOTHER, V10, P1421, DOI 10.4161/hv.28284
   Thomson CA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00087
   Tinsley CR, 1996, P NATL ACAD SCI USA, V93, P11109, DOI 10.1073/pnas.93.20.11109
   Tomei S, P30 POTENTIAL COVERA
   Tozer SJ, 2013, 27 ICP AUG 24 29
   Velasquez DE, 2014, INFECT GENET EVOL, V28, P561, DOI 10.1016/j.meegid.2014.10.008
   Vesikari T, 2007, LANCET, V370, P1757, DOI 10.1016/S0140-6736(07)61744-9
   Vestrheim DF, 2010, VACCINE, V28, P2214, DOI 10.1016/j.vaccine.2009.12.054
   Vipond C, 2012, VACCINE, V30, pB10, DOI 10.1016/j.vaccine.2011.12.060
   Webby RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140702
   Wheeler CM, 2012, LANCET ONCOL, V13, P100, DOI 10.1016/S1470-2045(11)70287-X
   Wheeler CM, 2009, J INFECT DIS, V199, P936, DOI 10.1086/597309
   Whelan J, 2016, EMERG INFECT DIS, V22, P1137, DOI 10.3201/eid2206.151093
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
   Wilkins AL, 2018, VACCINE, V36, P5470, DOI 10.1016/j.vaccine.2017.07.056
   Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12
   Wood P., 2006, UNDERSTANDING IMMUNO
   World Health Organization, PNEUM DIS
   Yin YY, 2009, IMMUNITY, V31, P849, DOI 10.1016/j.immuni.2009.12.002
NR 99
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 539
EP 549
DI 10.1016/j.vaccine.2018.12.005
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200001
PM 30591255
OA Other Gold
DA 2020-05-12
ER

PT J
AU Edler, M
   Fernandez, A
   Anderson, K
   Pierce, JY
   Scalici, J
   Daniel, CL
AF Edler, M.
   Fernandez, A.
   Anderson, K.
   Pierce, J. Y.
   Scalici, J.
   Daniel, C. L.
TI HPV vaccination, knowledge, and attitudes among young cervical cancer
   survivors in the Deep South
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccine; Cervical cancer; Prevention; Qualitative
   research; Survivor
ID HUMAN-PAPILLOMAVIRUS VACCINATION; BARRIERS; ADOLESCENTS
AB Introduction: Although FDA approved for over 10 years, uptake of the human papillomavirus (HPV) vaccination has been slow, particularly among states in the Deep South with high cervical cancer incidence and mortality. The purpose of this study was to explore variables associated with cervical cancer among survivors who were age-eligible for the HPV vaccine and to assess HPV vaccination history, barriers, perceptions, and other associated behaviors within this cohort.
   Methods: A mixed methods strategy was used for the study, first identifying eligible cervical cancer survivors from our institution and abstracting demographic and clinicopathologic medical record data. Twenty-three participants from this cohort then completed semi-structured qualitative telephone interviews regarding HPV vaccination participation, knowledge, and attitudes. Interviews were audio-recorded, transcribed, and analyzed using thematic content analysis.
   Results: Of the 464 cervical cancer patients treated at our institution from 2011 to 2016, 137 (30%) were under age 40 at diagnosis. Seventy-seven women with invasive disease were identified (median age = 33 years), and 56% had been seen by a gynecologist within 5 years of diagnosis. Forty-six of these women met eligibility criteria for inclusion in the qualitative interview, of which 23 successfully completed (response rate = 50%). Of those interviewed, the majority (84%) reported current access to regular medical care. While 90.9% did not receive any doses of HPV vaccination, 78.3% stated they likely would have been vaccinated if it had it been recommended. Four major themes were identified within the interviews: HPV knowledge, vaccine acceptability, healthcare engagement, and provider communication.
   Conclusions: Qualitative interviews revealed significant missed opportunities for prevention since most participants stated they would have been vaccinated if given the option. Substantial gaps in knowledge and mixed understanding HPV's association with cervical cancer were observed, demonstrating potential missed opportunities for education and communication between providers of multiple specialties and their patients. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Edler, M.] Univ S Alabama, Children & Womens Hosp, 1700 Ctr St, Mobile, AL 36604 USA.
   [Fernandez, A.; Pierce, J. Y.; Scalici, J.; Daniel, C. L.] Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.
   [Anderson, K.] Univ S Alabama, 307 North Univ Blvd, Mobile, AL 36688 USA.
RP Daniel, CL (reprint author), 1660 Springhill Ave, Mobile, AL 36604 USA.
EM jypierce@health.southalabama.edu; jscalici@health.southalabama.edu;
   cldaniel@health.southalabama.edu
CR [Anonymous], CERV CANC RAT STAT
   [Anonymous], HPV VACC COV MAPS
   [Anonymous], 2016, HPV VACC INF CLIN
   [Anonymous], USCS DAT VIS
   Berenson AB, 2015, HUM VACC IMMUNOTHER, V11, P1331, DOI 10.1080/21645515.2015.1022691
   Bratic JS, 2016, CURR OPIN PEDIATR, V28, P407, DOI 10.1097/MOP.0000000000000353
   Campbell JL, 2013, SOCIOL METHOD RES, V42, P294, DOI 10.1177/0049124113500475
   Centers for Disease Control and Prevention, MORBIDITY MORTALITY
   Centers for Disease Control and Prevention (CDC), HPV AND CANC
   Clark SJ, 2015, CLIN PEDIATR, V54, P1107, DOI 10.1177/0009922814557787
   de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357
   Dy Sydney M, 2017, J Patient Exp, V4, P162, DOI 10.1177/2374373517714451
   Hacker N., 2005, PRACTICAL GYNECOLOGI
   Haelle T., PEDIAT NEWS
   Hatch J. A., 2002, DOING QUALITATIVE RE
   Hoffman Barbara, WILLIAMS GYNECOLOGY
   Hoffman BL, WILLIAMS GYNECOLOGY, V3e
   Hofstetter AM, 2017, J PEDIATR ADOL GYNEC, V30, P88, DOI 10.1016/j.jpag.2016.08.005
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Kasting ML, 2016, VACCINE, V34, P1331, DOI 10.1016/j.vaccine.2016.01.050
   Ladd IG, 2018, J CANCER EDUC, DOI [10.1007/s13187-018-1348-2, DOI 10.1007/S513187-018-1348-A]
   National Cancer Institute, HUM PAP HPV VACC
   Reagan-Steiner, 2016, MORBIDITY MORTALITY
   Rutten LJF, 2017, VACCINE, V35, P164, DOI 10.1016/j.vaccine.2016.11.012
   United States Food and Drug Administration, GARD APPR PROD
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
NR 26
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 550
EP 557
DI 10.1016/j.vaccine.2018.12.039
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200002
PM 30598386
DA 2020-05-12
ER

PT J
AU Wagner, AL
   Shenton, LM
   Gillespie, BW
   Mathew, JL
   Boulton, ML
AF Wagner, Abram L.
   Shenton, Luke M.
   Gillespie, Brenda W.
   Mathew, Joseph L.
   Boulton, Matthew L.
TI Assessing the timeliness of vaccine administration in children under
   five years in India, 2013
SO VACCINE
LA English
DT Article
DE Immunization programs; India; Kaplan-Meier estimate
ID MISSED OPPORTUNITIES; INFANT IMMUNIZATION; COVERAGE; VACCINATIONS;
   MORTALITY
AB Morbidity from vaccine-preventable diseases is high in India, but precise estimates of vaccination timeliness are difficult to compute because many children lack records of vaccination dates. This study assessed vaccination timeliness after accounting for right and left censoring of data. This cross-sectional study used the 2012-2013 District Level Household and Facility Survey in India. The outcome was vaccination timeliness for 9 vaccine doses: 1 dose Bacillus Calmette-Guerin (BCG), 4 doses oral polio vaccine, 3 doses diphtheria-pertussis-tetanus vaccine (DPT), and 1 dose measles-containing vaccine. Age-specific probabilities of vaccination were calculated using Turnbull estimators: children not yet vaccinated were right censored, and children vaccinated but without a recorded date were left censored. Data from 108,783 children under 5 years were available. For children 25-60 months, maternal recall was a more common source of information than a vaccination record with dates. At one month past the recommended vaccination age, estimated coverage ranged from 35% for DPT-3 to 55% for BCG. Accounting for censored data improved vaccination timeliness measures, and demonstrated little increase in vaccination coverage after age one. Efforts to reduce morbidity from vaccine-preventable diseases in India should focus on eliminating missed opportunities for vaccination and instituting special vaccination programs for older children. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wagner, Abram L.; Shenton, Luke M.; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Gillespie, Brenda W.] Univ Michigan, Sch Publ Hlth, Dept Biostat, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Gillespie, Brenda W.] Univ Michigan, Consulting Stat Comp & Analyt Res, 915 E Washington St, Ann Arbor, MI 48109 USA.
   [Mathew, Joseph L.] PGIMER, Dept Pediat, Chandigarh, India.
   [Boulton, Matthew L.] Michigan Med, Dept Internal Med, Div Infect Dis, 1500 E Med Ctr Dr, Ann Arbor, MI USA.
RP Wagner, AL (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM awap@umich.edu
RI Wagner, Abram/X-6379-2019
OI Wagner, Abram/0000-0003-4691-7802; Shenton, Luke/0000-0001-5274-6048
FU PhRMA Foundation
FX This work was supported by a fellowship award from the PhRMA Foundation
   (to ALW).
CR Babirye JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035432
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   Cairncross S, 1996, TROP MED INT HEALTH, V1, P27, DOI 10.1046/j.1365-3156.1996.d01-9.x
   Canavan ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095709
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   An DTM, 2016, GLOBAL HEALTH ACTION, V9, P38, DOI 10.3402/gha.v9.29189
   Fadel SA, 2017, LANCET, V390, P1972, DOI 10.1016/S0140-6736(17)32162-1
   Fadnes LT, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-404
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Fu LY, 2015, J PEDIATR-US, V166, P412, DOI 10.1016/j.jpeds.2014.10.066
   GAVI, 2017, GAVI ANN REP 2016
   Gebremeskel BG, 2016, J PEDIAT INF DIS SOC, V5, P473, DOI 10.1093/jpids/piw034
   Khan J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207209
   Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6
   Laubereau B, 2002, EPIDEMIOL INFECT, V128, P185, DOI 10.1017/S0950268801006550
   Lernout T, 2014, VACCINE, V32, P284, DOI 10.1016/j.vaccine.2013.10.084
   Macharia K, 2015, TRANSF OUR WORLD 203, DOI [10.1017/CB09781107415324.004, DOI 10.1017/CB09781107415324.004]
   NARAIN JP, 1989, INT J EPIDEMIOL, V18, P952, DOI 10.1093/ije/18.4.952
   Narvaez J, 2017, VACCINE, V35, P1501, DOI 10.1016/j.vaccine.2017.01.073
   Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475
   Shenton LM, 2017, MATERN CHILD HLTH J, DOI [10.1007/510995-017-2409-6, DOI 10.1007/510995-017-2409-6]
   Shrivastava N., 2016, PEDIATR INFECT DIS J, P1, DOI [DOI 10.1097/INF0000000000001223, 10.1097/INF0000000000001223]
   TURNBULL BW, 1976, J R STAT SOC B, V38, P290
   VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120
   Wagner AL, 2018, J PUBLIC HEALTH-UK, V40, pE164, DOI 10.1093/pubmed/fdx087
   Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
NR 26
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 558
EP 564
DI 10.1016/j.vaccine.2018.12.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200003
PM 30595345
DA 2020-05-12
ER

PT J
AU Hurley, LP
   Allison, MA
   Kim, L
   O'Leary, ST
   Crane, LA
   Brtnikova, M
   Beaty, BL
   Allen, KE
   Poser, S
   Lindley, MC
   Kempe, A
AF Hurley, Laura P.
   Allison, Mandy A.
   Kim, Lindsay
   O'Leary, Sean T.
   Crane, Lori A.
   Brtnikova, Michaela
   Beaty, Brenda L.
   Allen, Kristen E.
   Poser, Sarah
   Lindley, Megan C.
   Kempe, Allison
TI Primary care physician's perspectives on respiratory syncytial virus
   (RSV) disease in adults and a potential RSV vaccine for adults
SO VACCINE
LA English
DT Article
DE RSV disease; Adults; Immunization; Physician perception
ID INFLUENZA; INFECTION; IMMUNIZATION; BEHAVIOR; HOSPITALIZATIONS;
   MORTALITY; BARRIERS; BURDEN; RATES; MAIL
AB Background: Deaths attributable to respiratory syncytial virus (RSV) among adults are estimated to exceed 11,000 annually, and annual adult hospitalizations for influenza and RSV may be comparable. RSV vaccines for older adults are in development. We assessed the following among primary care physicians (PCPs) who treat adults: (1) perception of RSV disease burden; (2) current RSV testing practices; and (3) anticipated barriers to adoption of an RSV vaccine.
   Methods: We administered an Internet and mail survey from February to March 2017 to national networks of 930 PCPs.
   Results: The response rate was 67% (620/930). Forty-nine percent of respondents (n = 303) were excluded from analysis as they reported never or rarely caring for an adult patient with possible RSV in the past year. Among respondents who reported taking care of RSV patients (n = 317), 73% and 57% responded that in patients >= 50 years, influenza is generally more severe than RSV and that they rarely consider RSV as a potential pathogen, respectively. Most (61%) agreed that they do not test for RSV because there is no treatment. The most commonly reported anticipated barriers to a RSV vaccine were potential outof-pocket expenses for patients if the vaccine is not covered by insurance (93%) and lack of reimbursement for vaccination (74%).
   Conclusions: Physicians reported little experience with RSV disease in adults. They are generally not testing for it and the majority believe that influenza disease is more severe. Physicians will require more information about RSV disease burden in adults and the potential need for a vaccine in their adult patients. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hurley, Laura P.; Allison, Mandy A.; O'Leary, Sean T.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Kempe, Allison] Univ Colorado, Anschutz Med Campus, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO USA.
   [Hurley, Laura P.; Allison, Mandy A.; O'Leary, Sean T.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA.
   [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA.
   [Allison, Mandy A.; O'Leary, Sean T.; Brtnikova, Michaela; Kempe, Allison] Univ Colorado, Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Pediat, Aurora, CO USA.
   [Crane, Lori A.] Univ Colorado, Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Aurora, CO USA.
   [Kim, Lindsay; Allen, Kristen E.; Poser, Sarah; Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Kim, Lindsay] US PHS, Rockville, MD USA.
RP Hurley, LP (reprint author), 301 W 6th Ave,MC3251, Denver, CO 80204 USA.
EM Laura.Hurley@dhha.org
FU Centers for Disease Control and Prevention through the Rocky Mountain
   Prevention Research Center, University of Colorado Anschutz Medical
   Campus [1U011I000849]
FX This investigation was funded by the Centers for Disease Control and
   Prevention and administered through the Rocky Mountain Prevention
   Research Center, University of Colorado Anschutz Medical Campus (Grant
   #1U01IP000849). The findings and conclusions in this report are those of
   the authors and do not necessarily represent the official position of
   the Centers for Disease Control and Prevention.
CR [Anonymous], 2015, VOV FEEDB
   Armstrong K, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(00)00263-4
   Atkeson LR, 2011, POLIT BEHAV, V33, P161, DOI 10.1007/s11109-010-9121-1
   Brownfield E, 2012, AM J INFECT CONTROL, V40, P672, DOI 10.1016/j.ajic.2011.12.006
   Centers for Disease and Control and Prevention, 2016, ADV COMM IMM PRACT
   Centers for Disease and Control and Prevention, 2018, 2018 NAT NOT COND
   Chartrand C, 2015, J CLIN MICROBIOL, V53, P3738, DOI 10.1128/JCM.01816-15
   Crane LA, 2008, EVAL HEALTH PROF, V31, P43, DOI 10.1177/0163278707311872
   Dillman D. A., 2014, INTERNET PHONE MAIL
   Falsey AR, 2014, J INFECT DIS, V209, P1873, DOI 10.1093/infdis/jit839
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   HealthCare.gov, 2018, DON HOL MED PRESCR D
   Hurley LP, 2010, ANN INTERN MED, V152, P555, DOI 10.7326/0003-4819-152-9-201005040-00005
   Kwon YS, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2897-4
   Langley G, 2016, EPIDEMIOLOGY RESP SY
   Lee N, 2013, CLIN INFECT DIS, V57, P1069, DOI 10.1093/cid/cit471
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   McMahon SR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e299
   National Foundation for Infectious Diseases, 2016, REG BARR MOR AUT ROA, P16
   NICHOL KL, 1992, ARCH INTERN MED, V152, P106, DOI 10.1001/archinte.152.1.106
   Nichol KL, 1996, J GEN INTERN MED, V11, P673, DOI 10.1007/BF02600158
   PATH, 2017, RSV VACC MAB SNAPSH
   Seewald Laura, 2013, Healthc Policy, V8, P71
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   University of Colorado, 2017, VACC POL COLL IN
   Widmer K, 2012, J INFECT DIS, V206, P56, DOI 10.1093/infdis/jis309
   Winston CA, 2006, J AM GERIATR SOC, V54, P303, DOI 10.1111/j.1532-5415.2005.00585.x
   Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 565
EP 570
DI 10.1016/j.vaccine.2018.12.031
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200004
PM 30598385
DA 2020-05-12
ER

PT J
AU Gangwar, M
   Jha, R
   Goyal, M
   Srivastava, M
AF Gangwar, Mamta
   Jha, Ruchi
   Goyal, Manish
   Srivastava, Mrigank
TI Immunogenicity and protective efficacy of Recombinase A from Wolbachia
   endosymbiont of filarial nematode Brugia malayi (wBmRecA)
SO VACCINE
LA English
DT Article
DE Filariasis; Brugia malayi; Wolbachia; Vaccine; wBmRecA
ID IMMUNE-RESPONSE; ANTIFILARIAL ACTIVITY; ONCHOCERCA-LIENALIS; CHALLENGES;
   BACTERIA; PROTEIN; GENE; NEUTRALIZATION; TETRACYCLINE; DISCOVERY
AB Lymphatic filariasis causes global morbidity. Wolbachia, an endo-symbiotic intracellular bacterium of the filarial nematode helps in their growth and development, regulates fecundity in female worms and contributes to the immunopathogenesis of the disease. However, genes and proteins of Wolbachia that may act as putative vaccine candidates are not known. In this study, we cloned recombinase-A protein of Wolbachia from Brugia malayi (wBmRecA) and carried out its detailed biochemical and immunological characterization. Bioinformatics analysis, circular dichroism and fluorescence spectral studies showed significant sequence and structural similarities between wBmRecA and RecA of other alpha-proteo- bacterial species. wBmRecA was ubiquitously expressed in all the three major life stages of B. malayi, including excretory-secretory products of the adult worm. In silico studies suggested immunogenic potential of wBmRecA, and mice immunized with wBmRecA exhibited elevated levels of immunoglobulins IgG1, IgG2a, IgG2b and IgG3 in their serum along with increased percentages of CD4+ , CD8(+) T cells and CD19(+) B cells in their spleens. Notably, splenocytes from immunized mice showed increased m-RNA expression of T-bet, elevated proinflammatory cytokines IFN-gamma and IL-12, while peritoneal Meis exhibited increased levels of iNOS, downregulated Arg-1 and secreted copious amounts of nitric oxide which contributed to severely impaired development of the infective larvae (Bm-L3). Interestingly, sera from immunized mice promoted significant cellular adherence and cytotoxicity against microfilariae and Bm-L3. Importantly, wBmRecA demonstrated strong immuno-reactivity with bancroftian sera from endemic normal individuals. These results suggest that wBmRecA is highly immunogenic, and should be explored further as a putative vaccine candidate against lymphatic filariasis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gangwar, Mamta; Jha, Ruchi; Goyal, Manish; Srivastava, Mrigank] CSIR Cent Drug Res Inst, Parasitol Div, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Srivastava, Mrigank] Acad Sci & Innovat Res AcSIR, New Delhi, India.
   [Goyal, Manish] Hebrew Univ Jerusalem, Hadassah Med Sch, Kuvin Ctr Study Infect & Trop Dis, Dept Microbiol & Mol Genet,IMRIC, IL-91120 Jerusalem, Israel.
RP Goyal, M; Srivastava, M (reprint author), CSIR Cent Drug Res Inst, Parasitol Div, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.; Goyal, M (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Kuvin Ctr Study Infect & Trop Dis, Dept Microbiol & Mol Genet,IMRIC, IL-91120 Jerusalem, Israel.
EM manish.goyal@mail.huji.ac.il; Mrigank_Srivastava@cdri.res.in
OI Srivastava, Mrigank/0000-0001-9324-7843
FU DST-SERB, India [EMR/2016/001880]; CSIR, IndiaCouncil of Scientific &
   Industrial Research (CSIR) - India
FX This work was supported by DST-SERB, India, Grant No. EMR/2016/001880
   and grants provided under CSIR, India - Network projects "New approaches
   toward understanding of Disease dynamics and to accelerate drug
   discovery (UNDO)" and "Emerging and re-emerging challenges in infectious
   diseases: Systems based drug design for infectious diseases (SPLenDID)"
   to MS. The funders had no role in study design, data collection,
   analysis, decision to publish, or preparation of the manuscript. This is
   communication number 9785 from CSIR-CDRI.
CR Albers A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-12
   Bhardwaj J, 2015, PARASITOL RES, V114, P3445, DOI 10.1007/s00436-015-4570-4
   Cano J, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0466-x
   CHANDRASHEKAR R, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P15
   Chen ZC, 2008, NATURE, V453, P489, DOI 10.1038/nature06971
   Dash Y, 2007, PARASITE IMMUNOL, V29, P567, DOI 10.1111/j.1365-3024.2007.00977.x
   FOLKARD SG, 1995, PARASITE IMMUNOL, V17, P541, DOI 10.1111/j.1365-3024.1995.tb00885.x
   Geary TG, 2011, EXPERT REV ANTI-INFE, V9, P681, DOI [10.1586/eri.11.76, 10.1586/ERI.11.76]
   Gupta J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142548
   Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768
   Hoerauf A, 2011, CLIN MICROBIOL INFEC, V17, P977, DOI 10.1111/j.1469-0691.2011.03586.x
   HORII T, 1981, CELL, V27, P515, DOI 10.1016/0092-8674(81)90393-7
   HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313
   Hotez PJ, 2016, VACCINE, V34, P3549, DOI 10.1016/j.vaccine.2016.03.112
   Karlin S, 1996, J BACTERIOL, V178, P1881, DOI 10.1128/jb.178.7.1881-1894.1996
   KING CL, 1991, IMMUNOPARASITOL TOD, pA54, DOI 10.1016/S0167-5699(05)80016-7
   Kushwaha S, 2012, MICROBES INFECT, V14, P1330, DOI 10.1016/j.micinf.2012.08.006
   Landmann F, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002351
   Landmann F, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000758
   Langworthy NG, 2000, P ROY SOC B-BIOL SCI, V267, P1063, DOI 10.1098/rspb.2000.1110
   Lin ZG, 2006, P NATL ACAD SCI USA, V103, P10328, DOI 10.1073/pnas.0604232103
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lustigman S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001582
   Michael E, 1996, PARASITOLOGY, V112, P409, DOI 10.1017/S0031182000066646
   Nag JK, 2013, COMP IMMUNOL MICROB, V36, P25, DOI 10.1016/j.cimid.2012.09.004
   Pathak M, 2016, IMMUNOLOGY, V147, P190, DOI 10.1111/imm.12550
   Pathak M, 2015, IMMUNOLOGY, V144, P231, DOI 10.1111/imm.12364
   Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038/nrd1824
   Rajan B, 2005, J IMMUNOL, V175, P1827, DOI 10.4049/jimmunol.175.3.1827
   Rana AK, 2013, ANTIMICROB AGENTS CH, V57, P3843, DOI 10.1128/AAC.02264-12
   Shahab M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099884
   Sharma A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00194
   Sharma A, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00818-16, 10.1128/iai.00818-16]
   Sharma P, 2017, EUR J IMMUNOL, V47, P1501, DOI 10.1002/eji.201747086
   Sharma P, 2016, J LEUKOCYTE BIOL, V99, P619, DOI 10.1189/jlb.4A0715-309RR
   Slatko BE, 2010, SYMBIOSIS, V51, P55, DOI 10.1007/s13199-010-0067-1
   Srivastava M, 2015, FUTURE MICROBIOL, V10, P1783, DOI 10.2217/fmb.15.73
   Taylor MJ, 2014, PARASITOLOGY, V141, P119, DOI 10.1017/S0031182013001108
   Taylor MJ, 1999, PARASITOL TODAY, V15, P437, DOI 10.1016/S0169-4758(99)01533-1
   Taylor MJ, 2002, ARCH MED RES, V33, P422, DOI 10.1016/S0188-4409(02)00377-6
   Townson S, 2000, ANN TROP MED PARASIT, V94, P801, DOI 10.1080/00034980020027988
   WHO, 2010, GLOB PROGR EL LYMPH
   Wu B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000475
NR 43
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 571
EP 580
DI 10.1016/j.vaccine.2018.12.015
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200005
PM 30595344
DA 2020-05-12
ER

PT J
AU Van Mulder, TJS
   Withanage, K
   Beyers, KCL
   Vankerckhoven, VVJ
   Theeten, H
   Van Damme, P
AF Van Mulder, T. J. S.
   Withanage, K.
   Beyers, K. C. L.
   Vankerckhoven, V. V. J.
   Theeten, H.
   Van Damme, P.
TI Immunogenicity and safety of intradermal delivery of hepatitis B booster
   vaccine using the novel drug delivery device VAX-ID (TM)
SO VACCINE
LA English
DT Article
DE Hepatitis B vaccine; Intradermal; Intramuscular; Booster; Device
ID ADULTS; OPTIONS
AB Background: Although intramuscular (IM) injection is still the most preferred method for vaccination, intradermal (ID) delivery may have several advantages over intramuscular and subcutaneous (SC), including an improved immune response and antigen dose sparing effect. However it is currently limited due to the difficulty in standardizing the injection technique often based on the Mantoux technique. Difficulties encountered using the Mantoux technique could be overcome by the use of alternative ID delivery systems that confer more uniform and standardized procedures.
   The aim of this study was to evaluate the performance of a newly developed intradermal injection device, VAX-ID (TM), via a proof-of-concept to assess the immunogenicity of a commercially available hepatitis B booster vaccination in healthy hepatitis B pre-immunised subjects. Additionally, device safety and tolerability was evaluated.
   Materials and methods: Three different routes of administration were compared over 4 groups, each receiving hepatitis B vaccine antigen: (1) standard IM injection in the deltoid region (HBVAXPRO (R) 10 mu g/1 ml), (2) ID injection in the proximal posterior area of the forearm according to the Mantoux technique, (3) with VAX-ID (TM) in one forearm, or (4) with VAX-ID (TM) in both forearms. For ID injections 0.11 cc, of which 0.01 cc is overfill, was drawn from a vial containing HBVAXPRO (R) 40 mu g/1 ml. Immunogenicity and safety were followed-up at day 0, 14, 30 and 210.
   Results: A total of 48 subjects were included. All subjects showed an anamnestic response at 14 days post booster vaccination. Elevated titres persisted until end of follow-up at day 210. For the ID groups a 3 fold higher immune response at day 14 and day 30 was recorded compared to IM group. Local adverse events were more reported for ID compared to IM.
   Conclusions: The investigated ID injection device VAX-ID (TM) proves to be a good alternative to offer ID vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Van Mulder, T. J. S.; Beyers, K. C. L.; Vankerckhoven, V. V. J.] Novosanis, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium.
   [Van Mulder, T. J. S.; Withanage, K.; Vankerckhoven, V. V. J.; Theeten, H.; Van Damme, P.] Univ Antwerp, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, Campus Drie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Beyers, K. C. L.] Voxdale, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium.
RP Van Mulder, TJS (reprint author), Univ Antwerp, Campus Drie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
EM timothi.vanmulder@uantwerpen.be
FU Flemish Government (VLAIO VAX-ID<SUP>TM</SUP> project)
FX This study was supported by the Flemish Government (VLAIO
   VAX-ID<SUP>TM</SUP> project). Van Mulder TJS is supported via VLAIO
   Baekeland.
CR Barraclough KA, 2009, AM J KIDNEY DIS, V54, P95, DOI 10.1053/j.ajkd.2009.03.010
   David MC, 2015, VACCINE, V33, P6564, DOI 10.1016/j.vaccine.2015.09.051
   Donadei A, 2017, VACCINE, V35, P3930, DOI 10.1016/j.vaccine.2017.06.018
   Fabrizi F, 1997, NEPHROL DIAL TRANSPL, V12, P1204, DOI 10.1093/ndt/12.6.1204
   Ghabouli MJ, 2004, EUR J EPIDEMIOL, V19, P871, DOI 10.1023/B:EJEP.0000040532.99890.9f
   Hickling JK, 2011, B WORLD HEALTH ORGAN, V89, P221, DOI 10.2471/BLT.10.079426
   HogenEsch H, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00406
   Kalchiem-Dekel O, 2015, J GASTROEN HEPATOL, V30, P1782, DOI 10.1111/jgh.13022
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Kim YC, 2012, ADV DRUG DELIVER REV, V64, P1547, DOI 10.1016/j.addr.2012.04.005
   Lambert PH, 2008, VACCINE, V26, P3197, DOI 10.1016/j.vaccine.2008.03.095
   Launay O, 2011, JAMA-J AM MED ASSOC, V305, P1432, DOI 10.1001/jama.2011.351
   lcardi G, 2012, HUMAN VACCINES IMMUN, V8, P67
   Levin Y, 2016, VACCINE, V34, P5262, DOI 10.1016/j.vaccine.2016.09.008
   Madhusudana SN, 2014, EXPERT REV VACCINES, V13, P641, DOI 10.1586/14760584.2014.901893
   Prausnitz MR, 2009, CURR TOP MICROBIOL, V333, P369, DOI 10.1007/978-3-540-92165-3_18
   Van Mulder TJS, 2017, VACCINE, V35, P1810, DOI 10.1016/j.vaccine.2016.07.039
   Van Mulder TJS, 2014, HUM VACC IMMUNOTHER, V10, P3746, DOI 10.4161/21645515.2014.979655
   Vankerckhoven V, 2010, EXPERT OPIN DRUG DEL, V7, P1109, DOI 10.1517/17425247.2010.507668
   Young F, 2011, VACCINE, V29, P8788, DOI 10.1016/j.vaccine.2011.09.077
   Yousaf F, 2015, RENAL FAILURE, V37, P1080, DOI 10.3109/0886022X.2015.1055698
   Zehrung D, 2017, VACCINE, V35, P2265, DOI 10.1016/j.vaccine.2016.11.095
   Zehrung D, 2013, VACCINE, V31, P3392, DOI 10.1016/j.vaccine.2012.11.021
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 581
EP 586
DI 10.1016/j.vaccine.2018.12.016
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200006
PM 30587432
DA 2020-05-12
ER

PT J
AU Rochanathimoke, O
   Riewpaiboon, A
   Tharmaphornpilas, P
   Jiamsiri, S
   Thavorncharoensap, M
   Postma, MJ
AF Rochanathimoke, Onwipa
   Riewpaiboon, Arthorn
   Tharmaphornpilas, Piyanit
   Jiamsiri, Suchada
   Thavorncharoensap, Montarat
   Postma, Maarten J.
TI Economic burden of rotavirus diarrhea in Thailand: Report from a pilot
   study on rotavirus vaccination
SO VACCINE
LA English
DT Article
DE Rotavirus; Diarrhea; Cost; Economic burden; Child; Thailand
ID POLYMERASE-CHAIN-REACTION; COST-EFFECTIVENESS; BUDGET IMPACT; CHILDREN;
   GASTROENTERITIS; CARE; EPIDEMIOLOGY; MORTALITY; DISEASE; SEVERITY
AB Background: Rotavirus diarrhea is the leading cause of morbidity and mortality in young children in both developed and developing countries. Hospitalization costs are a significant burden of both governments and households. The objective of this study was to estimate the economic burden associated with the hospitalization of children with non-rotavirus and rotavirus diarrhea in two provinces in Thailand.
   Method: A prospective incidence-based cost-of-illness study was conducted on children under five years old with acute diarrhea who had been admitted to public hospitals in two provinces during October 2012 and June 2013. Caregivers were interviewed to estimate costs from a societal perspective at 2014 values. Stool samples were examined for rotavirus antigens. Multivariate regression analysis was used to assess the relationship of predictor variables to costs. Annual economic burden of rotavirus hospitalization was estimated by multiplying the number of hospitalized children and the hospitalization cost per episode. The costs were converted to international dollars (I$) using purchasing power parity (PPP) (1 USD = 12.36 baht for the year 2014).
   Results: Seven hundred and eighty-eight cases of acute diarrhea were included in the analysis. Of the total, one hundred and ninety-seven (25%) were detected as being rotavirus positive. Total societal costs of inpatient care per episode were 822.68 USD (10,165 Baht). The average costs of children with and without rotavirus were 903.39 USD (11,162 Baht) and 795.40 USD (9,827 Baht), respectively. Based on the multiple regression analysis, rotavirus infection, severity, and younger age were significantly associated with the higher costs.
   Conclusion: Diarrhea, rotavirus diarrhea in particular, represents of a substantial economic burden in the society in Thailand. The accurate estimates that societal costs of the rotavirus diarrhea hospitalizations provide valuable input for considering a preventive program. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Rochanathimoke, Onwipa; Riewpaiboon, Arthorn; Thavorncharoensap, Montarat] Mahidol Univ, Fac Pharm, Dept Pharm, Div Social & Adm Pharm, 447 Sri Ayutthaya Rd, Bangkok 10400, Thailand.
   [Tharmaphornpilas, Piyanit; Jiamsiri, Suchada] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand.
   [Postma, Maarten J.] Univ Groningen, GRIP, Unit PharmacoTherapy Epidemiol & Econ, Groningen, Netherlands.
   [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.
   [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Groningen, Netherlands.
RP Riewpaiboon, A (reprint author), Mahidol Univ, Fac Pharm, Dept Pharm, Div Social & Adm Pharm, 447 Sri Ayutthaya Rd, Bangkok 10400, Thailand.
EM arthorn.rie@mahidol.ac.th
FU Department of Disease Control; Thailand Research Fund through the Royal
   Golden Jubilee Ph.D. ProgramThailand Research Fund (TRF) [PHD/0186/2552]
FX We thank the staffs of public hospitals in Sukhothai and Phetchabun
   provinces for helping with data collection and the Department of Disease
   Control for supporting and facilitating the study. This work was
   supported by the Thailand Research Fund through the Royal Golden Jubilee
   Ph.D. Program (Grant No. PHD/0186/2552) and the Department of Disease
   Control. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ahmeti A, 2015, VACCINE, V33, pA201, DOI 10.1016/j.vaccine.2014.12.075
   Albano F, 2007, EUR J PEDIATR, V166, P241, DOI 10.1007/s00431-006-0237-6
   Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS220, DOI 10.1093/cid/civ1025
   Bureau of Epidemiology Department of Disease Control Ministry of Public Health, ANN EP SURV REP 2014
   Bureau of Trade and Economic Indices Ministry of Commerce, REP CONS PRIC IND TH
   Burke RM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-642
   Chotivitayatarakorn P, 2010, SE ASIAN J TROP MED, V41, P114
   Hernandez SID, 2018, DIAGN MICR INFEC DIS, V90, P272, DOI 10.1016/j.diagmicrobio.2017.12.005
   DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126
   Fischer TK, 2005, J INFECT DIS, V192, P1720, DOI 10.1086/497339
   Granados-Garcia V, 2009, REV INVEST CLIN, V61, P18
   HUSAIN M, 1995, ARCH VIROL, V140, P1225, DOI 10.1007/BF01322748
   Imaz I, 2014, PREV MED, V61, P116, DOI 10.1016/j.ypmed.2013.12.013
   Intusoma Utcharee, 2008, Journal of the Medical Association of Thailand, V91, P1350
   Jacobs P, 2002, Can J Infect Dis, V13, P167
   Jin H, 2011, VACCINE, V29, P7801, DOI 10.1016/j.vaccine.2011.07.104
   Jiraphongsa C, 2005, J INFECT DIS, V192, pS87, DOI 10.1086/431508
   Kobelt G, 2013, HLTH EC INTRO EC EVA
   Lee WS, 2007, J PAEDIATR CHILD H, V43, P818, DOI 10.1111/j.1440-1754.2007.01160.x
   Lewis K., 2011, VESIKARI CLIN SEVERI
   Maneekarn N, 2000, PEDIATR INT, V42, P415, DOI 10.1046/j.1442-200x.2000.01251.x
   Maneekarn Niwat, 2014, VirusDisease, V25, P201, DOI 10.1007/s13337-014-0201-4
   Bezerra DAM, 2012, J VIROL METHODS, V185, P189, DOI 10.1016/j.jviromet.2012.07.017
   Mendelsohn AS, 2008, TROP MED INT HEALTH, V13, P934, DOI 10.1111/j.1365-3156.2008.02094.x
   Milne RJ, 2009, VALUE HEALTH, V12, P888, DOI 10.1111/j.1524-4733.2009.00534.x
   Muangchana C, 2012, VACCINE, V30, P2839, DOI 10.1016/j.vaccine.2012.02.047
   Nelson EAS, 2005, J INFECT DIS, V192, pS64, DOI 10.1086/431493
   Ngabo F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149805
   Nitiema LW, 2011, INT J INFECT DIS, V15, pE646, DOI 10.1016/j.ijid.2011.05.009
   Osano BO, 2011, VACCINE, V29, P4019, DOI 10.1016/j.vaccine.2011.03.053
   Parashar UD, 2009, J INFECT DIS, V200, pS9, DOI 10.1086/605025
   Rerksuppaphol S, 2011, INT J COLLAB RES INT, V3, P695
   Riewpaiboon A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3458-2
   Riewpaiboon Arthorn, 2014, Journal of the Medical Association of Thailand, V97, pS127
   Riewpaiboon Arthorn, 2014, Journal of the Medical Association of Thailand, V97, pS17
   RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046
   Smith ER, 2011, VACCINE, V29, P6704, DOI 10.1016/j.vaccine.2011.05.038
   Sowmyanarayanan TV, 2012, INDIAN J MED RES, V136, P68
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5
   Tharmaphornpilas P, 2017, VACCINE, V35, P796, DOI 10.1016/j.vaccine.2016.12.043
   The World Bank, 2018, PPP CONV FACT GDP
   *WHO, 2005, GUID EST EC BURD DIA
   Wilopo SA, 2009, VACCINE, V27, pF67, DOI 10.1016/j.vaccine.2009.09.040
   World Health Organization, 2009, MAN ROT DET CHAR MET
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 587
EP 594
DI 10.1016/j.vaccine.2018.12.013
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200007
PM 30579755
DA 2020-05-12
ER

PT J
AU Hirth, JM
   Fuchs, EL
   Chang, MY
   Fernandez, ME
   Berenson, AB
AF Hirth, Jacqueline M.
   Fuchs, Erika L.
   Chang, Mihyun
   Fernandez, Maria E.
   Berenson, Abbey B.
TI Variations in reason for intention not to vaccinate across time, region,
   and by race/ethnicity, NIS-Teen (2008-2016)
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; HPV vaccination; Reasons for vaccine hesitancy;
   Vaccine disparities
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HPV VACCINATION; SEXUAL-BEHAVIOR;
   UNITED-STATES; COVERAGE; INTERVENTIONS; ADOLESCENTS; ACCEPTANCE;
   INITIATION; ATTITUDES
AB Background: Human papillomavirus (HPV) vaccination is expected to reduce HPV-related disease and cancer in the US. However, many parents are hesitant to obtain the vaccine for their children. The purpose of this study is to examine how the reasons for refusing the HPV vaccine vary across regions of the US, across time, and by race/ethnicity.
   Methods: This study used data on 13-17 year old adolescents collected by the National Immunization Survey - Teen (NIS-Teen) annually between 2008 and 2016. We evaluated the frequencies of parents who did not intend to vaccinate their children in the next year among unvaccinated children. Among these non-intenders, we evaluated how reasons for HPV vaccine hesitancy changed across time, by region of the US, and race/ethnicity.
   Results: The proportion of non-intenders among unvaccinated decreased from 72% in 2010 to 58% in 2016. The most frequent reason for vaccine hesitancy was that parents felt HPV vaccination was not necessary (22.4%), followed by lack of provider recommendation (16.2%), and lack of knowledge (15.6%). Lack of provider recommendation increased in frequency as a reason for HPV vaccine hesitancy until 2012, then decreased in frequency through 2016. Cost was one reason that was elevated in all regions compared to the Northeast. Black non-intenders were less likely to report safety, costs, or their children's fear as reasons for not intending to vaccinate their children compared to white non-intenders. Hispanic non-intenders were more likely to report lack of knowledge and that the vaccine is not a school requirement as reasons not to vaccinate their children compared to white non-intenders.
   Conclusions: National advocacy for improving provider recommendation for HPV vaccination likely contributed to a sharp decline in HPV vaccine hesitancy due to lack of provider recommendation. Results indicate the need for multifaceted interventions to increase HPV vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hirth, Jacqueline M.; Fuchs, Erika L.; Chang, Mihyun] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Fernandez, Maria E.] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Hlth Promot & Behav Sci, Houston, TX 77030 USA.
   [Berenson, Abbey B.] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, Galveston, TX 77555 USA.
RP Hirth, JM (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, 301 Univ Blvd, Galveston, TX 77555 USA.
EM jmhirth@utmb.edu
FU Office of Research on Women's Health (ORWH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Office of Research on Women's Health (ORWH) [K12HD052023]; Office of the
   Director (OD); Eunice Kennedy Shriver National Institute of Child Health
   and Human Development (NICHD) at the National Institutes of Health
FX E.L. Fuchs is a Scholar supported by a research career development award
   (K12HD052023: Building Interdisciplinary Research Careers in Women's
   Health Program-BIRCWH; Principal Investigator: Berenson) from the Office
   of Research on Women's Health (ORWH), the Office of the Director (OD),
   the Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) at the National Institutes of Health. The findings
   and conclusions in this paper are those of the authors and do not
   necessarily represent the views of the Research Data Center, the
   National Center for Health Statistics, or the Centers for Disease
   Control and Prevention. The sponsors did not have any role in the study
   design, collection, analysis, and interpretation of the data or any
   other aspect of this study or manuscript.
CR Agenor M, 2020, ETHNIC HEALTH, V25, P393, DOI 10.1080/13557858.2018.1427703
   Beachler DC, 2016, PAPILLOMAVIRUS RES, V2, P11, DOI 10.1016/j.pvr.2015.12.001
   Beavis A, 2018, J ADOLESCENT HEALTH, V63, P652, DOI 10.1016/j.jadohealth.2018.06.024
   Beavis AL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00019
   Berenson AB, 2015, HUM VACC IMMUNOTHER, V11, P1331, DOI 10.1080/21645515.2015.1022691
   Centers for Disease Control and Prevention (CDC), 2018, CANC ASS HUM PAP STA
   Centers for Disease Control and Prevention (CDC), NAT IMM SURV NIS
   Chesson HW, 2004, PERSPECT SEX REPRO H, V36, P11, DOI 10.1111/j.1931-2393.2004.tb00003.x
   Dorell C, 2013, CLIN PEDIATR, V52, P162, DOI 10.1177/0009922812468208
   Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091
   Galbraith KV, 2016, SOC SCI MED, V159, P116, DOI 10.1016/j.socscimed.2016.04.028
   Gilkey MB, 2017, HUM VACC IMMUNOTHER, V13, P680, DOI 10.1080/21645515.2016.1247134
   Henley SJ, 2017, MMWR-MORBID MORTAL W, V66, P69, DOI 10.15585/mmwr.mm6603a1
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Hopfer S, 2017, HEALTH EDUC BEHAV, V44, P738, DOI 10.1177/1090198117728761
   Hswen Y, 2017, SEX TRANSM DIS, V44, P43, DOI 10.1097/OLQ.0000000000000543
   Kaufman J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub3
   Kim M, 2017, CLIN J ONCOL NURS, V21, pE239, DOI 10.1188/17.CJON.E239-E247
   Lee Haeok, 2018, Ethn Health, P1, DOI 10.1080/13557858.2018.1514455
   Mullins TLK, 2015, VACCINE, V33, P3907, DOI 10.1016/j.vaccine.2015.06.060
   Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206
   Niccolai LM, 2015, JAMA PEDIATR, V169, P686, DOI 10.1001/jamapediatrics.2015.0310
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Rysavy MB, 2014, J PEDIATR ADOL GYNEC, V27, P67, DOI 10.1016/j.jpag.2013.08.009
   Schmidt-Grimminger D, 2013, J CANCER EDUC, V28, P357, DOI 10.1007/s13187-013-0468-y
   Shay LA, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2312
   Singh G, 2017, J ENV PUBLIC HLTH, V2017, P19, DOI [10. 1155/2017/2189372, DOI 10.1155/2017/2189372]
   Smith PJ, 2016, VACCINE, V34, P1604, DOI 10.1016/j.vaccine.2016.01.061
   Smulian EA, 2016, HUM VACC IMMUNOTHER, V12, P1566, DOI 10.1080/21645515.2015.1125055
   Thompson EL, 2017, J ADOLESCENT HEALTH, V61, P288, DOI 10.1016/j.jadohealth.2017.05.015
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   Walling EB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3863
   Whelan AM, 2016, J LAW MED ETHICS, V44, P462, DOI 10.1177/1073110516667942
   Yzer M, 2018, PREV MED, V115, P104, DOI 10.1016/j.ypmed.2018.08.021
   Zimet GD, 2005, J ADOLESC HLTH, V37
NR 36
TC 2
Z9 2
U1 3
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 595
EP 601
DI 10.1016/j.vaccine.2018.12.017
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200008
PM 30580838
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Bernstein, DI
   Pasetti, MF
   Brady, R
   Buskirk, AD
   Wahid, R
   Dickey, M
   Cohen, M
   Baughman, H
   El-Khorazaty, J
   Maier, N
   Sztein, MB
   Baqar, S
   Bourgeoi, AL
AF Bernstein, David, I
   Pasetti, Marcela F.
   Brady, Rebecca
   Buskirk, Amanda D.
   Wahid, Rezwanul
   Dickey, Michelle
   Cohen, Mitchell
   Baughman, Holly
   El-Khorazaty, Jill
   Maier, Nicole
   Sztein, Marcelo B.
   Baqar, Shahida
   Bourgeoi, A. Louis
TI A Phase 1 dose escalating study of double mutant heat-labile toxin
   LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by
   sublingual or oral immunization
SO VACCINE
LA English
DT Article
DE ETEC; Escherichia coli; Vaccine; Sublingual; Oral; dmLT
ID MUCOSAL IMMUNE-RESPONSES; HELICOBACTER-PYLORI INFECTION; TRAVELERS
   DIARRHEA; DOUBLE-BLIND; INTRAGASTRIC VACCINATION; PARATYPHI B;
   IMMUNOGENICITY; SAFETY; ADJUVANT; PROTECTION
AB Background: The public health burden of Enterotoxigenic Escherichia coli (ETEC) is high but no vaccine is specifically approved to prevent ETEC infections.
   Methods: We performed a Phase 1, dose escalation study (1-50 mu g) evaluating the sublingual (SL) delivery of the double mutant heat-labile toxin LTR192G/L211A (dmLT) in 80 healthy adult volunteers. The primary objective was safety and the secondary was the immunogenicity of the dmLT. Subjects received 3 doses of dmLT at days 1,15, and 29. Subjects receiving the first dose at each dosage level were observed overnight in a research facility. The second and third doses were administered on an outpatient basis. Data from cohorts 1-4 were used to select the cohort 5 dose (25 mu g), comparing SL and oral routes.
   Results: The vaccine appeared safe and well tolerated with only rare development of vomiting or diarrhea. The serum anti-dmLT IgA and IgG and neutralizing antibody responses were modest after any of the SL immunizations. Serum IgA and IgG titers were increased at the higher antigen doses (25 or 50 mu g) but the percent with 4-fold increases was at best 38% for both IgA and IgG. The 4-fold increase among subjects receiving all 3 doses was 43% for both IgA and IgG. Antibody titers following oral administration were, in general, significantly higher than after SL. The frequency of IgA- or IgG-ASCs in circulation were somewhat vaccine dose dependent and were detected at a moderate level. However, antibodies in saliva or stool were rarely detected. Post-vaccination increases in T cells or cytokine production were also infrequent.
   Conclusion: The dmLT vaccine formulation evaluated here was safe but only moderately immunogenic at doses up to 50 mu g when administered by the SL or oral route. Studies at higher doses with better formulations appear warranted. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bernstein, David, I; Brady, Rebecca; Dickey, Michelle; Cohen, Mitchell] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Pasetti, Marcela F.; Buskirk, Amanda D.; Wahid, Rezwanul; Sztein, Marcelo B.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Baughman, Holly; El-Khorazaty, Jill] Emmes Corp, Rockville, MD USA.
   [Maier, Nicole; Bourgeoi, A. Louis] PATH, Washington, DC USA.
   [Baqar, Shahida] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Buskirk, Amanda D.] US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Qual, Off Proc & Facil,Div Microbiol Assessment, Silver Spring, MD USA.
   [Cohen, Mitchell] Univ Alabama Birmingham, Birmingham, AL USA.
RP Bernstein, DI (reprint author), Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
EM david.bernstein@cchmc.org
OI Brady, Rebecca/0000-0002-7635-6172; Pasetti, Marcela/0000-0003-0894-4009
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute of Health (Cincinnati Children's Hospital)
   [HHSN272200800006C]; National Institute of Health (University of
   Maryland, Baltimore) [HHSN272200800057C]; National Institute of Health
   (Emmes Corporation) [HHSN272200800013C]; PATHUnited States Agency for
   International Development (USAID) [OPP1112376]
FX This work was supported by funds from the National Institute of Allergy
   and Infectious Diseases, the National Institutes of Health, under
   contracts HHSN272200800006C (Cincinnati Children's Hospital),
   HHSN272200800057C (University of Maryland, Baltimore); and
   HHSN272200800013C (Emmes Corporation) and PATH under agreement
   OPP1112376.
CR AHREN CM, 1982, INFECT IMMUN, V38, P74
   Akhtar M, 2018, VACCINE
   Amorij JP, 2012, J CONTROL RELEASE, V161, P363, DOI 10.1016/j.jconrel.2011.12.039
   Amuguni H, 2012, MICROBES INFECT, V14, P447, DOI 10.1016/j.micinf.2011.12.001
   Behrens RH, 2014, LANCET INFECT DIS, V14, P197, DOI 10.1016/S1473-3099(13)70297-4
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Cheng E, 1999, VACCINE, V18, P38, DOI 10.1016/S0264-410X(99)00168-1
   CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372
   Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015
   Cuburu N, 2007, VACCINE, V25, P8598, DOI 10.1016/j.vaccine.2007.09.073
   da Hora VP, 2011, VACCINE, V29, P1538, DOI 10.1016/j.vaccine.2010.11.091
   DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995
   El-Kamary SS, 2013, CLIN VACCINE IMMUNOL, V20, P1764, DOI 10.1128/CVI.00464-13
   Ellingsworth L, 2011, 6 INT C VACC ENT DIS
   Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9
   Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010
   Gallorini S, 2014, VACCINE, V32, P2382, DOI 10.1016/j.vaccine.2013.12.043
   Ghiara P, 1997, INFECT IMMUN, V65, P4996, DOI 10.1128/IAI.65.12.4996-5002.1997
   Glenn GM, 2007, INFECT IMMUN, V75, P2163, DOI 10.1128/IAI.01740-06
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Huo ZM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033736
   Kotloff KL, 2001, INFECT IMMUN, V69, P3581, DOI 10.1128/IAI.69.6.3581-3590.2001
   Kraan H, 2014, J CONTROL RELEASE, V190, P580, DOI 10.1016/j.jconrel.2014.05.060
   Lal M, 2016, METHOD MOL BIOL, P153
   Lapa JA, 2008, CLIN VACCINE IMMUNOL, V15, P1222, DOI 10.1128/CVI.00491-07
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Luo QW, 2016, CLIN VACCINE IMMUNOL, V23, P628, DOI 10.1128/CVI.00248-16
   LYCKE N, 1992, EUR J IMMUNOL, V22, P2277, DOI 10.1002/eji.1830220915
   Marchetti M, 1998, VACCINE, V16, P33, DOI 10.1016/S0264-410X(97)00153-9
   Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10
   Ottsjo LS, 2017, IMMUNOLOGY, V150, P172, DOI 10.1111/imm.12676
   Ottsjo LS, 2013, INFECT IMMUN, V81, P1532, DOI 10.1128/IAI.01407-12
   PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X
   Peppoloni Samuele, 2003, Expert Rev Vaccines, V2, P285, DOI 10.1586/14760584.2.2.285
   Torrell JMR, 2009, VACCINE, V27, P4074, DOI 10.1016/j.vaccine.2009.04.025
   Shim Byoung-Shik, 2013, Immune Netw, V13, P81, DOI 10.4110/in.2013.13.3.81
   Simon JK, 2009, VACCINE, V27, P565, DOI 10.1016/j.vaccine.2008.10.081
   Summerton NA, 2010, VACCINE, V28, P1404, DOI 10.1016/j.vaccine.2009.10.147
   Tacket CO, 2004, VACCINE, V22, P4385, DOI 10.1016/j.vaccine.2004.01.073
   Toapanta FR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00374
   Tribble DR, 2008, CAMPYLOBACTER, 3RD EDITION, P429
   Wahid R, 2015, MUCOSAL IMMUNOL, V8, P1349, DOI 10.1038/mi.2015.24
   Wahid R, 2016, CLIN IMMUNOL, V173, P87, DOI 10.1016/j.clim.2016.09.006
   Wahid R, 2011, CLIN IMMUNOL, V138, P187, DOI 10.1016/j.clim.2010.11.006
   Walker RI, 2007, VACCINE, V25, P2545, DOI 10.1016/j.vaccine.2006.12.028
   White JA, 2014, HUM VACC IMMUNOTHER, V10, P3611, DOI 10.4161/hv.32253
   Zhang WP, 2012, EXPERT REV VACCINES, V11, P677, DOI [10.1586/erv.12.37, 10.1586/ERV.12.37]
NR 47
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 602
EP 611
DI 10.1016/j.vaccine.2018.12.011
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200009
PM 30563789
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Kimoto, T
   Kim, H
   Sakai, S
   Takahashi, E
   Kido, H
AF Kimoto, Takashi
   Kim, Hyejin
   Sakai, Satoko
   Takahashi, Etsuhisa
   Kido, Hiroshi
TI Oral vaccination with influenza hemagglutinin combined with human
   pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces
   efficient local and systemic immunity compared with nasal and
   subcutaneous vaccination and provides protective immunity in mice
SO VACCINE
LA English
DT Article
DE Pulmonary surfactant; Synthetic mucosal adjuvant; Oral vaccination;
   Gastrointestinal immunity; Influenza vaccine; Th17 cytokine
ID DELIVERY VEHICLE; VIRUS INFECTION; T-CELLS; INDUCTION; RESPONSES;
   MACROPHAGE; LIPOSOMES; OUTBREAK; FERRETS
AB We reported previously that a synthetic mucosal adjuvant SF-10, which mimics human pulmonary surfactant, delivers antigen to mucosal dendritic cells in the nasal cavity and promotes induction of humoral and cellular immunity. The aim of the present study was to determine the effects of oral administration of antigen combined with SF-10 (antigen-SF-10) on systemic and local immunity. Oral administration of ovalbumin, a model antigen, combined with SF-10 enhanced ovalbumin uptake into intestinal antigen presenting MHC II(+)CD11c(+) cells and their CD11b(+)CD103(+) and CD11b(+)CD103(-) subtype dendritic cells, which are the major antigen presenting subsets of the intestinal tract, more efficiently compared to without SF-10. Oral vaccination with influenza hemagglutinin vaccine (HAv)-SF-10 induced HAv-specific IgA and IgG in the serum, and HAv-specific secretory IgA and IgG in bronchoalveolar lavage fluid, nasal washes, gastric extracts and fecal material; their levels were significantly higher than those induced by subcutaneous HAv or intranasal HAv and HAv-SF-10 vaccinations. Enzyme-linked immunospot assay showed high numbers of HAv-specific IgA and IgG antibody secreting cells in the gastrointestinal and respiratory mucosal lymphoid tissues after oral vaccination with HAv-SF-10, but no or very low induction following oral vaccination with HAv alone. Oral vaccination with HAv-SF-10 provided protective immunity against severe influenza A virus infection, which was significantly higher than that induced by HAv combined with cholera toxin. Oral vaccination with HAv-SF-10 was associated with unique cytokine production patterns in the spleen after HAv stimulation; including marked induction of HAv-responsive Th17 cytokines (e.g., IL-17A and IL-22), high induction of Th1 cytokines (e.g., IL-2 and IFN-gamma) and moderate induction of Th2 cytokines (e.g., IL-4 and IL-5). These results indicate that oral vaccination with HAv-SF-10 induces more efficient systemic and local immunity than nasal or subcutaneous vaccination with characteristically high levels of secretory HAv-specific IgA in various mucosal organs and protective immunity. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Kimoto, Takashi; Kim, Hyejin; Sakai, Satoko; Takahashi, Etsuhisa; Kido, Hiroshi] Tokushima Univ, Inst Enzyme Res, Div Enzyme Chem, Tokushima, Japan.
RP Kido, H (reprint author), Tokushima Univ, Inst Enzyme Res, Div Enzyme Chem, Tokushima, Japan.
EM kido@tokushima-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [17K16267, 16H05348]; Medical Research and Development
   Programs Focused on Technology Transfer of Japan Agency for Medical
   Research and Development, AMEDJapan Agency for Medical Research and
   Development (AMED) [18im0210112]
FX We thank M. Ohuchi from Kawasaki Medical School, Kurashiki, Japan, for
   providing the IAV PR/8 virus. This study was supported in part by
   Grant-in-Aid for Young Scientists (B) (17K16267), Grant-in-Aid for
   Scientific Research (B) (16H05348) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan, and a grant from the
   Medical Research and Development Programs Focused on Technology Transfer
   of Japan Agency for Medical Research and Development, AMED
   (#18im0210112).
CR Barackman JD, 2001, CLIN DIAGN LAB IMMUN, V8, P652, DOI 10.1128/CDLI.8.3.652-657.2001
   Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974
   Chen HM, 1996, J CONTROL RELEASE, V42, P263, DOI 10.1016/0168-3659(96)01459-9
   Cong YZ, 2009, P NATL ACAD SCI USA, V106, P19256, DOI 10.1073/pnas.0812681106
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Flannigan KL, 2015, AM J PATHOL, V185, P1809, DOI 10.1016/j.ajpath.2015.02.024
   Flores-Langarica A, 2018, MUCOSAL IMMUNOL, V11, P681, DOI 10.1038/mi.2017.105
   Gurel O, 2001, AM J PHYSIOL-LUNG C, V280, pL1266
   Gurwith M, 2013, LANCET INFECT DIS, V13, P238, DOI 10.1016/S1473-3099(12)70345-6
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Harusato A, 2016, METHODS MOL BIOL, V1422, P171, DOI 10.1007/978-1-4939-3603-8_16
   Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552
   HOOK GER, 1978, AM REV RESPIR DIS, V117, P541
   Katz JM, 1997, J INFECT DIS, V175, P352, DOI 10.1093/infdis/175.2.352
   Kim H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191133
   Kimoto T, 2013, INFLUENZA OTHER RESP, V7, P1218, DOI 10.1111/irv.12124
   Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529
   Lamichhane A, 2014, VACCINE, V32, P6711, DOI 10.1016/j.vaccine.2014.08.089
   Lee CT, 2017, CLIN INFECT DIS, V65, P1927, DOI 10.1093/cid/cix668
   Liu J, 2014, J MED VIROL, V86, P886, DOI 10.1002/jmv.23768
   Mann JFS, 2009, VACCINE, V27, P3643, DOI 10.1016/j.vaccine.2009.03.040
   Maroof A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003875
   MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547
   Mizuno D, 2006, J IMMUNOL, V176, P1122, DOI 10.4049/jimmunol.176.2.1122
   Mizuno D, 2016, VACCINE, V34, P1881, DOI 10.1016/j.vaccine.2016.02.061
   Mizuno D, 2011, VACCINE, V29, P5368, DOI 10.1016/j.vaccine.2011.05.090
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157
   Nicholls JM, 2008, TRENDS MICROBIOL, V16, P149, DOI 10.1016/j.tim.2008.01.008
   Nishijima K, 2006, PEDIATR RES, V60, P196, DOI 10.1203/01.pdr.0000228329.90502.3a
   Nishijima K, 2012, AM J PHYSIOL-LUNG C, V303, pL208, DOI 10.1152/ajplung.00081.2011
   Nishino M, 2009, VACCINE, V27, P5620, DOI 10.1016/j.vaccine.2009.07.024
   Pei ZL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129276
   Rahman MM, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-105
   Rhee JH, 2012, CLIN EXP VACCINE RES, V1, P50, DOI 10.7774/cevr.2012.1.1.50
   Ruane DT, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00025
   Scallan CD, 2013, CLIN VACCINE IMMUNOL, V20, P85, DOI 10.1128/CVI.00552-12
   Shakya AK, 2016, J CONTROL RELEASE, V240, P394, DOI 10.1016/j.jconrel.2016.02.014
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Shinya K, 2011, J VIROL, V85, P4673, DOI 10.1128/JVI.00148-11
   Takahashi E, 2010, MICROBES INFECT, V12, P778, DOI 10.1016/j.micinf.2010.04.013
   Tamura SI, 2004, JPN J INFECT DIS, V57, P236
   Watson CE, 2017, VET PATHOL, V54, P527, DOI 10.1177/0300985816681411
   World Health Organization, 2018, INFL SEAS FACT SHEET
   WRIGHT JR, 1987, AM REV RESPIR DIS, V136, P426, DOI 10.1164/ajrccm/136.2.426
   Zhang L, 2017, J VIROL, V91
NR 46
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 612
EP 622
DI 10.1016/j.vaccine.2018.12.002
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200010
PM 30553569
OA Other Gold
DA 2020-05-12
ER

PT J
AU Krishnamoorthy, Y
   Eliyas, SK
   Nair, NP
   Sakthivel, M
   Sarveswaran, G
   Chinnakali, P
AF Krishnamoorthy, Yuvaraj
   Eliyas, Salin K.
   Nair, Nayana P.
   Sakthivel, Manikandanesan
   Sarveswaran, Gokul
   Chinnakali, Palanivel
TI Impact and cost effectiveness of pneumococcal conjugate vaccine in India
SO VACCINE
LA English
DT Article
DE Cost-effectiveness analysis; Impact; Pneumococcal infections;
   Pneumococcal vaccines
ID CHILDREN; BURDEN; STATE
AB Background: World Health Organization has recommended the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunisation programme of all the countries in the world. In lieu of its introduction in India, there is a need to generate evidence on cost-effectiveness of this vaccine. The current study looks into the impact and cost-effectiveness of PCV vaccine in India.
   Methods: We evaluated the cost effectiveness of implementation of PCV 13 vaccination program at national level by comparing with no vaccination program for a period of 10 birth cohorts from 2018 to 2027. UNIVAC, a deterministic static cohort model is developed by giving the conservative estimates of vaccine program related to mortality, disease event rates, vaccine efficacy and coverage projections, system and health care costs for the first five years of life. Cost effectiveness is reported as Incremental Cost Effectiveness Ratio (ICER). Further scenario and sensitivity analysis were done. Probability of PCV intervention to be cost effective at a willingness to pay (WTP) threshold equal to per capita gross domestic product (GDP) is calculated using the government perspective.
   Results: We found that the introduction of PCV vaccination program can cost an additional $467 (INR 31,666) for averting per DALY which is less than one time GDP per capita of India. Even with the most unfavourable scenario for PCV vaccine, cost per DALY averted is found to be $2323 (INR 1,57,520) which is still a cost effective intervention in India. Probabilistic sensitivity analysis found the ICER for PCV to be $649 (INR 44,008) with 95% CI: $374-$1161.
   Conclusion: This study shows that the PCV program is a highly cost effective intervention and justifies the introduction of PCV into routine immunisation schedule in some of the states and recommends introducing it throughout the country to reduce morbidity and mortality among the under-five children. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Krishnamoorthy, Yuvaraj; Eliyas, Salin K.; Sakthivel, Manikandanesan; Sarveswaran, Gokul; Chinnakali, Palanivel] JIPMER, Dept Prevent & Social Med, Pondicherry 605008, India.
   [Nair, Nayana P.] Christian Med Coll & Hosp, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India.
RP Nair, NP (reprint author), Christian Med Coll & Hosp, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India.
EM nayanapnair.chinnu@gmail.com
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   [Anonymous], 2002, WORLD HLTH REP 2002
   Chatterjee S, 2016, INDIAN J MED RES, V143, P801, DOI 10.4103/0971-5916.192073
   Clark A, 2013, VACCINE, V31, pC19, DOI 10.1016/j.vaccine.2013.05.045
   DeAntonio R, 2016, INT J PEDIATR OTORHI, V85, P65, DOI 10.1016/j.ijporl.2016.03.032
   Gupta M, 2013, HEALTH POLICY PLANN, V28, P51, DOI 10.1093/heapol/czs025
   Internal Revenue Service, 2018, YEARL AV CURR EXCH R
   Laxminarayan R, 2011, HEALTH AFFAIR, V30, P1096, DOI 10.1377/hlthaff.2011.0405
   Lucero MG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004977.pub2
   Mackenzie GA, 2017, LANCET INFECT DIS, V17, P965, DOI 10.1016/S1473-3099(17)30321-3
   Megiddo I, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000636
   Megiddo I, 2014, VACCINE, V32, pA151, DOI 10.1016/j.vaccine.2014.04.080
   Ministry of Health and Family Welfare, NAT IMM SCHED NIS IN
   MoHFW, 2013, MULT STRAT PLAN 2013
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Press Information Bureau Ministry of Health and Family Welfare Government of India, JP NADD LAUNCH PNEUM
   Prinja S, 2017, CANCER-AM CANCER SOC, V123, P3253, DOI 10.1002/cncr.30734
   Prinja S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160986
   Prinja S, 2015, APPL HEALTH ECON HEA, V13, P595, DOI 10.1007/s40258-015-0201-6
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   Tan-Torres Edejer T., 2003, MAKING CHOICES HLTH
   UNICEF Supply Division, 2013, VACC PRIC DAT PCV
   WHO, 2013, INTR PNEUM VACC PCV1
   World Health Organization, UN HLTH COV IND
   World Health Organization, PNEUM DIS
   World Health Organization (WHO), IMM COUNTR PROF
   Wu DBC, 2012, VALUE HEALTH, V15, pS15, DOI 10.1016/j.jval.2011.11.013
   Zhang Xu-Hao, 2014, Value Health Reg Issues, V3, P156, DOI 10.1016/j.vhri.2014.04.004
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 623
EP 630
DI 10.1016/j.vaccine.2018.12.004
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200011
PM 30587430
DA 2020-05-12
ER

PT J
AU Tak, CR
   Gunning, K
   Kim, J
   Sherwin, CM
   Ruble, JH
   Nickman, NA
   Biskupiak, JE
AF Tak, Casey R.
   Gunning, Karen
   Kim, Jaewhan
   Sherwin, Catherine M.
   Ruble, James H.
   Nickman, Nancy A.
   Biskupiak, Joseph E.
TI The effect of a prescription order requirement for
   pharmacist-administered vaccination on herpes zoster vaccination rates
SO VACCINE
LA English
DT Article
DE State policy; Herpes zoster; Pharmacy; Complex survey data
ID RISK-FACTORS; EPIDEMIOLOGY; SURVEILLANCE
AB Objective: To determine the effect of a prescription order requirement for pharmacist-administered zoster vaccination on zoster vaccination in adults aged 60+.
   Methods: A 50-state law review of statutes and regulations regarding pharmacists' ability to administer the zoster vaccine with/without a prescription order was performed. States were classified as prescription order required or not required as of January 1, 2014. Data on adults aged 60+ were obtained from the 2014 Behavioral Risk Factor Surveillance System (BRFSS). Chi-square tests and multilevel logistic regression models with and without propensity scores methods were used.
   Results: Of the 50 states, 39 and the District of Columbia did not require a prescription order. After propensity score matching, zoster vaccination rates for adults ages 60 and older were significantly higher in states that did not require a prescription order (23.0% vs 21.1%, p = 0.0022). The propensity score-matched multilevel logistic regression model for adults aged 60+ found modestly higher odds of HZ vaccination for states that removed the prescription order requirement (OR 1.17, 95% CI 1.01-1.35). Similar estimates were found across other methodologies employed and age strata, although statistical significance varied.
   Conclusions: Prescription order requirements are associated with HZ vaccination rates. By removing a prescription order requirement, states may be able to promote increases in HZ vaccination in adults aged 60+. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Tak, Casey R.; Gunning, Karen; Kim, Jaewhan; Sherwin, Catherine M.; Ruble, James H.; Nickman, Nancy A.; Biskupiak, Joseph E.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, 30 South 2000 East, Salt Lake City, UT 84112 USA.
   [Kim, Jaewhan] Univ Utah, Coll Hlth, Dept Hlth Promot & Educ, 250 S 1850 E Rm 239, Salt Lake City, UT 84112 USA.
RP Tak, CR (reprint author), Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Pharmaceut Outcomes & Policy, One Univ Hts,Karpen Hall 143, Asheville, NC 28804 USA.; Tak, CR (reprint author), MAHEC, UNC Hlth Sci, Asheville, NC 28803 USA.
EM casey_tak@unc.edu; Karen.gunning@pharm.utah.edu; jaewhan.kim@utah.edu;
   Catherine.sherwin@hsc.utah.edu; jim.ruble@hsc.utah.edu;
   Nancy.nickman@pharm.utah.edu; joseph.biskupiak@pharm.utah.edu
RI Sherwin, Catherine Mary Turner/B-2888-2012
OI Sherwin, Catherine Mary Turner/0000-0002-0844-3207
FU American Foundation for Pharmaceutical Education; Skaggs Institute for
   Research
FX This work was supported by the American Foundation for Pharmaceutical
   Education and the Skaggs Institute for Research.
CR Agnelli R., 2014, SAS404
   Association of American Medical Colleges, 2015, 2015 STAT PHYS WORKF
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Bradford WD, 2015, HEALTH AFFAIR, V34, P1383, DOI 10.1377/hlthaff.2014.1428
   Brisson M, 2001, EPIDEMIOL INFECT, V127, P305, DOI 10.1017/S0950268801005921
   Centers for Disease Control and Prevention, 2015, BEH RISK FACT SURV S
   Centers for Disease Control and Prevention, 2013, VAR CHICK HERP ZOST
   Centers for Disease Control and Prevention, 2016, SHINGL HERP ZOST
   DuGoff EH, 2014, HEALTH SERV RES, V49, P284, DOI 10.1111/1475-6773.12090
   Esteban-Vasallo MD, 2014, HUM VACC IMMUNOTHER, V10, P1650, DOI 10.4161/hv.28620
   Gomez AM, 2017, JAMA-J AM MED ASSOC, V318, P2253, DOI 10.1001/jama.2017.15674
   Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3
   Higby GJ, 1997, AM J HEALTH-SYST PH, V54, P1805, DOI 10.1093/ajhp/54.16.1805
   Irving SA, 2009, VACCINE, V27, P6546, DOI 10.1016/j.vaccine.2009.08.050
   Leyland AH, 2003, SCAND J PUBLIC HEALT, V31, P267, DOI 10.1080/14034940210165028
   NASPA, 2017, PHARM AUTH PRESCR BI
   National Community Pharmacists Association, 2015, NCPA DIG
   Nkansah N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000336.pub2
   Rolnick SJ, 2013, VACCINE, V31, P3928, DOI 10.1016/j.vaccine.2013.06.041
   Sakshaug JW, 2014, AM J PUBLIC HEALTH, V104, P15, DOI 10.2105/AJPH.2013.301515
   Salmond C., 2006, FITTING COMPLEX MODE
   Silva NM, 2014, INT J AGING HUM DEV, V79, P336, DOI 10.1177/0091415015574184
   Steyer TE, 2004, VACCINE, V22, P1001, DOI 10.1016/j.vaccine.2003.08.045
   Taitel MS, 2013, AM J MANAG CARE, V19
   Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0
   Traynor K., 2009, AM J HLTH SYST PHARM, V66
   United States Census Bureau, POP 65 YEARS US TABL
   United States Department of Health and Human Services, 2016, GOAL 4 ENS STABL SUP
   United States Government Accountability Office, 2011, MAN FACT INCL ADM D
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
NR 30
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 631
EP 636
DI 10.1016/j.vaccine.2018.12.003
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200012
PM 30563788
DA 2020-05-12
ER

PT J
AU Wedlock, PT
   Mitgang, EA
   Haidari, LA
   Prosser, W
   Brown, ST
   Krudwig, K
   Siegmund, SS
   DePasse, JV
   Bakal, E
   Leonard, J
   Welling, J
   Steinglass, R
   Mwansa, FD
   Phiri, G
   Lee, BY
AF Wedlock, Patrick T.
   Mitgang, Elizabeth A.
   Haidari, Leila A.
   Prosser, Wendy
   Brown, Shawn T.
   Krudwig, Kirstin
   Siegmund, Sheryl S.
   DePasse, Jay, V
   Bakal, Ejennifer
   Leonard, Jim
   Welling, Joel
   Steinglass, Robert
   Mwansa, Frances Dien
   Phiri, Guissimon
   Lee, Bruce Y.
TI The value of tailoring vial sizes to populations and locations
SO VACCINE
LA English
DT Article
DE Measles-rubella; Supply chain logistics; Tailoring; Vial size
ID VACCINE; CONTAINER; SINGLE; IMPACT
AB Background: Frequently, a country will procure a single vaccine vial size, but the question remains whether tailoring the use of different size vaccine vial presentations based on populations or location characteristics within a single country could provide additional benefits, such as reducing open vial wastage (OVW) or reducing missed vaccination opportunities.
   Methods: Using the Highly Extensible Resource for Modeling Supply Chains (HERMES) software, we built a simulation model of the Zambia routine vaccine supply chain. At baseline, we distributed 10-dose Measles-Rubella (MR) vials to all locations, and then distributed 5-dose and 1-dose MR vials to (1) all locations, (2) rural districts, (3) rural health facilities, (4) outreach sites, and (5) locations with average MR session sizes <5 and <10 children. We ran sensitivity on each scenario using MR vial opening thresholds of 0% and 50%, i.e. a healthcare worker opens an MR vaccine for any number of children (0%) or if at least half will be used (50%).
   Results: Replacing 10-dose MR with 5-dose MR vials everywhere led to the largest reduction in MR OVW, saving 573,892 doses (103,161 doses with the 50% vial opening threshold) and improving MR availability by 1% (9%). This scenario, however, increased cold chain utilization and led to a 1% decrease in availability of other vaccines. Tailoring 5-dose MR vials to rural health facilities or based on average session size reduced cold transport constraints, increased total vaccine availability (+1%) and reduced total cost per dose administered (-$0.01) compared to baseline.
   Conclusions: In Zambia, tailoring 5-dose MR vials to rural health facilities or by average session size results in the highest total vaccine availability compared to all other scenarios (regardless of OVT policy) by reducing open vial wastage without increasing cold chain utilization. (C) 2018 Published by Elsevier Ltd.
C1 [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Haidari, Leila A.; Brown, Shawn T.; Siegmund, Sheryl S.; DePasse, Jay, V; Bakal, Ejennifer; Leonard, Jim; Welling, Joel; Lee, Bruce Y.] HERMES Logist Modeling Team, Baltimore, MD USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Haidari, Leila A.; Brown, Shawn T.; Siegmund, Sheryl S.; DePasse, Jay, V; Bakal, Ejennifer; Leonard, Jim; Welling, Joel; Lee, Bruce Y.] HERMES Logist Modeling Team, Pittsburgh, PA USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Siegmund, Sheryl S.; Lee, Bruce Y.] Johns Hopkins Univ, GOPC, 615 North Wolfe St, Baltimore, MD 21205 USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Siegmund, Sheryl S.; Lee, Bruce Y.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 North Wolfe St, Baltimore, MD 21205 USA.
   [Haidari, Leila A.; DePasse, Jay, V; Bakal, Ejennifer; Leonard, Jim; Welling, Joel] Carnegie Mellon Univ, PSC, 300 Craig St, Pittsburgh, PA 15213 USA.
   [Prosser, Wendy; Krudwig, Kirstin; Steinglass, Robert] JSI Res & Training Inst Inc JSI, Denver, CO USA.
   [Brown, Shawn T.] McGill Univ, McGill Ctr Integrat Neurosci, McGill Neurol Inst, Montreal, PQ, Canada.
   [Mwansa, Frances Dien; Phiri, Guissimon] Minist Hlth, Lusaka, Zambia.
RP Lee, BY (reprint author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, GOPC, 615 North Wolfe St, Baltimore, MD 21205 USA.
EM brucelee@jhu.edu
OI Wedlock, Patrick/0000-0001-7635-5949; Brown, Shawn/0000-0001-6980-8372
FU Bill and Melinda Gates FoundationGates Foundation; Agency for Healthcare
   Research and Quality (AHRQ)United States Department of Health & Human
   ServicesAgency for Healthcare Research & Quality [R01HS023317]; USAID
   System and Complexity Monitoring, Evaluation, Research, and Learning
   (System and Complexity MERL)United States Agency for International
   Development (USAID) [AID-OAA-A-15-00064]; Global Obesity Prevention
   Center (GOPC) at Johns Hopkins; National Institute of General Medical
   Sciences Modeling Infectious Disease Agent Study (MIDAS) Informatics
   Services Group [1U24GM110707]; Eunice Kennedy Shriver National Institute
   of Child Health and Human Development (NICHD)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD); Office of the Director, National Institutes of
   Health (OD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U54HD070725]
FX This work was supported by the Bill and Melinda Gates Foundation, the
   Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317,
   USAID System and Complexity Monitoring, Evaluation, Research, and
   Learning (System and Complexity MERL) via AID-OAA-A-15-00064, National
   Institute of General Medical Sciences Modeling Infectious Disease Agent
   Study (MIDAS) Informatics Services Group grant 1U24GM110707, and the
   Global Obesity Prevention Center (GOPC) at Johns Hopkins and the Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   (NICHD) and the Office of the Director, National Institutes of Health
   (OD) under award number U54HD070725. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The funders had no
   role in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; and preparation, review, or
   approval of the manuscript.
CR [Anonymous], 2017, VACC PRIC DAT
   Assi TM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-425
   Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090
   CS Office, 2012, ZAMB 2010 CENS POP H, P1
   DPCP, 2018, VACCINE
   Haidari LA, 2015, VACCINE, V33, P3242, DOI 10.1016/j.vaccine.2015.04.018
   Heaton A, 2017, VACCINE, V35, P2272, DOI 10.1016/j.vaccine.2016.11.066
   Lee BY, 2017, VACCINE, V35, P3135, DOI 10.1016/j.vaccine.2017.03.081
   Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036
   Lee BY, 2011, VACCINE, V29, P3811, DOI 10.1016/j.vaccine.2011.03.013
   Lee BY, 2010, VACCINE, V28, P5292, DOI 10.1016/j.vaccine.2010.05.048
   PAHO Revolving Fund, 2017, EXP PROGR IMM VACC P
   World Bank, 2017, WORLD BANK NAT ACC N
   World Bank, 2017, WORLD BANK NAT ACC P
   World Bank, 2017, WORLD BANK NAT ACC I
   World Bank Bank, 2017, WORLD BANK NAT ACC C
   World Health Organization, 2017, WHO PREQ VACC
   World Health Organization, 2017, WHO VACC PREV DIS MO
NR 18
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 637
EP 644
DI 10.1016/j.vaccine.2018.12.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200013
PM 30578087
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Wedlock, PT
   Mitgang, EA
   Elsheikh, F
   Leonard, J
   Bakal, J
   Welling, J
   Crawford, J
   Assy, E
   Magadzire, BP
   Bechtel, R
   DePasse, JV
   Siegmund, SS
   Brown, ST
   Lee, BY
AF Wedlock, Patrick T.
   Mitgang, Elizabeth A.
   Elsheikh, Fayad
   Leonard, Jim
   Bakal, Jenn
   Welling, Joel
   Crawford, Jessica
   Assy, Emmanuelle
   Magadzire, Bvudzai P.
   Bechtel, Ruth
   DePasse, Jay, V
   Siegmund, Sheryl S.
   Brown, Shawn T.
   Lee, Bruce Y.
TI The potential effects of introducing microneedle patch vaccines into
   routine vaccine supply chains
SO VACCINE
LA English
DT Article
DE Delivery; Logistics; Microneedle patch; Supply chain
ID IMPACT
AB Background: Microneedle patch (MNP) technology is designed to simplify the process of vaccine administration; however, depending on its characteristics, MNP technology may provide additional benefits beyond the point-of-use, particularly for vaccine supply chains.
   Methods: Using the HERMES modeling software, we examined replacing four routine vaccines - Measles-containing vaccine (MCV), Tetanus toxoid (TT), Rotavirus (Rota) and Pentavalent (Penta) - with MNP versions in the routine vaccine supply chains of Benin, Bihar (India), and Mozambique.
   Results: Replacing MCV with an MNP (5 cm 3 -per-dose, 2-month thermostability, current single-dose price-per-dose) improved MCV availability by 13%, 1% and 6% in Benin, Bihar and Mozambique, respectively, and total vaccine availability by 1% in Benin and Mozambique, while increasing the total cost per dose administered by $0.07 in Benin, $0.56 in Bihar and $0.11 in Mozambique. Replacing TT with an MNP improved TT and total vaccine availability (3% and <1%) in Mozambique only, when the patch was 5 cm(3) and 2-months thermostable but increased total cost per dose administered by $0.14. Replacing Rota with an MNP (at 5-15 cm(3)-per-dose, 1-2 month thermostable) improved Rota and total vaccine availability, but only improved Rota vaccine availability in Bihar (at 5 cm(3), 1-2 months thermostable), while decreasing total vaccine availability by 1%. Finally, replacing Penta with an MNP (at 5 cm(3), 2-months thermostable) improved Penta vaccine availability by 1-8% and total availability by <1-9%.
   Conclusions: An MNP for MCV, TT, Rota, or Penta would need to have a smaller or equal volume-per-dose than existing vaccine formulations and be able to be stored outside the cold chain for a continuous period of at least two months to provide additional benefits to all three supply chains under modeled conditions. (C) 2018 Published by Elsevier Ltd.
C1 [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Siegmund, Sheryl S.; Lee, Bruce Y.] Johns Hopkins Univ, GOPC, Baltimore, MD USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Elsheikh, Fayad; Leonard, Jim; Bakal, Jenn; Welling, Joel; DePasse, Jay, V; Siegmund, Sheryl S.; Brown, Shawn T.; Lee, Bruce Y.] HERMES Logist Modeling Team, Baltimore, MD USA.
   [Wedlock, Patrick T.; Mitgang, Elizabeth A.; Elsheikh, Fayad; Leonard, Jim; Bakal, Jenn; Welling, Joel; DePasse, Jay, V; Siegmund, Sheryl S.; Brown, Shawn T.; Lee, Bruce Y.] HERMES Logist Modeling Team, Pittsburgh, PA USA.
   [Leonard, Jim; Bakal, Jenn; Welling, Joel; DePasse, Jay, V] PSC, Pittsburgh, PA USA.
   [Crawford, Jessica; Assy, Emmanuelle; Magadzire, Bvudzai P.; Bechtel, Ruth] VillageReach, Seattle, WA USA.
   [Brown, Shawn T.] McGill Univ, McGill Ctr Integrat Neurosci, McGill Neurol Inst, Montreal, PQ, Canada.
RP Lee, BY (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, GOPC, Dept Int Hlth, Publ Hlth Computat & Operat Res PHICOR,IVAC, 615 N Wolfe St,Room W3501, Baltimore, MD 21205 USA.
EM brucelee@jhu.edu
OI Brown, Shawn/0000-0001-6980-8372; Wedlock, Patrick/0000-0001-7635-5949
FU Bill and Melinda Gates FoundationGates Foundation; Agency for Healthcare
   Research and Quality (AHRQ)United States Department of Health & Human
   ServicesAgency for Healthcare Research & Quality [R01HS023317]; National
   Institute of General Medical Sciences Modeling Infectious Disease Agent
   Study (MIDAS) Informatics Services Group [1U24GM110707]; Global Obesity
   Prevention Center (GOPC) at Johns Hopkins; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); Office of the Director, National
   Institutes of Health (OD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54HD070725]
FX The authors would like to extend thanks to Mark Prausnitz, Regents'
   Professor, J. Erskine Love Jr. Chair in Chemical & Biomolecular
   Engineering, and Director of the Center for Drug Design, Development and
   Delivery at Georgia Tech, for providing expert consultation on
   microneedle patch technology. This work was supported by the Bill and
   Melinda Gates Foundation, the Agency for Healthcare Research and Quality
   (AHRQ) via grant R01HS023317, National Institute of General Medical
   Sciences Modeling Infectious Disease Agent Study (MIDAS) Informatics
   Services Group grant 1U24GM110707, and the Global Obesity Prevention
   Center (GOPC) at Johns Hopkins and the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD) and the Office
   of the Director, National Institutes of Health (OD) under award number
   U54HD070725. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health. The funders had no role in the design and conduct
   of the study; collection, management, analysis, and interpretation of
   the data; and preparation, review, or approval of the manuscript.
CR Adhikari BB, 2016, DRUGS R&D, V16, P327, DOI 10.1007/s40268-016-0144-x
   Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6
   Arya J, 2017, BIOMATERIALS, V128, P1, DOI 10.1016/j.biomaterials.2017.02.040
   Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019
   Ashok A, 2017, VACCINE, V35, P2217, DOI 10.1016/j.vaccine.2016.08.045
   Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090
   Brown ST, 2014, VACCINE, V32, P2518, DOI 10.1016/j.vaccine.2014.02.060
   Edens C, 2015, VACCINE, V33, P4712, DOI 10.1016/j.vaccine.2015.02.074
   Edens C, 2013, VACCINE, V31, P3403, DOI 10.1016/j.vaccine.2012.09.062
   Esser ES, 2016, J CONTROL RELEASE, V236, P47, DOI 10.1016/j.jconrel.2016.06.026
   Haidari LA, 2016, VACCINE, V34, P4062, DOI 10.1016/j.vaccine.2016.06.022
   Kaufmann JR, 2011, HEALTH AFFAIR, V30, P1113, DOI 10.1377/hlthaff.2011.0368
   Lee BY, 2017, VACCINE, V35, P3135, DOI 10.1016/j.vaccine.2017.03.081
   Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036
   Lee BY, 2012, VACCINE, V30, P5637, DOI 10.1016/j.vaccine.2012.06.087
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Moon S, 2013, VACCINE, V31, P3396, DOI 10.1016/j.vaccine.2012.11.027
   Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514
   Product WHO, 2018, DEV VACC ADV COMM NE
   Prosser W, 2017, VACCINE, V35, P2162, DOI 10.1016/j.vaccine.2016.09.073
   Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5
   WHO, 2016, GUID STAB EV VACC US
   Wong C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169030
   Zehrung D., 2017, OVERVIEW STATUS NOVE
NR 24
TC 1
Z9 1
U1 3
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 645
EP 651
DI 10.1016/j.vaccine.2018.12.008
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200014
PM 30578088
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Biedma, ME
   Cayet, D
   Tabareau, J
   Rossi, AH
   Ivicak-Kocjan, K
   Moreno, G
   Errea, A
   Soulard, D
   Parisi, G
   Jerala, R
   Berguer, P
   Rumbo, M
   Sirard, JC
AF Biedma, Marina E.
   Cayet, Delphine
   Tabareau, Julien
   Rossi, Andres H.
   Ivicak-Kocjan, Karolina
   Moreno, Griselda
   Errea, Agustina
   Soulard, Daphnee
   Parisi, Gustavo
   Jerala, Roman
   Berguer, Paula
   Rumbo, Martin
   Sirard, Jean Claude
TI Recombinant flagellins with deletions in domains D1, D2, and D3:
   Characterization as novel immunoadjuvants
SO VACCINE
LA English
DT Article
DE Flagellin; TLR5; Adjuvant; Epithelium; Innate response; Antibody
   response
ID MUCOSAL ADJUVANT ACTIVITY; SALMONELLA-FLAGELLIN; BACTERIAL FLAGELLIN;
   IMMUNE-RESPONSE; FUSION PROTEIN; TLR5 BINDING; T-CELLS; ACTIVATION;
   TOLL-LIKE-RECEPTOR-5; INFLAMMASOME
AB Bacterial flagellin activates the innate immune system and ultimately the adaptive immune system through a Toll-like receptor 5 (TLR5)-dependent signaling mechanism. Given that TLR5 is widely distributed in epithelia, flagellin is currently being developed as a mucosal adjuvant. Flagellin FliC from Salmonella enterica has four domains: the conserved D0 and D1 domains and the hypervariable D2 and D3 domains. The deletion of D3 and partial deletion of D2 in the recombinant FliC(Delta 174-400) strongly impairs flagellin's intrinsic antigenicity but does not affect the TLR5-dependent immunostimulation activity, i.e., the capacity to promote innate responses and adaptive responses to co-administered antigens. Here, we describe the development of novel recombinant flagellins with various deletions encompassing all of D2 and D3, and part of D1. Most of the recombinant molecules conserved an alpha-helical secondary structure that was as resistant to heat denaturation as the native protein. Whereas the recombinant flagellins' ability to trigger TLR5 varied markedly in vitro, most gave equivalent in vivo TLR5-dependent innate immune responses following intranasal administration of 2 mu g of flagellin to mice. Concordantly, the recombinant flagellins were also valuable respiratory adjuvants for eliciting antibody responses to the foreign antigen ovalbumin, although their intrinsic antigenicity was decreased compared to the native flagellin and not increased compared to FliC(Delta 174-400). Our results show that the additional deletions of D2 and the distal part of D1 of FliC(Delta 174-400) does not impact on antigenicity and does not significantly modify the immunostimulatory adjuvant activity. Altogether, this study generated a novel set of recombinant flagellin that constitutes a portfolio of TLR5-dependent candidate adjuvants for vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Biedma, Marina E.; Moreno, Griselda; Errea, Agustina; Rumbo, Martin] Inst Estudios Inmunol & Fisiopatol IIFP, B1900, La Plata, Buenos Aires, Argentina.
   [Cayet, Delphine; Tabareau, Julien; Soulard, Daphnee; Sirard, Jean Claude] CHU Lille, CNRS, Inserm, Inst Pasteur Lille,U1019,UMR8204,CIIL, F-59000 Lille, France.
   [Rossi, Andres H.; Berguer, Paula] Consejo Nacl Invest Cient & Tecn, Fdn Inst Leloir, IIBBA, C1405BWE, Buenos Aires, DF, Argentina.
   [Parisi, Gustavo] Univ Nacl Quilmes, Grp Bioinformat Estruct, B1878, Quilmes, Argentina.
   [Ivicak-Kocjan, Karolina; Jerala, Roman] Univ Ljubljana, Natl Inst Chem, SI-1000 Ljubljana, Slovenia.
RP Rumbo, M (reprint author), Inst Estudios Inmunol & Fisiopatol IIFP, B1900, La Plata, Buenos Aires, Argentina.; Sirard, JC (reprint author), CHU Lille, CNRS, Inserm, Inst Pasteur Lille,U1019,UMR8204,CIIL, F-59000 Lille, France.
EM martinr@biol.unlp.edu.ar; jean-claude.sirard@inserm.fr
RI Berguer, Paula/AAI-6353-2020; Sirard, Jean-Claude/B-5932-2011
OI Sirard, Jean-Claude/0000-0001-9854-4652
FU France (Inserm); France (CNRS)Centre National de la Recherche
   Scientifique (CNRS); France (Institut Pasteur de Lille); France
   (Universite de Lille); Argentina (CONICET)Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); InsermTransfert; ECOS
   - French Ministry for Research and Higher Education - Argentinean
   Ministry of Science, Technology and Productive Innovation [A12B03];
   Agenda Nacional de Promocion Cientifica y Tecnologica [PICTO GSK 0048];
   MINCYT-MHEST - Slovenian Ministry of Science - Argentinean Ministry of
   Science, Technology and Productive Innovation [SL01406]; CONICETConsejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
FX The work was funded by the institutional support from France (Inserm,
   CNRS, Institut Pasteur de Lille, and Universite de Lille), and Argentina
   (CONICET), as well as grants from InsermTransfert (grant CoPoC
   MucoFlag), ECOS - French Ministry for Research and Higher Education -
   Argentinean Ministry of Science, Technology and Productive Innovation
   (grant number A12B03), Agenda Nacional de Promocion Cientifica y
   Tecnologica (grant number PICTO GSK 0048), and MINCYT-MHEST - Slovenian
   Ministry of Science - Argentinean Ministry of Science, Technology and
   Productive Innovation (grant number SL01406). AE received a Bernardo
   Houssay fellowship from CONICET. MEB and AR are fellows from CONICET.
CR Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102
   Andersen-Nissen E, 2007, J EXP MED, V204, P393, DOI 10.1084/jem.20061400
   Bates JT, 2008, MECH AGEING DEV, V129, P271, DOI 10.1016/j.mad.2008.01.009
   Bobat S, 2011, EUR J IMMUNOL, V41, P1606, DOI 10.1002/eji.201041089
   Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986
   Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922
   Donnelly MA, 2002, J BIOL CHEM, V277, P40456, DOI 10.1074/jbc.M206851200
   Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009
   Forstneric V, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006574
   Forstneric V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158894
   Fougeron D, 2015, VACCINE, V33, P3331, DOI 10.1016/j.vaccine.2015.05.022
   Gewirtz AT, 2004, J INFECT DIS, V189, P1914, DOI 10.1086/386289
   Hajam IA, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.172
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   HE XS, 1994, J BACTERIOL, V176, P2406, DOI 10.1128/JB.176.8.2406-2414.1994
   Hiriart Y, 2017, PROTEIN SCI, V26, P1049, DOI 10.1002/pro.3151
   Hu MD, 2012, INFLAMM RES, V61, P837, DOI 10.1007/s00011-012-0475-1
   Ivicak-Kocjan K, 2018, J LEUKOCYTE BIOL, V104, P767, DOI 10.1002/JLB.3VMA0118-035R
   KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988
   Kwang J, 1996, CLIN DIAGN LAB IMMUN, V3, P523, DOI 10.1128/CDLI.3.5.523-526.1996
   Lightfield KL, 2008, NAT IMMUNOL, V9, P1171, DOI 10.1038/ni.1646
   Lim JS, 2015, AGING CELL, V14, P907, DOI 10.1111/acel.12383
   Liu F, 2010, BIOCHEM BIOPH RES CO, V392, P582, DOI 10.1016/j.bbrc.2010.01.077
   Lu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep18379
   Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
   Matusiak M, 2015, P NATL ACAD SCI USA, V112, P1541, DOI 10.1073/pnas.1417945112
   McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000
   McNeilly TN, 2010, VACCINE, V28, P1412, DOI 10.1016/j.vaccine.2009.10.148
   McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914
   Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156
   Mizel SB, 2009, CLIN VACCINE IMMUNOL, V16, P21, DOI 10.1128/CVI.00333-08
   Nempont C, 2008, J IMMUNOL, V181, P2036, DOI 10.4049/jimmunol.181.3.2036
   NEWTON SMC, 1991, MOL MICROBIOL, V5, P419, DOI 10.1111/j.1365-2958.1991.tb02124.x
   Porte R, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00806-16
   Porte R, 2015, ANTIMICROB AGENTS CH, V59, P6064, DOI 10.1128/AAC.01210-15
   Qian F, 2015, VACCINE, V33, P2038, DOI 10.1016/j.vaccine.2015.03.006
   Sanders CJ, 2006, J IMMUNOL, V177, P2810, DOI 10.4049/jimmunol.177.5.2810
   Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011
   Song WS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40878
   Song WS, 2014, BIOCHEM BIOPH RES CO, V444, P109, DOI 10.1016/j.bbrc.2014.01.008
   Tina KG, 2007, NUCLEIC ACIDS RES, V35, pW473, DOI 10.1093/nar/gkm423
   Van Maele L, 2014, MUCOSAL IMMUNOL, V7, P489, DOI 10.1038/mi.2013.66
   VANASTEN AJAM, 1995, J BACTERIOL, V177, P1610, DOI 10.1128/jb.177.6.1610-1613.1995
   Vijayan A, 2018, TRENDS MICROBIOL, V26, P423, DOI 10.1016/j.tim.2017.10.008
   VONDERVISZT F, 1990, J MOL BIOL, V214, P97, DOI 10.1016/0022-2836(90)90149-G
   VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9
   Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830
   Yoon SI, 2012, SCIENCE, V335, P859, DOI 10.1126/science.1215584
   Zhao Y, 2015, IMMUNOL REV, V265, P85, DOI 10.1111/imr.12293
NR 49
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 652
EP 663
DI 10.1016/j.vaccine.2018.12.009
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200015
PM 30583910
DA 2020-05-12
ER

PT J
AU Hook, LM
   Awasthi, S
   Dubin, J
   Flechtner, J
   Long, D
   Friedman, HM
AF Hook, Lauren M.
   Awasthi, Sita
   Dubin, Jonathan
   Flechtner, Jessica
   Long, Deborah
   Friedman, Harvey M.
TI A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates
   antibody responses that block immune evasion domains on gC2 better than
   natural infection
SO VACCINE
LA English
DT Article
DE Herpes simplex virus; Vaccine; Glycoprotein C; Immune evasion;
   Complement C3b; Genital herpes
ID GENITAL HSV-2 INFECTION; SUBUNIT ANTIGEN VACCINE; GLYCOPROTEIN-C;
   TYPE-1; IDENTIFICATION; PREVENTION; MECHANISM; EFFICACY; HIV-1
AB Vaccines for prevention and treatment of genital herpes are high public health priorities. Our approach towards vaccine development is to focus on blocking virus entry mediated by herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) and to prevent the virus from evading complement and antibody attack by blocking the immune evasion domains on HSV-2 glycoproteins C (gC2) and E (gE2), respectively. HSV-2 gC2 and gE2 are expressed on the virion envelope and infected cell surface where they are potential targets of antibodies that bind and block their immune evasion activities. We demonstrate that antibodies produced during natural infection in humans or intravaginal inoculation in guinea pigs bind to gC2 but generally fail to block the immune evasion domains on this glycoprotein. In contrast, immunization of naive or previously HSV-2-infected guinea pigs with gC2 subunit antigen administered with CpG and alum as adjuvants produces antibodies that block domains involved in immune evasion. These results indicate that immune evasion domains on gC2 are weak antigens during infection, yet when used as vaccine immunogens with adjuvants the antigens produce antibodies that block immune evasion domains. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hook, Lauren M.; Awasthi, Sita; Dubin, Jonathan; Friedman, Harvey M.] Univ Penn, Perelman Sch Med, Dept Med, Infect Dis Div, Philadelphia, PA 19104 USA.
   [Flechtner, Jessica; Long, Deborah] Genocea Biosci, Cambridge, MA 02140 USA.
RP Hook, LM (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Infect Dis Div, Philadelphia, PA 19104 USA.
EM lhook@pennmedicine.upenn.edu; sawasthi@pennmedicine.upenn.edu;
   jessica.flechtner@genocea.com; debbie.long@genocea.com;
   hfriedma@pennmedicine.upenn.edu
OI Flechtner, Jessica/0000-0002-7034-7689; Hook, Lauren/0000-0002-5540-2459
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI105959, RO1AI104854, P30 AI045008]
FX This work was supported by the National Institutes of Health (NIH),
   National Institute of Allergy and Infectious Diseases (NIAID) under
   grants R21AI105959 (Awasthi and Friedman co-PI), RO1AI104854 (Friedman
   PI), and P30 AI045008 (Center for AIDS Research). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Awasthi S., 2017, HUM VACC IMMUNOTHER, p[1, 1]
   Awasthi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006141
   Awasthi S, 2014, CURR OPIN VIROL, V6, P6, DOI 10.1016/j.coviro.2014.02.006
   Awasthi S, 2014, J VIROL, V88, P8421, DOI 10.1128/JVI.01130-14
   Awasthi S, 2014, J VIROL, V88, P2000, DOI 10.1128/JVI.03163-13
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   BOLMSTEDT A, 1992, J GEN VIROL, V73, P3099, DOI 10.1099/0022-1317-73-12-3099
   Cairns TM, 2014, J VIROL, V88, P12612, DOI 10.1128/JVI.01930-14
   Chang YJ, 2005, VACCINE, V23, P4658, DOI 10.1016/j.vaccine.2005.04.034
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331
   Dasgupta G, 2012, J VIROL, V86, P4358, DOI 10.1128/JVI.07107-11
   FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989
   HARRIS SL, 1990, J INFECT DIS, V162, P331, DOI 10.1093/infdis/162.2.331
   Hook LM, 2008, J VIROL, V82, P6935, DOI 10.1128/JVI.02599-07
   Hook LM, 2006, J VIROL, V80, P4038, DOI 10.1128/JVI.80.8.4038-4046.2006
   Judson KA, 2003, J VIROL, V77, P12639, DOI 10.1128/JVI.77.23.12639-12645.2003
   Kalantari-Dehaghi M, 2012, J VIROL, V86, P4328, DOI 10.1128/JVI.05194-11
   Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594
   Kostavasil I, 1997, J IMMUNOL, V158, P1763
   Long D, 2014, VIROLOGY, V464, P296, DOI 10.1016/j.virol.2014.07.018
   Lubinski JM, 2011, J VIROL, V85, P3239, DOI 10.1128/JVI.02509-10
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915
   Whitbeck JC, 2014, J VIROL
   WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0
NR 25
TC 5
Z9 5
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 664
EP 669
DI 10.1016/j.vaccine.2018.11.076
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200016
PM 30551986
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Basta, NE
   Becker, AB
   Li, QX
   Nederhoff, D
AF Basta, Nicole E.
   Becker, Andrew B.
   Li, Qingxiao
   Nederhoff, Dawn
TI Parental awareness of Meningococcal B vaccines and willingness to
   vaccinate their teens
SO VACCINE
LA English
DT Article
DE Meningococcal vaccines; Meningococcal B; Awareness; Parents;
   Adolescents; Survey
ID AGED 13-17 YEARS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DISEASE
   RECOMMENDATIONS; UNITED-STATES; ADOLESCENTS; KNOWLEDGE; ATTITUDES;
   ACCEPTABILITY; BEHAVIORS
AB Background: In the US, Meningococcal B (MenB) vaccines were first licensed in 2014. In 2015, the Advisory Committee on Immunization Practices recommended that parents of teens talk to their provider about receiving MenB vaccine, rather than issuing a routine recommendation. We assessed parental awareness of MenB vaccines and willingness to vaccinate their teens with MenB vaccines compared to MenACWY vaccines, which have been routinely recommended for many years.
   Methods: We surveyed parents of teens attending high school in 2017-18 during the Minnesota State Fair. Parents reported via iPad their knowledge of and concern about meningococcal disease and their awareness of and willingness to vaccinate with MenB and MenACWY vaccines. We assessed the relationship between meningococcal disease knowledge and concern, MenB and MenACWY vaccine awareness, and willingness to vaccinate with MenB and MenACWY using adjusted logistic regression.
   Results: Among 445 parents, the majority had not heard of the newly introduced MenB vaccines Bexsero (R) (80.0%; 95% CI: 76.0-83.6) or Trumenba (R) (82.0%; 95% CI: 78.1-85.5) or the MenACWY vaccines Menactra (R) or Menveo (R) (68.8%; 95% CI: 64.2-73.0). The majority were at least somewhat willing to vaccinate their teen with MenB vaccine (89.6%; 95% CI: 86.5, 92.3) and MenACWY vaccine (91.2%; 95% CI: 88.2, 93.7). Awareness of MenB vaccines (OR: 3.8; 95% CI: 1.2-12.2) and concern about meningococcal disease (OR: 3.1; 95% CI: 1.5-6.3) were significantly associated with willingness to vaccinate with MenB vaccine.
   Conclusions: Awareness of MenB vaccine is lacking among parents of teens but is an important predictor of willingness to vaccinate with the newly licensed MenB vaccines. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Basta, Nicole E.; Nederhoff, Dawn] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
   [Becker, Andrew B.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55454 USA.
   [Li, Qingxiao] Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA.
RP Basta, NE (reprint author), Univ Minnesota, 1300 Second St South,West Bank Off Bldg,Suite 300, Minneapolis, MN 55454 USA.
EM nebasta@umn.edu
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI132496]; Office of The
   Director of the National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [DP50D009162]
FX This research was supported by the National Institute of Allergy and
   Infectious Diseases of the National Institutes of Health (NIH) under
   Award Number R01AI132496 (PI: Nicole E. Basta) and the Office of The
   Director of the National Institutes of Health under Award Number
   DP50D009162 (PI: Nicole E. Basta). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH. Funding sources had no role in the study
   design; in the collection, analysis and interpretation of data; in the
   writing of the report; and in the decision to publish.
CR American Academy of Family Physicians, 2016, MEN DIS VACC
   Breakwell L, 2016, J ADOLESC HLTH
   Chang Qiuzhi, 2012, Clin Epidemiol, V4, P237, DOI 10.2147/CLEP.S28410
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Committee on Infectious Diseases, 2016, PEDIATRICS, V138
   de Waure C, 2016, PUBLIC HEALTH, V141, P136, DOI 10.1016/j.puhe.2016.09.006
   Dorell CG, 2011, PUBLIC HEALTH REP, V126, P60, DOI 10.1177/00333549111260S208
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
   Gilkey MB, 2016, HUM VACC IMMUNOTHER, V12, P1454, DOI 10.1080/21645515.2015.1129090
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jackson C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012851
   Kaplan SL, 2006, PEDIATRICS, V118, pE979, DOI 10.1542/peds.2006-0281
   Kempe A, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0344
   MacDougall DM, 2017, VACCINE, V35, P2520, DOI 10.1016/j.vaccine.2017.02.011
   MacNeil JR, 2015, MMWR-MORBID MORTAL W, V64, P1171, DOI 10.15585/mmwr.mm6441a3
   Mameli C, 2014, HUM VACC IMMUNOTHER, V10, P3004, DOI 10.4161/21645515.2014.971602
   Marshall HS, 2016, VACCINE, V34, P671, DOI 10.1016/j.vaccine.2015.11.075
   Mbaeyi SA, 2018, CLIN INFECT DIS
   Meningitis B Action Project, MEN B MAND TRACK
   Morrone T, 2017, HUM VACC IMMUNOTHER, V13, P1921, DOI 10.1080/21645515.2017.1313940
   National Meningitis Association, 2016, SER B MEN DIS OUTBR
   Patton ME, 2017, MMWR-MORBID MORTAL W, V66, P509, DOI 10.15585/mmwr.mm6619a6
   Soeters HM, 2015, MMWR-MORBID MORTAL W, V64, P606
   Takla A, 2014, VACCINE, V32, P6349, DOI 10.1016/j.vaccine.2014.09.040
   Thigpen MC, 2011, NEW ENGL J MED, V364, P2016, DOI 10.1056/NEJMoa1005384
   Tho SLN, 2015, VACCINE, V33, P3463, DOI 10.1016/j.vaccine.2015.05.073
   Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4
   US Centers for Disease Control and Prevention, MEN VACC AD INF HEAL
   US Centers for Disease Control and Prevention, 2017, ENH MEN DIS SURV REP
   US Centers for Disease Control and Prevention, 2018, 2017 AD MEN CONJ MEN
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
NR 31
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 21
PY 2019
VL 37
IS 4
BP 670
EP 676
DI 10.1016/j.vaccine.2018.11.078
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HJ1EH
UT WOS:000456904200017
PM 30587431
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Attwell, K
   Dube, E
   Gagneur, A
   Omer, SB
   Suggs, LS
   Thomson, A
AF Attwell, Katie
   Dube, Eve
   Gagneur, Arnaud
   Omer, Saad B.
   Suggs, L. Suzanne
   Thomson, Angus
TI Vaccine acceptance: Science, policy, and practice in a 'post-fact' world
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 5th Annual Meeting of Fondation-Merieux-Les
   Pensieres-Center-for-Global-Health
CY SEP 25-27, 2017
CL FRANCE
SP Fondat Merieux Pensieres Ctr Global Hlth
DE Vaccine acceptance; Vaccine uptake; Vaccination; Health communication;
   Motivational interviewing
ID SOCIAL MARKETING CAMPAIGN; CHILDHOOD IMMUNIZATION; HESITANCY;
   COMMUNICATION; DISCUSSIONS; EXEMPTIONS; COMMUNITY
AB Suboptimal vaccination uptake may be associated with outbreaks of vaccine-preventable diseases in many parts of the world. Researchers and practitioners working on improving vaccine acceptance and uptake gathered together for the fifth annual meeting on vaccine acceptance, organized by the Fondation Merieux at its conference centre in Veyrier-du-Lac, France, to share their experiences in building, improving and sustaining vaccine confidence and uptake. The importance and value of truly listening to people and seeking to understand the perspectives of vaccine hesitant people was emphasized throughout the meeting. The benefits of social marketing, which can be used to influence behavior that benefit individuals and communities for the greater social good, and its integration into strategies aimed at improving vaccine acceptance and uptake, were discussed. Healthcare professionals (HCPs) need tools and training to help them engage effectively in vaccination acceptance conversations with parents and other patients. Two potential tools, motivational interviewing (MI) and AIMS (Announce, Inquire, Mirror, Secure), were presented. Examples of MI approaches that have successfully improved vaccination acceptance and uptake included a project in Canada aimed at parents just after the birth of their baby. The role of mandates to increase vaccination uptake in the short-term was discussed, but to achieve sustainable vaccination uptake this must be complemented with other strategies. These annual meetings have led to the creation of an informal community of practice that facilitates cross-pollination between the various disciplines and different settings of those involved in this area of research and implementation. It was agreed that we must continue our efforts to promote vaccine acceptance and thus increase vaccination uptake, by fostering more effective vaccination communication, monitoring of the media conversation on vaccination, designing and rigorously evaluating targeted interventions, and surveillance of vaccine acceptance and uptake with pertinent, reliable measures.
C1 [Attwell, Katie] Univ Western Australia, Sch Social Sci, 35 Stirling Highway, Crawley, WA 6009, Australia.
   [Attwell, Katie] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Nedlands, WA, Australia.
   [Dube, Eve] Univ Laval, CHU Quebec, Ctr Rech, Inst Natl Sante Publ Quebec, 2400 DEstimauville, Quebec City, PQ G1E 7G9, Canada.
   [Gagneur, Arnaud] Univ Sherbrooke, Dept Pediat, Fac Med & Hlth Sci, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Suggs, L. Suzanne] Univ Svizzera Italiana, Fac Commun Sci, Inst Publ Commun, BeCHANGE Res Grp, Via G Buffi 13, Lugano, Switzerland.
   [Suggs, L. Suzanne] SSPH, Zurich, Switzerland.
   [Suggs, L. Suzanne] Imperial Coll London, Inst Global Hlth Innovat, London, England.
   [Thomson, Angus] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
RP Thomson, A (reprint author), Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
EM katie.attwell@uwa.edu.au; eve.dube@inspq.qc.ca;
   Arnaud.Gagneur@USherbrooke.ca; somer@emory.edu; Suzanne.suggs@usi.ch;
   Angus.Thomson@sanofi.com
RI attwell, Katie/D-4346-2018
OI attwell, Katie/0000-0002-0366-2160
FU Sanofi Pasteur
FX The authors would like to thank Margaret Haugh, MediCom Consult,
   Villeurbanne, France for providing medical writing and editorial
   services. The meeting was funded by an unrestricted grant from Sanofi
   Pasteur.
CR Abbott T., 2015, PRIME MINISTER T ABB
   [Anonymous], 2016, VACCINESTODAY
   [Anonymous], 2017, VACCINESTODAY
   [Anonymous], 2017, THE EAGLE ONLINE
   [Anonymous], 2017, SCI ALERT
   Attwell K, 2015, VACCINE, V33, P6235, DOI 10.1016/j.vaccine.2015.09.092
   Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Butler R, 2017, PEDIAT VACCINES VACC, P27
   Cates JR, 2014, VACCINE, V32, P4171, DOI 10.1016/j.vaccine.2014.05.044
   Cates JR, 2011, SOC MARK Q, V17, P4, DOI 10.1080/15245004.2010.546943
   Connors JT, 2017, J PEDIATR NURS, V33, P10, DOI 10.1016/j.pedn.2016.11.002
   Cozolino L., 2014, NEUROSCIENCE HUMAN R
   Dempsey AF, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0016
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   European Centre for Disease Prevention and Control, 2017, MONTHL MEASL RUB MON
   Evans W. D., 2008, PUBLIC HLTH BRANDING
   Evans WD, 2006, BRIT MED J, V332, P1207, DOI 10.1136/bmj.332.7551.1207-a
   Fondation Merieux, 2016, EV STRAT INCR VACC A
   Fondation Merieux, 2017, EV VACC ACC SCI POL
   Fondation Merieux, 2018, EV ADV VACC
   Frew PM, 2018, HUM VACC IMMUNOTHER, V14, P1
   Gache P, 2006, REV MED SUISSE, V2, P6
   Gagneur A, 2013, SHOULD INNOVATIVE PR, P112
   Gagneur A, 2016, MAY 2016 34 ANN M EU
   Gagneur A, 2017, CAN MOTIVATIONAL INT
   Gagneur A, 2018, VACCINE, V36, P6553, DOI 10.1016/j.vaccine.2017.10.049
   Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y
   Hasson U, 2012, TRENDS COGN SCI, V16, P114, DOI 10.1016/j.tics.2011.12.007
   Hastings G, 2006, BRIT MED J, V332, P1210, DOI 10.1136/bmj.332.7551.1210
   Hastings G, 2014, SOCIAL MARKETING: FROM TUNES TO SYMPHONIES, 2ND EDITION, P300
   Hickler B, 2017, VACCINE, V35, P3515, DOI 10.1016/j.vaccine.2017.04.056
   Hofstetter AM, 2017, VACCINE, V35, P2709, DOI 10.1016/j.vaccine.2017.03.077
   International Social Marketing Association European Social Marketing Association and Australian Association of Social Marketing, 2013, ISMA ESMA AASM CONS
   Kreuter MW, 2004, AM J PUBLIC HEALTH, V94, P122, DOI 10.2105/AJPH.94.1.122
   Larson H, 2013, VACCINES-BASEL, V1, P293, DOI 10.3390/vaccines1030293
   Levy-Bruhl D, 2018, EUROSURVEILLANCE, P23
   LING JC, 1992, ANNU REV PUBL HEALTH, V13, P341, DOI 10.1146/annurev.pu.13.050192.002013
   Lombardi P., 2017, WALL STREET J
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Manjoo F., 2008, TRUE ENOUGH LEARNING
   Miller WR, 2013, MOTIVATIONAL INTERVI
   Nature Editorial, 2017, NATURE, V541, P259
   Navin M., 2016, VALUES VACCINE REFUS
   Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039
   Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263
   Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037
   Parrish-Sprowl J, 2017, COMMUNICATION IS BIO
   Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089
   Schoeppe J, 2017, HEALTH PROMOT PRACT, V18, P654, DOI 10.1177/1524839917697303
   STEWART MA, 1995, CAN MED ASSOC J, V152, P1423
   The Vaccine Confidence Project, 2017, IT 5 STAR MOV BLAM S
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   World Health Organization, 2014, REP SAGE WORK GROUP
NR 54
TC 1
Z9 1
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 677
EP 682
DI 10.1016/j.vaccine.2018.12.014
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000001
PM 30616955
DA 2020-05-12
ER

PT J
AU Lin, X
   Shrader, L
   Rodgers, L
   Stokley, S
   Markowitz, LE
AF Lin, Xia
   Shrader, Lauren
   Rodgers, Loren
   Stokley, Shannon
   Markowitz, Lauri E.
TI Increasing human papillomavirus vaccination at the recommended age
SO VACCINE
LA English
DT Article
DE Human Papillomavirus (HPV) vaccine; Immunization Information System
   (IIS); Vaccination initiation age; Vaccination coverage
ID UNITED-STATES; COVERAGE; ADOLESCENTS; COMPLETION; INITIATION
AB In the United States, human papillomavirus (HPV) vaccine has been recommended for females since 2006 and for males since 2011. However, national HPV vaccination coverage among adolescents is lower than national targets, and many adolescents initiate HPV vaccination later than the recommended age. We analyzed records for >2 million persons born during 1996-2000 who initiated HPV vaccination at age 9 through 16 years from six Immunization Information Systems Sentinel Sites, displayed the distribution of HPV vaccination initiation age, and calculated HPV vaccination coverage. More adolescents in recent cohorts initiated HPV vaccination at the recommended age of 11-12 years, the majority of whom received another recommended vaccine on the same day. However, >40% of all vaccinated adolescents did not initiate the HPV vaccination until age 13 years or later. Continued efforts are needed to increase HPV vaccination initiation at the recommended age. Published by Elsevier Ltd.
C1 [Lin, Xia; Rodgers, Loren; Stokley, Shannon; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Shrader, Lauren] Northrop Grumman Corp, Atlanta, GA USA.
RP Lin, X (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mailstop A19, Atlanta, GA 30329 USA.
EM wft4@cdc.gov
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX The sentinel site project is funded by the Centers for Disease Control
   and Prevention.
CR Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Cardemil C, 2013, MMWR-MORBID MORTAL W, V62, P1005
   Donahue Kelly L, 2015, Prev Med Rep, V2, P892
   Dorell CG, 2011, PEDIATRICS, V128, P830, DOI 10.1542/peds.2011-0950
   Lin X, 2017, VACCINE, V35, P5759, DOI 10.1016/j.vaccine.2017.08.090
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Rahman M, 2015, VACCINE, V33, P585, DOI 10.1016/j.vaccine.2014.12.021
   Rosen BL, 2018, ACAD PEDIATR, V18, pS53, DOI 10.1016/j.acap.2017.10.007
   Stokley S, 2014, MMWR-MORBID MORTAL W, V63, P620
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 686
EP 689
DI 10.1016/j.vaccine.2018.12.023
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000004
PM 30591254
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Pollock, KG
   Tait, B
   Tait, J
   Bielecki, K
   Kirolos, A
   Willocks, L
   Gorman, DR
AF Pollock, K. G.
   Tait, B.
   Tait, J.
   Bielecki, K.
   Kirolos, A.
   Willocks, L.
   Gorman, D. R.
TI Evidence of decreased HPV vaccine acceptance in Polish communities
   within Scotland
SO VACCINE
LA English
DT Article
DE Acceptance; HPV; Vaccine; Immunisation; Polish
AB Human papillomavirus (HPV) vaccines are currently utilised globally in national immunisation programmes. Many new European migrants have settled in the United Kingdom (UK) since the 2004 European Union expansion with approximately 91,000 Polish people resident in Scotland. Following anecdotal reports from several NHS Boards within Scotland of lower HPV vaccine uptake in Polish communities compared with other ethnic minorities, an extract containing both forename and surname, was taken from the Scottish Immunisation Recall System (SIRS) for all girls in S2 and S3 in school years 2014/15 to 2016/17. We then used the OnoMap algorithm software to derive ethnicity. OnoMap identified between 289 and 321 age-eligible girls as Polish with significant disparity noted for completed HPV vaccine uptake between UK (87.2-89.8%) and Polish ethnicities (69.7-77.2%) (P < 0.01). Preliminary discussions with Polish families suggest that vaccine programme differences, trust in medical/healthcare practitioners, and cultural influences may be important drivers of acceptance. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Pollock, K. G.] Hlth Protect Scotland, Meridian Court, Cadogan St, Glasgow, Lanark, Scotland.
   [Bielecki, K.; Kirolos, A.; Willocks, L.; Gorman, D. R.] NHS Lothian, Directorate Publ Hlth & Hlth Policy, Edinburgh, Midlothian, Scotland.
   [Tait, B.; Tait, J.] Informat Serv Div, Gyle Sq, Edinburgh, Midlothian, Scotland.
   [Pollock, K. G.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Cowcaddens Rd, Glasgow, Lanark, Scotland.
RP Pollock, KG (reprint author), Glasgow Caledonian Univ, Sch Hlth & Life Sci, Cowcaddens Rd, Glasgow, Lanark, Scotland.
EM Kevin.pollock@nhs.net
OI Bielecki, Klaudia/0000-0002-0178-9758
CR Braczkowska Bogumila, 2017, Przegl Epidemiol, V71, P227
   Ganczak M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040645
   Hanson KE, 2018, CLIN INFECT DIS, V67, P1018, DOI 10.1093/cid/ciy232
   Jaroszewska K., 2014, Postepy Nauk Medycznych, V27, P617
   Lakha F, 2011, PUBLIC HEALTH, V125, P688, DOI 10.1016/j.puhe.2011.05.003
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Mazdziarz A, 2017, ANN AGR ENV MED, V24, P592, DOI 10.5604/12321966.1232093
   Migone C, 2017, Ir Med J, V110, P603
   Sinka K, 2014, J EPIDEMIOL COMMUN H, V68, P57, DOI 10.1136/jech-2013-202620
   Smith L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016332
NR 10
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 690
EP 692
DI 10.1016/j.vaccine.2018.10.097
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000005
PM 30392767
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Bielecki, K
   Kirolos, A
   Willocks, LJ
   Pollock, KG
   Gorman, DR
AF Bielecki, K.
   Kirolos, A.
   Willocks, L. J.
   Pollock, K. G.
   Gorman, D. R.
TI Low uptake of nasal influenza vaccine in Polish and other ethnic
   minority children in Edinburgh, Scotland
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Immunisation; Poland; Migrants; Uptake
ID VACCINATIONS; HESITANCY; MIGRANTS
AB Failure to vaccinate is well-recognised in Europe as a contributing factor to outbreaks of infectious diseases. Low immunisation rates are often associated with religious, social and ethnic minorities, including refugees or migrant groups. Polish people form Scotland's newest and largest migrant group. They have moved to Scotland since 2004, joining established ethnic minorities from China, the Indian subcontinent and Africa.
   Scotland has had a seasonal influenza nasal vaccination programme for all primary school children since 2013. We investigated three primary schools in Edinburgh, which had reported low influenza vaccination uptake rates in 2016 and 2017 and found that these schools contained many pupils from ethnic minorities, the majority of whom were Polish. Pupils were categorized as one of three ethnic groupings: White British, Polish and Other Identified Ethnic Minority (DIEM). We ascertained ethnicity using NHS and Education Department information sources and name recognition. We examined vaccine acceptance, declination and non-return of consent forms.
   In 2017, nasal influenza vaccine uptake was 70.7% (65.2-75.6%, p < 0.001) in White British, 60.9% (53.967.6%%, p < 0.001) in other identified ethnic minorities and 25.0% (20.9-29.6%, p > 0.001) in Polish children. White British children were more likely to return completed forms (78.9%) than other groups (OIEM 68.2% and Polish 61.8%). 36.8% of Polish families completed a consent form declining vaccination compared to 6.2% of White British families.
   These findings demonstrate that significant differences exist in nasal influenza vaccination uptake rates, which have important implications for the trans-national study of vaccine hesitancy. Further qualitative work and an investigation of uptake rates of other childhood immunisations in Polish and other migrant groups is required to assess differences in uptake and behaviours. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bielecki, K.; Kirolos, A.; Willocks, L. J.; Gorman, D. R.] NHS Lothian, Directorate Publ Hlth & Hlth Policy, Edinburgh, Midlothian, Scotland.
   [Pollock, K. G.] Hlth Protect Scotland, Meridian Court, Cadogan St, Glasgow, Lanark, Scotland.
RP Bielecki, K (reprint author), Lothian Analyt Serv, 2-4 Waterloo Pl, Edinburgh EH1 3EG, Midlothian, Scotland.
EM Klaudia.Bielecki@nhslothian.scot.nhs.uk
OI Bielecki, Klaudia/0000-0002-0178-9758
CR Braczkowska B, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040756
   Braczkowska Bogumila, 2017, Przegl Epidemiol, V71, P227
   Brydak LB, 2012, MED SCI MONITOR, V18, pRA166, DOI 10.12659/MSM.883534
   Condon LJ, 2016, J PUBL HLTH OXFORD, V39, P455
   Czarkowski Miroslaw P, 2014, Przegl Epidemiol, V68, P455
   ECDC, 2017, POL REC VACC
   Economist, 2013, ECONOMIST
   Falenczyk K., 2016, Postepy Nauk Medycznych, V29, P380, DOI 10.5604/08606196.1205281
   Forster A. S., 2016, EPIDEMIOLOGY COMMUNI, V71, P544
   Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8
   Ganczak M, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14060665
   Ganczak M, 2013, VACCINE, V31, P5687, DOI 10.1016/j.vaccine.2013.09.056
   Gorman DR, 2018, PUBLIC HEALTH, V158, P86, DOI 10.1016/j.puhe.2017.11.026
   Gorman DR, 2015, DIVERS EQUAL HLTH CA, V12, P152
   Harvala H, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.37.20903
   Immunisation Scotland, 2018, CHILDH FLU CONS GUID
   ISD Scotland, 2018, CHI NUMB
   Jaroszewska K., 2014, Postepy Nauk Medycznych, V27, P617
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012
   Kuchar E, 2018, ADV EXP MED BIOL, V1039, P19, DOI 10.1007/5584_2017_78
   Lakha F, 2011, PUBLIC HEALTH, V125, P688, DOI 10.1016/j.puhe.2011.05.003
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mateos P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022943
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   National Records of Scotland, 2014, CENS 2011 DET CHAR E
   NHS Health Scotland, 2018, CHILD FLU VACC
   Olszewska M, 2018, CHILD HEALTH CARE, V47, P289, DOI 10.1080/02739615.2017.1354293
   Paterson P, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040622
   Public Health England, 2016, TAIL IMM PROGR CHAR
   Sheikh S, 2018, VACCINE, V36, P4979, DOI 10.1016/j.vaccine.2018.06.044
   Sim JA, 2011, PUBLIC HEALTH, V125, P505, DOI 10.1016/j.puhe.2011.05.005
   Sime D, 2014, HEALTH PLACE, V30, P86, DOI 10.1016/j.healthplace.2014.08.006
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   VENICE, 2017, POLAND POLISH IMMUNI
   WHO, 2014, REP SAGE WORK VACC H
NR 38
TC 3
Z9 3
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 693
EP 697
DI 10.1016/j.vaccine.2018.11.029
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000006
PM 30448336
DA 2020-05-12
ER

PT J
AU Wang, YH
   Zade, J
   Moon, SS
   Weldon, W
   Pisal, SS
   Glass, RI
   Dhere, RM
   Jiang, BM
AF Wang, Yuhuan
   Zade, Jagdish
   Moon, Sung-Sil
   Weldon, William
   Pisal, S. S.
   Glass, Roger I.
   Dhere, Rajeev M.
   Jiang, Baoming
TI Lack of immune interference between inactivated polio vaccine and
   inactivated rotavirus vaccine co-administered by intramuscular injection
   in two animal species
SO VACCINE
LA English
DT Article
DE IRV; IPV; Combination vaccine; Dose sparing
ID IMMUNOGENICITY; MORTALITY
AB A parenteral inactivated rotavirus vaccine (IRV) in development could address three problems with current live oral rotavirus vaccines (ORV): their lower efficacy in low and middle-income countries (LMICs), lingering concerns about their association with intussusception, and their requirement for a separate supply chain with large volume cold storage. Adding a new parenteral IRV to the current schedule of childhood immunizations would be more acceptable if it could be combined with another injectable vaccine such as inactivated polio vaccine (IPV). Current plans for polio eradication call for phasing out oral polio vaccine (OPV) and transitioning to IPV, initially in LMICs as a single dose booster after two doses of OPV and ultimately as a two dose schedule. Today in many LMICs, IPV is administered as a standalone vaccine, which involves a separate cold chain and is relatively costly. We therefore tested in two animal models formulations of IPV with IRV to determine whether co-administration might interfere with the immune response to each product and spare antigen dose for both vaccines. Our results demonstrate that IRV when adjuvanted with alum and administered alone or in combination with IPV did not impair the immune responses to either rotavirus or poliovirus serotypes 1, 2 and 3. Similarly, IPV when formulated and administered alone or together with IRV induced comparable levels of neutralizing antibody to poliovirus type 1, 2 and 3. Furthermore, comparable antibody titers were observed in animals vaccinated with low, middle or high dose of IPV or IRV in combination. This dose sparing and the lack of interference between IPV and IRV administered together represent another step to support the further development of this novel combination vaccine for children. Published by Elsevier Ltd.
C1 [Wang, Yuhuan; Moon, Sung-Sil; Weldon, William; Glass, Roger I.; Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [Zade, Jagdish; Pisal, S. S.; Dhere, Rajeev M.] Serum Inst India Pvt Ltd, Pune, Maharashtra, India.
   [Glass, Roger I.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
RP Jiang, BM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, MS G04, Atlanta, GA 30333 USA.
EM bxj4@cdc.gov
FU Centers for Disease Control and Prevention, Atlanta, United States
FX We thank S. Reddy, Rajendra Sabale, Ravindra Kadam and Abhijeet Kambale
   of SIIPL and Deborah Moore, Yiting Zhang, Sharla McDonald, Larin
   McDuffie, William Hendley, Mario Nicolas, and Daniel Velasquez of CDC
   for their support in laboratory analysis and assistance in manuscript
   preparation. This study was supported in part by Centers for Disease
   Control and Prevention, Atlanta, United States.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P301
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Esona MD, 2010, HUM VACCIN, V6
   Glass RI, 2018, VACCINE, V36, P2233, DOI 10.1016/j.vaccine.2018.03.008
   Jiang BM, 2008, HUM VACCINES, V4, P143, DOI 10.4161/hv.4.2.5263
   Jiang BM, 2013, HUM VACC IMMUNOTHER, V9, P1634, DOI 10.4161/hv.24958
   Jiang BM, 2008, VACCINE, V26, P6754, DOI 10.1016/j.vaccine.2008.10.008
   John J, 2017, J INFECT DIS, V215, P529, DOI 10.1093/infdis/jiw595
   John T J, 1972, Indian Pediatr, V9, P252
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   Patel MM, 2009, EXPERT REV VACCINES, V8, P1555, DOI [10.1586/erv.09.106, 10.1586/ERV.09.106]
   PATRIARCA PA, 1991, REV INFECT DIS, V13, P926
   Resch TK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18973-9
   Robertson SE, 2001, VACCINE, V20, P31, DOI 10.1016/S0264-410X(01)00261-4
   Sutter RW, 2013, VACCINES, P598
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Velasquez DE, 2018, EXPERT REV VACCINES, V17, P145, DOI 10.1080/14760584.2018.1418665
   Wang YH, 2010, VACCINE, V28, P5432, DOI 10.1016/j.vaccine.2010.06.006
   Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8
   Zaman K, 2016, J INFECT DIS, V213, P1686, DOI 10.1093/infdis/jiw024
NR 22
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 698
EP 704
DI 10.1016/j.vaccine.2018.12.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000007
PM 30626530
DA 2020-05-12
ER

PT J
AU Moran, A
   Agaliotis, M
   Seale, H
AF Moran, Alexis
   Agaliotis, Maria
   Seale, Holly
TI The views of key stakeholders around mandatory influenza vaccination of
   hospital and aged care staff: Examining the current climate in Australia
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Healthcare workers; Aged care; Mandatory
ID WORKERS; EMPLOYEES; COVERAGE
AB Background: Healthcare worker (HCW) vaccination against seasonal influenza is considered a key preventative measure within hospitals and aged-care facilities (ACFs) to reduce the risk of transmission and related disease. Despite this, many facilities experience persistently low vaccination coverage rates and mandatory vaccination has been explored as a potential strategy to improve coverage. This study explored the current climate around staff vaccination in Australia from the perspective of opinion leaders and key stakeholders.
   Methods: Qualitative semi-structured interviews were conducted between April and July 2018 with 22 individuals involved in vaccination policy and program development and implementation from a range of organisations including state health departments, hospitals and ACFs across Australia. In addition, interviews were undertaken with individuals from aged care and nursing peak bodies/colleges. Interviews were transcribed, and thematic analysis was undertaken using NVivo 12 software.
   Results: Major themes emerging from the interviews included a sense that attitudes around staff vaccination are changing; the persistence of administrative and resource barriers; the importance of positive workplace culture towards influenza vaccination; and the need for individualised and personal communication strategies. Perspectives were diverse on the necessity of introducing stronger policies, with participants divided in their support mandatory influenza vaccinations. Some advocated that key performance indicators should be used as an alternative to vaccine mandates.
   Conclusions: This study provides policy makers with useful insights into the current Australian context around occupational vaccination policies, to inform acceptable and effective strategies to improve influenza vaccination uptake among Australian hospital and aged care staff. (C) 2018 Published by Elsevier Ltd.
C1 [Moran, Alexis] Univ New South Wales, Fac Med, Undergrad Med Program, Kensington, NSW, Australia.
   [Agaliotis, Maria; Seale, Holly] Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
RP Seale, H (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
EM m.agaliotis@unsw.edu.au; h.seale@unsw.edu.au
RI Agaliotis, Maria/M-3399-2019
OI Agaliotis, Maria/0000-0002-3691-2234; Seale, Holly/0000-0002-1877-5395
CR Apenteng BA, 2014, AM J INFECT CONTROL, V42, P294, DOI 10.1016/j.ajic.2013.09.021
   Australian Government Department of Health, 2018, MAND INFL FLU VACC P
   Australian Government Department of Health, 2015, AUSTR IMM HDB
   Babcock HM, 2010, CLIN INFECT DIS, V50, P459, DOI 10.1086/650752
   Baines R., 2017, ABC NEWS
   Ballestas T, 2009, J HOSP INFECT, V73, P203, DOI 10.1016/j.jhin.2009.07.028
   Braun V., 2013, SUCCESSFUL QUALITATI
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Bull AL, 2007, MED J AUSTRALIA, V186, P185, DOI 10.5694/j.1326-5377.2007.tb00858.x
   *CDCP, STAT IMM LAWS HEALTH
   Chean R., 2014, Healthcare Infection, V19, P42, DOI 10.1071/HI13041
   Communicable Diseases Network Australia, 2017, GUID PREV CONTR PUBL
   Department of Health & Human Services, 2014, VACC HEALTHC WORK
   Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006
   Grove A, 2016, AGED CARE QUICK GUID
   Health NSW, OCC ASS SCREEN VACC
   Heinrich-Morrison K, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0765-7
   Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056
   Hunt Greg, 2018, MAND VACC PROGR CURB
   Johnson SA, 2017, AUST NZ J PUBLIC HLT, V41
   Johnson SA, 2016, AUST NZ J PUBL HEAL, V40, P281, DOI 10.1111/1753-6405.12517
   Leask Julie, 2010, N S W Public Health Bull, V21, P243, DOI 10.1071/NB10042
   Lee SJ, 2013, AM J INFECT CONTROL, V41, pE65, DOI 10.1016/j.ajic.2012.10.014
   Lim YC, 2014, VACCINE, V32, P606, DOI 10.1016/j.vaccine.2013.11.063
   lmai C, 2018, PLOS ONE, V13
   Maltezou HC, 2011, INFLUENZA OTHER RESP, V5, P382, DOI 10.1111/j.1750-2659.2011.00240.x
   Melia M, 2009, INFECT CONT HOSP EP, V30, P361, DOI 10.1086/596043
   National Centre for Immunisation Research, 2018, REV INF CONTR PRACT
   NSW Health, 2018, OCC ASS SCREEN VACC
   NSW Health, 2011, OCC ASS SCREEN VACC
   Ofstead CL, 2017, VACCINE, V35, P2390, DOI 10.1016/j.vaccine.2017.03.041
   Person CJ, 2013, AM J INFECT CONTROL, V41, P743, DOI 10.1016/j.ajic.2012.09.025
   Poland GA, 2005, VACCINE, V23, P2251, DOI 10.1016/j.vaccine.2005.01.043
   Queensland Health, 2016, VACC HEALTHC WORK
   Rakita RM, 2010, INFECT CONT HOSP EP, V31, P881, DOI 10.1086/656210
   Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087
   SA Health, 2017, IMM HLTH CAR WORK S
   Seale H, 2010, OCCUP MED-OXFORD, V60, P335, DOI 10.1093/occmed/kqq037
   Seale H, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-325
   Seale H, 2011, MED J AUSTRALIA, V195, P336, DOI 10.5694/mja11.10067
   Seale H, 2009, INFLUENZA OTHER RESP, V3, P15, DOI 10.1111/j.1750-2659.2008.00063.x
   Talbot TR, 2010, INFECT CONT HOSP EP, V31, P987, DOI 10.1086/656558
   Western Australia Department of Health, HLTH CAR WORK IMM PO
   Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073724
   Zimmerman RK, 2009, INFECT CONT HOSP EP, V30, P691, DOI 10.1086/598343
NR 45
TC 2
Z9 3
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 705
EP 710
DI 10.1016/j.vaccine.2018.12.029
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000008
PM 30626529
DA 2020-05-12
ER

PT J
AU Xian, TH
   Parasuraman, S
   Sinniah, K
   Ravichandran, M
   Prabhakaran, G
AF Xian, Tew Hui
   Parasuraman, Subramani
   Sinniah, Kurunathan
   Ravichandran, Manickam
   Prabhakaran, Guruswamy
TI Repeated dose toxicity evaluation of a cold chain-free, live, attenuated
   oral cholera vaccine in Sprague Dawley rats
SO VACCINE
LA English
DT Article
DE Cholera; Live attenuated vaccine; Cold chain supply; Oral toxicity;
   Vibrio cholerae; Thermostable vaccine
ID VIBRIO-CHOLERAE; IMMUNOGENICITY; MODEL
AB The repeated dose toxicity of a prototype cold chain-free, live, attenuated oral cholera vaccine containing 5 x 10(6) CFU/mL of the VCUSM14P strain was evaluated in Sprague Dawley (SD) rats (single dose administered daily for 30 days) to ascertain its safety for clinical use. Repeated dose toxicity studies for cholera vaccines in the literature have administered 2 or 3 fixed doses at 7, 14, 21 or 69 day intervals. The present study reports an evaluation of 30 repeated doses of cholera vaccine administered at three different concentrations (Group II (1.25 x 10(6) CFU), Group III (2.5 x 10(6) CFU) and Group IV (5 x 10(6) CFU)) in SD rats. The liquid vaccine was administered orally to the rats with the respective dose every day, and normal saline was administered to the control group (Group I). No significant difference (P> 0.05) was observed in the body weights and biochemical parameters of the rats after 15 and 30 repeated doses compared to those of the control group. However, compared to those of Group I, a significant increase (P < 0.05) in the organ to body weight ratios of the lungs, ureter, liver, kidney, heart and spleen was found in G-II, G-III and G-IV. In the haematological analysis, a significant increase in the WBC was observed in G-II and G-IV compared to that in G-I. The histopathological findings indicated mild to moderate degeneration in the liver, kidney, heart and spleen in the treated rats. Mild to moderate lymphocytic infiltration in the lungs was observed in the G-II and G-III rats, and severe infiltration was observed in the G-IV rats. These histopathological findings may be attributed to the 30 doses of vaccine given in daily succession without an interval. In the acute toxicity study, a single dose of vaccine up to 10 x 10(6) CFU did not cause any adverse effects and lethality in SD rats. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xian, Tew Hui; Sinniah, Kurunathan; Ravichandran, Manickam; Prabhakaran, Guruswamy] AIMST Univ, Fac Sci Appl, Dept Biotechnol, Semeling 08100, Kedah, Malaysia.
   [Parasuraman, Subramani] AIMST Univ, Fac Pharm, Pharmacol Unit, Semeling 08100, Kedah, Malaysia.
RP Prabhakaran, G (reprint author), AIMST Univ, Fac Sci Appl, Dept Biotechnol, Semeling 08100, Kedah, Malaysia.
EM guruswamy.prabhakaran@gmail.com
RI RAVICHANDRAN, MANICKAM/A-7128-2011; Subramani, Parasuraman/F-3147-2011
OI RAVICHANDRAN, MANICKAM/0000-0001-5321-1344; Subramani,
   Parasuraman/0000-0003-3655-8375
FU Ministry of Higher Education (MOHE), Malaysia under the Prototype
   Development Research Grant Scheme (PRGS) [PRGS/2/2015/SKK10/AIMST/02/1]
FX The authors are grateful to The Ministry of Higher Education (MOHE),
   Malaysia, for funding this research under the Prototype Development
   Research Grant Scheme (PRGS) -(PRGS/2/2015/SKK10/AIMST/02/1). The
   authors are also thankful to AIMST University, Malaysia, for providing
   the laboratory facilities to carry out the toxicological study and the
   biochemical and histological analyses.
CR Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Angelichio MJ, 1999, INFECT IMMUN, V67, P3733, DOI 10.1128/IAI.67.8.3733-3739.1999
   Azman AS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001867
   Baek YO, 2012, TOX RESEARCH, V28, P225, DOI 10.5487/TR.2012.28.4.225
   Chan M, 2010, MICROB PATHOGENESIS, V49, P211, DOI 10.1016/j.micpath.2010.06.001
   Humphreys G, 2011, B WORLD HEALTH ORGAN, V89, P324, DOI 10.2471/BLT.11.030511
   Lopez AL, 2018, CLIN INFECT DIS, V66, P1960, DOI 10.1093/cid/cix1039
   Lopez Y, 2011, VACCINE, V29, P3596, DOI 10.1016/j.vaccine.2011.02.074
   Marino DJ, 2012, J TOXICOL ENV HEAL A, V75, P1484, DOI 10.1080/15287394.2012.722520
   Mukherjee KL, 1988, MED LAB TECHNOLOGY, VI
   Parasuraman S, 2010, J PHARMACOL PHARMACO, V1, P87, DOI 10.4103/0976-500X.72350
   Petterino C, 2006, EXP TOXICOL PATHOL, V57, P213, DOI 10.1016/j.etp.2005.10.002
   Ravichandran M., Vibrio cholerae strains VCUSM1 and VCUSM4 method of making same and vaccine derivatives thereof. USA patent, Patent No. [10/ 981,760, 10981760]
   Ravichandran M., Vibrio cholerae strains VCUSM1 and VCUSM4 method of making same and vaccine derivatives thereof. European patent, Patent No. [04025319.7, 040253197]
   Raza M, 2002, SCI PHARM, V70, P135, DOI DOI 10.3797/SCIPHARM.AUT-02-16
   Schmid-Hempel P, 2007, PLOS PATHOG, V3, P1372, DOI 10.1371/journal.ppat.0030147
   Sifontes-Rodriguez S, 2009, ARCH MED RES, V40, P527, DOI 10.1016/j.arcmed.2009.09.003
   SPIRA WM, 1981, INFECT IMMUN, V32, P739, DOI 10.1128/IAI.32.2.739-747.1981
   Thungapathra M, 1999, IMMUNOL LETT, V68, P219, DOI 10.1016/S0165-2478(99)00076-0
   Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 711
EP 720
DI 10.1016/j.vaccine.2018.12.027
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000009
PM 30630696
DA 2020-05-12
ER

PT J
AU Yan, ZY
   Cui, YL
   Zhou, W
   Li, WS
   Tan, X
   Chen, W
   Zhang, J
   Jiang, YM
AF Yan, Ziyi
   Cui, Yali
   Zhou, Wei
   Li, Wensheng
   Tan, Xi
   Chen, Wen
   Zhang, Jing
   Jiang, Yongmei
TI Molecular characterization of Streptococcus pneumoniae in children
   living in southwest China and assessment of a potential protein vaccine,
   rPfbA
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; MLST; Serotypes; Antibiotic resistance;
   Mucosal immunization; rPfbA
ID PNEUMOCOCCAL INFECTION; BINDING PROTEIN; IN-VIVO; MENINGITIS;
   SUSCEPTIBILITY; EPIDEMIOLOGY; IMMUNIZATION; COMBINATION; PROTECTION;
   MANAGEMENT
AB Background: Few children living in southwest China are vaccinated against Streptococcus pneumoniae (S. pneumoniae), which is an important pathogen in causing high morbidity and high mortality. This study aimed the molecular characterization of S. pneumoniae strains isolated from children and a new vaccine strategy based on a potential protein antigen.
   Methods: Molecular characterizations, including serotype, virulence gene and pilus analyses, were performed using PCR. Seven housekeeping genes were sequenced to identify the sequence types (STS), and antibiotic resistance was analysed using the microdilution broth method. In addition, we evaluated the protective effects of recombinant plasmin- and fibronectin-binding protein A (rPfbA) in murine pneumococcal infection models by challenge and passive transfer analyses, and assessed cytokine changes after immunization.
   Results: The prevalent serotypes were 19F (31.4%),19A (21.6%), 6B (13.7%), 14 (11.8%) and 23F (9.8%), and the coverage rates of the 13-valent pneumococcal conjugate vaccine (PCV13) were high in 93.3% of the isolates. The predominant STS were ST271 (23.5%), ST320 (21.6%) and ST876 (11.8%). Most of the S. pneumoniae isolates were resistant to erythromycin (95.1%) and clindamycin (90.2%). The molecular distributions and antibiotic resistance rates of the S. pneumoniae isolates differed between the plateau and the basin regions. More than 93% of the S. pneumoniae isolates carried ply, cbpA, phtD and nanA, and over half of the isolates carried pilus-1, pilus-2 and pfbA. Mucosal immunization with rPfbA induced pneumococcal specific antibody responses which provided to eliminate colonization in lung and nasopharynx, and protection against pneumococcal challenge.
   Conclusion: Vaccine strategies based on epidemiological surveillance can be more adaptive to specific areas, reduce costs and protect against changing antigenic sites. We advise that children currently living in southwest China be vaccinated with PCV13. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yan, Ziyi; Cui, Yali; Zhou, Wei; Li, Wensheng; Tan, Xi; Zhang, Jing; Jiang, Yongmei] Sichuan Univ, West China Univ Hosp 2, Dept Lab Med, 20,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Cui, Yali; Zhou, Wei; Li, Wensheng; Zhang, Jing; Jiang, Yongmei] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, 17,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Chen, Wen] Sichuan Univ, West China Hosp, Dept Endocrinol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
RP Jiang, YM (reprint author), 20,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.; Zhang, J (reprint author), 17,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
EM jingz9080@163.com; jiangyongmeiwst@163.com
FU Chinese National Natural Science FoundationNational Natural Science
   Foundation of China [81301399]; Science & Technology Department of
   Sichuan Province [2017SZ0122, 2016SZ0021]
FX This work was supported by the Chinese National Natural Science
   Foundation (No. 81301399), and the Science & Technology Department of
   Sichuan Province (No. 2017SZ0122, No. 2016SZ0021). The funders had no
   role in study design, data collection and analysis and interpretation of
   the data.
CR Ahn Jong Gyun, 2012, Korean J Pediatr, V55, P424, DOI 10.3345/kjp.2012.55.11.424
   Anderson RJ, 2016, VACCINE, V34, P6292, DOI 10.1016/j.vaccine.2016.10.061
   Ball P, 1999, AM J MED, V107, P77, DOI 10.1016/S0002-9343(99)00104-7
   Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031
   Cao J, 2007, VACCINE, V25, P4996, DOI 10.1016/j.vaccine.2007.04.069
   Clinical and Laboratory Standards Institute (CLSI), 2016, PERF STAND ANT SUSC, VM100-S26
   Cui YL, 2011, VACCINE, V29, P1736, DOI 10.1016/j.vaccine.2010.12.126
   Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049
   Falup-Pecurariu Oana, 2012, Biomed J, V35, P450, DOI 10.4103/2319-4170.104409
   Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006
   Ferreira DM, 2009, CLIN VACCINE IMMUNOL, V16, P636, DOI 10.1128/CVI.00395-08
   Ferreira DM, 2008, CLIN VACCINE IMMUNOL, V15, P499, DOI 10.1128/CVI.00400-07
   Francisco AP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-87
   Fukuyama Y, 2010, J IMMUNOL, V185, P1755, DOI 10.4049/jimmunol.1000831
   Geng Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093752
   Gentile A, 2012, INT J INFECT DIS, V16, pE5, DOI 10.1016/j.ijid.2011.09.013
   Harfouche C, 2012, INFECT IMMUN, V80, P451, DOI 10.1128/IAI.05780-11
   Hilleringmann M, 2009, EMBO J, V28, P3921, DOI 10.1038/emboj.2009.360
   Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x
   Jardine A, 2010, PEDIATR INFECT DIS J, V29, P607, DOI 10.1097/INF.0b013e3181d7d09c
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Le Saux N, 2014, PAED CHILD HEALT-CAN, V19, P141, DOI 10.1093/pch/19.3.141
   Li L, 2018, VACCINE, V36, P599, DOI 10.1016/j.vaccine.2017.12.063
   Lofling J, 2011, CELL MICROBIOL, V13, P186, DOI 10.1111/j.1462-5822.2010.01560.x
   Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159
   Mann B, 2014, J INFECT DIS, V209, P1116, DOI 10.1093/infdis/jit502
   Manoharan A, 2017, LANCET INFECT DIS, V17, P305, DOI [10.1016/S1473-3099(16)30466-2, 10.1016/s1473-3099(16)30466-2]
   McGill F, 2016, J INFECTION, V72, P405, DOI 10.1016/j.jinf.2016.01.007
   McIntosh EDG, 2011, EXPERT REV VACCINES, V10, P109, DOI [10.1586/erv.10.145, 10.1586/ERV.10.145]
   Moffitt KL, 2011, CELL HOST MICROBE, V9, P158, DOI 10.1016/j.chom.2011.01.007
   Murshid A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122529
   Nelson AL, 2007, MOL MICROBIOL, V66, P329, DOI 10.1111/j.1365-2958.2007.05908.x
   Oodate M, 2018, JPN J INFECT DIS, V71, P14, DOI 10.7883/yoken.JJID.2017.236
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Proft T, 2009, CELL MOL LIFE SCI, V66, P613, DOI 10.1007/s00018-008-8477-4
   Rabinovitch A, 2002, ACCREDIT QUAL ASSUR, V7, P473, DOI 10.1007/s00769-002-0537-0
   Shakrin NNSM, 2014, COMP IMMUNOL MICROB, V37, P347, DOI 10.1016/j.cimid.2014.10.005
   Suits MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067190
   Sun K, 2008, NAT MED, V14, P558, DOI 10.1038/nm1765
   van de Beek D, 2016, CLIN MICROBIOL INFEC, V22, pS37, DOI 10.1016/j.cmi.2016.01.007
   Verghese VP, 2017, INDIAN J MED MICROBI, V35, P228, DOI 10.4103/ijmm.IJMM_17_124
   Wang L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2816-8
   WHO Publication, 2012, VACCINE, V30, P4717, DOI 10.1016/j.vaccine.2012.04.093
   Wu KF, 2010, INFECT IMMUN, V78, P1276, DOI 10.1128/IAI.00473-09
   Xu QF, 2017, VACCINE, V35, P337, DOI 10.1016/j.vaccine.2016.11.046
   Yamaguchi M, 2008, J BIOL CHEM, V283, P36272, DOI 10.1074/jbc.M807087200
   Yang F, 2008, INT J ANTIMICROB AG, V32, P386, DOI 10.1016/j.ijantimicag.2008.05.004
   Zhang YJ, 2013, CHINESE MED J-PEKING, V126, P2296, DOI 10.3760/cma.j.issn.0366-6999.20122925
   Zhao CJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2880-0
   Zhou L, 2011, VACCINE, V29, P7704, DOI 10.1016/j.vaccine.2011.07.137
   Zhou X, 2016, EUR J CLIN MICROBIOL, V35, P633, DOI 10.1007/s10096-016-2582-3
NR 51
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 721
EP 731
DI 10.1016/j.vaccine.2018.12.021
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000010
PM 30611601
DA 2020-05-12
ER

PT J
AU Truelove, SA
   Graham, M
   Moss, WJ
   Metcalf, CJE
   Ferrari, MJ
   Lessler, J
AF Truelove, Shaun A.
   Graham, Matthew
   Moss, William J.
   Metcalf, C. Jessica E.
   Ferrari, Matthew J.
   Lessler, Justin
TI Characterizing the impact of spatial clustering of susceptibility for
   measles elimination
SO VACCINE
LA English
DT Article
DE Heterogeneity; Clustering; Measles; Effective reproductive number;
   Critical vaccination threshold; Critical immunity threshold; Disease
   transmission; Outbreak risk; Vaccination; Stochastic individual-based
   model
ID VACCINATION COVERAGE; MOUTH EPIDEMIC; HERD-IMMUNITY; TRANSMISSION;
   EXEMPTIONS; COMMUNITY; PROGRESS; CHILDREN; RUBELLA; FOOT
AB Measles elimination efforts are primarily focused on achieving and maintaining national vaccination coverage goals, based on estimates of the critical vaccination threshold (V-c): the proportion of the population that must be immune to prevent sustained epidemics. Traditionally, V-c estimates assume evenly mixing populations, an invalid assumption. If susceptible individuals preferentially contact one another, communities may remain vulnerable to epidemics even when vaccination coverage targets are met at the national level. Here we present a simple method to estimate V-c and the effective reproductive number, R, while accounting for spatial clustering of susceptibility. For measles, assuming R-0 = 15 and 95% population immunity, adjustment for high clustering of susceptibility increases R from 0.75 to 1.29, V-c from 93% to 96%, and outbreak probability after a single introduction from <1% to 23%. The impact of clustering remains minimal until vaccination coverage nears elimination levels. We illustrate our approach using Demographic and Health Survey data from Tanzania and show how non-vaccination clustering potentially contributed to continued endemic transmission of measles virus during the last two decades. Our approach demonstrates why high national vaccination coverage sometimes fails to achieve measles elimination, and that a shift from national to subnational focus is needed as countries approach elimination. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Truelove, Shaun A.; Graham, Matthew; Moss, William J.; Lessler, Justin] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Graham, Matthew] Oxford Univ Clin Res Unit, Wellcome Trust Overseas Programme, Hosp Trop Dis, Ho Chi Minh City, Vietnam.
   [Metcalf, C. Jessica E.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Metcalf, C. Jessica E.] Princeton Univ, Woodrow Wilson Sch, Off Populat Res, Princeton, NJ 08544 USA.
   [Ferrari, Matthew J.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
   [Ferrari, Matthew J.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA.
RP Truelove, SA (reprint author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
EM shauntruelove@jhu.edu
OI Lessler, Justin/0000-0002-9741-8109
FU Bill and Melinda Gates FoundationGates Foundation [90057624]
FX This work was supported by a Bill and Melinda Gates Foundation grant No.
   90057624.
CR ANDERSON RM, 1992, VACCINE, V10, P928, DOI 10.1016/0264-410X(92)90327-G
   Anderson RM, 1992, INFECT DIS HUMANS DY
   Attwell K, 2017, INT J HEALTH GOV, V22, P183, DOI 10.1108/IJHG-03-2017-0008
   Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878
   Bhoomiboonchoo P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003138
   Brownwright TK, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4961-9
   Chao DL, 2011, P NATL ACAD SCI USA, V108, P7081, DOI 10.1073/pnas.1102149108
   Colson KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130697
   Cutts FT, 2013, EXPERT REV VACCINES, V12, P917, DOI 10.1586/14760584.2013.814847
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116
   FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121
   Funk S, 2018, BIORXIV, DOI [10.1101/201574, DOI 10.1101/201574]
   Gastanaduy PA, 2016, NEW ENGL J MED, V375, P1343, DOI 10.1056/NEJMoa1602295
   Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9
   Kanaan MN, 2005, EPIDEMIOL INFECT, V133, P1009, DOI 10.1017/S0950268805004528
   Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973
   Keeling MJ, 2011, MODELING INFECT DIS
   Lessler J, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002144
   Lessler J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155249
   May RM, 2006, TRENDS ECOL EVOL, V21, P394, DOI 10.1016/j.tree.2006.03.013
   Metcalf CJE, 2015, EPIDEMIOL INFECT, V143, P1457, DOI 10.1017/S0950268814001988
   Metcalf CJE, 2016, LANCET, V388, P728, DOI 10.1016/S0140-6736(16)30164-7
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Noulas A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037027
   Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263
   Plans-Rubio Pedro, 2012, Hum Vaccin Immunother, V8, P184, DOI 10.4161/hv.18444
   Read JM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0268
   Sakai R, 2015, J EPIDEMIOL, V25, P359, DOI 10.2188/jea.JE20140121
   Salathe M, 2008, J R SOC INTERFACE, V5, P1505, DOI 10.1098/rsif.2008.0271
   Salje H, 2016, EPIDEMICS-NETH, V17, P10, DOI 10.1016/j.epidem.2016.10.001
   Salje H, 2012, P NATL ACAD SCI USA, V109, P9535, DOI 10.1073/pnas.1120621109
   Searle KM, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170046
   Seither R, 2015, MMWR-MORBID MORTAL W, V64, P897, DOI 10.15585/mmwr.mm6433a2
   Shim E, 2012, J THEOR BIOL, V295, P194, DOI 10.1016/j.jtbi.2011.11.005
   Shrivastwa N, 2015, VACCINE, V33, pD99, DOI 10.1016/j.vaccine.2015.09.034
   Takahashi S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585
   Takashima Y, 2015, MMWR-MORBID MORTAL W, V64, P357
   Verelst F, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0820
   Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317
   Weston D, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5223-1
   WHO, DAT STAT GRAPH
   Williamson G, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0298
   World Health Organization, MEASL RUB SURV DAT
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
NR 45
TC 5
Z9 5
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 732
EP 741
DI 10.1016/j.vaccine.2018.12.012
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000011
PM 30579756
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU McDonald, P
   Limaye, RJ
   Omer, SB
   Buttenheim, AM
   Mohanty, S
   Klein, NP
   Salmon, DA
AF McDonald, Pamela
   Limaye, Rupali J.
   Omer, Saad B.
   Buttenheim, Alison M.
   Mohanty, Salini
   Klein, Nicola P.
   Salmon, Daniel A.
TI Exploring California's new law eliminating personal belief exemptions to
   childhood vaccines and vaccine decision-making among homeschooling
   mothers in California
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; SB-277; Home school; Vaccine safety; Exemptions
ID SCHOOL IMMUNIZATION REQUIREMENTS; STATE POLICIES; UNITED-STATES;
   ASSOCIATION; HESITANCY; REFUSAL; PARENTS; MEASLES; RISKS
AB Background: California's Senate Bill 277 (SB-277) law eliminated the personal belief exemption to school immunization requirements. A potential consequence may be that parents choose homeschooling to avoid immunization. Vaccine attitudes and behaviors have not been well studied among the homeschooling population. This study explored the effect of SB-277 and vaccine decision-making among California home schoolers.
   Methods: Purposive and snowball sampling were used recruit home-schooling parents through homeschooling Facebook groups based on home school type in high-exemption regions in California for in-depth interviews. Participants had to have a child in a legalized form of homeschooling in California in grades kindergarten-twelfth grade.
   Results: Twenty-four mothers were interviewed. Participants were categorized based on self-reported vaccine attitudes and behavior into three groups: Confident and Accepting, Hesitant and Accepting, and Skeptical and Refusing. All reported the belief that SB-277 is an infringement on parental rights but was not currently impacting them. Confident and Accepting mothers (n = 10) generally believed vaccinations were safe, effective, and posed a lower risk than vaccine preventable disease (VPD). Hesitant and Accepting mothers (n = 5) expressed varying confidence levels in the belief that vaccinations were safe and effective, were not confident in the belief that vaccination posed lower risks than VPD risk, and risk perception affected vaccine decision-making. Skeptical and Refusing mothers (n = 9) generally believed that vaccinations were unsafe and ineffective, refused select vaccines, believed that vaccination posed a more serious risk than VPD risks, and belief of vaccine harm was a salient factor in vaccine decision-making.
   Conclusion: Home-schooling mothers were concerned about SB-277 but did not report that it was directly impacting their children, their vaccine decisions, or reason to home school. Vaccine attitudes and beliefs among homeschooling mothers broadly fell into categories similar to parents of non-home-schooled children. Future quantitative studies should measure vaccine hesitancy and refusal prevalence and potential confounders. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [McDonald, Pamela; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Limaye, Rupali J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe E6608, Baltimore, MD 21205 USA.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Buttenheim, Alison M.; Mohanty, Salini] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.
   [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
RP Limaye, RJ (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe E6608, Baltimore, MD 21205 USA.
EM rlimaye@jhu.edu
OI Limaye, Rupali/0000-0002-3883-9720
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI125405]
FX This work was supported in part by the National Institutes of Health
   R01AI125405 (all authors). The funder had no role in the design and
   conduct of the study; collection, management, analysis, or
   interpretation of data; or preparation, review or approval of the
   manuscript.
CR Amin AB, 2017, NAT HUM BEHAV, V1, P873, DOI 10.1038/s41562-017-0256-5
   Baldwin P., 1999, CONTAGION STATE EURO
   Ball LK, 1998, PEDIATRICS, V101, P453, DOI 10.1542/peds.101.3.453
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Brunson Emily K, 2015, Glob Pediatr Health, V2, p2333794X15616332, DOI 10.1177/2333794X15616332
   California Department of Education, SCH AT HOM
   Centers For Disease Control (CDC), 2014, CHILD HLTH DEATHS FI
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Immunization action coalition, 2015, PERS BEL EX VACC PUT
   Keane MT, 2005, VACCINE, V23, P2486, DOI 10.1016/j.vaccine.2004.10.026
   Kennedy AM, 2005, J SCHOOL HEALTH, V75, P276, DOI 10.1111/j.1746-1561.2005.00037.x
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048
   Lieu TA, 2015, PEDIATRICS
   Luthy KE, 2013, J SCH NURS, V29, P95, DOI 10.1177/1059840512455365
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   National Center for Education Statistics, CHART SCH ENR 1999 2
   National Vaccine Information Center, 2018, STAT LAW VACC REQ
   Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Redford J., 2016, 2016096 NCES US DEP
   Salmon DA, 2006, LANCET, V367, P436, DOI 10.1016/S0140-6736(06)68144-0
   Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47
   Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Stadlin S, 2012, J INFECT DIS, V206, P989, DOI 10.1093/infdis/jis436
   Strauss A, 1990, BASICS QUALITATIVE R
   Troupe D, 2017, CALIFORNIAN J HLTH P, V15
   United States Department of Education, SCH CHOIC PAR
NR 34
TC 4
Z9 4
U1 5
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 742
EP 750
DI 10.1016/j.vaccine.2018.12.018
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000012
PM 30626531
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Peng, XD
   Hu, XJ
   Salazar, MA
AF Peng, Xiangdong
   Hu, Xiaojiang
   Salazar, Miguel A.
TI First case in China of vaccine-associated poliomyelitis after sequential
   Inactivated and bivalent oral polio vaccination
SO VACCINE
LA English
DT Article
DE Vaccine associated poliomyelitis (VAPP); Perianal abscess; IPV-bOPV
   sequential vaccination
ID PARALYTIC POLIOMYELITIS; INTRAMUSCULAR INJECTIONS; IMMUNIZATION;
   ABSCESS; RISK
AB A 16 week newborn vaccinated with bOPV 4 weeks after his first routine IPV vaccination. Nineteen days later, asymmetrical paralysis was developed on his legs, and it was diagnosed to be VAPP. Perianal abscess is suspected to be a risk factor based on some limited results of retrospective studies in China. This is a risk factor similar to the multiple intramuscular injections found by researchers in last century. The two risk factors remind us that, apart from the routine infection route of the fecal to mouth and intestinal tract, skin injury (ulceration) exposure pathway should not be ignored as another possible way of causing polio, for the local injury and lesions of the skin may increase the possibility of oral poliovirus vaccine's entry into the body. As a result, to further reduce the incidence of VAPP, bOPV should be avoided for perianal abscess. If there is perianal abscess, skin injury, or if injection is unavoidable after bOPV vaccination of an infant, much attention should be paid to the treatment and cleaning of infant feces. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Peng, Xiangdong] Shanghai Univ Med & Hlth Sci, Shanghai, Peoples R China.
   [Peng, Xiangdong] Beijing Yian Res Ctr Hlth & Immunizat, Beijing, Peoples R China.
   [Hu, Xiaojiang; Salazar, Miguel A.] Beijing Normal Univ, Sch Social Dev & Publ Policy, Beijing, Peoples R China.
RP Salazar, MA (reprint author), Beijing Normal Univ, Sch Social Dev & Publ Policy, Beijing, Peoples R China.
EM salazar@bnu.edu.cn
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China [71373027]; Fundamental research funds for the central
   universities in China
FX This project is supported by the National Science Foundation of China,
   "The social management of the risk of social amplification of adverse
   events following immunization" (Project No. 71373027); Fundamental
   research funds for the central universities in China.
CR ANDERSON GW, 1951, PEDIATRICS, V7, P741
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P145
   Bosley ARJ, 2003, J INFECTION, V47, P82, DOI 10.1016/S0163-4453(03)00007-0
   Desai S, 2014, CAN J INFECT DIS MED, V25, P227, DOI 10.1155/2014/378320
   Ferreyra-Reyes L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185594
   Festen C, 1998, J PEDIATR SURG, V33, P711, DOI 10.1016/S0022-3468(98)90193-2
   Garon J, 2016, EXPERT REV VACCINES, V15, P693, DOI 10.1586/14760584.2016.1140041
   GOERKE L S, 1951, Calif Med, V74, P383
   Higashigawa M, 2010, J INFECT CHEMOTHER, V16, P356, DOI 10.1007/s10156-010-0065-5
   Hu Wu Zhimei, 1999, CHINESE J VACCINE IM, V5, P321
   Huang Jia, 2016, ALL HLTH ACAD VERSIO, V10, P25
   IZURIETA HS, 1995, PEDIATR INFECT DIS J, V14, P840, DOI 10.1097/00006454-199510000-00004
   Jiang Cailing, 2011, PREV MED TRIB, V17, P576
   Li Chunhua, 2016, HEBEI MED, V22, P1228
   [梁殉 Liang Xun], 2013, [中华小儿外科杂志, Chinese Journal of Pediatric Surgery], V34, P893
   Liu DW, 2003, CHINESE J VACCINES I, V9, P201
   Ma Cuirong, 2010, MED INNOVATION CHINA, V07, P196
   Ma Jingcang, 2013, OCCUP HLTH, V29, P2540
   Nakano T, 2011, TRAVEL MED INFECT DI, V9, P169, DOI 10.1016/j.tmaid.2010.05.004
   Old MO, 1999, PEDIATR RES, V45, p170A, DOI 10.1203/00006450-199904020-01012
   Peng XD, 2018, LANCET, V392, P610, DOI 10.1016/S0140-6736(18)30483-5
   Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184
   REN RB, 1992, J INFECT DIS, V166, P747, DOI 10.1093/infdis/166.4.747
   STREBEL PM, 1995, NEW ENGL J MED, V332, P500, DOI 10.1056/NEJM199502233320804
   Troy SB, 2014, J INFECT DIS, V209, P1693, DOI 10.1093/infdis/jit831
   Wang HongZeng, 2013, Disease Surveillance, V28, P818
   Wu WD, 2018, VACCINE, V36, P1209, DOI 10.1016/j.vaccine.2018.01.019
   WYATT H V, 1976, Medical Hypotheses, V2, P269, DOI 10.1016/S0306-9877(76)80007-2
   WYATT HV, 1989, T ROY SOC TROP MED H, V83, P545, DOI 10.1016/0035-9203(89)90286-1
   Xu JianRong, 2012, Disease Surveillance, V27, P839
   Xu JiaWei, 2013, Journal of Tropical Medicine (Guangzhou), V13, P1547
   Yan Wei, 2012, CAPITAL J PUB HLTH, V6, P272
   Zhang Xiaoxiao, 2016, CONT MED, V22, P24
   Zhang Xiaoxiao, 2016, CHINESE J VACCINE IM, V22, P511
   Zhao D, 2017, MMWR-MORBID MORTAL W, V66, P1357, DOI 10.15585/mmwr.mm6649a4
   [邹丽萍 ZOU Li-ping], 2010, [中国实用儿科杂志, Chinese Journal of Practical Pediatrics], V25, P179
NR 36
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 751
EP 754
DI 10.1016/j.vaccine.2018.12.022
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000013
PM 30630693
DA 2020-05-12
ER

PT J
AU Regan, AK
   Gibbs, R
   Bloomfield, L
   Effler, PV
AF Regan, Annette K.
   Gibbs, Robyn
   Bloomfield, Lauren
   Effler, Paul V.
TI Estimating influenza vaccine effectiveness using data routinely
   available in electronic primary care records
SO VACCINE
LA English
DT Article
DE Influenza; Vaccines and immunisation; Test-negative design; Vaccine
   effectiveness; Surveillance; Primary health care
ID TEST-NEGATIVE DESIGN; AUSTRALIA; PCR
AB Background: To support timely, annual estimation of influenza vaccine effectiveness (VE), we explored the use of automated data extraction from general practice records to estimate VE over four consecutive southern hemisphere influenza seasons.
   Methods: A software tool installed at 130 practices in Western Australia identified all outpatients tested for influenza by polymerase-chain-reaction (PCR) during annual influenza seasons occurring 2012-2015. Laboratory test results were collated with any existing record of influenza vaccine administered in the same year; limited patient demographic and clinical information was also collected. A case test-negative control analysis compared the odds of seasonal influenza vaccination between patients positive or negative for influenza by PCR with VE =1 - the odds ratio.
   Results: A total of 7270 influenza PCR test results were identified of which 1907 (26.2%) were positive; 9.4% of patients with a positive result had received contemporaneous influenza vaccination >= 14 days prior to specimen collection, compared to 17.9% of those with a negative result. Overall VE was 52% (95% CI, 43-60%); annual VE estimates ranged from 46% (95% CI, 22-63%) in 2012 to 60% (95% CI, 41-73%) in 2014.
   Conclusion: Electronic records routinely maintained by general practice provide a promising opportunity for estimating annual influenza VE in a timely and resource-efficient manner. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Regan, Annette K.] Curtin Univ, Sch Publ Hlth, Kent St, Bentley, WA 6152, Australia.
   [Regan, Annette K.; Gibbs, Robyn; Bloomfield, Lauren; Effler, Paul V.] Dept Hlth Western Australia, Communicable Dis Control Directorate, 189 Royal St, Perth, WA 6004, Australia.
   [Bloomfield, Lauren] Edith Cowan Univ, Med & Hlth Sci, 270 Joondalup Dr, Joondalup, WA 6027, Australia.
   [Effler, Paul V.] Univ Western Australia, Sch Pathol & Lab Med, 35 Stirling Ave, Crawley, WA 6008, Australia.
RP Regan, AK (reprint author), Curtin Univ, Sch Publ Hlth, GPO Box U1987, Perth, WA 6846, Australia.
EM Annette.Regan@curtin.edu.au
RI Regan, Annette/Q-9159-2016
OI Regan, Annette/0000-0002-3879-6193; Bloomfield`,
   Lauren/0000-0001-5890-4254
FU Communicable Disease Control Directorate at the Department of Health
   Western Australia
FX This work was supported by the Communicable Disease Control Directorate
   at the Department of Health Western Australia.
CR Ainslie KEC, 2017, VACCINE, V35, P7297, DOI 10.1016/j.vaccine.2017.10.107
   Arche Health, 2016, THE CANN TOOL
   El Omeiri N, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2001-1
   Emborg H, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.14.30189
   Fielding JE, 2016, VACCINE, V34, P4905, DOI 10.1016/j.vaccine.2016.08.067
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Hardelid P, 2012, VACCINE, V30, P1371, DOI 10.1016/j.vaccine.2011.12.038
   Heintzman J, 2014, J AM MED INFORM ASSN, V21, P720, DOI 10.1136/amiajnl-2013-002333
   Henderson J, 2014, ROYAL AUSTR COLL GEN
   Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069
   Jimenez-Jorge S, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.28.21187
   Kaczmarek MC, 2016, EPIDEMIOL INFECT, V144, P306, DOI 10.1017/S0950268815001004
   Levy A, 2014, VACCINE, V32, P6312, DOI 10.1016/j.vaccine.2014.08.066
   Omer SB, 2016, CLIN INFECT DIS, V63, P1574, DOI 10.1093/cid/ciw637
   Ozasa K, 2008, VACCINE, V26, P6462, DOI 10.1016/j.vaccine.2008.06.039
   Pebody RG., 2016, EUROSURVEILLANCE, V21, DOI [10.2807/1560-7917.ES.2016.21.16.30209, DOI 10.2807/1560-7917.ES.2016.21.16.30709]
   Redlberger-Fritz M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149916
   Regan AK, 2018, VACCINE, V36, P3195, DOI 10.1016/j.vaccine.2018.04.076
   Rizzo C, 2016, VACCINE, V34, P3102, DOI 10.1016/j.vaccine.2016.04.072
   Savage RD, 2015, EURO SURVEILL, V20
   Schwartz Kevin L, 2016, CMAJ Open, V4, pE463
   Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176
   Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998
   Su WJ, 2015, INT J INFECT DIS, V30, P115, DOI 10.1016/j.ijid.2014.11.011
   Sullivan SG, 2016, EPIDEMIOL INFECT, V144, P2317, DOI 10.1017/S0950268816000819
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695
   Sy LS, 2010, VACCINE, V28, P5254, DOI 10.1016/j.vaccine.2010.05.061
   van Velthoven MH, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0332-1
NR 29
TC 0
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2019
VL 37
IS 5
BP 755
EP 762
DI 10.1016/j.vaccine.2018.12.006
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK3JR
UT WOS:000457813000014
PM 30600119
DA 2020-05-12
ER

PT J
AU Sullivan, JC
   Goldsmith, J
   Rojas, R
   Varma, H
   Kasper, EM
AF Sullivan, Jensyn Cone
   Goldsmith, Jeffrey
   Rojas, Rafael
   Varma, Hemant
   Kasper, Ekkehard M.
TI Intracranial Dural Parafalcine Chondroma: Case Report and Systematic
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chondroma; Intracranial; Osteochondroma
ID MAFFUCCIS-SYNDROME; OLLIERS-DISEASE; ENCHONDROMA; MUTATIONS; IDH1
AB Intracranial chondromas are rare, benign neoplasms representing only 0.2%-0.3% of neoplastic intracranial lesions. They commonly originate from the skull base but can infrequently arise from the falx, convexity dura, or ventricular ependyma. Diagnosis requires histopathologic confirmation, as patients present with nonspecific symptoms related to mass effect, and imaging characteristics often resemble meningiomas, oligodendrogliomas, and vascular malformations. We describe the case of a patient harboring a parafalcine dural chondroma that was discovered incidentally and was managed surgically at our institution. We also provide a systematic review of the literature to elucidate incidence, origin, imaging findings, surgical management approaches, and prognosis of this rare tumor.
C1 [Sullivan, Jensyn Cone; Goldsmith, Jeffrey; Varma, Hemant] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
   [Rojas, Rafael] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Radiol, Boston, MA USA.
   [Kasper, Ekkehard M.] McMaster Univ, Hamilton Gen Hosp, Div Neurosurg, Hamilton, ON, Canada.
   [Goldsmith, Jeffrey] Boston Childrens Hosp, Dept Pathol, Boston, MA USA.
RP Varma, H (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
EM hvarma@bidmc.harvard.edu
RI Kasper, Ekkehard M/AAF-8357-2020
OI Kasper, Ekkehard/0000-0002-7600-3051
CR Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994
   CHAKRABORTTY S, 1991, SURG NEUROL, V36, P216, DOI 10.1016/0090-3019(91)90116-Q
   Cherekaev VA, 2015, J CRANIOFAC SURG, V26, P14, DOI 10.1097/SCS.0000000000001307
   Duan FH, 2012, ACTA RADIOL, V53, P1146, DOI 10.1258/ar.2012.120433
   Fatehi F, 2012, ACTA NEUROL BELG, V112, P399, DOI 10.1007/s13760-012-0076-3
   Fletcher CDM, 2013, WHO CLASSIFICATION T
   Fountas KN, 2008, CLIN NEUROL NEUROSUR, V110, P8, DOI 10.1016/j.clineuro.2007.08.020
   Huang Jin, 2009, Chinese Journal of Pathology, V38, P820, DOI 10.3760/cma.j.issn.0529-5807.2009.12.008
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Nakase H, 1998, ACTA NEUROCHIR, V140, P100, DOI 10.1007/s007010050066
   Nakayama M, 2001, J NEUROSURG, V94, P331, DOI 10.3171/jns.2001.94.2.0331
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   SALAZAR J, 1986, NEUROSURGERY, V18, P781, DOI 10.1227/00006123-198606000-00018
   Schmidinger A, 2002, NEURORADIOLOGY, V44, P268, DOI 10.1007/s002340100698
   Tibbs RE, 1997, SKULL BASE SURG, V7, P49, DOI 10.1055/s-2008-1058625
   TRAFLET RF, 1989, J NEUROSURG, V70, P274, DOI 10.3171/jns.1989.70.2.0274
   van Nielen KMB, 1999, CLIN NEUROL NEUROSUR, V101, P106, DOI 10.1016/S0303-8467(98)00072-9
   Weng JC, 2017, WORLD NEUROSURG, V108, P264, DOI 10.1016/j.wneu.2017.08.151
   Xin Y, 2011, J CLIN NEUROSCI, V18, P1064, DOI 10.1016/j.jocn.2010.12.028
NR 19
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 1
EP 7
DI 10.1016/j.wneu.2018.09.169
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100200
PM 30273721
DA 2020-05-12
ER

PT J
AU McClelland, S
   Mitin, T
   Jaboin, JJ
   Ciporen, JN
AF McClelland, Shearwood, III
   Mitin, Timur
   Jaboin, Jerry J.
   Ciporen, Jeremy N.
TI RADIANS: A Multidisciplinary Central Nervous System Clinic Model for
   Radiation Oncology and Neurosurgery Practice
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system metastases; Community hospital; Multidisciplinary
   clinic; Neurosurgery; RADIANS; Radiation oncology
ID CARE
AB BACKGROUND: Radiation therapy for central nervous system disease commonly involves collaboration between Radiation Oncology and Neurosurgery. We describe our early experience with a multidisciplinary clinic model.
   METHODS: In 2016, the novel RADIANS (RADIation oncology And NeuroSurgery) clinic model was initiated at a community hospital. Disease and treatment demographics were collected and analyzed. Patient satisfaction was assessed via a blinded survey questionnaire.
   RESULTS: Forty-two patients have been seen since the inception of RADIANS. The median age was 65; and the median patient distance from RADIANS was 42.7 miles (mean = 62.6; range = 0.7-285). Half of the patients traveled >50 miles to receive care, and >80% were seen for central nervous system metastases. Of the patients receiving radiation, 75% received stereotactic radiosurgery/stereotactic body radiation therapy. The mean overall satisfaction from 0 (not satisfied) to 5 (very satisfied) was 4.8.
   CONCLUSIONS: The RADIANS clinic model has proved viable and well-liked by patients in a community setting, with the majority of radiation therapy administered being stereotactic radiosurgery/stereotactic body radiation therapy rather than conventional fractionation.
C1 [McClelland, Shearwood, III] Indiana Univ Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA.
   [McClelland, Shearwood, III; Mitin, Timur; Jaboin, Jerry J.] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA.
   [Ciporen, Jeremy N.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
RP McClelland, S (reprint author), Indiana Univ Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA.; McClelland, S (reprint author), Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA.
EM drwood@post.harvard.edu
CR Abou-Jaoude PM, 2007, J OTOLARYNGOL, V36, P322, DOI 10.2310/7070.2007.0051
   Aizer AA, 2012, J CLIN ONCOL, V30, P3071, DOI 10.1200/JCO.2012.42.8466
   Halasz LM, 2018, JAMA ONCOL, V4, P504, DOI 10.1001/jamaoncol.2017.5062
   Harper JL, 2015, SOUTH MED J, V108, P372, DOI 10.14423/SMJ.0000000000000300
   LUNSFORD LD, 1988, JAMA-J AM MED ASSOC, V259, P2544, DOI 10.1001/jama.1988.03720170020017
   McClelland S, 2018, INT J RADIAT ONCOL, V100, P803, DOI 10.1016/j.ijrobp.2017.11.027
NR 6
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 8
EP 10
DI 10.1016/j.wneu.2018.10.083
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100201
PM 30366142
DA 2020-05-12
ER

PT J
AU Guo, JF
   Guo, Q
   Li, J
   Fang, Z
   Liao, H
   Xiong, W
   Li, F
AF Guo, Jianfeng
   Guo, Qian
   Li, Jing
   Fang, Zhong
   Liao, Hui
   Xiong, Wei
   Li, Feng
TI Wedge Hemivertebra Forward-Shifting Technique for Treatment of
   Congenital Kyphosis: Case Report, Technical Note, and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Congenital kyphosis; Spinal deformity; Wedge hemivertebra; Wedge
   hemivertebra forward-shifting technique
ID VERTEBRAL COLUMN RESECTION; SURGICAL-TREATMENT; NATURAL-HISTORY;
   OSTEOTOMY; SPINE; KYPHOSCOLIOSIS; SCOLIOSIS
AB BACKGROUND: Congenital kyphosis due to wedge hemivertebra is an uncommon spinal deformity that could progressively develop into sagittal imbalance accompanied by subsequent neurologic deterioration if no intervention is performed. Numerous surgical techniques have been reported, since congenital kyphosis has shown no response to conservative treatments. Currently, osteotomy procedures, which are considered technically demanding and risky, have become the mainstream techniques for the correction of congenital kyphosis.
   METHODS: We describe the use of a novel surgical procedure combining forward-shifting of anterior column of the wedge hemivertebra and circumferential fusion for treatment of congenital kyphosis secondary to a wedge hemivertebra in a case of a 13-year-old boy who showed a 49 degrees angular kyphosis from T12 to L2 secondary to a wedge hemivertebra in L1.
   RESULTS: The focal kyphosis was corrected to 5 degrees with a correction rate of 89.8% after operation, and the sagittal balance was significantly preserved with no complication. Solid fusion was detected at the final follow-up.
   CONCLUSIONS: This novel procedure, combining forward-shifting of anterior column of the wedge hemivertebra and circumferential fusion, is a feasible, effective, and safe technique for the treatment of some special type 1 congenital kyphosis cases, with a high correction rate and no major complications.
C1 [Guo, Jianfeng; Guo, Qian; Fang, Zhong; Liao, Hui; Xiong, Wei; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Li, Jing] Shihezi Univ, Affiliated Hosp 1, Dept Orthoped, Med Sch, Shihezi, Peoples R China.
RP Li, F (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM lifengmd@hust.edu.cn
CR Atici Y, 2013, EUR SPINE J, V22, P1368, DOI 10.1007/s00586-013-2755-z
   BRADFORD DS, 1982, J BONE JOINT SURG AM, V64, P680, DOI 10.2106/00004623-198264050-00005
   Chang KW, 2008, SPINE, V33, P1470, DOI 10.1097/BRS.0b013e3181753bcd
   Cheh G, 2008, SPINE, V33, P1093, DOI 10.1097/BRS.0b013e31816f5f73
   Gertzbein SD, 1992, SPINE, V17, P9
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   HERBERT J J, 1951, Rev Chir Orthop Reparatrice Appar Mot, V37, P506
   HODGSON AR, 1965, J BONE JOINT SURG AM, VA 47, P1221, DOI 10.2106/00004623-196547060-00011
   Kawahara N, 2001, SPINE, V26, P391, DOI 10.1097/00007632-200102150-00016
   Kim YJ, 2001, SPINE, V26, P2251, DOI 10.1097/00007632-200110150-00017
   LORENZO RL, 1983, SKELETAL RADIOL, V10, P255, DOI 10.1007/BF00357900
   Marks DS, 2009, SPINE, V34, P1751, DOI 10.1097/BRS.0b013e3181af1caf
   MAYFIELD JK, 1980, J BONE JOINT SURG AM, V62, P1291, DOI 10.2106/00004623-198062080-00008
   McMaster MJ, 2001, SPINE, V26, P2146, DOI 10.1097/00007632-200110010-00021
   McMaster MJ, 1999, J BONE JOINT SURG AM, V81A, P1367, DOI 10.2106/00004623-199910000-00002
   MCMASTER PE, 1965, PAC MED SURG, V73, P314
   MONTGOMERY SP, 1982, SPINE, V7, P360, DOI 10.1097/00007632-198207000-00006
   Noordeen MHH, 2009, SPINE, V34, P1808, DOI 10.1097/BRS.0b013e3181ab6307
   Ozturk C, 2012, SPINE, V37, P1054, DOI 10.1097/BRS.0b013e31823b4142
   Shimada Y, 2000, SPINAL CORD, V38, P382, DOI 10.1038/sj.sc.3101004
   Shimode M, 2002, SPINE, V27, P2260, DOI 10.1097/00007632-200210150-00015
   Spiro AS, 2013, BONE JOINT J, V95B, P1527, DOI 10.1302/0301-620X.95B11.31376
   Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/00007632-200211010-00012
   TSOU PM, 1977, CLIN ORTHOP RELAT R, P18
   Wang SR, 2017, EUR SPINE J, V26, P1817, DOI 10.1007/s00586-015-4344-9
   WINTER RB, 1973, J BONE JOINT SURG AM, VA 55, P223, DOI 10.2106/00004623-197355020-00001
   WINTER RB, 1985, SPINE, V10, P224, DOI 10.1097/00007632-198504000-00006
   WINTER RB, 1977, CLIN ORTHOP RELAT R, P26
   Zeng Y, 2013, J SPINAL DISORD TECH, V26, P367, DOI 10.1097/BSD.0b013e3182499237
   Zeng Y, 2013, EUR SPINE J, V22, P372, DOI 10.1007/s00586-012-2463-0
   Zhang ZF, 2017, CLIN SPINE SURG, V30, pE1098, DOI 10.1097/BSD.0000000000000350
NR 31
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 11
EP 15
DI 10.1016/j.wneu.2018.08.234
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100202
PM 30205229
DA 2020-05-12
ER

PT J
AU Ma, J
   Jia, GJ
   Chen, SY
   Jia, W
AF Ma, Jun
   Jia, Guijun
   Chen, Siyuan
   Jia, Wang
TI Clinical Perspective on Dysplastic Gangliocytoma of the Cerebellum
   (Lhermitte-Duclos Disease)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system (CNS); Dysplastic gangliocytoma of the
   cerebellum; Lhermitte-Duclos disease (LDD)
ID CT; SPECTROSCOPY; DIFFUSION; PATHOLOGY; MRI
AB BACKGROUND: Dysplastic gangliocytoma of the cerebellum, also called Lhermitte-Duclos disease (LDD), is known as a rare, benign brain tumor. Around 200 cases have been reported.
   CASE DESCRIPTION: Here we introduced a newly diagnosed adult case with intratumoral hemorrhage. Then we reviewed 18 cases diagnosed in our institute, including 12 adults and 6 children.
   CONCLUSIONS: Preoperative diagnosis based on magnetic resonance imaging is 50% in adults and 16.7% in pediatrics. Diagnostic tiger stripes are not always seen in pediatric cases. The prognosis of the disease is good if total resection can be achieved. Further examinations for PTEN mutation and other comorbidities are recommended.
C1 [Ma, Jun; Jia, Guijun; Chen, Siyuan; Jia, Wang] Capital Med Univ, Dept Neurosurg, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Ma, Jun; Jia, Guijun; Chen, Siyuan; Jia, Wang] Beijing Inst Brain Disorders, Ctr Brain Tumor, Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Ma, Jun; Jia, Guijun; Chen, Siyuan; Jia, Wang] Beijing Key Lab Brian Tumor, Beijing, Peoples R China.
RP Jia, W (reprint author), Capital Med Univ, Dept Neurosurg, Beijing Tiantan Hosp, Beijing, Peoples R China.; Jia, W (reprint author), Beijing Inst Brain Disorders, Ctr Brain Tumor, Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Jia, W (reprint author), Beijing Key Lab Brian Tumor, Beijing, Peoples R China.
EM jwttyy@sina.com
FU pediatric and adult tumor group of the neurosurgery department of
   Beijing Tiantan Hospital; neuro-radiology department of Beijing Tiantan
   Hospital; neuropathology department of Beijing Tiantan Hospital;
   Organization Department of Beijing Municipal Committee
   [20150000214696223]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [81471229]
FX This work was supported by the pediatric and adult tumor group of the
   neurosurgery department, the neuro-radiology department, and the
   neuropathology department of Beijing Tiantan Hospital. J. Ma is
   supported by a funding project for a development program for Beijing
   superior talent by the Organization Department of Beijing Municipal
   Committee (20150000214696223). W Jia is supported by national natural
   science funding by the National Natural Science Foundation of China
   (81471229).
CR Afshar-Oromieh A, 2010, NEUROSURG REV, V33, P401, DOI 10.1007/s10143-010-0278-1
   Andres RH, 2009, CLIN NEUROPATHOL, V28, P83
   Anik Y, 2007, NEURORADIOL J, V20, P278, DOI 10.1177/197140090702000304
   ASHLEY DG, 1990, J COMPUT ASSIST TOMO, V14, P984, DOI 10.1097/00004728-199011000-00022
   AWWAD EE, 1995, AM J NEURORADIOL, V16, P1719
   BANERJEE AK, 1979, IRISH J MED SCI, V148, P97, DOI 10.1007/BF02938059
   Cianfoni A, 2008, J NEURORADIOLOGY, V35, P297, DOI 10.1016/j.neurad.2008.05.002
   Fauria-Robinson Christian, 2014, J La State Med Soc, V166, P193
   Fernandes-Cabral DT, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.04.128
   Gaballo A, 2005, RADIOL MED, V110, P378
   Golden Nyoman, 2016, Asian J Neurosurg, V11, P170, DOI 10.4103/1793-5482.145091
   Goto Y, 2010, J NEURO-ONCOL, V97, P445, DOI 10.1007/s11060-009-0042-y
   Huang SY, 2015, INT J CLIN EXP PATHO, V8, P7583
   Klisch J, 2001, AM J NEURORADIOL, V22, P824
   Lhermitte J, 1920, B ASSOC FR ETUD CANC, V9, P99
   Louis DN, 2016, WHO CLASSIFICATION T
   Matsumoto H, 2015, TURK NEUROSURG, V25, P783, DOI 10.5137/1019-5149.JTN.9835-13.2
   MELTZER CC, 1995, RADIOLOGY, V194, P699, DOI 10.1148/radiology.194.3.7862965
   Moonis G, 2004, NEURORADIOLOGY, V46, P351, DOI 10.1007/s00234-004-1190-6
   Nagaraja S, 2004, NEURORADIOLOGY, V46, P355, DOI 10.1007/s00234-004-1201-7
   Nowak DA, 2002, ACTA NEUROL SCAND, V105, P137, DOI 10.1034/j.1600-0404.2002.1r127.x
   PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511
   RAINOV NG, 1995, CLIN NEUROL NEUROSUR, V97, P175, DOI 10.1016/0303-8467(95)00017-E
   Thomas B, 2007, NEURORADIOLOGY, V49, P733, DOI 10.1007/s00234-007-0241-1
   Uchida D, 2018, WORLD NEUROSURG, V114, P326, DOI [10.1016/J.WNEU.2018.03.184, 10.1016/j.wneu.2018.03.184]
   VIECO PT, 1992, PEDIATR RADIOL, V22, P366, DOI 10.1007/BF02016259
   Wang QG, 2017, CLIN NEUROL NEUROSUR, V162, P53, DOI 10.1016/j.clineuro.2017.09.007
   Wei GQ, 2014, MOL CLIN ONCOL, V2, P415, DOI 10.3892/mco.2014.258
   Wolansky LJ, 1996, SURG NEUROL, V45, P470, DOI 10.1016/0090-3019(95)00244-8
NR 29
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 16
EP 23
DI 10.1016/j.wneu.2018.10.085
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100203
PM 30366139
DA 2020-05-12
ER

PT J
AU Lv, JH
   Qi, XC
   Wang, YR
   Wu, HJ
   Wang, K
   Niu, HJ
   Li, XW
AF Lv, Junhui
   Qi, Xuchen
   Wang, Yirong
   Wu, Haijian
   Wang, Kun
   Niu, Huanjiang
   Li, Xinwei
TI Contralateral Subdural Hematoma Following Surgical Evacuation of Acute
   Subdural Hematoma: Super-Early Intervention and Clinical Implications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contralateral subdural hematoma; Intraoperative brain swelling;
   Super-early intervention
ID DECOMPRESSIVE CRANIECTOMY; MORTALITY; OUTCOMES; INJURY
AB BACKGROUND: Contralateral acute subdural hematoma (ASDH) is an uncommon but devastating complication during craniotomy and hematoma evacuation. It can lead to extremely poor outcomes if not treated properly and promptly.
   CASE DESCRIPTION: We present a case of a 49-year-old male who suffered contralateral ASDH during surgical evacuation of ASDH on the left side. Before the operation, we noticed slight contralateral ASDH on preoperative cranial computed tomography and were aware of its enlargement during operation. Decompression with a burr-hole craniotomy promptly followed by a decompressive craniectomy was performed to prevent contralateral ASDH. Unfortunately, we found intraoperative brain swelling, which indicated the development of a contralateral hematoma. The patient was reoperated and eventually had a poor prognosis.
   CONCLUSIONS: We highlight that super-early intervention of contralateral hematoma is important to improve the prognosis of these patients.
C1 [Lv, Junhui; Qi, Xuchen; Wang, Yirong; Wu, Haijian; Wang, Kun; Niu, Huanjiang; Li, Xinwei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Neurosurg, Coll Med, Hangzhou, Zhejiang, Peoples R China.
RP Li, XW (reprint author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Neurosurg, Coll Med, Hangzhou, Zhejiang, Peoples R China.
EM 3199025@zju.edu.cn
FU Natural Science Foundation of Zhejiang Province of ChinaNatural Science
   Foundation of Zhejiang Province [LY14H180017]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [81402044]
FX This work was supported by the Natural Science Foundation of Zhejiang
   Province of China (LY14H180025), the National Natural Science Foundation
   of China (81402044), and the Natural Science Foundation of Zhejiang
   Province of China (LY14H180017).
CR BAN M, 1991, Neurologia Medico-Chirurgica, V31, P927, DOI 10.2176/nmc.31.927
   Fridley J, 2011, J CLIN NEUROSCI, V18, P422, DOI 10.1016/j.jocn.2010.05.004
   Guilburd JN, 2001, J NEUROSURG, V95, P263, DOI 10.3171/jns.2001.95.2.0263
   Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989
   Karibe H, 2014, NEUROL MED-CHIR, V54, P887, DOI 10.2176/nmc.cr.2014-0204
   Kinoshita T, 2016, WORLD NEUROSURG, V89, P187, DOI 10.1016/j.wneu.2016.01.071
   Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5
   Moon KS, 2007, J CLIN NEUROSCI, V14, P283, DOI 10.1016/j.jocn.2005.11.016
   Murzin V E, 1979, Zh Vopr Neirokhir Im N N Burdenko, P43
   Ryan CG, 2012, J TRAUMA ACUTE CARE, V73, P1348, DOI 10.1097/TA.0b013e31826fcb30
   Shen J, 2013, NEUROL MED-CHIR, V53, P221, DOI 10.2176/nmc.53.221
   Shen J, 2013, ACTA NEUROCHIR, V155, P335, DOI 10.1007/s00701-012-1569-9
   Shibahashi K, 2017, BRIT J NEUROSURG, V31, P618, DOI 10.1080/02688697.2016.1211251
   Takeuchi S, 2013, TURK NEUROSURG, V23, P294, DOI 10.5137/1019-5149.JTN.5009-11.1
   Talbott JF, 2014, AM J NEURORADIOL, V35, P1930, DOI 10.3174/ajnr.A4001
   Tomycz Nestor D, 2010, J Trauma, V68, pE11, DOI 10.1097/TA.0b013e31811eaaf5
   Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9
NR 17
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 24
EP 27
DI 10.1016/j.wneu.2018.10.106
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100204
PM 30429101
DA 2020-05-12
ER

PT J
AU Matsushima, K
   Kohno, M
   Nakajima, N
AF Matsushima, Ken
   Kohno, Michihiro
   Nakajima, Nobuyuki
TI Retrosigmoid Intradural Temporal Bone Drilling for Intrapetrous
   Chondrosarcoma Extending to Cerebellopontine Angle
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle; Chondrosarcoma; Internal acoustic meatus;
   Lateral suboccipital approach; Petrosal bone; Petrous carotid artery;
   Skull base surgery
C1 [Matsushima, Ken; Kohno, Michihiro; Nakajima, Nobuyuki] Tokyo Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
RP Kohno, M (reprint author), Tokyo Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
EM mkouno-nsu@umin.ac.jp
OI Matsushia, Ken/0000-0002-6492-3694
CR Matsushima K, 2017, WORLD NEUROSURG, V103, P620, DOI 10.1016/j.wneu.2017.04.079
   Samii M, 2013, NEUROSURGERY, V73, P53, DOI 10.1227/NEU.0b013e3182889e59
NR 2
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 28
EP 28
DI 10.1016/j.wneu.2018.10.104
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100205
PM 31108064
DA 2020-05-12
ER

PT J
AU Beer-Furlan, A
   Neto, SG
   Teixeira, MJ
   Figueiredo, EG
AF Beer-Furlan, Andre
   Neto, Sergio G.
   Teixeira, Manoel J.
   Figueiredo, Eberval G.
TI Fulfilling Need for Neurosurgical Services in Sub-Saharan Africa:
   Initial Angola-Brazil Training Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Africa; Angola; Brazil; Neurosurgery delivery; Neurosurgery training
AB BACKGROUND: Although Africa accounts for 15% of the global volume of neurosurgical disease, African hospitals and health care networks have access to <1% of the neurosurgeon community. Health care and neurosurgical care are particularly scarce in sub-Saharan Africa due to long periods of imperialism, civil war, poverty, and famines that have plagued the area.
   METHODS: We provide a historical perspective and initial experience of the development of neurosurgery in Angola.
   RESULTS: The Republic of Angola has the seventh largest territory in Africa and a population of approximately 29 million people; however, it has a severe deficit of neurosurgery specialists. Between 1975 and 2012, only 5 neurosurgeons practiced in the country. We report the initial experience of the first Angolan physician who completed a full neurosurgical residency in Brazil through the Hospital das Clinicas-University of Sao Paulo Medical School international medical training program. The challenges of fulfilling the need for neurosurgical services and the future perspectives of building a sustainable program in Angola are discussed.
   CONCLUSIONS: Partnerships between developing countries and sub-Saharan African countries may be the starting point in supplying neurosurgical specialists to the countries in need.
C1 [Beer-Furlan, Andre] Rush Univ, Dept Neurol Surg, Med Ctr, Chicago, IL 60612 USA.
   [Neto, Sergio G.] Clin Girassol, Dept Surg, Neurosurg Serv, Luanda, Angola.
   [Neto, Sergio G.] Clin Sagrada Esperanca, Dept Surg, Neurosurg Serv, Luanda, Angola.
   [Teixeira, Manoel J.; Figueiredo, Eberval G.] Univ Sao Paulo, Dept Neurol, Discipline Neurosurg, Med Sch, Sao Paulo, Brazil.
RP Beer-Furlan, A (reprint author), Rush Univ, Dept Neurol Surg, Med Ctr, Chicago, IL 60612 USA.
EM andre_beerfurlan@rush.edu
RI Figueiredo, Eberval Gadelha/H-3488-2012
CR Budohoski KP, 2018, WORLD NEUROSURG, V113, P436, DOI 10.1016/j.wneu.2018.01.085
   Burton A, 2017, LANCET NEUROL, V16, P499, DOI [10.1016/S1474-4422(17)30246-6, 10.1016/S1474-4422(17)30164-3, 10.1016/S1474-4422(17)30087-X]
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   El-Fiki M, 2010, WORLD NEUROSURG, V73, P254, DOI 10.1016/j.wneu.2010.02.012
   Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1
   Teixeira MJ, 2014, ARQ NEURO-PSIQUIAT, V72, P251, DOI 10.1590/0004-282X20130245
   World Health Organization, COUNTR KEY IND
NR 7
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 29
EP 32
DI 10.1016/j.wneu.2018.10.081
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100206
PM 30366143
DA 2020-05-12
ER

PT J
AU Piedade, GS
   Schirmer, CM
   Goren, O
   Zhang, H
   Aghajanian, A
   Faber, JE
   Griessenauer, CJ
AF Piedade, Guilherme Santos
   Schirmer, Clemens M.
   Goren, Oded
   Zhang, Hua
   Aghajanian, Amir
   Faber, James E.
   Griessenauer, Christoph J.
TI Cerebral Collateral Circulation: A Review in the Context of Ischemic
   Stroke and Mechanical Thrombectomy
SO WORLD NEUROSURGERY
LA English
DT Review
DE Collateral circulation; Collateral score; Genetics; Mechanical
   thrombectomy; Stroke
ID NITRIC-OXIDE SYNTHASE; GROWTH FACTOR-A; CT-ANGIOGRAPHY; INTRAVENOUS
   THROMBOLYSIS; ENDOVASCULAR THERAPY; PIAL COLLATERALS; RANDOMIZED-TRIAL;
   PERFUSION; OUTCOMES; OCCLUSION
AB The pial (leptomenigeal) collateral circulation is a key determinant of functional outcome after mechanical thrombectomy after large-vessel ischemic stroke. Patients with good collateral blood flow benefit up to 24 hours after stroke onset, whereas those with poor collateral flow evidence less or no benefit. However, clues to why collateral flow varies so widely among patients have remained elusive. Recent findings in animal studies, which are currently being tested for confirmation in humans, have found that naturally occurring variants of a novel "collateral gene," Rabep2, result in large differences in the extent of anatomic collaterals and thus blood flow and infarct size in mice after stroke. The comprehension of collagerogenesis in humans and the evaluation of collateral status could aid in identifying patients who will benefit not only from mechanical thrombectomy in the extended time window but also from any reperfusion strategy. We performed a literature review focused on radiographic, clinical, and genetic aspects of the collateral circulation.
C1 [Piedade, Guilherme Santos; Schirmer, Clemens M.; Goren, Oded; Griessenauer, Christoph J.] Geisinger, Dept Neurosurg, Danville, PA 17822 USA.
   [Piedade, Guilherme Santos] Univ Dusseldorf, Dept Neurosurg, Dusseldorf, Germany.
   [Zhang, Hua; Aghajanian, Amir; Faber, James E.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Dept Neurosurg, Salzburg, Austria.
RP Griessenauer, CJ (reprint author), Geisinger, Dept Neurosurg, Danville, PA 17822 USA.; Griessenauer, CJ (reprint author), Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.; Griessenauer, CJ (reprint author), Paracelsus Med Univ, Dept Neurosurg, Salzburg, Austria.
EM christoph.griessenauer@gmail.com
RI Piedade, Guilherme Santos/AAG-2731-2019
OI Piedade, Guilherme Santos/0000-0002-1907-4558; Griessenauer,
   Christoph/0000-0002-2952-3812; Schirmer, Clemens/0000-0003-1743-8781
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Alves HC, 2018, STROKE, V49, P391, DOI 10.1161/STROKEAHA.117.019509
   Anan M, 2009, NEUROL RES, V31, P917, DOI 10.1179/174313209X383231
   Arenillas JF, 2018, J CEREBR BLOOD F MET, V38, P1839, DOI 10.1177/0271678X17740293
   Bang OY, 2015, STROKE, V46, P3302, DOI 10.1161/STROKEAHA.115.010508
   Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chalothorn D, 2010, J MOL CELL CARDIOL, V49, P251, DOI 10.1016/j.yjmcc.2010.03.014
   Christoforidis GA, 2009, AM J NEURORADIOL, V30, P165, DOI 10.3174/ajnr.A1276
   Christoforidis GA, 2005, AM J NEURORADIOL, V26, P1789
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   Clayton JA, 2008, CIRC RES, V103, P1027, DOI 10.1161/CIRCRESAHA.108.181115
   Dai XM, 2010, CIRC RES, V106, P1870, DOI 10.1161/CIRCRESAHA.109.212746
   DeFazio RA, 2012, J CEREBR BLOOD F MET, V32, P2012, DOI 10.1038/jcbfm.2012.102
   Faber J, 2014, 20 INT STROK C FEBR
   Galimanis A, 2012, STROKE, V43, P1052, DOI 10.1161/STROKEAHA.111.639112
   Gerber JC, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.513
   Ginsberg MD, 2018, NEUROPHARMACOLOGY, V134, P280, DOI 10.1016/j.neuropharm.2017.08.003
   Ginsberg MD, 2013, LANCET NEUROL, V12, P1049, DOI 10.1016/S1474-4422(13)70223-0
   Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Griessenauer CJ, 2017, WORLD NEUROSURG, V104, P968, DOI 10.1016/j.wneu.2017.06.102
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Hohenhaus M, 2012, CEREBROVASC DIS, V34, P63, DOI 10.1159/000339012
   Ichijo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138029
   Iwasawa E, 2016, NEURAL REGEN RES, V11, P368, DOI 10.4103/1673-5374.179033
   Jung S, 2013, BRAIN, V136, P3554, DOI 10.1093/brain/awt246
   Kalin S, 2015, J CELL SCI, V128, P4126, DOI 10.1242/jcs.174664
   Kofler N, 2018, J BIOL CHEM, V293, P4805, DOI 10.1074/jbc.M117.812172
   Kufner A, 2015, AM J NEURORADIOL, V36, P1426, DOI 10.3174/ajnr.A4320
   Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5
   Lee MJ, 2014, CEREBROVASC DIS, V37, P77, DOI 10.1159/000356114
   Leng X, 2016, EUR J NEUROL, V23, P1738, DOI 10.1111/ene.13111
   Liebeskind DS, 2014, STROKE, V45, P2036, DOI 10.1161/STROKEAHA.114.004781
   Liebeskind DS, 2003, STROKE, V34, P2279, DOI 10.1161/01.STR.0000086465.41263.06
   Lucitti JL, 2016, STROKE, V47, P3022, DOI 10.1161/STROKEAHA.116.014160
   Lucitti JL, 2012, CIRC RES, V111, P1539, DOI 10.1161/CIRCRESAHA.112.279109
   Marks MP, 2014, STROKE, V45, P1035, DOI 10.1161/STROKEAHA.113.004085
   Matsuda T, 2005, NEUROL RES, V27, P503, DOI 10.1179/016164105X25144
   McVerry F, 2012, AM J NEURORADIOL, V33, P576, DOI 10.3174/ajnr.A2794
   Menon BK, 2011, AM J NEURORADIOL, V32, P1640, DOI 10.3174/ajnr.A2564
   Menon BK, 2015, RADIOLOGY, V275, P510, DOI 10.1148/radiol.15142256
   Miteff F, 2009, BRAIN, V132, P2231, DOI 10.1093/brain/awp155
   Molina CA, 2015, INT J STROKE, V10, P619, DOI 10.1111/ijs.12157
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Ovbiagele B, 2007, NEUROLOGY, V68, P2129, DOI 10.1212/01.wnl.0000264931.34941.f0
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Raymond Scott B, 2017, Top Magn Reson Imaging, V26, P67, DOI 10.1097/RMR.0000000000000123
   Rost N, NEUROL GENET
   Rzechorzek W, 2017, J CEREBR BLOOD F MET, V37, P3544, DOI 10.1177/0271678X17718966
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Scott CC, 2014, SEMIN CELL DEV BIOL, V31, P2, DOI 10.1016/j.semcdb.2014.03.034
   Sealock R, 2014, CIRC RES, V114, P660, DOI 10.1161/CIRCRESAHA.114.302931
   Seker F, 2016, J NEUROINTERV SURG, V8, P1116, DOI 10.1136/neurintsurg-2015-012101
   Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933
   Tan BYQ, 2016, STROKE, V47, P2292, DOI 10.1161/STROKEAHA.116.013879
   Tan IYL, 2009, AM J NEURORADIOL, V30, P525, DOI 10.3174/ajnr.A1408
   Tan JC, 2007, ANN NEUROL, V61, P533, DOI 10.1002/ana.21130
   Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419
   Treurniet KM, 2018, J NEUROINTERV SURG, V10, P107, DOI 10.1136/neurintsurg-2017-012988
   Wang Qingsong, 2017, Zhejiang Da Xue Xue Bao Yi Xue Ban, V46, P377
   Wang SL, 2010, CIRC RES, V107, P558, DOI 10.1161/CIRCRESAHA.110.224634
   Woodhouse L, 2015, STROKE, V46, P3194, DOI 10.1161/STROKEAHA.115.009647
   Xu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038701
   Yang J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007589
   Yeo LLL, 2016, J STROKE CEREBROVASC, V25, P2423, DOI 10.1016/j.jstrokecerebrovasdis.2016.06.014
   Zhang H, 2010, J CEREBR BLOOD F MET, V30, P923, DOI 10.1038/jcbfm.2010.10
   Zhu ZL, 2015, CIRCULATION, V132, P1104, DOI 10.1161/CIRCULATIONAHA.115.016371
NR 71
TC 3
Z9 4
U1 3
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 33
EP 42
DI 10.1016/j.wneu.2018.10.066
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100207
PM 30342266
DA 2020-05-12
ER

PT J
AU Dias, SF
   Jehli, E
   Regli, L
   Sarnthein, J
   Germans, MR
AF Dias, Sandra Fernandes
   Jehli, Elisabeth
   Regli, Luca
   Sarnthein, Johannes
   Germans, Menno R.
TI Multimodal Monitoring Strategy Is Decisive in Elective Middle Cerebral
   Artery Aneurysm Clipping: A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Clipping; Indocyanine green-video angiography; Intraoperative
   neurophysiological monitoring; Vascular neurosurgery
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; SOMATOSENSORY-EVOKED POTENTIALS;
   VIDEO-ANGIOGRAPHY
AB BACKGROUND: The intraoperative use of neurophysiological monitoring (IONM) and indocyanine green video angiography (ICGVA) for aneurysm clipping have evolved during the last years. Both modalities are useful and safe by allowing greater rates of complete aneurysm occlusion with less intraoperative complications and postoperative neurologic deficits. We report a case of attempted aneurysm clipping in which the combined use of ICGVA and IONM was crucial for intraoperative decision-making.
   CASE DESCRIPTION: A 62-year-old woman was operated for an incidental 6-mm aneurysm at the origin of the right fronto-opercular branch. During aneurysm clipping, IONM amplitudes dropped drastically, despite patency of the parent artery and perforators in ICGVA. Several attempts for clipping were made with recurring drops in IONM amplitudes, which forced us to leave the aneurysm untreated. The patient had a postoperative left-sided hemiparesis that improved on follow-up. Thereafter, the aneurysm was treated with stent-assisted coiling.
   CONCLUSIONS: The combination of IONM and ICGVA during aneurysm surgery allows for a better assessment of vascular integrity and patient's postoperative outcome than ICGVA alone. Simultaneous evaluation of vessel patency and integrity of the somatosensory and motor pathways illustrates the complementarity of testing different modalities for intraoperative decision-making and for maximizing safeness in aneurysm clipping.
C1 [Dias, Sandra Fernandes; Jehli, Elisabeth; Regli, Luca; Sarnthein, Johannes; Germans, Menno R.] Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr, Zurich, Switzerland.
   [Sarnthein, Johannes] ETH, Zurich Neurosci Ctr, Zurich, Switzerland.
RP Dias, SF (reprint author), Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr, Zurich, Switzerland.
EM sandrafs.dias12@gmail.com
RI Sarnthein, Johannes/E-7959-2010; Germans, Menno/AAI-8211-2020
OI Sarnthein, Johannes/0000-0001-9141-381X; Fernandes Dias,
   Sandra/0000-0002-3146-5164
CR Alshekhlee A, 2010, STROKE, V41, P1471, DOI 10.1161/STROKEAHA.110.580647
   Dashti R, 2009, SURG NEUROL, V71, P543, DOI 10.1016/j.surneu.2009.01.027
   de Oliveira JG, 2008, NEUROSURGERY, V62, P1300, DOI [10.1227/01.NEU.0000279982.48426.A1, 10.1227/01.neu.0000333795.21468.d4]
   Della Puppa A, 2018, WORLD NEUROSURG, V113, pE336, DOI 10.1016/j.wneu.2018.02.029
   Esposito G, 2016, ACTA NEUROCHIR, V158, P565, DOI 10.1007/s00701-016-2703-x
   Esposito G, 2014, ACTA NEUROCHIR SUPPL, V119, P59, DOI 10.1007/978-3-319-02411-0_10
   Esposito G, 2012, NEUROSURGERY, V71, P274, DOI 10.1227/NEU.0b013e3182684c45
   Grasso G, 2017, WORLD NEUROSURG, V101, P763, DOI 10.1016/j.wneu.2017.02.103
   Kashkoush AI, 2017, WORLD NEUROSURG, V104, P442, DOI 10.1016/j.wneu.2017.05.036
   Raabe A, 2005, J NEUROSURG, V103, P982, DOI 10.3171/jns.2005.103.6.0982
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Roessler K, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13475
   Scerrati A, 2014, CLIN NEUROL NEUROSUR, V124, P106, DOI 10.1016/j.clineuro.2014.06.032
   SCHRAMM J, 1994, NEUROL RES, V16, P20
   Spina A, 2017, WORLD NEUROSURG, V101, P773, DOI 10.1016/j.wneu.2017.02.005
   Staarmann B, 2017, WORLD NEUROSURG, V100, P522, DOI 10.1016/j.wneu.2017.01.009
   Wicks RT, 2012, NEUROSURGERY, V70, P1114, DOI 10.1227/NEU.0b013e31823f5cf7
   Yue Q, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.004
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 43
EP 47
DI 10.1016/j.wneu.2018.10.096
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100208
PM 31108065
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Yang, DX
   Jing, Y
   Xu, ZM
   Yuan, F
   Liu, YL
   Wang, GS
   Tian, HL
AF Yang, Dian-xu
   Jing, Yao
   Xu, Zhi-ming
   Yuan, Fang
   Liu, Ying-liang
   Wang, Gui-song
   Tian, Heng-li
TI Primary Glioblastoma of Cerebellopontine Angle in Adult Mimicking
   Acoustic Neuroma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle; Cranial nerve VIII; Diagnosis; Glioblastoma
ID PILOCYTIC ASTROCYTOMA; CEREBELLAR GLIOBLASTOMA; MULTIFORME; NERVE; RARE
AB BACKGROUND: Gliomas are usually located in the supratentorial region and are extremely rare at the cerebellopontine angle (CPA). Consequently, gliomas in the CPA are easy to misdiagnose preoperatively.
   CASE DESCRIPTION: This paper presents a 55-year-old man with an extraaxial CPA glioblastoma arising from the proximal portion of cranial nerve (CN) VIII. Preoperative imaging findings suggested an acoustic neuroma. The tumor was removed subtotally, and it was completely separated from the brainstem and cerebellum. The histopathologic examination showed a glioblastoma.
   CONCLUSIONS: To our knowledge, this case is the second report of a true primary extraaxial CPA glioblastoma. Therefore glioma should be considered in the differential diagnosis of CPA masses with atypical imaging features, although they are extremely rare.
C1 [Yang, Dian-xu; Jing, Yao; Xu, Zhi-ming; Yuan, Fang; Liu, Ying-liang; Tian, Heng-li] Shanghai Jiao Tong Univ, Affiliated Peoples 6, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, Gui-song] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Tian, HL (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples 6, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.
EM tianhlsh@126.com
CR Arnautovic KI, 2000, J NEURO-ONCOL, V49, P205, DOI 10.1023/A:1006488905526
   BEUTLER AS, 1995, NEUROSURGERY, V37, P125, DOI 10.1227/00006123-199507000-00019
   Cushing H, 1917, TUMORS NERVUS ACUSTI
   Demir Mustafa Kemal, 2005, Diagn Interv Radiol, V11, P83
   Forton G., 1992, Acta Oto-Rhino-Laryngologica Belgica, V46, P405
   HEGEDUS K, 1983, J NEUROSURG, V58, P589, DOI 10.3171/jns.1983.58.4.0589
   Henson JW, 2006, ARCH NEUROL-CHICAGO, V63, P337, DOI 10.1001/archneur.63.3.337
   KASANTIKUL V, 1980, ARCH OTOLARYNGOL, V106, P456
   Kasliwal MK, 2008, PEDIATR NEUROSURG, V44, P224, DOI 10.1159/000121380
   Kawase T, 1993, Noshuyo Byori, V10, P53
   KUROIWA T, 1995, AM J NEURORADIOL, V16, P583
   Lee JH, 2017, J KOREAN NEUROSURG S, V60, P380, DOI 10.3340/jkns.2015.0303.006
   Linsenmann T, 2013, J NEUROL SURG PART A, V74, P262, DOI 10.1055/s-0032-1304218
   Matsuda M, 2014, J NEUROL SURG REP, V75, pE67, DOI 10.1055/s-0033-1364167
   Mirone G, 2009, CHILD NERV SYST, V25, P247, DOI 10.1007/s00381-008-0690-9
   MORNEX F, 1993, RADIOTHER ONCOL, V27, P181, DOI 10.1016/0167-8140(93)90072-G
   Panse, 1904, ARCH OHRENH, V61, P251
   Rasalingam K, 2008, MALAYS J MED SCI, V15, P44
   Reifenberger G, 1996, J NEUROSURG, V84, P1062, DOI 10.3171/jns.1996.84.6.1062
   Salunke P, 2012, BRIT J NEUROSURG, V26, P96, DOI 10.3109/02688697.2011.585670
   Takada Y, 1999, NEURORADIOLOGY, V41, P949, DOI 10.1007/s002340050874
   Tomita T, 2015, CHILD NERV SYST, V31, P1739, DOI 10.1007/s00381-015-2747-x
   Wu B, 2011, J NEUROSURG, V114, P1288, DOI 10.3171/2010.12.JNS10912
   Yamamoto Masaaki, 1997, Neurologia Medico-Chirurgica, V37, P411, DOI 10.2176/nmc.37.411
NR 24
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 48
EP 52
DI 10.1016/j.wneu.2018.10.073
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100209
PM 30347301
DA 2020-05-12
ER

PT J
AU Hernandez, RN
   Wipplinger, C
   Navarro-Ramirez, R
   Patsalides, A
   Tsiouris, AJ
   Stieg, PE
   Kirnaz, S
   Schmidt, FA
   Hartl, R
AF Hernandez, R. Nick
   Wipplinger, Christoph
   Navarro-Ramirez, Rodrigo
   Patsalides, Athos
   Tsiouris, Apostolos John
   Stieg, Philip E.
   Kirnaz, Sertac
   Schmidt, Franziska Anna
   Hartl, Roger
TI Bow Hunter Syndrome with Associated Pseudoaneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bow hunter syndrome; Case report; Pseudoaneurysm; Rotational vertebral
   artery occlusion
ID VERTEBRAL ARTERY-OCCLUSION; MANAGEMENT; DIAGNOSIS
AB BACKGROUND: Bow hunter syndrome describes a mechanical compression of the vertebral artery on head rotation leading to reversible symptomatic vertebrobasilar insufficiency. Patients are commonly presenting with syncope, vertigo, dizziness, and visual disturbances. These symptoms usually resolve when the head is turned back into neutral position. Treatment options involve surgical decompression with or without fusion, bypass surgery, or endovascular intervention.
   CASE DESCRIPTION: We report about a 49-year-old female who presented with vague neck pain and severe vertigo, nausea, and near syncope when her head turned up and right. Computed tomography angiography revealed a pseudoaneurysm at the dominant left V3 and near total occlusion of the left vertebral artery as it exited the C2 foramen when the head was turned to the previously mentioned position. The patient could be successfully treated by computed tomography-navigated posterior instrumentation using bilateral C1 lateral mass screws and C2 translaminar screws. To promote segmental fusion, bilateral intrafacet cages were implanted. Postoperatively, the patient remained without neurologic deficits and experienced no further episodes of the preoperatively reported transient vertebrobasilar insufficiency symptoms.
   CONCLUSIONS: The reported case is unique as the bow hunter syndrome was further complicated by a pseudoaneurysm of the V3 segment. Surgical intervention proved to be an efficient treatment by stabilizing the affected segment in this patient.
C1 [Hernandez, R. Nick; Wipplinger, Christoph; Navarro-Ramirez, Rodrigo; Patsalides, Athos; Stieg, Philip E.; Kirnaz, Sertac; Schmidt, Franziska Anna; Hartl, Roger] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Neurol Surg, Weill Cornell Brain & Spine Ctr, New York, NY 10065 USA.
   [Tsiouris, Apostolos John] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Neuroradiol, Weill Cornell Brain & Spine Ctr, New York, NY USA.
RP Wipplinger, C (reprint author), Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Neurol Surg, Weill Cornell Brain & Spine Ctr, New York, NY 10065 USA.
EM chw2035@med.cornell.edu
OI Navarro-Ramirez, Rodrigo/0000-0003-2543-9063
CR Choi KD, 2013, STROKE, V44, P1817, DOI 10.1161/STROKEAHA.113.001219
   Cornelius JF, 2012, NEUROSURG REV, V35, P127, DOI 10.1007/s10143-011-0343-4
   Daou B, 2016, J NEUROSURG, V125, P936, DOI 10.3171/2015.10.JNS151846
   Duan GX, 2016, INTERV NEUROL, V5, P29, DOI 10.1159/000444306
   Jost GF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14791
   Kan P, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.050
   Kleyn AD, 1933, DTSCH Z NERVENHEILK, V132, P157
   Kuether TA, 1997, NEUROSURGERY, V41, P427, DOI 10.1097/00006123-199708000-00019
   Lu DC, 2010, NEUROSURGERY, V67, P1066, DOI 10.1227/NEU.0b013e3181ee36db
   Matsuyama T, 1997, J NEUROSURG, V86, P619, DOI 10.3171/jns.1997.86.4.0619
   Motiei-Langroudi R, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.067
   Rastogi Vaibhav, 2015, J Vasc Interv Neurol, V8, P7
   SORENSEN BF, 1978, NEUROSURGERY, V2, P259, DOI 10.1227/00006123-197805000-00013
   Strickland B, 2017, WORLD NEUROSURG, V103, DOI 10.1016/j.wneu.2017.04.101
   Zaidi HA, 2014, WORLD NEUROSURG, V82, P733, DOI 10.1016/j.wneu.2014.02.027
NR 15
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 53
EP 57
DI 10.1016/j.wneu.2018.10.102
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100210
PM 30463807
DA 2020-05-12
ER

PT J
AU Wang, L
   Qian, H
   Shi, XE
AF Wang, Long
   Qian, Hai
   Shi, Xiang'en
TI The "SHI" Internal Maxillary Bypass for Giant Fusiform Middle Cerebral
   Artery Bifurcation Aneurysms: 2-Dimensional Operative Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complex middle cerebral artery aneurysm; Extracranial-intracranial
   bypass; Internal maxillary artery bypass
C1 [Wang, Long; Qian, Hai; Shi, Xiang'en] Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, L; Shi, XE (reprint author), Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM wanglong@mail.ccmu.edu.cn; shixen@sina.com
RI WANG, LONG/AAI-5029-2020
FU Beijing Municipal Natural Science FoundationBeijing Natural Science
   Foundation [7161005]; Science and Technology Commission Foundation of
   Beijing [Z161100000516019]
FX Funding was from the Beijing Municipal Natural Science Foundation
   (7161005, Dr. Xiang'en Shi) and Science and Technology Commission
   Foundation of Beijing (Z161100000516019, Dr. Xiang'en Shi).
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 58
EP 58
DI 10.1016/j.wneu.2018.10.063
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100211
PM 30347305
DA 2020-05-12
ER

PT J
AU Li, LF
   Pu, JKS
   Chung, JCK
   Lui, WM
   Leung, GKK
AF Li, Lai-fung
   Pu, Jenny Kan-suen
   Chung, Joseph Chun-kit
   Lui, Wai-man
   Leung, Gilberto Ka-kit
TI Repair of Anterior Skull Base Defect by Dual-Layer/Split-Frontal
   Pericranial Flap
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leakage; Endoscopic surgical procedure; Pedicled
   flap; Skull base
ID SUCCESSFUL RECONSTRUCTION; CLOSURE
AB INTRODUCTION: Normal skull base structures are destroyed either by the skull base pathology itself or during surgery that results in cerebrospinal fluid (CSF) leak. Skull base repair is usually performed transnasally by using a nasal septal flap. But when NSF is not available and failed repeated transnasal repair, a cranionasal repair with frontal pericranial flap (PF) can be attempted to achieve the highest successful chance. We performed a dual layer/split PF repair of a skull base defect using cranionasal approach and here we describe the technique.
   CASE DESCRIPTION: A 74-year-old man suffered from CSF leak and ventriculitis after multiple transnasal surgeries for pituitary macroadenoma despite multiple repairs with intranasal vascularized flaps. We performed repair by cranionasal approach and using frontal PF. The frontal PF was divided into left and right halves. The left half went intradural, through the chiasmatic window to reach the sella and cover the tubercular and sellar defect from above. The right half went through the nasion into the nose to cover the defect from below. So the defect was covered by two vascularized flap from a single frontal PF. The repair was successful with no CSF leak and infection successfully treated by antibiotics.
   CONCLUSION: We introduced the cranionasal dual layer/split PF technique to repair anterior skull base and successfully stopped the CSF leak in a patient after multiple EEA surgeries. This technique should only be considered in specific difficult situation where usual repair by EEA is impossible.
C1 [Li, Lai-fung; Pu, Jenny Kan-suen; Lui, Wai-man; Leung, Gilberto Ka-kit] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg,Pokfulam, Hong Kong, Peoples R China.
   [Chung, Joseph Chun-kit] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Otorhinolaryngol,Dept Surg,Pokfulam, Hong Kong, Peoples R China.
RP Leung, GKK (reprint author), Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg,Pokfulam, Hong Kong, Peoples R China.
EM gilberto@hkucc.hku.hk
RI Leung, Gilberto Ka Kit/C-4337-2009
OI Leung, Gilberto Ka Kit/0000-0003-3147-3057
CR Chaaban MR, 2013, LARYNGOSCOPE, V123, P2383, DOI 10.1002/lary.24071
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P970, DOI 10.1097/MLG.0b013e3180471482
   Garcia-Navarro V, 2013, WORLD NEUROSURG, V80, P563, DOI 10.1016/j.wneu.2011.08.034
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Leung GKK, 2012, PITUITARY, V15, P237, DOI 10.1007/s11102-011-0319-y
   Liu JK, 2018, WORLD NEUROSURG, V113, P49, DOI 10.1016/j.wneu.2018.01.142
   Dolci RLL, 2019, BRAZ J OTORHINOLAR, V85, P427, DOI 10.1016/j.bjorl.2018.03.008
   Patel MR, 2010, NEUROSURGERY, V66, P506, DOI 10.1227/01.NEU.0000365620.59677.FF
   Shonka DC, 2011, LARYNGOSCOPE, V121, P2305, DOI 10.1002/lary.22191
   Tomio R, 2014, ACTA NEUROCHIR, V156, P1911, DOI 10.1007/s00701-014-2174-x
   Wormald PJ, 2003, AM J RHINOL, V17, P299, DOI 10.1177/194589240301700508
   Wormald PJ, 1997, J LARYNGOL OTOL, V111, P1042, DOI 10.1017/S0022215100139295
   Yeo IS, 2014, J CRANIOFAC SURG, V25, P1376, DOI 10.1097/SCS.0000000000000858
   Zanation AM, 2009, LARYNGOSCOPE, V119, P13, DOI 10.1002/lary.20022
   Zanation AM, 2009, AM J RHINOL ALLERGY, V23, P518, DOI 10.2500/ajra.2009.23.3378
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 59
EP 62
DI 10.1016/j.wneu.2018.10.112
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100212
PM 31108066
DA 2020-05-12
ER

PT J
AU Nunes, JC
   Perret, C
   Ordookhanian, C
   Kaloostian, P
   Abdulrauf, SI
   Mattei, TA
AF Nunes, Julio C.
   Perret, Caio
   Ordookhanian, Christ
   Kaloostian, Paul
   Abdulrauf, Saleem I.
   Mattei, Tobias A.
TI "Crimes against the Nervous System": Neurological References During the
   Nuremberg Doctors' Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Human experimentation; Medical ethics; Neurology; Nuremberg Trials; The
   Harvard Nuremberg Trials Project; World War II
AB The Nuremberg Trials were a sequence of tribunal sessions held by the Allied Forces between November 1945 and October 1946 with the intent of prosecuting prominent representatives of the Nazi Party for crimes committed before and during the war. Because medical experiments in human prisoners were among the most heinous offenses, a specific series of court cases, known as the Doctor's Trials (the USA vs. Karl Brandt et al), was carried out. A considerable part of the official documents of the Nuremberg Trials has been recently made publicly available through the Nuremberg Trials Project, an initiative of the Harvard Law School Library. We performed a comprehensive analysis of the Doctors' Trials original documents (NMT 1: Medical Case) as well as other available academic and historical sources focusing on references to the nervous system, neurosurgical, and neurologic diseases. Besides providing a brief glance of a unique source of original historical documents, this historical vignette also attempts to fulfill, at least in some limited sense, the moral duty toward the Holocaust victims laid on our generation by remembering their fate.
C1 [Nunes, Julio C.] Fed Univ State Rio de Janeiro UNIRIO, Rio De Janeiro, RJ, Brazil.
   [Perret, Caio] Fed Univ Rio de Janeiro UFRJ, Fundacao Osvaldo Cruz FioCruz, Lab Neuroprotect & Regenerat Strategies, Rio De Janeiro, RJ, Brazil.
   [Ordookhanian, Christ; Kaloostian, Paul] Univ Calif Riverside, Sch Med, Riverside, CA 92521 USA.
   [Abdulrauf, Saleem I.; Mattei, Tobias A.] St Louis Univ, Dept Neurol Surg, St Louis, MO 63103 USA.
RP Mattei, TA (reprint author), St Louis Univ, Dept Neurol Surg, St Louis, MO 63103 USA.
EM tobias.mattei@health.slu.edu
OI Mattei, Tobias/0000-0001-8024-7094
CR Annas GJ, 2009, MINN JL SCI TECH, V10, P19
   Atlas MC, 2001, B MED LIBR ASSOC, V89, P51
   BERGER RL, 1990, NEW ENGL J MED, V322, P1435, DOI 10.1056/NEJM199005173222006
   Bruns Florian, 2009, MEDIZINETHIK NATIONA
   Chan TYK, 2009, CLIN TOXICOL, V47, P279, DOI 10.1080/15563650902904407
   Cockburn Alexander, 1998, WHITEOUT CIA DRUGS P
   Deichmann U, 2015, PRACTICES HUMAN GENE, V21, P143
   Heller Kevin Jon, 2011, NUREMBERG MILITARY T
   Jonathan DM, 2001, UNDUE RISK SECRET ST
   Koonz C, 2003, NAZI CONSCIENCE, P25
   Michalczyk JJ, 1994, MED ETHICS 3 REICH H
   Mikaberidze A, 2013, ATROCITIES MASSACRES, P501
   Mitscherlich A, 1949, DOCTORS INFAMY STORY
   Moll F, 2012, SKELETONS CLOSET IND, P79
   Ohler Norman, 2018, BLITZED DRUGS 3 REIC
   Snyder LL, 1998, ENCY 3 REICH
   Wiesel E, 1993, COMMUNICATION
   Yu SB, 2015, BEHAV NEUROL, DOI 10.1155/2015/103969
   Zeidman LA, 2011, CAN J NEUROL SCI, V38, P696, DOI 10.1017/S0317167100054068
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 63
EP 70
DI 10.1016/j.wneu.2018.10.092
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100213
PM 30368013
DA 2020-05-12
ER

PT J
AU Khayat, HA
   Al-Saadi, T
   Panet-Raymond, V
   Diaz, RJ
AF Khayat, Hassan A.
   Al-Saadi, Tariq
   Panet-Raymond, Valerie
   Diaz, Roberto Jose
TI Surgical Management of Isolated Fourth Ventricular Hydrocephalus
   Associated with Injury to the Guillain-Mollaret Triangle
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ependymoma; Guillain-Mollaret triangle; Isolated fourth ventricle;
   Ventriculoperitoneal shunt
ID HYPERTROPHIC OLIVARY DEGENERATION
AB BACKGROUND: The occurrence of isolated fourth ventricle and injury to the Guillain-Mollaret triangle in the setting of posterior fossa ependymoma represents a new association. In this case report, we discuss the clinical, theoretical, and therapeutic aspects of this problem. We describe a lateral transcerebellar trajectory and shunt valve configuration for safe fourth ventricle shunting in a patient with prior posterior fossa surgery.
   CASE DESCRIPTION: A 45-year-old woman underwent subtotal resection of a fourth ventricle ependymoma (World Health Organization grade III) followed by radiation therapy to control the residual tumor. Her course was complicated by a cerebral abscess and subsequent communicating hydrocephalus, for which she received a lateral ventriculoperitoneal shunt. After placement of the lateral ventricle shunt, there was a progressive increase in the volume of the fourth ventricle over the next 2 years, from 2.5 to 12.0 mL. She developed palatal myoclonus, hand incoordination, bilateral foot numbness, and progressive ataxia. Neuroimaging also revealed hypertrophic degeneration of the inferior olivary nuclei bilaterally. The isolated fourth ventricle was treated by a separate fourth ventriculoperitoneal shunt inserted through a lateral transcerebellar trajectory. A programmable variable pressure valve was implemented.
   CONCLUSIONS: Development of an isolated fourth ventricle and injury to the Guillain-Mollaret triangle in the setting of fourth ventricular ependymoma is a newly encountered complication. Choice of treatment modality and timing of intervention should be carefully considered on a case-by-case basis. The data presented in this report may assist in the selection of surgical treatment for isolated fourth ventricle.
C1 [Khayat, Hassan A.] Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Dept Neurosurg, Jeddah, Saudi Arabia.
   [Al-Saadi, Tariq; Diaz, Roberto Jose] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
   [Panet-Raymond, Valerie] McGill Univ, Hlth Ctr, Radiat Oncol, Montreal, PQ, Canada.
RP Diaz, RJ (reprint author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
EM roberto.diaz@mcgill.ca
RI Al-Saadi, Tariq/AAL-9337-2020
OI Al-Saadi, Tariq/0000-0002-9674-5175
CR ABERFELD DC, 1966, ACTA NEUROL SCAND, V42, P296
   Carr CM, 2015, J NEUROIMAGING, V25, P289, DOI 10.1111/jon.12118
   Colpan ME, 2003, MINIM INVAS NEUROSUR, V46, P57, DOI 10.1055/s-2003-37960
   Dincer A, 2011, J NEUROIMAGING, V21, P145, DOI 10.1111/j.1552-6569.2009.00461.x
   FOLTZ EL, 1966, J NEUROSURG, V24, P520, DOI 10.3171/jns.1966.24.2.0520
   GOTO N, 1981, ACTA NEUROPATHOL, V54, P275, DOI 10.1007/BF00697000
   Harter D, 2018, CHILD NERV SYST, V20, P710
   HAWKINS JC, 1978, J NEUROSURG, V49, P910, DOI 10.3171/jns.1978.49.6.0910
   Hayashi T, 2014, INTERNAL MED, V53, P1453, DOI 10.2169/internalmedicine.53.2436
   LEE M, 1995, PEDIATR NEUROSURG, V22, P309, DOI 10.1159/000120921
   Mohanty A, 2003, NEUROSURGERY, V53, P1223, DOI 10.1227/01.NEU.0000088810.75724.0E
   MURAKAMI M, 1986, Neurological Surgery, V14, P817
   Onen MR, 2018, WORLD NEUROSURG, V112, pE763, DOI 10.1016/j.wneu.2018.01.150
   Sanverdi SE, 2012, BRIT J RADIOL, V85, P511, DOI 10.1259/bjr/60727602
   Sharma RR, 2001, CLIN NEUROL NEUROSUR, V103, P143, DOI 10.1016/S0303-8467(01)00129-9
   Tartaglione T, 2015, RADIOL MED, V120, P474, DOI 10.1007/s11547-014-0477-x
   Wein S, 2015, J CLIN NEUROSCI, V22, P1213, DOI 10.1016/j.jocn.2015.02.005
   Yun JH, 2013, ACTA NEUROCHIR, V155, P469, DOI 10.1007/s00701-012-1567-y
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 71
EP 76
DI 10.1016/j.wneu.2018.10.091
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100214
PM 30368016
DA 2020-05-12
ER

PT J
AU Rege, S
   Tadghare, J
   Jatav, G
   Pounikar, M
AF Rege, Shrikant
   Tadghare, Jitendra
   Jatav, Gourav
   Pounikar, Minakshi
TI An Unusual Presentation as Recurrent Abortions in a Case of Giant
   Presacral Epidermoid Cyst Mimicking an Anterior Sacral Meningocele
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidermoid cyst; Giant; Meningocele; Presacral; Recurrent abortions
AB BACKGROUND: An epidermoid cyst is a congenital benign tumor and is extremely rare at the presacral region. Only a few cases have been reported in the literature.
   CASE DESCRIPTION: We herein report a case of a 40-year-old woman with a giant presacral epidermoid cyst mimicking an anterior sacral meningocele who presented with recurrent abortions. This increases risk to the mother and fetus. Magnetic resonance imaging is the investigation of choice.
   CONCLUSIONS: The diagnosis and surgical management of this case are discussed.
C1 [Rege, Shrikant; Tadghare, Jitendra; Jatav, Gourav] Sri Aurobindo Med Coll & PG Inst, Dept Neurosurg, Indore, Madhya Pradesh, India.
   [Pounikar, Minakshi] Lokmanya Tilak Municipal Gen Hosp & Med Coll, Dept Obstet & Gynaecol, Mumbai, India.
RP Tadghare, J (reprint author), Sri Aurobindo Med Coll & PG Inst, Dept Neurosurg, Indore, Madhya Pradesh, India.
EM manage_jitu@yahoo.co.in
CR Dahan H, 2001, RADIOGRAPHICS, V21, P575, DOI 10.1148/radiographics.21.3.g01ma13575
   Horii T, 2001, ARCH ORTHOP TRAUM SU, V121, P114, DOI 10.1007/s004020000169
   Isik N, 2008, TURK NEUROSURG, V18, P254
   Kansal R, 2012, TURK NEUROSURG, V22, P659, DOI 10.5137/1019-5149.JTN.3985-10.1
   Manara R, 2008, RADIOL MED, V113, P739, DOI 10.1007/s11547-008-0283-4
   NAKAMURA S, 1980, CHILD BRAIN, V6, P103
   SHEDID D, 2006, SEMIN SPINE SURG, V18, P161
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 77
EP 80
DI 10.1016/j.wneu.2018.10.120
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100215
PM 31108068
DA 2020-05-12
ER

PT J
AU Barkley, AS
   Kuo, CH
   Leary, SES
   Ojemann, JG
   Susarla, SM
AF Barkley, Ariana S.
   Kuo, Chao-Hung
   Leary, Sarah E. S.
   Ojemann, Jeffrey G.
   Susarla, Srinivas M.
TI Unusual Radiographic Presentation of Intracranial Mature Teratoma and
   Resection via Supraorbital Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Fat globules; Supraorbital; Teratoma
ID CHILDHOOD
AB BACKGROUND: Primary intracranial teratomas account for <1% of intracranial masses during childhood after infancy. When supratentorial, they commonly occur in the pineal and suprasellar regions, demonstrating multilocularity, areas of fat, and calcifications and increasing enhancement correlating with decreased maturity. However, the presence of a teratoma as a mobile fat lesion within a large unilocular suprasellar cyst is rarely documented in this patient population.
   CASE DESCRIPTION: We present the first pediatric case of a suprasellar mature teratoma presenting as a mobile fat suppressing lesion within a large unilocular suprasellar cyst and describe a supraorbital approach with adjunctive use of the endoscope for resection. We also provide a literature review of other cases presenting with similar radiographic findings.
   CONCLUSIONS: Mature teratomas may manifest atypically as unilocular cystic lesions with a central mobile fatty component and are treated by gross total surgical resection. The supraorbital approach with adjunctive use of an endoscope can provide adequate exposure for resection with optimal cosmetic outcome.
C1 [Barkley, Ariana S.; Kuo, Chao-Hung; Ojemann, Jeffrey G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Ojemann, Jeffrey G.] Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA.
   [Ojemann, Jeffrey G.] Univ Washington, Grad Program Neurosci, Seattle, WA 98195 USA.
   [Susarla, Srinivas M.] Univ Washington, Dept Surg, Div Plast Surg, Med Ctr, Seattle, WA 98195 USA.
   [Leary, Sarah E. S.] Seattle Childrens Hosp, Canc & Blood Disorders Ctr, Seattle, WA USA.
   [Ojemann, Jeffrey G.] Seattle Childrens Hosp, Dept Pediat Neurosurg, Seattle, WA USA.
   [Susarla, Srinivas M.] Seattle Childrens Hosp, Craniofacial Plast Surg Oral & Maxillofacial Surg, Seattle, WA USA.
   [Leary, Sarah E. S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Kuo, Chao-Hung] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
   [Kuo, Chao-Hung] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
RP Barkley, AS (reprint author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
EM arianab@uw.edu
RI Susarla, Srinivas/P-1051-2019
OI Susarla, Srinivas/0000-0003-0155-8260; Kuo,
   Chao-Hung/0000-0001-5528-204X
CR Canan A, 2000, BRAIN DEV-JPN, V22, P340, DOI 10.1016/S0387-7604(00)00128-5
   Fujimoto N, 2008, BRIT J DERMATOL, V158, P415, DOI 10.1111/j.1365-2133.2007.08321.x
   Governale LS, 2015, PEDIATR NEUROL, V52, P389, DOI 10.1016/j.pediatrneurol.2014.08.036
   Kuratsu J, 1996, PEDIATR NEUROSURG, V25, P240, DOI 10.1159/000121132
   Liu ZY, 2014, ACTA RADIOL, V55, P874, DOI 10.1177/0284185113507824
   Orozco-Covarrubias L, 2013, PEDIATR DERMATOL, V30, P706, DOI 10.1111/pde.12080
   Park JT, 2018, J NEUROSURG-PEDIATR, V22, P497, DOI 10.3171/2018.5.PEDS1896
   SMIRNIOTOPOULOS JG, 1995, RADIOGRAPHICS, V15, P1437, DOI 10.1148/radiographics.15.6.8577967
   Sudhir Jayanand, 2011, Indian J Radiol Imaging, V21, P228, DOI 10.4103/0971-3026.85374
   TAPPER D, 1983, ANN SURG, V198, P398, DOI 10.1097/00000658-198309000-00016
   Zada G, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14464
NR 11
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 81
EP 84
DI 10.1016/j.wneu.2018.10.089
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100216
PM 30368015
DA 2020-05-12
ER

PT J
AU Ishikawa, T
   Matsuda, M
   Sakakura, K
   Ishikawa, E
   Akutsu, H
   Matsumura, A
AF Ishikawa, Takaaki
   Matsuda, Masahide
   Sakakura, Kazuki
   Ishikawa, Eiichi
   Akutsu, Hiroyoshi
   Matsumura, Akira
TI Huge Greater Superficial Petrosal Nerve Schwannoma with Intradural
   Peritumoral Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Greater superficial petrosal nerve; Peritumoral cyst; Schwannoma
ID TUMOR
AB BACKGROUND: Schwannoma originating from the greater superficial petrosal nerve is an extremely rare type of facial nerve schwannoma located in the middle cranial fossa around the midportion of the petrous bone. Here, we provide the first report of greater superficial petrosal nerve schwannoma presenting with contralateral facial palsy and hemiparesis due to compression of the pyramidal tract by associated intradural peritumoral cyst.
   CASE DESCRIPTION: A 69-year-old woman presented with a 6-month history of gradually worsening gait unsteadiness. Magnetic resonance imaging demonstrated a well-defined tumor occupying the right middle cranial fossa and extending into the tympanic cavity. Notably, the tumor accompanied a large cyst in the intradural space, resulting in a leftward midline shift. Extradural exploration through thinned periosteal dura mater revealed the tumor within the interdural space. After debulking of most of the tumor in a pull-out, piecemeal fashion, intradural exploration revealed the peritumoral cyst located between the meningeal dura mater and brain parenchyma. Following the disappearance of the mass effect from the tumor, fenestration of the peritumoral cyst, which had been deeper-seated than the tumor, was easily achieved while avoiding excessive retraction of the temporal lobe. Postoperatively, mild left hemiparesis involving the face resolved completely and no new symptoms such as right facial palsy, hearing disturbance, or xerophthalmia developed as postoperative complications.
   CONCLUSION: The combination of extradural and intradural approaches in the appropriate order is essential for fenestration of an intradural peritumoral cyst along with removal of an interdural tumor.
C1 [Ishikawa, Takaaki; Matsuda, Masahide; Sakakura, Kazuki; Ishikawa, Eiichi; Akutsu, Hiroyoshi; Matsumura, Akira] Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
RP Matsuda, M (reprint author), Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
EM m-matsuda@md.tsukuba.ac.jp
CR Aihara N, 2001, SKULL BASE-INTERD AP, V11, P77, DOI 10.1055/s-2001-12780
   Amirjamshidi A, 2010, J NEUROSURG, V113, P1093, DOI 10.3171/2009.9.JNS09439
   Ayberk G, 2008, NEUROSURGERY, V63, pE814
   Baggenstos Martin A, 2007, Neurosurg Focus, V22, pE9
   De Paulis Danilo, 2011, Surg Neurol Int, V2, P60, DOI 10.4103/2152-7806.80352
   Dolenc VV, 1996, BRIT J NEUROSURG, V10, P519, DOI 10.1080/02688699647203
   FURLOW LT, 1960, J NEUROSURG, V17, P721, DOI 10.3171/jns.1960.17.4.0721
   Ginsberg LE, 1996, AM J NEURORADIOL, V17, P389
   Goel A, 2018, WORLD NEUROSURG, V110, pE835, DOI 10.1016/j.wneu.2017.11.127
   Herde RF, 2015, J NEUROSURG, V123, P789, DOI 10.3171/2014.12.JNS141031
   Ichimura S, 2010, NEUROSURG REV, V33, P477, DOI 10.1007/s10143-010-0277-2
   Kinouchi H, 2001, NEUROSURGERY, V49, P999, DOI 10.1097/00006123-200110000-00041
   Kumon Y, 1999, J NEUROSURG, V91, P691, DOI 10.3171/jns.1999.91.4.0691
   Kusumi M, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.08.048
   Michel O, 2000, OTOLARYNG HEAD NECK, V122, P302, DOI 10.1016/S0194-5998(00)70260-9
   Prasad SC, 2018, NEUROSURGERY, V83, P740, DOI 10.1093/neuros/nyx489
   Sade B, 2007, J NEUROSURG, V107, P181, DOI 10.3171/JNS-07/07/0181
   Schmidinger A, 2005, ACTA NEUROCHIR, V147, P659, DOI 10.1007/s00701-004-0434-x
   TALI ET, 1993, AM J NEURORADIOL, V14, P1241
   Tremble GE, 1936, ARCHIV OTOLARYNGOL, V23, P573
   Umredkar A, 2011, NEUROL INDIA, V59, P154, DOI 10.4103/0028-3886.86578
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 85
EP 89
DI 10.1016/j.wneu.2018.10.129
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100217
PM 30391603
OA Green Published
DA 2020-05-12
ER

PT J
AU Soliman, MAR
   Kwan, BYM
   Jhawar, BS
AF Soliman, Mohamed A. R.
   Kwan, Benjamin Y. M.
   Jhawar, Balraj S.
TI Minimally Invasive Unilateral Percutaneous Transfracture Fixation of a
   Hangman's Fracture Using Neuronavigation and Intraoperative Fluoroscopy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical fracture; Hangman's fracture; Image guidance; Minimally
   invasive; Neuronavigation; Unilateral
ID PEDICLE SCREW FIXATION; AXIS; NAVIGATION; COMPLICATIONS; MANAGEMENT;
   ACCURACY; SURGERY
AB BACKGROUND: Traumatic spondylolisthesis or hangman's fracture is a common cervical spine fracture. Most cases of traumatic spondylolisthesis are treated nonoperatively with external immobilization. The indications for surgery have generally included fracture instability or failed nonoperative management. Operative stabilization can be performed through either anterior or posterior approaches and has generally required instrumentation using open methods. We propose a technique for surgical repair of hangman's fracture that is minimally invasive and motion preserving using recent advances in 3-dimensional image-guidance technology. We believe this method represents another option in the treatment of hangman's fractures, because it allows for immediate stabilization, prompt recovery, and quick mobilization.
   CASE DESCRIPTION: We present the case of 2 patients with hangman's fractures who had undergone surgical unilateral transfixation with minimally invasive percutaneous screw placement. In both cases, we used 3-dimensional neuronavigation and bidirectional intraoperative fluoroscopy. The operative time from incision to closure was <30 minutes. Preparation and positioning after intubation varied from 40 to 150 minutes. No intraoperative complications occurred. Both patients were discharged within 48 hours postoperatively. The follow-up examinations at 3 months, 12 months, and 5 years revealed healthy bony fusion on computed tomography imaging and an excellent clinical recovery.
   CONCLUSION: We have provided 2 examples in which minimally invasive unilateral fixation of hangman's fractures proved to be safe and effective. In both cases, the patients were immediately relieved of their pain, quickly mobilized, and promptly discharged. The achievement of successful fusion confirmed at the follow-up examinations.
C1 [Soliman, Mohamed A. R.] Cairo Univ, Dept Neurosurg, Cairo, Egypt.
   [Kwan, Benjamin Y. M.; Jhawar, Balraj S.] Western Univ, Windsor Reg Hosp, Dept Neurosurg, Windsor, ON, Canada.
RP Soliman, MAR (reprint author), Cairo Univ, Dept Neurosurg, Cairo, Egypt.
EM moh.ar.sol@kasralainy.edu.eg
RI Soliman, Mohamed AR/B-9397-2018
OI Soliman, Mohamed AR/0000-0003-1855-2551
CR Abumi K, 2000, SPINE, V25, P962, DOI 10.1097/00007632-200004150-00011
   BORNE GM, 1984, J NEUROSURG, V60, P88, DOI 10.3171/jns.1984.60.1.0088
   Costa F, 2011, SPINE, V36, P2094, DOI 10.1097/BRS.0b013e318201129d
   Dekutoski MB, 2010, SPINE, V35, pS9, DOI 10.1097/BRS.0b013e3181d830de
   EFFENDI B, 1981, J BONE JOINT SURG BR, V63, P319
   FRANCIS WR, 1981, J BONE JOINT SURG BR, V63, P313
   Greene KA, 1997, SPINE, V22, P1843, DOI 10.1097/00007632-199708150-00009
   Hadley MN, 2002, NEUROSURGERY, V50, pS125
   Holly LT, 2007, ORTHOP CLIN N AM, V38, P451, DOI 10.1016/j.ocl.2007.04.001
   Holly LT, 2003, SPINE, V28, pS54, DOI 10.1097/00007632-200308011-00010
   Jaikumar S, 2002, NEUROSURGERY, V51, pS1, DOI 10.1227/01.NEU.0000030922.20555.BB
   Judet R, 1970, FRACTURES RACHIS CER, P174
   Li XF, 2006, EUR SPINE J, V15, P257, DOI 10.1007/s00586-005-0918-2
   LIND B, 1987, SPINE, V12, P449, DOI 10.1097/00007632-198706000-00005
   Longo UG, 2010, INJURY, V41, P1127, DOI 10.1016/j.injury.2010.09.025
   Ma WH, 2011, SPINE, V36, P529, DOI 10.1097/BRS.0b013e3181d60067
   Papadopoulos Elias C, 2005, Spine J, V5, P263, DOI 10.1016/j.spinee.2004.10.048
   Park Paul, 2010, Surg Neurol Int, V1, P44, DOI 10.4103/2152-7806.68705
   Pryputniewicz DM, 2010, NEUROSURGERY, V66, pA68, DOI 10.1227/01.NEU.0000366118.21964.A8
   Rajasekaran S, 2007, J Orthop Surg (Hong Kong), V15, P73
   Rajasekaran S, 2007, J SPINAL DISORD TECH, V20, P616, DOI 10.1097/BSD.0b013e318074f978
   Scheufler KM, 2011, NEUROSURGERY, V69, P782, DOI 10.1227/NEU.0b013e318222ae16
   Song GS, 1997, J NEUROSURG, V87, P851, DOI 10.3171/jns.1997.87.6.0851
   Taitsman LA, 2008, ORTHOPEDICS, V31, P446, DOI 10.3928/01477447-20080501-35
   Taller S, 2000, EUR SPINE J, V9, P393, DOI 10.1007/s005860000159
   Tashjian RZ, 2006, J TRAUMA, V60, P199, DOI 10.1097/01.ta.0000197426.72261.17
   Tjardes T, 2010, EUR SPINE J, V19, P25, DOI 10.1007/s00586-009-1091-9
   von Jako R, 2011, ACTA NEUROCHIR, V153, P589, DOI 10.1007/s00701-010-0882-4
   Xu H, 2010, INT ORTHOP, V34, P85, DOI 10.1007/s00264-008-0658-0
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 90
EP 95
DI 10.1016/j.wneu.2018.10.140
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100218
PM 30391610
DA 2020-05-12
ER

PT J
AU Yamaguchi, S
   Hamabe, J
   Yamashita, A
   Irie, J
   Yagi, N
   Suyama, K
AF Yamaguchi, Susumu
   Hamabe, Junpei
   Yamashita, Aya
   Irie, Junji
   Yagi, Nobuhiro
   Suyama, Kazuhiko
TI Rare Case of Floating Intimal Flap Associated with Atheromatous Carotid
   Plaque
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Internal carotid artery stenosis; Mobile plaque;
   Monckeberg sclerosis
ID ARTERY; THROMBUS; STROKE; CALCIFICATION; MANAGEMENT; MECHANISMS;
   SCLEROSIS
AB BACKGROUND: A mobile carotid plaque can be detected by duplex ultrasonography and is a high-risk factor for embolic stroke.
   CASE DESCRIPTION: We herein present a case involving an 80-year-old man with an asymptomatic carotid floating flap diagnosed by duplex ultrasonography and treated with carotid endarterectomy. Intraoperatively, an ulceration was found immediately proximal to the neck of the floating flap, and the shape and size of the ulceration were quite similar to those of the floating flap. In a histopathologic examination of the specimen resected by carotid endarterectomy, the plaque lacked the internal elastic lamina (IEL) at the ulceration, calcification was observed in the plaque and medial layer at the ulceration, and the floating flap consisted of the IEL accompanied by calcification, fibrin, and foamy cells.
   CONCLUSIONS: Progression of the atheroma and Monckeberg sclerosis might have affected disruption of the IEL, causing the IEL to finally peel off. A floating intimal flap accompanied by an atheroma without intraplaque hemorrhage is a rare cause of mobile plaque formation. This type of mobile plaque might not be dissolved by medical treatment alone. In such cases, surgical treatment is a suitable therapeutic choice to prevent stroke.
C1 [Yamaguchi, Susumu; Yagi, Nobuhiro; Suyama, Kazuhiko] Nagasaki Harbor Med Ctr, Dept Neurosurg, Nagasaki, Japan.
   [Hamabe, Junpei; Yamashita, Aya] Nagasaki Harbor Med Ctr, Dept Neurol & Strokol, Nagasaki, Japan.
   [Irie, Junji] Nagasaki Harbor Med Ctr, Dept Pathol, Nagasaki, Japan.
RP Yamaguchi, S (reprint author), Nagasaki Harbor Med Ctr, Dept Neurosurg, Nagasaki, Japan.
EM ssmymgc@gmail.com
CR Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721
   Bhatti AF, 2007, J VASC SURG, V45, P199, DOI 10.1016/j.jvs.2006.09.057
   Chakhtoura EY, 2003, J ENDOVASC THER, V10, P653, DOI 10.1583/1545-1550(2003)010<0653:MOMFCP>2.0.CO;2
   Chistiakov DA, 2014, CURR PHARM DESIGN, V20, P5870, DOI 10.2174/1381612820666140212210451
   Di Tullio MR, 2009, CIRCULATION, V119, P2376, DOI 10.1161/CIRCULATIONAHA.108.811935
   Ferrero E, 2011, ANN VASC SURG, V25, P805, DOI 10.1016/j.avsg.2011.02.030
   Giragani S, 2017, J NEUROINTERV SURG, V9, DOI 10.1136/neurintsurg-2016-012904.rep
   Khurana D, 2009, ANN INDIAN ACAD NEUR, V12, P185, DOI 10.4103/0972-2327.56320
   Kobayashi E, 2000, INTERV NEURORADIOL, V6, P165, DOI 10.1177/15910199000060S125
   Kobayashi M, 2007, NEUROL MED-CHIR, V47, P121, DOI 10.2176/nmc.47.121
   Kockelkoren R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168360
   Kume S, 2010, NEUROSURG REV, V33, P419, DOI 10.1007/s10143-010-0270-9
   McCullough PA, 2008, CLIN J AM SOC NEPHRO, V3, P1585, DOI 10.2215/CJN.01930408
   Micheletti RG, 2008, ARCH PATHOL LAB MED, V132, P43, DOI 10.1043/1543-2165(2008)132[43:MSRACO]2.0.CO;2
   Ogata T, 2010, CEREBROVASC DIS, V30, P606, DOI 10.1159/000319889
   Park JW, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010023
   Raghib MF, 2018, J CLIN NEUROSCI, V47, P56, DOI 10.1016/j.jocn.2017.10.042
   STEINKE W, 1994, CIRCULATION, V89, P2578, DOI 10.1161/01.CIR.89.6.2578
   Tan AP, 2014, J STROKE CEREBROVASC, V23, pE437, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.005
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 98
EP 101
DI 10.1016/j.wneu.2018.10.139
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100220
PM 30391611
DA 2020-05-12
ER

PT J
AU Onishi, S
   Sakamoto, S
   Sadatomo, T
   Hara, T
   Ochiai, J
   Yuki, K
   Kurisu, K
AF Onishi, Shumpei
   Sakamoto, Shigeyuki
   Sadatomo, Takashi
   Hara, Takeshi
   Ochiai, Junichiro
   Yuki, Kiyoshi
   Kurisu, Kaoru
TI Endovascular Coil Embolization with Low-Profile Visualized Intraluminal
   Support Junior Stent for Ruptured Dissecting Aneurysm of Proximal
   Superior Cerebellar Artery-Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Coil; LVIS Jr.; Stent; Superior cerebellar artery aneurysm
ID POSTERIOR CIRCULATION
AB BACKGROUND: Superior cerebellar artery (SCA) aneurysm arising from the SCA itself is rare, and treatment of this aneurysm is challenging because of the important anatomic structures, such as the perforating arteries to the brainstem and cranial nerves. We describe a successful coil embolization with a Low-profile Visualized Intraluminal Support Junior (LVIS Jr.) stent for the proximal SCA dissecting aneurysm.
   CASE DESCRIPTION: A 50-year-old woman presented with right oculomotor nerve palsy and subarachnoid hemorrhage. Cerebral angiography showed a dissecting wide neck aneurysm at the anterior pontomesencephalic segment of the right SCA (diameter 1 mm). The patient was treated with coiling assisted by an LVIS Jr. stent. Postoperative angiography demonstrated a complete embolized aneurysm and parent artery preservation.
   CONCLUSIONS: Endovascular treatment assisted with LVIS Jr. stent for proximal SCA dissecting aneurysm arising from small parent artery was safely and effectively feasible.
C1 [Onishi, Shumpei; Sadatomo, Takashi; Hara, Takeshi; Ochiai, Junichiro; Yuki, Kiyoshi] Higahsihiroshima Med Ctr, Dept Neurosurg, Higashihiroshima, Hiroshima, Japan.
   [Onishi, Shumpei; Sakamoto, Shigeyuki; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Hiroshima, Japan.
RP Onishi, S (reprint author), Higahsihiroshima Med Ctr, Dept Neurosurg, Higashihiroshima, Hiroshima, Japan.; Onishi, S (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Hiroshima, Japan.
EM shumpei.ohnishi@gmail.com
OI Sakamoto, Shigeyuki/0000-0003-3683-4771
CR Atalay B, 2007, ACTA NEUROCHIR, V149, P291, DOI 10.1007/s00701-006-1067-z
   Chaloupka JC, 1996, AM J NEURORADIOL, V17, P1338
   Cho Su-Hee, 2017, Neurointervention, V12, P31, DOI 10.5469/neuroint.2017.12.1.31
   Cho YD, 2014, NEURORADIOLOGY, V56, P543, DOI 10.1007/s00234-014-1363-x
   Di Stefano G, 2017, WORLD NEUROSURG, V101
   Fiorella D, 2019, J NEUROINTERV SURG, V11, P357, DOI 10.1136/neurintsurg-2018-014309
   Garcia-Gonzalez U, 2012, NEUROSURGERY, V70, P764, DOI 10.1227/NEU.0b013e3182351f8e
   Gotoh H, 2004, J CLIN NEUROSCI, V11, P196, DOI 10.1016/S0967-5868(03)00136-X
   HARDY DG, 1980, NEUROSURGERY, V6, P10, DOI 10.1227/00006123-198001000-00002
   Leonardi M, 2001, INTERV NEURORADIOL, V7, P343, DOI 10.1177/159101990100700411
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219
   Lubicz B, 2003, AM J NEURORADIOL, V24, P1208
   Pandley AS, 2007, NEUROSURGERY, V60, P626, DOI 10.1227/NEU.0000255433.47044.8F
   Patra DP, 2016, WORLD NEUROSURG, V94, P229, DOI 10.1016/j.wneu.2016.07.007
   Rho MH, 2013, ACTA NEUROCHIR, V155, P2009, DOI 10.1007/s00701-013-1866-y
   Samaniego EA, 2016, J NEUROINTERV SURG, V8, P1030, DOI 10.1136/neurintsurg-2015-012070
   Santillan A, 2018, INTERV NEURORADIOL, V24, P246, DOI 10.1177/1591019918759307
   Wang C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0959-9
   Zenteno M, 2007, J NEUROSURG, V107, P860, DOI 10.3171/JNS-07/10/0860
NR 19
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 102
EP 105
DI 10.1016/j.wneu.2018.10.137
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100221
PM 30391607
DA 2020-05-12
ER

PT J
AU Donnally, CJ
   Madhavan, K
   Lugo-Pico, JG
   Chieng, LO
   Vanni, S
AF Donnally, Chester J., III
   Madhavan, Karthik
   Lugo-Pico, Julian G.
   Chieng, Lee Onn
   Vanni, Steven
TI Fish-Mouth Thoracic Fracture Fixation with Minimally Invasive
   Percutaneous Reduction: A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fish mouth fracture; Minimally invasive surgery; Novel technique; Trauma
ID SURGICAL TECHNIQUE; SPINE; INSTRUMENTATION
AB BACKGROUND: Surgical stabilization of thoracic spine fractures is recommended for unstable patterns, yet much debate exists regarding the best approach for reduction. The aim of this article was to report the outcome of a novel method for stabilization of a fish-mouth thoracic spine fracture.
   METHODS: A retrospective patient chart review was conducted. Data collected included blood loss, operative time, length of stay, perioperative complications, neurologic deficits, and secondary procedures. The patient underwent percutaneous reduction of a hyperextension injury to the thoracic spine. Sufficient reduction was achieved through a percutaneous approach, followed by sequential distraction of 1 rod with sequential locking of the contralateral rod to maintain deformity correction. Electrophysiologic monitoring was used during the procedure.
   RESULTS: Sufficient fracture reduction was achieved and evaluated on postoperative computed tomography. Operative time was 145 minutes, and estimated blood loss was 120 mL. There were no cerebrospinal fluid leaks, iatrogenic neurologic deficits, implant failures, other systemic events or revisions during the 8-month follow-up.
   CONCLUSIONS: This article describes the feasibility of using a novel model for reduction and stabilization of fish-mouth thoracic spine fracture with minimal soft tissue violation.
C1 [Donnally, Chester J., III; Lugo-Pico, Julian G.] Univ Miami Hosp, Dept Orthopaed Surg, Miami, FL 33136 USA.
   [Madhavan, Karthik; Vanni, Steven] Univ Miami Hosp, Dept Neurosurg, Miami, FL USA.
   [Chieng, Lee Onn] Univ Miami, Miller Sch Med, Dept Educ, Miami, FL 33136 USA.
RP Donnally, CJ (reprint author), Univ Miami Hosp, Dept Orthopaed Surg, Miami, FL 33136 USA.
EM Chester.Donnally@jhsmiami.org
OI Donnally III, Chester/0000-0002-1701-0745
CR Abdelaal Abdelbaky M, 2016, EGYPT SPINE J, V17, P34
   Alander DH, 2018, J AM ACAD ORTHOP SUR, V26, P231, DOI 10.5435/JAAOS-D-15-00638
   Alobaid A, 2006, CAN J SURG, V49, P131
   Bellabarba C, 2010, SPINE, V35, pS138, DOI 10.1097/BRS.0b013e3181d830c1
   Chi JH, 2019, NEUROSURGERY, V84, pE59, DOI 10.1093/neuros/nyy364
   Cotler J M, 1999, Instr Course Lect, V48, P427
   Court C, 2012, ORTHOP TRAUMATOL-SUR, V98, P900, DOI 10.1016/j.otsr.2012.09.014
   Heintel TM, 2017, EUR SPINE J, V26, P1515, DOI 10.1007/s00586-016-4908-3
   Jiang XZ, 2012, J INT MED RES, V40, P1343, DOI 10.1177/147323001204000413
   Mazel C, 2018, ORTHOP TRAUMATOL-SUR, V104, pS55, DOI 10.1016/j.otsr.2017.04.018
   Mobbs RJ, 2011, J CLIN NEUROSCI, V18, P741, DOI 10.1016/j.jocn.2010.09.019
   Ntilikina Y, 2017, J NEUROSURG-SPINE, V27, P235, DOI 10.3171/2017.1.SPINE16886
   PANJABI MM, 1981, ACTA ORTHOP SCAND, V52, P315, DOI 10.3109/17453678109050109
   Ringer AJ, 2013, WORLD NEUROSURG, V80, P428, DOI 10.1016/j.wneu.2012.09.005
   Scaramuzzo L, 2013, EUR SPINE J, V22, pS933, DOI 10.1007/s00586-013-3011-2
   Whang PG, 2007, J AM ACAD ORTHOP SUR, V15, P695, DOI 10.5435/00124635-200711000-00008
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 106
EP 111
DI 10.1016/j.wneu.2018.10.152
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100222
PM 30391618
DA 2020-05-12
ER

PT J
AU Kim, HS
   Singh, R
   Adsul, NM
   Oh, SW
   Noh, JH
   Kim, PY
   Park, JH
   Park, CH
   Jang, IT
AF Kim, Hyeun Sung
   Singh, Ravindra
   Adsul, Nitin Maruti
   Oh, Sung Woon
   Noh, Jung Hoon
   Kim, Patrick Y.
   Park, Jun Hwan
   Park, Chang Hwan
   Jang, Il Tae
TI Symptomatic Tuberculous Ligamentum Flavum Cyst Treated by Full
   Endoscopic Resection: Review with Technical Notes
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antitubercular therapy; Chronic granulomatous inflammation; Ligamentum
   flavum cyst; Percutaneous endoscopic lumbar decompression; Tuberculosis
ID SPINE
AB BACKGROUND: Tuberculosis (TB) of the posterior spinal element is an uncommon condition. In a developed country its diagnosis is becoming difficult due to low incidence.
   CASE DESCRIPTION: A 60-year-old lady presented with low back pain and right leg pain for 6 months. On examination there was tenderness over L4 and L5, a positive straight leg raise test at 70 degrees on the right side and free on the left, and sensory involvement on the right L5 dermatome.
   Initial magnetic resonance imaging (MRI) showed an L4-5 ligamentum flavum cyst, high signal intensity in the right pedicle and facet joint. It was considered to be a degenerative spinal disorder. Later MRI showed increased size of the cyst, and computed tomography revealed erosion of the right pedicle of the L5 vertebrae, which raised the suspicion of the tubercular pathology.
   Initially the patient was managed for a degenerative spinal disorder. Later, when tubercular pathology was suspected, she underwent full endoscopic uniportal stenosis decompression and excision biopsy of the cyst. The histology of the cyst revealed chronic granulomatous inflammation with central necrosis. The diagnosis of a TB cyst was confirmed, and antitubercular therapy was started.
   CONCLUSION: TB of the posterior elements of the spine is a diagnostic challenge in developed parts of the world. We describe the first likely case of tubercular ligamentum flavum cyst, which was managed by a full endoscopic uniportal approach.
C1 [Kim, Hyeun Sung; Singh, Ravindra; Adsul, Nitin Maruti; Oh, Sung Woon; Noh, Jung Hoon; Jang, Il Tae] Nanoori Hosp, Dept Neurosurg, Seoul, South Korea.
   [Kim, Patrick Y.] Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA.
   [Park, Jun Hwan; Park, Chang Hwan] Med Sch Univ, Debrecen, Hungary.
RP Kim, HS (reprint author), Nanoori Hosp, Dept Neurosurg, Seoul, South Korea.
EM neurospinekim@gmail.com
RI Kim, Hyeun-Sung/H-3400-2018
OI Kim, Hyeun-Sung/0000-0001-5361-5234
CR Asamoto S, 2005, NEUROL MED-CHIR, V45, P653, DOI 10.2176/nmc.45.653
   BABHULKAR SS, 1984, J BONE JOINT SURG BR, V66, P239
   Bilbao J M, 1975, Can J Neurol Sci, V2, P135
   Gazzeri R, 2007, J SPINAL DISORD TECH, V20, P536, DOI 10.1097/BSD.0b013e31804b4605
   Houman M, 1999, AM J NEURORADIOL, V20, P1166
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P905, DOI 10.1302/0301-620X.92B7.24668
   Jain AK, 2007, CLIN ORTHOP RELAT R, P39, DOI 10.1097/BLO.0b013e318065b7c3
   Jain AK, 2012, INDIAN J ORTHOP, V46, P127, DOI 10.4103/0019-5413.93671
   Kumar V, 2013, ROBBINS BASIC PATHOL
   NAIMURRAHMAN, 1980, J BONE JOINT SURG BR, V62, P162
   Pandey V, 2009, INT ORTHOP, V33, P801, DOI 10.1007/s00264-007-0485-8
   Rasit AH, 2011, MALAYS ORTHOP J, V5, P8
   Taha H, 2010, J ORTHOP TRAUMATOL, V11, P117, DOI 10.1007/s10195-010-0094-y
   Tuli S.M., 2010, TUBERCULOSIS SKELETA
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 112
EP 115
DI 10.1016/j.wneu.2018.10.141
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100223
PM 30391612
DA 2020-05-12
ER

PT J
AU Saito, A
   Ninomiya, A
   Ishida, T
   Inoue, T
   Inoue, T
   Suzuki, S
   Ezura, M
   Uenohara, H
AF Saito, Atsushi
   Ninomiya, Atsuhiko
   Ishida, Tomohisa
   Inoue, Tomoo
   Inoue, Takashi
   Suzuki, Shinsuke
   Ezura, Masayuki
   Uenohara, Hiroshi
TI Intractable Repeated Intracerebral Hemorrhage Due to Primary Dural
   Leiomyosarcoma: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dura mater; Leiomyosarcoma; Venous thrombosis
ID EPSTEIN-BARR-VIRUS; INTRACRANIAL LEIOMYOSARCOMA
AB BACKGROUND: There are few case reports of primary leiomyosarcoma originating from the dura mater. We herein report a case of primary dural leiomyosarcoma that presented with repeated intracranial hemorrhage.
   CASE DESCRIPTION: A 62-year-old man presented with a 4-year history of a temporo-occipital bump. He showed a disturbance with reading words. The sudden onset of occipitalgia occurred 13 days after the onset. Computed tomography revealed a left temporal subcortical hematoma and thin subacute subdural hematoma associated with a temporal osteolytic mass lesion extending into the subcutaneous layer. The hematoma and tumorous mass lesion were removed. The subcutaneous tumor mass penetrating the skull bone originated from the dura mater and extended into the transverse sinus. No invasion into the cortical surface was observed. The lesion adjacent to the transverse sinus was not resected, and the remnant lesion was irradiated with local radiation therapy of 60 Gy. A left subdural hematoma and intrasylvian subarachnoid hemorrhage occurred 3 months after the first surgery, and a second removal was performed. Temporal subcortical hemorrhage repeatedly occurred 2 months after the second surgery, and the patient died.
   CONCLUSIONS: In the present case, primary dural leiomyosarcoma may have invaded the dural sinus and repeated intracranial hemorrhage occurred due to a venous circulatory disturbance. The aggressive clinical course observed is rare. A clearer understanding of the route of invasion and a careful evaluation after primary treatment are needed in order to avoid hemorrhagic complications.
C1 [Saito, Atsushi; Ninomiya, Atsuhiko; Ishida, Tomohisa; Inoue, Tomoo; Inoue, Takashi; Suzuki, Shinsuke; Ezura, Masayuki; Uenohara, Hiroshi] Sendai Med Ctr, Dept Neurosurg, Sendai, Miyagi, Japan.
RP Saito, A (reprint author), Sendai Med Ctr, Dept Neurosurg, Sendai, Miyagi, Japan.
EM satsushi2002@yahoo.co.jp
CR Alijani B, 2013, ARCH IRAN MED, V16, P606, DOI 0131610/AIM.0012
   ASAI A, 1988, J NEUROSURG, V68, P308, DOI 10.3171/jns.1988.68.2.0308
   Bejjani GK, 1999, NEUROSURGERY, V44, P199, DOI 10.1097/00006123-199901000-00119
   Chaves NJ, 2007, J HEART LUNG TRANSPL, V26, P753, DOI 10.1016/j.healun.2007.05.007
   Gallagher SJ, 2018, CLIN NEUROL NEUROSUR, V165, P76, DOI 10.1016/j.clineuro.2017.12.014
   Kaduri S, 2012, NEURORADIOL J, V25, P587, DOI 10.1177/197140091202500512
   Kaphan E, 2003, REV NEUROL-FRANCE, V159, P1055
   Kawabata Y., 2017, NMC CASE REP J, V7, P1
   Kleinschmidt-DeMasters BK, 1998, HUM PATHOL, V29, P240, DOI 10.1016/S0046-8177(98)90042-9
   Litofsky NS, 1998, J NEURO-ONCOL, V40, P179, DOI 10.1023/A:1006167629968
   Sivendran S, 2011, INT J CLIN ONCOL, V16, P63, DOI 10.1007/s10147-010-0110-5
   Takei H, 2013, J NEUROSURG, V119, P499, DOI 10.3171/2013.3.JNS121707
   Zhang H, 2012, ONKOLOGIE, V35, P609, DOI 10.1159/000342676
NR 13
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 116
EP 122
DI 10.1016/j.wneu.2018.10.132
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100224
PM 30391601
DA 2020-05-12
ER

PT J
AU Ito, Y
   Satow, T
   Matsubara, H
   Kataoka, H
   Takahashi, JC
AF Ito, Yoshiro
   Satow, Tetsu
   Matsubara, Hirofumi
   Kataoka, Hiroharu
   Takahashi, Jun C.
TI Selective Shunt Occlusion of Direct Carotid-Cavernous Fistula with
   Vascular Ehlers-Danlos Syndrome by Multidevice Technique: A Case Report
   and Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct carotid-cavernous fistula; Multidevice technique; Selective shunt
   occlusion; Vascular Ehlers-Danlos syndrome
ID SYNDROME TYPE-IV; ENDOVASCULAR TREATMENT; COIL EMBOLIZATION; NERVE
   PALSY; PATIENT
AB BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a vascular disease associated with a genetic collagen abnormality. It is characterized by vessel fragility, vessel rupture, and massive hemorrhage. Carotid-cavernous fistula (CCF) is the most frequent neurovascular complication of vEDS. However, CCF treatment using conventional diagnostic angiography and neuro-endovascular therapy can result in a high rate of major complications.
   CASE DESCRIPTION: We report a case of a right CCF in a 48-year-old man with vEDS. The carotid artery and jugular vein were exposed by direct neck dissection. To avoid systemic vascular complications, multiple catheters were inserted into the shunt segment via the carotid artery and jugular vein. This transarterial and transvenous multidevice technique enabled compact placement of coils in the shunt segment. The CCF was eliminated via selective shunt occlusion. Postoperative magnetic resonance imaging revealed occlusion of the right CCF.
   CONCLUSIONS: Selective shunt occlusion via a transarterial and transvenous multidevice technique is a useful and safe approach for treating vEDS-associated CCF.
C1 [Ito, Yoshiro; Satow, Tetsu; Matsubara, Hirofumi; Kataoka, Hiroharu; Takahashi, Jun C.] Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Suita, Osaka, Japan.
   [Ito, Yoshiro] Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
RP Ito, Y (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Suita, Osaka, Japan.; Ito, Y (reprint author), Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
EM yoshiro@md.tsukuba.ac.jp
OI Kataoka, Hiroharu/0000-0001-8507-7557
CR Adham S, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0842-2
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Bergqvist D, 2013, ANN SURG, V258, P257, DOI 10.1097/SLA.0b013e31829c7a59
   Boutouyrie P, 2004, CIRCULATION, V109, P1530, DOI 10.1161/01.CIR.0000121741.50315.C2
   Desal HA, 2005, NEURORADIOLOGY, V47, P300, DOI 10.1007/s00234-005-1378-4
   Freeman RK, 1996, AM SURGEON, V62, P869
   Gemmete JJ, 2010, CURR TREAT OPTION N, V12, P43, DOI 10.1007/s11940-009-0051-3
   Hollands JK, 2006, NEURORADIOLOGY, V48, P491, DOI 10.1007/s00234-006-0084-1
   Horowitz MB, 2000, AM J NEURORADIOL, V21, P974
   Kashiwazaki D, 2014, ACTA NEUROCHIR, V156, P97, DOI 10.1007/s00701-013-1926-3
   Kiyosue H, 2015, NEURORADIOLOGY, V57, P283, DOI 10.1007/s00234-014-1474-4
   Lu Xiaojian, 2014, J Vasc Interv Neurol, V7, P35
   Luo CB, 2013, J CHIN MED ASSOC, V76, P31, DOI 10.1016/j.jcma.2012.09.007
   Matsumura Hideaki, 2015, No Shinkei Geka, V43, P721, DOI 10.11477/mf.1436203109
   Nakagawa I, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2014-011414.rep
   Nishino K, 2008, J NEUROSURG, V109, P208, DOI 10.3171/JNS/2008/109/8/0208
   Oderich GS, 2005, J VASC SURG, V42, P98, DOI 10.1016/j.jvs.2005.03.053
   Ogilvy CS, 2017, WORLD NEUROSURG, V105, P812, DOI 10.1016/j.wneu.2017.06.113
   Marques MCP, 2010, NEURORADIOLOGY, V52, P1127, DOI 10.1007/s00234-010-0683-8
   Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001
   Pradeep N, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011786.rep
   Satow T, 2013, NEUROSURGERY, V73, P100, DOI 10.1227/NEU.0b013e31828ba578
   SCHIEVINK WI, 1991, J NEUROSURG, V74, P991, DOI 10.3171/jns.1991.74.6.0991
   Van Overmeire O, 2006, INTERV NEURORADIOL, V12, P45, DOI 10.1177/159101990601200109
   Wang QH, 2013, J NEUROL SURG PART A, V74, pE41, DOI 10.1055/s-0032-1322595
NR 25
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 123
EP 128
DI 10.1016/j.wneu.2018.10.158
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100225
PM 30391766
DA 2020-05-12
ER

PT J
AU Zhang, MZ
   Horiuchi, T
   Nitta, J
   Liu, R
   Miyaoka, Y
   Nakamura, T
   Hongo, K
AF Zhang, Mingzhe
   Horiuchi, Tetsuyoshi
   Nitta, Junpei
   Liu, Raynald
   Miyaoka, Yoshinari
   Nakamura, Takuya
   Hongo, Kazuhiro
TI Intraoperative Test Occlusion as Adjustment of
   Extracranial-to-Intracranial Bypass Strategy for Unclippable Giant
   Aneurysm of the Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE EC-IC bypass; Giant aneurysm; Intraoperative test occlusion; Outcome
ID BALLOON TEST OCCLUSION; MANAGEMENT; REVASCULARIZATION; EXPERIENCE
AB BACKGROUND: There is still a controversy for low-flow extracranial-intracranial or high-flow extracranial-intracranial bypass with proximal occlusion in the treatment of unclippable giant internal carotid artery aneurysms.
   CASE DESCRIPTION: A 61-year-old woman presented with a 1-month history of double vision. Neuroimages revealed an unclippable giant internal carotid artery aneurysm located from the cavernous sinus to proximal site of the posterior communicating artery. Ipsilateral A1 of the anterior cerebral artery was hypoplastic, and posterior communicating artery was patent. Intraoperative proximal test occlusion at cervical internal carotid artery under neurophysiological monitoring, instead of preoperative balloon test occlusion, was performed to assess whether low-flow bypass was sufficient. The monitoring was unchanged during test occlusion, and the aneurysm was successfully trapped without high-flow bypass. Neither ischemic lesion nor neurologic deficits were found postoperatively.
   CONCLUSIONS: Intraoperative proximal test occlusion is useful to decide on the surgical procedure of revascularization in patients with unclippable internal carotid aneurysm.
C1 [Zhang, Mingzhe; Horiuchi, Tetsuyoshi; Miyaoka, Yoshinari; Nakamura, Takuya; Hongo, Kazuhiro] Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
   [Nitta, Junpei] Kobayashi Neurosurg Hosp, Nagano, Japan.
   [Zhang, Mingzhe] Hebei Med Univ, Harrison Int Peace Hosp, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
   [Liu, Raynald] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China.
RP Horiuchi, T (reprint author), Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
EM tetuyosi@shinshu-u.ac.jp
CR ANON VV, 1992, NEURORADIOLOGY, V34, P245, DOI 10.1007/BF00596347
   Babbu DR, 2006, MINIM INVAS NEUROSUR, V49, P331, DOI 10.1055/s-2006-954578
   BARNETT DW, 1994, NEUROSURGERY, V35, P92, DOI 10.1227/00006123-199407000-00014
   Cantore G, 2008, NEUROSURGERY, V63, P279, DOI 10.1227/01.NEU.0000313122.58694.91
   FOX AJ, 1987, J NEUROSURG, V66, P40, DOI 10.3171/jns.1987.66.1.0040
   GELBER BR, 1980, J NEUROSURG, V52, P1, DOI 10.3171/jns.1980.52.1.0001
   Ishishita Y, 2014, WORLD NEUROSURG, V82, P130, DOI 10.1016/j.wneu.2013.02.063
   Kumar NG, 2017, J NEUROL SCI, V372, P250, DOI 10.1016/j.jns.2016.11.057
   Kurokawa R, 2001, NEUROL MED-CHIR, V41, P436, DOI 10.2176/nmc.41.436
   Lawton MT, 2005, NEUROSURGERY, V56, P441, DOI 10.1227/01.NEU.0000153927.70897.A2
   MATHIS JM, 1995, AM J NEURORADIOL, V16, P749
   Mohit AA, 2007, NEUROSURGERY, V60
   Mohit AA, 2007, NEUROSURGERY, V60, P105, DOI 10.1227/01.NEU.0000249243.25429.EE
   Navratil O, 2009, NEUROSURGERY S, V64
   Navratil O, 2009, NEUROSURGERY, V64, pS113, DOI 10.1227/01.NEU.0000330400.68015.88
   NISHIOKA H, 1966, J NEUROSURG, V25, P574, DOI 10.3171/jns.1966.25.5.0574
   Patel HC, 2010, BRIT J NEUROSURG, V24, P173, DOI 10.3109/02688690903531075
   Quinones-Hinojosa A, 2005, SKULL BASE-INTERD AP, V15, P119, DOI 10.1055/s-2005-870598
   Ramanathan D, 2012, NEUROSURGERY, V70, P1442, DOI 10.1227/NEU.0b013e31824c046f
   Sano H, 2010, ACTA NEUROCHIR SUPPL, V107, P27, DOI 10.1007/978-3-211-99373-6_4
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   SEKHAR LN, 1990, J NEUROSURG, V72, P35, DOI 10.3171/jns.1990.72.1.0035
   SEN C, 1992, NEUROSURGERY, V30, P732
   Seo BR, 2009, CLIN NEUROL NEUROSUR, V111, P670, DOI 10.1016/j.clineuro.2009.06.002
   Song JP, 2015, ACTA NEUROCHIR, V157, P1833, DOI 10.1007/s00701-015-2568-4
   SUNDT TM, 1979, J NEUROSURG, V51, P731, DOI 10.3171/jns.1979.51.6.0731
   van Rooij WJJ, 2000, NEUROSURGERY, V47, P116, DOI 10.1097/00006123-200007000-00025
   Zhu W, 2011, WORLD NEUROSURG, V75, P476, DOI 10.1016/j.wneu.2010.07.043
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 129
EP 132
DI 10.1016/j.wneu.2018.10.156
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100226
PM 30391770
DA 2020-05-12
ER

PT J
AU Hou, K
   Ji, TF
   Guo, YB
   Xu, BF
   Xu, K
   Yu, JL
AF Hou, Kun
   Ji, Tiefeng
   Guo, Yunbao
   Xu, Baofeng
   Xu, Kan
   Yu, Jinlu
TI Current Status of Endovascular Treatment for Dural Arteriovenous
   Fistulas in the Superior Sagittal Sinus Region: A Systematic Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dural arteriovenous fistula; Endovascular treatment; Review; Superior
   sagittal sinus
ID MIDDLE MENINGEAL ARTERY; TRANSARTERIAL ONYX EMBOLIZATION; PRESSURE
   COOKER TECHNIQUE; DUAL-LUMEN BALLOON; TRANSVENOUS EMBOLIZATION;
   STEREOTACTIC RADIOSURGERY; COIL EMBOLIZATION; THROMBOSED SINUS;
   CLASSIFICATION; MALFORMATIONS
AB BACKGROUND: Dural arteriovenous fistulas (DAVFs) occurring in the superior sagittal sinus (SSS) region are difficult to cure. Endovascular treatment (EVT) is an effective method for the treatment of SSS region DAVFs. Currently, no systematic review of EVT for SSS region DAVFs is available. A systematic review of the literature is necessary.
   METHODS: A systematic PubMed search for studies related to SSS region DAVFs published after 1990 in English was performed on October 15, 2018.
   RESULTS: Thirty-three studies involving 42 patients, including 31 (73.8%, 31/42) men, were finally identified. Of the 42 patients, 12 (28.6%, 12/42) patients mainly presented with intracranial hemorrhage, and 9 (21.4%, 9/42) patients presented with cognitive impairment. Of the 42 patients, 31 (73.8%, 31/42) patients were treated via transarterial embolization, and 11 (26.2%, 11/42) patients were treated via transvenous embolization. Of the 42 patients, 41 (97.6%, 41/42) patients had a clear angiographic outcome, and complete angiographic cure was achieved in 36 (87.8%, 36/41) patients. Of the 42 patients, 4 (9.5%, 4/42) patients were reported to have procedural complications. Of the 42 patients, 37 (88.1%, 37/42) patients had a definite description of the follow-up outcome, 22 (59.5%, 22/37) patients had a modified Ranking Scale score of 0, and 12 (32.4%, 12/37) patients had an improved neurologic state.
   CONCLUSIONS: In treating SSS region DAVFs, EVT can completely obliterate the fistula point and correct venous shunting. Thus, currently EVT is an effective treatment for SSS region DAVFs. Although many complications can occur, this approach achieves good outcomes in most cases.
C1 [Hou, Kun; Guo, Yunbao; Xu, Baofeng; Xu, Kan; Yu, Jinlu] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130021, Jilin, Peoples R China.
   [Ji, Tiefeng] Jilin Univ, Hosp 1, Dept Radiol, Changchun 130021, Jilin, Peoples R China.
RP Yu, JL (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun 130021, Jilin, Peoples R China.
EM jlyu@jlu.edu.cn
RI Yu, Jinlu/S-7854-2019
OI Yu, Jinlu/0000-0003-2329-7946; Xu, Kan/0000-0001-8947-1172; Hou,
   Kun/0000-0001-7112-7883
CR Abud DG, 2016, J NEURORADIOLOGY, V43, P218, DOI 10.1016/j.neurad.2016.01.146
   Arat A, 2006, NEUROSURGERY, V59, P169
   Ayad M, 2006, EXPERT REV MED DEVIC, V3, P705, DOI 10.1586/17434440.3.6.705
   Baum Griffin R, 2016, Surg Neurol Int, V7, pS223, DOI 10.4103/2152-7806.179577
   Bavinzski G, 1999, NEUROL MED-CHIR, V39, P362, DOI 10.2176/nmc.39.362
   Bertalanffy A, 2001, MINIM INVAS NEUROSUR, V44, P205, DOI 10.1055/s-2001-19932
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Chai EQ, 2011, NEUROL INDIA, V59, P262, DOI 10.4103/0028-3886.79141
   Chong Brian W, 2008, Radiol Case Rep, V3, P158, DOI 10.2484/rcr.v3i1.158
   Clarencon F, 2016, ACTA NEUROCHIR, V158, P1917, DOI 10.1007/s00701-016-2906-1
   Cloft HJ, 1997, NEUROSURGERY, V41, P1191, DOI 10.1097/00006123-199711000-00034
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Doolan BJ, 2018, J CLIN NEUROSCI, V48, P214, DOI 10.1016/j.jocn.2017.10.070
   Ertl Lorenz, 2017, J Neurosurg, V126, P360, DOI 10.3171/2016.2.JNS152081
   Friedman JA, 2001, J NEUROSURG, V94, P886, DOI 10.3171/jns.2001.94.6.0886
   Fujii H, 2014, BMJ CASE REP, V2014
   Fukai J, 2001, SURG NEUROL, V55, P353, DOI 10.1016/S0090-3019(01)00469-4
   Gabrieli J, 2017, J NEUROINTERV SURG, V9, pE8, DOI 10.1136/neurintsurg-2015-011829
   Gist TL, 2014, J NEUROINTERV SURG, V6, DOI 10.1136/neurintsurg-2012-010619.rep
   GOBIN YP, 1993, AM J NEURORADIOL, V14, P1102
   Gomez J, 2012, NEUROSURG CLIN N AM, V23, P55, DOI 10.1016/j.nec.2011.09.003
   Griessenauer CJ, 2016, CLIN ANAT, V29, P718, DOI 10.1002/ca.22733
   Guo F, 2018, WORLD NEUROSURG, V116, pE203, DOI 10.1016/j.wneu.2018.04.163
   HALBACH VV, 1988, AM J NEURORADIOL, V9, P337
   Houdart E, 2002, J NEUROSURG, V97, P280, DOI 10.3171/jns.2002.97.2.0280
   Hurst RW, 1998, SURG NEUROL, V49, P42, DOI 10.1016/S0090-3019(97)00177-8
   Hwang SK, 2015, J KOREAN NEUROSURG S, V57, P204, DOI 10.3340/jkns.2015.57.3.204
   Imazeki Ryoko, 2015, Tokai J Exp Clin Med, V40, P22
   Kakarla UK, 2007, NEUROSURGERY, V61, P447, DOI 10.1227/01.NEU.0000290889.62201.7F
   Kakarla UK, 2007, NEUROSURGERY, V61
   Katz JM, 2003, NEUROLOGY, V61, P557, DOI 10.1212/01.WNL.0000079461.56675.B4
   Kawaguchi S, 2000, J CLIN NEUROSCI, V7, P47
   Kawaguchi T, 2000, NEUROL MED-CHIR, V40, P366, DOI 10.2176/nmc.40.366
   Kawaguchi T, 2004, INTERV NEURORADIOL, V10, P127, DOI 10.1177/15910199040100S122
   Kim Sung Tae, 2013, Neurointervention, V8, P110, DOI 10.5469/neuroint.2013.8.2.110
   Kiyosue H, 2004, CARDIOVASC INTER RAD, V27, P405, DOI 10.1007/s00270-003-5028-0
   Kiyosue H, 2013, AM J NEURORADIOL, V34, P1612, DOI 10.3174/ajnr.A3428
   Serizawa Toru, 1994, Neurological Surgery, V22, P447
   Kurata A, 2006, INTERV NEURORADIOL, V12, P363, DOI 10.1177/159101990601200412
   Kurl S, 1996, SURG NEUROL, V45, P250, DOI 10.1016/0090-3019(95)00361-4
   Kurosu A, 1998, BRIT J NEUROSURG, V12, P176, DOI 10.1080/02688699845375
   Lekkhong E, 2011, AM J NEURORADIOL, V32, P1738, DOI 10.3174/ajnr.A2566
   Liu CH, 2014, NEUROL RES, V36, P983, DOI 10.1179/1743132814Y.0000000383
   Liu JK, 2009, J NEUROSURG, V110, P913, DOI 10.3171/2008.9.JNS08733
   Maruyama K, 2002, J NEUROSURG, V97, P481, DOI 10.3171/jns.2002.97.supplement_5.0481
   Masuo O, 1998, INTERV NEURORADIOL, V4, P113, DOI 10.1177/15910199980040S124
   Meguro T, 2012, NO SHINKEI GEKA, V40, P629
   Mineta T, 1991, Neurol Med Chir (Tokyo), V31, P41, DOI 10.2176/nmc.31.41
   Miyamoto N, 2015, NEUROL MED-CHIR, V55, P163, DOI 10.2176/nmc.oa.2014-0223
   Nakamura M, 1997, Interv Neuroradiol, V3 Suppl 2, P97
   Nishino A, 1991, No To Shinkei, V43, P62
   Nishio A, 2002, NEUROL MED-CHIR, V42, P217, DOI 10.2176/nmc.42.217
   Oh JS, 2015, J KOREAN NEUROSURG S, V57, P54, DOI 10.3340/jkns.2015.57.1.54
   Ohara N, 2012, INTERV NEURORADIOL, V18, P333, DOI 10.1177/159101991201800314
   Pan DHC, 2002, J NEUROSURG, V96, P823, DOI 10.3171/jns.2002.96.5.0823
   Pierot L, 1998, NEUROSURGERY, V42, P194, DOI 10.1097/00006123-199801000-00044
   Piske RL, 2005, AM J NEURORADIOL, V26, P1715
   Sarma D, 2003, EUR J RADIOL, V46, P206, DOI 10.1016/S0720-048X(03)00092-5
   Shen SC, 2014, BMJ CASE REP
   Shen Shih-Chieh, 2014, Surg Neurol Int, V5, P10, DOI 10.4103/2152-7806.125780
   Shi ZS, 2009, J NEUROSURG, V110, P921, DOI 10.3171/2008.10.JNS08119
   Shimizu Takashi, 2014, No Shinkei Geka, V42, P1151, DOI 10.11477/mf.1436200051
   Singla A, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011879.rep
   Song WZ, 2017, NEUROLOGIST, V22, P186, DOI 10.1097/NRL.0000000000000137
   Spiotta AM, 2015, J NEUROINTERV SURG, V7, P721, DOI 10.1136/neurintsurg-2014-011285
   Spiotta AM, 2012, J STROKE CEREBROVASC, V21, P283, DOI 10.1016/j.jstrokecerebrovasdis.2010.08.009
   Takase K, 2017, J NEUROL SCI, V376, P91, DOI 10.1016/j.jns.2017.03.004
   Tao YH, 2016, NEUROSCIENCES, V21, P158, DOI 10.17712/nsj.2016.2.20150331
   Tonetti DA, 2017, WORLD NEUROSURG, V107, P371, DOI 10.1016/j.wneu.2017.07.170
   Toyota S, 2008, INTERV NEURORADIOL, V14, P319, DOI 10.1177/159101990801400313
   Urtasun F, 1996, RADIOLOGY, V199, P209, DOI 10.1148/radiology.199.1.8633147
   VanLandingham M, 2014, NEUROSURGERY, V74, pS42, DOI 10.1227/NEU.0000000000000180
   Watanabe Jun, 2016, Surg Neurol Int, V7, pS410, DOI 10.4103/2152-7806.183518
   Willinsky R, 1999, AM J NEURORADIOL, V20, P1031
   Wong GKC, 2007, ACTA NEUROCHIR, V149, P929, DOI 10.1007/s00701-007-1264-4
   Wong GK, 2007, ACTA NEUROCHIR WIEN, V149, P935
   Yoshioka T, 2007, Interv Neuroradiol, V13 Suppl 1, P123
   Yu JL, 2016, INT J MED SCI, V13, P790, DOI 10.7150/ijms.16489
   Zhang G, 2017, INTERV NEURORADIOL, V23, P194, DOI 10.1177/1591019916682357
   Zhang YX, 2015, INTERV NEURORADIOL, V21, P94, DOI 10.15274/INR-2014-10098
NR 80
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 133
EP 143
DI 10.1016/j.wneu.2018.10.145
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100227
PM 30391606
DA 2020-05-12
ER

PT J
AU Yonemoto, N
   Ogihara, S
   Kobayashi, Y
   Sawano, M
   Matsuda, M
   Saita, K
AF Yonemoto, Naofumi
   Ogihara, Satoshi
   Kobayashi, Yosuke
   Sawano, Makoto
   Matsuda, Masaki
   Saita, Kazuo
TI Two-Staged Circumferential Decompression and Fusion Surgery for Upper
   Thoracic Myelopathy Caused by Concurrent Beak-Type Ossification of the
   Posterior Longitudinal Ligament and Ligamentum Flavum at T1-T2 Level: A
   Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervicothoracic junction; Circumferential fusion; Ligamentum flavum;
   Ossification; Posterior longitudinal ligament; Thoracic spine
ID CEREBROSPINAL-FLUID LEAKAGE; SPINAL-CORD DECOMPRESSION; ANTERIOR
   DECOMPRESSION; TRANSIENT PARAPARESIS; INSTRUMENTED FUSION; LAMINECTOMY;
   OPLL
AB BACKGROUND: Upper thoracic myelopathy caused by combined ossification of the posterior longitudinal ligament (OPLL) and ossification of the ligamentum flavum (OLF) is relatively rare. This clinical condition is difficult to treat, and a surgical method has not been fully established. We report an extremely rare case of severe thoracic myelopathy caused by concurrent beak-type OPLL and OLF at T1-T2.
   CASE DESCRIPTION: A 53-year-old woman with paresthesia of both legs and an inability to hold a standing position presented to our hospital. Radiological images showed a large beak-type OPLL at T1-T2 and an OLF at T1-T7. The spinal cord was severely compressed at T1-T2. First, posterior decompression and instrumentation fusion at C6-T4 was performed, with a T1-T2 bilateral parallel gutter along the dural tube into the vertebral bodies covering the extent of the OPLL. Second, anterior decompression of the OPLL with corpectomy of T1-T2 and fusion using iliac bone grafting was performed after the sternal manubrium splitting approach. In the deep operating field of the second surgery, the gutters created during the first surgery were helpful for judging the width and thickness of the OPLL during the anterior decompression procedure. Postoperatively, her neurological symptoms greatly improved, the patient could walk independently, and the Japanese Orthopaedic Association score had improved from 3 preoperatively to 8 at the final follow-up examination at 16 months postoperatively.
   CONCLUSIONS: Two-stage circumferential decompression and fusion surgery can be considered an effective surgical method for upper thoracic concurrent OPLL and OLF. The bilateral gutters created during the first surgery improved the safety and feasibility of this difficult operation.
C1 [Yonemoto, Naofumi; Ogihara, Satoshi; Kobayashi, Yosuke; Saita, Kazuo] Saitama Med Univ, Saitama Med Ctr, Dept Orthopaed Surg, Saitama, Japan.
   [Sawano, Makoto; Matsuda, Masaki] Saitama Med Univ, Saitama Med Ctr, Dept Emergency & Crit Care Med, Saitama, Japan.
RP Ogihara, S (reprint author), Saitama Med Univ, Saitama Med Ctr, Dept Orthopaed Surg, Saitama, Japan.
EM sogihara@saitama-med.ac.jp
OI Ogihara, Satoshi/0000-0002-1814-3195
CR Chen Y, 2012, ARCH ORTHOP TRAUM SU, V132, P1219, DOI 10.1007/s00402-012-1540-5
   Chitoku S, 2017, WORLD NEUROSURG, V103, DOI 10.1016/j.wneu.2017.04.097
   Cho JY, 2012, J SPINAL DISORD TECH, V25, pE72, DOI 10.1097/BSD.0b013e318246b89a
   Fujimura Y, 1996, SPINAL CORD, V34, P387, DOI 10.1038/sc.1996.70
   Guo QF, 2011, EUR SPINE J, V20, pS195, DOI 10.1007/s00586-010-1538-z
   Hanai K, 2002, SPINE, V27, P1070, DOI 10.1097/00007632-200205150-00012
   Hioki A, 2008, ARCH ORTHOP TRAUM SU, V128, P175, DOI 10.1007/s00402-007-0336-5
   Hirai T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160117
   Ikeda Y, 2011, EUR SPINE J, V20, P1450, DOI 10.1007/s00586-011-1688-7
   Jellinger KA, 1997, NEUROLOGY, V48, P1474, DOI 10.1212/WNL.48.5.1474-b
   Karikari IO, 2009, NEUROSURGERY, V65, P165, DOI 10.1227/01.NEU.0000347472.07670.EB
   Kato S, 2015, J NEUROSURG-SPINE, V23, P479, DOI 10.3171/2015.1.SPINE14960
   Kato S, 2012, J NEUROSURG-SPINE, V17, P525, DOI 10.3171/2012.9.SPINE12617
   Kawaguchi Y, 2018, EUR SPINE J, V27, pS335, DOI 10.1007/s00586-017-5244-y
   Kawahara N, 2008, SPINE, V33, P39, DOI 10.1097/BRS.0b013e31815e3911
   Koda Masao, 2015, BMC Res Notes, V8, P133, DOI 10.1186/s13104-015-1106-z
   Matsuyama Y, 2005, J SPINAL DISORD TECH, V18, P492, DOI 10.1097/01.bsd.0000155033.63557.9c
   Matsuyama Y, 2009, EUR SPINE J, V18, P943, DOI 10.1007/s00586-009-0956-2
   Moon JH, 2017, J CLIN NEUROSCI, V45, P172, DOI 10.1016/j.jocn.2017.05.028
   Onishi E, 2016, CLIN SPINE SURG, V29, pE389, DOI 10.1097/BSD.0000000000000059
   Takahata M, 2008, SPINE, V33, P1199, DOI 10.1097/BRS.0b013e3181714515
   Teng HL, 2009, J NEUROSURG-SPINE, V10, P531, DOI 10.3171/2009.2.SPINE08372
   Tian W, 2013, J SPINAL DISORD TECH, V26, pE227, DOI 10.1097/BSD.0b013e318286ba39
   Yamazaki M, 2006, SPINAL CORD, V44, P130, DOI 10.1038/sj.sc.3101807
   Yamazaki M, 2005, SPINE, V30, pE343, DOI 10.1097/01.brs.0000166504.31627.06
   Yamazaki M, 2010, EUR SPINE J, V19, P691, DOI 10.1007/s00586-009-1266-4
   Zhang HQ, 2010, J NEUROSURG-SPINE, V13, P116, DOI 10.3171/2010.3.SPINE09237
NR 27
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 144
EP 149
DI 10.1016/j.wneu.2018.10.142
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100228
PM 30391614
DA 2020-05-12
ER

PT J
AU Borni, M
   Abdelhedi, A
   Kammoun, B
   Kolsi, F
   Boudawara, MZ
AF Borni, Mehdi
   Abdelhedi, Anis
   Kammoun, Brahim
   Kolsi, Fatma
   Boudawara, Mohamed Zaher
TI Ruptured Central Nervous System Dermoid Cyst of Suprasellar Region
   Manifesting as Unusual Epileptic Seizure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dermoid cyst; Fat; Spontaneous rupture
AB BACKGROUND: Central nervous system dermoid cysts are rare lesions derived from ectopic epithelial cells. They are slow-growing benign tumors but may cause significant morbidity through compression of neurologic and vascular structures and, rarely, rupture into the subarachnoid space.
   CASE DESCRIPTION: We present a rare case of a spontaneously ruptured intracranial dermoid cyst in a 32-year-old man presenting as new-onset epileptic seizures due to chemical meningitis caused by dissemination of fat or lipid droplets.
   CONCLUSIONS: The dermoid cyst is a rare entity, the rupture of which is exceptional and often spontaneous. It is manifested by a polymorphic and nonspecific clinical picture requiring the use of imaging. This is based on CT and especially MRI, which make it possible to positively diagnose the nature of the cyst and the rupture, specify the extent of the dissemination of the lipid content in the subarachnoid spaces, and detect possible complications such as hydrocephalus. It also makes it possible to carry out a precise topographic assessment to plan the therapeutic conduct and guide a possible surgical intervention.
C1 [Borni, Mehdi; Abdelhedi, Anis; Kammoun, Brahim; Kolsi, Fatma; Boudawara, Mohamed Zaher] UHC Habib Bourguiba, Dept Neurosurg, Sfax, Tunisia.
RP Borni, M (reprint author), UHC Habib Bourguiba, Dept Neurosurg, Sfax, Tunisia.
EM borni.mehdi13@gmail.com
CR ARSENI C, 1976, NEUROCHIRURGIA, V19, P104
   Carvalho GA, 2000, NEUROSURGERY, V47, P760, DOI 10.1097/00006123-200009000-00047
   Cha JG, 2006, BRIT J RADIOL, V79, P167, DOI 10.1259/bjr/17232685
   Das CJ, 2007, J NEUROL NEUROSUR PS, V78, P624, DOI 10.1136/jnnp.2006.109835
   El-Bahy K, 2006, ACTA NEUROCHIR, V148, P457, DOI 10.1007/s00701-005-0722-0
   GRAHAM DV, 1988, NEUROSURGERY, V23, P765, DOI 10.1227/00006123-198812000-00016
   Karabulut N, 2000, EUR RADIOL, V10, P1810, DOI 10.1007/s003300000440
   Kim IY, 2008, J CLIN NEUROSCI, V15, P469, DOI 10.1016/j.jocn.2006.10.028
   KIM KS, 1981, SURG NEUROL, V15, P375, DOI 10.1016/0090-3019(81)90175-0
   Liu JK, 2008, NEUROSURGERY, V62, P377, DOI 10.1227/01.neu.0000316004.88517.29
   LUNARDI P, 1991, J NEUROSURG, V75, P262, DOI 10.3171/jns.1991.75.2.0262
   Orakcioglu B, 2008, ACTA NEUROCHIR, V150, P1227, DOI 10.1007/s00701-008-0152-x
   OSBORN A, 1994, DIAGNOSTIC NEURORADI
   Park SK, 2012, CLIN NEUROL NEUROSUR, V114, P421, DOI 10.1016/j.clineuro.2011.11.006
   Rai SPV, 2009, NEUROL INDIA, V57, P98, DOI [10.4103/0028-3886.48803, 10.4103/0028-3886.48802]
   Stendel R, 2002, SURG NEUROL, V57, P391, DOI 10.1016/S0090-3019(02)00723-1
   Venkatesh SK, 2002, NEUROL INDIA, V50, P480
   WILMS G, 1991, NEURORADIOLOGY, V33, P149, DOI 10.1007/BF00588254
   YASARGIL MG, 1989, NEUROSURGERY, V24, P561
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 150
EP 154
DI 10.1016/j.wneu.2018.10.153
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100229
PM 30395941
DA 2020-05-12
ER

PT J
AU Sokolowski, JD
   Guilliams, EL
   Diaz, M
   Wildeman, ME
   Nguyen, JH
   Gish, DS
   Sheehan, JP
   Kalani, MYS
   Park, MS
AF Sokolowski, Jennifer D.
   Guilliams, Evin L.
   Diaz, Maria
   Wildeman, Miriam E.
   Nguyen, James H.
   Gish, David S.
   Sheehan, Jason P.
   Kalani, M. Yashar S.
   Park, Min S.
TI Neoplastic Cerebral Aneurysm from Metastatic Lung Adenocarcinoma with
   Neuroendocrine Features
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cerebral; Hemorrhage; Lung; Metastasis; Neoplastic;
   Radiosurgery
ID CARDIAC MYXOMA; CARCINOMA
AB BACKGROUND: Neoplastic cerebral aneurysms are exceedingly rare. We describe a case of a ruptured, distal middle cerebral artery aneurysm as the presenting symptom leading to the identification of metastatic lung cancer.
   CASE DESCRIPTION: The patient underwent an uncomplicated surgical trapping and ligation of the aneurysm. Histopathologic examination of the aneurysm confirmed the neoplastic cerebral aneurysm was due to a metastatic lung adenocarcinoma with neuroendocrine features. The patient subsequently underwent stereotactic radiosurgery to the resection cavity.
   CONCLUSIONS: Neoplastic cerebral aneurysms are rare, and there are insufficient data to support specific guidelines for management. This case is novel as the patient received adjuvant stereotactic radiosurgery to the operative bed, as well as systemic chemotherapy, and has maintained good functional status as of last follow-up at 6 months.
C1 [Sokolowski, Jennifer D.; Guilliams, Evin L.; Nguyen, James H.; Sheehan, Jason P.; Kalani, M. Yashar S.; Park, Min S.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
   [Diaz, Maria] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
   [Wildeman, Miriam E.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.
   [Gish, David S.] Univ Virginia, Dept Radiol, Charlottesville, VA 22903 USA.
   [Guilliams, Evin L.] Carill Clin, Dept Neurosurg, Roanoke, VA USA.
RP Sokolowski, JD (reprint author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
EM soko@virginia.edu
CR Ashalatha R, 2005, Neurol India, V53, P216
   Brown PD, 2017, LANCET ONCOL, V18, P1049, DOI 10.1016/S1470-2045(17)30441-2
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Gliemroth J, 1999, J NEUROL NEUROSUR PS, V66, P246, DOI 10.1136/jnnp.66.2.246
   HO KL, 1982, CANCER, V50, P2935, DOI 10.1002/1097-0142(19821215)50:12<2935::AID-CNCR2820501238>3.0.CO;2-Z
   KOCHI N, 1984, J NEUROSURG, V60, P640, DOI 10.3171/jns.1984.60.3.0640
   MURATA J, 1993, NEUROSURGERY, V32, P124, DOI 10.1227/00006123-199301000-00019
   Nomura R, 2009, NEUROL MED-CHIR, V49, P33, DOI 10.2176/nmc.49.33
   Omofoye OA, 2018, NEUROSURGERY, V83, pE221, DOI 10.1093/neuros/nyx588
   Radoi MP, 2012, BRIT J NEUROSURG, V26, P893, DOI 10.3109/02688697.2012.692841
   Sedat J, 2007, INTERV NEURORADIOL, V13, P179, DOI 10.1177/159101990701300209
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Zheng J, 2015, CLIN NEUROL NEUROSUR, V128, P107, DOI 10.1016/j.clineuro.2014.11.010
NR 13
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 155
EP 160
DI 10.1016/j.wneu.2018.10.185
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100230
PM 30399471
DA 2020-05-12
ER

PT J
AU Preet, K
   Udawatta, M
   Duong, C
   Gopen, Q
   Yang, I
AF Preet, Komal
   Udawatta, Methma
   Duong, Courtney
   Gopen, Quinton
   Yang, Isaac
TI Bilateral Superior Semicircular Canal Dehiscence Associated with
   Ehlers-Danlos Syndrome: A Report of 2 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; Ehlers-Danlos syndrome; Hypermobility; Middle fossa
   craniotomy; Superior semicircular canal dehiscence
ID HEARING-LOSS; BONE; PREVALENCE; COMPLICATIONS; MANAGEMENT
AB BACKGROUND: Superior semicircular canal dehiscence (SSCD) is a rare bony defect in the petrosal temporal bone, creating a new opening between the inner ear and middle cranial fossa. Ehlers-Danlos syndrome (EDS) is an inherited connective tissue disorder characterized by a defect in collagen synthesis. Patients with EDS are more likely to have bony abnormalities, which may pre-dispose them to developing SSCD.
   CASE DESCRIPTION: We report the cases of 2 women with history of EDS hypermobility type (HT). Both patients presented with bilateral auditory and vestibular symptoms, and computed tomography scan confirmed the presence of bilateral dehiscence in their superior semicircular canals. They underwent elective surgical repair via middle fossa craniotomy and report improvement in their symptoms.
   CONCLUSIONS: Because of the rarity of both diseases and their pathophysiology, a history of EDS may predispose an individual to developing SSCD. Although further research is necessary, this report aims to improve clinical screening of patients with EDS HT by suggesting an auditory and vestibular evaluation and assessment of pertinent bony abnormalities.
C1 [Preet, Komal; Udawatta, Methma; Duong, Courtney; Yang, Isaac] Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Gopen, Quinton] Ronald Reagan UCLA Med Ctr, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, Off Patient Experience, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA.
   [Yang, Isaac] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst LA BioMed, Torrance, CA 90509 USA.
RP Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA.; Yang, I (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst LA BioMed, Torrance, CA 90509 USA.
EM iyang@mednet.ucla.edu
RI Duong, Courtney/AAD-4121-2019
OI Udawatta, Methma/0000-0002-5225-7006
FU David Geffen Medical Scholarship; UCLA Visionary Ball Fund Grant; UCLA
   Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell
   Research Scholars in Translational Medicine Program Award; Jason Dessel
   Memorial Seed Grant; UCLA Honberger Endowment Brain Tumor Research Seed
   Grant; Stop Cancer (US) Research Career Development Award
FX M. Udawatta is supported by a David Geffen Medical Scholarship. I. Yang
   is supported by the UCLA Visionary Ball Fund Grant, UCLA Eli and Edythe
   Broad Center of Regenerative Medicine and Stem Cell Research Scholars in
   Translational Medicine Program Award, Jason Dessel Memorial Seed Grant,
   UCLA Honberger Endowment Brain Tumor Research Seed Grant, and Stop
   Cancer (US) Research Career Development Award.
CR Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O
   Bi WL, 2017, J NEUROSURG, V127, P1268, DOI 10.3171/2016.9.JNS16503
   Brady AF, 2017, AM J MED GENET C, V175, P70, DOI 10.1002/ajmg.c.31550
   Brandolini C, 2014, EUR ARCH OTO-RHINO-L, V271, P435, DOI 10.1007/s00405-013-2497-x
   Carey JP, 2000, ARCH OTOLARYNGOL, V126, P137, DOI 10.1001/archotol.126.2.137
   Ceylan N, 2010, ACTA OTO-LARYNGOL, V130, P996, DOI 10.3109/00016481003602108
   Chung LK, 2017, CUREUS, V9, DOI 10.7759/cureus.1141
   De Paepe A, 2012, CLIN GENET, V82, P1, DOI 10.1111/j.1399-0004.2012.01858.x
   Dolan AL, 1998, ANN RHEUM DIS, V57, P630, DOI 10.1136/ard.57.10.630
   Eagleton MJ, 2016, J VASC SURG, V64, P1869, DOI 10.1016/j.jvs.2016.06.120
   Ehlers-Danlos Syndrome, 2017, EHL DANL SYNDR
   Eller-Vainicher C, 2016, OSTEOPOROSIS INT, V27, P2525, DOI 10.1007/s00198-016-3562-2
   Fiorino F, 2010, OTOL NEUROTOL, V31, P136, DOI 10.1097/MAO.0b013e3181b76b9e
   Gazit Y, 2016, RAMBAM MAIMONIDES ME, V7, DOI 10.5041/RMMJ.10261
   Kaufman Carolyn S, 2016, World J Med Genet, V6, P17, DOI 10.5496/wjmg.v6.i2.17
   Lee YH, 2014, J COMPUT ASSIST TOMO, V38, P190, DOI 10.1097/RCT.0b013e3182ab2afb
   Malfait F, 2017, AM J MED GENET C, V175, P8, DOI 10.1002/ajmg.c.31552
   McEvoy TP, 2013, AM J OTOLARYNG, V34, P345, DOI 10.1016/j.amjoto.2013.01.009
   Milojcic R, 2013, OTOL NEUROTOL, V34, P360, DOI 10.1097/MAO.0b013e31827b4fb5
   Parapia LA, 2008, BRIT J HAEMATOL, V141, P32, DOI 10.1111/j.1365-2141.2008.06994.x
   Russo JE, 2014, OTOL NEUROTOL, V35, P310, DOI 10.1097/MAO.0000000000000183
   Savasta S, 2011, CHILD NERV SYST, V27, P365, DOI 10.1007/s00381-010-1256-1
   Shirley ED, 2012, SPORTS HEALTH, V4, P394, DOI 10.1177/1941738112452385
   Sobey G, 2015, ARCH DIS CHILD, V100, P57, DOI 10.1136/archdischild-2013-304822
   Sood D, 2017, EUR J RADIOL OPEN, V4, P144, DOI 10.1016/j.ejro.2017.10.003
   Stimmer H, 2012, EUR ARCH OTO-RHINO-L, V269, P475, DOI 10.1007/s00405-011-1688-6
   Sugihara EM, 2016, OTOL NEUROTOL, V37, P1370, DOI 10.1097/MAO.0000000000001194
   Nguyen T, 2018, ACTA NEUROCHIR, V160, P1219, DOI 10.1007/s00701-017-3346-2
   Thomson S, 2014, CLIN RADIOL, V69, pE146, DOI 10.1016/j.crad.2013.10.020
   Vlastarakos PV, 2009, EUR ARCH OTO-RHINO-L, V266, P177, DOI 10.1007/s00405-008-0840-4
   Williamson RA, 2003, OTOLARYNG HEAD NECK, V129, P481, DOI 10.1016/S0194-5998(03)01391-3
   Yew A, 2012, J NEUROL SURG PART B, V73, P365, DOI 10.1055/s-0032-1324397
   Zhou GW, 2007, OTOL NEUROTOL, V28, P920, DOI 10.1097/MAO.0b013e31814b25f2
NR 33
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 161
EP 164
DI 10.1016/j.wneu.2018.10.126
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100231
PM 30385359
DA 2020-05-12
ER

PT J
AU Patel, NP
   Robinson, TM
   Lesley, WS
   Garrett, D
   Shan, Y
   Huang, JH
AF Patel, Nitesh P.
   Robinson, Timothy M.
   Lesley, Walter S.
   Garrett, David
   Shan, Yuan
   Huang, Jason H.
TI Retromedullary Hemangioblastoma Mimicking a Posterior Inferior
   Cerebellar Artery Aneurysm: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hemangioblastoma; PICA aneurysm; Retromedullary vascular lesion
ID CENTRAL-NERVOUS-SYSTEM; CLINICAL-FEATURES
AB BACKGROUND: Hemangioblastomas (HBMs) are benign vascular neoplasms that most commonly arise within the cerebellum. Although other vascular lesions should be considered in the differential diagnosis, HBMs rarely resemble aneurysms on neuroimaging and only 1 case of a cerebellar HBM mimicking a posterior fossa aneurysm has been reported. Here we describe a retromedullary HBM that masqueraded as a distal posterior inferior cerebellar artery (PICA) medullary branch aneurysm.
   CASE DESCRIPTION: A 63-year-old asymptomatic male was incidentally diagnosed with an unruptured 3-mm left PICA aneurysm via computed tomography angiography during a workup for carotid stenosis. Two years later, the presumed aneurysm enlarged to 6.5 mm and prompted elective treatment. Endovascular treatment was unsuccessful, and the patient was immediately transitioned to a craniotomy for aneurysm clipping. After microsurgical dissection, the lesion was visualized on the posterior medullary surface with several small arterial feeders extending from the brainstem into the aneurysm dome, but no major parent vessel was observed. Because a clip could not be safely applied to these small vessels, they were instead coagulated and the lesion was completely resected. Final pathology revealed hemangioblastoma (World Health Organization grade I).
   CONCLUSIONS: To our knowledge, this is the second case of HBM mimicking a PICA aneurysm. Given the rarity of PICA medullary branch aneurysms and their highly symptomatic nature, other etiologies, especially HBM, should be strongly considered when an apparent distal PICA aneurysm is diagnosed in an asymptomatic patient. If the lesion is unamenable to endovascular treatment, there should be high suspicion for HBM and subsequent craniotomy should be pursued.
C1 [Patel, Nitesh P.; Robinson, Timothy M.; Lesley, Walter S.; Garrett, David; Huang, Jason H.] Texas A&M Coll Med, Temple, TX 77807 USA.
   [Robinson, Timothy M.; Lesley, Walter S.; Garrett, David; Shan, Yuan; Huang, Jason H.] Baylor Scott & White Hlth, Dept Neurosurg, Temple, TX 76502 USA.
   [Shan, Yuan] Baylor Scott & White Hlth, Dept Pathol, Temple, TX USA.
RP Huang, JH (reprint author), Texas A&M Coll Med, Temple, TX 77807 USA.; Huang, JH (reprint author), Baylor Scott & White Hlth, Dept Neurosurg, Temple, TX 76502 USA.
EM Jason.Huang@BSWHealth.org
RI Huang, Jason H/J-4739-2019
OI Huang, Jason H/0000-0002-4426-0168; Patel, Nitesh/0000-0003-2511-6897
CR Cushing HWB, 1928, TUMORS ARISING BLOOD
   Drake Charles G., 1996, SURG VERTEBROBASILAR
   HO VB, 1992, AM J NEURORADIOL, V13, P1343
   Hoh BL, 2004, NEUROSURGERY, V54, P1329, DOI 10.1227/01.NEU.0000125325.22576.83
   Horiuchi T, 2003, NEUROSURGERY, V53, P589, DOI 10.1227/01.NEU.0000079493.50657.1D
   ISHIKAWA T, 1990, Neurologia Medico-Chirurgica, V30, P100, DOI 10.2176/nmc.30.100
   Ji YC, 2016, ONCOL LETT, V12, P2622, DOI 10.3892/ol.2016.4979
   Lehto H, 2014, WORLD NEUROSURG, V82, P702, DOI 10.1016/j.wneu.2014.06.012
   Lewis SB, 2002, J NEUROSURG, V97, P756, DOI 10.3171/jns.2002.97.4.0756
   Li XE, 2008, SURG NEUROL, V70, P425, DOI 10.1016/j.surneu.2007.04.017
   LISTER JR, 1982, NEUROSURGERY, V10, P170
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   NEUMANN HPH, 1989, J NEUROSURG, V70, P24, DOI 10.3171/jns.1989.70.1.0024
   OKAWARA SH, 1973, J NEUROSURG, V39, P514, DOI 10.3171/jns.1973.39.4.0514
   Phi JH, 2010, NEUROSURGERY, V66, P221, DOI 10.1227/01.NEU.0000360378.84853.A0
   Tokimura H, 2011, NEUROSURG REV, V34, P57, DOI 10.1007/s10143-010-0296-z
   White PM, 2000, RADIOLOGY, V217, P361, DOI 10.1148/radiology.217.2.r00nv06361
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 165
EP 170
DI 10.1016/j.wneu.2018.10.188
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100232
PM 30404062
DA 2020-05-12
ER

PT J
AU Gandhoke, GS
   Smith, KJ
   Pandya, YK
   Alan, N
   Kanter, AS
   Okonkwo, DO
AF Gandhoke, Gurpreet S.
   Smith, Kenneth J.
   Pandya, Yash K.
   Alan, Nima
   Kanter, Adam S.
   Okonkwo, David O.
TI Cost-Effectiveness of a Radio Frequency Hemostatic Sealer (RFHS) in
   Adult Spinal Deformity Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost-effectiveness; Radiofrequency hemostatic sealer; Spine deformity
   surgery
ID BLOOD-TRANSFUSION; BIPOLAR SEALER; ARTHROPLASTY; PROGRAM; US
AB BACKGROUND: Patients undergoing posterior spinal fusion surgery can lose a substantial amount of blood. This can prolong operative time and require transfusion of allogeneic blood components, which increases the risk of infection and can be the harbinger of serious complications. Does a saline-irrigated bipolar radiofrequency hemostatic sealer (RFHS) help reduce transfusion requirements?
   METHODS: In an observational cohort study, we compared transfusion requirements in 30 patients undergoing surgery for adult spinal deformity using the RFHS with that of a historical control group of 30 patients in which traditional hemostasis was obtained with bipolar electrocautery and matched them for blood loss-related variables. Total expense to the hospital for the RFHS, laboratory expenses, and blood transfusions was used for cost calculations. The incremental cost-effectiveness ratio was calculated using the number of blood transfusions avoided as the effectiveness payoff.
   RESULTS: Using a multivariable linear regression model, we found that only estimated blood loss (EBL) was an independent significant predictor of transfusion requirement in both groups. We evaluated the variables of age, EBL, time duration of surgery, preoperative hemoglobin, hemoglobin nadir during surgery, body mass index, length of stay, and number of levels operated on. Mean EBL was greater in the control group (2201 vs. 1416 mL, P = 0.0099). The number of transfusions also was greater in the control group (14.5 vs. 6.5, P = 0.0008). In the cost-effectiveness analysis, we found that the RFHS cost $108 more (compared with not using the RFHS) to avoid 1 unit of blood transfusion.
   CONCLUSIONS: The cost-effectiveness analysis revealed that if we are willing to pay $108 to avoid 1 unit of blood transfusion, the use of the RFHS is a reasonable choice to use in open surgery for adult spinal deformity.
C1 [Gandhoke, Gurpreet S.] St Lukes Hosp, Dept Neurosurg, Kansas City, MO 64111 USA.
   [Smith, Kenneth J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Smith, Kenneth J.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
   [Pandya, Yash K.; Alan, Nima; Kanter, Adam S.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA.
RP Gandhoke, GS (reprint author), St Lukes Hosp, Dept Neurosurg, Kansas City, MO 64111 USA.
EM Gurpreet.gandhoke@gmail.com
CR Alvarez JC, 2008, TRANSFUSION, V48, P519, DOI 10.1111/j.1537-2995.2007.01564.x
   Barsoum WK, 2011, J BONE JOINT SURG AM, V93A, P513, DOI 10.2106/JBJS.J.00036
   Frank SM, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0050-2
   Geller David A, 2005, HPB (Oxford), V7, P208, DOI 10.1080/13651820510028945
   Huang ZY, 2015, ORTHOPEDICS, V38, P757, DOI 10.3928/01477447-20151119-07
   Mankin KP, 2012, J SPINAL DISORD TECH, V25, P259, DOI 10.1097/BSD.0b013e3182334ec5
   Marulanda GA, 2008, EXPERT REV MED DEVIC, V5, P125, DOI 10.1586/17434440.5.2.125
   Marulanda German A, 2005, Surg Technol Int, V14, P281
   Paul JE, 2007, CAN J ANAESTH, V54, P799, DOI 10.1007/BF03021707
   Roehr B, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5721
   Toner RW, 2011, APPL HEALTH ECON HEA, V9, P29, DOI 10.2165/11530740-000000000-00000
   Waters JH, 2011, TRANSFUSION, V51, P2126, DOI 10.1111/j.1537-2995.2011.03111.x
   Williamson K R, 1990, J Clin Apher, V5, P100
NR 13
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 171
EP 175
DI 10.1016/j.wneu.2018.10.131
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100233
PM 30391604
DA 2020-05-12
ER

PT J
AU Lavrador, JP
   Kandeel, H
   Patel, S
   Jung, J
   Acharya, S
   Giamouriadis, A
   Ashkan, K
   Bhangoo, R
   Vergani, F
AF Lavrador, Jose Pedro
   Kandeel, Hussein
   Patel, Sabina
   Jung, Josephine
   Acharya, Shami
   Giamouriadis, Anastasios
   Ashkan, Keyoumars
   Bhangoo, Ranjeev
   Vergani, Francesco
TI Navigated Transcranial Magnetic Stimulation in Patient with Cranioplasty
   in Situ: Safe and Accurate Procedure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranioplasty; Mapping; Safety; Transmagnetic stimulation
ID ELECTROMAGNETIC-FIELDS; CRANIOTOMY; SURGERY; RISK; TMS; GLIOBLASTOMA;
   TOLERABILITY; INFECTION; IMPLANTS; IMPROVES
AB BACKGROUND: Navigated transcranial magnetic stimulation (nTMS) is a nonsurgical mapping technique used in mapping of motor and language eloquent areas within and/or surrounding brain tumors. Previous reports support this as a safe technique with minor side effects associated with minor headaches and discomfort around the stimulation area. Currently there are no published reports concerning the accuracy and safety of this procedure in patients with a titanium cranioplasty in situ.
   CASE PRESENTATION: A 59-year-old lady was diagnosed with a recurrent glioma in the context of increasing seizure frequency, left-sided numbness, and weakness. She was diagnosed with a World Health Organization grade 2 oli-godendroglioma 10 years before her presentation, which was initially treated with radiotherapy and then surgical resection of this lesion 5 years later. The procedure was complicated with a wound infection, treated with a craniectomy and wound washout, followed by a titanium cranioplasty. Before proceeding with surgery for recurrence, nTMS was performed for motor mapping. No complications were identified. She underwent a craniotomy for tumor resection with aminolevulinic acid HCl (Gliolan), and the tumor was completely removed. Intraoperatively, the direct cortical stimulation correlated with the preoperative nTMS. The pathologic diagnosis on recurrence was an anaplastic oligoden-droglioma grade III, and the patient is currently undergoing adjuvant chemotherapy.
   CONCLUSION: This report confirms that nTMS is a safe and accurate procedure in patients who have a titanium cranioplasty in situ.
C1 [Lavrador, Jose Pedro; Kandeel, Hussein; Patel, Sabina; Acharya, Shami; Giamouriadis, Anastasios; Ashkan, Keyoumars; Bhangoo, Ranjeev; Vergani, Francesco] Kings Coll Hosp London, Dept Neurosurg, London, England.
   [Jung, Josephine] Kings Coll Hosp London, Neurosci Clin Trials Unit, London, England.
RP Kandeel, H (reprint author), Kings Coll Hosp London, Dept Neurosurg, London, England.
EM Hussein.kandeel@nhs.net
OI Kandeel, Hussein/0000-0002-8264-9094
CR Chen YR, 2018, WORLD NEUROSURG, V113, pE179, DOI 10.1016/j.wneu.2018.01.211
   Crouzier D, 2012, ORTHOP TRAUMATOL-SUR, V98, P90, DOI 10.1016/j.otsr.2011.08.012
   Dashti SR, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E10
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Hoosein Sharon, 2006, Axone, V28, P15
   Krieg SM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00261
   Lefaucheur JP, 2016, NEUROPHYSIOL CLIN, V46, P125, DOI 10.1016/j.neucli.2016.05.001
   Lipton RB, 2010, LANCET NEUROL, V9, P373, DOI 10.1016/S1474-4422(10)70054-5
   McCutcheon BA, 2016, WORLD NEUROSURG, V88, P350, DOI 10.1016/j.wneu.2015.12.068
   Nossek E, 2013, J NEUROSURG, V118, P243, DOI 10.3171/2012.10.JNS12511
   Picht T, 2016, J NEURO-ONCOL, V126, P535, DOI 10.1007/s11060-015-1993-9
   Rosenstock T, 2017, J NEUROSURG, V126, P1227, DOI 10.3171/2016.4.JNS152896
   Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016
   Tarapore PE, 2016, CLIN NEUROPHYSIOL, V127, P1895, DOI 10.1016/j.clinph.2015.11.042
   Tarapore PE, 2016, CLIN NEUROPHYSIOL, V127, P1916, DOI 10.1016/j.clinph.2015.11.043
   Tully PA, 2016, NEUROSURGERY, V79, P678, DOI 10.1227/NEU.0000000000001338
   Uppstrom TJ, 2016, CLIN NEUROL NEUROSUR, V151, P18, DOI 10.1016/j.clineuro.2016.09.013
   Virtanen H, 2006, BIOELECTROMAGNETICS, V27, P431, DOI 10.1002/bem.20224
   Wallace DJ, 2018, NEUROSURG REV, V41, P1071, DOI 10.1007/s10143-018-0955-z
   Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 176
EP 179
DI 10.1016/j.wneu.2018.09.198
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100234
PM 30296623
DA 2020-05-12
ER

PT J
AU Qin, RQ
   Liu, BS
   Zhou, P
   Yao, Y
   Hao, J
   Yang, K
   Xu, TL
   Zhang, F
   Chen, XQ
AF Qin, Rongqing
   Liu, Baoshan
   Zhou, Pin
   Yao, Yu
   Hao, Jie
   Yang, Kai
   Xu, Tian Li
   Zhang, Feng
   Chen, Xiaoqing
TI Minimally Invasive Versus Traditional Open Transforaminal Lumbar
   Interbody Fusion for the Treatment of Single-Level Spondylolisthesis
   Grades 1 and 2: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Lumbar spondylolisthesis; Meta-analysis; Minimal invasive;
   Transforaminal lumbar interbody fusion
ID OPEN SURGERY; CLINICAL-OUTCOMES; POSTERIOR; ANTERIOR
AB OBJECTIVE: To compare the clinical efficacy and safety between minimally invasive and traditional open transforaminal lumbar interbody fusion in the treatment of single-level spondylolisthesis grades 1 and 2.
   METHODS: This was a systematic review and meta-analysis. A comprehensive literature retrieval was performed in 3 electronic databases (PubMed, Embase, and Cochrane library). Randomized or nonrandomized controlled studies published from January 2000 to April 2018 that compared minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) with traditional open transforaminal lumbar interbody fusion (TO-TLIF) for treating single-level spondylolisthesis grades 1 and 2 were retrieved. Quality of included studies were evaluated by the modified Jadad scale. Data were extracted according to the predefined clinical outcome measures, including preoperative and postoperative back pain visual analogue scale and Oswestry Disability Index score; operation time and estimated intraoperative blood loss; length of hospitalization; and the complications, reoperation, and fusion rate.
   RESULTS: Six studies (n = 394 patients) were finally included. Two were randomized controlled trials and the remaining 4 were prospective or retrospective cohort studies. The pooled data revealed that both techniques had similar preoperative and last follow-up back pain visual analogue scale scores, complication rate, reoperation rate, and fusion rate. However, with the exception of more operation time, MIS-TLIF was associated with less intraoperative blood loss, shorter hospital stay, and better long-term functional outcome when compared with TO-TLIF.
   CONCLUSIONS: Based on the available evidence, MIS-TLIF appears to be a more efficacious and safe technique with reduced tissue trauma, quicker postoperative recovery, and better long-term functional outcome for the treatment of single-level spondylolisthesis grades 1 and 2.
C1 [Qin, Rongqing; Liu, Baoshan; Yang, Kai; Xu, Tian Li] Nantong Univ, Med Coll, Nantong, Jiangsu, Peoples R China.
   [Qin, Rongqing; Yao, Yu; Hao, Jie; Yang, Kai; Xu, Tian Li; Zhang, Feng; Chen, Xiaoqing] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Jiangsu, Peoples R China.
   [Yao, Yu; Hao, Jie; Zhang, Feng; Chen, Xiaoqing] Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Jiangsu, Peoples R China.
   [Zhou, Pin] Gaoyou Hosp Integrated Tradit Chinese & Western M, Dept Orthoped, Gaoyou, Jiangsu, Peoples R China.
RP Chen, XQ (reprint author), Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Jiangsu, Peoples R China.; Chen, XQ (reprint author), Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Jiangsu, Peoples R China.
EM xq.c@live.com
OI Qin, Rongqing/0000-0003-1894-8361
CR Adogwa O, 2011, J SPINAL DISORD TECH, V24, P479, DOI 10.1097/BSD.0b013e3182055cac
   Archavlis E, 2013, EUR SPINE J, V22, P1731, DOI 10.1007/s00586-013-2732-6
   Brodano GB, 2015, J SPINAL DISORD TECH, V28, pE559, DOI 10.1097/BSD.0000000000000034
   Fan SW, 2010, SPINE, V35, P1615, DOI 10.1097/BRS.0b013e3181c70fe3
   Foley Kevin T, 2002, Clin Neurosurg, V49, P499
   Goldstein CL, 2014, CLIN ORTHOP RELAT R, V472, P1727, DOI 10.1007/s11999-014-3465-5
   Gu GF, 2014, INT ORTHOP, V38, P817, DOI 10.1007/s00264-013-2169-x
   HARMS J, 1982, Z ORTHOP GRENZGEB, V120, P343, DOI 10.1055/s-2008-1051624
   Kaloostian PE, 2014, WORLD NEUROSURG, V82, P65, DOI 10.1016/j.wneu.2013.01.117
   Karikari IO, 2010, SPINE, V35, pS294, DOI 10.1097/BRS.0b013e3182022ddc
   Khan NR, 2015, NEUROSURGERY, V77, P847, DOI 10.1227/NEU.0000000000000913
   Lee JC, 2012, SPINE, V37, P1548, DOI 10.1097/BRS.0b013e318252d44b
   Lee MJ, 2018, J AM ACAD ORTHOP SUR, V26, P124, DOI 10.5435/JAAOS-D-15-00756
   Lee N, 2017, WORLD NEUROSURG, V101, P216, DOI 10.1016/j.wneu.2017.01.114
   Lee WC, 2016, WORLD NEUROSURG, V85, P236, DOI 10.1016/j.wneu.2015.09.009
   Lin Y, 2006, J NEUROL SURG PART A, V77, P2
   Majid K, 2008, J AM ACAD ORTHOP SUR, V16, P208, DOI 10.5435/00124635-200804000-00004
   MEYERDING H W, 1956, J Int Coll Surg, V26, P566
   Mobbs RJ, 2012, J CLIN NEUROSCI, V19, P829, DOI 10.1016/j.jocn.2011.10.004
   Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263
   Parker SL, 2014, WORLD NEUROSURG, V82, P230, DOI 10.1016/j.wneu.2013.01.041
   Parker SL, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.013
   Phan K, 2015, EUR SPINE J, V24, P1017, DOI 10.1007/s00586-015-3903-4
   Rodriguez-Vela J, 2013, EUR SPINE J, V22, P2857, DOI 10.1007/s00586-013-2853-y
   Saetia Kriangsak, 2013, Journal of the Medical Association of Thailand, V96, P41
   Scheufler KM, 2007, NEUROSURGERY, V60, P203, DOI 10.1227/01.NEU.0000255388.03088.B7
   Schizas C, 2009, INT ORTHOP, V33, P1683, DOI 10.1007/s00264-008-0687-8
   Seng CS, 2013, SPINE, V38, P2049, DOI 10.1097/BRS.0b013e3182a8212d
   Serban D, 2017, BIOMED RES INT, V2017, P1
   Singh K, 2014, SPINE J, V14, P1694, DOI 10.1016/j.spinee.2013.10.053
   Tian NF, 2013, EUR SPINE J, V22, P1741, DOI 10.1007/s00586-013-2747-z
   Tian W, 2017, CLIN SPINE SURG, V30, P237, DOI 10.1097/BSD.0000000000000165
   Tsahtsarlis A, 2012, EUR SPINE J, V21, P2300, DOI 10.1007/s00586-012-2376-y
   Wang HL, 2011, CHINESE MED J-PEKING, V124, P3868, DOI 10.3760/cma.j.issn.0366-6999.2011.23.007
   Wang J, 2014, SPINE J, V14, P2078, DOI 10.1016/j.spinee.2013.12.016
   Wang JA, 2010, EUR SPINE J, V19, P1780, DOI 10.1007/s00586-010-1404-z
   Weinstein JN, 2007, NEW ENGL J MED, V356, P2257, DOI 10.1056/NEJMoa070302
   Wong AP, 2014, NEUROSURG CLIN N AM, V25, P279, DOI 10.1016/j.nec.2013.12.007
   Wu MH, 2017, SPINE J, V17, P1082, DOI 10.1016/j.spinee.2017.04.002
   Wu RH, 2010, SPINE, V35, P2273, DOI 10.1097/BRS.0b013e3181cd42cc
NR 40
TC 2
Z9 3
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 180
EP 189
DI 10.1016/j.wneu.2018.10.202
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100235
PM 30414524
DA 2020-05-12
ER

PT J
AU Mishra, A
   Prabhuraj, AR
   Bhat, D
   Nandeesh, BN
   Mhatre, R
AF Mishra, Ajit
   Prabhuraj, A. R.
   Bhat, Dhananjay
   Nandeesh, Bevinahalli N.
   Mhatre, Radhika
TI Intracranial Actinomycosis Manifesting as a Parenchymal Mass Lesion: A
   Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Actinomycosis; Cranial; Mass lesion; Parenchymal
AB BACKGROUND: Intracranial actinomycosis is a rare bacterial infection with no characteristic clinical or radiologic diagnostic features. The usual presentation is similar to pyogenic brain abscess or osteomyelitis with or without pachymeningitis. Intracranial actinomycosis rarely manifests as a parenchymal mass lesion. A high index of suspicion is warranted in a patient with immunosuppression or predisposing factors, such as dental procedure, sinusitis, cardiac septal defect, craniofacial trauma, cranial surgery, lung infection, or abdominopelvic infection.
   CASE DESCRIPTION: A young woman presented with a right parietal parenchymal lesion with involvement of the calvaria and pericranium. She had no predisposing factors for intracranial actinomycosis. She underwent complete microsurgical excision of the lesion followed by prolonged antibiotic therapy. She experienced a good functional recovery.
   CONCLUSIONS: Intracranial actinomycosis manifesting as a parenchymal mass lesion is extremely rare compared with abscess and pachymeningitis. Histopathologic examination remains the mainstay of definitive diagnosis, as culture may be negative in significant number of cases. Aggressive surgical excision with prolonged antibiotic therapy enhances the chances of a good functional outcome.
C1 [Mishra, Ajit; Prabhuraj, A. R.; Bhat, Dhananjay] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bengaluru, India.
   [Nandeesh, Bevinahalli N.; Mhatre, Radhika] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bengaluru, India.
RP Prabhuraj, AR (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bengaluru, India.
EM drprabhuraj@yahoo.co.in
OI Bhat, Dhananjaya/0000-0001-8595-8311
CR Akhaddar A, 2010, WORLD NEUROSURG, V74, P346, DOI 10.1016/j.wneu.2010.05.029
   Chopra S, 1995, ANN SAUDI MED, V15, P515, DOI 10.5144/0256-4947.1995.515
   Deora Harsh, 2018, Surg Neurol Int, V9, P39, DOI 10.4103/sni.sni_445_17
   KHOSLA VK, 1984, J NEUROSURG, V60, P204, DOI 10.3171/jns.1984.60.1.0204
   Mohindra S, 2012, NEUROL INDIA, V60, P325, DOI 10.4103/0028-3886.98527
   Ravindra N, 2018, WORLD NEUROSURG, V116, pE362, DOI 10.1016/j.wneu.2018.04.205
   SMEGO RA, 1987, REV INFECT DIS, V9, P855
   Sundaram C, 2004, CLIN NEUROPATHOL, V23, P173
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 190
EP 194
DI 10.1016/j.wneu.2018.10.134
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100236
PM 30391617
DA 2020-05-12
ER

PT J
AU Qian, H
   Wang, L
   Brooks, KS
   Zhao, XC
   Shi, XE
   Lei, T
AF Qian, Hai
   Wang, Long
   Brooks, Kenneth Scott
   Zhao, Xiaochun
   Shi, Xiang'en
   Lei, Ting
TI MCA-to-MCA Bypass with Interposition Graft for Ruptured Mycotic Middle
   Cerebral Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Interpositional bypass; Middle cerebral artery aneurysm; Mycotic
   aneurysm; Ruptured Aneurysm
ID PREVENTION; SURGERY; DEXTRAN
AB Mycotic aneurysm, also referred to as infected aneurysm, is a rare entity that may result from the bacterial infection or infective endocarditis.(1-3) The treatment options include conservative medication and endovascular or direct microsurgical intervention.(1,4,5) However, the optimal strategy remains unknown and cerebral revascularization may be required in some rare cases.(6) In this surgical video, we demonstrate a distal middle cerebral artery (MCA) mycotic aneurysm that we treated by intracranial-intracranial bypass with an interpositional graft.
   Our patient is a 53-year-old male who presented with a 6-day history of severe headache. He was subsequently admitted to our institution. Preoperative computed tomography angiography showed a left temporal hematoma (>30 mL) and an opercular segment of the MCA (M3) aneurysm, which was highly suspicious for mycotic origin. A standard frontotemporal craniotomy was carried out with preservation of superficial temporal artery (STA). Following the sylvian fissure dissection, the aneurysm was exposed with the characteristics of a thick wall and an undefinable neck, which made direct clip application difficult. The aneurysm was resected initially, and 2 cut ends were reconnected by an STA graft. Following arterial reconstruction, intraoperative Doppler revealed a patent status of the interpositional graft vessel. Postoperatively, no neurologic deficit was observed and computed tomography angiography demonstrated total elimination of the aneurysm without stenosis of the graft vessel. Low-molecular dextran was prescribed rather than aspirin, as there was concern for hemorrhage. Antibiotic treatment was used for at least 4 weeks, and the patient was transferred to the inpatient cardiology team for management of endocarditis. A 4-month follow-up angiogram showed a patent STA and excellent left distalMCA blood flow(Video 1). The favorable outcome of this case revealed that MCA-to-MCA bypass with interpositional graft is a safe, effective method for the unclippable cerebral aneurysm. As other authors have asserted, a full dose of long-term antibiotic therapy remains essential following intervention.(7) Meanwhile, dextran has proved to be a viable alternative for anticoagulation during perioperative management of bypass surgery.(8,9)
C1 [Qian, Hai; Wang, Long; Zhao, Xiaochun; Shi, Xiang'en; Lei, Ting] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Brooks, Kenneth Scott] Univ Arizona, Coll Med, Tucson, AZ USA.
RP Lei, T (reprint author), Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xiaobailt@hotmail.com
RI WANG, LONG/AAI-5029-2020
OI LEI, TING/0000-0002-4407-5253
CR Abecassis IJ, 2013, CLIN NEUROL NEUROSUR, V115, P2393, DOI 10.1016/j.clineuro.2013.08.026
   Burkhardt JK, 2018, OPER NEUROSURG, V15, P601, DOI 10.1093/ons/opx301
   Artal FJC, 2016, EXPERT REV NEUROTHER, V16, P205, DOI 10.1586/14737175.2015.1134321
   Ding D, 2014, J CLIN NEUROSCI, V21, P1163, DOI 10.1016/j.jocn.2013.11.013
   Esenkaya A, 2016, NEURORADIOLOGY, V58, P277, DOI 10.1007/s00234-015-1633-2
   Flor-de-Lima F, 2013, EUR J PEDIATR, V172, P1285, DOI 10.1007/s00431-013-2032-5
   FOSTER JH, 1966, ANN SURG, V163, P764, DOI 10.1097/00000658-196605000-00013
   Lin CT, 2017, WORLD NEUROSURG, V100, DOI 10.1016/j.wneu.2017.01.076
   Logason K, 2001, EUR J VASC ENDOVASC, V21, P261, DOI 10.1053/ejvs.2001.1332
NR 9
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 195
EP 195
DI 10.1016/j.wneu.2018.10.167
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100237
PM 30391761
DA 2020-05-12
ER

PT J
AU Rajasekar, G
   Nair, P
   Abraham, M
   Jaiswal, P
   Deepti, AN
AF Rajasekar, Gopikrishnan
   Nair, Prakash
   Abraham, Mathew
   Jaiswal, Palak
   Deepti, A. N.
TI Endoscopic Endonasal Repair of a Persistent Craniopharyngeal Canal and
   Sphenoid Meningoencephalocele: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endonasal repair; Endoscopic repair; Persistent craniopharyngeal canal;
   Sphenoidal meningoencephalocele
ID CEREBROSPINAL-FLUID LEAKS; RHINORRHEA
AB BACKGROUND: A persistent craniopharyngeal canal (PCC) is a rare cause of cerebrospinal fluid rhinorrhea in children. The condition often coexists with other midline facial defects, such as cleft palate. Children with PCC may also have pituitary dysfunction or neoplasms, such as craniopharyngiomas within the canal.
   CASE DESCRIPTION: A 5-year-old girl presented with bacterial meningitis and active cerebrospinal fluid rhinorrhea from her left nostril. Imaging showed a large nasopharyngeal meningoencephalocele, communicating with the sub-arachnoid space through a persistent craniopharyngeal canal. An endonasal approach was chosen to excise the PCC and meningoencephalocele and to repair the resulting skull base defect.
   CONCLUSIONS: The extended endonasal approach can be used to treat PCC with nasopharyngeal encephaloceles in young children. The approach is suitable to address both conditions at the same time. The extended endonasal approach avoids potentially morbid transfacial approaches and can help in earlier recovery after surgery.
C1 [Rajasekar, Gopikrishnan; Nair, Prakash; Abraham, Mathew; Jaiswal, Palak] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurosurg, Trivandrum, Kerala, India.
   [Deepti, A. N.] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Pathol, Trivandrum, Kerala, India.
RP Nair, P (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurosurg, Trivandrum, Kerala, India.
EM drprakashnair@gmail.com
CR Abele TA, 2014, AM J NEURORADIOL, V35, P772, DOI 10.3174/ajnr.A3745
   Akyel NG, 2018, CHILD NERV SYST, V34, P1407, DOI 10.1007/s00381-018-3747-4
   AREY LB, 1950, ANAT REC, V106, P1, DOI 10.1002/ar.1091060102
   Biswas S, 2015, BJR CASE REP, V1, DOI 10.1259/bjrcr.20150022
   Alonso RC, 2013, RADIOGRAPHICS, V33, P553, DOI 10.1148/rg.332125028
   Casiano RR, 1999, OTOLARYNG HEAD NECK, V121, P745, DOI 10.1053/hn.1999.v121.a98754
   Chen CJ, 2001, NEURORADIOLOGY, V43, P760, DOI 10.1007/s002340100581
   COHEN R, 1989, AM J NEURORADIOL, V10, P652
   CURRARINO G, 1985, AM J NEURORADIOL, V6, P39
   Formica F, 2002, CHILD NERV SYST, V18, P295, DOI 10.1007/s00381-002-0578-z
   FRITSCH MJ, 2000, OPER TECH NEUROSURG, V3, P25
   Hoff SR, 2014, J NEUROL SURG PART B, V75, P96, DOI 10.1055/s-0033-1358374
   Holanda Maurus Marques de Almeida, 2011, Radiol Bras, V44, P399, DOI 10.1590/S0100-39842011000600013
   Hughes ML, 1999, BRIT J RADIOL, V72, P204, DOI 10.1259/bjr.72.854.10365075
   Kassam A, 2007, J NEUROSURG, V106, P75, DOI 10.3171/ped.2007.106.2.75
   Kau T, 2011, CHILD NERV SYST, V27, P771, DOI 10.1007/s00381-010-1326-4
   Kizilkilic O, 2005, AM J NEURORADIOL, V26, P65
   LEELA K, 1971, FOLIA PRIMATOL, V14, P118, DOI 10.1159/000155341
   Ma JY, 2015, CHILD NERV SYST, V31, P1493, DOI 10.1007/s00381-015-2746-y
   Marsot-Dupuch K, 2004, AM J NEURORADIOL, V25, P285
   Mohindra S, 2015, NEUROL INDIA, V63, P434, DOI 10.4103/0028-3886.158243
   Nyquist GG, 2010, J NEUROSURG, V113, P961, DOI 10.3171/2009.10.JNS08986
   Pinilla-Arias D, 2009, NEUROCIRUGIA, V20, P50
NR 23
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 196
EP 202
DI 10.1016/j.wneu.2018.10.138
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100238
PM 30391602
DA 2020-05-12
ER

PT J
AU Omoto, K
   Nakagawa, I
   Park, HS
   Wada, T
   Motoyama, Y
   Kichikawa, K
   Nakase, H
AF Omoto, Koji
   Nakagawa, Ichiro
   Park, Hun Soo
   Wada, Takeshi
   Motoyama, Yasushi
   Kichikawa, Kimihiko
   Nakase, Hiroyuki
TI Successful Emergent Endovascular Mechanical Thrombectomy for Pediatric
   and Young Adult Cerebral Venous Sinus Thrombosis in Coma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous sinus thrombosis; Endovascular mechanical thrombectomy;
   Pediatric
ID RHEOLYTIC THROMBECTOMY; OCCLUSION; CHILDREN
AB BACKGROUND: Cerebral venous sinus thrombosis (CVST) is a relatively uncommon cause of stroke in pediatric patients and young adults. The clinical course of CVST is also highly variable. In particular, coma has been noted as a predictor of poor outcome. The standard treatment for CVST in adults is systemic anticoagulation, which can lead to recanalization. Endovascular mechanical thrombectomy (EMT) is considered as possibly indicated in the event of failure to respond to anticoagulation or a comatose state. However, the role of endo-vascular therapy in the management of pediatric and young adult CVST is unclear. Here, we describe 3 cases of successful emergent EMT for pediatric and young adult CVST presenting in a comatose state.
   CASE DESCRIPTION: A 17-year-old boy presented with rapid deterioration and a comatose state despite anticoagulation using heparin. Emergent EMT was performed for CVST. Balloon percutaneous transmural angioplasty and catheter aspiration were repeatedly performed, and partial recanalization of the superior sagittal sinus was achieved by the end of the procedure. The child was discharged without neurologic deficits. Another 2 comatose cases with CVST underwent emergent EMT with balloon percutaneous transmural angioplasty and catheter aspiration, and partial recanalization was again achieved. These patients finally showed complete superior sagittal sinus recanalization and were discharged without neurologic deficits.
   CONCLUSION: Pediatric and young comatose CVST warrants endovascular mechanical thrombectomy as soon as possible.
C1 [Omoto, Koji; Nakagawa, Ichiro; Park, Hun Soo; Motoyama, Yasushi; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Nara, Japan.
   [Wada, Takeshi; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Nara, Japan.
RP Nakagawa, I (reprint author), Nara Med Univ, Dept Neurosurg, Nara, Japan.
EM nakagawa@nmu-gw.naramed-u.ac.jp
CR Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7
   Canhao P, 2003, CEREBROVASC DIS, V15, P159, DOI 10.1159/000068833
   Carvalho KS, 2001, J CHILD NEUROL, V16, P574, DOI 10.1177/088307380101600807
   de Bruijn SFTM, 2001, J NEUROL NEUROSUR PS, V70, P105, DOI 10.1136/jnnp.70.1.105
   Einhaupl K, 2006, EUR J NEUROL, V13, P553, DOI 10.1111/j.1468-1331.2006.01398.x
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   Grunt S, 2010, DEV MED CHILD NEUROL, V52, P1145, DOI 10.1111/j.1469-8749.2010.03722.x
   Ilyas A, 2017, J NEUROINTERV SURG, V9, P1086, DOI 10.1136/neurintsurg-2016-012938
   Jankowitz BT, 2013, J NEUROINTERV SURG, V5, P534, DOI 10.1136/neurintsurg-2012-010476
   Kanaiwa H, 1995, SURG NEUROL, V44, P172, DOI 10.1016/0090-3019(95)00126-3
   La Barge DV, 2009, AM J NEURORADIOL, V30, P1672, DOI 10.3174/ajnr.A1677
   Lee DJ, 2017, J NEUROINTERV SURG, V9, P34, DOI 10.1136/neurintsurg-2015-012237
   Modi K, 2009, J NEUROIMAGING, V19, P366, DOI 10.1111/j.1552-6569.2008.00311.x
   Mokin M, 2015, INTERV NEURORADIOL, V21, P520, DOI 10.1177/1591019915583015
   Mortimer AM, 2013, PEDIATR NEUROL, V49, P305, DOI 10.1016/j.pediatrneurol.2013.07.008
   Renowden S, 2004, EUR RADIOL, V14, P215, DOI 10.1007/s00330-003-2021-6
   Schaller B, 2003, AM J NEURORADIOL, V24, P1876
   Sebire G, 2005, BRAIN, V128, P477, DOI 10.1093/brain/awh412
   Siddiqui FM, 2015, STROKE, V46, P1263, DOI 10.1161/STROKEAHA.114.007465
   Teksam M, 2008, AM J NEURORADIOL, V29, P1961, DOI 10.3174/ajnr.A1246
   Zhang A, 2008, NEUROCRIT CARE, V9, P17, DOI 10.1007/s12028-008-9058-y
NR 21
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 203
EP 208
DI 10.1016/j.wneu.2018.10.189
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100239
PM 30404063
DA 2020-05-12
ER

PT J
AU Vigo, V
   Ortiz, RZ
   Paganelli, SL
   da Costa, MDS
   Campos, JM
   Chaddad-Neto, F
AF Vigo, Vera
   Ortiz, Robert Zanabria
   Paganelli, Samantha Lorena
   Silva da Costa, Marcos Devanir
   Campos Filho, Jose Maria
   Chaddad-Neto, Feres
TI Awake Craniotomy for Removal of Left Insular Cavernous Malformation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake craniotomy; Cavernous malformation; Insular anatomy;
   Microneuroanatomy
C1 [Vigo, Vera; Ortiz, Robert Zanabria; Paganelli, Samantha Lorena; Silva da Costa, Marcos Devanir; Campos Filho, Jose Maria; Chaddad-Neto, Feres] Univ Fed Sao Paulo, Dept Neurosurg, Sao Paulo, SP, Brazil.
   [Campos Filho, Jose Maria; Chaddad-Neto, Feres] Hosp Beneficencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil.
   [Vigo, Vera] Catholic Univ, Sch Med, Dept Neurosurg, Rome, Italy.
RP da Costa, MDS (reprint author), Univ Fed Sao Paulo, Dept Neurosurg, Sao Paulo, SP, Brazil.
EM marcoscostaneuro@gmail.com
OI Silva da Costa, Marcos Devanir/0000-0003-3552-6347
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 209
EP 209
DI 10.1016/j.wneu.2018.10.220
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100240
PM 30415050
DA 2020-05-12
ER

PT J
AU Reiss, S
   Zemmoura, I
   Joly, A
   Kun-Darbois, JD
   Laure, B
   Pare, A
AF Reiss, Segolene
   Zemmoura, Ilyess
   Joly, Aline
   Kun-Darbois, Jean-Daniel
   Laure, Boris
   Pare, Arnaud
TI Muscle Forehead Flap: Salvage Surgery for Closure of Cutaneous Fistula
   After Cranioplasty Exposure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranioplasty exposure; Forehead flap; Infection; Skin fistula
ID BASE
AB BACKGROUND: Infection and skin fistula are well-known complications after cranioplasty leading to reconstruction exposure and usually requiring new surgical procedure with poor condition for cutaneous closure. We describe 2 cases using muscle forehead flap (MFF) to treat skin fistula and cranioplasty exposure.
   CASE DESCRIPTION: The first case was a 43-year-old man who underwent a calvarial bone graft of the frontal sinus anterior wall after craniofacial trauma. Three months postoperatively, osteitis of the bone reconstruction and a skin fistula occurred in the median frontal region. The second case was a 37-year-old woman treated for a cingular glioblastoma by 3 surgeries, concomitant chemoradiation therapy, and frontal reconstruction using a titanium plate. She presented a plate exposure associated with cerebrospinal fluid leak and meningitis. Both patients were successfully treated by surgical removal of the frontal cranioplasty and skin closure using MFF. We observed a satisfying cosmetic result with no recurrence of infection or fistula at 12 and 4 months, respectively.
   CONCLUSIONS: MFF is a surgical option to treat complex cases of cutaneous fistula secondary to cranioplasty exposure of the anterior cranial fossa.
C1 [Reiss, Segolene; Joly, Aline; Laure, Boris; Pare, Arnaud] Univ Hosp Ctr Tours, Trousseau Hosp, Dept Maxillofacial & Facial Plast Surg, Tours, France.
   [Zemmoura, Ilyess] Univ Hosp Ctr Tours, Bretonneau Hosp, Dept Neurosurg, Tours, France.
   [Zemmoura, Ilyess; Laure, Boris; Pare, Arnaud] Univ Tours, Sch Med, Tours, France.
   [Zemmoura, Ilyess] Univ Tours, INSERM, UMR 1253, iBrain, Tours, France.
   [Kun-Darbois, Jean-Daniel] Univ Angers, Hosp Angers, Dept Maxillofacial Surg, Angers, France.
RP Pare, A (reprint author), Univ Hosp Ctr Tours, Trousseau Hosp, Dept Maxillofacial & Facial Plast Surg, Tours, France.; Pare, A (reprint author), Univ Tours, Sch Med, Tours, France.
EM Arnaud.pare@univ-tours.fr
RI Kun-Darbois, Jean-Daniel/AAD-6194-2019
OI Kun-Darbois, Jean-Daniel/0000-0002-0818-7856
CR Carloni R, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.116
   Ciporen J, 2017, TURK NEUROSURG, DOI [10.5137/1019-5149.JTN.20662-17.1, DOI 10.5137/1019-5149.JTN.20662-17.1]
   Griner D, 2014, ANN PLAS SURG, V72, pS121, DOI 10.1097/SAP.0000000000000105
   Newman J, 2003, SKULL BASE-INTERD AP, V13, P205, DOI 10.1055/s-2004-817696
   Noland ME, 2016, PLAST RECONSTR SURG, V138, p519E, DOI 10.1097/PRS.0000000000002480
   Noone MC, 2002, OTOLARYNG HEAD NECK, V127, P494, DOI 10.1067/mhn.2002.129737
   Tessier P, 2005, PLAST RECONSTR SURG, V116, p72S, DOI 10.1097/01.prs.0000173841.59063.7e
   Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3
   Williams LR, 2015, INT J ORAL MAX SURG, V44, P599, DOI 10.1016/j.ijom.2014.09.006
   Zhao JY, 2018, WORLD NEUROSURG, V112, pE514, DOI 10.1016/j.wneu.2018.01.070
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 210
EP 214
DI 10.1016/j.wneu.2018.10.184
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100241
PM 30404060
DA 2020-05-12
ER

PT J
AU Arai, S
   Ikeda, H
   Kawamo, M
   Kamiya, Y
   Mizutani, T
AF Arai, Shintaro
   Ikeda, Hisato
   Kawamo, Michiari
   Kamiya, Yuki
   Mizutani, Tohru
TI Surgical Rescue Retrieval of a Filter Protection Device in Carotid
   Artery Stenting with Stent Deformation: Case Report and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery stenting; Common carotid artery; Internal carotid artery;
   Neuroendovascular treatment; Severe calcification; Stent deformation
ID ANGIOPLASTY; PREVALENCE; FRACTURES
AB BACKGROUND: Despite the development of neuroendovascular treatment, device-related complications requiring surgical procedures remain. We report a case requiring surgical retrieval of a filter protection device in carotid artery stenting (CAS) with an open-cell stent, due to stent deformation, and review past reports on CAS in which surgical retrieval of devices was required.
   CASE DESCRIPTION: An 82-year-old man underwent CAS for symptomatic right internal carotid artery stenosis with severe calcification and tortuosity. Immediately after placement of the open-cell stent, stent deformation was detected and the filter protection device could not be retrieved. All noninvasive device retrieval attempts failed, and the device was ultimately retrieved surgically. After surgery, right cerebral infarction progressed increased, but no permanent deficit was observed.
   CONCLUSIONS: As the treatment of cerebrovascular disease shifts from surgical to endovascular approaches, surgeons must be familiar with devices and techniques to manage complications of neuroendovascular treatment.
C1 [Arai, Shintaro; Mizutani, Tohru] Showa Univ, Sch Med, Dept Neurosurg, Shinagawa, Tokyo, Japan.
   [Arai, Shintaro; Ikeda, Hisato; Kawamo, Michiari] Showa Univ, Koto Toyosu Hosp, Dept Neurosurg, Tokyo, Japan.
   [Kamiya, Yuki] Showa Univ, Koto Toyosu Hosp, Dept Neurol, Tokyo, Japan.
RP Arai, S (reprint author), Showa Univ, Sch Med, Dept Neurosurg, Shinagawa, Tokyo, Japan.; Arai, S (reprint author), Showa Univ, Koto Toyosu Hosp, Dept Neurosurg, Tokyo, Japan.
EM sarai@med.showa-u.ac.jp
CR Campbell JE, 2007, J ENDOVASC THER, V14, P600, DOI 10.1583/1545-1550(2007)14[600:EROAFM]2.0.CO;2
   Chang CK, 2011, J VASC SURG, V54, P685, DOI 10.1016/j.jvs.2011.03.257
   Coppi G, 2010, J VASC SURG, V51, P1397, DOI 10.1016/j.jvs.2010.02.009
   Cremonesi A, 2003, STROKE, V34, P1936, DOI 10.1161/01.STR.0000081000.23561.61
   Daugherty WP, 2008, AM J NEURORADIOL, V29, P1594, DOI 10.3174/ajnr.A1118
   Lee JH, 2014, INTERV NEURORADIOL, V20, P100, DOI 10.15274/INR-2014-10015
   Li T, 2016, J SURG CASE REP, V6, P1
   Lian XG, 2012, CARDIOVASC INTER RAD, V35, P43, DOI 10.1007/s00270-011-0117-y
   Ling AJ, 2008, J VASC SURG, V47, P1220, DOI 10.1016/j.jvs.2008.01.043
   Malik RK, 2009, J VASC SURG, V50, P216, DOI 10.1016/j.jvs.2009.01.040
   Nii K, 2015, J STROKE CEREBROVASC, V24, P210, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.022
   Page Paul, 2018, Surg Neurol Int, V9, P123, DOI 10.4103/sni.sni_32_18
   Seo KD, 2014, KOREAN J RADIOL, V15, P858, DOI 10.3348/kjr.2014.15.6.858
   Sfyroeras GS, 2010, J VASC SURG, V51, P1280, DOI 10.1016/j.jvs.2010.01.050
   Shilling Kimberly, 2006, Vasc Endovascular Surg, V40, P229, DOI 10.1177/153857440604000308
   Varcoe RL, 2008, J ENDOVASC THER, V15, P485, DOI 10.1583/08-2420R.1
   Vijayvergiya R, 2010, TEX HEART I J, V37, P226
   Vos A W Floris, 2004, Vascular, V12, P369
NR 18
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 215
EP 219
DI 10.1016/j.wneu.2018.10.214
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100242
PM 30415040
DA 2020-05-12
ER

PT J
AU Jain, N
   Tadghare, J
   Patel, A
AF Jain, Nilesh
   Tadghare, Jitendra
   Patel, Akhilesh
TI Epidermoid Cyst of the Cerebellopontine Angle Presenting with
   Contralateral Trigeminal Neuralgia: Extremely Rare Case and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebellopontine angle; Contralateral; Epidermoid cyst; Trigeminal
   neuralgia
ID FALSE LOCALIZING SIGN; MANAGEMENT
AB BACKGROUND: An epidermoid cyst is a rare tumor of the cerebellopontine angle region. It usually presents with ipsilateral compressive symptoms. The contralateral trigeminal neuralgia is an unusual presentation in such cases. We did not find such case reports in the literature.
   CASE DESCRIPTION: Here, we report a case of a 62-year-old female with a right cerebellopontine angle epidermoid cyst presenting with right hearing impairment and the contralateral trigeminal neuralgia.
   CONCLUSION: The possible mechanism leading to the contralateral trigeminal neuralgia is discussed here along with the diagnosis and management of the case.
C1 [Jain, Nilesh; Tadghare, Jitendra] Sri Aurobindo Med Coll & PG Inst, Dept Neurosurg, Indore, Madhya Pradesh, India.
   [Patel, Akhilesh] Sri Aurobindo Med Coll & PG Inst, Dept Gen Surg, Indore, India.
RP Tadghare, J (reprint author), Sri Aurobindo Med Coll & PG Inst, Dept Neurosurg, Indore, Madhya Pradesh, India.
EM manage_jitu@yahoo.co.in
CR Ahmed I, 2009, J NEUROSURG-PEDIATR, V4, P91, DOI 10.3171/2009.4.PEDS08489
   Barker FG, 1996, J NEUROSURG, V84, P818, DOI 10.3171/jns.1996.84.5.0818
   BERGER MS, 1985, J NEUROSURG, V62, P214, DOI 10.3171/jns.1985.62.2.0214
   Chowdhury Forhad Hossain, 2013, Asian J Neurosurg, V8, P21, DOI 10.4103/1793-5482.110276
   Dutt SN, 2002, OTOL NEUROTOL, V23, P84, DOI 10.1097/00129492-200201000-00019
   FLORENSA R, 1987, NEUROSURGERY, V20, P1
   HADDAD FS, 1990, NEUROSURGERY, V26, P1033, DOI 10.1227/00006123-199006000-00019
   JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145
   KOENIG M, 1984, NEUROSURGERY, V14, P335, DOI 10.1227/00006123-198403000-00014
   Matthies C, 1997, NEUROSURGERY, V40, P1
   Nobuki M, 1996, J NEUROSURG, V84, P1067
   Pikis S, 2016, J CLIN NEUROSCI, V33, P59, DOI 10.1016/j.jocn.2016.04.008
   Raghunath A, 2013, BRIT J NEUROSURG, V27, P69, DOI 10.3109/02688697.2012.703352
   Snow RB, 1987, NEUROSURGERY, V26, P1033
   Tancredi A, 2003, ACTA NEUROCHIR, V145, P905, DOI 10.1007/s00701-003-0008-3
   YASARGIL MG, 1989, NEUROSURGERY, V24, P561
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 220
EP 223
DI 10.1016/j.wneu.2018.10.204
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100243
PM 30414520
DA 2020-05-12
ER

PT J
AU Serrato-Avila, JL
   Navarro-Fernandez, JO
   Hernandez-Resendiz, R
   Cacho-Diaz, B
   Reyes-Soto, G
   Monroy-Sosa, A
AF Leonardo Serrato-Avila, Juan
   Omar Navarro-Fernandez, Jose
   Hernandez-Resendiz, Rodrigo
   Cacho-Diaz, Bernardo
   Reyes-Soto, Gervith
   Monroy-Sosa, Alejandro
TI Gelatin Paste as an Alternative Cost-Effective Hemostatic Agent in
   Cranial Surgery: Doing More with Less
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost-effective; Hemostasis; Hemostatic agent; Self-made; Surgical
   technique
ID INTRAOPERATIVE ANAPHYLAXIS; MATRIX; SEALANT
AB OBJECTIVE: To present an alternative cost-effective hemostatic agent ( HA) for cranial surgery and to describe the technique to produce it.
   METHODS: This HA has been used in 3 reference centers over the last year during 230 procedures, including different types of pathology, such as skull base, oncology, vascular, and trauma, either for endoscopic or open approaches. This agent was made from a low-cost and worldwide-available gelatin foam which was mixed with saline solution in 2 syringes and connected by a 3-way stopcock, making a useful hemostatic paste.
   RESULTS: The cost was 16 and 28 times less than SURGIFLO and FLOSEAL, respectively. The mean time to prepare the mix was 4 minutes. It was very effective for venous and low-flow bleeding.
   CONCLUSIONS: The presented technique offers a reliable and cost-effective way of achieving hemostasis in cranial surgery, therefore allowing hospitals with limited resources to perform advanced procedures in a safer way.
C1 [Leonardo Serrato-Avila, Juan] ISSSTE, Natl Med Ctr 20 November, Dept Neurosurg, Mexico City, DF, Mexico.
   [Omar Navarro-Fernandez, Jose; Cacho-Diaz, Bernardo; Reyes-Soto, Gervith; Monroy-Sosa, Alejandro] Natl Canc Inst, Neurosci Unit, Head & Neck Dept, Mexico City, DF, Mexico.
   [Hernandez-Resendiz, Rodrigo] PEMEX, South Cent High Specialty Hosp, Dept Neurol & Neurosurg, Mexico City, DF, Mexico.
RP Serrato-Avila, JL (reprint author), ISSSTE, Natl Med Ctr 20 November, Dept Neurosurg, Mexico City, DF, Mexico.
EM jls_avila@hotmail.com
RI Fernandez, Jose Omar Navarro/B-9955-2017
OI Fernandez, Jose Omar Navarro/0000-0003-2973-035X; Monroy Sosa,
   Alejandro/0000-0001-7107-6166; Cacho-Diaz, Bernardo/0000-0001-9289-5312
CR Agarwal NS, 2015, J ALLER CL IMM-PRACT, V3, P110, DOI 10.1016/j.jaip.2014.05.010
   Alonso F, 2017, WORLD NEUROSURG, V108, P90, DOI 10.1016/j.wneu.2017.08.154
   Cappabianca P, 2009, ACTA NEUROCHIR, V151, P69, DOI 10.1007/s00701-008-0172-6
   Ellegala DB, 2002, NEUROSURGERY, V51, P513, DOI 10.1097/00006123-200208000-00041
   Ereth MH, 2008, NEUROSURGERY, V63, P369, DOI 10.1227/01.NEU.0000327031.98098.DD
   Fiss I, 2007, NEUROL MED-CHIR, V47, P462, DOI 10.2176/nmc.47.462
   Gazzeri R, 2009, J NEUROSURG, V110, P939, DOI 10.3171/2008.8.JNS17642
   Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D
   Kassam Amin, 2005, Neurosurg Focus, V19, pE7
   Katsumori T, 2006, CARDIOVASC INTER RAD, V29, P1077, DOI 10.1007/s00270-006-0059-y
   Makhija D, 2017, J MED ECON, V20, P606, DOI 10.1080/13696998.2017.1292916
   Price JS, 2015, J MED ECON, V18, P777, DOI 10.3111/13696998.2015.1046879
   Spencer HT, 2012, SPINE J, V12, pE1, DOI 10.1016/j.spinee.2012.08.425
   Stokes ME, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-135
NR 14
TC 2
Z9 2
U1 3
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 224
EP 228
DI 10.1016/j.wneu.2018.10.224
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100244
PM 30415038
DA 2020-05-12
ER

PT J
AU Zhang, SM
   Wang, WN
   Su, XR
   Tan, QY
   Sun, HQ
   Liu, ZF
   Chen, N
   Gong, QY
   Yue, Q
AF Zhang, Simin
   Wang, Weina
   Su, Xiaorui
   Tan, Qiaoyue
   Sun, Huaiqiang
   Liu, Zefan
   Chen, Ni
   Gong, Qiyong
   Yue, Qiang
TI Amelanotic Meningeal Melanoma with Leptomeningeal Dissemination: A Case
   Report and Systematic Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Amelanotic melanoma; Diffusion-weighted imaging; Dynamic susceptibility
   contrast perfusion-weighted imaging; Functional MRI; Proton MR
   spectroscopy
ID MAGNETIC-RESONANCE-SPECTROSCOPY; PRIMITIVE CEREBRAL MELANOMA; PRIMARY
   MALIGNANT-MELANOMA; CENTRAL-NERVOUS-SYSTEM; CNS MELANOMA; IN-VIVO; MR;
   DIAGNOSIS; TUMOR; PROGRESSION
AB BACKGROUND: Meningeal melanoma is a rare tumor of the central nervous system, whose amelanotic variant is called "amelanotic meningeal melanoma" (AMM). AMM does not produce melanin and therefore does not exhibit typical short T1 and short T2 signal on magnetic resonance imaging and thus can be easily misdiagnosed and be inappropriately managed. To date, only 4 AMM cases have been reported in the English literature. Here, we report the fifth case.
   CASE DESCRIPTION: A 26-year-old female patient presented with a 4-month history of progressive headache and nausea, the conventional magnetic resonance imaging demonstrated a posterior fossa mass accompanied by diffuse leptomeningeal dissemination. Repeated cerebrospinal fluid cytology screening showed negative results. The functional magnetic resonance examinations, including diffusion-weighted imaging, proton magnetic resonance spectroscopy, and dynamic susceptibility contrast perfusion-weighted imaging, provided complementary information. The final diagnosis of AMM was made by immunohistochemistry. Despite gross total excision of the tumor, the disease progressed, and the patient died 10 months after diagnosis.
   CONCLUSIONS: Our experience with this case demonstrated that meningeal melanoma should be included in the differential diagnosis when an intracranial mass is accompanied by leptomeningeal dissemination, and especially when proton magnetic resonance spectroscopy and dynamic susceptibility contrast perfusion-weighted imaging indicate a malignant tumor whereas diffusion-weighted imaging does not. And the loss of a typical melanin signal should not server as an excluding criterion for meningeal melanoma.
C1 [Zhang, Simin; Wang, Weina; Su, Xiaorui; Tan, Qiaoyue; Sun, Huaiqiang; Gong, Qiyong] Sichuan Univ, West China Hosp, Dept Radiol, Huaxi MR Res Ctr HMRRC, Chengdu, Sichuan, Peoples R China.
   [Yue, Qiang] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
   [Liu, Zefan] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Sichuan, Peoples R China.
   [Chen, Ni] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China.
RP Yue, Q (reprint author), Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
EM scu_yq@163.com
RI Gong, Qiyong/W-3052-2019
OI Gong, Qiyong/0000-0002-5912-4871
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371528]; Sichuan Provincial Foundation of Science
   and Technology of China [2013SZ0047]
FX Funded by the National Natural Science Foundation of China: Grant No.
   81371528; and Sichuan Provincial Foundation of Science and Technology of
   China: Grant No. 2013SZ0047.
CR Abdelaziz O, 2016, J NEUROL SURG PART A, V77, P283, DOI 10.1055/s-0035-1571162
   ALLCUTT D, 1993, NEUROSURGERY, V32, P721, DOI 10.1227/00006123-199305000-00004
   Angelino G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2556-y
   [Anonymous], 2009, NEOPLASIA, V11, P102, DOI 10.1593/neo.81328
   Balakrishnan R, 2015, CASE REP ONCOL MED, DOI 10.1155/2015/293802
   Bhandari L, 2012, TURK NEUROSURG, V22, P469, DOI 10.5137/1019-5149.JTN.3632-10.2
   Bourne RM, 2005, EUR J RADIOL, V53, P506, DOI 10.1016/j.ejrad.2004.03.016
   Breckwoldt M, 2015, RADIOLOGE, V55, P113, DOI 10.1007/s00117-014-2761-0
   Covarrubias DJ, 2004, ONCOLOGIST, V9, P528, DOI 10.1634/theoncologist.9-5-528
   Crasto SG, 2001, SURG NEUROL, V55, P163, DOI 10.1016/S0090-3019(01)00348-2
   Demir MK, 2008, RADIOLOGY, V247, P905, DOI 10.1148/radiol.2473050507
   Dinesh SM, 2013, INDIAN J NUCL MED, V28, P234, DOI 10.4103/0972-3919.121971
   FARWELL JR, 1987, ACTA NEUROCHIR, V86, P1, DOI 10.1007/BF01419496
   Foti PV, 2017, RADIOL MED, V122, P131, DOI 10.1007/s11547-016-0697-3
   Gahramanov S, 2013, RADIOLOGY, V266, P842, DOI 10.1148/radiol.12111472
   Gempt J, 2011, J NEURO-ONCOL, V102, P323, DOI 10.1007/s11060-010-0311-9
   Gupta PK, 2017, J NEUROSCI RURAL PRA, V8, P185, DOI 10.4103/0976-3147.203823
   Harstad L, 2008, NEURO-ONCOLOGY, V10, P1010, DOI 10.1215/15228517-2008-062
   Hirota K, 2017, J KOREAN NEUROSURG S, V60, P98, DOI 10.3340/jkns.2015.0506.007
   Hoefnagels FWA, 2009, J NEUROL, V256, P878, DOI 10.1007/s00415-009-5034-5
   Hsieh YY, 2015, J CLIN ONCOL, V33, pE57, DOI 10.1200/JCO.2013.50.0264
   IIZUKA H, 1990, Neurologia Medico-Chirurgica, V30, P698, DOI 10.2176/nmc.30.698
   ISIKLAR I, 1995, AM J ROENTGENOL, V165, P1503, DOI 10.2214/ajr.165.6.7484597
   Jacob S, 2006, J NEURO-OPHTHALMOL, V26, P49, DOI 10.1097/01.wno.0000204665.79300.f8
   Jouanneau E, 2006, NEUROSURGERY, V58, P789
   Law M, 2003, AM J NEURORADIOL, V24, P1989
   Lev MH, 2004, AM J NEURORADIOL, V25, P214
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Lopez-Castilla JD, 2001, PEDIATR NEUROL, V24, P390, DOI 10.1016/S0887-8994(01)00261-2
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma J, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0600-z
   Maia ACM, 2005, AM J NEURORADIOL, V26, P777
   Mayer S, 2018, J NEUROL SURG PART A, V79, P96, DOI 10.1055/s-0037-1604326
   Meyer HJ, 2015, CLIN IMAG, V39, P965, DOI 10.1016/j.clinimag.2015.06.015
   Miller BA, 2013, J INVESTIG MED HIGH, V1
   Mitsuya K, 2010, J NEURO-ONCOL, V99, P81, DOI 10.1007/s11060-009-0106-z
   Mondot L, 2012, J NEURORADIOLOGY, V39, P200, DOI 10.1016/j.neurad.2011.10.004
   Naik H, 2016, NEUROL INDIA, V64, P193, DOI 10.4103/0028-3886.173657
   Onal C, 2006, TURK J CANC, V36, P185
   Pan ZY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-265
   POPTANI H, 1995, AM J NEURORADIOL, V16, P1593
   Qin JB, 2017, MED SCI MONITOR, V23, P2168, DOI 10.12659/MSM.901270
   Rosa M, 2015, ARQ NEURO-PSIQUIAT, V73, P636, DOI 10.1590/0004-282X20150063
   Rosenthal G, 2003, J CLIN ONCOL, V21, P3875, DOI [10.1200/JCO.2003.10.014, 10.1200/JCO.2003.03.061]
   Roser F, 2004, J NEUROSURG, V101, P528, DOI 10.3171/jns.2004.101.3.0528
   Sahin N, 2013, NEURORADIOL J, V26, P531, DOI 10.1177/197140091302600506
   Said S, 2014, POL J RADIOL, V79, P199, DOI 10.12659/PJR.890733
   Santhosh K, 2008, J NEURORADIOLOGY, V35, P236, DOI 10.1016/j.neurad.2008.01.079
   Saranya A, 2017, NEUROL INDIA, V65, P1427, DOI 10.4103/0028-3886.217953
   Sarmast Arif Hussain, 2018, Asian J Neurosurg, V13, P168, DOI 10.4103/1793-5482.224832
   Schneider M, 2013, J NEUROL, V260, P680, DOI 10.1007/s00415-012-6789-7
   Somers KE, 2013, J CLIN ONCOL, V31, pE9, DOI 10.1200/JCO.2012.41.6115
   Svolos P, 2014, CANCER IMAGING, V14, DOI 10.1186/1470-7330-14-20
   Tang K, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005805
   Tosaka M, 2001, J NEUROSURG, V94, P528, DOI 10.3171/jns.2001.94.3.0528
   Trinh Victoria, 2014, Surg Neurol Int, V5, P147, DOI 10.4103/2152-7806.142795
   Wadasadawala T, 2010, J CLIN NEUROSCI, V17, P1014, DOI 10.1016/j.jocn.2009.12.020
   Wang J, 2014, EJSO-EUR J SURG ONC, V40, P1062, DOI 10.1016/j.ejso.2013.11.024
   Watanabe M, 2008, NEUROL MED-CHIR, V48, P519, DOI 10.2176/nmc.48.519
   Whinney D, 2001, OTOL NEUROTOL, V22, P218, DOI 10.1097/00129492-200103000-00018
   Xie ZY, 2014, J CLIN NEUROSCI, V21, P1051, DOI 10.1016/j.jocn.2013.08.018
   Yamashita Y, 2009, NEUROL RES, V31, P940, DOI 10.1179/174313209X382520
   Zhang X, 2017, ONCOTARGET, V8, P47816, DOI 10.18632/oncotarget.18001
   이창주, 2004, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V36, P425
NR 64
TC 0
Z9 0
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 229
EP 239
DI 10.1016/j.wneu.2018.10.199
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100245
PM 30404049
DA 2020-05-12
ER

PT J
AU Akamatsu, Y
   Kashimura, H
   Suzuki, T
   Aso, K
   Oshida, S
AF Akamatsu, Yosuke
   Kashimura, Hiroshi
   Suzuki, Taro
   Aso, Kenta
   Oshida, Sotaro
TI Utility of Single Fenestrated Miniclip in Management of Small Cerebral
   Aneurysm: Technical Report of 2 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Clipping; Fenestrated miniclip
AB BACKGROUND: Fenestrated miniclips were developed as an effective tool for dog-ear-shaped remnants of aneurysms. However, the special property of these clips may have other applications. Here, we report 2 cases of ruptured small aneurysm and suggest the alternative utility of a single application of a fenestrated miniclip.
   CASE DESCRIPTION: A 77-year-old woman was admitted to our hospital with subarachnoid hemorrhage due to an anterior communicating aneurysm. The aneurysm was treated with surgical clipping via a right pterional approach. Because dissection of tight adhesion between the aneurysm and ipsilateral A2 might cause intraoperative bleeding, the angled fenestrated miniclip was applied across the ipsilateral A2 without dissection of adhesion and obliterated the aneurysm without complications. In another case, a 60-year-old man presented with sub-arachnoid hemorrhage due to ruptured vertebral artery-posterior inferior cerebellar artery (PICA) aneurysm and was treated with surgical clipping via a far-lateral approach. Because aneurysm visualization was impeded by PICA even after mobilization of the PICA and vertebral artery, a fenestrated standard-clip was applied across the PICA. However, this clip impeded visualization of the aneurysm and could not be opened in the tight surgical field. In contrast, subsequent application of a fenestrated miniclip allowed better visualization of the aneurysm, even in a tight field, and resulted in successful obliteration of the aneurysm.
   CONCLUSION: Single application of fenestrated miniclips may be suitable in cases of small aneurysms with thin walls adhering to branch vessels or where visualization of the aneurysm is impeded by the parent artery.
C1 [Akamatsu, Yosuke; Kashimura, Hiroshi; Suzuki, Taro; Aso, Kenta; Oshida, Sotaro] Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
RP Kashimura, H (reprint author), Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
EM h-kashimura@pref.iwate.jp
CR Ota Nakao, 2015, Surg Neurol Int, V6, pS553, DOI 10.4103/2152-7806.168072
   SUGITA K, 1982, J NEUROSURG, V57, P240, DOI 10.3171/jns.1982.57.2.0240
   Yang I, 2008, NEUROSURGERY, V62, P371, DOI 10.1227/01.NEU.0000312719.93685.9A
   Zada G, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08314
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 240
EP 244
DI 10.1016/j.wneu.2018.10.222
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100246
PM 30415049
DA 2020-05-12
ER

PT J
AU Dixon, A
   Silva, NA
   Sotayo, A
   Mazzola, CA
AF Dixon, Ashley
   Silva, Nicole A.
   Sotayo, Alaba
   Mazzola, Catherine A.
TI Female Medical Student Retention in Neurosurgery: A Multifaceted
   Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gender disparity; Glass ceiling; Medical student; Women in neurosurgery;
   Women in surgery
ID WOMEN; RECRUITMENT; SURGERY; EXPOSURE; CAREER; TRENDS; IMPACT
AB BACKGROUND: Since 2011, more women than men have graduated from medical school, yet there remains a paucity of female physicians in surgical specialties. After the 2018 Neurosurgery Match, only 17.5% of neurosurgery residents are women. Previous literature documented gender inequality, poor medical school exposure, and lack of female mentorship as reasons for this disparity. We sought to further explore factors that deter female medical students from pursuing neurosurgery.
   METHODS: A comprehensive survey was created and distributed to the 2017-2018 Rutgers New Jersey Medical School student body, requesting anonymous input from female medical students.
   RESULTS: Of 104 female respondents, 26.9% had considered neurosurgery as a career and felt dissuaded because of their gender. Of respondents, 88% did not have a senior female medical student pursuing neurosurgery or a female neurosurgical resident as a mentor. More than half of respondents disagreed that they would be dissuaded from a field if they did not have a female mentor. The 88.46% of women who felt that there was a glass ceiling in medicine were also more likely to feel that they would face inequality and adversity that would inhibit training in a male-dominated field. Women who described themselves as seeking challenging and competitive careers strongly felt that they would benefit from exposure to surgical subspecialties during their preclinical years.
   CONCLUSIONS: Female medical students remain resilient, ambitious, interested in competitive specialties, and eager to explore surgical subspecialties during preclinical years. A multifaceted approach is imperative to recruit and retain qualified women interested in neurosurgery.
C1 [Dixon, Ashley; Silva, Nicole A.; Sotayo, Alaba; Mazzola, Catherine A.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA.
RP Mazzola, CA (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA.
EM cmazzola@njpni.com
CR Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Acai A, 2018, CAN J SURG, V61, P6, DOI 10.1503/cjs.010717
   Agarwal Nitin, 2013, World Neurosurg, V80, P745, DOI 10.1016/j.wneu.2013.08.027
   [Anonymous], TABL 2 DISTR RES SPE
   Awad AJ, 2016, WORLD NEUROSURG, V92, P349, DOI 10.1016/j.wneu.2016.05.029
   Bean J, 2008, J NEUROSURG, V109, P377, DOI 10.3171/JNS/2008/109/9/0377
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Bonney PA, 2017, WORLD NEUROSURG, V98, P859, DOI 10.1016/j.wneu.2016.10.121
   Brinjikji W, 2013, AM J NEURORADIOL, V34, P1022, DOI 10.3174/ajnr.A3321
   Durham SR, 2018, J NEUROSURG, V129, P282, DOI 10.3171/2017.11.JNS171831
   JAKOBY R K, 1964, J Am Med Womens Assoc, V19, P783
   Kashkoush A, 2017, WORLD NEUROSURG, V108, P101, DOI 10.1016/j.wneu.2017.08.125
   Kato Y, 2016, WORLD NEUROSURG, V86, pA16, DOI 10.1016/j.wneu.2015.12.018
   Kerr HL, 2016, POSTGRAD MED J, V92, P576, DOI 10.1136/postgradmedj-2015-133273
   Mummareddy N, 2018, WORLD NEUROSURG, V110, P504, DOI 10.1016/j.wneu.2017.10.131
   Quintana LM, 2013, WORLD NEUROSURG, V80, P789, DOI 10.1016/j.wneu.2013.09.004
   Ramani P, 2016, WORLD NEUROSURG, V86, P44, DOI 10.1016/j.wneu.2015.09.089
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Renfrow JJ, 2016, J NEUROSURG, V124, P834, DOI 10.3171/2015.3.JNS142313
   Resnick DK, 2000, J NEUROSURG, V92, P637, DOI 10.3171/jns.2000.92.4.0637
   Saleh M, 2013, BRIT J NEUROSURG, V27, P405, DOI 10.3109/02688697.2013.793293
   Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627
   Surawicz CM, 2016, J AM COLL RADIOL, V13, P1433, DOI 10.1016/j.jacr.2016.08.026
   Tomei KL, 2014, J CLIN NEUROSCI, V21, P1102, DOI 10.1016/j.jocn.2013.11.006
   Yan H, 2018, LANCET, V391, P830, DOI 10.1016/S0140-6736(18)30436-7
   Ying ZG, 2011, ANN SURG, V253, P637, DOI 10.1097/SLA.0b013e3182111120
   Zanon N, 2011, CHILD NERV SYST, V27, P337, DOI 10.1007/s00381-010-1380-y
   Zuccato JA, 2016, CAN J NEUROL SCI, V43, P410, DOI 10.1017/cjn.2015.332
   Zuckerman SL, 2016, WORLD NEUROSURG, V86, P120, DOI 10.1016/j.wneu.2015.08.081
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 245
EP 251
DI 10.1016/j.wneu.2018.10.166
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100247
PM 30391758
DA 2020-05-12
ER

PT J
AU Desai, VR
   Gadgil, N
   Saad, S
   Raskin, JS
   Lam, SK
AF Desai, Virendra R.
   Gadgil, Nisha
   Saad, Shahbaz
   Raskin, Jeffrey S.
   Lam, Sandi K.
TI Measures of Health-Related Quality of Life Outcomes in Pediatric
   Neurosurgery: Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Health-related quality of life; HRQoL; Neurosurgery; Pediatric; QoL;
   Quality of life
ID EPILEPSY INVENTORY QOLIE-31; CHILD HEALTH; PSYCHOMETRIC PROPERTIES;
   CONCEPTUAL-FRAMEWORK; SURVEY SF-36; RELIABILITY; VALIDATION; VALIDITY;
   QUESTIONNAIRE; ADOLESCENTS
AB BACKGROUND: Improving value in healthcare means optimizing outcomes and minimizing costs. The emerging pay-for-performance era requires understanding of the effect of healthcare services on health-related quality of life (HRQoL). Pediatric and surgical subspecialties have yet to fully integrate HRQoL measures into practice. The present study reviewed and characterized the HRQoL outcome measures across various pediatric neurosurgical diagnoses.
   METHODS: A literature review was performed by searching PubMed and Google Scholar with search terms such as "health-related quality of life" and "pediatric neurosurgery" and then including the specific pathologies for which a HRQoL instrument was found (e.g., "health-related quality of life" plus "epilepsy"). Each measurement was evaluated by content and purpose, relative strengths and weaknesses, and validity.
   RESULTS: We reviewed 68 reports. Epilepsy, brain tumor, cerebral palsy, spina bifida, hydrocephalus, and scoliosis were diagnoses found in reported studies that had used disease-specific HRQoL instruments. Information using general HRQoL instruments was also reported. Internal, test-retest, and/or interrater reliability varied across the instruments, as did face, content, concurrent, and/or construct validity. Few instruments were tested enough for robust reliability and validity. Significant variability was found in the usage of these instruments in clinical studies within pediatric neurosurgery.
   CONCLUSIONS: The HRQoL instruments used in pediatric neurosurgery are currently without standardized guidelines and thus exhibit high variability in use. Clinicians should support the development and application of these methods to optimize these instruments, promote standardization of research, improve performance measures to reflect clinically modifiable and meaningful outcomes, and, ultimately, lead the national discussion in healthcare quality and patient-centered care.
C1 [Desai, Virendra R.; Gadgil, Nisha; Saad, Shahbaz; Lam, Sandi K.] Texas Childrens Hosp, Div Pediat Neurosurg, Houston, TX 77030 USA.
   [Desai, Virendra R.; Gadgil, Nisha; Saad, Shahbaz; Lam, Sandi K.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Raskin, Jeffrey S.] Riley Hosp Children, Div Pediat Neurosurg, Indianapolis, IN USA.
   [Raskin, Jeffrey S.] Indiana Univ, Goodman Campbell Brain & Spine, Dept Neurosurg, Indianapolis, IN 46204 USA.
RP Desai, VR (reprint author), Texas Childrens Hosp, Div Pediat Neurosurg, Houston, TX 77030 USA.; Desai, VR (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM vrdesai@houstonmethodist.org
CR BARR RD, 1994, INT J ONCOL, V4, P639
   Beghi E, 2005, SEIZURE-EUR J EPILEP, V14, P452, DOI 10.1016/j.seizure.2005.07.008
   Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x
   Bjornson KF, 2001, EUR J NEUROL, V8, P183, DOI 10.1046/j.1468-1331.2001.00051.x
   Blond BN, 2016, NEUROL CLIN, V34, P395, DOI 10.1016/j.ncl.2015.11.002
   BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160
   Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d
   Buck D, 2007, EPILEPSY BEHAV, V10, P38, DOI 10.1016/j.yebeh.2006.10.010
   Camfield C, 2003, DEV MED CHILD NEUROL, V45, P152, DOI 10.1017/S0012162203000306
   Canaway AG, 2013, QUAL LIFE RES, V22, P173, DOI 10.1007/s11136-012-0119-5
   Carlon S, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-81
   Centers for Disease Control and Prevention, HLTH REL QUAL LIF HR
   Chan CYW, 2009, MALAYS ORTHOP J, V3, P56
   Chen Tian-Hui, 2005, J Zhejiang Univ Sci B, V6, P936, DOI 10.1631/jzus.2005.B0936
   CLIMENT JM, 1995, SPINE, V20, P2006, DOI 10.1097/00007632-199509150-00011
   Cowan J, 2004, QUAL LIFE RES, V13, P1435, DOI 10.1023/B:QURE.0000040796.54498.69
   Cramer JA, 1996, EPILEPSIA, V37, P577, DOI 10.1111/j.1528-1157.1996.tb00612.x
   Cramer JA, 1998, EPILEPSIA, V39, P81, DOI 10.1111/j.1528-1157.1998.tb01278.x
   Cramer JA, 1999, EPILEPSIA, V40, P1114, DOI 10.1111/j.1528-1157.1999.tb00828.x
   Davis E, 2006, DEV MED CHILD NEUROL, V48, P311, DOI 10.1017/S0012162206000673
   DEVINSKY O, 1995, EPILEPSIA, V36, P1089, DOI 10.1111/j.1528-1157.1995.tb00467.x
   Eiser C, 2001, ARCH DIS CHILD, V84, P205, DOI 10.1136/adc.84.3.205
   Emery Marie-Pierre, 2005, Health Qual Life Outcomes, V3, P12, DOI 10.1186/1477-7525-3-12
   England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016
   Feise RJ, 2005, SPINE, V30, P1310, DOI 10.1097/01.brs.0000163885.12834.ca
   Fekkes M, 2000, QUAL LIFE RES, V9, P961, DOI 10.1023/A:1008981603178
   Ferro MA, 2016, EPILEPSIA, V57, P427, DOI 10.1111/epi.13296
   Ferro MA, 2013, EPILEPSIA, V54, P1889, DOI 10.1111/epi.12388
   Forrest CB, 2004, MED CARE, V42, P232, DOI 10.1097/01.mlr.0000115196.02425.05
   Franco RA, 2000, OTOLARYNG HEAD NECK, V123, P9, DOI 10.1067/mhn.2000.105254
   GLASCOE FP, 1993, CLIN PEDIATR, V32, P203
   Glaser AW, 1999, EUR J CANCER, V35, P256, DOI 10.1016/S0959-8049(98)00367-0
   Hansen D, 2016, J NEUROSURG-PEDIATR, V18, P480, DOI 10.3171/2016.3.PEDS15641
   Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667
   Hoare P, 2000, QUAL LIFE RES, V9, P637, DOI 10.1023/A:1008980608568
   Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007
   Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54
   da Silva TI, 2007, EPILEPSY BEHAV, V10, P234, DOI 10.1016/j.yebeh.2006.08.022
   Kulkarni AV, 2004, J NEUROSURG, V101, P134, DOI 10.3171/ped.2004.101.2.0134
   Lachapelle Y, 2005, J INTELL DISABIL RES, V49, P740, DOI 10.1111/j.1365-2788.2005.00743.x
   Ladner TR, 2016, J NEUROSURG-PEDIATR, V17, P76, DOI 10.3171/2015.5.PEDS1513
   Lai JS, 2007, CHILD NERV SYST, V23, P47, DOI 10.1007/s00381-006-0176-6
   Leidy NK, 1999, EPILEPSIA, V40, P97, DOI 10.1111/j.1528-1157.1999.tb01995.x
   Mattejat F, 2006, Z KINDER JUG-PSYCH, V34, P445, DOI 10.1024/1422-4917.34.6.445
   Matza LS, 2004, VALUE HEALTH, V7, P79, DOI 10.1111/j.1524-4733.2004.71273.x
   May TW, 2001, EPILEPSY BEHAV, V2, P106, DOI 10.1006/ebeh.2001.0170
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Palmer SN, 2007, PEDIATR BLOOD CANCER, V49, P287, DOI 10.1002/pbc.21026
   Parkin PC, 1997, QUAL LIFE RES, V6, P123
   Phelan C, EXPLORING RELIABILIT
   Picot MC, 2004, EPILEPTIC DISORD, V6, P275
   Rapley M, 1995, MENT HANDICAP RES, V8, P194
   Ravens-Sieberer U, 2007, BUNDESGESUNDHEITSBLA, V50, P810, DOI 10.1007/s00103-007-0244-4
   Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715
   Richardson J, 2016, MED DECIS MAKING, V36, P147, DOI 10.1177/0272989X15613522
   Riley AW, 2004, MED CARE, V42, P221, DOI 10.1097/01.mlr.0000114910.46921.73
   Rocque BG, 2015, J NEUROSURG-PEDIATR, V15, P144, DOI 10.3171/2014.10.PEDS1441
   Ronen Gabriel M, 2003, Health Qual Life Outcomes, V1, P36, DOI 10.1186/1477-7525-1-36
   Ronen GM, 2000, J CHILD NEUROL, V15, P775, DOI 10.1177/088307380001501201
   Ronen GM, 2003, EPILEPSIA, V44, P598, DOI 10.1046/j.1528-1157.2003.46302.x
   Sabaz M, 2000, EPILEPSIA, V41, P765, DOI 10.1111/j.1528-1157.2000.tb00240.x
   Sherman EMS, 2002, EPILEPSIA, V43, P1230, DOI 10.1046/j.1528-1157.2002.03602.x
   Sintonen H, 1995, 42 NAT CTR HLTH PROG
   Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00
   Sohn H, 2003, OTOLARYNG HEAD NECK, V128, P344, DOI 10.1067/mhn.2003.4
   Solans M, 2008, VALUE HEALTH, V11, P742, DOI 10.1111/j.1524-4733.2007.00293.x
   Speechley KN, 2006, J CLIN ONCOL, V24, P2536, DOI 10.1200/JCO.2005.03.9628
   SPILKER B, 1996, QUALITY LIFE PHARMAC, P25
   STARFIELD B, 1995, MED CARE, V33, P553, DOI 10.1097/00005650-199505000-00008
   Stevens K, 2012, VALUE HEALTH, V15, P1092, DOI 10.1016/j.jval.2012.07.011
   Theunissen NCM, 2001, DEV MED CHILD NEUROL, V43, P460, DOI 10.1017/S0012162201000846
   Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004
   Townsend-White C, 2012, J INTELL DISABIL RES, V56, P270, DOI 10.1111/j.1365-2788.2011.01427.x
   Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006
   Verrips EGH, 1999, EUR J PUBLIC HEALTH, V9, P188, DOI 10.1093/eurpub/9.3.188
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Warschausky S, 2002, PLAST RECONSTR SURG, V110, P409, DOI 10.1097/00006534-200208000-00004
   Waters E, 2000, J PEDIATR PSYCHOL, V25, P381, DOI 10.1093/jpepsy/25.6.381
   Waters E, 2005, CHILD CARE HLTH DEV, V31, P127, DOI 10.1111/j.1365-2214.2004.00476.x
   Wildrick D, 1996, J Neurosci Nurs, V28, P192
   World Health Organization, 1993, WHO QOL MEAS QUAL LI
   World Health Organization, 1948, OFF REC WHO
   Yoo HJ, 2011, J KOREAN NEUROSURG S, V49, P147, DOI 10.3340/jkns.2011.49.3.147
   Zhao YQ, 2007, EPILEPSY BEHAV, V11, P53, DOI 10.1016/j.yebeh.2007.03.013
NR 84
TC 1
Z9 3
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 252
EP 265
DI 10.1016/j.wneu.2018.10.194
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100248
PM 30399472
DA 2020-05-12
ER

PT J
AU Liu, LH
   Li, N
   Wang, Q
   Wang, HM
   Wu, YX
   Jin, WD
   Zhou, Q
   Wang, ZL
AF Liu, Liehua
   Li, Nan
   Wang, Qian
   Wang, Haoming
   Wu, Yuexiang
   Jin, Weidong
   Zhou, Qiang
   Wang, Zili
TI Iatrogenic Lumbar Artery Injury in Spine Surgery: A Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Iatrogenic injury; Lumbar artery; Lumbar artery pseudoaneurysm; Spine
   surgery
ID LATERAL INTERBODY FUSION; VASCULAR INJURY; PSEUDOANEURYSM;
   VERTEBROPLASTY; DECOMPRESSION; EMBOLIZATION; MANAGEMENT;
   INSTRUMENTATION; COMPLICATIONS; COMPRESSION
AB BACKGROUND: We reviewed the reported data related to iatrogenic lumbar artery injury (ILAI) in spine surgery with a focus on which iatrogenic procedure might cause lumbar artery injury.
   METHODS: We conducted a comprehensive search in the Web of Science, PubMed, EMBASE, and Chinese biomedical databases in July 2018.
   RESULTS: A total of 20 reports on ILAI were selected for the present study. Most of these were case reports, with a total of 26 cases. The causes of ILAI were as follows: puncture injury in 9 cases, transforaminal endoscopic operation in 5 cases, pedicle screw injury in 3 cases, intervertebral foramen decompression in 2 cases, disc rongeur injury during discectomy in 2 cases, lumbar artery tear caused by transverse process fracture in 1 case, vertebral fracture restoration in 1 case, retractor injury in 1 case, cage insertion or pedicle screw injury in 1 case, and drainage tube stimulation in 1 case. The treatment methods included transarterial embolization in 20 cases, percutaneous embolization in 2 cases, surgical ligation in 1 case, and steroid and cyclophosphamide treatment in 1 case. All patients were treated successfully. One patient died during antishock therapy, and another patient died because her family refused any further intervention.
   CONCLUSIONS: Attention should be given to the surgical procedures that are likely to cause ILAI, such as percutaneous vertebroplasty/percutaneous kyphoplasty, vertebral biopsy, pedicle screw implantation, discectomy, transforaminal endoscopic operation, and intervertebral foramen decompression. Once a diagnosis of ILAI has been confirmed, selective endovascular transarterial embolization is the preferred treatment.
C1 [Liu, Liehua] Ningxia Med Univ, Gen Hosp, Grad Sch, Yinchuan, Ningxia Hui Aut, Peoples R China.
   [Wu, Yuexiang] Ningxia Med Univ, Gen Hosp, Outpatient Dept, Yinchuan, Ningxia Hui Aut, Peoples R China.
   [Jin, Weidong; Wang, Zili] Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Ningxia Hui Aut, Peoples R China.
   [Liu, Liehua; Zhou, Qiang] Chongqing Med Univ, Gen Hosp, Affiliated Hosp 3, Dept Spine Surg, Chongqing, Peoples R China.
   [Li, Nan; Wang, Haoming] Three Gorges Cent Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Wang, Qian] Hillsborough Community Coll, Tampa, FL USA.
RP Wang, ZL (reprint author), Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Ningxia Hui Aut, Peoples R China.
EM wangzlnx@126.com
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Alvarez Postigo M, 2017, Rev Esp Cir Ortop Traumatol, V61, P436, DOI 10.1016/j.recot.2017.06.003
   Aoki M, 2017, ANN VASC SURG, V45, DOI 10.1016/j.avsg.2017.06.035
   Beveridge TS, 2015, CLIN ANAT, V28, P649, DOI 10.1002/ca.22504
   Biafora SJ, 2006, SPINE, V31, pE84, DOI 10.1097/01.brs.0000197596.88416.02
   Blocher M, 2015, SPINE, V40, pE1195, DOI 10.1097/BRS.0000000000001057
   Busardo FP, 2015, FORENSIC SCI INT, V246, pE7, DOI 10.1016/j.forsciint.2014.11.006
   [陈水兵 Chen Shuibing], 2017, [介入放射学杂志, Journal of Interventional Radiology], V26, P1033
   Cho SM, 2011, J KOREAN NEUROSURG S, V49, P273, DOI 10.3340/jkns.2011.49.5.273
   Dausse F, 2006, SKELETAL RADIOL, V35, P949, DOI 10.1007/s00256-005-0064-2
   Domenicucci M, 2008, SPINE, V33, pE81, DOI 10.1097/BRS.0b013e3181624b93
   Eun JP, 2015, BRIT J NEUROSURG, V29, P742, DOI 10.3109/02688697.2015.1039490
   Giordano AV, 2017, CARDIOVASC INTER RAD, V40, P776, DOI 10.1007/s00270-016-1551-7
   Heo DH, 2011, J KOREAN NEUROSURG S, V49, P131, DOI 10.3340/jkns.2011.49.2.131
   Ikeda O, 2012, ACTA RADIOL, V53, P541, DOI 10.1258/ar.2012.110210
   Ishigaki T, 2017, EJVES SHORT REP, V38, P1
   Ito T, 2016, CLIN EXP NEPHROL, V20, P145, DOI 10.1007/s10157-015-1157-4
   Iwamoto S, 2016, J MED INVESTIG, V63, P45, DOI 10.2152/jmi.63.45
   Karaikovic EE, 2010, SPINE, V35, pE163, DOI 10.1097/BRS.0b013e3181bdc2f7
   Kim Do Hyun, 2016, Korean J Neurotrauma, V12, P171, DOI 10.13004/kjnt.2016.12.2.171
   Koakutsu T, 2016, EUR SPINE J, V25, pS124, DOI 10.1007/s00586-015-4225-2
   Kulkarni K, 2007, SKELETAL RADIOL, V36, P1195, DOI 10.1007/s00256-007-0355-x
   Liu L, 2016, BIOMED RES INT, V2016
   Mirza AK, 2017, CLIN NEUROL NEUROSUR, V163, P53, DOI 10.1016/j.clineuro.2017.10.011
   Nijenhuis RJ, 2009, J NEUROSURG-SPINE, V10, P585, DOI 10.3171/2009.2.SPINE08702
   Nishihara M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185923
   Nojiri H, 2016, EUR SPINE J, V25, P4195, DOI 10.1007/s00586-016-4729-4
   Ntourantonis D, 2018, SPINE, V43, pE976, DOI 10.1097/BRS.0000000000002587
   Oh YM, 2013, J KOREAN NEUROSURG S, V54, P344, DOI 10.3340/jkns.2013.54.4.344
   Puri AS, 2011, J NEUROSURG-SPINE, V14, P296, DOI 10.3171/2010.10.SPINE1082
   Santillan A, 2010, VASC ENDOVASC SURG, V44, P601, DOI 10.1177/1538574410374655
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   SMITH DW, 1991, SPINE, V16, P387, DOI 10.1097/00007632-199103000-00030
   Stevens K J, 1997, Eur Spine J, V6, P205, DOI 10.1007/BF01301438
   Sugimoto Y, 2013, ACTA MED OKAYAMA, V67, P113
   Thomas R, 2018, J MED IMAG RADIAT ON, V62, P528, DOI 10.1111/1754-9485.12724
   Tomescot A, 2013, J VASC SURG, V58, P1084, DOI 10.1016/j.jvs.2012.12.070
   Tulamo R, 2018, J NEUROINTERV SURG, V10, pI58, DOI 10.1136/jnis.2009.002055.rep
   Ventura F, 2019, BRIT J NEUROSURG, V33, P434, DOI 10.1080/02688697.2017.1351523
   Wang YL, 2018, ANN VASC SURG, V53, DOI 10.1016/j.avsg.2018.05.032
NR 40
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 266
EP 271
DI 10.1016/j.wneu.2018.10.219
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100249
PM 30419401
DA 2020-05-12
ER

PT J
AU Baruah, S
   Dubey, S
   Ghavghave, U
   Jha, AN
AF Baruah, Satyakam
   Dubey, Sudhir
   Ghavghave, Utkarsh
   Jha, Ajaya Nand
TI Dengue Fever Presenting with Cervicodorsal Acute Spinal Spontaneous
   Subdural Hematoma-Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dengue; Oblique-cervical-corpectomies; Spinal-subdural-hematoma
AB BACKGROUND: Neurologic complications are increasingly being reported in dengue epidemics. Intraspinal hematomas are rare, and those associated with dengue fever are still rarer with only 1 being reported in the literature.
   CASE DESCRIPTION: We report a case of dengue fever presenting with acute-onset quadriparesis (upper limbs Medical Research Council [MRC] 4/5 and lower limbs 0/5) and urinary incontinence. The patient was radiologically diagnosed with cervicodorsal acute to subacute anterior epidural hematoma. On the basis of clinical and radiologic evaluations, the patient underwent an anterior cervical approach via a split-manubriotomy, C6-D4 right anterolateral partial oblique corpectomies for evacuation of the hematoma. Intraoperatively, however, there was no evidence of anterior epidural collection and the dura revealed a bluish hue. A durotomy revealed a subdural hematoma. After evacuation of the hematoma, the patient remained paraplegic and her upper limb power worsened by MRC 1 grade. Postoperative magnetic resonance imaging revealed good evacuation and no new bleed; however, the intramedullary T2-weighted signal hyperintensities extending up to C2 persisted. She was on ventilatory support for almost 5 months. For diaphragmatic incapacity she underwent bilateral cervical phrenic nerve stimulation (diaphragmatic pacing). Despite initial improvement, she succumbed to multiple underlying comorbidities.
   CONCLUSIONS: Acute spontaneous spinal subdural hematoma (SSDH) is extremely rare but should be kept in mind in patients with dengue hemorrhagic fever. The radiologic findings could be deceptive and plain computed tomography and magnetic resonance imaging should be used as complementary studies to establish the diagnosis of acute spontaneous SSDH. The outcomes of SSDH are guarded, and elaborate patient counseling should be done preoperatively, keeping these in perspective.
C1 [Baruah, Satyakam; Dubey, Sudhir; Ghavghave, Utkarsh; Jha, Ajaya Nand] Medanta Medicity, Inst Neurosci, Dept Neurosurg, Gurgaon, Haryana, India.
   [Baruah, Satyakam; Jha, Ajaya Nand] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
RP Baruah, S (reprint author), Medanta Medicity, Inst Neurosci, Dept Neurosurg, Gurgaon, Haryana, India.; Baruah, S (reprint author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
EM sbaruah2007@gmail.com
CR Domenicucci M, 1999, J NEUROSURG, V91, P65, DOI 10.3171/spi.1999.91.1.0065
   GABL M, 1988, NEUROCHIRURGIA, V31, P99
   HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017
   Kaur Jaslovleen, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-221251
   LANGMAYR JJ, 1995, J NEUROL NEUROSUR PS, V59, P442, DOI 10.1136/jnnp.59.4.442
   Massimiliano V, 2015, INT J SURG CASE REP, V15, P57, DOI [10.1016/j.ijscr.2015.06.032, 10.1016/j.ijscr.2015.08.032]
   Morandi X, 2001, Spine (Phila Pa 1976), V26, pE547, DOI 10.1097/00007632-200112010-00022
   NIGHOGHOSSIAN N, 1990, REV NEUROL-FRANCE, V146, P221
   Oh SH, 2009, J KOREAN NEUROSURG S, V45, P390, DOI 10.3340/jkns.2009.45.6.390
   Pancharoen Chitsanu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P341
   Panciani PP, 2009, ACTA NEUROL BELG, V109, P146
   POST MJD, 1994, AM J NEURORADIOL, V15, P1895
   REYNOLDS AF, 1978, ROCKY MT MED J, V75, P199
   SCHILLER F, 1948, LANCET, V252, P842, DOI 10.1016/S0140-6736(48)91427-5
   SCHWARTZ FT, 1973, J NEUROSURG, V39, P249, DOI 10.3171/jns.1973.39.2.0249
   SMITH RA, 1985, SURG NEUROL, V23, P367, DOI 10.1016/0090-3019(85)90208-3
   SWANN KW, 1984, J NEUROSURG, V61, P975, DOI 10.3171/jns.1984.61.5.0975
   TOLEDO E, 1981, NEUROSURGERY, V8, P600, DOI 10.1227/00006123-198105000-00018
   VAZQUEZBARQUERO A, 1994, BRIT J NEUROSURG, V8, P739, DOI 10.3109/02688699409101190
   Yamaguchi S, 2003, SURG NEUROL, V59, P408, DOI 10.1016/S0090-3019(03)00016-8
   Zochodne D, 1986, Pediatr Neurol, V2, P311, DOI 10.1016/0887-8994(86)90027-5
NR 21
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 272
EP 277
DI 10.1016/j.wneu.2018.10.201
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100250
PM 30404065
DA 2020-05-12
ER

PT J
AU Novik, Y
   Vassiliev, D
   Tomycz, ND
AF Novik, Yuri
   Vassiliev, Dmitri
   Tomycz, Nestor D.
TI Spinal Cord Stimulation in Adult Tethered Cord Syndrome: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic low back pain; Lipomyelomeningocele; Spina bifida; Spinal cord
   stimulation; Tethered cord syndrome
AB BACKGROUND: Spinal cord stimulation (SCS) is an evidence - based treatment for chronic neuropathic pain, however there is a dearth of evidence investigating this modality in patients with tethered cord syndrome (TCS).
   CASE DESCRIPTION: We present a case of 55-year old woman with history of lipo-myelomeningocele repair and multiple detethering surgeries who presented with chronic low back and leg pain accompanied by progressive gait dysfunction. After a successful trial, she underwent SCS paddle lead placement that resulted in decrease of her visual analog scale (VAS) for pain from 9/10 to 0-2/10 as well as daily opioid intake from 90-199mg Morphine Equivalents Doses (MED) to 40-60mg MED. On last follow-up she reported 70-85% relief of her low back and leg pain, better ambulation, and improved quality of life.
   CONCLUSION: The literature review identified 2 other case reports of SCS in TCS with similar improvement in pain alleviation.
C1 [Novik, Yuri; Tomycz, Nestor D.] Allegheny Hlth Network, Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA.
   [Vassiliev, Dmitri] Allegheny Hlth Network, Allegheny Gen Hosp, Dept Pain Med, Pittsburgh, PA USA.
RP Novik, Y (reprint author), Allegheny Hlth Network, Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA.
EM yuri.novik@ahn.org
OI Novik, Yurii/0000-0002-3107-8586
CR De Ridder D, 2015, CLIN J PAIN, V31, P433, DOI 10.1097/AJP.0000000000000129
   Hsieh PC, 2009, J NEUROSURG-SPINE, V10, P278, DOI 10.3171/2008.10.SPINE08123
   Klekamp J, 2011, J NEUROSURG-SPINE, V15, P258, DOI 10.3171/2011.4.SPINE10504
   Moens Maarten, 2010, J Med Case Rep, V4, P74, DOI 10.1186/1752-1947-4-74
   Tyagi R, 2016, J NEUROSURG-PEDIATR, V18, P105, DOI 10.3171/2015.12.PEDS14645
NR 5
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 278
EP 281
DI 10.1016/j.wneu.2018.10.215
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100251
PM 30415046
DA 2020-05-12
ER

PT J
AU Wangqin, RQ
   Xu, KY
   Mokin, M
   Uribe, J
   Rojas, H
   Ren, ZG
AF Wangqin, Runqi
   Xu, Kaya
   Mokin, Maxim
   Uribe, Juan
   Rojas, Haydy
   Ren, Zeguang
TI Covered Stent to Salvage Iatrogenic Vertebral Artery Injury with
   Uncontrolled Bleeding in the Operating Room Setting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Covered stent; Iatrogenic; Operating room; Vertebral artery injury
ID CERVICAL-SPINE SURGERY; ENDOVASCULAR EMBOLIZATION; DISKECTOMY
AB BACKGROUND: Iatrogenic vertebral artery injury is an uncommon but well recognized complication during cervical spine surgery. Intraoperative surgical repair is extremely challenging and options for endovascular repair are limited due to lack of proper equipment in the operating room setting.
   CASE DESCRIPTION: A 53 year-old female who presented with myleopathy underwent anterior cervical discectomy and fusion of C3-7. A significant laceration injury of left vertebral artery was encountered during surgery, which was salvaged by intraoperative, endovascular repair with a covered stent under portable fluoroscopy guidance. The salvage and repair led to the rest of the surgery to be finished as planned preoperatively without any consequences.
   CONCLUSIONS: Vertebral artery injury is an uncommon but severe complication of cervical spine surgery. For the uncontrolled bleeding, intraoperative endovascular repair with portable fluoroscopy is warranted and possible. Covered stent can seal the laceration and stop the bleeding completely which enables completion of the surgery.
C1 [Wangqin, Runqi] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA.
   [Xu, Kaya; Mokin, Maxim; Uribe, Juan; Rojas, Haydy; Ren, Zeguang] Univ S Florida, Dept Neurol Surg, Tampa, FL 33620 USA.
   [Xu, Kaya] Guiyang Med Univ, Dept Neurosurg, Guiyang, Guizhou, Peoples R China.
   [Uribe, Juan] Barrow Neurol Inst, Div Spinal Disorders, Phoenix, AZ 85013 USA.
RP Ren, ZG (reprint author), Univ S Florida, Dept Neurol Surg, Tampa, FL 33620 USA.
EM zren@health.usf.edu
OI xu, kaya/0000-0002-5649-9678
CR Alzamora MG, 2005, NEURORADIOLOGY, V47, P282, DOI 10.1007/s00234-005-1343-2
   Ambekar Sudheer, 2014, Case Rep Vasc Med, V2014, P341748, DOI 10.1155/2014/341748
   Bilbao G, 2010, ACTA NEUROCHIR, V152, P1155, DOI 10.1007/s00701-010-0660-3
   Choi JW, 2006, SPINE, V31, pE891, DOI 10.1097/01.brs.0000244614.84685.c2
   Daentzer D, 2003, SURG NEUROL, V59, P300, DOI 10.1016/S0090-3019(03)00113-7
   Dolati P, 2015, CUREUS, V7, DOI 10.7759/cureus.356
   Ebraheim NA, 1998, SURG RADIOL ANAT, V20, P389, DOI 10.1007/BF01653127
   Epstein Nancy E, 2003, Spine J, V3, P404, DOI 10.1016/S1529-9430(03)00079-2
   Eskander MS, 2009, SPINAL CORD, V47, P773, DOI 10.1038/sc.2009.29
   Gantwerker BR, 2010, NEUROSURGERY, V67, pE874, DOI 10.1227/01.NEU.0000374858.18717.33
   Gok M, 2018, TURK NEUROSURG, V28, P469, DOI 10.5137/1019-5149.JTN.19286-16.2
   Herrera DA, 2008, AM J NEURORADIOL, V29, P1585, DOI 10.3174/ajnr.A1123
   Jecko V, 2015, NEUROCHIRURGIE, V61, P38, DOI 10.1016/j.neuchi.2014.08.002
   Jung HJ, 2011, J KOREAN NEUROSURG S, V50, P520, DOI 10.3340/jkns.2011.50.6.520
   Katsaridis V, 2007, CLIN NEUROL NEUROSUR, V109, P512, DOI 10.1016/j.clineuro.2007.02.017
   Khan SA, 2014, BRIT J NEUROSURG, V28, P423, DOI 10.3109/02688697.2014.913772
   Lang SS, 2006, SURG NEUROL, V65, P283, DOI 10.1016/j.surneu.2005.06.040
   Lo WB, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.12.084
   Neo M, 2008, SPINE, V33, P779, DOI 10.1097/BRS.0b013e31816957a7
   Obermuller T, 2015, ACTA NEUROCHIR, V157, P1941, DOI 10.1007/s00701-015-2594-2
   Rosenthal P, 2013, SPINE, V38, pE1567, DOI 10.1097/BRS.0b013e3182a528e9
   Shakir Hakeem J, 2016, Surg Neurol Int, V7, P104, DOI 10.4103/2152-7806.196235
NR 22
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 282
EP 286
DI 10.1016/j.wneu.2018.10.217
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100252
PM 30415047
DA 2020-05-12
ER

PT J
AU Tsutsumi, S
   Oishi, H
   Nonaka, S
   Okura, H
   Suzuki, T
   Yasumoto, Y
   Ishii, H
AF Tsutsumi, Satoshi
   Oishi, Hidenori
   Nonaka, Senshu
   Okura, Hidehiro
   Suzuki, Takamoto
   Yasumoto, Yukimasa
   Ishii, Hisato
TI Orbital Arteriovenous Fistula Coexistent with an Arteriovenous
   Hemangioma: A Rare Occurrence and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Coexistence; Orbital AVF; Orbital hemangioma; Treatment strategy
ID CAVERNOUS HEMANGIOMA; TRANSVENOUS EMBOLIZATION; COIL EMBOLIZATION
AB BACKGROUND: Orbital arteriovenous fistula (AVF) is a rare entity with only 17 cases reported so far. Arteriovenous hemangioma is a distinct entity of angioma that most frequently affects the skin. However, to our knowledge, there has not been a case arising in the orbit.
   CASE PRESENTATION: A previously healthy, 73-year-old man had progressive proptosis for one month. At presentation, the patient showed considerable proptosis, hyperemia in the lower eyelid, chemosis, and total ophthalmoplegia on the right side. Computed tomography and magnetic resonance imaging revealed a round retro-orbital mass, 23 mm in maximal dimension, and lying in the inferomedial aspect of the orbit with an irregular-shaped lesion in the orbital apex. Cerebral angiography detected an orbital AVF fed by the ipsilateral maxillary and ophthalmic arteries and draining into the inferior ophthalmic vein. Stain of the retro-orbital mass was not identified. A transvenous coil embolization via the facial and superior ophthalmic veins achieved complete isolation of the AVF with satisfactory outcome. Two months later, the orbital mass, well-circumscribed and lacking perilesional hemosiderin deposition, was microsurgically resected via a lateral orbitotomy. Histological diagnosis was consistent with arteriovenous hemangioma.
   CONCLUSIONS: An AVF and arteriovenous hemangioma may simultaneously develop in the same orbit. In patients with symptomatic orbital AVF and coexisting other orbital pathology, strategies should be carefully planned before setting about the treatment.
C1 [Tsutsumi, Satoshi; Nonaka, Senshu; Okura, Hidehiro; Suzuki, Takamoto; Yasumoto, Yukimasa; Ishii, Hisato] Juntendo Univ, Urayasu Hosp, Dept Neurol Surg, Chiba, Japan.
   [Oishi, Hidenori] Juntendo Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan.
RP Tsutsumi, S (reprint author), Juntendo Univ, Urayasu Hosp, Dept Neurol Surg, Chiba, Japan.
EM shotaro@juntendo-urayasu.jp
OI Tsutsumi, Satoshi/0000-0002-4651-3018
CR Akiyama M, 2001, BRIT J DERMATOL, V144, P604, DOI 10.1046/j.1365-2133.2001.04094.x
   Calandriello L, 2017, SURV OPHTHALMOL, V62, P393, DOI 10.1016/j.survophthal.2017.01.004
   Caragine LP, 2006, NEUROSURGERY S, V58
   Chaichana KL, 2012, NEUROSURG CLIN N AM, V23, P7, DOI 10.1016/j.nec.2011.09.001
   Chen BY, 2018, EUR NEUROL, V80, P17, DOI 10.1159/000492062
   Cheng KC, 2009, OPHTHAL PLAST RECONS, V25, P245, DOI 10.1097/IOP.0b013e3181a33706
   Deguchi J, 2005, J NEUROSURG, V103, P756, DOI 10.3171/jns.2005.103.4.0756
   Downs E, 2018, J RADIOL CASE REP, V12, P1, DOI 10.3941/jrcr.v12i2.2807
   Hamada J, 2006, SURG NEUROL, V65, P55, DOI 10.1016/j.surneu.2005.03.043
   Kobkitsuksakul C, 2016, DIAGN INTERV RADIOL, V22, P555, DOI 10.5152/dir.2016.16073
   Kodama T, 2004, JPN J OPHTHALMOL, V48, P415, DOI 10.1007/s10384-003-0065-4
   Konstas AA, 2017, OPHTHAL PLAST RECONS, V33, pE63, DOI 10.1097/IOP.0000000000000753
   KOUTLAS IG, 1994, J CUTAN PATHOL, V21, P343, DOI 10.1111/j.1600-0560.1994.tb00710.x
   Kuwayama Naoya, 2016, Acta Neurochir Suppl, V123, P185, DOI 10.1007/978-3-319-29887-0_26
   Lee AG, 2019, SURV OPHTHALMOL, V64, P248, DOI 10.1016/j.survophthal.2017.10.001
   Lin CJ, 2010, J CLIN NEUROSCI, V17, P783, DOI 10.1016/j.jocn.2009.09.035
   Lv M, 2015, INTERV NEURORADIOL, V21, P357, DOI 10.1177/1591019915582925
   Naqvi J, 2013, ORBIT, V32, P124, DOI 10.3109/01676830.2013.764444
   Sato M, TURK NEUROSURG, DOI [10.5137/1019-5149.JNT.21114-17.2, DOI 10.5137/1019-5149.JNT.21114-17.2]
   Shields JA, 2004, OPHTHALMOLOGY, V111, P997, DOI 10.1016/j.ophtha.2003.01.002
   Strianese D, 2014, NEURORADIOL J, V27, P223, DOI 10.15274/NRJ-2014-10016
   Subramanian PS, 2005, NEURORADIOLOGY, V47, P62, DOI 10.1007/s00234-004-1305-0
   van den Berg R, 2009, ORBIT, V28, P417, DOI 10.3109/01676830903104769
   Wang CY, 2016, CAN J OPHTHALMOL, V51, pE34, DOI 10.1016/j.jcjo.2015.10.001
   Williamson RW, 2013, NEUROSURGERY, V72, pE130, DOI 10.1227/NEU.0b013e31827242cb
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 287
EP 292
DI 10.1016/j.wneu.2018.11.003
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100253
PM 30447460
DA 2020-05-12
ER

PT J
AU Panagiotopoulos, V
   Zampakis, P
   Karnabatidis, D
   Messinis, L
   Gatzounis, G
AF Panagiotopoulos, Vasileios
   Zampakis, Petros
   Karnabatidis, Dimitrios
   Messinis, Lampros
   Gatzounis, Georgios
TI Retrieval of Distally Migrated Coil with Direct Aspiration Technique
   During Temporary Bridging Device Embolization of a Wide-Neck
   Supraophthalmic Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE ADAPT; Coil migration; Coil retrieval
AB BACKGROUND: Dislodgement of coils during endovascular embolization of brain aneurysms is a potentially hazardous complication due to high risk for cerebral infarct and subsequent neurological deficits or death. We describe a case of whole coil mesh dislodgement due to interaction between the coil loops and a temporary neck-bridging device struts and subsequent successful retrieval of a distally migrated coil into the left middle cerebral artery branch with direct aspiration technique.
   CASE DESCRIPTION : A 32-year-old man was referred to our hospital for treatment of an unruptured wide-neck supraophthalmic aneurysm of the left internal carotid artery. A temporary bridging-neck device was placed and expanded across the aneurysm neck in order to support coil deployment inside the aneurysm sac and avoid coil prolapse into the lumen of the parent vessel. Retrieval of the bridging-neck device after coil embolization resulted in whole coil mesh dislodgement due to interaction between the coil loops and the device struts and finally distal migration of a single coil into the left middle cerebral artery temporal branch. The coil was successfully retrieved using direct aspiration technique similar to thrombektomy in acute ischemic stroke. The patient did not have any neurologic deficit.
   CONCLUSIONS: Our case indicates that first-line direct aspiration technique is an atraumatic and effective procedure for coil retrieval when dislodged even in distal cerebral vessels, minimizing the chance for additional retrieval technique-related risks. Interventionists should be aware of coil dislodgment as a potential temporary bridging-neck device-related complication.
C1 [Panagiotopoulos, Vasileios; Gatzounis, Georgios] Univ Hosp Patras, Dept Neurosurg, Patras, Greece.
   [Panagiotopoulos, Vasileios; Zampakis, Petros] Univ Hosp Patras, Dept Endovasc Neurosurg Intervent Neuroradiol, Patras, Greece.
   [Karnabatidis, Dimitrios] Univ Hosp Patras, Dept Intervent Radiol, Patras, Greece.
   [Messinis, Lampros] Univ Hosp Patras, Dept Neurol, Neuropsychol Sect, Patras, Greece.
RP Panagiotopoulos, V (reprint author), Univ Hosp Patras, Dept Neurosurg, Patras, Greece.; Panagiotopoulos, V (reprint author), Univ Hosp Patras, Dept Endovasc Neurosurg Intervent Neuroradiol, Patras, Greece.
EM panagiotopoulos2000@yahoo.com
CR Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Amuluru K, 2018, WORLD NEUROSURG, V117, P382, DOI 10.1016/j.wneu.2018.06.175
   Ding D, 2014, J NEUROINTERV SURG, V6, P428, DOI 10.1136/neurintsurg-2013-010872
   Fischer S, 2017, J NEUROINTERV SURG, V9, P1093, DOI 10.1136/neurintsurg-2016-012664
   Masahira N, 2015, BMJ CASE REP, V2015
   Singh Devendra Pal, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P48, DOI 10.7461/jcen.2016.18.1.48
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 294
EP 297
DI 10.1016/j.wneu.2018.10.210
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100255
PM 30414519
DA 2020-05-12
ER

PT J
AU Shaaya, E
   Fridley, J
   Barber, SM
   Syed, S
   Xia, J
   Galgano, M
   Oyelese, A
   Telfeian, A
   Gokaslan, Z
AF Shaaya, Elias
   Fridley, Jared
   Barber, Sean M.
   Syed, Sohail
   Xia, Jimmy
   Galgano, Michael
   Oyelese, Adetokunbo
   Telfeian, Albert
   Gokaslan, Ziya
TI Posterior Nerve-Sparing Multilevel Cervical Corpectomy and
   Reconstruction for Metastatic Cervical Spine Tumors: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervical spine reconstruction; Polymethylmethacrylate; Posterior
   cervical corpectomy; Spine metastasis; Spine tumor; Thyroid carcinoma
ID RESECTION; CANCER
AB BACKGROUND: Cervical spine metastases with circumferential spinal cord compression are often treated with combined anterior-posterior decompression and stabilization. In patients with large anterior neck masses, prior radiotherapy to the neck, or prior anterior neck surgery, however, anterior approaches may pose additional risk. In such cases, posterior-only approaches that allow for circumferential decompression and anterior column reconstruction may be beneficial.
   CASE DESCRIPTION: We present the case of a seventy-year-old male with follicular thyroid carcinoma metastatic to the cervical spine causing spinal cord compression. We utilized a posterior-only approach for a C6-C7 partial corpectomy and posterior decompression and fusion from C2 to T2. Our technique involved pre-operative embolization of the right vertebral artery to safely gain access to the ventral surface of the spinal cord and vertebral bodies. Anterior column support was provided by a chest tube/polymethylmethacrylate construct, allowing the implant to be placed within the anterior column from a posterior approach without nerve root sacrifice. The patient tolerated the procedure well. He had no post-operative neurologic deficits. Two months later he underwent a total thyroidectomy followed by stereotactic radiotherapy to the tumor bed (2700 cGy total, 3 fractions). At one-year follow-up he was active and without significant pain or focal neurologic deficits.
   CONCLUSIONS: We propose a novel approach to ventral/circumferential cervical spine tumors that combines epidural decompression and cervical stabilization via a posterior-only approach. By using a chest tube/polymethylmethacrylate construct, anterior column support can be achieved through a posterior approach without nerve root sacrifice.
C1 [Shaaya, Elias; Fridley, Jared; Barber, Sean M.; Syed, Sohail; Xia, Jimmy; Galgano, Michael; Oyelese, Adetokunbo; Telfeian, Albert; Gokaslan, Ziya] Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Warren Alpert Med Sch, Providence, RI 02903 USA.
RP Gokaslan, Z (reprint author), Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Warren Alpert Med Sch, Providence, RI 02903 USA.
EM ziya_gokaslan@brown.edu
OI Xia, Jimmy/0000-0001-6532-7184
CR Bilsky MH, 2010, J NEUROSURG-SPINE, V13, P324, DOI 10.3171/2010.3.SPINE09459
   Bydon M, 2015, OPER NEUROSURG, V11, pE585, DOI 10.1227/NEU.0000000000000961
   COOPER PR, 1993, NEUROSURGERY, V32, P1, DOI 10.1227/00006123-199301000-00001
   ERRICO TJ, 1993, NEUROSURGERY, V32, P678, DOI 10.1227/00006123-199304000-00030
   Fehlings MG, 2009, SPINE, V34, pS108, DOI 10.1097/BRS.0b013e3181bae1d2
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Kushchayev S, 2010, THYROID, V20, P555, DOI 10.1089/thy.2009.0420
   Kushchayeva YS, 2014, THYROID, V24, P1488, DOI 10.1089/thy.2013.0633
   Laufer I, 2013, J NEUROSURG-SPINE, V18, P207, DOI 10.3171/2012.11.SPINE12111
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Molina C, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16129
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Placantonakis DG, 2008, J NEUROSURG-SPINE, V9, P111, DOI 10.3171/SPI/2008/9/8/111
NR 13
TC 0
Z9 0
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 298
EP 302
DI 10.1016/j.wneu.2018.11.010
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100256
PM 30447451
DA 2020-05-12
ER

PT J
AU Mlaver, E
   Keifer, O
   Tora, MS
   Campbell, M
   Boulis, NM
AF Mlaver, Eli
   Keifer, Orion, Jr.
   Tora, Muhibullah S.
   Campbell, Melissa
   Boulis, Nicholas M.
TI Phantom Sensation-Underreported Sensory Outcome Following
   Intercostal-to-Musculocutaneous Nerve Transfer
SO WORLD NEUROSURGERY
LA English
DT Article
DE Avulsion; Brachial plexopathy; Brachial plexus; Intercostal to
   musculocutaneous nerve transfer; Neurotization; Peripheral nerve
   surgery; Sensory outcome
ID BRACHIAL-PLEXUS INJURY; RECONSTRUCTION
AB BACKGROUND: Intercostal-to-musculocutaneous nerve transfer is commonly performed in patients with brachial plexus avulsion injuries. As techniques have improved since its inception in 1963, most patients now experience some level of motor function improvement of their affected arm. While motor outcomes are well described, there is a paucity of literature describing sensory outcomes. It is thus difficult to gauge surgical success with respect to sensory function, and there is a necessity to share clear expectations with patients regarding intended or unintended postoperative sensation.
   CASE DESCRIPTION: In this case report, we describe an unintended sensory outcome of this procedure. Three years after the operation, our patient experiences a "phantom sensation" on his chest when he is touched on the lateral forearm in the distribution of the lateral antebrachial cutaneous nerve. This outcome can be explained with review of the anatomy before and after the operation. The persistence of this adverse outcome suggests limitations in sensory cortical neuroplasticity.
   CONCLUSIONS: It is important to be aware of potential sensory complications in intercostal-to-musculocutaneous nerve transfer. Although this complication is known, it is often overlooked and underreported. Complications such as this should be emphasized in order to set expectations for patients and guide evaluation of sensory outcomes in future study.
C1 [Mlaver, Eli; Tora, Muhibullah S.; Boulis, Nicholas M.] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Keifer, Orion, Jr.; Tora, Muhibullah S.; Campbell, Melissa; Boulis, Nicholas M.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
RP Tora, MS (reprint author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.; Tora, MS (reprint author), Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
EM mtora@emory.edu
OI Boulis, Nicholas/0000-0002-7271-3953; Tora,
   Muhibullah/0000-0002-3300-6367
CR Bhandari P S, 2009, Indian J Plast Surg, V42, P150, DOI 10.4103/0970-0358.59272
   BURGE PD, 1995, J HAND SURG-BRIT EUR, V20B, P215, DOI 10.1016/S0266-7681(05)80054-3
   CHUANG DC, 1992, J HAND SURG-AM, V17A, P822, DOI 10.1016/0363-5023(92)90451-T
   FREILINGER G, 1978, PLAST RECONSTR SURG, V62, P240, DOI 10.1097/00006534-197808000-00013
   Hems T, 2011, J HAND MICROSURG, V3, P6, DOI 10.1007/s12593-011-0031-1
   Malessy MJA, 1998, NEUROSURGERY, V42, P787, DOI 10.1097/00006123-199804000-00062
   MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593
   OGINO T, 1995, MICROSURG, V16, P571, DOI 10.1002/micr.1920160812
   SEDDON HJ, 1963, J BONE JOINT SURG BR, V45, P447
   Socolovsky M, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.12.FOCUS16431
   Songcharoen P, 2008, SCAND J SURG, V97, P317, DOI 10.1177/145749690809700408
   Squintani G, 2013, J NEUROSURG, V119, P907, DOI 10.3171/2013.6.JNS121801
   Sulaiman OAR, 2009, NEUROSURGERY, V65, pA55, DOI 10.1227/01.NEU.0000341165.83218.AC
   THOMAS DGT, 1983, J NEUROL NEUROSUR PS, V46, P924, DOI 10.1136/jnnp.46.10.924
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 303
EP 307
DI 10.1016/j.wneu.2018.10.216
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100257
PM 30415052
DA 2020-05-12
ER

PT J
AU Keifer, OP
   Zeising, K
   Tora, MS
   Campbell, M
   Bezchlibnyk, YB
   Boulis, N
AF Keifer, Orion P., Jr.
   Zeising, Kate
   Tora, Muhibullah S.
   Campbell, Melissa
   Bezchlibnyk, Yarema B.
   Boulis, Nicholas
TI Use of a Subtemporal Approach for a Salvage Placement of a Trigeminal
   Ganglion Stimulating Electrode for the Treatment of Trigeminal
   Neuropathic Pain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Approach; Functional neurosurgery; Neuropathic pain; Neurostimulation;
   Subtemporal; Trigeminal ganglion; Trigeminal neuralgia
ID NERVE-STIMULATION; NEURALGIA
AB BACKGROUND: Trigeminal ganglion stimulation can be effective for trigeminal neuralgia. For patients who respond well to neurostimulation delivered percutaneously through the foramen ovale but require extensive revision and removal of instrumentation, a subtemporal approach for stimulation of the trigeminal ganglion is an alternative option as a salvage procedure.
   CASE DESCRIPTION: We report on a 47-year-old woman who responded well to neurostimulation for trigeminal neuropathic pain over a 1-year period from 2008 to 2009. Her preoperative pain on the numerical rating scale (NRS) was between 7 and 8 out of 10, which decreased to 2 out of 10 postoperatively. However, she developed lead migration because of a motor vehicle accident. After revision surgeries to correct this, she continued to experience pain relief until 2011. At follow-up, signs of infection prompted removal of instrumentation and subsequent return of her pain. She continued to experience persistent and severe pain (NRS score 7 of 10), which was intractable to pharmacologic treatment over 5 years. She returned in 2016 to discuss neurosurgical options, and the original approach was ruled out because of her history of lead migration, erosion, and scarring. A subtemporal approach was pursued as a salvage option, which provided several advantages for this patient.
   CONCLUSIONS: The subtemporal approach for salvage placement of the trigeminal ganglion stimulating electrode was effective in this patient and minimized risks given her history of erosion and multiple operations. This suggests that the subtemporal approach is a viable salvage operation for trigeminal ganglion stimulation for trigeminal neuropathic pain.
C1 [Keifer, Orion P., Jr.; Zeising, Kate; Tora, Muhibullah S.; Campbell, Melissa; Bezchlibnyk, Yarema B.; Boulis, Nicholas] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Tora, Muhibullah S.; Boulis, Nicholas] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.
RP Tora, MS (reprint author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.; Tora, MS (reprint author), Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA.
EM mtora@emory.edu
OI Tora, Muhibullah/0000-0002-3300-6367
CR Bick SKB, 2017, NEUROSURG CLIN N AM, V28, P429, DOI 10.1016/j.nec.2017.02.009
   Hitchon PW, 2016, CLIN NEUROL NEUROSUR, V149, P166, DOI 10.1016/j.clineuro.2016.08.016
   Keifer OP, 2017, WORLD NEUROSURG, V105, P599, DOI 10.1016/j.wneu.2017.06.064
   Kustermans L, 2017, J CRANIO MAXILL SURG, V45, P39, DOI 10.1016/j.jcms.2016.10.014
   MEYERSON BA, 1986, NEUROSURGERY, V18, P59, DOI 10.1227/00006123-198601000-00010
   Singla S, 2011, J NEUROSCI RURAL PRA, V2, P150, DOI 10.4103/0976-3147.83580
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 308
EP 310
DI 10.1016/j.wneu.2018.11.034
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100258
PM 30447440
DA 2020-05-12
ER

PT J
AU Tan, CL
   Anil, G
   Yeo, TT
   Chou, N
AF Tan, Chin Lik
   Anil, Gopinathan
   Yeo, Tseng Tsai
   Chou, Ning
TI Challenges in the Management of a Ruptured Bihemispheric Posterior
   Inferior Cerebellar Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bihemispheric posterior inferior cerebellar artery; Dissecting aneurysm;
   Endovascular treatment of cerebral aneurysm; Parent vessel occlusion;
   Suboccipital craniectomy
ID ENDOVASCULAR TREATMENT; ANOMALOUS ORIGIN; PICA
AB BACKGROUND: Bihemispheric posterior inferior cerebellar artery (PICA) is a rare anatomic variant wherein a single PICA supplies both cerebellar hemispheres. Inasmuch as it is the only PICA, treatment of aneurysms arising from this anatomic variant is more complex. We present a case of a ruptured bihemispheric PICA aneurysm and the challenges encountered in its management.
   CASE DESCRIPTION: A 54-year-old man presented with giddiness and nausea. Otherwise, he was neurologically intact. Computed tomography of the brain showed a right cerebellar hematoma and intraventricular hemorrhage. Cerebral angiography revealed a dissecting aneurysm in the retromedullary segment of a right bihemispheric PICA with a prominent saccular component. Initially, the patient refused to undergo any invasive treatment. However, when a follow-up angiogram showed an increase in the size of the aneurysm sac, he consented to treatment. Although parent vessel occlusion (PVO) was the clinical recommendation, in view of the patient's apprehensions, only the saccular component of the aneurysm was coil embolized without sacrifice of the parent vessel. Fifteen days after the coiling, there was a rebleed from this dissecting aneurysm, which was treated with PVO followed by suboccipital craniectomy. The patient made a reasonable recovery, and his modified Rankin score was 1 at his 6-month follow-up visit.
   CONCLUSIONS: In dissecting aneurysms of a bihemispheric PICA, isolated endosaccular occlusion provides uncertain protection from a rebleed, whereas a more reliable treatment with PVO carries an unpredictable risk of ischemic complications. The risks of a PVO may be rationalized as a life-saving measure; however, the subsequent threshold for posterior fossa decompression should be low.
C1 [Tan, Chin Lik; Yeo, Tseng Tsai; Chou, Ning] Natl Univ Singapore Hosp, Dept Diagnost Imaging, Div Neurosurg, Singapore, Singapore.
   [Anil, Gopinathan] Natl Univ Singapore Hosp, Dept Diagnost Imaging, Div Intervent Radiol, Singapore, Singapore.
RP Anil, G (reprint author), Natl Univ Singapore Hosp, Dept Diagnost Imaging, Div Intervent Radiol, Singapore, Singapore.
EM ivyanil10@gmail.com
RI Chou, Ning/B-5314-2011
OI Anil, Gopinathan/0000-0002-8192-1287
CR AHUJA A, 1992, AM J NEURORADIOL, V13, P1625
   Carlson AP, 2015, J NEUROL SURG REP, V76, pE275, DOI 10.1055/s-0035-1564607
   Carlson AP, 2013, J NEUROINTERV SURG, V5, P601, DOI 10.1136/neurintsurg-2012-010527
   Cellerini M, 2008, NEURORADIOLOGY, V50, P315, DOI 10.1007/s00234-007-0333-y
   Cullen SP, 2005, NEURORADIOLOGY, V47, P809, DOI 10.1007/s00234-005-1427-z
   Li H, 2015, J STROKE CEREBROVASC, V24, P2134, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.034
   Mazighi M, 2002, INTERV NEURORADIOL, V8, P15, DOI 10.1177/159101990200800103
   Ogasawara Y, 2017, J NEUROSCI RURAL PRA, V8, P654, DOI 10.4103/jnrp.jnrp_285_17
   OGAWA T, 1991, AM J NEURORADIOL, V12, P186
   Peluso JP, 2008, AM J NEURORADIOL, V29, P86, DOI 10.3174/ajnr.A0758
   Reinacher P, 2006, CLIN NEURORADIOL, V16, P190
   Sardhara J, 2013, ACTA NEUROCHIR, V155, P1539, DOI 10.1007/s00701-013-1776-z
   Scialfa G, 1975, ADV CEREBRAL ANGIOGR, P55
NR 13
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 317
EP 321
DI 10.1016/j.wneu.2018.11.051
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100261
PM 30448579
DA 2020-05-12
ER

PT J
AU Okazaki, T
   Sakamoto, S
   Ishii, D
   Oshita, J
   Matsushige, T
   Shinagawa, K
   Ichinose, N
   Matsuda, S
   Kurisu, K
AF Okazaki, Takahito
   Sakamoto, Shigeyuki
   Ishii, Daizo
   Oshita, Jumpei
   Matsushige, Toshinori
   Shinagawa, Katsuhiro
   Ichinose, Nobuhiko
   Matsuda, Shingo
   Kurisu, Kaoru
TI A Pial Arteriovenous Fistula in Infancy as the Presenting Manifestation
   of Hereditary Hemorrhagic Telangiectasia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous fistula; Endovascular; Heart failure; Hemorrhage;
   Hereditary hemorrhagic telangiectasia; Hydrocephalus; Varix
ID MALFORMATIONS; CHILDREN
AB BACKGROUND: Pial arteriovenous fistulas (PAVFs) are rare, accounting for 1.6%-4.7% of all intracranial vascular malformations. Often diagnosed in childhood, about 30% are associated with hereditary hemorrhagic telangiectasia. A case of PAVF diagnosed soon after birth and given cerebrovascular therapy 4 months after birth is reported.
   CASE DESCRIPTION: The patient presented with heart failure immediately after birth. Ultrasonography of the head showed abnormal blood flow in the brain. On digital subtraction angiography performed 4 months after birth, a PAVF with a dural feeder shunt and a giant varix at the posterior temporal part was confirmed. After transarterial embolization (TAE), shunt blood flow disappeared. New shunt flow from the right posterior cerebral artery into the varix was confirmed by magnetic resonance imaging 3 months after the operation. A second TAE procedure using a liquid embolic material was performed and confirmed the complete disappearance of the shunt.
   CONCLUSIONS: This report describes a case of infant PAVF with heart failure, a giant varix, hydrocephalus, and intraventricular hemorrhage treated by TAE using platinum coils and liquid embolic material.
C1 [Okazaki, Takahito; Sakamoto, Shigeyuki; Ishii, Daizo; Oshita, Jumpei; Matsushige, Toshinori; Shinagawa, Katsuhiro; Ichinose, Nobuhiko; Matsuda, Shingo; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
RP Okazaki, T (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM okazaki@hiroshima-u.ac.jp
OI Sakamoto, Shigeyuki/0000-0003-3683-4771
CR GARCIAMONACO R, 1991, CHILD NERV SYST, V7, P48, DOI 10.1007/BF00263834
   Giordano P, 2013, J PEDIATR-US, V163, P179, DOI 10.1016/j.jpeds.2013.02.009
   HALBACH VV, 1989, AM J NEURORADIOL, V10, P747
   Hetts SW, 2012, AM J NEURORADIOL, V33, P1710, DOI 10.3174/ajnr.A3194
   Hoh BL, 2001, NEUROSURGERY, V49, P1351, DOI 10.1097/00006123-200112000-00011
   Komiyama M., 2015, SURG CEREB STROKE JP, V43, P193
   LASJAUNIAS PL, 2006, NEUROSURGERY S3, V59, P184
   Lv X, 2009, AM J NEURORADIOL, V30, P851, DOI 10.3174/ajnr.A1436
   Mahadevan J, 2004, INTERV NEURORADIOL, V10, P27, DOI 10.1177/159101990401000102
   NELSON PK, 1992, NEUROIMAG CLIN N AM, V2, P309
   ROMAN G, 1978, ANN NEUROL, V4, P130, DOI 10.1002/ana.410040207
   Terada A, 2018, J NEUROSURG PEDIAT, V27, P1
   Weon YC, 2005, ACTA NEUROCHIR, V147, P17, DOI 10.1007/s00701-004-0341-1
   Willemse RB, 2000, J NEUROSURG, V92, P779, DOI 10.3171/jns.2000.92.5.0779
NR 14
TC 1
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 322
EP 325
DI 10.1016/j.wneu.2018.10.146
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100262
PM 30391600
DA 2020-05-12
ER

PT J
AU Xu, QL
   Gu, R
   Zhu, QS
   Suya, D
AF Xu, Qinli
   Gu, Rui
   Zhu, Qingsan
   Suya, Danny
TI A Severe Case of Hirayama Disease Successfully Treated by Posterior
   Cervical Fixation without Decompression and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hirayama disease; Nondecompression; Nonfusion; Posterior cervical
   fixation; Surgical treatment
ID JUVENILE MUSCULAR-ATROPHY; SPINAL-CORD
AB BACKGROUND: Hirayama disease (HD) is a rare disease traditionally treated with nonsurgical procedures. Surgical treatment, which is performed by decompression and/or fusion of the cervical spine, is generally considered for rapidly progressive or advanced cases, and the choice of surgical technique is debatable. We describe the first severe case of HD that was successfully treated by posterior lateral mass screw fixation without decompression or fusion.
   CASE DESCRIPTION: The patient was a 17-year-old adolescent boy who presented with progressive symptoms bilaterally with an unsatisfactory history of conservative treatment. We performed posterior lateral mass screw fixation without decompression or fusion and removed the internal fixation after 4 years of follow-up. Symptom remission and imaging performance improvement were achieved, and the stability and range of motion of the cervical spine were maintained.
   CONCLUSIONS: Nondecompression and nonfusion surgery was successful and achieved satisfactory results in this case; therefore, it serves as a promising candidate for the surgical treatment of HD.
C1 [Xu, Qinli; Gu, Rui; Zhu, Qingsan; Suya, Danny] Jilin Univ, China Japan Union Hosp, Dept Orthoped, Changchun, Jilin, Peoples R China.
RP Zhu, QS (reprint author), Jilin Univ, China Japan Union Hosp, Dept Orthoped, Changchun, Jilin, Peoples R China.
EM zhuqs@jlu.edu.cn
FU Shanghai Sanyou Medical Co.,Ltd. [3R215P403430]
FX This study was supported by the crosswise tasks of Shanghai Sanyou
   Medical Co.,Ltd. (3R215P403430) in providing the cost of imaging
   examination for the patient.
CR Anuradha S, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/5839761
   Arrese I, 2009, NEUROCIRUGIA, V20, P555
   Brandicourt P, 2018, NEUROCHIRURGIE, V64, P303, DOI 10.1016/j.neuchi.2018.04.004
   Desai JA, 2011, NEUROLOGY, V77, pE73, DOI 10.1212/WNL.0b013e31822f02d0
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   HIRAYAMA K, 1963, NEUROLOGY, V13, P373, DOI 10.1212/WNL.13.5.373
   Hirayama K, 2010, INTERNAL MED, V39, P283
   Hirayama K, 1959, PSYCHIATR NEUROL JAP, V61, P2190
   Hirayama Keizo, 2008, Brain and Nerve (Tokyo), V60, P17
   Imamura H, 2001, No To Shinkei, V53, P1033
   Ito S, 2005, J NEUROL NEUROSUR PS, V76, P132, DOI 10.1136/jnnp.2003.031609
   Jin X, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-349
   Kohno M, 1998, SURG NEUROL, V50, P421, DOI 10.1016/S0090-3019(97)00451-5
   Lee Kyoung Hee, 2016, Korean J Spine, V13, P170, DOI 10.14245/kjs.2016.13.3.170
   Lewis D, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.123
   Narayana Gowda B S, 2013, J Orthop Case Rep, V3, P11, DOI 10.13107/jocr.2250-0685.107
   Panchal M, 2018, INDIAN J MED SPEC, V9, P20, DOI 10.1016/j.injms.2017.12.004
   Paredes I, 2014, J NEUROSURG-SPINE, V20, P191, DOI 10.3171/2013.10.SPINE13508
   Rai GS, 2014, J CLIN DIAGN RES, V8, pRD4, DOI 10.7860/JCDR/2014/10394.5316
   Sim K, 2014, J CLIN NEUROSCI, V21, P487, DOI 10.1016/j.jocn.2013.06.028
   Song J, 2018, WORLD NEUROSURG, V114, pE1094, DOI 10.1016/j.wneu.2018.03.152
   Song J, 2017, WORLD NEUROSURG, V105, P69, DOI 10.1016/j.wneu.2017.05.097
   Tokumaru Y, 2001, Rinsho Shinkeigaku, V41, P173
NR 23
TC 0
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 326
EP 330
DI 10.1016/j.wneu.2018.10.157
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100263
PM 30391760
DA 2020-05-12
ER

PT J
AU Newhart, H
   Patterson, J
   Gunasekaran, A
   Pandey, T
   Kumar, M
   Kazemi, N
AF Newhart, Hamilton
   Patterson, John
   Gunasekaran, Arunprasad
   Pandey, Tarun
   Kumar, Manoj
   Kazemi, Noojan
TI The Incremental Value of Magnetic Resonance Neurography for the
   Neurosurgeon: Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brachial plexus; Lumbar plexus; Neurography; Peripheral nerve;
   Peripheral nerve sheath tumor; Spine surgery
ID PERIPHERAL-NERVE DEGENERATION; MR NEUROGRAPHY; LUMBOSACRAL PLEXUS;
   NEUROPATHY; BENIGN; DIAGNOSIS; LESIONS; TUMORS
AB INTRODUCTION: Magnetic resonance neurography (MRN) is a newer imaging technique that is increasingly used for detailed visualization of peripheral nerves not reliably achieved with conventional imaging modalities. Although MRN has been previously characterized in the literature, few studies have assessed its utility to neurosurgery, where there is potentially substantial impact particularly with preoperative assessment. In this article, we performed a retrospective review of cases in which MRN was used for clinical evaluation and surgical decision making.
   METHODS: MRN, clinical assessment, and operative decision making were retrospectively assessed in 206 consecutive patients at our institution between 2015 and 2018.
   RESULTS: MRN was determined to lead to a change in diagnosis or surgical decision making in 44 patients (21.4%: 27 female, 17 male). These were classified into 6 major diagnostic categories: trauma, postsurgical evaluation, compressive/degenerative conditions, tumors, neuritis/inflammation, and other neurogenic lesions. Nine representative cases were selected from these categories to highlight the range of neurosurgical pathologies in which MRN was useful in diagnostic assessment and surgical decision making.
   CONCLUSIONS: MRN is an underused resource with great potential value in the diagnoses, surgical planning, and postoperative assessment of various neurosurgical conditions. These present incremental utility to the neurosurgeon as well as socioeconomic benefit in the detection of potentially surgically treatable lesions.
C1 [Newhart, Hamilton; Patterson, John; Gunasekaran, Arunprasad; Kazemi, Noojan] Univ Arkansas Med Sci, Dept Neurosurg, Little Rock, AR 72205 USA.
   [Pandey, Tarun; Kumar, Manoj] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.
RP Kazemi, N (reprint author), Univ Arkansas Med Sci, Dept Neurosurg, Little Rock, AR 72205 USA.
EM njkazemi@uams.edu
CR Ahlawat S, 2014, NEUROIMAG CLIN N AM, V24, P171, DOI 10.1016/j.nic.2013.03.035
   Andreou A, 2015, CANCER IMAGING, V15, DOI 10.1186/s40644-015-0041-5
   Assaker R, 2015, NEUROCHIRURGIE, V61, pS77, DOI 10.1016/j.neuchi.2014.10.108
   Bergmeister KD, 2018, HANDCHIR MIKROCHIR P, V50, P232, DOI 10.1055/s-0044-101833
   Bhargava R, 1997, PEDIATR RADIOL, V27, P124, DOI 10.1007/s002470050082
   Breckwoldt MO, 2015, INVEST RADIOL, V50, P498, DOI 10.1097/RLI.0000000000000156
   Chan CW, 2011, PAIN MED, V12, P577, DOI 10.1111/j.1526-4637.2011.01089.x
   Chhabra A, 2013, AM J NEURORADIOL, V34, P486, DOI 10.3174/ajnr.A3287
   Chhabra A, 2016, J MAGN RESON IMAGING, V44, P1513, DOI 10.1002/jmri.25293
   Chhabra A, 2016, EUR RADIOL, V26, P1235, DOI 10.1007/s00330-015-3958-y
   Chhabra A, 2016, WORLD J RADIOL, V8, P109, DOI 10.4329/wjr.v8.i1.109
   Chhabra A, 2011, SKELETAL RADIOL, V40, P1249, DOI 10.1007/s00256-011-1183-6
   Chhabra A, 2011, AM J ROENTGENOL, V197, P583, DOI 10.2214/AJR.10.6012
   Dailey AT, 1997, LANCET, V350, P1221, DOI 10.1016/S0140-6736(97)24043-2
   Dessouky R, 2018, SPINE, V43, P839, DOI 10.1097/BRS.0000000000002460
   Filler AG, 2005, J NEUROSURG-SPINE, V2, P99, DOI 10.3171/spi.2005.2.2.0099
   Filler AG, 1996, J NEUROSURG, V85, P299, DOI 10.3171/jns.1996.85.2.0299
   FILLER AG, 1993, LANCET, V341, P659, DOI 10.1016/0140-6736(93)90422-D
   HOWE FA, 1992, MAGNET RESON MED, V28, P328, DOI 10.1002/mrm.1910280215
   Lewis AM, 2006, ARCH NEUROL-CHICAGO, V63, P1469, DOI 10.1001/archneur.63.10.1469
   Maravilla KR, 1998, AM J NEURORADIOL, V19, P1011
   Mauermann ML, 2009, BRAIN, V132, P2265, DOI 10.1093/brain/awp169
   Mautner VF, 2008, NEURO-ONCOLOGY, V10, P593, DOI 10.1215/15228517-2008-011
   Muniz Neto FJ, 2018, BIOMED RES INT, V2018
   Petchprapa CN, 2010, RADIOGRAPHICS, V30, P983, DOI 10.1148/rg.304095135
   Pham M, 2015, ANN NEUROL, V78, P939, DOI 10.1002/ana.24524
   Robbins NM, 2016, CLIN IMAG, V40, P1118, DOI 10.1016/j.clinimag.2016.07.003
   Seddon HJ, 1943, J PHYSIOL-LONDON, V102, P191, DOI 10.1113/jphysiol.1943.sp004027
   Shibuya K, 2015, ANN NEUROL, V77, P333, DOI 10.1002/ana.24314
   Simon NG, 2014, NEURAL REGEN RES, V9, P2122, DOI 10.4103/1673-5374.147941
   Soldatos T, 2013, RADIOGRAPHICS, V33, P967, DOI 10.1148/rg.334115761
   Spinner RJ, 2003, J NEUROSURG, V99, P319, DOI 10.3171/jns.2003.99.2.0319
   SUNDERLAND S, 1951, BRAIN, V74, P491, DOI 10.1093/brain/74.4.491
   Thawait SK, 2011, AM J NEURORADIOL, V32, P1365, DOI 10.3174/ajnr.A2257
   Yuh EL, 2015, AM J NEURORADIOL, V36, P202, DOI 10.3174/ajnr.A4080
NR 35
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 331
EP 341
DI 10.1016/j.wneu.2018.10.212
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100264
PM 30415042
DA 2020-05-12
ER

PT J
AU Chen, WJ
   Xie, WX
   Xiao, ZL
   Chen, HY
   Jin, DX
   Ding, JY
AF Chen, Weijian
   Xie, Weixing
   Xiao, Zenglin
   Chen, Haoyan
   Jin, Daxiang
   Ding, Jinyong
TI Incidence of Cement Leakage Between Unilateral and Bilateral
   Percutaneous Vertebral Augmentation for Osteoporotic Vertebral
   Compression Fractures: A Meta-Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cement leakage; Meta-analysis; Percutaneous vertebral augmentation
ID TRANSVERSE PROCESS-PEDICLE; SPINAL ARTERY SYNDROME; BALLOON KYPHOPLASTY;
   PULMONARY-EMBOLISM; PUNCTURE TECHNIQUES; ACRYLIC CEMENT; BONE-CEMENT;
   VERTEBROPLASTY; COMPLICATION; VOLUME
AB BACKGROUND: A meta-analysis of randomized controlled trials (RCTs) was performed to compare the incidence of cement leakage between unilateral and bilateral percutaneous vertebral augmentation (PVA) in treating osteoporotic vertebral compression fractures (OVCFs).
   METHODS: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched to retrieve the reported data from the establishment of the databases until August 1, 2018. The RCTs on unilateral and bilateral PVA for OVCFs were included. RevMan software, version 5.3, was used for the meta-analysis.
   RESULTS: Six RCTs were selected from the reported data. The studies included a total of 676 vertebras, 339 of which had received unilateral PVA and the rest, bilateral PVA. The incidence of cement leakage in the unilateral PVA group was less than that in the bilateral PVA group, and the difference between the 2 groups was statistically significant (risk ratio, 0.50; 95% confidence interval, 0.35-0.72; P = 0.0002). The cement dosage in the unilateral PVA group was less than that in the bilateral PVA group, and the difference between the 2 groups was statistically significant (weighted mean difference, -1.98; 95% confidence interval, -2.24 to -1.72; P < 0.00001). The cement dosage and the incidence of cement leakage in the unilateral PVA group were lower than those in the bilateral PVA group.
   CONCLUSIONS: The results of our meta-analysis have provided sufficient evidence to show that the unilateral approach can decrease the incidence of cement leakage in PVA. We believe the unilateral approach could reduce the risk of cement leakage owing to the lower cement dosage in the treated vertebra.
C1 [Chen, Weijian; Xiao, Zenglin; Chen, Haoyan] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Xie, Weixing; Jin, Daxiang; Ding, Jinyong] Guangzhou Univ Chinese Med, Dept Spinal Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Jin, DX (reprint author), Guangzhou Univ Chinese Med, Dept Spinal Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM 642366579@qq.com
OI Chan, Hao Yan/0000-0001-8513-5526
CR Alvarez L, 2003, EUR SPINE J, V12, P356, DOI 10.1007/s00586-003-0525-z
   Braiteh F, 2009, HEART, V95, P275, DOI 10.1136/hrt.2008.158790
   Caynak B, 2009, ANN THORAC SURG, V87, P299, DOI 10.1016/j.athoracsur.2008.05.074
   Chen CM, 2014, J SPINAL DISORD TECH, V27, pE301, DOI 10.1097/BSD.0000000000000118
   Chen CM, 2011, J SPINAL DISORD TECH, V24, pE62, DOI 10.1097/BSD.0b013e318228f470
   Chen CM, 2010, INJURY, V41, P356, DOI 10.1016/j.injury.2009.09.021
   Chen LA, 2011, SPINE, V36, P534, DOI 10.1097/BRS.0b013e3181f99d70
   Cheng X, 2016, EUR SPINE J, V25, P3439, DOI 10.1007/s00586-016-4395-6
   Cho SM, 2011, J KOREAN NEUROSURG S, V49, P273, DOI 10.3340/jkns.2011.49.5.273
   Chung HJ, 2008, INT ORTHOP, V32, P817, DOI 10.1007/s00264-007-0439-1
   Chung Seung-Eun, 2006, Eur Spine J, V15 Suppl 5, P590, DOI 10.1007/s00586-005-0037-0
   Cotten A, 1996, RADIOLOGY, V200, P525, DOI 10.1148/radiology.200.2.8685351
   Feng H, 2015, J ORTHOP RES, V33, P1713, DOI 10.1002/jor.22957
   Feng YWH, 2014, J CLIN EXP MED, V13, P911
   Garfin SR, 2001, SPINE, V26, P1511, DOI 10.1097/00007632-200107150-00002
   Hao D, 2014, EUR SPINE J, V23, pS477
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   Kaufmann TJ, 2006, AM J NEURORADIOL, V27, P1933
   Kim KW, 2013, ASIAN SPINE J, V7, P301, DOI 10.4184/asj.2013.7.4.301
   Lai PL, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-116
   Lee SB, 2008, ACT NEUR S, V101, P157
   Lee YK, 2012, OSTEOPOROSIS INT, V23, P1859, DOI 10.1007/s00198-011-1833-5
   Li LH, 2013, CHINESE MED J-PEKING, V126, P3956, DOI 10.3760/cma.j.issn.0366-6999.20131398
   Li XG, 2012, J SPINAL DISORD TECH, V25, P142, DOI 10.1097/BSD.0b013e318213c113
   Liebschner MAK, 2001, SPINE, V26, P1547, DOI 10.1097/00007632-200107150-00009
   Lin EP, 2004, AM J NEURORADIOL, V25, P175
   Ma XL, 2012, EUR SPINE J, V21, P1844, DOI 10.1007/s00586-012-2441-6
   Padovani B, 1999, AM J NEURORADIOL, V20, P375
   Papadopoulos EC, 2008, J SPINAL DISORD TECH, V21, P589, DOI 10.1097/BSD.0b013e31815d6997
   Phillips FM, 2003, SPINE, V28, pS45, DOI 10.1097/00007632-200308011-00009
   Phillips FM, 2002, SPINE, V27, P2173, DOI 10.1097/00007632-200210010-00018
   Rahimi B, 2018, RESPIR MED CASE REP, V25, P78, DOI 10.1016/j.rmcr.2018.06.009
   Rebolledo BJ, 2013, BONE JOINT J, V95B, P401, DOI 10.1302/0301-620X.95B3.29819
   Rho YJ, 2012, EUR SPINE J, V21, P905, DOI 10.1007/s00586-011-2099-5
   Sakuma M, 2014, J BONE MINER METAB, V32, P200, DOI 10.1007/s00774-013-0486-1
   Scroop R, 2002, AM J NEURORADIOL, V23, P868
   Sun HL, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0479-6
   Teng MMH, 2006, AM J NEURORADIOL, V27, P224
   Tsai YD, 2010, SPINE, V35, pE134, DOI 10.1097/BRS.0b013e3181b52221
   Wang ZR, 2012, J CLIN NEUROSCI, V19, P723, DOI 10.1016/j.jocn.2011.08.023
   Yan L, 2016, OSTEOPOROSIS INT, V27, P1849, DOI 10.1007/s00198-015-3430-5
   Yan L, 2014, SPINE, V39, pB19, DOI 10.1097/BRS.0000000000000493
   Yang LY, 2013, PAIN PHYSICIAN, V16, P277
   Yang SP, 2017, ACTA ORTHOP TRAUMATO, V51, P290, DOI 10.1016/j.aott.2017.05.006
   Yazbeck PG, 2011, SPINE J, V11, pE5, DOI 10.1016/j.spinee.2011.06.020
   Zhang L, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0590-6
   Zhang L, 2015, CLIN NEUROL NEUROSUR, V129, P10, DOI 10.1016/j.clineuro.2014.11.018
NR 47
TC 1
Z9 1
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 342
EP 348
DI 10.1016/j.wneu.2018.10.143
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100265
PM 30391616
DA 2020-05-12
ER

PT J
AU Haglin, JM
   Godzik, J
   Mauria, R
   Cole, TS
   Walker, CT
   Kakarla, U
   Uribe, JS
   Turner, JD
AF Haglin, Jack M.
   Godzik, Jakub
   Mauria, Rohit
   Cole, Tyler S.
   Walker, Corey T.
   Kakarla, Udaya
   Uribe, Juan S.
   Turner, Jay D.
TI Continuous Activity Tracking Using a Wrist-Mounted Device in Adult
   Spinal Deformity: A Proof of Concept Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accelerometer device; Activity monitor; Adult spinal deformity; Fitbit
ID SCOLIOSIS-RESEARCH-SOCIETY-22 PATIENT QUESTIONNAIRE; OUTCOMES;
   RELIABILITY; PARAMETERS; SCOLIOSIS; VALIDITY; IMPACT; GAIT
AB BACKGROUND: Sagittal imbalance in adult spinal deformity (ASD) likely influences balance and ambulatory capacity because of muscular demand, pain, and disability. Disability measures for ASD rely heavily on ambulatory function; however, current metrics may fail to fully capture its contribution. We sought 1) to determine the utility of continuous remote step count monitoring and activity tracking in ASD using a consumer-friendly accelerometer, and 2) to investigate trends and patterns both before and after surgical intervention.
   CASE DESCRIPTION: One patient with progressive ASD was enrolled. Daily step count (SC), distance traveled (DT), and levels of activity were measured using a wrist-mounted device for 17 months. Spinopelvic parameters were measured from standing radiographs. The patient underwent T4-ilium long-segment fusion for correction of progressive deformity (coronal cobb angle: 8 degrees; sagittal vertical axis: 4 cm; coronal vertical axis: 2 cm); recovery was uneventful. The device was worn for 216 of 520 (41%) recorded days during waking hours, with an average SC of 5254 +/- 2696 per day. SC (P < 0.001), DT (P < 0.001), and minutes of light activity (LA) (P < 0.001) declined over the 9-month preoperative course, whereas sedentary activity increased (P < 0.001). After surgery, SC, DT, and LA decreased in the early postoperative period, with a significant increase at 7-8 months compared with the preoperative period (P < 0.001).
   CONCLUSIONS: Wrist-mounted devices are a noninvasive and effective measure to track daily activity and ambulatory capacity of patients with spinal deformity. In a single case, progressive deformity correlated with worsening activity levels, whereas deformity correction improved SC and activity level. These results support remote activity monitoring as an exploratory outcome for future studies.
C1 [Haglin, Jack M.] Mayo Clin, Sch Med, Scottsdale, AZ 85259 USA.
   [Godzik, Jakub; Mauria, Rohit; Cole, Tyler S.; Walker, Corey T.; Kakarla, Udaya; Uribe, Juan S.; Turner, Jay D.] St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ USA.
RP Haglin, JM (reprint author), Mayo Clin, Sch Med, Scottsdale, AZ 85259 USA.
EM Neuropub@barrowneuro.org
CR Ailon T, 2015, NEUROSURGERY, V77, pS75, DOI 10.1227/NEU.0000000000000938
   Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621
   Asher M, 2003, SPINE, V28, P63, DOI 10.1097/00007632-200301010-00015
   Asher M, 2003, SPINE, V28, P70, DOI 10.1097/00007632-200301010-00016
   Bang A, 2008, INT J CARDIOL, V129, P325, DOI 10.1016/j.ijcard.2007.09.001
   Bourke AK, 2008, MED ENG PHYS, V30, P84, DOI 10.1016/j.medengphy.2006.12.001
   Bowyer AJ, 2016, ANAESTHESIA, V71, P72, DOI 10.1111/anae.13312
   Burton DC, 2007, NEUROSURG CLIN N AM, V18, P403, DOI 10.1016/j.nec.2007.03.001
   Djurasovic M, 2007, NEUROSURG CLIN N AM, V18, P223, DOI 10.1016/j.nec.2007.01.006
   Elenko E, 2015, NAT BIOTECHNOL, V33, P456, DOI 10.1038/nbt.3222
   Evenson KR, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0183-7
   Glassman SD, 2005, SPINE, V30, P682, DOI 10.1097/01.brs.0000155425.04536.f7
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Haefeli M, 2008, EUR SPINE J, V17, P104, DOI 10.1007/s00586-007-0541-5
   Hubble RP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123705
   Imagama S, 2013, EUR SPINE J, V22, P1346, DOI 10.1007/s00586-013-2721-9
   Ishikawa Y, 2013, GAIT POSTURE, V38, P260, DOI 10.1016/j.gaitpost.2012.11.024
   Kramers-de Quervain IA, 2004, EUR SPINE J, V13, P449, DOI 10.1007/s00586-003-0588-x
   Pryce R, 2012, SPINE, V37, P1316, DOI 10.1097/BRS.0b013e31824a8314
   Scheer JK, 2017, CLIN SPINE SURG, V30, pE1434, DOI 10.1097/BSD.0000000000000521
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P464, DOI 10.3171/2013.7.SPINE12901
   Schwab F, 2005, SPINE, V30, P1082, DOI 10.1097/01.brs.0000160842.43482.cd
   Schwab F, 2003, SPINE, V28, P602, DOI 10.1097/00007632-200303150-00016
   Simon AL, 2017, GAIT POSTURE, V55, P37, DOI 10.1016/j.gaitpost.2017.03.036
   Steinhubl SR, 2016, AM HEART J, V175, P77, DOI 10.1016/j.ahj.2016.02.011
   Straiton N, 2018, MATURITAS, V112, P85, DOI 10.1016/j.maturitas.2018.03.016
   Tao WJ, 2012, SENSORS-BASEL, V12, P2255, DOI 10.3390/s120202255
   Verma S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149014
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 349
EP 354
DI 10.1016/j.wneu.2018.10.235
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100266
PM 30439522
DA 2020-05-12
ER

PT J
AU McCarthy, DJ
   Chen, SH
   Brunet, MC
   Shah, S
   Peterson, E
   Starke, RM
AF McCarthy, David J.
   Chen, Stephanie H.
   Brunet, Marie-Christine
   Shah, Sumedh
   Peterson, Eric
   Starke, Robert M.
TI Distal Radial Artery Access in the Anatomical Snuffbox for
   Neurointerventions: Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Access; Distal radial; Endovascular; Neurointerventional; Stroke
ID TRANSRADIAL ACCESS; EXPERIENCE
AB BACKGROUND: The distal transradial approach (dTRA) is being widely adopted by interventional cardiologists, primarily owing to reduced morbidity and mortality from access site complications. The distal radial artery has advantages over standard radial access in relation to procedural positioning and radial artery preservation, particularly in patients who may require multiple angiograms. One disadvantage is the smaller diameter of the artery with more challenging puncture of a smaller, weaker artery. We demonstrate the feasibility of dTRA in 2 patients who underwent successful diagnostic angiography and mechanical thrombectomy.
   CASE DESCRIPTION: Two patients underwent dTRA for neurointerventions. In patient 1, a 5-F Glidesheath Slender and a Sim2 catheter were used for a 6-vessel cerebral angiogram. In patient 2, an 0.88-inch sheathless guide catheter was used to perform a mechanical thrombectomy. Successful hemostasis in both cases was achieved with a Safeguard Radial Compression Device; no complications were observed.
   CONCLUSIONS: Neurovascular access via dTRA is feasible, and further exploration is warranted.
C1 [McCarthy, David J.; Chen, Stephanie H.; Brunet, Marie-Christine; Shah, Sumedh; Peterson, Eric; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP McCarthy, DJ (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM djm77@med.miami.edu
CR Al-Azizi KM, 2018, CARDIOVASC REVASCULA, V19, pS35, DOI 10.1016/j.carrev.2018.03.020
   Almandoz JED, 2016, J NEUROINTERV SURG, V8, P1123, DOI 10.1136/neurintsurg-2015-012122
   Amin MR, 2017, U HEART J, V13, P40
   de Andrade PB, 2018, J TRANSCAT INTERVENT, V26
   Haussen DC, 2016, J NEUROINTERV SURG, V8, P247, DOI 10.1136/neurintsurg-2014-011519
   Kiemeneij F, 2017, EUROINTERVENTION, V13, P851, DOI 10.4244/EIJ-D-17-00079
   Kwok CS, 2015, CARDIOVASC REVASCULA, V16, P484, DOI 10.1016/j.carrev.2015.08.008
   Mendiz OA, 2011, VASC ENDOVASC SURG, V45, P499, DOI 10.1177/1538574411405547
   Ovalsecchi O, 2018, J INVASIVE CARDIOL, V30, P218
   Sheikh AR, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.006579
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P874, DOI 10.1136/neurintsurg-2017-013584
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P493, DOI 10.1136/neurintsurg-2017-013295
   Soydan E, 2018, ANATOL J CARDIOL, V19, P243, DOI 10.14744/AnatolJCardiol.2018.59932
   Sur S, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.1.FOCUS16525
NR 14
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 355
EP 359
DI 10.1016/j.wneu.2018.11.030
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100267
PM 30447446
DA 2020-05-12
ER

PT J
AU Baltus, C
   Costa, E
   Vaz, G
   Raftopoulos, C
AF Baltus, Cedric
   Costa, Emmanuel
   Vaz, Geraldo
   Raftopoulos, Christian
TI Granulomatous Reaction on a Double-Level Cervical Total Disc
   Arthroplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Breakdown; Cervical artificial disc replacement; Cervicalgias;
   Granuloma; Nylon; Prosthesis; Total disc arthroplasty
AB BACKGROUND: Cervical total disc arthroplasty (TDA), or cervical artificial disc replacement, is an alternative technique to anterior cervical discectomy and fusion for treatment of symptomatic degenerative cervical spine disease. The main goal of TDA is to maintain cervical motion and lower the risk of deterioration of adjacent levels. Granuloma formation on a cervical TDA is exceptional.
   CASE DESCRIPTION: A 48-year-old woman with left cervicobrachialgia underwent a double-level TDA (M6-C Artificial Cervical Disc) on C5-C6 and C6-C7 at another hospital in 2010. Two years later, she reported a recurrence of cervicalgia, which was refractory to conservative treatment by rigid collar and analgesics. Cervical magnetic resonance imaging suggested a granulomatous formation on the C6-C7 prosthesis. She underwent removal of the C6-C7 prosthesis, which showed a rupture with nylon thread extrusion. An arthrodesis with plate was subsequently performed. Follow-up showed improvement of her clinical status. Histopathologic studies showed a giant cell granulomatous formation in contact with nylon threads described in hip, shoulder, and ankle arthroplasty. It has been described in 6 cases following lumbar TDA and 2 cases following cervical TDA.
   CONCLUSIONS: We report a third case of granulomatous reaction on nylon thread extrusion after partial breakdown of a prosthesis for cervical TDA.
C1 [Baltus, Cedric; Costa, Emmanuel; Vaz, Geraldo; Raftopoulos, Christian] Catholic Univ Louvain, St Luc Hosp, Dept Neurosurg, Brussels, Belgium.
RP Raftopoulos, C (reprint author), Catholic Univ Louvain, St Luc Hosp, Dept Neurosurg, Brussels, Belgium.
EM christian.raftopoulos@uclouvain.be
CR Berry MR, 2010, J BONE JOINT SURG AM, V92A, P1242, DOI 10.2106/JBJS.H.01625
   Cabraja M, 2012, SPINE, V37, pE809, DOI 10.1097/BRS.0b013e3182404b9e
   Campbell P, 2010, CLIN ORTHOP RELAT R, V468, P2321, DOI 10.1007/s11999-010-1372-y
   Cavanaugh DA, 2009, SPINE, V34, pE262, DOI 10.1097/BRS.0b013e318195dd60
   Francois J, 2007, ACTA ORTHOP BELG, V73, P122
   Glyn-Jones S, 2009, J BONE JOINT SURG BR, V91B, P1566, DOI 10.1302/0301-620X.91B12.22287
   Guyer RD, 2011, SPINE, V36, pE492, DOI 10.1097/BRS.0b013e31820ea9a2
   Hallab N, 2003, SPINE, V28, pS139, DOI 10.1097/01.BRS.0000092214.87225.80
   Laratta JL, 2018, GLOB SPINE J, V8, P78, DOI 10.1177/2192568217701095
   Nusselt T, 2010, ARCH ORTHOP TRAUM SU, V130, P1037, DOI 10.1007/s00402-010-1125-0
   Pandit H, 2008, J BONE JOINT SURG BR, V90B, P847, DOI 10.1302/0301-620X.90B7.20213
   Popelka S, 2010, ACTA CHIR ORTHOP TR, V77, P24
   Spinal Kinetics, M6 C OV
   Wu TK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006503
NR 14
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 360
EP 363
DI 10.1016/j.wneu.2018.11.070
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100268
PM 30458326
DA 2020-05-12
ER

PT J
AU Tucker, DW
   Gogia, AS
   Donoho, DA
   Yim, B
   Yu, C
   Fredrickson, VL
   Chang, EL
   Freidman, RA
   Zada, G
   Giannotta, SL
AF Tucker, Douglass W.
   Gogia, Angad S.
   Donoho, Daniel A.
   Yim, Benjamin
   Yu, Cheng
   Fredrickson, Vance L.
   Chang, Eric L.
   Freidman, Rick A.
   Zada, Gabriel
   Giannotta, Steven L.
TI Long-Term Tumor Control Rates Following Gamma Knife Radiosurgery for
   Acoustic Neuroma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acoustic neuroma; Gamma knife; Hearing loss; Vestibular schwannoma
ID VESTIBULAR SCHWANNOMAS; STEREOTACTIC RADIOSURGERY; NATURAL-HISTORY;
   HEARING-LOSS; PRESERVATION; GROWTH; PREDICTORS; CONFORMITY; MANAGEMENT;
   SERIES
AB BACKGROUND: Acoustic neuromas (ANs) are benign intracranial tumors that arise from myelin-forming Schwann cells surrounding the vestibular branch of the vestibulocochlear nerve (cranial nerve VIII). Treatment options for AN include observation, radiosurgery, and microsurgical resection. Gamma Knife radiosurgery (GKRS) for AN has well-documented short-term safety and efficacy for carefully selected patients. Recent innovations in GKRS technology may improve long-term outcomes. The aim of this study was to report long-term tumor control and complication rates after GKRS for sporadic AN.
   METHODS: A retrospective review was performed of patients with sporadic ANs at Keck Hospital of USC who underwent GKRS from 1995 to 2015 with a minimum follow-up of 12 months.
   RESULTS: Median age at treatment was 63.7 years (range, 19.4-84.2 years). Median follow-up time was 69 months. Median tumor diameter was 17.5 mm (range, 5.0-29.0 mm), and median treatment volume was 2.41 cm(3) (range, 0.09-12.8 cm(3)). Median prescribed dose was 12.50 Gy. Tumor control was achieved in 51 (98.1%) patients over the follow-up period (12-192 months). One patient experienced tumor progression at 22 months after GKRS, requiring surgical intervention, which ultimately resulted in remission. Complications included hearing loss (17.3%), worsened balance/ataxia (7.7%), and hydrocephalus (1.92%).
   CONCLUSIONS: Patients undergoing GKRS for sporadic ANs had high rates of tumor control over a median follow-up time of >5 years. Improvements in radiosurgery treatment planning were seen in the most recent cohort of patients. GKRS is a safe and effective modality for treating sporadic ANs in selected patients.
C1 [Tucker, Douglass W.; Gogia, Angad S.; Donoho, Daniel A.; Yim, Benjamin; Yu, Cheng; Fredrickson, Vance L.; Zada, Gabriel; Giannotta, Steven L.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90089 USA.
   [Chang, Eric L.] Univ Southern Calif, Keck Sch Med, Dept Radiat Oncol, Los Angeles, CA USA.
   [Freidman, Rick A.] Univ Southern Calif, Keck Sch Med, USC Tina & Rick Caruso Dept Otolaryngol Head & Ne, Los Angeles, CA USA.
RP Tucker, DW (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90089 USA.
EM dwtucker@usc.edu
OI Tucker, Douglass/0000-0002-0859-0522
CR Bailo M, 2016, WORLD NEUROSURG, V95, P487, DOI 10.1016/j.wneu.2016.07.117
   Bhandare N, 2010, INT J RADIAT ONCOL, V76, pS50, DOI 10.1016/j.ijrobp.2009.04.096
   Boari N, 2014, J NEUROSURG, V121, P123, DOI 10.3171/2014.8.GKS141506
   Brown M, 2011, NEUROSURGERY, V69, P605, DOI 10.1227/NEU.0b013e31821a42f3
   Fu VX, 2018, J NEUROSURG, V129, P137, DOI 10.3171/2017.3.JNS162033
   Gal TJ, 2010, OTOLARYNG HEAD NECK, V142, P677, DOI 10.1016/j.otohns.2010.01.037
   Garsa AA, 2014, INT J RADIAT ONCOL, V90, P407, DOI 10.1016/j.ijrobp.2014.05.047
   Gephart MGH, 2013, WORLD NEUROSURG, V80, P359, DOI 10.1016/j.wneu.2012.04.001
   Harun A, 2012, OTOL NEUROTOL, V33, P1604, DOI 10.1097/MAO.0b013e31826dba9e
   Hughes M, 2011, SKULL BASE-INTERD AP, V21, P295, DOI 10.1055/s-0031-1284219
   Hunter JB, 2016, OTOL NEUROTOL, V37, P1630, DOI 10.1097/MAO.0000000000001219
   Inoue HK, 2013, J NEUROSURG, V119, P114
   JORGENSEN BG, 1994, CLIN OTOLARYNGOL, V19, P478, DOI 10.1111/j.1365-2273.1994.tb01273.x
   Lasak JM, 2008, OTOL NEUROTOL, V29, P1179, DOI 10.1097/MAO.0b013e31818b6639
   Marston AP, 2017, J NEUROSURG, V127, P380, DOI 10.3171/2016.5.JNS153013
   Massick DD, 2000, LARYNGOSCOPE, V110, P1843, DOI 10.1097/00005537-200011000-00015
   Miller T, 2014, J CLIN NEUROSCI, V21, P914, DOI 10.1016/j.jocn.2013.11.029
   Nakamura JL, 2001, INT J RADIAT ONCOL, V51, P1313, DOI 10.1016/S0360-3016(01)01757-6
   Nikolopoulos TP, 2010, OTOL NEUROTOL, V31, P478, DOI 10.1097/MAO.0b013e3181d279a3
   Nonaka Y, 2013, NEUROSURGERY, V72, P103, DOI 10.1227/NEU.0b013e3182752b05
   Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219
   Paddick I, 2006, J NEUROSURG, V105, P194, DOI 10.3171/sup.2006.105.7.194
   Paek SH, 2005, CANCER-AM CANCER SOC, V104, P580, DOI 10.1002/cncr.21190
   Paldor I, 2016, J CLIN NEUROSCI, V32, P1, DOI 10.1016/j.jocn.2016.05.003
   Roland JT, 2004, SKULL BASE-INTERD AP, V14, P85, DOI 10.1055/s-2004-828699
   Roland JT, 2004, SKULL BASE, V14
   Rosenberg SI, 2000, LARYNGOSCOPE, V110, P497, DOI 10.1097/00005537-200004000-00002
   Sandstrom H, 2016, RADIOTHER ONCOL, V121, P180, DOI 10.1016/j.radonc.2016.10.014
   Schumacher AJ, 2017, J NEUROL SURG PART B, V78, P2, DOI 10.1055/s-0036-1584231
   Sharma M, 2017, CANCER MED-US, V6, P2076, DOI 10.1002/cam4.1149
   Stapleton E, 2017, OTOL NEUROTOL, V38, P260, DOI 10.1097/MAO.0000000000001280
   Wagner TH, 2003, INT J RADIAT ONCOL, V57, P1141, DOI 10.1016/S0360-3016(03)01563-3
   Wu Q-R Jackie, 2003, J Appl Clin Med Phys, V4, P374, DOI 10.1120/1.1621372
   Yoshimoto Y, 2005, J NEUROSURG, V103, P59, DOI 10.3171/jns.2005.103.1.0059
   You YP, 2013, CNS NEUROSCI THER, V19, P289, DOI 10.1111/cns.12080
NR 35
TC 0
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 366
EP 371
DI 10.1016/j.wneu.2018.11.009
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100270
PM 30447465
DA 2020-05-12
ER

PT J
AU Sturda, C
   Rapisarda, A
   Gessi, M
   Stifano, V
   Pompucci, A
   Anile, C
   Trevisi, G
AF Sturda, Cosimo
   Rapisarda, Alessandro
   Gessi, Marco
   Stifano, Vito
   Pompucci, Angelo
   Anile, Carmelo
   Trevisi, Gianluca
TI Bullough's Lesion: An Unexpected Diagnosis After the Resection of a
   Slowly Growing Osseous-Like Retroauricular Bump-Case Report and Review
   of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bullough lesion; Calvarial lesion; Protuberant fibro-osseous lesion
ID PROTUBERANT FIBROOSSEOUS LESIONS; TEMPORAL BONE
AB We describe the case of a 33-year-old woman with a history of over 15 years of a slow growing firm osseous-like right retroauricular mass. Surgical resection was easily performed using a sharp technique, because of a clear cleavage plane. The histologic diagnosis was a rare, unexpected, protuberant fibroosseous lesion named "Bullough lesion." Only few cases of this benign pathologic entity have been described in English literature. Clinical differential diagnosis must be done with osteoma, periosteal chondroma, and other fibroosseous lesions such as fibrodysplasia and ossifying fibroma. Because of the paucity of data, the natural history of this lesion is unknown and serial clinical and radiological follow-up is advised.
C1 [Sturda, Cosimo; Rapisarda, Alessandro; Stifano, Vito; Pompucci, Angelo; Anile, Carmelo; Trevisi, Gianluca] Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
   [Gessi, Marco] Fdn Policlin Univ A Gemelli IRCCS, Histopathol Div, Rome, Italy.
RP Stifano, V (reprint author), Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
EM stifano89@gmail.com
RI Stifano, Vito/I-9032-2019; Rapisarda, Alessandro/AAF-3354-2019; Trevisi,
   Gianluca/K-9664-2016
OI Stifano, Vito/0000-0002-5509-9592; Trevisi, Gianluca/0000-0002-2879-8451
CR BAUER TW, 1982, AM J SURG PATHOL, V6, P631, DOI 10.1097/00000478-198210000-00004
   DORFMAN HD, 1994, HUM PATHOL, V25, P1234, DOI 10.1016/0046-8177(94)90041-8
   GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475
   Hamadani Mehdi, 2006, J Coll Physicians Surg Pak, V16, P376
   Jiang BW, 2018, J NEUROSURG-PEDIATR, V21, P107, DOI 10.3171/2017.8.PEDS17391
   Kim YH, 2009, ACTA OTO-LARYNGOL, V129, P1374, DOI 10.3109/00016480902806112
   Lee M, 2014, AM J SURG PATHOL, V38, P1510, DOI 10.1097/PAS.0000000000000302
   Lee SE, 2012, HUM PATHOL, V43, P1234, DOI 10.1016/j.humpath.2011.09.012
   Li G, 2009, DENTOMAXILLOFAC RAD, V38, P59, DOI 10.1259/dmfr/17949583
   MASTERS SB, 1989, J BIOL CHEM, V264, P15467
   Nagarajan K, 2013, INDIAN J OTOL, V19, P143, DOI 10.4103/0971-7749.117464
   Sato N, 2017, VIRCHOWS ARCH, V470, P717, DOI 10.1007/s00428-017-2111-5
   Selesnick SH, 1999, AM J OTOL, V20, P394
   Sia SF, 2010, AM J SURG PATHOL, V34, P1217, DOI 10.1097/PAS.0b013e3181df9672
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 372
EP 375
DI 10.1016/j.wneu.2018.11.055
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100271
PM 30448575
DA 2020-05-12
ER

PT J
AU Giorgianni, A
   Pozzi, F
   Pellegrino, C
   Padovan, S
   Karligkiotis, A
   Castelnuovo, P
   Locatelli, D
AF Giorgianni, Andrea
   Pozzi, Fabio
   Pellegrino, Carlo
   Padovan, Stefania
   Karligkiotis, Apostolos
   Castelnuovo, Paolo
   Locatelli, Davide
TI Emergency placement of a Flow Diverter Stent for an Iatrogenic Internal
   Carotid Artery Injury During Endoscopic Pituitary Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Endovascular; Flow diverter stent; Internal carotid artery
   injury; Pituitary adenoma; Transsphenoidal
ID PIPELINE EMBOLIZATION DEVICE; PSEUDOANEURYSMS; ANEURYSMS
AB BACKGROUND: Internal carotid artery (ICA) injury is 1 of the most feared complications in endoscopic pituitary surgery. Different endovascular techniques are available for the management of early and delayed ICA injuries.
   CASE REPORT: We report a case of emergency endovascular treatment with a flow diverter stent for an ICA injury that occurred during endoscopic transphenoidal surgery for pituitary macroadenoma in a 66-year-old man. Effective intraoperative hemostasis was achieved by direct packing of the sphenoid sinus. Digital subtraction angiography demonstrated extravasation of the contrast agent into the sphenoidal sinus from the anterior genu of the intracavernous portion of the right ICA. Balloon test occlusion resulted in a prominent delay in the venous phase in the right hemisphere during occlusion of the right ICA. Taking into account the hemodynamic stability and the absence of intracranial bleeding, we considered the ICA injury as if it were a pseudoaneurysm. Therefore, an emergency release of a flow diverter stent was performed, in association with antiplatelet therapy. No periprocedural complications occurred. The patient was discharged without neurologic deficits. The last follow-up studies at 6 months (digital subtraction angiography and magnetic resonance imaging) confirmed the regular placement of the stent and vessel reconstruction.
   CONCLUSIONS: Despite the presence of acute hemorrhage and the need for antiplatelet therapy, a flow diverter stent can be used as emergency treatment of ICA injury in selected circumstances.
C1 [Giorgianni, Andrea; Pellegrino, Carlo] Osped Circolo & Fdn Macchi, Div Neuroradiol, Varese, Italy.
   [Pozzi, Fabio; Locatelli, Davide] Univ Insubria Varese, Osped Circolo & Fdn Macchi, Div Neurosurg, Varese, Italy.
   [Padovan, Stefania; Karligkiotis, Apostolos; Castelnuovo, Paolo] Univ Insubria Varese, Osped Circolo & Fdn Macchi, Div Otorhinolaryngol, Varese, Italy.
   [Pozzi, Fabio; Karligkiotis, Apostolos; Castelnuovo, Paolo; Locatelli, Davide] Univ Insubria Varese, Osped Circolo & Fdn Macchi, Head & Neck Surg & Forens Dissect Res Ctr, Varese, Italy.
   [Padovan, Stefania] Univ Pavia, Div Neurosurg, Policlin San Matteo Fdn IRCCS, Pavia, Italy.
RP Pozzi, F (reprint author), Univ Insubria Varese, Osped Circolo & Fdn Macchi, Div Neurosurg, Varese, Italy.; Pozzi, F (reprint author), Univ Insubria Varese, Osped Circolo & Fdn Macchi, Head & Neck Surg & Forens Dissect Res Ctr, Varese, Italy.
EM fabio.wells@asst-settelaghi.it
RI Locatelli, Davide/AAH-5844-2020
OI Locatelli, Davide/0000-0003-1163-9611
CR AlQahtani A, 2016, OTOLARYNG CLIN N AM, V49, P237, DOI 10.1016/j.otc.2015.09.009
   Amenta Peter S, 2012, Surg Neurol Int, V3, P160, DOI 10.4103/2152-7806.105099
   Berker M, 2012, PITUITARY, V15, P288, DOI 10.1007/s11102-011-0368-2
   Celil G, 2004, AURIS NASUS LARYNX, V31, P275, DOI 10.1016/j.anl.2004.03.007
   Chalouhi N, 2015, NEUROSURGERY, V77, P581, DOI 10.1227/NEU.0000000000000887
   Ciceri EFM, 2006, NEUROL SCI, V27, P317, DOI 10.1007/s10072-006-0703-y
   Giorgianni A, 2015, INTERV NEURORADIOL, V21, P325, DOI 10.1177/1591019915582154
   Hardy J, 1992, BRAIN SURG COMPLICAT, P276
   Lehmann P, 2009, EUR ARCH OTO-RHINO-L, V266, P767, DOI 10.1007/s00405-008-0743-4
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Nerva JD, 2015, J NEUROINTERV SURG, V7, P210, DOI 10.1136/neurintsurg-2013-011047
   Raymond J, 1997, AM J NEURORADIOL, V18, P655
   Sylvester PT, 2016, J NEUROSURG, V15, P1
NR 13
TC 3
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 376
EP 379
DI 10.1016/j.wneu.2018.10.234
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100272
PM 30439523
DA 2020-05-12
ER

PT J
AU Yerneni, K
   Burke, JF
   Nichols, N
   Tan, LA
AF Yerneni, Ketan
   Burke, John F.
   Nichols, Noah
   Tan, Lee A.
TI Delayed Recurrent Laryngeal Nerve Palsy Following Anterior Cervical
   Discectomy and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Anterior cervical discectomy and fusion; Delayed; Recurrent
   laryngeal nerve palsy; RLNP
ID MICROVASCULAR DECOMPRESSION; SPINE SURGERY; FACIAL PALSY; PARALYSIS;
   RESECTION
AB BACKGROUND: Vocal cord dysfunction resulting from recurrent laryngeal nerve palsy (RLNP) is a known complication following anterior cervical discectomy and fusion. RLNP occurs typically secondary to neurapraxia caused by intraoperative compression or traction on the nerve and less commonly from direct nerve injury intraoperatively in the setting of anterior cervical spine surgery. Patients with RLNP typically present with hoarseness immediately after surgery owing to unilateral vocal cord paralysis. In rare cases, there is late-onset, progressive development of RLNP that may potentially lead to permanent vocal cord paralysis or respiratory failure.
   CASE DESCRIPTION: A 75-year-old woman presented with myeloradiculopathy and chronic urinary incontinence. Imaging showed severe foraminal and central stenosis with T2 cord signal change. A C4-7 anterior cervical discectomy and fusion was successfully performed without immediate complications following surgery. The patient had a normal voice and was tolerating a regular diet well. On postoperative day 3, the patient developed new hoarseness and dysphagia. An otolaryngologist was consulted, and flexible nasolaryngoscopy showed left vocal cord paralysis consistent with left RLNP. The patient was treated with a course of steroids, and her hoarseness and dysphagia had resolved at the 6-month follow-up visit.
   CONCLUSIONS: To our knowledge, this is the first report of delayed RLNP in patients undergoing anterior cervical discectomy and fusion. This rare complication should be discussed during preoperative patient counseling. Previous literature indicates the underlying pathophysiology for delayed onset of RLNP may be small vessel ischemia, vasospasm, or viral resurgence that leads to recurrent laryngeal nerve dysfunction.
C1 [Yerneni, Ketan; Burke, John F.; Nichols, Noah; Tan, Lee A.] Univ Calif San Francisco, Dept Neurol Surg, UCSF Med Ctr, San Francisco, CA 94143 USA.
RP Tan, LA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, UCSF Med Ctr, San Francisco, CA 94143 USA.
EM Lee.Tan@ucsf.edu
OI Tan, Lee/0000-0003-3497-3321
CR Apfelbaum RI, 2000, SPINE, V25, P2906, DOI 10.1097/00007632-200011150-00012
   Brackmann DE, 2008, LARYNGOSCOPE, V118, P1617, DOI 10.1097/MLG.0b013e3181788d5d
   Bures C, 2014, BRIT J SURG, V101, P1556, DOI 10.1002/bjs.9648
   de Almeida SM, 2015, EPILEPSY BEHAV CASE, V4, P76, DOI 10.1016/j.ebcr.2014.08.007
   Gianoli GJ, 1996, AM J OTOL, V17, P625
   Gokaslan ZL, 2017, GLOB SPINE J, V7, P535, DOI 10.1177/2192568216687547
   Goyal DN, 2014, IOSR J DENT MED SCI, V13, P23
   Grant GA, 2002, J NEUROSURG, V97, P93, DOI 10.3171/jns.2002.97.1.0093
   Han JS, 2012, J KOREAN NEUROSURG S, V52, P288, DOI 10.3340/jkns.2012.52.4.288
   Jung A, 2005, J NEUROSURG-SPINE, V2, P123, DOI 10.3171/spi.2005.2.2.0123
   Khan JS, 2008, J RAWALPINDI MED COL, V12, P16
   Kim HJ, 2012, STEREOT FUNCT NEUROS, V90, P260, DOI 10.1159/000338685
   Kimura F, 2010, SURG TODAY, V40, P793, DOI 10.1007/s00595-010-4323-z
   MAGNUSSEN CR, 1979, ARCH INTERN MED, V139, P1423, DOI 10.1001/archinte.139.12.1423
   Mesolella M, 2016, OPEN MED-WARSAW, V11, P215, DOI 10.1515/med-2016-0041
   Sampath P, 1998, Neurosurg Focus, V5, pe6
   Schulze T, 2013, SIGNA VITAE, V8, P56, DOI 10.22514/SV82.102013.9
   Smith J, 2014, ANN ROY COLL SURG, V96, P130, DOI 10.1308/003588414X13814021676594
   Tan TP, 2014, SPINE J, V14, P1332, DOI 10.1016/j.spinee.2014.02.017
   Thermann M, 1998, CHIRURG, V69, P951, DOI 10.1007/s001040050520
NR 20
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 380
EP 383
DI 10.1016/j.wneu.2018.11.066
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100273
PM 30465958
DA 2020-05-12
ER

PT J
AU Muroi, C
   Hugelshofer, M
   Seehusen, F
   Keller, E
AF Muroi, Carl
   Hugelshofer, Michael
   Seehusen, Frauke
   Keller, Emanuela
TI Natural Cerebral Aneurysm and Spontaneous Subarachnoid Hemorrhage in
   Mammals Other Than Man: Is There a Scope for Comparative Medicine?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm formation; Animal models; Comparative medicine; Intracranial
   aneurysm; Subarachnoid hemorrhage
ID PERFORATION MODEL; ANIMAL-MODELS; PATHOLOGY; ARTERIES; BRAIN; MOUSE
AB BACKGROUND: Concepts that showed substantial efficacy in animal models of subarachnoid hemorrhage (SAH) often failed to improve outcome in humans with aneurysmal SAH. The concept of "comparative medicine," an open-minded comparison across species, might offer an alternative to the "constructed" animal models' approach. Naturally occurring diseases in animals might bear more similarity to human diseases than models. In this context, the question arises whether spontaneous intracranial aneurysms exist in animals or not, and whether they cause SAH or not.
   METHODS: A systematic literature search was performed. Only articles dealing with natural aneurysms and/or SAH of mammals other than man were included. All articles dealing with induced aneurysms and/or SAH were removed.
   RESULTS: Of 2812 screened articles, 9 articles describing natural intracranial aneurysms and/or SAH were found. In total 1979 individual animals of 29 species were examined. Natural intracranial aneurysms were described in 7 individual animals of 6 species. Spontaneous SAH was described in 3 species. In 1 chimpanzee, a ruptured intracranial aneurysm caused an SAH. Histological descriptions of the aneurysms were strikingly similar to those of humans.
   CONCLUSIONS: Although interesting and innovative, the concept of "comparative medicine" seems to be impracticable due to the seemingly ultralow incidence of natural aneurysmal SAH in mammals other than man. The answer to the question "why intracranial aneurysms are less common in animals despite the strong histological similarity of cerebral arteries" might be a key issue. Last but not least, primates likely matter in SAH-related research, as aneurysmal SAH occurs in primates.
C1 [Muroi, Carl; Keller, Emanuela] Univ Zurich, Neurocrit Care Unit, Zurich, Switzerland.
   [Hugelshofer, Michael] Univ Zurich, Dept Neurosurg, Univ Hosp Zurich, Zurich, Switzerland.
   [Seehusen, Frauke] Univ Zurich, Inst Vet Pathol, Vetsuisse Fac, Zurich, Switzerland.
RP Muroi, C (reprint author), Univ Zurich, Neurocrit Care Unit, Zurich, Switzerland.
EM carlizumi.muroi@uzh.ch
OI Hugelshofer, Michael/0000-0002-3057-0472; /0000-0001-9999-3345
CR Andelfinger G, 2003, J MED GENET, V40, P320, DOI 10.1136/jmg.40.5.320
   [Anonymous], 2005, Vet Rec, V156, P559
   ASKUPMARK E, 1950, ACTA MED SCAND, V138, P15
   Bagshaw RJ, 1996, NEUROL RES, V18, P33
   Bertolini G, 2013, CASE REP VET MED, V2013, P1
   Coleman RA, 2003, DRUG DISCOV TODAY, V8, P233, DOI 10.1016/S1359-6446(03)02613-8
   CROMPTON MR, 1966, BRAIN, V89, P789, DOI 10.1093/brain/89.4.789
   Garosi LS, 2010, VET CLIN N AM-SMALL, V40, P65, DOI 10.1016/j.cvsm.2009.09.001
   Hassler O, 1961, ACTA PSYCHIAT S S154, V36, P108
   Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413
   Kegler K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133916
   KIM C, 1991, ACTA NEUROCHIR, V109, P63, DOI 10.1007/BF01405700
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Macleod MR, 2012, J CEREBR BLOOD F MET, V32, P1643, DOI 10.1038/jcbfm.2012.56
   Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386
   Marbacher S, 2010, BRIT J NEUROSURG, V24, P415, DOI 10.3109/02688691003746274
   Milner E, 2014, J CEREB BLOOD FLOW M, V34, pe1, DOI DOI 10.1038/JCBFM.2014.108
   Muroi C, 2014, BRIT J NEUROSURG, V28, P722, DOI 10.3109/02688697.2014.918579
   Muroi C, 2012, CURR OPIN CRIT CARE, V18, P119, DOI 10.1097/MCC.0b013e32835075ae
   Niu YY, 2014, CELL, V156, P836, DOI 10.1016/j.cell.2014.01.027
   OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282
   Ovadia S, 2001, COMPARATIVE MED, V51, P562
   Phillips KA, 2014, AM J PRIMATOL, V76, P801, DOI 10.1002/ajp.22281
   POTTER KA, 1993, AM J PATHOL, V142, P803
   Prufer K, 2012, NATURE, V486, P527, DOI 10.1038/nature11128
   Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008
   Silasi G, 2009, BEHAV BRAIN RES, V198, P380, DOI 10.1016/j.bbr.2008.11.019
   STEHBENS WE, 1963, J PATHOL BACTERIOL, V86, P161, DOI 10.1002/path.1700860120
   STEHBENS WE, 1957, NATURE, V179, P327, DOI 10.1038/179327a0
   TEIGE J, 1973, NORD VET MED, V25, P473
   Tvarijonaviciute A, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-147
   Vandevelde M, 2012, VET NEUROPATHOLOGY E
   Youssef SA, 2016, VET PATHOL, V53, P327, DOI 10.1177/0300985815623997
   Zhang D, 2003, CHINESE MED J-PEKING, V116, P424
   정해원, 2014, [Journal of Veterinary Clinics, 한국임상수의학회지], V31, P337
NR 35
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 384
EP 389
DI 10.1016/j.wneu.2018.11.007
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100274
PM 30447438
DA 2020-05-12
ER

PT J
AU Lopez, WOC
   Navarro, PA
   Vargas, MD
   Alape, E
   Lopez, PAC
AF Contreras Lopez, William Omar
   Alejandra Navarro, Paula
   David Vargas, Marcos
   Alape, Eduardo
   Camacho Lopez, Paul Anthony
TI Pulsed Radiofrequency Versus Continuous Radiofrequency for Facet Joint
   Low Back Pain: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Low back pain; Pulsed radiofrequency treatment; Zygapophyseal joint
ID ZYGAPOPHYSIAL JOINT; LUMBAR; DENERVATION; PREVALENCE; ACCURACY;
   EFFICACY; BLOCKS
AB OBJECTIVE: To compare pulsed radiofrequency (PRF) treatment with continuous radiofrequency (CRF) to improve pain, functionality, and safety profile in patients with facet joint chronic low back pain.
   METHODS: A systematic, critical review of recent literature was conducted in accordance with Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines. PubMed, Embase, Cochrane, Clinical Trials, and LILACS databases were searched. Medical Subject Heading terms were "low back pain," "zygapophyseal joint," and "pulsed radiofrequency treatment." Original research articles in peer-reviewed journals were included in the review. The articles were thoroughly examined and compared on the basis of study design and outcomes. Only studies that met the eligibility criteria were included.
   RESULTS: Three randomized clinical trials comprising 103 patients (39 in PRF group, 44 in CRF group, and 20 in control group) were included in the final analysis. Two trials compared PRF with CRF, and 1 trial compared 3 groups: PRF, CRF, and control with intervention as conventional treatment. The studies reported greater pain control and better functionality with CRF compared with PRF. PRF showed a decrease in visual analog scale and Oswestry Disability Index in 2 studies, and 1 study reported increased pain and disability after the intervention. No side effects were reported.
   CONCLUSIONS: PRF treatment is less effective than CRF regarding pain control and return of functionality in patients with facet joint chronic low back pain. We recommend CRF with a large safety profile after conventional treatment.
C1 [Contreras Lopez, William Omar; Alejandra Navarro, Paula; David Vargas, Marcos] Ctr Int Invest NEMOD, Bucaramanga, Colombia.
   [Contreras Lopez, William Omar; Alejandra Navarro, Paula; David Vargas, Marcos] Clin FOSCAL, Div Neurocirugia Func, Dept Neurocirugia, Bucaramanga, Colombia.
   [Camacho Lopez, Paul Anthony] Clin FOSCAL, Direcc Invest Desarrollo & Innovac Tecnol, Bucaramanga, Colombia.
   [Contreras Lopez, William Omar; Alejandra Navarro, Paula; David Vargas, Marcos; Alape, Eduardo; Camacho Lopez, Paul Anthony] Univ Autonoma Bucaramanga, UNAB, Bucaramanga, Colombia.
   [Contreras Lopez, William Omar] Ctr Colombiano, Cartagena, Colombia.
   [Contreras Lopez, William Omar] Fdn Epilepsia & Enfermedades Neurol FIRE, Cartagena, Colombia.
   [Alape, Eduardo] Clin FOSCAL Int, Ctr Dolor, Bucaramanga, Colombia.
RP Lopez, WOC (reprint author), Ctr Int Invest NEMOD, Bucaramanga, Colombia.; Lopez, WOC (reprint author), Clin FOSCAL, Div Neurocirugia Func, Dept Neurocirugia, Bucaramanga, Colombia.; Lopez, WOC (reprint author), Univ Autonoma Bucaramanga, UNAB, Bucaramanga, Colombia.; Lopez, WOC (reprint author), Ctr Colombiano, Cartagena, Colombia.; Lopez, WOC (reprint author), Fdn Epilepsia & Enfermedades Neurol FIRE, Cartagena, Colombia.
EM williamomar.contreraslopez@hotmail.com
OI Navarro, Paula Alejandra/0000-0003-2191-033X
CR Beresford ZM, 2010, CURR SPORT MED REP, V9, P50, DOI 10.1249/JSR.0b013e3181caba05
   BOGDUK N, 1983, SPINE, V8, P286, DOI 10.1097/00007632-198304000-00009
   Bogduk N, 1997, ZYGAPOPHYSIAL JOINTS, P33
   Cohen SP, 2007, ANESTHESIOLOGY, V106, P591, DOI 10.1097/00000542-200703000-00024
   Datta S, 2009, PAIN PHYSICIAN, V12, P437
   Dreyfuss P, 2000, SPINE, V25, P1270, DOI 10.1097/00007632-200005150-00012
   Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543
   Garau JA, 2018, PHYS MED REH CLIN N, V29, P139, DOI 10.1016/j.pmr.2017.08.011
   Higgins JPT, 2011, BMJ-BRIT MED J, V343
   Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428
   Kaplan M, 1998, SPINE, V23, P1847, DOI 10.1097/00007632-199809010-00008
   Kornick C, 2004, SPINE, V29, P1352, DOI 10.1097/01.BRS.0000128263.67291.A0
   Kroll HR, 2008, J CLIN ANESTH, V20, P534, DOI 10.1016/j.jclinane.2008.05.021
   Leggett LE, 2014, PAIN RES MANAG, V19, pE146, DOI 10.1155/2014/834369
   Lopez WOC, 2017, PULSED RADIOFREQUENC
   Maas ET, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008572.pub2
   Manchikanti Laxmaiah, 2002, Pain Physician, V5, P83
   Manchikanti L, 2010, PAIN PHYSICIAN, V13, P133
   MOONEY V, 1976, CLIN ORTHOP RELAT R, P149
   Nebreda C., 2016, Rev. Soc. Esp. Dolor, V23, P170, DOI 10.20986/resed.2016.3417/2016
   Patel VB, 2015, ANESTH PAIN MED, V5
   SCHWARZER AC, 1995, ANN RHEUM DIS, V54, P100, DOI 10.1136/ard.54.2.100
   Sehgal Nalini, 2007, Pain Physician, V10, P213
   SHEALY CN, 1975, J NEUROSURG, V43, P448, DOI 10.3171/jns.1975.43.4.0448
   Sluijter Menno E, 2013, Anesth Pain Med, V2, P139, DOI 10.5812/aapm.10213
   Tekin I, 2007, CLIN J PAIN, V23, P524, DOI 10.1097/AJP.0b013e318074c99c
   Tome Bermejo F, 2006, PATOLOGIA APARATO LO, V4, P139
   Younger J, 2009, CURR PAIN HEADACHE R, V13, P39, DOI 10.1007/s11916-009-0009-x
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 390
EP 396
DI 10.1016/j.wneu.2018.10.191
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100275
PM 30404055
DA 2020-05-12
ER

PT J
AU Shuman, W
   Loewenstern, J
   Pai, A
   Bederson, J
   Shrivastava, R
AF Shuman, William
   Loewenstern, Joshua
   Pai, Akila
   Bederson, Joshua
   Shrivastava, Raj
TI Variability in Clinical Presentation and Pathologic Implications of
   Ectopic Pituitary Tumors: Critical Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Ectopic pituitary tumors; Extrasellar; Secretory tumors
ID SPHENOID SINUS; EMPTY SELLA; CUSHINGS-DISEASE; ADENOMA; PATIENT; ORIGIN;
   CT
AB OBJECTIVE: Pituitary tumors are common, well-described skull base tumors of sellar origin. However, there are reports of rare ectopic pituitary tumors that are found exclusively outside of the sella turcica. Ectopic pituitary tumors have not been holistically analyzed. This study describes presentation and clinical patterns found among patients with ectopic pituitary tumors.
   METHODS: A comprehensive review of the literature was performed for clinical descriptions of ectopic pituitary tumors. Reports of 85 applicable cases were evaluated.
   RESULTS: The most common locations of ectopic pituitary tumors were the sphenoid sinus, clivus, suprasellar space, nasopharynx, and cavernous sinus. The majority of ectopic pituitary tumors were reported as being functional secretory tumors; they were statistically significantly more likely to be functional tumors than sellar pituitary tumors. Adrenocorticotrophic hormone, prolactin, growth hormone, and thyroid-stimulating hormoneLsecreting tumors were most commonly found. Bone invasion was reported in more than one third of the cases, and malignant transformations were reported in 6 cases. A large majority of patients presented with hormonal, neurologic, or physiologic symptoms.
   CONCLUSIONS: Ectopic pituitary tumors are a rare entity of pituitary tumors with a presentation that can mimic those of other skull base tumors. Clinical presentation often correlates to location of the tumor. Ectopic pituitary tumors were significantly more likely to be functional secretory tumors. They may also exhibit more aggressive behavior than sellar-located tumors. Ectopic pituitary tumors may be part of a spectrum of presenting pathologies. Further genetic or genomic analysis is necessary to better understand their pathogenesis and clinical presentations.
C1 [Shuman, William; Loewenstern, Joshua; Pai, Akila; Bederson, Joshua; Shrivastava, Raj] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Shrivastava, R (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM raj.shrivastava@mountsinai.org
CR Ali R, 2010, IRISH J MED SCI, V179, P593, DOI 10.1007/s11845-008-0236-x
   ANAND VK, 1993, OTOLARYNG HEAD NECK, V108, P178, DOI 10.1177/019459989310800213
   Appel Julia Goulart, 2012, Pituitary, V15 Suppl 1, pS53, DOI 10.1007/s11102-011-0345-9
   Arzamendi AE, 2016, J NEUROL SURG REP, V77, pE113, DOI 10.1055/s-0036-1585091
   Askitis D, 2018, ENDOCRINE, V60, P255, DOI 10.1007/s12020-018-1570-z
   Bethge H, 1999, CLIN ENDOCRINOL, V51, P809, DOI 10.1046/j.1365-2265.1999.00897.x
   Bi WL, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0811-0
   Bi WYLD, 2017, ENDOCRINOLOGY, V158, P2284, DOI 10.1210/en.2016-1967
   Bobeff EJ, 2017, FOLIA NEUROPATHOL, V55, P60, DOI 10.5114/fn.2017.66714
   Collie RB, 2005, OTOLARYNG HEAD NECK, V133, P453, DOI 10.1016/j.otohns.2004.10.015
   Cooper DS, 1996, THYROID, V6, P337, DOI 10.1089/thy.1996.6.337
   Das CJ, 2006, AM J ROENTGENOL, V186, P1468, DOI 10.2214/AJR.05.0329
   DYER EH, 1994, NEUROSURGERY, V34, P529, DOI 10.1227/00006123-199403000-00022
   Endo T, 2018, J NEUROL SURG PART A, V79, P90, DOI 10.1055/s-0037-1600515
   Erdogan N, 2012, CLIN NEUROL NEUROSUR, V114, P414, DOI 10.1016/j.clineuro.2011.11.011
   Ferraz JRL, 2012, ARQ NEURO-PSIQUIAT, V70, P744, DOI 10.1590/S0004-282X2012000900019
   Flitsch J, 2015, PITUITARY, V18, P279, DOI 10.1007/s11102-014-0591-8
   Foulad A, 2015, PITUITARY GLAND ANAT
   Fuminari K, 2015, TURK NEUROSURG, V25, P503, DOI 10.5137/1019-5149.JTN.11212-14.1
   Gondim JA, 2004, ACTA RADIOL, V45, P689, DOI 10.1080/02841850410008405
   Guerrero CA, 2007, NEUROSURGERY, V61, P879, DOI 10.1227/01.NEU.0000280059.90596.85
   Gurazada K, 2014, PITUITARY, V17, P423, DOI 10.1007/s11102-013-0520-2
   Hamon M, 2003, J COMPUT ASSIST TOMO, V27, P424, DOI 10.1097/00004728-200305000-00021
   Hata N, 2003, NEUROL MED-CHIR, V43, P399, DOI 10.2176/nmc.43.399
   HERMAN V, 1990, J CLIN ENDOCR METAB, V71, P1427, DOI 10.1210/jcem-71-6-1427
   Hong JF, 2012, NEUROL INDIA, V60, P304, DOI 10.4103/0028-3886.98517
   HORI A, 1985, J NEUROSURG, V63, P113, DOI 10.3171/jns.1985.63.1.0113
   Horiuchi Tetsuyoshi, 1997, Neurologia Medico-Chirurgica, V37, P399, DOI 10.2176/nmc.37.399
   Hosaka N, 2002, AM J SURG PATHOL, V26, P1078, DOI 10.1097/00000478-200208000-00015
   Hou L, 2002, NEUROSURGERY, V50, P618, DOI 10.1097/00006123-200203000-00035
   KAMMER H, 1981, JAMA-J AM MED ASSOC, V246, P2722, DOI 10.1001/jama.246.23.2722
   KAMPHORST W, 1992, J NEUROL NEUROSUR PS, V55, P73, DOI 10.1136/jnnp.55.1.73
   Karras CL, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/8371697
   KLEINSCHMIDTDEMASTERS BK, 1990, J NEUROSURG, V72, P139, DOI 10.3171/jns.1990.72.1.0139
   Knappe UJ, 2017, NEUROSURGERY, V80, P525, DOI 10.1227/NEU.0000000000001319
   Kohno Michihiro, 1994, Neurologia Medico-Chirurgica, V34, P538, DOI 10.2176/nmc.34.538
   Kusano Y, 2013, J NEUROIMAGING, V23, P135, DOI 10.1111/j.1552-6569.2011.00620.x
   Liang JC, 2014, CLIN NEUROPATHOL, V33, P197, DOI 10.5414/NP300702
   LLOYD RV, 1986, AM J SURG PATHOL, V10, P546, DOI 10.1097/00000478-198608000-00004
   LUK KH, 1992, POSTGRAD MED J, V68, P467, DOI 10.1136/pgmj.68.800.467
   Madonna D, 2001, ANN OTO RHINOL LARYN, V110, P99, DOI 10.1177/000348940111000118
   MATSUMURA A, 1990, NEUROSURGERY, V26, P681, DOI 10.1227/00006123-199004000-00021
   Matsuno A, 2001, ANZ J SURG, V71, P495, DOI 10.1046/j.1440-1622.2001.02173.x
   Mizutani A, 2009, BRIT J NEUROSURG, V23, P321, DOI 10.1080/02688690902842767
   Mudd PA, 2012, CLIN NEUROPATHOL, V31, P24, DOI 10.5414/NP300421
   Nishiike S, 2014, AURIS NASUS LARYNX, V41, P586, DOI 10.1016/j.anl.2014.07.004
   Pasquini E, 2003, EUR J ENDOCRINOL, V148, P253, DOI 10.1530/eje.0.1480253
   Pojskic M, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.070
   Ramirez Claudia, 2013, BMC Res Notes, V6, P411, DOI 10.1186/1756-0500-6-411
   RASMUSSEN P, 1979, CLIN ENDOCRINOL, V11, P69, DOI 10.1111/j.1365-2265.1979.tb03047.x
   Rocque BG, 2009, ENDOCR PRACT, V15, P143, DOI 10.4158/EP.15.2.143
   ROTHMAN LM, 1976, J NEUROSURG, V44, P96, DOI 10.3171/jns.1976.44.1.0096
   SASANO N, 1963, TOHOKU J EXP MED, V78, P352, DOI 10.1620/tjem.78.352
   SCHTEINGART DE, 1987, NEUROSURGERY, V21, P223, DOI 10.1227/00006123-198708000-00016
   Seltzer J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14685
   Shah R, 2011, ENDOCR PRACT, V17, P966, DOI 10.4158/EP11178.VV
   Sindoni A, 2018, CLIN NUCL MED, V43, pE25, DOI 10.1097/RLU.0000000000001889
   Song MQ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-544
   Suzuki J, 2004, ENDOCR J, V51, P97, DOI 10.1507/endocrj.51.97
   Tajudeen BA, 2017, J NEUROL SURG PART B, V78, P120, DOI 10.1055/s-0036-1592081
   TAKAHATA T, 1995, J NEUROSURG, V83, P1092, DOI 10.3171/jns.1995.83.6.1092
   TAL A, 1993, SOUTHERN MED J, V86, P249, DOI 10.1097/00007611-199302000-00026
   Thompson LDR, 2012, HEAD NECK PATHOL, V6, P75, DOI 10.1007/s12105-012-0336-9
   TOVI F, 1990, HEAD NECK-J SCI SPEC, V12, P264
   Vakharia Rushabh M, 2016, Radiol Case Rep, V11, P419
   Veit JA, 2013, LARYNGOSCOPE, V123, P1132, DOI 10.1002/lary.23867
   Wang H, 2010, J NEURO-OPHTHALMOL, V30, P135, DOI 10.1097/WNO.0b013e3181c5d1a2
   Wang Q, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.062
   Wu XF, 2015, HEAD NECK-J SCI SPEC, V37, pE120, DOI 10.1002/hed.23908
   Yang J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008912
   Yao A, 2017, WORLD NEUROSURG, V104, P489, DOI 10.1016/j.wneu.2017.04.128
   Zerikly RK, 2009, NAT CLIN PRACT ENDOC, V5, P174, DOI 10.1038/ncpendmet1039
   Zhou HJ, 2017, PITUITARY, V20, P477, DOI 10.1007/s11102-017-0807-9
NR 73
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 397
EP 403
DI 10.1016/j.wneu.2018.10.200
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100276
PM 30404064
DA 2020-05-12
ER

PT J
AU Lau, JC
   Kosteniuk, SE
   Walker, T
   Iansavichene, A
   Macdonald, DR
   Megyesi, JF
AF Lau, Jonathan C.
   Kosteniuk, Suzanne E.
   Walker, Thomas
   Iansavichene, Alla
   Macdonald, David R.
   Megyesi, Joseph F.
TI Operative Complications with and without Image Guidance: A Systematic
   Review and Meta-Analysis of the Ommaya Reservoir Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chemotherapy; Image guidance; Meta-analysis; Neuronavigation;
   Neurosurgery; Ventricular shunt
ID VENTRICULAR CATHETER PLACEMENT; CENTRAL NERVOUS-SYSTEM; INTRAVENTRICULAR
   CHEMOTHERAPY; LEPTOMENINGEAL METASTASES; BREAST-CANCER; FRAMELESS;
   EXPERIENCE; INSERTION; THERAPY; SHUNT
AB BACKGROUND: The use of image guidance (IG) in neurosurgery is ubiquitous, even though evidence from patient outcome data has remained limited to smaller, mostly observational, studies. Ommaya reservoir insertion (ORI) has been available as a treatment option for targeted intraventricular pharmaco-therapy since the 1960s, far preceding the modern neuronavigation era. We conducted a systematic review and meta-analysis investigating the impact of IG on surgical outcome from ORI.
   METHODS: A systematic database search of MEDLINE and EMBASE was performed to identify studies on operative outcomes from ORI. Only studies reporting patient demographics and perioperative outcomes (hemorrhage, infection, malposition, malfunction, and mortality) were included. Study quality was assessed via MINORS criteria.
   RESULTS: Of the 3560 records screened, 43 studies met study inclusion criteria, for a total of 1995 ORI procedures. Pooled rates of outcome for IG compared with non-IG were 6.4% versus 14.1% for overall complications; 2.0% compared with 2.8% for catheter malfunction; 2.3% compared with 3.3% for catheter malposition; 0.7% compared with 4.5% for early infection; and 0.6% compared with 1.4% for mortality. Postoperative hemorrhage was increased at 3.4% compared with 2.4%. Subgroup analysis revealed a difference in early infection rate between frameless and frame-based IG at 0.0% versus 1.9%. Metaregression revealed a relationship between publication date and all operative outcomes except for catheter malposition and hemorrhage.
   CONCLUSIONS: This study offers a historical context on the evolution of the practice of ORI and comprises the largest observational analysis of operative outcomes providing objective support for the use of IG in neurosurgery.
C1 [Lau, Jonathan C.; Kosteniuk, Suzanne E.; Walker, Thomas; Macdonald, David R.; Megyesi, Joseph F.] Western Univ, Dept Clin Neurol Sci, London, ON, Canada.
   [Lau, Jonathan C.] Western Univ, Imaging Res Labs, Robarts Res Inst, London, ON, Canada.
   [Megyesi, Joseph F.] Western Univ, Dept Pathol, London, ON, Canada.
   [Iansavichene, Alla] London Hlth Sci Ctr, Hlth Sci Lib, Victoria Campus, London, ON, Canada.
   [Macdonald, David R.] London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada.
RP Lau, JC (reprint author), Western Univ, Dept Clin Neurol Sci, London, ON, Canada.; Lau, JC (reprint author), Western Univ, Imaging Res Labs, Robarts Res Inst, London, ON, Canada.
EM jonathan.lau@londonhospitals.ca
CR Al-Anazi A, 2000, J NEUROSURG, V92, P1050, DOI 10.3171/jns.2000.92.6.1050
   Azeem SS, 2007, NEUROSURGERY, V60, P243, DOI 10.1227/01.NEU.0000255387.03088.53
   BARNETT GH, 1993, NEUROSURGERY, V33, P674, DOI 10.1227/00006123-199310000-00017
   Barone DG, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009685.pub2
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   BAYSTON R, 1989, J NEUROL NEUROSUR PS, V52, P605, DOI 10.1136/jnnp.52.5.605
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boogerd W, 2004, EUR J CANCER, V40, P2726, DOI 10.1016/j.ejca.2004.08.012
   BOOGERD W, 1991, CANCER, V67, P1685, DOI 10.1002/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M
   Chamberlain MC, 1997, J NEUROSURG, V87, P694, DOI 10.3171/jns.1997.87.5.0694
   CRAMOND T, 1993, J PAIN SYMPTOM MANAG, V8, P465, DOI 10.1016/0885-3924(93)90189-3
   DAKHIL S, 1981, CANCER TREAT REP, V65, P401
   DEVISSER BWO, 1983, NEUROLOGY, V33, P1565, DOI 10.1212/WNL.33.12.1565
   DIAMOND RD, 1973, NEW ENGL J MED, V288, P186, DOI 10.1056/NEJM197301252880405
   Dickerman RD, 2005, J SURG ONCOL, V89, P36, DOI 10.1002/jso.20174
   GALICICH JH, 1974, SURG CLIN N AM, V54, P915
   GRANT R, 1994, ARCH NEUROL-CHICAGO, V51, P457, DOI 10.1001/archneur.1994.00540170033013
   Greenfield JP, 2008, STEREOT FUNCT NEUROS, V86, P101, DOI 10.1159/000112431
   Gwak HS, 2011, ACTA NEUROCHIR, V153, P1971, DOI 10.1007/s00701-011-1086-2
   HAAXMAREICHE H, 1988, BLUT, V57, P351, DOI 10.1007/BF00320756
   HAGEN NA, 1987, J NEURO-ONCOL, V5, P273, DOI 10.1007/BF00151231
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   HITCHINS RN, 1987, J CLIN ONCOL, V5, P1655, DOI 10.1200/JCO.1987.5.10.1655
   IACOANGELI M, 1995, ANN ONCOL, V6, P377, DOI 10.1093/oxfordjournals.annonc.a059187
   JACOBS A, 1981, CLIN ONCOL, V7, P123
   Kakarla UK, 2008, OPER NEUROSURG S, V63
   KELLY PJ, 1987, J NEUROSURG, V66, P865, DOI 10.3171/jns.1987.66.6.0865
   Kennedy BC, 2015, STEREOT FUNCT NEUROS, V93, P415, DOI 10.1159/000442423
   Khan NR, 2019, NEUROSURGERY, V84, P624, DOI 10.1093/neuros/nyy074
   Lau JC, 2018, ACTA NEUROCHIR, V160, P539, DOI 10.1007/s00701-017-3454-z
   LEVY WJ, 1981, NEUROSURGERY, V9, P559, DOI 10.1227/00006123-198111000-00012
   Lollis SS, 2009, BRIT J NEUROSURG, V23, P516, DOI 10.1080/02688690902948192
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Morgenstern PF, 2016, WORLD NEUROSURG, V93, P154, DOI 10.1016/j.wneu.2016.04.090
   Nesvick CL, 2015, NEUROSURGERY, V77, P321, DOI 10.1227/NEU.0000000000000849
   OBBENS EAMT, 1985, NEUROLOGY, V35, P1274, DOI 10.1212/WNL.35.9.1274
   OMMAYA AK, 1963, LANCET, V2, P983
   PERRIN RG, 1990, CAN J NEUROL SCI, V17, P190, DOI 10.1017/S0317167100030432
   PFEFFER MR, 1988, ISRAEL J MED SCI, V24, P611
   POLSKY B, 1986, AM J MED, V81, P24, DOI 10.1016/0002-9343(86)90177-4
   RATCHESON RA, 1968, NEW ENGL J MED, V279, P1025, DOI 10.1056/NEJM196811072791904
   Sampath R, 2012, STEREOT FUNCT NEUROS, V90, P97, DOI 10.1159/000333831
   Sandberg DI, 2000, NEUROSURGERY, V47, P49, DOI 10.1097/00006123-200007000-00011
   Sarrafzadeh A, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-478
   Schlegel U, 2001, J NEUROL NEUROSUR PS, V71, P118, DOI 10.1136/jnnp.71.1.118
   Shamir RR, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820828d9
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   WASSERSTROM WR, 1982, CANCER, V49, P759, DOI 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
   Weiner GM, 2015, CLIN NEUROL NEUROSUR, V130, P61, DOI 10.1016/j.clineuro.2014.12.018
   Xu LW, 2016, CLIN NEUROL NEUROSUR, V147, P46, DOI 10.1016/j.clineuro.2016.05.024
   YOUNG GAR, 1986, AUST NZ J MED, V16, P373, DOI 10.1111/j.1445-5994.1986.tb01190.x
   YOUNG RF, 1985, J NEUROSURG, V63, P371, DOI 10.3171/jns.1985.63.3.0371
   Zairi F, 2015, J NEURO-ONCOL, V124, P317, DOI 10.1007/s11060-015-1842-x
NR 55
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 404
EP 414
DI 10.1016/j.wneu.2018.11.036
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100277
PM 30447448
DA 2020-05-12
ER

PT J
AU Rotman, LE
   Vaughan, TB
   Hackney, JR
   Riley, KO
AF Rotman, Lauren E.
   Vaughan, T. Brooks
   Hackney, James R.
   Riley, Kristen O.
TI Long-Term Survival After Transformation of an Adrenocorticotropic
   Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph
   Pituitary Carcinoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Long-term survival; Pituitary carcinoma; Pituitary neoplasm
   transformation
ID CUSHINGS-SYNDROME; TUMORS; TEMOZOLOMIDE; ADENOMA; DISEASE;
   CLASSIFICATION; METASTASIS; REMISSION
AB BACKGROUND: Pituitary carcinomas are rare and aggressive neoplasms that despite current treatment regimens continue to have a poor prognosis. Adrenocorticotrophic hormone pituitary tumors have been shown to alter their clinical manifestations with conversion to Cushing disease and silent types.
   CASE DESCRIPTION: The purpose of this paper is to present the first documented case of an adrenocorticotrophic hormone-secreting pituitary adenoma with Cushing disease that differentiated into a silent corticotroph pituitary carcinoma with metastases to distant sites in the central nervous system.
   CONCLUSIONS: This patient was later treated with radiotherapy, temozolo-mide, and bevacizumab, with 8 years of progression-free survival.
C1 [Rotman, Lauren E.; Riley, Kristen O.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Vaughan, T. Brooks] Univ Alabama Birmingham, Dept Endocrinol, Birmingham, AL USA.
   [Hackney, James R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
RP Rotman, LE (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM lerotman@uabmc.edu
FU University of Alabama Department of Neurosurgery
FX We acknowledge and thank the University of Alabama Department of
   Neurosurgery for their support in the writing of this paper.
CR Annamalai AK, 2012, PITUITARY, V15, P276, DOI 10.1007/s11102-011-0363-7
   Baldeweg SE, 2005, BRIT J NEUROSURG, V19, P38, DOI 10.1080/02688690500081230
   Brown Rebecca L, 2007, Endocr Pract, V13, P463
   Bruno OD, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/587893
   COOPER ME, 1987, AUST NZ J MED, V17, P249, DOI 10.1111/j.1445-5994.1987.tb00055.x
   Cooper O, 2015, PITUITARY, V18, P225, DOI 10.1007/s11102-014-0624-3
   Cooper Odelia, 2010, Hormones & Cancer, V1, P80, DOI 10.1007/s12672-010-0014-x
   DICKSTEIN G, 1991, ARCH INTERN MED, V151, P185, DOI 10.1001/archinte.151.1.185
   Dickstein G, 1997, ARCH INTERN MED, V157, P2377, DOI 10.1001/archinte.157.20.2377
   Farrell William E, 2003, Pituitary, V6, P41, DOI 10.1023/A:1026233927714
   Figarella-Branger D, 2006, ACTA NEUROPATHOL, V111, P71, DOI 10.1007/s00401-005-1099-0
   Gaffey TA, 2005, CLIN NEUROPATHOL, V24, P56
   Gaffey TA, 2002, J NEUROSURG, V96, P352, DOI 10.3171/jns.2002.96.2.0352
   Garmes Heraldo Mendes, 2017, Surg Neurol Int, V8, P162, DOI 10.4103/sni.sni_498_16
   Garrao AF, 1997, EUR J ENDOCRINOL, V137, P176, DOI 10.1530/eje.0.1370176
   GOLLARD R, 1995, CANCER, V76, P1814, DOI 10.1002/1097-0142(19951115)76:10<1814::AID-CNCR2820761021>3.0.CO;2-T
   Halevy C, 2017, PITUITARY, V20, P261, DOI 10.1007/s11102-016-0745-y
   Hansen TM, 2014, NEUROSURG REV, V37, P279, DOI 10.1007/s10143-014-0525-y
   He L, 2016, J NEUROSURG SCI, V60, P272
   Heaney AP, 2011, J CLIN ENDOCR METAB, V96, P3649, DOI 10.1210/jc.2011-2031
   Kageyama K, 2014, ENDOCR J, V61, P941, DOI 10.1507/endocrj.EJ14-0120
   Kemink SAG, 1999, J ENDOCRINOL INVEST, V22, P70, DOI 10.1007/BF03345482
   Koetsveld AC, 2001, J NEUROSURG, V95, P719, DOI 10.3171/jns.2001.95.4.0719
   Kovacs K, 2006, ACTA NEUROPATHOL, V111, P62, DOI 10.1007/s00401-005-1095-4
   Koyama J, 2007, NEUROL MED-CHIR, V47, P475, DOI 10.2176/nmc.47.475
   Landman RE, 2002, J CLIN ENDOCR METAB, V87, P3084, DOI 10.1210/jc.87.7.3084
   Lasolle H, 2017, EUR J ENDOCRINOL, V176, P769, DOI 10.1530/EJE-16-0979
   Lehman NL, 2003, J NEUROSURG, V98, P1120, DOI 10.3171/jns.2003.98.5.1120
   Meinardi JR, 2007, EUR J ENDOCRINOL, V157, P245, DOI 10.1530/EJE-07-0262
   Melcescu E, 2013, NEUROSURGERY, V72, pE144, DOI 10.1227/NEU.0b013e3182750850
   Mohammed S, 2009, NEUROSURGERY, V64, P773, DOI 10.1227/01.NEU.0000339115.12803.4E
   Ortiz LD, 2012, PITUITARY, V15, P445, DOI 10.1007/s11102-011-0346-8
   Ortiz LD, 2012, CLINICS, V67, P119, DOI 10.6061/clinics/2012(Sup01)20
   Park KS, 2014, PITUITARY, V17, P514, DOI 10.1007/s11102-013-0537-6
   Pernicone PJ, 1997, CANCER, V79, P804, DOI 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3
   Ragel Brian T, 2004, Neurosurg Focus, V16, pE7
   Roncaroli F, 2003, AM J SURG PATHOL, V27, P477, DOI 10.1097/00000478-200304000-00007
   Sansur CA, 2010, SEMIN ONCOL, V37, P591, DOI 10.1053/j.seminoncol.2010.10.012
   Scheithauer BW, 2006, NEUROSURGERY, V59, P341, DOI 10.1227/01.NEU.0000223437.51435.6E
   Scheithauer BW, 2005, NEUROSURGERY, V56, P1066, DOI 10.1227/01.NEU.0000157926.72826.DB
   Scheithauer BW, 2001, ULTRASTRUCT PATHOL, V25, P227, DOI 10.1080/019131201300343865
   Scheithauer BW, 2000, NEUROSURGERY, V47, P723, DOI 10.1097/00006123-200009000-00039
   Solcia E, HISTOLOGICAL TYPING
   Song Ye, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P539
   Velez Dennis A, 2007, Neurosurg Focus, V23, pE4a
   Zoli M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.11.FOCUS14679
NR 46
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 417
EP 423
DI 10.1016/j.wneu.2018.11.011
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100279
PM 30447452
DA 2020-05-12
ER

PT J
AU Shakil, H
   Wang, AP
   Horth, DA
   Nair, SS
   Reddy, KKV
AF Shakil, Husain
   Wang, Alick P.
   Horth, Dillon A.
   Nair, Saeda S.
   Reddy, Kesava K. V.
TI Trigeminocardiac Reflex: Case Report and Literature Review of
   Intraoperative Asystole in Response to Manipulation of the Temporalis
   Muscle
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anesthesia; Asystole; Oculocardiac reflex; Skull base; Temporal muscle;
   Trigeminal nerve; Trigeminocardiac reflex
ID OCULOCARDIAC REFLEX; CARDIAC REFLEX; VAGAL; SURGERY; RAT
AB BACKGROUND: The trigeminocardiac reflex is a sudden onset of bradycardia, hypotension, apnea, or gastric hypermotility in response to stimulation of the trigeminal nerve.
   CASE DESCRIPTION: A 60-year-old female underwent a left orbitozygomatic craniotomy to debulk a large skull base epidermoid cyst compressing the brainstem and cranial nerves. Intraoperatively, retraction of the temporalis muscle consistently produced asystole. Cessation of retraction resulted in prompt return of sinus rhythm.
   CONCLUSIONS: Our report describes an unusual and extreme example of the trigeminocardiac reflex and explores possible etiologies. This is the third reported surgical case in which manipulation of the temporalis muscle alone was sufficient to elicit bradycardia and asystole, and the first such case within the context of neurosurgery. We emphasize the importance of surgical teams to be cognizant of such extreme examples of this reflex.
C1 [Shakil, Husain; Wang, Alick P.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada.
   [Horth, Dillon A.; Nair, Saeda S.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Reddy, Kesava K. V.] McMaster Univ, Div Neurosurg, Dept Surg, Hamilton, ON, Canada.
RP Reddy, KKV (reprint author), McMaster Univ, Div Neurosurg, Dept Surg, Hamilton, ON, Canada.
EM reddy@hhsc.ca
OI Wang, Alick/0000-0003-2641-8205; Shakil, Husain/0000-0003-3995-6811
CR ARMOUR JA, 1985, CAN J PHYSIOL PHARM, V63, P1122, DOI 10.1139/y85-184
   Arnold RW, 1999, YALE J BIOL MED, V72, P237
   AYLWARD PE, 1985, PFLUG ARCH EUR J PHY, V403, P21, DOI 10.1007/BF00583276
   Bauer DF, 2005, SURG NEUROL, V63, P143, DOI 10.1016/j.surneu.2004.03.022
   BLANC VF, 1983, CAN ANAESTH SOC J, V30, P360, DOI 10.1007/BF03007858
   BROWN JA, 1988, NEUROSURGERY, V23, P745, DOI 10.1227/00006123-198812000-00010
   Burggasser G, 2002, PLAST RECONSTR SURG, V109, P1862, DOI 10.1097/00006534-200205000-00012
   CHESLEY LD, 1989, J ORAL MAXIL SURG, V47, P522, DOI 10.1016/0278-2391(89)90290-5
   Chowdhury T, 2015, J NEUROSURG ANESTH, V27, P136, DOI 10.1097/ANA.0000000000000065
   Devakumari S, 2013, IOSR J DENT MED SCI, V12, P7
   Dong XD, 2006, NEUROSCIENCE, V141, P939, DOI 10.1016/j.neuroscience.2006.04.024
   KIMURA T, 1985, J PHARMACOL EXP THER, V235, P793
   LEVY MN, 1984, FED PROC, V43, P2598
   LIMWONGSE V, 1977, AM J ANAT, V149, P477, DOI 10.1002/aja.1001490405
   Luco K, 2018, OJNBD, V1, P1
   Lv X, 2010, INTERV NEURORADIOL, V16, P59, DOI 10.1177/159101991001600107
   Meuwly C., 2015, MEDICINE, V94, P1
   Peddireddy A, 2005, CLIN NEUROPHYSIOL, V116, P1611, DOI 10.1016/j.clinph.2005.02.022
   PRECIOUS DS, 1990, INT J ORAL MAX SURG, V19, P279, DOI 10.1016/S0901-5027(05)80420-5
   Schaller B, 2005, CLIN NEUROL NEUROSUR, V107, P468, DOI 10.1016/j.clineuro.2004.12.004
   Schaller B, 1999, J NEUROSURG, V90, P215, DOI 10.3171/jns.1999.90.2.0215
   Schaller B, 2005, J NEUROSURG ANESTH, V17, P45
   Schaller B, 2009, J NEUROSURG ANESTH, V21, P187, DOI 10.1097/ANA.0b013e3181a2bf22
   SHELLY MP, 1988, ANAESTHESIA, V43, P422, DOI 10.1111/j.1365-2044.1988.tb09042.x
   VANBROCKLIN MD, 1982, J AM OPTOM ASSOC, V53, P407
   WELHAF WR, 1965, ARCH OPHTHALMOL-CHIC, V73, P43
   YASSIN IBHM, 1979, NEUROSCI LETT, V11, P63
   Ziccardi VB, 1998, J CRANIOFAC SURG, V9, P185, DOI 10.1097/00001665-199803000-00019
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 424
EP 427
DI 10.1016/j.wneu.2018.10.186
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100280
PM 30399470
DA 2020-05-12
ER

PT J
AU Muhammad, S
   Niemela, M
   Lehecka, M
AF Muhammad, Sajjad
   Niemela, Mika
   Lehecka, Martin
TI Utility of Video Indocyanine Angiography to Detect the Cortical Entry
   Point of a Draining Vein with a Superficial Vein During Arteriovenous
   Malformation Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Draining vein; Indocyanine angiography;
   Surgical treatment
C1 [Muhammad, Sajjad] Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
   Helsinki Univ Hosp, Helsinki, Finland.
RP Muhammad, S (reprint author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
EM ext-sajjad.muhammad@hus.fi
OI Lehecka, Martin/0000-0003-4088-1116; Muhammad,
   Sajjad/0000-0002-6734-7979
NR 0
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 428
EP 428
DI 10.1016/j.wneu.2018.11.054
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100281
PM 30448578
OA Green Published
DA 2020-05-12
ER

PT J
AU Morita, T
   Maki, Y
   Notohara, K
   Kinosada, M
   Yasuda, T
   Chin, M
AF Morita, Takumi
   Maki, Yoshinori
   Notohara, Kenji
   Kinosada, Masanori
   Yasuda, Takaya
   Chin, Masaki
TI Subarachnoid Hemorrhage From a Distal Middle Cerebral Artery Aneurysm
   Possibly Related to Segmental Arterial Mediolysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography angiography; Dissecting aneurysm; Distal middle
   cerebral artery aneurysm; Pathology; Segmental arterial mediolysis;
   Subarachnoid hemorrhage
ID DISSECTING ANEURYSM; MANAGEMENT
AB BACKGROUND: Distal middle cerebral artery aneurysm (DMCAAn) is rare, and the clinical features and the etiology are not well understood. Segmental artery mediolysis (SAM) is a pathologic entity that affects the media of the muscular artery and can cause arterial dissection and a hemorrhagic event. Subarachnoid hemorrhage (SAH) due to SAM in the vertebral artery has been documented. However, SAH from a ruptured DMCAAn due to SAM has not yet been described.
   CASE DESCRIPTION: A 49-year-old woman presented with a headache and vomiting. Computed tomography (CT) revealed SAH, and CT angiography showed a DMCAAn, which was treated by trapping and resection. Histopathologic studies showed loss of the media and reparative changes in the arterial wall including intimal hyperplasia and increased vasa vasorum in the adventitia. These findings were indicative of SAM in the reparative phase. She did not show any other possible etiologies of DMCAAn including infectious endocarditis and vasculitis, and CT angiography of the trunk did not show any other vascular lesions. She was discharged from the hospital approximately 3 weeks after the surgery without any apparent neurological deficits.
   CONCLUSIONS: Our case suggests that SAM can also occur in the middle cerebral artery and result in DMCAAn.
C1 [Morita, Takumi; Maki, Yoshinori; Kinosada, Masanori; Yasuda, Takaya; Chin, Masaki] Kurashiki Cent Hosp, Dept Neurosurg, Okayama, Japan.
   [Notohara, Kenji] Kurashiki Cent Hosp, Dept Pathol, Okayama, Japan.
RP Morita, T (reprint author), Kurashiki Cent Hosp, Dept Neurosurg, Okayama, Japan.
EM kapipara10000@gmail.com
OI sen tian, jiang/0000-0003-3212-1811
CR Alturkustani M, 2013, AM J FOREN MED PATH, V34, P98, DOI 10.1097/PAF.0b013e31828879e8
   Asaithambi G, 2014, INT J EMERG MED, V7, DOI 10.1186/s12245-014-0044-1
   Baikoussis NG, 2011, EUR J CARDIO-THORAC, V40, P412, DOI 10.1016/j.ejcts.2010.11.045
   Baker-Lepain JC, 2010, ARTHRIT CARE RES, V62, P1655, DOI 10.1002/acr.20294
   Dashti R, 2007, SURG NEUROL, V67, P553, DOI 10.1016/j.surneu.2007.03.023
   Horiuchi T, 2004, J NEUROSURG, V100, P384, DOI 10.3171/jns.2004.100.3.0384
   Joo SP, 2007, ACTA NEUROCHIR, V149, P661, DOI 10.1007/s00701-007-1061-5
   Leu H J, 1994, Cardiovasc Surg, V2, P350
   Matsuda R, 2012, J NEUROSURG, V116, P948, DOI 10.3171/2012.1.JNS111967
   Nishi M, 2017, INTERNAL MED, V56, P1363, DOI 10.2169/internalmedicine.56.8043
   Ro A, 2010, CARDIOVASC PATHOL, V19, P248, DOI 10.1016/j.carpath.2009.02.002
   Sakamoto S, 2003, NEUROL MED-CHIR, V43, P188, DOI 10.2176/nmc.43.188
   Shinoda N, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.12.058
   SLAVIN RE, 1976, LAB INVEST, V35, P23
   STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391
   Tsutsumi K, 2017, J CLIN NEUROSCI, V40, P14, DOI 10.1016/j.jocn.2016.12.019
   Umeoka K, 2011, NEUROL MED-CHIR, V51, P777
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 429
EP 432
DI 10.1016/j.wneu.2018.11.031
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100282
PM 30447466
DA 2020-05-12
ER

PT J
AU Wat, R
   Mammi, M
   Paredes, J
   Haines, J
   Alasmari, M
   Liew, A
   Lu, VM
   Arnaout, O
   Smith, TR
   Gormley, WB
   Aglio, LS
   Mekary, RA
   Zaidi, H
AF Wat, Ricky
   Mammi, Marco
   Paredes, Jose
   Haines, Jordan
   Alasmari, Mohammed
   Liew, Aaron
   Lu, Victor M.
   Arnaout, Omar
   Smith, Timothy R.
   Gormley, William B.
   Aglio, Linda S.
   Mekary, Rania A.
   Zaidi, Hasan
TI The Effectiveness of Antiepileptic Medications as Prophylaxis of Early
   Seizure in Patients with Traumatic Brain Injury Compared with Placebo or
   No Treatment: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antiepileptic drug; Epilepsy; Levetiracetam; Phenytoin; Posttraumatic
   seizure; Traumatic brain injury; Valproate
ID POSTTRAUMATIC SEIZURES; PHENYTOIN; PREVENTION; LEVETIRACETAM;
   HETEROGENEITY; VALPROATE; EPILEPSY; TRIALS
AB BACKGROUND: The use of antiepileptic drugs (AEDs) to prevent early post-traumatic seizure (PTS) for patients with severe traumatic brain injury (TBI) is currently recommended, although published studies present contradictory results concerning the protective effect of AEDs.
   OBJECTIVE: The purpose of this study was to quantify the association between the use of prophylactic AEDs, particularly of the 4 main drugs of interest (phenytoin, levetiracetam, valproate, or carbamazepine) versus placebo or no treatment, and risk of early seizures after TBI.
   METHODS: A comprehensive search was performed on PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. The selection criteria were English written randomized controlled trials (RCTs) and observational studies, comparing AEDs with placebo or no treatment, for prevention of early PTS. Random-effects models were used to calculate pooled relative risk (RR). Subgroup analysis and meta-regression were used to assess heterogeneity sources.
   RESULTS: This research included 3 RCTs (750 patients) and 6 observational studies (3362 patients), analyzing the efficacy of phenytoin, levetiracetam, and valproate. The pooled RR estimate across RCTs trended toward a protective effect (RR, 0.58; 95% confidence interval, 0.20-1.72; I-2 = 59.5%); a significant protective association was shown when pooling the results across all 6 observational studies (RR, 0.42; 95% confidence interval, 0.29-0.62; I-2 = 0%). When stratifying the observational studies by drug, no significant difference was observed (P interaction = 0.73). Begg and Egger tests indicated no publication bias among observational studies.
   CONCLUSIONS: Only modest evidence suggested effectiveness of AEDs as prophylaxis of early PTS. Phenytoin was the most studied drug; more prospective studies are needed to assess the efficacy of other AEDs.
C1 [Wat, Ricky; Paredes, Jose; Haines, Jordan; Alasmari, Mohammed; Mekary, Rania A.] MCPHS Univ, Sch Pharm, Dept Pharmaceut Business & Adm Sci, Boston, MA 02115 USA.
   [Mammi, Marco; Lu, Victor M.; Arnaout, Omar; Smith, Timothy R.; Gormley, William B.; Aglio, Linda S.; Mekary, Rania A.; Zaidi, Hasan] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.
   [Aglio, Linda S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.
   [Liew, Aaron] NUIG, Galway, Ireland.
RP Mekary, RA (reprint author), MCPHS Univ, Sch Pharm, Dept Pharmaceut Business & Adm Sci, Boston, MA 02115 USA.; Mekary, RA (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.
EM rania.mekary@mcphs.edu
OI Wat, Ricky/0000-0002-0298-2517
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhullar IS, 2014, J TRAUMA ACUTE CARE, V76, P54, DOI 10.1097/TA.0b013e3182aafd15
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Cook AM, 2013, AM J HEALTH-SYST PH, V70, P2062, DOI 10.2146/ajhp130271
   Debenham S, 2011, CAN J NEUROL SCI, V38, P896, DOI 10.1017/S031716710001249X
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84
   Inglet S, 2016, CUREUS, V8, DOI 10.7759/cureus.753
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3
   Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187
   Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518
   Ma CY, 2010, CHIN J TRAUMATOL, V13, P293, DOI 10.3760/cma.j.issn.1008-1275.2010.05.008
   Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2
   Ohimor Stephen O., 1996, Journal of Pharmacy Technology, V12, P160
   Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f
   RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155
   Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254
   Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y
   TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801
   Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593
   Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x
   Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203
   Wells GA, 2013, NEWCASTLE OTTAWA SCA, P1, DOI [10.2307/632432, DOI 10.2307/632432]
   Wilson CD, 2018, WORLD NEUROSURG, V110, pE901, DOI 10.1016/j.wneu.2017.11.116
   Yang Y, 2016, CNS DRUGS, V30, P677, DOI 10.1007/s40263-016-0365-0
   YOUNG B, 1983, CHILD BRAIN, V10, P185
   Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016
   Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30
   Zangbar B, 2016, WORLD J SURG, V40, P2667, DOI 10.1007/s00268-016-3606-y
NR 36
TC 4
Z9 4
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 433
EP 440
DI 10.1016/j.wneu.2018.11.076
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100283
PM 30465951
DA 2020-05-12
ER

PT J
AU Di Somma, A
   Gimenez, JLN
   Bethencourt, JMA
   Cavallo, LM
   Marquez-Rivas, J
AF Di Somma, Alberto
   Narros Gimenez, Jose Luis
   Almarcha Bethencourt, Jose Manuel
   Maria Cavallo, Luigi
   Marquez-Rivas, Javier
TI Neuroendoscopic Intraoperative Ultrasound-Guided Technique for Biopsy of
   Paraventricular Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic third ventriculostomy; Neuroendoscopic intraoperative
   ultrasound
ID STEREOTACTIC BIOPSY; ENDOSCOPIC BIOPSY; DIAGNOSTIC YIELD; SMALL
   FRAGMENTS; EXPERIENCE; LESIONS; MANAGEMENT; ADVANTAGES; ACCURACY
AB Different tumors can be encountered in the paraventricular regions, and whereas their deep location often make them difficult to access surgically, they may be amenable to chemotherapy and/or radiotherapy. Therefore, tumor biopsy and histologic diagnosis are mandatory to optimize treatment. Different technical procedures have been recommended; the neuroendoscopic approach is accepted and widely used, in particular with an enlarged ventricular system. However, specifically with paraventricular tumors, tissue sampling may be challenging. In such a scenario, the use of intraoperative ultrasonography technique can add some advantages regarding diagnostic accuracy and procedure safety. Accordingly, in this study we describe a novel technical procedure in 7 selected patients in whom tumor tissue biopsy was performed in a coupled neuroendoscopic and ultrasound-guided environment. We define a neuroendoscopic intraoperative ultrasound technique. The main advantages of this technique are the identification of the tumor that may not been clearly identified underneath the ventricular ependymal through the neuroendoscopic window alone, and furthermore, that this technique gives the possibility to detect the depth of the needle advance\ment in the selected tissue while labeling the lesion beneath the ventricular ependyma. Moreover, intraoperative ultrasonography can reveal in a real-time fashion intracranial hemorrhages that may occur after tissue biopsy, therefore providing a useful tool to achieve valid and directed hemostasis when needed.
C1 [Di Somma, Alberto; Maria Cavallo, Luigi] Univ Napoli Federico II, Sch Med & Surg, Div Neurosurg, Naples, Italy.
   [Narros Gimenez, Jose Luis; Almarcha Bethencourt, Jose Manuel; Marquez-Rivas, Javier] Hosp Univ Virgen del Rocio, Dept Neurol Surg, Seville, Spain.
RP Di Somma, A (reprint author), Univ Napoli Federico II, Sch Med & Surg, Div Neurosurg, Naples, Italy.
EM albertodisomma87@gmail.com
RI Marquez-Rivas, Javier/C-8940-2015; Di Somma, Alberto/AAG-5690-2020
OI Marquez-Rivas, Javier/0000-0002-5136-4723; Di Somma,
   Alberto/0000-0002-3253-3448
CR Allouch H, 2007, ACTA NEUROCHIR, V149, P91, DOI 10.1007/s00701-006-1043-7
   Allouch H, 2014, WORLD NEUROSURG, V82, P202, DOI 10.1016/j.wneu.2013.01.019
   Awa R, 2014, NEURORADIOLOGY, V56, P525, DOI 10.1007/s00234-014-1369-4
   Balossier A, 2015, NEUROCHIRURGIE, V61, P146, DOI 10.1016/j.neuchi.2014.06.002
   BERGER MS, 1986, J NEUROSURG, V65, P550, DOI 10.3171/jns.1986.65.4.0550
   Bozinov O, 2012, NEUROSURG REV, V35, P269, DOI 10.1007/s10143-011-0364-z
   Bozinov O, 2011, ACTA NEUROCHIR SUPPL, V109, P191, DOI [10.1007/978-3-211-99651-530, 10.1007/978-3-211-99651-5_30]
   CAPPABIANCA P, 1991, ACTA CYTOL, V35, P505
   Catapano G, 2019, NEUROSURG REV, V42, P309, DOI 10.1007/s10143-018-0947-z
   Chernov MF, 2009, CLIN NEUROL NEUROSUR, V111, P527, DOI 10.1016/j.clineuro.2009.03.006
   Cinalli G, 2005, EXPERT REV MED DEVIC, V2, P351, DOI 10.1586/17434440.2.3.351
   Colosimo C, 2002, CHILD NERV SYST, V18, P426, DOI 10.1007/s00381-002-0607-y
   Cordone I, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0404-1
   Dammers R, 2010, ACTA NEUROCHIR, V152, P1915, DOI 10.1007/s00701-010-0752-0
   DEDIVITIIS E, 1983, APPL NEUROPHYSIOL, V46, P295
   Eigenbrod S, 2014, ACTA NEUROCHIR, V156, P1427, DOI 10.1007/s00701-014-2073-1
   Fiorindi A, 2017, OPER NEUROSURG, V13, P173, DOI 10.1093/ons/opw008
   Fiorindi A, 2008, ACTA NEUROCHIR, V150, P1235, DOI 10.1007/s00701-008-0155-7
   Frati A, 2011, STEREOT FUNCT NEUROS, V89, P234, DOI 10.1159/000325704
   Fukami S, 2018, WORLD NEUROSURG, V114, pE366, DOI 10.1016/j.wneu.2018.02.185
   Hakan T, 2016, TURK NEUROSURG, V26, P890, DOI 10.5137/1019-5149.JTN.13742-14.0
   Hayashi N, 2011, J NEUROSURG, V115, P1147, DOI 10.3171/2011.7.JNS101976
   Iijima K, 2015, J NEUROSURG, V123, P978, DOI 10.3171/2014.10.JNS14963
   Jung TY, 2012, ONCOL REP, V27, P707, DOI 10.3892/or.2011.1522
   Krahenbuhl AK, 2016, J NEUROL SURG PART A, V77, P93, DOI 10.1055/s-0035-1559809
   Macarthur DC, 2002, BRIT J NEUROSURG, V16, P465, DOI 10.1080/0268869021000030276
   Mahboob S, 2016, WORLD NEUROSURG, V92, P255, DOI 10.1016/j.wneu.2016.05.007
   MORINGLANE JR, 1995, ACTA NEUROCHIR, V132, P134, DOI 10.1007/BF01404861
   Oppido PA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10326
   Owen CM, 2009, J NEURO-ONCOL, V93, P139, DOI 10.1007/s11060-009-9871-y
   Prada F, 2015, BIOMED RES INT, DOI 10.1155/2015/925729
   Sasagawa Y, 2014, ACTA NEUROCHIR, V156, P681, DOI 10.1007/s00701-014-1995-y
   Smith H, 2016, J NEUROSURG-PEDIATR, V18, P578, DOI 10.3171/2016.5.PEDS15739
   Strowitzki M, 2000, SURG NEUROL, V54, P134, DOI 10.1016/S0090-3019(00)00267-6
   Velasquez C, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.043
NR 35
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 441
EP 450
DI 10.1016/j.wneu.2018.11.057
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100284
PM 30448577
DA 2020-05-12
ER

PT J
AU Xu, T
   Yan, Y
   Wang, HX
   Chen, JX
AF Xu, Tao
   Yan, Yong
   Wang, Hongxiang
   Chen, Juxiang
TI Transclinoid-Transcavernous Approach to a Giant Cavernous Sinus
   Hemangioma: 2-Dimensional Operative Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Hemangioma; Operative video; Orbitozygomatic
   craniotomy; Surgical video
C1 [Xu, Tao; Yan, Yong; Wang, Hongxiang; Chen, Juxiang] Naval Med Univ, Changzheng Hosp, Shanghai Neurosurg Inst PLA, Dept Neurosurg,Neurosurg Inst, Shanghai, Peoples R China.
RP Chen, JX (reprint author), Naval Med Univ, Changzheng Hosp, Shanghai Neurosurg Inst PLA, Dept Neurosurg,Neurosurg Inst, Shanghai, Peoples R China.
EM juxiangchen@smmu.edu.cn
OI Xu, Tao/0000-0003-1984-1689
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 453
EP 453
DI 10.1016/j.wneu.2018.11.053
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100286
PM 30448589
DA 2020-05-12
ER

PT J
AU Singh, V
   Borkar, A
   Moiyadi, A
   Shetty, P
AF Singh, Vikas
   Borkar, Ashwin
   Moiyadi, Aliasgar
   Shetty, Prakash
TI Tetraventricular Atypical Central Neurocytoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical; Central neurocytoma; Tetraventricular
ID INDEX
AB BACKGROUND: Central neurocytomas are benign tumors accounting for <0.5% of all intracranial tumors. They are usually intraventricular, the most common site being the lateral ventricles, and are associated with good prognosis if they are completely resected surgically.
   CASE REPORT: We report the case of a middle-aged woman who was evaluated for recent-onset headache and for whom magnetic resonance imaging of the brain was suggestive of a solid cystic intraventricular mass spanning all the ventricles. The patient underwent subtotal excision of the mass, with intraoperative neuromonitoring. The result of Histopathologic examination was suggestive of atypical neurocytoma. The patient had complete neurologic recovery in spite of immediate postoperative deficits.
   CONCLUSIONS: Gross total resection should be the goal in all patients with central neurocytoma, but it may be limited because of proximity of the tumor to eloquent areas, especially in large tumors. Intraoperative neuromonitoring plays a pivotal role in maximal safe resection of such large tumors. Tetraventricular atypical central neurocytoma is a very rare entity; and this case could be, to the best of our knowledge, only the second reported case.
C1 [Singh, Vikas; Moiyadi, Aliasgar; Shetty, Prakash] Tata Mem Hosp, Dept Surg Oncol, Neurosurg Serv, Mumbai, India.
   [Borkar, Ashwin] Artemis Hosp, Dept Neurosurg, New Delhi, India.
RP Singh, V (reprint author), Tata Mem Hosp, Dept Surg Oncol, Neurosurg Serv, Mumbai, India.
EM drvikaskumarsingh@gmail.com
OI Moiyadi, Aliasgar/0000-0002-4082-2004
CR Akakin A, 2015, J NEUROSCI RURAL PRA, V6, P594, DOI 10.4103/0976-3147.165415
   Choudhari KA, 2009, BRIT J NEUROSURG, V23, P585, DOI 10.3109/02688690903254350
   Eng DY, 1997, J NEUROSURG, V86, P547, DOI 10.3171/jns.1997.86.3.0547
   Fujimaki T, 1997, J NEURO-ONCOL, V32, P103, DOI 10.1023/A:1005740205113
   HASSOUN J, 1982, ACTA NEUROPATHOL, V56, P151, DOI 10.1007/BF00690587
   Jhawar Sukhdeep Singh, 2015, Asian J Neurosurg, V10, P60, DOI 10.4103/1793-5482.151530
   Louis DN, 2016, WHO CLASSIFICATION T, P156
   Rades D, 2004, NEUROLOGY, V62, P987, DOI 10.1212/01.WNL.0000115392.21898.E3
   ROCHE PH, 1995, ACTA NEUROCHIR, V133, P95, DOI 10.1007/BF01404957
   Sharma MC, 1998, PATHOLOGY, V30, P355, DOI 10.1080/00313029800169626
   Soylemezoglu F, 1997, J NEUROPATH EXP NEUR, V56, P551
   Vasiljevic A, 2012, AM J SURG PATHOL, V36, P220, DOI 10.1097/PAS.0b013e31823b8232
   YASARGIL MG, 1992, J NEUROSURG, V76, P32, DOI 10.3171/jns.1992.76.1.0032
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 454
EP 457
DI 10.1016/j.wneu.2018.10.233
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100287
PM 30439524
DA 2020-05-12
ER

PT J
AU Sweid, A
   Noureldine, MHA
   Nasser, S
   Badra, M
   Saikali, I
AF Sweid, Ahmad
   Noureldine, Mohammad Hassan A.
   Nasser, Selim
   Badra, Mohammad
   Saikali, Ibrahim
TI A Case Report of Meningeal Hemangiopericytoma: A 9-Year Journey from the
   Brain to the Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Extra-axial tumor; Hemangiopericytoma; Solitary fibrous
   tumor; Spinal metastasis
AB BACKGROUND: Hemangiopericytomas (HPCs) are rare and aggressive vascular mesenchymal tumors. Unlike meningiomas, which have a similar radiologic appearance, these tumors have a higher risk of local recurrence after resection, and distant metastasis can reach up to 23%. Metastases to the vertebral bones from an intracranial HPC are very rare, with so far only 9 cases reported in the literature.
   CASE DESCRIPTION: We present the case of a 46-year-old man who was surgically treated for a presumed left parieto-occipital falx meningioma in 2008. He presented 9 years later with a thoracic vertebral mass that was causing relentless pain. Reexamination of the cranial pathology allowed correction of the diagnosis performed in 2008 to a meningeal HPC, and the spinal lesion was confirmed after surgery to be a metastatic tumor.
   CONCLUSIONS: The literature lacks randomized controlled trials and large studies defining the natural history of HPC to draw clear recommendations for a precise management of the disease. However, en bloc resection followed by radiation therapy seems to provide the optimal treatment for a long disease-free survival.
C1 [Sweid, Ahmad; Noureldine, Mohammad Hassan A.; Saikali, Ibrahim] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Div Neurosurg, Beirut, Lebanon.
   [Nasser, Selim] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Dept Pathol, Beirut, Lebanon.
   [Badra, Mohammad] Clemenceau Med Ctr, Div Orthoped Spine Surg, Beirut, Lebanon.
RP Saikali, I (reprint author), Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Div Neurosurg, Beirut, Lebanon.
EM ibrahim.saikali@lau.edu.lb
OI Sweid, Ahmad/0000-0002-2652-2451
CR Batson OV, 1940, ANN SURG, V112, P138, DOI 10.1097/00000658-194007000-00016
   Fukuda Y, 2015, J ORTHOP SCI, V20, P425, DOI 10.1007/s00776-013-0450-x
   Ghose A, 2017, AM J CLIN ONCOL-CANC, V40, P223, DOI 10.1097/COC.0000000000000146
   GUTHRIE BL, 1989, NEUROSURGERY, V25, P514, DOI 10.1227/00006123-198910000-00003
   Joo Myung Sung, 2016, Brain Tumor Res Treat, V4, P128
   Kim JH, 2003, SURG NEUROL, V59, P47, DOI 10.1016/S0090-3019(02)00917-5
   Louis DN, 2016, WHO CLASSIFICATION T, V1
   Melone AG, 2014, WORLD NEUROSURG, V81, P556, DOI 10.1016/j.wneu.2013.11.009
   Rutkowski MJ, 2011, J CLIN NEUROSCI, V18, P1500, DOI 10.1016/j.jocn.2011.04.009
   Soyuer S, 2004, CANCER-AM CANCER SOC, V100, P1491, DOI 10.1002/cncr.20109
   Zhang P, 2014, TURK NEUROSURG, V24, P948, DOI 10.5137/1019-5149.JTN.8299-13.1
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 459
EP 463
DI 10.1016/j.wneu.2018.11.028
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100288
PM 30447454
DA 2020-05-12
ER

PT J
AU Hogan, E
   Almira-Suarez, I
   Li, SY
   Collins, SP
   Jean, WC
AF Hogan, Elizabeth
   Almira-Suarez, Isabel
   Li, Siyuan
   Collins, Sean P.
   Jean, Walter C.
TI Clinical Management of Prostate Cancer Metastasis to Pineal Gland: Case
   Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic biopsy; Metastasis; Pineal; Prostate; Radiosurgery; Third
   ventriculostomy
ID ENDOSCOPIC 3RD VENTRICULOSTOMY; REGION TUMORS; STEREOTACTIC PROCEDURE;
   BIOPSY; HYDROCEPHALUS; SERIES
AB BACKGROUND: Prostate cancer is the most common cancer among American men, with an incidence of approximately 233,000 cases per year. Intracranial metastases are rare and, specifically, metastasis to the pineal gland has only been reported in 2 postmortem cases in the literature.
   CASE DESCRIPTION: We present the first documented case of confirmed prostate cancer metastasis to the pineal gland in a living patient. The patient underwent an endoscopic third ventriculostomy and pineal lesion biopsy with complete resolution of his hydrocephalus and presenting symptoms. His biopsy results confirmed the prostate origin of the metastasis, and he subsequently underwent stereotactic radiosurgery for treatment of this lesion.
   CONCLUSIONS: This is the first report of the clinical management of metastatic prostate cancer to the pineal region and description of the clinical outcome. Although prostate cancer is the most common cancer in American men, metastasis to the pineal has only been reported twice from autopsy examinations. Overall, pineal tumors in the geriatric population are exceedingly rare and the age and comorbidities in this patient made management quite unique.
C1 [Hogan, Elizabeth; Jean, Walter C.] George Washington Univ, Dept Neurol Surg, Washington, DC 20052 USA.
   [Almira-Suarez, Isabel] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA.
   [Li, Siyuan; Collins, Sean P.] Georgetown Univ, Dept Radiat Med, Washington, DC USA.
RP Jean, WC (reprint author), George Washington Univ, Dept Neurol Surg, Washington, DC 20052 USA.
EM wjean@mfa.gwu.edu
RI Jean, Walter/L-2780-2019
OI Jean, Walter/0000-0001-6774-2066; Hogan, Elizabeth/0000-0002-1754-5643;
   Almira-Suarez, Isabel/0000-0002-8866-7381
CR Abbassy M, 2018, CHILD NERV SYST, V34, P1335, DOI 10.1007/s00381-018-3840-8
   Balossier A, 2015, NEUROCHIRURGIE, V61, P146, DOI 10.1016/j.neuchi.2014.06.002
   Balossier A, 2016, WORLD NEUROSURG, V92, P223, DOI 10.1016/j.wneu.2016.03.088
   Cole B, 2008, BRAIN PATHOL, V18, P602, DOI 10.1111/j.1750-3639.2008.00210.x
   Faucett EA, 2015, CASE REP OTOLARYNGOL, DOI 10.1155/2015/250312
   Gandaglia G, 2014, PROSTATE, V74, P210, DOI 10.1002/pros.22742
   Knaus H, 2011, CHILD NERV SYST, V27, P1233, DOI 10.1007/s00381-011-1405-1
   Kumar SVR, 2007, CHILD NERV SYST, V23, P1135, DOI 10.1007/s00381-007-0371-0
   Li J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003622
   LYNES WL, 1986, UROLOGY, V28, P280, DOI 10.1016/0090-4295(86)90005-1
   Morgenstern PF, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10301
   Nandana S, 2014, AM J CLIN EXP UROL, V2, P92
   Oi S, 2001, J NEURO-ONCOL, V54, P277, DOI 10.1023/A:1012754616544
   Pople IK, 2001, BRIT J NEUROSURG, V15, P305
   Tremont-Lukats IW, 2003, CANCER, V98, P363, DOI 10.1002/cncr.11522
   Veto F, 1997, NEUROSURGERY, V40, P871, DOI 10.1097/00006123-199704000-00048
   Yamini B, 2004, J NEUROSURG, V100, P437, DOI 10.3171/ped.2004.100.5.0437
   Zhu XL, 2013, ASIAN J SURG, V36, P74, DOI 10.1016/j.asjsur.2012.11.008
NR 18
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 464
EP 468
DI 10.1016/j.wneu.2018.11.111
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100289
PM 30476672
DA 2020-05-12
ER

PT J
AU Kotheeranurak, V
   Lin, GX
   Mahatthanatrakul, A
   Kim, JS
AF Kotheeranurak, Vit
   Lin, Guang-Xun
   Mahatthanatrakul, Akaworn
   Kim, Jin-Sung
TI Endoscope-Assisted Anterior Lumbar Interbody Fusion with Computed
   Tomography-Guided, Image-Navigated Unilateral Cortical Bone Trajectory
   Screw Fixation in Managing Adjacent Segment Disease in L5/S1: Technical
   Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope-assisted ALIF
AB OBJECTIVE: We sought to describe a novel technique in managing a patient with adjacent segment disease at the L5/S1 level.
   METHODS: We performed an endoscope-assisted anterior lumbar interbody fusion with computed tomography-guided, image-navigated unilateral cortical bone trajectory screw fixation to treat L5/S1 intervertebral disk pathology.
   RESULTS: Patient was successfully treated by a direct endoscopic decompression through the anterior access, interbody fusion using an anterior lumbar interbody fusion cage, unilateral cortical bone trajectory instrumentation under computed tomography-guided image navigation.
   CONCLUSIONS: This minimally invasive technique is effective in terms of decompression and fixation. It could be used as an alternative method to treat patients with L5/S1 adjacent segment disease.
C1 [Kotheeranurak, Vit] Queen Savang Vadhana Mem Hosp, Dept Orthoped, Sriracha, Chonburi, Thailand.
   [Lin, Guang-Xun; Kim, Jin-Sung] Catholic Univ Korea, St Marys Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Mahatthanatrakul, Akaworn] Naresuan Univ Hosp, Dept Orthoped, Phisanulok, Thailand.
RP Kim, JS (reprint author), Catholic Univ Korea, St Marys Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM mddavidk@dreamwiz.com
RI Kim, Jin-Sung/Y-2904-2019; Mahatthanatrakul, Akaworn/AAF-3835-2019
OI Kim, Jin-Sung/0000-0001-5086-0875; Mahatthanatrakul,
   Akaworn/0000-0003-4216-8541
CR Ahlquist S, 2018, SPINE J, V18, P1999, DOI 10.1016/j.spinee.2018.03.014
   Chen CH, 2018, J CLIN NEUROSCI, V48, P224, DOI 10.1016/j.jocn.2017.11.008
   Chen W J, 2001, Spine (Phila Pa 1976), V26, pE519, DOI 10.1097/00007632-200111150-00024
   Choi KC, 2014, CLIN ORTHOP RELAT R, V472, P1845, DOI 10.1007/s11999-013-3256-4
   Harrop JS, 2008, SPINE, V33, P1701, DOI 10.1097/BRS.0b013e31817bb956
   Heo DH, 2016, WORLD NEUROSURG, V96, P530, DOI 10.1016/j.wneu.2016.09.033
   Hilibrand Alan S, 2004, Spine J, V4, p190S, DOI 10.1016/j.spinee.2004.07.007
   Ishihara H, 2001, J SPINAL DISORD, V14, P91, DOI 10.1097/00002517-200104000-00001
   Kim JS, 2017, EUR SPINE J, V26, P397, DOI 10.1007/s00586-016-4902-9
   Kim JS, 2010, J NEUROSURG-SPINE, V12, P171, DOI 10.3171/2009.9.SPINE09272
   Lee JC, 2015, ASIAN SPINE J, V9, P807, DOI 10.4184/asj.2015.9.5.807
   Lee Sang-Ho, 2004, Spine J, V4, P644, DOI 10.1016/j.spinee.2004.04.012
   Matsukawa K, 2014, SPINE, V39, pE240, DOI 10.1097/BRS.0000000000000116
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Perez-Orribo L, 2013, SPINE, V38, P635, DOI 10.1097/BRS.0b013e318279a95e
   Phillips FM, 2000, J SPINAL DISORD, V13, P432, DOI 10.1097/00002517-200010000-00011
   Rodriguez A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13521
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Shin SH, 2013, SPINE J, V13, P1190, DOI 10.1016/j.spinee.2013.07.458
   Suk KS, 2000, SPINE, V25, P1843
NR 20
TC 1
Z9 2
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 469
EP 473
DI 10.1016/j.wneu.2018.10.029
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100290
PM 30321680
DA 2020-05-12
ER

PT J
AU Heo, DH
   Kim, JS
   Park, CW
   Quillo-Olvera, J
   Park, CK
AF Heo, Dong Hwa
   Kim, Jin Sung
   Park, Cheol Woong
   Quillo-Olvera, Javier
   Park, Choon Keun
TI Contralateral Sublaminar Endoscopic Approach for Removal of Lumbar
   Juxtafacet Cysts Using Percutaneous Biportal Endoscopic Surgery:
   Technical Report and Preliminary Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cyst; Facet joint; Lumbar; Minimally invasive surgery; Stenosis;
   Surgical decompression; Surgical endoscopy
ID SYNOVIAL CYSTS; DECOMPRESSION; RESECTION; FUSION
AB BACKGROUND: Use of a contralateral sublaminar endoscopic approach may minimize facet violation and better visualize the dura and cystic lesions during operation. The aim of this study was to introduce a surgical technique for contralateral sublaminar endoscopic removal of lumbar juxtafacet cysts using a percutaneous biportal endoscopic approach.
   METHODS: Ten cases of lumbar juxtafacet cyst were consecutively treated via a contralateral sublaminar endoscopic approach using percutaneous biportal endoscopic surgery. Postoperative magnetic resonance imaging scans were evaluated on postoperative day 1 for optimal removal of cysts and neural decompression status. Clinical findings were evaluated in preoperative and postoperative periods using a visual analog scale for leg pain and the Oswestry Disability Index.
   RESULTS: Ten lumbar juxtafacet cysts in 10 patients were treated using the contralateral sublaminar biportal endoscopic approach. Postoperative magnetic resonance imaging depicted complete removal of juxtafacet cysts and optimal neural decompression of treated segments in all patients. Preoperative visual analog scale and Oswestry Disability Index scores improved significantly after surgery: visual analog scale scores changed from 7.64 +/- 0.71 preoperatively to 1.63 +/- 1.28 at last follow-up visit (P < 0.05), and Oswestry Disability Index scores changed from 45.35 +/- 16.15 to 15.82 +/- 10.21 (P < 0.05). Mean operative time was 60.1 +/- 23.4 minutes.
   CONCLUSIONS: A contralateral sublaminar approach using percutaneous biportal endoscopy may be an alternative treatment for symptomatic lumbar juxtafacet cysts. This approach may minimize iatrogenic facet violation and traumatization of posterior musculoligamentous structures.
C1 [Heo, Dong Hwa; Quillo-Olvera, Javier; Park, Choon Keun] Leon Wiltse Mem Hosp, Dept Neurosurg, Spine Ctr, Suwon, South Korea.
   [Kim, Jin Sung] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Park, Cheol Woong] Daejeon Woori Spine Hosp, Dept Neurosurg, Daejeon, South Korea.
RP Kim, JS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM mddavidk@gmail.com
RI Kim, Jin-Sung/Y-2904-2019; Heo, Dong Hwa/AAE-2785-2019
OI Kim, Jin-Sung/0000-0001-5086-0875; Heo, Dong Hwa/0000-0003-1203-4550
CR Berra LV, 2010, SPINE, V35, P709, DOI 10.1097/BRS.0b013e3181bac710
   Campbell R, 2018, WORLD NEUROSURG, V119, pE502, DOI 10.1016/j.wneu.2018.07.190
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Hagen T, 2001, RADIOLOGE, V41, P1056, DOI 10.1007/s001170170005
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17146
   Hwang JH, 2017, WORLD NEUROSURG, V101, P33, DOI 10.1016/j.wneu.2017.01.079
   Jha RT, 2017, WORLD NEUROSURG, V100, P583, DOI 10.1016/j.wneu.2017.01.059
   Kim JH, 2018, NEUROSPINE, V15, P131, DOI 10.14245/ns.1836046.023
   Knafo S, 2015, J SPINAL DISORD TECH, V28, P211, DOI 10.1097/BSD.0b013e31827179c8
   Nizamani Waseem Mehmood, 2018, Radiol Case Rep, V13, P302, DOI 10.1016/j.radcr.2017.09.009
   Scholz C, 2017, CLIN NEUROL NEUROSUR, V153, P35, DOI 10.1016/j.clineuro.2016.12.008
   Sukkarieh HG, 2015, J NEUROSURG-SPINE, V23, P444, DOI 10.3171/2015.1.SPINE14996
   Themistoklis KM, 2018, J CLIN NEUROSCI, V57, P173, DOI 10.1016/j.jocn.2018.08.038
   van Dijke M, 2017, CLIN SPINE SURG, V30, pE1399, DOI 10.1097/BSD.0000000000000449
NR 14
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 474
EP 479
DI 10.1016/j.wneu.2018.11.072
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100291
PM 30458327
DA 2020-05-12
ER

PT J
AU Krug, RG
   Chang, AY
   Raghunathan, A
   Van Gompel, JJ
AF Krug, Randall G., II
   Chang, Alice Y.
   Raghunathan, Aditya
   Van Gompel, Jamie J.
TI Apoplectic Silent Crooke Cell Adenoma with Adjacent Pseudoaneurysms:
   Causation or Bystander?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysms; Apoplexy; Crooke cell adenoma; Pituitary gland
ID PITUITARY-ADENOMA; ANEURYSM; TUMORS
AB BACKGROUND: Crooke cell adenomas (CCAs) are rare and potentially aggressive pituitary tumors that often invade the cavernous sinuses. Although clinical presentations of pituitary tumors may include the development of accompanying intracranial aneurysms, there are no documented cases of coexistent intracranial aneurysms and CCAs to date. Herein we describe an apoplectic silent CCA that presented with adjacent cavernous internal carotid artery (ICA) aneurysms.
   CASE DESCRIPTION: A 45-year old male patient presented for evaluation of headaches and diplopia. Subsequent imaging series revealed a hemorrhagic pituitary macroadenoma that had invaded the left cavernous sinus and circumferentially involved the ICA. Two pseudoaneurysms were visualized along regions of the ICA directly attached to the tumor. A transnasal transsphenoidal endoscopic approach was used for resection of the tumor, which was identified histologically as a CCA. Endocrine evaluations characterized the tumor as nonfunctional. The patient experienced an excellent recovery with resolution of related symptoms. A pseudoaneurysm was treated with a Pipeline embolization device; however, it persisted at last follow-up.
   CONCLUSIONS: CCAs are a poorly characterized and rare pituitary tumor type. In this case, an apoplectic silent CCA invaded the left cavernous sinus and presented with pseudoaneurysms along its involvement of the ICA. Accordingly, the authors speculated that the invasive qualities of this silent corticotroph adenoma may have directly contributed to the development of these aneurysms.
C1 [Krug, Randall G., II] Mayo Clin, Alix Sch Med, Rochester, MN USA.
   [Chang, Alice Y.] Mayo Clin, Dept Internal Med, Div Endocrinol Diabet Metab & Nutr, Rochester, MN USA.
   [Raghunathan, Aditya] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   [Van Gompel, Jamie J.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
   [Van Gompel, Jamie J.] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA.
RP Van Gompel, JJ (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.; Van Gompel, JJ (reprint author), Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA.
EM vangompel.jamie@mayo.edu
OI Raghunathan, Aditya/0000-0001-6198-7441
CR Di Ieva A, 2015, NEUROSURGERY, V76, P616, DOI 10.1227/NEU.0000000000000657
   George DH, 2003, AM J SURG PATHOL, V27, P1330, DOI 10.1097/00000478-200310000-00005
   MANGIARDI JR, 1983, SURG NEUROL, V19, P38, DOI 10.1016/0090-3019(83)90208-2
   Oh MC, 2012, J NEUROSURG, V116, P942, DOI 10.3171/2011.12.JNS11875
   Pant B, 1997, NEUROSURG REV, V20, P13, DOI 10.1007/BF01390519
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Rajah GB, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.1.FOCUS16497
   Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326
   Suzuki H, 2001, STROKE, V32, P567, DOI 10.1161/01.STR.32.2.567
   Tsang ACO, 2015, J NEUROINTERV SURG, V7, P603, DOI 10.1136/neurintsurg-2014-011154
   Turgut M, 2010, ACTA NEUROCHIR, V152, P749, DOI 10.1007/s00701-009-0595-8
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Xu K, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0653-z
NR 13
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 480
EP 484
DI 10.1016/j.wneu.2018.10.232
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100292
PM 30465959
DA 2020-05-12
ER

PT J
AU Deora, H
   Tripathi, M
   Yagnick, NS
   Deora, S
   Mohindra, S
   Batish, A
AF Deora, Harsh
   Tripathi, Manjul
   Yagnick, Nishant S.
   Deora, Sonali
   Mohindra, Sandeep
   Batish, Aman
TI Changing Hands: Why Being Ambidextrous Is a Trait That Needs to Be
   Acquired and Nurtured in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Review
DE Ambidexterity; Neurosurgery; Surgical skills
ID HANDEDNESS
AB OBJECTIVE: The aim of this article is examine the issue of ambidexterity under the neurosurgical lens and demonstrate its need, its validity, and its advantages to neurosurgery as a whole.
   METHODS: Inspiration can be derived from extraordinary circumstances that shaped ordinary people into legends. There have been instances in history where highly skilled professionals relying on hand motor skills had the misfortune of having to relearn their skill set with the other, less dominant hand.
   RESULTS: We as neurosurgeons have always been ahead of the curve. It is only natural for us to understand the need and advantages of using both our hands with equal dexterity. Whether ambidexterity is an inherited trait or one that can be taught and, if practiced, mastered has been controversial.
   CONCLUSION: These remarkable individuals from history demonstrate that if one is willing to practice without ego and one has the right motivation, one can use both hands with equal dexterity.
C1 [Deora, Harsh] Sanjay Gandhi Post Grad Inst Med Educ & Res, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
   [Tripathi, Manjul; Mohindra, Sandeep; Batish, Aman] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
   [Yagnick, Nishant S.] Paras Hosp Gurgaon, Dept Neurosurg, Gurgaon, India.
   [Deora, Sonali] Narayana Hruduyala Hosp, Dept Radiodiag, Bangalore, Karnataka, India.
RP Tripathi, M (reprint author), Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
EM drmanjultripathi@gmail.com
RI Tripathi, Manjul/AAE-7128-2019; DEORA, HARSH/A-5817-2019
OI Tripathi, Manjul/0000-0002-5679-3439; DEORA, HARSH/0000-0003-3247-1117;
   batish, aman/0000-0003-3257-9443
CR Beehler B, 2018, WORLD NEUROSURG, V114, pE323, DOI 10.1016/j.wneu.2018.02.180
   GILBERT AN, 1992, NEUROPSYCHOLOGIA, V30, P601, DOI 10.1016/0028-3932(92)90065-T
   Knecht S, 2000, BRAIN, V123, P2512, DOI 10.1093/brain/123.12.2512
   Liebert PS, 1987, NY TIMES, P30
   Nielsen JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071275
   Quintana LM, 2016, WORLD NEUROSURG, V89, P686, DOI 10.1016/j.wneu.2015.11.005
   Torgerson CS, 2007, ANN OTO RHINOL LARYN, V116, P819, DOI 10.1177/000348940711601105
   Wilder JR., 1987, NY TIMES, P31
   Yaman O, 2014, ACTA ORTHOP TRAUMATO, V48, P479, DOI 10.3944/AOTT.2014.13.0046
NR 9
TC 4
Z9 4
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 487
EP 490
DI 10.1016/j.wneu.2018.11.106
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100293
PM 30472285
DA 2020-05-12
ER

PT J
AU Yamamoto, Y
   Hashikata, H
   Toda, H
   Iwasaki, K
AF Yamamoto, Yu
   Hashikata, Hirokuni
   Toda, Hiroki
   Iwasaki, Koichi
TI Nervus Intermedius Section to Mobilize the Anterior Inferior Cerebellar
   Artery in Microvascular Decompression Surgery for Hemifacial Spasm: A
   Technical Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Hemifacial spasm; Microvascular
   decompression; Nervus intermedius
ID GENICULATE NEURALGIA; SURGICAL-MANAGEMENT; COMPRESSION
AB BACKGROUND: The course of the anterior inferior cerebellar artery (AICA) in the cerebellopontine angle may affect the technical options in microvascular decompression surgery for hemifacial spasm. A complex relationship between the AICA and the nervus intermedius has rarely been discussed in patients with hemifacial spasms.
   CASE DESCRIPTION: A 74-year-old woman presented with left facial spasms for 8 years. Intraoperative endoscopic observation confirmed that the left nervus intermedius crossed over the left AICA and limited its mobilization from the root exit zone (REZ) of the left facial nerve. Nervus intermedius section enabled mobilization of the AICA to decompress the facial nerve REZ. Her hemifacial spasm was resolved completely after the surgery with no significant complication.
   CONCLUSIONS: The AICA may be found between the nervus intermedius and the facial nerve proper in patients with hemifacial spasm. Endoscope can visualize the relationship between the AICA and the nervus intermedius. Nervus intermedius section is a useful option in case that the nervus intermedius limits adequate mobilization of the AICA from the facial nerve REZ.
C1 [Yamamoto, Yu; Hashikata, Hirokuni; Toda, Hiroki; Iwasaki, Koichi] Tazuke Kofukai Med Res Inst, Dept Neurosurg, Osaka, Japan.
   [Yamamoto, Yu; Hashikata, Hirokuni; Toda, Hiroki; Iwasaki, Koichi] Kitano Hosp, Osaka, Japan.
   [Toda, Hiroki] Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
RP Toda, H (reprint author), Tazuke Kofukai Med Res Inst, Dept Neurosurg, Osaka, Japan.; Toda, H (reprint author), Kitano Hosp, Osaka, Japan.; Toda, H (reprint author), Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
EM htoda-nsu@umin.ac.jp
OI Toda, Hiroki/0000-0002-1596-4131
CR Alonso F, 2017, CUREUS, V9, DOI 10.7759/cureus.1570
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Burmeister HP, 2011, AM J NEURORADIOL, V32, P460, DOI 10.3174/ajnr.A2338
   Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   Chen YL, 2014, J CRANIOFAC SURG, V25, P1187, DOI 10.1097/SCS.0000000000000837
   Ho SL, 1999, NEUROLOGY, V53, P2132, DOI 10.1212/WNL.53.9.2132
   Holste KG, 2019, J NEUROSURG, V131, P352, DOI 10.3171/2018.3.JNS172495
   Ikeda N, 2015, OPER NEUROSURG, V11, P382, DOI 10.1227/NEU.0000000000000855
   Inoue Takuro, 2017, NMC Case Rep J, V4, P75, DOI 10.2176/nmccrj.cr.2016-0261
   Ishikawa M, 2015, ACTA NEUROCHIR, V157, P329, DOI 10.1007/s00701-014-2294-3
   Kesser BW, 2014, ANATOMY FACIAL NERVE, P1
   KIM HN, 1990, ANN OTO RHINOL LARYN, V99, P288, DOI 10.1177/000348949009900408
   Lovely TJ, 1997, AM J OTOL, V18, P512
   MARTIN RG, 1980, NEUROSURGERY, V6, P483, DOI 10.1227/00006123-198005000-00001
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Mohr JP, 2011, STROKE PATHOPHYSIOLO, P446
   Nagatani T, 1999, J NEUROL NEUROSUR PS, V67, P73, DOI 10.1136/jnnp.67.1.73
   Park JS, 2008, ACTA NEUROCHIR, V150, P235, DOI 10.1007/s00701-007-1457-x
   Peris-Celda M, 2019, J NEUROSURG, V131, P343, DOI 10.3171/2018.3.JNS172920
   Pirillo V, 2018, WORLD NEUROSURG, V115, P277, DOI 10.1016/j.wneu.2018.04.177
   PULEC JL, 1976, LARYNGOSCOPE, V86, P955, DOI 10.1288/00005537-197607000-00008
   RUPA V, 1991, J NEUROSURG, V75, P505, DOI 10.3171/jns.1991.75.4.0505
   SACHS E, 1968, J NEUROSURG, V28, P54, DOI 10.3171/jns.1968.28.1.0054
   Saers SJF, 2011, J LARYNGOL OTOL, V125, P520, DOI 10.1017/S0022215110002677
   Sakas DE, 2007, J NEUROSURG, V107, P1228, DOI 10.3171/JNS-07/12/1228
   Toda H, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18122
   Tubbs RS, 2013, WORLD NEUROSURG, V80, pE353, DOI 10.1016/j.wneu.2012.11.053
   Tubbs R Shane, 2013, World Neurosurg, V79, P763, DOI 10.1016/j.wneu.2012.03.023
   Younes WM, 2010, STEREOT FUNCT NEUROS, V88, P193, DOI 10.1159/000313873
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 491
EP 494
DI 10.1016/j.wneu.2018.11.126
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100294
PM 30476669
DA 2020-05-12
ER

PT J
AU Nakahara, M
   Uozumi, Y
   Chiba, Y
   Miyake, S
   Fujita, A
   Kohmura, E
AF Nakahara, Masahiro
   Uozumi, Yoichi
   Chiba, Yoshiyuki
   Miyake, Shigeru
   Fujita, Atsushi
   Kohmura, Eiji
TI Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid
   Aneurysm Embedded Within a Prolactinoma After Cabergoline Administration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute subdural hematoma; Carotid cavernous fistula; Cavernous carotid
   aneurysm; Direct surgery; Endovascular treatment; Prolactinoma
ID ARTERY ANEURYSM; SUBARACHNOID HEMORRHAGE; PITUITARY APOPLEXY
AB BACKGROUND: A small number of reports have described subarachnoid hemorrhage resulting from a ruptured aneurysm embedded within a prolactinoma. To the best of our knowledge, no reports have described an embedded carotid cavernous fistula. We report a patient with carotid cavernous fistula secondary to a ruptured internal carotid artery aneurysm embedded within a prolactinoma.
   CASE DESCRIPTION: A 61-year-old woman was referred to our hospital with sudden headache, vomiting, and dizziness. Magnetic resonance imaging demonstrated a small acute subdural hematoma, recurrent prolactinoma, and left cavernous carotid aneurysm. Conservative therapy was initiated. Her serum prolactin level at hospitalization was 11,300 mu g/L; therefore, we initiated cabergoline therapy. Twenty days after cabergoline administration, she suddenly presented with left conjunctival injection and pulsatile tinnitus. Angiography showed a left direct carotid cavernous fistula with a connection between the cavernous internal carotid artery and the cavernous sinus via the aneurysm and venous congestion. To prevent hemorrhagic stroke, we scheduled staged surgery. First, we urgently performed embolization of the cavernous sinus and fistula. One month later, to prevent aneurysm rerupture, we performed a radical operation with superficial temporal artery-middle cerebral artery double anastomosis with proximal occlusion of the left internal carotid artery at the cervical portion. The patient was discharged 2 weeks after surgery without neurological deficits. Follow-up angiography revealed complete occlusion of the aneurysm 2 months postoperatively.
   CONCLUSIONS: An aneurysm embedded within a prolactinoma should be closely observed when cabergoline administration is started.
C1 [Nakahara, Masahiro; Uozumi, Yoichi; Chiba, Yoshiyuki; Miyake, Shigeru] Kita Harima Med Ctr, Dept Neurosurg, Ono, Hokkaido, Japan.
   [Uozumi, Yoichi; Fujita, Atsushi; Kohmura, Eiji] Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
RP Nakahara, M (reprint author), Kita Harima Med Ctr, Dept Neurosurg, Ono, Hokkaido, Japan.
EM nakkfm@gmail.com
RI Fujita, Atsushi/Q-6619-2019
OI Fujita, Atsushi/0000-0003-1294-6584; Uozumi, Yoichi/0000-0002-5985-2764
CR Akutsu N, 2014, J NEUROL SURG REP, V75, pE73, DOI 10.1055/s-0033-1364166
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Chavan RG, 2014, NEURORADIOL J, V27, P207, DOI 10.15274/NRJ-2014-10032
   HALBACH VV, 1987, AM J ROENTGENOL, V149, P587, DOI 10.2214/ajr.149.3.587
   Khalsa SS, 2017, J NEUROINTERV SURG, V9, pE9, DOI 10.1136/neurintsurg-2016-012446.rep
   Mustafa W, 2010, INTERV NEURORADIOL, V16, P447, DOI 10.1177/159101991001600412
   Ogilvy CS, 2017, WORLD NEUROSURG, V105, P812, DOI 10.1016/j.wneu.2017.06.113
   Peng ZS, 2015, INT J CLIN EXP PATHO, V8, P14189
   Suzuki H, 2001, STROKE, V32, P567, DOI 10.1161/01.STR.32.2.567
   Wang AYC, 2013, J STROKE CEREBROVASC, V22, pE533, DOI 10.1016/j.jstrokecerebrovasdis.2013.05.036
   Wendl CM, 2017, CLIN NEURORADIOL, V27, P493, DOI 10.1007/s00062-016-0511-6
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 495
EP 499
DI 10.1016/j.wneu.2018.11.071
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100295
PM 30465960
DA 2020-05-12
ER

PT J
AU Karthigeyan, M
   Malik, P
   Garg, S
   Radotra, BD
   Salunke, P
   Sunil, N
   Kumar, N
AF Karthigeyan, Madhivanan
   Malik, Puneet
   Garg, Sumit
   Radotra, Bishan D.
   Salunke, Pravin
   Sunil, Narasimhaiah
   Kumar, Narendra
TI Intracranial Low-Grade Fibromyxoid Sarcoma with Atypical Radiology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system; Dural-based; Falx; Intracranial sarcoma;
   Low-grade fibromyxoid sarcoma; Sarcoma; Solid cystic
AB BACKGROUND: Low-grade fibromyxoid sarcoma (LGFMS), an uncommon soft tissue tumor, generally occurs in extremities and is characterized by an aggressive clinical course with frequent recurrences. Primary intracranial occurrence of LGFMS is rare. The few existing descriptions present the clinicopathologic aspects of LGFMS and lack information from a radiologic perspective. In these reports, the lesions appeared solid on imaging.
   CASE DESCRIPTION: In a 45-year-old woman, a falx-based lesion with solid-cystic radiologic appearance that turned out to be LGFMS on histopathology. The patient's clinical follow-up (2 years) is presented along with a literature review of other primary central nervous system cases.
   CONCLUSIONS: This report emphasizes the radiologic aspects of LGFMS and describes an atypical solid-cystic appearance of this uncommon central nervous system tumor. This adds another facet to the imaging of LGFMS. Although rare, LGFMS can form a differential diagnosis of dural-based lesions.
C1 [Karthigeyan, Madhivanan; Malik, Puneet; Salunke, Pravin; Sunil, Narasimhaiah] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
   [Garg, Sumit; Radotra, Bishan D.] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India.
   [Kumar, Narendra] Postgrad Inst Med Educ & Res, Dept Radiotherapy, Chandigarh, India.
RP Karthigeyan, M (reprint author), Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
EM karthigeyanm82@gmail.com
CR Chen N, 2015, NEUROPATHOLOGY, V35, P348, DOI 10.1111/neup.12197
   Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687
   EVANS HL, 1987, AM J CLIN PATHOL, V88, P615, DOI 10.1093/ajcp/88.5.615
   PAULUS W, 1991, HISTOPATHOLOGY, V18, P395, DOI 10.1111/j.1365-2559.1991.tb00869.x
   Saito R, 2008, J NEUROSURG, V108, P798, DOI 10.3171/JNS/2008/108/4/0798
   Tun K, 2008, J CLIN NEUROSCI, V15, P1298, DOI 10.1016/j.jocn.2007.07.085
   White IK, 2015, J NEUROSURG-PEDIATR, V16, P372, DOI 10.3171/2015.3.PEDS14564
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 500
EP 504
DI 10.1016/j.wneu.2018.11.082
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100296
PM 30465950
DA 2020-05-12
ER

PT J
AU Kim, HS
   Singh, R
   Adsul, NM
   Oh, SW
   Noh, JH
   Jang, IT
AF Kim, Hyeun Sung
   Singh, Ravindra
   Adsul, Nitin Maruti
   Oh, Sung Woon
   Noh, Jung Hoon
   Jang, Il Tae
TI Management of Root-Level Double Crush: Case Report with Technical Notes
   on Contralateral Interlaminar Foraminotomy with Full Endoscopic
   Uniportal Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Double crush; Facet joint; Nerve root; Percutaneous endoscopic
   contralateral interlaminar foraminotomy; Superior articular process
AB BACKGROUND: Double crush of a nerve at the root level is not common. We describe here a double crush of the right L4 nerve with foramina to far lateral disk (ventral) and extraforaminal (dorsal) compression. The double crush was managed by endoscopy with a contralateral uniportal approach from the left interlaminar space. Right lateral recess stenosis at the same level was subsequently managed with the same approach.
   CASE DESCRIPTION: A 79-year-old lady presented to our clinic with a low backache, right leg pain, and weakness. On her right side, the straight leg raise test was 70 degrees, great toe dorsiflexion was grade 3/5, and hypoesthesia was present in the L4 dermatome. Her preoperative visual analog scale score was 9. Magnetic resonance imaging showed right lateral recess stenosis and a double compression of L4 nerve root from the dorsal and ventral sides. A diagnosis of right lateral recess stenosis with double crush of the right L4 nerve root was made.
   The patient was managed with percutaneous endoscopic contralateral interlaminar foraminotomy from the left interlaminar approach. She got relief for the symptoms and her postoperative visual analog scale score was 2. Magnetic resonance imaging and computed tomography showed nerve root decompression and well-preserved facet joints
   CONCLUSIONS: We conclude that the management of double crush at the nerve root level with interlaminar contralateral approach endoscopy (percutaneous endoscopic contralateral interlaminar foraminotomy) can deal with the issue effectively with facet joint preservation and other benefits of the minimally invasive spine procedure.
C1 [Kim, Hyeun Sung; Singh, Ravindra; Oh, Sung Woon; Noh, Jung Hoon; Jang, Il Tae] Nanoori Hosp, Dept Neurosurg, Seoul, South Korea.
   [Adsul, Nitin Maruti] Sir Ganga Ram Hosp, Dept Orthospine, Delhi, India.
RP Kim, HS (reprint author), Nanoori Hosp, Dept Neurosurg, Seoul, South Korea.
EM neurospinekim@gmail.com
RI Kim, Hyeun-Sung/H-3400-2018
OI Kim, Hyeun-Sung/0000-0001-5361-5234
CR Cohen BH, 2016, J HAND SURG-AM, V41, P1171, DOI 10.1016/j.jhsa.2016.09.009
   EPSTEIN JA, 1962, J NEUROL NEUROSUR PS, V25, P165, DOI 10.1136/jnnp.25.2.165
   Iwasaki Motoyuki, 2017, NMC Case Rep J, V4, P121, DOI 10.2176/nmccrj.cr.2016-0308
   Kane PM, 2015, J AM ACAD ORTHOP SUR, V23, P558, DOI 10.5435/JAAOS-D-14-00176
   Kikuike K, 2009, J SPINAL DISORD TECH, V22, P593, DOI 10.1097/BSD.0b013e3181929cbd
   Kim HS, 2017, WORLD NEUROSURG, V103, P201, DOI 10.1016/j.wneu.2017.03.130
   Matsumoto Y, 2012, ARCH ORTHOP TRAUM SU, V132, P465, DOI 10.1007/s00402-011-1438-7
   Schmid AB, 2011, MANUAL THER, V16, P557, DOI 10.1016/j.math.2011.05.005
   UPTON ARM, 1973, LANCET, V2, P359, DOI 10.1016/S0140-6736(73)93196-6
   Yeom KS, 2011, J ORTHOP SCI, V16, P263, DOI 10.1007/s00776-011-0048-0
NR 10
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 505
EP 507
DI 10.1016/j.wneu.2018.11.110
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100297
PM 30476660
DA 2020-05-12
ER

PT J
AU Paolini, S
   Severino, R
   Cardarelli, G
   Missori, P
   Bartolo, M
   Esposito, V
AF Paolini, Sergio
   Severino, Rocco
   Cardarelli, Giovanni
   Missori, Paolo
   Bartolo, Marcello
   Esposito, Vincenzo
TI Indocyanine Green Videoangiography in the Surgical Treatment of Spinal
   Dural Arterovenous Fistula: A Useful Application
SO WORLD NEUROSURGERY
LA English
DT Article
DE Indocyanine green videoangiography; Mini-invasive spine surgery; Spinal
   dural arterovenous fistulas; Vertebral level miscounting
ID ANGIOGRAPHY
AB BACKGROUND: Indocyanine green videoangiography (ICG-V) is used with increasing frequency in neurovascular surgery. ICG-V use in spinal dural arteriovenous fistulas (DAVFs) allows visualization of the hemodynamics of the fistula and to confirm its exclusion after ligation of the feeder. Here, we illustrate how ICG-V is useful for centering the surgical exposure during mini-invasive approaches to spinal DAVFs.
   METHODS: An overweight 66-year-old woman with progressive paraparesis and sphincter disturbances underwent treatment for a spinal DAVF fed by the left T6 radicular artery. After intraoperative fluoroscopy, T6 hemilaminectomy was performed. Because of slight misplacement of the bone opening, the feeder was not visible at the dural opening. We placed a temporary clip on a perimedullary arterialized vein and performed ICG-V while removing the clip.
   RESULTS: Reviewing the video clip and analyzing the direction of ICG flow inside the perimedullary venous plexus allowed us to locate the fistula with respect to the bone window and to extend the laminectomy in the correct direction.
   CONCLUSIONS: IGC-V can be helpful in mini-invasive approaches to spinal DAVFs to recalibrate the bone opening after misplacement of the initial hemilaminectomy.
C1 [Paolini, Sergio; Esposito, Vincenzo] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Rome, Italy.
   [Paolini, Sergio; Severino, Rocco; Cardarelli, Giovanni; Esposito, Vincenzo] IRCCS Neuromed, Div Neurosurg, Pozzilli, IS, Italy.
   [Bartolo, Marcello] IRCCS Neuromed, Div Neuroradiol, Pozzilli, IS, Italy.
   [Missori, Paolo] Policlin Umberto 1, Div Neurosurg, Rome, Italy.
RP Severino, R (reprint author), IRCCS Neuromed, Div Neurosurg, Pozzilli, IS, Italy.
EM severinorocco@gmail.com
RI Esposito, Vincenzo/E-9994-2011
OI Esposito, Vincenzo/0000-0001-7316-5461
CR Colby GP, 2009, J NEUROSURG-SPINE, V11, P705, DOI 10.3171/2009.6.SPINE09315
   Fontes RB, 2013, NEUROSURG FOCUS S, V35
   Hacein-Bey L, 2014, CLIN NEUROL NEUROSUR, V121, P64, DOI 10.1016/j.clineuro.2014.01.018
   Hanel RA, 2010, NEUROSURGERY, V66, P978, DOI 10.1227/01.NEU.0000368108.94233.22
   Imizu S, 2008, MINIM INVAS NEUROSUR, V51, P199, DOI 10.1055/s-2008-1080916
   Killory BD, 2011, NEUROSURGERY, V68, P781, DOI 10.1227/NEU.0b013e318207ac3b
   Paolini S, 2005, BRIT J NEUROSURG, V19, P74, DOI 10.1080/02688690500089209
   Raabe A, 2005, ZBL NEUROCHIR, V66, P1, DOI 10.1055/s-2004-836223
   Raabe A, 2005, ZENTRALBL NEUROCHIR, V66, P7
   Julian JAS, 2013, EUR SPINE J, V22, pS471, DOI 10.1007/s00586-012-2646-8
   Spiotta AM, 2011, J NEUROINTERV SURG, V3, P182, DOI 10.1136/jnis.2010.003210
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
NR 12
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 508
EP 511
DI 10.1016/j.wneu.2018.11.164
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100298
PM 30481619
DA 2020-05-12
ER

PT J
AU Ge, SN
   Chen, YK
   Li, N
   Qu, L
   Li, Y
   Jing, JP
   Wang, X
   Wang, J
   Wang, XL
AF Ge, Shunnan
   Chen, Yukun
   Li, Nan
   Qu, Liang
   Li, Yang
   Jing, Jiangpeng
   Wang, Xin
   Wang, Jing
   Wang, Xuelian
TI Deep Brain Stimulation of Nucleus Accumbens for Methamphetamine
   Addiction: Two Case Reports
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Methamphetamine addiction; Nucleus accumbens
ID HEROIN-ADDICTION; PATTERNS
AB BACKGROUND: Methamphetamine (MA) addiction is one of the most prevalent socioeconomic and health problems worldwide. In recent years, deep brain stimulation (DBS) has increasingly been used for the treatment of addiction.
   CASE DESCRIPTION: This study reports on 2 MA-dependent patients who received DBS of the nucleus accumbens (NAc). During the approximately 2-year follow-up period, one patient (A) remained abstinent and presented with positive emotional experiences, whereas the other (B) had no significant psychobehavioral changes during stimulation at low-to-moderate voltages and subsequently relapsed. Through coregistration of preoperative magnetic resonance imaging with postoperative computed tomography/magnetic resonance imaging, the DBS electrode of patient A was confirmed to be accurately implanted in the NAc, whereas one side of the electrode of patient B deviated from the target.
   CONCLUSIONS: These case reports demonstrate that NAc-DBS maybe a possible treatment option for MA addiction.
C1 [Ge, Shunnan; Chen, Yukun; Li, Nan; Qu, Liang; Li, Yang; Jing, Jiangpeng; Wang, Xin; Wang, Jing; Wang, Xuelian] Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
RP Wang, XL (reprint author), Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
EM tdwxlian@126.com
RI Qu, Liang/AAH-6548-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81401104, 81671366]; Young Stars of Science and
   Technology Project of Shaanxi Province, China [S2019-ZC-XXXM-0079]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81401104 and 81671366) and the Young Stars of Science and
   Technology Project of Shaanxi Province, China (S2019-ZC-XXXM-0079).
CR Angres DH, 2008, DM-DIS MON, V54, P696, DOI 10.1016/j.disamonth.2008.07.002
   Batra V, 2017, J NEUROSURG, V126, P1339, DOI 10.3171/2016.4.JNS152524
   Brackins Todd, 2011, J Pharm Pract, V24, P541, DOI 10.1177/0897190011426557
   Chomchai C, 2015, CURR OPIN PSYCHIATR, V28, P269, DOI 10.1097/YCO.0000000000000168
   Ge SN, 2018, CLIN NEUROPHYSIOL, V129, P1242, DOI 10.1016/j.clinph.2018.03.008
   GOLDSTEIN A, 1991, J PSYCHOACTIVE DRUGS, V23, P123, DOI 10.1080/02791072.1991.10472231
   Goncalves-Ferreira A, 2016, BIOL PSYCHIAT, V79, pE87, DOI 10.1016/j.biopsych.2015.06.023
   HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y
   Heinze HJ, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.022.2009
   Heldmann M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036572
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kuhn J, 2014, MOL PSYCHIATR, V19, P145, DOI 10.1038/mp.2012.196
   Kuhn J, 2007, J NEUROL NEUROSUR PS, V78, P1152, DOI 10.1136/jnnp.2006.113092
   Kuhn J, 2011, ADDICT BIOL, V16, P620, DOI 10.1111/j.1369-1600.2011.00337.x
   Lee NK, 2008, DRUG ALCOHOL REV, V27, P309, DOI 10.1080/09595230801919494
   McCracken CB, 2007, J NEUROSCI, V27, P12601, DOI 10.1523/JNEUROSCI.3750-07.2007
   McCracken CB, 2009, J NEUROSCI, V29, P5354, DOI 10.1523/JNEUROSCI.0131-09.2009
   Mohajerin Banafsheh, 2013, Int J High Risk Behav Addict, V2, P8, DOI 10.5812/ijhrba.8514
   Muller UJ, 2016, PHARMACOPSYCHIATRY, V49, P170, DOI 10.1055/s-0042-104507
   Muller UJ, 2009, PHARMACOPSYCHIATRY, V42, P288, DOI 10.1055/s-0029-1233489
   Muller UJ, 2013, ANN NY ACAD SCI, V1282, P119, DOI 10.1111/j.1749-6632.2012.06834.x
   O'Brien CP, 2008, PHILOS T R SOC B, V363, P3277, DOI 10.1098/rstb.2008.0105
   Panenka WJ, 2013, DRUG ALCOHOL DEPEN, V129, P167, DOI 10.1016/j.drugalcdep.2012.11.016
   Schlaepfer TE, 2008, NEUROPSYCHOPHARMACOL, V33, P368, DOI 10.1038/sj.npp.1301408
   Stelten BML, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/7/E5
   Sturm V, 2003, J CHEM NEUROANAT, V26, P293, DOI 10.1016/j.jchemneu.2003.09.003
   Tye SJ, 2009, MAYO CLIN PROC, V84, P522, DOI 10.1016/S0025-6196(11)60584-3
   Valencia-Alfonso CE, 2012, BIOL PSYCHIAT, V71, pE35, DOI 10.1016/j.biopsych.2011.12.013
   Vearrier D, 2012, DM-DIS MON, V58, P38, DOI 10.1016/j.disamonth.2011.09.004
   Voges J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.011
   Zhou HY, 2011, BIOL PSYCHIAT, V69, pE41, DOI 10.1016/j.biopsych.2011.02.012
NR 31
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 512
EP 517
DI 10.1016/j.wneu.2018.11.056
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100299
PM 30448569
DA 2020-05-12
ER

PT J
AU Rao, KVLN
   Deora, H
   Vazhayil, V
   Tatineni, S
AF Rao, Narasinga K. V. L.
   Deora, Harsh
   Vazhayil, Vikas
   Tatineni, Suresh
TI Spontaneous Recovery of Complete Foot Drop in Case of Lumbar Disk
   Herniation: Catcher in the Rye?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankle dorsiflexion; Foot drop; Prolapsed Lumbar disc; Spine
ID INFARCTION; DISEASES
AB BACKGROUND: Foot drop is defined as inability to dorsiflex the foot at the ankle joint. Although a well-documented entity with a myriad of causes along the neuraxis, starting from parasagittal intracranial pathologies to peripheral nerve lesions, treatment has always remained uniform (i.e., elimination of the causative pathology. A conservative approach with complete recovery has never been documented with video evidence).
   CASE DESCRIPTION: A 74-year-old female presented with dorsiflexion weakness of the left ankle secondary to a prolapsed disk at the L4-5 level. The duration of the foot drop was short (3 days). She was planned for surgery but kept under close observation considering the consistent recovery of the symptoms. To our astonishment she had rapid pain relief in the next 5 days. Motor power improved over 3 weeks, and she had complete recovery in 4 weeks. Video recordings were made to document the improved power at both stages.
   CONCLUSIONS: Spontaneous recovery of complete foot drop is possible, and there is a role for the conservative management even with dense neurologic deficit in cases of lumbar disk herniation. Careful repeated examination is the key for conservative management before jumping to aggressive surgical intervention.
C1 [Rao, Narasinga K. V. L.; Deora, Harsh; Vazhayil, Vikas] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Tatineni, Suresh] Mycure Hosp, Dept Neurosurg, Visakhapatnam, Andhra Prades, India.
RP Rao, KVLN (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM neuronarsi@gmail.com
RI DEORA, HARSH/A-5817-2019
OI DEORA, HARSH/0000-0003-3247-1117
CR Awad JN, 2006, CLIN ORTHOP RELAT R, P183, DOI 10.1097/01.blo.0000198724.54891.3a
   Deora Harsh, 2017, Surg Neurol Int, V8, P302, DOI 10.4103/sni.sni_395_17
   Kim KW, 2014, J KOREAN NEUROSURG S, V56, P254, DOI 10.3340/jkns.2014.56.3.254
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080375
   Park KM, 2013, CLIN NEUROL NEUROSUR, V115, P2240, DOI 10.1016/j.clineuro.2013.07.008
   Stewart John D, 2008, Pract Neurol, V8, P158, DOI 10.1136/jnnp.2008.149393
   Takenaka S, 2017, CLIN ORTHOP RELAT R, V475, P872, DOI 10.1007/s11999-016-5180-x
   Tural S, 2007, J CLIN NEUROSCI, V14, P490, DOI 10.1016/j.jocn.2006.01.028
   Van Langenhove M, 1989, Electromyogr Clin Neurophysiol, V29, P145
   Wang Y, 2014, CLIN NEUROL NEUROSUR, V117, P33, DOI 10.1016/j.clineuro.2013.11.018
NR 10
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 518
EP 521
DI 10.1016/j.wneu.2018.09.119
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100300
PM 30266693
DA 2020-05-12
ER

PT J
AU Yang, I
   Udawatta, M
   Prashant, GN
   Lagman, C
   Bloch, O
   Jensen, R
   Sheehan, J
   Kalkanis, S
   Warnick, R
AF Yang, Isaac
   Udawatta, Methma
   Prashant, Giyarpuram N.
   Lagman, Carlito
   Bloch, Orin
   Jensen, Randy
   Sheehan, Jason
   Kalkanis, Steven
   Warnick, Ronald
TI Stereotactic Radiosurgery for Neurosurgical Patients: A Historical
   Review and Current Perspectives
SO WORLD NEUROSURGERY
LA English
DT Review
DE Education; History; Medical residency; Radiosurgery; Stereotactic
   radiosurgery
ID GAMMA-KNIFE RADIOSURGERY; WHOLE-BRAIN RADIOTHERAPY; RADIATION-THERAPY;
   ARTERIOVENOUS-MALFORMATIONS; TRIGEMINAL NEURALGIA; VESTIBULAR
   SCHWANNOMAS; PHASE-III; ACCELERATED HYPERFRACTIONATION; CYBERKNIFE
   RADIOSURGERY; UNITED-STATES
AB Today, stereotactic radiosurgery is an effective therapy for a variety of intracranial pathology that were treated solely with open neurosurgery in the past. The technique was developed from the combination of therapeutic radiation and stereotactic devices for the precise localization of intracranial targets. Although stereotactic radiosurgery was originally performed as a partnership between neurosurgeons and radiation oncologists, this partnership has weakened in recent years, with some procedures being performed without neurosurgeons. At the same time, neurosurgeons across the United States and Canada have found their stereotactic radiosurgery training during residency inadequate. Although neurosurgeons, residency directors, and department chairs agree that stereotactic radiosurgery education and exposure during neurosurgery training could be improved, a limited number of resources exist for this kind of education. This review describes the history of stereotactic radiosurgery, assesses the state of its use and education today, and provides recommendations for the improvement of neurosurgical education in stereotactic radiosurgery for the future.
C1 [Yang, Isaac; Udawatta, Methma; Prashant, Giyarpuram N.; Lagman, Carlito] Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, Off Patient Experience, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Ronald Reagan UCLA Med Ctr, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA.
   [Yang, Isaac] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst La BioMed, Torrance, CA 90509 USA.
   [Bloch, Orin] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Jensen, Randy] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT USA.
   [Sheehan, Jason] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA.
   [Kalkanis, Steven] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI USA.
   [Warnick, Ronald] Mayfield Clin, Cincinnati, OH USA.
RP Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, Off Patient Experience, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Ronald Reagan UCLA Med Ctr, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA.; Yang, I (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst La BioMed, Torrance, CA 90509 USA.
EM iyang@mednet.ucla.edu
OI Warnick, Ronald/0000-0001-8509-7988; Udawatta,
   Methma/0000-0002-5225-7006
FU UCLA Visionary Ball Fund Grant; Eli and Edythe Broad Center of
   Regenerative Medicine and Stem Cell Research UCLA Scholars in
   Translational Medicine Program Award; Jason Dessel Memorial Seed Grant;
   UCLA Honberger Endowment Brain Tumor Research Seed Grant; Stop Cancer
   (US) Development Award; David Geffen Medical Scholarship; Tina and Fred
   Segal Benign Brain Tumor & Skull Base Surgery Research Fellowship
FX Isaac Yang is partially supported by the UCLA Visionary Ball Fund Grant,
   Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell
   Research UCLA Scholars in Translational Medicine Program Award, Jason
   Dessel Memorial Seed Grant, UCLA Honberger Endowment Brain Tumor
   Research Seed Grant, and Stop Cancer (US) Development Award. Methma
   Udawatta is a recipient of the David Geffen Medical Scholarship. Carlito
   Lagman is supported by the Tina and Fred Segal Benign Brain Tumor &
   Skull Base Surgery Research Fellowship.
CR Accreditation Council for Graduate Medical Education, NON TRADITIONAL REF
   Adler JR, 2009, NEUROSURGERY, V64, pA1, DOI 10.1227/01.NEU.0000312703.46158.54
   Adler JR, 1997, STEREOT FUNCT NEUROS, V69, P124, DOI 10.1159/000099863
   American Association of Neurological Surgeons, 2018, NON TRADITIONAL REF
   American Association of Neurological Surgeons Neurosrugery Research and Education Foundation, 2017, NON TRADITIONAL REF
   Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483
   Apisarnthanarax S, 2005, RADIAT RES, V163, P1, DOI 10.1667/RR3279
   Archer BR, 2005, HEALTH PHYS, V88, P579, DOI 10.1097/01.HP.0000158736.59917.93
   Auchter RM, 1996, INT J RADIAT ONCOL, V35, P27, DOI 10.1016/S0360-3016(96)85008-5
   Badakhshi H, 2014, J RADIAT RES, V55, P288, DOI 10.1093/jrr/rrt101
   Balagamwala EH, 2013, DEV OPHTHALMOL, V52, P1, DOI 10.1159/000351045
   Baschnagel AM, 2014, CLIN NEUROL NEUROSUR, V117, P107, DOI 10.1016/j.clineuro.2013.12.003
   Bauer-Nilsen K, 2018, J NEURO-ONCOL, V140, P83, DOI 10.1007/s11060-018-2933-2
   Belykh E, 2017, WORLD NEUROSURG, V105, P952, DOI 10.1016/j.wneu.2017.06.045
   Benghiat H, 2014, CLIN ONCOL-UK, V26, P309, DOI 10.1016/j.clon.2014.02.008
   BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9
   Bova FJ, 2013, NEUROSURGERY, V73, P138, DOI 10.1227/NEU.0000000000000113
   Bowden G, 2014, J NEUROSURG, V121, P637, DOI 10.3171/2014.5.JNS132244
   Brandes A A, 2003, Forum (Genova), V13, P4
   Casentini L, 2015, J NEUROSURG, V122, P818, DOI 10.3171/2014.11.JNS131552
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Chang SD, 2001, STEREOT FUNCT NEUROS, V76, P204, DOI 10.1159/000066719
   Chang SD, 1998, NEUROL MED-CHIR, V38, P780, DOI 10.2176/nmc.38.780
   CHAO JH, 1954, CANCER, V7, P682, DOI 10.1002/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S
   Chen CJ, 2018, WORLD NEUROSURG, V119, pE429, DOI 10.1016/j.wneu.2018.07.178
   Cheshier SH, 2007, TECHNOL CANCER RES T, V6, P329, DOI 10.1177/153303460700600410
   CHU FC, 1961, CANCER, V14, P577, DOI 10.1002/1097-0142(199005/06)14:3<577::AID-CNCR2820140318>3.0.CO;2-F
   Citrin DE, 2017, NEW ENGL J MED, V377, P2200, DOI 10.1056/NEJMc1713349
   Clarke DB, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0669-2
   de Roos A, 2014, RADIOLOGY, V273, pS142, DOI 10.1148/radiol.14140432
   Dhople AA, 2009, J NEUROSURG, V111, P351, DOI 10.3171/2009.2.JNS08977
   Ding D, 2017, J NEUROSURG-PEDIATR, V19, P127, DOI 10.3171/2016.9.PEDS16283
   Ding DL, 2016, WORLD NEUROSURG, V85, P263, DOI 10.1016/j.wneu.2015.10.001
   Dong M, BRIT J NEUROSURG, DOI [10.1080/02688697.2018.142432, DOI 10.1080/02688697.2018.142432]
   Dutta SW, 2018, J CLIN NEUROSCI, V57, P6, DOI 10.1016/j.jocn.2018.08.029
   Eaton DJ, 2018, PRACT RADIAT ONCOL, V8, pE295, DOI 10.1016/j.prro.2018.02.006
   ELKE M, 1995, EXPERIENTIA, V51, P665, DOI 10.1007/BF01941264
   FABRIKANT JI, 1991, STEREOT FUNCT NEUROS, V57, P50, DOI 10.1159/000099555
   Ferraro DJ, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-38
   FLICKINGER JC, 1994, INT J RADIAT ONCOL, V28, P797, DOI 10.1016/0360-3016(94)90098-1
   Germano IM, 2018, NEUROSURGERY, V82, pE49, DOI 10.1093/neuros/nyx515
   Ghobrial GM, 2013, NEUROSURGERY, V73, P111, DOI 10.1227/NEU.0000000000000100
   Gildenberg P L, 1990, Neurosurg Clin N Am, V1, P765
   Girgis F, 2018, CAN J NEUROL SCI, V45, P76, DOI 10.1017/cjn.2017.234
   Han JN, 2014, AM J CLIN ONCOL-CANC, V37, P255, DOI 10.1097/COC.0b013e318271b36a
   Harrison G, 2014, WORLD NEUROSURG, V82, P292, DOI 10.1016/j.wneu.2014.05.016
   Hayashi M, 2011, NEUROSURG REV, V34, P497, DOI 10.1007/s10143-011-0330-9
   Heilbrun MP, 2010, J NEUROSURG, V113, P10, DOI 10.3171/2010.1.JNS09842
   Ho AL, 2016, J RADIOSURGERY SBRT, V4, P165
   Katsoulakis E, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.10.FOCUS16368
   Kaul D, 2015, ACTA NEUROCHIR, V157, P565, DOI 10.1007/s00701-014-2315-2
   Kaul D, 2015, ACTA NEUROCHIR, V157, P559, DOI 10.1007/s00701-014-2272-9
   Kemeny A, 2012, ACTA NEUROCHIR, V154, P941, DOI 10.1007/s00701-012-1332-2
   Khan F. M., 2010, PHYS RAD THERAPY
   Kim YH, 2013, INT J RADIAT ONCOL, V85, P61, DOI 10.1016/j.ijrobp.2012.03.036
   King CR, 2003, TECHNOL CANCER RES T, V2, P25, DOI 10.1177/153303460300200104
   KJELLBERG RN, 1986, ANN CLIN RES, V18, P17
   KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503
   Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655
   Kondziolka D, 2002, CLIN J PAIN, V18, P42, DOI 10.1097/00002508-200201000-00007
   Lasak JM, 2009, OTOLARYNG CLIN N AM, V42, P593, DOI 10.1016/j.otc.2009.04.003
   LEDERMAN M, 1981, INT J RADIAT ONCOL, V7, P639, DOI 10.1016/0360-3016(81)90379-5
   Lee CC, 2018, WORLD NEUROSURG, V112, pE569, DOI 10.1016/j.wneu.2018.01.088
   Lee M, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E4
   Lehrer EJ, 2019, RADIOTHER ONCOL, V130, P104, DOI 10.1016/j.radonc.2018.08.025
   LEKSELL L, 1971, ACTA CHIR SCAND, V137, P311
   LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316
   Lesueur P, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1083-1
   Linskey ME, 2010, J NEURO-ONCOL, V96, P45, DOI 10.1007/s11060-009-0073-4
   LOEFFLER JS, 1992, INT J RADIAT ONCOL, V24, P885, DOI 10.1016/0360-3016(92)90466-U
   Lunsford LD, 2012, J NEUROSURG, V117, P2, DOI 10.3171/2012.6.GKS12838
   Lunsford L Dade, 2008, Clin Neurosurg, V55, P108
   LUNSFORD LD, 1987, APPL NEUROPHYSIOL, V50, P253
   Lunsford LD, 1997, STEREOT FUNCT NEUROS, V67, P153, DOI 10.1159/000099445
   Lunsford LD, 2009, INTRACRANIAL STEREOT
   Maesawa S, 2001, J NEUROSURG, V94, P14, DOI 10.3171/jns.2001.94.1.0014
   Mansouri A, 2017, CAN J NEUROL SCI, V44, P51, DOI 10.1017/cjn.2016.314
   Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23
   MEHTA MP, 1995, CURR PROB CANCER, V19, P270, DOI 10.1016/S0147-0272(06)80003-6
   Miranpuri AS, 2014, J NEUROINTERV SURG, V6, P561, DOI 10.1136/neurintsurg-2013-010826
   Monaco EA, 2012, EXPERT REV NEUROTHER, V12, P437, DOI [10.1586/ERN.12.16, 10.1586/ern.12.16]
   Moreau J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195608
   Muacevic A, 2008, J NEURO-ONCOL, V87, P299, DOI 10.1007/s11060-007-9510-4
   Muns Andrea, 2014, Surg Neurol Int, V5, P173, DOI 10.4103/2152-7806.146346
   Murray KJ, 1997, INT J RADIAT ONCOL, V39, P571, DOI 10.1016/S0360-3016(97)00341-6
   Nabavizadeh N, 2016, INT J RADIAT ONCOL, V94, P228, DOI 10.1016/j.ijrobp.2015.10.014
   Niranjan A, 2012, STEREOT FUNCT NEUROS, V90, P1, DOI 10.1159/000334673
   Niranjan Ajay, 2007, Prog Neurol Surg, V20, P50, DOI 10.1159/000100095
   Park SH, 2014, J NEUROSURG, V120, P708, DOI 10.3171/2013.11.JNS131607
   Patibandla MR, 2018, J NEUROSURG, V129, P1249, DOI 10.3171/2017.6.JNS17993
   PICARD C, 1983, J NEUROSURG, V59, P673, DOI 10.3171/jns.1983.59.4.0673
   Potters L, 2010, INT J RADIAT ONCOL, V76, P319, DOI 10.1016/j.ijrobp.2009.09.041
   Prados MD, 2001, INT J RADIAT ONCOL, V49, P71, DOI 10.1016/S0360-3016(00)01458-9
   Przybylowski CJ, 2015, J NEUROSURG, V122, P1299, DOI 10.3171/2014.11.JNS141388
   Puataweepong P, 2014, J RADIAT RES, V55, P351, DOI 10.1093/jrr/rrt121
   Rahman M, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.7.FOCUS09118
   Ray WZ, 2013, NEUROSURGERY, V73, P100, DOI 10.1227/NEU.0000000000000088
   Regis J, 2016, J NEUROSURG, V124, P1079, DOI 10.3171/2015.2.JNS142144
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Romanelli P, 2003, STEREOT FUNCT NEUROS, V81, P105, DOI 10.1159/000075112
   Sahgal A, 2009, TECHNOL CANCER RES T, V8, P271, DOI 10.1177/153303460900800404
   Sahyouni Ronald, 2017, Surg Neurol Int, V8, P68, DOI 10.4103/sni.sni_277_16
   Samblas J, 2014, J BUON, V19, P250
   Samuel N, 2018, WORLD NEUROSURG, V112, pE208, DOI 10.1016/j.wneu.2018.01.019
   Sandler KA, 2017, CANCER-AM CANCER SOC, V123, P2274, DOI 10.1002/cncr.30607
   Sanghavi SN, 2001, INT J RADIAT ONCOL, V51, P426, DOI 10.1016/S0360-3016(01)01622-4
   Sansur CA, 2000, STEREOT FUNCT NEUROS, V74, P37, DOI 10.1159/000056462
   Schipani S, 2012, INT J RADIAT ONCOL, V84, pE571, DOI 10.1016/j.ijrobp.2012.06.049
   Schirmer CM, 2013, NEUROSURGERY, V73, P66, DOI 10.1227/NEU.0000000000000074
   Sheehan J, 2018, WORLD NEUROSURG, V109, pE669, DOI 10.1016/j.wneu.2017.10.053
   Sheehan Jason, 2013, World Neurosurg, V80, pe27, DOI 10.1016/j.wneu.2012.09.007
   Sheehan J, 2010, J NEUROSURG, V113, P3, DOI 10.3171/2009.10.JNS091421
   Sheehan JP, 2014, J CLIN ONCOL, V32, P2836, DOI 10.1200/JCO.2013.53.7365
   Sheehan JP, 2010, J NEUROSURG, V113, P59, DOI 10.3171/2010.1.JNS091686
   Sio Terence T, 2014, J Appl Clin Med Phys, V15, P4095, DOI 10.1120/jacmp.v15i1.4095
   Snyder MH, 2018, WORLD NEUROSURG, V119, pE874, DOI 10.1016/j.wneu.2018.07.289
   Soffietti R, 2010, EUR J NEUROL, V17, P1124, DOI 10.1111/j.1468-1331.2010.03151.x
   SPIEGEL EA, 1947, SCIENCE, V106, P349, DOI 10.1126/science.106.2754.349
   Starke RM, 2013, J NEUROSURG, V119, P981, DOI 10.3171/2013.5.JNS1311
   STEINER L, 1972, ACTA CHIR SCAND, V138, P459
   Takeuchi H, 2003, MINIM INVAS NEUROSUR, V46, P82, DOI 10.1055/s-2003-39342
   The American Board of Neurological Surgery, 2018, TRAIN REQ
   Thibault I, 2014, J NEUROSURG-SPINE, V21, P711, DOI 10.3171/2014.7.SPINE13895
   Tsao M, 2012, CANCER-AM CANCER SOC, V118, P2486, DOI 10.1002/cncr.26515
   Waxman SG, 2014, PROG BRAIN RES, V215, P67, DOI 10.1016/B978-0-444-63520-4.00007-7
   Wolf A, 2018, J NEUROSURG, V128, P891, DOI 10.3171/2016.12.JNS161862
   Xu ZY, 2019, NEUROSURGERY, V84, P499, DOI 10.1093/neuros/nyy142
   Yianni J, 2012, ACTA NEUROCHIR, V154, P277, DOI 10.1007/s00701-011-1146-7
NR 128
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 522
EP 531
DI 10.1016/j.wneu.2018.10.193
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100301
PM 30399473
DA 2020-05-12
ER

PT J
AU Tirado-Caballero, J
   Rivero-Garvia, M
   Gomez-Gonzalez, E
   Kaen, A
   Ruiz-Valdepenas, EC
   Marquez-Rivas, J
AF Tirado-Caballero, Jorge
   Rivero-Garvia, Monica
   Gomez-Gonzalez, Emilio
   Kaen, Ariel
   Cardenas Ruiz-Valdepenas, Eugenio
   Marquez-Rivas, Javier
TI Dynamic Chess-Table Cranial Expansion for Treatment of Craniocerebral
   Disproportion: Technical Note and Volumetric Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chess-table; Cranial expansion; Craniocerebral disproportion;
   Oxycephaly; Slit ventricle; Surgical technique
ID SLIT-VENTRICLE SYNDROME; VAULT EXPANSION; SHUNT; CRANIOSYNOSTOSIS;
   DISTRACTION; COMPLICATIONS; SECONDARY
AB OBJECTIVE: Craniocerebral disproportion (CCD) is a challenging disease, and several expansile procedures have been used for its treatment. This report describes the dynamic chess-table cranial expansion technique and reports on 9 patients with primary and secondary CCD treated with this procedure.
   METHODS: Nine patients affected by CCD were treated with chess-table cranial expansion and reviewed. Symptoms of increased intracranial pressure (ICP) and radio-logic findings were analyzed. ICP was monitored using epidural or telemetric sensors. Intracranial volume was measured using computed tomography image processing tools before the surgery, 24 hours after the surgery, and 1 month later. A mathematical model was developed to explain the clinical and surgical results.
   RESULTS: Five patients had secondary CCD and 4 had primary CCD. The mean age for cranial expansion was 16.78 years. The most frequent symptoms were headaches, nausea/vomiting, and decreased consciousness. Slit ventricles and sutural sclerosis were observed in 33.3% and 55.6% of patients. The mean ICP before the procedure was 48.67 mm Hg. Progressive cranial expansion was seen in all patients after surgery. The mean ICP decreased to 11 mm Hg and mean intracranial volume expansion was 85.8 cm(3) at 1 month after surgery. There were no serious complications after surgery. All patients improved their symptoms, and no patient needed additional cranial expansion procedures.
   CONCLUSIONS: Chess-table cranial expansion is a safe and effective procedure and may be used as an alternative treatment for CCD. Progressive expansion of the intracranial volume is related to a decrease in ICP recordings and an improvement of symptoms.
C1 [Tirado-Caballero, Jorge; Rivero-Garvia, Monica; Kaen, Ariel; Cardenas Ruiz-Valdepenas, Eugenio; Marquez-Rivas, Javier] Univ Hosp Virgen del Rocio, Neurosurg Serv, Seville, Spain.
   [Gomez-Gonzalez, Emilio] Univ Seville, Engn Sch, Grp Interdisciplinary Phys, Seville, Spain.
   [Marquez-Rivas, Javier] Ctr Adv Neurol, Seville, Spain.
RP Tirado-Caballero, J (reprint author), Univ Hosp Virgen del Rocio, Neurosurg Serv, Seville, Spain.
EM jtiradocaballero@gmail.com
RI Marquez-Rivas, Javier/C-8940-2015; kaen, ariel/G-3786-2015;
   Rivero-Garvia, Monica/F-1567-2015
OI Marquez-Rivas, Javier/0000-0002-5136-4723; Rivero-Garvia,
   Monica/0000-0001-5125-6151
CR ABBOTT R, 1991, NEUROSURGERY, V28, P72, DOI 10.1227/00006123-199101000-00012
   Albright AL, 2001, NEUROSURGERY, V48, P764, DOI 10.1097/00006123-200104000-00013
   Arts S, 2018, J NEUROSURG-PEDIATR, V21, P112, DOI 10.3171/2017.7.PEDS17155
   BENZEL EC, 1992, ACTA NEUROCHIR, V117, P7, DOI 10.1007/BF01400628
   CARINCI F, 1994, CLEFT PALATE-CRAN J, V31, P201, DOI 10.1597/1545-1569(1994)031<0201:CSCAAE>2.3.CO;2
   Cohen S R, 1993, J Craniofac Surg, V4, P167, DOI 10.1097/00001665-199307000-00011
   Czosnyka M, 2012, ACTA NEUROCHIR SUPPL, V113, P9, DOI 10.1007/978-3-7091-0923-6_2
   Derderian CA, 2015, PLAST RECONSTR SURG, V135, P1665, DOI 10.1097/PRS.0000000000001294
   Deschamps-Braly J, 2011, PEDIATR NEUROSURG, V47, P396, DOI 10.1159/000337873
   EPSTEIN FJ, 1974, J NEUROSURG, V41, P29, DOI 10.3171/jns.1974.41.1.0029
   Greives MR, 2016, ANN PLAS SURG, V76, P211, DOI 10.1097/SAP.0000000000000518
   HOFFMAN HJ, 1976, CHILD BRAIN, V2, P167
   Khechoyan D, 2012, PLAST RECONSTR SURG, V129, P504, DOI 10.1097/PRS.0b013e31823aec1d
   Lilja A, 2014, CLIN NEUROL NEUROSUR, V120, P36, DOI 10.1016/j.clineuro.2014.02.010
   LOOP J W, 1972, Acta Radiologica Diagnosis, V13, P8
   MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332
   Martinez-Lage JF, 2006, NEUROSURG REV, V29, P229, DOI 10.1007/s10143-006-0022-z
   Nowinski D, 2012, CHILD NERV SYST, V28, P1537, DOI 10.1007/s00381-012-1809-6
   Rivero-Garvia M, 2012, CHILD NERV SYST, V28, P427, DOI 10.1007/s00381-011-1621-8
   Rivero-Garvia M, 2011, J NEUROSURG-PEDIATR, V7, P218, DOI 10.3171/2010.8.PEDS10298
   Sandler AL, 2013, CHILD NERV SYST, V29, P1997, DOI 10.1007/s00381-013-2257-7
   Sandler AL, 2013, J NEUROSURG-PEDIATR, V11, P653, DOI 10.3171/2013.2.PEDS12404
   Shimizu A, 2016, J CRANIOFAC SURG, V27, P1135, DOI 10.1097/SCS.0000000000002739
   Thompson DR, 2018, ANESTH ANALG, V126, P968, DOI 10.1213/ANE.0000000000002454
   Tirado-Caballero J, 2019, J NEUROSURG, V131, P578, DOI 10.3171/2018.4.JNS172988
   Tubbs RS, 2012, CHILD NERV SYST, V28, P23, DOI 10.1007/s00381-011-1637-0
   Weinzweig J, 2008, PLAST RECONSTR SURG, V122, P1171, DOI 10.1097/PRS.0b013e3181858c84
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 533
EP 543
DI 10.1016/j.wneu.2018.11.119
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100302
PM 30476673
DA 2020-05-12
ER

PT J
AU Penner, F
   Prencipe, N
   Pennacchietti, V
   Pacca, P
   Cambria, V
   Garbossa, D
   Zenga, F
AF Penner, Federica
   Prencipe, Nunzia
   Pennacchietti, Valentina
   Pacca, Paolo
   Cambria, Valeria
   Garbossa, Diego
   Zenga, Francesco
TI Super Giant Growth Hormone-Secreting Pituitary Adenoma in Young Woman:
   From Ventricles to Nose
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complex surgery; Cushing disease; Endoscopic endonasal surgery; Giant
   pituitary adenoma; Multidisciplinary team
ID ENDOSCOPIC ENDONASAL APPROACH; SURGERY
AB BACKGROUND: Giant pituitary adenomas are rare tumors that can have a devastating impact on a patient's life. They require a well-studied therapeutic approach that often combines different strategies.
   CASE DESCRIPTION: A 29-year-old woman was diagnosed with the largest GH-secreting pituitary adenoma reported in the literature, to the best of the author's knowledge. The tumor was removed with a combined approach: endoscopic endonasal transsphenoidal and transcortical transventricular. All available acromegaly drugs were used.
   After 2 surgeries, a large part of the tumor was removed. Both postoperative courses were uneventful. Because the disease was still active, medical therapy was initiated. The combination of pasireotide, pegvisomant, and cabergoline permitted satisfactory control of hormonal levels.
   CONCLUSIONS: Giant adenomas, >4 cm, are rare pituitary tumors. Therefore in order to achieve the best clinical results, they require complex management that involves a multidisciplinary team of ear, nose, and throat surgeons; endocrinologists; radiation therapists; ophthalmologists; and neurosurgeons.
C1 [Penner, Federica; Pennacchietti, Valentina; Pacca, Paolo; Garbossa, Diego; Zenga, Francesco] Univ Turin, Sect Neurosurg, Div Neurosci, Dept Med Sci, Turin, Italy.
   [Prencipe, Nunzia; Cambria, Valeria] Univ Turin, Div Endocrinol Diabet & Metab, Dept Med Sci, Turin, Italy.
RP Penner, F (reprint author), Univ Turin, Sect Neurosurg, Div Neurosci, Dept Med Sci, Turin, Italy.
EM federica.penner@gmail.com
RI Garbossa, Diego/AAC-8888-2019
OI Penner, Federica/0000-0002-4491-1725
CR Abe Takumi, 1997, Neurologia Medico-Chirurgica, V37, P830, DOI 10.2176/nmc.37.830
   Alleyne CH, 2002, SURG NEUROL, V57, P380, DOI 10.1016/S0090-3019(02)00705-X
   Altieri R, 2016, SURG TECHNOL INT, VXXIX, P359
   Cappabianca P, 2008, ADV TECH STAND NEURO, V33, P151, DOI 10.1007/978-3-211-72283-1_4
   Dicuonzo F, 2019, ENDOCR METAB IMMUNE, V19, P214, DOI 10.2174/1871530318666180807160712
   Elshazly K, 2018, WORLD NEUROSURG, V114, pE447, DOI 10.1016/j.wneu.2018.03.006
   Garg K, 2013, BMJ CASE REP, P1
   Gondim JA, 2014, WORLD NEUROSURG, V82, pE281, DOI 10.1016/j.wneu.2013.08.028
   HARDY J, 1965, J NEUROSURG, V23, P612, DOI 10.3171/jns.1965.23.6.0612
   Hwang Juyoung, 2016, Brain Tumor Res Treat, V4, P63
   Iglesias P, 2018, ENDOCRINE, V16, P1
   Jamshidi AO, 2018, J NEUROL SURG PART B, V79, pP049
   Koutourousiou M, 2013, J NEUROSURG, V118, P621, DOI 10.3171/2012.11.JNS121190
   MOHR G, 1990, CAN J NEUROL SCI, V17, P62, DOI 10.1017/S0317167100030055
   Mortini P, 2007, NEUROSURGERY, V60, P993, DOI 10.1227/01.NEU.0000255459.14764.BA
   SAITO K, 1995, NEUROSURGERY, V36, P668, DOI 10.1227/00006123-199504000-00005
   Takeuchi Kazuhito, 2015, NMC Case Rep J, V2, P101, DOI 10.2176/nmccrj.2014-0335
   Zenga F, 2016, WORLD NEUROSURG, V89, P394, DOI 10.1016/j.wneu.2016.02.011
NR 18
TC 0
Z9 0
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 544
EP 548
DI 10.1016/j.wneu.2018.11.069
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100303
PM 30472284
DA 2020-05-12
ER

PT J
AU Beltran, JQ
   Carrillo-Ruiz, JD
AF Beltran, Jesus Q.
   Carrillo-Ruiz, Jose D.
TI Neurological Functional Surgery in Mexico: From Pre-Columbian Cranial
   Surgery to Functional Neurosurgery in the 21st Century
SO WORLD NEUROSURGERY
LA English
DT Review
DE Functional neurosurgery; History; Mexico
ID CENTROMEDIAN THALAMIC NUCLEUS; ELECTRICAL-STIMULATION;
   PARKINSONS-DISEASE; PRELEMNISCAL RADIATIONS; CAUDATE-NUCLEUS;
   SPINAL-CORD; AMERICAN CONTINENT; MAJOR DEPRESSION; ADRENAL-MEDULLA;
   EPILEPSY
AB From the predominance of the pre-Columbian cultures to the present, an interest has existed in Mexico in brain structure and function, in both normal and pathological conditions. This interest has resulted in both medical and surgical attempts to treat some neurological conditions. Eighty years ago, with the influence of American and European neurosurgeons, modern Mexican neurosurgery emerged. Since then, it has progressively grown and diversified into several high specialties. At present, functional neurosurgery in Mexico constitutes, similar to that in other countries, a recognized surgical subspecialty that provides valuable information to treat brain dysfunctions such as movement disorders, pain, epilepsy, and other conditions. In the present report, we have briefly described the main historical aspects of the emergence and development of functional neurosurgery in Mexico.
C1 [Beltran, Jesus Q.] Gen Hosp Mexico, Dept Neurosurg, Mexico City, DF, Mexico.
   [Carrillo-Ruiz, Jose D.] Gen Hosp Mexico, Stereotact & Funct Neurosurg & Radiosurg Unit, Mexico City, DF, Mexico.
   [Carrillo-Ruiz, Jose D.] Anahuac Univ, Pyschophysiol & Neurosci Coordinat, North Campus, Huixquilucan Degollado, Mexico.
RP Carrillo-Ruiz, JD (reprint author), Gen Hosp Mexico, Stereotact & Funct Neurosurg & Radiosurg Unit, Mexico City, DF, Mexico.; Carrillo-Ruiz, JD (reprint author), Anahuac Univ, Pyschophysiol & Neurosci Coordinat, North Campus, Huixquilucan Degollado, Mexico.
EM josecarrilloruiz@yahoo.com
OI Beltran Mendoza, Jesus Quetzalcoatl/0000-0002-0023-1787
CR Aguilar-Rebolledo F, 2000, GAC MED MEX, V137, P403
   Albright TD, 2000, CELL, V100, pS1, DOI 10.1016/S0896-6273(00)80912-5
   Ernesto MFA, 2009, REV MEX NEUROCIENC, V10, P434
   Apuzzo MLJ, 2007, NEUROSURGERY, V61, P5, DOI 10.1227/01.NEU.0000255493.34063.7B
   Arellano-Reynoso A., 2010, ARCH NEUROSCI, V15, P233
   BAKAY RAE, 1989, STEREOT FUNCT NEUROS, V53, P1, DOI 10.1159/000099513
   Ballesteros-Zebadua P, 2016, BRIT J NEUROSURG, V30, P606, DOI 10.3109/02688697.2016.1173188
   Brailowsky S., 1992, ELEMENTOS, V2, P3
   Campos M., 2008, TXB EPILEPSY SURG, P15
   Carrillo-Ruiz JD, 2012, TRACTOS HISTORICOS N, P165
   Carrillo-Ruiz JD, 2008, NEUROSURGERY, V62, P347, DOI 10.1227/01.neu.0000316001.03765.e8
   Castaneda-Lopez G, 2010, SALUD MENT, V33, P111
   Celis MA, 2007, CHILD NERV SYST, V23, P917, DOI 10.1007/s00381-007-0356-z
   Chavez Balderas X., 2007, HUMAN SACRIFICE MORT
   de Leon FCP, 2009, NEUROCIRUGIA, V20, P388
   Corsi-Cabrera M, 2006, CLIN NEUROPHYSIOL, V117, P1826, DOI 10.1016/j.clinph.2006.05.008
   Cuellar-Herrera M, 2014, EPILEPSY RES, V108, P1853, DOI 10.1016/j.eplepsyres.2014.09.013
   De la Fuente B., 1987, ANN I INVESTIG ESTET, V15, P13
   de Leon FCP, 2000, NEUROSURGERY, V47, P216, DOI 10.1097/00006123-200007000-00044
   de Leon FCP, 2004, CHILD NERV SYST, V20, P8, DOI 10.1007/s00381-003-0815-0
   del Valle R, 2006, SALUD MENT, V29, P18
   Doerr J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14162
   Durazo F, 1991, Gac Med Mex, V127, P521
   Elder JB, 2008, NEUROSURGERY, V62, P1, DOI 10.1227/01.NEU.0000311058.80249.6B
   Escalante-Gonzalbo P., 2004, NUEVA HISTORIA MINIM, P11
   Escobedo F, 2001, STEREOT FUNCT NEUROS, V76, P129, DOI 10.1159/000066707
   Garza-Mercado Roman, 2004, Gac Med Mex, V140, P477
   GOETZ CG, 1991, NEUROLOGY, V41, P1719, DOI 10.1212/WNL.41.11.1719
   Gomez-Mendez F, 1977, Neurosurgery, V1, P317
   Goodrich JT, 2010, WORLD NEUROSURG, V74, P81, DOI 10.1016/j.wneu.2010.08.018
   Gowda S, 2010, J NEUROSURG-PEDIATR, V5, P603, DOI 10.3171/2010.1.PEDS08301
   Garcia-Gomar MG, 2017, BRAIN STRUCT FUNCT, V222, P71, DOI 10.1007/s00429-016-1201-5
   Guizar-Sahagun G, 1998, P W PHARMACOL SOC, V41, P237
   Guizar-Sahagun G, 2005, NEUROSCIENCE, V130, P639, DOI 10.1016/j.neuroscience.2004.09.056
   GUIZARSAHAGUN G, 1994, SURG NEUROL, V41, P241, DOI 10.1016/0090-3019(94)90131-7
   Hernandez-Salazar M, 2009, ARCH NEUROSCI, V14, P94
   Humberto-Mateos Jose, 2003, Gac Med Mex, V139, P565
   Jimenez F, 2007, ACTA NEUROCHIR SUPPL, V97, P393
   Jimenez F, 2005, NEUROSURGERY, V57, P585, DOI 10.1227/01.NEU.0000170434.44335.19
   Jimenez F, 2000, ARCH MED RES, V31, P270, DOI 10.1016/S0188-4409(00)00066-7
   Jimenez F, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.07.010
   Jimenez F, 2012, STEREOT FUNCT NEUROS, V90, P151, DOI 10.1159/000336746
   Kandel ER, 2013, NAT REV NEUROSCI, V14, P659, DOI 10.1038/nrn3578
   Leon-Portilla M., 1962, BROKEN SPEARS AZTEC
   Li W, 2016, P NATL ACAD SCI USA, V113, P6544, DOI 10.1073/pnas.1605245113
   Velasco AL, 2009, INT J NEURAL SYST, V19, P139, DOI 10.1142/S0129065709001914
   Lujan-Castilla Pomponio Jose, 2005, Gac Med Mex, V141, P367
   Machado Andre G, 2005, Neurosurgery, V57, pE1318
   MACHADOSALAS J, 1990, STEREOT FUNCT NEUROS, V54-5, P297, DOI 10.1159/000100226
   MADRAZO I, 1988, NEW ENGL J MED, V318, P51
   MADRAZO I, 1990, ARCH NEUROL-CHICAGO, V47, P1281, DOI 10.1001/archneur.1990.00530120025005
   MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402
   MADRAZO I, 1995, NEUROL RES, V17, P312, DOI 10.1080/01616412.1995.11740334
   Madrazo-Navarro I, 1985, Arch Invest Med (Mex), V16 Suppl 3, P143
   Madrazo-Navarro I, 1984, CEREBELLAR STIMULATI, P273
   Mercado R, 2006, MOVEMENT DISORD, V21, P1457, DOI 10.1002/mds.20935
   Mercado R, 2006, J NEUROSURG, V105, P279, DOI 10.3171/jns.2006.105.2.279
   Ocana B, 2013, ESTUD ANTROPOL BIOL, VXVI, P31
   Perez-de la Torre Ramiro Antonio, 2016, Rev Med Inst Mex Seguro Soc, V54 Suppl 2, pS124
   Revuelta-Gutierrez Rogelio, 2016, Surg Neurol Int, V7, P51, DOI 10.4103/2152-7806.181824
   Revuelta-Gutierrez R, 2013, WORLD NEUROSURG, V80, P385, DOI 10.1016/j.wneu.2012.07.030
   Rocha L, 2014, EPILEPSY BEHAV, V38, P25, DOI 10.1016/j.yebeh.2014.01.001
   Romero y Huesca Andres, 2008, Rev Invest Clin, V60, P432
   Salazar MH, 2009, ARCH NEUROCIENC, V14, P11
   Serrano-Rubio AA, 2014, REV NEUROLOGIA, V59, P249, DOI 10.33588/rn.5906.2014177
   SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201
   Tiesler Blos V., 1998, COSTUMBRE DEFORMACIO
   Vazquez JZ, 2004, NUEVA HIST MINIMA ME, P137
   VELASCO F, 1987, EPILEPSIA, V28, P421, DOI 10.1111/j.1528-1157.1987.tb03668.x
   VELASCO F, 1993, EPILEPSIA, V34, P1052, DOI 10.1111/j.1528-1157.1993.tb02134.x
   VELASCO F, 1995, EPILEPSIA, V36, P63, DOI 10.1111/j.1528-1157.1995.tb01667.x
   Velasco F, 2001, STEREOT FUNCT NEUROS, V77, P223, DOI 10.1159/000064610
   Velasco F, 2001, NEUROSURGERY, V49, P293, DOI 10.1097/00006123-200108000-00009
   Velasco F, 2016, NEUROMODULATION, V19, P357, DOI 10.1111/ner.12433
   Velasco F, 2009, PAIN, V147, P91, DOI 10.1016/j.pain.2009.08.024
   VELASCO SUAREZ M, 1952, Cir Cir, V20, P225
   VELASCO-SUAREZ M M, 1959, J Int Coll Surg, V31, P479
   VELASCO-SUAREZ MANUEL, 1964, MED ANN DIST COLUMBIA, V33, P251
   VELASCOSUAREZ M, 1992, NEUROSURGERY, V31, P313, DOI 10.1227/00006123-199208000-00017
   VELASCOSUAREZ M, 1994, STEREOT FUNCT NEUROS, V62, P26, DOI 10.1159/000098594
   VELASCOSUAREZ MM, 1970, CONFIN NEUROL, V32, P149
   Viesca C, 2003, SCI AC CULT, V3, P259
   WILKINSON RG, 1975, B NEW YORK ACAD MED, V51, P838
   William Osler, 1913, EVOLUTION MODERN MED
   Zamorano L, 2003, HDB STEREOTACTIC FUN, P363
NR 85
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 549
EP 558
DI 10.1016/j.wneu.2018.11.165
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100304
PM 30481635
DA 2020-05-12
ER

PT J
AU Gong, M
   Liu, GM
   Chen, L
   Chen, R
   Xiang, Z
AF Gong, Min
   Liu, Guoming
   Chen, Li
   Chen, Ran
   Xiang, Zhou
TI The Efficacy and Safety of Intravenous Tranexamic Acid in Reducing
   Surgical Blood Loss in Posterior Lumbar Interbody Fusion for the Adult:
   A Systematic Review and a Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Blood loss; Meta-analysis; Posterior lumbar interbody fusion; Spine
   surgery; Tranexamic acid
ID ANTIFIBRINOLYTIC AGENTS; SURGERY
AB OBJECTIVE: To evaluate the efficacy and safety of tranexamic acid (TXA), we conducted a systematic review and meta-analysis of studies on intravenous TXA in posterior lumbar interbody fusion (PLIF) in adults.
   METHODS: We searched databases, including PubMed, EMBASE, and the Cochrane Library. The included articles, limited to English, compared intravenous TXA with placebo in adults who underwent PLIF. The methodologic quality of the studies was assessed using the following parameters: heterogeneity, weighted mean difference (WMD), relative risk, 95% confidence interval (CI), and subgroup analysis.
   RESULTS: Seven studies (5 randomized controlled trials and 2 nonrandomized controlled trials) were included in which 529 patients were treated by PLIF. We found that intravenous TXA can reduce total blood loss (WMD = -172.04, 95% confidence interval [CI] -204.70 to -139.37), intraoperative blood loss (WMD = -83.10, 95% CI -117.61 to -48.60), and postoperative blood loss (WMD = -83.10, 95% CI -117.61 to -48.60) but cannot reduce the blood transfusion rates (relative risk = 0.39; 95% CI 0.21-0.72). High-dose TXA could more effectively reduce the blood loss than the low-dose TXA. The risk of thrombotic events was not observed.
   CONCLUSIONS: This meta-analysis showed that intravenous TXA can significantly reduce surgical blood loss and patients treated with TXA did not have a significant decrease in transfusion rates. Furthermore, it is safe and does not increase the risk of thrombotic events. We recommend intravenous TXA and the use of high-dose TXA during PLIF in adults. However, more high-quality and large-sample studies will be needed to confirm this result.
C1 [Gong, Min; Liu, Guoming; Chen, Li; Chen, Ran; Xiang, Zhou] Sichuan Univ, West China Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
RP Xiang, Z (reprint author), Sichuan Univ, West China Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
EM xiangzhou15@hotmail.com
FU Chinese-German cooperation: Repair and Reconstruction of Musculoskeletal
   Tissue [GZ 1219]; National Nature Science Foundation of ChinaNational
   Natural Science Foundation of China [31870961]
FX This work was supported by the Chinese-German cooperation: Repair and
   Reconstruction of Musculoskeletal Tissue (GZ 1219) and National Nature
   Science Foundation of China (31870961).
CR [Anonymous], 2014, REV MAN REVMAN
   Brown JR, 2007, CIRCULATION, V115, P2801, DOI 10.1161/CIRCULATIONAHA.106.671222
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017
   Endres S, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-29
   Farrokhi MR, 2011, J NEUROSURG ANESTH, V23, P290, DOI 10.1097/ANA.0b013e31822914a1
   Gausden EB, 2017, J ORTHOP TRAUMA, V31, P513, DOI 10.1097/BOT.0000000000000913
   Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706
   Hao LQ, 2017, INT J SURG, V47, P52, DOI 10.1016/j.ijsu.2017.09.009
   HE J, 2017, [No title captured], V96, DOI DOI 10.1097/MD.0000000000007880
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hu SS, 2004, EUR SPINE J, V13, pS3, DOI 10.1007/s00586-004-0753-x
   Hui SY, 2018, SPINE J, V18, P1325, DOI 10.1016/j.spinee.2017.11.017
   Ju Jeong-Hyuk, 2012, Korean J Spine, V9, P244, DOI 10.14245/kjs.2012.9.3.244
   Kasper SM, 1997, TRANSFUSION, V37, P1058, DOI 10.1046/j.1537-2995.1997.371098016445.x
   Kebaish Khaled M, 2004, Neurosurg Focus, V16, pe1
   Kim KT, 2017, EUR SPINE J, V26, P2851, DOI 10.1007/s00586-017-5230-4
   Kushioka J, 2017, J NEUROSURG-SPINE, V26, P363, DOI 10.3171/2016.8.SPINE16528
   Li G, 2017, EUR SPINE J, V26, P140, DOI 10.1007/s00586-016-4792-x
   Lin Z, 2016, SEIZURE-EUR J EPILEP, V36, P70, DOI 10.1016/j.seizure.2016.02.011
   Liu XY, 2014, EUR SPINE J, V23, P43, DOI 10.1007/s00586-013-2880-8
   Mahdy AM, 2004, BRIT J ANAESTH, V93, P842, DOI 10.1093/bja/aeh227
   Mannucci PM, 2007, NEW ENGL J MED, V356, P2301, DOI 10.1056/NEJMra067742
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Neilipovitz DT, 2004, EUR SPINE J, V13, pS62, DOI 10.1007/s00586-004-0716-2
   Nuttall GA, 2000, SPINE, V25, P596, DOI 10.1097/00007632-200003010-00010
   Ou YF, 2018, SURG INNOV, V25, P128, DOI 10.1177/1553350617751449
   PILBRANT A, 1981, EUR J CLIN PHARMACOL, V20, P65, DOI 10.1007/BF00554669
   Ritter MA, 2002, ORTHOPEDICS, V25, P915
   Rohrich RJ, 2018, PLAST RECONSTR SURG, V141, P507, DOI 10.1097/PRS.0000000000003926
   Roopa MN, 2018, SPINE, V43, pE267
   Schouten ES, 2009, PEDIATR CRIT CARE ME, V10, P182, DOI 10.1097/PCC.0b013e3181956d61
   Shi HY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005718
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Sokolowski MJ, 2008, SPINE, V33, P108, DOI 10.1097/BRS.0b013e31815e39af
   Tsutsumimoto T, 2011, SPINE, V36, P1913, DOI 10.1097/BRS.0b013e3181fb3a42
   VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003
   Wang Q, 2013, EUR SPINE J, V22, P2035, DOI 10.1007/s00586-013-2836-z
   YONENOBU K, 1991, SPINE, V16, P1277, DOI 10.1097/00007632-199111000-00006
   Yuan QM, 2017, EUR SPINE J, V26, P131, DOI 10.1007/s00586-016-4899-0
NR 40
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 559
EP 568
DI 10.1016/j.wneu.2018.09.115
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100305
PM 30336299
DA 2020-05-12
ER

PT J
AU Yang, KY
   Algird, AR
   Lu, JQ
AF Yang, Kaiyun
   Algird, Almunder R.
   Lu, Jian-Qiang
TI Dural-Based Marginal Zone Lymphoma in a Patient with Sarcoidosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural-based lesions; Dural-based lymphoma; Lymphoma; Meningioma;
   Sarcoidosis
ID B-CELL LYMPHOMA
AB BACKGROUND: Primary dural-based lymphoma is a rare disease entity. It has been hypothesized that patients with sarcoidosis are at increased risk of developing lymphoma, an association known as "sarcoidosis-lymphoma syndrome," although dural disease has not yet been reported in the literature.
   CASE DESCRIPTION: Here we report the first case of dural-based lymphoma in a 60-year-old man with a history of sarcoidosis, in keeping with sarcoidosis-lymphoma syndrome. His dural-based tumor was surgically resected. Pathology examination revealed a marginal zone B-cell lymphoma. Subsequent neural and systemic staging confirmed a localized lymphoma. The patient received local radiotherapy to control leptomeningeal disease.
   CONCLUSIONS: Given the association between sarcoidosis and lymphoma, we suggest lymphoma to be considered as one of the top differentials for a dural-based mass lesion in patients with sarcoidosis.
C1 [Yang, Kaiyun; Algird, Almunder R.] Hamilton Hlth Sci, Div Neurosurg, Hamilton, ON, Canada.
   [Lu, Jian-Qiang] Hamilton Hlth Sci, Neuropathol Sect, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Lu, Jian-Qiang] McMaster Univ, Hamilton, ON, Canada.
RP Yang, KY (reprint author), Hamilton Hlth Sci, Div Neurosurg, Hamilton, ON, Canada.
EM Kaiyun.yang@medportal.ca
RI LU, JIAN-QIANG/AAL-1634-2020
OI LU, JIAN-QIANG/0000-0003-1945-5569; Yang, Kaiyun/0000-0003-4020-9514
CR Arcaini L, 2004, CANCER, V100, P107, DOI 10.1002/cncr.11893
   Chalayer E, 2015, QJM-INT J MED, V108, P871, DOI 10.1093/qjmed/hcv039
   Goswami T, 2010, CL LYMPH MYELOM LEUK, V10, P241, DOI 10.3816/CLML.2010.n.052
   Isaacson PG, 2004, NAT REV CANCER, V4, P644, DOI 10.1038/nrc1409
   Iwamoto Fabio M, 2006, Neurosurg Focus, V21, pE5
   Iwamoto FM, 2006, NEUROLOGY, V66, P1763, DOI 10.1212/01.wnl.0000218284.23872.eb
   Kumar S, 1997, AM J SURG PATHOL, V21, P81, DOI 10.1097/00000478-199701000-00009
   Papanikolaou IC, 2010, EUR RESPIR J, V36, P1207, DOI 10.1183/09031936.00043010
   Tsang RW, 2003, J CLIN ONCOL, V21, P4157, DOI 10.1200/JCO.2003.06.085
   Tu PH, 2005, J CLIN ONCOL, V23, P5718, DOI 10.1200/JCO.2005.17.624
   Venkataraman G, 2011, MODERN PATHOL, V24, P355, DOI 10.1038/modpathol.2010.206
   Villeneuve A, 2018, EUR ANN OTORHINOLARY, V135, P131, DOI 10.1016/j.anorl.2017.12.002
   Zucca E, 2003, BLOOD, V101, P2489, DOI 10.1182/blood-2002-04-1279
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 569
EP 572
DI 10.1016/j.wneu.2018.11.125
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100306
PM 30476667
DA 2020-05-12
ER

PT J
AU Chanchotisatien, A
   Xiong, J
   Yu, JT
   Chu, SG
AF Chanchotisatien, Apisara
   Xiong, Jie
   Yu, Jintai
   Chu, Shuguang
TI Exophytic Primary Intramedullary Spinal Cord Glioblastoma: Case Report
   and Critical Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Exophytic growth; Intramedullary spinal cord tumor; Magnetic resonance
   imaging; Pathology; Primary spinal cord glioblastoma
ID LYMPHOMA; LESIONS
AB BACKGROUND: Primary intramedullary spinal cord (IMSC) glioblastoma (GBM) is an extremely rare entity; we report the first case of primary IMSC GBM presenting with exophytic involvement. The prognosis of glioblastoma remains poor due to the aggressive nature of the disease and lack of effective treatment.
   CASE DESCRIPTION: A 27-year-old Asian female presented to our hospital with a 1-month history of dysuria, incomplete bladder emptying, progressive numbness, and weakness of both lower limbs, as well as a 1-year history of back pain. Spinal magnetic resonance imaging (MRI) revealed an intramedullary lesion and exophytic growth in the T4-T12 and T5-12 regions, respectively. The patient's MRI findings were atypical of spinal glioblastoma. The diagnosis was made on the basis of immunohistochemical and pathologic analyses of tissue samples obtained from an open biopsy. The patient received a standard course of glioblastoma radiotherapy and adjuvant temozolomide chemotherapy, which improved her symptoms in the absence of an apparent reduction in tumor size.
   CONCLUSIONS: Although MRI is of indisputable importance in the diagnosis of spinal cord lesions, immunohistochemical and histopathologic studies are often required to establish a definitive diagnosis. It remains unclear how the unusual involvement of exophytic growth will affect the prognosis of primary IMSC GBM.
C1 [Chanchotisatien, Apisara] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.
   [Xiong, Jie] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai, Peoples R China.
   [Yu, Jintai] Qingdao Univ, Qingdao Municipal Hosp, Dept Neurol, Qingdao, Peoples R China.
   [Chu, Shuguang] Fudan Univ, Huashan Hosp, Dept Radiol, Shanghai, Peoples R China.
RP Chu, SG (reprint author), Fudan Univ, Huashan Hosp, Dept Radiol, Shanghai, Peoples R China.
EM chushu1018@hotmail.com
OI Chanchotisatien, Apisara/0000-0003-3687-2137
CR Behmanesh B, 2017, WORLD NEUROSURG, V98, P198, DOI 10.1016/j.wneu.2016.10.075
   Bhushanam TV, 2014, SPINAL CORD, V52, pS21, DOI 10.1038/sc.2014.96
   Cacchione A, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0107-1
   Carra BJ, 2013, J AM OSTEOPATH COLL, V2, P13
   Celano E, 2016, J NEURO-ONCOL, V128, P377, DOI 10.1007/s11060-016-2135-8
   Cooper AJL, 2015, EBIOMEDICINE, V2, P1016, DOI 10.1016/j.ebiom.2015.08.029
   Do-Dai DD, 2010, CURR PROBL DIAGN RAD, V39, P160, DOI 10.1067/j.cpradiol.2009.05.004
   Gao Y, 2018, NEUROPATHOLOGY, V38, P165, DOI 10.1111/neup.12413
   Guzzetta M, 2015, LABMEDICINE, V46, P159, DOI 10.1309/LM85GPXDT8NJSDAB
   Louis DN, 2018, ACTA NEUROPATHOL, V135, P639, DOI 10.1007/s00401-018-1826-y
   Mallick S, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.137998
   Morais N, 2013, ONCOL LETT, V5, P992, DOI 10.3892/ol.2012.1076
   Samartzis D, 2015, GLOB SPINE J, V5, P425, DOI 10.1055/s-0035-1549029
   Shen CX, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006634
   Singh S, 2018, WORLD NEUROSURG, V113, P184, DOI 10.1016/j.wneu.2018.02.048
   Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336
   Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050
   Warade AG, 2014, J CLIN NEUROSCI, V21, P1823, DOI 10.1016/j.jocn.2014.01.014
   Watts J, 2014, J MED IMAG RADIAT ON, V58, P569, DOI 10.1111/1754-9485.12202
NR 19
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 573
EP 576
DI 10.1016/j.wneu.2018.11.113
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100307
PM 30476666
DA 2020-05-12
ER

PT J
AU Diyora, B
   Bhende, B
   Dhall, G
   Patil, A
   Nayak, N
AF Diyora, Batuk
   Bhende, Bhagyashri
   Dhall, Gagan
   Patil, Aditya
   Nayak, Naren
TI Ventral Craniovertebral Junction Arachnoid Cyst in an Elderly Patient-A
   Case Report of a Unique Occurrence at Extremes of Age
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Craniovertebral junction; Cystic central nervous system
   lesions; Intradural cyst; Posterior approach
ID CRANIOCERVICAL JUNCTION; NEURENTERIC CYST; SPINAL-CORD; ANTERIOR; TUMORS
AB BACKGROUND: Craniovertebral junction arachnoid cysts are uncommon. Among those reported, ventrally located arachnoid cysts at the extremes of age have been even rarer. We report a successfully managed case of a ventrally placed arachnoid cyst in an 88-year-old man using an unconventional surgical approach.
   CASE DESCRIPTION: An 88-year-old man presented to us with complaints of tingling and numbness in both upper and lower limbs. He had a weak handgrip on both sides. Spinal magnetic resonance imaging (MRI) showed a none-contrast-enhancing cystic lesion over the anterior lip of the foreman magnum that had displaced the cervicomedullary junction posteriorly. The lesion was homogenously hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. The lesion was excised using a posterior approach. The cyst contents were drained, followed by complete wall excision. Complete improvement in clinical symptoms and an absence of neurological deficits were noted in the patient.
   CONCLUSION: Arachnoid cysts are congenital lesions and can present at the extremes of age. Ventrally placed small symptomatic arachnoid cysts can be managed successfully through the posterior approach, especially in the elderly population.
C1 [Diyora, Batuk] Lokmanya Municipal Gen Hosp, Dept Neurosurg, Mumbai, India.
   Lokmanya Tilak Municipal Gen Hosp & Med Coll, Mumbai, India.
RP Diyora, B (reprint author), Lokmanya Municipal Gen Hosp, Dept Neurosurg, Mumbai, India.
EM bhagyashribhende@gmail.com
OI Patil, Aditya/0000-0001-9057-7724
CR Abdullah KG, 2012, NEUROSURGERY, V70, P202, DOI 10.1227/NEU.0b013e31824042e6
   Abe K, 1999, NEUROL MED-CHIR, V39, P875, DOI 10.2176/nmc.39.875
   ALVISI C, 1987, J NEUROSURG, V67, P333, DOI 10.3171/jns.1987.67.3.0333
   Ayoub B, 2011, TURK NEUROSURG, V21, P494, DOI [10.5137/1019-5149.JTN.4277-11.2, 10.5137/1019-5149.JTN .4277-11.2]
   Banczerowski Peter, 2003, Ideggyogy Sz, V56, P115
   Barami K, 2007, MINIM INVAS NEUROSUR, V50, P370, DOI 10.1055/s-2007-993203
   BHATIA S, 1992, POSTGRAD MED J, V68, P829, DOI 10.1136/pgmj.68.804.829
   Bond AE, 2012, J NEUROSURG-PEDIATR, V9, P432, DOI 10.3171/2012.1.PEDS11391
   Cakirer S, 2004, ACTA RADIOL, V45, P460, DOI 10.1080/02841850410005453
   Catala M, 1998, REV NEUROL-FRANCE, V154, P489
   Chandra PS, 2003, NEUROL INDIA, V51, P193
   Das Kuntal Kanti, 2014, Asian J Neurosurg, V9, P223, DOI 10.4103/1793-5482.146616
   Ding Zihai, 2002, Zhonghua Wai Ke Za Zhi, V40, P427
   Erdincler P, 1999, BRIT J NEUROSURG, V13, P10, DOI 10.1080/02688699944122
   Fukushima Y, 1996, NEUROL SURG TOKYO, V24, P75
   Fuse T, 1998, SURG NEUROL, V50, P431, DOI 10.1016/S0090-3019(97)00280-2
   Gezici AR, 2008, ACTA NEUROCHIR, V150, P695, DOI 10.1007/s00701-008-1603-0
   GO KG, 1993, EUR J RADIOL, V17, P69, DOI 10.1016/0720-048X(93)90038-O
   Gomez E, 2011, NEURORADIOL J, V24, P535, DOI 10.1177/197140091102400407
   Gupta SK, 2004, BRIT J NEUROSURG, V18, P164, DOI 10.1080/02688690410001681028
   Hirano A, 2004, NEUROPATHOLOGY, V24, P1, DOI 10.1111/j.1440-1789.2003.00526.x
   Kazan S, 1999, J NEUROSURG, V91, P211, DOI 10.3171/spi.1999.91.2.0211
   KENDALL BE, 1982, NEURORADIOLOGY, V22, P225, DOI 10.1007/BF00342069
   Khan IS, 2013, J NEUROSURG-SPINE, V18, P161, DOI 10.3171/2012.11.SPINE12463
   KUROIWA T, 1991, Neurological Surgery, V19, P1097
   Lanzino G, 2005, NEUROSURGERY, V57, P367, DOI 10.1227/01.NEU.0000176848.05925.80
   Lee Wei-Yuh, 1992, Journal of the Formosan Medical Association, V91, P722
   Martinez-Perez R, 2016, NEUROCIRUGIA, V27, P121, DOI 10.1016/j.neucir.2015.10.004
   MILLER JD, 1989, SURG NEUROL, V31, P239, DOI 10.1016/0090-3019(89)90125-0
   Mohindra S, 2007, SURG NEUROL, V68, P85, DOI 10.1016/j.surneu.2006.07.024
   PALMER JJ, 1974, ARCH NEUROL-CHICAGO, V31, P214
   Panigrahi S, 2012, J CRANIOVERTEBRAL JU, V3, P16, DOI 10.4103/0974-8237.110119
   Pego-Reigosa R, 2000, ARCH NEUROL-CHICAGO, V57, P128, DOI 10.1001/archneur.57.1.128
   Petridis AK, 2010, EUR SPINE J, V19, pS124, DOI 10.1007/s00586-009-1156-9
   Pillai MK, 2017, J SPINAL CORD MED, V40, P250, DOI 10.1080/10790268.2016.1244987
   Price SJ, 2001, NEUROSURGERY, V49, P212, DOI 10.1097/00006123-200107000-00034
   RABB CH, 1992, J NEUROSURG, V77, P369, DOI 10.3171/jns.1992.77.3.0369
   Sakata H, 2008, NEUROL MED-CHIR, V48, P86, DOI 10.2176/nmc.48.86
   Samii M, 1999, SURG NEUROL, V51, P376, DOI 10.1016/S0090-3019(98)00095-0
   Shah A, 2016, J CRANIOVERTEBRAL JU, V7, P59, DOI 10.4103/0974-8237.176627
   Shi W, 2010, SKULL BASE-INTERD AP, V20, P435, DOI 10.1055/s-0030-1265823
   Shukla R, 1998, BRIT J NEUROSURG, V12, P271, DOI 10.1080/02688699845131
   Takanashi Y, 1995, No To Shinkei, V47, P68
NR 43
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 577
EP 582
DI 10.1016/j.wneu.2018.11.107
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100308
PM 30472283
DA 2020-05-12
ER

PT J
AU Liu, J
   Zhu, LJ
   Jiang, EZ
   Zou, SL
   Xu, GH
AF Liu, Jia
   Zhu, Lingjun
   Jiang, Enze
   Zou, Sili
   Xu, Guohua
TI Ankylosing Spondylitis Manifested by Extensive Cervical Erosions with
   Spontaneous Anterior Atlantoaxial Subluxation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; Anterior atlantoaxial subluxation; Bone erosion;
   Cervical spine; Cervical spondylopathy
ID VERTEBRAL EROSIONS; FOLLOW-UP; PREVALENCE; JOINTS; SPINE
AB BACKGROUND: Atlantoaxial instability owing to bone erosions in a patient with ankylosing spondylitis (AS) is rare. We describe the radiographic characteristics, pathology, and treatment of a patient with this rare clinical manifestation and review the literature.
   CASE DESCRIPTION: A 36-year-old man with an 8-year history of AS presented with progressive neck pain, low back pain, hand numbness, and limited mobility of the neck. Cervical radiography showed anterior atlantoaxial sub-luxation with bone erosions at the odontoid process and a mass lateral to the atlas and edge of vertebrae. AS was diagnosed according to the modified New York criteria, and the patient underwent a posterior C0-C6 occipitocervical arthrodesis surgery and C3-C6 laminectomy to reconstruct atlantoaxial stability and relieve cervical compression. The symptoms of neck pain and hand numbness improved at the 1-year follow-up, and the patient completely resumed normal activities. Imaging showed realignment of C1-2 with complete decompression of the spinal cord and fusion of the atlantooccipital joint. The internal fixation has remained stable, and progressive bone erosion changes were not found after surgery.
   CONCLUSIONS: Extensive cervical erosions with spontaneous atlantoaxial subluxation in AS is extremely rare. The erosive change of atlantoaxial bone may be an early feature of AS. Cervical spine radiographs are essential for patients with AS who present with neck pain. Complete decompression and internal fixation are necessary to prevent serious neurologic morbidity from spinal cord injury in such patients.
C1 [Liu, Jia; Zhu, Lingjun; Jiang, Enze; Xu, Guohua] Second Mil Med Univ, Dept Orthopaed Surg, Spine Ctr, Changzheng Hosp, Shanghai, Peoples R China.
   [Zou, Sili] Second Mil Med Univ, Changzheng Hosp, Dept Vasc & Endovasc Surg, Shanghai, Peoples R China.
RP Xu, GH (reprint author), Second Mil Med Univ, Dept Orthopaed Surg, Spine Ctr, Changzheng Hosp, Shanghai, Peoples R China.
EM xuguohuamail@smmu.edu.cn
CR [Anonymous], 1955, JAMA-J AM MED ASSOC, V159, P827
   Baraliakos X, 2013, J RHEUMATOL, V40, P1891, DOI 10.3899/jrheum.120533
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   Daumen-Legre V, 1999, J RHEUMATOL, V26, P687
   Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387
   Lee JS, 2012, J RHEUMATOL, V39, P2321, DOI 10.3899/jrheum.120260
   Maas F, 2017, SEMIN ARTHRITIS RHEU, V46, P562, DOI 10.1016/j.semarthrit.2016.11.003
   MARTEL W, 1960, ARTHRITIS RHEUM, V3, P546, DOI 10.1002/art.1780030608
   Ramiro S, 2014, ARTHRITIS RHEUMATOL, V66, P2773, DOI 10.1002/art.38775
   RamosRemus C, 1997, J RHEUMATOL, V24, P507
   Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Weber U, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3854
   Wick MC, 2010, J RHEUMATOL, V37, P622, DOI 10.3899/jrheum.090602
   WU PC, 1988, CLIN ORTHOP RELAT R, P154
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 583
EP 589
DI 10.1016/j.wneu.2018.10.155
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100309
PM 30404050
DA 2020-05-12
ER

PT J
AU Spake, CSL
   Reid, DBC
   Daniels, AH
AF Spake, Carole S. L.
   Reid, Daniel B. C.
   Daniels, Alan H.
TI Rapid Progression of Metastatic Panspinal Epidural Non-Small Cell Lung
   Cancer After Discontinuation of Alectinib
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alectinib; ALK-positive; Anaplastic lymphoma linase gene rearrangement
   positive; Disease flare; Epidural abscess; Non-small cell lung cancer
ID DISEASE FLARE; ACQUIRED-RESISTANCE; SKELETAL METASTASES; BONE
   METASTASES; GEFITINIB; PATIENT
AB BACKGROUND: Rapid progression of metastatic non-small cell lung cancer (NSCLC) after discontinuation of tyrosine kinase inhibitors or anaplastic lymphoma kinase (ALK) inhibitors has been described and is associated with a poor prognosis. We describe the first reported case of accelerated NSCLC tumor extension throughout the entire spinal epidural space.
   CASE DESCRIPTION: A 68-year-old woman with stage IV ALK-positive metastatic NSCLC presented with acute neck pain, urinary retention, and lower extremity weakness 15 days post discontinuation of alectinib. Magnetic resonance imaging (MRI) with contrast was significant for a new compressive lesion spanning the entire cervical, thoracic, and lumbar spine, which was new compared with MRI obtained 20 days before and was suspicious for infection. Cervical (C3-C7), thoracic (T9-T12), and lumbar (L3-L5) decompression were performed with collection of culture and pathology specimens. Repeat MRI obtained for acute neurologic deterioration on postoperative day 2 noted further progression of disease and continued thoracic cord compression. After urgent T1-9 laminectomy, specimens were again sent for pathology, cultures, and cytology. No evidence of infection was noted, and all pathologic specimens evaluated were consistent with metastatic adenocarcinoma. Despite operative intervention, the patient continued to decline, suffering from recurrent pleural effusions, and eventual cardiopulmonary arrest 11 days after admission.
   CONCLUSIONS: The differential diagnosis when evaluating presumed spine epidural abscess should include tumor and metastatic disease, even in cases of rapid development. Recent termination of tyrosine kinase inhibitors or ALK inhibitors may result in severe disease flares, and a history of such should raise clinical suspicion for metastatic progression. In addition to cultures, biopsy for pathologic diagnosis should be collected during decompressive surgery.
C1 [Spake, Carole S. L.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
   [Reid, Daniel B. C.; Daniels, Alan H.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed Surg, Providence, RI 02912 USA.
RP Spake, CSL (reprint author), Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
EM carole_spake@brown.edu
CR Biermann JS, 2009, J BONE JOINT SURG AM, V91A, P1518
   Chaft JE, 2011, CLIN CANCER RES, V17, P6298, DOI 10.1158/1078-0432.CCR-11-1468
   Kosteva J, 2004, LUNG CANCER-J IASLC, V46, pS45
   Kuchuk M, 2015, LUNG CANCER, V89, P197, DOI 10.1016/j.lungcan.2015.04.007
   Kuchuk M, 2013, J BONE ONCOL, V2, P22, DOI 10.1016/j.jbo.2012.12.004
   Kuriyama Y, 2013, CASE REP ONCOL, V6, P430, DOI 10.1159/000354756
   Park EH, 2017, J THORAC DIS, V9, pE543, DOI 10.21037/jtd.2017.05.10
   Pop O, 2012, J THORAC ONCOL, V7, pE1, DOI 10.1097/JTO.0b013e318257fc1d
   Roskoski R, 2017, PHARMACOL RES, V117, P343, DOI 10.1016/j.phrs.2017.01.007
   Siddiq F, 2004, ARCH INTERN MED, V164, P2409, DOI 10.1001/archinte.164.22.2409
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 590
EP 592
DI 10.1016/j.wneu.2018.11.118
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100310
PM 30476657
DA 2020-05-12
ER

PT J
AU Ward, AL
   Risman, A
   Segar, S
   Sharma, S
   Vender, JR
AF Ward, Ayobami L.
   Risman, Aida
   Segar, Sharmila
   Sharma, Suash
   Vender, John R.
TI Atypical Intracranial Meningioma with Metastasis to C7 Vertebral Body: A
   Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical; Meningioma; Metastatic; Radiosurgery; Resection; Spine
ID TUMORS; SPINE; BONE; LUNG
AB BACKGROUND: Extracranial metastasis, mainly a feature of World Health Organization (WHO) grade III meningiomas, is only rarely reported in grade II meningiomas.
   CASE DESCRIPTION: We report a case of a 48-year-old man who was initially diagnosed in 2010 with an occipital convexity meningioma based on computed tomography scan/magnetic resonance imaging (MRI) and treated with surgical therapy and gamma knife. The first operation achieved a macroscopically complete resection. The tumor was histologically classified as an atypical meningioma. The patient had a recurrence in 2014 on the left tentorial leaflet as noted on postcontrast MRI. The patient was asymptomatic, without focal neurologic deficits. In 2016, the patient reported new-onset pain in the neck and left upper extremity. MRI indicated complete replacement of the C7 vertebral marrow, with a soft tissue component extending posteriorly into the epidural space that appeared to be flattening the thecal sac but without evidence of abnormal cord signal. Histopathology of resection confirmed atypical meningioma.
   CONCLUSIONS: This case represents a rare instance of intraosseous spine as the first site of metastasis of WHO grade II atypical meningioma and is the first reported case of extracranial metastasis of a meningioma to the C7 vertebral body.
C1 [Ward, Ayobami L.; Risman, Aida; Segar, Sharmila; Vender, John R.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30904 USA.
   [Sharma, Suash] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA USA.
RP Vender, JR (reprint author), Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30904 USA.
EM jvender@augusta.edu
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Backer-Grondahl T, 2012, INT J CLIN EXP PATHO, V5, P231
   Barthelemy E, 2018, J CANCER RES CLIN, V144, P969, DOI 10.1007/s00432-018-2618-4
   Chen WC, 2019, J NEUROSURG, V130, P443, DOI 10.3171/2017.9.JNS171609
   Delgado-Lopez PD, 2006, NEUROCIRUGIA, V17, P240
   Enam SA, 1996, ACTA NEUROCHIR, V138, P1172
   Esiri, 2000, J Neurol Neurosurg Psychiatry, V68, p538D, DOI 10.1136/jnnp.68.4.538d
   Fabi A, 2006, ANTICANCER RES, V26, P3835
   Frydrychowicz C, 2015, NEUROPATHOLOGY, V35, P175, DOI 10.1111/neup.12177
   Fuentes S, 2002, NEUROCHIRURGIE, V48, P53
   Garcia-Conde M, 2009, NEUROCIRUGIA, V20, P541
   Kaminski JM, 2001, AM J CLIN ONCOL-CANC, V24, P579, DOI 10.1097/00000421-200112000-00010
   Kessler RA, 2017, WORLD NEUROSURG, V101, P47, DOI 10.1016/j.wneu.2017.01.070
   Lee GC, 2009, J KOREAN NEUROSURG S, V45, P107, DOI 10.3340/jkns.2009.45.2.107
   Lee YY, 2002, SPINE, V27, pE100, DOI 10.1097/00007632-200202150-00022
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17752
   Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5
   OLSON PN, 1994, SKELETAL RADIOL, V23, P405, DOI 10.1007/BF02417004
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Paix A, 2017, CANCER RADIOTHER, V21, P55, DOI 10.1016/j.canrad.2016.09.012
   PALMER JD, 1994, BRIT J NEUROSURG, V8, P215, DOI 10.3109/02688699409027971
   Perry A, 2016, WHO CLASSIFICATION T, P232
   Pinsker MO, 2005, ZBL NEUROCHIR, V66, P35, DOI 10.1055/s-2004-836245
   Rogers L, 2010, J NEURO-ONCOL, V99, P393, DOI 10.1007/s11060-010-0343-1
   Shakir SI, 2018, J NEUROSURG, V129, P1240, DOI 10.3171/2017.6.JNS17120
   Singh R, 2016, J NEUROSURG-SPINE, V25, P775, DOI 10.3171/2016.5.SPINE151457
   STRANG RR, 1964, J NEUROSURG, V21, P1098, DOI 10.3171/jns.1964.21.12.1098
   Strong MJ, 2015, OCHSNER J, V15, P200
   Surov A, 2013, J NEURO-ONCOL, V112, P323, DOI 10.1007/s11060-013-1074-x
   TOMINAGA T, 1994, NEUROSURGERY, V34, P538, DOI 10.1227/00006123-199403000-00024
   Tournat Helene, 2006, Cancer Radiother, V10, P590, DOI 10.1016/j.canrad.2006.06.008
   Walcott BP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00227
NR 33
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 593
EP 598
DI 10.1016/j.wneu.2018.11.067
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100311
PM 30465962
DA 2020-05-12
ER

PT J
AU Macki, M
   Anand, SK
   Surapaneni, A
   Park, P
   Chang, V
AF Macki, Mohamed
   Anand, Sharath Kumar
   Surapaneni, Ashwin
   Park, Paul
   Chang, Victor
TI Subsidence Rates After Lateral Lumbar Interbody Fusion: A Systematic
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Direct lateral interbody fusion; DLIF; Extreme lateral interbody
   fusions; Lateral Lumbar interbody fusion; LLIF; Subsidence; XLIF
ID ANTERIOR COLUMN RECONSTRUCTION; 2-YEAR COMPARATIVE OUTCOMES;
   STAND-ALONE; CLINICAL-OUTCOMES; CAGE SUBSIDENCE; REVISION SURGERY;
   TITANIUM CAGES; MINI-OPEN; CORPECTOMY; INSTRUMENTATION
AB OBJECTIVE: The evidence regarding the consequences of subsidence with lateral lumbar interbody fusion (LLIF) has been sparse. The objective of this study is to calculate the incidence of subsidence and reoperation for subsidence after LLIF. A secondary outcome examined the quantitative degree of subsidence by calculating the percent change in the height of the intervertebral space secondary to interbody subsidence at various postoperative follow-up times.
   METHODS: Following the MOOSE (Meta-analysis [and Systematic Review] Of Observational Studies in Epidemiology) guidelines, a systematic review searched for all cohort studies that focused on subsidence rates after LLIF, including extreme lateral interbody fusions (XLIFs) and direct lateral interbody fusion. Neoplastic, infectious, and/or metabolic indications for LLIF were similarly excluded because these diseases may compromise bone quality and, thus, confound the rate of cage subsidence. Corpectomies were removed from the systematic review because 1) indications for removal of vertebral body typically reflect those excluded diseases and 2) subsidence refers to a different biomechanical process.
   RESULTS: This systematic review identified a subsidence incidence with LLIF of 10.3% (N = 141/1362 patients in 14 articles) and reoperation rate for subsidence of 2.7% (N = 41/1470 patients in 16 articles). In the secondary outcome measure, the disc height decreased from 5.6% after 3 months, 6.0% after 6 months, and 10.2% after 12 months, to 8.9% after 24 months (P < 0.001).
   CONCLUSIONS: Subsidence after LLIF carries a nonnegligible risk that may be incorporated in surgical consent discussions in selected patients.
C1 [Macki, Mohamed; Anand, Sharath Kumar; Surapaneni, Ashwin; Chang, Victor] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
   [Park, Paul] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Chang, V (reprint author), Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
EM vchang1@hfhs.org
CR Ahmadian A, 2015, J CLIN NEUROSCI, V22, P740, DOI 10.1016/j.jocn.2014.08.036
   Alimi M, 2014, J NEUROSURG-SPINE, V20, P623, DOI 10.3171/2014.1.SPINE13569
   Blizzard DJ, 2015, J CLIN NEUROSCI, V22, P1758, DOI 10.1016/j.jocn.2015.05.021
   Castro C, 2014, CLIN ORTHOP RELAT R, V472, P1776, DOI 10.1007/s11999-013-3263-5
   Chin KR, 2016, SPINE, V41, P686, DOI 10.1097/BRS.0000000000001285
   Cho JH, 2017, SPINE J, V17, P1794, DOI 10.1016/j.spinee.2017.05.029
   Deukmedjian AR, 2014, J CLIN NEUROSCI, V21, P1632, DOI 10.1016/j.jocn.2013.12.028
   Dvorak MF, 2003, SPINE, V28, P902, DOI 10.1097/00007632-200305010-00012
   Essig DA, 2014, SPINE J, V14, pS114
   Fang TL, 2012, J NEUROSURG-SPINE, V17, P271, DOI 10.3171/2012.7.SPINE111086
   Hepworth G, 2017, J AGR BIOL ENVIR ST, V22, P602, DOI 10.1007/s13253-017-0297-2
   Holland CM, 2015, CLIN NEUROL NEUROSUR, V129, P37, DOI 10.1016/j.clineuro.2014.11.022
   Isaacs RE, 2016, SPINE, V41, pS133, DOI 10.1097/BRS.0000000000001472
   Jandial R, 2013, J NEUROSURG-SPINE, V19, P27, DOI 10.3171/2013.4.SPINE12344
   Karaeminogullari Oguz, 2005, Acta Orthop Belg, V71, P726
   Karikari IO, 2011, NEUROSURGERY, V68, P897, DOI 10.1227/NEU.0b013e3182098bfa
   Kim Shin Jae, 2014, Korean J Spine, V11, P145, DOI 10.14245/kjs.2014.11.3.145
   Knoeller SM, 2012, INT ORTHOP, V36, P111, DOI 10.1007/s00264-011-1288-5
   Kobayashi Y, 2017, J CLIN NEUROSCI, V35, P92, DOI 10.1016/j.jocn.2016.10.011
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Lang G, 2017, WORLD NEUROSURG, V104, P644, DOI 10.1016/j.wneu.2017.05.035
   Lau D, 2013, NEUROSURGERY, V72, P529, DOI 10.1227/NEU.0b013e318282a558
   Le TV, 2012, SPINE, V37, P1268, DOI 10.1097/BRS.0b013e3182458b2f
   Liang BW, 2017, INDIAN J ORTHOP, V51, P43, DOI 10.4103/0019-5413.197524
   Lim Jae Kwan, 2013, Korean J Spine, V10, P65, DOI 10.14245/kjs.2013.10.2.65
   Malham GM, 2012, THESCIENTIFICWORLDJO, V2012, DOI DOI 10.1100/2012/246989
   Malham GM, 2017, CLIN SPINE SURG, V30, pE90, DOI 10.1097/BSD.0b013e3182aa4c94
   Malham GM, 2015, J NEUROSURG-SPINE, V23, P589, DOI 10.3171/2015.1.SPINE14566
   MARCHI LUIS, 2016, Coluna/Columna, V15, P226, DOI 10.1590/S1808-185120161503162720
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Marchi Luis, 2012, ScientificWorldJournal, V2012, P456346, DOI 10.1100/2012/456346
   McAfee PC, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2012.10.001
   Nemani VM, 2014, SPINE, V39, pE326, DOI 10.1097/BRS.0000000000000141
   Oh KW, 2017, CLIN SPINE SURG, V30, pE683, DOI 10.1097/BSD.0000000000000315
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pawar AY, 2015, ASIAN SPINE J, V9, P668, DOI 10.4184/asj.2015.9.5.668
   Pham MH, 2017, CLIN SPINE SURG, V30, P360, DOI 10.1097/BSD.0000000000000312
   Pimenta L., 2001, 8 BRAZ SPIN SOC M MA
   Pimenta L, 2011, 4 ANN SOLAS RES M MA
   Pimenta L, 2013, J NEUROL SURG PART A, V74, P343, DOI 10.1055/s-0032-1333420
   Robertson PA, 2004, J SPINAL DISORD TECH, V17, P44, DOI 10.1097/00024720-200402000-00010
   Rodgers WB, 2012, SCI WORLD J, DOI 10.1100/2012/356712
   Schnake KJ, 2014, J NEUROSURG-SPINE, V20, P497, DOI 10.3171/2014.1.SPINE13246
   Sembrano JN, 2016, SPINE, V41, pS123, DOI 10.1097/BRS.0000000000001471
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sung SH, 2014, J KOREAN NEUROSURG S, V56, P323, DOI 10.3340/jkns.2014.56.4.323
   Tempel ZJ, 2018, J NEUROSURG-SPINE, V28, P50, DOI 10.3171/2017.5.SPINE16427
   Tempel ZJ, 2015, EUR SPINE J, V24, pS414, DOI 10.1007/s00586-015-3844-y
   Thaler KJ, 2013, J CLIN EPIDEMIOL, V66, P1082, DOI 10.1016/j.jclinepi.2013.05.002
   Theologis AA, 2016, J NEUROSURG-SPINE, V24, P60, DOI 10.3171/2015.4.SPINE14944
   Tohmeh AG, 2015, EUR SPINE J, V24, pS447, DOI 10.1007/s00586-015-3949-3
   Tohmeh AG, 2014, SPINE, V39, pE1582, DOI 10.1097/BRS.0000000000000645
   Wang B, 2011, TURK NEUROSURG, V21, P575, DOI [10.5137/1019-5149.JTN .4639-11.1, 10.5137/1019-5149.JTN.4639-11.1]
   Yang X, 2012, ORTHOPEDICS, V35, pE66, DOI 10.3928/01477447-20111122-10
   Yen CP, 2017, J NEUROSURG-SPINE, V26, P419, DOI 10.3171/2016.8.SPINE16421
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
NR 56
TC 3
Z9 4
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 599
EP 606
DI 10.1016/j.wneu.2018.11.121
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100312
PM 30476670
DA 2020-05-12
ER

PT J
AU Okromelidze, L
   Vilanilam, G
   Gupta, V
   Trifiletti, DM
   Brown, BL
   Middlebrooks, EH
AF Okromelidze, Lela
   Vilanilam, George
   Gupta, Vivek
   Trifiletti, Daniel M.
   Brown, Benjamin L.
   Middlebrooks, Erik H.
TI Trigeminal Neuralgia Caused by Dural Arteriovenous Fistula in Meckel
   Cave Treated with Gamma Knife Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistula; Gamma knife radiosurgery; Meckel cave;
   Stereotactic radiosurgery with gamma knife; Trigeminal neuralgia
ID MICROVASCULAR DECOMPRESSION; STEREOTACTIC RADIOSURGERY; MALFORMATION;
   CLASSIFICATION; EMBOLIZATION; COMPRESSION; SURGERY
AB BACKGROUND: Classic trigeminal neuralgia is an often debilitating condition that frequently results from vascular compression at the root entry zone of the trigeminal nerve. We report a case of dural arteriovenous fistula surrounding the trigeminal nerve from near the root entry zone extending as far ventral as the Meckel cave treated solely with Gamma Knife radiosurgery.
   CASE DESCRIPTION: A 71-year-old woman presented with a history of persistent attacks of right facial pain after failed conservative management. Magnetic resonance imaging of the brain demonstrated dilated vasculature in the right cerebellopontine angle, and diagnostic cerebral angiography revealed a dural arteriovenous fistula surrounding the right trigeminal nerve. Stereotactic radiosurgery using Gamma Knife was performed. At 6-month follow-up, she was symptom-free with decreased caliber of abnormal vascularity surrounding the trigeminal nerve on magnetic resonance imaging.
   CONCLUSIONS: This case suggests that trigeminal neuralgia associated with dural arteriovenous fistula can potentially be treated with Gamma Knife radiosurgery; however, more extensive studies and long-term follow-up to evaluate vessel patency will be necessary to elucidate further the role of stereotactic radiosurgery alone in treating this entity.
C1 [Okromelidze, Lela; Gupta, Vivek; Brown, Benjamin L.; Middlebrooks, Erik H.] Mayo Clin, Dept Radiol, Jacksonville, FL 32224 USA.
   [Vilanilam, George] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
   [Trifiletti, Daniel M.] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL 32224 USA.
   [Trifiletti, Daniel M.; Brown, Benjamin L.; Middlebrooks, Erik H.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
RP Middlebrooks, EH (reprint author), Mayo Clin, Dept Radiol, Jacksonville, FL 32224 USA.; Middlebrooks, EH (reprint author), Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
EM middlebrooks.erik@mayo.edu
RI Vilanilam, George Koshy/AAJ-3847-2020; Middlebrooks, Erik/Q-9389-2019
OI Middlebrooks, Erik/0000-0002-4418-9605; Vilanilam,
   George/0000-0003-0845-670X
CR Akhaddar A, 2010, HEADACHE, V50, P861, DOI 10.1111/j.1526-4610.2009.01555.x
   Anderson William S, 2006, J Headache Pain, V7, P217, DOI 10.1007/s10194-006-0306-2
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Cifarelli CP, 2010, NEUROSURGERY, V67, P1230, DOI 10.1227/NEU.0b013e3181eff6f7
   DANDY WE, 1934, AM J SURG, V24, P447, DOI DOI 10.1016/S0002-9610(34)90403-7
   Lucas CD, 2007, ACTA NEUROCHIR, V149, P1249, DOI 10.1007/s00701-007-1367-y
   Dmytriw AA, 2017, INTERV NEURORADIOL, V23, P211, DOI 10.1177/1591019916683689
   Du R, 2003, NEUROSURGERY, V53, P216, DOI 10.1227/01.NEU.0000069535.42897.1F
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Ge HJ, 2016, INTERV NEURORADIOL, V22, P600, DOI 10.1177/1591019916654430
   Hanakita S, 2012, J NEUROSURG, V117, P158, DOI 10.3171/2012.7.GKS12967
   HARDERS A, 1982, ACTA NEUROCHIR, V66, P95, DOI 10.1007/BF01809308
   Ito M, 1996, SURG NEUROL, V45, P370, DOI 10.1016/0090-3019(95)00438-6
   Jiang LD, 2019, WORLD NEUROSURG, V121, P243, DOI 10.1016/j.wneu.2018.08.176
   Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347
   Lu X, 2013, BMJ CASE REP, V2013
   Matsushige T, 2006, SURG NEUROL, V66, P519, DOI 10.1016/j.surneu.2006.01.022
   MENDELOWITSCH A, 1990, EUR NEUROL, V30, P338, DOI 10.1159/000117368
   Mendes GAC, 2016, CLIN NEURORADIOL, V26, P117, DOI 10.1007/s00062-015-0417-8
   Obermann Mark, 2010, Ther Adv Neurol Disord, V3, P107, DOI 10.1177/1756285609359317
   OTT D, 1993, HEADACHE, V33, P503, DOI 10.1111/j.1526-4610.1993.hed3309503.x
   Pan David Hung-Chi, 2013, Acta Neurochir Suppl, V116, P113, DOI 10.1007/978-3-7091-1376-9_18
   Prasad S, 2009, NEUROLOGIST, V15, P87, DOI 10.1097/NRL.0b013e3181775ac3
   Rahme R, 2007, ACTA NEUROCHIR, V149, P937, DOI 10.1007/s00701-007-1251-9
   Robert T, 2015, CLIN NEUROL NEUROSUR, V138, P83, DOI 10.1016/j.clineuro.2015.08.004
   Sharma R, 2018, NEUROL INDIA, V66, P688, DOI 10.4103/0028-3886.232342
   Soderman M, 2006, J NEUROSURG, V104, P867, DOI 10.3171/jns.2006.104.6.867
   Tomak PR, 2003, NEUROSURGERY, V52, P750, DOI 10.1227/01.NEU.0000053221.22954.85
   Wakuta N, 2013, MED BULL FUKUOKA UNI, V40, P61
   Yoshino N, 2003, RADIOLOGY, V228, P539, DOI 10.1148/radiol.2282020439
   Yuan YJ, 2016, EXP THER MED, V12, P69, DOI 10.3892/etm.2016.3277
   Zakrzewska JM, 2014, BMJ CLIN EVID, V2014, P2014
NR 33
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 607
EP 612
DI 10.1016/j.wneu.2018.11.177
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100313
PM 30500585
DA 2020-05-12
ER

PT J
AU Srivatsan, A
   Mohanty, A
   Nascimento, FA
   Hafeez, MU
   Srinivasan, VM
   Thomas, A
   Chen, SR
   Johnson, JN
   Kan, P
AF Srivatsan, Aditya
   Mohanty, Alina
   Nascimento, Fabio A.
   Hafeez, Muhammad U.
   Srinivasan, Visish M.
   Thomas, Ajith
   Chen, Stephen R.
   Johnson, Jeremiah N.
   Kan, Peter
TI Middle Meningeal Artery Embolization for Chronic Subdural Hematoma:
   Meta-Analysis and Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic subdural hematoma; Chronic subdural hemorrhage; Middle meningeal
   artery embolization; Refractory subdural hematoma; Refractory subdural
   hemorrhage
ID MANAGEMENT; RECURRENCE
AB BACKGROUND: Chronic subdural hematoma is a very common neurosurgical condition. Although conventional surgical methods, such as burr hole irrigation, have been the mainstay of treatment, middle meningeal artery (MMA) embolization has emerged as a promising adjunctive or alternative treatment. The aim of this article was to present a meta-analysis and systematic review of this topic.
   METHODS: A literature search using keywords "chronic subdural hematoma," "chronic subdural hemorrhage," "refractory subdural hematoma," "refractory subdural hemorrhage," and "middle meningeal artery embolization" was conducted through October 2018. Outcome variables of hematoma recurrence, surgical complications, and modified Rankin Scale score were analyzed and compared between MMA embolization and conventional surgery cohorts.
   RESULTS: Three double-arm studies comparing embolization and conventional surgery groups and 6 single-arm case series were identified and analyzed. Hematoma recurrence rate was significantly lower in the embolization group compared with conventional treatment group (2.1% vs. 27.7%; odds ratio = 0.087; 95% confidence interval, 0.026-0.292; P < 0.001; I-2 = 0%); surgical complication rates were similar between groups (2.1% vs. 4.4%; odds ratio = 0.563; 95% confidence interval, 0.107-2.96; P = 0.497; I-2 = 27.5%). Number of patients with modified Rankin Scale score >2 in the embolization (12.5%) versus conventional treatment (9.1%) group showed no statistical difference (P = 0.689). A composite hematoma recurrence rate of 3.6% was found after summing the 6 case series. Composite recurrence and complication rates in the embolization cohorts of the double-arm studies and the case series were lower than literature values for conventional surgical treatments.
   CONCLUSIONS: MMA embolization is a promising treatment for chronic subdural hematoma. Future randomized clinical trials are needed.
C1 [Srivatsan, Aditya; Mohanty, Alina; Srinivasan, Visish M.; Johnson, Jeremiah N.; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Nascimento, Fabio A.; Hafeez, Muhammad U.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
   [Chen, Stephen R.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
   [Thomas, Ajith] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA USA.
RP Kan, P (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM peter.kan@bcm.edu
RI Nascimento, Fabio A./W-8395-2019
OI Nascimento, Fabio A./0000-0002-7161-6385; Johnnson,
   Jeremiah/0000-0002-9920-5895; Chen, Stephen/0000-0002-5580-831X;
   Srivatsan, Aditya/0000-0001-5596-0613
CR Ban SP, 2018, RADIOLOGY, V286, P909, DOI 10.1148/radiol.2017170053
   Cousseau D, 2001, REV NEUROLOGIA, V32, P821, DOI 10.33588/rn.3209.2000458
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Forster MT, 2010, J CLIN NEUROSCI, V17, P975, DOI 10.1016/j.jocn.2009.11.023
   Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024
   HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017
   Hashimoto Takao, 2013, Surg Neurol Int, V4, P104, DOI 10.4103/2152-7806.116679
   Hirai S, 2004, INTERV NEURORADIOL, V10, P101, DOI 10.1177/15910199040100S218
   Ishihara H, 2007, Interv Neuroradiol, V13 Suppl 1, P141
   ITO H, 1976, J NEUROSURG, V45, P26, DOI 10.3171/jns.1976.45.1.0026
   Kalamatianos T, 2013, J NEUROSURG, V118, P353, DOI 10.3171/2012.10.JNS12327
   Kang Jiin, 2015, Korean J Neurotrauma, V11, P187, DOI 10.13004/kjnt.2015.11.2.187
   Kim E, 2017, WORLD NEUROSURG, V101, P520, DOI 10.1016/j.wneu.2017.02.070
   Link TW, 2018, WORLD NEUROSURG, V118, pE570, DOI 10.1016/j.wneu.2018.06.241
   Mandai S, 2000, J NEUROSURG, V93, P686, DOI 10.3171/jns.2000.93.4.0686
   Matsumoto H, 2018, J CLIN NEUROSCI, V49, P40, DOI 10.1016/j.jocn.2017.11.009
   Mino Masaki, 2010, Surg Neurol Int, V1, P78, DOI 10.4103/2152-7806.73801
   ORLIN JR, 1991, ANAT RECORD, V230, P22, DOI 10.1002/ar.1092300104
   Pont LMEB, 2012, EUR J NEUROL, V19, P1397, DOI 10.1111/j.1468-1331.2012.03768.x
   Poulsen FR, 2014, CLIN NEUROL NEUROSUR, V123, P4, DOI 10.1016/j.clineuro.2014.05.003
   QIU S, 2017, MEDICINE, V96, DOI DOI 10.1097/MD.0000000000007290
   Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013
   Santarius Thomas, 2010, Clin Neurosurg, V57, P112
   Stanisic M, 2012, INFLAMM RES, V61, P845, DOI 10.1007/s00011-012-0476-0
   Sun TFD, 2005, BRIT J NEUROSURG, V19, P327, DOI 10.1080/02688690500305332
   Takahashi K, 2002, NEUROL SURG TOKYO, V30, P535
   Tempaku A, 2015, INTERV NEURORADIOL, V21, P366, DOI 10.1177/1591019915583224
   Thotakura AK, 2015, WORLD NEUROSURG, V84, P1968, DOI 10.1016/j.wneu.2015.08.044
   Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17
   Tsukamoto Y, 2011, ACTA NEUROCHIR, V153, P1145, DOI 10.1007/s00701-010-0891-3
NR 30
TC 9
Z9 10
U1 4
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 613
EP 619
DI 10.1016/j.wneu.2018.11.167
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100314
PM 30481628
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Wang, L
   Cai, L
   Qian, H
   Oh, JS
   Tanikawa, R
   Shi, XE
AF Wang, Long
   Cai, Li
   Qian, Hai
   Oh, Jae-Sang
   Tanikawa, Rokuya
   Shi, Xiang'en
TI Repositioning Technique for the Decompression of Symptomatic
   Dolichoectatic Vertebrobasilar Pathology: A Comprehensive Review of
   Sling Characteristics and Surgical Experience
SO WORLD NEUROSURGERY
LA English
DT Review
DE Clip repositioning; Dolichoectasia; Dolichoectatic aneurysm; Ectatic
   vertebrobasilar artery; Sling repositioning; Vasculopexy
ID MICROVASCULAR DECOMPRESSION; TRIGEMINAL NEURALGIA; VERTEBRAL ARTERY;
   HEMIFACIAL SPASM; BRAIN-STEM; MEDULLA-OBLONGATA; CLINICAL ANALYSIS;
   BASILAR ARTERY; COMPRESSION; TRANSPOSITION
AB OBJECTIVE: The repositioning of a dolichoectatic vertebrobasilar artery (VBA) for arterial decompression has been extensively used in the clinical setting. We aimed to describe and summarize the technical characteristics and clinical results of the sling technique.
   METHODS: The terms "dolichoectatic aneurysm," "dolichoectasia," "ectasia," and "megadolichoectasia" were used to search for pertinent reports related to the VBA territory. Studies related to the "decompression," "repositioning," "transposition," "anchoring," "pexy," and "sling" techniques were screened, collected, and summarized by 1 of us (L.W.).
   RESULTS: We identified 20 pertinent reports involving 59 cases. The sling repositioning techniques were divided into the following 4 subtypes: suture-lasso, vasculopexy, clip-lasso, and wrap-sling. Overall, 35 of the 59 patients (59.3%) were treated using the wrap-sling technique. Among these cases, Gore-Tex grafts were the most common sling material used. Of the cases with reported postoperative characteristics, all the patients except for 1 had experienced complete or significant remission of symptoms. Although 11 of the 59 patients (18.6%) had developed complications, the rate of adverse effects had decreased to 3.6% (2 of 55) during the long-term follow-up period (mean, 40.4 months; range, 2.1-168), and the outcomes were unremarkable in 54 of the 55 patients (98.2%).
   CONCLUSIONS: The excellent surgical outcomes and durable long-term results suggest that the repositioning technique is highly effective in resolving symptoms related to the compression of DVB pathology. The wrap-sling technique might be the preferred option owing to the simultaneous symptom relief and lower rate of temporary complications. However, cranial nerve manipulation should be meticulously implemented to avoid permanent negative effects.
C1 [Wang, Long; Qian, Hai; Shi, Xiang'en] Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Long; Tanikawa, Rokuya] Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Sapporo, Hokkaido, Japan.
   [Cai, Li] Univ South China, Dept Neurosurg, Affiliated Hosp 1, Hengyang, Peoples R China.
   [Cai, Li] St Vincent Hosp, Arkansas Neurosci Inst, Little Rock, AR USA.
   [Oh, Jae-Sang] Soonchunhyang Univ, Cheonan Hosp, Dept Neurosurg, Cheonan, South Korea.
   [Shi, Xiang'en] Capital Med Univ, Fuxing Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, L (reprint author), Capital Med Univ, SanBo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.; Wang, L (reprint author), Teishinkai Hosp, Dept Neurosurg, Stroke Ctr, Sapporo, Hokkaido, Japan.
EM wanglong@mail.ccmu.edu.cn
RI WANG, LONG/AAI-5029-2020
FU Beijing Municipal Natural Science FoundationBeijing Natural Science
   Foundation [7161005]; Science and Technology Commission Foundation of
   Beijing [Z161100000516019]
FX The present study was funded by the Beijing Municipal Natural Science
   Foundation (grant 7161005 to XS.) and the Science and Technology
   Commission Foundation of Beijing (grant Z161100000516019 to XS.).
CR Attabib N, 2007, J NEUROSURG, V106, P929, DOI 10.3171/jns.2007.106.5.929
   BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359
   Bejjani GK, 1997, J NEUROSURG, V86, P728, DOI 10.3171/jns.1997.86.4.0728
   BINGAS B, 1972, NEURORADIOLOGY, V3, P165, DOI 10.1007/BF00341503
   CARELLA A, 1973, NEURORADIOLOGY, V6, P233, DOI 10.1007/BF00335330
   Chang JW, 2000, STEREOT FUNCT NEUROS, V74, P167, DOI 10.1159/000056476
   Cheng CY, 2019, OPER NEUROSURG, V16, pE2, DOI 10.1093/ons/opy058
   Choudhri O, 2017, NEUROSURGERY, V81, P367, DOI 10.1093/neuros/nyx110
   CORKILL G, 1982, SURG NEUROL, V18, P262, DOI 10.1016/0090-3019(82)90340-8
   El-Ghandour NMF, 2010, NEUROSURGERY, V67, P330, DOI 10.1227/01.NEU.0000371978.86528.60
   Ferreira M, 2011, J NEUROSURG, V114, P1800, DOI 10.3171/2010.12.JNS10891
   Fujimaki T, 2015, J NEUROSURG, V123, P293, DOI 10.3171/2011.9.JNS111585
   Garibaldi DC, 2003, ARCH NEUROL-CHICAGO, V60, P626, DOI 10.1001/archneur.60.4.626
   GIBSON WPR, 1975, J LARYNGOL OTOL, V89, P721, DOI 10.1017/S0022215100080932
   HARSH GR, 1991, J NEUROSURG, V74, P999, DOI 10.3171/jns.1991.74.6.0999
   Gonzalez-Quarante LH, 2017, WORLD NEUROSURG, V106, P775, DOI 10.1016/j.wneu.2017.07.110
   HIMI T, 1995, AM J OTOL, V16, P377
   Honey CM, 2018, WORLD NEUROSURG, V118, pE155, DOI 10.1016/j.wneu.2018.06.145
   HONGO K, 1993, J NEUROSURG, V79, P116, DOI 10.3171/jns.1993.79.1.0116
   Ishii A, 2013, NEUROSURG REV, V36, P657, DOI 10.1007/s10143-013-0454-1
   Kang JH, 2012, J KOREAN NEUROSURG S, V52, P85, DOI 10.3340/jkns.2012.52.2.85
   Komatsu F, 2017, J NEUROL SURG PART A, V78, P291, DOI 10.1055/s-0036-1592077
   Kondo A, 1998, J NEUROSURG, V88, P221, DOI 10.3171/jns.1998.88.2.0221
   Kurokawa Y, 2004, SURG NEUROL, V61, P398, DOI 10.1016/S0090-3019(03)00425-7
   Kyoshima K, 1999, NEUROSURGERY, V45, P1487, DOI 10.1097/00006123-199912000-00048
   Lin CF, 2012, CLIN NEUROL NEUROSUR, V114, P951, DOI 10.1016/j.clineuro.2012.02.021
   LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001
   Ma XY, 2013, NEUROSURG REV, V36, P573, DOI 10.1007/s10143-013-0468-8
   Masuoka J, 2015, NEUROSURG REV, V38, P361, DOI 10.1007/s10143-015-0607-5
   Mitsos AP, 2008, NEUROSURG REV, V31, P327, DOI 10.1007/s10143-008-0144-6
   Moss MS, 1996, BRIT J NEUROSURG, V10, P497, DOI 10.1080/02688699647159
   Munich SA, 2019, OPER NEUROSURG, V16, P267, DOI 10.1093/ons/opy111
   OGAWA A, 1992, SURG NEUROL, V38, P232, DOI 10.1016/0090-3019(92)90174-L
   Ohta M, 2008, NEUROL MED-CHIR, V48, P30, DOI 10.2176/nmc.48.30
   Pereira AD, 2008, ARQ NEURO-PSIQUIAT, V66, P408, DOI 10.1590/S0004-282X2008000300026
   Pham Thong, 2018, Am J Ophthalmol Case Rep, V10, P229, DOI 10.1016/j.ajoc.2018.02.029
   Raabe A, 2011, ACTA NEUROCHIR, V153, P2393, DOI 10.1007/s00701-011-1183-2
   Rak R, 2004, NEUROSURGERY, V54, P876, DOI 10.1227/01.NEU.0000115151.52925.37
   Rawlinson J N, 1988, Br J Neurosurg, V2, P173, DOI 10.3109/02688698808992667
   RESTA M, 1984, NEURORADIOLOGY, V26, P213, DOI 10.1007/BF00342416
   Sadashiva N, 2016, ACTA NEUROCHIR, V158, P797, DOI 10.1007/s00701-016-2715-6
   Shimano H, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.06.026
   Singh H, 2018, OPER NEUROSURG, V14, P194, DOI 10.1093/ons/opx087
   Steinberg JA, J NEUROSURG, DOI [10.3171/2017, DOI 10.3171/2017]
   STONE JL, 1993, J NEUROSURG, V79, P943, DOI 10.3171/jns.1993.79.6.0943
   Sun SJ, 2017, INT J SURG, V41, P183, DOI 10.1016/j.ijsu.2017.04.015
   SUZUKI S, 1990, Neurologia Medico-Chirurgica, V30, P1020, DOI 10.2176/nmc.30.1020
   Tabani H, 2019, OPER NEUROSURG, V16, pE4, DOI 10.1093/ons/opy117
   TAKAMIYA Y, 1985, SURG NEUROL, V24, P559, DOI 10.1016/0090-3019(85)90274-5
   Takeda R, 2016, SURG J-NY, V2, pE105, DOI 10.1055/s-0036-1593447
   Tomasello Francesco, 2005, Neurosurgery, V56, P117
   Ubogu EE, 2002, J NEUROSURG, V96, P140, DOI 10.3171/jns.2002.96.1.0140
   Vieco PT, 1997, AM J NEURORADIOL, V18, P1385
   WAGA S, 1979, SURG NEUROL, V11, P13
   Wolters FJ, 2013, NEUROL RES, V35, P131, DOI 10.1179/1743132812Y.0000000149
   Yoon S, 2019, OPER NEUROSURG, V16, pE178, DOI 10.1093/ons/opy215
   YOSHIMOTO Y, 1995, SURG NEUROL, V43, P151, DOI 10.1016/0090-3019(95)80126-2
   Zaidi HA, 2015, J CLIN NEUROSCI, V22, P62, DOI 10.1016/j.jocn.2014.09.008
   Zhang HW, 2018, WORLD NEUROSURG, V119, pE407, DOI 10.1016/j.wneu.2018.07.176
NR 59
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 620
EP 631
DI 10.1016/j.wneu.2018.11.200
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100315
PM 30503287
DA 2020-05-12
ER

PT J
AU Moteki, Y
   Yamada, M
   Shimizu, A
   Suzuki, N
   Kobayashi, T
AF Moteki, Yosuke
   Yamada, Masatoshi
   Shimizu, Atsushi
   Suzuki, Naoki
   Kobayashi, Tomonori
TI Langerhans Cell Histiocytosis of the Skull in a Burr Hole Site Covered
   with Hydroxyapatite Material
SO WORLD NEUROSURGERY
LA English
DT Article
DE Foreign-body reaction; Hydroxyapatite; Langerhans cell histiocytosis;
   Tumor of skull
ID EOSINOPHILIC GRANULOMA; EPIDURAL HEMATOMA; HEMORRHAGE
AB BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare dendritic histiocytic disorder that affects the bones, especially the skull. Langerhans cell histiocytosis (LCH) developing in a burr hole site for chronic subdural hematoma is extremely rare.
   CASE DESCRIPTION: A 53-year-old man underwent a burr hole irrigation for chronic subdural hematoma, and the burr hole was covered with a burr hole button made of hydroxyapatite. Seven months after the first surgery, the connective tissue rapidly proliferated around the burr hole button, and the pathologic diagnosis was LCH. LCH recurred at 13 and 19 months after the first operation, with curettage performed each time. At 3 months after the final operation, no recurrence was identified on magnetic resonance imaging.
   CONCLUSIONS: If there is rapid proliferation of connective tissue at an operative site where artificial material has been used, LCH should be considered.
C1 [Moteki, Yosuke; Shimizu, Atsushi; Suzuki, Naoki; Kobayashi, Tomonori] Ebina Gen Hosp, Dept Neurosurg, Ebina, Kanagawa, Japan.
   [Yamada, Masatoshi] Ebina Gen Hosp, Dept Diagnost Pathol, Ebina, Kanagawa, Japan.
RP Moteki, Y (reprint author), Ebina Gen Hosp, Dept Neurosurg, Ebina, Kanagawa, Japan.
EM moteki.yosuke@twmu.ac.jp
CR ARSENI C, 1977, NEUROCHIRURGIA, V20, P189
   BAKER GS, 1948, SURG CLIN N AM, V28, P1057
   Bakhaidar MG, 2016, J PEDIATR NEUROSCI, V11, P52, DOI 10.4103/1817-1745.181248
   Baumgartner I, 1997, MED PEDIATR ONCOL, V28, P9, DOI 10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P
   CECI A, 1993, MED PEDIATR ONCOL, V21, P259, DOI 10.1002/mpo.2950210405
   Chee E, 2013, OPHTHAL PLAST RECONS, V29, pE40, DOI 10.1097/IOP.0b013e3182696577
   Cho DY, 2001, PEDIATR NEUROSURG, V35, P266, DOI 10.1159/000050434
   De Angulo G, 2013, J NEUROSURG-PEDIATR, V12, P1, DOI 10.3171/2013.4.PEDS12482
   Grois N, 2006, PEDIATR BLOOD CANCER, V46, P228, DOI 10.1002/pbc.20425
   Hata N, 2011, NEUROL MED-CHIR, V51, P236, DOI 10.2176/nmc.51.236
   KNIGHTON RS, 1956, JAMA-J AM MED ASSOC, V162, P1294, DOI 10.1001/jama.1956.02970310022005
   Lavrador JP, 2013, ACTA NEUROCHIR, V155, P321, DOI 10.1007/s00701-012-1601-0
   Lee KW, 2000, PEDIATR RADIOL, V30, P326, DOI 10.1007/s002470050750
   Lee YS, 2008, J KOREAN NEUROSURG S, V43, P304, DOI 10.3340/jkns.2008.43.6.304
   Martinez-Lage JF, 2002, CHILD NERV SYST, V18, P74, DOI 10.1007/s003810100491
   Mut M, 2004, CHILD NERV SYST, V20, P765, DOI 10.1007/s00381-004-0913-7
   Oliveira M, 2003, PEDIATR NEUROSURG, V38, P247, DOI 10.1159/000069828
   Pan Zenggang, 2011, Dermatol Online J, V17, P6
   Pawar RV, 2011, NEURORADIOL J, V24, P767, DOI 10.1177/197140091102400516
   Pui CM, 2011, J BONE JOINT SURG AM, V93
   Sadashiva N, 2017, PEDIATR NEUROSURG, V52, P41, DOI 10.1159/000448047
   SLATER JM, 1980, MED PEDIATR ONCOL, V8, P151, DOI 10.1002/mpo.2950080208
   Yee KS, 2013, PEDIATR NEUROSURG, V49, P243, DOI 10.1159/000362341
   Zhang XH, 2017, ANN PALLIAT MED, V6, P159, DOI 10.21037/apm.2016.11.04
NR 24
TC 5
Z9 5
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 632
EP 637
DI 10.1016/j.wneu.2018.11.198
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100316
PM 30503292
DA 2020-05-12
ER

PT J
AU Alberio, N
   Cicero, S
   Iacopino, DG
   Giammalva, GR
   Visocchi, M
   Olivi, A
   Francaviglia, N
   Battaglia, R
   Spitaleri, A
   Lipani, R
   Ruggeri, L
   Alessandrello, R
   Cinquemani, A
   Maugeri, R
AF Alberio, Nicola
   Cicero, Salvatore
   Iacopino, Domenico Gerardo
   Giammalva, Giuseppe Roberto
   Visocchi, Massimiliano
   Olivi, Alessandro
   Francaviglia, Natale
   Battaglia, Roberto
   Spitaleri, Angelo
   Lipani, Rita
   Ruggeri, Luca
   Alessandrello, Raffaele
   Cinquemani, Alessandro
   Maugeri, Rosario
TI Minimally Invasive Management of Spontaneous Supratentorial
   Intracerebral Lobar Hemorrhages by a "Homemade" Endoscopic Strategy: The
   Evangelical Doctrine of "Venite ad Me" Allied to the Legacy of King
   Leonida
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain edema; Cerebral hemorrhage; Clot evacuation; Endoscopy;
   Intracranial hypertension; Minimally invasive surgery; Stroke
ID SURGERY; EVACUATION; METAANALYSIS; VOLUME
AB BACKGROUND: Although the incidence of intracerebral hemorrhage (ICH) has appeared to be increasing over the years, its prognosis remains dismal. No consensus has yet been reached regarding the management of ICH; however, minimally invasive surgery should limit, if not avoid, intraoperative parenchymal damage. Therefore, we have presented a novel, modified "homemade" approach aimed to shorten the operative time and minimize the corticectomy and brain manipulation.
   METHODS: From 2008 to 2017, 53 patients (32 men and 21 women; mean age, 63.8 years) were admitted to our neurosurgery department and surgically treated for a lobar ICH. A modified suction tube, coupled with the endoscope light source, was used. Clot evacuation was performed under loupe magnification without the use of the microscope or endoscope. The light source of the latter was only used to provide light in the working cavity.
   RESULTS: The mean hematoma volume was 69.2 mL (range, 40-100) preoperatively and 12.1 mL (range, 0-20) postoperatively, with a mean clot evacuation of 84.3% (range, 60%-100%). The mean postoperative Glasgow coma scale score was 11.6, with an improvement of 14% from the admission score (mean, 9.2).
   CONCLUSIONS: The results from our clinical series have shown the effectiveness of endoscopic clot evacuation in surgical ICH. In addition, we have demonstrated an efficient technique that can be used in urgent cases and in less-developed areas owing to its reduced demand on resources and its shorter learning curve. The outcomes were good and comparable to those with the classical endoscopic approach.
C1 [Alberio, Nicola; Cicero, Salvatore; Spitaleri, Angelo] Hosp Cannizzaro, Unit Neurosurg, Palermo, Italy.
   [Iacopino, Domenico Gerardo; Giammalva, Giuseppe Roberto; Maugeri, Rosario] Univ Palermo, AOUP Paolo Giaccone, Dept Expt Biomedicine & Clin Neurosci,Sch Med, Postgrad Residency Program Neurol Surg,Neurosurg, Palermo, Italy.
   [Visocchi, Massimiliano; Olivi, Alessandro] Univ Catholic, Inst Neurosurg, Rome, Italy.
   [Francaviglia, Natale] Hosp Civico, Unit Neurosurg, Palermo, Italy.
   [Battaglia, Roberto; Lipani, Rita; Ruggeri, Luca; Alessandrello, Raffaele; Cinquemani, Alessandro] S Elia Hosp, Unit Neurosurg, Caltanissetta, Italy.
RP Visocchi, M (reprint author), Univ Catholic, Inst Neurosurg, Rome, Italy.
EM nchido2018@gmail.com
RI visocchi, massimiliano/AAA-4267-2019; Iacopino, Domenico/C-1539-2013
OI visocchi, massimiliano/0000-0002-5277-4468; Iacopino,
   Domenico/0000-0003-1685-5209
CR Angileri FF, 2016, WORLD NEUROSURG, V94, P268, DOI 10.1016/j.wneu.2016.07.015
   Beynon C, 2015, NEUROSURG REV, V38, P421, DOI 10.1007/s10143-015-0606-6
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Chen CC, 2007, SURG NEUROL, V68, P438, DOI 10.1016/j.surneu.2006.11.054
   Cho DY, 2006, SURG NEUROL, V65, P547, DOI 10.1016/j.surneu.2005.09.032
   Fiorella D, 2015, WORLD NEUROSURG, V84, P1136, DOI 10.1016/j.wneu.2015.05.063
   Gaab MR, 2011, WORLD NEUROSURG, V75, P206, DOI 10.1016/j.wneu.2010.10.003
   Giugno A, 2014, INTERDISCIP NEUROSUR, V1, P84, DOI 10.1016/j.inat.2014.09.005
   Graziano Francesca, 2016, Surg Neurol Int, V7, pS77, DOI 10.4103/2152-7806.174894
   Graziano Francesca, 2015, Surg Neurol Int, V6, P77, DOI 10.4103/2152-7806.156871
   Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Ma LC, 2017, WORLD NEUROSURG, V101, P57, DOI 10.1016/j.wneu.2017.01.072
   Maugeri R, 2015, INTERDISCIP NEUROSUR, V2, P160, DOI 10.1016/j.inat.2015.07.002
   Mendelow AD, 2005, LANCET, V365, P387
   Nievas MNC, 2005, MED SCI MONITOR, V11, pRA24
   Reichart R, 2011, OPEN CRITICAL CARE M, V24, p[68, 68]
   Siddique MS, 2000, BRIT MED BULL, V56, P444, DOI 10.1258/0007142001903085
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Wang WJ, 2017, WORLD NEUROSURG, V105, P348, DOI 10.1016/j.wneu.2017.05.158
   Yang CD, 2014, FORMOS J SURG, V47, P90, DOI 10.1016/j.fjs.2013.12.005
NR 21
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 638
EP 647
DI 10.1016/j.wneu.2018.11.136
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100317
PM 30481620
DA 2020-05-12
ER

PT J
AU Eichberg, DG
   Achua, JK
   Locatelli, E
   Shah, AH
   Komotar, RJ
   Ghods, AJ
AF Eichberg, Daniel G.
   Achua, Justin K.
   Locatelli, Eduardo
   Shah, Ashish H.
   Komotar, Ricardo J.
   Ghods, Ali J.
TI Primary Diffuse Leptomeningeal Melanomatosis: Case Report and Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain biopsy; Brain tumor; Leptomeningeal enhancement; Melanocyte;
   Melanomatosis; Positron emission tomography; Spinal nerve root biopsy
ID CENTRAL-NERVOUS-SYSTEM; MENINGEAL MELANOMATOSIS; MALIGNANT-MELANOMA;
   CEREBROSPINAL-FLUID; DIAGNOSIS; MELANOCYTOMA; CYTOLOGY; PET/CT
AB BACKGROUND: Primary diffuse leptomeningeal melanomatosis (PDLM) is an extremely rare pathologic condition that can mimic several other neurologic disease states.
   METHODS: We report a rare case of PDLM without evidence of a primary focus. In addition, we performed a comprehensive review of the literature to describe all previously reported cases of PDLM.
   RESULTS: In the reported case, making the diagnosis of PDLM was difficult. A brain and frontal dural biopsy was nondiagnostic. Computed tomography of the chest, abdomen, and pelvis did not show any distinct solitary mass. After a positron emission tomography scan was performed that showed lumbar sacral enhancement, lumbar dorsal rootlet biopsy was initiated, which was diagnostic of PDLM. Our literature review found 32 previously reported cases of PDLM. Sixteen cases (48.5%) had a distinct focus or mass discovered on imaging workup. The reported case was the seventeenth reported case of PDLM without a distinct focus or mass found on imaging workup.
   CONCLUSIONS: PDLM is an extremely rare disease, and diagnosis is difficult because of nonspecific clinical, radiographic, and laboratory findings. In approximately half of cases, no distinct mass is shown on imaging workup, which may further complicate diagnosis. PDLM should be on the differential diagnosis for cases of diffuse dural enhancement. Neurosurgical intervention is often limited to ventriculoperitoneal shunting for increased intracranial pressure and dural and cranial biopsy to obtain diagnosis. If the initial biopsy is nondiagnostic, hypermetabolic activity as seen on positron emission tomography may be helpful to find an alternative biopsy site.
C1 [Eichberg, Daniel G.; Achua, Justin K.; Shah, Ashish H.; Komotar, Ricardo J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Locatelli, Eduardo; Ghods, Ali J.] Holy Cross Hosp, Phil Smith Neurosci Inst, Ft Lauderdale, FL USA.
RP Eichberg, DG (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM daniel.eichberg@jhsmiami.org
OI Eichberg, Daniel/0000-0002-7654-2944
CR AICHNER F, 1982, CANCER-AM CANCER SOC, V50, P1751, DOI 10.1002/1097-0142(19821101)50:9<1751::AID-CNCR2820500918>3.0.CO;2-Q
   Angelino G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2556-y
   Arias M, 2011, ACTA NEUROL BELG, V111, P228
   Aslan S, 2018, NEURORADIOL J, V31, DOI 10.1177/1971400917708581
   Bajer-Czajkowska A, 2007, NEUROL NEUROCHIR POL, V41, P82
   BARKOVICH AJ, 1994, AM J NEURORADIOL, V15, P859
   Bobba R, 2004, SOUTH MED J, V97, P1118, DOI 10.1097/01.SMJ.0000136229.27817.45
   Bocquillon P, 2010, REV NEUROL-FRANCE, V166, P927, DOI 10.1016/j.neurol.2010.03.011
   Celli P, 2001, J Neurosurg Sci, V45, P235
   Demir MK, 2008, RADIOLOGY, V247, P905, DOI 10.1148/radiol.2473050507
   Di Rocco F, 2004, CHILD NERV SYST, V20, P23, DOI 10.1007/s00381-003-0835-9
   Fujimori K, 2018, NEUROSURG REV, V41, P333, DOI 10.1007/s10143-017-0914-0
   GAETANI P, 1993, ACTA NEUROCHIR, V121, P206, DOI 10.1007/BF01809277
   Jacob M, 2016, ACTA NEUROL BELG, V116, P647, DOI 10.1007/s13760-015-0586-x
   Jaiswal S, 2011, NEUROL INDIA, V59, P413, DOI 10.4103/0028-3886.82758
   Kim DH, 2015, J KOREAN NEUROSURG S, V58, P554, DOI 10.3340/jkns.2015.58.6.554
   Kolin DL, 2017, CYTOPATHOLOGY, V28, P235, DOI 10.1111/cyt.12366
   Lee HJ, 2013, KOREAN J RADIOL, V14, P343, DOI 10.3348/kjr.2013.14.2.343
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Makin GWJ, 1999, CANCER, V86, P878
   Michael BD, 2010, BMJ CASE REP, V2010
   Monso G, 1996, Rev Neurol, V24, P87
   Ng RYT, 2013, HONG KONG MED J, V19, P80
   NICOLAIDES P, 1995, PEDIATR NEUROL, V12, P172, DOI 10.1016/0887-8994(94)00155-U
   Padilla-Vazquez F, 2017, CIR CIR, V85, P273, DOI 10.1016/j.circir.2016.11.006
   Pirini MG, 2003, AM J NEURORADIOL, V24, P115
   Ren YM, 2015, NEUROL INDIA, V63, P260, DOI 10.4103/0028-3886.156300
   Saadeh YS, 2018, J CLIN NEUROSCI, V50, P139, DOI 10.1016/j.jocn.2018.01.052
   Schneider Frank, 2002, Spine (Phila Pa 1976), V27, pE545, DOI 10.1097/00007632-200212150-00026
   Szathmari A, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.06.039
   TOLNAI G, 1966, ARCH NEUROL-CHICAGO, V15, P404, DOI 10.1001/archneur.1966.00470160070010
   Tosaka M, 2001, J NEUROSURG, V94, P528, DOI 10.3171/jns.2001.94.3.0528
   Trinh VT, 2016, J CLIN NEUROSCI, V30, P124, DOI 10.1016/j.jocn.2015.12.027
   Wang FL, 2011, NEUROPATHOLOGY, V31, P414, DOI 10.1111/j.1440-1789.2010.01160.x
   Zadro I, 2010, NEUROLOGIST, V16, P117, DOI 10.1097/NRL.0b013e3181c29ef8
NR 35
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 648
EP 655
DI 10.1016/j.wneu.2018.11.163
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100318
PM 30496931
DA 2020-05-12
ER

PT J
AU Zhou, HY
   Ye, XL
   Hong, J
   Liu, QQ
   Ma, JF
   Xu, JW
AF Zhou, Hongyu
   Ye, Xiaolai
   Hong, Jing
   Liu, Qiangqiang
   Ma, Junfeng
   Xu, Jiwen
TI Multiphasic Side-Switching Seizures Are Easily Misdiagnosed as
   Unilateral Seizures During a Single EEG Monitoring Session: A Specific
   Subtype of Bitemporal Epilepsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bitemporal epilepsy; Epilepsy; Multiphasic; Side-switching; Subtype
ID TEMPORAL-LOBE EPILEPSY; VIDEO-EEG; SURGERY; DEPTH; LATERALIZATION;
   LOBECTOMY; FOCI
AB BACKGROUND: Bitemporal epilepsy (BTLE) is a specific anatomoelectroclinical phenotype in the spectrum of temporal lobe epilepsy. The diagnosis of BTLE and the evaluation of the degree of seizure lateralization in BTLE patients are greatly influenced by the duration of EEG recording and the number of recorded habitual seizures.
   CASE DESCRIPTION: A 25-year-old woman had a 5-year history of seizures. Her habitual seizures were described as sudden behavioral arrest, staring, unresponsiveness, and oral automatisms, with auras of fear and palpitation. Intermittent scalp electroencephalography (EEG) and intracranial EEG monitoring over 3 years showed multiphasic side-switching seizures. The seizures were limited to 1 temporal lobe within 1 phase and switched sides between phases. Despite antiepileptic drugs and vagus nerve stimulation, her seizures remained uncontrolled. The patient finally underwent unilateral anteromedial temporal lobectomy, mainly based on >60% of seizures recorded originating from the left side. The patient has been seizure free for more than 1 year at last follow-up.
   CONCLUSIONS: This patient presented 1 specific subtype of BTLE that is prone to be misdiagnosed as unilateral temporal lobe epilepsy if the patient is recorded for a relatively short term, e.g., over a common EEG monitoring duration of 1 to 2 weeks.
C1 [Zhou, Hongyu; Ye, Xiaolai; Hong, Jing; Liu, Qiangqiang; Ma, Junfeng; Xu, Jiwen] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Funct Neurosurg, Shanghai, Peoples R China.
RP Zhou, HY (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Funct Neurosurg, Shanghai, Peoples R China.
EM iamrains@hotmail.com
CR Aghakhani Y, 2014, EPILEPSIA, V55, P1892, DOI 10.1111/epi.12856
   Barba C, 2016, BRAIN, V139, P444, DOI 10.1093/brain/awv372
   BLUM D, 1994, ELECTROEN CLIN NEURO, V91, P329, DOI 10.1016/0013-4694(94)90120-1
   Boling W, 2009, J NEUROL NEUROSUR PS, V80, P533, DOI 10.1136/jnnp.2008.155291
   Di Vito L, 2016, EPILEPSY RES, V128, P73, DOI 10.1016/j.eplepsyres.2016.10.015
   Didato G, 2015, SEIZURE-EUR J EPILEP, V31, P112, DOI 10.1016/j.seizure.2015.07.013
   Gollwitzer S, 2017, EPILEPSY BEHAV, V68, P17, DOI 10.1016/j.yebeh.2016.12.027
   Gupta K, 2017, WORLD NEUROSURG, V101, P161, DOI 10.1016/j.wneu.2017.01.109
   Haut SR, 2006, EPILEPSY BEHAV, V8, P50, DOI 10.1016/j.yebeh.2005.08.018
   Haut SR, 1997, EPILEPSIA, V38, P937, DOI 10.1111/j.1528-1157.1997.tb01260.x
   HIRSCH LJ, 1991, ANN NEUROL, V30, P347, DOI 10.1002/ana.410300306
   Holmes MD, 2003, EPILEPSIA, V44, P1075, DOI 10.1046/j.1528-1157.2003.58302.x
   King-Stephens D, 2015, EPILEPSIA, V56, P959, DOI 10.1111/epi.13010
   Liu CY, 2016, EPILEPSY RES, V127, P233, DOI 10.1016/j.eplepsyres.2016.09.006
   Massot-Tarrus A, 2016, EPILEPSY RES, V127, P324, DOI 10.1016/j.eplepsyres.2016.08.008
   Michel V, 2015, NEUROPHYSIOL CLIN, V45, P47, DOI 10.1016/j.neucli.2014.11.004
   Page T, 2018, EPILEPSY BEHAV, V84, P166, DOI 10.1016/j.yebeh.2018.03.016
   Sainju RK, 2012, ARQ NEURO-PSIQUIAT, V70, P694, DOI 10.1590/S0004-282X2012000900009
   Sirven JI, 1997, ANN NEUROL, V42, P873, DOI 10.1002/ana.410420608
   SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502
   Spencer D, 2011, EPILEPSY RES, V93, P221, DOI 10.1016/j.eplepsyres.2010.12.010
   Valentin A, 2017, CLIN NEUROPHYSIOL, V128, P418, DOI 10.1016/j.clinph.2016.12.018
   Velis DN, 2008, TXB EPILEPSY SURG, P580
   Waseem H, 2015, CLIN NEUROL NEUROSUR, V139, P199, DOI 10.1016/j.clineuro.2015.10.016
   Wei PH, 2017, J CLIN NEUROSCI, V39, P103, DOI 10.1016/j.jocn.2017.01.012
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 656
EP 660
DI 10.1016/j.wneu.2018.11.138
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100319
PM 30481627
DA 2020-05-12
ER

PT J
AU Armocida, D
   Pesce, A
   Frati, A
   Miscusi, M
   Paglia, F
   Raco, A
AF Armocida, Daniele
   Pesce, Alessandro
   Frati, Alessandro
   Miscusi, Massimo
   Paglia, Francesco
   Raco, Antonino
TI Pneumoventricle of Unknown Origin: A Personal Experience and Literature
   Review of a Clinical Enigma
SO WORLD NEUROSURGERY
LA English
DT Review
DE Head trauma; HRCT; MRI; Pneumocephalus; Pneumoventricle
ID TENSION PNEUMOCEPHALUS
AB BACKGROUND: Pneumocephalus is an uncommon and life-threatening neurologic condition. Air within the ventricular system of the brain is also known as pneumoventricle (PV). It requires emergency treatments to prevent catastrophic neurologic outcomes. Head injury is the most common cause of PV, but there are other well-recognized etiologies in case there is no clear radiological evidence of skull discontinuity.
   CASE DESCRIPTION: Although this clinical entity has been well described in the literature, our report presents the unique feature of describing a purely ventricular pneumocephalus without evidence of skull base or cranial vault fracture. Therefore, this case presentation explores mysterious causes of fistulous connections with the atmosphere that may lead to air trapped in and around the cranial vault.
   CONCLUSIONS: The aim of the present paper is to report a case of post-traumatic PV without radiological signs of skull base or convexity fracture in a 72-year-old man, underlining the diagnostic and clinical features, and review the relevant literature.
C1 [Armocida, Daniele; Pesce, Alessandro; Paglia, Francesco; Raco, Antonino] Sapienza Univ Rome, AUO St Andrea, Neurosurg Div, NESMOS Dept, Rome, Italy.
   [Armocida, Daniele; Pesce, Alessandro; Paglia, Francesco] Sapienza Univ Rome, AUO Policlin Umberto I, Neurosurg Div, Human Neurosci Dept, Rome, Italy.
   [Frati, Alessandro] Sapienza Univ Rome, IRCCS Neuromed, Neurosurg Div, Rome, Italy.
   [Miscusi, Massimo] Sapienza Univ Rome, AUO St Andrea, Neurosurg Div, Medicosurg Sci & Biotechnol Dept, Rome, Italy.
RP Armocida, D (reprint author), Sapienza Univ Rome, AUO St Andrea, Neurosurg Div, NESMOS Dept, Rome, Italy.; Armocida, D (reprint author), Sapienza Univ Rome, AUO Policlin Umberto I, Neurosurg Div, Human Neurosci Dept, Rome, Italy.
EM danielearmocida@yahoo.it
RI Frati, Alessandro/AAC-2204-2020; Pesce, Alessandro/AAC-2223-2020
CR Al-Aieb A, 2017, INT J SURG CASE REP, V31, P145, DOI 10.1016/j.ijscr.2017.01.038
   Ansari AS, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0154-9
   Basheer A, 2017, BMJ CASE REP, V2017
   Cho H. L., 2004, J KOREAN NEUROSURG S, V35, P536
   Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001
   Komolafe E. O., 2010, AFR J NEURSCI, V2, P9
   Kon T, 2003, NEUROL MED-CHIR, V43, P242, DOI 10.2176/nmc.43.242
   Lee MR, 2009, AM J EMERG MED, V27, DOI 10.1016/j.ajem.2008.09.034
   Lee SH, 2009, J KOREAN NEUROSURG S, V45, P318, DOI 10.3340/jkns.2009.45.5.318
   Maier W, 1996, ANN OTO RHINOL LARYN, V105
   Nair SR, 2005, RESP MED EXTRA, V1, P75
   Ruiz-Juretschke F, 2007, NEUROCIRUGIA, V18, P134
   Satapathy GC, 2000, BRIT J ANAESTH, V84, P115
   Webber-Jones Joan E, 2005, J Neurosci Nurs, V37, P272
NR 14
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 661
EP 664
DI 10.1016/j.wneu.2018.11.050
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100320
PM 30448588
DA 2020-05-12
ER

PT J
AU Liu, J
   Lu, WP
   Han, H
   Zheng, LJ
   Feng, L
   Chen, WM
AF Liu, Jun
   Lu, Wenpeng
   Han, Hao
   Zheng, Lijian
   Feng, Lei
   Chen, Weimei
TI Correlation Studies and Literature Review of Medullary Artery Occlusion
   After Intracranial Vertebral Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracranial vertebral artery; Lateral medullary syndrome; Perforating
   artery occlusion; Stent angioplasty
ID ANGIOPLASTY; STENOSIS; DISEASE; ATHEROSCLEROSIS; EXPERIENCE; THERAPY
AB BACKGROUND: Stenosis of the target intracranial vertebral artery is one of the major causes of posterior circulation ischemic stroke. The objective of this paper is to explore methods for reducing the occurrence of medullary artery occlusion after intracranial vertebral artery stenting.
   CASE DESCRIPTION: The current research presents a retrospective analysis of 48 patients who received Gateway-Wingspan stent angioplasty to treat severe stenosis of the intracranial vertebral artery, evaluates the results of stenosis remission and perfusion improvement after stent angioplasty, and explores the causes of postoperative medullary artery occlusion. A total of 49 Wingspan stents were implanted in the 48 patients, with a surgical success rate of 100%. After stent implantation, the patients' rates of intracranial vertebral artery stenosis dropped from 75.9% +/- 6.3% to 28.4% +/- 5.1%. Transcranial Doppler or cranial computed tomography angiography 3 months after surgery showed that none of the patients suffered from in-stent restenosis. Within 24 hours after surgery, medullary perforating artery occlusion occurred in 2 patients, probably because atherosclerotic plaque in the stenotic area became less stable and displaced under the mechanical action of postoperative saccule and stent. As a result, the medullary artery was blocked. After drug and rehabilitation therapies, the patients' symptoms were alleviated.
   CONCLUSIONS: Perforating artery occlusion after intracranial vertebral artery stenting can be prevented by strict assessment and preparation before surgery, correct choices of saccule and stent during operation, and other measures. However, large sample data are needed for verification.
C1 [Liu, Jun; Lu, Wenpeng; Han, Hao; Zheng, Lijian; Feng, Lei] First Peoples Hosp Jining, Dept Neurosurg, Jining, Shandong, Peoples R China.
   [Chen, Weimei] First Peoples Hosp Jining, Dept Neurol, Jining, Shandong, Peoples R China.
RP Chen, WM (reprint author), First Peoples Hosp Jining, Dept Neurol, Jining, Shandong, Peoples R China.
EM weimeichen15@sina.com
OI Feng, Lei/0000-0002-5946-1130
CR BAKER AB, 1961, NEUROLOGY, V11, P852, DOI 10.1212/WNL.11.10.852
   Birch PC, 1999, EUR J VASC ENDOVASC, V17, P185, DOI 10.1053/ejvs.1998.0672
   BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083
   Bose A, 2007, STROKE, V38, P1531, DOI 10.1161/STROKEAHA.106.477711
   Caputo RP, 1996, AM J CARDIOL, V77, P1226, DOI 10.1016/S0002-9149(96)00168-3
   Chaturvedi Seemant, 2014, Continuum (Minneap Minn), V20, P323, DOI 10.1212/01.CON.0000446104.90043.a5
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Chimowitz MI, 1998, STROKE, V29, P1389, DOI 10.1161/01.str.29.7.1389
   Compter A, 2015, J NEUROL, V262, P410, DOI 10.1007/s00415-014-7583-5
   Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3
   DUVERNOY HM, 1999, HUMAN BRAIN STEM VES
   Fiorella D, 2007, STROKE, V38, P881, DOI 10.1161/01.STR.0000257963.65728.e8
   Grewe PH, 2000, J AM COLL CARDIOL, V35, P157, DOI 10.1016/S0735-1097(99)00486-6
   Hatano T, 2014, ACTA NEUROCHIR SUPPL, V119, P83, DOI 10.1007/978-3-319-02411-0_15
   Hu S, 2010, CHINESE J CEREBROVAS, V7, p388 
   Lanzino G, 1999, NEUROSURGERY, V45, P404, DOI 10.1097/00006123-199908000-00047
   Lawson MF, 2010, NEUROSURGERY, V67, P166, DOI 10.1227/01.NEU.0000380948.85926.3C
   Li TX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139377
   Mori T, 1999, AM J NEURORADIOL, V20, P787
   Rasmussen PA, 2000, J NEUROSURG, V92, P771, DOI 10.3171/jns.2000.92.5.0771
   Samaniego EA, 2013, J NEUROINTERV SURG, V5, P302, DOI 10.1136/neurintsurg-2012-010321
   Savitz SI, 2005, NEW ENGL J MED, V352, P2618, DOI 10.1056/NEJMra041544
   Schoenhagen P, 2006, CIRCULATION, V113, P2826, DOI 10.1161/CIRCULATIONAHA.105.585703
   Silber T, 2014, EUR J RADIOL, V83, P2190, DOI 10.1016/j.ejrad.2014.08.018
   Starke RM, 2015, NEUROSURGERY, V77, pN11, DOI 10.1227/01.neu.0000473806.53232.3e
   Wallenburg A, 1901, PSYCHIAT NEUROLOGICA, V34, P923
   Wang ZL, 2015, EUR J RADIOL, V84, P1801, DOI 10.1016/j.ejrad.2015.05.033
   Zhang DP, 2016, NEUROSCIENCES, V21, P361, DOI 10.17712/nsj.2016.4.20160282
   Zhang E, 1986, ACTA ANATOMICA SINIC, V17, P237
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 665
EP 670
DI 10.1016/j.wneu.2018.11.068
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100321
PM 30465957
DA 2020-05-12
ER

PT J
AU Bruns, AK
   Jeibmann, A
   Brokinkel, B
   Holling, M
   Stummer, W
   Ewelt, C
AF Bruns, Ann-Katrin
   Jeibmann, Astrid
   Brokinkel, Benjamin
   Holling, Markus
   Stummer, Walter
   Ewelt, Christian
TI Heterotopic Neuroglial Tissue in Sphenoid Ridge
SO WORLD NEUROSURGERY
LA English
DT Article
DE Heterotopia; Heterotopic brain tissue; Heterotopic neuroglial tissue;
   Skull base; Sphenoid ridge meningioma
ID ECTOPIC BRAIN-TISSUE; MIDDLE-EAR; OBSTRUCTION; NECK; FACE
AB BACKGROUND: Extracerebral neuroglial heterotopias are rare manifestations of cerebral tissue outside the brain whose most common form is the so-called nasal glioma. In this case report we illustrate the first case of heterotopic neuroglial tissue within the bone of the skull.
   CASE DESCRIPTION: Our patient underwent surgery for a sphenoid ridge meningioma. Aside from the expected meningioma, histopathologic examination showed a small amount of intraosseous heterotopic neuroglial tissue.
   CONCLUSIONS: The pathogenesis of cerebral heterotopias is diverse. Most of the midline lesions are probably residuals of former meningoencephaloceles. The pathogenesis of extracranial nonmidline lesions is more questionable. Their cause might be a former trauma, inflammatory disease, or surgery. Another option is that they represent primary neuroglial heterotopias, as it is supposed for manifestations of the lung.
   The coexistence of a heterotopia and a meningioma in this case is probably a coincidence. It is also debatable whether the broad tumor extension within the bone and/or the heterotopia might go back to alterations of the bone structure.
C1 [Bruns, Ann-Katrin; Brokinkel, Benjamin; Holling, Markus; Stummer, Walter; Ewelt, Christian] Univ Hosp Muenster, Dept Neurosurg, Munster, Germany.
   [Jeibmann, Astrid] Univ Hosp Muenster, Inst Neuropathol, Munster, Germany.
RP Bruns, AK (reprint author), Univ Hosp Muenster, Dept Neurosurg, Munster, Germany.
EM ann-katrin.bruns@ukmuenster.de
RI Stummer, Walter/AAF-9043-2019; Stummer, Walter/AAA-3319-2020
OI Brokinkel, Benjamin/0000-0003-3462-3479
CR Abdelsayed RA, 1999, ORAL SURG ORAL MED O, V87, P215, DOI 10.1016/S1079-2104(99)70275-1
   BOSSEN EH, 1987, AM J SURG PATHOL, V11, P571, DOI 10.1097/00000478-198707000-00010
   COHEN AH, 1970, J PEDIATR-US, V76, P119, DOI 10.1016/S0022-3476(70)80141-X
   FULLER C, 1989, THORAX, V44, P1045, DOI 10.1136/thx.44.12.1045
   Ghose S, 2005, CLIN EXP OPHTHALMOL, V33, P67, DOI 10.1111/j.1442-9071.2004.00945.x
   GOLD AH, 1980, PLAST RECONSTR SURG, V66, P434, DOI 10.1097/00006534-198066030-00022
   HENDRICKSON M, 1990, J PEDIATR SURG, V25, P766, DOI 10.1016/S0022-3468(05)80015-6
   Husein OF, 2008, EUR J PEDIATR, V167, P1351, DOI 10.1007/s00431-008-0810-2
   Kallman JE, 1997, AM J NEURORADIOL, V18, P176
   KLEIN MV, 1989, J COMPUT ASSIST TOMO, V13, P1058, DOI 10.1097/00004728-198911000-00020
   Kurban Y, 2013, J MATERN-FETAL NEO M, V26, P619, DOI 10.3109/14767058.2012.743525
   LEE CM, 1955, J NEUROSURG, V12, P190, DOI 10.3171/jns.1955.12.2.0190
   Longo D, 2009, INT J PEDIATR OTORHI, V73, P1308, DOI 10.1016/j.ijporl.2009.05.014
   MCGREGOR DH, 1994, AM J MED SCI, V308, P180, DOI 10.1097/00000441-199409000-00012
   Ortube MC, 2010, J CRANIOFAC SURG, V21, P1551, DOI 10.1097/SCS.0b013e3181ebcf40
   Scheiner AJ, 1999, EYE, V13, P251, DOI 10.1038/eye.1999.61
   Uemura T, 1999, CLEFT PALATE-CRAN J, V36, P248, DOI 10.1597/1545-1569(1999)036<0248:HNBTAW>2.3.CO;2
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 671
EP 673
DI 10.1016/j.wneu.2018.10.101
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100322
PM 31108067
DA 2020-05-12
ER

PT J
AU Kim, J
   Rajadurai, J
   Choy, WJ
   Cassar, L
   Phan, K
   Harris, L
   Fiechter, M
   Mobbs, RJ
AF Kim, Jiwon
   Rajadurai, Jeremy
   Choy, Wen Jie
   Cassar, Lachlan
   Phan, Kevin
   Harris, Leigh
   Fiechter, Meinrad
   Mobbs, Ralph J.
TI Three-Dimensional Patient-Specific Guides for Intraoperative Navigation
   for Cortical Screw Trajectory Pedicle Fixation
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D-printed guide; Cortical bone trajectory (CBT); Patient-specific drill
   guide (PSDG); Pedicle screw; Spinal fusion and fixation; Spine;
   Three-dimensional printing
ID PLACEMENT; ACCURACY; INSERTION; TEMPLATE; FUSION
AB BACKGROUND: Cortical bone trajectory (CBT) technique for pedicle fixation has been proposed and adopted in recent years. This technique involves a mediolateral direction and a caudocephalad path to maximize screw purchase in cortical bone. Various techniques have been proposed to increase the accuracy of screw placement. A novel technique for CBT screw placement using a three-dimensional printed patient-specific drill guide (PSDG) is presented.
   METHODS: CBT screw fixation combined with posterior lumbar interbody fusion was performed for reduction of an L4-5 spondylolisthesis in a 71-year-old woman. PSDGs (MySpine MC Guides) were designed and printed based on the patient's preoperative computed tomography scan. PSDGs were used intraoperatively to facilitate screw trajectory and placement.
   RESULTS: Postoperative imaging performed at 6 weeks and 3 months revealed accurate screw trajectory with excellent reduction of spondylolisthesis. The patient improved clinically with minimal mechanical pain and claudication at 3-month follow-up.
   CONCLUSIONS: PSDG for CBT screw fixation offers significant benefits, including preoperative planning; improved screw placement accuracy while minimizing cortical breach; reduction of operative time; and lower cost compared with intraoperative computed tomography-based neuronavigation, thus expanding the availability of this technique. Drawbacks include time required for PSDG planning and learning curve for surgeons.
C1 [Kim, Jiwon; Rajadurai, Jeremy; Choy, Wen Jie; Cassar, Lachlan; Phan, Kevin; Mobbs, Ralph J.] Univ New South Wales, Fac Med, Sydney, NSW, Australia.
   [Kim, Jiwon; Choy, Wen Jie; Cassar, Lachlan; Phan, Kevin; Mobbs, Ralph J.] NeuroSpine Surg Res Grp, Randwick, NSW, Australia.
   [Rajadurai, Jeremy; Phan, Kevin; Mobbs, Ralph J.] Prince Wales Private Hosp, Randwick, NSW, Australia.
   [Harris, Leigh; Fiechter, Meinrad] Medacta Int, Castel San Peitro, Switzerland.
RP Mobbs, RJ (reprint author), Univ New South Wales, Fac Med, Sydney, NSW, Australia.; Mobbs, RJ (reprint author), NeuroSpine Surg Res Grp, Randwick, NSW, Australia.; Mobbs, RJ (reprint author), Prince Wales Private Hosp, Randwick, NSW, Australia.
EM r.mobbs@unsw.edu.au
OI Choy, Wen Jie/0000-0001-8929-8170; KIM, JIWON/0000-0002-1413-809X
CR Ammirati M, 2013, NEUROSURG REV, V36, P157, DOI 10.1007/s10143-012-0421-2
   BOUCHER HH, 1959, J BONE JOINT SURG BR, V41, P248
   Choy WJ, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.05.133
   Delgado-Fernandez J, 2017, ASIAN SPINE J, V11, P817, DOI 10.4184/asj.2017.11.5.817
   Deng T, 2016, COMPUT ASSIST SURG, V21, P143, DOI 10.1080/24699322.2016.1236146
   Iwatsuki K, 2014, ORTHOP SURG, V6, P244, DOI 10.1111/os.12122
   Kaiser MG, 2014, J NEUROSURG-SPINE, V21, P2, DOI 10.3171/2014.4.SPINE14257
   Kaneyama S, 2015, SPINE, V40, pE341, DOI 10.1097/BRS.0000000000000772
   Karsy M, 2017, CUREUS, V9, DOI 10.7759/cureus.1419
   Liu K, 2017, EUR SPINE J, V26, P1684, DOI 10.1007/s00586-016-4926-1
   Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111979
   Lu T, 2017, MED SCI MONITOR, V23, P3105, DOI 10.12659/MSM.901993
   Manbachi A, 2014, SPINE J, V14, P165, DOI 10.1016/j.spinee.2013.03.029
   Marcus HJ, 2014, EUR SPINE J, V23, P291, DOI 10.1007/s00586-013-2879-1
   Mason A, 2014, J NEUROSURG-SPINE, V20, P196, DOI 10.3171/2013.11.SPINE13413
   Matsukawa K, 2016, ACTA NEUROCHIR, V158, P465, DOI 10.1007/s00701-016-2705-8
   Mitchell SM, 2016, CONT SPINE SURG, V17, P1
   Mobbs RJ, 2017, J NEUROSURG-SPINE, V26, P513, DOI 10.3171/2016.9.SPINE16371
   Mobbs RJ, 2013, ORTHOP SURG, V5, P135, DOI 10.1111/os.12042
   Mobbs RJ, 2013, ORTHOP SURG, V5, P56, DOI 10.1111/os.12027
   Mobbs RJST, 2004, J BONE JOINT SURG BR, V86, pS456
   Owen BD, 2007, COMPUT AIDED SURG, V12, P303, DOI 10.1080/10929080701662826
   Phan Kevin, 2017, J Spine Surg, V3, P679, DOI 10.21037/jss.2017.11.03
   Phan Kevin, 2016, J Spine Surg, V2, P314, DOI 10.21037/jss.2016.12.06
   Phan K, 2015, ORTHOP SURG, V7, P213, DOI 10.1111/os.12185
   Popescu D, 2016, P I MECH ENG H, V230, P495, DOI 10.1177/0954411916636919
   Pu XW, 2018, WORLD NEUROSURG, V114, pE1, DOI 10.1016/j.wneu.2017.11.042
   Puvanesarajah V, 2014, WORLD J ORTHOP, V5, P112, DOI 10.5312/wjo.v5.i2.112
   Rodriguez A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13521
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Shao ZX, 2017, PEERJ, V5, DOI 10.7717/peerj.3564
   Shea TM, 2014, BIOMED RES INT, DOI 10.1155/2014/748393
   Shin MH, 2015, J SPINAL DISORD TECH, V28, pE347, DOI 10.1097/BSD.0b013e31829047a7
   Song TF, 2014, CHINESE MED J-PEKING, V127, P3808, DOI 10.3760/cma.j.issn.0366-6999.20141887
   Wilcox Ben, 2017, J Spine Surg, V3, P433, DOI 10.21037/jss.2017.09.01
   Wray S, 2015, J NEUROSURG-SPINE, V22, P503, DOI 10.3171/2014.10.SPINE14205
NR 36
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 674
EP 679
DI 10.1016/j.wneu.2018.11.159
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100323
PM 30481632
DA 2020-05-12
ER

PT J
AU Arocho-Quinones, EV
   Koop, J
   Lew, SM
AF Arocho-Quinones, Elsa V.
   Koop, Jennifer
   Lew, Sean M.
TI Improvement of Hypothalamic Hamartoma-Related Psychiatric Disorder After
   Stereotactic Laser Ablation: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Gelastic seizures; Hypothalamic hamartoma; Psychiatric disorder;
   Psychosis; Stereotactic laser ablation
ID REFRACTORY EPILEPSY; CHILDREN; AGGRESSION
AB BACKGROUND: Hypothalamic hamartomas (HHs) are nonneoplastic congenital malformations associated with refractory epilepsy and behavioral disorders. Improvement in behavioral functioning following resection of HHs has been reported. Stereotactic laser ablation (SLA), a minimally invasive technique, has been used for the treatment of HH-related epilepsy. We report the case of child with an HH, gelastic seizures, and severe psychiatric dysfunction who was successfully treated via SLA therapy.
   CASE DESCRIPTION: The patient was an 11-year-old female with a history of central hypothyroidism, precocious puberty, and localization-related epilepsy thought to be secondary to an HH. She had a significant psychiatric history including attention deficit hyperactivity disorder, depressed mood, impulsivity, threatening behavior, and suicidal ideation requiring management with dexmethylphenidate, bupropion, and aripiprazole. Seizure onset occurred at age 7, and her semiology included nighttime hypermotor seizures and uncontrollable laughing spells thought to be gelastic seizures. Her hypermotor seizures were successfully managed with oxcabazepine monotherapy, but she continued to have several weekly laughing spells and self-harming behavior. Her HH was successfully treated via SLA. Postoperatively, she remained neurologically intact and was discharged the next day. At her 6-month follow-up, she had a markedly improved affect and general mood. At 3 years post-procedure, she remains seizure free and has been weaned off her antiepileptic and antipsychotic medications.
   CONCLUSIONS: Severe behavioral dysfunction in the setting of an HH may constitute an indication for surgical intervention. The outcome of this case suggests there may be a role for SLA in the management of HH-related psychiatric dysfunction, even in patients with good seizure control.
C1 [Arocho-Quinones, Elsa V.; Koop, Jennifer; Lew, Sean M.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Lew, Sean M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
   [Koop, Jennifer] Med Coll Wisconsin, Dept Neurol Neuropsychol, Milwaukee, WI 53226 USA.
RP Lew, SM (reprint author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.; Lew, SM (reprint author), Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
EM slew@mcw.edu
OI Arocho-Quinones, Elsa/0000-0002-6000-5503
CR Achenbach T. M., 2001, MANUAL ASEBA SCH AGE
   Al-Hail HJ, 2010, NEUROSCIENCES, V15, P43
   Anderson JFI, 2010, EPILEPSY BEHAV, V18, P81, DOI 10.1016/j.yebeh.2010.02.018
   Curry DJ, 2018, EPILEPSY RES, V142, P131, DOI 10.1016/j.eplepsyres.2018.03.013
   Davies S, 2003, DEV MED CHILD NEUROL, V45, P292, DOI 10.1017/S0012162203000550
   Delalande O, 2003, NEUROL MED-CHIR, V43, P61, DOI 10.2176/nmc.43.61
   Errichiello L, 2014, NEUROL SCI, V35, P469, DOI 10.1007/s10072-013-1559-6
   Fohlen M, 2003, EPILEPTIC DISORD, V5, P267
   Kanner AM, 2004, EPILEPSIA, V45, P22, DOI 10.1111/j.0013-9580.2004.452004.x
   Kerrigan John F, 2005, Semin Pediatr Neurol, V12, P119, DOI 10.1016/j.spen.2005.04.002
   Ng YT, 2011, EPILEPSY BEHAV, V20, P75, DOI 10.1016/j.yebeh.2010.10.027
   Nguyen D, 2003, EPILEPSY BEHAV, V4, P246, DOI 10.1016/S1525-5050(03)00086-6
   Prigatano George P, 2007, Semin Pediatr Neurol, V14, P65, DOI 10.1016/j.spen.2007.03.004
   Rolston JD, 2016, NEUROSURG CLIN N AM, V27, P59, DOI 10.1016/j.nec.2015.08.007
   Southwell DG, 2018, J NEUROSURG-PEDIATR, V21, P460, DOI 10.3171/2017.10.PEDS17292
   Tandon V, 2018, WORLD NEUROSURG, V112, P267, DOI 10.1016/j.wneu.2018.01.193
   Veendrick-Meekes MJBM, 2007, EPILEPSY BEHAV, V11, P218, DOI 10.1016/j.yebeh.2007.03.005
   Weissenberger AA, 2001, J AM ACAD CHILD PSY, V40, P696, DOI 10.1097/00004583-200106000-00015
NR 18
TC 0
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 680
EP 683
DI 10.1016/j.wneu.2018.11.166
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100324
PM 30481631
DA 2020-05-12
ER

PT J
AU Inayama, Y
   Kondoh, E
   Chigusa, Y
   Io, S
   Funaki, T
   Matsumura, N
   Miyamoto, S
   Mandai, M
AF Inayama, Yoshihide
   Kondoh, Eiji
   Chigusa, Yoshitsugu
   Io, Shingo
   Funaki, Takeshi
   Matsumura, Noriomi
   Miyamoto, Susumu
   Mandai, Masaki
TI Moyamoya Disease in Pregnancy: A 20-Year Single-Center Experience and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral infarction; Intracranial hemorrhage; Moyamoya disease;
   Pregnancy
ID CESAREAN-SECTION; INTRAVENTRICULAR HEMORRHAGE; ANESTHETIC MANAGEMENT;
   INTRACEREBRAL HEMORRHAGE; VAGINAL DELIVERY; ISCHEMIC-STROKE;
   INTRACRANIAL HEMORRHAGE; CEREBRAL INFARCTION; EPIDURAL-ANESTHESIA;
   PATIENT
AB BACKGROUND: Pregnancy is a potential risk factor for stroke in women with Moyamoya disease. However, the rarity of the disease has limited clinical expertise to ensure a healthy pregnancy. The aim of the present study was to explore the possible risk factors for hemorrhagic and ischemic stroke in pregnant women with Moyamoya disease.
   METHODS: A retrospective review of cases in our hospital during a 20-year period and a review of the reported data were conducted to investigate pregnancy-related cerebrovascular events in women with Moyamoya disease.
   RESULTS: Thirty pregnancies in 20 women with Moyamoya disease were identified in the case review of our hospital. All were previously diagnosed cases, and no stroke had occurred during the study period. In the reported data review, pregnancy-related stroke in women with Moyamoya disease was identified in 54 (44 intracranial hemorrhage and 10 cerebral infarction). Intracranial hemorrhage occurred most commonly during the antepartum period (n = 39; 88.6%), with most events occurring at >= 24 weeks. Of the intracranial hemorrhage cases, 7 (15.9%) were complicated by hypertensive disorders of pregnancy, and 8 patients (18.2%) died of stroke. The onset of cerebral infarction was either in the antepartum (n = 4; 40.0%) or postpartum (n = 6; 60.0%) period. All postpartum cases occurred within 3-7 days after delivery.
   CONCLUSION: Pregnancy-related stroke in patients with Moyamoya disease might be susceptible to gestational age. Intracranial hemorrhage is prone to occur during the antepartum period, especially at >= 24 weeks, and cerebral infarction tends to occur postpartum.
C1 [Inayama, Yoshihide; Kondoh, Eiji; Chigusa, Yoshitsugu; Io, Shingo; Matsumura, Noriomi; Mandai, Masaki] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Japan.
   [Funaki, Takeshi; Miyamoto, Susumu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan.
RP Kondoh, E (reprint author), Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Japan.
EM kondo@kuhp.kyoto-u.ac.jp
OI Io, Shingo/0000-0001-8769-134X; Kondoh, Eiji/0000-0002-8379-3143
CR Abe T, 1999, Masui, V48, P773
   Abouleish E, 1998, ACTA ANAESTH SCAND, V42, P1120, DOI 10.1111/j.1399-6576.1998.tb05388.x
   Akamatsu Y, 2014, NEUROL MED-CHIR, V54, P824, DOI 10.2176/nmc.cr.2014-0071
   Alonso-Martinez I, 1999, BRAIN DEV-JPN, V21, P135, DOI 10.1016/S0387-7604(98)00093-X
   AMINHANJANI S, 1993, AM J OBSTET GYNECOL, V169, P395, DOI 10.1016/0002-9378(93)90095-Z
   [Anonymous], 2018, Obstet Gynecol, V132, pe44, DOI 10.1097/AOG.0000000000002708
   Asano Nobumasa, 2009, Masui, V58, P649
   BACON RC, 1994, ANAESTHESIA, V49, P1058, DOI 10.1111/j.1365-2044.1994.tb04356.x
   BINGHAM WF, 1980, WISC MED J, V79, P21
   Conn JJ, 2008, AUST NZ J OBSTET GYN, V48, P609, DOI 10.1111/j.1479-828X.2008.00917.x
   Cunningham FG, 2014, WILLIAMS OBSTET, P728
   Cunningham FG, 2014, WILLIAMS OBSTET, P46
   Cunningham FG, 2014, WILLIAMS OBSTET, P668
   DelaFuente AL, 1997, BRIT J ANAESTH, V78, P478
   Dutta B, 2011, SINGAP MED J, V52, pE108
   ENOMOTO H, 1987, NEUROSURGERY, V20, P33, DOI 10.1227/00006123-198701000-00009
   Fujimura M, 2013, NEUROL MED-CHIR, V53, P561, DOI 10.2176/nmc.53.561
   Fukushima K, 2012, J CLIN NEUROSCI, V19, P1358, DOI 10.1016/j.jocn.2011.12.021
   Furlan A, 2009, AM J ROENTGENOL, V193, P1077, DOI 10.2214/AJR.08.2231
   Furuya A, 1998, J CLIN ANESTH, V10, P242, DOI 10.1016/S0952-8180(98)00015-4
   Fuster V, 2011, CIRCULATION, V123, P768, DOI 10.1161/CIRCULATIONAHA.110.963843
   Galambosi PJ, 2017, ACTA OBSTET GYN SCAN, V96, P852, DOI 10.1111/aogs.13137
   Gimovsky AC, 2012, CASE REP OBSTET GYNE, V2012
   Gordon Michael C., 2012, GABBE OBSTET NORMAL, P42
   Hashimoto K, 1988, Neurol Med Chir (Tokyo), V28, P588, DOI 10.2176/nmc.28.588
   Ida Yoriko, 2006, Masui, V55, P1005
   Iguchi Y, 2007, J NEUROL SCI, V260, P253, DOI 10.1016/j.jns.2007.04.004
   Ishimori ML, 2006, SEMIN ARTHRITIS RHEU, V35, P250, DOI 10.1016/j.semarthrit.2005.09.001
   Jung YJ, 2015, YONSEI MED J, V56, P793, DOI 10.3349/ymj.2015.56.3.793
   Kakogawa Jun, 2011, Arch Gynecol Obstet, V283 Suppl 1, P19, DOI 10.1007/s00404-010-1654-3
   Kamel H, 2014, NEW ENGL J MED, V370, P1307, DOI 10.1056/NEJMoa1311485
   KARASAWA J, 1980, SURG NEUROL, V13, P118
   Kato R, 2006, INT J OBSTET ANESTH, V15, P152, DOI 10.1016/j.ijoa.2005.06.012
   Kee WDN, 1996, BRIT J ANAESTH, V77, P550
   Khalil RA, 2005, HYPERTENSION, V46, P249, DOI 10.1161/01.HYP.0000172945.06681.a4
   Kim A, 2009, J PERINATOL, V29, P317, DOI 10.1038/jp.2008.183
   Kim JY, 2001, INT J CARDIOL, V80, P101, DOI 10.1016/S0167-5273(01)00475-2
   Kim TS, 2004, J CLIN NEUROSCI, V11, P525, DOI 10.1016/j.jocn.2003.07.005
   Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605
   Komiyama M, 1998, NEUROSURGERY, V43, P360, DOI 10.1097/00006123-199808000-00114
   Kronenburg A, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-013-0423-7
   Kume N, 1997, J NUCL MED, V38, P1894
   Kuriyama S, 2008, STROKE, V39, P42, DOI 10.1161/STROKEAHA.107.490714
   Lee SU, 2016, WORLD NEUROSURG, V90, P66, DOI 10.1016/j.wneu.2016.02.062
   Liu XJ, 2014, INT J GYNECOL OBSTET, V125, P150, DOI 10.1016/j.ijgo.2013.10.020
   Llorente de la Fuente A, 1998, REV ESP ANESTESIOL R, V45, P24
   Ma Jacklyn C, 2011, Hawaii Med J, V70, P161
   Martel C, 2015, A A CASE REP, V5, P176, DOI 10.1213/XAA.0000000000000208
   Maruyama K, 2016, J STROKE CEREBROVASC, V25, pE158, DOI 10.1016/j.jstrokecerebrovasdis.2016.06.036
   Matsumoto Y, 2009, J OBSTET GYNAECOL RE, V35, P787, DOI 10.1111/j.1447-0756.2009.01038.x
   Mehrkens JH, 2006, ACTA NEUROCHIR, V148, P685, DOI 10.1007/s00701-006-0731-7
   Misme H, 2016, J GYNECOL OBST BIO R, V45, P71, DOI 10.1016/j.jgyn.2015.01.004
   MIYAKAWA I, 1986, ARCH GYNECOL OBSTET, V237, P175, DOI 10.1007/BF02133862
   Miyakoshi K, 2009, J OBSTET GYNAECOL RE, V35, P974, DOI 10.1111/j.1447-0756.2009.01031.x
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   MIYAZAKI Y, 1992, Neurological Surgery, V20, P815
   Montiel V, 2009, CASE REP NEUROL, V1, P1, DOI 10.1159/000205406
   Murakami Yuta, 2014, No Shinkei Geka, V42, P961, DOI 10.11477/mf.1436200013
   Nagashima Michio, 2002, Masui, V51, P1349
   Nakai Y, 2002, J CLIN NEUROSCI, V9, P456, DOI 10.1054/jocn.2001.0970
   Newman P, 1998, J NEUROL NEUROSUR PS, V64, P686, DOI 10.1136/jnnp.64.5.686
   O'Connor K, 2007, INT J OBSTET ANESTH, V16, P94, DOI 10.1016/j.ijoa.2006.09.005
   Pacini L, 2009, INT J CARDIOL, V136, P156, DOI 10.1016/j.ijcard.2008.04.035
   Pascual-Castroviejo I, 2006, NEUROLOGIA, V21, P695
   POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302
   Prabhu M, 2008, J OBSTET GYNAECOL, V28, P345, DOI 10.1080/01443610802048032
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Sasaki Takashi, 2012, No Shinkei Geka, V40, P1095
   Sato K, 2015, J STROKE CEREBROVASC, V24, P921, DOI 10.1016/j.jstrokecerebrovasdis.2014.11.030
   Sei K, 2015, CLIN CASE REP, V3, P251, DOI 10.1002/ccr3.199
   SHARMA SK, 1994, ANESTH ANALG, V79, P183
   Shimamoto Yoshinori, 1994, Neurological Surgery, V22, P867
   Smiley RM, 2002, INT J OBSTET ANESTH, V11, P211, DOI 10.1054/ijoa.2002.0947
   Stafford I, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.049
   Sun JCL, 2000, CAN J NEUROL SCI, V27, P73, DOI 10.1017/S0317167100052021
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takahashi JC, 2012, NEUROL MED-CHIR, V52, P304, DOI 10.2176/nmc.52.304
   Takahashi JC, 2010, NEUROL MED-CHIR, V50, P824, DOI 10.2176/nmc.50.824
   Tanaka H, 2015, J OBSTET GYNAECOL RE, V41, P517, DOI 10.1111/jog.12557
   Tzeng DZ, 2005, LANCET, V365, P2150, DOI 10.1016/S0140-6736(05)66742-6
   Unno S, 2000, Rinsho Shinkeigaku, V40, P378
   Urushigawa K, 1986, Josanpu Zasshi, V40, P408
   USHIMURA S, 1993, OPHTHALMOLOGICA, V207, P169, DOI 10.1159/000310428
   USUKI F, 1991, THROMB HAEMOSTASIS, V65, P335
   VENKATESH B, 1994, CAN J ANAESTH, V41, P79, DOI 10.1007/BF03009678
   Williams DL, 2000, CAN J ANAESTH, V47, P996, DOI 10.1007/BF03024873
   Yamada T, 1999, OBSTET GYNECOL, V94, P822, DOI 10.1016/S0029-7844(99)00361-0
   Yoshimatsu J, 2014, J OBSTET GYNAECOL RE, V40, P1267, DOI 10.1111/jog.12336
NR 88
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 684
EP +
DI 10.1016/j.wneu.2018.10.071
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100325
PM 30347298
DA 2020-05-12
ER

PT J
AU Boriani, F
   Fazio, N
   Bolognesi, F
   Pedrini, FA
   Marchetti, C
   Baldini, N
   Goel, A
AF Boriani, Filippo
   Fazio, Nicola
   Bolognesi, Federico
   Pedrini, Francesca Alice
   Marchetti, Claudio
   Baldini, Nicola
   Goel, Atul
TI Noncellular Modification of Acellular Nerve Allografts for Peripheral
   Nerve Reconstruction: A Systematic Critical Review of the Animal
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acellular nerve allograft; Nerve regeneration; Noncellular enhancement;
   Peripheral nerve reconstruction; Schwann cell; Stem cell; Systematic
   review
ID SCIATIC-NERVE; LOCAL RELEASE; GROWTH-FACTOR; REGENERATION; GRAFTS;
   REPAIR
AB BACKGROUND: Acellular nerve allografts (ANAs) have been established as promising alternatives to autologous nerve grafts, which represent the reference standard. Our research group recently performed a systematic review of reported cell-based-enriching methods for recellularization of ANAs. Recellularization results in consistent improvement of peripheral neuroregeneration compared with plain ANAs. We systematically reviewed the effects on nerve regeneration when ANA enrichment was obtained through biological, chemical, and physical modification instead of cells.
   METHODS: The PubMed, ScienceDirect, Medline, and Scopus databases were searched for reports of noncellular modification of ANAs, reported from January 2007 to December 2017. The inclusion criteria were English language, noncellular enrichment of ANAs in peripheral nerve regeneration, an in vivo study design, and postgrafting neuroregenerative outcomes assessment. The exclusion criteria were the central nervous system as the site of ANA application, nerve conduits, xenografts, case series, case reports, and reviews.
   RESULTS: Only animal studies were found to be eligible. We included 16 studies, which were analyzed regarding the animal model, decellularization method, graft-enriching mode, and neuroregenerative tests performed.
   CONCLUSIONS: Noncellular-based stimulation of ANAs demonstrated positive effects on recovery of nerve function compared with nerve grafting compared with plain ANAs. The neuroregenerative effect of autografting still appeared superior to ANAs, even with noncellular enrichment of ANAs. However, we found that in a few studies, modified ANAs closely approached or even outperformed autografts. Future research should include more preclinical investigations of this promising tool and clinical translation to increase the level of evidence available in the challenging field of peripheral nerve reconstruction.
C1 [Boriani, Filippo; Bolognesi, Federico; Pedrini, Francesca Alice; Marchetti, Claudio; Baldini, Nicola] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
   [Fazio, Nicola; Pedrini, Francesca Alice; Baldini, Nicola] IRCCS, Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Bologna, Italy.
   [Bolognesi, Federico; Marchetti, Claudio] St Orsola Marcello Malpighi Hosp, Maxillofacial Surg Unit, Bologna, Italy.
   [Goel, Atul] KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, India.
RP Boriani, F (reprint author), Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.; Goel, A (reprint author), KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, India.
EM borianifilippo@gmail.com; atulgoel62@hotmail.com
RI Baldini, Nicola/J-4806-2016; Marchetti, Claudio/K-7242-2016; Fazio,
   Nicola/C-7962-2019
OI Baldini, Nicola/0000-0003-2228-3833; Fazio, Nicola/0000-0002-2758-0899
FU Fondazione del Monte [551bis/201]; Ministry of HealthMinistry of Health
   - Turkey
FX F Boriani was supported by the Fondazione del Monte (grant 551bis/201).
   N. Baldini was supported by the "5x 1000 2015" from the Ministry of
   Health. The remaining authors declare that the article content was
   composed in the absence of any commercial or financial relationships
   that could be construed as a potential conflict of interest.
CR Boyer RB, 2015, J SURG RES, V193, P969, DOI 10.1016/j.jss.2014.09.023
   Dai T, 2014, J RECONSTR MICROSURG, V30, P381, DOI 10.1055/s-0034-1381751
   Eggers R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071076
   English AW, 2007, DEV NEUROBIOL, V67, P158, DOI 10.1002/dneu.20339
   Giusti G, 2016, MICROSURG, V36, P134, DOI 10.1002/micr.22371
   Goel A, 1995, SURG NEUROL, V44, P181, DOI 10.1016/0090-3019(95)00161-1
   Goel A, 1997, NEUROSURGERY COMPLEX, P401
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hudson TW, 2004, TISSUE ENG, V10, P1346, DOI 10.1089/1076327042500319
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Li Z, 2008, EXP NEUROL, V214, P47, DOI 10.1016/j.expneurol.2008.07.007
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   LIU CHJ, 2003, PROG ANAT SCI, V9, P197
   Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165
   Neubauer D, 2007, EXP NEUROL, V207, P163, DOI 10.1016/j.expneurol.2007.06.006
   Nobre MC, 2018, WORLD NEUROSURG, V120, pE269, DOI 10.1016/j.wneu.2018.08.048
   Ovalle F, 2012, ANN PLAS SURG, V68, P518, DOI 10.1097/SAP.0b013e3182380974
   Pedrini FA, 2019, NEUROSURGERY, V85, P575, DOI 10.1093/neuros/nyy374
   Saheb-Al-Zamani M, 2013, EXP NEUROL, V247, P165, DOI 10.1016/j.expneurol.2013.04.011
   Sondell M, 1998, BRAIN RES, V795, P44, DOI 10.1016/S0006-8993(98)00251-0
   Sridharan R, 2015, J MECH BEHAV BIOMED, V41, P124, DOI 10.1016/j.jmbbm.2014.10.002
   Sun H.Z., 2004, PROG ANAT SCI, V10, P106
   Tajdaran K, 2016, ACTA BIOMATER, V29, P62, DOI 10.1016/j.actbio.2015.10.001
   Wang QL, 2017, SAUDI PHARM J, V25, P469, DOI 10.1016/j.jsps.2017.04.008
   Wang Y, 2016, NEUROL RES, V38, P242, DOI 10.1080/01616412.2015.1105584
   Yu HL, 2009, MICROSURG, V29, P330, DOI 10.1002/micr.20635
   Zhang LX, 2008, CELL MOL NEUROBIOL, V28, P501, DOI 10.1007/s10571-007-9226-1
   Zhang LX, 2010, SYNAPSE, V64, P152, DOI 10.1002/syn.20724
   Zhang YR, 2014, NEURAL REGEN RES, V9, P1358, DOI 10.4103/1673-5374.137588
   Zheng CB, 2014, TISSUE ENG PT A, V20, P3228, DOI [10.1089/ten.tea.2013.0729, 10.1089/ten.TEA.2013.0729]
   Zhou X, 2014, MUSCLE NERVE, V50, P235, DOI 10.1002/mus.24131
   Zhu ZW, 2015, CELL MOL NEUROBIOL, V35, P273, DOI 10.1007/s10571-014-0122-1
NR 32
TC 6
Z9 6
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP 692
EP +
DI 10.1016/j.wneu.2018.10.195
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100326
PM 30414518
DA 2020-05-12
ER

PT J
AU Abe, Y
   Yamada, K
   Abumi, K
   Iwasaki, N
   Sudo, H
AF Abe, Yuichiro
   Yamada, Katsuhisa
   Abumi, Kuniyoshi
   Iwasaki, Norimasa
   Sudo, Hideki
TI Long-Term Changes in Vertebral Morphology After Cervical Spinal Fusion
   in Adolescent Pediatric Patients: Retrospective Case Series with up to a
   Minimum 12 Years of Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical deformity; Cervical kyphosis; Cervical spine; Instrumentation;
   Morphologic change; Spinal fusion; Stress shielding
ID SCREW FIXATION; SUBLUXATION; CHILDREN; OUTCOMES; GROWTH
AB OBJECTIVE:The mechanical alteration in the adolescent/pediatric cervical spine after spinal fusion remains unknown. The purpose of this study was to investigate morphologic changes in the cervical spine in adolescent/pediatric patients who underwent spinal fusion.
   METHODS:Ten adolescent/pediatric patients (9-18 years) who underwent cervical spinal fusion were included. The anteroposterior diameter (AP-D) of the vertebral body was evaluated using lateral radiographs. The AP-D ratio was defined as the ratio of the AP-D at final follow-up to the postoperative value. The kyphosis angles at the fused level and cervical spine (C2-C7) also were measured.
   RESULTS:The mean follow-up period was 20.0 years (range, 12-40 years). The AP-D was reduced in 4 patients and increased or remained unchanged in 6 patients. The AP-D reduction was usually seen at the middle of the fused levels and was remarkable in patients who underwent kyphosis correction using posterior instrumentation combined with anterior fusion. The AP-D ratio was significantly correlated to segments of anterior fusion (P = 0.029) and the kyphosis angle of the fused levels (P = 0.016).
   CONCLUSIONS:Cervical kyphosis correction using posterior instrumentation combined with endplate destruction by anterior bone grafting is a risk factor for atrophic morphologic changes in the vertebral body in adolescent/pediatric patients. Endplate destruction and instrumentation-induced stress shielding could alter bone remodeling.
C1 [Abe, Yuichiro] Eniwa Hosp, Dept Orthopaed Surg, Eniwa, Hokkaido, Japan.
   [Abe, Yuichiro; Yamada, Katsuhisa; Iwasaki, Norimasa; Sudo, Hideki] Hokkaido Univ Hosp, Dept Orthopaed Surg, Sapporo, Hokkaido, Japan.
   [Abumi, Kuniyoshi] Sapporo Orthopaed Hosp, Sapporo, Hokkaido, Japan.
RP Sudo, H (reprint author), Hokkaido Univ Hosp, Dept Orthopaed Surg, Sapporo, Hokkaido, Japan.
EM hidekisudo@yahoo.co.jp
RI Sudo, Hideki/G-2748-2012
CR Abumi K, 2012, SPINE, V37, pE349, DOI 10.1097/BRS.0b013e318239cf1f
   DALENBERG DD, 1993, SPINE, V18, P1862, DOI 10.1097/00007632-199310000-00023
   Felbaum D, 2015, J NEUROSURG-SPINE, V23, P8, DOI 10.3171/2014.11.SPINE14484
   FOSTER HE, 1995, J RHEUMATOL, V22, P548
   Garber ST, 2016, J NEUROSURG-SPINE, V24, P892, DOI 10.3171/2015.10.SPINE15537
   Gupta SN, 2007, SPINAL CORD, V45, P637, DOI 10.1038/sj.sc.3101999
   Heller JG, 2005, CERVICAL SPINE, P3
   Hojo Y, 2011, EUR SPINE J, V20, P890, DOI 10.1007/s00586-010-1590-8
   Ito M, 1997, SPINE, V22, P382, DOI 10.1097/00007632-199702150-00005
   Johnson KT, 2016, J NEUROSURG-PEDIATR, V18, P377, DOI 10.3171/2016.3.PEDS1612
   Kanayama M, 1997, J BONE JOINT SURG AM, V79A, P1710, DOI 10.2106/00004623-199711000-00013
   Kennedy BC, 2016, J NEUROSURG-PEDIATR, V17, P94, DOI 10.3171/2015.5.PEDS14728
   Knox J, 2014, J PEDIATR ORTHOPED, V34, P376, DOI 10.1097/BPO.0000000000000111
   KOTANI Y, 1994, SPINE, V19, P2529, DOI 10.1097/00007632-199411001-00007
   Martinez-del-Campo E, 2016, J NEUROSURG-PEDIATR, V18, P644, DOI 10.3171/2016.4.PEDS15567
   MCAFEE PC, 1989, SPINE, V14, P919, DOI 10.1097/00007632-198909000-00003
   Myers MA, 1996, SPINE, V21, P2368, DOI 10.1097/00007632-199610150-00012
   Saphier PS, 2007, J NEUROSURG-SPINE, V6, P391, DOI 10.3171/spi.2007.6.5.391
   Sayama C, 2015, J NEUROSURG-PEDIATR, V16, P4, DOI 10.3171/2014.10.PEDS14199
   SHOHAT M, 1989, J PEDIATR-US, V114, P239, DOI 10.1016/S0022-3476(89)80789-9
   Sudo H, 2006, J NEUROSURG-SPINE, V5, P313, DOI 10.3171/spi.2006.5.4.313
   Sudo H, 2013, SPINE, V38, P819, DOI 10.1097/BRS.0b013e31827ddc60
   Vanek P, 2015, EUR SPINE J, V24, P2756, DOI 10.1007/s00586-015-3879-0
   Xu HZ, 2006, CLIN BIOMECH, V21, P330, DOI 10.1016/j.clinbiomech.2005.12.004
   Yamada K, 2018, J NEUROSURG-PEDIATR, V22, P694, DOI 10.3171/2018.6.PEDS18256
   Yoshihara H, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2013.01.023
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E765
EP E772
DI 10.1016/j.wneu.2018.10.136
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100092
PM 30391605
DA 2020-05-12
ER

PT J
AU Acioly, MA
   Shaikh, KA
   White, IK
   Ziemba-Davis, M
   Bohnstedt, BN
   Cohen-Gadol, A
AF Acioly, Marcus Andre
   Shaikh, Kashif A.
   White, Ian K.
   Ziemba-Davis, Mary
   Bohnstedt, Bradley N.
   Cohen-Gadol, Aaron
TI Predictors of Outcomes and Complications After Microsurgical and
   Endovascular Treatment of 1300 Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Complication; Endovascular treatment; Microsurgery;
   Outcome; Risk factors
ID SHUNT-DEPENDENT HYDROCEPHALUS; PIPELINE EMBOLIZATION DEVICE; ACUTE
   MYOCARDIAL-INFARCTION; SUBARACHNOID HEMORRHAGE; SYMPTOMATIC VASOSPASM;
   CEREBRAL ANEURYSMS; SINGLE-INSTITUTION; COILING; TRIAL; MORTALITY
AB BACKGROUND: We performed a rigorous statistical analysis of the complications and outcomes of patients with ruptured or unruptured intracranial aneurysms. Our emphasis was on the potential predictive factors when both surgical and endovascular management are offered by a team with balanced microsurgical and endovascular expertise.
   METHODS: From January 2005 to December 2011, 1297 consecutive patients presenting with ruptured (n = 829) or unruptured (n = 468) aneurysms were prospectively enrolled in our vascular database. The treatment modality was determined by consensus of the endovascular and microsurgical teams. The patients' medical and neurological conditions and aneurysm characteristics were compared against the postintervention complication rates and outcomes using multivariate analyses.
   RESULTS: The patients mostly underwent clipping for ruptured (63.7%) or unruptured (56.6%) aneurysms. For ruptured aneurysms, higher Hunt and Hess and Fisher grades on admission were key predictors of increased neurological (P < 0.001 and P < 0.001, respectively) and medical (P < 0.001 and P = 0.041, respectively) complication rates. No significant differences in the outcomes were observed between the coiling or clipping groups during the follow-up period. For the unruptured group, a family history of intracranial aneurysms was the most relevant predictor for reducing neurological complication rates and increasing survival at 6 months. Hypertension was, however, the strongest factor associated with complications
   CONCLUSIONS: For the ruptured and unruptured groups both, the outcomes were generally good, although neurological and medical complications were reasonably more frequent for the ruptured aneurysms. Coiling provided a sustained benefit in lowering the complication rates only in the short term for the unruptured aneurysms. Smoking was associated, paradoxically, with improved outcomes.
C1 [Acioly, Marcus Andre] Univ Fed Rio de Janeiro, Div Neurosurg, Rio De Janeiro, Brazil.
   [Acioly, Marcus Andre] Fluminense Fed Univ, Div Neurosurg, Niteroi, RJ, Brazil.
   [Shaikh, Kashif A.; White, Ian K.; Ziemba-Davis, Mary; Cohen-Gadol, Aaron] Indiana Univ, Dept Neurol Surg, Sch Med, Indianapolis, IN 46204 USA.
   [Shaikh, Kashif A.; White, Ian K.; Ziemba-Davis, Mary; Cohen-Gadol, Aaron] Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.
   [Bohnstedt, Bradley N.] Oklahoma Univ, Dept Neurosurg, Oklahoma City, OK USA.
RP Cohen-Gadol, A (reprint author), Indiana Univ, Dept Neurol Surg, Sch Med, Indianapolis, IN 46204 USA.; Cohen-Gadol, A (reprint author), Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.
EM acohenmd@gmail.com
CR Abla AA, 2014, J NEUROSURG, V120, P391, DOI 10.3171/2013.10.JNS13419
   Adeeb N, 2017, WORLD NEUROSURG, V105, P232, DOI 10.1016/j.wneu.2017.05.128
   Adeeb N, 2017, WORLD NEUROSURG, V105, P206, DOI 10.1016/j.wneu.2017.05.104
   Alshekhlee A, 2010, STROKE, V41, P1471, DOI 10.1161/STROKEAHA.110.580647
   BARBASH GI, 1993, CIRCULATION, V87, P53, DOI 10.1161/01.CIR.87.1.53
   Barker FG, 2004, NEUROSURGERY, V54, P18, DOI 10.1227/01.NEU.0000097195.48840.C4
   Choudhari KA, 2006, BRIT J NEUROSURG, V20, P375, DOI 10.1080/02688690601048336
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   Dehdashti AR, 2004, J NEUROSURG, V101, P402, DOI 10.3171/jns.2004.101.3.0402
   Delgado AF, 2017, J NEUROINTERV SURG, V9, P264, DOI 10.1136/neurintsurg-2016-012292
   Feng ZZ, 2017, WORLD NEUROSURG, V108, P506, DOI 10.1016/j.wneu.2017.09.040
   Gennaro G, 2016, AM J CARDIOL, V118, P1097, DOI 10.1016/j.amjcard.2016.07.019
   Harrod CG, 2005, NEUROSURGERY, V56, P633, DOI 10.1227/01.NEU.0000156644.45384.92
   John S, 2017, WORLD NEUROSURG, V107, P142, DOI [10.1016/J.WNEU.2017.07.146, 10.1016/j.wneu.2017.07.146]
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Li H, 2013, STROKE, V44, P29, DOI 10.1161/STROKEAHA.112.663559
   Li ZQ, 2012, J INT MED RES, V40, P2145, DOI 10.1177/030006051204000612
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Murayama Y, 2016, STROKE, V47, P365, DOI 10.1161/STROKEAHA.115.010698
   Nam KH, 2010, J KOREAN NEUROSURG S, V48, P313, DOI 10.3340/jkns.2010.48.4.313
   Nanda A, 2017, WORLD NEUROSURG, V100, P85, DOI 10.1016/j.wneu.2016.12.099
   Nussbaum ES, 2019, J NEUROSURG, V130, P1498, DOI 10.3171/2018.1.JNS172466
   Petr O, 2016, AM J NEURORADIOL, V37, P1106, DOI 10.3174/ajnr.A4699
   Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531
   Ryttlefors M, 2008, STROKE, V39, P2720, DOI 10.1161/STROKEAHA.107.506030
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   Steklacova A, 2018, NEUROSURG REV, V41, P825, DOI 10.1007/s10143-017-0932-y
   Taki W, 2011, WORLD NEUROSURG, V76, P437, DOI 10.1016/j.wneu.2011.04.026
   Thiarawat P, 2017, WORLD NEUROSURG, V101, P379, DOI 10.1016/j.wneu.2017.02.033
   Weisz G, 2005, AM HEART J, V150, P358, DOI 10.1016/j.ahj.2004.01.032
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Wilson DA, 2012, NEUROSURGERY, V71, P869, DOI 10.1227/NEU.0b013e318267360f
   Zhao B, 2016, AM J NEURORADIOL, V37, P873, DOI 10.3174/ajnr.A4649
NR 40
TC 0
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E516
EP E529
DI 10.1016/j.wneu.2018.10.094
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100063
PM 31108070
DA 2020-05-12
ER

PT J
AU Adachi, K
   Hasegawa, M
   Hayakawa, M
   Tateyama, S
   Hirose, Y
AF Adachi, Kazuhide
   Hasegawa, Mituhiro
   Hayakawa, Motoharu
   Tateyama, Shinichiro
   Hirose, Yuichi
TI Susceptibility-Weighted Imaging of Deep Venous Congestion in Petroclival
   Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior transpetrosal approach; Deep venous congestion; Petroclival
   meningioma; Skull base meningioma; Susceptibility-weighted imaging
ID CEREBRAL MICROBLEEDS; DRAINAGE PATTERNS; PETROSECTOMY; EXPERIENCE;
   RESECTION; CONTRAST; LESIONS; GLIOMA; VEINS
AB BACKGROUND: Protecting the venous drainage route during surgery in cases of petroclival meningioma (PCM) is important. Identifying venous congestion preoperatively can be valuable in reducing the risks associated with venous congestion during surgery. In this study, we examined the utility of susceptibility-weighted imaging (SWI) in identifying the presence of venous congestion in PCM cases preoperatively and identified the factors associated with it.
   METHODS: We retrospectively examined 24 patients who had undergone surgery for primary PCM. The areas of the basal and internal cerebral veins on the affected and unaffected sides, obtained using SWI, were compared to identify venous congestion. We further examined the association between multiple candidate factors that are thought to be related to venous congestion and venous congestion using statistical analyses.
   RESULTS: SWI could successfully identify venous congestion in 11 of 24 PCM cases. Among the 12 factors examined, those associated with venous congestion were an extension of the tumor, over the midline or upward, which is known to disturb the venous flow at the brainstem surface; anastomosis of the superficial cerebral vein (i.e., bypass route for venous congestion); and a high ABC Surgical Risk Scale score, an indicator of postoperative neurologic deterioration.
   CONCLUSIONS: We showed that SWI is useful for evaluating venous congestion in PCM cases preoperatively and for identifying factors reflecting the risk of venous congestion. Taken together, our findings provide a multi-modal strategy for the preoperative prediction of venous congestion, which could facilitate the treatment of PCM.
C1 [Adachi, Kazuhide; Hasegawa, Mituhiro; Hayakawa, Motoharu; Tateyama, Shinichiro; Hirose, Yuichi] Fujita Hlth Univ, Sch Med, Dept Neurosurg, Toyoake, Aichi, Japan.
RP Adachi, K (reprint author), Fujita Hlth Univ, Sch Med, Dept Neurosurg, Toyoake, Aichi, Japan.
EM kazu-adachi@rio.odn.ne.jp
RI Hirose, Yuichi/P-1731-2019
OI Hirose, Yuichi/0000-0002-1305-1830; ADACHI, KAZUHIDE/0000-0002-5275-8572
CR Adachi K, 2018, WORLD NEUROSURG, V116, pE611, DOI 10.1016/j.wneu.2018.05.052
   Adachi K, 2017, NEUROL MED-CHIR, V57, P505, DOI 10.2176/nmc.ra.2016-0336
   Adachi K, 2016, WORLD NEUROSURG, V92, P339, DOI 10.1016/j.wneu.2016.05.019
   Adachi K, 2009, J NEUROSURG, V111, P1053, DOI 10.3171/2007.11.17446
   ALMEFTY O, 1988, NEUROSURGERY, V22, P510, DOI 10.1227/00006123-198803000-00010
   Almefty R, 2014, J NEUROSURG, V120, P40, DOI 10.3171/2013.8.JNS13535
   [Anonymous], 1999, NEUROSURGERY
   Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801
   Bambakidis NC, 2007, NEUROSURGERY, V61, P202, DOI [10.1227/01.NIEU.0000280119.36270.BA, 10.1227/01.neu.0000303218.61230.39]
   Bian W, 2014, NEURORADIOLOGY, V56, P91, DOI 10.1007/s00234-013-1297-8
   Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842
   Di Ieva A, 2013, NEURORADIOLOGY, V55, P35, DOI 10.1007/s00234-012-1081-1
   Di Ieva A, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.09.006
   Di Ieva A, 2011, NEUROIMAGE, V54, P74, DOI 10.1016/j.neuroimage.2010.07.045
   DiMeco F, 2004, NEUROSURGERY, V55, P1263, DOI 10.1227/01.NEU.0000143373.74160.F2
   Gasparetto E L, 2011, AJNR Am J Neuroradiol, V32, pE54, DOI 10.3174/ajnr.A2457
   Grabner G, 2012, MAGN RESON IMAGING, V30, P139, DOI 10.1016/j.mri.2011.08.004
   Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400
   Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198
   Hafez A, 2011, J NEUROSURG, V114, P1294, DOI 10.3171/2010.6.JNS091461
   Ichimura S, 2012, NEUROSURG REV, V35, P609, DOI 10.1007/s10143-012-0405-2
   KAWASE T, 1994, ACTA NEUROCHIR, V129, P113, DOI 10.1007/BF01406489
   Koerbel A, 2009, EJSO-EUR J SURG ONC, V35, P773, DOI 10.1016/j.ejso.2008.02.015
   Letourneau-Guillon L, 2012, AM J NEURORADIOL, V33, P301, DOI 10.3174/ajnr.A2777
   Li CT, 2010, EUR J RADIOL, V75, pE81, DOI 10.1016/j.ejrad.2009.08.003
   Little KM, 2005, NEUROSURGERY, V56, P546, DOI 10.1227/01.NEU.0000153906.12640.62
   Matsushima S, 2018, J COMPUT ASSIST TOMO, V42, P100, DOI 10.1097/RCT.0000000000000637
   Noguchi K, 2010, AM J NEURORADIOL, V31, P1903, DOI 10.3174/ajnr.A2231
   PADGET DH, 1956, AM J ANAT, V98, P307, DOI 10.1002/aja.1000980302
   Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365
   Rhoton AL, 2000, NEUROSURGERY, V47, pS69, DOI 10.1097/00006123-200009001-00012
   Saini J, 2009, AJNR Am J Neuroradiol, V30, pE6, DOI 10.3174/ajnr.A1265
   Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598
   Sekhar LN, 1999, NEUROSURGERY, V44, P537, DOI 10.1097/00006123-199903000-00060
   Shibao S, 2016, J NEUROSURG, V124, P432, DOI 10.3171/2015.1.JNS141854
   Shibao S, 2015, WORLD NEUROSURG, V84, P574, DOI 10.1016/j.wneu.2015.03.055
   Siddiqui FM, 2015, STROKE, V46, P1263, DOI 10.1161/STROKEAHA.114.007465
   SPETZLER RF, 1992, J NEUROSURG, V76, P588, DOI 10.3171/jns.1992.76.4.0588
   Wang Q, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000191
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E20
EP E31
DI 10.1016/j.wneu.2018.08.218
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100004
PM 30236813
DA 2020-05-12
ER

PT J
AU Agarwal, N
   Lariviere, WR
   Henry, LC
   Faramand, A
   Koschnitzky, JE
   Friedlander, RM
AF Agarwal, Nitin
   Lariviere, William R.
   Henry, Luke C.
   Faramand, Andrew
   Koschnitzky, Jenna E.
   Friedlander, Robert M.
TI Observations from Social Media Regarding the Symptomatology of Adult
   Hydrocephalus Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognition; Headache; Memory; Mobility; Patient participation; Review;
   Social Media
ID NORMAL-PRESSURE HYDROCEPHALUS; LONG-TERM OUTCOMES; CONGENITAL
   HYDROCEPHALUS; AQUEDUCTAL STENOSIS; PEDIATRIC HYDROCEPHALUS;
   EPIDEMIOLOGY; PREVALENCE; NETWORKING; SYMPTOMS; DISEASE
AB BACKGROUND: Patients with hydrocephalus experience symptoms related to hydrocephalus in an age-dependent manner. However, prevalence estimates of hydrocephalus symptoms in young and middle-aged (YMA) adult patients are rare and variable. Highlighting the importance of hydrocephalus symptom management, the persistence and intensity of headache or gait disturbance have been associated with signs of brain white matter integrity loss, including in treated YMA adult patients. Thus, it is important to ascertain which symptoms adult patients with hydrocephalus report most to confirm their relative importance.
   METHODS: Observations of symptom complaints were made from publicly viewable online responses to an inquiry posted by the Hydrocephalus Association to 2 Facebook webpages.
   RESULTS: Within 7 days of inquiry posting, 381 complaints of signs and symptoms were identified in 82 online responses. Headache, cognitive deficits (cognition and memory), and mobility issues (dizziness, balance, or gait problems) were most commonly reported by 63%, 45%, and 40% of respondents, respectively. Results were highly similar for the subgroup of 53 patients reported as treated. For self-identified YMA patients (<60 years old), results were similar, but with fewer mobility complaints. Not previously reported, hypersensitivity to external stimuli was reported by one-half of the patients that reported headache.
   CONCLUSIONS: The current results provide further quantitative support for the prioritization of study of headache, cognitive deficits, and mobility issues in YMA adult patients with hydrocephalus. Warranting further study, cranial hypersensitivity to external stimuli may represent a novel outcome measure, and treated YMA adult hydrocephalus patients continue to report symptoms associated with signs of brain damage.
C1 [Agarwal, Nitin; Lariviere, William R.; Henry, Luke C.; Faramand, Andrew; Friedlander, Robert M.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
   [Koschnitzky, Jenna E.] Hydrocephalus Assoc, Bethesda, MD USA.
RP Friedlander, RM (reprint author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA.
EM friedlanderr@upmc.edu
RI friedlander, robert/A-2845-2016
OI friedlander, robert/0000-0003-4423-9219; Agarwal,
   Nitin/0000-0003-0256-3897
FU shunt
FX The Hydrocephalus Association is an education, support, advocacy, and
   research non-profit organization dedicated to patients, families,
   providers, and researchers. Some outreach activities of the
   Hydrocephalus Association, such as the biennial National Conference on
   Hydrocephalus, are sponsored by shunt and other industry partners. This
   research was not supported by any industry partners.
CR Andersson S, 2006, DEV MED CHILD NEUROL, V48, P836, DOI 10.1017/S0012162206001794
   Bakar EE, 2010, J KOREAN NEUROSURG S, V47, P191, DOI 10.3340/jkns.2010.47.3.191
   BLACKBURN BL, 1994, AM J MED GENET, V52, P123, DOI 10.1002/ajmg.1320520202
   Bugalho P, 2013, J NEURAL TRANSM, V120, P1201, DOI 10.1007/s00702-013-0975-3
   Chou WYS, 2014, TRANSL BEHAV MED, V4, P314, DOI 10.1007/s13142-014-0256-1
   Cowan JA, 2005, NEUROL RES, V27, P540, DOI 10.1179/016164105X17242
   Demarquay G, 2016, HEADACHE, V56, P1418, DOI 10.1111/head.12651
   Elkarim GA, 2017, J NEUROSURG-PEDIATR, V20, P119, DOI 10.3171/2017.3.PEDS16552
   Flor H, 2016, PAIN PHYSICIAN, V19, P507
   FORRESTER MB, 2005, HAWAII MED J, V64, P302
   Fukuhara T, 2001, SURG NEUROL, V55, P132, DOI 10.1016/S0090-3019(01)00359-7
   Greene JA, 2011, J GEN INTERN MED, V26, P287, DOI 10.1007/s11606-010-1526-3
   Gupta N, 2007, J NEUROSURG, V106, P334, DOI 10.3171/ped.2007.106.5.334
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   HOGAN PA, 1966, J AMER MED ASSOC, V198, P524
   Hydrocephalus Association, 2003, HYDR DIAGN YOUNG MID
   JACOBSON GP, 1994, NEUROLOGY, V44, P837, DOI 10.1212/WNL.44.5.837
   Jeng S, 2011, PEDIATR NEUROL, V45, P67, DOI 10.1016/j.pediatrneurol.2011.03.009
   Jensen R, 2008, LANCET NEUROL, V7, P354, DOI 10.1016/S1474-4422(08)70062-0
   Kalevski S, 2015, SANAMED, V10, P37
   Kharkar S, 2011, BEHAV NEUROL, V24, P143, DOI [10.1155/2011/630475, 10.3233/BEN-2011-0325]
   KIRKPATRICK M, 1989, ARCH DIS CHILD, V64, P124, DOI 10.1136/adc.64.1.124
   Koschnitzky JE, 2017, WHITE PAPER INCORPOR, P22
   Koyama T, 2012, NEUROL MED-CHIR, V52, P68, DOI 10.2176/nmc.52.68
   Kraemer MR, 2017, J NEUROSURG-PEDIATR, V20, P216, DOI 10.3171/2017.2.PEDS16265
   LITTLE JR, 1975, J NEUROSURG, V43, P546, DOI 10.3171/jns.1975.43.5.0546
   McAllister JP, 2015, J NEUROSURG, V123, P1427, DOI 10.3171/2014.12.JNS132352
   McGirt MJ, 2005, NEUROSURGERY, V57, P699, DOI 10.1227/01.NEU.0000175724.00147.10
   Nakatsu D, 2016, NEUROL MED-CHIR, V56, P51, DOI 10.2176/nmc.oa.2015-0027
   Oi S, 2000, J NEUROSURG, V92, P933, DOI 10.3171/jns.2000.92.6.0933
   Patel R, 2015, AM J MED, V128, P1335, DOI 10.1016/j.amjmed.2015.06.015
   Paulsen AH, 2015, J NEUROSURG-PEDIATR, V16, P633, DOI 10.3171/2015.5.PEDS14532
   Preuss M, 2015, CHILD NERV SYST, V31, P49, DOI 10.1007/s00381-014-2571-8
   Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P27, DOI 10.1016/j.spen.2009.01.001
   Rodis I, 2016, CHILD NERV SYST, V32, P617, DOI 10.1007/s00381-016-3029-y
   Sankey EW, 2016, J NEUROSURG, V124, P1413, DOI 10.3171/2015.4.JNS15129
   Sankey EW, 2015, J CLIN NEUROSCI, V22, P1303, DOI 10.1016/j.jocn.2015.02.019
   Tan K, 2018, J NEUROSURG, V129, P1611, DOI 10.3171/2017.6.JNS162784
   Tisell M, 2003, ACTA NEUROL SCAND, V107, P311, DOI 10.1034/j.1600-0404.2003.00124.x
   Vinchon M, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-18
   Vinchon M, 2012, CHILD NERV SYST, V28, P847, DOI 10.1007/s00381-012-1723-y
   Younis S, 2016, PAIN, V157, P1407, DOI 10.1097/j.pain.0000000000000528
NR 42
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E307
EP E314
DI 10.1016/j.wneu.2018.10.027
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100036
PM 30321673
DA 2020-05-12
ER

PT J
AU Ahmadipour, Y
   Jabbarli, R
   Gembruch, O
   Pierscianek, D
   Oppong, MD
   Dammann, P
   Wrede, K
   Ozkan, N
   Muller, O
   Sure, U
   El Hindy, N
AF Ahmadipour, Yahya
   Jabbarli, Ramazan
   Gembruch, Oliver
   Pierscianek, Daniela
   Oppong, Marvin Darkwah
   Dammann, Philipp
   Wrede, Karsten
   Oezkan, Neriman
   Mueller, Oliver
   Sure, Ulrich
   El Hindy, Nicolai
TI Impact of Multifocality and Molecular Markers on Survival of
   Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Molecular markers; Multifocality; Overall survival
ID PROLIFERATION INDEX; IDH1; CRANIOTOMY; KI-67
AB OBJECTIVE: Several parameters like extent of resection and MGMT promotor methylation in glioblastoma (GBM) are known to influence survival. Other elements like multifocality and proliferation indices are not commonly used. The aim of the present study was to analyze routinely and not routinely assessed prognostic markers for survival of patients suffering from GBM in a single center.
   METHODS: Adult cases with GBM operated at our institution were included in this survey. The association of age, Karnofsky performance status (KPS), MGMT promotor methylation, Ki67 proliferation index, IDH1/2 mutational status, and multifocality on overall survival (OS) was analyzed in univariate and multivariate cox regression models.
   RESULTS: We analyzed 565 patients with a mean age of 62.2 (18-84) years. Median OS was 12.5 months. MGMT promoter methylation and IDH 1/2 mutation were associated with significant better OS (P < 0.01). In 48 cases (8.5%), the tumor was localized in both hemispheres, which was associated with a significant worse OS than tumor infiltration of 1 hemisphere (P = 0.039). Mean Ki67 proliferation index increased to 18% when both hemispheres were infiltrated. Multivariate analysis for OS revealed IDH 1/2 wildtype (adjusted odds ratio [aOR] 4.3), higher age (aOR 4.2), unmethylated MGMT promotor (aOR 3.5), preoperative KPS score <70 (aOR 1.9), and multifocality (aOR 2.1) as independent parameters for worse survival.
   CONCLUSIONS: This study confirms well-known parameters like MGMT promoter methylation, IDH 1/2 mutational status, KPS, and age as independent prognostic factors for survival and reveals multifocality as further independent prognostic marker for survival. The dismal prognosis of multifocal involvement is associated with an increasing Ki67 proliferation index.
C1 [Ahmadipour, Yahya; Jabbarli, Ramazan; Gembruch, Oliver; Pierscianek, Daniela; Oppong, Marvin Darkwah; Dammann, Philipp; Wrede, Karsten; Oezkan, Neriman; Mueller, Oliver; Sure, Ulrich; El Hindy, Nicolai] Univ Hosp, Dept Neurosurg, Essen, Germany.
   [El Hindy, Nicolai] St Christophorus Hosp, Dept Spine & Peripheral Nerve Surg, Werne, Germany.
RP Ahmadipour, Y (reprint author), Univ Hosp, Dept Neurosurg, Essen, Germany.
EM yahya.ahmadipour@uk-essen.de
OI Jabbarli, Ramazan/0000-0002-8356-6629; Ahmadipour,
   Yahya/0000-0003-3759-8301; Gembruch, Oliver/0000-0002-0054-1611
CR Adeberg S, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-95
   Berghoff AS, 2013, CLIN NEUROPATHOL, V32, P148, DOI 10.5414/NP300646
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Gerber NK, 2014, NEURO-ONCOLOGY, V16, P1186, DOI 10.1093/neuonc/nou043
   Gessler F, 2017, J NEURO-ONCOL, V133, P399, DOI 10.1007/s11060-017-2448-2
   Gzell C, 2016, CLIN ONCOL-UK, V28, P215, DOI 10.1016/j.clon.2015.08.009
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Johannessen AL, 2006, PATHOL ONCOL RES, V12, P143, DOI 10.1007/BF02893360
   Litofsky NS, 1998, SURG NEUROL, V50, P579, DOI 10.1016/S0090-3019(97)00312-1
   Lorimer CF, 2017, CLIN ONCOL-UK, V29, P739, DOI 10.1016/j.clon.2017.05.010
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
   Nieder C, 2000, CANCER TREAT REV, V26, P67, DOI 10.1053/ctrv.1999.0145
   Persson A, 2008, CLIN NEUROPATHOL, V27, P224
   Batista KMP, 2015, FOLIA NEUROPATHOL, V53, P52, DOI 10.5114/fn.2015.49974
   Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
NR 18
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E461
EP E466
DI 10.1016/j.wneu.2018.10.075
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100055
PM 30347300
DA 2020-05-12
ER

PT J
AU Aljobeh, A
   Sorenson, TJ
   Bortolotti, C
   Cloft, H
   Lanzino, G
AF Aljobeh, Ahmad
   Sorenson, Thomas Joseph
   Bortolotti, Carlo
   Cloft, Harry
   Lanzino, Giuseppe
TI Vertebral Arteriovenous Fistula: A Review Article
SO WORLD NEUROSURGERY
LA English
DT Review
DE Fistula; Treatment; Vascular; Vertebral artery
ID INTERNAL JUGULAR-VEIN; STENT-GRAFT TREATMENT; NEUROFIBROMATOSIS TYPE-I;
   ENDOVASCULAR TREATMENT; COIL EMBOLIZATION; HIGH-FLOW; TRANSVENOUS
   EMBOLIZATION; VERTEBROJUGULAR FISTULA; SUBARACHNOID HEMORRHAGE;
   SPONTANEOUS RESOLUTION
AB OBJECTIVE: Vertebrovertebral fistulas (VVFs) are uncommon lesions that can arise spontaneously or secondarily to iatrogenic or mechanical trauma. We performed a systematic review of the literature to obtain information regarding demographics, clinical presentation, treatment modalities, outcome, and complications associated with treatment.
   METHODS: A literature search was performed by a reference librarian and after screening, 128 case reports and 16 case series were left for inclusion in the review. All possible data were abstracted by 3 authors, results were tabulated, and descriptive statistics (mean, range, and proportions) were reported. No formal statistical analysis was performed as part of this study.
   RESULTS: A total of 280 patients were analyzed. VVFs can be categorized in 3 subgroups (iatrogenic, spontaneous, and traumatic), based on the mechanism of formation, and these different causes share different underlying demographics that bear important treatment considerations. Traumatic VVFs are more commonly seen in young men; the spontaneous form is more commonly seen in young women. Iatrogenic VVFs are more commonly seen in elderly people. Spontaneous VVFs are most commonly located between C1 and C2. Most iatrogenic (n = 39; 57%), spontaneous (n = 106; 82%), and traumatic (n = 53; 73%) VVFs were treated with deconstructive (defined as occlusion of fistula and feeding vessels) endovascular therapy. Overall treatment-related permanent morbidity was 3.3% (9/270) and mortality was 1.5% (4/270).
   CONCLUSIONS: VVFs are uncommon lesions, and treatment is often indicated, even in patients without retrograde venous drainage. When treatment is undertaken, the cause of presentation and associated patient demographics should be considered when planning the treatment strategy.
C1 [Aljobeh, Ahmad] Mayo Clin, Sch Med, Rochester, MN USA.
   [Sorenson, Thomas Joseph; Lanzino, Giuseppe] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Cloft, Harry; Lanzino, Giuseppe] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
   [Bortolotti, Carlo] Inst Neurol Sci Bologna, Dept Neurol Surg, Bologna, Italy.
RP Lanzino, G (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.; Lanzino, G (reprint author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
EM Lanzino.Giuseppe@mayo.edu
OI Aljobeh, Ahmad/0000-0003-3606-2214
CR Acerbi G, 2004, ANGIOLOGY, V55, P329, DOI 10.1177/000331970405500313
   Adams A, 2013, J CHILD NEUROL, V28, P255, DOI 10.1177/0883073812441066
   Amdani SM, 2018, INDIAN J PEDIATR, V85, P325, DOI 10.1007/s12098-017-2466-2
   Amirjamshidi A, 1999, BRIT J NEUROSURG, V13, P201, DOI 10.1080/02688699944005
   Asai J, 2002, CLIN NEUROL NEUROSUR, V104, P146, DOI 10.1016/S0303-8467(01)00194-9
   Ashour R, 2016, J NEUROINTERV SURG, V8, P643, DOI 10.1136/neurintsurg-2015-011677
   Baltacioglu F, 2009, MARMARA MED J, V22, P248
   Barkhordarian Siamak, 2007, Vasc Endovascular Surg, V41, P153, DOI 10.1177/1538574406298085
   BEAUJEUX RL, 1992, RADIOLOGY, V183, P361, DOI 10.1148/radiology.183.2.1561336
   Benndorf G, 2000, INTERV NEURORADIOL, V6, P67, DOI 10.1177/159101990000600109
   Boot BP, 2011, NEUROLOGY, V76, pE29, DOI 10.1212/WNL.0b013e31820c2eaa
   Bostroem A, 2008, MINIM INVAS NEUROSUR, V51, P54, DOI 10.1055/s-2007-1004549
   Breda MS, 2018, BMJ CASE REP
   Bricelj V, 1998, CATHETER CARDIO DIAG, V43, P434
   Briganti F, 2004, MINIM INVAS NEUROSUR, V47, P386, DOI 10.1055/s-2004-830131
   Briganti F, 2013, NEURORADIOL J, V26, P339, DOI 10.1177/197140091302600315
   Burger T, 1999, VASA-J VASCULAR DIS, V28, P297, DOI 10.1024/0301-1526.28.4.297
   Buyukkaya R, 2013, VASC ENDOVASC SURG, V47, P648, DOI 10.1177/1538574413503559
   Causey MW, 2016, J VASC SURG CASES IN, V2, P165, DOI 10.1016/j.jvscit.2016.04.006
   Choudhri O, 2018, NEURORADIOLOGY, V60, P221, DOI 10.1007/s00234-017-1963-3
   CLUZEL P, 1994, NEURORADIOLOGY, V36, P321, DOI 10.1007/BF00593272
   Coric D, 1996, J NEUROSURG, V85, P340, DOI 10.3171/jns.1996.85.2.0340
   Crowley RW, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2008.12.FOCUS08274
   Dashti SR, 2010, NEUROSURGERY, V67, pE208, DOI 10.1227/01.NEU.0000371064.91216.AB
   de Keukeleire K, 2006, CARDIOVASC INTER RAD, V29, P311, DOI 10.1007/s00270-004-9197-2
   DESOUZA NM, 1992, CLIN RADIOL, V46, P170, DOI 10.1016/S0009-9260(05)80439-8
   Dublin AB, 2010, J VASC INTERV RADIOL, V21, P392, DOI 10.1016/j.jvir.2009.11.008
   Duncan IC, 2003, J ENDOVASC THER, V10, P882, DOI 10.1583/1545-1550(2003)010<0882:PMOCPH>2.0.CO;2
   Edwards MK, 2017, CASE REP EMERG MED, V2017
   Emery DJ, 1998, INTERV NEURORADIOL, V4, P127, DOI 10.1177/159101999800400204
   Erdem A, 2011, BALK MED J, V28, P202, DOI 10.5174/tutfd.2009.02713.0
   Felbaum D, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011796.rep
   Felber S, 2004, NEUROSURGERY, V55, P631, DOI 10.1227/01.NEU.0000134455.02947.1F
   Finlay DJ, 2002, ANN VASC SURG, V16, P774, DOI 10.1007/s10016-001-0196-3
   Friedman DP, 1998, RADIOGRAPHICS, V18, P527, DOI 10.1148/radiographics.18.2.9536496
   FUKAO S, 1995, NEURORADIOLOGY, V37, P400
   Gao P, 2013, TURK NEUROSURG, V23, P289, DOI 10.5137/1019-5149.JTN.4993-11.0
   Girn HRS, 2009, J VASC SURG, V49, P1570, DOI 10.1016/j.jvs.2009.01.002
   GOKALP HZ, 1993, ACTA NEUROCHIR, V124, P153, DOI 10.1007/BF01401139
   Gokalp HZ, 1993, TURKISH NEUROSURG, V3, P114
   Gonzalez A, 2001, NEURORADIOLOGY, V43, P784, DOI 10.1007/s002340100586
   Goyal M, 1999, INTERV NEURORADIOL, V5, P219, DOI 10.1177/159101999900500304
   Graves VB, 1997, AM J NEURORADIOL, V18, P1201
   GUGLIELMI G, 1995, AM J NEURORADIOL, V16, P325
   Guneyli S, 2016, DIAGN INTERV IMAG, V97, P871, DOI 10.1016/j.diii.2015.08.006
   Gurer B, 2013, CLIN NEUROL NEUROSUR, V115, P468, DOI 10.1016/j.clineuro.2012.05.035
   Guzel A, 2007, NEURORADIOL J, V20, P566, DOI 10.1177/197140090702000515
   Haller W, 2011, CARDIOVASC INTER RAD, V34, P1109, DOI 10.1007/s00270-011-0107-0
   HALLIDAY AL, 1993, J NEUROSURG, V79, P589, DOI 10.3171/jns.1993.79.4.0589
   Herrera DA, 2008, AM J NEURORADIOL, V29, P1585, DOI 10.3174/ajnr.A1123
   Heuer GG, 2008, J NEUROSURG-SPINE, V8, P381, DOI 10.3171/SPI/2008/8/4/381
   Higa G, 2010, VASCULAR, V18, P166, DOI 10.2310/6670.2010.00032
   Honarmand AR, 2013, INTERV NEURORADIOL, V19, P215, DOI 10.1177/159101991301900211
   Hori Y, 2000, INTERV NEURORADIOL, V6, P239, DOI 10.1177/159101990000600310
   Hughes DG, 2012, BMJ CASE REP
   Hung CL, 2003, CATHETER CARDIO INTE, V60, P267, DOI 10.1002/ccd.10634
   Huttl K, 2004, J VASC INTERV RADIOL, V15, P201, DOI 10.1097/01.RVI.0000109406.52762.98
   Iampreechakul P, 2016, INTERV NEURORADIOL, V22, P717, DOI 10.1177/1591019916659263
   Jang HJ, 2014, J KOREAN NEUROSURG S, V56, P348, DOI 10.3340/jkns.2014.56.4.348
   Jansen O, 1999, NEURORADIOLOGY, V41, P951, DOI 10.1007/s002340050875
   Jayaraman MV, 2007, AM J NEURORADIOL, V28, P352
   John S, 2014, J CLIN NEUROSCI, V21, P167, DOI 10.1016/j.jocn.2013.01.016
   JOHNSON CE, 1990, NEURORADIOLOGY, V31, P529, DOI 10.1007/BF00340135
   Kahara V, 2002, ACTA NEUROCHIR, V144, P493, DOI 10.1007/s007010200071
   Kai Y, 2001, ACTA NEUROCHIR, V143, P125, DOI 10.1007/s007010170116
   Kidd J, 2015, J VASC ULTRASOUND, V39, P21
   Kim DW, 2009, J KOREAN NEUROSURG S, V46, P498, DOI 10.3340/jkns.2009.46.5.498
   Kinoshita Y, 1998, INTERV NEURORADIOL, V4, P203, DOI 10.1177/15910199980040S142
   KOCAK H, 1991, VASCULAR SURG, V25, P584, DOI 10.1177/153857449102500713
   Koenigsberg RA, 1997, SURG NEUROL, V47, P265, DOI 10.1016/S0090-3019(96)00254-6
   Kominami S, 1996, Interv Neuroradiol, V2, P229
   KUBOTA M, 1992, Neurologia Medico-Chirurgica, V32, P84, DOI 10.2176/nmc.32.84
   Kurt A, 2006, INTERV NEURORADIOL, V12, P171, DOI 10.1177/159101990601200213
   Kypson AP, 2000, J TRAUMA, V49, P1141, DOI 10.1097/00005373-200012000-00031
   Li FD, 2014, ANN VASC SURG, V28, DOI 10.1016/j.avsg.2012.12.013
   Lin ZC, 2013, CHINESE J RADIOLOGY, V38, P135
   Ma XP, 2000, NEUROLOGY, V55, P288
   Maheshwari Sharad, 2002, Australas Radiol, V46, P316, DOI 10.1046/j.1440-1673.2002.01069.x
   Majeski JA, 1999, INT SURG, V84, P74
   Maki Y, 2018, NEUROL MED-CHIR, V58, P185, DOI 10.2176/nmc.cr.2017-0241
   Matsko DE, 1996, PATHOL RES PRACT, V192, P942
   Mei QY, 2014, ACTA NEUROCHIR, V156, P1781, DOI 10.1007/s00701-014-2074-0
   Miralbes S, 1998, NEURORADIOLOGY, V40, P761, DOI 10.1007/s002340050680
   Modi M, 2010, CARDIOVASC INTER RAD, V33, P1253, DOI 10.1007/s00270-009-9708-2
   Mohabbat W, 2001, ANZ J SURG, V71, P688, DOI 10.1046/j.1445-1433.2001.02238.x
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   MORELLO F, 1992, ITAL J NEUROL SCI, V13, P603, DOI 10.1007/BF02233405
   MORIMOTO T, 1995, ACTA NEUROCHIR, V137, P98, DOI 10.1007/BF02188790
   Mortimer A, 2009, J RADIOL CASE REP, V3, P9, DOI 10.3941/jrcr.v3i6.81
   Murayama Y, 1999, NEURORADIOLOGY, V41, P328, DOI 10.1007/s002340050758
   Nakano S, 2006, CHILD NERV SYST, V22, P13, DOI 10.1007/s00381-005-1237-y
   Nakstad PH, 1997, ACTA RADIOL, V38, P25
   Narayana Randhi Venkata, 2015, Indian J Radiol Imaging, V25, P18, DOI 10.4103/0971-3026.150132
   Narayanamurthy H, 2017, BRIT J NEUROSURG, V31, P736, DOI 10.1080/02688697.2016.1226257
   Nikolopoulos Panos, 2012, Perspect Vasc Surg Endovasc Ther, V24, P149, DOI 10.1177/1531003513482735
   Nunez F, 2010, ACTA PAEDIATR, V99, P1434, DOI 10.1111/j.1651-2227.2010.01831.x
   O'Shaughnessy BA, 2005, SURG NEUROL, V64, P335, DOI 10.1016/j.surneu.2004.11.010
   OLTEANUNERBE V, 1993, NEUROSURG REV, V16, P267, DOI 10.1007/BF00383833
   Paolini S, 2008, J NEUROSURG-SPINE, V8, P181, DOI 10.3171/SPI/2008/8/2/181
   Patro SN, 2009, J NEUROSURG, V111, P37, DOI 10.3171/2008.12.JNS081209
   PEETERS FLM, 1990, ROFO FORTSCHR RONTG, V153, P724, DOI 10.1055/s-2008-1033473
   Pereira VM, 2007, INTERV NEURORADIOL, V13, P315, DOI 10.1177/159101990701300402
   Priestley R, 2003, J ENDOVASC THER, V10, P657, DOI 10.1583/1545-1550(2003)010<0657:IVAFTW>2.0.CO;2
   Ra IH, 2013, SPINE J, V13, P1413, DOI 10.1016/j.spinee.2013.07.472
   Reddy M, 2002, NEUROL MED-CHIR, V42, P289, DOI 10.2176/nmc.42.289
   Righi C, 2002, J Neurosurg Sci, V46, P71
   Righi C, 2002, J NEUROSURG SCI, V46
   Romano A, 2016, NEURORADIOL J, V29, P455, DOI 10.1177/1971400916666557
   Roth TC, 2000, SKULL BASE SURG, V10, P35, DOI 10.1055/s-2000-6786
   Ruckert RI, 2001, J ENDOVASC THER, V8, P495, DOI 10.1177/152660280100800511
   Saavedra-Pozo F, 2017, J CRANIOVERTEBRAL JU, V8, P268, DOI 10.4103/jcvjs.JCVJS_49_17
   Sadato A, 2003, NEUROL MED-CHIR, V43, P250, DOI 10.2176/nmc.43.250
   Saket RR, 2004, J VASC INTERV RADIOL, V15, P1151, DOI 10.1097/01.RVI.0000134496.71252
   Sancak T, 2008, KOREAN J RADIOL, V9, pS68, DOI 10.3348/kjr.2008.9.s.s68
   SCHIEVINK WI, 1991, NEUROSURGERY, V29, P760, DOI 10.1227/00006123-199111000-00020
   Sen RD, 2017, J NEUROSURG-SPINE, V26, P341, DOI 10.3171/2016.8.SPINE16351
   Shin Sang Hoon, 1996, Journal of Korean Medical Science, V11, P532
   Shirakawa M, 2008, NEUROL MED-CHIR, V48, P167, DOI 10.2176/nmc.48.167
   Shownkeen H, 2003, PEDIATR RADIOL, V33, P354, DOI 10.1007/s00247-003-0866-0
   Siddhartha W, 2003, Australas Radiol, V47, P457, DOI 10.1046/j.1440-1673.2003.01221.x
   Stock U, 1996, ANAESTHESIA, V51, P687
   Surber R, 2003, J ENDOVASC THER, V10, P49, DOI 10.1583/1545-1550(2003)010<0049:RVAFAS>2.0.CO;2
   Syre P, 2013, J NEUROSURG-SPINE, V19, P759, DOI 10.3171/2013.8.SPINE12907
   Takahashi S, 2015, ANN VASC SURG, V29, DOI 10.1016/j.avsg.2014.07.038
   Taylor CG, 2001, NEURORADIOLOGY, V43, P1118, DOI 10.1007/s002340100651
   TENG MMH, 1991, NEURORADIOLOGY, V33, P195, DOI 10.1007/BF00588216
   Tenjin H, 2005, SURG NEUROL, V63, P80, DOI 10.1016/j.surneu.2004.01.026
   Tse GH, 2017, INTERV NEURORADIOL, V23, P399, DOI 10.1177/1591019917708569
   Uneda A, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.09.036
   Ushikoshi S, 1999, SURG NEUROL, V51, P168, DOI 10.1016/S0090-3019(98)00011-1
   VANROMPHEY A, 1990, VASCULAR SURG, V24, P206, DOI 10.1177/153857449002400310
   VANTETS WF, 1992, EUR J SURG, V158, P627
   Varga ZA, 2002, J THORAC CARDIOV SUR, V123, P575, DOI 10.1067/mtc.2002.119878
   Vergouwen MDI, 2006, J PEDIATR-US, V149, P576, DOI 10.1016/j.jpeds.2006.06.049
   Vinchon M, 1994, Cardiovasc Surg, V2, P359
   Waitzman AA, 1996, J OTOLARYNGOL, V25, P322
   Walcott BP, 2013, J CLIN NEUROSCI, V20, P1295, DOI 10.1016/j.jocn.2013.01.006
   Wang QH, 2011, ACTA NEUROCHIR, V153, P347, DOI 10.1007/s00701-010-0850-z
   WILLINSKY R, 1993, AM J NEURORADIOL, V14, P812
   Yamamoto A, 2016, ACUTE MED SURG, V3, P265, DOI 10.1002/ams2.177
   YARDLEY MPJ, 1992, BRIT J CLIN PRACT, V46, P71
   Yeh CH, 2014, INTERV NEURORADIOL, V20, P766, DOI 10.15274/INR-2014-10072
   Yilmaz MB, 2015, TURK NEUROSURG, V25, P141, DOI 10.5137/1019-5149.JTN.8247-13.1
   Yoshida S, 2000, NEUROL MED-CHIR, V40, P211, DOI 10.2176/nmc.40.211
   Yoshimura S, 1996, J CLIN NEUROSCI, V3, P261, DOI 10.1016/S0967-5868(96)90062-4
   Zhong H, 2011, J VASC SURG, V53, P492, DOI 10.1016/j.jvs.2010.02.025
NR 146
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1388
EP E1397
DI 10.1016/j.wneu.2018.11.063
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100170
PM 30458324
DA 2020-05-12
ER

PT J
AU Angulo, M
   Springer, L
   Behbahani, M
   Fagaragan, L
   Tabbilos, SJ
   Alaraj, A
   Testai, FD
   Amin-Hanjani, S
AF Angulo, Melissa
   Springer, Lauren
   Behbahani, Mandana
   Fagaragan, Lolita
   Tabbilos, Snyder John
   Alaraj, Ali
   Testai, Fernando D.
   Amin-Hanjani, Sepideh
TI Improving Ventriculostomy Management: Risk and Cost Reduction Through a
   Multidisciplinary Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE External ventricular drain; Infection; Neurocritical care; Quality
   improvement; Resource utilization; Ventriculostomy
ID VENTRICULITIS; EFFICACY; DRAINS; CATHETERS
AB OBJECTIVE: Infection is a life-threatening complication of ventriculostomy. The purpose of this quality improvement project was to develop a cost-effective, evidence-based intervention to reduce ventriculostomy-associated infection (VAI) rates.
   METHODS: In this retrospective study, patients undergoing ventriculostomy insertion between June 2008 and December 2016 were identified, and charts were reviewed. The study period between June 2008 and August 2010 constituted the baseline (phase 1) in which non-antibiotic-coated ventriculostomy catheters were used and cerebrospinal fluid (CSF) sampling was done daily. Then, 2 sequential interventions were implemented. Between September 2010 and January 2013, antibiotic-coated ventriculostomy catheters (AC-Vs) were used (phase 2). Then, between February 2013 and December 2016, the frequency of CSF sampling was minimized to twice a week (phase 3). The rates of VAI and operational costs, or cost incurred for the external ventricular drain catheter, antibiotics, laboratory analysis, and CSF sampling supplies, were compared for each phase.
   RESULTS: The average infection rate for phase 1 was 3.3 infections per 1000 device-days. The VAI rates for phases 2 and 3 were 1.6 and 0.8, respectively. The use of AC-Vs and reduced CSF sampling resulted in a VAI rate decrease of 75.8% (P = 0.01). During 2014, there were no VAIs. The intervention produced an estimated $1.02 million in savings for the institution during phase 3. The average projected savings of this intervention was $175 per patient per day and reduced cost by 72%.
   CONCLUSIONS: The use of AC-Vs in combination with decreased frequency of CSF sampling was cost saving and resulted in a significant reduction in device-related infections.
C1 [Angulo, Melissa; Fagaragan, Lolita; Tabbilos, Snyder John] Univ Illinois Hosp & Hlth Sci Syst, Dept Patient Care, Nursing Serv, Chicago, IL 60612 USA.
   [Behbahani, Mandana; Alaraj, Ali; Amin-Hanjani, Sepideh] Univ Illinois Hosp & Hlth Sci Syst, Dept Neurosurg, Chicago, IL USA.
   [Testai, Fernando D.] Univ Illinois Hosp & Hlth Sci Syst, Dept Neurol, Chicago, IL USA.
   [Springer, Lauren] Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
RP Angulo, M (reprint author), Univ Illinois Hosp & Hlth Sci Syst, Dept Patient Care, Nursing Serv, Chicago, IL 60612 USA.
EM mnlara2@uic.edu
OI Angulo, Melissa/0000-0002-7519-9005; Amin-Hanjani,
   Sepideh/0000-0002-1289-4596; behbahani, mandana/0000-0003-3882-8658
CR Alleyne CH, 2000, NEUROSURGERY, V47, P1124, DOI 10.1097/00006123-200011000-00020
   Bayston R, 2007, J HOSP INFECT, V65, P39, DOI 10.1016/S0195-6701(07)60013-9
   Beer R, 2008, J NEUROL, V255, P1617, DOI 10.1007/s00415-008-0059-8
   Avila SC, 2016, J ACUTE DIS, V5, P143, DOI 10.1016/j.joad.2015.12.001
   Chatzi M, 2014, CRIT CARE MED, V42, P66, DOI 10.1097/CCM.0b013e31829a70a5
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661
   Hagel S, 2014, Interdiscip Perspect Infect Dis, V2014, P708531, DOI 10.1155/2014/708531
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Lackner P, 2008, NEUROCRIT CARE, V8, P360, DOI 10.1007/s12028-008-9071-1
   Leverstein-van Hall MA, 2010, J NEUROSURG, V112, P345, DOI 10.3171/2009.6.JNS09223
   Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492
   Mikhaylov Y, 2014, J CLIN NEUROSCI, V21, P765, DOI 10.1016/j.jocn.2013.09.002
   Murray L, 2010, RED BOOK PHARM FUND
   Ramanan M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0712-z
   Sonabend AM, 2011, NEUROSURGERY, V68, P996, DOI 10.1227/NEU.0b013e3182096d84
   Wang X, 2013, CRIT CARE, V17, DOI 10.1186/cc12608
   Williams TA, 2011, J NEUROSURG, V115, P1040, DOI 10.3171/2011.6.JNS11167
   Williamson RA, 2014, J CRIT CARE, V29, P77, DOI 10.1016/j.jcrc.2013.08.012
   Wright K, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12271
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1259
EP E1265
DI 10.1016/j.wneu.2018.11.025
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100153
PM 30447459
DA 2020-05-12
ER

PT J
AU Pereira, BJA
   de Almeida, AN
   de Aguiar, PHP
   Paiva, WS
   Teixeira, MJ
   Marie, SKN
AF Araujo Pereira, Benedito Jamilson
   de Almeida, Antonio Nogueira
   Pires de Aguiar, Paulo Henrique
   Paiva, Wellingson Silva
   Teixeira, Manoel Jacobsen
   Nagahashi Marie, Suely Kazue
TI Multiple Intracranial Meningiomas: A Case Series and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Multiple meningioma; Recurrence; Surgery
ID CENTRAL-NERVOUS-SYSTEM; COWDEN-LIKE SYNDROME; NATURAL-HISTORY;
   THYROID-CANCER; GERMLINE PTEN; MUTATIONS; NEUROFIBROMATOSIS;
   EPIDEMIOLOGY; RECURRENCE; VARIANTS
AB OBJECTIVE: To review the published data to create a more comprehensive natural history of multiple meningiomas (MM).
   METHODS: A review of MM published until now was carried out through a Medline search up to August 2018. The use of the "multiple meningiomas" keyword returned 278 articles, and the characteristics analyzed in our present cohort were searched on those publications. Articles without detailed description of clinical findings, neuroimaging confirmation of tumor multiplicity, follow-up at least of 5 years, and clear description of clinical findings were excluded. We added series to this review.
   RESULTS: 293 patients with MM were analyzed: 220 women and 73 men, with a total of 932 tumors (3.1 tumors per patient). The majority of tumors were located in the convexity (653% to 74.5%). The total number of tumors treated was 429 (43.9%): 338 (78.8%) by surgical resection and 91 (21.2%) by radiotherapy. Histopathologic description was available in 303 of 429 cases, being grade I in 272 (90.3%) cases, with a predominance of the meningothelial subtype (30.7%). Tumor recurrence was described in 32 (8.07%) among 397 and only 10 deaths (3.4%) of 281 reported cases, where this characteristic was evaluated.
   CONCLUSIONS: World Health Organization grade I predominance was observed among multiple meningiomas in similarity to single meningiomas. Only a fraction of MM patients (43.89%) needed treatment. A benign tumor behavior was corroborated by the observed low frequency of recurrence and mortality.
C1 [Araujo Pereira, Benedito Jamilson; de Almeida, Antonio Nogueira; Pires de Aguiar, Paulo Henrique; Paiva, Wellingson Silva; Teixeira, Manoel Jacobsen; Nagahashi Marie, Suely Kazue] Univ Sao Paulo, Hosp Clin, Dept Neurol, Sao Paulo, Brazil.
   [de Almeida, Antonio Nogueira] Univ Sao Paulo, Hosp Clin, Div Neurocirurgia Func IPQ, Sao Paulo, Brazil.
RP Pereira, BJA (reprint author), Univ Sao Paulo, Hosp Clin, Dept Neurol, Sao Paulo, Brazil.
EM benedito.jamilson@hotmail.com
RI de Aguiar, Paulo Henrique Pires/U-2040-2019; Almeida,
   Antonio/O-5506-2019; Marie, Suely/D-1870-2012
OI de Aguiar, Paulo Henrique Pires/0000-0002-9059-4978; Almeida,
   Antonio/0000-0002-0796-7025; Marie, Suely/0000-0003-4419-7928
CR BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4
   Bennett KL, 2010, JAMA-J AM MED ASSOC, V304, P2724, DOI 10.1001/jama.2010.1877
   Birckhead B, 2016, J NEURO-ONCOL, V130, P553, DOI 10.1007/s11060-016-2257-z
   Blumenthal GM, 2008, EUR J HUM GENET, V16, P1289, DOI 10.1038/ejhg.2008.162
   Boetto J, 2017, NEURO-ONCOLOGY, V19, P345, DOI 10.1093/neuonc/now276
   BUTTI G, 1989, SURG NEUROL, V31, P225
   Cahill KS, 2011, J NEUROSURG, V115, P259, DOI 10.3171/2011.3.JNS101748
   Cea-Soriano L, 2012, NEUROEPIDEMIOLOGY, V39, P27, DOI 10.1159/000338081
   Christiaans I, 2011, J MED GENET, V48, P93, DOI 10.1136/jmg.2010.082420
   de Almeida AN, 2017, WORLD NEUROSURG, V102, P139, DOI 10.1016/j.wneu.2017.03.009
   DOMENICUCCI M, 1989, J NEUROSURG, V70, P41, DOI 10.3171/jns.1989.70.1.0041
   ELJAMEL MSM, 1989, SURG NEUROL, V32, P131, DOI 10.1016/0090-3019(89)90201-2
   Fink J, 2012, CURR NEUROL NEUROSCI, V12, P276, DOI 10.1007/s11910-012-0258-7
   Fromme JC, 2008, TRENDS CELL BIOL, V18, P330, DOI 10.1016/j.tcb.2008.04.006
   Granger A, 2000, J CLIN NEUROSCI, V7, P149, DOI 10.1054/jocn.1999.0171
   Heinrich B, 2003, INT J CANCER, V103, P483, DOI 10.1002/ijc.10840
   Huang HG, 2005, NEUROL RES, V27, P324, DOI 10.1179/016164105X39932
   JAASKELAINEN J, 1986, SURG NEUROL, V26, P461, DOI 10.1016/0090-3019(86)90259-4
   Joachim T, 2001, INT J CANCER, V94, P218, DOI 10.1002/ijc.1467
   Kerr K, 2018, NEUROSURGERY, V83, P1107, DOI 10.1093/neuros/nyy121
   Klaeboe L, 2005, INT J CANCER, V117, P996, DOI 10.1002/ijc.21255
   Koech F, 2013, CASE REP SURG, DOI 10.1155/2013/131962
   Koh YC, 2001, J CLIN NEUROSCI, V8, P40, DOI 10.1054/jocn.2001.0875
   LARSON JJ, 1995, J NEUROSURG, V83, P705, DOI 10.3171/jns.1995.83.4.0705
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   LUSINS JO, 1981, NEUROSURGERY, V9, P137, DOI 10.1227/00006123-198108000-00004
   Lynch JC, 2008, ARQ NEURO-PSIQUIAT, V66, P702, DOI 10.1590/S0004-282X2008000500018
   Mahdi H, 2015, CANCER-AM CANCER SOC, V121, P688, DOI 10.1002/cncr.29106
   Mocker K, 2011, PATHOL RES PRACT, V207, P67, DOI 10.1016/j.prp.2010.09.001
   NAGANO T, 1985, SURG NEUROL, V23, P425, DOI 10.1016/0090-3019(85)90223-X
   NAHSER HC, 1981, NEURORADIOLOGY, V21, P259, DOI 10.1007/BF02100156
   Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58
   Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289
   Neuss M, 1988, Br J Neurosurg, V2, P249, DOI 10.3109/02688698808992676
   Ngeow J, 2011, J CLIN ENDOCR METAB, V96, pE2063, DOI 10.1210/jc.2011-1616
   Ni Y, 2012, HUM MOL GENET, V21, P300, DOI 10.1093/hmg/ddr459
   OLIVERO WC, 1995, J NEUROSURG, V83, P222, DOI 10.3171/jns.1995.83.2.0222
   Orloff MS, 2013, AM J HUM GENET, V92, P76, DOI 10.1016/j.ajhg.2012.10.021
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Pereira BJA, NEUROSURG REV, DOI 1007/s10143-018-0959-8
   Rhoton AL, 2007, NEUROSURGERY, V61, P37, DOI 10.1227/01.NEU.0000255490.88321.CE
   Rhoton AL, 2007, NEUROSURGERY, V61, P1, DOI 10.1227/01.NEU.0000280027.92382.2B
   Salvati M, 2004, ZBL NEUROCHIR, V65, P180, DOI 10.1055/s-2004-832349
   SHEEHY JP, 1983, J NEUROSURG, V59, P1, DOI 10.3171/jns.1983.59.1.0001
   Shen YP, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-42
   STANECZEK W, 1992, CLIN NEUROPATHOL, V11, P135
   Stangl AP, 1997, J NEUROSURG, V86, P853, DOI 10.3171/jns.1997.86.5.0853
   STARINK TM, 1986, CLIN GENET, V29, P222
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Touat M, 2014, ACTA NEUROCHIR, V156, P1831, DOI 10.1007/s00701-014-2188-4
   Tsermoulas G, 2018, J NEUROSURG, V128, P1403, DOI 10.3171/2017.2.JNS162608
   Turgut M, 1997, NEUROSURG REV, V20, P117, DOI 10.1007/BF01138195
   Umansky F, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E7
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   VONDEIMLING A, 1995, BRAIN PATHOL, V5, P11
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Wong Ricky H, 2013, Surg Neurol Int, V4, P71, DOI 10.4103/2152-7806.112617
   Yakubov Eduard, 2016, Oncoscience, V3, P149, DOI 10.18632/oncoscience.305
   Yehia L, 2015, AM J HUM GENET, V97, P661, DOI 10.1016/j.ajhg.2015.10.001
   Zhu JJG, 1999, NEUROSURGERY, V45, P409, DOI 10.1097/00006123-199908000-00049
NR 60
TC 2
Z9 2
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1536
EP E1541
DI 10.1016/j.wneu.2018.11.097
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100188
PM 30471445
DA 2020-05-12
ER

PT J
AU Arrighi-Allisan, AE
   Neifert, SN
   Gal, JS
   Deutsch, BC
   Caridi, JM
AF Arrighi-Allisan, Annie E.
   Neifert, Sean N.
   Gal, Jonathan S.
   Deutsch, Brian C.
   Caridi, John M.
TI Discharge Destination as a Predictor of Postoperative Outcomes and
   Readmission Following Posterior Lumbar Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bundled payments; Nonhome discharge; Outcomes; Post-acute care
   facilities; Posterior lumbar fusion; Readmissions; Spine surgery
ID ANTERIOR CERVICAL DISKECTOMY; TOTAL JOINT ARTHROPLASTY; LENGTH-OF-STAY;
   30-DAY READMISSIONS; RISK-FACTORS; SURGICAL-TREATMENT; POSTDISCHARGE
   OUTCOMES; UNPLANNED READMISSION; HOSPITAL READMISSION; ELDERLY-PATIENTS
AB BACKGROUND: Posterior lumbar fusions are performed to treat various spinal deformities, degenerative diseases, fractures, infections, and tumors. The possibility of episode-based bundled payments for spine surgery necessitates analysis of the factors predicting readmissions and postoperative complications.
   METHODS: Patients undergoing posterior lumbar fusion in the American College of Surgeons National Surgical Quality Improvement Program were queried via Current Procedural Terminology codes 22630, 22633, and 22612. Patients were grouped based on discharge destination, either to home/home health care or to a facility. Relevant demographics, comorbidities, perioperative statistics, and predischarge and postdischarge complications were compared. Multivariable logistic regression models for severe postdischarge complications and 30-day read-missions were created with the exposure of nonhome discharge.
   RESULTS: Patients discharged to nonhome destinations were significantly older (68.42 vs. 58.15 years; P < 0.0001), sicker (68.11% of patients had American Society of Anesthesiologists Physical Status Classification > 2 vs. 44.25%; P < 0.0001), more dependent (5.92% vs. 1.40%; P < 0.0001), and had significantly greater body mass indices (10.60% of patients had body mass index > 40 vs. 7.63%; P < 0.0001) than patients discharged home. Following discharge, patients in the nonhome discharge group experienced higher mortality (0.28% vs. 0.08%; P < 0.0001) and were more likely to experience a severe complication (5.96% vs. 2.85%; P < 0.0001), minor complication (4.59% vs. 1.74%; P < 0.0001), and readmission (8.92% vs. 4.78%; P < 0.0001). Nonhome discharge proved to be a risk factor for both readmission (odds ratio 1.43; 95% confidence interval 1.28-1.60; P < 0.0001) and severe postdischarge complication (odds ratio 1.73; 95% confidence interval 1.52e1.97; P < 0.0001).
   CONCLUSIONS: Nonhome discharge patients experienced higher rates of complications and 30-day readmissions.
C1 [Arrighi-Allisan, Annie E.; Neifert, Sean N.; Deutsch, Brian C.] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA.
   [Gal, Jonathan S.] Mt Sinai Hosp, Dept Anesthesiol, New York, NY 10029 USA.
   [Caridi, John M.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
RP Arrighi-Allisan, AE (reprint author), Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA.
EM annie.arrighi-allisan@icahn.mssm.edu
OI Deutsch, Brian/0000-0002-8622-9951; Caridi, John/0000-0003-2841-585X
CR Akamnonu C, 2015, SPINE, V40, P423, DOI 10.1097/BRS.0000000000000759
   Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759
   Bini SA, 2010, J ARTHROPLASTY, V25, P114, DOI 10.1016/j.arth.2008.11.007
   Choy W, 2018, SPINE, V43, P356, DOI 10.1097/BRS.0000000000001450
   Cole T, 2017, CLIN SPINE SURG, V30, pE633, DOI 10.1097/BSD.0000000000000238
   De la Garza-Ramos R, 2016, J CLIN NEUROSCI, V31, P137, DOI 10.1016/j.jocn.2016.02.017
   Di Capua J, 2018, GLOB SPINE J, V8, P266, DOI 10.1177/2192568217717971
   Di Capua J, 2017, SPINE, V42, P1538, DOI 10.1097/BRS.0000000000002140
   Dimick JB, 2010, J AM COLL SURGEONS, V210, P503, DOI 10.1016/j.jamcollsurg.2010.01.018
   Dombrowski W, 2012, ARCH PHYS MED REHAB, V93, P1808, DOI 10.1016/j.apmr.2012.04.018
   Epstein Nancy E, 2014, Surg Neurol Int, V5, pS66, DOI 10.4103/2152-7806.130674
   Garcia RM, 2017, GLOB SPINE J, V7, P220, DOI 10.1177/2192568217694144
   Goldstein CL, 2016, J NEUROSURG-SPINE, V24, P416, DOI 10.3171/2015.2.SPINE14973
   Goldstein CL, 2014, CLIN ORTHOP RELAT R, V472, P1727, DOI 10.1007/s11999-014-3465-5
   Hackett NJ, 2015, INT J SURG, V18, P184, DOI 10.1016/j.ijsu.2015.04.079
   Jancuska JM, 2016, SPINE, V41, P1508, DOI 10.1097/BRS.0000000000001567
   Keswani A, 2016, J ARTHROPLASTY, V31, P1866, DOI 10.1016/j.arth.2016.02.053
   Keswani A, 2016, J ARTHROPLASTY, V31, P1155, DOI 10.1016/j.arth.2015.11.044
   Kim BD, 2014, J NEUROSURG-SPINE, V20, P606, DOI 10.3171/2014.3.SPINE13699
   Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415
   Manoharan SR, 2016, SPINE J, V16, P862, DOI 10.1016/j.spinee.2016.03.014
   Mechanic R, 2014, NEW ENGL J MED, V370, P692, DOI 10.1056/NEJMp1315607
   Minhas SV, 2017, J HEALTHC QUAL, V39, P34, DOI 10.1097/JHQ.0000000000000045
   Morandi A, 2013, J AM MED DIR ASSOC, V14, P761, DOI 10.1016/j.jamda.2013.03.013
   Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981
   Ondeck NT, 2018, SPINE J, V18, P44, DOI 10.1016/j.spinee.2017.05.028
   Ouslander JG, 2011, J AM MED DIR ASSOC, V12, P195, DOI 10.1016/j.jamda.2010.02.015
   Pannell WC, 2015, SPINE J, V15, P1719, DOI 10.1016/j.spinee.2013.10.014
   Phan K, 2017, SPINE, V42, P85, DOI 10.1097/BRS.0000000000001680
   Pugely AJ, 2014, SPINE, V39, P761, DOI 10.1097/BRS.0000000000000270
   Ramos NL, 2014, J ARTHROPLASTY, V29, P674, DOI 10.1016/j.arth.2013.09.010
   Rolland Y, 2012, J AM MED DIR ASSOC, V13, P407
   Schoenfeld AJ, 2017, J BONE JOINT SURG AM, V99, P1753, DOI 10.2106/JBJS.17.00368
   Schoenfeld AJ, 2016, SURGERY, V159, P1461, DOI 10.1016/j.surg.2015.12.012
   Schoenfeld AJ, 2014, SPINE J, V14, P2793, DOI 10.1016/j.spinee.2014.07.002
   Shih T, 2015, CIRCULATION, V131, P2151, DOI 10.1161/CIRCULATIONAHA.114.010393
   Spoonamore M, 2018, POSTERIOR LUMBAR FUS
   Su AW, 2016, SPINE, V41, P1523, DOI 10.1097/BRS.0000000000001558
   Taheri PA, 2000, J AM COLL SURGEONS, V191, P123, DOI 10.1016/S1072-7515(00)00352-5
   Vaccaro A, 2017, INT SOC ADV SPIN SUR
   Vasquez RA, 2017, NEUROSURGERY, V81, P772, DOI 10.1093/neuros/nyx114
   Yoshihara H, 2015, SPINE J, V15, P265, DOI 10.1016/j.spinee.2014.09.026
NR 42
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E139
EP E146
DI 10.1016/j.wneu.2018.09.147
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100015
PM 30268552
DA 2020-05-12
ER

PT J
AU Atsumi, H
   Sorimachi, T
   Honda, Y
   Sunaga, A
   Matsumae, M
AF Atsumi, Hideki
   Sorimachi, Takatoshi
   Honda, Yumie
   Sunaga, Azusa
   Matsumae, Mitsunori
TI Effects of Pre-Existing Comorbidities on Outcomes in Patients with
   Chronic Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute-on-chronic subdural hematoma; Anticoagulant; Antiplatelet;
   Antithrombotic; Comorbidity
ID HEMODIALYSIS-PATIENTS; RECURRENCE; ANTICOAGULATION; MANAGEMENT; DISEASE;
   RISK; CONSCIOUSNESS; COMPLICATIONS; RESTORATION; CRANIOSTOMY
AB OBJECTIVE: The number of patients with chronic subdural hematoma (CSDH) showing comorbidities and/or impaired activities of daily living (ADL) before the onset of CSDH has increased with the recent aging of society. The purposes of this study were to evaluate ADL worsening by comparing premorbid ADL and ADL at discharge and to investigate the effects of pre-existing comorbidity-related clinical factors on the outcomes.
   METHODS: A total of 570 patients with CSDH admitted from 2006 to 2016 were studied retrospectively. Clinical factors, including pre-existing comorbidities, related to outcomes were identified by multivariate analysis. A variation of the modified Rankin Scale (mRS) using 5 united categories of mRS scores 0/1, 2, 3/4, 5, and dead was used for evaluation of ADL.
   RESULTS: Of 570 patients, 390 (68.4%) had pre-existing comorbidities and 120 (21.1%) showed premorbid impaired ADL (mRS scores 2 and worse). Considering preexisting impaired ADL, ADL deteriorated after CSDH in 92 patients (16.1%), whereas ADL impairment at discharge was found in 173 patients (30.4%). Comorbidities related to ADL deterioration on multivariate analysis were hemodialysis and chronic heart failure. Antithrombotic use for cardiovascular diseases was a predictor of acute-onchronic subdural hematoma, which was the sole common predictor for ADL deterioration and the occurrence of surgical complications.
   CONCLUSIONS: In patients with CSDH, pre-existing comorbidity-linked factors related to outcomes were hemodialysis, chronic heart failure, and antithrombotic use. Patients with acute-on-chronic subdural hematoma with these factors should be regarded as a high-risk group.
C1 [Atsumi, Hideki; Sorimachi, Takatoshi; Honda, Yumie; Sunaga, Azusa; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
RP Sorimachi, T (reprint author), Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
EM sorimachi@tokai-u.jp
CR Abboud T, 2018, NEUROCIRUGIA, V29, P86, DOI 10.1016/j.neucir.2017.09.006
   Abe Y, 2017, J NEUROSURG, V126, P1042, DOI 10.3171/2016.3.JNS152957
   Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255
   Arca R, 2016, NEUROL SCI, V37, P1299, DOI 10.1007/s10072-016-2588-8
   Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008
   Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Balser D, 2015, J NEUROSURG, P1
   Borger V, 2012, ACTA NEUROCHIR, V154, P1549, DOI 10.1007/s00701-012-1434-x
   Chen CC, 2019, J NEUROSURG, V130, P302, DOI 10.3171/2017.8.JNS171103
   De Bonis P, 2013, PLOS ONE, V12
   De Bonis P, 2018, CLIN NEUROL NEUROSUR, V170, P88, DOI 10.1016/j.clineuro.2018.05.002
   Elliott MJ, 2007, AM J KIDNEY DIS, V50, P433, DOI 10.1053/j.ajkd.2007.06.017
   Forster MT, 2010, J CLIN NEUROSCI, V17, P975, DOI 10.1016/j.jocn.2009.11.023
   Frontera JA, 2011, NEUROCRIT CARE, V14, P260, DOI 10.1007/s12028-010-9418-2
   HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471
   Hiremath S, 2009, CLIN J AM SOC NEPHRO, V4, P1347, DOI 10.2215/CJN.00810209
   Honda Y, 2015, NEUROL RES, V37, P985, DOI 10.1179/1743132815Y.0000000083
   Hori YS, 2017, WORLD NEUROSURG, V105, P714, DOI 10.1016/j.wneu.2017.06.043
   Horn EM, 2006, SURG NEUROL, V65, P150, DOI 10.1016/j.surneu.2005.05.030
   Hotta K, 2017, WORLD NEUROSURG, V105, P47, DOI 10.1016/j.wneu.2017.05.105
   Izumihara A, 2013, NEUROL MED-CHIR, V53, P323, DOI 10.2176/nmc.53.323
   Javadi A, 2011, WORLD NEUROSURG, V75, P731, DOI 10.1016/j.wneu.2010.11.042
   Le Roux P, 2014, J NEUROSURG, V121, P1, DOI 10.3171/2014.8.paradigm
   LEONARD A, 1975, ANN INTERN MED, V82, P650, DOI 10.7326/0003-4819-82-5-650
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Levi M, 2011, J THROMB HAEMOST, V9, P1705, DOI 10.1111/j.1538-7836.2011.04432.x
   Licci M, 2018, CRIT CARE MED, V46, pE26, DOI 10.1097/CCM.0000000000002804
   Lindvall P, 2009, J CLIN NEUROSCI, V16, P1287, DOI 10.1016/j.jocn.2009.01.001
   Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371
   Phelan PJ, 2011, CLIN NEPHROL, V75, P204, DOI 10.5414/CN106481
   Power A, 2010, NEPHROL DIAL TRANSPL, V25, P2272, DOI 10.1093/ndt/gfq013
   Ramachandran R, 2007, SURG NEUROL, V67, P367, DOI 10.1016/j.surneu.2006.07.022
   ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263
   Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182
   Rovlias Aristedis, 2015, Surg Neurol Int, V6, P127, DOI 10.4103/2152-7806.161788
   ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x
   Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013
   Schoedel P, 2016, WORLD NEUROSURG, V94, P465, DOI 10.1016/j.wneu.2016.07.027
   Seizeur R, 2017, BRIT J NEUROSURG, V31, P258, DOI 10.1080/02688697.2016.1220503
   Smely C, 1997, ACTA NEUROCHIR, V139, P818, DOI 10.1007/BF01411399
   Sood P, 2007, CLIN J AM SOC NEPHRO, V2, P956, DOI 10.2215/CJN.03781106
   Sucu HK, 2006, SURG NEUROL, V66, P178, DOI 10.1016/j.surneu.2005.12.036
   Szczygielski J, 2016, WORLD NEUROSURG, V92, P426, DOI 10.1016/j.wneu.2016.05.049
   Takami H, 2013, CLIN NEUROL NEUROSUR, V115, P2236, DOI 10.1016/j.clineuro.2013.07.009
   Tanaka Yoji, 2013, J Med Dent Sci, V60, P55
   Tonelli M, 2014, J NEPHROL, V27, P1, DOI 10.1007/s40620-014-0038-3
   Tran H, 2004, JAMA-J AM MED ASSOC, V292, P1867, DOI 10.1001/jama.292.15.1867
   Wang IK, 2014, EUR J NEUROL, V21, P894, DOI 10.1111/ene.12406
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E924
EP E932
DI 10.1016/j.wneu.2018.10.176
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100111
PM 30408607
DA 2020-05-12
ER

PT J
AU Aydogmus, E
   Gul, S
   Bahadir, B
AF Aydogmus, Evren
   Gul, Sanser
   Bahadir, Burak
TI Neuroprotective Effects of Hesperidin on Cerebral Vasospasm After
   Experimental Subarachnoid Hemorrhage in Rats: Biochemical, Pathologic,
   and Histomorphometric Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral vasospasm; Hesperidin; Subarachnoid hemorrhage
ID REPERFUSION INJURY; BRAIN-INJURY; APOPTOSIS; DYSFUNCTION; FLAVONOIDS;
   HESPERETIN; LEPTIN; MICE
AB OBJECTIVE: We examined the protective effects of hesperidin on cerebral vasospasm by establishing an experimental rat model of subarachnoid hemorrhage and performing biochemical, pathologic, and histomorphometric analysis on these data.
   METHODS: Forty albino Wistar rats were randomly divided into 5 groups of n = 8 in each: group (G)1, no experimental interventions; G2, subjected to subarachnoid hemorrhage; G3, subjected to subarachnoid hemorrhage and administered saline (100 mg/kg); G4, subjected to subarachnoid hemorrhage and treated with low-dose hesperidin (50 mg/kg); and G5, subjected to subarachnoid hemorrhage and treated with high-dose hesperidin (100 mg/kg). Subarachnoid hemorrhage was created by injecting 0.15 cc of autologous blood taken from the rat-tail artery and injected into the cisterna magna from the craniocervical junction. Drugs were administered intraperitoneally as twice daily doses for 48 hours. Rats were euthanized at the end of this period.
   RESULTS: No statistically significant decrease was observed in malondialdehyde levels, which is the end-product of lipid peroxidation, among the drug groups (G4 and G5). Thin sections prepared from the basilar artery were examined morphologically. Severe luminal narrowing and vessel-wall thickening were observed in the subarachnoid hemorrhage groups (G2, G3). In the hesperidin-administered groups (G4, G5), it was determined that vessel wall thickness measurements revealed thinner walls than in the subarachnoid hemorrhage groups (G2, G3) and the luminal diameters were significantly larger than in the subarachnoid hemorrhage groups (G2, G3).
   CONCLUSIONS: These findings suggest that hesperidin has no effect on malondialdehyde-associated lipid-peroxidation activity; however, it might be useful in subarachnoid hemorrhage therapy because of its beneficial effects on vessel wall thickness and luminal diameters.
C1 [Aydogmus, Evren] Univ Hlth Sci, Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Gul, Sanser] Bulent Ecevit Univ Hosp, Dept Neurosurg, Zonguldak, Turkey.
   [Bahadir, Burak] Bulent Ecevit Univ Hosp, Dept Pathol, Zonguldak, Turkey.
RP Aydogmus, E (reprint author), Univ Hlth Sci, Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM evren.aydogmus@gmail.com
CR Ayer RE, 2008, ACTA NEUROCHIR SUPPL, V104, P33
   Cahill J, 2006, STROKE, V37, P1868, DOI 10.1161/01.STR.0000226995.27230.96
   Choi EJ, 2008, ARCH PHARM RES, V31, P1457, DOI 10.1007/s12272-001-2130-1
   de Oliveira DM, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-27
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   GALATI EM, 1994, FARMACO, V49, P709
   Gaur V, 2010, PHARMACOL REP, V62, P635, DOI 10.1016/S1734-1140(10)70321-2
   Grasso G, 2004, BRAIN RES REV, V44, P49, DOI 10.1016/j.brainresrev.2003.10.003
   HAVSTEEN B, 1983, BIOCHEM PHARMACOL, V32, P1141, DOI 10.1016/0006-2952(83)90262-9
   Hwang SL, 2012, J AGR FOOD CHEM, V60, P877, DOI 10.1021/jf204452y
   Jagetia GC, 2005, LIFE SCI, V77, P780, DOI 10.1016/j.lfs.2005.01.015
   Jestaedt L, 2008, NEUROSURGERY, V62, P610, DOI 10.1227/01.NEU.0000311351.32904.8B
   Kamisli S, 2015, TOXICOL IND HEALTH, V31, P841, DOI 10.1177/0748233713483192
   KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424
   Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386
   Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014
   Megyesi JF, 2000, NEUROSURGERY, V46, P448, DOI 10.1097/00006123-200002000-00035
   Menze ET, 2012, NEUROTOXICOLOGY, V33, P1265, DOI 10.1016/j.neuro.2012.07.007
   Oztanir MN, 2014, NEUROL SCI, V35, P1393, DOI 10.1007/s10072-014-1725-5
   Pluta RM, 1998, J NEUROSURG, V88, P557, DOI 10.3171/jns.1998.88.3.0557
   Rong Z, 2013, NEUROSCIENCE, V255, P292, DOI 10.1016/j.neuroscience.2013.09.030
   Sen O, 2006, NEUROL RES, V28, P859, DOI 10.1179/016164106X115099
   Shagirtha K, 2011, ECOTOX ENVIRON SAFE, V74, P2105, DOI 10.1016/j.ecoenv.2011.06.002
   Tamilselvam K, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/102741
   Tirkey N, 2005, BMC PHARM, V5, P1, DOI DOI 10.1186/1471-2210-5-2
   Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001
   WACKER A, 1975, NATURWISSENSCHAFTEN, V62, P301, DOI 10.1007/BF00608965
   Yan JH, 2006, EXP NEUROL, V202, P348, DOI 10.1016/j.expneurol.2006.06.009
   Zeng LH, 2013, J ZHEJIANG UNIV-SC B, V14, P1004, DOI 10.1631/jzus.B1300138
   Zhang S, 2013, NEUROCHEM INT, V63, P522, DOI 10.1016/j.neuint.2013.08.008
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1332
EP E1337
DI 10.1016/j.wneu.2018.11.043
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100162
PM 30448580
DA 2020-05-12
ER

PT J
AU Azab, MA
   O'Hagan, M
   Abou-Al-Shaar, H
   Karsy, M
   Guan, J
   Couldwell, WT
AF Azab, Mohammed A.
   O'Hagan, Molly
   Abou-Al-Shaar, Hussam
   Karsy, Michael
   Guan, Jian
   Couldwell, William T.
TI Safety and Outcome of Transsphenoidal Pituitary Adenoma Resection in
   Elderly Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Pituitary adenoma; Safety; Transsphenoidal approach
ID SURGICAL-TREATMENT; CLINICAL CHARACTERISTICS; SURGERY; TUMORS;
   MACROADENOMAS; FRAILTY
AB OBJECTIVE: Pituitary adenomas account for 10%-20% of intracranial brain tumors but have greater incidence in elderly patients. We assessed microsurgical treatment for pituitary adenomas in this population.
   METHODS: A retrospective cohort of patients >= 60 years of age was identified. Patients were divided into deciles by age for evaluation of variables affecting outcome: 60-70 (group 1), 71-80 (group 2), and >80 years (group 3).
   RESULTS: Two hundred five patients were identified among group 1 (n = 131), group 2 (n = 65), and group 3 (n = 9). Preoperative variables other than age did not differ. Most patients presented with visual disturbance, in 56.5%, 73.8%, and 50% in groups 1, 2, and 3, respectively. The next most common indication was headache, followed by endocrinopathy. Tumors were overwhelmingly nonfunctional (P = 0.97) and macroadenomas (P = 0.5) in all 3 groups. Gross total resection occurred in 56.9%-80% of patients, and this rate did not differ among groups. Complication rates of 6.9% in group 1, 9.2% in group 2, and 0.0% in group 3 were observed (P = 0.8). No perioperative mortality was identified. Mean length of follow-up ranged from 8.9 to 28.3 months.
   CONCLUSIONS: In this series of microsurgical resection of pituitary adenomas in elderly patients, good efficacy and safety of treatment were observed. Preclusion of surgical treatment, including open resection, simply because of age is not warranted and instead a comprehensive evaluation of a patient's risk profile and surgical goals should be undertaken.
C1 [Azab, Mohammed A.; Abou-Al-Shaar, Hussam; Karsy, Michael; Guan, Jian; Couldwell, William T.] Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84132 USA.
   [O'Hagan, Molly] New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA.
   [Abou-Al-Shaar, Hussam] Hofstra Northwell Sch Med, Dept Neurosurg, Manhasset, NY USA.
RP Couldwell, WT (reprint author), Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84132 USA.
EM neuropub@hsc.utah.edu
RI Karsy, Michael/AAH-8583-2020
OI Karsy, Michael/0000-0002-0422-7937; Guan, Jian/0000-0002-4762-7113
CR Benbow SJ, 1997, CLIN ENDOCRINOL, V46, P657, DOI 10.1046/j.1365-2265.1997.1180933.x
   Chinezu R, 2017, WORLD NEUROSURG, V106, P315, DOI [10.1016/J.WNEU.2017.06.151, 10.1016/j.wneu.2017.06.151]
   Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9
   Couldwell WT, 2004, NEUROSURGERY, V55, P539, DOI 10.1227/01.NEU.0000134287.19377.A2
   Couldwell WT, 2004, J NEURO-ONCOL, V69, P237, DOI 10.1023/B:NEON.0000041886.61149.ab
   Couldwell WT, 2003, NEUROSURG CLIN N AM, V14, P89, DOI 10.1016/S1042-3680(02)00090-6
   Del Monte P, 2007, AGING CLIN EXP RES, V19, P34, DOI 10.1007/BF03325208
   Ferrante L, 2002, J NEURO-ONCOL, V60, P185, DOI 10.1023/A:1020652604014
   Fraioli B, 1999, SURG NEUROL, V51, P261, DOI 10.1016/S0090-3019(98)00097-4
   Fujimoto Kenji, 2017, Surg Neurol Int, V8, P213, DOI 10.4103/sni.sni_189_17
   Gondim JA, 2015, J NEUROSURG, V123, P31, DOI 10.3171/2014.10.JNS14372
   Guan J, 2018, NEUROSURGERY, V83, P726, DOI 10.1093/neuros/nyx471
   He W, 2016, INT POPULATION REPOR
   Hong JF, 2008, J CLIN NEUROSCI, V15, P1091, DOI 10.1016/j.jocn.2007.11.003
   Hornyak M, 2009, POSTGRAD MED, V121, P168, DOI 10.3810/pgm.2009.03.1989
   Karsy M, 2019, NEUROSURGERY, V84, P1104, DOI 10.1093/neuros/nyy269
   Kinoshita Y, 2018, J CLIN NEUROSCI, V53, P127, DOI 10.1016/j.jocn.2018.04.054
   Kurosaki M, 2001, PATHOL RES PRACT, V197, P493, DOI 10.1078/0344-0338-00117
   Kurosaki M, 2000, NEUROSURGERY, V47, P843, DOI 10.1097/00006123-200010000-00009
   Letournel F, 2003, J AM GERIATR SOC, V51, P729
   Liu JK, 2004, J NEUROSURG, V100, P161, DOI 10.3171/jns.2004.100.1.0161
   Liu JK, 2003, NEUROSURG CLIN N AM, V14, P93, DOI 10.1016/S1042-3680(02)00033-5
   Liu JF, 2015, J AM GERIATR SOC, V63, P1924, DOI 10.1111/jgs.13590
   Locatelli M, 2013, PITUITARY, V16, P146, DOI 10.1007/s11102-012-0390-z
   Marenco HA, 2015, ARQ NEURO-PSIQUIAT, V73, P764, DOI 10.1590/0004-282X20150112
   McDowell BD, 2011, PITUITARY, V14, P23, DOI 10.1007/s11102-010-0253-4
   Moncef B, 2017, BRAIN SPINE SURG ELD
   Pereira EAC, 2014, BRIT J NEUROSURG, V28, P616, DOI 10.3109/02688697.2013.872225
   PUCHNER MJA, 1995, NEUROSURGERY, V36, P677, DOI 10.1227/00006123-199504000-00006
   Robenshtok E, 2014, ENDOCR PRACT, V20, P159, DOI 10.4158/EP13182.OR
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Sasagawa Y, 2018, WORLD NEUROSURG, V118, pE229, DOI 10.1016/j.wneu.2018.06.165
   Sheehan JM, 2008, ACTA NEUROCHIR, V150, P571, DOI 10.1007/s00701-008-1581-2
   Taussky P, 2011, J NEUROSURG, V115, P55, DOI 10.3171/2011.2.JNS10566
   Turner HE, 1999, EUR J ENDOCRINOL, V140, P383, DOI 10.1530/eje.0.1400383
   Wilson PJ, 2018, J NEUROSURG, V128, P429, DOI 10.3171/2016.11.JNS162286
   Yunoue S, 2014, NEUROSURG REV, V37, P269, DOI 10.1007/s10143-013-0509-3
   Zhan RC, 2015, WORLD NEUROSURG, V84, P1572, DOI 10.1016/j.wneu.2015.08.035
   Zhao Y, 2017, J CLIN NEUROSCI, V46, P13, DOI 10.1016/j.jocn.2017.08.038
NR 39
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1252
EP E1258
DI 10.1016/j.wneu.2018.11.024
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100152
PM 30447462
DA 2020-05-12
ER

PT J
AU Bae, IS
   Chun, HJ
   Bak, KH
   Yi, HJ
   Choi, KS
   Kim, KD
AF Bae, In-Suk
   Chun, Hyoung-Joon
   Bak, Koang-Hum
   Yi, Hyeong-Joong
   Choi, Kyu-Sun
   Kim, Kee D.
TI Medial Branch Block Versus Vertebroplasty for 1-Level Osteoporotic
   Vertebral Compression Fracture: 2-Year Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medial branch block; Osteoporosis; Vertebral compression fracture;
   Vertebroplasty
ID PERCUTANEOUS VERTEBROPLASTY; OLDER WOMEN; FOLLOW-UP; BONE; PAIN;
   AUGMENTATION; MORTALITY
AB OBJECTIVE: Percutaneous vertebroplasty (VP) and medial branch block (MBB) are used to treat osteoporotic vertebral compression fractures (VCF). We compared the clinical outcomes, radiologic changes, and economic results of MBB with those of VP in treating osteoporotic VCFs.
   METHODS: A total of 164 patients with 1-level osteoporotic VCF were reviewed retrospectively. The clinical outcomes were measured with a visual analogue scale (VAS) and the Oswestry Disability Index (ODI). To compare economic costs between groups, total hospital costs at the last follow-up day were calculated.
   RESULTS: The patients were divided into 2 groups: 72 patients in the conservative group treated by MBB (MBB group) and 92 patients in the group who underwent VP (VP group). The VAS and ODI scores improved significantly within postoperative week 1 in the VP group compared with the MBB group. However, the VAS and ODI scores did not differ between the groups after 1 postoperative year. After 2 years of follow-up, 14 new fractures occurred in the VP group and 3 in the MBB group. The improvement in compression ratio was statistically greater in the VP group than in the MBB group. However, after 2 years the radiologic changes between groups did not differ statistically. After the final follow-up visits, the hospital costs were significantly lower in the MBB group.
   CONCLUSIONS: After 2 years of follow-up, VP and MBB both had similar efficacy in terms of pain relief and radiologic changes. MBB was more cost effective than VP. Thus, MBB alone can be a possible alternative to VP in patients with 1-level osteoporotic VCFs.
C1 [Bae, In-Suk; Chun, Hyoung-Joon; Bak, Koang-Hum; Yi, Hyeong-Joong; Choi, Kyu-Sun] Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Kim, Kee D.] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA.
RP Chun, HJ (reprint author), Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul, South Korea.
EM tdy815@hanyang.ac.kr
CR Alvarez L, 2006, SPINE, V31, P1113
   Anselmetti GC, 2007, CARDIOVASC INTER RAD, V30, P441, DOI 10.1007/s00270-006-0146-0
   Boonen S, 2011, J BONE MINER RES, V26, P1627, DOI 10.1002/jbmr.364
   Chen Jyi-Feng, 2002, Chang Gung Med J, V25, P306
   Diamond TH, 2003, AM J MED, V114, P257, DOI 10.1016/S0002-9343(02)01524-3
   Dublin AB, 2005, AM J NEURORADIOL, V26, P489
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532-5415.2000.tb02641.x
   Farrokhi MR, 2011, J NEUROSURG-SPINE, V14, P561, DOI 10.3171/2010.12.SPINE10286
   Ha KY, 2013, ASIAN SPINE J, V7, P294, DOI 10.4184/asj.2013.7.4.294
   Hiwatashi A, 2009, AM J NEURORADIOL, V30, P669, DOI 10.3174/ajnr.A1442
   Hoshino M, 2009, EUR SPINE J, V18, P1279, DOI 10.1007/s00586-009-1041-6
   Itshayek E, 2012, J CLIN NEUROSCI, V19, P786, DOI 10.1016/j.jocn.2011.12.015
   Iwata A, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1509-1
   Kado DM, 2003, OSTEOPOROSIS INT, V14, P589, DOI 10.1007/s00198-003-1412-5
   Klazen CAH, 2010, LANCET, V376, P1085, DOI 10.1016/S0140-6736(10)60954-3
   Lee HM, 2012, SPINE J, V12, P998, DOI 10.1016/j.spinee.2012.08.024
   Mitra R, 2010, PAIN MED, V11, P1674, DOI 10.1111/j.1526-4637.2010.00953.x
   Mpotsaris A, 2011, DTSCH ARZTEBL INT, V108, P331, DOI 10.3238/arztebl.2011.0331
   Park KD, 2013, ANN REHABIL MED-ARM, V37, P191, DOI 10.5535/arm.2013.37.2.191
   Ren HL, 2015, EUR SPINE J, V24, P750, DOI 10.1007/s00586-015-3786-4
   Rousing R, 2010, SPINE, V35, P478, DOI 10.1097/BRS.0b013e3181b71bd1
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Shin Chang Jin, 2016, Korean J Neurotrauma, V12, P123, DOI 10.13004/kjnt.2016.12.2.123
NR 23
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1599
EP E1605
DI 10.1016/j.wneu.2018.11.142
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100197
PM 30481629
DA 2020-05-12
ER

PT J
AU Baeesa, S
   Jarzem, P
   Mansi, M
   Bokhari, R
   Bassi, M
AF Baeesa, Saleh
   Jarzem, Peter
   Mansi, Mohammed
   Bokhari, Rakan
   Bassi, Mahdi
TI Spontaneous Spinal Epidural Hematoma: Correlation of Timing of Surgical
   Decompression and MRI Findings with Functional Neurological Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE MRI; Outcome; Spontaneous spinal epidural hematoma; Surgical
   decompression
AB OBJECTIVE: Spontaneous spinal epidural hematoma (SSEH) is a rare and morbid entity, with the prognosis affected by delayed diagnosis and surgical intervention. The correlation between the timing of the intervention and neurological recovery has not been clearly reported. We present a retrospective study of SSEH to determine the correlation between the timing of surgical intervention and changes in the spinal cord signal on magnetic resonance imaging (MRI) with the neurological outcome.
   METHODS: The records of 14 patients who had undergone surgical decompression of SSEHs during a 10-year duration were reviewed. The diagnosis was established from the MRI, intraoperative, and histopathological examination findings.
   RESULTS: We identified 14 patients from both centers, 6 of whom were male. Their mean age was 54.1 years. The onset was spontaneous, and 2 patients were receiving anticoagulant therapy. The most common presentation was paraplegia (n = 8), followed by paraparesis (n = 3) and quadriparesis (n = 2). Spinal cord signal changes were demonstrated on all T2-weighted MRI studies. The response to surgery was favorable for 13 of our patients at the 6-month follow-up examination. The spinal cord changes had persisted in 5 patients on the 6-month postoperative MRI scan. All 14 patients, except for 1, had a favorable neurological outcome at the last follow-up examination.
   CONCLUSIONS: Significant neurological recovery after surgical decompression of SSEHs can be achieved, despite the significant preoperative neurological deficits, spinal cord changes on MRI, and delayed timing of intervention.
C1 [Baeesa, Saleh; Mansi, Mohammed; Bokhari, Rakan; Bassi, Mahdi] King Abdulaziz Univ, Div Neurosurg, Dept Surg, Fac Med, Jeddah, Saudi Arabia.
   [Jarzem, Peter; Mansi, Mohammed; Bokhari, Rakan] McGill Univ, Dept Orthoped Surg, Montreal, PQ, Canada.
RP Baeesa, S (reprint author), King Abdulaziz Univ, Div Neurosurg, Dept Surg, Fac Med, Jeddah, Saudi Arabia.
EM sbaeesa@kau.edu.sa
OI Baeesa, Saleh/0000-0002-3053-7912
CR Akimoto T, 2014, J CENT NERV SYST DIS, V6, P15, DOI [10.4137/JCNSNSD.S13252, 10.4137/JCNSD.S13252]
   BEATTY RM, 1984, J NEUROSURG, V61, P143, DOI 10.3171/jns.1984.61.1.0143
   Endo T, 2014, SPINAL CORD, V52, P729, DOI 10.1038/sc.2014.53
   Figueroa Jessica, 2017, J Spine Surg, V3, P58, DOI 10.21037/jss.2017.02.04
   Fukui MB, 1999, AM J NEURORADIOL, V20, P1365
   Groen RJM, 1996, NEUROSURGERY, V39, P494, DOI 10.1097/00006123-199609000-00012
   GROEN RJM, 1990, J NEUROL SCI, V98, P121, DOI 10.1016/0022-510X(90)90253-J
   GUNDRY CR, 1993, RADIOLOGY, V187, P427, DOI 10.1148/radiology.187.2.8475285
   Holtas S, 1996, RADIOLOGY, V199, P409, DOI 10.1148/radiology.199.2.8668786
   Jackson R, 1869, LANCET, V2, P5
   Kim T, 2012, J KOREAN NEUROSURG S, V52, P523, DOI 10.3340/jkns.2012.52.6.523
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   Kunizawa A, 2009, J NEUROSURG-SPINE, V10, P574, DOI 10.3171/2009.2.SPINE08342
   LAWTON MT, 1995, J NEUROSURG, V83, P1, DOI 10.3171/jns.1995.83.1.0001
   Liu Z, 2008, SURG NEUROL, V69, P253, DOI 10.1016/j.surneu.2007.02.019
   Lonjon MMC, 1997, NEUROSURGERY, V41, P483, DOI 10.1097/00006123-199708000-00035
   Mahieu X., 1994, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V23, P99
   MATSUMAE M, 1987, SURG NEUROL, V28, P381, DOI 10.1016/0090-3019(87)90062-0
   MATTLE H, 1987, NEUROLOGY, V37, P1351, DOI 10.1212/WNL.37.8.1351
   Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432
   Gonzalez AM, 2015, NEUROLOGIA, V30, P393, DOI 10.1016/j.nrl.2014.03.007
   Raasck Kyle, 2017, Spinal Cord Ser Cases, V3, P16043, DOI 10.1038/scsandc.2016.43
   Sarica FB, 2009, J NEUROSURG SCI, V53, P63
   Sathirapanya P, 2013, J SPINAL CORD MED, V36, P707, DOI 10.1179/2045772313Y.0000000104
   SERIZAWA Y, 1995, INTERNAL MED, V34, P992, DOI 10.2169/internalmedicine.34.992
   Villas Carlos, 2006, Eur Spine J, V15 Suppl 5, P569, DOI 10.1007/s00586-005-0023-6
NR 26
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E241
EP E247
DI 10.1016/j.wneu.2018.09.224
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100026
PM 30336292
DA 2020-05-12
ER

PT J
AU Bandt, SK
   de Rochefort, L
   Chen, WW
   Dimov, AV
   Spincemaille, P
   Kopell, BH
   Gupta, A
   Wang, Y
AF Bandt, S. Kathleen
   de Rochefort, Ludovic
   Chen, Weiwei
   Dimov, Alexey V.
   Spincemaille, Pascal
   Kopell, Brian H.
   Gupta, Ajay
   Wang, Yi
TI Clinical Integration of Quantitative Susceptibility Mapping Magnetic
   Resonance Imaging into Neurosurgical Practice
SO WORLD NEUROSURGERY
LA English
DT Article
DE Advanced imaging techniques; Deep brain stimulation; Glioma; Meningioma;
   Neuro-oncology; Quantitative susceptibility mapping; Stereotactic
   navigation
ID DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; CAVERNOUS MALFORMATIONS;
   CEREBRAL MICROBLEEDS; DIPOLE INVERSION; IRON; MRI; CONTRAST; ECHO;
   VENOGRAPHY
AB OBJECTIVE: To introduce quantitative susceptibility mapping (QSM), a novel magnetic resonance imaging sequence, to the field of neurosurgery.
   METHODS: QSM is introduced both in its historical context and by providing a brief overview of the physics behind the technique tailored to a neurosurgical audience. Its application to clinical neurosurgery is then highlighted using case examples.
   RESULTS: QSM offers a quantitative assessment of susceptibility (previously considered as an artifact) via a single, straightforward gradient echo acquisition. QSM differs from standard susceptibility weighted imaging in its ability to both quantify and precisely localize susceptibility effects. Clinical applications of QSM are wide reaching and include precise localization of the deep nuclei for deep brain stimulation electrode placement, differentiation between blood products and calcification within brain lesions, and enhanced sensitivity of cerebral micrometastasis identification.
   CONCLUSIONS: We present this diverse range of QSM's clinical applications to neurosurgical care via case examples. QSM can be obtained in all patients able to undergo magnetic resonance imaging and is easily integratable into busy neuroradiology programs because of its short acquisition time and straightforward, automated offline post-processing workflow. Clinical integration of QSM may help clinicians better identify and characterize neurosurgical lesions, thereby improving patient care.
C1 [Bandt, S. Kathleen; de Rochefort, Ludovic; Wang, Yi] Aix Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille, France.
   [Bandt, S. Kathleen] Hop La Timone, AP HM, CEMEREM, Marseille, France.
   [Bandt, S. Kathleen] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Chen, Weiwei] Tongji Hosp, Dept Radiol, Wuhan, Hubei, Peoples R China.
   [Dimov, Alexey V.; Wang, Yi] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA.
   [Spincemaille, Pascal; Gupta, Ajay; Wang, Yi] Weill Cornell Med Coll, Dept Radiol, New York, NY USA.
   [Kopell, Brian H.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
RP Bandt, SK (reprint author), Aix Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille, France.; Bandt, SK (reprint author), Hop La Timone, AP HM, CEMEREM, Marseille, France.; Bandt, SK (reprint author), Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA.
EM skbandt@gmail.com
RI Dimov, Alexey V./AAC-4157-2019; de Rochefort, Ludovic/F-8742-2011
OI Wang, Yi/0000-0003-1404-8526; de Rochefort, Ludovic/0000-0001-7466-6452
FU American Association of Neurological Surgeons via the William P Van
   Wagenen Fellowship
FX This study was supported by the American Association of Neurological
   Surgeons via the William P Van Wagenen Fellowship (S.K.E).
CR Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2
   Atlas SW, 2016, MAGNETIC RESONANCE I
   Bao LJ, 2016, IEEE T MED IMAGING, V35, P2040, DOI 10.1109/TMI.2016.2544958
   Baumann CR, 2006, EPILEPSIA, V47, P563, DOI 10.1111/j.1528-1167.2006.00468.x
   Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001
   Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6
   Brown P, 2005, CLIN NEUROPHYSIOL, V116, P2510, DOI 10.1016/j.clinph.2005.05.009
   Chandran AS, 2016, J NEUROSURG, V124, P96, DOI 10.3171/2015.1.JNS142066
   Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640
   Cho ZH, 2010, J NEUROSURG, V113, P639, DOI 10.3171/2010.3.JNS091385
   de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710
   de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187
   de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748
   DECRESPIGNY AJ, 1993, MAGNET RESON MED, V30, P135, DOI 10.1002/mrm.1910300121
   Deistung A, 2017, NMR BIOMED, V30
   Deistung A, 2006, Z MED PHYS, V16, P261, DOI 10.1078/0939-3889-00324
   Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924
   Du GW, 2016, MOVEMENT DISORD, V31, P317, DOI 10.1002/mds.26417
   Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989
   Ghiglia D.C., 1998, 2 DIMENSIONAL PHASE
   Golby A. J., 2015, IMAGE GUIDED NEUROSU
   Graat I, 2017, INT REV PSYCHIATR, V29, P178, DOI 10.1080/09540261.2017.1282439
   Haacke E.M., 2011, SUSCEPTIBILITY WEIGH
   Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004
   Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198
   Ito K, 1999, RADIOLOGY, V212, P235, DOI 10.1148/radiology.212.1.r99jl41235
   Jain R, 2015, BRAIN TUMOR IMAGING
   Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175
   Kaaouana T, 2017, NEUROIMAGE-CLIN, V15, P274, DOI 10.1016/j.nicl.2016.08.005
   Kaaouana T, 2015, NEUROIMAGE, V104, P287, DOI 10.1016/j.neuroimage.2014.08.024
   Kim KM, 1995, SCANNING MICROSCOPY, V9, P1137
   Langkammer C, 2018, MAGN RESON MED, V79, P1661, DOI 10.1002/mrm.26830
   Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041
   Li JQ, 2012, MAGN RESON MED, V68, P1563, DOI 10.1002/mrm.24135
   Li W, 2015, NEUROIMAGE, V108, P111, DOI 10.1016/j.neuroimage.2014.12.043
   Liu CL, 2015, TOMOGRAPHY, V1, P3, DOI 10.18383/j.tom.2015.00136
   Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082
   Liu T, 2013, RADIOLOGY, V269, P216, DOI 10.1148/radiol.13121991
   Lumenta CB, 2010, EUR MAN MED, P1, DOI 10.1007/978-3-540-79565-0
   McDonald DM, 2002, CANCER RES, V62, P5381
   Milovic C, 2018, MAGN RESON MED, V80, P814, DOI 10.1002/mrm.27073
   Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461
   Nagy JA, 2009, BRIT J CANCER, V100, P865, DOI 10.1038/sj.bjc.6604929
   Ozbay PS, 2018, MAGN RESON MED, V79, P770, DOI 10.1002/mrm.26735
   Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365
   Rasouli J, 2018, OPER NEUROSURG, V14, P412, DOI 10.1093/ons/opx131
   Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309
   Reichenbach JR, 1998, MAGN RESON MATER PHY, V6, P62, DOI 10.1016/S1352-8661(98)00011-8
   Schweser F, 2016, Z MED PHYS, V26, P6, DOI 10.1016/j.zemedi.2015.10.002
   Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067
   Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598
   Sun HF, 2016, MAGN RESON MED, V76, P781, DOI 10.1002/mrm.25919
   Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043
   Vercueil L, 2001, J NEUROL, V248, P695, DOI 10.1007/s004150170116
   Wang Y., 2012, PRINCIPLES MAGNETIC
   Wang Y, 2013, QUANTITATIVE SUSCEPT
   Wang Y, 2017, J MAGN RESON IMAGING, V46, P951, DOI 10.1002/jmri.25693
   Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   Wharton S, 2012, P NATL ACAD SCI USA, V109, P18559, DOI 10.1073/pnas.1211075109
   Wichmann T, 2006, NEURON, V52, P197, DOI 10.1016/j.neuron.2006.09.022
   Wodarg F, 2012, MOVEMENT DISORD, V27, P874, DOI 10.1002/mds.25006
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
NR 63
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E10
EP E19
DI 10.1016/j.wneu.2018.08.213
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100003
PM 30201583
DA 2020-05-12
ER

PT J
AU Bao, XY
   Wang, QN
   Zhang, Y
   Zhang, Q
   Li, DS
   Yang, WZ
   Zhang, ZS
   Zong, R
   Han, C
   Duan, L
AF Bao, Xiang-Yang
   Wang, Qian-Nan
   Zhang, Yong
   Zhang, Qian
   Li, De-Sheng
   Yang, Wei-Zhong
   Zhang, Zheng-Shan
   Zong, Rui
   Han, Cong
   Duan, Lian
TI Epidemiology of Moyamoya Disease in China: Single-Center,
   Population-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE China; Epidemiology; Moyamoya disease
ID CLINICAL-FEATURES; PEDIATRIC MOYAMOYA; ADULT PATIENTS; NATIONWIDE;
   PREVALENCE; JAPAN; KOREA
AB BACKGROUND: To our knowledge, no previous study has described the nationwide epidemiologic features of moyamoya disease (MMD) in China. We describe the epidemiologic features including the relative prevalence, age distribution, gender distribution, and initial clinical manifestations of patients with MMD treated at a single institution in China.
   METHODS: Our cohort included 4128 patients with MMD. Their demographic and clinical characteristics were obtained by retrospective chart review.
   RESULTS: The median age for the onset of symptoms was 30.36 years. The age distribution of patients with MMD was bimodal, with the highest peak detection rate at 35-45 years of age and a smaller peak at 5-9 years of age. The ratio of female-to-male patients was 1:1. The disease occurred mainly in the Han people and was rarely seen in minority nationalities. In our cohort, transient ischemic attack was the most common initial clinical manifestation (48.13%). The other initial manifestations included infarction (22.62%), hemorrhage (16.45%), and headache 230/4128 (5.57%). In north and northeast China, the ischemic type was more predominate while the hemorrhagic type was relatively rare. However, the percentage of hemorrhagic type in East China was higher than anywhere else in China.
   CONCLUSIONS: This study confirmed some unique epidemiologic features as the studies previously reported in China, but it also revealed some new sight and tendency about moyamoya in China. As a lack of national epidemiologic studies, this study indicated the outline of moyamoya in China.
C1 [Bao, Xiang-Yang; Wang, Qian-Nan; Zhang, Yong; Zhang, Qian; Li, De-Sheng; Yang, Wei-Zhong; Zhang, Zheng-Shan; Zong, Rui; Han, Cong; Duan, Lian] Acad Mil Med Sci, Dept Neurosurg, Ctr Cerebral Vasc Dis, Beijing, Peoples R China.
RP Duan, L (reprint author), Acad Mil Med Sci, Dept Neurosurg, Ctr Cerebral Vasc Dis, Beijing, Peoples R China.
EM duanlian307@sina.com
CR Ahn IM, 2014, STROKE, V45, P1090, DOI 10.1161/STROKEAHA.113.004273
   Baba T, 2008, J NEUROL NEUROSUR PS, V79, P900, DOI 10.1136/jnnp.2007.130666
   Chen PC, 2014, STROKE, V45, P1258, DOI 10.1161/STROKEAHA.113.004160
   Cheng JH, 2016, J CLIN NEUROSCI, V32, P30, DOI 10.1016/j.jocn.2015.12.042
   Duan L, 2012, STROKE, V43, P56, DOI 10.1161/STROKEAHA.111.621300
   Han C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088765
   Hoshino H, 2012, NEUROL MED-CHIR, V52, P295, DOI 10.2176/nmc.52.295
   Huang Z, 2015, NEUROL RES, V37, P886, DOI 10.1179/1743132815Y.0000000073
   Hung CC, 1997, CLIN NEUROL NEUROSUR, V99, pS23, DOI 10.1016/S0303-8467(97)00036-X
   Im Sang Hyuk, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P75, DOI 10.7461/jcen.2012.14.2.75
   Jiang HQ, 2014, J NEUROSURG, V121, P1048, DOI 10.3171/2014.7.JNS132434
   Kainth D, 2013, NEUROEPIDEMIOLOGY, V40, P282, DOI 10.1159/000345957
   Kim SK, 2010, ANN NEUROL, V68, P92, DOI 10.1002/ana.21981
   Kim T, 2015, J KOREAN NEUROSURG S, V57, P390, DOI 10.3340/jkns.2015.57.6.390
   Kleinloog R, 2012, J NEUROL NEUROSUR PS, V83, P531, DOI 10.1136/jnnp-2011-301387
   Kossorotoff M, 2012, CEREBROVASC DIS, V33, P76, DOI 10.1159/000333424
   Kraemer M, 2012, NEUROL MED CHIR TOKY, V52, P299
   Kuriyama S, 2008, STROKE, V39, P42, DOI 10.1161/STROKEAHA.107.490714
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Liu WY, 2012, NEUROL MED-CHIR, V52, P299, DOI 10.2176/nmc.52.299
   Miao W, 2010, CLIN NEUROL NEUROSUR, V112, P199, DOI 10.1016/j.clineuro.2009.11.009
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takeuchi KSK., 1957, NO TO SHINKEI, V9, P37
   Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82
   Wakai K, 1997, CLIN NEUROL NEUROSUR, V99, pS1, DOI 10.1016/S0303-8467(97)00031-0
NR 27
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E917
EP E923
DI 10.1016/j.wneu.2018.10.175
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100110
PM 30404059
DA 2020-05-12
ER

PT J
AU Beeler, WH
   Paradis, KC
   Gemmete, JJ
   Chaudhary, N
   Kim, MM
   Smith, SR
   Paradis, E
   Matuszak, MM
   Park, P
   Archer, PG
   Szerlip, NJ
   Spratt, DE
AF Beeler, Whitney H.
   Paradis, Kelly C.
   Gemmete, Joseph J.
   Chaudhary, Neeraj
   Kim, Michelle M.
   Smith, Sean R.
   Paradis, Eric
   Matuszak, Martha M.
   Park, Paul
   Archer, Paul G.
   Szerlip, Nicholas J.
   Spratt, Daniel E.
TI Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging
   Registration to Delineate the Spinal Cord During Spine Stereotactic
   Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Myelography; Radiosurgery; Spine; Simulation; Stereotactic
ID BODY RADIATION-THERAPY; INTRAFRACTION MOTION; RADIOTHERAPY;
   COMPLICATIONS; TOLERANCE; IMPACT
AB BACKGROUND: Underestimation of the spinal cord's volume or position during spine stereotactic radiosurgery can lead to severe myelopathy, whereas overestimation can lead to tumor underdosage. Spinal cord delineation is commonly achieved by registering a magnetic resonance imaging (MRI) study with a computed tomography (CT) simulation scan or by performing myelography during CT simulation (myelosim). We compared treatment planning outcomes for these 2 techniques.
   METHODS: Twenty-three cases of spine stereotactic radiosurgery were analyzed that had both a myelosim and corresponding MRI study for registration. The spinal cord was contoured on both imaging data sets by 2 independent blinded physicians, and Dice similarity coefficients were calculated to compare their spatial overlap. Two treatment plans (16 Gy and 18 Gy) were created using the MRI and CT contours (92 plans total). Dosimetric parameters were extracted and compared by modality to assess tumor coverage and spinal cord dose.
   RESULTS: No differences were found in the partial spinal cord volumes contoured on MRI versus myelosim (4.71 +/- 1.09 vs. 4.55 +/- 1.03 cm(3); P = 0.34) despite imperfect spatial agreement (mean Dice similarity coefficient, 0.68 +/- 0.05). When the registered MRI contours were used for treatment planning, significantly worse tumor coverage and greater spinal cord doses were found compared with myelosim planning. For the 18-Gy plans, 10 of 23 MRI cases (43%) exceeded the spinal cord or cauda dose constraints when using myelosim as the reference standard.
   CONCLUSIONS: Significant spatial, rather than volumetric, differences were found between the MRI- and myelosim-defined spinal cord structures. Tumor coverage was compromised with MRI-based planning, and the high spinal cord doses were a concern. Future work is necessary to compare thin-cut, volumetric MRI registration or MRI simulation with myelosim.
C1 [Beeler, Whitney H.; Paradis, Kelly C.; Kim, Michelle M.; Matuszak, Martha M.; Archer, Paul G.; Spratt, Daniel E.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
   [Gemmete, Joseph J.; Chaudhary, Neeraj] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA.
   [Smith, Sean R.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA.
   [Szerlip, Nicholas J.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
   [Paradis, Eric; Park, Paul] Eastern Michigan Univ, Dept Phys & Astron, Ypsilanti, MI 48197 USA.
RP Szerlip, NJ (reprint author), Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
EM nszerlip@med.umich.edu
RI Spratt, Daniel/AAM-4612-2020; Beeler, Whitney/O-1308-2018
OI Smith, Sean/0000-0001-9936-8750; Beeler, Whitney/0000-0002-8854-6555
CR Bilsky MH, 2010, J NEUROSURG-SPINE, V13, P324, DOI 10.3171/2010.3.SPINE09459
   Bishop AJ, 2015, INT J RADIAT ONCOL, V92, P1016, DOI 10.1016/j.ijrobp.2015.03.037
   EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y
   Foy JJ, 2017, PRACT RADIAT ONCOL, V7, pE355, DOI 10.1016/j.prro.2017.02.007
   Guckenberger M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-172
   Hall WA, 2011, INT J SURG ONCOL, DOI 10.1155/2011/979214
   Hyde D, 2012, INT J RADIAT ONCOL, V82, pE555, DOI 10.1016/j.ijrobp.2011.06.1980
   Kumar KA, 2015, INT J RADIAT ONCOL, V93, pE118, DOI 10.1016/j.ijrobp.2015.07.848
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Li WN, 2012, INT J RADIAT ONCOL, V84, P520, DOI 10.1016/j.ijrobp.2011.12.039
   Rodriguez D, 2016, AM J ROENTGENOL, V206, P20, DOI 10.2214/AJR.15.14664
   Ryu S, 2011, INT J RADIAT ONCOL, V81, pS131, DOI 10.1016/j.ijrobp.2011.06.271
   Ryu S, 2007, CANCER, V109, P628, DOI 10.1002/cncr.22442
   Sahgal A, 2011, J NEUROSURG-SPINE, V14, P151, DOI 10.3171/2010.9.SPINE091005
   Sahgal A, 2010, INT J RADIAT ONCOL, V77, P548, DOI 10.1016/j.ijrobp.2009.05.023
   Spratt DE, 2017, LANCET ONCOL, V18, pE720, DOI 10.1016/S1470-2045(17)30612-5
   Thariat J, 2009, NEUROSURGERY, V64, pA60, DOI 10.1227/01.NEU.0000339129.51926.D6
   Thibault I, 2015, LANCET ONCOL, V16, pE595, DOI 10.1016/S1470-2045(15)00166-7
   Timmerman RD, 2014, J CLIN ONCOL, V32, P2847, DOI 10.1200/JCO.2014.55.4675
   TUBIANAHULIN M, 1991, BONE, V12, pS9, DOI 10.1016/8756-3282(91)90059-R
   Yamada Y, 2008, INT J RADIAT ONCOL, V71, P484, DOI 10.1016/j.ijrobp.2007.11.046
   Yamada Y, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.9.FOCUS16369
   Zou KH, 2004, ACAD RADIOL, V11, P178, DOI 10.1016/S1076-6332(03)00671-8
NR 24
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E655
EP E666
DI 10.1016/j.wneu.2018.10.118
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100080
PM 30992117
DA 2020-05-12
ER

PT J
AU Bernstock, JD
   Wright, Z
   Bag, AK
   Gessler, F
   Gillespie, GY
   Markert, JM
   Friedman, GK
   Johnston, JM
AF Bernstock, Joshua D.
   Wright, Zachary
   Bag, Asim K.
   Gessler, Florian
   Gillespie, George Yancey
   Markert, James M.
   Friedman, Gregory K.
   Johnston, James M.
TI Stereotactic Placement of Intratumoral Catheters for Continuous Infusion
   Delivery of Herpes Simplex Virus-1 G207 in Pediatric Malignant
   Supratentorial Brain Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Oncolytic virotherapy; Pediatric brain tumors; Recurrent brain tumors;
   Stereotactic surgery
ID CONVECTION-ENHANCED DELIVERY; FUNCTIONAL NEUROSURGICAL PROCEDURES;
   FRAMELESS STEREOTAXY; APPLICATION ACCURACY; CHILDREN; MEDULLOBLASTOMA;
   LOCALIZATION; TRIAL; CHEMOTHERAPY; VARIOGUIDE
AB OBJECTIVE: The engineered herpes simplex virus-1 G207, is a promising therapeutic option for central nervous system tumors. The first-ever pediatric phase 1 trial of continuous-infusion delivery of G207 via intratumoral catheters for recurrent or progressive malignant brain tumors is ongoing. In this article, we describe surgical techniques for the accurate placement of catheters in multiple supratentorial locations and perioperative complications associated with such procedures.
   METHODS: A prospective study of G207 in children with recurrent malignant supratentorial tumors is ongoing. Preoperative stereotactic protocol magnetic resonance imaging was performed, and catheter trajectories planned using StealthStation planning software. Children underwent placement of 3-4 silastic catheters using a small incision burr hole and the Vertek system. Patients had a preinfusion computed tomography scan to confirm correct placement of catheters.
   RESULTS: Six children underwent implantation of 3-4 catheters. Locations of catheter placement included frontal, temporal, parietal, and occipital lobes, and the insula and thalamus. There were no clinically significant perioperative complications. Postoperative computed tomography scans coupled with preoperative MRI scans demonstrated accurate placement of 21 of 22 catheters, with 1 misplaced catheter pulled back to an optimal location at the bedside. One patient had hemorrhage along the catheter tract that was clinically asymptomatic. Another patient had cerebrospinal fluid leak from a biopsy incision 9 days after surgery that was oversewn without complication.
   CONCLUSIONS: The placement of multiple intratumoral catheters in pediatric patients with supratentorial tumors via frameless stereotactic techniques is feasible and safe. Intratumoral catheters provide a potentially effective route for the delivery of G207 and may be employed in other trials utilizing oncolytic virotherapy for brain tumors.
C1 [Bernstock, Joshua D.] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA.
   [Bernstock, Joshua D.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol Oncol, Birmingham, AL 35294 USA.
   [Wright, Zachary; Friedman, Gregory K.; Johnston, James M.] Univ Alabama Birmingham, Dept Neurosurg, Div Pediat Neurosurg, Birmingham, AL 35294 USA.
   [Bag, Asim K.] Univ Alabama Birmingham, Dept Radiol, Neuroradiol Sect, Birmingham, AL USA.
   [Gillespie, George Yancey; Markert, James M.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.
   [Gessler, Florian] Goethe Univ Frankfurt, Dept Neurosurg, Frankfurt, Germany.
RP Friedman, GK (reprint author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol Oncol, Birmingham, AL 35294 USA.; Friedman, GK (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Div Pediat Neurosurg, Birmingham, AL 35294 USA.
EM gfriedman@peds.uab.edu
RI Bag, Asim/G-8308-2019
OI Bag, Asim/0000-0001-6164-5863; Friedman, Gregory/0000-0002-6653-7420;
   Gessler, Florian/0000-0002-3471-0575; Bernstock,
   Joshua/0000-0002-7814-3867
FU FDA HHS [R01 FD005379]
CR Benencia F, 2008, CANCER BIOL THER, V7, P1194, DOI 10.4161/cbt.7.8.6216
   BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076
   Bradac O, 2017, WORLD NEUROSURG, V104, P831, DOI 10.1016/j.wneu.2017.04.104
   CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860
   CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247
   Coenen VA, 2011, CENT EUR NEUROSURG, V72, P181, DOI 10.1055/s-0031-1279748
   Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191
   Cripe TP, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.15
   Diller L, 2009, J CLIN ONCOL, V27, P2339, DOI 10.1200/JCO.2008.21.1953
   Dorward NL, 1999, J NEUROSURG, V90, P160, DOI 10.3171/jns.1999.90.1.0160
   Elenes EY, 2017, GLIOBLASTOMA, P359, DOI 10.15586/codon.glioblastoma.2017.ch18
   Friedman GK, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.16
   Friedman GK, 2016, NEURO-ONCOLOGY, V18, P227, DOI 10.1093/neuonc/nov123
   Friedman GK, 2009, J NEURO-ONCOL, V95, P199, DOI 10.1007/s11060-009-9926-0
   Furlanetti LL, 2015, CLIN NEUROL NEUROSUR, V130, P42, DOI 10.1016/j.clineuro.2014.12.011
   Gajjar A, 2010, PEDIATR BLOOD CANCER, V54, P649, DOI 10.1002/pbc.22378
   Gatta G, 2002, CANCER-AM CANCER SOC, V95, P1767, DOI 10.1002/cncr.10833
   Giese H, 2010, J NEUROSURG-PEDIATR, V5, P350, DOI 10.3171/2009.10.PEDS09292
   Gillory LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077753
   Henderson JM, 2004, STEREOT FUNCT NEUROS, V82, P135, DOI 10.1159/000081345
   Hosainey SAM, 2014, J NEUROSURG-PEDIATR, V14, P604, DOI 10.3171/2014.8.PEDS13585
   Leddon JL, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.10
   Lonser RR, 2015, J NEUROSURG, V122, P697, DOI 10.3171/2014.10.JNS14229
   MACIUNAS RJ, 1994, NEUROSURGERY, V35, P682, DOI 10.1227/00006123-199410000-00015
   Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22
   Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228
   Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205
   MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332
   MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938
   Nikitovic M, 2016, CHILD NERV SYST, V32, P97, DOI 10.1007/s00381-015-2945-6
   Ostrom QT, 2015, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou327
   PACKER RJ, 1989, J NEUROSURG, V70, P707, DOI 10.3171/jns.1989.70.5.0707
   Paraskevopoulos D, 2011, NEUROSURG REV, V34, P217, DOI 10.1007/s10143-010-0302-5
   Parreno MG, 2011, CHILD NERV SYST, V27, P2137, DOI 10.1007/s00381-011-1506-x
   Quick-Weller J, 2016, J CHILD NEUROL, V31, P907, DOI 10.1177/0883073815627883
   Quinones-Hinojosa A, 2006, J NEURO-ONCOL, V76, P65, DOI 10.1007/s11060-005-2915-z
   Ribi K, 2005, NEUROPEDIATRICS, V36, P357, DOI 10.1055/s-2005-872880
   Ringel F, 2009, NEUROSURGERY, V64, P365, DOI 10.1227/01.NEU.0000341532.15867.1C
   St George EJ, 2004, CHILD NERV SYST, V20, P163, DOI 10.1007/s00381-003-0897-8
   Steinmeier R, 2000, STEREOT FUNCT NEUROS, V75, P188, DOI 10.1159/000048404
   Vogelbaum MA, 2015, NEURO-ONCOLOGY, V17, pII3, DOI 10.1093/neuonc/nou354
   Walton L, 1996, STEREOT FUNCT NEUROS, V66, P49, DOI 10.1159/000099700
   Walton L, 1997, NEUROSURGERY, V41, P131, DOI 10.1097/00006123-199707000-00027
   Waters AM, 2017, HUM GENE THER CL DEV, V28, P7, DOI [10.1089/humc.2017.002, 10.1089/hum.2017.002]
NR 44
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1592
EP E1598
DI 10.1016/j.wneu.2018.11.122
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100196
PM 30481622
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Bjarko, VV
   Skandsen, T
   Moen, KG
   Gulati, S
   Helseth, E
   Nilsen, TIL
   Vik, A
AF Bjarko, Vera Vik
   Skandsen, Toril
   Moen, Kent Goran
   Gulati, Sasha
   Helseth, Eirik
   Nilsen, Tom I. L.
   Vik, Anne
TI Time of Injury and Relation to Alcohol Intoxication in
   Moderate-to-Severe Traumatic Brain Injury: A Decade-Long Prospective
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alcohol; Epidemiology; Prevention; TBI; Time of injury
ID EPIDEMIOLOGY; DRINKING; TRENDS
AB BACKGROUND: Knowledge about the causes and time of injury for traumatic brain injury (TBI) is important for the development of efficient prevention policies. We aimed to study time of injury and relation to alcohol intoxication for moderate-to-severe TBI in a level 1 trauma center in Norway.
   METHODS: From October 2004 to September 2014, 493 consecutive patients (>= 16 years) with moderate (Glasgow Coma Scale [GCS] score 9-13) and severe TBI (GCS score 3-8) were prospectively included in the Trondheim TBI Study (222 patients with moderate and 270 patients with severe TBI).
   RESULTS: Mean age was 47 years (standard deviation 21 years). Positive blood alcohol concentration (BAC) was found in 29%, and median BAC was 41.5 mmol/L (inter-quartile range 28.7-54.3), equal to 1.91 parts per thousand. Admissions were more frequent on Saturdays (relative risk [RR] 2.67, 95% confidence interval [CI] 1.87-3.80) and Sundays (RR 2.10, 95% CI 1.45-3.03) compared with Mondays, and positive BAC was more common on weekends than weekdays (43% vs. 16%). Furthermore, admissions were more frequent in June (RR 2.26, 95% CI 1.44-3.55), July (RR 2.07, 95% CI 1.31-3.28), and December (RR 2.07, 95% CI 1.31-3.28) compared with January. The number of patients with positive BAC was greatest in December (RR 5.75, 95% CI 1.99-16.63), and 70% of these were caused by falls.
   CONCLUSIONS: Our findings demonstrate that moderate-to-severe TBI admissions display a clear weekly and seasonal variation and that alcohol is an important modifiable risk factor for moderate-to-severe TBI.
C1 [Bjarko, Vera Vik; Helseth, Eirik] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
   [Skandsen, Toril; Moen, Kent Goran; Gulati, Sasha; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neuromed & Movement Sci, Trondheim, Norway.
   [Nilsen, Tom I. L.] Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Nursing, Trondheim, Norway.
   [Skandsen, Toril] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway.
   [Gulati, Sasha; Vik, Anne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway.
   [Nilsen, Tom I. L.] Trondheim Reg & Univ Hosp, St Olavs Hosp, Clin Anesthesia & Intens Care, Trondheim, Norway.
   [Moen, Kent Goran] Levanger Hosp, Dept Med Imaging, Levanger, Norway.
   [Helseth, Eirik] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway.
RP Bjarko, VV (reprint author), Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
EM vbjarko@gmail.com
RI Helseth, Eirik/AAH-2466-2020
CR Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032
   Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034
   Brazinova A, 2016, J NEUROTRAUM, DOI 10.1089/neu.2015.4126
   Cantwell K, 2015, PREHOSP EMERG CARE, V19, P425, DOI 10.3109/10903127.2014.995843
   Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Khorshidi A, 2016, ARCH TRAUMA RES, V5, DOI 10.5812/atr.27894
   Knudsen AK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1533-8
   Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9
   Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X
   Makela P, 2001, ADDICTION, V96, P1575
   Peeters S, 2017, WORLD NEUROSURG, V97, P580, DOI 10.1016/j.wneu.2016.09.127
   Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7
   Puljula J, 2013, ACTA NEUROL SCAND, V127, P192, DOI 10.1111/j.1600-0404.2012.01697.x
   Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003
   Reich RR, 2015, J ABNORM PSYCHOL, V124, P635, DOI 10.1037/abn0000061
   Rossow I, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1076
   Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322
   Siliquini R, 2012, J PUBLIC HEALTH RES, V1, P83, DOI 10.4081/jphr.2012.e15
   Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131
   Strand Bjorn Heine, 2003, Tidsskr Nor Laegeforen, V123, P2849
   Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099
NR 22
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E684
EP E689
DI 10.1016/j.wneu.2018.10.122
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100083
PM 30385362
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Bohnstedt, BN
   Conger, AR
   Edwards, J
   Ziemba-Davis, M
   Edwards, G
   Brom, J
   Shah, K
   Cohen-Gadol, AA
AF Bohnstedt, Bradley N.
   Conger, Andrew R.
   Edwards, John
   Ziemba-Davis, Mary
   Edwards, Gary
   Brom, Jacqueline
   Shah, Kushal
   Cohen-Gadol, Aaron A.
TI Anterior Communicating Artery Complex Aneurysms: Anatomic
   Characteristics as Predictors of Surgical Outcome in 300 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Anterior communicating artery; Clip ligation; Intracranial
   aneurysm; Microsurgery; Treatment outcome
ID MICRONEUROSURGICAL MANAGEMENT; CEREBRAL ANEURYSMS; INTRACRANIAL
   ANEURYSMS; UNRUPTURED ANEURYSMS; COILING; TRIAL; SIZE
AB OBJECTIVE: Anterior communicating artery (ACoA) complex aneurysms are challenging to treat microsurgically. The authors report their experience with microsurgical treatment of ACoA aneurysms and examine the anatomic characteristics of these aneurysms as predictors of outcome.
   METHODS: The authors queried their institution's aneurysm database for records of consecutive patients treated for ACoA aneurysms via microsurgical clip ligation. Data included patient demographics and clinical/radiographic presentation characteristics as well as operative techniques. Glasgow Outcome Scale (GOS) scores at hospital discharge and 6-month as well as 1-year follow-up were analyzed.
   RESULTS: Of 319 ACoA aneurysms that underwent treatment, 259 were ruptured and 60 were unruptured. Average GOS at 1-year follow-up for all patients was 4.6. Average GOS for patients with ruptured aneurysms correlated with Hunt and Hess grade at presentation, presence of frontal hemorrhages, and need for multiple clips during surgery. Notably, 142 (44.5%) of aneurysms originated mainly from the ACoA artery; 12 (3.8%) primarily from the A1 branch; 3 (0.9%) from the A2 branch; and 162 (50.8%) from the A1/A2 junction. Aneurysm projection was superior in 118 (37%), inferior in 106 (33.2%), anterior in 88 (27.6%), and posterior in 7 (2.2%). Patients with aneurysms originating from the A1 segment had worse outcomes. Posteriorly projecting aneurysms were more likely to be unruptured and larger than other aneurysm configurations.
   CONCLUSIONS: The aneurysm's exact location in relation to the adjacent neurovascular structures is potentially predictive of outcomes in the microsurgical treatment of ACoA aneurysms.
C1 [Bohnstedt, Bradley N.] Oklahoma Univ, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Conger, Andrew R.] Geisinger Med Ctr, Dept Neurosurg, Danville, PA 17822 USA.
   [Edwards, John; Edwards, Gary; Brom, Jacqueline; Cohen-Gadol, Aaron A.] Indiana Univ Sch Med, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.
   [Ziemba-Davis, Mary] Indiana Univ Hlth, Indianapolis, IN USA.
   [Shah, Kushal] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
   [Cohen-Gadol, Aaron A.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
RP Cohen-Gadol, AA (reprint author), Indiana Univ Sch Med, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.; Cohen-Gadol, AA (reprint author), Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
EM acohenmd@gmail.com
OI Cohen-Gadol, Aaron/0000-0002-4946-1524
CR Abla AA, 2014, J NEUROSURG, V120, P391, DOI 10.3171/2013.10.JNS13419
   Agrawal A, 2008, MINIM INVAS NEUROSUR, V51, P131, DOI 10.1055/s-2008-1073169
   Barker FG, 2004, NEUROSURGERY, V54, P18, DOI 10.1227/01.NEU.0000097195.48840.C4
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Carter BS, 2006, NEUROSURGERY, V58, P217, DOI 10.1227/01.NEU.0000194639.37803.F8
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   Debono B, 2004, NEUROCHIRURGIE, V50, P21, DOI 10.1016/S0028-3770(04)98302-6
   Fisher C M, 1977, Neurosurgery, V1, P245
   Hernesniemi J, 2008, SURG NEUROL, V70, P8, DOI 10.1016/j.surneu.2008.01.056
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Hyun SJ, 2010, J CLIN NEUROSCI, V17, P592, DOI 10.1016/j.jocn.2009.09.024
   JENNETT B, 1975, LANCET, V1, P480
   Johnson AK, 2013, J NEUROINTERV SURG, V5, pIII62, DOI 10.1136/neurintsurg-2012-010503
   Kheireddin A S, 2007, Zh Vopr Neirokhir Im N N Burdenko, P33
   Lai LT, 2013, J CLIN NEUROSCI, V20, P1688, DOI 10.1016/j.jocn.2013.02.015
   Lawton MT, 2006, SCHMIDEK SWEET OPERA
   Lehecka M, 2008, SURG NEUROL, V70, P232, DOI 10.1016/j.surneu.2008.03.008
   Leipzig TJ, 2005, NEUROSURGERY, V56, P455, DOI 10.1227/01.NEU.0000154697.75300.C2
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Nanda A, 2002, SURG NEUROL, V58, P13, DOI 10.1016/S0090-3019(02)00774-7
   Ohashi Y, 2004, SURG NEUROL, V61, P239, DOI 10.1016/S0090-3019(03)00427-0
   PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259
   Proust F, 2003, J NEUROSURG, V99, P3, DOI 10.3171/jns.2003.99.1.0003
   RHOTON AL, 1980, SURG NEUROL, V14, P59
   Suzuki M, 2008, ACTA NEUROCHIR, V150, P31, DOI 10.1007/s00701-007-1466-9
   Willinsky RA, 2003, RADIOLOGY, V227, P522, DOI 10.1148/radiol.2272012071
   Zada G, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08314
NR 28
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E896
EP E906
DI 10.1016/j.wneu.2018.10.172
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100108
PM 30404067
DA 2020-05-12
ER

PT J
AU Bozkurt, H
   Bektasoglu, PK
   Borekci, A
   Ozturk, OC
   Kertmen, H
   Egilmez, R
   Yuce, MF
   Gurer, B
AF Bozkurt, Huseyin
   Bektasoglu, Pinar Kuru
   Borekci, Ali
   Ozturk, Ozden Caglar
   Kertmen, Hayri
   Egilmez, Reyhan
   Yuce, Mehmet Fatih
   Gurer, Bora
TI Antifibrotic Effect of Boric Acid in Rats with Epidural Fibrosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Boric acid; Epidural fibrosis; Laminectomy
ID DIETARY BORON; PROSTATE; MIGRATION
AB BACKGROUND: Epidural fibrosis is a major problem after spine surgery, with some patients having recurrent symptoms secondary to excessive formation of scar tissue resulting in neurologic compression. We used a rat laminectomy model to determine if topical application of boric acid could be helpful in the prevention of epidural fibrosis.
   METHODS: Rats were randomly assigned to 2 control and 2 experimental groups (n = 8 for each group). The negative control group received no surgery, and the positive control group underwent laminectomy only. Experimental groups were classified according to the study agents applied onto the dura mater after laminectomy at the L3 level: 2.5% boric acid solution and 5% boric acid solution. The extent of epidural fibrosis was assessed 4 weeks later macroscopically and histopathologically.
   RESULTS: Boric acid reduced epidural fibrosis in rats after laminectomy. The effect of 5% boric acid solution was more pronounced (P < 0.05) compared with the 2.5% solution.
   CONCLUSIONS: The antifibrotic effect of boric acid solution for the prevention of epidural fibrosis suggests that boric acid should be further evaluated in future studies for the prevention of epidural fibrosis.
C1 [Bozkurt, Huseyin] Sivas Cumhuriyet Univ, Sch Med, Dept Neurosurg, Sivas, Turkey.
   [Egilmez, Reyhan] Sivas Cumhuriyet Univ, Sch Med, Dept Pathol, Sivas, Turkey.
   [Bektasoglu, Pinar Kuru; Ozturk, Ozden Caglar; Gurer, Bora] Univ Hlth Sci, Turkish Minist Hlth, Fatih Sultan Mehmet Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Yuce, Mehmet Fatih] Univ Hlth Sci, Fatih Sultan Mehmet Educ & Res Hosp, Turkish Minist Hlth, Dept Anesthesia, Istanbul, Turkey.
   [Bektasoglu, Pinar Kuru] Marmara Univ, Sch Med, Dept Physiol, Istanbul, Turkey.
   [Borekci, Ali] Sancaktepe Sehit Prof Dr Ilhan Varank Educ & Res, Dept Neurosurg, Turkish Minist Hlth, Istanbul, Turkey.
   [Kertmen, Hayri] Univ Hlth Sci, Diskapi Educ & Res Hosp, Turkish Minist Hlth, Dept Neurosurg, Ankara, Turkey.
RP Bektasoglu, PK (reprint author), Univ Hlth Sci, Turkish Minist Hlth, Fatih Sultan Mehmet Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.; Bektasoglu, PK (reprint author), Marmara Univ, Sch Med, Dept Physiol, Istanbul, Turkey.
EM pnr.kuru@gmail.com
OI Kuru Bektasoglu, Pinar/0000-0001-9889-9955
CR Barranco WT, 2006, BRIT J CANCER, V94, P884, DOI 10.1038/sj.bjc.6603009
   Benderdour M, 2000, J TRACE ELEM MED BIO, V14, P168, DOI 10.1016/S0946-672X(00)80006-1
   Bozkurt H, 2018, WORLD NEUROSURG, V117, pE403, DOI 10.1016/j.wneu.2018.06.044
   Bradke TM, 2008, CELL ADHES MIGR, V2, P153, DOI 10.4161/cam.2.3.6484
   Cox N, 2008, THESIS
   Cui Y, 2004, ONCOL REP, V11, P887
   Del Rosso James Q, 2014, J Clin Aesthet Dermatol, V7, P13
   Demirci S, 2016, MOL CELL BIOCHEM, V417, P119, DOI 10.1007/s11010-016-2719-9
   Devirian TA, 2003, CRIT REV FOOD SCI, V43, P219, DOI 10.1080/10408690390826491
   Dinca L, 2013, J NUTR THER, V2, P22, DOI DOI 10.6000/1929-5634.2013.02.01.3
   Durick KA, 2005, FASEB J, V19, pA1705
   Eldin MMM, 2015, ASIAN SPINE J, V9, P370, DOI 10.4184/asj.2015.9.3.370
   Gurer B, 2015, SPINE J, V15, P522, DOI 10.1016/j.spinee.2014.10.018
   Henderson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006009
   HUNT CD, 1994, ENVIRON HEALTH PERSP, V102, P35, DOI 10.2307/3431960
   Hunt CD, 1998, BIOL TRACE ELEM RES, V66, P205, DOI 10.1007/BF02783139
   Hunt CD, 1999, J TRACE ELEM EXP MED, V12, P221, DOI 10.1002/(SICI)1520-670X(1999)12:3&lt;221::AID-JTRA6&gt;3.0.CO;2-X
   Ince S, 2012, DRUG CHEM TOXICOL, V35, P285, DOI 10.3109/01480545.2011.607825
   Ince S, 2010, J TRACE ELEM MED BIO, V24, P161, DOI 10.1016/j.jtemb.2010.01.003
   KEY JA, 1948, J BONE JOINT SURG AM, V30-A, P621, DOI 10.2106/00004623-194830030-00009
   Laurent GJ, 2007, BIOCHEM SOC T, V35, P647, DOI 10.1042/BST0350647
   Masopust V, 2009, CLIN J PAIN, V25, P600, DOI 10.1097/AJP.0b013e3181a5b665
   Naghii M. R., 1999, Nutrition and Health (Bicester), V13, P31
   Najafabadi BAHM, 2016, CELL J, V18, P62
   NIELSEN FH, 1991, FASEB J, V5, P2661
   Nielsen FH, 2008, NUTR REV, V66, P183, DOI 10.1111/j.1753-4887.2008.00023.x
   Nielsen FH, 2011, J EVID-BASED INTEGR, V16, P169, DOI 10.1177/2156587211407638
   Pawa S, 2006, CHEM-BIOL INTERACT, V160, P89, DOI 10.1016/j.cbi.2005.12.002
   Ross JS, 1996, NEUROSURGERY, V38, P855, DOI 10.1227/00006123-199604000-00053
   RYDELL N, 1970, ACTA ORTHOP SCAND, V41, P307, DOI 10.3109/17453677008991516
   Scorei R, 2011, BIOL TRACE ELEM RES, V144, P253, DOI 10.1007/s12011-011-9083-0
   Sogut I, 2015, EXP THER MED, V9, P1023, DOI 10.3892/etm.2014.2164
   Turkez H, 2007, Z NATURFORSCH C, V62, P889
   Turkoglu E, 2014, EUR J PHARMACOL, V724, P86, DOI 10.1016/j.ejphar.2013.12.017
   Ustundag A, 2014, ARCH TOXICOL, V88, P1281, DOI 10.1007/s00204-014-1235-5
   Wei Y, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028300
   Yilmaz S, 2016, CELL J, V17, P748
NR 37
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E989
EP E994
DI 10.1016/j.wneu.2018.10.187
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100119
PM 30399469
DA 2020-05-12
ER

PT J
AU Brown, EC
   Lucke-Wold, B
   Cetas, JS
   Dogan, A
   Gupta, S
   Hullar, TE
   Smith, TL
   Ciporen, JN
AF Brown, Erik C.
   Lucke-Wold, Brandon
   Cetas, Justin S.
   Dogan, Aclan
   Gupta, Sachin
   Hullar, Timothy E.
   Smith, Timothy L.
   Ciporen, Jeremy N.
TI Surgical Parameters for Minimally Invasive Trans-Eustachian Tube CSF
   Leak Repair: A Cadaveric Study and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cadaver; Catheter; Cerebrospinal leak; Endoscopy; Eustachian tube
ID AIDED 3-DIMENSIONAL RECONSTRUCTION; CEREBROSPINAL-FLUID RHINORRHEA;
   TEMPORAL BONE; LENGTH; ANGLE; PACKING; ANATOMY; CT
AB BACKGROUND: Cerebrospinal fluid rhinorrhea from a lateral skull base defect refractory to spontaneous healing and/or conservative management is most commonly managed via open surgery. Approach for repair is dictated by location of the defect, which may require surgical exploration. The final common pathway is the eustachian tube (ET). Endoscopic ET obliteration via endonasal and lateral approaches is under development. Whereas ET anatomy has been studied, surgical landmarks have not been previously described or quantified. We aimed to define surgical parameters of specific utility to endoscopic ET obliteration.
   METHODS: A literature review was performed of known ET anatomic parameters. Next, using a combination of endoscopic and open techniques in cadavers, we cannulated the intact ET and dissected its posterior component to define the major curvature position of the ET, defined as the genu, and quantified the relative distances through the ET lumen. The genu was targeted as a major obstacle encountered when cannulating the ET from the nasopharynx.
   RESULTS: Among 10 ETs, we found an average distance of 23 +/- 5 mm from the nasopharynx to the ET genu, distance of 24 +/- 3 mm from the genu to the anterior aspect of the tympanic membrane and total ET length of 47 +/- 4 mm.
   CONCLUSIONS: Although membranous and petrous components of the ET are important to its function, the genu may be a more useful surgical landmark. Basic surgical parameters for endoscopic ET obliteration are defined.
C1 [Brown, Erik C.; Cetas, Justin S.; Dogan, Aclan; Ciporen, Jeremy N.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Gupta, Sachin; Hullar, Timothy E.; Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
   [Lucke-Wold, Brandon] West Virginia Univ, Sch Med, MD PhD Scholars Program, Morgantown, WV 26506 USA.
RP Ciporen, JN (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
EM ciporen@ohsu.edu
RI Dogan, Aclan/AAF-8305-2019
OI Lucke-Wold, Brandon/0000-0001-6577-4080
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM104942]
CR Avci S, 2015, SURG RADIOL ANAT, V37, P1069, DOI 10.1007/s00276-015-1477-9
   Businco LD, 2017, HNO, V65, P840, DOI 10.1007/s00106-017-0346-8
   Daudia A, 2007, ANN OTO RHINOL LARYN, V116, P902, DOI 10.1177/000348940711601206
   Deep NL, 2017, OTOL NEUROTOL, V38, P283, DOI 10.1097/MAO.0000000000001282
   Dinc AE, 2015, LARYNGOSCOPE, V125, P2187, DOI 10.1002/lary.25231
   Hong J, 2018, AURIS NASUS LARYNX, V45, P88, DOI 10.1016/j.anl.2017.05.010
   Ishijima K, 2000, ANN OTO RHINOL LARYN, V109, P542, DOI 10.1177/000348940010900603
   Jacob A, 2007, OTOL NEUROTOL, V28, P934, DOI 10.1097/MAO.0b013e31814619bd
   Kaneko A, 2001, AURIS NASUS LARYNX, V28, P121, DOI 10.1016/S0385-8146(00)00090-0
   Kemaloglu YK, 2000, INT J PEDIATR OTORHI, V53, P195, DOI 10.1016/S0165-5876(00)82007-8
   Lemonnier LA, 2015, AM J RHINOL ALLERGY, V29, P207, DOI 10.2500/ajra.2015.29.4146
   Lucke-Wold B, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.12.FOCUS17664
   Manes RP, 2013, AM J RHINOL ALLERGY, V27, P314, DOI 10.2500/ajra.2013.27.3914
   Orlandi RR, 2004, AM J RHINOL, V18, P363, DOI 10.1177/194589240401800604
   PROCTOR B, 1967, ARCHIV OTOLARYNGOL, V86, P503
   ROBERT Y, 1994, SURG RADIOL ANAT, V16, P63, DOI 10.1007/BF01627923
   Selesnick SH, 2004, OTOL NEUROTOL, V25, P387, DOI 10.1097/00129492-200405000-00030
   Spielberg W, 1927, ARCHIV OTOLARYNGOL, V5, P334
   Sudo M, 1998, ANN OTO RHINOL LARYN, V107, P547, DOI 10.1177/000348949810700701
   Sudo M, 1997, ANN OTO RHINOL LARYN, V106, P583, DOI 10.1177/000348949710600710
   Taghi AS, 2015, J LARYNGOL OTOL, V129, P1028, DOI 10.1017/S0022215115002157
   Takasaki K, 2007, LARYNGOSCOPE, V117, P1251, DOI 10.1097/MLG.0b013e318058a09f
   TODD NW, 1988, ANN OTO RHINOL LARYN, V97, P277, DOI 10.1177/000348948809700313
   Tsai LT, 2010, NEURORADIOL J, V23, P307, DOI 10.1177/197140091002300308
   Yegin Y, 2017, J CRANIOFAC SURG, V28, pE5, DOI 10.1097/SCS.0000000000003153
   Yegin Y, 2016, J CRANIOFAC SURG, V27, P2088, DOI 10.1097/SCS.0000000000003071
   Yoshida H, 2004, ACTA OTO-LARYNGOL, V124, P918, DOI 10.1080/00016480410017422
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E121
EP E129
DI 10.1016/j.wneu.2018.09.123
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100013
PM 30266704
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Buchanan, IA
   Lin, M
   Donoho, DA
   Patel, A
   Ding, L
   Amar, AP
   Giannotta, SL
   Mack, WJ
   Attenello, F
AF Buchanan, Ian A.
   Lin, Michelle
   Donoho, Daniel A.
   Patel, Arati
   Ding, Li
   Amar, Arun P.
   Giannotta, Steven L.
   Mack, William J.
   Attenello, Frank
TI Predictors of Venous Thromboembolism After Nonemergent Craniotomy: A
   Nationwide Readmission Database Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult cohort; Craniotomy; Deep vein thrombosis (DVT); Nationwide
   database; Pulmonary embolism (PE); Readmission; Venous thromboembolism
   (VTE)
ID DEEP-VEIN THROMBOSIS; MALIGNANT BRAIN-TUMORS; TISSUE FACTOR ACTIVITY;
   RISK-FACTORS; PULMONARY-EMBOLISM; SINGLE-CENTER; NEUROSURGICAL PATIENTS;
   PLASMINOGEN-ACTIVATOR; UNITED-STATES; PREVENTION
AB BACKGROUND: Venous thromboembolism (VTE) is responsible for many hospital readmissions each year, particularly among postsurgical cohorts. Because early and indiscriminate VTE prophylaxis carries catastrophic consequences in postcraniotomy cohorts, identifying factors associated with a high risk for thromboembolic complications is important for guiding postoperative management.
   OBJECTIVE: To determine VTE incidence in patients undergoing nonemergent craniotomy and to evaluate for factors that predict 30-day and 90-day readmission with VTE.
   METHODS: The 2010-2014 cohorts of the Nationwide Readmissions Database were used to generate a large heterogeneous craniotomy sample.
   RESULTS: There were 89,450 nonemergent craniotomies that met inclusion criteria. Within 30 days, 1513 patients (1.69%) were readmitted with VTE diagnoses; among them, 678 (44.8%) had a diagnosis of deep vein thrombosis alone, 450 (29.7%) had pulmonary embolism alone, and 385 (25.4%) had both. The corresponding 30-day deep vein thrombosis and pulmonary embolism incidences were 1.19% and 0.93%, respectively. In multivariate analysis, several factors were significantly associated with VTE readmission, namely, craniotomy for tumor, corticosteroids, advanced age, greater length of stay, and discharge to institutional care.
   CONCLUSIONS: Craniotomies for tumor, corticosteroids, advanced age, prolonged length of stay, and discharge to institutional care are significant predictors of VTE readmission. The implication of steroids, coupled with their ubiquity in neurosurgery, makes them a potentially modifiable risk factor and a prime target for VTE reduction in craniotomy cohorts. Furthermore, the fact that dose is proportional to VTE risk in the literature suggests that careful consideration should be given toward decreasing regimens in situations in which use of a lower dose might prove equally sufficient.
C1 [Buchanan, Ian A.; Lin, Michelle; Donoho, Daniel A.; Patel, Arati] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Ding, Li] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   [Buchanan, Ian A.; Donoho, Daniel A.; Amar, Arun P.; Giannotta, Steven L.; Mack, William J.; Attenello, Frank] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
RP Buchanan, IA (reprint author), Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA.; Buchanan, IA (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
EM ianbuchanan07@gmail.com
RI Ding, Li/G-4031-2019; ding, li/AAN-2113-2020
OI Ding, Li/0000-0001-8565-430X; 
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR001854]
CR Agnelli G, 2004, CIRCULATION, V110, P4, DOI 10.1161/01.CIR.0000150639.98514.6c
   Algattas H, 2015, WORLD NEUROSURG, V84, P1372, DOI 10.1016/j.wneu.2015.06.033
   Beckman MG, 2010, AM J PREV MED, V38, pS495, DOI 10.1016/j.amepre.2009.12.017
   Bick RL, 2003, NEW ENGL J MED, V349, P109, DOI 10.1056/NEJMp030086
   Brandes AA, 1997, EUR J CANCER, V33, P1592, DOI 10.1016/S0959-8049(97)00167-6
   Brotman DJ, 2006, THROMB RES, V118, P247, DOI 10.1016/j.thromres.2005.06.006
   Browd SR., 2004, NEUROSURG FOCUS, V17, pE1, DOI DOI 10.3171/F0C.2004.17.4.1
   CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378
   Collen JF, 2008, CHEST, V134, P237, DOI 10.1378/chest.08-0023
   Cote DJ, 2016, J CLIN NEUROSCI, V25, P13, DOI 10.1016/j.jocn.2015.05.053
   Donoho DA, 2018, J NEURO-ONCOL, V136, P87, DOI 10.1007/s11060-017-2625-3
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Farray D, 2004, NEUROL CLIN, V22, P423, DOI 10.1016/j.ncl.2004.01.002
   Fernandez MM, 2015, CLINICOECONOMIC OUTC, V7, P451, DOI 10.2147/CEOR.S85635
   Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S
   Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656
   Hamilton MG, 2011, NEUROSURGERY, V68, P571, DOI 10.1227/NEU.0b013e3182093145
   HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012
   HEATON JH, 1989, MOL ENDOCRINOL, V3, P185, DOI 10.1210/mend-3-1-185
   Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809
   Heit JA, 2005, J THROMB HAEMOST, V3, P1611, DOI 10.1111/j.1538-7836.2005.01415.x
   Hoefnagel D, 2014, CLIN NEUROL NEUROSUR, V123, P150, DOI 10.1016/j.clineuro.2014.06.001
   Houchens RL, 2008, JT COMM J QUAL PATIE, V34, P154, DOI 10.1016/S1553-7250(08)34018-5
   Huerta C, 2007, ARCH INTERN MED, V167, P935, DOI 10.1001/archinte.167.9.935
   IBERTI TJ, 1994, NEUROSURGERY, V34, P389, DOI 10.1227/00006123-199403000-00001
   Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327
   Johannesdottir SA, 2013, JAMA INTERN MED, V173, P743, DOI 10.1001/jamainternmed.2013.122
   Khan NR, 2018, J NEUROSURG, V129, P906, DOI 10.3171/2017.2.JNS162040
   Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632
   Kimmell KT, 2014, J NEURO-ONCOL, V120, P567, DOI 10.1007/s11060-014-1587-y
   Kshettry VR, 2014, J CLIN NEUROSCI, V21, P282, DOI 10.1016/j.jocn.2013.07.003
   Lieber BA, 2016, WORLD NEUROSURG, V89, P126, DOI 10.1016/j.wneu.2016.01.033
   Lip GYH, 2002, LANCET ONCOL, V3, P27, DOI 10.1016/S1470-2045(01)00619-2
   Mahan CE, 2012, THROMB HAEMOSTASIS, V108, P291, DOI 10.1160/TH12-03-0162
   Manly DA, 2010, THROMB RES, V125, P511, DOI 10.1016/j.thromres.2009.09.019
   Morange PE, 1999, DIABETES, V48, P890, DOI 10.2337/diabetes.48.4.890
   Patel AP, 2013, J NEUROSURG, V118, P505, DOI 10.3171/2012.11.JNS121243
   Petterson TM, 2015, THROMB RES, V135, P472, DOI 10.1016/j.thromres.2014.12.013
   POWERS SK, 1982, NEUROSURGERY, V10, P509, DOI 10.1227/00006123-198204000-00018
   Qian CF, 2016, THROMB RES, V137, P58, DOI 10.1016/j.thromres.2015.11.018
   QUEVEDO JF, 1994, MAYO CLIN PROC, V69, P329, DOI 10.1016/S0025-6196(12)62216-2
   Rolston JD, 2014, J NEUROSURG, V121, P908, DOI 10.3171/2014.6.JNS131419
   Rumalla K, 2018, WORLD NEUROSURG, V110, pE100, DOI 10.1016/j.wneu.2017.10.089
   Rumalla K, 2017, NEUROSURGERY, V81, P740, DOI 10.1093/neuros/nyx063
   Sartori MT, 2011, J NEURO-ONCOL, V104, P225, DOI 10.1007/s11060-010-0462-8
   SAWAYA R, 1992, J NEURO-ONCOL, V14, P127
   Sciacca FL, 2004, CLIN CANCER RES, V10, P1312, DOI 10.1158/1078-0432.CCR-03-0198
   Senders JT, 2018, J NEURO-ONCOL, V136, P135, DOI 10.1007/s11060-017-2631-5
   Shah MN, 2013, J NEUROSURG, V119, P1043, DOI 10.3171/2013.3.JNS121769
   Smith TR, 2015, J CLIN NEUROSCI, V22, P519, DOI 10.1016/j.jocn.2014.10.003
   Smith TR, 2014, J NEURO-ONCOL, V120, P347, DOI 10.1007/s11060-014-1557-4
   Stein PD, 2006, AM J MED, V119, P60, DOI 10.1016/j.amjmed.2005.06.058
   Stein PD, 2004, ARCH INTERN MED, V164, P2260, DOI 10.1001/archinte.164.20.2260
   Stuijver DJE, 2013, CHEST, V143, P1337, DOI 10.1378/chest.12-1446
   Tesselaar MET, 2007, J THROMB HAEMOST, V5, P520, DOI 10.1111/j.1538-7836.2007.02369.x
   Tesselaar MET, 2009, J THROMB HAEMOST, V7, P1421, DOI 10.1111/j.1538-7836.2009.03504.x
   Vahidy FS, 2017, STROKE, V48, P1386, DOI 10.1161/STROKEAHA.116.016085
   White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66
   Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401
   Zwicker JI, 2009, CLIN CANCER RES, V15, P6830, DOI 10.1158/1078-0432.CCR-09-0371
NR 60
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1102
EP E1110
DI 10.1016/j.wneu.2018.10.237
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100135
PM 30465948
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Burford, C
   Hanrahan, J
   Ansaripour, A
   Smith, B
   Sysum, K
   Rajwani, K
   Huett, M
   Vergani, F
   Zebian, B
AF Burford, Charlotte
   Hanrahan, John
   Ansaripour, Ali
   Smith, Brandon
   Sysum, Katie
   Rajwani, Kapil
   Huett, Marian
   Vergani, Francesco
   Zebian, Bassel
TI Factors Influencing Medical Student Interest in a Career in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Career; Conference; Education; Medical student; Neurosurgery
ID EXPOSURE; IMPACT
AB BACKGROUND: Exposure to neurosurgery at the undergraduate level is an important factor in determining future interest in and applications to the specialty. Given the high competition for training posts, this exposure is also becoming an almost essential addition to an applicant's portfolio. We organized a neurosurgical conference aimed at undergraduate medical students. The aim of this study was to determine factors attracting and deterring students from the specialty before and after the conference.
   METHODS: Responses were collected prospectively from students attending a national neurosurgical conference organized by medical students with support from the local neurosurgical unit. Questionnaires were distributed before and after the conference examining students' perceptions of a career in neurosurgery using free-text responses.
   RESULTS: Poor lifestyle or work-life balance was the most important factor deterring students from a career in the specialty both before (29.7%) and after (60%) the conference. The most important factor attracting students to the specialty before the conference was the practical (surgical approaches and techniques) aspect (21.9%). After the conference, the most important attracting factor was the rewarding nature of the specialty (18.9%).
   CONCLUSIONS: The most notable factor deterring students from a career in neurosurgery was work-life balance. Other deterring factors were much less prevalent following the conference. Understanding how exposure to neurosurgery influences students' perceptions is important for developing future initiatives to prevent misconceptions and allow students to make informed choices as well as encourage the right candidates to apply.
C1 [Burford, Charlotte; Hanrahan, John; Ansaripour, Ali; Smith, Brandon; Sysum, Katie; Huett, Marian] Kings Coll London, Fac Life Sci & Med, London, England.
   [Rajwani, Kapil; Vergani, Francesco; Zebian, Bassel] Kings Coll Hosp London, Dept Neurosurg, London, England.
RP Burford, C (reprint author), Kings Coll London, Fac Life Sci & Med, London, England.
EM charlotte.burford@kcl.ac.uk
OI Hanrahan, John/0000-0003-4584-2298
CR Baschera D, 2015, WORLD J SURG, V39, P2908, DOI 10.1007/s00268-015-3195-1
   Brem H, 2003, SURGERY, V134, P414, DOI 10.1067/S0039-6060(03)00120-X
   Burford C, 2017, J NEUROL SCI, V377, P77, DOI 10.1016/j.jns.2017.03.043
   Clark DJ, 2016, BRIT J NEUROSURG, V30, P4, DOI 10.3109/02688697.2015.1114590
   Dias MS, 2013, J NEUROSURG-PEDIATR, V12, P422, DOI 10.3171/2013.7.PEDS12597
   Kamour AH, 2016, J NEUROL SCI, V369, P312, DOI 10.1016/j.jns.2016.08.046
   Kolias AG, 2013, BRIT J NEUROSURG, V27, P706, DOI 10.3109/02688697.2013.833166
   McAbee JH, 2015, J NEUROSURG, V123, P161, DOI 10.3171/2014.12.JNS141348
   Saleh M, 2013, BRIT J NEUROSURG, V27, P405, DOI 10.3109/02688697.2013.793293
   Shakir HJ, 2018, NEUROSURGERY, V83, P582, DOI 10.1093/neuros/nyx494
   Zuccato JA, 2016, CAN J NEUROL SCI, V43, P410, DOI 10.1017/cjn.2015.332
   Zuckerman SL, 2016, WORLD NEUROSURG, V86, P120, DOI 10.1016/j.wneu.2015.08.081
NR 12
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E367
EP E374
DI 10.1016/j.wneu.2018.10.056
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100043
PM 30336295
DA 2020-05-12
ER

PT J
AU Cavalcanti, DD
   Morais, BA
   Figueiredo, EG
   Spetzler, RF
   Preul, MC
AF Cavalcanti, Daniel Dutra
   Morais, Barbara Albuquerque
   Figueiredo, Eberval Gadelha
   Spetzler, Robert F.
   Preul, Mark C.
TI Supracerebellar Infratentorial Variant Approaches to the Intercollicular
   Safe Entry Zone
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intercollicular region; Microsurgery; Safe entry zones; Supracerebellar
   infratentorial; Surgical anatomy; Surgical approaches
ID BRAIN-STEM; MICROSURGICAL ANATOMY; SURGERY; REGION
AB OBJECTIVE: To describe and compare surgical exposure through microsurgical cadaveric dissection of the intercollicular region afforded by the median, paramedian, and extreme-lateral supracerebellar infratentorial (SCIT) approaches.
   METHODS: Ten cadaveric heads were dissected using SCIT variant approaches. A neuronavigation system was used to determine tridimensional coordinates for the intercollicular zone in each route. The areas of surgical and angular exposure were evaluated and determined by software analysis for each specimen.
   RESULTS: The median surgical exposure was similar for the different craniotomies: 282.9 +/- 72.4 mm(2) for the median, 341.2 +/- 71.2 mm(2) for the paramedian, and 312.0 +/- 79.3 mm(2) for the extreme-lateral (P = 0.33). The vertical angular exposure to the center of the intercollicular safe entry zone was also similar between the approaches (P = 0.92). On the other hand, the horizontal angular exposure was significantly wider for the median approach (P < 0.001).
   CONCLUSIONS: All the SCIT approaches warrant a safe route to the quadrigeminal plate. Among the different variants, the median approach had the smallest median surgical area exposure but presented superior results to access the intercollicular safe entry zone.
C1 [Cavalcanti, Daniel Dutra; Morais, Barbara Albuquerque; Figueiredo, Eberval Gadelha] Univ Sao Paulo, Sch Med, Dept Neurol Surg, Sao Paulo, Brazil.
   [Spetzler, Robert F.; Preul, Mark C.] Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.
RP Figueiredo, EG (reprint author), Univ Sao Paulo, Sch Med, Dept Neurol Surg, Sao Paulo, Brazil.
EM ebgadelha@yahoo.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
OI Cavalcanti, Daniel/0000-0002-2284-9297
CR Ammirati M, 2002, J NEUROSURG, V97, P922, DOI 10.3171/jns.2002.97.4.0922
   Bricolo A, 1995, Adv Tech Stand Neurosurg, V22, P261
   Cantore G, 1999, SURG NEUROL, V52, P84, DOI 10.1016/S0090-3019(99)00036-1
   Cavalcanti DD, 2016, J NEUROSURG, V124, P1359, DOI 10.3171/2015.4.JNS141945
   Chen X, 2010, NEUROSCI BULL, V26, P479, DOI 10.1007/s12264-010-1036-7
   de Oliveira JG, 2010, NEUROSURGERY, V66, P389, DOI 10.1227/01.NEU.0000363702.67016.5D
   Figueiredo EG, 2016, WORLD NEUROSURG, V87, P584, DOI 10.1016/j.wneu.2015.10.063
   Horsley V., 1910, P ROY SOC MED, V3, P77
   Jittapiromsak P, 2010, SKULL BASE-INTERD AP, V20, P311, DOI 10.1055/s-0030-1249571
   Komune N, 2015, OPER NEUROSURG, V11, P306, DOI 10.1227/NEU.0000000000000736
   Matsushima K, 2016, J NEUROSURG, V124, P248, DOI 10.3171/2015.2.JNS142707
   Ramina R, 2011, NEUROL SCI, V32, P1013, DOI 10.1007/s10072-011-0477-8
   Recalde RJ, 2008, NEUROSURGERY, V63, P9, DOI [10.1227/01.neu.0000317368.69523.40, 10.1227/01.NEU.0000297062.52433.3F]
   STEIN BM, 1971, J NEUROSURG, V35, P197, DOI 10.3171/jns.1971.35.2.0197
   STEIN BM, 1979, SURG NEUROL, V11, P331
   Ueyama T, 1998, NEUROSURGERY, V43, P1137, DOI 10.1097/00006123-199811000-00068
   VANDENBERGH R, 1990, CLIN NEUROL NEUROSUR, V92, P311, DOI 10.1016/0303-8467(90)90056-B
   Vince GH, 2010, J CLIN NEUROSCI, V17, P107, DOI 10.1016/j.jocn.2009.06.034
   VOIGT K, 1976, NEUROCHIRURGIA, V19, P59
   Yagmurlu K, 2014, OPER NEUROSURG, V10, P602, DOI 10.1227/NEU.0000000000000466
   Zaidi HA, 2015, WORLD NEUROSURG, V84, P257, DOI 10.1016/j.wneu.2015.03.009
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1285
EP E1290
DI 10.1016/j.wneu.2018.11.033
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100156
PM 30447444
DA 2020-05-12
ER

PT J
AU Chang, KT
   Lin, YY
   Lin, YY
   Lin, YL
   Cheng, H
   Chang, Y
   Huang, MC
AF Chang, Kai-Ting
   Lin, Yu-Yi
   Lin, Ya-Yu
   Lin, Yi-Lo
   Cheng, Henrich
   Chang, Yin
   Huang, Ming-Chao
TI In Vivo Real-Time Discrimination Among Glioma, Infiltration Zone, and
   Normal Brain Tissue via Autofluorescence Technology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Auto-fluorescence; Glioblastoma; Infiltration; Optical-fiber
ID GLIOBLASTOMA-MULTIFORME; 5-AMINOLEVULINIC ACID; PROGNOSTIC-FACTORS;
   RESECTION; SURVIVAL; EXTENT; SPECTROSCOPY; ASSOCIATION; RECURRENCE; CELL
AB BACKGROUND:Surgery is the first-line therapy for glioblastoma. There is evidence that extent of resection is significantly associated with patient survival. Unfortunately, optimal surgical resection is usually limited because of the difficulty in discriminating tumor-infiltrated region and normal brain tissue. This study aimed to develop a tool to distinguish between infiltration zone and normal tissue in real time during glioma surgery.
   METHODS:In an in vivo study, C6 glioma cells were implanted into the left cerebral hemispheres of 6 rats to mimic tumorigenesis. A newly designed optical fiber-embedded needle probe was used to measure the autofluorescence of both cerebral hemispheres at various depths 5 days after the implantation. These rats were then sacrificed, and both cerebral hemispheres were removed for histopathologic analysis.
   RESULTS:Comparative analyses of corresponding areas by histopathology and autofluorescence revealed highly significant (P < 0.001) differences among the normal tissue, infiltration zone, tumors, and the contralateral cerebral hemispheres. The area of the receiver operating characteristic curve was 0.978, and the sensitivity and specificity of tumor delineation were 93.9% and 94.4%, respectively.
   CONCLUSIONS:The newly designed in vivo fiber-optic probe can distinguish tumor-infiltration zones from normal brain tissue in this in vivo study. Therefore, it may help neurosurgeons to increase extent of resection without damaging normal brain tissue and thus potentially improve the patients' survival and quality of life.
C1 [Chang, Kai-Ting; Cheng, Henrich] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei, Taiwan.
   [Lin, Yu-Yi; Lin, Ya-Yu; Chang, Yin] Natl Yang Ming Univ, Dept Biomed Engn, Taipei, Taiwan.
   [Huang, Ming-Chao] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan.
   [Chang, Kai-Ting; Lin, Yi-Lo; Cheng, Henrich] Taipei Vet Gen Hosp, Neural Regenerat Lab, Dept Neurosurg, Taipei, Taiwan.
   [Cheng, Henrich] Taipei Vet Gen Hosp, Ctr Neural Regenerat, Taipei, Taiwan.
   [Huang, Ming-Chao] Taipei Vet Gen Hosp, Neurol Inst, Div Pediat Neurosurg, Taipei, Taiwan.
   [Lin, Yi-Lo] Natl Chung Hsing Univ, Grad Inst Vet Pathobiol, Coll Vet Med, Taichung, Taiwan.
   [Huang, Ming-Chao] Cent Taiwan Univ Sci & Technol, Basic Med Educ Ctr, Taichung, Taiwan.
   [Huang, Ming-Chao] Taipei Med Univ, Sch Med, Taipei, Taiwan.
RP Huang, MC (reprint author), Natl Yang Ming Univ, Fac Med, Taipei, Taiwan.; Huang, MC (reprint author), Taipei Vet Gen Hosp, Neurol Inst, Div Pediat Neurosurg, Taipei, Taiwan.; Huang, MC (reprint author), Cent Taiwan Univ Sci & Technol, Basic Med Educ Ctr, Taichung, Taiwan.; Huang, MC (reprint author), Taipei Med Univ, Sch Med, Taipei, Taiwan.
EM mchuang@vghtpe.gov.tw
FU Division of Experimental Surgery, Taipei Veterans General Hospital;
   National Science CouncilNational Science Council of Taiwan [NSC
   99-2314-B-075-010-MY3]; Ministry of Science and TechnologyMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST
   102-2314-B-075-031-MY3, MOST 104-2221-E-010-006]; Taipei Veterans
   General HospitalTaipei Veterans General Hospital [V102E6-001,
   V103E6-001, V104E6-001]; Vivian Wu Foundation [VWY 103-001, VWY 104-001]
FX This study was supported, in part, by the Division of Experimental
   Surgery, Taipei Veterans General Hospital and by grants from the
   National Science Council (NSC 99-2314-B-075-010-MY3), the Ministry of
   Science and Technology (MOST 102-2314-B-075-031-MY3, MOST
   104-2221-E-010-006), the Taipei Veterans General Hospital (V102E6-001,
   V103E6-001, V104E6-001), and the Vivian Wu Foundation (VWY 103-001, VWY
   104-001).
CR AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325
   Barnholtz-Sloan JS, 2007, J NEURO-ONCOL, V85, P171, DOI 10.1007/s11060-007-9405-4
   Belykh E, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00055
   BURGER PC, 1988, J NEUROSURG, V68, P698, DOI 10.3171/jns.1988.68.5.0698
   Chaichana K, 2010, J NEUROSURG, V112, P997, DOI 10.3171/2009.9.JNS09805
   Chaichana KL, 2008, J NEURO-ONCOL, V89, P219, DOI 10.1007/s11060-008-9609-2
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081
   Chaichana KL, 2011, ANN SURG ONCOL, V18, P239, DOI 10.1245/s10434-010-1242-6
   Chung Yong Gu, 1997, Journal of Korean Medical Science, V12, P135
   Coluccia D, 2010, ACTA NEUROCHIR, V152, P1711, DOI 10.1007/s00701-010-0708-4
   Croce AC, 2003, PHOTOCHEM PHOTOBIOL, V77, P309, DOI 10.1562/0031-8655(2003)077<0309:DPOAFA>2.0.CO;2
   CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704
   Faraggi D, 2002, STAT MED, V21, P3093, DOI 10.1002/sim.1228
   Haidar DA, 2015, BIOMED OPT EXPRESS, V6, P1219, DOI 10.1364/BOE.6.001219
   HajianTilaki KO, 1997, MED DECIS MAKING, V17, P94, DOI 10.1177/0272989X9701700111
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006
   Ji MB, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0195
   Ji MB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005954
   Kajimoto Y, 2007, J NEUROSURG, V106, P1070, DOI 10.3171/jns.2007.106.6.1070
   Kawaguchi T, 2016, J NEURO-ONCOL, V129, P505, DOI 10.1007/s11060-016-2201-2
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Lamborn KR, 2004, NEURO-ONCOLOGY, V6, P227, DOI 10.1215/S1152851703000620
   Lin WC, 2001, PHOTOCHEM PHOTOBIOL, V73, P396, DOI 10.1562/0031-8655(2001)073<0396:IVBTDU>2.0.CO;2
   Lin WC, 2000, J BIOMED OPT, V5, P214, DOI 10.1117/1.429989
   Marcu L, 2004, PHOTOCHEM PHOTOBIOL, V80, P98, DOI 10.1562/2003-12-09-RA-023.1
   Martirosyan NL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15559
   McGirt MJ, 2009, NEUROSURGERY, V65, P463, DOI 10.1227/01.NEU.0000349763.42238.E9
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Monici M, 2005, BIOTECHNOL ANN REV, V11, P227, DOI 10.1016/S1387-2656(05)11007-2
   MOOK GA, 1969, CLIN CHIM ACTA, V26, P170, DOI 10.1016/0009-8981(69)90304-0
   Orringer D, 2012, J NEUROSURG, V117, P851, DOI 10.3171/2012.8.JNS12234
   Osman H, 2018, WORLD NEUROSURG, V115, P110, DOI 10.1016/j.wneu.2018.03.218
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Poulen G, 2019, J NEUROSURG, V130, P1289, DOI 10.3171/2017.10.JNS171825
   Price SJ, 2011, BRIT J RADIOL, V84, pS159, DOI 10.1259/bjr/26838774
   RATTAN SIS, 1982, BIOSCIENCE REP, V2, P561, DOI 10.1007/BF01314216
   Sainz B, 2015, EUR J HISTOCHEM, V59, P74, DOI 10.4081/ejh.2015.2512
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
NR 42
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E773
EP E782
DI 10.1016/j.wneu.2018.10.144
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100093
PM 30391621
DA 2020-05-12
ER

PT J
AU Chen, EL
   Xu, JJ
   Yang, SZ
   Zhang, QS
   Yi, HL
   Liang, DX
   Lan, SB
   Duan, MY
   Wu, ZH
AF Chen, Enliang
   Xu, Junjie
   Yang, Shanzhi
   Zhang, Qingshun
   Yi, Honglei
   Liang, Daxuan
   Lan, Sibin
   Duan, Mingyang
   Wu, Zenghui
TI Cage Subsidence and Fusion Rate in Extreme Lateral Interbody Fusion with
   and without Fixation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cage subsidence; Fusion; Internal fixation; XLIF
ID CLINICAL-EVALUATION; ALIGNMENT; ANTERIOR; OUTCOMES
AB OBJECTIVE: To examine the subsidence rate in patients undergoing extreme lateral interbody fusion (XLIF) using data from a 2-year retrospective study to assess the effect of supplemental fixation on the stand-alone procedure.
   METHODS: Demographic and perioperative data for all patients who underwent XLIF for degenerative lumbar disorders between June 2012 and January 2016 were collected and divided into 4 groups: the stand-alone (SA), lateral fixation, unilateral pedicle screw, and bilateral pedicle screw (BPS) groups. The disk height (DH), lumbar lordotic (LL) angle, and segmental lordotic (SL) angle were measured preoperatively and 3 days, 3 months, 1 year, and 2 years postoperatively. Clinical outcomes were evaluated using Japanese Orthopaedic Association (JOA) and visual analog scale (VAS) scores. Fusion was defined according to computed tomography scan.
   RESULTS: There were 126 vertebrae in 107 patients treated. SL angle, LL angle, and DH significantly increased postoperatively in all groups. Although the preoperative and 2-year postoperative DHs in the SA group were similar, the other measures showed significant differences from baseline at each follow-up visit. No significant effects on SL angle or DH were found in any of the groups. A significant difference in the LL angle was found in the BPS group compared with the other groups. At the last follow-up, high-grade subsidence was found in 26.89% of all cases, the fusion rate was 85.71%, and the VAS and JOA scores were significantly improved in all groups.
   CONCLUSIONS: Supplemental fixation did not significantly influence cage subsidence or SL angle. Only BPS fixation significantly improved the LL angle. The 2-year fusion rate was satisfactory.
C1 [Chen, Enliang; Xu, Junjie; Liang, Daxuan; Wu, Zenghui] Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
   [Chen, Enliang; Xu, Junjie; Yang, Shanzhi; Zhang, Qingshun; Yi, Honglei; Liang, Daxuan; Wu, Zenghui] Guangzhou Gen Hosp, Dept Orthoped, Guangzhou Mil Command, Guangzhou, Guangdong, Peoples R China.
   [Xu, Junjie; Zhang, Qingshun; Yi, Honglei; Wu, Zenghui] Inst Traumat Orthopaed Peoples Liberat Army, Guangzhou, Guangdong, Peoples R China.
   [Yang, Shanzhi; Duan, Mingyang] Guangzhou Univ Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Lan, Sibin] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
RP Wu, ZH (reprint author), Southern Med Univ, Guangzhou, Guangdong, Peoples R China.; Wu, ZH (reprint author), Guangzhou Gen Hosp, Dept Orthoped, Guangzhou Mil Command, Guangzhou, Guangdong, Peoples R China.; Wu, ZH (reprint author), Inst Traumat Orthopaed Peoples Liberat Army, Guangzhou, Guangdong, Peoples R China.
EM 3094206329@qq.com
OI Chen, Enliang/0000-0002-8395-0313
CR Afathi M, 2017, ORTHOP TRAUMATOL-SUR, V103, P1245, DOI 10.1016/j.otsr.2017.09.014
   Alimi M, 2014, J NEUROSURG-SPINE, V20, P623, DOI 10.3171/2014.1.SPINE13569
   Beutler William J, 2003, Spine J, V3, P289, DOI 10.1016/S1529-9430(03)00061-5
   Bocahut N, 2018, ORTHOP TRAUMATOL-SUR, V104, P405, DOI 10.1016/j.otsr.2017.11.018
   Choi JY, 2006, EUR SPINE J, V15, P16, DOI 10.1007/s00586-004-0817-y
   Fogel GR, 2014, SPINE, V39, pE1138, DOI 10.1097/BRS.0000000000000485
   Jagannathan J, 2009, NEUROSURGERY, V64, P955, DOI 10.1227/01.NEU.0000343544.77456.46
   Karikari IO, 2011, J SPINAL DISORD TECH, V24, P368, DOI 10.1097/BSD.0b013e3181ffefd2
   Kim BR, 2015, TUMOR BIOL, V36, P9475, DOI 10.1007/s13277-015-3681-y
   Kim SJ, 2014, J SEX MED, V11, P145, DOI 10.14257/jse.2014.04.01
   Lang G, 2017, WORLD NEUROSURG, V104, P644, DOI 10.1016/j.wneu.2017.05.035
   Malham GM, 2012, THESCIENTIFICWORLDJO, V2012, DOI DOI 10.1100/2012/246989
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pawar AY, 2015, ASIAN SPINE J, V9, P668, DOI 10.4184/asj.2015.9.5.668
   Pimenta L, 2013, J NEUROL SURG PART A, V74, P343, DOI 10.1055/s-0032-1333420
   Pimenta L, 2012, SCI WORLD J, DOI 10.1100/2012/381814
   Satake K, 2016, ASIAN SPINE J, V10, P907, DOI 10.4184/asj.2016.10.5.907
   Schiffman Michael, 2003, Spine J, V3, P377, DOI 10.1016/S1529-9430(03)00145-1
   Sembrano JN, 2017, CLIN SPINE SURG, V30, pE338, DOI 10.1097/BSD.0000000000000114
   Tohmeh AG, 2014, SPINE, V39, pE1582, DOI 10.1097/BRS.0000000000000645
   Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052
   Williams AL, 2005, AM J NEURORADIOL, V26, P2057
NR 23
TC 0
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E969
EP E977
DI 10.1016/j.wneu.2018.10.182
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100117
PM 30404061
DA 2020-05-12
ER

PT J
AU Chen, GH
   Yin, MC
   Liu, WB
   Xin, BQ
   Bai, GJ
   Wang, J
   Wang, J
   Gao, X
   Wang, Y
   Liu, C
   Cheng, L
   Xiao, JR
   Liu, TL
AF Chen, Guanghui
   Yin, Mengchen
   Liu, Weibo
   Xin, Baoquan
   Bai, Guangjian
   Wang, Jian
   Wang, Jing
   Gao, Xin
   Wang, Yang
   Liu, Chao
   Cheng, Li
   Xiao, Jianru
   Liu, Tielong
TI A Novel Height-Adjustable Nano-Hydroxyapatite/Polyamide-66 Vertebral
   Body for Reconstruction of Thoracolumbar Structural Stability After
   Spinal Tumor Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deformity; Endplate geometry; Nano-hydroxyapatite/polyamide-66;
   Reconstruction; Spinal tumor; Vertebral body
ID TITANIUM MESH CAGE; EN-BLOC SPONDYLECTOMY; EXPANDABLE CAGE; COLUMN
   RESECTION; LUMBAR VERTEBRAE; REPLACEMENT; VERTEBRECTOMY; CORPECTOMY;
   SUBSIDENCE; MANAGEMENT
AB BACKGROUND: Reconstruction of thoracolumbar structural stability is a formidable challenge for spine surgeons after vertebral body tumor resection. Various disadvantages of the currently used expandable or nonexpandable cages have limited their clinical applications. We sought to develop a novel prosthesis for clinical use and assess its preliminary clinical outcome in reconstruction of thoracolumbar structural stability after spinal tumor resection.
   METHODS: Using data obtained from a retrospective analysis of the morphological characteristics of the thoracolumbar vertebrae and endplates in previously reported studies, we modified the nano-hydroxyapatite/polyamide-66 (n-HA/PA66) strut into a novel height-adjustable vertebral body. A retrospective study was performed of 7 patients who had undergone reconstruction of thoracolumbar structural stability with this novel prosthesis from August 2016 to January 2017.
   RESULTS: A novel height-adjustable vertebral body (AHVB) composed of n-HA/PA66 with 2 separate components with a 163 degrees contact surface at each end was manufactured. The height-adjustable range was 28-37 mm. No significant implant-related complications were observed in the process of operation. All patients experienced a significant reduction in pain, with the visual analog scale score decreasing from 7.9 to 4.0. Neurological improvement was assessed using the Frankel grading system after surgery. Postoperative radiographic and computed tomography/magnetic resonance imaging findings indicated that the operated segment was stable, the outcome of kyphosis correction was good, and no prosthesis subsidence or dislocation was observed.
   CONCLUSION: This novel prosthesis has many advantages in the reconstruction of height, lordosis, and alignment after thoracolumbar spinal tumor resection and has a favorable prospect for clinical application.
C1 [Chen, Guanghui; Liu, Weibo; Wang, Jing; Gao, Xin; Wang, Yang; Liu, Chao; Xiao, Jianru; Liu, Tielong] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Ctr Oncol, Shanghai, Peoples R China.
   [Yin, Mengchen] Longhua Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Wang, Jian] Peoples Hosp Shanghai Pudong New Area, Dept Orthopaed, Shanghai, Peoples R China.
   [Xin, Baoquan; Bai, Guangjian] Taishan Med Univ, Tai An, Shandong, Peoples R China.
   [Cheng, Li] Peoples Hosp Cixi, Dept Orthopaed, Cixi, Zhejiang, Peoples R China.
RP Liu, TL (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Ctr Oncol, Shanghai, Peoples R China.
EM czyyltl_spine@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51573207]; Ningbo Natural Science Foundation
   [2018A810008]
FX .The present study was supported by the National Natural Science
   Foundation of China (grant 51573207) and Ningbo Natural Science
   Foundation (grant 2018A810008).
CR AHARINEJAD S, 1990, AM J ANAT, V189, P69, DOI 10.1002/aja.1001890109
   Arts MP, 2008, NEUROSURGERY, V63, P537, DOI 10.1227/01.NEU.0000325260.00628.DC
   Awwad W, 2017, J CRANIOVERTEBRAL JU, V8, P50, DOI 10.4103/0974-8237.199869
   Chan KK, 1997, RADIOLOGY, V202, P253, DOI 10.1148/radiology.202.1.8988219
   Chen Y, 2008, J SPINAL DISORD TECH, V21, P489, DOI 10.1097/BSD.0b013e318158de22
   Crocker M, 2008, BRIT J NEUROSURG, V22, P235, DOI 10.1080/02688690701837273
   Duan PG, 2015, EUR SPINE J, V24, pS514, DOI 10.1007/s00586-014-3625-z
   Duran S, 2017, CAN ASSOC RADIOL J, V68, P210, DOI 10.1016/j.carj.2016.11.002
   Ernstberger T, 2005, ARCH ORTHOP TRAUM SU, V125, P660, DOI 10.1007/s00402-005-0057-6
   Graillon T, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.5.FOCUS1452
   Grant JP, 2001, SPINE, V26, P889, DOI 10.1097/00007632-200104150-00012
   Gressot LV, 2015, J NEUROSURG-PEDIATR, V15, P207, DOI 10.3171/2014.9.PEDS14151
   Grob D, 2005, EUR SPINE J, V14, P211, DOI 10.1007/s00586-004-0748-7
   Hasegawa K, 2001, SPINE, V26, P957, DOI 10.1097/00007632-200104150-00022
   Herrero CFPS, 2014, BIOMED RES INT, DOI 10.1155/2014/545017
   Holland CM, 2015, CLIN NEUROL NEUROSUR, V129, P37, DOI 10.1016/j.clineuro.2014.11.022
   Huang M, 2003, J MATER SCI-MATER M, V14, P655, DOI 10.1023/A:1024087410890
   Jandial R, 2013, J NEUROSURG-SPINE, V19, P27, DOI 10.3171/2013.4.SPINE12344
   Klezl Z, 2007, EUR SPINE J, V16, pS306, DOI 10.1007/s00586-007-0377-z
   Kotani Y, 2002, SPINE, V27, P929, DOI 10.1097/00007632-200205010-00008
   Lau D, 2013, NEUROSURGERY, V72, P529, DOI 10.1227/NEU.0b013e318282a558
   Lee JH, 2017, CLIN SPINE SURG, V30, pE398, DOI 10.1097/BSD.0000000000000236
   Lowe TG, 2004, SPINE, V29, P2389, DOI 10.1097/01.brs.0000143623.18098.e5
   Lu MP, 2016, SCI REP-UK, V6, DOI 10.1038/srep39174
   Luzzati AD, 2015, CLIN ORTHOP RELAT R, V473, P858, DOI 10.1007/s11999-014-3578-x
   Mesfin A, 2015, ORTHOPEDICS, V38, pE995, DOI 10.3928/01477447-20151020-08
   NISSAN M, 1986, J BIOMECH, V19, P753, DOI 10.1016/0021-9290(86)90198-3
   Papanastassiou ID, 2011, J SURG ONCOL, V104, P552, DOI 10.1002/jso.21910
   Reinhold M, 2009, ARCH ORTHOP TRAUM SU, V129, P1375, DOI 10.1007/s00402-009-0823-y
   Robinson Y, 2009, INT ORTHOP, V33, P745, DOI 10.1007/s00264-008-0567-2
   Ropper AE, 2017, NEW ENGL J MED, V376, P1358, DOI 10.1056/NEJMra1516539
   Sasani M, 2009, SPINE, V34, pE33, DOI 10.1097/BRS.0b013e318189fcfd
   Skovrlj B, 2016, GLOB SPINE J, V6, pE35, DOI 10.1055/s-0035-1550341
   Suzuki T, 2013, J SPINAL DISORD TECH, V26, pE170, DOI 10.1097/BSD.0b013e318286fc18
   Tan SH, 2004, EUR SPINE J, V13, P137, DOI 10.1007/s00586-003-0586-z
   Thongtrangan Issada, 2003, Neurosurg Focus, V15, pE8
   Tullberg T, 1998, SPINE, V23, P1804, DOI 10.1097/00007632-199808150-00016
   van der Houwen EB, 2010, ANN BIOMED ENG, V38, P33, DOI 10.1007/s10439-009-9827-6
   Viljoen SV, 2014, J NEUROSURG-SPINE, V21, P577, DOI 10.3171/2014.6.SPINE13751
   Wang SJ, 2015, INT J CLIN EXP MED, V8, P5559
   Wang Y, 2012, EUR SPINE J, V21, P2316, DOI 10.1007/s00586-012-2415-8
   Wong ML, 2014, NEUROL RES, V36, P544, DOI 10.1179/1743132814Y.0000000363
   Wu JX, 2015, INT J CLIN EXP MED, V8, P7405
   Xiong Y, 2014, INT J NANOMED, V9, P485, DOI 10.2147/IJN.S52990
   Xu QA, 2010, INT J NANOMED, V5, P331
   Yang X, 2013, INT ORTHOP, V37, P2421, DOI 10.1007/s00264-013-2101-4
   Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26751
   Zhao SC, 2016, EUR SPINE J, V25, P2218, DOI 10.1007/s00586-015-4336-9
   Zhong WY, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000333
NR 49
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E206
EP E214
DI 10.1016/j.wneu.2018.09.213
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100022
PM 30308342
DA 2020-05-12
ER

PT J
AU Chen, J
   Jiang, Q
   Zhang, Y
   Yu, YF
   Zheng, YF
   Chen, J
   Zhao, YQ
   Miao, ZZ
   Fan, FF
   Wang, Y
AF Chen, Jun
   Jiang, Qian
   Zhang, Yu
   Yu, Yufei
   Zheng, Yifeng
   Chen, Juan
   Zhao, Yiqing
   Miao, Zhuangzhuang
   Fan, Fanfan
   Wang, Yu
TI Clinical Features and Long-Term Outcome of Primary Intracranial Ewing
   Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases From a
   Single Institution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ewing sarcoma; Intracranial; Primitive neuroectodermal tumors; Treatment
ID ROUND-CELL TUMORS; IMMUNOHISTOCHEMICAL DETECTION; SARCOMA; FAMILY; PNET
AB OBJECTIVE: Primary intracranial Ewing sarcoma (ES)/peripheral primitive neuroectodermal tumors (pPNETs) are extremely rare, and only a few studies have reported >4 cases of this disease. The purpose of this study was to explore the clinical features, treatment, and outcome of primary intracranial ES/pPNETs.
   METHODS: The clinical data of 14 patients who had been surgically treated from February 2003 to November 2017 and in whom immunohistochemical staining results had confirmed the diagnosis of primary intracranial ES/pPNETs were retrospectively analyzed. Kaplan-Meier survival analysis was used to estimate the survival rate and the median survival time (MST).
   RESULTS: Gross total resection (GTR) was achieved in 7 cases, and subtotal resection was performed in 7 cases. During follow-up, 10 (71.4%) patients had local recurrence and 3 (21.4%) patients had distant metastasis. The overall 1-, 2-, and 5-year survival rates were 78.6%, 47.6%, and 19.0%, respectively. Kaplan-Meier survival analysis showed that postoperative radiotherapy was a significant prognostic factor for longer MST (P = 0.034). GTR and radiotherapy with or without adjuvant chemotherapy yielded the highest 2-year survival rate (100%). Three patients who underwent GTR, radiotherapy, and chemotherapy had the highest 2-year survival rates (100%) and the longest MST (48 months).
   CONCLUSIONS: Primary intracranial ES/pPNETs have an aggressive clinical course, with a high tendency for local recurrence and distant metastasis. Radiotherapy plays a significant role in improving the survival of patients. GTR combined with radiotherapy and chemotherapy may be the most beneficial treatment modality.
C1 [Chen, Jun; Jiang, Qian; Zheng, Yifeng; Chen, Juan; Zhao, Yiqing; Miao, Zhuangzhuang; Fan, Fanfan; Wang, Yu] Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Zhang, Yu; Yu, Yufei] Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Operating Room, Wuhan, Hubei, Peoples R China.
RP Wang, Y (reprint author), Huazhong Univ Sci & Technol, Tongji Med Sch, Tongji Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM 330722474@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571242]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81571242).
CR Alqahtani A, 2017, CASE REP PEDIAT, DOI 10.1155/2017/1521407
   BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230
   Craft A, 1998, J CLIN ONCOL, V16, P3628, DOI 10.1200/JCO.1998.16.11.3628
   Craft AW, 1997, EUR J CANCER, V33, P1061, DOI 10.1016/S0959-8049(97)00043-9
   Dedeurwaerdere F, 2002, MODERN PATHOL, V15, P673, DOI 10.1038/modpathol.3880585
   DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503
   El Asri AC, 2018, WORLD NEUROSURG, V115, P346, DOI 10.1016/j.wneu.2018.04.164
   Folpe AL, 2005, AM J SURG PATHOL, V29, P1025
   Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010
   Gessi M, 2009, AM J SURG PATHOL, V33, P211, DOI 10.1097/PAS.0b013e318186235b
   Guo X, 2012, CLIN NEUROL NEUROSUR, V114, P1181, DOI 10.1016/j.clineuro.2012.02.042
   Idrees M, 2005, ARCH PATHOL LAB MED, V129, P11
   Izycka-Swieszewska E, 2003, CLIN NEUROPATHOL, V22, P66
   Jing Z, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130631
   Ke CS, 2017, NEUROPATHOLOGY, V37, P35, DOI 10.1111/neup.12325
   Llombart-Bosch A, 2001, APPL IMMUNOHISTO M M, V9, P255, DOI 10.1097/00022744-200109000-00010
   Mattogno PP, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.12.045
   Muller K, 2013, STRAHLENTHER ONKOL, V189, P372, DOI 10.1007/s00066-013-0315-4
   Pekala JS, 2006, AM J NEURORADIOL, V27, P580
   Tanboon J, 2012, NEUROPATHOLOGY, V32, P293, DOI 10.1111/j.1440-1789.2011.01258.x
   VandenHeuvel KA, 2015, INT J CLIN EXP PATHO, V8, P260
   Velivela K, 2014, NEUROL INDIA, V62, P669, DOI 10.4103/0028-3886.149400
   Yang MJ, 2018, CHILD NERV SYST, V34, P441, DOI 10.1007/s00381-017-3684-7
   Zhang Y, 2016, ONCOTARGETS THER, V9, P3327, DOI 10.2147/OTT.S103988
NR 24
TC 5
Z9 5
U1 0
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1606
EP E1614
DI 10.1016/j.wneu.2018.11.151
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100198
PM 30496933
DA 2020-05-12
ER

PT J
AU Chen, WH
   Yi, TY
   Wu, YM
   Zhang, MF
   Lin, DL
   Lin, XH
AF Chen, Wen-Huo
   Yi, Ting-yu
   Wu, Yan-Min
   Zhang, Mei-Fang
   Lin, Ding-lai
   Lin, Xiao-hui
TI Safety of Endovascular Therapy in Progressive Ischemic Stroke and
   Anterior Circulation Large Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular therapy; Ischemic stroke; Progressive; Subacute;
   Symptomatic intracranial hemorrhage
ID SYMPTOM ONSET; THROMBECTOMY; DESMOTEPLASE; REPERFUSION; MANAGEMENT;
   STENOSIS; OUTCOMES; WINDOW; TRIAL
AB BACKGROUND AND OBJECTIVE: The prognosis of progressive ischemic stroke (PIS) caused by large proximal artery occlusion with hemodynamic was poor. Our study aimed to investigate the safety of endovascular therapy (ET) for patients with PIS who were selected based on ischemic penumbra detected on brain imaging.
   METHODS: A cohort of consecutive patients with PIS, who were treated with ET, were identified. Patients were selected for ET based on the presence of ischemic penumbra using magnetic resonance imaging. Clinical outcome includes 90-day modified Rankin scale, mortality, and symptomatic intracerebral hemorrhage (sICH) rate. Multivariate analysis was performed to compare treatment time of <= 6 hours (early) with >6 hours (late) after stroke.
   RESULTS: One hundred forty-eight patients were treated (100 early and 48 late). Compared with the early group, more successful recanalization rate in the late group (100% vs. 89%, P = 0.017), lower mortality (2.1% vs. 12%, P = 0.046), better clinical outcome (modified Rankin scale score <= 2, 81.3% vs. 65%, P = 0.046), and sICH rate was similar between the 2 groups (7.0% vs. 9.5%, P = 1.00). Only pretreatment National Institutes of Health Stroke Scale score (odds ratio [OR] = 0.836, P = 0.025), successful recanalization (OR = 7.077, P = 0.038), collateral status (OR = 3.121, P = 0.016), and sICH (OR = 0.053, P = 0.013) were predictors of a good prognosis.
   CONCLUSIONS: In appropriately selected patients with PIS, ET can be performed safely. Furthermore, randomized clinical trials are needed to assess its effectiveness.
C1 [Chen, Wen-Huo; Yi, Ting-yu; Wu, Yan-Min; Zhang, Mei-Fang; Lin, Ding-lai; Lin, Xiao-hui] Fujian Med Univ, Dept Neurol, Zhangzhou Affiliated Hosp, Fuzhou, Fujian, Peoples R China.
RP Yi, TY (reprint author), Fujian Med Univ, Dept Neurol, Zhangzhou Affiliated Hosp, Fuzhou, Fujian, Peoples R China.
EM siyuyufen@163.com
RI Yi, Ting-yu/AAH-1027-2020
OI Yi, Ting-yu/0000-0003-3110-5844
CR Alawneh JA, 2009, STROKE, V40, pE443, DOI 10.1161/STROKEAHA.108.532465
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3
   Fanou EM, 2015, AM J NEURORADIOL, V36, P2285, DOI 10.3174/ajnr.A4453
   Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Gupta R, 2006, STROKE, V37, P986, DOI 10.1161/01.STR.0000209303.02474.27
   Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c
   Hao YG, 2017, STROKE, V48, P1203, DOI 10.1161/STROKEAHA.116.016368
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Jung S, 2013, EUR J NEUROL, V20, P865, DOI 10.1111/ene.12069
   Kim SK, 2015, AM J NEURORADIOL, V36, P1266, DOI 10.3174/ajnr.A4280
   Lansberg MG, 2015, NEUROLOGY, V85, P708, DOI 10.1212/WNL.0000000000001853
   Legrand L, 2016, STROKE, V47, P424, DOI 10.1161/STROKEAHA.115.010999
   Natarajan SK, 2009, STROKE, V40, P3269, DOI 10.1161/STROKEAHA.109.555102
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Power S, 2014, STROKE, V45, P2330, DOI 10.1161/STROKEAHA.114.005618
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Qureshi AI, 2013, J STROKE CEREBROVASC, V22, P1076, DOI 10.1016/j.jstrokecerebrovasdis.2012.07.015
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Seo WK, 2017, STROKE, V48, P1077, DOI 10.1161/STROKEAHA.116.015429
   Verclytte S, 2017, INSIGHTS IMAGING, V8, P91, DOI 10.1007/s13244-016-0529-y
   Vora NA, 2011, STROKE, V42, P645, DOI 10.1161/STROKEAHA.110.596312
   Wang YJ, 2014, STROKE, V45, P663, DOI 10.1161/STROKEAHA.113.003508
   Wang ZL, 2014, STROKE, V45, P2811, DOI 10.1161/STROKEAHA.114.004286
   Wheeler HM, 2015, INT J STROKE, V10, P723, DOI 10.1111/ijs.12436
   Wouters A, 2016, INT J STROKE, V11, P127, DOI 10.1177/1747493015607503
   Yi TY, 2017, WORLD NEUROSURG, V103, P65, DOI 10.1016/j.wneu.2017.03.108
   Yu X, 2016, AM J NEURORADIOL, V37, P423, DOI 10.3174/ajnr.A4541
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
   Zhang J, 2008, STROKE, V39, P967, DOI 10.1161/STROKEAHA.107.497412
NR 33
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E383
EP E389
DI 10.1016/j.wneu.2018.10.059
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100045
PM 30391620
DA 2020-05-12
ER

PT J
AU Chen, Y
   Wang, JX
   Sun, B
   Cao, P
   Tian, Y
   Shen, XL
   Liu, Y
   Chen, HJ
   Wang, XW
   Yuan, W
   Wu, XD
AF Chen, Yu
   Wang, Jian-Xi
   Sun, Bin
   Cao, Peng
   Tian, Ye
   Shen, Xiao-Long
   Liu, Yang
   Chen, Hua-Jiang
   Wang, Xin-Wei
   Yuan, Wen
   Wu, Xiao-Dong
TI Percutaneous Endoscopic Lumbar Discectomy in Treating Calcified Lumbar
   Intervertebral Disc Herniation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcification; Clinical efficacy; Lumbar disc herniation; Percutaneous
   endoscopic lumbar discectomy
ID PEID
AB BACKGROUND: We retrospectively analyzed and report the clinical results of percutaneous endoscopic lumbar discectomy (PELD) in treating patients with calcified lumbar intervertebral disc herniation (CLDH).
   METHODS: The data from 40 patients with CLDH treated with PELD in our hospital from June 2013 to June 2017 were reviewed. Of the 40 patients, 27 (19 men; 8 women; average age, 45.5 +/- 7.5 years) had undergone percutaneous endoscopic transforaminal discectomy and 13 (8 men, 5 women; average age, 46.9 +/- 6.9 years) had undergone percutaneous endoscopic interlaminar discectomy. The Peak method was used for both groups. The preoperative demographic data of both groups were analyzed. The pre- and postoperative leg visual analog scale scores and Oswestry disability index were compared and complications were evaluated.
   RESULTS: All procedures were performed successfully, and follow-up data were obtained for all patients for 24 months. The leg visual analog scale and Oswestry disability index scores at the last follow-up visit had decreased in both groups and were significantly different statistically from the preoperative data. No nerve root injury, intestinal injury, intervertebral disc infection, or recurrence was detected in any patient. Dural tear and cerebrospinal fluid leakage were observed in 3 patients (2, percutaneous endoscopic transforaminal discectomy; 1, percutaneous endoscopic interlaminar discectomy), because of adhesions between the calcification and nerve root. However, their symptoms resolved, and they were discharged after 1 week of bed rest.
   CONCLUSIONS: With the application of Peak philosophy, PELD is safe and effective in treating patients with CLDH. The use of PELD results in good neurological recovery, pain relief, and a low incidence of complications.
C1 [Chen, Yu; Wang, Jian-Xi; Sun, Bin; Cao, Peng; Tian, Ye; Shen, Xiao-Long; Liu, Yang; Chen, Hua-Jiang; Wang, Xin-Wei; Yuan, Wen; Wu, Xiao-Dong] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
RP Wu, XD (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM wxdstonecold@163.com
FU project "Biofunctionalization of titanium coating via biochemical
   modification to improve its osseointegration of NSFC" [31200718];
   project "The mechanism on the Th17/Treg balance affected by IL17
   secretion in degenerative nucleus pulposus" of Shanghai Municipal
   Commission of Health and Family Planning [20174Y0131]
FX The present study was supported by the project "Biofunctionalization of
   titanium coating via biochemical modification to improve its
   osseointegration of NSFC" (grant 31200718) and the project "The
   mechanism on the Th17/Treg balance affected by IL17 secretion in
   degenerative nucleus pulposus" of Shanghai Municipal Commission of
   Health and Family Planning (grant 20174Y0131).
CR Ahn Y, 2016, CLIN NEUROL NEUROSUR, V147, P11, DOI 10.1016/j.clineuro.2016.05.016
   ALBECK MJ, 1991, ACTA NEUROCHIR, V113, P52, DOI 10.1007/BF01402115
   Choi KC, 2015, NEUROSURGERY, V76, P372, DOI 10.1227/NEU.0000000000000628
   Choi KC, 2013, PAIN PHYSICIAN, V16, P547
   Cong L, 2016, EUR SPINE J, V25, P134, DOI 10.1007/s00586-015-3776-6
   Gille O, 2006, EUR SPINE J, V15, P537, DOI 10.1007/s00586-005-1014-3
   Gu X, 2013, CLIN ANAT, V26, P728, DOI 10.1002/ca.22286
   Jasper GP, 2013, CLIN NEUROL NEUROSUR, V115, P1961, DOI 10.1016/j.clineuro.2013.05.033
   Kim HS, 2013, PAIN PHYSICIAN, V16, P359
   Lee S, 2007, EUR SPINE J, V16, P431, DOI 10.1007/s00586-006-0219-4
   Okuda S, 2006, J NEUROSURG-SPINE, V4, P304, DOI 10.3171/spi.2006.4.4.304
   Paolini S, 2016, EUR SPINE J, V25, P200, DOI 10.1007/s00586-015-3858-5
   Xu DB, 2016, PAIN PHYSICIAN, V19, P69
NR 13
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1449
EP E1456
DI 10.1016/j.wneu.2018.11.083
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100178
PM 30465964
DA 2020-05-12
ER

PT J
AU Cheng, W
   Kang, QY
   Xiao, QH
AF Cheng, Wei
   Kang, Qiaoying
   Xiao, Qinghua
TI Bibliometric Analysis of the Top 100 Influential Studies on Carotid
   Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometric analysis; Carotid artery stenosis; Carotid artery stenting;
   CAS
ID ENDARTERECTOMY; MANAGEMENT
AB BACKGROUND: Artery stenting is an effective therapy for carotid artery stenosis to prevent ischemic stroke. We aimed to identify and analyze the 100 top-cited reports on carotid artery stenting (CAS) to review the achievements and developments in this field.
   METHODS: The Web of Knowledge database was searched from its inception up to May 3, 2018, using the terms "carotid artery stenting" and "CAS." The 100 most-cited reports were extracted to analyze their characteristics.
   RESULTS: The number of citations for the 100 most-cited reports ranged from 120 to 1813, with an accumulated citation number of 26,265. These reports were from 13 countries, with the most publications from the United States (n = 62), followed by the United Kingdom (n = 11), Germany (n = 6), and Italy (n = 6). Stroke (n = 21) was the lead-producing journal, followed by the Journal of Vascular Surgery (n = 11) and Journal of the American College of Cardiology (n = 10). Those reports with a greater impact factor were likely to be cited more often (P < 0.0001). These reports were categorized as clinical trial (n = 74), review (n = 13), basic study (n = 5), guideline (n = 5), commentary (n = 1), expert consensus (n = 1), and protocol (n = 1).
   CONCLUSIONS: The results of the present study provide scientific data for CAS. The United States contributed the most reports. Stroke was the lead productive journal. Those reports with a greater impact factor were likely to be cited more often.
C1 [Cheng, Wei; Xiao, Qinghua] Xinfeng Peoples Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
   [Kang, Qiaoying] Xinfeng Peoples Hosp, Dept Pediat, Ganzhou, Jiangxi, Peoples R China.
RP Xiao, QH (reprint author), Xinfeng Peoples Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
EM drqinghuaxiao@sina.com
CR Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095
   AbuRahma Ali F, 2016, Adv Surg, V50, P235, DOI 10.1016/j.yasu.2016.04.004
   Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215
   Eckstein HH, 2018, EUR J VASC ENDOVASC, V55, P1, DOI 10.1016/j.ejvs.2017.06.026
   Fuchs VR, 2013, NEW ENGL J MED, V369, P107, DOI 10.1056/NEJMp1305298
   Gahremanpour A, 2012, TEX HEART I J, V39, P474
   GARFIELD E, 1987, JAMA-J AM MED ASSOC, V257, P52, DOI 10.1001/jama.257.1.52
   Guo CQ, 2018, WORLD NEUROSURG, V115, pE472, DOI 10.1016/j.wneu.2018.04.072
   Krishnamurthi RV, 2015, NEUROEPIDEMIOLOGY, V45, P190, DOI 10.1159/000441098
   Merigo JM, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/s12992-016-0186-4
   Meschia JF, 2017, MAYO CLIN PROC, V92, P1144, DOI 10.1016/j.mayocp.2017.02.020
   Moresoli P, 2017, STROKE, V48, P2150, DOI 10.1161/STROKEAHA.117.016824
   Ozsoy Z, 2018, OBES SURG, V28, P2339, DOI 10.1007/s11695-018-3163-6
   Park JH, 2018, KOREAN CIRC J, V48, P97, DOI 10.4070/kcj.2017.0208
   Powell AGMT, 2018, WORLD J SURG, V42, P2745, DOI 10.1007/s00268-018-4579-9
   Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10
   Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]
   Seglen PO, 1998, ACTA ORTHOP SCAND, V69, P224, DOI 10.3109/17453679809000920
   Yao HQ, 2018, PEERJ, V6, DOI 10.7717/peerj.5091
NR 19
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1321
EP E1331
DI 10.1016/j.wneu.2018.11.042
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100161
PM 30448570
DA 2020-05-12
ER

PT J
AU Choque-Velasquez, J
   Resendiz-Nieves, JC
   Jahromi, BR
   Colasanti, R
   Raj, R
   Tynninen, O
   Collan, J
   Hernesniemi, J
AF Choque-Velasquez, Joham
   Resendiz-Nieves, Julio C.
   Jahromi, Behnam Rezai
   Colasanti, Roberto
   Raj, Rahul
   Tynninen, Olli
   Collan, Juhani
   Hernesniemi, Juha
TI Pineal Parenchymal Tumors of Intermediate Differentiation: A long-Term
   Follow-Up Study in Helsinki Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microneurosurgery; Pineal parenchymal tumors of intermediate
   differentiation; Pineal region lesions; Radiotherapy; Sitting position;
   Supracerebellar infratentorial approach
ID HEALTH-ORGANIZATION CLASSIFICATION; CENTRAL-NERVOUS-SYSTEM
AB BACKGROUND: Pineal parenchymal tumors of intermediate differentiation (PPTIDs) are rare lesions with particular features compared with other pineal parenchymal tumors.
   METHODS: We present a retrospective review of patients with histologically confirmed PPTIDs who were operated on in our department between 1997 and 2015. A demographic analysis and an evaluation of preoperative status, surgical treatment, as well as immediate and long-term clinical and radiologic outcomes were conducted.
   RESULTS: Fifteen patients with PPTIDs were operated on between 1997 and 2015. Gross total removal was achieved in 11 cases; 2 patients underwent near-total resection, 1 partial resection, and 1 received brachytherapy after an endoscopic biopsy. Nine patients required external radiation therapy (4 due to a pleomorphic histology of their lesion including pineoblastoma features in 3 of them; 3 after a subtotal resection; and 2 for tumor recurrence). No patient received chemotherapy. The survival rate of our patients was 57.1% at a mean follow-up of 137.2 +/- 77.6 months (39-248 months).
   CONCLUSIONS: A proper multidisciplinary management of PPTIDs based on a gross total removal of the lesion, and an adjuvant radiotherapy in selected cases, may improve the overall survival of these aggressive tumors.
C1 [Choque-Velasquez, Joham; Resendiz-Nieves, Julio C.; Jahromi, Behnam Rezai; Raj, Rahul] Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
   [Tynninen, Olli] Univ Helsinki, Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland.
   [Collan, Juhani] Univ Helsinki, Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.
   HUSLAB, Helsinki, Finland.
   [Colasanti, Roberto] Univ Politecn Marche, Umberto I Gen Hosp, Dept Neurosurg, Ancona, Italy.
   [Colasanti, Roberto] Osped Riuniti Marche Nord, Dept Neurosurg, Pesaro, Italy.
   [Hernesniemi, Juha] Henan Prov Peoples Hosp, Juha Hernesniemi Int Ctr Neurosurg, Zhengzhou, Henan, Peoples R China.
RP Choque-Velasquez, J (reprint author), Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
EM johchove@hotmail.com
RI Colasanti, Roberto/P-5574-2018; Raj, Rahul/K-7693-2012
OI Colasanti, Roberto/0000-0001-5026-8089; Raj, Rahul/0000-0003-4243-9591;
   Choque-Velasquez, Joham/0000-0001-5220-1216; Rezai Jahromi,
   Behnam/0000-0003-3937-2816
CR Amato-Watkins AC, 2016, BRIT J NEUROSURG, V30, P11, DOI 10.3109/02688697.2015.1096912
   Chatterjee D, 2019, APPL IMMUNOHISTO M M, V27, P210, DOI 10.1097/PAI.0000000000000565
   Choque Velasquez J, 2016, J NEUROSURG SCI, V60, P44
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V117, pE669, DOI 10.1016/j.wneu.2018.06.110
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V117, P195, DOI 10.1016/j.wneu.2018.06.080
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V117, P144, DOI 10.1016/j.wneu.2018.06.020
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V113, pE604, DOI 10.1016/j.wneu.2018.02.107
   Choque-Velasquez J, 2017, WORLD NEUROSURG, V105, P534, DOI 10.1016/j.wneu.2017.06.007
   Fauchon F, 2000, INT J RADIAT ONCOL, V46, P959, DOI 10.1016/S0360-3016(99)00389-2
   Fevre-Montange M, 2012, NEUROPATH APPL NEURO, V38, P87, DOI 10.1111/j.1365-2990.2011.01202.x
   Han SJ, 2011, NEUROSURG CLIN N AM, V22, P335, DOI 10.1016/j.nec.2011.05.006
   Iacoangeli M, 2017, ACTA NEUROCHIR, V159, P645, DOI 10.1007/s00701-017-3117-0
   Iorio-Morin C, 2017, WORLD NEUROSURG, V107, P974, DOI 10.1016/j.wneu.2017.07.097
   Ito T, 2014, WORLD NEUROSURG, V81, P783, DOI 10.1016/j.wneu.2013.02.007
   Kang YJ, 2016, WORLD NEUROSURG, V85, P96, DOI 10.1016/j.wneu.2015.07.032
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lutterbach J, 2002, NEUROSURGERY, V51, P44, DOI 10.1097/00006123-200207000-00006
   Nakazato Y, 2007, WHO CLASSIFICATION T, P126
   Osborn AG, 2012, AM J NEURORADIOL, V33, P795, DOI 10.3174/ajnr.A2583
   Scheithauer BW, 2008, BRAIN PATHOL, V18, P307, DOI 10.1111/j.1750-3639.2008.00179.x
   Vasiljevic A, 2010, PRACTICAL SURG NEURO, P151
   Yu T, 2016, J NEUROL NEUROSUR PS, V87, P386, DOI 10.1136/jnnp-2014-309805
NR 22
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E729
EP E739
DI 10.1016/j.wneu.2018.10.128
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100088
PM 30391615
OA Green Published
DA 2020-05-12
ER

PT J
AU Clifton, WE
   Stone, JJ
   Kumar, N
   Marek, T
   Spinner, RJ
AF Clifton, William E.
   Stone, Jonathan J.
   Kumar, Neeraj
   Marek, Tomas
   Spinner, Robert J.
TI Delayed Myelopathy in Patients with Traumatic Preganglionic Brachial
   Plexus Avulsion Injuries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brachial plexus; Myelopathy; Pseudomeningocele; Siderosis; Trauma
ID SPINAL-CORD HERNIATION; CENTRAL-NERVOUS-SYSTEM; SUPERFICIAL SIDEROSIS;
   ROOT AVULSION; NEUROLOGICAL DYSFUNCTION; ARACHNOID CYST; ADULT;
   MYELOGRAPHY; PSEUDOMENINGOCELE; DIAGNOSIS
AB BACKGROUND: Cervical and upper thoracic nerve root avulsions are preganglionic lesions that occur after extreme traction of the brachial plexus. The tearing of the roots from the spinal cord pia leads, not only to immediate and permanent deficits, but also to delayed neurologic complications. Symptomatic myelopathy can present in a late fashion owing to chronic sequelae from the inciting traumatic event. No unifying theory has yet been provided that can explain the causes of delayed spinal cord dysfunction after preganglionic brachial plexus injury. We have proposed a collective mechanism for the development of delayed spinal cord injury.
   METHODS: An institutional database search and a literature review were performed to find patients who had presented with delayed myelopathy after brachial plexus injury.
   RESULTS: We found 454 adult patients with traumatic brachial plexus injury and spinal cord injury from 1997 to 2018 in the institutional search. Of these patients, 74 had a delayed presentation of new myelopathic findings on physical examination that had developed >= 6 months after the initial presentation. In these 74 patients with delayed myelopathic symptoms, radiologic findings of spinal cord herniation, syringomyelia, superficial siderosis, or pathologic intradural or extradural cerebrospinal fluid collections from traumatic dural tears were present. Each of these pathologic entities was present in isolation or combination in our patient population.
   CONCLUSIONS: Four overlapping etiologies appeared to compose the primary foundation for delayed spinal cord dysfunction after brachial plexus injury. We have highlighted this continuum by providing institutional case examples and a review of the reported data.
C1 [Clifton, William E.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
   [Stone, Jonathan J.; Marek, Tomas; Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Kumar, Neeraj] Mayo Clin, Dept Neurol, Rochester, MN USA.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM spinner.robert@mayo.edu
RI Marek, Tomas/T-4236-2018; Clifton, William/AAA-6109-2019
OI Marek, Tomas/0000-0003-3588-9236; Clifton, William/0000-0003-3533-8776
CR ALNOT JY, 1995, MICROSURG, V16, P22, DOI 10.1002/micr.1920160108
   ALNOT JY, 1988, CLIN ORTHOP RELAT R, P9
   Aquilina K, 2005, ACTA NEUROCHIR, V147, P291, DOI 10.1007/s00701-004-0460-8
   BONITO V, 1994, J NEUROSURG, V80, P931, DOI 10.3171/jns.1994.80.5.0931
   BURRES KP, 1978, J NEUROSURG, V48, P289, DOI 10.3171/jns.1978.48.2.0289
   Carvalho GA, 1997, J NEUROSURG, V86, P69, DOI 10.3171/jns.1997.86.1.0069
   Cohen-Gadol AA, 2004, NEUROSURG FOCUS, V16, P1
   COUTURE D, 2003, [No title captured], V15, P1
   DAVIS DH, 1978, MAYO CLIN PROC, V53, P799
   Doi K, 2002, J NEUROSURG, V96, P277, DOI 10.3171/spi.2002.96.3.0277
   Hader WJ, 2000, NEUROSURGERY, V46, P1245, DOI 10.1097/00006123-200005000-00044
   Hawasli AH, 2014, OPER NEUROSURG, V10, pE498, DOI 10.1227/NEU.0000000000000437
   Hawk MW, 2000, NEUROSURG FOCUS, V9, P1, DOI DOI 10.3171/F0C.2000.9.1.5
   Kumar N, 2006, NEUROLOGY, V66, P1144, DOI 10.1212/01.wnl.0000208510.76323.5b
   Kumar N, 2010, AM J NEURORADIOL, V31, P5, DOI 10.3174/ajnr.A1628
   Kumar N, 2007, ARCH NEUROL-CHICAGO, V64, P491, DOI 10.1001/archneur.64.4.491
   Kumar N, 2012, NEUROLOGY, V78, P1992, DOI 10.1212/WNL.0b013e318259e272
   Liu JH, 2007, MATER MANUF PROCESS, V22, P1, DOI 10.1080/10426910600727858
   Martin G, 2000, J CLIN NEUROSCI, V7, P330, DOI 10.1054/jocn.1999.0205
   MASUZAWA H, 1981, J NEUROSURG, V55, P983, DOI 10.3171/jns.1981.55.6.0983
   Moran SL, 2005, HAND CLIN, V21, P13, DOI 10.1016/j.hcl.2004.09.004
   Myles LM, 1999, J NEUROSURG, V91, P116, DOI 10.3171/spi.1999.91.1.0116
   Prevo RL, 1999, CLIN NEUROL NEUROSUR, V101, P260, DOI 10.1016/S0303-8467(99)00050-5
   Rankine JJ, 2004, CLIN RADIOL, V59, P767, DOI 10.1016/j.crad.2004.03.014
   Rhee PC, 2011, J BONE JOINT SURG AM, V93A, P2271, DOI [10.2106/JBJS.J.00922, 10.2106/JBJSJ.00922]
   Shih Patrick, 2009, Spine J, V9, pe16, DOI 10.1016/j.spinee.2009.03.004
   Shin AY, 2005, J AM ACAD ORTHOP SUR, V13, P382, DOI 10.5435/00124635-200510000-00003
   Spinner RJ, 2000, MUSCLE NERVE, V23, P680, DOI 10.1002/(SICI)1097-4598(200005)23:5<680::AID-MUS4>3.0.CO;2-H
   SWANSON HS, 1947, J NEUROSURG, V4, P530, DOI 10.3171/jns.1947.4.6.0530
   Tanaka M, 2008, EUR SPINE J, V17, pS263, DOI 10.1007/s00586-007-0537-1
   Tapscott SJ, 1996, ANN NEUROL, V40, P936, DOI 10.1002/ana.410400620
   Tari-Capone F, 2013, NEUROL SCI, V34, P1861, DOI 10.1007/s10072-013-1336-6
   Walker AT, 1996, AM J ROENTGENOL, V167, P1283, DOI 10.2214/ajr.167.5.8911196
   Yokota Hiroshi, 2007, Neurosurgery, V60, pE205, DOI 10.1227/01.NEU.0000249195.76527.61
   Yoshikawa T, 2006, RADIOGRAPHICS, V26, pS133, DOI 10.1148/rg.26si065511
   한석, 2002, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V31, P21
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1562
EP E1569
DI 10.1016/j.wneu.2018.11.102
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100192
PM 30471442
DA 2020-05-12
ER

PT J
AU Cornelius, JF
   Kamp, MA
   Tortora, A
   Knipps, J
   Krause-Molle, Z
   Beez, T
   Petridis, AK
   Sabel, M
   Schipper, J
   Steiger, HJ
AF Cornelius, Jan Frederick
   Kamp, Marcel A.
   Tortora, Angelo
   Knipps, Johannes
   Krause-Molle, Zarela
   Beez, Thomas
   Petridis, Athanasios K.
   Sabel, Michael
   Schipper, Joerg
   Steiger, Hans Jakob
TI Surgery of Small Anterior Skull Base Meningiomas by Endoscopic
   5-Aminolevulinic Acid Fluorescence Guidance: First Clinical Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-ALA; Endoscopy; Fluorescence guidance; Keyhole; Meningioma; Minimally
   invasive; Skull base
ID GUIDED SURGERY; RESECTION; MICROSCOPE
AB BACKGROUND: Minimally invasive surgery of small skull base meningiomas is technically challenging. We report the role of endoscopic 5-aminolevulinic acid fluorescence guidance (e-5-ALA-FGS) for small and deep-seated anterior skull base meningiomas.
   METHODS: We report the cases of 2 patients. The first case was a small olfactory groove meningioma resected via a trans-eyebrow, subfrontal approach. The second case was a clinoid meningioma with invasion of the optic canal resected via a small frontolateral approach. Intraoperative documentation demonstrated the usefulness of 5-ALA endoscopy. In either case, residual fluorescing tumor tissue was detected. No complication was encountered. The clinical and radiological outcomes were good. No regrowth had occurred after 54 and 17 months of follow-up, respectively.
   RESULTS: Residual meningioma tissue on the far side of a keyhole approach (e.g., in the olfactory groove or at the optic canal) can be difficult to visualize. Visualization can be improved by use of an endoscope. To date, fluorescence guidance with a microscope was limited by insufficient fluorescence signals in deep corridors. With a specially equipped 5-ALA fluorescence endoscope, one can combine the advantages of both endoscopic vision and fluorescence guidance. The results of present report have demonstrated the usefulness of 5-ALA endoscopy for difficult to visualize areas.
   CONCLUSION: Endoscopic 5-ALA fluorescence guidance was shown to be feasible when resecting small and deep-seated skull base meningiomas via minimally invasive approaches. Based on this proof of principle, we encourage its evaluation for the middle or posterior fossa (e.g., internal auditory canal) and other difficult areas (e.g., behind neurovascular structures or the brainstem). The sensitivity and specificity of this method should be prospectively and systematically investigated.
C1 [Cornelius, Jan Frederick; Kamp, Marcel A.; Tortora, Angelo; Knipps, Johannes; Krause-Molle, Zarela; Beez, Thomas; Petridis, Athanasios K.; Sabel, Michael; Steiger, Hans Jakob] Heinrich Heine Univ, Fac Med, Dept Neurosurg, Dusseldorf, Germany.
   [Schipper, Joerg] Heinrich Heine Univ, Fac Med, Dept Otorhinolaryngol, Dusseldorf, Germany.
RP Cornelius, JF (reprint author), Heinrich Heine Univ, Fac Med, Dept Neurosurg, Dusseldorf, Germany.
EM cornelius@hhu.de
OI Kamp, Marcel/0000-0002-1252-2944
CR Bekelis K, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1112
   Coluccia D, 2010, ACTA NEUROCHIR, V152, P1711, DOI 10.1007/s00701-010-0708-4
   Cornelius JF, 2017, PHOTODIAGN PHOTODYN, V17, P147, DOI 10.1016/j.pdpdt.2016.12.007
   Cornelius JF, 2014, PHOTODIAGN PHOTODYN, V11, P481, DOI 10.1016/j.pdpdt.2014.07.008
   Cornelius JF, 2014, J NEUROSURG, V121, P766, DOI 10.3171/2014.4.JNS14775
   Cornelius JF, 2013, J NEUROL SURG PART B, V74, P211, DOI 10.1055/s-0033-1342918
   Della Puppa A, 2014, J NEUROSURG, V120, P840, DOI 10.3171/2013.12.JNS131642
   Foster N, 2016, PHOTODIAGN PHOTODYN, V15, P73, DOI 10.1016/j.pdpdt.2016.05.006
   Hong CS, 2016, J NEUROSURG, V124, P799, DOI 10.3171/2015.1.JNS141113
   Joseph V, 2005, BRIT J NEUROSURG, V19, P33, DOI 10.1080/02688690500089415
   Kajimoto Y, 2007, J NEUROSURG, V106, P1070, DOI 10.3171/jns.2007.106.6.1070
   Knipps J, 2017, WORLD NEUROSURG, V108, P118, DOI 10.1016/j.wneu.2017.08.140
   Kurucz P, 2018, J NEUROL SURG PART B, V79, pS227, DOI 10.1055/s-0037-1620246
   Marx S, 2018, J NEUROSURG, V128, P32, DOI 10.3171/2016.11.JNS16713
   Millesi M, 2016, J NEUROSURG, V125, P1408, DOI 10.3171/2015.12.JNS151513
   Ottenhausen M, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17734
   Rapp M, 2014, WORLD NEUROSURG, V82, pE277, DOI 10.1016/j.wneu.2013.07.002
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Schroeder HWS, 2011, NEUROSURG REV, V34, P441, DOI 10.1007/s10143-011-0322-9
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
NR 20
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E890
EP E895
DI 10.1016/j.wneu.2018.10.171
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100107
PM 30419399
DA 2020-05-12
ER

PT J
AU Cui, SS
   Li, K
   Xu, MZ
   Yu, W
AF Cui, Shusen
   Li, Kai
   Xu, Mingzhu
   Yu, Wei
TI Effect of Reneurorrhaphy of Distal Coaptation on Nerve Regeneration
   After Nerve Grafting: Animal Experimental Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Nerve grafting; Nerve regeneration; Peripheral nerve
ID NEUROTROPHIC FACTOR; EXPRESSION; NEURONS; LESIONS; INDEX
AB BACKGROUND: Previous studies have shown that reneurorrhaphy of a distal coaptation at an appropriate time after nerve grafting can upregulate neurotrophins in rat spinal cord neurons. The objective of the present study was to evaluate the effect this procedure has on peripheral nerve regeneration.
   METHODS: Fifteen Wistar rats were randomly assigned to sham-surgery, control, or experimental (transection and rerepair of the distal coaptation of the grafting nerve) groups. The sciatic nerve was evaluated via electromyogram and histology at 20 weeks.
   RESULTS: When crossing the proximal coaptation of the grafting nerve, the electromyogram and histologic evaluations did not significantly differ between experimental and control groups (P > 0.05). In contrast, crossing the distal coaptation yielded significantly better values (P < 0.05) in the experimental group.
   CONCLUSIONS: These results indicate that reneurorrhaphy of the distal coaptation at an appropriate time after nerve grafting can improve nerve function and facilitate the regeneration of axons.
C1 [Cui, Shusen; Yu, Wei] Jilin Univ, China Japan Union Hosp, Dept Hand Surg, Changchun, Jilin, Peoples R China.
   [Li, Kai] Jilin Univ, China Japan Union Hosp, Dept Anesthesia, Changchun, Jilin, Peoples R China.
   [Xu, Mingzhu] Jilin Univ, China Japan Union Hosp, Dept Nephrol, Changchun, Jilin, Peoples R China.
RP Yu, W (reprint author), Jilin Univ, China Japan Union Hosp, Dept Hand Surg, Changchun, Jilin, Peoples R China.
EM liuzhongling1988@163.com
FU National Key Clinical Specialist Special Fund of the Ministry of Health
   [[2010]439]
FX This work was supported by National Key Clinical Specialist Special Fund
   of the Ministry of Health [2010]439.
CR Albert E, 1885, WIEN MED PRESSE, V26, P1285
   Hoffman PN, 2010, EXP NEUROL, V223, P11, DOI 10.1016/j.expneurol.2009.09.006
   Johnson EO, 2005, INJURY, V36, pS24, DOI 10.1016/j.injury.2005.10.012
   Kanaya F, 1996, PLAST RECONSTR SURG, V98, P1264, DOI 10.1097/00006534-199612000-00023
   Korte N, 2011, MUSCLE NERVE, V44, P63, DOI 10.1002/mus.22023
   Krishnan KG, 2008, NEUROSURGERY, V62, P873, DOI 10.1227/01.neu.0000318173.28461.32
   Lee S K, 2000, J Am Acad Orthop Surg, V8, P243
   Lenz-Scharf O, 2004, Handchir Mikrochir Plast Chir, V36, P19
   Meek MF, 2005, MICROSURG, V25, P396, DOI 10.1002/micr.20137
   Millesi H, 2007, BRIDGING DEFECTS AUT
   Monte-Raso VV, 2008, J NEUROSCI METH, V170, P255, DOI 10.1016/j.jneumeth.2008.01.022
   Seddon HJ, 1943, J PHYSIOL-LONDON, V102, P191, DOI 10.1113/jphysiol.1943.sp004027
   SJOBERG J, 1990, BRAIN RES, V529, P79, DOI 10.1016/0006-8993(90)90812-P
   The Ministry of Science and Technology of the People's Republic of China, 2006, GUID SUGG CAR US LAB
   Wolthers M, 2005, MICROSURG, V25, P508, DOI 10.1002/micr.20156
   Wood MD, 2011, ANN ANAT, V193, P321, DOI 10.1016/j.aanat.2011.04.008
   Yu W, 2012, NEURAL REGEN RES, V7, P2012, DOI 10.3969/j.issn.1673-5374.2012.26.002
   Zhou XF, 1999, NEUROSCIENCE, V92, P841, DOI 10.1016/S0306-4522(99)00027-5
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1365
EP E1373
DI 10.1016/j.wneu.2018.11.049
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100167
PM 30448571
DA 2020-05-12
ER

PT J
AU Da Ros, V
   Bozzi, A
   Comelli, C
   Semeraro, V
   Comelli, S
   Lucarelli, N
   Burdi, N
   Gandini, R
AF Da Ros, Valerio
   Bozzi, Alessio
   Comelli, Chiara
   Semeraro, Vittorio
   Comelli, Simone
   Lucarelli, Nicola
   Burdi, Nicola
   Gandini, Roberto
TI Ruptured Intracranial Aneurysms Treated with Woven Endobridge
   Intrasaccular Flow Disruptor: A Multicenter Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Aortic arch reconstruction; Stroke
ID ENDOVASCULAR TREATMENT; WEB DEVICE; SUBARACHNOID HEMORRHAGE;
   COMPLICATIONS; COILING; REGION; SERIES; RISK; DL
AB BACKGROUND: The woven endobridge intrasaccular flow disruptor (WEB) device for ruptured broad-based intracranial aneurysm (rBBA) remains underrepresented in existing studies. In this case series, the safety and efficacy results of the use of WEB in rBBA were evaluated from a multi-center experience.
   MATERIALS AND METHODS: Between November 2014 and October 2017, data of all patients with rBBA (>= 4 mm and/or dome/neck ratio >= 1 and >= 1.6) treated with WEB were prospectively collected and retrospectively analyzed from 3 Italian neurointerventional centers. The interventional procedures and the clinical and angiographic outcomes are reported for the periprocedural phase with midterm follow-up.
   RESULTS: 33 patients were included in this series (10 patients with Hunt-Hess scores 4-5; 23 patients with Hunt-Hess scores 1-3). Technical success was obtained for all 33 patients (100%). The mean fluoroscopy time was 24 minutes (range, 8-40 minutes). Adjunctive devices were used in 6% of patients (2 stents). At the 1-month follow-up visit, the overall mortality was 33%. The overall rate of WEB-related complications was 27% (5 device protrusion, 2 sac perforation, 2 thromboembolism), with a WEB-related mortality of 12% and permanent neurologic deficit of 3%. Of the surviving patients, 1 was lost to follow-up. At 14 months, the mean follow-up (range, 2-35 months), no early or delayed reruptured aneurysms were observed; complete occlusion was obtained in 7/21 patients (33%), neck remnant in 8/21 (38%), and residual aneurysm filling in 6/21 (29%) patients, with a modified Rankin Scale of 0sto 2 observed in 17/21 patients (80%).
   CONCLUSIONS: The WEB device for rBBA is a fast and effective treatment, with a low rate of aneurysm rebleeding; however, procedure-related complications seem not negligible. Further evaluation comparing this device with other treatment options should be performed.
C1 [Da Ros, Valerio; Bozzi, Alessio; Semeraro, Vittorio; Gandini, Roberto] Tor Vergata Univ Hosp, Dept Diagnost Imaging & Intervent Radiol, Rome, Italy.
   [Comelli, Chiara] Osped San Giovanni Bosco, SC Radiodiagnost, Turin, Italy.
   [Comelli, Simone] Osped S Michele, SC Neuroradiol & Interventist Vasc, Cagliari, Italy.
   [Lucarelli, Nicola; Burdi, Nicola] SS Annunziata Hosp, Dept Intervent Radiol & Neuroradiol, Taranto, Italy.
RP Da Ros, V (reprint author), Tor Vergata Univ Hosp, Dept Diagnost Imaging & Intervent Radiol, Rome, Italy.
EM darosvalerio@gmail.com
RI LUCARELLI, NICOLA MARIA/AAC-1775-2019
OI LUCARELLI, NICOLA MARIA/0000-0002-6654-4751; Semeraro,
   Vittorio/0000-0002-7546-4251; Da Ros, Valerio/0000-0001-7167-7594;
   Bozzi, Alessio/0000-0002-5094-9738
CR Alurkar Anand, 2012, Surg Neurol Int, V3, P131, DOI 10.4103/2152-7806.102946
   Ambrosi PB, 2015, INTERV NEURORADIOL, V21, P462, DOI 10.1177/1591019915590083
   Armoiry X, 2016, AM J NEURORADIOL, V37, P868, DOI 10.3174/ajnr.A4611
   ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z
   Bechan RS, 2016, AM J NEURORADIOL, V37, P502, DOI 10.3174/ajnr.A4542
   Caroff J, 2014, AM J NEURORADIOL, V35, P1353, DOI 10.3174/ajnr.A3860
   Caroff J, 2016, NEURORADIOLOGY, V58, P887, DOI 10.1007/s00234-016-1715-9
   Caroff J, 2014, NEURORADIOLOGY, V56, P755, DOI 10.1007/s00234-014-1390-7
   Cognard C, 2015, NEUROSURGERY, V76, P522, DOI 10.1227/NEU.0000000000000669
   Cognard C, 2011, NEUROSURGERY, V69, P837, DOI 10.1227/NEU.0b013e3182257b30
   Colla R, 2013, NEURORADIOL J, V26, P669, DOI 10.1177/197140091302600610
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   Gherasim DN, 2015, AM J NEURORADIOL, V36, P1150, DOI 10.3174/ajnr.A4282
   Jeong YG, 2009, J KOREAN NEUROSURG S, V45, P11, DOI 10.3340/jkns.2009.45.1.11
   Johnston SC, 2008, STROKE, V39, P120, DOI 10.1161/STROKEAHA.107.495747
   Leyon JJ, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011649.rep
   Liebig T, 2015, AM J NEURORADIOL, V36, P1721, DOI 10.3174/ajnr.A4347
   Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625
   Lubicz B, 2014, AM J NEURORADIOL, V35, P432, DOI 10.3174/ajnr.A3869
   McDonald JS, 2014, AM J NEURORADIOL, V35, P164, DOI 10.3174/ajnr.A3642
   Meckel S, 2011, AM J NEURORADIOL, V32, P764, DOI 10.3174/ajnr.A2392
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   MULLAN S, 1965, J NEUROSURG, V22, P539, DOI 10.3171/jns.1965.22.6.0539
   Papagiannaki C, 2014, AM J NEURORADIOL, V35, P2106, DOI 10.3174/ajnr.A4028
   Pierot L, 2016, AM J NEURORADIOL, V37, P655, DOI 10.3174/ajnr.A4578
   Pierot L, 2012, AM J NEURORADIOL, V33, P1232, DOI 10.3174/ajnr.A3191
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Pierot L, 2016, J NEUROSURG, V124, P1250, DOI 10.3171/2015.2.JNS142634
   Pierot L, 2016, NEUROSURGERY, V78, P133, DOI 10.1227/NEU.0000000000001106
   Pierot L, 2010, RADIOLOGY, V256, P916, DOI 10.1148/radiol.10092209
   Sivan-Hoffmann R, 2015, AM J NEURORADIOL, V36, P2320, DOI 10.3174/ajnr.A4457
   van Rooij SBT, 2017, AM J NEURORADIOL, V38, P2282, DOI 10.3174/ajnr.A5371
   Weir B, 2002, J NEUROSURG, V96, P64, DOI 10.3171/jns.2002.96.1.0064
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
NR 35
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E498
EP E505
DI 10.1016/j.wneu.2018.10.088
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100060
PM 30394356
DA 2020-05-12
ER

PT J
AU Darsaut, TE
   Fahed, R
   Raymond, J
AF Darsaut, Tim E.
   Fahed, Robert
   Raymond, Jean
TI Reporting Interim Results Can Show the Feasibility of Practicing
   Outcome-Based Neurovascular Care Within Randomized Trials: An Opinion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Care trial; Interim results; Randomized controlled trials; Trial
   methodology
ID INTRAVENOUS T-PA; ENDOVASCULAR TREATMENT; PUBLICATION BIAS; MEDICAL
   THERAPY; FLOW DIVERSION; ACUTE STROKE; ANEURYSMS; THROMBECTOMY;
   MULTICENTER
AB BACKGROUND: Randomized trials of commonly performed surgical interventions are notoriously difficult to conduct. The trial methodology may nevertheless be the best way to offer outcome-based neurovascular care in the presence of uncertainty. One obstacle to promoting such trials is the conventional prohibition of publication and dissemination of interim results as the trial progresses.
   METHODS: We review the scientific and statistical reasons against the publication of interim analyses as well as exceptions that can occur when 1 treatment is unexpectedly shown to be harmful or when the results of other trials have convincingly shown the comparative benefits of a new intervention. We also discuss the promotion of difficult surgical trials.
   RESULTS: Reasons to support the conventional ban on publication of interim results include control of statistical errors, prevention of invalid conclusions, and dissemination of false claims of equivalence of rival interventions. In the early phases of a trial, usually 1 treatment cannot be shown superior to the other. We believe, contrary to the received view, that a transparent report of the early progress of certain trials can be justified, even when interim results are inconclusive, to promote the recruitment of participating centers and the practice of a novel way to offer neurovascular care in the presence of uncertainty in the best medical interest of patients.
   CONCLUSIONS: In our opinion, the early publication of inconclusive interim results may increase awareness of the feasibility of surgical care trials.
C1 [Darsaut, Tim E.] Univ Alberta Hosp, Mackenzie Hlth Sci Ctr, Dept Surg, Div Neurosurg, Edmonton, AB, Canada.
   [Fahed, Robert; Raymond, Jean] Notre Dame Hosp, Ctr Hosp Univ Montreal, Dept Radiol, Serv Neuroradiol, Montreal, PQ, Canada.
   [Fahed, Robert] Rothschild Fdn Hosp, Dept Intervent Neuroradiol, Paris, France.
RP Raymond, J (reprint author), Notre Dame Hosp, Ctr Hosp Univ Montreal, Dept Radiol, Serv Neuroradiol, Montreal, PQ, Canada.
EM jean.raymond@Umontreal.ca
CR ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300
   BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Counsell N, 2017, CLIN TRIALS, V14, P67, DOI 10.1177/1740774516664689
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   Darsaut TE, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-156
   Darsaut TE, 2012, J NEUROINTERV SURG, V4, P178, DOI 10.1136/neurintsurg-2011-010065
   Darsaut TE, 2011, CAN J NEUROL SCI, V38, P236, DOI 10.1017/S0317167100011392
   Dirnagl U, 2010, J CEREBR BLOOD F MET, V30, P1263, DOI 10.1038/jcbfm.2010.51
   Faden RR, 2013, HASTINGS CENT REP, V43, pS16, DOI 10.1002/hast.134
   Fahed R, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2870-6
   Fiorella D, 2015, J NEUROINTERV SURG, V7, P861, DOI 10.1136/neurintsurg-2015-012110
   Fleming TR, 2008, CLIN TRIALS, V5, P157, DOI 10.1177/1740774508089459
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Kallmes DF, 2017, J NEUROSURG, V127, P703, DOI 10.3171/2016.12.JNS163176
   Khoury NN, 2017, J NEURORADIOLOGY, V44, P198, DOI 10.1016/j.neurad.2017.01.126
   Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793
   Law M G, 2000, HIV Clin Trials, V1, P30, DOI 10.1310/UD11-JYBQ-E1ME-9X79
   Liebeskind DS, 2006, NEUROLOGY, V67, P973, DOI 10.1212/01.wnl.0000237331.16541.ac
   Macdonald RL, 2015, J NEUROSURG, V123, P605, DOI 10.3171/2014.11.JNS142261
   Magro E, 2016, NEUROCHIRURGIE, V62, P197, DOI 10.1016/j.neuchi.2015.12.008
   Magro E, 2018, J NEUROSURG, V128, P1823, DOI 10.3171/2017.2.JNS162751
   Mansouri A, 2016, J NEUROSURG, V124, P558, DOI 10.3171/2014.12.JNS142465
   Misemer BS, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1595-7
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Raymond I, 2011, AM J NEURORADIOL, V32, P1568, DOI 10.3174/ajnr.A2764
   Raymond J, 2017, J NEURORADIOLOGY, V44, P291, DOI 10.1016/j.neurad.2017.03.004
   Raymond J, 2017, J NEUROSURG, V127, P454, DOI 10.3171/2016.4.JNS152662
   Raymond J, 2014, J CLIN EPIDEMIOL, V67, P1150, DOI 10.1016/j.jclinepi.2014.04.010
   Raymond J, 2011, CAN J NEUROL SCI, V38, P198, DOI 10.1017/S0317167100011343
   Raymond J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-64
   Raymond J, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-43
   Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Wayant C, 2018, ANN ONCOL, V29, P2384, DOI 10.1093/annonc/mdy447
NR 39
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E955
EP E960
DI 10.1016/j.wneu.2018.10.180
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100115
PM 30404058
DA 2020-05-12
ER

PT J
AU Della Puppa, A
   Munari, M
   Gardiman, MP
   Volpin, F
AF Della Puppa, Alessandro
   Munari, Marina
   Gardiman, Marina Paola
   Volpin, Francesco
TI Combined Fluorescence Using 5-Aminolevulinic Acid and Fluorescein Sodium
   at Glioblastoma Border: Intraoperative Findings and Histopathologic Data
   About 3 Newly Diagnosed Consecutive Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-ALA; Fluorescein; Glioblastoma; Tumor border
ID HIGH-GRADE GLIOMAS; GUIDED SURGERY; MALIGNANT GLIOMA; RESECTION;
   ANGIOGRAPHY; MICROSCOPE; MULTIFORME; HISTOLOGY; SURVIVAL; EXTENT
AB OBJECTIVE: Fluorescence-guided glioblastoma surgery is an intraoperative technique developed in recent years. Two main compounds have been used so far: 5-amilovelulinic acid (5-ALA) and fluorescein sodium (Fl-Na). Despite a large amount of literature on both techniques, few data are available on the use of both compounds in the same patient.
   METHODS: Three consecutive patients affected by a newly diagnosed glioblastoma underwent surgical resection using both 5-ALA and Fl-Na. 5-ALA was orally administered 3 hours before induction of anesthesia at a dosage of 20 mg/kg, whereas fluorescein was intravenously administered at induction of anesthesia at a dosage of 4 mg/kg. Tumor resection was carried out combining these fluorophores. At tumor borders, multiple samples were collected, and fluorescent pattern of each sample was registered. Samples were then analyzed by a neuropathologist blinded for intraoperative fluorescence findings.
   RESULTS: Eighteen samples were analyzed. At tumor margin, bright pink fluorescence was highly indicative of residual tumor (positive predictive value [PPV], 94%), and it was superior to faint pink and fluorescein (PPVs, 89% and 87%, respectively). The gradual reduction of pink fluorescence warned of the risk of gradually entering healthy tissue (specificity of 67% compared with 33% with fluorescein). Using 5-ALA, detecting no fluorescence was highly suggestive of healthy tissue (negative predictive value of 100% compared with 50% with fluorescence).
   CONCLUSIONS: In our experience with 3 patients, the 2 techniques presented different advantages and limitations in specific steps of tumor resection, showing complementary properties. Larger studies are mandatory to investigate the synergistic use of both techniques.
C1 [Della Puppa, Alessandro; Volpin, Francesco] Padua Univ Hosp, Dept Neurosurg, Padua, Italy.
   [Munari, Marina] Padua Univ Hosp, Intens Care Unit, Padua, Italy.
   [Gardiman, Marina Paola] Padua Univ Hosp, Dept Pathol, Padua, Italy.
RP Volpin, F (reprint author), Padua Univ Hosp, Dept Neurosurg, Padua, Italy.
EM volpin.francesco@gmail.com
CR Acerbi F, 2018, CLIN CANC RES
   Acerbi F, 2015, ACTA NEUROCHIR, V157, P1377, DOI 10.1007/s00701-015-2455-z
   Acerbi F, 2014, NEUROSURG REV, V37, P547, DOI 10.1007/s10143-014-0546-6
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Idoate MA, 2011, NEUROPATHOLOGY, V31, P575, DOI 10.1111/j.1440-1789.2011.01202.x
   Coburger J, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13463
   Della Puppa A, 2017, NEUROSURGERY, V80, pE188, DOI 10.1093/neuros/nyw033
   Della Puppa A, 2014, BIOMED RES INT, DOI 10.1155/2014/232561
   Della Puppa A, 2013, ACTA NEUROCHIR, V155, P965, DOI 10.1007/s00701-013-1660-x
   Diaz RJ, 2015, J NEUROSURG, V122, P1360, DOI 10.3171/2015.2.JNS132507
   Hadjipanayis CG, 2015, NEUROSURGERY, V77, P663, DOI 10.1227/NEU.0000000000000929
   Hefti M, 2008, SWISS MED WKLY
   Kreth FW, 2013, ANN ONCOL, V24, P3117, DOI 10.1093/annonc/mdt388
   Kuroiwa T, 1999, NEUROL RES, V21, P130, DOI 10.1080/01616412.1999.11740909
   Kuroiwa T, 1998, SURG NEUROL, V50, P41, DOI 10.1016/S0090-3019(98)00055-X
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Molina ES, 2018, J NEUROSURG, V128, P399, DOI 10.3171/2016.11.JNS161072
   MURRAY KJ, 1982, SURG NEUROL, V17, P316, DOI 10.1016/0090-3019(82)90298-1
   Ningning Z, 2017, BIOMED RES INT
   Orringer D, 2012, J NEUROSURG, V117, P851, DOI 10.3171/2012.8.JNS12234
   Panciani PP, 2012, CLIN NEUROL NEUROSUR, V114, P37, DOI 10.1016/j.clineuro.2011.09.001
   Rampazzo E, 2014, J NEURO-ONCOL, V116, P505, DOI 10.1007/s11060-013-1348-3
   Roberts DW, 2011, J NEUROSURG, V114, P595, DOI 10.3171/2010.2.JNS091322
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Senders JT, 2017, ACTA NEUROCHIR, V159, P151, DOI 10.1007/s00701-016-3028-5
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 1998, J PHOTOCH PHOTOBIO B, V45, P160, DOI 10.1016/S1011-1344(98)00176-6
   Stummer W, 2000, J NEUROSURG, V93, P1003, DOI 10.3171/jns.2000.93.6.1003
   Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017
   Stummer W, 1998, ACTA NEUROCHIR, V140, P995, DOI 10.1007/s007010050206
   Stummer W, 2016, ACTA NEUROCHIR WIEN, V157, P877
   Stummer W, 2014, NEUROSURGERY, V74, P310, DOI 10.1227/NEU.0000000000000267
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yano H, 2017, J NEURO-ONCOL, V133, P389, DOI 10.1007/s11060-017-2445-5
NR 36
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E856
EP E863
DI 10.1016/j.wneu.2018.10.163
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100103
PM 30391771
DA 2020-05-12
ER

PT J
AU DePasse, JM
   Durand, W
   Palumbo, MA
   Daniels, AH
AF DePasse, J. Mason
   Durand, Wesley
   Palumbo, Mark A.
   Daniels, Alan H.
TI Sex- and Sport-Specific Epidemiology of Cervical Spine Injuries
   Sustained During Sporting Activities
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Epidemiology; Sports medicine; Trauma
ID UNITED-STATES; ICE HOCKEY; FRACTURES
AB BACKGROUND: Although several investigations have examined the epidemiology of cervical spine injuries in sports, few studies have analyzed the nationwide incidence and sex-specific epidemiology of cervical spine injuries.
   METHOD: The National Electronic Injury Surveillance System database, which collects information on patients presenting to the emergency department at 100 hospitals across the United States, was queried for neck sprains and cervical fractures associated with sporting activities from 2000-2015.
   RESULT: A total of 26,380 neck sprains and 1166 fractures were identified. Compared with females, the incidence for injuries in males was 1.7 times greater for neck sprains and 3.6 times greater for fractures (P < 0.0001). Football was the most common cause of cervical sprains in males, followed by cycling and weightlifting/aerobics. Females sustained most neck sprains in weightlifting/aerobics, trampoline, and cheerleading. From 2000 to 2015, the incidence of neck sprains from aerobics increased from 15.5 to 25.3 per million person-years (P < 0.0001). Similarly, the incidence of cervical fractures from cycling increased from 0.67 to 2.7 per million (P < 0.0001). For males, cycling was the most common cause of fracture, followed by diving/swimming and football. For females, horseback riding was most common, followed by cycling and diving/swimming.
   CONCLUSIONS: Football is the leading cause of cervical sprains in the United States. The most common cause of cervical fracture in men is cycling, while in women it is horseback riding. The incidence of sport-related cervical fractures has increased by 35% from 2000 to 2015, which has been driven by an increase in cycling-related injuries.
C1 [DePasse, J. Mason] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA.
   [Palumbo, Mark A.; Daniels, Alan H.] Brown Univ, Dept Orthopaed, Div Spine Surg, Alpert Med Sch, Providence, RI 02912 USA.
   [Durand, Wesley] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
RP DePasse, JM (reprint author), Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA.
EM jmdepasse@gmail.com
CR Aune KT, 2017, SPORTS HEALTH, V9, P52, DOI 10.1177/1941738116674895
   BAILES JE, 1991, NEUROSURGERY, V29, P491, DOI 10.1227/00006123-199110000-00001
   Banerjee R, 2004, AM J SPORT MED, V32, P1077, DOI 10.1177/0363546504265605
   Boden BP, 2004, AM J SPORT MED, V32, P1189, DOI 10.1177/0363546503262161
   Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501
   Boran S, 2011, IRISH J MED SCI, V180, P859, DOI 10.1007/s11845-011-0730-4
   Broe MP, 2018, SURG-J R COLL SURG E, V16, P202, DOI 10.1016/j.surge.2017.07.004
   Buehler R, 2017, AM J PUBLIC HEALTH, V107, P281, DOI 10.2105/AJPH.2016.303546
   Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88
   Clarke KS, 1998, CLIN SPORT MED, V17, P83, DOI 10.1016/S0278-5919(05)70063-6
   Han GM, 2015, TRAFFIC INJ PREV, V16, P605, DOI 10.1080/15389588.2014.999856
   Hutton MJ, 2016, GLOB SPINE J, V6, P721, DOI 10.1055/s-0036-1586744
   Klimek C, 2018, J SPORT REHABIL, V27, P295, DOI 10.1123/jsr.2016-0040
   Kriz J, 2017, SPINAL CORD, V55, P870, DOI 10.1038/sc.2017.20
   Kucera K, 2017, ANN SURVEY FOOTBALL
   Kucera KL, 2016, CATASTROPHIC SPORTS
   Lieutaud T, 2012, J NEUROTRAUM, V29, P479, DOI 10.1089/neu.2011.1880
   Nakashian Michael N, 2012, Hand (N Y), V7, P426, DOI 10.1007/s11552-012-9442-0
   Norton K, 2010, J SCI MED SPORT, V13, P496, DOI 10.1016/j.jsams.2009.09.008
   Ong AW, 2017, AM J SURG, V213, P579, DOI 10.1016/j.amjsurg.2016.11.040
   Passias PG, 2018, WORLD NEUROSURG, V110, pE427, DOI 10.1016/j.wneu.2017.11.011
   Polites SF, 2014, PEDIATRICS, V133, pE1601, DOI 10.1542/peds.2013-3628
   Puvanesarajah V, 2017, CLIN SPINE SURG, V30, P50, DOI 10.1097/BSD.0000000000000441
   Schroeder GD, 2016, J AM ACAD ORTHOP SUR, V24, pE122, DOI 10.5435/JAAOS-D-15-00716
   Stoneback JW, 2012, J BONE JOINT SURG AM, V94A, P240, DOI 10.2106/JBJS.J.01663
   Tator CH, 2016, CLIN J SPORT MED, V26, P232, DOI 10.1097/JSM.0000000000000232
   Tenenbaum S, 2017, INJURY, V48, P2140, DOI 10.1016/j.injury.2017.08.020
   Van Tassel D, 2014, INT J SPORTS MED, V35, P83, DOI 10.1055/s-0033-1345127
NR 28
TC 2
Z9 2
U1 5
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E540
EP E545
DI 10.1016/j.wneu.2018.10.097
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100065
PM 30889777
DA 2020-05-12
ER

PT J
AU Dey, JK
   Van Gompel, JJ
   Lane, JI
   Carlson, ML
AF Dey, Jacob K.
   Van Gompel, Jamie J.
   Lane, John I.
   Carlson, Matthew L.
TI Fallopian Canal Meningocele with Spontaneous Cerebrospinal Fluid
   Otorrhea: Case Report and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid otorrhea; CSF; Facial canal; Facial paralysis;
   Fallopian canal; Meningitis; Meningocele
ID SUBARACHNOID SPACE; ARACHNOID CYST; FISTULA
AB OBJECTIVE: To present a case of spontaneous cerebrospinal fluid (CSF) otorrhea from a fallopian canal meningocele involving the geniculate fossa and review all cases of fallopian canal CSF leak reported in the literature with discussion of management and outcomes.
   METHODS: A 53-year-old woman with history of morbid obesity and hypertension presented to a tertiary care referral center with unilateral high-volume CSF otorrhea. High-resolution temporal bone computed tomography demonstrated significant dilatation of the geniculate fossa. Rates of postoperative facial paralysis and refractory CSF leak were reported for the present case and prior cases reported in the literature.
   RESULTS: Locations of fallopian canal dehiscence, surgical approaches, techniques for packing dehiscence, rates of postoperative facial paralysis and CSF leak, and revision procedures were reported for the present case and 14 cases in the literature. The present case involved dehiscence of the geniculate fossa that was approached via combined transmastoide-middle cranial fossa exploration with facial nerve monitoring. The area of dehiscence was carefully packed with temporalis fascia, muscle, and artificial dural substitute overlay to repair the CSF leak without injuring the facial nerve. Postoperatively, no facial weakness was noted; however, right-sided high-volume CSF otorrhea persisted. After discussing treatment options, the patient underwent subtotal petrosectomy and blind-sac closure of the external auditory canal the following day. This successfully resolved the CSF leak without causing facial nerve weakness.
   CONCLUSIONS: Fallopian canal meningocele is an exceedingly rare cause of CSF otorrhea. Successful repair requires precise packing of the dilated facial canal to occlude the leak without injuring the facial nerve. For refractory CSF leak, subtotal petrosectomy and closure of the external auditory canal warrants consideration.
C1 [Dey, Jacob K.; Van Gompel, Jamie J.; Carlson, Matthew L.] Mayo Clin, Sch Med, Dept Otorhinolaryngol, Rochester, MN 55905 USA.
   [Van Gompel, Jamie J.; Carlson, Matthew L.] Mayo Clin, Sch Med, Dept Neurosurg, Rochester, MN 55905 USA.
   [Lane, John I.] Mayo Clin, Sch Med, Dept Radiol, Rochester, MN USA.
RP Carlson, ML (reprint author), Mayo Clin, Sch Med, Dept Otorhinolaryngol, Rochester, MN 55905 USA.; Carlson, ML (reprint author), Mayo Clin, Sch Med, Dept Neurosurg, Rochester, MN 55905 USA.
EM carlson.matthew@mayo.edu
OI Dey, Jacob/0000-0001-8197-2079
CR BARCZ DV, 1985, AM J OTOL, V6, P157
   Dhanasekar G, 2010, J LARYNGOL OTOL, V124, P460, DOI 10.1017/S0022215109991599
   Foyt D, 2000, ARCH OTOLARYNGOL, V126, P540, DOI 10.1001/archotol.126.4.540
   Franco-Vidal V, 2009, OTOL NEUROTOL, V30, P123, DOI 10.1097/MAO.0b013e318166188e
   GACEK RR, 1979, ANN OTO RHINOL LARYN, V88, P358, DOI 10.1177/000348947908800311
   Gacek RR, 1998, AM J OTOL, V19, P358
   HARRINGTON JW, 1967, ARCHIV OTOLARYNGOL, V85, P572
   Isaacson JE, 2002, OTOL NEUROTOL, V23, P589, DOI 10.1097/00129492-200207000-00031
   Legent F, 1989, Ann Otolaryngol Chir Cervicofac, V106, P197
   Mong S, 2009, OTOL NEUROTOL, V30, P525, DOI 10.1097/MAO.0b013e3181a66f16
   Petrus LV, 1999, AM J NEURORADIOL, V20, P275
   Piane R, 2001, Acta Otorhinolaryngol Belg, V55, P279
   Teufert Karen B, 2013, Ear Nose Throat J, V92, pE20
   van la Parra RFD, 2007, OTOL NEUROTOL, V28, P1153, DOI 10.1097/MAO.0b013e318067bd0c
NR 14
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E285
EP E290
DI 10.1016/j.wneu.2018.10.021
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100032
PM 30321684
DA 2020-05-12
ER

PT J
AU Donato, D
   Abunimer, AM
   Abou-Al-Shaar, H
   Willcockson, J
   Frazer, L
   Mahan, MA
AF Donato, Daniel
   Abunimer, Abdullah M.
   Abou-Al-Shaar, Hussam
   Willcockson, James
   Frazer, Leah
   Mahan, Mark A.
TI First Carpometacarpal Joint Denervation for Primary Osteoarthritis:
   Technique and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carpometacarpal joint; Grip strength; Nerve denervation; Osteoarthritis;
   Pain; Thumb; Trapeziectomy
ID LIGAMENT RECONSTRUCTION; TRAPEZIOMETACARPAL OSTEOARTHRITIS; ARTHRODESIS;
   TRAPEZIECTOMY; PLATE
AB BACKGROUND: First carpometacarpal (CMC) joint osteoarthritis (OA) is commonly encountered in clinical practice. The preferred surgical option when conservative therapy fails varies with the stage and nature of the disease. Denervation of the first CMC joint is a relatively new procedure for managing stable thumb CMC joint OA. Our objective was to review our experience and surgical technique with first CMC joint denervation surgery.
   METHODS: All patients who underwent first CMC joint denervation surgery from January 2015 through September 2017 were retrospectively identified. Before undergoing surgical CMC denervation, patients received a joint block at the first CMC joint with 0.25% bupivacaine. Only patients with a good response to injection were selected for surgical denervation. Patient demographics, preoperative and postoperative pain scores using a numeric rating scale, and grip strength using the Jamar Hydraulic Hand Dynamometer were analyzed.
   RESULTS: Of 10 patients (13 hands) with CMC joint OA, 8 patients (11 hands) met the inclusion criteria. Patients' average grip strength improved significantly after the procedure (from 38.4 +/- 26.7 foot/lb to 50.2 +/- 27.6 foot/lb; P = 0.007). The numeric rating scale pain score improved significantly from 7.8 +/- 2.4 to 2.4 +/- 1.8 (P < 0.001). Seven of 8 patients reported satisfaction with surgery. There were 2 complications.
   CONCLUSIONS: First CMC joint denervation provided good pain relief and improvement in grip strength in patients with thumb CMC joint OA. This minimally invasive technique proved to be a good option for providing optimal pain control and improvement in strength with minimal and mild complications.
C1 [Donato, Daniel; Willcockson, James] Univ Utah, Clin Neurosci Ctr, Div Plast Surg, Dept Surg, Salt Lake City, UT USA.
   [Abou-Al-Shaar, Hussam; Frazer, Leah; Mahan, Mark A.] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
   [Abunimer, Abdullah M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA.
   [Abou-Al-Shaar, Hussam] Hofstra Northwell Sch Med, Dept Neurosurg, Manhasset, NY USA.
RP Mahan, MA (reprint author), Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
EM mark.mahan@hsc.utah.edu
CR Arenas-Prat Joan M, 2012, Tech Hand Up Extrem Surg, V16, P107, DOI 10.1097/BTH.0b013e31824f8c96
   Camitz H, 1933, ACTA ORTHOP SCAND, V4, P193
   Cozzi E, 1991, SURG OF THE HAND, VIV, P781
   Dellon AL, 2017, CASE REP PLAST SURG, V4, P13, DOI 10.1080/23320885.2016.1278171
   DUBERT T, 1990, Annales de Chirurgie de la Main et du Membre Superieur, V9, P15, DOI 10.1016/S0753-9053(05)80431-4
   Ehrl D, 2016, J PLAST RECONSTR AES, V69, P972, DOI 10.1016/j.bjps.2016.02.005
   Elvebakk K, 2015, J HAND SURG-ASIAN-PA, V20, P435, DOI 10.1142/S0218810415500367
   Foucher G, 1992, Ann Chir Main Memb Super, V11, P292, DOI 10.1016/S0753-9053(05)80474-0
   Gangopadhyay S, 2012, J HAND SURG-AM, V37A, P411, DOI 10.1016/j.jhsa.2011.11.027
   Harenberg PS, 2018, HAND SURG REHABIL, V37, P48, DOI 10.1016/j.hansur.2017.10.235
   Hippensteel KJ, 2017, J HAND SURG-AM, V42, P685, DOI 10.1016/j.jhsa.2017.05.018
   Lorea DP, 2002, J HAND SURG-BRIT EUR, V27B, P232, DOI 10.1054/jhsb.2001.0716
   Lorea Patrick D, 2003, Tech Hand Up Extrem Surg, V7, P26
   Spekreijse KR, 2016, J HAND SURG-AM, V41, P910, DOI 10.1016/j.jhsa.2016.07.089
   Tuffaha SH, 2019, J HAND SURG-AM, V44, DOI 10.1016/j.jhsa.2018.04.030
   Wilder FV, 2006, OSTEOARTHR CARTILAGE, V14, P953, DOI 10.1016/j.joca.2006.04.013
   Yuan F, 2017, J HAND SURG-AM, V42, P104, DOI 10.1016/j.jhsa.2016.11.029
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1374
EP E1380
DI 10.1016/j.wneu.2018.11.061
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100168
PM 30465956
DA 2020-05-12
ER

PT J
AU Dziedzic, TA
   Balasa, A
   Bielecki, M
   Przepiorka, L
   Kunert, P
   Marchel, A
AF Dziedzic, Tomasz A.
   Balasa, Artur
   Bielecki, Mateusz
   Przepiorka, Lukasz
   Kunert, Przemyslaw
   Marchel, Andrzej
TI Morphometric Analysis for Surgical Treatment of Cervical Discopathy by
   Posterior Laminoforaminotomy: Radiologic Study and Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Facetectomy; Foraminal stenosis; Keyhole;
   Laminoforaminotomy; Posterior approach
ID FORAMINOTOMY; ANTERIOR; FUSION; DISKECTOMY; EXPERIENCE; HERNIATION;
   DISEASE
AB BACKGROUND: The main concern with the posterior approach is the risk of postoperative segmental instability. The most commonly cited rule is that removal of the medial half of the articular facet provides adequate surgical exposure and has no effect on stability. The aim of this study was to define the areas of the articular processes in the cervical spine that can be safely removed.
   METHODS: Computed tomography scans of 50 cervical spines were analyzed. Measurements were analyzed for bone removal assuming the standard technique of posterior laminoforaminotomy. The width of the facet was measured at the level of the widest dimension. The height of the articular process was taken from the bottom (in the case of inferior process) or top (in the case of superior process) of the process.
   RESULTS: The mean width of the articular process ranged from 11.8 +/- 1.5 mm (range, 8.3-15.7 mm) at the C2-C3 level to 14.6 +/- 1.7 mm at the C6-C7 level. At the cervicothoracic junction (C7-T1 level), the mean width decreased to 14.0 +/- 1.7 mm. The mean value for both sides when the inferior articular process was measured at all levels was 5.0 +/- 1.4 mm (range, 4.5-5.8 mm). The mean height of the superior articular process was 7.7 +/- 1.5 mm (range, 6.8-8.3 mm).
   CONCLUSIONS: Based on our findings, our "5-5-7 mm rule" corresponds to the amount of bone removal for each step of the laminoforaminotomy.
C1 [Dziedzic, Tomasz A.; Balasa, Artur; Bielecki, Mateusz; Przepiorka, Lukasz; Kunert, Przemyslaw; Marchel, Andrzej] Med Univ Warsaw, Dept Neurosurg, Warsaw, Poland.
RP Dziedzic, TA (reprint author), Med Univ Warsaw, Dept Neurosurg, Warsaw, Poland.
EM tdziedzic@wum.edu.pl
RI Dziedzic, Tomasz/AAE-5071-2019
OI Dziedzic, Tomasz/0000-0002-2832-5064; Kunert,
   Przemyslaw/0000-0002-0583-9505; Przepiorka, Lukasz/0000-0002-2877-0475
CR Abdullah KG, 2009, SPINE, V34, P1476, DOI 10.1097/BRS.0b013e3181a8f649
   Barakat M, 2012, EUR SPINE J, V21, P1383, DOI 10.1007/s00586-012-2158-6
   Bevevino AJ, 2014, SPINE, V39, P1572, DOI 10.1097/BRS.0000000000000469
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   Dodwad SJM, 2016, CLIN SPINE SURG, V29, P177, DOI 10.1097/BSD.0000000000000384
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   HENDERSON CM, 1983, NEUROSURGERY, V13, P504, DOI 10.1227/00006123-198311000-00004
   HERKOWITZ HN, 1990, SPINE, V15, P1026, DOI 10.1097/00007632-199015100-00009
   Hwang JC, 2010, J KOREAN NEUROSURG S, V47, P358, DOI 10.3340/jkns.2010.47.5.358
   Jagannathan J, 2009, J NEUROSURG-SPINE, V10, P347, DOI 10.3171/2008.12.SPINE08576
   Kunert P, 2010, NEUROL NEUROCHIR POL, V44, P375
   Matsumoto M, 2010, SPINE, V35, P36, DOI 10.1097/BRS.0b013e3181b8a80d
   ONIMUS M, 1995, REV CHIR ORTHOP, V81, P296
   RAYNOR RB, 1985, J NEUROSURG, V63, P278, DOI 10.3171/jns.1985.63.2.0278
   Riew KD, 2007, NEUROSURGERY, V60, P57, DOI 10.1227/01.NEU.0000215409.64026.E2
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Selvanathan SK, 2015, ACTA NEUROCHIR, V157, P1595, DOI 10.1007/s00701-015-2491-8
   Skovrlj B, 2014, SPINE J, V14, P2405, DOI 10.1016/j.spinee.2014.01.048
   Spurling RG, 1944, SURG GYNECOL OBSTET, V78, P350
   van Eck CF, 2014, SPINE, V39, P2143, DOI 10.1097/BRS.0000000000000636
   Wang TY, 2015, SPINE J, V15, P971, DOI 10.1016/j.spinee.2013.05.042
   WILLIAMS RW, 1983, SPINE, V8, P708, DOI 10.1097/00007632-198310000-00005
   ZDEBLICK TA, 1992, J BONE JOINT SURG AM, V74A, P22, DOI 10.2106/00004623-199274010-00004
NR 23
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E455
EP E460
DI 10.1016/j.wneu.2018.10.070
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100054
PM 30347299
DA 2020-05-12
ER

PT J
AU Eroglu, U
   Bozkurt, M
   Kahilogullari, G
   Dogan, I
   Ozgural, O
   Shah, KJ
   Zaimoglu, M
   Al-Beyati, ESM
   Ugur, HC
   Cohen-Gadol, AA
AF Eroglu, Umit
   Bozkurt, Melih
   Kahilogullari, Gokmen
   Dogan, Ihsan
   Ozgural, Onur
   Shah, Kushal J.
   Zaimoglu, Murat
   Al-Beyati, Eyyub S. M.
   Ugur, Hasan Caglar
   Cohen-Gadol, Aaron A.
TI Surgical Management of Spinal Arachnoid Cysts in Adults
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extradural; Intradural; Intramedullary; Spinal arachnoid cysts; Surgical
   resection
ID PEDIATRIC AGE GROUP; DIAGNOSIS; CLASSIFICATION; DIVERTICULA
AB BACKGROUND: Spinal arachnoid cysts (SACs) are uncommon lesions in the spinal canal. They are usually asymptomatic, but can occasionally cause mass effect leading to neurologic symptoms. They can be congenital or secondary to a variety of causes. They can produce a variety of neurologic symptoms including pain, weakness, sensory changes, incontinence, and more. Surgical intervention may be necessary when SACs cause symptomatic mass effect.
   METHODS: Thirteen consecutive patients who underwent surgical intervention for an SAC were retrospectively reviewed. The data included presenting symptoms, imaging findings, neurologic status, and follow-up.
   RESULTS: Of the 13 patients, the majority of cases were located in the thoracic spine (54%) and all but one case were located dorsally or dorsolaterally. Furthermore, 38% were located extradurally and 54% were located intradurally. Pain (80%) was the most common presenting symptom. Most patients had improvement or complete resolution of their symptoms after intervention. Extradural SACs and their capsules were completely resected, whereas intradural SACs underwent fenestration. No complications occurred in this series.
   CONCLUSIONS: SACs are usually asymptomatic, but rarely cause mass effect and neurologic deficits requiring surgical intervention. Surgical intervention is tailored to the position of the cysts' dorsal or ventral locations. Pain and weakness are the most likely symptoms to improve, whereas sensory symptoms are least likely to improve.
C1 [Eroglu, Umit; Bozkurt, Melih; Kahilogullari, Gokmen; Dogan, Ihsan; Ozgural, Onur; Zaimoglu, Murat; Al-Beyati, Eyyub S. M.; Ugur, Hasan Caglar] Ankara Univ, Sch Med, Dept Neurosurg, Ankara, Turkey.
   [Shah, Kushal J.] Univ Kansas, Dept Neurosurg, Kansas City, KS USA.
   [Cohen-Gadol, Aaron A.] Indiana Univ, Dept Neurosurg, Goodman Campbell Brain & Spine, Indianapolis, IN 46204 USA.
RP Cohen-Gadol, AA (reprint author), Indiana Univ, Dept Neurosurg, Goodman Campbell Brain & Spine, Indianapolis, IN 46204 USA.
EM ACohenMD@gmail.com
RI Zaimoglu, Murat/AAE-9665-2020; eroglu, umit/P-2500-2017
OI Zaimoglu, Murat/0000-0001-5330-1251; dogan, ihsan/0000-0002-1985-719X;
   Eroglu, Umit/0000-0001-8623-071X
CR ALVISI C, 1987, J NEUROSURG, V67, P333, DOI 10.3171/jns.1987.67.3.0333
   Bond AE, 2012, J NEUROSURG-PEDIATR, V9, P432, DOI 10.3171/2012.1.PEDS11391
   Carrillo R, 1998, NEUROSURGERY, V42, P952, DOI 10.1097/00006123-199804000-00162
   Cho Ho-Yeon, 2015, Korean J Spine, V12, P217, DOI 10.14245/kjs.2015.12.3.217
   CILLUFFO JM, 1981, MAYO CLIN PROC, V56, P93
   CLOWARD RB, 1968, ANN SURG, V168, P851, DOI 10.1097/00000658-196811000-00011
   DUNCAN AW, 1978, RADIOLOGY, V126, P423, DOI 10.1148/126.2.423
   FORTUNA A, 1977, ACTA NEUROCHIR, V39, P259, DOI 10.1007/BF01406736
   Garg K, 2017, BRIT J NEUROSURG, V31, P172, DOI 10.1080/02688697.2016.1229747
   Goyal A, 2002, J NEUROSURG, V96, P104, DOI 10.3171/spi.2002.96.1.0104
   GOYAL RN, 1987, SPINE, V12, P209, DOI 10.1097/00007632-198704000-00003
   James HE, 2007, PEDIATR NEUROSURG, V43, P456, DOI 10.1159/000108787
   Kazan S, 1999, J NEUROSURG, V91, P211, DOI 10.3171/spi.1999.91.2.0211
   KENDALL BE, 1982, NEURORADIOLOGY, V22, P225, DOI 10.1007/BF00342069
   Kong Woo-Keun, 2013, Korean J Spine, V10, P32, DOI 10.14245/kjs.2013.10.1.32
   Kriss TC, 1997, SPINE, V22, P568, DOI 10.1097/00007632-199703010-00023
   Krstacic A, 2016, ACTA CLIN BELG, V71, P267, DOI 10.1080/17843286.2016.1139288
   Lee HJ, 2001, PEDIATR NEUROSURG, V35, P181, DOI 10.1159/000050419
   Lee SW, 2018, WORLD NEUROSURG, V116, P343, DOI 10.1016/j.wneu.2018.05.199
   Lee TT, 2000, J NEUROSURG, V92, P149, DOI 10.3171/spi.2000.92.2.0149
   LESOIN F, 1984, ACTA NEUROCHIR, V70, P227, DOI 10.1007/BF01406651
   MCCRUM C, 1982, J NEUROSURG, V57, P849, DOI 10.3171/jns.1982.57.6.0849
   NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366
   Neo M, 2004, SPINE, V29, pE426, DOI 10.1097/01.brs.0000141189.41705.70
   Netra R, 2011, J SPINAL DISORD TECH, V24, P132, DOI 10.1097/BSD.0b013e3181e47b47
   OSENBACH RK, 1992, NEUROSURGERY, V30, P35, DOI 10.1227/00006123-199201000-00007
   PERRET G, 1962, RADIOLOGY, V79, P425, DOI 10.1148/79.3.425
   Qi W, 2015, ACTA NEUROCHIR, V157, P539, DOI 10.1007/s00701-014-2278-3
   RABB CH, 1992, J NEUROSURG, V77, P369, DOI 10.3171/jns.1992.77.3.0369
   Santamarta D, 2001, MINIM INVAS NEUROSUR, V44, P128, DOI 10.1055/s-2001-18148
   Suryaningtyas W, 2007, J NEUROSURG, V106, P158, DOI 10.3171/ped.2007.106.2.158
   TARLOV IM, 1970, J NEUROL NEUROSUR PS, V33, P833, DOI 10.1136/jnnp.33.6.833
   Turel MK, 2017, NEUROL INDIA, V65, P863, DOI 10.4103/neuroindia.NI_56_17
   Wang MY, 2003, SURG NEUROL, V60, P49, DOI 10.1016/S0090-3019(03)00149-6
   Woo Joon Bum, 2016, Korean J Neurotrauma, V12, P185, DOI 10.13004/kjnt.2016.12.2.185
NR 35
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1146
EP E1152
DI 10.1016/j.wneu.2018.11.005
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100140
PM 30447456
DA 2020-05-12
ER

PT J
AU Esposito, G
   Dias, SF
   Burkhardt, JK
   Fierstra, J
   Serra, C
   Bozinov, O
   Regli, L
AF Esposito, Giuseppe
   Dias, Sandra Fernandes
   Burkhardt, Jan-Karl
   Fierstra, Jorn
   Serra, Carlo
   Bozinov, Oliver
   Regli, Luca
TI Selection Strategy for Optimal Keyhole Approaches for Middle Cerebral
   Artery Aneurysms: Lateral Supraorbital Versus Minipterional Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Keyhole strategy; Lateral supraorbital approach; Middle
   cerebral artery; Minicraniotomy; Minimally invasive neurosurgery;
   Minipterional approach
ID EXPERIENCE; SURGERY; MCA
AB BACKGROUND/OBJECTIVE: The lateral supraorbital (LS) and minipterional (MP) approaches have been reported for treating intracranial aneurysms as alternative to the pterional approach. We describe our decision making for selecting the minicraniotomy, LS versus MP, for managing noncomplex aneurysms of the middle cerebral artery (MCA), based on the depth of the aneurysm within the Sylvian fissure.
   METHODS: We report on a consecutive case series of 50 patients who underwent clipping of 54 ruptured/unruptured MCA aneurysms by means of LS or MP craniotomies. The distance between the MCA (M1) origin and the aneurysmal neck is key to selection of the approach: LS was used for MCA aneurysms < 15 mm from the M1 origin and MP for MCA aneurysms >= 15 mm from the M1 origin.
   RESULTS: 11 of 50 patients presented with subarachnoid hemorrhage (10 ruptured MCA aneurysms). Overall, 59 aneurysms were successfully clipped (54 of the MCA). The mean distance between the M1 origin and the aneurysmal neck was 10.1 mm (range, 4-17 mm) for patients treated by LS and 20 mm (range, 15-30 mm) for those treated by MP. All but 1 MCA aneurysms were successfully treated. At last follow-up (mean, 14 months), no reperfusion of the clipped aneurysms was observed.
   CONCLUSION: Our strategy for selecting the keyhole approach based on the depth of the aneurysm within the Sylvian fissure is efficient and safe. We suggest the use of the LS approach when the aneurysm is < 15 mm from the M1 origin and the MP approach when the aneurysm is >= 15 mm from the M1 origin.
C1 [Esposito, Giuseppe; Dias, Sandra Fernandes; Burkhardt, Jan-Karl; Fierstra, Jorn; Serra, Carlo; Bozinov, Oliver; Regli, Luca] Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr Zurich, Zurich, Switzerland.
RP Esposito, G (reprint author), Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr Zurich, Zurich, Switzerland.
EM giuseppe.esposito@usz.ch
OI Bozinov, Oliver/0000-0002-4620-3992; Fernandes Dias,
   Sandra/0000-0002-3146-5164; Fierstra, Jorn/0000-0001-6220-0727
CR Caplan JM, 2014, OPER NEUROSURG, V10, P200, DOI 10.1227/NEU.0000000000000348
   Cha KC, 2012, J KOREAN NEUROSURG S, V51, P334, DOI 10.3340/jkns.2012.51.6.334
   Elsharkawy A, 2014, ACTA NEUROCHIR, V156, P17, DOI 10.1007/s00701-013-1894-7
   Esposito G, 2016, ACTA NEUROCHIR, V158, P1523, DOI 10.1007/s00701-016-2868-3
   Esposito G, 2014, ACTA NEUROCHIR SUPPL, V119, P3, DOI 10.1007/978-3-319-02411-0_1
   Esposito G, 2012, NEUROSURGERY, V71, P274, DOI 10.1227/NEU.0b013e3182684c45
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2016, J CLIN NEUROSCI, V27, P34, DOI 10.1016/j.jocn.2015.07.032
   Figueiredo EG, 2014, NEUROSURGERY, V75, pN324, DOI 10.1227/NEU.0000000000000456
   Fischer G, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820934ca
   Hernesniemi J, 2005, ACT NEUR S, V94, P17
   JAIN K. K., 1964, CANADIAN JOUR SURG, V7, P134
   Lan Q, 2006, SURG NEUROL, V66, P2, DOI 10.1016/j.surneu.2006.06.039
   Madhugiri VS, 2013, WORLD NEUROSURG, V80, P836, DOI 10.1016/j.wneu.2013.02.072
   Paladino J, 2005, MINIM INVAS NEUROSUR, V48, P251, DOI 10.1055/s-2005-915599
   Salma A, 2011, NEUROSURGERY, V68, P364, DOI 10.1227/NEU.0b013e318211721f
   Sarnthein J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163154
   Welling LC, 2015, J NEUROSURG, V122, P1012, DOI 10.3171/2014.11.JNS146
   Yasargil M G, 1975, Surg Neurol, V3, P7
   Yasargil MG, 1984, MICROSURGICAL ANATOM, V1
   Zador Z, 2013, ACTA NEUROCHIR, V155, P99, DOI 10.1007/s00701-012-1552-5
NR 21
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E349
EP E357
DI 10.1016/j.wneu.2018.09.238
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100041
PM 30326308
DA 2020-05-12
ER

PT J
AU Fernandez-Fairen, M
   Alvarado, E
   Torres, A
AF Fernandez-Fairen, Mariano
   Alvarado, Enrique
   Torres, Ana
TI Eleven-Year Follow-Up of Two Cohorts of Patients Comparing Stand-Alone
   Porous Tantalum Cage Versus Autologous Bone Graft and Plating in
   Anterior Cervical Fusions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Degenerative disc disease; Interbody fusion; Long-term
   follow-up; Tantalum cage
ID ADJACENT SEGMENT DEGENERATION; INTERBODY FUSION; DISC DISEASE;
   INTERVERTEBRAL DISCS; MOTION ADJACENT; SPANISH VERSION; SPINAL-FUSION;
   RISK-FACTORS; SUBSIDENCE; DISKECTOMY
AB BACKGROUND: Anterior cervical discectomy and fusion with a porous tantalum cage is an accepted method to treat degenerated cervical discs, with good results, similar to those with autologous bone graft and plating at short- and mid-term follow-up. However, to date, long-term follow-up studies have been performed.
   METHODS: We performed a retrospective, single-center study to evaluate the outcomes of 2 cohorts from a previous prospective randomized controlled trial comparing stand-alone tantalum cage (group 1, 27 patients) with autologous bone graft and plating (group 2, 30 patients) for single-level anterior cervical discectomy and fusion at 11 years of follow-up. The usual clinical and radiological outcomes and "overall success," proposed by the Food and Drug Administration, were evaluated.
   RESULTS: The improvement in clinical outcomes achieved postoperatively was maintained similarly in the 2 cohorts at 11 years of follow-up. In group 1, the cage had subsided 2e3 mm in 12 patients (44%), segmental lordosis was maintained in 16 patients (59%), adjacent segment degeneration had developed or progressed in 27 of the adjacent segments (50%) in 15 patients (56%), and postoperative nonprogressive deformation of the anterior aspect of the cage was observed in 7 (26%) and minor fragmentation in 3 (11%) patients. In group 2, segmental lordosis was maintained in 90% of the patients and adjacent segment degeneration had developed or progressed in 15 patients (50%).
   CONCLUSIONS: These results show that the clinical and radiological outcomes achieved at mid-term follow-up using a tantalum cage for single-level anterior cervical discectomy and fusion will be maintained for 11 years postoperatively, similar to the results with autologous bone graft and plating.
C1 [Fernandez-Fairen, Mariano; Alvarado, Enrique] Inst Cirugia Ortoped & Traumatol, Clin Tres Torres, Barcelona, Spain.
   [Torres, Ana] Hosp Univ Santa Lucia, Serv Cirugia Ortoped & Traumatol, Murcia, Spain.
RP Fernandez-Fairen, M (reprint author), Inst Cirugia Ortoped & Traumatol, Clin Tres Torres, Barcelona, Spain.
EM mferfai@gmail.com
OI Fernandez-Fairen, Mariano/0000-0002-1133-8141
CR Ahn SS, 2016, J KOREAN NEUROSURG S, V59, P129, DOI 10.3340/jkns.2016.59.2.129
   ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771
   Ortega JAA, 2010, SPINE, V35, pE114, DOI 10.1097/BRS.0b013e3181afea5d
   Barsa P, 2007, EUR SPINE J, V16, P1395, DOI 10.1007/s00586-006-0284-8
   Bartels RHMA, 2006, NEUROSURGERY, V58, P502, DOI 10.1227/01.NEU.0000197258.30821.50
   Bisson EF, 2011, ACTA NEUROCHIR, V153, P123, DOI 10.1007/s00701-010-0832-1
   Bolesta Michael J, 2002, Spine J, V2, P197, DOI 10.1016/S1529-9430(02)00186-9
   Bono CM, 2011, SPINE J, V11, P64, DOI 10.1016/j.spinee.2010.10.023
   Cannada LK, 2003, SPINE, V28, P46, DOI 10.1097/00007632-200301010-00012
   Chung JY, 2014, SPINE J, V14, P2290, DOI 10.1016/j.spinee.2014.01.027
   Conde V, 1970, Arch Neurobiol (Madr), V33, P185
   Daltroy LH, 1996, SPINE, V21, P741, DOI 10.1097/00007632-199603150-00017
   Elsawaf A, 2009, NEUROSURG REV, V32, P215, DOI 10.1007/s10143-008-0164-2
   Fernandez-Fairen M, 2008, SPINE, V33, P465, DOI 10.1097/BRS.0b013e3181657f49
   Fernandez-Fairen M, 2012, SPINE, V37, P1734, DOI 10.1097/BRS.0b013e318255a184
   Food and Drug Administration, 2008, 1637 FDA
   Fountas KN, 2007, EUR SPINE J, V16, P39, DOI 10.1007/s00586-006-0116-x
   Fujibayashi S, 2008, J CLIN NEUROSCI, V15, P1017, DOI 10.1016/j.jocn.2007.05.011
   Gercek E, 2003, EUR SPINE J, V12, P513, DOI 10.1007/s00586-003-0539-6
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Goldberg G, 2007, SPINE, V32, pE371, DOI 10.1097/BRS.0b013e318060cca9
   Hansen MA, 2012, SPINE, V37, pS75, DOI 10.1097/BRS.0b013e31826d62a6
   Hermansen A, 2013, J NEUROSURG-SPINE, V19, P403, DOI 10.3171/2013.7.SPINE12843
   Hilibrand Alan S, 2004, Spine J, V4, p190S, DOI 10.1016/j.spinee.2004.07.007
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Hu XB, 2015, INT J SPINE SURG, V9, DOI 10.14444/2061
   Ikenaga M, 2005, J NEUROSURG-SPINE, V3, P79, DOI 10.3171/spi.2005.3.2.0079
   Kao TH, 2014, ARCH ORTHOP TRAUM SU, V134, P1343, DOI 10.1007/s00402-014-2047-z
   Karikari IO, 2014, J SPINAL DISORD TECH, V27, P1, DOI 10.1097/BSD.0b013e31825bd26d
   Kasliwal MK, 2013, J SPINAL DISORD TECH, V26, P239, DOI 10.1097/BSD.0b013e318241e70f
   Kast E, 2009, NEUROSURG REV, V32, P207, DOI 10.1007/s10143-008-0168-y
   Katsuura A, 2001, EUR SPINE J, V10, P320, DOI 10.1007/s005860000243
   Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9
   Kellgren JH, 1963, ATLAS STANDARD RADIO, V2
   Kolstad F, 2007, SPINE, V32, P512, DOI 10.1097/01.brs.0000256448.04035.bb
   Kong LD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004171
   Lawrence BD, 2012, SPINE, V37, pS52, DOI 10.1097/BRS.0b013e31826d60fb
   Lee CH, 2013, J SPINAL DISORD TECH, V26, P112, DOI 10.1097/BSD.0b013e318274148e
   Lee MJ, 2012, SPINE PHILA PA 197 S, V37, P18
   Levin DA, 2007, BULL HOSP JT DIS, V65, P29
   Lofgren H, 2010, EUR SPINE J, V19, P464, DOI 10.1007/s00586-009-1161-z
   Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929
   Matsumoto M, 2010, SPINE, V35, P1359, DOI 10.1097/BRS.0b013e3181c17067
   Matsumoto M, 2010, SPINE, V35, P36, DOI 10.1097/BRS.0b013e3181b8a80d
   Okada E, 2009, SPINE, V34, P706, DOI 10.1097/BRS.0b013e31819c2003
   Ordway NR, 2012, J ORTHOP RES, V30, P587, DOI 10.1002/jor.21566
   Pait TG, 1996, NEUROSURGERY, V39, P769, DOI 10.1097/00006123-199610000-00026
   Palit M, 1999, SPINE, V24, P2224, DOI 10.1097/00007632-199911010-00009
   Papacci F, 2016, J CLIN NEUROSCI, V33, P159, DOI 10.1016/j.jocn.2016.03.036
   Park JY, 2016, J CLIN NEUROSCI, V33, P83, DOI 10.1016/j.jocn.2016.01.042
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Pinder EM, 2016, J ORTHOP SURG-HONG K, V24, P97, DOI 10.1177/230949901602400122
   Pool JJM, 2007, SPINE, V32, P3047, DOI 10.1097/BRS.0b013e31815cf75b
   Reitman CA, 2004, SPINE, V29, pE221, DOI 10.1097/00007632-200406010-00022
   Samartzis Dino, 2004, Spine J, V4, P636, DOI 10.1016/j.spinee.2004.04.010
   Sampath P, 1999, SPINE, V24, P591, DOI 10.1097/00007632-199903150-00021
   Schmieder K, 2006, J NEUROSURG-SPINE, V4, P447, DOI 10.3171/spi.2006.4.6.447
   Seo M, 2008, BRIT J NEUROSURG, V22, P195, DOI 10.1080/02688690701790605
   Shin Jae Sik, 2014, Korean J Spine, V11, P169, DOI 10.14245/kjs.2014.11.3.169
   Sinclair SK, 2012, SPINE, V37, pE571, DOI 10.1097/BRS.0b013e318240f981
   Song KJ, 2014, ASIAN SPINE J, V8, P720, DOI 10.4184/asj.2014.8.6.720
   Song KJ, 2011, EUR SPINE J, V20, P1940, DOI 10.1007/s00586-011-1864-9
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Tewarie RDSN, 2007, EUR SPINE J, V16, P1411, DOI 10.1007/s00586-007-0309-y
   Togawa D, 2003, SPINE, V28, P246, DOI 10.1097/00007632-200302010-00008
   Tome-Bermejo F, 2017, CLIN SPINE SURG, V30, pE648, DOI 10.1097/BSD.0000000000000293
   Troyanovich SJ, 2002, J SPINAL DISORD TECH, V15, P69, DOI 10.1097/00024720-200202000-00013
   Tullberg T, 1998, SPINE, V23, P1804, DOI 10.1097/00007632-199808150-00016
   van Eck CF, 2014, SPINE, V39, P2143, DOI 10.1097/BRS.0000000000000636
   Viera AJ, 2005, FAM MED, V37, P360
   Wigfield C, 2003, BRIT J NEUROSURG, V17, P418, DOI 10.1080/02688690310001611206
   Wilder FV, 2011, RHEUMATOL INT, V31, P45, DOI 10.1007/s00296-009-1216-9
   Wu WJ, 2012, EUR SPINE J, V21, P1374, DOI 10.1007/s00586-011-2131-9
   Yang JJ, 2011, CLIN ORTHOP SURG, V3, P16, DOI 10.4055/cios.2011.3.1.16
   Yao NZ, 2011, EUR SPINE J, V20, P899, DOI 10.1007/s00586-010-1642-0
   Young BA, 2009, SPINE J, V9, P802, DOI 10.1016/j.spinee.2009.06.002
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
   Zajonz D, 2014, PATIENT SAF SURG, V8, DOI 10.1186/s13037-014-0043-4
   Zoega B, 1998, ACTA ORTHOP SCAND, V69, P363, DOI 10.3109/17453679808999048
   Zoega B, 2000, EUR SPINE J, V9, P137, DOI 10.1007/s005860050224
NR 81
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E156
EP E167
DI 10.1016/j.wneu.2018.09.160
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100017
PM 30268546
DA 2020-05-12
ER

PT J
AU Fiaschi, P
   Piatelli, G
   Cama, A
   Capra, V
   Consales, A
   Ravegnani, M
   Pavanello, M
AF Fiaschi, Pietro
   Piatelli, Gianluca
   Cama, Armando
   Capra, Valeria
   Consales, Alessandro
   Ravegnani, Marcello
   Pavanello, Marco
TI Intraspinal Inclusion Tumor After Myelomeningocele Repair: A Long-Term
   Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Cyst; Dermoid; Epidermoid; Inclusion; Myelomeningocele;
   Tumor
ID LUMBAR DERMOID CYST; EPIDERMOID TUMORS; FETAL SURGERY; CONUS MEDULLARIS;
   HYDROCEPHALUS; MANAGEMENT; NEWBORN; CLOSURE; SERIES
AB OBJECTIVE: Given the lack of significant responses to many queries regarding behavior, treatment options, and possible prevention of iatrogenic intraspinal inclusion tumors (IITs), we think that further clinical, radiologic, and follow-up data are mandatory to better characterize this entity. We retrospectively reviewed a series of 14 consecutive patients with IIT occurring after myelomeningocele repair. The long follow-up is a mainstay of this series and may help a better understanding of the history of this slow-growing disease. To date, this is the largest series of IITs after myelomeningocele repair reported in the literature.
   METHODS: A retrospective chart review was performed to identify all cases of surgically repaired myelomeningocele at the Department of Neurosurgery of G. Gaslini Children's Hospital in Genoa, from January 1993 to January 2018. Among them, data regarding patients in whom an IIT developed were recovered. The medical records of these patients and their clinical history, neurologic examination, and diagnostic workup were reviewed.
   RESULTS: From January 1993 to January 2018, 160 cases of myelomeningocele were surgically treated. Among them, 14 cases of IIT developed. The mean time between myelomeningocele repair and IIT diagnosis was 94.7 months. The mean follow-up time was 60.1 months.
   CONCLUSIONS: It is well established that IITs may be discovered in patients who have previously undergone myelomeningocele repair. In our series, with a long follow-up time, we describe the possible range of behavior of such lesions and the utility of surgical treatment of primary therapy. Our series confirms that residual IITs showed marked stability during our long follow-up.
C1 [Fiaschi, Pietro] San Martino IST Univ Hosp, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Div Neurosurg, Genoa, Italy.
   [Piatelli, Gianluca; Cama, Armando; Capra, Valeria; Consales, Alessandro; Ravegnani, Marcello; Pavanello, Marco] Ist Giannina Gaslini, Dept Pediat Neurosurg, Genoa, Italy.
RP Fiaschi, P (reprint author), San Martino IST Univ Hosp, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Div Neurosurg, Genoa, Italy.
EM pietrofiaschi@gmail.com
RI Valeria, Capra/AAB-1501-2019; Marco, Pavanello/K-2859-2019; Fiaschi,
   Pietro/AAC-6208-2020; Fiaschi, Pietro/AAC-1636-2019
OI Marco, Pavanello/0000-0001-7312-0204; Fiaschi,
   Pietro/0000-0002-6034-5524; 
CR Adzick NS, 2011, NEW ENGL J MED, V364, P993, DOI 10.1056/NEJMoa1014379
   Aoun SG, 2018, J CLIN NEUROSCI, V50, P247, DOI 10.1016/j.jocn.2018.01.049
   BAILEY LC, 1970, J NEUROSURG, V33, P676
   Bristow RG, 1997, J NEURO-ONCOL, V33, P251, DOI 10.1023/A:1005739606895
   CAVAZZANI P, 1995, SURG NEUROL, V43, P466, DOI 10.1016/0090-3019(95)80091-T
   CHADDUCK WM, 1993, PEDIATR NEUROSURG, V19, P81, DOI 10.1159/000120705
   Danzer E, 2008, J NEUROSURG-PEDIATR, V2, P406, DOI 10.3171/PED.2008.2.12.406
   Falavigna A, 2009, ARQ NEURO-PSIQUIAT, V67, P293, DOI 10.1590/S0004-282X2009000200023
   Gao BQ, 2007, PEDIATRICS, V120, pE220, DOI 10.1542/peds.2006-2053
   GUIDETTI B, 1977, J NEUROSURG, V47, P12, DOI 10.3171/jns.1977.47.1.0012
   Gupta N, 2017, CHILD NERV SYST, V33, P1143, DOI 10.1007/s00381-017-3439-5
   Gupta N, 2012, J NEUROSURG-PEDIATR, V9, P265, DOI 10.3171/2011.12.PEDS11403
   INO M, 1995, INT ORTHOP, V19, P185
   Ivianzo G, 2013, NEURORADIOL J, V26, P469, DOI 10.1177/197140091302600412
   Kudo N, 2007, J ORTHOP SCI, V12, P300, DOI 10.1007/s00776-007-1125-2
   Liu H, 2012, J CLIN NEUROSCI, V19, P712, DOI 10.1016/j.jocn.2011.07.046
   LUNARDI P, 1989, NEUROSURGERY, V25, P860, DOI 10.1227/00006123-198912000-00002
   Martinez-Lage JF, 2006, CHILD NERV SYST, V22, P698, DOI 10.1007/s00381-005-0029-8
   MARTINEZLAGE JF, 1983, J NEUROSURG, V59, P1095, DOI 10.3171/jns.1983.59.6.1095
   MARTINEZLAGE JF, 1994, PEDIATR NEUROSURG, V20, P274, DOI 10.1159/000120803
   Marton E, 2018, ACTA NEUROCHIR, V160, P1625, DOI 10.1007/s00701-018-3577-x
   Mazzola CA, 2002, NEW ENGL J MED, V347, P256, DOI 10.1056/NEJMoa013325
   Messori A, 2002, EUR J RADIOL, V43, P19, DOI 10.1016/S0720-048X(01)00432-6
   Moldenhauer JS, 2017, SEMIN FETAL NEONAT M, V22, P360, DOI 10.1016/j.siny.2017.08.004
   Park Min Ho, 2014, Korean J Spine, V11, P195, DOI 10.14245/kjs.2014.11.3.195
   Per H, 2007, J CHILD NEUROL, V22, P332, DOI 10.1177/0883073807300531
   Ramos E, 2008, J NEUROSURG-PEDIATR, V2, P414, DOI 10.3171/PED.2008.2.12.414
   Sandler AL, 2013, CHILD NERV SYST, V29, P105, DOI 10.1007/s00381-012-1916-4
   SCOTT RM, 1986, J NEUROSURG, V65, P779, DOI 10.3171/jns.1986.65.6.0779
   STORRS BB, 1994, PEDIATR NEUROSURG, V20, P160, DOI 10.1159/000120780
   Thompson DNP, 2013, CHILD NERV SYST, V29, P1647, DOI 10.1007/s00381-013-2147-z
   Tufan K, 2008, J CHILD NEUROL, V23, P934, DOI 10.1177/0883073808314961
   van Aalst J, 2009, PEDIATR NEUROSURG, V45, P281, DOI 10.1159/000235602
   VANGILDER JC, 1967, J NEUROSURG, V26, P14, DOI 10.3171/jns.1967.26.1part1.0014
   Wright MH, 2013, ORTHOP NURS, V22, P215
   Wright MH, 2013, ORTHOP NURS, V22, P220
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1338
EP E1344
DI 10.1016/j.wneu.2018.11.044
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100163
PM 30448586
DA 2020-05-12
ER

PT J
AU Fiaschi, P
   Prior, A
   Sbaffi, PF
   Bizzi, F
   D'Andrea, A
   Cagetti, B
   Badaloni, F
   Allegretti, L
   Mavilio, N
   Padolecchia, R
   Valsania, V
   Zona, G
AF Fiaschi, Pietro
   Prior, Alessandro
   Sbaffi, Pier Filippo
   Bizzi, Fabiola
   D'Andrea, Alessandro
   Cagetti, Bernarda
   Badaloni, Filippo
   Allegretti, Luca
   Mavilio, Nicola
   Padolecchia, Riccardo
   Valsania, Valtero
   Zona, Gianluigi
TI Spinal Dural Arteriovenous Fistulas: Clinical Results and Quality of
   Life Assessment with Surgical Treatment as a Crucial Therapy. The Joint
   Experience of Two Centers
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous fistulas; Fistula; SDAVF; SF-36; Spinal vascular
   malformation; Surgery quality of life
ID LOCALIZATION; MANAGEMENT; SERIES
AB OBJECTIVE: Dorsal intradural arteriovenous fistulas (AVFs) consist of a direct connection between a radicular feeding artery and the coronal venous plexus; this direct connection leads to arterialization of the venous plexus, venous congestion, and myelopathy. Controversy still exists regarding the best treatment modality of spinal dural AVFs. Surgical disconnection of spinal dural AVFs is a straight-forward procedure with a high success rate and virtually no risk of recurrence or incomplete treatment.
   To identify factors associated with the clinical progression of dorsal intradural AVFs and quantify the range of surgical outcomes in terms of neurologic improvement as well as patients' perception of quality of life (QOL).
   METHODS: A retrospective observational study of 19 consecutive patients treated with surgery over a 10-year period was carried out. We analyzed surgical results and clinical outcomes. We also evaluated the impact of this disease and its sequelae on the patients' postoperative health-related QOL.
   RESULTS: The surgical procedure showed good results in terms of neurologic improvement as well as patients' perception of QOL.
   CONCLUSIONS: Our series confirmed that surgical obliteration of dorsal intradural AVFs is an effective and safe procedure. The results of this retrospective analysis make us believe that surgery, given its low morbidity and high success rate, represents a safe and effective first therapeutic option for these spinal vascular malformations. It could be considered to avoid unsuccessful endovascular attempts that could delay the definitive treatment of this disease. The surgical procedure showed good results in terms of neurologic improvement as well as patients' perception of QOL.
C1 [Fiaschi, Pietro; Prior, Alessandro; Sbaffi, Pier Filippo; D'Andrea, Alessandro; Zona, Gianluigi] San Martino Univ Hosp, Dept Neurosci DINOGMI, Sect Neurosurg, Genoa, Italy.
   [Bizzi, Fabiola] Univ Genoa, Dept Educ Sci DISFOR, Genoa, Italy.
   [Cagetti, Bernarda; Badaloni, Filippo; Valsania, Valtero] S Corona Hosp, Dept Neurosurg, Pietra Ligure, Italy.
   [Padolecchia, Riccardo] S Corona Hosp, Dept Neuroradiol, Pietra Ligure, Italy.
   [Allegretti, Luca; Mavilio, Nicola] San Martino Univ Hosp, Dept Diagnost & Intervent Neuroradiol, Genoa, Italy.
RP Fiaschi, P (reprint author), San Martino Univ Hosp, Dept Neurosci DINOGMI, Sect Neurosurg, Genoa, Italy.
EM pietro.fiaschi@alice.it
RI Fiaschi, Pietro/AAC-1636-2019; Badaloni, Filippo/AAE-5487-2019; Fiaschi,
   Pietro/AAC-6208-2020; Bizzi, Fabiola/K-9781-2016
OI Badaloni, Filippo/0000-0002-0041-0945; Fiaschi,
   Pietro/0000-0002-6034-5524; Bizzi, Fabiola/0000-0003-0141-1218
CR Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   Bakker NA, 2015, NEUROSURGERY, V77, P137, DOI 10.1227/NEU.0000000000000727
   Bertuccio Alessandro, 2016, Acta Neurochir Suppl, V123, P177, DOI 10.1007/978-3-319-29887-0_25
   Binning MJ, 2010, SPINE, V35, P1821, DOI 10.1097/BRS.0b013e3181c90bdf
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P380, DOI 10.3174/ajnr.A4504
   Britz GW, 2004, NEUROSURGERY, V55, P252, DOI 10.1227/01.NEU.0000127883.26964.81
   Cenzato M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1218
   Eskandar EN, 2002, J NEUROSURG, V96, P162, DOI 10.3171/spi.2002.96.2.0162
   Iovtchev I, 2015, SPINE J, V15, pE39, DOI 10.1016/j.spinee.2013.08.029
   Kim LJ, 2006, NEUROSURGERY, V59, P53, DOI 10.1227/01.NEU.0000219219.97287.91
   Muralidharan R, 2011, SPINE, V36, pE1641, DOI 10.1097/BRS.0b013e31821352dd
   Patsalides A, 2011, J NEUROINTERV SURG, V3, P80, DOI 10.1136/jnis.2010.003178
   Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821
   Sasamori T, 2017, NEUROSURG REV, V40, P83, DOI 10.1007/s10143-016-0752-5
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   Takai K, 2015, J NEUROSURG-SPINE, V23, P526, DOI 10.3171/2014.11.SPINE14786
   Watson JC, 1999, NEUROSURG CLIN N AM, V10, P73, DOI 10.1016/S1042-3680(18)30211-0
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E270
EP E278
DI 10.1016/j.wneu.2018.10.019
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100030
PM 30339911
DA 2020-05-12
ER

PT J
AU Fredrickson, VL
   Strickland, B
   Ravina, K
   Rennert, RC
   Donoho, DA
   Buchanan, IA
   Russin, JJ
   Mack, WJ
   Giannotta, SL
AF Fredrickson, Vance L.
   Strickland, Ben A.
   Ravina, Kristine
   Rennert, Robert C.
   Donoho, Daniel A.
   Buchanan, Ian A.
   Russin, Jonathan J.
   Mack, William J.
   Giannotta, Steven L.
TI State of the Union in Open Neurovascular Training
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrovascular; Fellowship; Learning curve; Neurovascular; Open
   vascular; Training
ID UNRUPTURED INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSM;
   CAROTID-ENDARTERECTOMY; SURGEON VOLUME; UNITED-STATES; OUTCOMES; IMPACT;
   COMPLICATIONS; ASSOCIATION; MORTALITY
AB BACKGROUND: The evolution of minimally invasive endovascular approaches and training paradigms has reduced open neurovascular case exposure for neurosurgical residents. There are no published estimates of open neurovascular case volumes during residency or Committee on Advanced Subspecialty Training (CAST) accredited fellowships.
   METHODS: Case volumes from residency programs submitting data for CAST accredited fellowship applications were collected and analyzed. The study period covered the academic years of 2013-2016. Case index volumes were calculated to provide an estimate of total volume of cases each trainee participated in a given year. The case index volume was defined as the total volume of cases per year divided by the total training complement.
   RESULTS: Over the study period, institutional data from 46 programs were available. Of those programs, 9 programs had CAST accredited open cerebrovascular fellowships. Across all 46 programs, the median number of vascular cases was 246 (interquartile range [IQR]: 148-340), whereas the median number of open vascular cases was 105 (IQR: 67-152). The median number of open aneurysm cases among programs with CAST cerebrovascular fellowships was 80 (IQR: 54-103) and among programs without CAST cerebrovascular fellowships was 34 (IQR: 24-63). The median open aneurysm case index volume for trainees at programs with and without CAST cerebrovascular fellowships was 23 (IQR: 14-29) and 19 (IQR: 11-24).
   CONCLUSIONS: Strong neurovascular training can be obtained through dedication and planning. Completion of a CAST accredited cerebrovascular fellowship will often more than double aneurysm case exposure of trainees.
C1 [Fredrickson, Vance L.; Strickland, Ben A.; Donoho, Daniel A.; Buchanan, Ian A.; Russin, Jonathan J.; Mack, William J.; Giannotta, Steven L.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90089 USA.
   [Ravina, Kristine; Russin, Jonathan J.] Univ Southern Calif, Neurorestorat Ctr, Keck Sch Med, Los Angeles, CA 90089 USA.
   [Rennert, Robert C.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.
RP Fredrickson, VL (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90089 USA.
EM vance.fredrickson@gmail.com
OI Ravina, Kristine/0000-0002-0927-5719
CR Abla AA, 2011, J NEUROSURG, V115, P1231, DOI 10.3171/2011.7.JNS102013
   Ahmed N, 2014, ANN SURG, V259, P1041, DOI 10.1097/SLA.0000000000000595
   Barker FG, 2003, NEUROSURGERY, V52, P995, DOI 10.1227/01.NEU.0000057743.56678.5F
   Bekelis K, 2016, J NEUROSURG-PEDIATR, V18, P623, DOI 10.3171/2016.5.PEDS16137
   Bekelis K, 2016, J NEUROINTERV SURG, V8, P977, DOI 10.1136/neurintsurg-2015-011986
   Belykh E, 2017, WORLD NEUROSURG, V105, P952, DOI 10.1016/j.wneu.2017.06.045
   Belykh E, 2016, J NEUROSURG, V125, P915, DOI 10.3171/2015.8.JNS151346
   Belykh EG, 2015, NEUROSURGERY, V77, P825, DOI 10.1227/NEU.0000000000000924
   Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205
   Chowdhry SA, 2014, NEUROSURGERY, V74, pS198, DOI 10.1227/NEU.0000000000000225
   Chyatte D, 2001, J NEUROSURG, V94, P417, DOI 10.3171/jns.2001.94.3.0417
   Coon Alexander L, 2011, Surg Neurol Int, V2, P152, DOI 10.4103/2152-7806.86832
   Cowan JA, 2003, J NEUROSURG, V99, P947, DOI 10.3171/jns.2003.99.6.0947
   Cowan JA, 2002, J AM COLL SURGEONS, V195, P814, DOI 10.1016/S1072-7515(02)01345-5
   Cunningham EJ, 2003, BRIT J NEUROSURG, V17, P124, DOI 10.1080/0268869031000108963
   Fridriksson S, 2002, J NEUROSURG, V96, P515, DOI 10.3171/jns.2002.96.3.0515
   Giannotta SL, 2012, WORLD NEUROSURG, V77, P289, DOI 10.1016/j.wneu.2011.06.022
   Goldschlager T, 2007, J CLIN NEUROSCI, V14, P1055, DOI 10.1016/j.jocn.2006.12.002
   Hattori N, 2007, NEUROL MED-CHIR, V47, P95, DOI 10.2176/nmc.47.95
   Heros RC, 2000, NEUROSURGERY, V47, P1007, DOI 10.1097/00006123-200011000-00001
   Hino A, 2003, NEUROSURGERY, V52, P1495, DOI 10.1227/01.NEU.0000065174.83840.62
   Hopkins LN, 2001, NEUROSURGERY, V48, P463, DOI 10.1097/00006123-200103000-00001
   Hsu CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151805
   Jabbarli R, 2016, WORLD NEUROSURG, V89, P666, DOI 10.1016/j.wneu.2015.12.043
   Jagannathan J, 2009, J NEUROSURG, V110, P820, DOI 10.3171/2009.2.JNS081446
   Lawton MT, 2002, NEUROSURGERY, V50, P1
   MAURICEWILLIAMS RS, 1994, BRIT J NEUROSURG, V8, P519, DOI 10.3109/02688699409002944
   Meier AH, 2010, SURG CLIN N AM, V90, P491, DOI 10.1016/j.suc.2010.02.003
   Morgan MK, 2007, J NEUROSURG, V106, P961, DOI 10.3171/jns.2007.106.6.961
   Russin JJ, 2012, NEUROSURGERY, V71, P315, DOI 10.1227/NEU.0b013e318266e7c6
   Stranjalis G, 1996, ACTA NEUROCHIR, V138, P1067, DOI 10.1007/BF01412309
   van Lindert EJ, 2001, SURG NEUROL, V56, P151, DOI 10.1016/S0090-3019(01)00547-X
   Woodrow SI, 2005, J NEUROSURG, V102, P616, DOI 10.3171/jns.2005.102.4.0616
   Yasunaga H, 2008, NEUROL MED-CHIR, V48, P531, DOI 10.2176/nmc.48.531
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E553
EP E560
DI 10.1016/j.wneu.2018.10.099
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100067
PM 31108071
DA 2020-05-12
ER

PT J
AU Freyschlag, CF
   Gruber, R
   Bauer, M
   Grams, AE
   Thome, C
AF Freyschlag, Christian F.
   Gruber, Ricarda
   Bauer, Marlies
   Grams, Astrid E.
   Thome, Claudius
TI Routine Postoperative Computed Tomography Is Not Helpful After Elective
   Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Complications; CT scan; Elective craniotomy
ID HEAD CT; RESECTION; RECOVERY; GLIOMA; RECONSTRUCTION; QUALITY
AB BACKGROUND: Next-day postoperative computed tomography (CT) has been routinely used to obtain radiographic "clearance" for transferring patients after elective craniotomy out of the intensive care unit. The value of this traditional policy, however, has repeatedly been questioned. However, the limited patient numbers might have underestimated the very rare, but catastrophic, events. Therefore, we analyzed the value of routine postoperative CT in a larger cohort of elective tumor, epilepsy, and vascular cases.
   METHODS: All the patients who had undergone elective craniotomy were included in our study. The routine postoperative CT scans were analyzed by a neuroradiologist who was unaware of the clinical data. The medical records were retrospectively reviewed for events of arterial hypertension and clinical deterioration.
   RESULTS: The data from 660 patients with tumors (n = 393; 59.5%), aneurysms (n = 107; 16.2%), and skull base lesions were evaluated. In nearly one half of the patients (n = 264; 45.8%), CT depicted the presence of blood that was not associated with symptoms. Of the 660 patients, 21 (3.6%) showed a mass effect radiographically, 11 of whom underwent revision surgery. Arterial hypertension was documented in only 8 patients (1.3%) and was related to the revision surgery (P = 0.018). The overall revision rate was 2.7% (n = 18). All patients who had undergone revision for postoperative hematoma had presented with a new neurological deficit immediately before CT.
   CONCLUSION: Routine postoperative CT did not reveal 1 patient with a serious hematoma that would not have been identified by clinical examination. Patients could be transferred safely from the intensive care unit, if the weaning process and clinical observation findings were uneventful, without deterioration of neurological symptoms or consciousness.
C1 [Freyschlag, Christian F.; Gruber, Ricarda; Bauer, Marlies; Thome, Claudius] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
   [Grams, Astrid E.] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria.
RP Bauer, M (reprint author), Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
EM marlies.bauer@tirol-kliniken.at
RI Grams, Astrid/AAH-6325-2019
CR ALBERT FK, 1994, NEUROSURGERY, V34, P45, DOI 10.1097/00006123-199401000-00008
   Alkhalili K, 2018, WORLD NEUROSURG, V111, pE199, DOI 10.1016/j.wneu.2017.12.038
   Almohiy H, 2014, WORLD J RADIOL, V6, P1, DOI 10.4329/wjr.v6.i1.1
   Altieri R, 2018, J NEUROL SURG PART A, V79, P25, DOI 10.1055/s-0037-1599238
   Ayrian Eugenia, 2015, J Clin Med Res, V7, P731, DOI 10.14740/jocmr2256w
   Benveniste RJ, 2014, J NEURO-ONCOL, V118, P363, DOI 10.1007/s11060-014-1440-3
   Bette S, 2016, WORLD NEUROSURG, V91, P548, DOI 10.1016/j.wneu.2016.03.034
   Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
   Bruder N, 1999, ANESTH ANALG, V89, P674, DOI 10.1097/00000539-199909000-00027
   Fontes RBV, 2014, J NEUROSURG, V121, P307, DOI 10.3171/2014.4.JNS132429
   Gempt J, 2013, J NEUROSURG, V119, P1395, DOI 10.3171/2013.9.JNS13596
   Hamada N, 2017, INT J RADIAT BIOL, V93, P1024, DOI 10.1080/09553002.2016.1266407
   Hussain SA, 2001, BRIT J NEUROSURG, V15, P116
   HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85
   Khaldi A, 2010, J NEUROSURG, V113, P1021, DOI 10.3171/2009.11.JNS081048
   LESLIE JB, 1987, ANESTHESIOLOGY, V67, P413, DOI 10.1097/00000542-198709000-00023
   Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024
   Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581
   Nakaura T, 2016, NEURORADIOLOGY, V58, P245, DOI 10.1007/s00234-015-1631-4
   Olsen KS, 2002, J NEUROSURG ANESTH, V14, P171, DOI 10.1097/00008506-200207000-00001
   Ozdoba C, 2014, CLIN NEURORADIOL, V24, P23, DOI 10.1007/s00062-013-0263-5
   Pala A, 2016, WORLD NEUROSURG, V93, P191, DOI 10.1016/j.wneu.2016.04.120
   Royse CF, 2010, ANESTHESIOLOGY, V113, P892, DOI 10.1097/ALN.0b013e3181d960a9
   Schar RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153499
   Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3
   Vassilouthis J, 1999, BRIT J NEUROSURG, V13, P154, DOI 10.1080/02688699943916
   Wen L, 2016, ACTA NEUROCHIR, V158, P1447, DOI 10.1007/s00701-016-2883-4
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1426
EP E1431
DI 10.1016/j.wneu.2018.11.079
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100175
PM 30465965
DA 2020-05-12
ER

PT J
AU Fu, CH
   Wang, N
   Chen, B
   Wang, PL
   Chen, HY
   Liu, WW
   Liu, LJ
AF Fu, Chuhua
   Wang, Ning
   Chen, Bo
   Wang, Pingli
   Chen, Huayun
   Liu, Wangwang
   Liu, Lijun
TI Surgical Management of Moderate Basal Ganglia Intracerebral Hemorrhage:
   Comparison of Safety and Efficacy of Endoscopic Surgery, Minimally
   Invasive Puncture and Drainage, and Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Deep hematoma; Endoscopic surgery; Spontaneous
   intracerebral hemorrhage
ID INITIAL CONSERVATIVE TREATMENT; EVACUATION; MECHANISMS; EDEMA;
   HEMATOMAS; INJURY; STROKE; STICH
AB OBJECTIVE: To date, no standard surgical procedure has been proven effective for intracerebral hemorrhage (ICH), particularly deep hematomas. This retrospective study evaluated the effectiveness and safety of endoscopic surgery, minimally invasive puncture and drainage, and craniotomy for treating moderate basal ganglia ICH.
   METHODS: Patients with basal ganglia ICH (N = 177) were divided into 3 groups based on therapeutic intervention as follows: endoscopic surgery group (n = 61), minimally invasive puncture and drainage group (n = 60), and craniotomy group (n = 56). Patient characteristics at admission were recorded. Operative time; blood loss during operation; evacuation rate; postoperative complications secondary to perihematomal edema, including rebleeding, infectious meningitis, pulmonary infection, gastrointestinal bleeding, and epilepsy; mortality; and Glasgow Outcome Scale scores were compared among the 3 groups.
   RESULTS: Minimally invasive puncture and drainage was the least traumatic procedure and had the shortest operative time, but it could not remove the hematoma quickly; moreover, it had the highest rebleeding rate. Craniotomy was effective in removing the hematoma but resulted in marked trauma and had the highest incidence of pulmonary infection. Endoscopic surgery was safer and more effective than the other 2 surgical methods, with greater improvement in neurologic outcomes and no change in mortality.
   CONCLUSIONS: Minimally invasive neuroendoscopic management has the advantages of direct vision, efficient hematoma evacuation, and relatively good results. Endoscopic surgery may be a more promising approach for the treatment of moderate basal ganglia ICH.
C1 [Fu, Chuhua; Wang, Ning; Chen, Bo; Wang, Pingli; Chen, Huayun; Liu, Wangwang; Liu, Lijun] Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Neurosurg, Xiangyang, Peoples R China.
RP Liu, LJ (reprint author), Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Neurosurg, Xiangyang, Peoples R China.
EM 87848946@qq.com
CR Alexander LD, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-6
   Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839
   Beynon C, 2015, NEUROSURG REV, V38, P421, DOI 10.1007/s10143-015-0606-6
   Chambers IR, 2001, BRIT J NEUROSURG, V15, P140
   Dey M, 2014, NEUROSURGERY, V74, pS142, DOI 10.1227/NEU.0000000000000221
   Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451
   Eroglu U, 2018, WORLD NEUROSURG, V9, P261
   Fiorella D, 2016, CURR NEUROL NEUROSCI, V18, P34
   Garibi J, 2002, BRIT J NEUROSURG, V16, P355, DOI 10.1080/0268869021000007579
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Li ZH, 2017, NEUROPSYCH DIS TREAT, V13, P213, DOI 10.2147/NDT.S120368
   Longatti P, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.025
   Lopez VE, 2000, J NEUROL SCI, V174, P1
   Ma LC, 2017, WORLD NEUROSURG, V101, P57, DOI 10.1016/j.wneu.2017.01.072
   MAYER SA, 1994, NEUROLOGY, V44, P1379, DOI 10.1212/WNL.44.8.1379
   McCarron MO, 2001, NEW ENGL J MED, V345, P769
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   MENDELOW AD, 1993, STROKE, V24, pI115
   Miller CM, 2008, SURG NEUROL, V69, P441, DOI 10.1016/j.surneu.2007.12.016
   Morgenstern LB, 2001, NEUROLOGY, V56, P1294, DOI 10.1212/WNL.56.10.1294
   Mould WA, 2013, STROKE, V44, P627, DOI 10.1161/STROKEAHA.111.000411
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Rennert RC, 2015, EXPERT REV NEUROTHER, V15, P919, DOI 10.1586/14737175.2015.1059755
   Staykov D, 2011, STROKE, V42, P2625, DOI 10.1161/STROKEAHA.111.618611
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Wang WZ, 2017, CIRCULATION, V135, P759, DOI 10.1161/CIRCULATIONAHA.116.025250
   Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820
   Xu XH, 2014, STROKE, V45, P3433, DOI 10.1161/STROKEAHA.114.007095
   Yao Z, 2018, WORLD NEUROSURG, V113, P348, DOI 10.1016/j.wneu.2018.02.022
   Zhao Yi-Ning, 2016, Chronic Dis Transl Med, V2, P140, DOI 10.1016/j.cdtm.2016.11.002
NR 32
TC 3
Z9 3
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E995
EP E1001
DI 10.1016/j.wneu.2018.10.192
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100120
PM 30404051
DA 2020-05-12
ER

PT J
AU Gallazzi, E
   Cannavo, L
   Perrucchini, GG
   Morelli, I
   Luzzati, AD
   Zoccali, C
   Scotto, G
AF Gallazzi, Enrico
   Cannavo, Luca
   Perrucchini, Giuseppe G.
   Morelli, Ilaria
   Luzzati, Alessandro D.
   Zoccali, Carmine
   Scotto, Gennaro
TI Is the Posterior-Only Approach Sufficient for Treating Cervical Spine
   Metastases? The Evidence from a Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior approach; Cervical fixation; Cervical spine; Cord
   decompression; Metastasis; Oncology; Pain; Pedicle screws; Posterior
   approach; Spinal cord compression; Surgery
ID RETROSPECTIVE ANALYSIS; CORD COMPRESSION; DECOMPRESSION; SURGERY;
   LESIONS
AB OBJECTIVES:Few studies have evaluated surgical options in the treatment of cervical metastatic disease. The aim of this study is to report the surgical outcomes of patients treated with the posterior-only approach for metastatic cervical disease.
   METHODS:In this retrospective analysis, all cases treated in our institution from 2009 to 2017 were reviewed. Six (20%) patients had intracompartimental lesions (Tomita 1-3), whereas 24 (80%) patients had extracompartimental lesions (Tomita 4-7), with extensive anterior column involvement. All patients were surgically treated with laminectomy and posterior stabilization. Pain and neurologic function were evaluated before and after surgery.
   RESULTS:Thirty patients were included (15 female, 15 male), with a mean age of 60.6 +/- 11.56 years (range 35-82 years). Lesions were located in 7 patients (23.3%) in the upper cervical spine and in 14 patients (46.6%) and in 9 patients (30,1%) in the mid-cervical and in the cervicothoracic junction, respectively. At a mean follow up of 13.7 +/- 14.8 months, 15 (50%) patients died from their disease. Pain decreased in all patients after surgery, (preoperative NRS 5.57 +/- 1.81 postoperative Numeric Rating Scale of 2.1 +/- 1.0, P < 0.00001). Two patients (6.7%) had significant neurologic worsening after surgery. Two (6.9%) patients had surgical-site infection that required reintervention. No mechanical failures were observed.
   CONCLUSIONS:In our series, posterior-only fixation provided postoperative pain relief and achieve spinal stability, ultimately improving the quality of life. In conclusion, posterior-approach decompression and stabilization is a safe and feasible procedure in patients with neurologic or mechanical instability for cervical spine metastasis.
C1 [Gallazzi, Enrico; Cannavo, Luca; Perrucchini, Giuseppe G.; Morelli, Ilaria; Luzzati, Alessandro D.; Scotto, Gennaro] IRCCS Ist Ortoped Galeazzi, Dept Orthopaed Oncol & Spinal Reconstruct, Milan, Italy.
   [Zoccali, Carmine] Regina Elena Inst Canc Res, Oncol Orthoped, Rome, Italy.
RP Gallazzi, E (reprint author), IRCCS Ist Ortoped Galeazzi, Dept Orthopaed Oncol & Spinal Reconstruct, Milan, Italy.
EM enrico.gallazzi@gmail.com
RI Morelli, Ilaria/AAG-2428-2020; Zoccali, Carmine/K-6030-2016
OI Morelli, Ilaria/0000-0001-5719-0739; Gallazzi,
   Enrico/0000-0001-9287-9937; Zoccali, Carmine/0000-0001-8847-6772
CR ATANASIU JP, 1993, SPINE, V18, P1279, DOI 10.1097/00007632-199308000-00006
   Bartels RHMA, 2008, CA-CANCER J CLIN, V58, P245, DOI 10.3322/CA.2007.0016
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   DUNN E J, 1977, Spine, V2, P15, DOI 10.1097/00007632-197703000-00002
   Fan Y, 2016, EUR SPINE J, V25, P4060, DOI 10.1007/s00586-016-4406-7
   Fehlings MG, 2009, SPINE, V34, pS108, DOI 10.1097/BRS.0b013e3181bae1d2
   Fuentes S, 2007, NEUROCHIRURGIE, V53, P49, DOI 10.1016/j.neuchi.2007.04.001
   HALL DJ, 1991, SPINE, V16, pS80, DOI 10.1097/00007632-199103001-00013
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Ibrahim A, 2008, J NEUROSURG-SPINE, V8, P271, DOI 10.3171/SPI/2008/8/3/271
   Jenis LG, 1999, CLIN ORTHOP RELAT R, P89
   Jonsson B, 1994, Eur Spine J, V3, P76, DOI 10.1007/BF02221444
   Katagiri H, 2005, J BONE JOINT SURG BR, V87B, P698, DOI 10.1302/0301-620X.87B5.15185
   Lapresle P, 1991, Chirurgie, V117, P49
   Lei M, 2015, EJSO-EUR J SURG ONC, V41, P1691, DOI 10.1016/j.ejso.2015.09.025
   Mavrogenis AF, 2012, RADIOL MED, V117, P616, DOI 10.1007/s11547-011-0753-y
   Molina C, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16129
   Muhlbauer M, 2000, ACTA NEUROCHIR, V142, P1219, DOI 10.1007/s007010070018
   Nakamura M, 1996, J SPINAL DISORD, V9, P195
   Oda I, 2006, SPINE, V31, P1439, DOI 10.1097/01.brs.0000219952.40906.1f
   ONO K, 1975, J NEUROSURG, V42, P562, DOI 10.3171/jns.1975.42.5.0562
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Quan GM, 2011, J NEUROSURG-SPINE, V14, P612, DOI 10.3171/2011.1.SPINE10463
   RAO S, 1992, SPINE, V17, pS407, DOI 10.1097/00007632-199210001-00011
   Sciubba DM, 2010, SPINE J, V10, P63, DOI 10.1016/j.spinee.2009.10.004
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Yang J, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1085-0
NR 27
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E783
EP E789
DI 10.1016/j.wneu.2018.10.147
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100094
PM 30391608
DA 2020-05-12
ER

PT J
AU Gao, XL
   Yang, Y
   Liu, H
   Meng, Y
   Zeng, JF
   Wu, TK
   Hong, Y
AF Gao, Xinlin
   Yang, Yi
   Liu, Hao
   Meng, Yang
   Zeng, Junfeng
   Wu, Tingkui
   Hong, Ying
TI A Comparison of Cervical Disc Arthroplasty and Anterior Cervical
   Discectomy and Fusion in Patients with Two-Level Cervical Degenerative
   Disc Disease: 5-Year Follow-Up Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE 2-Level disc disease; Cervical arthrodesis; Cervical arthroplasty;
   Comparison; Prestige-LP disc replacement; ZERO-P Spacer
ID ADJACENT-SEGMENT DISEASE; SINGLE-LEVEL; ARTHRODESIS; REPLACEMENT;
   MYELOPATHY; RADICULOPATHY; ACDF
AB OBJECTIVE: To present a long-term clinical and radiographic comparison between the Prestige LP cervical disc replacement and the Zero-P spacer cervical disc fusion in the treatment of patients with symptomatic 2-level cervical degenerative disease.
   METHODS: In total, 36 patients in the anterior cervical discectomy and fusion (ACDF) group and 24 patients in the cervical disc arthroplasty (CDA) group were analyzed before surgery and at 1 week and 3, 6, 12, 24, and 60 months after surgery. Clinical assessments included the Japanese Orthopaedic Association score, visual analog scale, and Neck Disability Index scores. Radiographic assessments included cervical lordosis, range of motion (ROM) of the total cervical spine, functional spinal unit (FSU), and superior and inferior adjacent segments. Complications including heterotopic ossification and adjacent-segment degeneration (ASD) at 5-year follow-up were collected as well.
   RESULTS: Mean follow-up period was 65.6 months. Both the ACDF and CDA groups showed significant clinical improvements in terms of Japanese Orthopaedic Association score, visual analog scale, and Neck Disability Index (P < 0.05), but there was no significant difference between groups at the last follow-up period. A significant increase of cervical lordosis was observed in the CDA group after surgery whereas a significant difference was not observed between groups. ROM of the total cervical spine and FSU were maintained during the follow-up, and a significant decrease was observed in the ACDF group after surgery (P < 0.05). The ROM of the superior adjacent segment did not show any difference whereas the ROM of the inferior adjacent segment in the ACDF group presented a significant increase at 6 months and 1 year after surgery and a significant decrease at the last follow-up period. A total of 8 (33.3%) patients in the CDA group had an occurrence of heterotopic ossification. ASD was observed in 2 (8.3%) patients who underwent CDA surgery and 8 (22.2%) patients who underwent ACDF surgery.
   CONCLUSIONS: The use of the Prestige-LP and ZERO-P Spacer implantations is safe and effective. At 5 years after surgery, CDA with Prestige-LP is superior in terms of ROM of the total cervical spine, FSU, and inferior adjacent segment. It also has a relatively low occurrence rate of ASD. This procedure may be a suitable choice for the treatment of contiguous 2-level CDDD.
C1 [Gao, Xinlin; Yang, Yi; Liu, Hao; Meng, Yang; Zeng, Junfeng; Wu, Tingkui] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
   [Hong, Ying] Sichuan Univ, West China Hosp, Dept Operat Room, Chengdu, Sichuan, Peoples R China.
RP Liu, H (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
EM liuhao6304@126.com
RI Zeng, Junfeng/AAA-9707-2019
CR Ament JD, 2014, JAMA SURG, V149, P1231, DOI 10.1001/jamasurg.2014.716
   Anderson Paul A, 2004, Spine J, V4, p303S, DOI 10.1016/j.spinee.2004.07.026
   BOHLMAN HH, 1993, J BONE JOINT SURG AM, V75A, P1298, DOI 10.2106/00004623-199309000-00005
   Carette S, 2005, NEW ENGL J MED, V353, P192
   Chagas H, 2005, SURG NEUROL, V64, pS30, DOI 10.1016/j.surneu.2005.02.016
   Chen YY, 2015, EUR SPINE J, V24, P1666, DOI 10.1007/s00586-015-3919-9
   Cho SK, 2013, J AM ACAD ORTHOP SUR, V21, P3, DOI 10.5435/JAAOS-21-01-3
   Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003
   Ferch RD, 2004, J NEUROSURG, V100, P13, DOI 10.3171/spi.2004.100.1.0013
   Gandhi AA, 2015, SPINE, V40, P1578, DOI 10.1097/BRS.0000000000001044
   Gao FQ, 2015, SPINE, V40, P1816, DOI 10.1097/BRS.0000000000001138
   Goffin J, 2003, SPINE, V28, P2673, DOI 10.1097/01.BRS.0000099392.90849.AA
   Helgeson MD, 2013, SPINE J, V13, P342, DOI 10.1016/j.spinee.2012.12.009
   Hilibrand AS, 1997, SPINE, V22, P1574, DOI 10.1097/00007632-199707150-00009
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Hisey MS, 2015, J SPINAL DISORD TECH, V28, pE237, DOI 10.1097/BSD.0000000000000185
   Hui CFF, 2011, SPINE, V36, P1010, DOI 10.1097/BRS.0b013e318205c5f5
   Jawahar A, 2010, SPINE J, V10, P1043, DOI 10.1016/j.spinee.2010.08.014
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Katsuura A, 2001, EUR SPINE J, V10, P320, DOI 10.1007/s005860000243
   Kim SW, 2009, EUR SPINE J, V18, P218, DOI 10.1007/s00586-008-0854-z
   Lopez-Espina CG, 2006, SPINE, V31, P972, DOI 10.1097/01.brs.0000215205.66437.c3
   McAfee PC, 2003, J SPINAL DISORD TECH, V16, P384, DOI 10.1097/00024720-200308000-00010
   McAnany SJ, 2014, SPINE, V23, P1924
   Robertson JT, 2005, J NEUROSURG-SPINE, V3, P417, DOI 10.3171/spi.2005.3.6.0417
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Yin MC, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1274-6
NR 27
TC 2
Z9 2
U1 3
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1083
EP E1089
DI 10.1016/j.wneu.2018.10.231
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100133
PM 30415055
DA 2020-05-12
ER

PT J
AU Ge, L
   Arul, K
   Mesfin, A
AF Ge, Laurence
   Arul, Karan
   Mesfin, Addisu
TI Spinal Cord Injury From Spinal Tumors: Prevalence, Management, and
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cancer; Epidemiology; Management; Outcomes; Spinal cord injury; Spinal
   tumor; Spine
ID COMPRESSION; CANCER; COMPLICATIONS; POPULATION; SURGERY; METASTASIS;
   MORTALITY; DIAGNOSIS; SURVIVAL; IMPACT
AB BACKGROUND: With the aging population in the United States, it can be anticipated that the prevalence of spinal cord injuries (SCIs) and cancer will increase. Primary or metastatic spine tumors sit at a unique intersection of these 2 realms. Our objective was to evaluate the prevalence, outcomes, and complications after the management of SCI arising from spinal tumors.
   METHODS: In the present retrospective evaluation, all patients with SCI and a diagnosis of primary or metastatic spinal cancer who had been admitted to the inpatient rehabilitation unit at a level 1 trauma center from January 2003 to January 2014 were evaluated. The demographic data (age, sex, race/ethnicity), tumor characteristics, American Spinal Injury Association score, and complications were evaluated.
   RESULTS: A total of 757 SCI entries were identified, and 685 unique patients met our inclusion criteria. Of those, 81 had SCIs due to spinal tumors (11.8% of all SCIs and 19.2% of nontraumatic SCIs). Most tumors were located in the thoracic region (65.4%) and were primary central nervous system in origin (21.0%), including meningioma (7.4%), schwannoma (3.7%), and ependymoma (2.5%). The next most common origins of the spinal tumors were metastases from the lung (17.3%), prostate (9.9%), kidney (8.6%), lymphoma (7.4%), and multiple myeloma (7.4%). Of these patients, 76.5% underwent surgical management, with a complications rate of 61.3%. The overall mortality rate at the latest follow-up examination was 63.0%.
   CONCLUSIONS: SCI associated with spinal tumor is often managed surgically and associated with high rates of complications. The present study has demonstrated longer survival rates compared with the existing data.
C1 [Ge, Laurence; Arul, Karan; Mesfin, Addisu] Univ Rochester, Sch Med & Dent, Dept Orthopaed Surg, Rochester, NY 14627 USA.
RP Mesfin, A (reprint author), Univ Rochester, Sch Med & Dent, Dept Orthopaed Surg, Rochester, NY 14627 USA.
EM amesfin@gmail.com
OI Mesfin, Addisu/0000-0003-0076-4185
CR Carr J, 2008, REHABILITATION CANC, P99
   Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4
   Drudge-Coates L, 2008, INT J PALLIAT NURS, V14, P110, DOI 10.12968/ijpn.2008.14.3.28890
   Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593
   Etzioni DA, 2003, ANN SURG, V238, P170, DOI 10.1097/01.SLA.0000081085.98792.3d
   Furlan JC, 2009, J NEUROTRAUM, V26, P209, DOI 10.1089/neu.2008.0663
   Ge L, 2018, WORLD NEUROSURG, V111, pE411, DOI 10.1016/j.wneu.2017.12.008
   GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Heary RF, 2001, NEUROSURG FOCUS, V11, P1, DOI [10.3171/foc.2001.11.6.2, DOI 10.3171/FOC.2001.11.6.2]
   Helweg-Larsen S, 2000, INT J RADIAT ONCOL, V46, P1163, DOI 10.1016/S0360-3016(99)00333-8
   Hirano K, 2012, EUR SPINE J, V21, P2019, DOI 10.1007/s00586-012-2345-5
   Horn SR, 2018, J CLIN NEUROSCI, V53, P183, DOI 10.1016/j.jocn.2018.04.022
   Ikpeze TC, 2017, GERIATR ORTHOP SURG, V8, P115, DOI 10.1177/2151458517696680
   Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015
   Katagiri H, 1999, CANCER, V86, P533, DOI 10.1002/(SICI)1097-0142(19990801)86:3<533::AID-CNCR24>3.0.CO;2-1
   Laufer I, 2016, SPINE, V41, pS224, DOI 10.1097/BRS.0000000000001827
   MARANZANO E, 1991, CANCER, V67, P1311, DOI 10.1002/1097-0142(19910301)67:5<1311::AID-CNCR2820670507>3.0.CO;2-R
   Martin ND, 2011, J TRAUMA, V71, P380, DOI 10.1097/TA.0b013e318228221f
   McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P619, DOI 10.1016/S0003-9993(99)90162-4
   Mechtler LL, 2013, NEUROL CLIN, V31, P241, DOI 10.1016/j.ncl.2012.09.011
   Mesfin A, 2016, SPINE, V41, pS262, DOI 10.1097/BRS.0000000000001817
   Mesfin A, 2015, J AM ACAD ORTHOP SUR, V23, P38, DOI 10.5435/JAAOS-23-01-38
   Mesfin A, 2013, J BONE JOINT SURG AM, V95A, P1546, DOI 10.2106/JBJS.L.01730
   New PW, 2008, SPINAL CORD, V46, P406, DOI 10.1038/sj.sc.3102152
   Okafor R, 2016, GLOB SPINE J, V6, P207, DOI 10.1055/s-0035-1558655
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Quraishi NA, 2015, SPINE J, V15, P1738, DOI 10.1016/j.spinee.2015.03.040
   Rose PS, 2011, J AM ACAD ORTHOP SUR, V19, P37, DOI 10.5435/00124635-201101000-00005
   Schiff D, 1997, NEUROLOGY, V49, P452, DOI 10.1212/WNL.49.2.452
   Schuss P, 2020, NEUROSURG REV, V43, P211, DOI 10.1007/s10143-018-1032-3
   Stubblefield M, 2009, CANC REHABILITATION
   SUNDARESAN N, 1995, J CLIN ONCOL, V13, P2330, DOI 10.1200/JCO.1995.13.9.2330
   Tan M, 2011, J NEURO-ONCOL, V104, P233, DOI 10.1007/s11060-010-0464-6
   U.S. Cancer Statistics Working Group, 2014, US CANC STAT 1999 20
   Wilson JR, 2012, J NEUROSURG-SPINE, V17, P46, DOI 10.3171/2012.4.AOSPINE1246
   Yancik R, 1997, CANCER, V80, P1273, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4
NR 37
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1551
EP E1556
DI 10.1016/j.wneu.2018.11.099
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100190
PM 30471447
DA 2020-05-12
ER

PT J
AU Giovani, A
   Sandu, AM
   Petrescu, G
   Gorgan, RM
   Goel, A
AF Giovani, Andrei
   Sandu, Aurelia Mihaela
   Petrescu, George
   Gorgan, Radu Mircea
   Goel, Atul
TI Application of Microanastomosis Techniques in Vascular Neurosurgery
   Training and Innovation of Future Surgical Strategies for Giant
   Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anastomosis; Bypass; Cerebral aneurysm; Experimental model
ID MODEL; SIMULATION
AB BACKGROUND: With the development of endovascular neurosurgery, fewer patients have been requiring surgery, and those who do require surgery have more complex cases. Thus, neurosurgeons better trained in micro-neurosurgery and clipping skills are needed.
   METHODS: From 2014 to 2017, we built 296 aneurysms models from vessels harvested from chicken wings. The aneurysm models were created by anastomosing segments of arteries and veins with the same aneurysmal geometry and vascular relationships as in actual cases, using 3-dimensional computed tomography angiography. The models were injected with saline using a continuous infusion system, and different clipping techniques were attempted by different neurosurgeons. We have also described new technical solution for treatment of giant aneurysms, a surgical method that excludes them from flux using microsurgical endovascular bypass.
   RESULTS: We have described, in detail, the design for building middle cerebral artery, posterior communicating artery, anterior communicating artery, and basilar tip aneurysm models. All aneurysm models were patent, with no leakage points and with a good resemblance to the 3-dimensional computed tomography angiographic images that had served as the basis for the models. The aneurysm models were successfully clipped using different techniques. The neurosurgeons that trained on the aneurysm model before surgery found this experience useful.
   CONCLUSIONS: Aneurysm models respecting the real-case aneurysmal geometry provide a good training method for learning and preparing for surgery.
C1 [Giovani, Andrei; Sandu, Aurelia Mihaela; Petrescu, George; Gorgan, Radu Mircea] Emergency Clin Hosp Bagdasar Arseni, Dept Neurosurg, Bucharest, Romania.
   [Goel, Atul] King Edward Mem Hosp, Dept Neurosurg, Mumbai, India.
RP Giovani, A (reprint author), Emergency Clin Hosp Bagdasar Arseni, Dept Neurosurg, Bucharest, Romania.
EM giovani.andrei@gmail.com
OI Petrescu, George Emil Dragos/0000-0003-2651-3608
CR Abla AA, 2011, J NEUROSURG, V115, P1231, DOI 10.3171/2011.7.JNS102013
   Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   Aboud E, 2015, J NEUROSURG, V123, P1339, DOI 10.3171/2014.12.JNS141551
   Belykh E, 2016, J NEUROSURG, V125, P915, DOI 10.3171/2015.8.JNS151346
   Benet A, 2015, BIOMED RES INT, DOI 10.1155/2015/939387
   Guvencer M, 2007, TURK NEUROSURG, V17, P243
   Hino A, 2003, NEUROSURGERY, V52, P1495, DOI 10.1227/01.NEU.0000065174.83840.62
   Kimura T, 2009, NEUROSURGERY, V65, P719, DOI 10.1227/01.NEU.0000354350.88899.07
   Magaldi MO, 2014, OPER NEUROSURG, V10, P592, DOI 10.1227/NEU.0000000000000553
   Malone HR, 2010, NEUROSURGERY, V67, P1105, DOI 10.1227/NEU.0b013e3181ee46d0
   Mucke T, 2011, CENT EUR NEUROSURG, V72, P38, DOI 10.1055/s-0030-1249699
   Namba K, 2013, INTERV NEURORADIOL, V19, P153, DOI 10.1177/159101991301900202
   Olabe J, 2011, NEUROL INDIA, V59, P78, DOI 10.4103/0028-3886.76872
   Olabe J, 2009, SURG NEUROL, V72, P700, DOI 10.1016/j.surneu.2009.02.028
   Olabe J, 2009, SURG NEUROL, V72, P695, DOI 10.1016/j.surneu.2008.12.008
   de Oliveira MMR, 2018, J NEUROSURG, V128, P846, DOI 10.3171/2016.10.JNS162083
   Sarrami-Foroushani A, 2017, WIRES SYST BIOL MED, V9, DOI 10.1002/wsbm.1385
   Scholz M, 2008, MINIM INVAS NEUROSUR, V51, P76, DOI 10.1055/s-2008-1058088
   Yatomi K, 2012, J NEUROL SURG PART A, V73, P397, DOI 10.1055/s-0032-1322592
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1120
EP E1127
DI 10.1016/j.wneu.2018.10.239
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100137
PM 30439525
DA 2020-05-12
ER

PT J
AU Godzik, J
   Nayar, G
   Hunter, WD
   Tumialan, LM
AF Godzik, Jakub
   Nayar, Gautam
   Hunter, William D.
   Tumialan, Luis M.
TI Decreasing Radiation Emission in Minimally Invasive Spine Surgery Using
   Ultra-Low-Radiation Imaging with Image Enhancement: A Prospective Cohort
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lateral lumbar interbody fusion; Lateral transpsoas interbody fusion;
   Minimally invasive spine surgery; Occupational risk; Percutaneous screw;
   Radiation emission; Transforaminal interbody fusion
ID LUMBAR INTERBODY FUSION; EXPOSURE; FLUOROSCOPY; NAVIGATION
AB BACKGROUND: Visualization of the anatomy in minimally invasive surgery (MIS) of the spine is limited and dependent on radiographic imaging, leading to increased radiation exposure to patients and surgical staff. Ultra-low-radiation imaging (ULRI) with image enhancement is a novel technology that may reduce radiation in the operating room. The aim of this study was to compare radiation emission between standard-dose and ULRI fluoroscopy with image enhancement in patients undergoing MIS of the spine.
   METHODS: This study prospectively enrolled 60 consecutive patients who underwent lateral lumbar interbody fusion, lateral lumbar interbody fusion with percutaneous pedicle screws, or MIS transforaminal lumbar interbody fusion. Standard-dose fluoroscopy was used in 31 cases, and ULRI with image enhancement was used in 29 cases. All imaging emission and radiation doses were recorded.
   RESULTS: Radiation emission per level was significantly less with ULRI than with standard-dose fluoroscopy for lateral lumbar interbody fusion (36.4 mGy vs. 119.8 mGy, P < 0.001), per screw placed in lateral lumbar interbody fusion (15.4 mGy per screw vs. 47.1 mGy per screw, P < 0.001), and MIS transforaminal lumbar interbody fusion (24.4 mGy vs. 121.6 mGy, P = 0.003). These differences represented reductions in radiation emission of 69.6%, 67.3%, and 79.9%. Total radiation doses per case were also significantly decreased for the transpsoas approach by 68.8%, lateral lumbar interbody fusion with percutaneous pedicle screws by 65.8%, and MIS transforaminal lumbar interbody fusion by 81.0% (P ? 0.004).
   CONCLUSIONS :ULRI with image enhancement has the capacity to significantly decrease radiation emission in minimally invasive procedures without compromising visualization of anatomy or procedure safety.
C1 [Godzik, Jakub; Tumialan, Luis M.] Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Nayar, Gautam] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC USA.
   [Hunter, William D.] CaroMont Hlth Reg Med Ctr, Dept Neurosurg, Gastonia, NC USA.
   [Tumialan, Luis M.] HonorHealth, Spine Grp Arizona, Greenbaum Surg Specialty Hosp, Scottsdale, AZ 85260 USA.
RP Tumialan, LM (reprint author), Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurosurg, Phoenix, AZ 85013 USA.; Tumialan, LM (reprint author), HonorHealth, Spine Grp Arizona, Greenbaum Surg Specialty Hosp, Scottsdale, AZ 85260 USA.
EM Neuropub@barrowneuro.org
CR Bindal RK, 2008, J NEUROSURG-SPINE, V9, P570, DOI 10.3171/SPI.2008.4.08182
   Clark JC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13144
   Cohen Mervyn D, 2008, J Am Coll Radiol, V5, P205, DOI 10.1016/j.jacr.2007.09.014
   Commission USNR, STAND PROT RAD CO 20
   Drazin D, 2013, J CLIN NEUROSCI, V20, P1438, DOI 10.1016/j.jocn.2012.12.028
   Fraser J, 2010, MINIM INVAS NEUROSUR, V53, P184, DOI 10.1055/s-0030-1267926
   Joseph JR, 2016, J NEUROSURG-SPINE, V25, P339, DOI 10.3171/2016.2.SPINE151295
   Karikari Isaac O, 2016, Neurosurgery, V63 Suppl 1, P167, DOI 10.1227/01.neu.0000489736.23975.83
   Kim CW, 2008, SPINE J, V8, P584, DOI 10.1016/j.spinee.2006.12.012
   Mroz TE, 2011, J SPINAL DISORD TECH, V24, P264, DOI 10.1097/BSD.0b013e3181eed618
   Pass RH, 2015, CARDIOL YOUNG, V25, P963, DOI 10.1017/S1047951114001474
   Srinivasan D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.041
   Taher F, 2013, SPINE, V38, P1386, DOI 10.1097/BRS.0b013e31828705ad
   Tatsumi RL, 2012, INT J SPINE SURG, V6, P195, DOI 10.1016/j.ijsp.2012.09.001
   Tumialan LM, 2015, OPER NEUROSURG, V11, P537, DOI 10.1227/NEU.0000000000000960
   Vano E, 2013, J VASC INTERV RADIOL, V24, P197, DOI 10.1016/j.jvir.2012.10.016
   Wang JA, 2010, EUR SPINE J, V19, P1780, DOI 10.1007/s00586-010-1404-z
   Wang TY, 2017, SPINE, V42, P217, DOI 10.1097/BRS.0000000000001720
   Wu MH, 2017, SPINE J, V17, P1082, DOI 10.1016/j.spinee.2017.04.002
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P220, DOI 10.1016/j.wneu.2015.09.059
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E805
EP E811
DI 10.1016/j.wneu.2018.10.150
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100097
PM 30391598
DA 2020-05-12
ER

PT J
AU Grelat, M
   Gouteron, A
   Casillas, JM
   Orliac, B
   Beaurain, J
   Fournel, I
   Laroche, D
AF Grelat, Michael
   Gouteron, Anais
   Casillas, Jean-Marie
   Orliac, Baptiste
   Beaurain, Jacques
   Fournel, Isabelle
   Laroche, Davy
TI Walking Speed as an Alternative Measure of Functional Status in Patients
   with Lumbar Spinal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE 6-Minute walk test; Lumbar spinal stenosis; Walking perimeter; Walking
   speed
ID LOW-BACK-PAIN; 6-MINUTE WALK; FUSION SURGERY; GAIT; TREADMILL; CAPACITY;
   TESTS; DIAGNOSIS; PATTERNS
AB OBJECTIVE: The main objective was to compare estimated walking perimeter (WP) and actual WP during a free walking test (6-minute walk test [6MWT]) in patients with lumbar spinal stenosis (LSS). The second objective was to describe the correlation between measured gait parameters and functional parameters.
   METHODS: This was a single-center prospective study including 38 patients with symptomatic LSS (23 men, 15 women; mean age, 69.3 +/- 7.9 years). The intervention was the 6MWT. For the main outcome measure, patients were first asked to verbally estimate their WP. Then, WP was evaluated using a 6MWT at a self-selected speed. In the absence of need to stop, and if a distance of 500 m was not reached, the test was extended to this distance. Specific functional scores (Oswestry Disability Index and Quebec Back Pain Disability Scale) were recorded, and a quality of life questionnaire was completed.
   RESULTS: WP was estimated to be less than 500 m in 21 of 38 patients, but only 7 patients actually stopped walking before reaching 500 m. The median estimate error in these patients was 200 m (interquartile range, 65-250). The shorter the estimated distance was, the greater the estimation error (r = -0.63, P = 0.002). The average walking speed was slow. Functional parameters (Oswestry Disability Index and Quebec Back Pain Disability Scale) were weakly and inversely correlated with real WP (r = -0.44 and r = -0.31, respectively) and moderately inversely correlated with measured walking speed (r = -0.51, P <= 0.001 for both).
   CONCLUSIONS: Direct measurement of free walking speed should be considered as a valid functional assessment in current practice for patients with LSS instead of estimated WP. To assist therapeutic decision-making, the most relevant type of walking test (duration, distance, velocity) needs to be determined.
C1 [Grelat, Michael; Beaurain, Jacques] Univ Hosp Dijon, Neurosurg Dept, Dijon, France.
   [Grelat, Michael; Casillas, Jean-Marie; Laroche, Davy] Univ Hosp Dijon, CIC INSERM 1432, Technol Invest Platform, Dijon, France.
   [Gouteron, Anais; Casillas, Jean-Marie; Orliac, Baptiste; Laroche, Davy] Univ Burgundy Franche Comte, INSERM UMR 1093, Cognit Act & Sensorimotor Plast, Dijon, France.
   [Fournel, Isabelle] Dijon Univ Hosp, INSERM CIC 1432, Clin Epidemiol Unit, Dijon, France.
RP Grelat, M (reprint author), Univ Hosp Dijon, Neurosurg Dept, Dijon, France.; Grelat, M (reprint author), Univ Hosp Dijon, CIC INSERM 1432, Technol Invest Platform, Dijon, France.
EM michael.grelat@gmail.com
RI Laroche, Davy/K-4298-2015
OI Laroche, Davy/0000-0003-1599-4258
CR Al-Obaidi SM, 2003, INT J REHABIL RES, V26, P101, DOI 10.1097/00004356-200306000-00004
   BARD G, 1959, Arch Phys Med Rehabil, V40, P415
   Barz T, 2008, EUR SPINE J, V17, P686, DOI 10.1007/s00586-008-0593-1
   Casillas J. -M., 2013, Annals of Physical and Rehabilitation Medicine, V56, P561, DOI 10.1016/j.rehab.2013.09.003
   Chiarotto A, 2015, EUR SPINE J, V24, P1127, DOI 10.1007/s00586-015-3892-3
   Conrad BP, 2013, GAIT POSTURE, V38, P987, DOI 10.1016/j.gaitpost.2013.05.010
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   de Graaf I, 2006, SPINE, V31, P1168, DOI 10.1097/01.brs.0000216463.32136.7b
   Deyo RA, 2005, SPINE, V30, P1441, DOI 10.1097/01.brs.0000166503.37969.8a
   Fairbank J C, 1980, Physiotherapy, V66, P271
   Felix ZF, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-89
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Fritz S, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932020-00002
   Genevay S, 2010, SPINE, V35, P803, DOI 10.1097/BRS.0b013e3181bc9454
   Giantomaso T, 2003, CLIN REHABIL, V17, P394, DOI 10.1191/0269215503cr626oa
   GUYATT GH, 1985, CAN MED ASSOC J, V132, P919
   Harada ND, 1999, ARCH PHYS MED REHAB, V80, P837, DOI 10.1016/S0003-9993(99)90236-8
   HARDING VR, 1994, PAIN, V58, P367, DOI 10.1016/0304-3959(94)90131-7
   HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003
   Henchoz Y, 2015, EUR J APPL PHYSIOL, V115, P2433, DOI 10.1007/s00421-015-3227-4
   Katz JN, 2008, NEW ENGL J MED, V358, P818, DOI 10.1056/NEJMcp0708097
   KEEFE FJ, 1985, PAIN, V21, P153, DOI 10.1016/0304-3959(85)90285-4
   KOPEC JA, 1995, SPINE, V20, P341, DOI 10.1097/00007632-199502000-00016
   Kreiner DS, 2013, SPINE J, V13, P734, DOI 10.1016/j.spinee.2012.11.059
   Lenssen AF, 2010, EUR J CARDIOV PREV R, V17, P713, DOI 10.1097/HJR.0b013e32833a1963
   Lurie J, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6234
   Martinelli T A, 1992, Instr Course Lect, V41, P179
   Okoro T, 2010, EUR SPINE J, V19, P279, DOI 10.1007/s00586-009-1152-0
   Purser JL, 2005, J REHABIL RES DEV, V42, P535, DOI 10.1682/JRRD.2004.07.0087
   Rainville J, 2012, SPINE J, V12, P101, DOI 10.1016/j.spinee.2011.12.006
   Schizas C, 2010, SPINE, V35, P1919, DOI 10.1097/BRS.0b013e3181d359bd
   Shnayderman I, 2013, CLIN REHABIL, V27, P207, DOI 10.1177/0269215512453353
   Shumway-Cook A, 2007, J AM GERIATR SOC, V55, P58, DOI 10.1111/j.1532-5415.2006.00962.x
   Smuck M, 2018, SPINE J, V18, P15, DOI 10.1016/j.spinee.2017.08.262
   Solway S, 2001, CHEST, V119, P256, DOI 10.1378/chest.119.1.256
   Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923
   Suda Y, 2002, SPINE, V27, P2509, DOI 10.1097/00007632-200211150-00016
   Takahashi K, 1995, SPINE, V20, P2746, DOI 10.1097/00007632-199512150-00017
   Tomkins CC, 2009, SPINE, V34, P2444, DOI 10.1097/BRS.0b013e3181b03fc8
   Tomkins-Lane CC, 2010, SPINE, V35, P2097, DOI 10.1097/BRS.0b013e3181f5e13b
   Toosizadeh N, 2015, CLIN BIOMECH, V30, P528, DOI 10.1016/j.clinbiomech.2015.04.005
   VERBIEST H, 1954, J BONE JOINT SURG BR, V36, P230
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Watson CJE, 1997, EUR J VASC ENDOVASC, V14, P299, DOI 10.1016/S1078-5884(97)80242-0
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E591
EP E597
DI 10.1016/j.wneu.2018.10.109
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100072
PM 31108075
DA 2020-05-12
ER

PT J
AU Grewal, SS
   Alvi, MA
   Lu, VM
   Wahood, W
   Worrell, GA
   Tatum, W
   Wharen, RE
   Van Gompel, JJ
AF Grewal, Sanjeet S.
   Alvi, Mohammed Ali
   Lu, Victor M.
   Wahood, Waseem
   Worrell, Gregory A.
   Tatum, William
   Wharen, Robert E., Jr.
   Van Gompel, Jamie J.
TI Magnetic Resonance-Guided Laser Interstitial Thermal Therapy Versus
   Stereotactic Radiosurgery for Medically Intractable Temporal Lobe
   Epilepsy: A Systematic Review and Meta-Analysis of Seizure Outcomes and
   Complications
SO WORLD NEUROSURGERY
LA English
DT Review
DE Epilepsy; Epilepsy surgery; Gamma-knife; Magnetic resonance-guided laser
   interstitial thermal therapy; Minimally invasive; MRgLITT; SRS;
   Stereotactic radiosurgery; Temporal lobe epilepsy; TLE
ID GAMMA-KNIFE RADIOSURGERY; SURGERY OUTCOMES; ABLATION; PREDICTORS;
   LOBECTOMY; AMYGDALOHIPPOCAMPOTOMY; EFFICACY; MEMORY; TRIAL; TIME
AB INTRODUCTION: Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) and stereotactic radiosurgery (SRS) are 2 emerging minimally invasive procedures being increasingly used for surgical intervention in cases of medically intractable temporal lobe epilepsy (TLE). To date, no comparative analyses of these 2 procedures have been made. In the current study, we synthesized pooled data from existing studies in an attempt to present a systematic review and meta-analysis of seizure and clinical outcomes of the 2 procedures in patients with TLE.
   METHODS: The Population, Intervention, Comparator, and Outcome (PICO) approach and Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to perform an indirect meta-analysis of seizure and clinical outcomes between MRgLITT and SRS. Only studies reporting outcomes for patients with TLE were included in the current review.
   RESULTS: A total of 19 studies were included in the final analysis, giving a total of 415 TLE patients. Of those studies, 9 were on MRgLITT, with a total of 250 patients (60%), and 10 were on SRS, with a total of 165 patients (40%). We found that the overall seizure freedom rate was comparable between the 2 procedures (MRgLITT 50%, 95% confidence interval [CI] 44% to 56%, vs. SRS 42%, 95% CI 27% to 59%, P = 0.39). Similarly, among patients with lesional pathologic conditions only, the seizure freedom rate was comparable between the 2 procedures (MRgLITT 62%, 95% CI 48% to 74%, vs. SRS 50%, 95% CI 37% to 64%, P = 0.23). Compared with SRS, MRgLITT was associated with lower complication rates (MRgLITT 20%, 95% CI 14% to 26% vs. SRS 32%, 95% CI 20% to 46%, P = 0.06) but similar reoperation rates (15%, 95% CI 9% to 22% vs. 27%, 95% CI 12% to 46%, P = 0.31).
   CONCLUSIONS: As minimally invasive procedures continue to gain popularity for use in surgery for epilepsy, it is imperative to evaluate their efficacy and safety outcomes. In this study we pooled the data from existing studies to compare the seizure and clinical outcomes in patients with TLE undergoing MRgLITT and SRS. We found similar outcomes and complications between the 2 procedures.
C1 [Grewal, Sanjeet S.; Wahood, Waseem; Wharen, Robert E., Jr.; Van Gompel, Jamie J.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
   [Tatum, William] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
   [Alvi, Mohammed Ali] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
   [Worrell, Gregory A.] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Lu, Victor M.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia.
RP Van Gompel, JJ (reprint author), Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
EM vangompel.jamie@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Grewal,
   Sanjeet/0000-0002-4307-7062; Wahood, Waseem/0000-0002-2963-4096
CR Barbaro NM, 2018, EPILEPSIA, V59, P1198, DOI 10.1111/epi.14045
   Barbaro NM, 2009, ANN NEUROL, V65, P167, DOI 10.1002/ana.21558
   Bartolomei F, 1999, CLIN NEUROPHYSIOL, V110, P1741, DOI 10.1016/S1388-2457(99)00107-8
   Bell ML, 2009, EPILEPSIA, V50, P2053, DOI 10.1111/j.1528-1167.2009.02079.x
   Berger H, 1929, ARCH PSYCHIAT NERVEN, V87, P527, DOI 10.1007/BF01797193
   BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358
   Bien CG, 2009, ARCH NEUROL-CHICAGO, V66, P1491, DOI 10.1001/archneurol.2009.283
   Curry DJ, 2012, EPILEPSY BEHAV, V24, P408, DOI 10.1016/j.yebeh.2012.04.135
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Donos C, 2018, EPILEPSIA, V59, P1421, DOI 10.1111/epi.14443
   Drane DL, 2015, EPILEPSIA, V56, P101, DOI 10.1111/epi.12860
   Dredla BK, 2016, EPILEPSY BEHAV, V56, P44, DOI 10.1016/j.yebeh.2015.12.047
   Engel J, 1998, EPILEPSIA, V39, P1014, DOI 10.1111/j.1528-1157.1998.tb01453.x
   Fong JS, 2011, EPILEPSIA, V52, P1393, DOI 10.1111/j.1528-1167.2011.03091.x
   Georgiadis Iordanis, 2013, Epilepsy Res Treat, V2013, P752195, DOI 10.1155/2013/752195
   Grewal SS, 2018, EPILEPSY RES, V141, P19, DOI 10.1016/j.eplepsyres.2018.01.021
   Gross RE, 2018, ANN NEUROL, V83, P575, DOI 10.1002/ana.25180
   Hoggard N, 2008, NEUROSURGERY, V62, P336, DOI 10.1227/01.neu.0000316000.96140.12
   Immonen A, 2010, EPILEPSIA, V51, P2260, DOI 10.1111/j.1528-1167.2010.02720.x
   Jeha LE, 2006, NEUROLOGY, V66, P1938, DOI 10.1212/01.wnl.0000219810.71010.9b
   Jermakowicz WJ, 2017, EPILEPSIA, V58, P801, DOI 10.1111/epi.13715
   Kang JY, 2016, EPILEPSIA, V57, P325, DOI 10.1111/epi.13284
   Kawamura T, 2012, NEUROL MED-CHIR, V52, P892, DOI 10.2176/nmc.52.892
   Lagman C, 2017, J CLIN NEUROSCI, V36, P20, DOI 10.1016/j.jocn.2016.10.019
   LaRiviere MJ, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00064
   Liang SL, 2010, EPILEPSY RES, V90, P60, DOI 10.1016/j.eplepsyres.2010.03.008
   Mathon B, 2015, REV NEUROL-FRANCE, V171, P315, DOI 10.1016/j.neurol.2015.01.561
   McGonigal A, 2017, EPILEPSY RES, V137, P123, DOI 10.1016/j.eplepsyres.2017.08.016
   PENFIELD W, 1954, BRIT J SURG, V41, P337, DOI 10.1002/bjs.18004116802
   PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001
   PENFIELD W, 1950, AMA ARCH NEUROL PSY, V64, P491, DOI 10.1001/archneurpsyc.1950.02310280003001
   PENFIELD W, 1952, ANN SURG, V136, P625
   Quigg M, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2011.03339.x
   Radhakrishnan K, 1998, NEUROLOGY, V51, P465, DOI 10.1212/WNL.51.2.465
   Regis J, 2017, EPILEPSIA, V58, P60, DOI 10.1111/epi.13754
   Regis J, 2010, J NEURO-ONCOL, V98, P155, DOI 10.1007/s11060-010-0226-5
   Rheims S, 2008, EPILEPSY RES, V80, P23, DOI 10.1016/j.eplepsyres.2008.03.003
   SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256
   Shukla ND, 2017, NEUROPSYCH DIS TREAT, V13, P2469, DOI 10.2147/NDT.S139544
   Srikijvilaikul T, 2004, NEUROSURGERY, V54, P1395, DOI 10.1227/01.NEU.0000124604.29767.EB
   Tao JX, 2018, J NEUROL NEUROSUR PS, V89, P542, DOI 10.1136/jnnp-2017-316833
   Usami K, 2012, J NEUROSURG, V116, P1221, DOI 10.3171/2012.2.JNS111296
   Vakharia VN, 2018, EPILEPSIA, V59, P814, DOI 10.1111/epi.14034
   Vojtech Z, 2009, EPILEPSIA, V50, P2061, DOI 10.1111/j.1528-1167.2009.02071.x
   Wang XQ, 2017, EUR REV MED PHARMACO, V21, P1774
   Waseem H, 2017, J CLIN NEUROSCI, V38, P1, DOI 10.1016/j.jocn.2016.12.002
   Wells G, 2015, COHORT STUDIES
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Wieshmann UC, 2008, ACTA NEUROL SCAND, V118, P306, DOI 10.1111/j.1600-0404.2008.01043.x
   Willie JT, 2014, NEUROSURGERY, V74, P569, DOI 10.1227/NEU.0000000000000343
   Youngerman BE, 2018, EPILEPSIA, V59, P595, DOI 10.1111/epi.14004
NR 53
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E32
EP E47
DI 10.1016/j.wneu.2018.08.227
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100005
PM 30244184
DA 2020-05-12
ER

PT J
AU Griffin, A
   Chaparro, E
   Fedorova, E
   Holmes, C
   Manson, RJ
   Hauck, EF
AF Griffin, Andrew
   Chaparro, Eduardo
   Fedorova, Ekaterina
   Holmes, Christie
   Manson, Roberto J.
   Hauck, Erik F.
TI Thromboembolic Events with Enterprise Versus Pipeline: Porcine In Vivo
   Experiment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid stent; Cerebral aneurysm; Enterprise stent; Flow diversion;
   Pipeline stent
ID ENDOVASCULAR EMBOLIZATION; FLOW DIVERTORS
AB BACKGROUND: Thromboembolic complications are serious adverse events associated with stenting of intracranial aneurysms. For the development of novel devices, currently no practical model exists to evaluate distal embolic events. The purpose of the current study was 2-fold: 1) assess the feasibility of a porcine carotid bifurcation model for in vivo testing of stent thrombogenicity and 2) compare the thrombogenicity of the Enterprise vascular reconstruction device versus the Pipeline embolization device (PED).
   METHODS: Six Yorkshire pigs underwent implantation of size-matched devices across the carotid bifurcation. Each animal received 1 Enterprise and 1 PED contralaterally. Baseline and 2-week follow-up angiography were performed. Images were analyzed including detailed measurements of the rete mirabile, a small-vessel conglomerate supplied by branches of the common carotid artery.
   RESULTS: In the absence of thromboembolic events at 2 weeks (n = 8), the perfused rete area measured 134.4 +/- 6.9 mm(2). In the presence of thromboembolic events (n = 4), the perfused rete was reduced to an area covering 37.1 +/- 8.6 mm(2) (P < 0.01). There was no difference in thrombogenicity between Enterprise and PED with a thromboembolic event rate of 33.3% for both devices (P > 0.99).
   CONCLUSION: The swine carotid stent model allows in vivo analysis of device-related thrombogenicity and distal embolic event rates. Size reduction of the perfused rete mirabile indicates the presence of thromboembolic events. Both Enterprise and PED were associated with similar thrombogenicity in this experiment.
C1 [Griffin, Andrew; Chaparro, Eduardo; Fedorova, Ekaterina; Hauck, Erik F.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
   [Holmes, Christie; Manson, Roberto J.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
RP Griffin, A (reprint author), Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
EM asg32@duke.edu
OI Griffin, Andrew/0000-0003-3266-1359
CR Ahlhelm F, 2009, CARDIOVASC INTER RAD, V32, P1019, DOI 10.1007/s00270-009-9572-0
   Arakawa H, 2007, AM J NEURORADIOL, V28, P1191, DOI 10.3174/ajnr.A0536
   Becker TA, 2002, NEUROSURGERY, V51, P453, DOI 10.1097/00006123-200208000-00028
   Chen YN, 2009, BLOOD CELL MOL DIS, V43, P111, DOI 10.1016/j.bcmd.2009.02.004
   Fiorella D, 2010, J NEUROINTERV SURG, V2, P16, DOI 10.1136/jnis.2009.000521
   Hagen MW, 2017, J NEUROINTERV SURG, V9, P1006, DOI 10.1136/neurintsurg-2016-012612
   Hauck EF, 2009, SURG NEUROL, V71, P19, DOI 10.1016/j.surneu.2008.01.025
   Jeewandara TM, 2014, MATERIALS, V7, P769, DOI 10.3390/ma7020769
   Jiang XB, 2013, J NEUROINTERV SURG, V5, P473, DOI 10.1136/neurintsurg-2012-010401
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Matsuda Y, 2018, J NEUROINTERV SURG, V10, P162, DOI 10.1136/neurintsurg-2016-012969
   Moravej M, 2011, INT J MOL SCI, V12, P4250, DOI 10.3390/ijms12074250
   ReverdiauMoalic P, 1996, TRANSPLANT P, V28, P643
   Shapiro M, 2012, AM J NEURORADIOL, V33, P159, DOI 10.3174/ajnr.A2719
   Vollherbst DF, 2018, J NEUROINTERV SURG, V10, P268, DOI 10.1136/neurintsurg-2017-013144
   Zhang F., 2012, SPRINGER PROTOCOLS H, V2, P93
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1405
EP E1411
DI 10.1016/j.wneu.2018.11.073
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100172
PM 30468928
DA 2020-05-12
ER

PT J
AU Gui, SB
   Meng, GL
   Xiao, XR
   Wu, Z
   Zhang, JT
AF Gui, Songbai
   Meng, Guolu
   Xiao, Xinru
   Wu, Zhen
   Zhang, Junting
TI Surgical Management of Brainstem Cavernous Malformation: Report of 67
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brainstem; Cavernous malformation; Surgical approach; Surgical technique
ID RESECTION; SERIES
AB BACKGROUND: Brainstem cavernous malformations (CMs) are benign lesions, often show an acute onset, and result in a high rate of morbidity. Surgical resection could inhibit the progressive deterioration of neurologic function caused by repetitive hemorrhage. This study aimed to summarize timing, approaches, and techniques of surgery and to evaluate outcomes of treatment.
   METHODS: Between March 2011 and May 2013, 67 patients (32 male, 35 female; average age 40 years; range, 14-68 years) with brainstem CMs received surgical treatment. Clinical presentation, surgical approaches, and results of follow-up were retrospectively analyzed.
   RESULTS: Seven surgical approaches were used: orbitozygomatic approach (1 case), suboccipital transtentorial approach (Poppen approach; 3 cases), subtemporal transtentorial approach (32 cases), subtemporal transtentorial/anterior petrosectomy approach (9 cases), suboccipital retrosigmoid approach (3 cases), midline suboccipital approach (16 cases), and far lateral approach (3 cases). Total resection of the brainstem CM was achieved in all cases (100%). No operative mortality was encountered. Nine patients had new symptoms after surgery: 3 had diplopia, 3 had facial numbness, 1 had numbness of contralateral limbs, 1 had transient aphasia, and 1 had reduced muscle strength of contralateral limbs. Symptoms significantly improved in 23 patients (34.3%), symptoms were unchanged in 36 patients (53.7%), and new postoperative symptoms occurred in 9 patients (13.4%).
   CONCLUSIONS: Choosing a proper surgical approach and using appropriate techniques are fundamental for favorable outcomes of patients with brainstem CMs.
C1 [Gui, Songbai; Meng, Guolu; Xiao, Xinru; Wu, Zhen; Zhang, Junting] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Zhang, JT (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM zhangjunting2003@aliyun.com
OI KANG, JIE/0000-0002-2079-6742
CR Abla AA, 2011, NEUROSURGERY, V68, P403, DOI 10.1227/NEU.0b013e3181ff9cde
   Abla AA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10128
   Brown AP, 1996, BNI Q, V12, P20
   Chen LH, 2014, CLIN NEUROL NEUROSUR, V116, P72, DOI 10.1016/j.clineuro.2013.10.012
   Chen LA, 2011, NEUROSURGERY, V68, P609, DOI 10.1227/NEU.0b013e3182077531
   Francois P, 2010, ACTA NEUROCHIR, V152, P1321, DOI 10.1007/s00701-010-0667-9
   FRITSCHI JA, 1994, ACTA NEUROCHIR, V130, P35, DOI 10.1007/BF01405501
   Giliberto G, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10133
   Gross BA, 2013, WORLD NEUROSURG, V80, P89, DOI 10.1016/j.wneu.2012.04.002
   Hauck EF, 2009, NEUROSURGERY, V64, P61, DOI 10.1227/01.NEU.0000335158.11692.53
   Kin T, 2012, J NEUROSURG, V117, P78, DOI 10.3171/2012.3.JNS111541
   Li D, 2014, J NEUROSURG-PEDIATR, V13, P484, DOI 10.3171/2014.2.PEDS13536
   Li D, 2013, J NEUROSURG, V119, P996, DOI 10.3171/2013.7.JNS13462
   Mathiesen T, 2003, J NEUROSURG, V99, P31, DOI 10.3171/jns.2003.99.1.0031
   Pandey P, 2013, NEUROSURGERY, V72, P573, DOI 10.1227/NEU.0b013e318283c9c2
   Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050
   Ramina R, 2011, NEUROL SCI, V32, P1013, DOI 10.1007/s10072-011-0477-8
   RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605
   Sabatino G, 2012, ACTA NEUROCHIR, V154, P2009, DOI 10.1007/s00701-012-1496-9
   Samii M, 2001, J NEUROSURG, V95, P825, DOI 10.3171/jns.2001.95.5.0825
   Sandalcioglu IE, 2002, J NEUROL NEUROSUR PS, V72, P351, DOI 10.1136/jnnp.72.3.351
   Steno J, 2011, ACTA NEUROCHIR, V153, P1955, DOI 10.1007/s00701-011-1123-1
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1162
EP E1171
DI 10.1016/j.wneu.2018.11.008
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100142
PM 30447450
DA 2020-05-12
ER

PT J
AU Harrison, JD
   Seymann, G
   Imershein, S
   Amin, A
   Afsarmanesh, N
   Uppington, J
   Aledia, A
   Pretanvil, S
   Wilson, B
   Wong, J
   Varma, J
   Boggan, J
   Hsu, FPK
   Carter, B
   Martin, N
   Berger, M
   Lau, CY
AF Harrison, James D.
   Seymann, Gregory
   Imershein, Sarah
   Amin, Alpesh
   Afsarmanesh, Nasim
   Uppington, Jeffrey
   Aledia, Anna
   Pretanvil, Sarah
   Wilson, Bridget
   Wong, Josefina
   Varma, Jennifer
   Boggan, James
   Hsu, Frank P. K.
   Carter, Bob
   Martin, Neil
   Berger, Mitchel
   Lau, Catherine Y.
TI The Impact of Unmet Communication and Education Needs on Neurosurgical
   Patient and Caregiver Experiences of Care: A Qualitative Exploratory
   Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Communication; Comprehension; Needs assessment; Neurosurgery; Patient
   education; Qualitative research
ID QUESTION PROMPT LIST; INFORMATION PROVISION; INFORMED-CONSENT;
   CANCER-PATIENTS; INTERVENTIONS; EXPECTATIONS; SERVICES; IMPROVE; HELP
AB OBJECTIVE: To describe neurosurgical patient and caregiver perceptions of provider communication, the impact of patient education, and their understanding of information given to them throughout the neurosurgical care trajectory.
   METHODS: We organized focus groups composed of patients who had been hospitalized on the neurosurgical service at 5 urban academic tertiary referral hospitals within a large university health system, along with the patients' caregivers. During focus groups, we used semistructured questions to answer the study questions. Content analysis was used to analyze the data.
   RESULTS: Forty-three patients and caregivers took part in 5 focus groups. In total we identified 12 coding categories (or topics) that were associated with patient and family information needs. Despite the fact all patients were receiving care within the same health system, often with the same care team and clinical environments, their experiences often could not have been more different. We found stark variations in how patients and caregivers described the quality of communication and patient education they received that affected their satisfaction. Satisfied patients and caregivers generally felt well informed and reported good understanding of the clinical care plan throughout the perioperative course, whereas dissatisfied patients struggled with unanswered questions, unmet information needs, and a sense of confusion throughout their care experience.
   CONCLUSIONS: Our study describes several unmet needs, finds inconsistencies in how information is delivered and a lack of patient-centered and caregiver-centered approaches to communication. Neurosurgery groups should identify unmet needs at their institution and implement strategies and interventions to improve the patient and caregiver experience.
C1 [Harrison, James D.; Imershein, Sarah; Lau, Catherine Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Seymann, Gregory; Pretanvil, Sarah] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Amin, Alpesh; Aledia, Anna] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA.
   [Afsarmanesh, Nasim] Univ Calif Irvine Hlth, Irvine, CA USA.
   [Uppington, Jeffrey] Univ Calif Davis, Dept Anesthesia, Sacramento, CA 95817 USA.
   [Wilson, Bridget] Univ Calif Davis, Dept Obstet & Gynecol, Sacramento, CA 95817 USA.
   [Wong, Josefina] UC Davis Hlth, CTSC Clin Trials Ctr, Sacramento, CA USA.
   [Varma, Jennifer] Univ Calif Los Angeles, UCLA Neurosurg, Los Angeles, CA USA.
   [Boggan, James] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA.
   [Hsu, Frank P. K.] Univ Calif Irvine, Dept Neurol Surg, Irvine, CA USA.
   [Hsu, Frank P. K.] Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA USA.
   [Carter, Bob] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA.
   [Martin, Neil] Geisinger, Neurosci Inst, Danville, PA USA.
   [Berger, Mitchel] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
RP Harrison, JD (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM james.harrison@ucsf.edu
FU University of California Office of the President (UCOP), Center for
   Health Quality and Innovation Quality Enterprise Risk Management
   (CHQICIERM)
FX This study was grant funded by the University of California Office of
   the President (UCOP), Center for Health Quality and Innovation Quality
   Enterprise Risk Management (CHQICIERM).
CR Agarwal N, 2013, J CLIN NEUROSCI, V20, P1357, DOI 10.1016/j.jocn.2012.10.047
   Agency for Healthcare Quality & Research, HLTH LITERACY UNIVER
   American College of Surgeons, 2018, NEW APPR SURG MEAS P
   Arora VM, 2009, JT COMM J QUAL PATIE, V35, P613, DOI 10.1016/S1553-7250(09)35086-2
   Badiru A. B., 2013, J ENTERPRISE TRANSFO, V3, P1
   Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x
   Bramall AN, 2014, CAN J NEUROL SCI, V41, P66, DOI 10.1017/S0317167100016280
   Brandes K, 2015, PSYCHO-ONCOLOGY, V24, P245, DOI 10.1002/pon.3637
   Clayton JM, 2007, J CLIN ONCOL, V25, P715, DOI 10.1200/JCO.2006.06.7827
   Corbin J., 2008, BASICS QUALITATIVE R
   Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x
   Gottenborg E., 2014, FACE CARDS IMPROVE P
   Grawe JS, 2010, SCHMERZ, V24, P575, DOI 10.1007/s00482-010-0994-z
   Harrison JD, 2009, SUPPORT CARE CANCER, V17, P1117, DOI 10.1007/s00520-009-0615-5
   Kalogianni A, 2016, EUR J CARDIOVASC NUR, V15, P447, DOI 10.1177/1474515115602678
   Khabarov D, 2015, HEALTH SOC WORK, V40, P290, DOI 10.1093/hsw/hlv057
   Khan A, 2014, BMJ QUAL IMPROV REP, V3
   Kliot Tamara, 2015, Surg Neurol Int, V6, pS567, DOI 10.4103/2152-7806.169538
   Kolcun JPG, 2018, WORLD NEUROSURG, V109, P416, DOI 10.1016/j.wneu.2017.11.027
   Langbecker D, 2013, EUR J CANCER CARE, V22, P179, DOI 10.1111/ecc.12011
   Langbecker D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00001
   Lavrakas P., 2008, ENCY SURVEY RES METH
   Liamputtong P., 2011, FOCUS GROUP METHODOL
   McJannett M, 2003, EUR J CANCER PREV, V12, P397, DOI 10.1097/00008469-200310000-00009
   Monash B, 2017, J HOSP MED, V12, P143, DOI 10.12788/jhm.2694
   Park J, 2017, J KOREAN NEUROSURG S, V60, P385, DOI 10.3340/jkns.2017.0101.007
   Raju B, 2017, J NEUROSCI RURAL PRA, V8, P114, DOI 10.4103/0976-3147.193551
   Reiter K, 2014, ASSOC OPER ROOM NURS, V99, P376, DOI 10.1016/j.aorn.2014.01.008
   Rozmovits L, 2010, J NEURO-ONCOL, V96, P241, DOI 10.1007/s11060-009-9955-8
   Ryu JH, 2016, SPINE, V41, pE561, DOI 10.1097/BRS.0000000000001321
   Sahyouni R, 2017, NEUROSURGERY, V81, P787, DOI 10.1093/neuros/nyx095
   Sahyouni R, 2017, WORLD NEUROSURG, V107, P87, DOI [10.1016/J.WNEU.2017.07.118, 10.1016/j.wneu.2017.07.118]
   Scarrow AM, 2002, SURG NEUROL, V57, P63, DOI 10.1016/S0090-3019(01)00567-5
   Schreier M., 2012, QUALITATIVE CONTENT
   Schroeder J, 2017, AANS NEUROSURGEON, V26
   Tabibian BE, 2017, WORLD NEUROSURG, V106, P595, DOI 10.1016/j.wneu.2017.07.018
   Tan M, 2013, POSTGRAD MED J, V89, P604, DOI 10.1136/postgradmedj-2012-131296
   Tasdemir N, 2010, J NEUROL SCI TURK, V23
   Tripathi M, 2014, TURK NEUROSURG, V24, P828, DOI 10.5137/1019-5149.JTN.11840-14.0
   VanSuch M, 2006, QUAL SAF HEALTH CARE, V15, P414, DOI 10.1136/qshc.2005.017640
   Wong J, 2011, SUPPORT CARE CANCER, V19, P1841, DOI 10.1007/s00520-010-1027-2
   Zusman EE, 2017, NEUROSURGERY, V80, pS34, DOI 10.1093/neuros/nyw151
NR 42
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1528
EP E1535
DI 10.1016/j.wneu.2018.11.094
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100187
PM 30471444
DA 2020-05-12
ER

PT J
AU Hartman, C
   Hemphill, C
   Godzik, J
   Walker, CT
   Wewel, JT
   Turner, JD
   Uribe, JS
AF Hartman, Cory
   Hemphill, Courtney
   Godzik, Jakub
   Walker, Corey T.
   Wewel, Joshua T.
   Turner, Jay D.
   Uribe, Juan S.
TI Analysis of Cost and 30-Day Outcomes in Single-Level Transforaminal
   Lumbar Interbody Fusion and Less Invasive, Stand-Alone Lateral
   Transpsoas Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lateral lumbar interbody fusion; LIF; Minimally invasive spine surgery;
   MIS; TLIF; Transforaminal lumbar interbody fusion
AB BACKGROUND: A comparative evaluation of operative costs between single-level transforaminal interbody fusion (TLIF) and stand-alone lateral transpsoas interbody fusion (LIF) has not yet been done. We analyzed the costs, operative parameters, and early outcomes of single-level stand-alone LIF versus single-level TLIF.
   METHODS: Ten patients who underwent single-level TLIF and 10 patients who underwent single-level stand-alone LIF were included in the analysis. Total, variable, and fixed costs from perioperative data were available from a single institution. In addition, patient demographics, length of hospital stay, and 30-day outcomes and readmission rates were reviewed.
   RESULTS: Total cost, variable cost, and fixed costs were significantly lower in the LIF group, and there was no difference in outcomes.
   CONCLUSIONS: Single-level stand-alone LIF may prove to be more cost-effective and provide cost savings with analogous 30-day outcomes compared with single-level TLIF procedures.
C1 [Hartman, Cory; Hemphill, Courtney; Godzik, Jakub; Walker, Corey T.; Wewel, Joshua T.; Turner, Jay D.; Uribe, Juan S.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Uribe, JS (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Juan.Uribe@Barrowbrainandspine.com
OI /0000-0001-6867-3568
CR Chin KR, 2016, SPINE, V41, P686, DOI 10.1097/BRS.0000000000001285
   Emami A, 2016, ORTHOPEDICS, V39, pE1218, DOI 10.3928/01477447-20160721-04
   Idowu OA, 2017, SPINE, V42, pE1429, DOI 10.1097/BRS.0000000000002180
   Narain AS, 2018, CLIN SPINE SURG, V31, pE184, DOI 10.1097/BSD.0000000000000618
   Singh K, 2014, SPINE J, V14, P1694, DOI 10.1016/j.spinee.2013.10.053
   Sivaganesan A, 2018, NEUROSURGERY, V83, P159, DOI 10.1093/neuros/nyy057
   Smith WD, 2016, SPINE, V41, pS106, DOI 10.1097/BRS.0000000000001479
   Wang MY, 2012, J SPINAL DISORD TECH, V25, P324, DOI 10.1097/BSD.0b013e318220be32
NR 8
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1037
EP E1040
DI 10.1016/j.wneu.2018.10.207
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100126
PM 30414525
DA 2020-05-12
ER

PT J
AU Hayashi, Y
   Sasagawa, Y
   Oishi, M
   Kita, D
   Tanaka, S
   Ueda, F
   Tachibana, O
   Nakada, M
AF Hayashi, Yasuhiko
   Sasagawa, Yasuo
   Oishi, Masahiro
   Kita, Daisuke
   Tanaka, Shingo
   Ueda, Fumiaki
   Tachibana, Osamu
   Nakada, Mitsutoshi
TI Directional Regulation of Extrasellar Extension by Sellar Dura Integrity
   and Intrasphenoidal Septation In Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dura; Extension; Pituitary adenoma; Regulation; Sphenoid sinus
ID CAVERNOUS SINUS; TRANSSPHENOIDAL SURGERY; SPHENOID SINUS; ANATOMY;
   RESECTION; HEADACHE; INVASION; PARALLEL; PATTERNS; GROWTH
AB OBJECTIVE: Pituitary macroadenomas extend into the extrasellar space, such as the sphenoid sinus, cavernous sinuses, and suprasellar region. However, factors that regulate the direction of their extensions into the surrounding anatomical structures remain unknown.
   METHODS: This retrospective study included 162 patients who were treated for pituitary adenomas that had maximum diameters greater than 20 mm. According to the direction of adenoma extension, patients were divided into 4 groups: group A, inferior into the sphenoid sinus; group B, lateral into the cavernous sinus; group C, suprasellar region with enlarged sella turcica; and group D, supraellar region without enlarged sella turcica. Several anatomical structures surrounding the sella turcica were evaluated statistically, and multivariate logistic regression analysis was performed if the structures met the determining factors of adenomas extensions.
   RESULTS: The maximum diameter of adenomas was significantly larger in groups A and D. The maximumdiameter of the diaphragmatic foramenwas largest in group C (19.3mm) and was significantly narrower in groups B (12.7 mm) and D (12.5 mm). Intrasphenoid septation, attached on the midline of the sella turcica, was observed most frequently in group D (78.6%) andwas not detectable in group A (0%). Extension into the cavernous sinus, classified as dural discontinuity, was highly prevalent in group B (80.0%) and was uncommon in group C (12.3%). Erosion of the posterior clinoid process was most apparent in group B (92.0%).
   CONCLUSIONS: The integrity of the sella dura and the intrasphenoid septation can regulate adenoma extension by encouraging their growth towards paths of least resistance.
C1 [Hayashi, Yasuhiko; Sasagawa, Yasuo; Oishi, Masahiro; Kita, Daisuke; Tanaka, Shingo; Nakada, Mitsutoshi] Kanazawa Univ, Dept Neurosurg, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
   [Ueda, Fumiaki] Kanazawa Univ, Dept Radiol, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
   [Tachibana, Osamu] Kanazawa Med Univ, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
RP Hayashi, Y (reprint author), Kanazawa Univ, Dept Neurosurg, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
EM yahayashi@med.kanazawa-u.ac.jp
RI Nakada, Mitsutoshi/B-2790-2012
OI Nakada, Mitsutoshi/0000-0001-9419-6101; Oishi,
   Masahiro/0000-0002-9776-2399
CR AHMADI J, 1985, AM J NEURORADIOL, V6, P893
   Campero A, 2008, NEUROSURGERY, V62, P717, DOI 10.1227/01.neu.0000317321.79106.37
   Destrieux C, 1998, J NEUROSURG, V88, P743, DOI 10.3171/jns.1998.88.4.0743
   Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412
   FAHLBUSCH R, 1988, ACTA NEUROCHIR, V92, P93, DOI 10.1007/BF01401978
   Ferrareze Nunes C, 2018, J NEUROSURG, V13, P1
   Gondim J, 2009, J HEADACHE PAIN, V10, P15, DOI 10.1007/s10194-008-0084-0
   HARRIS FS, 1976, J NEUROSURG, V45, P169, DOI 10.3171/jns.1976.45.2.0169
   Hayashi Y, 2017, PITUITARY, V20, P531, DOI 10.1007/s11102-017-0814-x
   Hayashi Y, 2016, PITUITARY, V19, P552, DOI 10.1007/s11102-016-0739-9
   Hayashi Y, 2016, CLIN NEUROL NEUROSUR, V147, P53, DOI 10.1016/j.clineuro.2016.05.007
   Hayashi Y, 2016, PITUITARY, V19, P175, DOI 10.1007/s11102-015-0696-8
   Ishii K, 1996, Radiat Med, V14, P173
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Kursat E, 2008, NEUROSURG REV, V31, P91, DOI 10.1007/s10143-007-0112-6
   Nomura M, 2002, J CLIN NEUROSCI, V9, P175, DOI 10.1054/jocn.2000.0920
   Ramakrishnan VR, 2013, J NEUROSURG, V119, P669, DOI 10.3171/2013.3.JNS122113
   RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288
   Sarkar S, 2015, J CLIN NEUROSCI, V22, P1173, DOI 10.1016/j.jocn.2015.01.029
   Singh H, 2016, J NEURO-ONCOL, V130, P309, DOI 10.1007/s11060-016-2124-y
   Wang J, 2010, NEUROSURGERY, V66, P797, DOI 10.1227/01.NEU.0000367619.24800.B1
   Williams PL, 1995, GRAYS ANATOMY, P1211
   Yohannan DG, 2015, ANAT RES INT
   Yoneoka Y, 2008, J NEUROSURG, V108, P37, DOI 10.3171/JNS/2008/108/01/0037
   Zada G, 2011, J NEUROSURG, V114, P1319, DOI 10.3171/2010.11.JNS10768
   Zada G, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10155
   Zenonos GA, 2018, J NEUROL SURG PART B, V79, pS283, DOI 10.1055/s-0038-1625942
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E130
EP E138
DI 10.1016/j.wneu.2018.09.127
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100014
PM 30266706
DA 2020-05-12
ER

PT J
AU Hedderich, DM
   Maegerlein, C
   Baum, T
   Hapfelmeier, A
   Ryang, YM
   Zimmer, C
   Kirschke, JS
AF Hedderich, Dennis M.
   Maegerlein, Christian
   Baum, Thomas
   Hapfelmeier, Alexander
   Ryang, Y-Mi
   Zimmer, Claus
   Kirschke, Jan S.
TI Differentiation of Acute/Subacute versus Old Vertebral Fractures in
   Multislice Detector Computed Tomography: Is Magnetic Resonance Imaging
   Always Needed?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone marrow edema; Double compaction sign; Multislice detector computed
   tomography; Vertebral fracture
ID BONE-MARROW EDEMA; DUAL-ENERGY CT; COMPRESSION FRACTURES;
   VERTEBROPLASTY; PATTERN
AB OBJECTIVES: To assess the ability of multislice detector computed tomography (MDCT) to differentiate old versus acute/subacute vertebral fractures (VF) and to identify characteristic MDCT imaging signs.
   METHODS: 74 consecutive patients demonstrated 192 VF that were classified as either acute/subacute or old based on magnetic resonance imaging, MDCT, and clinical information as reference standard. Classification as acute/subacute versus old fractures based on MDCT alone was evaluated on a Likert scale by 2 independent radiologists. Morphologic MDCT features of fractures, such as trabecular compaction or fracture line, were recorded. Receiver operating characteristic analyses and Cohen's kappa were used to assess the discriminatory power of the MDCT and interrater agreement, respectively.
   RESULTS: Out of all 192 VF, 148 fractures were acute/subacute and 44 were old according to the reference standard. Receiver operating characteristic analyses of sole MDCT assessment showed very good identification of acute/subacute VF, with areas under the curve of 0.854 and 0.861 for readers 1 and 2, respectively. When indeterminate findings were treated as acute/subacute fractures, sensitivity and specificity were 97.2% and 58.1% for reader 1 and 94.5% and 65.1% for reader 2. Interrater agreement regarding fracture age was good (weighted Cohen's kappa = 0.607). Trabecular compression/callus distinct from the cortex (double compaction sign) was present in approximately half of acute/subacute VF and highly specific for acute/subacute VF (specificity = 93.2% and 88.6% for readers 1 and 2, respectively).
   CONCLUSION: The acuity of VF can be assessed by MDCT alone with high sensitivity and in case of a double compaction sign with high specificity.
C1 [Hedderich, Dennis M.; Maegerlein, Christian; Baum, Thomas; Zimmer, Claus; Kirschke, Jan S.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, Munich, Germany.
   [Hapfelmeier, Alexander] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, Munich, Germany.
   [Ryang, Y-Mi] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurosurg, Munich, Germany.
RP Hedderich, DM (reprint author), Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, Munich, Germany.
EM dennis.hedderich@tum.de
RI Hedderich, Dennis/AAF-6432-2020; Baum, Thomas/M-6522-2014; Ryang,
   Yu-Mi/Q-8373-2016; Kirschke, Jan/E-2550-2012; Hapfelmeier,
   Alexander/I-9966-2019
OI Baum, Thomas/0000-0002-4574-5212; Ryang, Yu-Mi/0000-0002-9045-5038;
   Kirschke, Jan/0000-0002-7557-0003; Hapfelmeier,
   Alexander/0000-0001-6765-6352
CR Bierry G, 2014, SKELETAL RADIOL, V43, P485, DOI 10.1007/s00256-013-1812-3
   Brinckman MA, 2015, SPINE J, V15, P454, DOI 10.1016/j.spinee.2014.09.032
   Diamond TH, 2007, BONE, V40, P775, DOI 10.1016/j.bone.2006.10.009
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Griffith JF, 2015, QUANT IMAGING MED SU, V5, P592, DOI 10.3978/j.issn.2223-4292.2015.08.01
   Henes FO, 2014, EUR J RADIOL, V83, P167, DOI 10.1016/j.ejrad.2013.09.015
   Hofstaetter JG, 2012, J ORTHOP RES, V30, P1089, DOI 10.1002/jor.22026
   Karaca L, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150300
   Kaup M, 2016, RADIOLOGY, V280, P510, DOI 10.1148/radiol.2016150472
   Kazawa N, 2012, EUR J RADIOL, V81, P1630, DOI 10.1016/j.ejrad.2011.04.052
   Kendler DL, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2015.09.020
   Kumar Y, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1169-6
   Muller D, 2008, EUR RADIOL, V18, P1696, DOI 10.1007/s00330-008-0920-2
   Obuchowski NA, 1997, BIOMETRICS, V53, P567, DOI 10.2307/2533958
   Petritsch B, 2017, RADIOLOGY, V284, P161, DOI 10.1148/radiol.2017162165
   Pizones J, 2013, SEMIN MUSCULOSKEL R, V17, P389, DOI 10.1055/s-0033-1356468
   Pizones J, 2011, EUR SPINE J, V20, P390, DOI 10.1007/s00586-011-1913-4
   Rollinghoff M, 2010, ARCH ORTHOP TRAUM SU, V130, P765, DOI 10.1007/s00402-010-1083-6
   Savage JW, 2014, J AM ACAD ORTHOP SUR, V22, P653, DOI 10.5435/JAAOS-22-10-653
   Schmeel FC, 2018, EUR RADIOL, V28, P2397, DOI 10.1007/s00330-017-5241-x
   Tsoumakidou G, 2017, CARDIOVASC INTER RAD, V40, P331, DOI 10.1007/s00270-017-1574-8
   Van Goethem JWM, 2005, EUR RADIOL, V15, P582, DOI 10.1007/s00330-004-2625-5
   Voormolen MHJ, 2006, AM J NEURORADIOL, V27, P983
   Wintermark M, 2003, RADIOLOGY, V227, P681, DOI 10.1148/radiol.2273020592
   Wood KB, 2014, SPINE J, V14, P145, DOI 10.1016/j.spinee.2012.10.041
   Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835
NR 26
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E676
EP E683
DI 10.1016/j.wneu.2018.10.121
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100082
PM 30385360
DA 2020-05-12
ER

PT J
AU Hitti, FL
   McShane, BJ
   Yang, AI
   Rinehart, C
   Albayar, A
   Branche, M
   Malhotra, NR
   Janjua, MB
   Ali, ZS
   Schuster, JM
   Ozturk, AK
AF Hitti, Frederick L.
   McShane, Brendan J.
   Yang, Andrew I.
   Rinehart, Cole
   Albayar, Ahmed
   Branche, Marc
   Malhotra, Neil R.
   Janjua, M. Burhan
   Ali, Zarina S.
   Schuster, James M.
   Ozturk, Ali K.
TI Predictors of Failure of Nonoperative Management Following Subaxial
   Spine Trauma and Creation of Modified Subaxial Injury Classification
   System
SO WORLD NEUROSURGERY
LA English
DT Article
DE mSLIC; Nonoperative failure; Predictors; Subaxial cervical spine; Trauma
   SLIC
ID SCORING SYSTEM; RELIABILITY; FRACTURES
AB BACKGROUND: Subaxial cervical spine injuries may be treated with either nonoperative stabilization or surgical fixation. The subaxial injury classification (SLIC) provides 1 method for suggesting the degree of necessity for surgery. In the current study, we examined if the SLIC score, or other preoperative metrics, can predict failure of nonoperative management.
   METHODS: We performed a retrospective chart review to identify patients who presented with acute, nonpenetrating, subaxial cervical spine injury within our health system between 2007 and 2016. Patient demographics, medical comorbidities, injuries, and treatments were collected. Logistic regression analysis was used to determine potential predictors of failure of nonoperative management.
   RESULTS: During the study period, 40 patients met the inclusion criteria. A small subset of patients failed nonoperative management (n = 5, 12.5%). The mean SLIC score was 3.9 +/- 1.9; however, 14 (35%) patients had scores >4. Neither total SLIC score (P = 0.68) nor SLIC subscores (morphology [P = 0.96], discoligamentous complex [P = 0.83], neurologic status [P = 0.60]) predicted failure of nonoperative treatment. Time to evaluation/treatment did predict failure of nonoperative management. Evaluation within 8 hours of injury was a negative predictor of failure (odds ratio = 0.03, P = 0.001) and evaluation 24 hours or more after injury was a positive predictor of failure (odds ratio = 66.00, P < 0.001). We created a modified SLIC score on the basis of these findings, which significantly predicted failure of nonoperative management (P = 0.044).
   CONCLUSIONS: Management of subaxial spine injuries is complex. In our cohort, SLIC scoring did not adequately predict odds of failure of nonoperative management. Time to evaluation, however, did. We created a modified SLIC score that significantly predicted failure of nonoperative management.
C1 [Hitti, Frederick L.; McShane, Brendan J.; Yang, Andrew I.; Rinehart, Cole; Albayar, Ahmed; Branche, Marc; Malhotra, Neil R.; Janjua, M. Burhan; Ali, Zarina S.; Schuster, James M.; Ozturk, Ali K.] Univ Penn, Penn Hosp, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Janjua, M. Burhan] Univ Penn, Penn Hosp, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
RP Hitti, FL (reprint author), Univ Penn, Penn Hosp, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM Frederick.Hitti@uphs.upenn.edu
OI Hitti, Frederick/0000-0002-5308-9817
CR Aarabi B, 2014, J NEUROSURG-SPINE, V20, P270, DOI 10.3171/2013.11.SPINE13733
   da Silva OT, 2016, J NEUROSURG-SPINE, V25, P303, DOI 10.3171/2016.2.SPINE151039
   Dvorak MF, 2007, SPINE, V32, P2620, DOI 10.1097/BRS.0b013e318158ce16
   Grauer JN, 2009, J SPINAL DISORD TECH, V22, P96, DOI 10.1097/BSD.0b013e31816a9ebd
   Joaquim AF, 2014, J CRANIOVERTEBRAL JU, V5, P65, DOI 10.4103/0974-8237.139200
   Joaquim AF, 2014, J SPINAL CORD MED, V37, P420, DOI 10.1179/2045772313Y.0000000143
   Kubben PL, 2012, SURG NEUROL INT, V3
   Lee WJ, 2012, J KOREAN NEUROSURG S, V52, P200, DOI 10.3340/jkns.2012.52.3.200
   Passias PG, 2018, WORLD NEUROSURG, V110, pE427, DOI 10.1016/j.wneu.2017.11.011
   Patel AA, 2010, SPINE, V35, pS228, DOI 10.1097/BRS.0b013e3181f330ae
   Patel AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E8
   Samuel S, 2015, SPINE, V40, P137, DOI 10.1097/BRS.0000000000000666
   Stone Addison T, 2010, Evid Based Spine Care J, V1, P19, DOI 10.1055/s-0030-1267064
   van Middendorp JJ, 2013, SPINE J, V13, P1055, DOI 10.1016/j.spinee.2013.02.040
   Whang PG, 2011, CLIN ORTHOP RELAT R, V469, P723, DOI 10.1007/s11999-010-1576-1
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1359
EP E1364
DI 10.1016/j.wneu.2018.11.048
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100166
PM 30448573
DA 2020-05-12
ER

PT J
AU Ishikawa, T
   Takeuchi, K
   Nagatani, T
   Aimi, Y
   Tanemura, E
   Tambara, M
   Nagata, Y
   Choo, J
   Wakabayashi, T
AF Ishikawa, Takayuki
   Takeuchi, Kazuhito
   Nagatani, Tetsuya
   Aimi, Yuri
   Tanemura, Eriko
   Tambara, Masao
   Nagata, Yuichi
   Choo, Jungsu
   Wakabayashi, Toshihiko
TI Quality of Life Changes Before and After Transsphenoidal Surgery for
   Sellar and Faros llar Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngioma; Endoscopic transsphenoidal approach; GHQ-30;
   Pituitary adenoma; Rathke cleft cyst; SF-36; Tuberculum sellae
   meningioma
ID GROWTH-HORMONE DEFICIENCY; CUSHINGS-SYNDROME; FOLLOW-UP; ADULTS;
   QUESTIONNAIRE; REMISSION; DIAGNOSIS; SYMPTOMS; THERAPY; ACROQOL
AB OBJECTIVE: Although reports regarding the relationship between surgical complications and quality of life MOO exist, a general consensus regarding this issue is lacking. The aim of this study was to evaluate DOI after endoscopic transsphenoidal approach.
   METHODS: We assessed patients with sellar or parasellar lesions that were removed with endoscopic transsphenoidal approach or extended endoscopic transsphenoidal approach betvveen January 2010 and December 2016, 36-Item Short Form Health Survey and 30-Item General Health Questionnaire DOI scores were obtained preoperatively and 1 month and 6 months postoperatively.
   RESULTS: We analyzed 89 patients with malfunctioning pituitary adenoma (NFPA) and 39 patients with acromegaly. Physical DOI decreased 1 month after surgery but recovered after 6 months in both groups. Mental GU improved postoperatively compared with preoperatively, Patients with acrornegaly had a worse Physical Component Summary (PCS) on 36-Item Short Form Health Survey (48.7, 28.9, and 41.0) at 6 months than patients with NEPA. The low preoperative PCS group did not improve until 6 months postoperatively. Multiple regression analysis revealed the following factors were key to postoperative DOI: age (NEPA PCS 6 months postoperatively; correlation coefficient = 0,489), preoperative Mental Component Summary (MCS) (NEPA MCS 6 months postoperatively, correlation coefficient = 0.573), body mass index (acromegaly PCS 6 months postoperatively; correlation coefficient = 0.376), preoperative PCS (acrornegaly PCS 6 months postoperatively; correlation coefficient = 0.905), and preoperative MCS (acromegaly MCS 6 months postoperatively, correlation coefficient = 0.726).
   CONCLUSIONS: Endoscopic transsphenoidal approach can improve DOI. in patients by 6 months postoperatively. In patients with aerating* with significant DOI impairments preoperatively, surgery sometimes may be unable to normalize Q01.
C1 [Ishikawa, Takayuki; Takeuchi, Kazuhito; Nagatani, Tetsuya; Aimi, Yuri; Tanemura, Eriko; Tambara, Masao; Nagata, Yuichi; Choo, Jungsu; Wakabayashi, Toshihiko] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan.
   [Ishikawa, Takayuki; Nagatani, Tetsuya] Japanese Red Cross Nagoya Daini Hosp, Dept Neurosurg, Nagoya, Aichi, Japan.
   [Aimi, Yuri] Yokkaichi Municipal Hosp, Dept Neurosurg, Yokaichi, Mie, Japan.
   [Tanemura, Eriko] Chuno Kosei Hosp, Dept Neurosurg, Gifu, Japan.
   [Tambara, Masao] Okazaki City Hosp, Dept Neurosurg, Okazaki, Aichi, Japan.
   [Choo, Jungsu] Chukyo Hosp, Dept Neurosurg, Nagoya, Aichi, Japan.
RP Ishikawa, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan.; Ishikawa, T (reprint author), Japanese Red Cross Nagoya Daini Hosp, Dept Neurosurg, Nagoya, Aichi, Japan.
EM ishikawa.takayuki@h.mbox.nagoya-u.ac.jp
OI Nagata, Yuichi/0000-0003-4130-5380
CR Alcalar N, 2013, PITUITARY, V16, P333, DOI 10.1007/s11102-012-0425-5
   Alobid I, 2013, AM J RHINOL ALLERGY, V27, P426, DOI 10.2500/ajra.2013.27.3932
   Andela CD, 2015, PITUITARY, V18, P752, DOI 10.1007/s11102-015-0636-7
   Barkan AL, 2001, J CLIN ENDOCR METAB, V86, P1905, DOI 10.1210/jc.86.5.1905
   Bohl MA, 2018, NEUROSURGERY, V82, P110, DOI 10.1093/neuros/nyx151
   Carluccio A, 2015, CLIN ENDOCRINOL, V82, P404, DOI 10.1111/cen.12521
   Naliato ECDO, 2008, PITUITARY, V11, P247, DOI 10.1007/s11102-008-0091-9
   Fathalla H, 2014, CAN J NEUROL SCI, V41, P735, DOI 10.1017/cjn.2014.106
   Fujio S, 2017, ENDOCR J, V64, P27, DOI 10.1507/endocrj.EJ16-0182
   Fujio S, 2013, PITUITARY, V16, P326, DOI 10.1007/s11102-012-0424-6
   GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644
   Gonzalez B, 2016, ENDOCR PRACT, V22, P540, DOI 10.4158/EP151100.OR
   Heinks K, 2018, ENDOCRINE, V59, P364, DOI 10.1007/s12020-017-1489-9
   Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x
   Hoybye C, 2010, EUR J ENDOCRINOL, V162, P677, DOI 10.1530/EJE-09-0836
   Hua SC, 2006, EUR J ENDOCRINOL, V155, P831, DOI 10.1530/eje.1.02292
   Kreitschmann-Andermahr I, 2017, ENDOCR PRACT, V23, P79, DOI 10.4158/EP161373.OR
   Lindsay JR, 2006, J CLIN ENDOCR METAB, V91, P447, DOI 10.1210/jc.2005-1058
   Little AS, 2015, J NEUROSURG, V123, P799, DOI 10.3171/2014.10.JNS14921
   Little AS, 2013, J NEUROSURG, V119, P1068, DOI 10.3171/2013.3.JNS122032
   Matta MP, 2008, EUR J ENDOCRINOL, V158, P305, DOI 10.1530/EJE-07-0697
   McCoul ED, 2015, INT FORUM ALLERGY RH, V5, P1124, DOI 10.1002/alr.21602
   Milian M, 2013, ACTA NEUROCHIR, V155, P1637, DOI 10.1007/s00701-013-1809-7
   Muller HL, 2004, J CLIN ENDOCR METAB, V89, P3298, DOI 10.1210/jc.2003-031751
   Neggers SJCMM, 2008, J CLIN ENDOCR METAB, V93, P3853, DOI 10.1210/jc.2008-0669
   Okamoto Y, 2010, INVEST OPHTH VIS SCI, V51, P3405, DOI 10.1167/iovs.09-3763
   Papoian V, 2016, ENDOCR PRACT, V22, P51, DOI 10.4158/EP15855.OR
   Pikkarainen L, 1999, J INTERN MED, V245, P463, DOI 10.1046/j.1365-2796.1999.00483.x
   Postma MR, 2012, EUR J ENDOCRINOL, V166, P585, DOI 10.1530/EJE-11-0853
   Rotenberg BW, 2011, LARYNGOSCOPE, V121, P1611, DOI 10.1002/lary.21890
   Rowles SV, 2005, J CLIN ENDOCR METAB, V90, P3337, DOI 10.1210/jc.2004-1565
   Takeuchi K, 2014, NAGOYA J MED SCI, V76, P73
   Tanemura E, 2012, ACTA NEUROCHIR, V154, P1895, DOI 10.1007/s00701-012-1473-3
   Tiemensma J, 2016, EUR J ENDOCRINOL, V174, P33, DOI 10.1530/EJE-15-0640
   van der Klaauw AA, 2008, CLIN ENDOCRINOL, V69, P775, DOI 10.1111/j.1365-2265.2008.03288.x
   van der Klaauw AA, 2008, CLIN ENDOCRINOL, V69, P123, DOI 10.1111/j.1365-2265.2007.03169.x
   Vandeva S, 2015, ENDOCRINE, V49, P774, DOI 10.1007/s12020-014-0521-6
   Wallymahmed ME, 1999, CLIN ENDOCRINOL, V51, P333
   Wassenaar MJE, 2010, GROWTH HORM IGF RES, V20, P226, DOI 10.1016/j.ghir.2010.02.003
   Webb SM, 2008, EUR J ENDOCRINOL, V158, P623, DOI 10.1530/EJE-07-0762
   Webb SM, 2002, CLIN ENDOCRINOL, V57, P251, DOI 10.1046/j.1365-2265.2002.01597.x
   Wexler T, 2009, J CLIN ENDOCR METAB, V94, P2471, DOI 10.1210/jc.2008-2671
   Wolf A, 2017, J NEUROSURG, V127, P409, DOI 10.3171/2016.7.JNS16200
   Ye VC, 2017, CAN J NEUROL SCI, V44, P69, DOI 10.1017/cjn.2016.295
NR 44
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1202
EP E1210
DI 10.7076/j.wneu.2018.71.017
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100146
PM 30447458
DA 2020-05-12
ER

PT J
AU Jin, L
   Gui, SB
   Li, CZ
   Bai, JW
   Cao, L
   Liu, CH
   Wang, XS
   Zhang, YZ
AF Jin, Lu
   Gui, Songbai
   Li, Chuzhong
   Bai, Jiwei
   Cao, Lei
   Liu, Chunhui
   Wang, Xinsheng
   Zhang, Yazhuo
TI Differential Diagnosis and Treatment Modality of Parasellar
   Plasmacytoma: Clinical Series and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Differential diagnosis; Parasellar plasmacytoma; Radiotherapy; Surgery;
   Treatment
ID SOLITARY PLASMACYTOMA; EXTRAMEDULLARY PLASMACYTOMA; MULTIPLE-MYELOMA;
   INTRASELLAR PLASMACYTOMA; MIMICKING; SELLA; BONE; MANAGEMENT; SINONASAL
AB BACKGROUND: Parasellar plasmacytomas are rare tumors arising from the sellar region that should be considered in the differential diagnosis of lesions involving the sella and clivus. Before surgical pathologic examination, parasellar plasmacytomas have often been misdiagnosed as invasive pituitary adenomas or chordomas owing to the similarity of the clinical presentation and imaging findings.
   METHODS: We retrospectively reviewed the data from 5 patients with parasellar plasmacytoma who underwent endonasal endoscopic tumor resection in Beijing Tiantan Hospital from January 2008 to January 2018. Their clinical symptoms, radiological features, and treatment modalities and outcomes were summarized.
   RESULTS: We enrolled a total of 5 patients (3 men and 2 women; median age at diagnosis, 54 years; range, 47-61) with parasellar plasmacytoma in the present clinical series. The presenting symptoms mainly included diplopia, headache, and blurred vision. All the patients had undergone endonasal endoscopic surgery combined with adjuvant therapy. After postoperative radiotherapy, complete remission was achieved within a median follow-up period of 41 months (range, 15-120).
   CONCLUSIONS: The differential diagnosis of parasellar plasmacytoma with pituitary adenoma and chordoma should include a thorough endocrine workup, neurological examination, and radiological assessment. Our findings support radiotherapy as the main treatment of choice for parasellar plasmacytoma, given its typical feature of relatively high radiosensitivity. Tumor resection through the endonasal endoscopic approach combined with adjuvant radiotherapy could be the optimal initial treatment strategy in long-term control of the lesion and alleviation of neurological symptoms.
C1 [Jin, Lu; Gui, Songbai; Bai, Jiwei; Cao, Lei; Liu, Chunhui; Wang, Xinsheng] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Chuzhong; Zhang, Yazhuo] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China.
RP Gui, SB (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM guisongbai@yeah.net
OI KANG, JIE/0000-0002-2079-6742
CR Alexiou C, 1999, CANCER, V85, P2305, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.3.CO;2-V
   Azarpira N, 2012, DIAGN CYTOPATHOL, V40, P248, DOI 10.1002/dc.21623
   Bhartiya M, 2016, INDIAN J HEMATOL BLO, V32, pS135, DOI 10.1007/s12288-015-0573-7
   BINDAL AK, 1995, J NEUROSURG, V83, P218, DOI 10.3171/jns.1995.83.2.0218
   BITTERMAN P, 1986, COMPUT RADIOL, V10, P201, DOI 10.1016/0730-4862(86)90109-5
   Bret P, 2002, NEUROCHIRURGIE, V48, P431
   Caers J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0549-1
   Comerford CM, 2018, IRISH J MED SCI, V187, P349, DOI 10.1007/s11845-017-1690-0
   D'Aguillo C, 2014, INT FORUM ALLERGY RH, V4, P156, DOI 10.1002/alr.21254
   Dekkers OM, 2008, J CLIN ENDOCR METAB, V93, P3717, DOI 10.1210/jc.2008-0643
   DICKMAN CA, 1992, J NEUROSURG, V77, P525, DOI 10.3171/jns.1992.77.4.0525
   ESTOPINAN V, 1987, MED CLIN-BARCELONA, V89, P128
   EVANS PJ, 1985, POSTGRAD MED J, V61, P513, DOI 10.1136/pgmj.61.716.513
   Fernandez-Miranda JC, 2014, HEAD NECK-J SCI SPEC, V36, P892, DOI 10.1002/hed.23415
   Fukai J, 2010, NEUROSURGERY, V67, pE505, DOI 10.1227/01.NEU.0000371985.32844.B7
   GALIENI P, 1995, ANN ONCOL, V6, P687, DOI 10.1093/oxfordjournals.annonc.a059285
   Grover Nancy, 2006, Ear Nose Throat J, V85, P434
   HARRISON LB, 1987, INT J RADIAT ONCOL, V13, P653, DOI 10.1016/0360-3016(87)90087-3
   HORNEDO J, 1982, MED CLIN-BARCELONA, V79, P377
   JACQUET G, 1991, NEUROCHIRURGIE, V37, P67
   Jiang CZ, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000058
   Joukhadar R, 2012, PITUITARY, V15, P146, DOI 10.1007/s11102-011-0352-x
   Kalwani N, 2015, J NEUROL SURG REP, V76, P156, DOI 10.1055/s-0035-1554930
   Kanoh T, 1996, Rinsho Ketsueki, V37, P260
   KERTY E, 1984, J NEUROL NEUROSUR PS, V47, P99, DOI 10.1136/jnnp.47.1.99
   Khalatbari MR, 2014, ARCH IRAN MED, V17, P526, DOI 0141707/AIM.0016
   Khan IS, 2012, J CLIN NEUROSCI, V19, P210, DOI 10.1016/j.jocn.2011.07.009
   Kontogeorgos George, 2005, Endocrine, V28, P27, DOI 10.1385/ENDO:28:1:027
   Kumar S, 2003, BLOOD, V101, P1715, DOI 10.1182/blood-2002-08-2441
   Kuyumcu G, 2017, CAN J NEUROL SCI, V44, P324, DOI 10.1017/cjn.2016.319
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Leah P, 2018, J CLIN NEUROSCI, V53, P6, DOI 10.1016/j.jocn.2018.04.008
   Lee J, 2017, PITUITARY, V20, P381, DOI 10.1007/s11102-017-0799-5
   Liebross RH, 1999, RADIOTHER ONCOL, V52, P245, DOI 10.1016/S0167-8140(99)00114-0
   LOSA M, 1992, SURG NEUROL, V37, P388, DOI 10.1016/0090-3019(92)90010-K
   Mandagere K A, 1998, Endocr Pract, V4, P382
   Oishi T, 2006, CLIN NEUROPATHOL, V25, P44
   Ozsahin M, 2006, INT J RADIAT ONCOL, V64, P210, DOI 10.1016/j.ijrobp.2005.06.039
   Pitini V, 2008, J NEURO-ONCOL, V88, P227, DOI 10.1007/s11060-008-9558-9
   POON MC, 1979, CANCER, V43, P1513, DOI 10.1002/1097-0142(197904)43:4<1513::AID-CNCR2820430444>3.0.CO;2-Q
   Rahman EZ, 2016, CAN J OPHTHALMOL, V51, pE49, DOI 10.1016/j.jcjo.2015.10.017
   Rivera J, 2010, PITUITARY, V13, P189, DOI 10.1007/s11102-008-0145-z
   SANCHEZ JA, 1977, ARCH PATHOL LAB MED, V101, P55
   Sinnott B P, 2006, Pituitary, V9, P65, DOI 10.1007/s11102-006-8281-9
   Soejbjerg A, 2016, ENDOCRINOL DIAB META, DOI 10.1530/EDM-16-0031
   Soutar R, 2004, BRIT J HAEMATOL, V124, P717, DOI 10.1111/j.1365-2141.2004.04834.x
   STOUT AP, 1949, CANCER, V2, P261, DOI 10.1002/1097-0142(194903)2:2<261::AID-CNCR2820020206>3.0.CO;2-K
   Terasaka T, 2016, INTERNAL MED, V55, P1501, DOI 10.2169/internalmedicine.55.6414
   Udiawar M, 2012, BMJ CASE REP, V2012
   URBANSKI SJ, 1980, SURG NEUROL, V14, P233
   Vallat M, 1981, Bull Soc Ophtalmol Fr, V81, P355
   VAQUERO J, 1982, ARCH NEUROL-CHICAGO, V39, P738, DOI 10.1001/archneur.1982.00510230064025
   Vento SI, 2017, ACTA OTO-LARYNGOL, V137, P975, DOI 10.1080/00016489.2017.1325514
   Weber J, 1999, ACTA NEUROCHIR, V141, P219, DOI 10.1007/s007010050291
   Weilbaecher C, 2004, NEUROL INDIA, V52, P365
   WU PW, 2017, MEDICINE, V96, DOI DOI 10.1097/MD.0000000000007277
   Yaman E, 2008, ACTA NEUROCHIR, V150, P921, DOI 10.1007/s00701-008-0012-8
   Zuo Z, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-123
NR 58
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E978
EP E988
DI 10.1016/j.wneu.2018.10.183
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100118
PM 30414521
DA 2020-05-12
ER

EF